Danmark Boehringer Ingelheim Danmark A/ S Tlf: +45 39 15 88 49
Danmark Cephalon Pharma Aps Sluseholmen 2-4 DK - SV 2450 København Tlf: +45 3694 4868
Danmark Ferring Lægemidler A/ S
Danmark Ms Birgitte KRISTENSEN (1) Dr Claus WILLADSEN (1)
Danmark Ms Birgitte KRISTENSEN Dr Claus WILLADSEN
121 Danmark Novartis Healthcare A/ S Tlf: +45 39 16 84 00
42 Danmark Novartis Healthcare A/ S Tlf: +45 39 16 84 00
48 Danmark Novartis Healthcare A/ S Tlf: +45 39 16 84 00
Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 00
Danmark Novartis Healthcare A/ S Tlf: +45 39 16 84 00
53 Danmark sanofi-aventis Denmark A/ S Tlf: +45 45 16 70 00
Merck AB Strandvejen 102 B, 4th DK-2900 Hellerup Tlf: +45 35253550
Danmark Swedish Orphan A/ S Wilders Plads 5 DK-1403 København K Tlf: +45 32 96 68 69
In 3 of these, moxifloxacin was used for treating less severe indications (sinusitis, pharyngitis and acute bronchitis).
In ASPIRE, more than 90% of patients had at least two evaluable X-rays.
In many cases, these symptoms will be signs of less serious side effects.
For these purposes, Cerenia can be given for up to five days.
In that case, talk to your doctor again after another 2 to 4 weeks.
Other treatments should be considered in these cases.
If this happens pull out the syringe, cover the injection site with a swab containing disinfectant and apply pressure; the site will stop bleeding in a minute or two.
As dosage adjustment of Combivir is not possible separate preparations of zidovudine and lamivudine should be used.
As dosage adjustment of Trizivir is not possible separate preparations of zidovudine, abacavir and lamivudine should be used.
It is recommended to use AMMONAPS granules instead.
If they occur, the dose of levodopa should be decreased.
If this changes you will start on the same dose as you have been receiving and your doctor will
In these cases, the vaccination will be postponed until your child has recovered.
In such cases, ciprofloxacin should immediately be discontinued, and an appropriate therapy initiated.
In these cases, ciprofloxacin should be discontinued.
In these circumstances the vaccination course should be continued with diphtheria, tetanus, hepatitis B and HIB vaccines. t
Effectiveness is immediate if re-implanted approximately 6 months following previous implantation.
You must then not be given LeukoScan.
Treatment with Viani should not be stopped abruptly.
If this occurs, the patient should consult a doctor.
In this case, the product expires at the end of this 3-month period; the new expiry date must be noted on the top of the outer carton.
In this case, the product expires at the end of this 3-month period; the new expiry date must be noted on the outer carton.
In this case, the product expires at the end of this 3-month period; you must note the new expiry date on the outer carton.
In this case, the product expires at the end of this 3-month period; you must note the new expiry date on the top of the outer carton.
When this happens, sugar (glucose) builds up in the blood.
In that case, the ciprofloxacin treatment must be discontinued, and medical treatment for shock should be given.
If this happens, do not inject Orgalutran, but remove the syringe, cover the injection site with a swab containing disinfectant and apply pressure; bleeding should stop in a minute or two.
In these cases take immediate contact to a doctor.
In that case, just carry on with the next dose as normal.
The infusion set should then be attached to the three-way stopcock and intravenous infusion started at a ” to keep open” (TKO) rate.
In this case, follow the instructions given below in the point 2. of the Note section.
In this event, all antipsychotics, including RISPERDAL CONSTA, should be discontinued.
In this case close monitoring is required. • lopinavir/ ritonavir combination (used to treat HIV infection)
This may include the administration of adrenaline and/or the maintenance of a patent airway.
If this is the case, you should speak to your doctor without delay.
In such cases, you will be closely monitored during your infusion and for an hour after your infusion has stopped. • If you have already received KIOVIG previously and received the last treatment recently, then you will only be observed during the infusion and for at least 20 minutes after your infusion.
You must use your fast acting ‘ rescue'medicine (such as salbutamol) for this purpose which you should carry with you at all times.
If this happens, you will get training on how to inject STELARA.
In this case you will get training on how to inject STELARA yourself.
For this group, the level of glycaemic control (HbA1c) was generally comparable to that observed in those without antibody titres.
In this trial 57% of the patients had baseline HbA1c above 9%; in these patients treatment with NovoMix 30 in combination with metformin resulted in significantly lower HbA1c than metformin in combination with sulfonylurea.
All parameters in the model were in line with those considered acceptable in the CVMP guideline (Environmental Impact Assessment for Veterinary Medicinal Products in support of the VICH guidelines GL6 and GL38 (EMEA/ CVMP/ ERA/ 418282/ 2005)).
Under certain circumstances larger amounts than those calculated may be required, especially in the case of the initial dose.
Under certain circumstances (e.g. presence of a low-titre inhibitor), doses larger than those calculated using the formula may be necessary.
Under certain circumstances (e. g. presence of a low titre inhibitor) doses larger than those calculated using the formula may be necessary.
Under certain circumstances (e. g. presence of a low-titre inhibitor) doses larger than those calculated using the formula may be necessary.
Under certain circumstances (e. g. presence of a low-titre inhibitor), doses larger than those calculated using the formula may be necessary.
However, in some cases these reactions have been severe, requiring treatment and/or causing incapacitation.
In some cases, these skin lesions were associated with skin striae and bone lesions first seen during an X-ray examination.
In some cases concomitant factors may have contributed to the development of these effects.
In some cases manifestations of toxicity have occurred.
Part of the treatment of diabetes is dietary control.
In individual cases, only some of these symptoms and/ or findings may be evident.
- There have been reports of increased bleeding in patients with haemophilia taking protease
In some cases your doctor will ask you to restart Ziagen in a place where you will be able to get ready access to medical care if needed.
In some cases you may have to stop taking one of the medicines.
If any of this happens, contact your doctor immediately
In these states, pulmonary vascular resistance (PVR) is high, which results in hypoxemia secondary to right-to-left shunting of blood through the patent ductus arteriosus and foramen ovale.
In these circumstances the vaccination course should be continued with vaccine not containing a pertussis component.
Therefore, caution should be exercised in such unusual cases.
It should be considered whether it is advisable to drive or operate machines in these circumstances.
Under these circumstances vision loss may be rapid and severe.
This way, you can be sure your medicine is fully effective and you reduce the risk of the virus developing resistance to the treatment.
Under these conditions the ability to react may be decreased.
Overall, 1.3% of aripiprazole-treated patients reported cerebrovascular adverse events compared with 0.6% of placebo-treated patients in these trials.
In these studies, the incidence of other types of arthritis-related adverse events were similar between the Raptiva and placebo groups.
In this subgroup, there was a 92% (89/ 97) sustained virological response rate.
In this subgroup, there was a 92% (89/97) sustained virological response rate.
In this subgroup, there was a 56% (463/823) sustained virological response rate.
In this subgroup, there was a 56% (463/ 823) sustained virological response rate.
Within all three of these prior disease subgroups, the effect of simvastatin on MVE and MCE were significant with or without the inclusion of patients who also had known CHD.
In this trial, 87% of patients had disease that was IHC 3+, and 95% of patients entered had disease that was IHC 3+ and/ or FISH positive.
The main test method used to determine HER2 positivity in this pivotal trial was immunohistochemistry (IHC).
The observed excess risk of fractures for women on pioglitazone in this study is therefore 0.5 fractures per 100 patient years of use.
The observed excess risk of fractures for women in this dataset on pioglitazone is therefore 0.8 fractures per 100 patient years of use.
The observed excess risk of fractures for women in this dataset on pioglitazone is therefore 0.8 fractures per 100 patient years of use.
In this analysis a successful response was seen in 41% of patients in both treatment arms.
The mean IGF-I concentration in this cohort fell from 917 ng/ ml to 299 ng/ ml on pegvisomant, with 92% achieving a normal (age-adjusted) IGF-I concentration.
In the latter study, at the lowest systemic exposure where this anomaly occurred in a single animal, the estimated margin relative to the recommended daily human dose was 2 times more than the recommended daily human dose (800 mg).
In the latter study, at the lowest systemic exposure where this anomaly occurred in a single animal, the estimated margin relative to the maximum recommended daily human dose was 3X.
61/ 64 Overdose At very high doses adverse effects on the nervous system (ataxia, unsteadiness, twitching, tremors, convulsions, etc.) may occur in cattle; in this target species overdosing may also give rise to oedema and swelling in the knee joints.
In this study, 358 patients with inoperable locally advanced SCCHN, and WHO perfomance status 0 or 1, were randomized to one of two treatment arms.
In this study, 358 patients with inoperable locally advanced SCCHN, and WHO perfomance status 0 or 1, were randomized to one of two treatment arms.
No adverse events previously unreported in shorter duration and/ or previous studies were observed in this long-term study.
In this study, in a subgroup analysis of osteoporotic women (37% of the total population who fulfilled the definition of osteoporosis given above) a significant difference was seen in the incidence of hip fractures (alendronate 1.0% versus placebo 2.2%, a reduction of 56%) and in the incidence of ≥ 1 vertebral fracture (2.9% versus 5.8%, a reduction of 50%).
In this study, a significant difference was observed in the analysis of the subgroup of osteoporotic women (37% of the global population who correspond with the above definition of osteoporosis) in the incidence of hip fractures (alendronate 1.0% vs. placebo 2.2%, a reduction of 56%) and in the incidence of ≥ 1 vertebral fracture (2.9% vs.
In this open label non- randomized single arm study, patients were treated with stavudine and lamivudine plus indinavir/ ritonavir 400/ 100 mg every 12 hours.
In this study abacavir increased the mean methadone systemic clearance by 22%.
In this study, abacavir increased the mean methadone systemic clearance by 22%.
In this study, mean (SD) terminal half-life was 74 (SD 27) hours.
In this study, mean (SD) terminal half-life was 74 (SD 27) hours.
In this study, mean (SD) terminal half-life was 74 (SD 27) hours.
In this study, mean (SD) terminal half-life was 74 (SD 27) hours.
In this study, mean (SD) terminal half-life was 74 (SD 27) hours.
In this study, mean (SD) terminal half-life was 74 (SD 27) hours.
In this study, levetiracetam dose was 3000 mg/ day for adults and adolescents or 60 mg/ kg/ day for children, given in 2 divided doses.
In this study the median PFS for the sunitinib-treated group was 47.3 weeks compared with 22.0 weeks for the IFN-α -treated group; the hazard ratio was 0.415 (95% CI:
In this study, levetiracetam, dose was 3000 mg/ day given in 2 divided doses.
In this study losartan was generally well tolerated, as shown by a therapy discontinuation rate on account of adverse events that was comparable to the placebo group.
In this study, the main measure of effectiveness was the amount of uric acid in the blood, measured over 96 hours.
Its main measure of effectiveness was the proportion of patients who had had a ‘ major cytogenetic response'(the proportion of the patient's white blood cells that contained the Philadelphia chromosome had fallen to below 35%).
In this study, the multiple dose pharmacokinetic disposition of nevirapine and the five oxidative metabolites were not altered.
10 this study the age range of patients was 65-75 years, with 41% (183/ 447) of patients 70 years old or older.
The general wording on absence of interactions should not be included.
In this study, the patients'condition at the accident scene was compared with that at the end of the infusion of Cyanokit and over the following three days.
32 In this study the ORR was 35,8% (95% C. I.
In this study the ORR was 35,8% (95% C. I.
(62/ 1,021) with dalteparin: odds ratio reduction [95%CI] = -25.8% [-49.7%, 9.5%].
(62/ 1021) with dalteparin: odds ratio reduction [95%CI] = -25.8% [-49.7%, 9.5%].
In this trial, only serious adverse events and discontinuations due to any adverse events were recorded.
In this leaflet the patient is addressed as ‘ you’.
please tell your doctor or pharmacist.
please tell your doctor or pharmacist.
tell you doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist. no
please tell your doctor or pharmacist.
please tell your doctor or pharmacist.
tell your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist. no
please tell your doctor or radiologist.
In this initial phase, the Veterinary Medicines Unit has been used as a pilot study with specific and measurable management targets.
In this patient population, the oral suspension should be taken without food and on an empty stomach.
Treatment in this patient population is therefore recommended only in men who are able or willing to follow the daily foreskin hygiene routine.
Risk factors that may predispose this patient population to increased mortality include age > 65 years, dysphagia, sedation, malnutrition and dehydration, pulmonary conditions (e. g., pneumonia, with or without aspiration), or concomitant use of benzodiazepines.
Risk factors that may predispose this patient population to increased mortality include age > 65 years, dysphagia, sedation, malnutrition and dehydration, pulmonary conditions (e. g., pneumonia, with or without aspiration), or concomitant use of benzodiazepines.
Risk factors that may predispose this patient population to increased mortality include age > 65 years, dysphagia, sedation, malnutrition and dehydration, pulmonary conditions (e. g., pneumonia, with or without aspiration), or concomitant use of benzodiazepines.
Hypotension, thrombophlebitis, phlebitis Lymphangitis
Successful outcome in this section is defined as complete or partial response.
Symptoms appeared immediately upon initiating the infusion (see also section 4.4).
Instead, regular insulin administered intravenously is recommended in such cases.
When bivalirudin is combined with a platelet inhibitor or an anti-coagulant medicine, clinical and biological parameters of haemostatsis should be regularly monitored.
Close surveillance with regard to immunological reactions is especially important in such situations.
In each trial, the daily dose was divided into two equal doses.
In each study, treatment with clomipramine was combined with behaviour modification techniques.
In CIMZIA, certolizumab has been ‘ pegylated'(attached to a chemical called polyethylene glycol).
In other cases, Prometax has been discontinued (see section 4.8).
In these cases, GONAL-f is started approximately 2 weeks after the start of agonist treatment, both being continued until adequate follicular development is achieved.
In other cases, increased monitoring and/or a change in the dose of the medicine may be needed.
In other circumstances, additional leukaphereses may be necessary.
In other studies, in which a daily foreskin hygiene routine was not followed, there were two cases of severe phimosis and one case of stricture leading to circumcision.
medicines called Kivexa and Trizivir.
Many may feel quite normal.
Rarely abnormal blood clots in veins have been seen to occur with similar medicines, so this could possibly occur with Luveris / FSH / hCG therapy.
In rare cases you may produce antibodies against the active substances of TachoSil.
In rare cases, patients have reported the following: gastroenteritis, oral thrush, vaginitis, benign skin growth, sleep disturbance, anxiety, affect lability, memory loss, numbness round the mouth (paraesthesia circumoral), hyperaesthesia, hypertonia, nerve root lesion, neuralgia, migraine, cerebrovascular disorder, parosmia, deafness, heart and circulatory problems (including palpitations, myocardial ischaemia, hypertension, varicose veins), lymphoedema, lung oedema, stridor, gastritis,
Tumour-associated haemorrhage was also seen rarely in other tumour types and locations, including a case of central nervous system (CNS) bleeding in a patient with hepatoma with occult CNS metastases (see section 4.3) and another patient who developed continuous oozing of blood from a thigh sarcoma with necrosis.
In extremely rare cases, paralysis, neuropathy, Guillain-Barré syndrome, encephalopathy, encephalitis and meningitis have been reported.
In extremely rare cases, paralysis, neuropathy, Guillain-Barré syndrome, encephalopathy, encephalitis and meningitis have been reported.
There is insufficient data on the diagnostic reliability of the Helicobacter Test INFAI for children of the age 3-11 for recommending its use in patients with gastrectomy.
In very rare cases, if necessary, a blood transfusion could be given.
Under normal circumstances, growth hormone (GH) binds to its receptor in the liver and other tissues, and stimulates the synthesis/ secretion of IGF-1.
Under similar conditions, bexarotene concentrations were not affected by concomitant administration of atorvastatin or levothyroxine.
In clinical trials (in which a total of 1361 patients were taking Circadin and 1247 patients were taking placebo), 37.0% of patients receiving Circadin reported an adverse reaction compared with 31.8% taking placebo.
In clinical trials, cases of colitis (including intestinal and rectal bleeding, sometimes fatal, intestinal perforation, intestinal necrosis and typhlitis) have been reported uncommonly in patients treated with pemetrexed.
In clinical trials among children and adolescents treated with other antidepressants, suicide-related behaviour (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed compared to those treated with placebo.
In trials with 5 times per week dosing 58% of patients experienced at least one adverse event.
In clinical trials involving 813 patients, the average prolongation was around 3%, and 1.2% of patients developed Q-Tc intervals greater than 500 msec (prolongation of 100 msecs in 0.3%), but with no arrhythmic effects.
In a rat pre- and postnatal development study, the no observed effect
In a rat pre- and postnatal development study, the no observed effect dose was 30 mg/ kg/ day.
In reproductive and developmental toxicity studies, reduced birth weight of the pups was noted.
In in vitro studies, enfuvirtide was not displaced from its binding sites by other medicinal products, nor did enfuvirtide displace other medicinal products from their binding sites.
In peri and post natal studies in rats, dystocia, increased foetal deaths in utero, and toxicity to post natal development (pup body weight and development land marks) were observed at systemic exposure levels up to 11 times higher than the expected clinical exposure.
In additional studies using non-selective NSAID comparators, approximately 7400 arthritis patients have been treated with celecoxib at daily doses up to 800 mg, including approximately 2300 patients treated for 1 year or longer.
Such situations may result in severe hypoglycaemia (and possibly loss of consciousness) prior to the patient's awareness of hypoglycaemia.
In very rare cases following administration of Profender transient alopecia, pruritus and/ or inflammation were observed at the application site.
In very rare cases following administration of Profender transient alopecia, pruritus and/or inflammation were observed at the application site.
In very rare cases, allergic reactions, some severe, sometimes with difficulty in breathing, have been reported and may require immediate medical care.
In very rare cases depression may develop.
In very rare cases they may be serious or fatal.
In very rare cases development of alopecia has also been observed.
In very rare cases the product may cause skin sensitisation or transient skin reactions (for example allergy, irritation or tingling).
In very rare cases the product may cause skin sensitisation or transient skin reactions (for example allergy, irritation or tingling).
In very rare cases an abscess and discharge may develop at the injection site, and the lymph nodes in the head may enlarge, which may be painful for a short while.
In very rare cases an abscess may develop at the injection site or in the regional lymph nodes.
In 2 studies in healthy subjects the median times to the peak plasma concentrations were 1 and 3 hours after dosing.
In two insulin- comparator controlled trials (n=475) comparable efficacy and adverse events were observed in BYETTA-treated patients regardless of antibody titre.
In two rat carcinogenicity studies, lansoprazole produced dose-related gastric ECL cell hyperplasia and ECL cell carcinoids associated with hypergastrinaemia due to inhibition of acid secretion.
In two long-term follow-up studies the effect of Copalia was maintained for over one year.
In two long-term follow-up studies the effect of Dafiro was maintained for over one year.
In two long-term follow-up studies the effect of Exforge was maintained for over one year.
In two long-term follow-up studies the effect of Imprida was maintained for over one year.
In two studies, Evra was compared with combined oral contraceptives: in one study, the comparator was a ‘ monophasic'contraceptive (pills containing constant amounts of the active substances over the first three weeks of the treatment cycle) and in the other study, they were ‘ triphasic'(with the amount of the active substances in the pills varying through the treatment cycle).
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
At A-grade level the balance was 56 percent woman and 44 percent men and at B-grade women represented 47 percent and men 53 percent of staff.
Intracellularly, cytarabine is converted into cytarabine-5'-triphosphate (ara-CTP), which is the active metabolite.
In acromegaly, this overproduction causes overgrowth of bone, swelling of soft tissue (such as the hands and feet), heart disease and other disorders.
Protopy alters the abnormal immune response and relieves the skin ct
In the offspring of pregnant rats treated with varenicline there were decreases in fertility and increases in the auditory startle response (see section 4.6).
The values in the second study were 96 and 78%, respectively.
In diplegia, the initial recommended total dose is 6 U/ kg body weight divided between the affected limbs.
Acute chest syndrome is a frequent life-threatening complication of Sickle Cell Syndrome and is characterized by chest pain or fever or dyspnoea with recent infiltrate on chest X-ray.
The extent of serum protein binding is independent of drug concentration over the test range of 0.1– 10 µg Starlix/ ml.
In most cases no specific treatment was required and the symptoms subsided after a couple of hours/ days.
It is recommended that dose adjustment of the benzodiazepine be considered during coadministration.
Successful response was seen in 24 patients (15 complete, 9 partial responses).
If possible, appropriate visual field testing (perimetry) by using a standardized static perimetry (Humphrey or Octopus) or kinetic perimetry (Goldmann) must be performed before treatment initiation and at six month intervals.
Since no studies were performed in clinically lame birds, Dicural oral solution should not be used in birds with existing leg-weakness or in birds suffering from osteoporosis.
Since no studies were performed in clinically lame birds, Dicural should not be used in birds with existing leg-weakness or in birds suffering from osteoporosis.
Since mitotane increases plasma levels of steroid binding proteins, free cortisol and corticotropin (ACTH) determinations are necessary for optimal dosing of steroid substitution (see section 4.8).
Since dasatinib is mainly metabolised through the liver, exposure to dasatinib is expected to increase if liver function is impaired.
- OPTISON should be withdrawn with care into a syringe within 1 minute after resuspension.
- OPTISON should be withdrawn with care into the syringe within 1 minute after resuspension.
In the combined study analysis at 24 weeks, the difference in the mean frequency of total satisfying episodes between Livensa and placebo was 1.07 per 4 weeks.
The estimated time to first emesis in the combined analysis is depicted by the Kaplan-Meier plot in Figure 1.
In the pooled safety analysis, there was no clear dose-response relationship but incidence and severity of the central nervous system related undesirable effects decreased over time.
In the analysis of responder rates (the non-completer equals failure analysis [NC = F]), patients who terminated the study early for any reason, or who had a missing HIV-RNA measurement that was
In HAE increased bradykinin concentrations are the key mediator in the development of the clinical symptoms.
In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including
In the open-label extension of Studies I, II, and III durable and sustained ACR 20, 50, and 70 responses have been observed through 48, 24, and 18 months, respectively, of abatacept treatment.
In most cases no specific treatment is required and the symptoms subside after a couple of hours or days.
In most cases no specific treatment is required and the symptoms subside after a couple of hours or days.
In most of the cases, these side effects are mild and do not last very long.
In most cases, adding betaine resulted in a further reduction in plasma homocysteine level.
In most cases, kidney impairment and kidney failure were reversible.
In most cases, the effect on your hearts function will not have any symptoms.
In most cases, the pain disappeared while patients continued taking Ferriprox.
In most cases, a 10-day treatment course will be sufficient.
In most cases, a 10 day-treatment course will be sufficient.
In most cases, a 10-day treatment course will be sufficient.
In most cases you will need a doctor.
In most cases you will need a doctor.
In most cases you will need a doctor.
In most studies, the main measure of effectiveness was the level of viral RNA circulating in the blood before and after 24 or 48 weeks of treatment, and at follow up (24 weeks later).
In rheumatoid arthritis, the B-cells are destroyed in the joints, helping to reduce inflammation.
161 In rheumatoid arthritis, methotrexate is continued while using Humira.
In rheumatoid arthritis, methotrexate is continued while using Humira.
In rheumatoid arthritis, your body produces too much of a cytokine called interleukin-1.
The patient population included 19.7% women and 29.2% patients ≥ 65 years.
The population included 27.8% women, 58.4% patients ≥ 60 years (26% ≥ 70 years) and 54.5% patients who received fibrinolytics.
In the ITT population the corresponding reduction was 23.9% (95% CI:
In the overall patient population of the study MF4411, no reduction was observed for non-vertebral fractures, however daily ibandronate appeared to be effective in a high-risk subpopulation (femoral neck BMD T-score < -3.0), where a non-vertebral fracture risk reduction of 69% was observed.
In the first and third studies, fewer patients taking Pelzont reported moderate, severe or extreme flushing than patients taking nicotinic acid alone.
In the first and third studies, fewer patients taking Trevaclyn reported moderate, severe or extreme flushing than patients taking nicotinic acid alone.
In the first short-term study, patients taking placebo had an average fall in their symptom score of 4.1 points, compared with an average fall of between 17.9 and 23.3 points in those taking Invega and of 19.9 in those taking olanzapine.
In the first kidney disease study, Karvea was more effective than placebo at reducing the risk of developing kidney damage as measured by protein excretion.
In the first study, Flebogammadif was used as replacement therapy in 46 patients with PID, with the medicine being infused every 21 to 28 days.
In the first study, adding Comtan increased the ‘ on'time by 1 hour and 18 minutes more than adding placebo.
In the first study, adding Comtess increased the ‘ on'time by 1 hour and 18 minutes more than adding placebo.
In the first study, a daily dose of 9 g reduced the number of cataplexy attacks by 16.1 (from 23.5 to 8.7) per week, compared to a fall of 4.3 per week in the patients taking placebo.
The first study enrolled patients who were clinically resistant to type A toxin (A-non responders), confirmed by a Frontalis Type A test.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
In the first study, the patients had an average of 0.08 serious infections per year.
In the first study, patients taking Tracleer had an average of 1.4 new digital ulcers after 16 weeks, compared with 2.7 in the patients taking placebo.
In the first study, Privigen was used as replacement therapy in 80 patients with PID, with the medicine being infused every three or four weeks.
In the first study, Viracept in combination with stavudine (another antiviral medicine) was compared with stavudine alone in 308 patients who had not taken stavudine or a protease inhibitor in the past.
In the prevention of VTEs, the recommended dose of Arixtra is 2.5 mg once a day by subcutaneous injection (under the skin).
In the second study (16 weeks) where acetylsalicylic acid was allowed, patients taking Pelzont experienced significantly fewer days per week with moderate or greater flushing compared to nicotinic acid (prolonged-release formulation taken as a 12-week multi-step 500 mg to 2000 mg titration) (p < 0.001).
In the second study (16 weeks) where acetylsalicylic acid was allowed, patients taking Tredaptive experienced significantly fewer days per week with moderate or greater flushing compared to nicotinic acid (prolonged-release formulation taken as a 12-week multi-step 500 mg to 2000 mg titration) (p < 0.001).
In the second study (16 weeks) where acetylsalicylic acid was allowed, patients taking Trevaclyn experienced significantly fewer days per week with moderate or greater flushing compared to nicotinic acid (prolonged-release formulation taken as a 12-week multi-step 500 mg to 2000 mg titration) (p < 0.001).
In the second study, 186 neonates with respiratory failure received either INOmax or placebo.
In the second main study, 30 (31%) of the neonates receiving INOmax needed ECMO, compared with 51 (57%) of the 89 receiving placebo.
In the second study, 52% of the patients receiving Relistor opened their bowels at least twice within four hours of the first four doses (32 out of 62), compared with 8% of those receiving placebo (6 out of 71).
In the second clinical study (IMPACT 2), efficacy and safety of infliximab were studied in 200 patients with active psoriatic arthritis (≥ 5 swollen joints and ≥ 5 tender joints).
In the second study, the ‘ on'time was increased by 35 minutes compared with placebo.
The second study compared the combination of Pelzont and simvastatin (a statin) with Pelzont alone or simvastatin alone in 1,398 patients.
The second study compared the combination of Tredaptive and simvastatin (a statin) with Tredaptive alone or simvastatin alone in 1,398 patients.
The second study compared the combination of Trevaclyn and simvastatin (a statin) with Trevaclyn alone or simvastatin alone in 1,398 patients.
The pharmacokinetic parameters in the second study were comparable.
The second study enrolled patients who continued to respond to type A toxin (A-responders).
In the second study, pain intensity had fallen by 9.7 points at 60 minutes after Effentora and by 4.9 points after placebo.
In the first study, type A resistant patients (A-non responders) were randomised to receive placebo or 10,000 U of NeuroBloc and in the second, type A toxin responsive patients (A-responders) were randomised to receive placebo, 5000 U or 10,000 U of toxin.
In the week following discontinuation of treatment the adverse reactions noted were: insomnia, increased fatigue, a trace of foot oedema, fine tremor, and weight gain.
In MS, your body's defence system reacts against it's own myelin – the ‘ insulation 'that surrounds nerve fibres.
In MS, your body’s defence system reacts against it’s own myelin – the ‘insulation'that surrounds nerve fibres.
In invasive aspergillosis, a successful response at the end of treatment was seen in 42% of the patients taking Posaconazole SP, compared with 26% of the comparison group.
In the other study, the increases were 7.1 cm for OPTISON and 3.1 cm for the reference medicine.
10 In Arm A of the ACUITY trial, UFH or enoxaparin was administered in accordance with the relevant guidelines for the management of ACS in patients with UA and NSTEMI.
50 percent) were charged against the new orphan drug fund earmarked by the Board.
To minimise the potential for inhalation, it is recommended that the product is applied in open air or in well ventilated rooms.
⋅ ICH Quality Guidelines related to stability, analytical validation and impurities:
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The study did not compare Evoltra with any other treatment.
In the first main study, which involved babies less than six months old, all 18 patients treated with Myozyme were alive at 18 months of age, and 15 of these did not need ventilation.
During post– marketing surveillance, cases of interference between daptomycin and particular reagents used in some assays of Prothrombin Time/ International Normalised Ratio (PT/ INR) have been reported.
Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.
In a thorough QT study, rufinamide produced a decrease in QTc interval proportional to concentration.
In a thorough QT study, rufinamide produced a decrease in QTc interval proportional to concentration.
In a study on pre- and postnatal development the survival rate of offspring was significantly reduced at doses which slightly reduced maternal weight.
Within the framework of the quality management system (QMS), five groups looked at performance measurement, Agency's partnership with interested parties, product information management, staff performance evaluation issues and the development of an electronic ‘ quality manual’.
During prophylaxis, concomitant use of medicinal products containing heparins (unfractionated and low-molecular weight heparins) and dextrans is not recommended.
Otherwise treatment must be delayed for up to 3 weeks until the criteria are met.
Otherwise treatment should be re-initiated with 4.6 mg/ 24 h.
For minor cuts and injuries e.g., cutting yourself, shaving, this is usually of no concern.
For minor cuts and injuries e.g., cutting yourself, shaving, this is usually of no concern.
For older or overweight patients lower doses may be necessary.
In the case of the following haemorrhagic events, the factor IX activity should not fall below the given plasma activity level (in% of normal or IU/ dl) in the corresponding period.
For cattle intended for consumption as either meat or offal, 49 days must be allowed before slaughter.
When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients.
For MD/ MPD (31 patients), HES and CEL (176 patients), GIST (147 patients) and DFSP (18 patients), the effects of Glivec were not compared to any other medicine.
In the case of overdosage discontinue therapy.
In type 1 diabetes, Exubera was compared to subcutaneous (injected) insulin.
In type 2 diabetes, Exubera was compared to subcutaneous insulin, and to oral anti-diabetes medicines.
Therefore, in case of an inadvertent administration of Ytracis, the radiotoxicity for the patient must be reduced by immediate (i. e. within 1 hour) administration of preparations containing chelators like Ca-DTPA or Ca- EDTA in order to increase the elimination of the radionuclide from the body.
Therefore, in case of an inadvertent administration of Yttriga, the radiotoxicity for the patient must be reduced by immediate (i. e. within 1 hour) administration of preparations containing chelators like Ca- DTPA or Ca-EDTA in order to increase the elimination of the radionuclide from the body.
In the case of subcutaneous administration, the weekly dose can be given as one injection per week or in divided doses three or seven times per week.
In case of a recent exposure to the hepatitis B virus, a first dose of HBVAXPRO together with the appropriate dose of immunoglobulin can be given.
Lameness was also observed when the hind leg was used as the injection site.
In the case of a severe allergic reaction (anaphylactic shock), immediately stop the administration of the product and contact your doctor immediately.
Re-treatment may be associated with lower or inadequate response to Raptiva than in the earlier treatment periods.
31 In case of acute thrombosis CEPROTIN may be administered to you every 6 hours.
In case of acute thrombosis CEPROTIN may be administered to you every 6 hours.
In case of suspected or confirmed thrombosis, hormonal contraceptive use should be discontinued.
In the case of suspected overdose the patient should be monitored.
In the case of overdose, appropriate monitoring and management of the patient should be implemented.
In the case of Ytracis, the product is used to label medicines that have been specially developed for use with the active ingredient yttrium (90Y) chloride.
Ideally Cetrotide 0.25 mg should be administered at 24 hours intervals.
In the most extreme case of overdose, the patient survived the oral intake of a total of 2000 mg memantine with effects on the central nervous system (coma for 10 days, and later diplopia and agitation).
In the most extreme case of overdose, the patient survived the oral intake of a total of 2000 mg memantine with effects on the central nervous system (coma for 10 days, and later diplopia and agitation).
In the most extreme case of overdose, the patient survived the oral intake of a total of 2000 mg memantine with effects on the central nervous system (coma for 10 days, and later diplopia and agitation).
In the case of the following haemorrhagic events, the factor VIII activity should not fall below the given plasma levels (in% of normal or in IU/ dl) in the corresponding period.
In the event that further dose reductions are necessary, treatment discontinuation should be considered.
In case the AT activity level is greater than 120% decrease the infusion rate by 30%.
If concomitant use of Atripla and nephrotoxic agents (e. g. aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir, interleukin-2) is unavoidable, renal function must be monitored weekly (see section 4.5).
In case an oral measuring syringe is provided with the bottle of syrup, you can alternatively use it to take the appropriate amount of syrup.
In case an oral measuring syringe is provided with the bottle of oral solution, you can alternatively use it to take the appropriate amount of oral solution.
HMG-CoA reductase inhibitors: if treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended because their metabolism is not dependent on CYP3A4 and interactions are not expected with protease inhibitors.
In the brain, GABA is involved in bringing about sleep.
In the brain, it attaches to several different receptors on the surface of nerve cells.
In the setting of central nervous system (CNS) inflammation in MS, it is the interaction of α 4β 1 with VCAM-1, CS-1 and osteopontin that mediates the firm adhesion and transmigration of leukocytes into the brain parenchyma and may perpetuate the inflammatory cascade in CNS tissue.
Within the VICH process, the EU will propose a concept paper to harmonise residue metabolism testing for veterinary medicines intended for use in food-producing animals.
Pioglitazone, the active ingredient in Actos, makes the cells more sensitive to
In the field of transparency, the Agency will build on the achievements of previous years, and will concentrate its efforts in three areas:
Where uncertainty exists, it is important that radiation exposure should be the minimum consistent with achieving the desired clinical information.
In Diractin gel, the ketoprofen is contained in special, small, fatty particles (called ‘ Transfersomes’) that are expected to carry the ketoprofen through the skin and release it deep below the skin, where the inflammation in osteoarthritis occurs.
In the 40 mg/ kg/ day group, pegaptanib concentrations in the amniotic fluid were 0.05% of the maternal plasma levels.
In the once weekly group, 75% of patients required dose reductions.
In the once weekly group, 75% of patients required dose reductions.
In the once every three weeks group, 72% of patients required dose reductions.
In the alteplase group 33.0% were fatal and 39.8% were disabling.
The percentage in the patients who had taken bupropion was 16%.
ra The incidence of all cause mortality at Day 30 was also significantly reduced from 8.9% for the control group to 7.8% in the fondaparinux group (hazard ratio 0.87, 95% CI, 0.77; 0.98, p = 0.02).
In the iloprost group, the median daily inhaled dose was 30 micrograms (range 12.5 to 45 micrograms/ day).
In the infliximab group, the mean change in total modified vdH-S score remained below 0 at the week 54 timepoint.
A significantly higher percentage of patients in the NEVANAC group reported no ocular pain following cataract surgery compared to those in the placebo group.
In the PDT + OM group, 133 patients were treated.
In the fixed dose group of 2.5 micrograms per inhalation chest pain, or chest discomfort (32.5%), pharyngolaryngeal pain, or throat irritation (22.5%) and nausea (7.5%) – (all non-serious and mild in intensity) – occurred more frequently in comparison with the adverse events obtained from the placebo controlled phase II and III studies in patients with doses of 2.5 micrograms or 5 micrograms per inhalation.
In the placebo treatment group 128 infusion- related reactions were reported in 21 out of 32 patients following administration of a total of 1612 infusions.
In the Tarceva plus gemcitabine arm, Grade 3/4 rash and diarrhoea were each reported in 5% of patients.
In the oseltamivir treated group, the median duration of illness was not reduced significantly.
In the oseltamivir treated group, the median duration of illness was not reduced significantly.
At the same time the EMEA is actively seeking, in liaison with the Financial Controller of the Commission and the other EU Agencies, a software solution for general ledger, analytical and cost accounting which satisfies both the needs of the EMEA and at the same time is acceptable to Financial Control.
In the pig model of allergic contact dermatitis, topical pimecrolimus is as effective as potent corticosteroids.
In myeloma, bortezomib affects the ability of myeloma cells to interact with the bone marrow microenvironment.
In all five studies, the main measure of effectiveness was the number of patients who had responded to treatment after six months.
In all of the studies, the main measure of effectiveness was the number of patients who had undetectable levels of HIV-1 in their blood (viral loads) after 24 or 48 weeks of treatment.
In human plasma, A771726 is extensively bound to protein (albumin).
In plasma, the relative exposures of the S- and R- enantiomers of lenalidomide are approximately 56% and 44%, respectively.
In the pooled MEDAL Program, 34,701 patients with OA or RA were treated for a mean duration of 17.9 months (maximum 42.3 months, median 16.3 months) with approximately 12,800 patients receiving treatment for more than 24 months.
In the SPS, the reduction in zoster was seen in almost all dermatomes.
In normal kidneys, antibodies are not excreted and are excluded from filtration by their size.
In both arms, quality of life measured by the EORTC questionnaire was comparable and stable during treatment and follow-up.
In the two studies in patients with digital ulcers the incidence of elevated liver aminotransferases (> 3 × ULN) was 11.3% in bosentan-treated patients (N = 168) compared with 0.8% in placebo-treated patients (N = 1 29).
In the two studies in patients with digital ulcers the incidence of elevated liver aminotransferases (> 3 × ULN) was 11.3% in bosentan-treated patients (N = 168) compared with 0.8% in placebo-treated patients (N = 129).
In both studies, a total of 67% patient viruses were resistant and 22% were possibly resistant to the pre-selected comparator PIs.
each of the first two injections.
Within the 42-day postvaccination reporting period in the SPS, the number of reported zosteriform rashes among all subjects was small (17 for ZOSTAVAX, 36 for placebo; p=0.009).
ratios for overall survival ranged between 1.25 and 2.47 in favour of controls.
123 Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached, At the request of the EMEA.
• When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached At the request of the EMEA.
- Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being
Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached.
Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached
- within 60 days of an important (pharmacovigilance or risk minimisation) milestone being
- Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached
- Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being
28  When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities  Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached  At the request of the EMEA
• Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached
- Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being
- Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being
In other circumstances, additional leukaphereses are recommended.
For candidiasis, Posaconazole SP is given as 200 mg (5 ml) on the first day followed by 100 mg (2.5 ml) once a day for the following 13 days.
In T-ALL the abnormal cells are mainly in the blood and bone marrow, and in T-LBL they are mainly in the lymphatic system (lymph nodes or thymus gland).
In invasive aspergillosis, 41% of the adults had a favourable response at the end of the study (26 out of 63).
In the overdose cases below 140 mg or unknown dose the patients revealed symptoms from central nervous system (confusion, drowsiness, somnolence, vertigo, agitation, aggression, hallucination, and gait disturbance) and/ or of gastrointestinal origin (vomiting and diarrhoea)
In major depressive disorder, patients have disturbances of mood that interfere with their everyday life.
In severe cases, these effects may interfere with certain daily activities, and may last for 4 weeks or longer before resolving completely.
In severe cases, deficiency results in secondary hyperparathyroidism, hypophosphataemia, proximal muscle weakness and osteomalacia, further increasing the risk of falls and fractures in osteoporotic individuals.
In all five studies, the main measure of effectiveness was the number of patients who responded to treatment.
In all five studies, the main measure of effectiveness was the change in symptoms after 6 months to a year of treatment.
Under normal physiologic conditions, full-length parathyroid hormone (1-84) constitutes only 5-30% of the circulating forms of the molecule, while 70-95% is present as carboxy-terminal fragments.
In the other two studies, around 34% of the patients responded partially or completely to treatment with Velcade.
In the other two studies, including a total of 256 patients, Velcade was not compared with any other treatments.
In the other two studies, the medicines were used as an add-on to existing treatment including methotrexate: one study, which involved 419 patients, used a range of doses of Kineret that depended on the patient's weight, and the other study, which involved 501 patients, used Kineret at a fixed dose of 100 mg once a day.
In both cases, the overdose occurred during the first induction dose and no additional cidofovir therapy was administered.
In both cases if a decision is made to restart abacavir this must be done in a setting where medical assistance is readily available.
In both cases, if a decision is made to restart abacavir this must be done in a setting where medical assistance is readily available.
In both cases if a decision is made to restart Trizivir this must be done in a setting where medical assistance is readily available.
In both cases, if a decision is made to restart Ziagen this must be done in a setting where medical assistance is readily available.
The second dose in both cases is given between one and three months after the first one.
Celecoxib has been shown to cause malformations in the two animal species studied (See 4.6 and 5.3).
In both trials, the primary endpoint was progression-free survival (PFS) defined by MRI scans or neurological worsening.
In both trials, treatment with Thelin resulted in a significant increase in exercise capacity.
In both studies, CHAMPIX was more effective than bupropion or placebo in helping patients to stop smoking.
92 In two clinical studies (study B2222 and an intergroup study S0033) the daily dose of Glivec was escalated to 800 mg in patients progressing at the lower daily doses of 400 mg or 600 mg.
In the two studies taken together, 55% of the patients receiving Relistor opened their bowels within four hours after first injection (91 out of 165), compared with 15% of the patients receiving placebo (18 out of 123).
11 In both prophylaxis studies, aspergillosis was the most common breakthrough infection.
In both studies, adding either Azopt or timolol caused a further decrease in eye pressure of around 3.5 mmHg after 12 weeks.
In both studies the primary measure of efficacy was the change from baseline to treatment period in the mean number of hours that were spent in the “ OFF” state during the day (determined from “ 24-hour ” home diaries completed for 3 days prior to each of the assessment visits).
In both studies, the primary efficacy endpoint was the proportion of patients who maintained vision, defined as losing fewer than 15 letters of visual acuity at 12 months compared with baseline.
In both studies, efficacy was determined by an increase in the proportion of patients who achieved a durable
In both studies, the main measure of effectiveness was the number of patients who formed blood clots in the veins or who died of any cause during the treatment period.
In both studies, the main measure of effectiveness was the time taken for the disease to get worse.
In both studies, patients also received other medicines to prevent blood clotting.
In both studies of the solution for injection, patients receiving Abilify at doses of 5.25, 9.75 or 15 mg had a significantly greater reduction in symptoms of agitation than those receiving placebo.
In both groups, 73% of patients experienced no seizures for six months once on an adequate dose.
In both groups, trastuzumab treatment was continued for a year.
The interactions for the first two sections are presented in the following order: contraindications, those requiring dosage adjustment and careful clinical and/ or biological monitoring and finally those that have no significant pharmacokinetic interaction but may be of clinical interest in this therapeutic field.
In the case of the haemorrhagic events listed, the factor VIII activity should not fall below the given level (in% of normal) in the corresponding period:
In the case of the haemorrhagic events listed, the factor VIII activity should not fall below the given level (in% of normal) in the corresponding period:
Based upon combined data from REST and the FES, the reduction up to 3 years post-vaccination in the rate of hospitalisations and emergency department visits for RV gastroenteritis was 94.4% (95% CI:
52 In the twelve controlled trials, 16% of patients treated with Trudexa developed injection site reactions (erythema and/ or itching, haemorrhage, pain or swelling), compared to 10% of patients receiving placebo or active control.
10 In the twelve controlled trials, 16% of patients treated with Trudexa developed injection site reactions (erythema and/ or itching, haemorrhage, pain or swelling), compared to 10% of patients receiving placebo or active control.
31 In the twelve controlled trials, 16% of patients treated with Trudexa developed injection site reactions (erythema and/ or itching, haemorrhage, pain or swelling), compared to 10% of patients receiving placebo or active control.
In the twelve controlled trials, 16% of patients treated with Trudexa developed injection site reactions (erythema and/ or itching, haemorrhage, pain or swelling), compared to 10% of patients receiving
In controlled clinical trials with the combination of vildagliptin 100 mg daily plus metformin, no withdrawal due to adverse reactions was reported in ei ther the vildagliptin 100 mg daily plus metformin or the placebo plus metformin treatment groups.
In controlled clinical trials with the combination of vildagliptin 100 mg daily plus metformin, no withdrawal due to adverse reactions was reported in either the vildagliptin 100 mg daily plus metformin or the placebo plus metformin treatment groups.
patient-years of study drug exposure was 0.130 (5 cases over 3800 patient-years) for Exubera-treated patients and 0.03 (1 case over 3900 patient-years) for comparator-treated patients.
In controlled clinical studies, use of NeoRecormon and other erythropoiesis-stimulating agents (ESAs) have shown:
Adverse events that may suggest increase in prolactin levels (e. g., amenorrhoea, galactorrhoea, gynaecomastia) were reported overall in 2% of subjects.
In clinical trials, adverse events seen on treatment discontinuation (tapering and post-tapering) occurred in approximately 35% of patients treated with venlafaxine and 17% of patients taking placebo.
In clinical trials, there was no difference observed between placebo and the 3 and 6 mg doses of INVEGA.
In the clinical program, there were nine cases of accidental extravasation of Myocet, none of which were associated with severe skin damage, ulceration or necrosis.
In clinical trials the effect on QTc was small (mean of approximately 1 msec).
In clinical trials, treated animals rapidly regained weight following cessation of treatment when diet was not restricted.
In clinical trials adverse events seen on treatment discontinuation occurred in approximately 60% of patients in both the fluoxetine and placebo groups.
In clinical trials, the effective dosing range was 900 to 3600 mg/ day.
In clinical trials with AMMONAPS, 56% of the patients experienced at least one adverse event and 78% of these adverse events were considered as not related to AMMONAPS.
In clinical trials (n=1,968), rash (all grades, at least possibly related) occurred in 5.6% of patients treated with PREZISTA.
In clinical trials, a treatment time of 2-3 months with Clomicalm in combination with behavioural modification techniques was sufficient to control the symptoms of separation-related disorders.
In the prevention population discontinuations of therapy due to any adverse reaction occurred in 10.7% of 581 EVISTA treated patients and 11.1% of 584 placebo-treated patients.
In the prevention population discontinuations of therapy due to any adverse reaction occurred in 10.7% of 581 OPTRUMA treated patients and 11.1% of 584 placebo-treated patients.
In osteoporosis treatment and prevention studies involving over 13,000 postmenopausal women all adverse reactions were recorded.
In osteoporosis treatment and prevention studies involving over 13,000 postmenopausal women all adverse reactionswere recorded.
In the treatment population discontinuations of therapy due to any clinical adverse event occurred in 12.8% of 2,557 EVISTA treated patients and 11.1% of 2,576 placebo treated patients.
In the treatment population discontinuations of therapy due to any clinical adverse event occurred in 12.8% of 2,557 OPTRUMA treated patients and 11.1% of 2,576 placebo treated patients.
In patients not given
In the pivotal trials, anti-adalimumab antibodies were identified in 58/ 1053 (5.5%) patients treated with adalimumab, compared to 2/ 370 (0.5%) on placebo.
In studies 700- 012, 700-014, 700-999 and study 13970-301 the time to complete response ranged from 4 to 12 weeks.
In fixed dose studies, the proportions of patients reporting that treatment improved their erections were 62% (25 mg), 74% (50 mg) and 82% (100 mg) compared to 25% on placebo.
In the fixed-dose studies, the proportions of patients reporting that treatment improved their erections were 62% (25 mg), 74% (50 mg) and 82% (100 mg), compared with 25% on placebo.
In animal models using lean growing and obese rats, sibutramine produces a reduction in bodyweight gain.
In clinical trials, 88% of patients experienced adverse drug reactions (ADRs).
In clinical studies at a dose of 250 micrograms (total 633 patients) the most frequently observed adverse reactions, at least possibly related to Aloxi, were headache (9%) and constipation (5%).
In clinical studies no patients developed antibodies to thyrotropin alfa.
In controlled clinical studies, the incidence of clinically important elevations in serum transaminases (ALT and/ or AST ≥ 3 X ULN, consecutive) was 1.0% for patients treated with Pelzont with or without a statin.
In controlled clinical studies, the incidence of clinically important elevations in serum transaminases (ALT and/ or AST ≥ 3 X ULN, consecutive) was 1.0% for patients treated with Tredaptive with or without a statin.
In controlled clinical studies, the incidence of clinically important elevations in serum transaminases (ALT and/ or AST ≥ 3 X ULN, consecutive) was 1.0% for patients treated with Trevaclyn with or without a statin.
In Phase 3 clinical studies, infection-related serious adverse events were more frequently reported for subjects treated with tigecycline (6.7%) vs comparators (4.6%).
In clinical studies, infections have been reported more frequently in paediatric patient populations than in adult patient populations (see section 4.8).
In clinical studies approximately 5% of subjects receiving abacavir develop a hypersensitivity reaction.
In clinical studies employing planar imaging techniques, QUADRAMET accumulates with a lesion- to-normal bone ratio of approximately 5 and a lesion-to-soft tissue ratio of approximately 6.
In paediatric clinical trials, fluoxetine treatment was associated with a decrease in alkaline phosphatase levels.
The maximum intended intrathecal dose of ziconotide in clinical trials was 912 μ g/ day following upward titration over 7 days.
58 In clinical trials in which pioglitazone was compared to other oral anti diabetic drugs or placebo (dummy pill), a higher number of bone fractures was seen in women (but not in men) taking pioglitazone.
In the clinical studies doses were reduced by 50 mg steps.
In clinical trials, FABLYN-treated women had an increased risk of venous thromboembolic events (deep vein thrombosis and pulmonary embolism) compared to placebo.
In clinical studies peripheral oedema was reported more commonly and tended to be more severe in patients ≥ 65 years (see section 4.4).
In clinical studies, patients with latent tuberculosis who were concurrently treated with isoniazid did not develop tuberculosis.
In clinical studies, LUMIGAN was used concomitantly with a number of different ophthalmic beta-blocking agents without evidence of interactions.
22 In studies in adults, montelukast, 10 mg once daily, compared with placebo, demonstrated significant improvements in morning FEV1 (10.4% vs 2.7% change from baseline), AM peak expiratory flow rate (PEFR) (24.5 L/ min vs 3.3 L/ min change from baseline), and significant decrease in total β -agonist use (-26.1% vs -4.6% change from baseline).
In clinical trials, over 3,900 depressed patients have received Thymanax.
In clinical trials, over 3,900 depressed patients have received Valdoxan.
In short-term trials (under 24 weeks), fluoxetine was shown to be significantly more effective than placebo.
In clinical studies, montelukast inhibits bronchoconstriction due to inhaled LTD4 at doses as low as 5 mg.
In clinical studies, inadequate response to treatment was seen in 10-15% of the dogs.
The incidence of withdrawal due to adverse events was 8% for BYETTA-treated patients, 3% for placebo-treated and 1% for insulin-treated patients in the long-term controlled trials (16 weeks or longer).
Following the first 4-weeks of study romiplostim maintained platelet counts ≥ 50 x 109/ l in between 50% to 70% of patients during the 6 month treatment period in the placebo-controlled studies.
In the echocardiography studies, SonoVue was more effective than the comparator and than placebo in improving the clarity of the image obtained of the left ventricle and left ventricle border.
In fertility studies, gemcitabine caused reversible hypospermatogenesis in male mice.
In the long bone fracture studies, over 418 patients received InductOs.
In long term safety studies, an analysis of data from 867 patients (< 18 years) treated with rasburicase at 0.20 mg/ kg/ day for 1 to 24 days (mainly 1 to 4 days) showed consistent findings with pivotal clinical studies in terms of efficacy and safety.
17 BYETTA-treated patients in the open-label extension studies at 82 weeks experienced similar types of adverse events observed in the controlled trials.
6 BYETTA-treated patients in the open-label extension studies at 82 weeks experienced similar types of adverse events observed in the controlled trials.
In Studies I, II, and V the efficacy and safety of abatacept compared to placebo were assessed in patients with an inadequate response to methotrexate and who continued on their stable dose of methotrexate.
Studies I, II, III, and V required patients to have at least 12 tender and 10 swollen joints at randomization.
In Studies I-IV, all individual components of the ACR response criteria (number of tender and swollen t
In Studies I-IV, all individual components of the ACR response criteria (number of tender and swollen t
statistically significantly better than patients treated with placebo plus standard of care (p < 0.001). dic
In Studies I-IV, Trudexa-treated patients achieved statistically significant ACR 20 and 50 responses na
In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses compared to placebo as early as one to two weeks after initiation of treatment.
In in vitro studies, no antagonism has been observed between tigecycline and other commonly used antibiotic classes.
In in vitro studies, nicotinic acid and its metabolites did not inhibit CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4-mediated reactions or UGT1A1-mediated 3-glucuronidation of estradiol.
In in vitro studies, the protein binding of amprenavir is approximately 90%.
In in vitro studies, laropiprant did not inhibit CYP1A2, CYP2B6, CYP2C19, CYP2D6, or CYP2E1-mediated reactions.
In in vitro studies, the protein binding of amprenavir is approximately 90%.
In treatment-experienced patients, the first two studies compared the effectiveness of Reyataz, taken with saquinavir (another antiviral medicine) but without ritonavir, with that of the combination of ritonavir and either saquinavir or lopinavir.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki; < 100 nM) for serotonin 5 HT2A/ 2C, 5 HT3, 5 HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors m1-m5; α 1 adrenergic; and histamine H1 receptors.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki; < 100 nM) for serotonin 5HT2A/ 2C, 5HT3, 5HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors m1-m5; α 1 adrenergic; and histamine H1 receptors.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki; < 100 nM) for serotonin 5 HT2A/ 2C, 5 HT3, 5 HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors m1-m5; α adrenergic; and histamine H1 receptors.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki; < 100 nM) for serotonin 5-HT2A/ 2C, 5-HT3, 5-HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors m1-m5; α -1 adrenergic; and histamine H1 receptors.
In studies supporting the use of oral ciprofloxacin in acute exacerbation of chronic sinusitis and exacerbation of chronic otitis media, the treatment duration was 10 days and efficacy results have shown that this duration was sufficient.
In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recovered from hyperammonaemic encephalopathy and were then treated chronically with dietary protein restriction and sodium phenylbutyrate, the survival rate was 98%.
In the vehicle controlled trials (n= 594), acne was observed in 41% of patients at baseline; 7% of patients
In the younger age groups (2-6 years and 7-11 years), exposure (Cmax and AUC) and elimination half-life for the same mg/ kg dose were reduced compared with adolescents.
In bone, percentage of injected activity increases from 3.1% at 5 min to 18% at 6 hours and then decreases with time.
In bone, percentage of injected activity increases from 3.1% at 5 min to 18% at 6 hours and then decreases with time.
In the subset of patients with genotype 1 infection and low viral load (< 600,000 IU/ ml) who become HCV-RNA negative at treatment week 4 and remain HCV-RNA negative at week 24, the treatment could either be stopped after this 24 week treatment course or pursued for an additional 24 weeks (i. e. overall 48 weeks treatment duration).
In the subset of patients with genotype 1 infection and low viral load (< 600,000 IU/ml) who become HCV-RN A negative at treatment week 4 and remain HCV-RNA negative at week 24, the treatment could either be stopped after this 24 week treatment course or pursued for an additional 24 weeks (i.e. overall 48 weeks treatment duration).
In the subset of patients with genotype 1 infection and low viral load (< 600,000 IU/ml) who become HCV-RNA negative at treatment week 4 and remain HCV-RNA negative at week 24, the treatment could either be stopped after this 24 week treatment course or pursued for an additional 24 weeks (i.e. overall 48 weeks treatment duration).
For the sub-group of patients with platinum-sensitive disease the difference was greater:
It is not known if rivastigmine is excreted into human
It is not known if rivastigmine is excreted into human milk.
The potential for human risk in pregnancy is unknown, but cannot be excluded.
The potential for human risk in pregnancy is unknown, but cannot be excluded.
In community acquired pneumonia, efficacy has been demonstrated in a limited number of patients with risk factors such as pneumococcal bacteraemia or age higher than 65 years.
In these study populations, mean additional reductions of supine blood pressure of 7/ 7 mmHg, 9/ 5 mmHg, and 8/ 4 mmHg, and mean additional reductions of standing blood pressure of 6/ 6 mmHg, 11/ 4 mmHg, and 4/ 5 mmHg, respectively, were observed.
In the study populations, some patients with common pre-existing co-morbidities (e.g. cardiovascular, respiratory, genitourinary disorders, neoplasms) experienced exacerbations of their prior disease
In populations where the dose may be increased to 8 mg once daily, the dose increase should be preceded by an evaluation of the individual response and tolerability.
In populations where the dose may be increased to 8 mg once daily, the dose increase should be preceded by an evaluation of the individual response and tolerability.
au four placebo-controlled studies the hazard ratios for overall survival ranged between 1.25 and 2.47 in favour of controls.
In the four placebo-controlled studies the hazard ratios for overall survival ranged between 1.25 and 2.47 in
th four placebo-controlled studies the hazard ratios for overall survival ranged between 1.25 and 2.47 in favour of controls.
Results from the Short Form Health Survey (SF 36) for all doses/ schedules of Trudexa in all four rod
In non-endemic areas there should be no risk of dogs having heartworm.
In non-endemic areas there should be no risk of dogs having heartworm.
In areas where hepatitis B is common, vaccination against hepatitis B at birth should be continued as normal, with Tritanrix HepB started at six weeks of age.
In study AC-052-331, patients had to have at least one digital ulcer of recent onset, and across the two studies 85% of patients had ongoing digital ulcer disease at baseline.
107 In the PegIntron combination trial, 1,530 naïve patients were treated for one year with one of the following combination regimens: • PegIntron (1.5 micrograms/kg/week) + ribavirin (800 mg/day), (n = 511). • PegIntron (1.5 micrograms/kg/week for one month followed by 0.5 microgram/kg/week for 11 months) + ribavirin (1,000/1,200 mg/day), (n = 514). • Interferon alfa-2b (3 MIU three times a week) + ribavirin (1,000/1,200 mg/day) (n = 505).
153 following combination regimens: • PegIntron (1.5 micrograms/kg/week) + ribavirin (800 mg/day), (n = 511). • PegIntron (1.5 micrograms/kg/week for one month followed by 0.5 microgram/kg/week for 11 months) + ribavirin (1,000/1,200 mg/day), (n = 514). • Interferon alfa-2b (3 MIU three times a week) + ribavirin (1,000/1,200 mg/day) (n = 505).
176 In the PegIntron combination trial, 1,530 naïve patients were treated for one year with one of the following combination regimens: • PegIntron (1.5 micrograms/kg/week) + ribavirin (800 mg/day), (n = 511). • PegIntron (1.5 micrograms/kg/week for one month followed by 0.5 microgram/kg/week for 11 months) + ribavirin (1,000/1,200 mg/day), (n = 514). • Interferon alfa-2b (3 MIU three times a week) + ribavirin (1,000/1,200 mg/day) (n = 505).
199 In the PegIntron combination trial, 1,530 naïve patients were treated for one year with one of the following combination regimens: • PegIntron (1.5 micrograms/kg/week) + ribavirin (800 mg/day), (n = 511). • PegIntron (1.5 micrograms/kg/week for one month followed by 0.5 microgram/kg/week for 11 months) + ribavirin (1,000/1,200 mg/day), (n = 514). • Interferon alfa-2b (3 MIU three times a week) + ribavirin (1,000/1,200 mg/day) (n = 505).
222 In the PegIntron combination trial, 1,530 naïve patients were treated for one year with one of the following combination regimens: • PegIntron (1.5 micrograms/kg/week) + ribavirin (800 mg/day), (n = 511). • PegIntron (1.5 micrograms/kg/week for one month followed by 0.5 microgram/kg/week for 11 months) + ribavirin (1,000/1,200 mg/day), (n = 514). • Interferon alfa-2b (3 MIU three times a week) + ribavirin (1,000/1,200 mg/day) (n = 505).
38 In the PegIntron combination trial, 1,530 naïve patients were treated for one year with one of the following combination regimens: • PegIntron (1.5 micrograms/kg/week) + ribavirin (800 mg/day), (n = 511). • PegIntron (1.5 micrograms/kg/week for one month followed by 0.5 microgram/kg/week for 11 months) + ribavirin (1,000/1,200 mg/day), (n = 514). • Interferon alfa-2b (3 MIU three times a week) + ribavirin (1,000/1,200 mg/day) (n = 505).
84 In the PegIntron combination trial, 1,530 naïve patients were treated for one year with one of the following combination regimens: • PegIntron (1.5 micrograms/kg/week) + ribavirin (800 mg/day), (n = 511). • PegIntron (1.5 micrograms/kg/week for one month followed by 0.5 microgram/kg/week for 11 months) + ribavirin (1,000/1,200 mg/day), (n = 514). • Interferon alfa-2b (3 MIU three times a week) + ribavirin (1,000/1,200 mg/day) (n = 505).
In the ViraferonPeg combination trial, 1,530 naïve patients were treated for one year with one of the following combination regimens: • ViraferonPeg (1.5 micrograms/kg/week) + ribavirin (800 mg/day), (n = 511). • ViraferonPeg (1.5 micrograms/kg/week for one month followed by 0.5 microgram/kg/week for 11 months) + ribavirin (1,000/1,200 mg/day), (n = 514). • Interferon alfa-2b (3 MIU three times a week) + ribavirin (1,000/1,200 mg/day) (n = 505).
In the AC-052-352 trial, 92% of the 213 patients were classified at baseline as WHO functional class III and 8% as class IV.
In standard safety pharmacology tests, cardiovascular and histamine releasing effects of micafungin were evident and appeared to be time above threshold dependent.
In biological tissue, nitric oxide may form peroxynitrite with superoxide (O2-), an unstable compound which may cause tissue damage through further redox reactions.
In the three studies of Prometax capsules in patients with Alzheimer's dementia, patients taking doses of Prometax between 6 and 9 mg per day had an average increase in cognitive symptoms of 0.2 points from a baseline of 22.9 points at the start of the study, where a lower score indicates better performance.
In all three studies, Cubicin was compared to standard treatments with other antibiotics used for such infections (either vancomycin or one of the penicillins, including oxacillin, cloxacillin, flucloxacillin and nafcillin).
In all three studies, the main measure of effectiveness was how long the patients survived.
In all studies, the main measure of effectiveness was the change in the Visual Analog Scale of Pain Intensity (VASPI).
In a follow-up treatment after consolidation, 7 patients in the single institution study and 18 patients in the multicentre study received further maintenance therapy with TRISENOX.
au disease, which complicates the risk estimation.
The relation of multiple sclerosis disease activity as measured by MRI and clinical outcome is currently not fully understood.
The relation of multiple sclerosis disease activity as measured by MRI and clinical outcome is currently not fully understood.
In human brain tissue, metabolite 1 and metabolite 2 are ~3-fold more potent as in vitro inhibitors of noradrenaline and serotonin reuptake than of dopamine reuptake.
Within muscle tissue this includes increasing glycogen, fatty acid, glycerol and protein synthesis and amino acid uptake, while decreasing glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and amino acid output.
Within muscle tissue this includes increasing glycogen, fatty acid, glycerol and protein synthesis and amino acid uptake, while decreasing glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and amino acid output.
Within muscle tissue this includes increasing glycogen, fatty acid, glycerol and protein synthesis and amino acid uptake, while decreasing glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and amino acid output.
In the long-term treatment of eczema, begin using < Invented Name > as soon as you notice signs and symptoms (redness and itch).
In combination with cisplatin and 5-fluorouracil for the treatment of patients with gastric adenocarcinoma, the pivotal clinical trial excluded patients with ALT and/ or AST > 1.5 × ULN associated with alkaline phosphatase > 2.5 × ULN, and bilirubin > 1 x ULN; for these patients, no dose-reductions can be recommended and docetaxel should not be used unless strictly indicated.
In combination with cisplatin and 5-fluorouracil for the treatment of patients with gastric adenocarcinoma, the pivotal clinical trial excluded patients with ALT and/ or AST > 1.5 × ULN associated with alkaline phosphatase > 2.5 × ULN, and bilirubin > 1 x ULN; for these patients, no dose-reductions can be recommended and docetaxel should not be used unless strictly indicated.
In combination with cisplatin and 5-fluorouracil for the treatment of patients with gastric adenocarcinoma, the pivotal clinical trial excluded patients with ALT and/ or AST > 1.5 × ULN associated with alkaline phosphatase > 2.5 × ULN, and bilirubin > 1 x ULN; for these patients, no dose-reductions can be recommended and docetaxel should not be used unless strictly indicated.
In combination with cisplatin and 5-fluorouracil for the treatment of patients with gastric adenocarcinoma, the pivotal clinical trial excluded patients with ALT and/ or AST > 1.5 × ULN associated with alkaline phosphatase > 2.5 × ULN, and bilirubin > 1 x ULN; for these patients, no dose-reductions can be recommended and docetaxel should not be used unless strictly indicated.
For ear mite treatment do not apply directly to the ear canal.
For ear mite treatment, do not apply directly to the ear canal.
For ear mite treatment, do not apply directly to the ear canal.
In PONV, the usual dose is one 40 mg capsule given within the three hours before the patient is anaesthetised (‘ put to sleep ’).
Cmax (mg/ l) - 0.50 (32%), Cmin (mg/ l) - 0.19 (58%). lo In DVT and PE treatment, patients receiving fondaparinux 5 mg (body weight< 50 kg), 7.5 mg (body weight 50- 100 kg inclusive) and 10 mg (body weight > 100 kg) once daily, the body weight-adjusted no
In smoking cessation therapy, risk of returning to smoking may be elevated in the period immediately following the end of treatment.
There were five cases of 12-month persistent HPV-16/ 18 infection (4 HPV-16; 1 HPV-18) in the control group and one HPV-16 case in the vaccine group in study 001.
In Study 1, 31% of patients treated with TORISEL were 65 or older.
In 1899, this was the period from randomization to 100 days post-randomization; in 316 it was the period from the baseline day to 111 days post-baseline. d:
In 1899, this was the period from randomization to 100 days post-randomization; in 316 it was the period from the baseline day to 111 days post-baseline. d:
In 1899 this was the period from randomization to last dose of study medicinal product plus 7 days; in 316 it was the period from first dose to last dose of study medicinal product plus 7 days. c:
In Study 2a (N = 99), the overall response rate increased to 56.1%.
In Study 316, overall mortality was similar (POS, 25%; FLU, 28%); however, the proportion of IFI- related deaths was significantly lower in the POS group (4/ 301) compared with the FLU group (12/ 299; P= 0.0413).
In the Scandinavian Simvastatin Survival Study (4S), the effect of therapy with< Zocord > on total mortality was assessed in 4,444 patients with CHD and baseline total cholesterol 212-309 mg/dL (5.5-8.0 mmol/L).
In the ANCHOR study, the treatment effect of ranibizumab over verteporfin PDT was essentially maintained for the three VFQ-25 scores after 24 months.
The placebo-adjusted improvement in mean 6MWD at week 12 compared to baseline was 30.6 m (95% CI:
In the study where NovoNorm was added to metformin, the effects of the two medicines were at least additive (equivalent to the effects of the two medicines added together).
In study BR.21, the median time to onset of rash was 8 days, and the median time to onset of diarrhoea was 12 days.
In study BR.21, the median time to onset of rash was 8 days, and the median time to onset of diarrhoea was 12 days.
r ge In CHARM, at week 4, 58% (499/ 854) of patients were in clinical response and were assessed in the primary analysis.
r ge In CHARM, at week 4, 58% (499/ 854) of patients were in clinical response and were assessed in the primary analysis.
In clinical trial C/I98-580, 1,530 naïve patients were treated for one year with one of the following combination regimens: • Rebetol (800 mg/day) + peginterferon alfa-2b (1.5 micrograms/kg/week) (n = 511). • Rebetol (1,000/1,200 mg/day) + peginterferon alfa-2b (1.5 micrograms/kg/week for one month followed by 0.5 microgram/kg/week for 11 months) (n = 514). • Rebetol (1,000/1,200 mg/day) + interferon alfa-2b (3 MIU three times a week) (n = 505).
In clinical trial C/ I98-580, 1,530 naïve patients were treated for one year with one of the following combination regimens: • Ribavirin (800 mg/ day) + peginterferon alfa-2b (1.5 micrograms/ kg/ week) (n = 511). • Ribavirin (1,000/ 1,200 mg/ day) + peginterferon alfa-2b (1.5 micrograms/ kg/ week for one month followed by 0.5 microgram/ kg/ week for 11 months) (n = 514). • Ribavirin (1,000/ 1,200 mg/ day) + interferon alfa-2b (3 MIU three times a week) (n = 505).
Additional monitoring of vitamins and folic acid is recommended in patients receiving peritoneal dialysis, since in the clinical study, vitamin A, D, E and K levels were not measured in these patients.
In the MaxCmin2 study, the safety and efficacy of saquinavir soft capsules/ ritonavir 1000/ 100 mg twice daily plus 2 NRTIs/ NNRTIs was compared with lopinavir/ ritonavir 400/ 100 mg twice daily plus 2 NRTIs/ NNRTIs in 324 (both protease inhibitor treatment naïve and experienced) subjects.
In the comparative study, Fasturtec was more effective than allopurinol: over the first 96 hours after treatment, patients treated with Fasturtec had a lower average blood level of uric acid compared that in the patients treated with allopurinol (128.1 and 328.5 mg. h/ dl, respectively).
In the HBeAg negative study patients on adefovir dipivoxil (0-48 weeks) were re-randomised in a blinded-manner to continue on adefovir dipivoxil or receive placebo for an additional 48 weeks.
In the 26-week study, the severity of the vitreous inflammation increased with the number of injections.
In the longer study, Protopy could be used repeatedly without losing its
In the osteoporosis treatment study, significantly fewer EVISTA-treated patients required initiation of hypolipidaemic therapy compared to placebo.
In the osteoporosis treatment study, significantly fewer OPTRUMA-treated patients required initiation of hypolipidaemic therapy compared to placebo.
Study conducted by Civeira et al. compared in a double-blind, randomised and placebo-controlled trial the effects of gemfibrozil (1200 mg/ day) and simvastatin (20 mg/ day) on lipids, apolipoprotein AI, apolipoprotein B, and apolipoprotein E and on lipids and apolipoprotein B content in VLDL, intermediate-density lipoprotein (IDL), LDL, and HDL in 10 patients with type III hyperlipoproteinemia.
In study FVF2587g (ANCHOR), patients with predominantly classic CNV lesions received either:
In study FVF2598g (MARINA), patients with minimally classic or occult with no classic choroidal neovascularisation (CNV) received monthly intravitreal injections of Lucentis 0.3 mg or 0.5 mg or sham injections.
response or were intolerant to infliximab were randomised to receive either 160 mg Trudexa at week 0 and 80 mg at week 2 or placebo at weeks 0 and 2.
In the HERA trial, Herceptin was initiated after completions of standard chemotherapy (most commonly, anthracycline-containing regimens or anthracyclines plus a taxane).
For HPS, only serious adverse events were recorded as well as myalgia, increases in serum transaminases and CK.
In study I, ACR 20 responses were observed in 71% (42/ 59) of patients, ACR 50 in 41% (24/ 59), and ACR 70 in 31% (18/ 58) at 48 months.
In study II, ACR 20 responses were observed in 88% (291/ 332) of patients, ACR 50 in 62% (205/ 332), and ACR 70 in 38% (127/ 334) at 24 months.
In study III, ACR 20 responses were observed in 70% (118/ 167) of patients, ACR 50 in 43% (73/ 168), and ACR 70 in 22% (37/ 169) at 18 months.
In CD Study II, at Week 4, 58% (499/ 854) of patients were in clinical response and were assessed in the primary analysis.
In CD Study III, at Week 4, 58% (499/ 854) of patients were in clinical response and were assessed in the primary analysis.
InCD Study III, at Week 4, 58% (499/ 854) of patients were in clinical response and were assessed in the primary analysis.
In CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to receive either 160 mg Humira at week 0 and 80 mg at week 2 or placebo at weeks 0 and 2.
PsA study II with 12 -week duration, treated 100 patients who had an inadequate response to DMARD therapy.
PsA study II with 12-week duration, treated 100 patients who had an inadequate response to DMARD therapy.
In the target population studied in study IMP24011, the infection rate in Raptiva-treated patients was approximately 25.7% versus 22.3% in placebo-treated patients.
In Study IV, the ACR 20 response of patients treated with Trudexa plus standard of care was i
In RA study IV, the ACR 20 response of patients treated with Humira plus standard of care was statistically significantly better than patients treated with placebo plus standard of care (p < 0.001).
In the Kaiser Permanente trial, efficacy was 87.5% (95% CI:
In the larger study (VIII) with 315 patients, results showed statistically significant improvement of the signs and symptoms of ankylosing spondylitis in patients treated with Trudexa compared to placebo. na
In the larger study (VIII) with 315 patients, results showed statistically significant improvement of the signs and symptoms of ankylosing spondylitis in patients treated with Trudexa compared to placebo.
These data were divided into 3 subgroups: patients with HDA negative, patients with positive antibodies< 5 mU/mL and patients with positive antibodies> 5 mU/ mL.
In study NV17317 in patients infected with viral genotype 2 or 3, all patients received Pegasys 180 μ g sc qw and a ribavirin dose of 800 mg and were randomized to treatment for either 16 or 24 weeks.
In PIER, most Lucentis-treated patients (82%) maintained their visual acuity at month 24.
In PIER, the primary efficacy endpoint was mean change in visual acuity at 12 months compared with baseline.
In the pivotal trial the initial docetaxel infusion was started the day following the first dose of trastuzumab.
In the confirmatory study comparing FIRMAGON to leuprorelin periodic electrocardiograms were performed.
22 Adverse events occurring more frequently (≥3%) in Tarceva 100 mg plus gemcitabine-treated patients than in the placebo plus gemcitabine group in the pivotal study PA.3, and in at least 10% of patients in the Tarceva 100 mg plus gemcitabine group, are summarised by National Cancer Institute-Common Toxicity Criteria (NCI-CTC) Grade in Table 2.
In the study of chronic phase CML, 156 (49%) of the 320 patients had a major cytogenetic response, after having received Tasigna for an average of 341 days (around eleven months).
In the study looking at booster vaccination, antibody levels against rhinotracheitis herpesvirus, calicivirus infection, feline panleucopenia and C. felis remained stable at a high level or increased slightly.
In the main study, 20% of the patients went into remission (12 out of 61).
In the original main study, both Optaflu and the comparator vaccine brought about adequate levels of antibodies for protection against all three flu strains, as defined in criteria laid down by the Committee for Medicinal Products for Human Use (CHMP) for flu vaccines produced in cell culture.
In the main study, the effectiveness of Advate in the prevention of bleeding was rated as ‘ excellent'or ‘ good'in 86% of the 510 new bleeding episodes.
In the 3.5 year cardiovascular risk PROactive study, 44/ 870 (5.1%; 1.0 fractures per 100 patient years) of pioglitazone-treated female patients experienced fractures compared to 23/ 905 (2.5%; 0.5 fractures
In SHEPHERD study, 96 of the 97 enrolled patients completed the study (one patient died following a thrombotic event).
OSSEOR reduced the relative risk of new vertebral fracture by 41% over 3 years in the SOTI study (table 1).
6 PROTELOS reduced the relative risk of new vertebral fracture by 41% over 3 years in the SOTI study (table 1).
In the add-on study with interferon beta-1a, the risk of disability getting worse and the number of relapses were reduced.
In the study of patients with a single clinical event suggestive of multiple sclerosis, neutralising activity measured every 6 months was observed at least once in 32% (88) of the patients treated immediately with Extavia; of these, 47% (41) returned to negative status over a 3-year period.
In the study of patients with a single clinical event suggestive of multiple sclerosis, neutralising activity measured every 6 months was observed at least once in 32% (88) of the patients treated immediately with Betaferon; of these, 47% (41) returned to negative status over a 3 year period.
In the adult study, 34% of both groups of adults had a favourable response.
In the study in children, the reduction in weekly seizure rate was 43.3% in the group of children who received Keppra, and 16.3% in the placebo group.
In the study of patients with advanced Parkinson's disease, patients taking Mirapexin had larger improvements after 24 weeks of steady-dose treatment than those taking placebo.
In the study of patients with advanced Parkinson's disease, patients taking Sifrol had larger improvements after 24 weeks of steady-dose treatment than those taking placebo.
In the study of patients taking glucocorticoids, Forsteo was more effective than alendronate: after 18 months, patients receiving Forsteo had a 7% increase in bone density in the spine, compared with 3% in those receiving alendronate.
In the study in patients receiving less emetogenic chemotherapy, the percentages were 50.8% (EMEND group) and 42.5% (comparator group).
In the field study of basic vaccination there was an increase in antibodies against feline rhinotracheitis herpesvirus, calicivirus infection, and feline panleucopenia viruses.
In the field study of basic vaccination there was an increase in antibodies against feline rhinotracheitis herpesvirus, calicivirus infection, and feline panleucopenia viruses.
In the field study of basic vaccination there was an increase in antibodies against feline rhinotracheitis herpesvirus and calicivirus infection.
In study WV16241, the primary efficacy endpoints were ALT normalisation and HBV-DNA below 2 x 104 copies/ ml.
In study WV16241, the primary efficacy endpoints were ALT normalisation and HBV-DNA below 2 x 104 copies/ ml.
In study WV16241, the primary efficacy endpoints were ALT normalisation and HBV-DNA below 2 x 104 copies/ ml.
In XPRESS serious bleeding rates were consistent with those observed in previous studies during the 28-day study period (days 0-28).
While a baby is inside its mother's womb it does not need to use its lungs.
In the large subgroup of patients undergoing cancer surgery (69% of the patient population), the VTE rate was 4.7% in the fondaparinux group, versus 7.7% in the dalteparin group.
Where uncertainty exists, it is important that radiation exposure should be the minimum consistent with achieving satisfactory imaging.
In the treated eye, abnormal or decreased vision, a change in the field of vision, bleeding of the retina or into the vitreous humour, displacement of the retina, and lack of blood circulation to the retina or choroid were reported by a few patients.
infection, coughing, gastric or stomach flu
In the body, FSH regulates reproductive function: in women, it stimulates the production of eggs, and in men, it stimulates the production of sperm by the testicles.
In the body, FSH regulates the reproductive function: in women, it stimulates the production of eggs and in men, it stimulates the production of sperm by the testicles.
In the body, natural growth hormone promotes growth in children by stimulating the body to produce IGF-I.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Luminity should not be used in children and adolescents as it has not been studied in these groups.
In one of these trials the women had previously undergone hysterectomy.
In urine, unchanged tipranavir was found in trace amounts (0.5% of urine radioactivity).
In many of these cases, no adverse events were reported.
In many of these cases, no adverse events were reported.
In many of these cases, no adverse events were reported.
macrolide antibiotics (e. g. azithromycin, clarithromycin, erythromycin).
macrolide antibiotics (e. g. azithromycin, clarithromycin, erythromycin). a
In four separate studies (N= 9 to 12) the mean steady state trough plasma concentration ranged from 2.6 to 3.4 μ g/ ml.
In four separate studies (N = 9 to 12) the mean steady state trough plasma concentration ranged from 2.6 to 3.4 μ g/ ml.
In four of the six studies in type 2 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
What is Equilis Prequenza Te used for?
muscle tissue at the injection site.
Peripheral neuropathy was the cause of paclitaxel discontinuation in a few cases.
A few cases have been reported where Zevalin leaked from the vein to the surrounding tissue, which then inflamed (infusion site dermatitis) and scars develop (infusion site desquamation) of the skin at the infusion site.
In its severest form, polio infection causes paralysis of the muscles (muscles cannot move), including those muscles needed for breathing and walking.
Six cases had been co-prescribed gemfibrozil and clopidogrel.
In all situations described below, the benefit/ risk balance of Remicade therapy should be very carefully considered.
In any case the blood parameters of the patient have to be monitored and the appropriate actions immediately taken if there is evidence of damage to the blood marrow.
In all of the studies, the main measure of effectiveness was the change in weight.
In all of the studies, the main measure of effectiveness was either overall survival time or progression- free survival time (the time taken for the disease to get worse or for the patient to die).
In all clinical trials, individuals who had received immunoglobulin or blood-derived products during the 6 months prior to the first vaccine dose were excluded.
11 In all clinical trials individuals who had received immunoglobulin or blood products within 3 months prior to the first vaccine dose were excluded.
In all clinical trials individuals who had received immunoglobulin or blood products within 3 months prior to the first vaccine dose were excluded.
In all studies, histological improvement was defined as a ≥ 2-point decrease in Knodell necro- inflammatory score from baseline with no worsening of the Knodell fibrosis score.
In all of the studies, the main measure of effectiveness was based on the degree of itching and redness in the eye.
In all studies, the main measure of effectiveness was the change in four symptoms of allergy affecting the nose.
Eye pressure is measured in ‘ millimetres of mercury'(mmHg).
In all of the studies, the main measure of effectiveness was how long it took for the muscles to recover.
In all studies, the main measure of effectiveness was the change in four symptoms of allergy affecting the nose.
The main measure of effectiveness in all studies was complete or partial response to treatment.
In all studies, the main measure of effectiveness was the number of patients with a complete or partial response to treatment.
In all studies, the main measure of effectiveness was the change in eye pressure measured in ‘ millimetres of mercury'(mmHg).
Betaferon was effective in all multiple sclerosis studies to reduce disease activity (acute inflammation in the central nervous system and permanent tissue alterations) as measured by magnetic resonance imaging (MRI).
In all studies, both IDflu and the comparator vaccine brought about adequate levels of antibodies for protection against all three flu strains.
For all practical purposes by the second 72-hour application, a steady state serum concentration is reached and is maintained during subsequent applications of a patch of the same size.
In three of these studies, patients were treated either with GANFORT once a day, or with eye drops containing only timolol or bimatoprost, for 3 months, followed by a further 9 months in two studies.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
In three clinical studies in combination with oral antidiabetic agents 2 in 100 subjects reported signs of allergy (for signs of allergy, see below).
23 CYP2C9*3/ *3, single-dose AUC 0-24 increased by approximately 3-fold compared to normal metabolizers.
In three separate single dose studies, involving a total of 5 subjects genotyped as CYP2C9*3/ *3, single-dose AUC 0-24 increased by approximately 3-fold compared to normal metabolizers.
In three studies, the effects of Quintarix were compared with those of the combination of Tritanrix HepB and a vaccine containing Hib: two of these studies involved a total of 1,208 infants who were vaccinated at two, four and six months of age and one involved 294 infants vaccinated at three, four and five months
13 In another case of a large overdose, the patient also survived and recovered.
20 In another case of a large overdose, the patient also survived and recovered.
5 In another case of a large overdose, the patient also survived and recovered.
In another case of a large overdose, the patient also survived and recovered.
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA.
- Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached
* In a combined analysis, atazanavir 300 mg and ritonavir 100 mg (n=33) was compared to atazanavir 400 mg without ritonavir (n=28).
In an analysis of data from the SMBR in November 2001, 15 cases of hypospadias were identified among 2,780 loratadine-exposed pregnancies.
In a subgroup analysis patients with pre-treatment total IgE ≥ 76 IU/ ml were more likely to experience clinically meaningful benefit to Xolair.
In a subgroup analysis, patients with pre-treatment total IgE ≥ 76 IU/ ml were more likely to experience clinically meaningful benefit to Xolair.
Zometa reduced the risk of SREs by 41% in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo.
In an analysis in which all patients who dropped out of the study for any reason were considered to have progressed, the percentage of patients without progression (TSS change ≤ 0.5) at 24 months was higher in the Enbrel in combination with methotrexate group compared with the Enbrel alone and methotrexate alone groups (62%, 50%, and 36%, respectively; p < 0.05).
In an analysis of patients who survived an ischaemic event, prasugrel was associated with a reduction in the incidence of subsequent primary endpoint events (7.8% for prasugrel vs 11.9% for clopidogrel).
In a post-hoc analysis, patients with favourable clinical status at baseline (low pain intensity, good QoL and good PS) may derive more benefit from Tarceva.
In a retrospective analysis (assessed by quantitative radiography) one new fracture (0.8%) was documented among patients treated with alendronate, compared with 6 new fractures (7.1%) for placebo (p=0.017).
In an additional two-centre study, 26 patients were randomised to the tacrolimus versus 24 patients to the ciclosporin group.
In another study in healthy volunteers, repeat dose administration of oral posaconazole (200 mg twice daily for 7 days) increased the Cmax and AUC of IV midazolam (0.4 mg single dose) by an average of 1.3- and 4.6-fold (range 1.7 to 6.4-fold), respectively; Posaconazole 400 mg twice daily for 7 days increased the IV midazolam Cmax and AUC by 1.6 and 6.2-fold (range 1.6 to 7.6-fold), respectively.
96 20 mg weekly, median dose 20 mg), and of the combination of Enbrel and methotrexate initiated concurrently were compared in 682 adult patients with active rheumatoid arthritis of 6 months to 20 years duration (median 5 years) who had a less than satisfactory response to at least 1 disease-modifying antirheumatic drug (DMARD) other than methotrexate.
In another monotherapy study in mild to moderate Alzheimer's disease a total of 470 patients (MMSE total scores at baseline of 11-23) were randomised.
5 In a separate phase I study, administration of TMZ with ranitidine did not result in alterations in the extent of absorption of temozolomide or the exposure to its active metabolite monomethyl triazenoimidazole carboxamide (MTIC).
In a separate phase I study, administration of TMZ with ranitidine did not result in alterations in the extent of absorption of temozolomide or the exposure to its active metabolite monomethyl triazenoimidazole carboxamide (MTIC).
In a separate phase I study, administration of TMZ with ranitidine did not result in alterations in the extent of absorption of temozolomide or the exposure to its active metabolite monomethyl triazenoimidazole carboxamide (MTIC).
In another monotherapy study in mild to moderate Alzheimer's disease a total of 470 patients (MMSE total scores at baseline of 11-23) were randomised.
In another study with somatropin, no increase in chromosomal abnormalities was found in the lymphocytes of patients who had received long-term somatropin therapy.
In a separate study, treatment with montelukast significantly decreased eosinophils in the airways (as measured in sputum).
In a separate pharmacokinetic study, plasma pharmacokinetic profiles in patients with mild to moderate hepatic impairment were similar to those observed in patients with normal hepatic function.
In a separate pharmacokinetic study, plasma pharmacokinetic profiles in patients with mild to moderate hepatic impairment were similar to those observed in patients with normal hepatic function.
In a small cohort of patients with rheumatoid arthritis, 280 patients received subsequent therapy with other DMARDs of whom 185 received a biologic DMARD following MabThera.
In a small cohort of patients with rheumatoid arthritis, 280 patients received subsequent therapy with other DMARDs of whom 185 received a biologic DMARD following MabThera.
In a second 26-week study hyperplasia of transitional cells in the urinary bladder occurred with a much lower incidence.
In one study, sixteen ferrets were divided into two cohorts and were vaccinated on days 0 and 21 with 7.5 µg of the A/ Vietnam/ 1203/ 2004 vaccine or were sham vaccinated.
23/ 30 In a 5-year trial in postmenopausal women (PROOF study), administration of 200 IU intranasal salmon calcitonin resulted in a reduction of 33% in the relative risk of developing vertebral fractures.
In a study in lactating, healthy women, olanzapine was excreted in breast milk.
In a study of healthy adult subjects, 1% retapamulin ointment was applied daily to intact and to abraded skin under occlusion for up to 7 days.
In a clinical study with ReFacto AF in previously treated patients (PTPs), the incidence of factor VIII inhibitors was the primary safety endpoint.
In a clinical study with ReFacto in PTPs, 1 inhibitor was observed in 113 patients.
In a clinical study with ReFacto PTPs, 1 inhibitor was observed in 113 patients.
In a clinical study of healthy adults a 4000 IU daily dose of vitamin D3 for up to five months was not associated with hypercalciuria or hypercalcaemia.
Liver enzymes: in a 144-week clinical study (GS-01-934), elevations of aspartate aminotransferase (AST > 5 times ULN (upper limit of normal)) and of alanine aminotransferase (ALT > 5 times ULN) were reported in 3% and 2% of patients treated with efavirenz, emtricitabine, and tenofovir disoproxil fumarate (n=257) and 3% and 3% of patients treated with efavirenz and fixed-dose zidovudine/ lamivudine (n=254), respectively.
In one clinical study, plasma bexarotene AUC and Cmax values were substantially higher following the administration of a fat-containing meal versus those following the administration of a glucose solution.
In one clinical study, baseline white cell cystine levels were 3.73 (range 0.13 to 19.8) nmol hemicystine/ mg protein and were maintained close to 1 nmol hemicystine/ mg protein with a cysteamine dose range of 1.3 to 1.95 g/ m2/ day.
Most patients experiencing virological failure with a regimen containing abacavir in a pivotal clinical trial with Combivir (fixed dose combination of lamivudine and zidovudine) showed either no NRTI-related changes from baseline (15%) or only M184V or M184I selection (78%).
In a study comparing EVRA to an oral contraceptive containing norgestimate (parent drug of norelgestromin) 250 µg/ ethinyl estradiol 35 µg, Cmax values were 2-fold higher for NGMN and EE in subjects administered the oral contraceptive compared to EVRA, while overall exposure (AUC and Css) was comparable in subjects treated with EVRA.
In a compassionate-use study of 64 patients there were 46 patients for whom confirmed LDL receptor information was available.
In a complementary study, eight pigs were slaughtered at 30 and 36 days after treatment with Suramox.
In a study involving healthy volunteers (N=12), when a 60 mg controlled-release morphine capsule was administered 2 hours prior to a 600 mg gabapentin capsule, mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.
In a placebo controlled trial, patients with inadequate glycaemic control despite a three month insulin optimisation period were randomised to pioglitazone or placebo for 12 months.
In a placebo controlled trial, patients with inadequate glycaemic control despite a three month insulin optimisation period were randomised to pioglitazone or placebo for 12 months.
In a cross-over study in 22 HIV-infected patients treated with Invirase/ritonavir 1000 mg/100 mg twice daily and receiving three consecutive doses under fasting conditions or after a high-fat, high-calorie meal (46 g fat, 1,091 Kcal), the AUC0-12, Cmax and Ctrough values of saquinavir under fasting conditions were about 70 per cent lower than with a high-fat meal.
In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides.
In a study of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations.
In a 6-month study of 599 patients with hypertension, type 2 diabetes mellitus and nephropathy, all of whom were receiving losartan 100 mg and optimised antihypertensive background therapy, addition of aliskiren 300 mg achieved a 20% reduction versus placebo in urinary albumin: creatinine ratio (UACR), i. e. from 58 mg/ mmol to 46 mg/ mmol.
In a 6-month study of 599 patients with hypertension, type 2 diabetes mellitus, and nephropathy, all of whom were receiving losartan 100 mg and optimised antihypertensive background therapy, addition of Enviage 300 mg achieved a 20% reduction versus placebo in urinary albumin: creatinine ratio (UACR), i. e. from 58 mg/ mmol to 46 mg/ mmol.
In a 6-month study of 599 patients with hypertension, type 2 diabetes mellitus, and nephropathy, all of whom were receiving losartan 100 mg and optimised antihypertensive background therapy, addition of Rasilez 300 mg achieved a 20% reduction versus placebo in urinary albumin: creatinine ratio (UACR), i. e. from 58 mg/ mmol to 46 mg/ mmol.
In a 6-month study of 599 patients with hypertension, type 2 diabetes mellitus, and nephropathy, all of whom were receiving losartan 100 mg and optimised antihypertensive background therapy, addition of Riprazo 300 mg achieved a 20% reduction versus placebo in urinary albumin: creatinine ratio (UACR), i. e. from 58 mg/ mmol to 46 mg/ mmol.
In a 6-month study of 599 patients with hypertension, type 2 diabetes mellitus, and nephropathy, all of whom were receiving losartan 100 mg and optimised antihypertensive background therapy, addition of Sprimeo 300 mg achieved a 20% reduction versus placebo in urinary albumin: creatinine ratio (UACR), i. e. from 58 mg/ mmol to 46 mg/ mmol.
In a 6-month study of 599 patients with hypertension, type 2 diabetes mellitus, and nephropathy, all of whom were receiving losartan 100 mg and optimised antihypertensive background therapy, addition of Tekturna 300 mg achieved a 20% reduction versus placebo in urinary albumin: creatinine ratio (UACR), i. e. from 58 mg/ mmol to 46 mg/ mmol.
In an 8-week study in paediatric patients 6 to 14 years of age, montelukast 5 mg once daily, compared with placebo, significantly improved respiratory function (FEV1 8.71% vs 4.16% change from baseline; AM PEFR 27.9 L/ min vs 17.8 L/ min change from baseline) and decreased "as-needed" β -agonist use (-11.7% vs +8.2% change from baseline).
In a two-year rat carcinogenicity study, non-neoplastic and neoplastic findings were observed and related or attributed to an exaggerated pharmacological effect.
In a 2-year carcinogenicity study in rats, an increase in ovarian tumors of granulosa/ theca cell origin was observed in high-dose females (279 mg/ kg/ day).
42 postnatal development assessment in rats, darunavir with and without ritonavir, caused a transient reduction in body weight gain of the offspring pre-weaning and there was a slight delay in the opening of eyes and ears.
In a pre- and postnatal development assessment in rats, darunavir with and without ritonavir, caused a transient reduction in body weight gain of the offspring pre-weaning and there was a slight delay in the opening of eyes and ears.
In a pre- and postnatal development study in rats, maternal exposure to nilotinib caused reduced pup body weight with associated changes in physical development parameters as well as reduced mating and fertility indices in the offspring.
In a dose finding study in subjects aged 18-60 years, 50 subjects received a dose of 3.75 micrograms HA/ AS03 in a volume of 1 ml at 0 and 21 days.
In a palatability study in healthy adults of efavirenz mixed with applesauce, grape jelly, yogurt, or infant formula, grape jelly received the highest rating of good overall taste.
22 Seven patients (3%) on SUTENT and none on placebo in a phase 3 GIST study experienced venous thromboembolic events; five of the seven were Grade 3 deep venous thrombosis (DVT) and two were Grade 1 or 2.
5 Seven patients (3%) on SUTENT and none on placebo in a phase 3 GIST study experienced venous thromboembolic events; five of the seven were Grade 3 deep venous thrombosis (DVT) and two were Grade 1 or 2.
Animals treated with tacrolimus ointment showed a statistically significant reduction in time to skin tumour (squamous cell carcinoma) development and an increase in the
In a photocarcinogenicity study, albino hairless mice were chronically treated with tacrolimus ointment and UV radiation.
In a relapse prevention study, patients responding to 6 months of acute treatment with open-label CYMBALTA were randomised to either CYMBALTA or placebo for further 6-months.
In a study, somewhat higher plasma concentrations of irbesartan were observed in female hypertensive patients.
A follow-up study after 36 months showed 137 women with at least one hip fracture in the calcium-vitamin D group (n=1176) and 178 in the placebo group (n=1127) (p≤0,02).
23 In a juvenile rat toxicity study, pups dosed from postnatal day 7 to 63 with 10, 25 and 50 mg/ kg of ribavirin demonstrated a dose-related decrease in overall growth, which was subsequently manifested as slight decreases in body weight, crown-rump length and bone length.
In a 26 week toxicity study performed in mice with a surrogate antibody directed against murine C5, treatment did not affect any of the toxicity parameters examined.
In an interaction study, tolcapone did not change the pharmacokinetics of tolbutamide.
In a specific interaction study, where sildenafil (100 mg) was co-administered with amlodipine in hypertensive patients, there was an additional reduction on supine systolic blood pressure of 8 mmHg.
6 In a specific interaction study, where sildenafil (100 mg) was co-administered with amlodipine in hypertensive patients, there was an additional reduction on supine systolic blood pressure of 8 mmHg.
In an embryo-foetal development study in the rat, increased incidences of dilated ureters, malformed sternebrae, and unossified forepaw phalanges were noticed at exposures of about 12 (valsartan) and 10
In the 1-year, open-label study of RISPERDAL CONSTA, changes in body weight in individual patients were generally within ±7% from baseline; 25% of patients had an increase in body weight of ≥ 7%.
In a two-year study of combination therapy comparing pioglitazone with gliclazide when added to metformin, glycaemic control measured as mean change from baseline in HbA1c was similar between treatment groups after one year.
In a two-year study of combination therapy comparing pioglitazone with gliclazide when added to metformin, glycaemic control measured as mean change from baseline in HbA1c was similar between treatment groups after one year.
In one study of two-year duration deferiprone was compared to deferoxamine.
In a single-dose study in healthy subjects, the administration of famotidine 10 hours prior to a single dose of SPRYCEL reduced dasatinib exposure by 61%.
Trevaclyn (2000 mg/ 40 mg) co-administered with simvastatin when compared with simvastatin alone or Trevaclyn (2000 mg/ 40 mg) alone for 12 weeks, significantly lowered LDL-C (-47.9%, -37.0%, -17.0% respectively), TG (-33.3%, -14.7%, -21.6% respectively), apo B
In a study with children receiving a second dose of M-M-RVAXPRO, sensitisation to rHA was not observed.
In one study, patients with type 2 diabetes also received anti-diabetes medicines by mouth.
In a study in 880 randomised patients not adequately responsive to aliskiren 300 mg treatment, the combination of aliskiren/ hydrochlorothiazide 300 mg/ 25 mg produced systolic/ diastolic blood pressure reductions of 15.8/ 11.0 mmHg, which were significantly greater than aliskiren 300 mg monotherapy.
In a peri-postnatal study in rats, no adverse effects on offspring were observed.
11 In a pharmacokinetic study of celecoxib 200 mg administered once daily in healthy volunteers, genotyped as either CYP2C9*1/ *1, CYP2C9*1/ *3, or CYP2C9*3/ *3, the median Cmax and AUC 0-24 of celecoxib on day 7 were approximately 4-fold and 7-fold, respectively, in subjects genotyped as CYP2C9*3/ *3 compared to other genotypes.
In a placebo-controlled polysomnography study over 3 weeks pramipexole significantly reduced the number of periodic limb movements during time in bed.
In a placebo-controlled polysomnography study over 3 weeks MIRAPEXIN significantly reduced the number of periodic limb movements during time in bed.
In a placebo-controlled polysomnography study over 3 weeks SIFROL significantly reduced the number of periodic limb movements during time in bed.
In the rat pre- and postnatal development study, a decrease in pup survival occurred between birth and postnatal day 21 at doses of 60 mg/ kg/ day or higher (5 times the expected human clinical exposure).
In a study in healthy subjects, systemic exposure (AUC and Cmax) of inhaled human insulin
In a supporting study of ReFacto AF, 1 de novo and 2 recurrent inhibitors (all low-titre, central laboratory determination) were observed in 110 patients; median exposure of 58 ED (range 5-140) and 98 patients had at least 50 ED to ReFacto AF.
In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides.
In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced postprandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides.
In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides.
In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides.
In a fertility and general reproductive function study, the number of pregnant mice was reduced following administration of the same analogous antibody.
In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg kg-1 day-1 caused malformations (including anophthalmia, agnathia and hydrocephaly) in the first generation offspring in the absence of maternal toxicity.
In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg kg-1 day-1 caused malformations (including anophthalmia, agnathia and hydrocephaly) in the first generation offspring in the absence of maternal toxicity.
In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg• kg-1• day-1 caused malformations (including anophthalmia, agnathia, and hydrocephaly) in the first generation offspring in the absence of maternal toxicity.
Among the 300 (221 patients in the phase III part of the study and 79 patients in the phase II part) patients treated with docetaxel in combination with cisplatin and 5-fluorouracil in the gastric cancer study, 74 were 65 years of age or older and 4 patients were 75 years of age or older.
In one study, patients with type 2 diabetes also received anti-diabetes medicines by mouth.
In the pre- and postnatal development assessment in rats, atazanavir
In the pre- and postnatal development assessment in rats, atazanavir produced a transient reduction in body weight in the offspring at a maternally toxic dose.
In a meta-analysis of five clinical trials where abacavir was added to intensify therapy, of 166 subjects, 123 (74%) had M184V/ I, 28 50 (30%) had T215Y/ F, 45 (27%) had M41L, 30 (18%) had K70R and 25 (15%) had D67N.
In a meta-analysis of five clinical trials where abacavir was added to intensify therapy, of 166 subjects, 123 (74%) had M184V/ I, 50 (30%) had T215Y/ F, 45 (27%) had M41L, 30 (18%) had K70R and 25 (15%) had D67N.
In a meta-analysis of five clinical trials where ABC was added to intensify therapy, of 166 subjects, 123 (74%) had M184V/ I, 50 (30%) had T215Y/ F, 45 (27%) had M41L, 30 (18%) had K70R and 25 (15%) had D67N.
In a small observational cohort, approximately 600 patients with evidence of continued disease activity received 2-5 repeated courses of treatment 6- 12 months after the previous course.
► In insulin infusion pumps ► If FlexPen is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Actraphane) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If FlexPen is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Insulatard) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If FlexPen is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Mixtard) ► If it's not uniformly white and cloudy when it's resuspended.
In insulin infusion pumps If FlexPen is dropped, damaged or crushed, there is a risk of leakage of insulin 92 If it hasn't been stored correctly or if it has been frozen (see 6 How to store NovoMix 30) If the insulin is not uniformly white and cloudy when it's mixed If clumps of material are present or if solid white particles stick to the bottom or the wall of the cartridge giving a frosted appearance.
In insulin infusion pumps If FlexPen is dropped, damaged or crushed, there is a risk of leakage of insulin If it hasn't been stored correctly or if it has been frozen (see 6 How to store NovoMix 50) If the insulin is not uniformly white and cloudy when it's mixed 102 If clumps of material are present or if solid white particles stick to the bottom or the wall of the cartridge giving a frosted appearance.
In insulin infusion pumps If FlexPen is dropped, damaged or crushed, there is a risk of leakage of insulin 113 If it hasn't been stored correctly or if it has been frozen (see 6 How to store NovoMix 70) If the insulin is not uniformly white and cloudy when it's mixed If clumps of material are present or if solid white particles stick to the bottom or the wall of the cartridge giving a frosted appearance.
In insulin infusion pumps If FlexPen is dropped, damaged or crushed there is a risk of leakage of insulin If it hasn't been stored correctly or been frozen (see 6 How to store Protaphane) If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If InnoLet is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Actraphane) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If InnoLet is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Actrapid) ► If it does not appear water clear and colourless.
► In insulin infusion pumps ► If InnoLet is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Insulatard) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If InnoLet is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Mixtard) ► If it's not uniformly white and cloudy when it's resuspended.
In insulin infusion pumps If InnoLet is dropped, damaged or crushed there is a risk of leakage of insulin If it hasn't been stored correctly or been frozen (see 6 How to store Protaphane) If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If the cartridge or the device containing the cartridge is dropped, damaged or crushed, there is a risk of leakage of insulin ► If it hasn 't been stored correctly or if it has been frozen (see 6 How to store Levemir) ► If the insulin does not appear water clear and colourless.
In insulin infusion pumps If the cartridge or the device containing the cartridge is dropped, damaged or crushed, there is a risk of leakage of insulin If it hasn't been stored correctly or if it has been frozen (see 6 How to store NovoMix 30) If the insulin is not uniformly white and cloudy when it's mixed If clumps of material are present or if solid white particles stick to the bottom or the wall of the cartridge giving a frosted appearance.
► In insulin infusion pumps ► If Penfill or the device containing Penfill is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Actraphane) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If Penfill or the device containing Penfill is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Mixtard) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If Penfill or the device containing Penfill is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Actraphane) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If Penfill or the device containing Penfill is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Actrapid) ► If it does not appear water clear and colourless.
► In insulin infusion pumps ► If Penfill or the device containing Penfill is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Insulatard) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If Penfill or the device containing Penfill is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Mixtard) ► If it's not uniformly white and cloudy when it's resuspended.
In insulin infusion pumps If Penfill or the device containing Penfill is dropped, damaged or crushed there is a risk of leakage of insulin If it hasn't been stored correctly or been frozen (see 6 How to store Protaphane) If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If NovoLet is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Actraphane) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If NovoLet is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Actraphane) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If NovoLet is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Actraphane) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If NovoLet is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Actraphane) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If NovoLet is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Insulatard) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If NovoLet is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Mixtard) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If NovoLet is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Mixtard) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If NovoLet is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Mixtard) ► If it's not uniformly white and cloudy when it's resuspended.
In insulin infusion pumps If NovoLet is dropped, damaged or crushed there is a risk of leakage of insulin If it hasn't been stored correctly or been frozen (see 6 How to store Protaphane) If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If FlexPen is dropped, damaged or crushed, there is a risk of leakage of insulin ► If it hasn 't been stored correctly or if it has been frozen (see 6 How to store Levemir) ► If the insulin does not appears water clear and colourless.
► In insulin infusion pumps ► If InnoLet is dropped, damaged or crushed, there is a risk of leakage of insulin ► If it hasn 't been stored correctly or if it has been frozen (see 6 How to store Levemir) ► If the insulin does not appear water clear and colourless.
In a recent publication updated information from 6 of these 11 patients revealed that all these patients remained in cytogenetic remission (range 32-38 months).
A total of 334 patients achieving a complete or partial remission following induction therapy were randomised in a second step to MabThera maintenance therapy (n=167) or observation (n=167).
In a second trial in treatment naïve type 2 diabetic obese patients (Serenade), the absolute change in HbA1c (with a baseline of 7.9% for both groups) at six months was -0.8 for rimonabant 20 mg and -0.3 under placebo (Difference -0.51 CI95% -0.78, -0.24 p < 0.001).
In a clinical trial adverse events seen on abrupt treatment discontinuation occurred in approximately 44% of patients treated with YENTREVE and 24% of patients taking placebo.
In a clinical trial, adverse events seen on abrupt treatment discontinuation occurred in approximately 44% of patients treated with YENTREVE and 24% of patients taking placebo.
7 Prevention of Venous Thromboembolic Events (VTE) in medical patients who are at high risk for thromboembolic complications due to restricted mobility during acute illness In a randomised double-blind clinical trial, 839 patients were treated with fondaparinux 2.5 mg once daily or placebo for 6 to 14 days.
In a smaller group (n=36) of mixed type 1 and 2 subjects treated with EXUBERA for > 36 months, cessation of therapy resulted in a mean FEV1 increase of 0.036L over the subsequent 6 months.
Within the range 0.47 to 2.0 Tesla, the relaxivity displays only slight dependency on the strength of the magnetic field.
In an animal model of pulmonary fibrosis, bosentan reduced collagen deposition in the lungs.
11 In an animal model for familial adenomatous polyposis (FAP), treatment with rosiglitazone at 200 times the pharmacologically active dose increased tumour multiplicity in the colon.
23 In an animal model for familial adenomatous polyposis (FAP), treatment with rosiglitazone at 200 times the pharmacologically active dose increased tumour multiplicity in the colon.
In an animal model for familial adenomatous polyposis (FAP), treatment with rosiglitazone at 200
In an animal model for familial adenomatous polyposis (FAP), treatment with rosiglitazone at 200 times the pharmacologically active dose increased tumour multiplicity in the colon.
In an animal model for familial adenomatous polyposis (FAP), treatment with rosiglitazone at 200 times the pharmacologically active dose increased tumour multiplicity in the colon.
In an animal model of familial adenomatous polyposis (FAP), treatment with two other thiazolidinediones increased tumour multiplicity in the colon.
M1, but not M2, possesses about 1/ 3 of the pharmacological activity as compared to its parent in an animal model.
In a rat model on the resistance to influenza infection, an impairment of IFN-γ production was observed.
Dexrazoxane undergoes intracellular hydrolysis first to its two one-ring open intermediates (B and C) and then to the two-ring opened form (ADR-925) which has a structure similar to EDTA and is a strong chelator of iron and divalent cations as calcium ions.
In the second bowl, add a suitable, small amount (1 teaspoon maximum) of sweetened food product to the mixture (to mask the bitter taste) and mix well.
In a pre-defined subset of subjects (Cervarix = 8,130 versus control = 5,786), adverse events were followed for 30 days after each injection.
If this occurs you should seek medical help immediately.
In such cases, a standard wash-out procedure should follow, using at least 2 litres of dextran 70 intravenous infusion or similar fluid.
In a taste preference study, efavirenz mixed with grape jelly received the highest rating.
(see list of ingredients in Section 6 Further Information).
er application site irritation, application site paraesthesia, application site rash
Based on the pharmacological mechanism of action of efalizumab, the use of Raptiva is not expected to affect patient's ability to drive and use machines.
Based on varenicline characteristics and clinical experience to date, CHAMPIX has no clinically meaningful drug interactions.
Based on literature reports, ceftriaxone is not compatible with amsacrine, vancomycin, fluconazole, aminoglycosides and labetalol.
Based on in vitro data, azacitidine metabolism does not appear to be mediated by cytochrome P450 isoenzymes (CYPs), UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), and glutathione transferases (GSTs); interactions related to these metabolizing enzymes in vivo are therefore considered unlikely.
Based on the in vitro data the mechanism of the interaction does not appear to be due to inhibition of CYP450 mediated metabolism but the exact mechanism remains unknown.
Based on animal studies, the rate of excretion is expected to be low.
Based upon in vitro studies, the circulating metabolites of duloxetine are considered pharmacologically inactive.
Based upon in vitro studies, the circulating metabolites of duloxetine are considered pharmacologically inactive.
Based on human and animal studies, any systemic effects attributable to the lipase-inhibiting properties of orlistat should be rapidly reversible.
According to the PSURs, covering more than 3 years of use, safety is consistent with the details of the SPCs.
55 Carcinogenicity Based on the results of studies in mice and rats, it was concluded that olanzapine is not carcinogenic.
Carcinogenicity Based on the results of studies in mice and rats, it was concluded that olanzapine is not carcinogenic.
From post marketing experience it appears that serotonin syndrome occurs very rarely in patients treated with Remeron alone (see section 4.8).
John's Wort – Hypericum perforatum – preparations) may lead to an incidence of serotonin associated effects (serotonin syndrome: see section 4.4).
A component interaction study demonstrated that the exposure (Cmax and AUC) of pseudoephedrine following administration of pseudoephedrine alone was bioequivalent to pseudoephedrine exposure following administration of the Aerinaze tablet.
Daronrix is a vaccine that can only be used once a flu ‘ pandemic'has been officially declared by the World Health Organization (WHO) or European Union (EU).
Daronrix, suspension for injection.
Darunavir/ ritonavir 400/ 100 mg BID
Dasatinib was considered to be non-phototoxic in vivo after a single oral administration to female hairless mice at exposures up to 3-fold the human exposure following administration of the recommended therapeutic dose (based on AUC).
Dasatinib is rapidly absorbed in patients following oral administration, with peak concentrations between 0.5-3 hours.
Date of approval of latest variation or transfer:
This summary was last updated in 1-2006.
DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION
DATE OF FIRST AU`THORISATION/ RENEWAL OF THE AUTHORISATION
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
DATE OF REVISION OF THE TEXT...............................................
EMEA/ CPMP/ 3736/ 03 20/ 21  EMEA 2003 EMEA/ CPMP/ 3736/ 03 21/ 21  EMEA 2003
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
09 July, 2003 Date of latest renewal:
21 February 1997 Date of latest renewal:
21 March 2002 Date of last renewal:
28/ 02/ 2002 Date of renewal:
30th April 1996 Date of last renewal:
9. ge DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION lon Date of first authorisation:
DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
8 Date of latest renewal:
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation/ renewal of the authorisation
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION 24 Date of first authorisation:
DATE OF FIRST AUTHORIZATION/RENEWAL OF AUTHORIZATION
DATE OF first AUTHORIZATION/ RENEWAL OF the AUTHORIZATION
DATE OF FIRST AUTHORIZATION/ RENEWAL OF THE AUTHORIZATION
DATE OF FIRST AUTHRORISATION/ RENEWAL OF AUTHORISATION
Virological response in previously untreated paediatric patients IntronA 3 MIU/m2 3 times a week + ribavirin 15 mg/kg/day
DATE OF THE FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION r Ma
DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION
Preparation Date: ______________ Preparation Time: ______________ Prepared By: __________________
Date removed from refrigerator: __/__/_____ End of 9-month period at room temperature: __/__/_____
date refers to the last day of the month.
The expiry date refers to the last day of that month.
Maximum shelf-life for sterile products for human use after first
increase the tendency for blood clotting, decreased number of red blood cells, known as anaemia, or higher levels of certain types of white blood cells),
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
Further intravenous administration is not contraindicated unless the reactions reoccur or worsen.
Therapy with octreotide acetate can produce severe hypoglycaemia in patients with insulinomas, and other somatostatin analogues are known to impair glucose tolerance.
Other dopamine antagonists, when administered to pregnant animals, have caused negative effects on learning and motor development in the offspring.
Other dopamine antagonists, when administered to pregnant animals, have caused negative effects on learning and motor development in the offspring.
Additional anti-emetics may be administered as needed.
Furthermore discussions took place on pharmacovigilance for mutually recognised products.
and in particular the costs of services provided by national authorities for inspections and rapporteurships.
Other possible dermatologic effects may include dryness, thickness or cracking of the skin, blisters or occasional rash on the palms of the hands and soles of the feet.
Other common side effects are pseudofolliculitis barbae (ingrown hairs), alopecia (hair loss), stinging skin, burning skin, dry skin, pruritus (itching), erythema (redness), tingling skin, irritated skin, rash, and folliculitis (infected hair follicles).
Other possible but less frequent undesirable effects are:
7 Additional studies in human plasma samples in vitro suggest that complexation with C1-inactivator, α 2-antiplasmin and α 2-antitrypsin contributes to the inactivation of reteplase in plasma.
Further in vitro studies suggest that metabolism of iloprost in the lungs is similar after intravenous administration or inhalation.
Other studies revealed changes in sperm parameters (motility and morphology) consistent with an observed reduction in fertility.
Other venous thromboembolic events could also occur.
If adverse events develop during the course of treatment with IntronA for any indication, modify the dosage or discontinue therapy temporarily until the adverse events abate.
Other negative prognostic factors (age > 40 years, male gender, bridging fibrosis) should be taken into account in order to extend therapy to 12 months.
Other negative prognostic factors (age > 40 years, male gender, bridging fibrosis) should be taken into dic
Other negative prognostic factors (age > 40 years, male gender, bridging fibrosis) should be taken into Me
Other infections were considered severe in 3% of patients.
Other experience with CEPROTIN covers case reports and a clinical study in overall 69 paediatric patients with acquired protein C deficiency.
Other initiatives included management and language training for staff.
Concerns were further raised with regards to the Paediatric Indication and the use of the comparator Magnevist.
Other transporter-related interactions cannot be excluded.
As greater technological advances are made in the biotechnology field, additional guidelines on critical topics will be required.
Other less common skin manifestations were reported in areas where photosensitivity reactions had occurred, such as increased hair growth, skin discolouration, skin nodules, skin wrinkling and skin fragility.
Other severe events occurring in patients that were recorded as related or possibly related to topotecan treatment were anorexia (12%), malaise (3%) and hyperbilirubinaemia (1%).
Other mechanisms, which have yet to be elucidated, may also be involved.
If any of these apply to you, your doctor will need to carry out a blood test before and possibly during your {PRODUCT NAME} treatment to predict your risk of muscle related side effects.
Other medicinal products, listed below, including examples of substrates, inhibitors or inducers of CYP3A4, may lead to interactions when administered with Agenerase.
Other medicines may also not mix well with Rapilysin.
Some other medicines may increase the risk for photosensitivity reactions for example antibiotics or antidiabetic medicines.
Some other medicines may increase the risk for photosensitivity reactions for example antibiotics or antidiabetic medicines.
Other unidentified metabolites are also found in the faeces.
Other unidentified metabolites are also found in the faeces.
Other possible side effects with {PRODUCT NAME}:
Others have signs of mild flu, t uc
Co- medication with other hepatotoxic medicinal products was frequently present.
Additional important adverse reactions reported in more than 25% of subjects included myalgia, fever, asthenia, alopecia, nausea, anorexia, weight decrease, depression, irritability and insomnia.
Other local reactions such as induration, ulceration, scabbing, and vesicles have also been reported.
Other neurological signs and symptoms have been reported and include convulsion, Guillain-Barré syndrome and focal neurological deficits.
Other symptoms of Kaposi's sarcoma, such as swelling around the tumour, may also improve or disappear.
Other symptoms may include: headache, anxiety, micturition difficulty, muscle weakness and tenseness, euphoria, excitement, tachycardia, palpitations, thirst, perspiration, nausea, vomiting, precordial pain, dizziness, tinnitus, ataxia, blurred vision and hypertension or hypotension.
Other phenotypic and genotypic assays are currently being evaluated.
- Other treatments for ulcers or heartburn may also reduce the effectiveness of ORACEA and
conditions (see the products listed in “ Taking other medicines”),
Uncommon (≥ 0.1% to < 1%) reports of other types of fistulae that involve areas of the body other than the gastrointestinal tract (e. g. bronchopleural, urogenital and biliary fistulae) were observed across various indications.
Results indicated that the quality of the products tested is satisfactory and the trial provided useful experience.
Dr Kroker held different positions in pharmacological institutes in Giessen and Munich.
From 1972 to 1974, Dr Purves worked in the pharmaceutical industry.
From 1972 to 1974, Dr Purves worked in the pharmaceutical industry.
From 1977 to 1986, Dr Le Courtois worked as a Dr Purves worked in the pharmaceutical industry.
Between 1973 and 1980 he was employed as a medicines inspector in the UK Department of Health.
Between 1973 and 1980 he was employed as a medicines inspector in the UK Department of Health.
Between 1973 and 1980 he was employed as a medicines inspector in the UK Department of Health.
From 1974 to 1985 he was an audit manager in Spain with Ernst and Young and from 1985 to 1995 he was Financial Controller at Johnson Wax Española.
From 1975 to 1990 Mrs Mendosa held a number of posts at the European Commission in Luxembourg, including the Conference Service, the Office for Official Publications and the Statistical Office.
From 1976 to 1978, lecturer at University of Uppsala.
From 1976 to 1978, lecturer at University of Uppsala.
From 1976 to 1986 Dr Brasseur worked as a paediatrician at the University Sint Pieter Hospital in Brussels.
From 1976 to 1987, Dr Grein held positions in Germany as scientific assistant at the Free University of Berlin and as pharmacist.
From 1976 to 1987, Dr Grein held positions in Germany as scientific assistant at the Free University of Berlin and as pharmacist.
From 1977 to 1986, Dr Le Courtois worked as a general practitioner and as director of a medical centre in Paris.
From 1977 to 1986, Dr Le Courtois worked as a general practitioner and as director of a medical centre in Paris.
Post- graduate degrees in tropical medicine, clinical research and epidemiology.
From 1978 to 1983 Dr Papaluca worked in the Third Internal Medicine Department of the University of Rome on research projects in the area of clinical immunology and cellular immunology.
From 1979 to 1984 Dr Teeling was employed as a hospital doctor in various teaching hospitals in Dublin.
From 1981 to 1983 Dr Abadie held a number of clinical and laboratory positions, before joining the pharmaceutical industry in 1983.
From 1981 to 1984, Dr Moulin worked in the Bovine Pathology Laboratory in Lyon.
Benefice University of Montpellier, France.
From 1982 to 1986, Dr Bénéfice was a researcher at the University of Montpellier, France.
From 1982 to 1986, Dr Bénéfice was a researcher at the University of Montpellier, France.
From 1982 to 1987, Dr Beechinor was a general veterinary practitioner in several mixed practices in Ireland.
He acted as senior pharmaceutical consultant for the Swedish health cooperation programme in Vietnam from 1982 to 1994.
From 1984 to 1985 she studied for a BSc (Honours) in pharmacology and from 1985 to 1988 was a Research Fellow in pharmacology/oncology at the Mater Misericordiae Hospital in Dublin.
Pharmaceutical Department of the Italian Ministry of Health,
From 1985 to 1987, Dr Kennedy was employed as Section Head of Microbiology Research and Development in a multinational pharmaceutical company.
From 1987 to 1992 she worked as a quality control microbiologist in a number of different pharmaceutical companies with responsibility for all aspects of microbiological quality control.
From 1987 to 1994, Dr Ashley-Smith was employed in the veterinary pharmaceutical industry, first as a technical adviser and subsequently as a registration manager.
From 1987 to 1999 he was Veterinary Assessor at the National Drugs Advisory Board (now the Irish Medicines Board).
From 1988 to 1992, Dr Brosch worked as an assistant professor at the Department of Pharmacology and Toxicology at the University of Vienna, where she was specialised in electrophysiology.
From 1988 to 1992, Dr Brosch worked as an assistant professor at the Department of Pharmacology and Toxicology at the University of Vienna, where she was specialised in electrophysiology.
From 1990 to 1994, he was Technical Counsellor in Clinical Evaluation at the Spanish Ministry of Health, Member of the CPMP/EWP and involved in the Efficacy Group of the ICH.
From 1990 to 1994, he was Technical Counsellor in Clinical Evaluation and Pharmacology at the Spanish Ministry of Health, Member of the CPMP Efficacy Working Party and involved in the Efficacy Group of the ICH.
From 1993 to 1997 she was seconded to the European Commission (DG XII) as Scientific Secretary for COST actions in the field of chemistry, with responsibility for coordination of research networks and organisation of scientific conferences and workshops in Europe.
From 1993 to 1997 she was seconded to the European Commission (DG XII) as Scientific Secretary for COST actions in the field of chemistry, with responsibility for coordination of research networks and organisation of scientific conferences and workshops in Europe.
From 1993 to 1997, as Scientific Secretary for COST Chemistry Actions at the European Commission in Brussels, she was involved in co-ordination of research networks in Europe and organisation of conferences.
From 1993 to 1995 he was coordinator of the C-Clin Paris-Nord (inter-regional centre for nosocomial infections).
Erosion score JSN score a
R(-) methadone AUC ↔ 1.06 (0.99-1.13) R(-) methadone Cmin ↔ 1.10 (1.02-1.19) R(-) methadone Cmax ↔ 1.02 (0.96-1.09) S(+) methadone AUC ↔ 0.89 (0.82-0.96) S(+) methadone Cmin ↔ 0.89 (0.81-0.98) S(+) methadone Cmax ↔ 0.89 (0.83-0.97) etravirine AUC ↔ a etravirine Cmin ↔ a etravirine Cmax ↔ a
In the first study, Myocet was compared with standard (non-liposomal) doxorubicin, both in 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Unwrap the needle suitable for reconstitution and fix it to the syringe from which you removed the tip cap before.
pulmonary or systemic blood flow (e. g. pulmonary atresia, severe tetralogy of Fallot, severe coarctation of the aorta);
Good relations with the European Parliament are very important for the EMEA.
- Overflow bladder, anuria or progressive renal insufficiency
Overflow bladder, anuria or progressive renal insufficiency
Support from the EMEA will in particular include the availability in early 2000 of better facilities for break-out sessions and videoconferencing on the third floor.
treatment may prove stressful to you.
Start of the treatment (the first 4 weeks) Week
Start on the day after your chemotherapy.
BYETTA should not be used if breast-feeding.
Harmful substances will be formed and accumulate in the body.
Therefore Herceptin and anthracyclines should not be used currently in combination except in a well-controlled clinical trial setting with cardiac monitoring.
Hence, the relevance of these mutations to maraviroc susceptibility in other viruses is not known.
After injection into the subcutaneous tissue, the acidic solution is neutralised leading to formation of micro-precipitates from which small amounts of insulin glargine are continuously released, providing a smooth, peakless, predictable concentration/ time profile with a prolonged duration of action.
After injection into the subcutaneous tissue, the acidic solution is neutralised leading to formation of micro-precipitates from which small amounts of insulin glargine are continuously released, providing a smooth, peakless, predictable concentration/ time profile with a prolonged duration of action.
Therefore deferiprone at the recommended dose could be less effective than deferoxamine.
Furthermore, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function and an increase in serum potassium.
Therefore, treatment is not recommended in this age group.
Therefore, breast-feeding women should not take this medicine.
Thus an interference of IG on the immune response to YF vaccine is not likely, and it is not necessary to include a statement on any potential interaction with IG in section 4.5.
This warrants monitoring and early treatment of diarrhoea.
Death from any cause Need for Revascularisation Hospitalisation for unstable angina
(based on non-TIMI criteria - see section 4.8)
In post-marketing spontaneous reports, there have been cases of medication error where the entire contents (up to 800 µg) of the teriparatide pen have been administered as a single dose.
This decreases the rate at which the substance is removed from the body and allows the medicine to be given less often.
In this way Corlentor helps to control and reduce the number of angina attacks.
In this way Procoralan helps to control and reduce the number of angina attacks.
- skin breakdown and tissue destruction (necrosis) at injection site*
- skin breakdown and tissue destruction (necrosis) at injection site*
post-operative injection, for 7+2 days.
Annex 10 Guidelines and working documents in 2001
Declaration of storage conditions for medicinal products
STATEMENT OF PRINCIPLES GOVERNING THE PARTNERSHIP BETWEEN THE NATIONAL COMPETENT AUTHORITIES AND THE EUROPEAN AGENCY FOR THE EVALUATION OF MEDICINAL PRODUCTS
- Statement of principles governing the partnership between the national competent authorities
- Statement of principles governing the partnership between the national competent authorities and the
Serous retinal detachment: frequency unknown.
Urticaria Skin, hair, beard, and nail discolorations
low 90% c onf idenc e int erv al
Decontaminate any spill with 10% caustic solution, or sodium hypochlorite (household chlorine bleach – 2 ml (0.5%):
Decontaminate any spill with 10% caustic solution, or sodium hypochlorite (household chlorine bleach – 2 ml (0.5%):
Tear off a section from the blister at the perforation.
Cut a 2-inch hole in a paper bag, put it on your hand or elbow (not your face).
Use for reversal of neuromuscular blocking agents other than rocuronium or vecuronium:
Routine reversal – moderate neuromuscular blockade:
Routine reversal – deep neuromuscular blockade:
Immediate reversal of rocuronium-induced blockade:
- depression or problems affecting your moods
5/25 surprisingly, the antibody peak concentration was higher after the second exposure.
It is general clinical experience that the risk of suicide may increase in the early stages of recovery.
Similarly, volumetric trabecular BMD at the total hip increased by 4.7%.
Similarly, volumetric trabecular BMD at the total hip increased by 9, 6, and 2%, respectively, in the 3 groups.
Uncommonly, you may develop an abnormality in your electrocardiogram (i. e. tracing of the electrical activity of your heart).
Small amounts of this medicine may pass into
failure of some organs, influenza like illness, increased sensitivity to heat and cold, feeling of pressure on your chest, jittery or abnormal feeling, increase of the enzyme lactate dehydrogenase in your blood, weight loss
ge unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating.
macrogol 3350, poly(vinyl alcohol), talc, titanium dioxide.
- reactions or illness, must be advised to contact their doctor before restarting.
reactions or illness, must be advised to contact their doctor before restarting.
Severe hepatic impairment Dosing adjustment of fondaparinux is not necessary.
Glucose-6-phosphate dehydrogenase deficiency Haemolytic reactions have been reported with ciprofloxacin in patients with glucose-6-phosphate dehydrogenase deficiency.
Defined as adverse events for which the frequency on ORACEA was higher than on placebo (by at least 1%)
Defined as HCV-RNA below limit of detection using a research based RT-PCR assay at end of treatment and during follow-up period
* Virological breakthrough: “ 1 log above nadir” definition assessed at week 104
DEFINING CLINICAL SIGNS None Definite pink to red coloration Increased redness, possible oedema Very red, with oedema, with or without vesiculation Deep red, swelling and oedema with or without signs of bullae formation and necrosis
Def inition of a new biological active substance in terms of active, passive immunity and immunomodulators which then constitute a new active ingredient
Large doses of somatropin may impair glucose tolerance.
High quantities of the active substance remain in the transdermal patches even after use.
Retinal degeneration, retinal disorder, retinal detachment, retinal tear, detachment of the retinal pigment epithelium, retinal pigment epithelium tear, visual acuity reduced, vitreous haemorrhage, vitreous disorder, uveitis, iritis, iridocyclitis, cataract, cataract subcapsular, posterior capsule opacification, punctuate keratitis, corneal abrasion, anterior chamber flare, vision blurred, injection site haemorrhage, eye haemorrhage, conjunctivitis, conjunctivitis allergic, eye discharge, photopsia, photophobia, ocular discomfort, eyelid oedema, eyelid pain, conjunctival hyperaemia.
GRADE 0 = No Reaction 1 = Mild 2 = Moderate 3 = Severe 4 = Very Severe
Spain France The Netherlands United Kingdom
Spain France The Netherlands United Kingdom
Spain France The Netherlands United Kingdom
Spain France The Netherlands United Kingdom
165 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
- were previously already controlled on rather low blood glucose levels,
From the 4th to the 8th year, patients were permitted the concomitant use of bisphosphonates, calcitonin and fluorides and all patients in this study received calcium and vitamin D supplementation.
- Carbamazepine (used to treat epilepsy/ seizures and some forms of pain or depression)
• The patient alert card, which is to be given to patients using Remicade.
The patient alert card, which is to be given to patients using Remicade.
creatinine clearance (ml/ min) ClCR ≥ 60 30 < ClCR < 60
The dose can be set in steps of 2 units, from a minimum of 2 units to a maximum of 40 units.
Where there is involvement of the tongue, glottis or larynx adrenaline should be administered.
Time (minutes) from administration of rocuronium and sugammadex or succinylcholine to recovery of the T1 10%
Time (minutes) from administration of sugammadex or neostigmine at reappearance of T2 after rocuronium or cis-atracurium to recovery of the T4/ T1 ratio to 0.9 Neuromuscular blocking agent
Time (minutes) from administration of sugammadex or neostigmine at reappearance of T2 after rocuronium or vecuronium to recovery of the T4/ T1 ratio to 0.9 Neuromuscular blocking agent Rocuronium
Time (minutes) from administration of sugammadex or neostigmine at deep neuromuscular blockade (1-2 PTCs) after rocuronium or vecuronium to recovery of the T4/ T1 ratio to 0.9
Waiting times for re-administration with neuromuscular blocking agents after reversal with sugammadex:
Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph-positive ALL).
- levodopa (used to treat Parkinson's disease)
Aujeszky's Disease Virus, strain NIA3- 783: ≥ 105.2 CCID50* per dose.
Likewise, EVISTA is indicated for the treatment of osteoporosis or established osteoporosis in women with BMD of the spine 2.5 SD below the mean value of a normal young population and/ or with vertebral fractures, irrespective of BMD.
Likewise, OPTRUMA is indicated for the treatment of osteoporosis or established osteoporosis in women with BMD of the spine 2.5 SD below the mean value of a normal young population and/ or with vertebral fractures, irrespective of BMD.
Perform a one- handed technique by GENTLY pressing the needle protection device against a flat surface.
- phenytonin (used to treat epilepsy), Warfarin or phenprocoumon (used to thin the blood) or
- atazanavir (another medicine to treat HIV-infection)
The safety of this drug combination has not been established and this combination is not recommended.
- Warfarin (used to prevent blood from clotting) or other anticoagulants
A supply of drinking water will be needed.
- efavirenz (another medicine to treat HIV-infection)
Mild erythematous lesions have been observed.
Erythropoietin was administered to 10% of patients in 8% of courses.
assessment Months (95% CI) Overall response rate by
Atazanavir inhibits UGT and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities.
Oxycodone – (used as a pain-killer) Lorazepam – (used for treating anxiety) Alcohol
stearate, polysorbate 80, red iron oxide (E172), sucrose, titanium dioxide (E171), and yellow iron oxide (E172).
Applications ended positively in 2000 (1st and 2nd level of classification)
Centralised applications Variations Pre -submission regulatory advice Scientific advice ICH-derived CPMP guidelines adopted Other CPMP guidelines adopted Non-EU AD reports Referrals Meeting days
I Applications for new MRLs I Applications for new medicinal products
• Preparation for implementation of the clinical trials directive
Applications for orphan medicinal product designation 2000-2002
Applications for orphan medicinal product designation by therapeutic class 2000
Applications for orphan medicinal product designation
MRL ext. / mod. applications New MRL applications
There were a total of 31 applications, of which 12 were for authorisation of designated orphan medicines.
I Applications received (non-orphan medicines) I Applications received (orphan medicines)
Pharmaceutical Strength
Ask your doctor or pharmacist to write it down (including the colour). • which days are your dosing days.
Ask your doctor or pharmacist to write it down (including the colour). • which days are your dosing days.
Ask your doctor to have someone help you become thoroughly familiar with the use of the nebuliser.
Talk with your doctor about the best way to feed your baby.
Ask your doctor for advice before breast-feeding your baby, as it is not known if TORISEL passes into breast milk.
Your doctor will be able to advise you. • if you have/ your child has a bleeding problem or bruise/ bruises easily.
overgrowth of tissue at the site of skin injury, scar pain, scab, presence of skin moles, abnormal hair growth
- if you have any signs of bleeding in the stomach or intestine, such as passing a black or blood-
- Itching, rash, hair loss, acne, increased sweating
- severe itching of the skin (with raised lumps).
Generally, one kit is used.
Preparation to take over EudraNet services from the European Commission Joint Research Centre as of January 2003 began in earnest September 2002, following earlier implementation of an EMEA firewall and new Internet service provider in July 2002.
Alimta was also compared with gemcitabine (another anticancer medicine), both in combination with cisplatin, in a study involving 1,725 patients who had not received chemotherapy for lung cancer in the past.
Also, in 53 paediatric patients under the age of 6, also diagnosed with severe to moderately severe haemophilia A (FVIII ≤ 2%), with previous exposure to factor VIII concentrates ≥ 50 days, no FVIII inhibitor was detected.
Combivir should also not be taken with stavudine, as zidovudine the other active substance in Combivir may reduce the action of this medicinal product.
Similarly, the significant advantages for Enbrel monotherapy compared with methotrexate monotherapy were also observed after 24 months.
Regular blood and urine tests to measure the levels of the body's important electrolytes are also necessary to help your or your child's doctor correctly adjust the doses of these supplements.
Similarly, mean free and total cobalamins-(III) Cmax values of 197 and 995 µg eq/ ml, respectively, were determined following the dose of 10 g Cyanokit.
The potential for cross-resistance between efavirenz and NRTIs is low because of the different binding sites on the target and mechanism of action.
The company will also carefully control the distribution of the medicine in each Member State, and collect information on its use in patients with systemic sclerosis and ongoing digital ulcers.
Equally, the European Parliament and Commission have continued to support the work of the EMEA; in particular the Commission has identified the possibility for reducing the time required for the granting of Community marketing authorisations.
(3.48 – 5.12) Similarly the ratio for the Cmax was 1.82 (1.52-2.17).
Other disorders of mineral metabolism (such as vitamin D deficiency and hypoparathyroidism) should also be effectively treated before starting alendronate.
Do not leave the syringe exposed to direct sunlight.
Similarly, there was no clinically significant pharmacokinetic interaction of Starlix with other oral antidiabetic agents such as metformin or glibenclamide.
Anticholinergic medicinal products should be used with caution in patients who have hiatus hernia/ gastro-oesophageal reflux and/ or who are concurrently taking medicinal products (such as bisphosphonates) that can cause or exacerbate oesophagitis.
Similarly, at least 5 weeks should elapse after discontinuing fluoxetine treatment before starting a MAOI.
ut evidence for the formation of active metabolites.
Albertslund Denmark
Half-life The half-life is approximately 28.5 days (95% confidence interval, 25.5 – 32.8 days).
ed baseline FEV1 < 70% predicted have not been established and the use of inhaled human insulin in this population is not recommended A follow-up lung function measurement is recommended after the first 6 months of therapy.
A great deal of additional information on the European Union is available on the Internet.
There are a number of known interactions between non selective MAO inhibitors and other medicinal products.
Many people have played a part in the Agency’s development, but I would like to pay special tribute to Strachan Heppell.
Many of the above adverse reactions are often due to an increase in plasma levels of other anticonvulsant medicinal products (See, sections 4.4 and 4.5) and may regress when the dose of these medicinal products is reduced.
Many of the above adverse reactions are often due to an increase in plasma levels of other anticonvulsant medicinal products (See, sections 4.4 and 4.5) and may regress when the dose of these medicinal products is reduced.
427 Many factors may influence your blood sugar level.
436 Many factors may influence your blood sugar level.
455 Many factors may influence your blood sugar level.
459 Many factors may influence your blood sugar level.
482 Many factors may influence your blood sugar level.
486 Many factors may influence your blood sugar level.
497 Many factors may influence your blood sugar level.
501 Many factors may influence your blood sugar level.
507 Many factors may influence your blood sugar level.
511 Many factors may influence your blood sugar level.
517 Many factors may influence your blood sugar level.
527 Many factors may influence your blood sugar level.
531 Many factors may influence your blood sugar level.
543 Many factors may influence your blood sugar level.
553 Many factors may influence your blood sugar level.
558 Many factors may influence your blood sugar level.
568 Many factors may influence your blood sugar level.
577 Many factors may influence your blood sugar level.
596 Many factors may influence your blood sugar level.
613 Many factors may influence your blood sugar level.
623 Many factors may influence your blood sugar level.
638 Many factors may influence your blood sugar level.
647 Many factors may influence your blood sugar level.
656 Many factors may influence your blood sugar level.
666 Many factors may influence your blood sugar level.
683 Many factors may influence your blood sugar level.
693 Many factors may influence your blood sugar level.
702 Many factors may influence your blood sugar level.
708 Many factors may influence your blood sugar level.
717 Many factors may influence your blood sugar level.
727 Many factors may influence your blood sugar level.
737 Many factors may influence your blood sugar level.
754 Many factors may influence your blood sugar level.
764 Many factors may influence your blood sugar level.
Many factors may influence your blood sugar level.
Because many medicinal products are excreted in human milk and because of the potential for serious adverse reactions, women taking< Zocord > should not breast-feed their infants (see section 4.3).
Many medicines affect the way glucose works in your body and they may influence your insulin dose.
Many patients with osteoporosis have no symptoms but they are still at risk of breaking bones because osteoporosis has made their bones weaker.
Many patients treated with Caelyx have baseline myelosuppression due to such factors as their pre-existing HIV disease or numerous concomitant or previous medications, or tumours involving bone marrow.
Drospirenone + Ethinylestradiol
OPINION FOLLOWING AN ARTICLE 29(4) 1 REFERRAL FOR Lisonorm and associated names International Non-Proprietary Name (INN): lisinopril + amlodipine
Haemophilus influenzae type b polysaccharide (polyribosyl ribitol phosphate) conjugated to tetanus toxoid and Neisseria meningitidis serogroup C (MenC) polysaccharide conjugated to tetanus toxoid
NAME OF THE MEDICINAL PRODUCT AND IF NECESSARY ROUTE(S) OF ADMINISTRATION
NAME OF THE MEDICINAL PRODUCT AND IF NECESSARY ROUTE(S) OF ADMINISTRATION
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION
NAME OF THE ADMINISTRATION
NAME OF THE MEDICINAL PRODUCT AND IF NECESSARY ROUTE(S) OF ADMINISTRATION
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION
Porcilis Porcoli emulsion for injection
New onset diabetes mellitus, hyperglycaemia or exacerbation of existing diabetes mellitus has been reported in patients receiving PIs.
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI:
resource measurement will be developed in collaboration with national competent authorities in order to streamline and improve the current process.
in advance of the formal 30 day limit.
Deoxyribose phosphorothioate (5’-
Deoxyribose phosphorothioate (5’- tct-ccc-agc-gtg-cgc-
International partners European Department for the Quality of Medicines Financial control
Japan, Turkey, Ukraine and US.
The European Department for the Quality of Medicines (EDQM)
Note for guidance on stability testing of existing active substances and related f inished products
Month 12 Proportion of patients with a clinically meaningful improvementd
OPERATING EXPENDITURE OPERATING EXPENDITURE Meetings
Small ad hoc expert working groups will be organised for some products during the evaluation phase to reinforce CPMP scientific expertise as appropriate.
- epilepsy or other seizure disorders not controlled by medication
In addition a further 24 patients with MDS/ MPD were reported in 13 publications.
In addition, salmon calcitonin could be administered by intravenous injection after previous rehydration.
In addition, salmon calcitonin could be administered by intravenous injection after previous rehydration.
Also, Atripla should not be taken with any other medicines that contain efavirenz, emtricitabine, tenofovir disoproxil, lamivudine or adefovir dipivoxil.
In addition, in twice daily application, 14 out of 18 (78%) and 11 out of 18 (61%) reached Cmin values of 1-3 µg/ml and Cmax values of 3-4 µg/ml, whereas in TID application only 4 out of 18 (22%) and 7 out of 18 (39%) reached these values.
Furthermore, Axura has minor or moderate influence on the ability to drive and use machines such that outpatients should be warned to take special care.
Furthermore, Axura has minor to moderate influence on the ability to drive and use machines such that outpatients should be warned to take special care.
Furthermore CEPROTIN is indicated for short-term prophylaxis in patients with severe congenital protein C deficiency if one or more of the following conditions are met: • surgery or invasive therapy is imminent • while initiating coumarin therapy • when coumarin therapy alone is not sufficient • when coumarin therapy is not feasible.
Furthermore CEPROTIN is used to prevent thrombosis in patients with severe congenital protein C deficiency if one or more of the following conditions are met: • surgery or invasive therapy is imminent • while initiating coumarin (anticoagulant medication, blood thinner) therapy • when coumarin therapy alone is not sufficient • when coumarin therapy is not feasible.
In turn, this allows efficient excretion of the serum phosphate load preventing further deterioration of renal function from calcium/ phosphorus precipitation.
John's Wort – Hypericum perforatum – preparations) may lead to an incidence of serotonin associated effects (serotonin syndrome: see section 4.4).
In addition, as with all protein medicines, some patients may develop antibodies (proteins that are produced in response to Valtropin).
Moreover, as is the case for all oral administrations, the active substance undergoes a first pass effect.
53 and/ or rash (Churg-Strauss syndrome) have been reported.
In addition, rare cases of transient loss of consciousness, which may be preceded by vagal symptoms, have been reported (see section 4.8).
Furthermore, work was done to improve version control and minimise duplication of documents.
In addition, measures necessary to ensure patient airways should be provided.
Furthermore, Ebixa has minor or moderate influence on the ability to drive and use machines such that outpatients should be warned to take special care.
Furthermore, Ebixa has minor to moderate influence on the ability to drive and use machines such that outpatients should be warned to take special care.
Furthermore, it is important that you carefully read the package leaflets that are provided with these medicines.
In addition it is not possible to separate blisters from cardboard wallets and therefore the users always have access to the required information.
It further induces the internalisation of EGFR, which can lead to down-regulation of EGFR.
In addition, there was no evidence of loss of efficacy throughout the duration of the clinical trial.
In addition, the oral cavity was inspected by the clinician or nurse 15-20 minutes after treatment to check for local irritation, no abnormal results were identified and the tablets were well tolerated after both single and repeat doses.
In addition, systemic clearance values were greater in younger paediatric patients and decreased with age, approaching adult values around 12 years of age.
Furthermore, the method provided was validated over a range using fortified samples.
In addition, an updated RMP should be submitted:
In addition, the powder will dissolve more readily if both vials are first allowed to reach room temperature (15°C – 25°C).
Furthermore, Activated Protein C is an important modulator of the systemic response to infection and has antithrombotic and profibrinolytic properties.
In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased 79% and 200% respectively.
In addition, simvastatin moderately increases high density lipoprotein (HDL) cholesterol and reduces plasma triglycerides.
In addition benzalkonium chloride may cause eye irritation and is known to discolour soft contact lenses.
Furthermore the CHMP concluded that the following information should be included in the Summaries of Product Characteristics and relevant sections of the Package Leaflets:
Furthermore, the CHMP did not agree that particles larger then 6 µm are not relevant for the demonstration of efficacy, as even such large particles may penetrate to the peripheral airways.
Further, GLP-1 does not impair the normal glucagon response to hypoglycaemia.
Furthermore, losartan does not inhibit ACE (kininase II), the enzyme that degrades bradykinin.
Furthermore Losartan does not inhibit ACE (kininase II), the enzyme that degrades bradykinin.
In addition, paclitaxel induces abnormal arrays or “ bundles ” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
In addition, paclitaxel induces bundles of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
Also, the process used for making the finished medicine had not been adequately validated.
In addition, patients with rheumatoid arthritis should not receive MabThera if they have an active severe infection, severe heart failure or severe heart disease.
In addition, patients without hypercalcaemia will also receive supplementary doses of calcium and vitamin D daily.
Additionally, patients treated with ribavirin and zidovudine could be at increased risk of developing anaemia (low number of red blood cells).
could be at increased risk of developing anaemia (low number of red blood cells).
In addition, the following issues should be included in the RMP proposal:
The relationship between national competent authorities and the EMEA was further consolidated with the conclusion of a partnership agreement at the end of the year.
In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased by 154% and 87%, respectively in cirrhotic subjects compared to subjects with normal hepatic function.
In addition, the test used in the study to investigate the potential for the medicine to trigger an immunological response (when the body makes special proteins, called antibodies, against the medicine) had not been sufficiently validated.
Moreover the MAH submitted a proposal for harmonised chemical-pharmaceutical sections of the SPC and PL.
In addition, the study demonstrated indirectly the same lung deposition with a trend to a deeper lung deposition based on a higher ratio in Cmax and a shorter Tmax.
Furthermore, polyoxol 40 hydrogenated castor oil and potassium present in Kaletra oral solution may cause only at high inadvertent doses gastrointestinal upset.
In addition, MabThera can be used to treat adults with severe rheumatoid arthritis (a disease that causes inflammation of the joints).
In addition there are only limited data available on the pharmacokinetics of salmeterol because of the technical difficulty of assaying the drug in plasma due to the low plasma concentrations at therapeutic doses (approximately 200 picogram/ ml or less) achieved after inhaled dosing.
20 Also, if you have/ your child has already been infected with hepatitis A or B virus (although not yet feeling unwell) before having both doses of Ambirix, the vaccine may not be able to prevent you/ your child becoming ill.
In addition, etravirine demonstrates a fold change (FC) in EC50 ≤ 3 against 60% of 6,171 NNRTI-resistant clinical isolates.
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, a post-hoc definition of response is provided in the same table.
In addition, an updated RMP should be submitted;
In addition, an updated RMP should be submitted:
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities. • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached. • At the request of the EMEA.
In addition, an updated RMP should be submitted − When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities − Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached − At the request of the EMEA
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA.
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
56 In addition, an updated RMP should be submitted: • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA.
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted: na
In addition, an updated RMP should be submitted:
In addition, an updated RMP should be submitted: − When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities. − Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached. − At the request of the EMEA.
Furthermore a reduction of dosage or termination of therapy may be considered.
In addition, a statistically significant reduction in the incidence of hip fractures was confirmed (1.1% versus 2.2%, a reduction of 51%). • FIT 2:
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted * When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities * Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached ''. * At the request of the EMEA.
In addition, an updated RMP should be submitted
In addition, an updated RMP should be submitted:
In addition, a vial at room temperature ensures sufficient elasticity of the rubber closure to minimise any coring of rubber particles.
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted: • when new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • within 60 days of an important (Pharmacovigilance or risk minimisation) milestone being reached • at the request of the EMEA.
In addition, an updated RMP should be submitted: • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, your doctor may consider giving you an additional dose of efavirenz to treat your HIV infection.
DepoCyte contains cytarabine in a special formulation: the active substance is contained in liposomes (small fatty particles) from which it is slowly released.
DepoCyte was to be injected intrathecally.
DepoCyte is to be administered by slow injection over a period of 1-5 minutes directly into the cerebrospinal fluid (CSF) via either an intraventricular reservoir or by direct injection into the lumbar sac.
DepoCyte should be injected slowly over a period of 1-5 minutes.
DepoCyte should be withdrawn from the vial immediately before administration.
DepoCyte should be administered only under the supervision of a physician experienced in the use of cancer chemotherapeutic agents.
DepoCyte must be used as supplied; do not dilute (see section 6.2).
DepoCyte must be used as supplied without further dilution.
DepoCyte is administered directly into the CSF via an intraventricular reservoir or by direct injection into the lumbar sac.
DepoCyte is a sustained-release formulation of cytarabine, designed for direct administration into the cerebrospinal fluid (CSF).
DepoCyte is a ‘ depot'injection (a type of injection where the medicine is prepared in such a way that it is absorbed by the body very slowly).
DepoCyte is a suspension for injection that contains 50 mg of the active substance cytarabine.
DepoCyte is a suspension for injection that contains 50 mg of the active substance, cytarabine.
DepoCyte is a vial containing a white to off-white-suspension for injection.
DepoCyte is used to treat lymphomatous meningitis.
DepoCyte must not be administered by any other way.
DepoCyte should only be given by a doctor who has experience in the use of anti-cancer medicines.
DepoCyte must not be administered by any other route of administration.
Place one drop of the vaccine solution on the eye of each bird, allow the drop to spread and release the bird.
Xanthine deposition As with other urate lowering medicinal products, in patients in whom the rate of urate formation is greatly increased (e. g. malignant disease and its treatment, Lesch-Nyhan syndrome) the absolute concentration of xanthine in urine could, in rare cases, rise sufficiently to allow deposition in the urinary tract.
Emotional disorder Suicidal ideation
Depression, irritability, insomnia, anxiety*, concentration impaired, emotional lability*
Depression*, sleep terror, nervousness, abnormal behaviour*, disorientation*
Depression Pre-existing depression may be unmasked during benzodiazepine or benzodiazepine-like agent use.
Classical Swine Fever Virus (CSFV) -E2 subunit antigen:
Labesfal - Laboratórios Almiro, S. A., Avenida Dr Afonso Costa P-3465-051 Campo de Besteiros Portugal
Since 1997 he is an active participant in the CVMP and VMRF group.
Since 2002, the MRP indications also include the monotherapy of 4 mg paediatric formulations in the treatment of mild asthma in exceptional cases, i. e. when inhaled corticosteroids cannot be used.
In some cases, severely elevated blood pressure requiring immediate treatment has been reported in postmarketing experience.
In the post-marketing period there was one reported overdose of 10,000 mg of bosentan taken by an
Adverse reactions have also been reported during post-marketing experience* as they are derived from spontaneous reports, incidences cannot be determined.
From the start the Management Board has laid great emphasis on the Agency's accountability and transparency.
From July onwards, new Windows NT4 workstations were gradually introduced.
This will lessen the chance for ribavirin to be left in the woman’s body.
Rare reports have been received of exacerbation of autoimmune conditions.
Lymphadenopathy was uncommonly (0.8%) reported in clinical trials.
Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received.
Seizures have been reported to occur rarely in patients when treated with olanzapine.
Rare cases of elevated liver enzymes and hepatocellular dysfunction have occurred in post-marketing experience.
Rare cases of elevated liver enzymes and hepatocellular dysfunction have occurred in post-marketing experience.
Rare cases of elevated liver enzymes and hepatocellular dysfunction have been reported. marketing experience.
Rare cases of thrombotic microangiopathy have been reported.
Rare reports of pancytopenia including aplastic anaemia have been reported with TNF antagonists.
Rare reports of pancytopenia including aplastic anaemia have been reported with TNFantagonists.
Rare reports of pancytopenia including aplastic anaemia have been reported with TNF atagonists.
Rare reports of pancytopenia including aplastic anaemia have been reported with TNF blocking agents.
Pulmonary disorders There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown aetiology such as pneumonitis, interstitial pneumonia, lung infiltration, and acute respiratory distress syndrome (ARDS) in patients receiving VELCADE (see section 4.8).
Rare cases of transient loss of consciousness (fainting), which may be preceded by vagal symptoms (malaise, gastrointestinal distress), have been reported.
ho The adverse event profile reported in the ACS program is consistent with the adverse drug reactions identified for VTE prophylaxis.
Rare cases of syncope in association with orthostatic hypotension have been observed.
Haemorrhage has been observed rarely in patients treated with SUTENT (see section 4.4).
Rare cases of hepatitis, potentially serious, have been reported during clinical studies with pemetrexed.
Rare cases of hyperthyroidism, some followed by hypothyroidism, have been reported in clinical trials and through post-marketing experience.
There have been rare reports of hypokalaemia and renal failure (including fatalities).
Rare cases of hepatic failure (including fatalities) have been reported during use of Tarceva.
Rare cases of hepatic failure (including fatalities) have been reported during use of Tarceva.
Rare cases of hepatic failure (including fatalities) have been reported during use of Tarceva.
Rare cases of hepatic failure (including fatalities) have been reported during use of Tarceva.
Ear and labyrinth disorders Rare cases of ototoxicity, hearing impaired and/ or hearing loss have been reported.
Rare cases reported as NMS have also been received in association with oral olanzapine.
Rare cases reported as NMS have also been received in association with olanzapine.
Post marketing Rare cases suggestive of hypersensitivity, which could include skin erythema, bradycardia, hypotension or anaphylactic shock have been reported following the injection of SonoVue.
Painful skin reactions at the opening of the vagina have very rarely made it difficult for some women to pass urine.
% reduction, p-value for rate ratio Emergency visits
% reduction, p-value for rate ratio Severe asthma exacerbations
With the bottle upright, fit the tip of the syringe into the bottle adapter.
% responders* p-value** AQL improvement
c - genotypic ETVr with virologic d breakthrough a
c - genotypic ETVr with virologic d breakthrough a
Dermapharm GmbH Arzneimittel Lochhamer Schlag 10 D-82166 Gräfelfing
Serous Drainage1, Herpes Simplex, Pustular Rash, Skin Discoloration3 Hair Disorder1, Nail Disorder1,3
Exfoliative dermatitis, petechiae, contusion, palmar-plantar erythrodysaesthesia syndrome, generalised rash, erythema, pruritic rash, alopecia, maculo-papular rash, skin disorder, localised exfoliation, erythematous rash, skin hyperpigmentation, increased sweating, dry skin
Percentage of Patients Experiencing the ADR Treatment Prevention
This leaflet was last approved in (MM/YYYY)
This summary was last updated on 18.12.2006.
This summary was last updated in 08-2006.
This summary was last updated in 04-2006
This summary was last updated in 04-2006.
This summary was last updated in April 2008.
This summary was last updated in 12-2005
This summary was last updated in December 2006.
This summary was last updated in 02-2006
This summary was last updated in February 2007.
This summary was last updated in 1-2006
This summary was last updated in January 2007
This summary was last updated in January 2009.
This summary was last updated in June 2006.
This summary was last updated on 17 March 2009.
This summary was last updated in 03-2006
This summary was last updated in 03-2006.
This summary was last updated in March 2006.
This summary was last updated in 03-2007.
This summary was last updated in November 2006.
This summary was last updated in November 2008.
This summary was last updated in October 2008.
This summary was last updated in September 2007.
This summary was last updated in September 2008.
This summary was last updated in September 2008.
median (range) EDSS-baseline, median (range)
8 From the 195 patients that originated in C04-001, C04-002 and other initial studies, Soliris-treated PNH patients were enrolled in a long term extension study (E05-001).
Abscesses may be observed at the injection site.
Abscesses may be seen at the injection site.
site has not been examined, it is advised to carry out the second vaccination at a different site than the first vaccination.
Various chromosome aberrations have been observed in cells from patients receiving oral busulfan.
Dose adjustment should be considered based on the patient’s clinical response to methadone therapy.
Uterine adenocarcinomas, of epigenetic origin, could be related to an enzyme induction of CYP1 family.
Some materials (allergens) like pollens, house dust or animal fur may cause allergic reactions resulting in itching, redness as well as swelling of the surface of your eye.
SVR after treatment of chronic HCV with non pegylated interferon alfa-2b (with or without ribavirin) results in long-term clearance of the virus providing resolution of the hepatic infection and clinical'cure' from chronic HCV.
As an adjunct to medication, good management and hygiene practices should be introduced in order to reduce the risk of infection and to control the build up of resistance.
In addition to medical treatment, good management and hygiene practices should be established on the farm in order to reduce the risk of infection and to control the build up of resistance.
As an adjunct to medication, good management and hygiene practices should be introduced in order to reduce the risk of infection and to control the potential build up of resistance.
Minimal increases in QTc, not considered to be clinically relevant, were observed in one study at a dose of 800 mg sitagliptin.
Impairments of sperm parameters have been observed among some patients treated with Rapamune.
Bone changes including premature epiphyseal closure, hyperostosis, and calcification of tendons and ligaments have occurred after several years of administration at very high doses for treating disorders of keratinisation.
Some specific areas for improvements were identified by the questionnaire, including preparation by companies for oral hearings, quality of translations as well as the mechanism for their submission and assessment, and clarification on how questions from the CPMP are dealt with by companies.
Improvements were made to streamline the process by which certificates are produced and in their detailed content following suggestions by user companies.
Improvements to the presentation of and access to information on the CD-ROM will be made.
Improvements will also be made to the information made available to delegates relating to new developments at the EMEA as well its immediate environment, Canary Wharf.
Analyses of estimated radiation absorbed dose were carried out using quantitative imaging with the gamma-emitter [111In]-radiolabelled Zevalin, blood sampling, and the MIRDOSE3 software program.
Angioedema of the face, extremities, lips, mucous membranes, tongue, glottis and/ or larynx has been reported rarely in patients treated with ACE inhibitors, including< COVERSYL and associated names > (see 4.8 Undesirable effects).
Congenital anomalies were reported in 14.5% of exposed pregnancies.
Developmental abnormalities in the brain have been detected in mice given azacitidine on or before closure of the hard palate.
Undesirable effects on the testis observed in rodent toxicity studies suggest that docetaxel may impair male fertility.
- bleeding in the gut or lung within the past three months.
Previous history of thromboembolic events or concomitant administration of erythropoietic agents or other agents such as hormone replacement therapy, may also increase thrombotic risk in these patients.
• antibiotics and antivirals may be given to provide you with extra protection.
- medicines used to prevent blood-clotting (warfarin, heparin and dicoumarol)
Antibodies to infliximab may develop and have been associated with an increased frequency of infusion reactions.
Post-dose neutralising antibodies were detected in 1 of 447 patients (0.2%) and 7 of 447 patients (1.6%) tested by the ELISA and Biosensor Immunoassay respectively.
Antibodies were detectable in adults and offspring during the gestation and lactation periods.
Antibodies were detected on only one occasion in an additional 4% of patients.
Serum and vitreous antibodies to ranibizumab were found in a subset of treated animals.
Elevated bilirubine (n=3) and elevated AST (n=1) were also observed.
Increased concentrations of simvastatin and lovastatin have been associated with rhabdomyolysis.
24 Dose-proportional increases in exposure of Pegasys are seen in healthy subjects and in patients with chronic hepatitis B or C after once-weekly dosing.
50 Dose-proportional increases in exposure of Pegasys are seen in healthy subjects and in patients with chronic hepatitis B or C after once-weekly dosing.
76 Dose-proportional increases in exposure of Pegasys are seen in healthy subjects and in patients with chronic hepatitis B or C after once-weekly dosing.
Increased levels of serum liver enzymes have been reported in patients taking deferiprone.
Elevations to > 8 × ULN were seen in 2.4% of bosentan-treated patients with digital ulcers.
Authorisation Holders has been assessed based on the documentation submitted and the scientific discussion within the Committee
other ingredients of MIRCERA (see section 6)
• See the ORENCIA package leaflet for more information. • Please make sure you also have a list of all your other medicines with you at any visit to a health care professional.
Significant advantages for Enbrel in combination with methotrexate compared with Enbrel monotherapy and methotrexate monotherapy were also observed after 24 months.
Significant advantages for Enbrel in combination with methotrexate compared with Enbrel monotherapy and methotrexate monotherapy were also observed after 24 months.
Final advice was given for 25 requests.
General advice has also been given on the manufacture and control of biotechnological and biological medicinal products, including products derived from blood and plasma, and of immunological products.
Packs of 3, 4, 5, 6, 9 and 10 cartridges of 3 ml are available.
Packs of 3, 4, 5, 6, 9 and 10 pens of 3 ml are available.
Packs of 3, 4, 5, 6, 9 and 10 cartridges of 3 ml are available.
Packs of 3, 4, 5, 6, 9 and 10 cartridges of 3 ml are available.
Packs of 3, 4, 5, 6, 9 and 10 cartridges of 3 ml are available.
Abuse of benzodiazepines and benzodiazepine-like active substances has been reported.
Insomnia AnxietySlee p disorder Agitation Libido decreased
Suicidal behaviour Suicidal ideation 4 Mania Aggression and anger 5
There have been reports of exacerbation of chronic liver dysfunction, including portal hypertension, in patients with underlying hepatitis B or C, cirrhosis and other underlying liver abnormalities.
Cases of agranulocytosis, thrombocytopenia, leukopenia, aplastic anaemia, pancytopenia and leucocytosis have been reported.
Haemophilia: there have been reports of increased bleeding, including spontaneous skin haematomas and haemarthrosis in patients with haemophilia type A and B treated with protease inhibitors.
There have been reports of increased bleeding including spontaneous skin haematomas and haemarthroses in haemophiliac patients type A and B treated with protease inhibitors (PIs).
There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophiliac patients type A and B treated with PIs.
There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophiliac patients type A and B treated with PIs.
Brady- and tachyarrhythmias have been reported.
• There have been cases of cancers, other than lymphoma in patients with a specific type of lung disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.
Cancers were reported in patients taking ISENTRESS.
Cancers were reported in treatment-experienced patients who initiated ISENTRESS with OBT; several were recurrent.
Diarrhoea has occurred in approximately 50% of patients on Tarceva and moderate or severe diarrhoea should be treated with e. g. loperamide.
Diarrhoea has occurred in approximately 50% of patients on Tarceva and moderate or severe diarrhoea should be treated with e.g. loperamide.
There have been reports of decreased lamotrigine plasma levels during pregnancy with a potential risk of loss of seizure control.
Reductions in blood cell and platelet counts have also occurred.
Abdominal pain, indigestion, diarrhoea, nausea and vomiting have been reported.
Dysphagia has been reported following injection to sites other than the cervical musculature.
Focal segmental glomerulosclerosis has been reported.
There have been reports of leukopenia, hepatic necrosis, nephrotic syndrome, and aplastic anaemia.
There have been post-marketing reports of leukopenia, thrombocytopenia or pancytopenia, or aggravation of these cytopenias in patients treated with EXJADE.
Reports of lack of effect, mainly in prophylaxis patients, have been received in the clinical trials and in the post-marketing setting for ReFacto.
Cases of Pulmonary embolism were observed in approximately 1.3% of patients with GIST and in approximately 0.8% of patients with MRCC, who received Sutent in Phase 3 studies (see section 4.4 - Venous Thromboembolic Events).
Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leucoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including Mycophenolate mofetil Teva.
There have been reports of cutaneous bleeding abnormalities such as ecchymosis and purpura with SSRI's.
Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam).
Cases of overdose (some with signs of systemic toxicity) have been reported.
Cases of overdose have been reported during post-marketing surveillance.
4.9 Overdose Reports of overdoses with mycophenolate mofetil have been received from clinical trials and during post-marketing experience.
Reports of overdoses with mycophenolate mofetil have been received from clinical trials and during post-marketing experience.
New or worse cases of macular oedema have occurred on rare occasions in people taking Avaglim and similar medicines.
New or worse cases of macular oedema have occurred on rare occasions in people taking Avandamet and similar medicines.
New or worse cases of macular oedema have occurred on rare occasions in people taking Avandia and similar medicines.
Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone.
Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone.
Serious antiepileptic drug hypersensitivity syndrome has occurred in association with rufinamide therapy.
Cases of abnormal electrical conduction in the heart and convulsion have been reported • See a doctor right away.
There have been reports of active tuberculosis in patients receiving Remicade.
- Cases of fulminant hepatitis potentially leading to life-threatening liver failure have been
Acute renal failure has been observed in severely ill patients undergoing treatment with VFEND.
Cystoid macular oedema has been reported with GANFORT.
Common but generally asymptomatic cases of splenomegaly and very rare cases of splenic rupture have been reported in healthy donors and patients following administration of G-CSFs.
Injury, poisoning and procedural complications
In case PRCA is diagnosed, therapy with Aranesp must be discontinued and patients should not be switched to another recombinant erythropoietic protein (see section 4.4).
Dicural 50 mg/ ml solution for injection should only be used based on susceptibility testing.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Whenever possible, fluoroquinolones should only be used based on susceptibility testing.
of a blood cloting factor (thrombocytes)
Headaches were observed in 44.2% (19/43 patients) of patients treated with eculizumab and 27.3% (12/44 patients) in placebo-treated patients and were mild/moderate in all but 1 eculizumab treated and 1 placebo-treated patients.
Similar changes in body fat distribution on pioglitazone have been accompanied by an improvement in insulin sensitivity.
Similar changes in body fat distribution on pioglitazone have been accompanied by an improvement in insulin sensitivity.
Locking intramedullary nails have been used in the majority of cases.
Pseudomembranous colitis may occur with most antibiotics including Tygacil.
The EudraTrack working group was chaired by Aurelio Fernandez Dominguez and Pia Næsborg Andersen, respectively, under the Spanish and Danish presidencies.
Supraventricular and ventricular premature complexes, sinus pause and 3rd degree AV block may be observed in rare cases.
Supraventricular and ventricular premature complexes, sinus pause and 3rd degree AV block may be observed in rare cases.
Suicide-related behaviours (suicide attempts and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger), were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo.
No significant differences were found in patients with mild renal impairment (creatinine clearance < 80 ml/ min) as compared to the control group. – cardiac diseases like conduction disturbances, angina pectoris and recent myocardial infarction, where normal precautions should be taken and concomitant medicines carefully administered. – low blood pressure. – diabetes mellitus:
10 mg film-coated tablets are available for adults 15 years of age and older.
Concentrations (up to 12x) were achieved in the cells (intracellular), compared to the extracellular concentration.
Internal competitions will be conducted to integrate the Agency’s secretarial and clerical staff within the Regulation and Rules applicable to officials and other servants of the European Communities.
Packs of 1, 3, 4, 5, 6, 8, 9 and 10 cartridges are available.
Packs of 1, 3, 4, 5, 6, 8, 9 and 10 pens are available.
Special packs with the correct quantities of syringes or cartridges are available when starting treatment.
62 Additional insulin inhaler, insulin release units and chamber packages are available.
Additional insulin inhaler, insulin release units and chamber packages are available. od
Aseptic conditions (meaning clean and germ free) are required during reconstitution and administration.
In the light of the creation of new scientific committees under the management of Directorate-General XXIV, contacts have been established in order to prevent possible overlap of activities with those of the EMEA scientific committees.
Convulsions (fits and seizures) have been reported in patients treated with Aranesp.
Seizures have been reported with high dose busulfan treatment.
Convulsions have been reported in patients receiving Aranesp.
Convulsions were reported very commonly in the newly- diagnosed glioblastoma multiforme patients receiving monotherapy, and rash was reported very
Convulsions were reported very commonly in the newly- diagnosed glioblastoma multiforme patients receiving monotherapy, and rash was reported very commonly in newly-diagnosed glioblastoma multiforme patients receiving TMZ concurrent with RT and also as monotherapy, and commonly in recurrent glioma.
Convulsions were reported very commonly in the newly- diagnosed glioblastoma multiforme patients receiving monotherapy, and rash was reported very commonly in newly-diagnosed glioblastoma multiforme patients receiving TMZ concurrent with RT and also as monotherapy, and commonly in recurrent glioma.
- inhaled corticosteroids and other medicines for allergic asthma.
3 Description of the patient population treated in clinical studies In two clinical trials of patients with nosocomial pneumonia (N=979), 60% of the clinically-evaluable Doribax-treated patients had ventilator-associated pneumonia (VAP).
Description As an adjunct to the population pharmacokinetics (PK) study nested in the ongoing Phase III trial, the applicant will conduct a clinical PK study in 24 patients with multiple myeloma receiving bortezomib at the doses of 1.0 and 1.3 mg/ m2, twice a week for two weeks followed by a rest period.
25 Seizures Seizures have been uncommonly reported in patients without previous history of seizures or epilepsy.
5 Seizures Seizures have been uncommonly reported in patients without previous history of seizures or epilepsy.
Short courses of corticosteroids can be used in combination with TYSABRI.
Further treatment cycles of TRACTOCILE can be used should contractions recur.
Further treatment cycles of TRACTOCILE can be used should contractions recur.
Stringent definitions, modelled after the Mycoses Study Group Criteria, were used for diagnosis of invasive aspergillosis and for response to therapy (favourable response required clinically significant improvement in radiographs as well as in signs and symptoms).
Depression, suicidal ideation and behaviour and suicide attempts have been reported in patients attempting to quit smoking with Champix in the post-marketing experience.
Depression, rarely including suicidal thoughts and suicide attempt, has been reported in patients undergoing a smoking cessation attempt.
− Diarrhoea or vomiting that is not improving (persistent), as this may reduce how well the medicines you are taking work.
Significant differences in sepsis/ septic shock with tigecycline (1.5%) vs comparators (0.5%) were observed.
Modest decreases in amprenavir activity were noted with a median increase of IC50 from 3.7- to 8-fold in the baseline and rebound isolates, respectively.
Larger decreases in plasma concentrations of paliperidone could occur with higher doses of carbamazepine.
Larger reductions in triglycerides (109±28.2 mg/ dl, p=0.005), VLDL cholesterol (24.7±10.9 mg/ dl, p=0.05), and VLDL triglycerides (86.3±20.2 mg/ dl, p=0.003) were obtained with gemfibrozil compared with simvastatin.
Preliminary discussions have begun on drafting guidelines for the following topics in 1996:
Biochemical data support selective inhibition of HSV-1, HSV-2 and HCMV DNA polymerases by cidofovir diphosphate, the active intracellular metabolite of cidofovir.
Clinical data confirm that CYP3A4 is responsible for the N-
Clinical data obtained from a limited number of patients also indicate that adult PID patients may tolerate an infusion rate of up to 8 ml/kg BW/hr.
Additional data is required to conclude on the influence of K103N when associated with other NNRTIs mutations.
A pooled analysis was conducted of adverse event reports of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8100 patients in the pioglitazone-treated groups and 7400 in the comparator-treated groups of up to 3.5 years duration.
Limited pharmacokinetic information is available in children and adolescents (see section 5.2).
Limited data from clinical trials do not indicate a significantly increased risk of adverse reactions to zidovudine with co-trimoxazole (see interaction information above relating to lamivudine and cotrimoxazole) aerosolised pentamidine, pyrimethamine and acyclovir at doses used in prophylaxis.
Limited data from clinical trials do not indicate a significantly increased risk of adverse reactions to zidovudine with co- trimoxazole (see interaction information above relating to lamivudine and co-trimoxazole), aerosolised pentamidine, pyrimethamine and acyclovir at doses used in prophylaxis.
Limited data are available for reversal of pancuronium induced blockade, but it is advised not to use sugammadex in this situation.
Only a small number of elderly patients (≥ 65 years, n=23/ 872; 2.6%) provided pharmacokinetic data.
Exact data on the main elimination routes for reteplase in humans are not available and the consequences of hepatic or renal insufficiency are not known.
12 Preliminary data suggest that irbesartan may decrease Riprazo AUC and Cmax.
3 Preliminary data suggest that irbesartan may decrease Riprazo AUC and Cmax.
12 Preliminary data suggest that irbesartan may decrease Sprimeo AUC and Cmax.
3 Preliminary data suggest that irbesartan may decrease Sprimeo AUC and Cmax.
Specific data have not been obtained on the use of this product in neurosurgery or in gastrointestinal anastomoses surgery.
Existing data suggest that evening dosing might have some advantages in the mean IOP reduction.
Further data on the clinical translation of the decrease in pharmacokinetic exposure is awaited.
Surveillance data on varicella vaccinated individuals for up to nine years suggest no increase in the frequency of herpes zoster in this population.
- the data on valdecoxib and parecoxib presented in the CABG (Coronary Artery Bypass
- the data on valdecoxib and parecoxib presented in the CABG (Coronary Artery Bypass Graft) and
Doses of up to 150 mg/ kg/ day have been used with good tolerability.
Adequate doses of this medicinal product may restore abnormally low immunoglobulin G levels to the normal range.
Adequate doses of this medicinal product may restore abnormally low immunoglobulin G levels to the normal range.
Doses as high as 15 g have been administered without reported specific dose related adverse reactions.
Doses of 10 mg or 25 mg Enbrel or placebo were administered subcutaneously twice a week for 6 consecutive months.
Doses of 10 mg or 25 mg Enbrel were administered SC twice a week for up to 24 months.
Doses of 200 mg did not result in increased efficacy but the incidence of adverse reactions (headache, flushing, dizziness, dyspepsia, nasal congestion, altered vision) was increased.
Doses of 25 mg Enbrel (based on dose-finding studies in patients with rheumatoid arthritis) or placebo were administered SC twice a week for 6 months.
Doses of 25 mg of Enbrel (based on dose-finding studies in patients with rheumatoid arthritis) or placebo were administered SC twice a week for 6 months.
Doses of 25 mg of Enbrel (based on dose-finding studies in patients with rheumatoid arthritis) or placebo were administered subcutaneously twice a week for 6 months in 138 patients.
Doses of 400 mg/ kg/ day DMA administered during organogenesis caused significant developmental anomalies.
Doses other than 50U per axilla have not been studied and therefore cannot be recommended.
High doses of exenatide during mid-gestation caused skeletal effects and reduced foetal growth in mice and reduced foetal growth in rabbits.
Excessive calcium folinate doses must be avoided since this might impair the antitumour activity of methotrexate, especially in CNS tumours where calcium folinate accumulates after repeated courses.
Increased doses of Botulinum neurotoxin type A may result in pronounced neuromuscular paralysis distant from the injection site.
Take-home doses were provided for weekends.
Multiple oral doses of bupropion had no statistically significant effects on the single dose pharmacokinetics of lamotrigine in 12 subjects and had only a slight increase in the AUC of lamotrigine glucuronide.
250 times the recommended dose) produced emesis, defecation, drooped eyes, trembling and quietness.
Higher doses can produce hepatic necrosis and liver damage can be seen following single high exposures.
Higher rufinamide doses may result in a more pronounced induction.
Doses of up to 3600 mg/ day have been studied in a limited number of patients.
Repeated doses of DMA produced signs of liver toxicity, the first being increases in serum clinical enzymes followed by histopatological changes in the hepatocytes.
Concomitant stable doses of oral aminosalicylates, corticosteroids, and/ or immunomodulatory agents were permitted.
Doses above 1.4 mg/ kg (or in excess of 100 mg) daily have not been studied in paediatric patients.
Doses higher than 70 mg daily have not been adequately studied.
Doses higher than 70 mg daily have not been adequately studied.
Doses higher than the recommended dose result in higher blood levels (as shown by an increase in AUC) but relative bioavailability does not increase.
Additional doses may need to be considered for persons who do not respond or have a sub- optimal response to a course of vaccinations.
Additional doses may need to be considered for persons who do not respond or have a sub-optimal response to a course of vaccinations.
Additional doses may need to be considered for persons who do not respond or have a sub-optimal response to a course of vaccinations.
Single doses of 80 mg/ kg in iron-overloaded thalassaemic patients caused mild nausea and diarrhoea.
Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
Single oral doses of Tarceva up to 1000 mg erlotinib in healthy subjects, and up to 1600 mg in cancer patients have been tolerated.
Single oral doses of Tarceva up to 1000 mg erlotinib in healthy subjects, and up to 1600 mg in cancer patients have been tolerated.
Single doses of the drug inhibit prolactin secretion in animals.
Single doses (up to 10 000 I. U.) of salmon calcitonin have been administered parenterally without adverse effects other than nausea and vomiting, and exacerbation of pharmacological effects.
Single doses up to 1400 mg and multiple doses up to 1400 mg twice daily have been administered to healthy subjects for nine days without clinically significant adverse events.
25 mg twice daily have been administered to healthy subjects for nine days without clinically significant adverse effects.
• Muscle pain or weakness and softening of the bones (both associated with kidney problems)
user; are a smoker,
If thyroid abnormalities are detected, the patient's thyroid status should be evaluated and
Ecchymosis easily occurs in the soft tissues of the eyelid.
Plasma samples were obtained up to 56 days (patients) or 36 days (volunteers) post injection.
Plasma samples taken from sibutramine-treated volunteers caused significant inhibition of both noradrenaline reuptake (73%) and serotonin reuptake (54%) with no significant inhibition of dopamine reuptake (16%).
In the original clinical studies (Phase II/III), adverse events with possible, probable or unknown relationship to ritonavir were reported in ≥ 2% of 1033 patients.
In the original clinical studies (Phase II/III), adverse events with possible, probable or unknown relationship to ritonavir were reported in ≥ 2% of 1033 patients.
21 patients on stiripentol had moderate side- effects (drowsiness, loss of appetite) compared with eight on placebo, but side-effects disappeared when the dose of comedication was decreased in 12 of the 21 cases (Chiron et al, Lancet, 2000).
21 patients on stiripentol had moderate side- effects (drowsiness, loss of appetite) compared with eight on placebo, but side-effects disappeared when the dose of comedication was decreased in 12 of the 21 cases (Chiron et al, Lancet, 2000).
21 patients on stiripentol had moderate side- effects (drowsiness, loss of appetite) compared with eight on placebo, but side-effects disappeared when the dose of comedication was decreased in 12 of the 21 cases (Chiron et al, Lancet, 2000).
Dose- dependent side effects are likely to occur.
Common side effects (likely to occur in fewer than 1 in 10 patients) include:
Gastrointestinal adverse reactions overall occurred in a higher proportion of patients on ORACEA (13.4%) than on placebo (8.6%).
Severe side effects affecting the brain and nervous system have been reported in patients taking Atriance, including somnolence, convulsions, and peripheral neuropathy causing numbness, unusual sensations, weakness and even paralysis.
Undesirable effects may occur from misplaced injections of Botulinum neurotoxin type A temporarily paralysing nearby muscle groups.
Adverse reactions could occur at any timepoint during this period.
Side effects may occur while you are receiving Paxene or following treatment.
Side effects could occur at least up to 3 months after your last dose of RoActemra.
Side effects reported rarely (more than 1 in 10,000 patients and less than 1 in 1,000 patients) are: • Decrease in white blood cells, decrease in blood platelet count • Low blood sugar • Agitation, anxiety, depression, tremor • Irregular heart rate, increased blood pressure, bleeding, fast heart rate • Nasal congestion, cough, bleeding from the nose, pneumonia, abnormal breathing sounds, wheezing • Inflammation of the gall bladder, difficulty in swallowing, faecal incontinence, jaundice, liver disorder • Inflammation of the skin, fungal infection of the skin, skin peeling, infection of the wound after an operation • Muscle cramp, shoulder pain • Urinary tract infection, kidney impairment • Miscarriage, genital bleeding • Allergy, feeling unwell, pelvic peritonitis, changes to the white part of the eye, fainting.
Additional side effects that have been reported include:
Additional side effects that have been reported include:
Adverse events of nausea, dizziness, hypotension and syncope have been observed in single dose interaction studies in healthy volunteers (see section 4.5)
Adverse events of nausea, dizziness, hypotension and syncope have been observed in single dose interaction studies in healthy volunteers (see section 4.5)
Side effects such as dizziness, vertigo, tiredness and visual disturbances sometimes occur in patients taking Agopton.
Adverse drug reactions such as nausea, vomiting, diarrhoea and sweating were reported.
Adverse drug reactions such as somnolence and vertigo have been reported in INTELENCE treated subjects at incidences similar to placebo (see section 4.8).
Side effects such as dizziness, vertigo, tiredness and visual disturbances sometimes occur in patients taking Agopton.
11 Effects in non-clinical studies were observed only at exposures sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.
32 Effects in non-clinical studies were observed only at exposures sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.
Effects in non-clinical studies were observed only at exposures sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.
Significant effects were also obtained in patients with less disseminated and less active disease at the time of the first event, the risk in two years for progression to CDMS in patients with monofocal onset was 47% for placebo and 24% for Extavia, without gadolinium (Gd-) enhancement 41% and 20%, with less than 9 T2 lesions 39% and 18%.
Significant effects were also obtained in patients with less disseminated and less active disease at the time of the first event, the risk in two years for progression to CDMS in patients with monofocal onset was 47% for placebo and 24% for Betaferon, without gadolinium (Gd-) enhancement 41% and 20%, with less than 9 T2 lesions 39% and 18%.
Gastrointestinal effects were observed in the dog at systemic exposure levels equivalent to or less than the clinical exposure at the recommended dose.
Gastrointestinal effects were observed in the dog at systemic exposure levels equivalent to or less than the clinical exposure at the recommended dose.
Gastrointestinal effects were observed in the dog at systemic exposure levels equivalent to or less than the clinical exposure at the recommended doses.
Gastrointestinal effects were observed in the dog at systemic exposure levels equivalent to or less than the clinical exposure at the recommended dose.
Vascular disorders Venous thromboembolic events have rarely been reported.
Considerable efforts were made in 1996 to investigate the costs of the EMEA Secretariat, rapporteurs and co-rapporteurs, and of the national competent authorities themselves.
Elevations in creatine kinase, which are usually asymptomatic, are common amongst patients on intrathecal ziconotide.
Liver function test elevations have been observed in patients treated with EXJADE.
Transient elevations in CSF protein and white blood cells have also been observed in patients following DepoCyte administration and also been noted after intrathecal treatment with methotrexate or cytarabine.
- children from the age of three years, adolescents and adult patients with malignant glioma, such
Sustained virological response rates in children and adolescents
The incidence of these AEs was also higher in patients taking concomitant lipid lowering medications compared with those who did not (0.58% vs 0.39%).
Bleeding episodes related to Paxene were reported in < 3% of patients and bleeding was localised.
Hypoglycaemia has been observed in patients with type 2 diabetes on diet and exercise, and in those treated with oral antidiabetic agents (see section 4.8).
Transient episodes of hypertonia and/ or severe muscular weakness that prevent voluntary movements may occur at any time during treatment.
Investigations: electrolyte imbalance (including hypokalaemia and hyponatraemia, see section 4.4), hyperuricaemia, glycosuria, hyperglycaemia, increases in cholesterol and triglycerides
- mild to moderate rash, including flat or raised rashes or sensitivity to the sun, have been
Mutagenicity testing in bacteria and in rodents yielded negative results.
Long-term studies to assess the safety of the combination are ongoing.
Long-term studies have not been performed to evaluate the carcinogenic potential of infliximab.
Appropriate studies have been made to show the effectiveness of Zactran in cattle.
There is evidence from animal studies that HMG-CoA reductase inhibitors may influence the development of embryos or foetuses.
Studies in the rat have shown that miglustat adversely affects spermatogenesis and sperm parameters, and reduces fertility (see sections 4.6 and 5.3).
In the 30-week placebo-controlled clinical trials, concomitant use of BYETTA and HMG CoA reductase inhibitors was not associated with consistent changes in lipid profiles (see section 5.1).
Evidence from clinical studies shows that lamivudine plus zidovudine delays the emergence of zidovudine resistant isolates in individuals with no prior antiretroviral therapy.
Evidence from clinical studies shows that lamivudine plus zidovudine delays the emergence of zidovudine resistant isolates in individuals with no prior antiretroviral therapy.
In clinical trials robenacoxib reduced the lameness and inflammation of dogs with chronic osteoarthritis and reduced pain and inflammation after orthopaedic or soft tissue surgery in dogs.
Additional in vitro studies in rat and human hepatocytes showed that ambrisentan did not inhibit sodium-taurocholate co-transporter (NTCP), organic anion export pump (OATP), bile salt export pump (BSEP) and multi-drug resistance protein isoform-2 (MRP2).
Additional studies supported these results, showing that Oxyglobin can take up, transport and release oxygen in animals other than cows.
Adequate and well-controlled studies have not been performed in pregnant women.
17 Carcinogenicity studies of etravirine in rodents are ongoing.
Peri- and postnatal development studies were not conducted.
Laboratory studies have shown that administration of the product during early pregnancy in the bitch is unlikely to affect that pregnancy (that is, pregnancy will be carried to full term with the birth of viable pups).
Longer term follow-up studies are ongoing (see section 5.1).
Interaction studies were performed in healthy, female volunteers with betamethasone and labetalol.
Interaction studies have only been performed in adults
Interaction studies have only been performed in adults.
Drug-drug interaction studies have been conducted with platelet inhibitors, including acetylsalicylic acid, ticlopidine, clopidogrel, abciximab, eptifibatide, or tirofiban.
Experimental investigations have shown that interactions are unlikely with medications that are metabolised in the liver.
Additional in vitro studies showed that ambrisentan does not inhibit NTCP, OATP or BSEP.
In vitro and in vivo studies have shown glucosamine stimulates the synthesis of physiological glycosaminoglycans and proteoglycans by chondrocytes and of hyaluronic acid by synoviocytes.
In vitro and in vivo studies have shown that gemfibrozil inhibits CYP2C8, CYP2C9, CYP2C19, CYP1A2, UGTA1 and UGTA3.
In vitro studies show that the metabolism of brinzolamide mainly involves CYP3A4 as well as at least four other isozymes (CYP2A6, CYP2B6, CYP2C8 and CYP2C9).
In vitro studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin and bilirubin encephalopathy can possibly develop in these patients.
20 In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin is CYP3A4, with contribution from CYP2C8.
In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin is CYP3A4, with contribution from CYP2C8.
In vitro experiments have shown that tolcapone binds mainly to serum albumin.
CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A up to the concentration of 3 mM (378 μ g/ ml).
In vitro plasma protein binding studies determined that the mean concentration of the free drug was 74%.
Limited studies have been conducted in patients under 4 years of age with BH4 deficiency using another formulation of the same active substance (sapropterin) or an un-registered preparation of BH4.
Studies in healthy volunteers have shown that tolcapone reversibly inhibits human erythrocyte COMT activity after oral administration.
Studies have confirmed that tadalafil does not inhibit or induce CYP450 isoforms, including CYP3A4, CYP1A2, CYP2D6, CYP2E1, CYP2C9 and CYP2C19.
Studies have shown that these two medicines can be mixed and injected together, without either product being adversely affected.
Studies have shown that Foscan is non-irritant.
Paclitaxel has been shown to be genotoxic in vivo (micronucleus test in mice), but it did not induce mutagenicity in the Ames test or the Chinese hamster ovary/ hypoxanthine-guanine phosphoribosyl transferase (CHO/ HGPRT) gene mutation assay.
Studies have shown that timolol does not dialyse readily.
Limited pharmacokinetic and/ or pharmacodynamic studies investigating possible interactions between anagrelide and other medicinal products have been conducted.
21 asymptomatic subjects with homozygous or double heterozygous protein C deficiency were evaluated for pharmacokinetic data.
21asymptomatic subjects with homozygous or double heterozygous protein C deficiency were evaluated for pharmacokinetic data.
Specific pharmacokinetic studies with elderly subjects showed an increase of 40 to 60% in the AUC and of more than 25% in Cmax compared to young subjects.
Specific pharmacokinetic studies with elderly subjects showed an increase of 40 to 60% in the AUC and of more than 25% in Cmax compared to young subjects.
Preclinical animal studies demonstrated that nephrotoxicity was the major dose-limiting toxicity of cidofovir.
12/ 25 Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenicity Studies in pregnant rabbits and rats at daily doses resulting in plasma concentrations 4 and 10 times the human exposure (Cmax and AUC), respectively, revealed no evidence of harm to the foetus.
There are ongoing studies to further establish the usefulness of potential salvage therapy regimens (e. g. amprenavir or saquinavir).
Specific in vitro interaction studies were performed with TRAVATAN and medicinal products containing thiomersal.
associated with delayed myelosuppression e. g., nitrosoureas. tn uc
Specific studies have not been conducted to assess of the reduction in the risk of complications.
Subsequent studies in man suggest that this effect is unlikely in humans, although a decrease in sperm concentration was seen in some men.
Baseline and periodic evaluations of LVEF should also be considered while the patient is receiving SUTENT.
Specific pharmacokinetic evaluations have not been performed on these patients.
Bleeding drug-related events, ranging from petechiae and epistaxis to severe gastrointestinal haemorrhage and CNS bleeding, were reported in patients taking SPRYCEL (see section 4.4).
Serious adverse events were reported by 44.4% of the patients in the placebo-treated group and 39.9% of the patients in the Zenapax-treated group. no
Adverse reactions were reported in approximately 41% of patients treated with tigecycline.
Infectious events (predominantly bacterial and viral) occurred in approximately 30-55% of patients during clinical trials in patients with NHL and in 30-50% of patients during clinical trial in patients with CLL
Infectious events (predominantly bacterial and viral) occurred in approximately 30-55% of patients during clinical trials in patients with NHL and in 30-50% of patients during clinical trial in patients with CLL.
12 events (heart failure, myocardial infarction, atrial fibrillation), pulmonary oedema, multi-organ failure, tumour lysis syndrome, cytokine release syndrome, renal failure, and respiratory failure were reported at lower or unknown frequencies.
39 events (heart failure, myocardial infarction, atrial fibrillation), pulmonary oedema, multi-organ failure, tumour lysis syndrome, cytokine release syndrome, renal failure, and respiratory failure were reported at lower or unknown frequencies.
Some additional tests might be necessary.
Periodic visual examinations during Viraferon therapy are recommended particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Periodic visual examinations during Viraferon therapy are recommended particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Periodic visual examinations during Viraferon therapy are recommended particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Periodic visual examinations during Viraferon therapy are recommended particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Periodic visual examinations during Viraferon therapy are recommended particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Periodic visual examinations during Viraferon therapy are recommended particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Periodic visual examinations during Viraferon therapy are recommended particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Periodic visual examinations during Viraferon therapy are recommended particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Periodic visual examinations during IntronA therapy are recommended particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Periodic visual examinations during IntronA therapy are recommended particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Periodic visual examinations are recommended during PegIntron therapy, particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Periodic visual examinations are recommended during Peg Intron therapy, particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Periodic visual examinations are recommended during PegIntron therapy, particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Periodic visual examinations are recommended during ViraferonPeg therapy, particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Periodic visual examinations are recommended during ViraferonPeg therapy, particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Periodic visual examinations during Viraferon therapy are recommended particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Ophthalmologic testing (including visual acuity testing, formal visual field testing and dilated funduscopic examination) was conducted in over 3600 patients within controlled clinical trials.
18 Periodic eye exams may be needed if you experience visual difficulties while taking this medicine.
These have shown no deleterious effect on joint cartilage.
You will also have blood tests and be weighed regularly while you are taking Glivec.
In vitro experiments indicated that the formation of lamotrigine's primary metabolite, the 2-N-glucuronide, was minimally inhibited by co-incubation with amitriptyline, bupropion, clonazepam, haloperidol or lorazepam.
Malformations of the skull, palate, eye, jaw, limbs, skeleton and gastrointestinal tract were noted.
Fever was reported in 87% of patients and graded as mild/ moderate in 84% and severe in 3%.
Use of filter devices which incorporate short inlet and outlet PVC-coated tubing has not resulted in significant leaching of DEHP.
Fistulae have also been reported in post-marketing experience.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Oral formulations of Ribavirin monotherapy have been investigated as therapy for chronic hepatitis C in several clinical trials.
Waterproof gloves should be utilised in the preparation and during the determination of radiochemical purity of [90Y]-radiolabelled Zevalin.
Ad-hoc groups will be formed for short-term tasks as needed at numbers and frequencies exceeding those introduced now considerably.
Ad-hoc groups may also be convened to address specialist topics.
Ad hoc expert groups will be convened on availability of medicines, extrapolation of MRLs, preparation for Codex Alimentarius and finalisation of EU input into VICH on environmental toxicity testing of veterinary medicines.
Towards the end of pregnancy high doses of buprenorphine may induce respiratory depression in the neonate even after a short period of administration.
Most frequently haemorrhage at the injection site, and occasionally genitourinary and gingival bleeding were observed.
- Dehydration, reduced protein or sugar in the blood, increased phosphate in the blood
dehydration, reduced protein or sugar in the blood, increased phosphate in the blood
dehydration, hypoproteinaemia, hyperphosphataemia, hypoglycaemia
Dehydration, severe infection, shock, intravascular administration of iodinated contrast agents (see 4.4 Warnings and special precautions for use).
dehydration, severe infection, shock, intravascular administration of iodinated contrast agents (see section 4.4);
Ventricular hypertrophy or hypertrophy of the septum, reported as cardiomyopathies, have been observed on rare occasions.
Among children and adolescents, treated with Rebetol in combination with interferon alfa-2b, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4% versus 1%) during treatment and during the 6-month follow-up after treatment.
Among children and adolescents, treated with Ribavirin in combination with interferon alfa-2b, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4% versus 1%) during treatment and during the 6-month follow-up after treatment.
Among children and adolescents treated with IntronA in combination with ribavirin, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4% vs 1%) during treatment and during the 6-month follow-up after treatment.
Among children and adolescents treated with Viraferon in combination with ribavirin, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4% vs 1%) during treatment and during the 6-month follow-up after treatment.
Among children and adolescents treated with Viraferon in combination with ribavirin, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4% vs 1%) during treatment and during the 6-month Me
Incompatibilities have been reported between injectable forms of calcium folinate and injectable forms of droperidol, fluorouracil, foscarnet and methotrexate.
Disinfect the rubber membrane of the cartridge with a cleansing swab 4.
● Wipe the top of the Fuzeon vial again with a new alcohol swab.
110 Disinfect the rubber membrane with a medicinal swab.
Disinfect the rubber membrane with a medicinal swab.
Disinfect the rubber membrane of the cartridge. • You must only use Liprolog Basal cartridges in compatible CE marked pens.
Disinfect the rubber membrane of the cartridge. • You must only use Liprolog Mix25 cartridges in compatible CE marked pens.
Disinfect the rubber membrane of the cartridge. • You must only use Liprolog cartridges in compatible CE marked pens.
Disinfect the rubber membrane of the cartridge. • You must only use Humalog BASAL cartridges in compatible CE marked pens.
Disinfect the rubber membrane of the cartridge. • You must only use Humalog Mix25 cartridges in compatible CE marked pens.
Disinfect the rubber membrane of the cartridge. • You must only use Humalog Mix50 cartridges in compatible CE marked pens.
Disinfect the rubber membrane of the cartridge. • You must only use Humalog cartridges in compatible CE marked pens.
Clean about 5 cm (two inches) around the point where the needle will go in and let the disinfectant dry for at least one minute before proceeding.
Infections of the mouth, throat and the upper airways have been observed in children with Increlex treatment.
These included abscess (at various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis, endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection, osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin infection, skin ulcer, urinary tract infection, vasculitis, and wound infection.
These included abscess (at various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis, endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection, osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin infection, skin ulcer, urinary tract infection, vasculitis, and wound infection.
Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed lp
Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed
 111 Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients, including those treated with IntronA.
 195 Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients, including those treated with IntronA.
 216 Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients, including those treated with IntronA.
 27 Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients, including those treated with IntronA.
 48 Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients, including those treated with IntronA.
 69 Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients, including those treated with IntronA.
 6 Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients, including those treated with IntronA.
 90 Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients, including those treated with IntronA.
Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients, including those treated with IntronA.
Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients, including those treated with Viraferon.
Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients.
The Marketing Authorisation Holder provided supplementary information on 20 April 2005, 20 December 2005, 27 March 2006 and 9 May 2006.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information for your doctor or other health personnel regarding simultaneous administration of Cyanokit with other medicines can be found at the end of this package leaflet (see'Handling instructions').
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Detailed information on this medicinal product is available on the website of the European Medicines a
Detailed information on this medicinal product is available on the website of the European Medicines ed
Detailed information on this medicinal product is available on the website of the European Medicines ic
is Detailed information on this medicinal product is available on the website of the European Medicines
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/
Detailed information on this medicinal product is available on the website of the European Medicines lp
Detailed information on this medicinal product is available on the website of the European Medicines ed
Detailed information on this medicinal product is available on the website of the European Medicines ed
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. eu. int/
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this medicinal product is available on the website of the European Medicines ed
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. eu. int/
< -------------------------------------------------------------------------------------------------------------------------- ---
------------------------------------------------------------------------------------------------------------------------------
11 Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
127 Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
135 Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
143 Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
14 Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/
19 Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
23 Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
31 Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
431 Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/
55 Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
8 Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
9 Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
DATE OF REVISION OF THE TEXT 16 Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
DATE OF REVISION OF THE TEXT 6 Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
DATE OF REVISION OF THE TEXT Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this medicinal product is available on the European Medicines Agency (EMEA): http: / www. emea. eu. int
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this medicinal product is available on the web site of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu. / >
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA): http: / /www. emea. europa. eu/
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/ t uc rod lp i na dic Me
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/. -----------------------------------------------------------------------------------------------------------------------------
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/. >
Detailed information on this medicine is available on the European Medicines Agency (EMEA) website http: / /www. emea. europa. eu/
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) website http: / /www. emea. europa. eu/.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/. -------------------------------------------------------------------------------------------------------------------------------
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/. --------------------------------------------------------------------------------------------------------------------------- --
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Detailed information on this medicine is available on the European Medicines Agency web site: http: / /www. emea. europa. eu/.
Detailed information on this medicine is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this medicine is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this medicine is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this medicine product is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this product is available on the web -site of the Europe an Medicines Agency (EMEA) http://www.emea.europa.eu
Detailed information on this product is available on the web-site of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this product is available on the web-site of the European Medicines Agency (EMEA) http://www.emea.europa.eu
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this product is available on the website of the European Medicines Agency (EMEA): http: / /www. emea. europa. eu/
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this product is available on the web-site of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this product is available on the website of the European Medicines Evaluation Agency (EMEA): http: / /www. emea. europa. eu/.
er {DD/ MM/ YYYY} ng lo Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu no ct du ro
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http://www.emea.europa.eu
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. eu. int/
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) www. emea. europa. eu
Detailed information on this medicinal product is available on the website of the European Medicines ed
Detailed information on this medicinal product is available on the website of the European Medicines ed
Detailed information on this medicinal product is available on the website of the European Medicines ic
This leaflet was last approved in
Detailed information on this medicinal product is available on the website of:{name of MS/Agency}[PIQ-QRD1]
< Detailed information on this medicine is available on the web site of {MA/Agency} >
< Detailed information on this medicine is available on the web site of {MA/Agency} >
Detailed information on this medicine is available on the web site of {MA/Agency}[PIQ-QRD3]
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu.
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /emea. europa. eu/.
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this product is available on the website of the European Medicines Agency (EMEA), http: / /www. emea. europa. eu/.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA), http: / /www. emea. europa. eu/.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Further information on the national competent authorities is also available on the national authorities'Internet sites: http: //heads.medagencies.org and http:/ /www .hevra.org
Further information on the national competent authorities is also available on the national authorities'Internet sites: http://heads.medagencies.org and http://www.hevra.org
Information on the prescription status of this product may be found on the label/ outer package.
Development of inhibitors occurred in approximately 2% of patients receiving ReFacto AF in a research study.
national inspection services of Belgium, Denmark, Germany, Spain, France, Italy, Ireland, The Netherlands, Portugal, Sweden, Finland and the UK were involved.
ge Patients started on EXUBERA must receive comprehensive instructions in the use of the inhaler (see IFU).
28 Interactions with other medicines that you take are unlikely to occur.
Pharmacokinetic interactions may be observed with gastrointestinal prokinetic agents such as cisapride and metoclopramide.
The possibility of interactions with other medicinal products administered concurrently with Combivir should be considered, particularly when the main route of elimination is active renal secretion, especially via the cationic transport system e. g. trimethoprim.
The possibility of interactions with other medicinal products administered concurrently with Kivexa should be considered, particularly when the main route of elimination is active renal secretion, especially via the cationic transport system e. g. trimethoprim.
16 The possibility of interactions with other medicinal products administered concurrently should be considered, particularly when the main route of elimination is active renal secretion via the organic cationic transport system e. g. trimethoprim.
5 The possibility of interactions with other medicinal products administered concurrently should be considered, particularly when the main route of elimination is active renal secretion via the organic cationic transport system e. g. trimethoprim.
The possibility of interactions with other medicinal products administered concurrently should be considered, particularly when the main route of elimination is active renal secretion via the organic cationic transport system e. g. trimethoprim.
Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving Aclasta for post- menopausal osteoporosis.
Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving zoledronic acid for postmenopausal osteoporosis.
HIV-1 isolates with decreased susceptibility to amprenavir have been selected during in vitro serial passage experiments.
HIV-1 isolates with a decreased susceptibility to amprenavir have been selected during in vitro serial passage experiments.
Benzalkonium chloride, which is commonly used as a preservative in ophthalmic products, has been reported to cause punctate keratopathy and/ or toxic ulcerative keratopathy.
Benzalkonium chloride, which is commonly used as a preservative in ophthalmic products, has been reported to cause punctate keratopathy and/ or toxic ulcerative keratopathy.
Benzalkonium chloride, which is commonly used as a preservative in ophthalmic products, has been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy.
• Damage to kidney tubule cells
Necrotic lesions of the tail were observed at ≥ 80 mg/ kg/ day.
Necrotic lesions of the tail were observed at ≥ 80 mg/kg/day.
Therefore, this product would not be considered interchangable with other ivermectin containing products already on the market.
It is not known whether darifenacin is excreted into human milk and therefore caution should be exercised before Emselex is administered to a nursing woman.
Therefore it should not be used in this age group.
Therefore the relevance of the bibliographical data regarding Eqvalan to the test product cannot be confirmed.
Therefore, the relevance of the bibliographical data regarding Eqvalan to the test product cannot be confirmed.
Therefore the CHMP has recommended that there are no objections for the granting of the Marketing Authorisation for Adartel, in the treatment of symptomatic treatment of moderate to severe idiopathic restless legs syndrome.
As a result the cells cannot multiply.
Therefore, inhibitors of these enzymes may increase darifenacin exposure.
As a consequence, the blood glucose is reduced and this helps to control type 2 diabetes.
Therefore the use of Comtan in children cannot be recommended.
Therefore, the use of Comtess in children cannot be recommended.
One outlier subject with raised voriconazole levels was identified in each of the ritonavir interaction studies. Coadministration of voriconazole and ritonavir (400 mg and above twice daily) is contraindicated.
Because the number of patients with multiple myeloma is low, the disease is considered ‘ rare’, and Thalidomide Celgene was designated an ‘ orphan medicine '(a medicine used in rare diseases) on 20 November 2001.
lymphoma) have been reported in patients treated with pimecrolimus cream.
diseases where transplant is today the only option, patients which have intractable bowel disorders and severely deficient pulmonary function (cystic fibrosis),
Most frequently reported were headache, nausea, vomiting, diarrhoea, abdominal pain, dizziness, flushing and fatigue.
- myelosuppressive medicines (decrease production of red, white, or coagulating blood cells) and
If there is clinical evidence of deterioration in the condition of these patients, appropriate measures including discontinuation of lumiracoxib should be taken.
Measures will be taken to ensure that the anticipated increase in the volume of mail can be handled.
er solarium, therapy with UVB or UVA in combination with psoralens (PUVA) should be avoided during use of Protopy ointment (see section 5.3).
microspheres and loss of contrast effect.
Warnings about the risk of myopathy, including rhabdomyolysis, as well as warnings about the interaction with gemfibrozil have been included in product information since Lipobay was first licensed in the EU.
10 Reversible, dose-dependent and usually mild or moderate elevations of lactate dehydrogenase (LDH), alkaline phosphatase, serum uric acid and gamma-glutamyltransferase (GGT) occurred with filgrastim in approximately 50%, 35%, 25%, and 10% of patients respectively, at recommended doses.
26 Reversible, dose-dependent and usually mild or moderate elevations of lactate dehydrogenase (LDH), alkaline phosphatase, serum uric acid and gamma-glutamyltransferase (GGT) occurred with filgrastim in approximately 50%, 35%, 25%, and 10% of patients respectively, at recommended doses.
In some cases concomitant factors may have contributed to the development of these effects. Sclerodermal-like changes usually proceded by peripheral lymphedema have been reported with docetaxel.
Sclerodermal-like changes usually preceded by peripheral lymphedema have been reported with docetaxel.
Hair and nail changes have been observed.
Changes in total fasting cholesterol levels from borderline at baseline (≥ 4.39 - < 5.17 mmol/ l) to high (≥ 5.17 mmol/ l) were very common.
Changes in total fasting cholesterol levels from borderline at baseline (≥ 4.39 - < 5.17 mmol/ l) to high (≥ 5.17 mmol/ l) were very common.
Changes in total fasting cholesterol levels from borderline at baseline (≥ 4.39- < 5.17 mmol/ l) to high (≥ 5.17 mmol/ l) were very common.
Changes in total fasting cholesterol levels from borderline at baseline (4.39 - < 5.17 mmol/ l) to high (5.17 mmol/ l) were very common.
Dose-dependent percent changes from baseline were observed across the placebo, simvastatin 40 mg and simvastatin 80 mg treatments for the primary end point (LDL cholesterol) and for the secondary end points (VLDL cholesterol, triglycerides, non HDL cholesterol, HDL cholesterol, apolipoprotein B, and apolipoprotein A-I).
Changes were observed in liver (hepatocyte hypertrophy, vacuolation, increased liver enzymes) and thyroid (follicular hypertrophy).
• involuntary rhythmic movements of the tongue, mouth and face.
Adequate contraceptive precautions should be used when receiving Paxene.
Common (≥ 1/ 100 to < 1/ 10) but generally asymptomatic cases of splenomegaly and very rare cases of splenic rupture, including some fatal cases, have been reported following administration of
Common (≥ 1/ 100 to < 1/ 10) but generally asymptomatic cases of splenomegaly and very rare cases of splenic rupture, including some fatal cases, have been reported following administration of
There have been reports in the postmarketing experience of hypersensitivity reactions, including cases of angioedema.
Public health objections were raised because no immunological correlates of protection were established for MenC conjugates and because the submission of data on pre-licensure effectiveness were required to cover infant and toddler use.
Similar observations have been made in the post- marketing environment.
Warfarin also had no clinically significant effects on the pharmacokinetics of ambrisentan.
The financial control and audit function at the EMEA will be brought in line with the new European Commission framework for resource management and internal auditing.
Analytical tools can be used as consistency criteria, but not as correlates for safety and efficacy (immunogenicity) of Hepatitis B batches produced at SPMSD.
Pharmacokinetic parameters were calculated for amlodipine and lisinopril by the means of Bioequiv 3.5 software using a model independent approach.
- adult patients with newly-diagnosed gliobl astoma multiforme concomitantly with radiotherapy
- adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy
- patients with exudative (wet) age-related macular degeneration (AMD) with predominantly
• Patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis (see section 5.1).
% of patients (CI95%) 1 Haematological response Complete haematological response (CHR)
The efficacy of REYATAZ/ ritonavir in combination with tenofovir in treatment-experienced patients has been demonstrated in clinical study 045 and in treatment naive patients in clinical study 138 (see sections 4.8 and 5.1).
Patients with proteinuria and a serum creatinine of 1.3 – 3.0 mg/ dl were randomised to receive Losartan 50 mg once a day, titrated if necessary, to achieve blood pressure response, or to placebo, on a background of conventional antihypertensive therapy excluding ACE-inhibitors and angiotension II antagonists.
% of patients who experienced peripheral oedema
Patients may develop antibodies to AVONEX.
Patients treated with Naglazyme have developed infusion-associated reactions (IARs), defined as any drug-related adverse event occurring during the infusion or until the end of the infusion day (see section 4.8).
Vaginal discharge occurred in about one in 26 patients.
Small volumes may be administered over 2 hours using electric syringes.
Tolerance, thought to be due to the development of an immune response, may occur uncommonly.
Very ill pigs might not eat all the feed offered and therefore might get an insufficient amount of the medicine.
Daily doses of up to 180 mg have been used.
Revised working practices will be introduced in reprographics to take into account the wide fluctuations in workload over each month.
Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed lp
Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rod
Caution should be exercised when considering concomitant use of other immunosuppressants and STELARA or when transitioning from other immunosuppressive biologics (see section 4.5).
Special precautionary measures (e. g. blood tests) may be appropriate.
Care is needed in patients who receive the medicine and are having dental treatment.
In certain circumstances, special precautions may be necessary.
Care should be taken in patients where fasting may have medical implications.
Viracept should be used with caution in patients who have problems with their liver or kidneys.
Blood and milk samples were collected at regular intervals and analysed using a solid phase enzyme-linked immunoassay (ELISA) test.
Blood and milk samples were collected at regular intervals and analysed using a solid phase enzyme-linked immunoassay (ELISA) test.
John's wort (Hypericum perforatum)
• heart, blood pressure or breathing problems • overactivity of the thyroid • diabetes or low blood sugar levels (hypoglycaemia) • severe allergic reactions • liver or kidney problems • known risk factors for macular oedema (swelling of the retina within the eye leading to worsening vision), for example, cataract surgery
- problems with blood clotting resulting in bleeding disorders such as bleeding from the intestines,
Technical translation problems with the Luxembourg Translation Centre or on the part of applicants were often the
20 GANFORT may cause your eyelashes to darken and grow, and cause the skin around the eyelid to darken too.
- breathing problems and bleeding in the lungs;
Amprenavir-related material was found in rat milk, but it is not known whether amprenavir is excreted in human milk.
Lactation Amprenavir-related material was found in rat milk, but it is not known whether amprenavir is excreted in human milk.
Significant progress was made on the review of the guideline for conduct of pharmacokinetic studies in animals.
It was attended by over 1 600 representatives of EU, Japanese, US and other observers from regulatory authorities and industry.
Good progress has been made in meeting the targets set out in the 1997 work programme, and details are provided in the sector reports below.
Good progress was made in 2001, but there is a constant need for development.
Projects of a more technical nature relating to security, integrity of data and optimisation of the system will be undertaken.
Proposals for the revision of the European system for the authorisation and supervision of medicines were transmitted to the European Parliament and Council in November 2001 (COM(2001) 404 final, 26.11.2001).
It is forwarded to the European Parliament, Council, Commission and Member States.
Once the injection site is dry, pull off the yellow inner needle cap carefully exposing the injection needle.
Driving and use of machines may resume under normal lighting or daylight conditions once photosensitivity has been shown to have subsided.
Furthermore, specific questions on development and requirements have been addressed by the SWP including anti-cancer medicinal products, vaccines, gene therapy, assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products.
Radiographs of hands and wrists were obtained at baseline and months 6, 12, and 24.
In addition, the working party worked closely with the CPMP Biotechnology Working Party in addressing issues relating to transmissible and bovine spongiform encephalopathies.
Rash, anaphylactoid events and progressive systemic events, sometimes serious (involving skin, kidney, liver or lung) have been reported.
Skin rashes may appear during EXJADE treatment.
Sudden severe allergic reactions have been reported in patients treated with Simulect.
Anaphylactic reactions can progress to a life-threatening shock, even after the first administration.
Injection site reactions are seen more frequently during treatment with Levemir than with human insulin.
Injection site reactions are seen more frequently during treatment with Levemir than with human insulin.
Remote site skin reactions, mainly erythema (44%), were also reported in the placebo controlled trials.
4.6 Pregnancy and lactation
Application site skin reactions may occur and are usually mild or moderate in intensity.
Careful monitoring of paediatric patients is especially warranted, particularly in the first 18 weeks of treatment, since these patients may be less likely than adults to notice, or report, skin reactions.
The Jarisch-Herxheimer reaction has been reported following cefuroxime axetil treatment of Lyme disease.
Photosensitivity reactions have been reported, especially during long-term therapy (see also section 4.4).
Sinusitis Anaphylactoid reaction, hypersensitivity
In a few individuals allergic-like reactions (i. e. flushing, erythematous rash) following sugammadex were reported of which one was a confirmed mild allergic reaction.
Hypersensitity reactions unrelated to dose can be observed.
3 Cognitive and neuropsychiatric adverse reactions, particularly confusion, are common in patients treated with ziconotide.
Cognitive and neuropsychiatric adverse reactions, particularly confusion, are common in patients treated with ziconotide.
Serious adverse reactions such as neutropenic sepsis (0.8%) and pneumonia (2.5%) were reported in patients receiving azacitidine.
Potentially immunocomplex-mediated reactions Potentially immunocomplex-mediated reactions, such as serum-sickness-type reaction, polyarthritis with rash and proliferative glomerulonephritis have been reported uncommonly.
Serious infusion reactions including urticaria, rales, tachycardia, decreased oxygen saturation, bronchospasm, tachypnea, periorbital edema and hypertension have been reported.
of 2833 patients, of which four were double-blind placebo-controlled studies and one was an open- label study.
• When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted: • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA.
• When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
• When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA.
In vitro metabolism studies have confirmed that the parent compound is rapidly metabolised to 3-O- acetyltylosin.
Dosing recommendations are not available for neonates with a gestational age < 37 weeks.
Guidelines were developed in clinical trials for dose modification.
Reductions in the growth of mean total lesion size, choroidal neovascularisation (CNV size), and fluorescein leak size, have been shown in patients with AMD treated with Macugen.
Decreases in parameters of peripheral activity characteristic of psoriatic arthritis (such as number of swollen joints, number of painful/ tender joints, dactylitis and presence of enthesopathy) were seen in the infliximab-treated patients.
Provisional rules on access to documents of the EMEA were adopted on 30 April 1997 and were distributed with a consultation paper to some 100 interested parties and dissemination points.
Continued durable responses were seen for over 24 months in the ongoing open label extension studies I, III, IV and V.
Responses were observed in 13/ 18 (72%, 95% confidence intervals:
Responses were seen in different immunophenotypes of ALL, including pre-B cell and T-cell.
Continued durable responses have been seen for up to 48 months in open-label extension
Continued durable responses have been seen for up to 48 months in open-label extension treatment trials when patients received Enbrel without interruption; longer-term experience in not available.
Continued durable responses have been seen for up to 48 months in open-label extension treatment trials when patients received Enbrel without interruption; longer-term experience is not available.
Representatives from Commission Directorate-General IX (Personnel and Administration) have addressed EMEA staff on medical insurance and pensions.
EMEA representatives also attended meetings of the informal European Parliament Intergroup on pharmaceuticals, chaired by Professor Umberto Scapagnini, MEP.
Participants of the workshop included representatives of the European Parliament, European Commission and members and experts of the CPMP, as well as representatives from industry, academia and patient groups.
of residues of amoxicillin when administered by injection it was not possible to establish a withdrawal period for cattle and pigs as:
Cross-resistance may occur between pirlimycin and other lincosamides or macrolides.
Analogous results have been found in animal experiments in uraemic and normal rats.
Consistent results were obtained with the last observation carried forward method of analysis.
Consistent results were obtained with the last observation carried forward method of analysis (time-averaged difference of 0.11, 97.5% confidence interval [-0.15, 0.36]).
In vitro results indicate that maraviroc could inhibit P- glycoprotein in the gut and may thus affect bioavailability of certain drugs.
In vitro results indicate that maraviroc could inhibit P- glycoprotein in the gut and may thus affect bioavailability of certain drugs..
Similar findings were found based on a 18-months landmark analysis.
This application format will be a mandatory requirement in the EU from mid-2003.
Special meetings were also held with some na- tional trade associations, e. g. the UK ABPI, the VFA from Germany and the Irish Trade Board.
increased risk of serious CV events,
- a rash, itching or hives
Breakthrough bleeding and unintended pregnancies have been reported.
Breakthrough bleeding or spotting may occur.
- lithium salts (used to treat psychiatric disorders).
- lithium salts (used to treat psychiatric disorders),
- lithium salts (used to treat psychiatric disorders).
- lithium salts (usedto treat psychiatric disorders).
- lithium salts (used to treat psychiatric disorders).
lithium salts (used to treat psychiatric disorders).
Your blood sugar level may either rise or fall if you take: − beta-blockers (used to treat high blood pressure), − clonidine (used to treat high blood pressure), − lithium salts (used to treat psychiatric disorders).
Short-lasting mild to moderate feelings of coldness, warmth or pain at the injection site have been uncommonly observed during or after the injection of Gadovist.
Additional signs may include myoglobinuria (rhabdomyolysis) and acute renal failure.
Signs of anaemia are a feeling of weakness and in more severe cases breathlessness and pale skin.
Signs of virilisation, such as voice deepening, hirsutism or clitoromegaly, may be irreversible and discontinuation of treatment should be considered.
Side effects such as lethargy (listlessness) and a reduction in appetite are also common, sometimes accompanied by fever and a stiff gait.
Abacavir-resistant isolates of HIV-1 have been selected in vitro and are associated with specific genotypic changes in the RT codon region (codons M184V, K65R, L74V and Y115F).
Harmful substances will be formed and accumulate in the body, causing progressive liver failure and liver cancer in young children.
Symptoms of hypoglycaemia (unconfirmed by blood glucose levels) were observed in patients whose baseline HbA1c was close to the therapeutic target (HbA1C < 7.5%).
Acute withdrawal symptoms, including nausea, vomiting, sweating, and insomnia have very rarely been described after abrupt cessation of high doses of antipsychotic medicines (see section 4.8).
A report on exacerbated asthma symptoms triggered after initiation of glucosamine therapy has been described (symptoms resolved after withdrawal of glucosamine).
However, possible symptoms of overdose are expected to include nausea, vomiting, diarrhoea and severe bone marrow depression.
Symptoms of hypoglycaemia (unconfirmed by blood glucose levels) were observed in patients whose baseline HbA1c was close to the therapeutic target (HbA1c < 7.5%).
Symptoms of benign increased brain pressure (benign intracranial hypertension), which are papilloedema, visual changes, headache, nausea and vomiting, may occur more often in children with chronic renal insufficiency receiving NutropinAq.
Symptoms and signs of peripheral neuropathy, such as pain, numbness, paresthesia, hypoaesthesia, weakness, and impaired bowel and bladder control (incontinence) have also been observed.
Syncope (fainting) may follow any vaccination, especially in adolescents and young adults.
Patients treated with tacrolimus have been reported to develop EBV-associated lymphoproliferative disorders.
Myelodysplastic/ myeloproliferative diseases (MDS/ MPD).
There have been reports of serotonin syndrome when SSRIs have been given with lithium or tryptophan and, therefore, the concomitant use of fluoxetine with these drugs should be undertaken with caution.
Firewall systems have been installed both in London and Ispra to protect the backbone services and are operated by the ETOMEP team.
down (haemolysis) or abnormal blood pigment levels (methaemoglobinaemia).
Persistently high calcium levels may lead to irreversible renal damage and soft tissue calcification.
Levels of antibodies of ≥ 100IU/ ml were achieved.
Increased amounts of TNFα are common in inflammatory diseases such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.
Low levels of neurotransmitters in the central nervous system may be associated with depression, anxiety or aggression.
Low levels of serotonin in the central nervous system may be associated with depression, anxiety or aggression.
Aseptic technique is required during preparation of the solution and administration.
A harmonized wording for age groups and relevant posology was agreed upon:
Skin testing should be conducted in patients with suspected sensitivity to calcitonin prior to their treatment with calcitonin.
Objective tests as demonstrated by other studies have demonstrated that usual daily activities are unaffected at the recommended daily dose in healthy young volunteers.
Objective tests as demonstrated by other studies have demonstrated that usual daily activities are unaffected at the recommended daily dose in healthy young volunteers.
For the long-term treatment of growth failure in children and adolescents with severe primary insulin- like growth factor-1 deficiency (Primary IGFD).
Trace amounts of hamster protein may be present in ReFacto AF.
Trace amounts of hamster protein may be present ReFacto AF.
Traces of the dissolved tablet(s) may be left behind in the glass.
Transfusions of cryoprecipitate, fibrinogen, fresh frozen plasma and platelets should be considered with clinical and laboratory reassessment after each administration.
Preparatory work will begin in 1997, with initiatives for implementation to be proposed in 1998.
The results of the testing were reported back to the group involved in the project in December 2002.
Speech disorder was also reported commonly.
The following table (table 1) shows all treatment-emergent adverse reactions from placebo-controlled studies in patients treated for weight loss and related metabolic disorders when these incidences were d
Urinary tract disorders (such as bladder infections, irregular urination and discomfort in passing urine) and central nervous system signs (such as incoordination and disorientation) were also observed.
48 Some late-onset neurological disorders have been reported (hypertonia, convulsion, abnormal behaviour).
Some late-onset neurological disorders have been reported (hypertonia, convulsion, abnormal behaviour).
Some late-onset neurological disorders have been reported (hypertonia, convulsion, abnormal behaviour).
Severe nail disorders are characterised by hypo- or hyperpigmentation and sometimes pain and onycholysis.
- death of liver cells (liver necrosis) very rarely leading to life-threatening liver failure
Gastrointestinal stromal tumours (GIST).
The use of a bronchodilator (reliever inhaler) for asthma or other airway conditions may cause a more pronounced fall in blood sugar in response to inhaled insulin (see section 2 “Do not take EXUBERA” lo and section 2 “Take special care with EXUBERA”). o
Upper gastrointestinal ulceration and haemorrhage have been reported in patients, including children and adolescents, receiving EXJADE.
- stomach ulcers or convulsions
Comparable self-monitored blood glucose values were observed.
Comparable self-monitored blood glucose values were observed.
Mean free and total cobalamins-(III) Cmax values of 113 and 579 µg eq/ ml, respectively, were determined following a dose of 5 g Cyanokit (the recommended initial dose).
HIV-1 variants with reduced susceptibility to maraviroc have been selected in vitro, following serial passage of two CCR5-tropic viruses (0 laboratory strains, 2 clinical isolates).
Cutaneous vasculitic toxicities, including vasculitic ulcerations and gangrene, have occurred in patients with myeloproliferative disorders during therapy with hydroxycarbamide.
Dizziness can sometimes occur and might affect the ability to drive and use machines.
Monitoring visits should be performed every 6 months; shorter intervals between visits are recommended in case of adverse events.
genitals (signs of Steven-Johnson syndrome)
Bacterial infections, for instance infections in wounds, respiratory tract, GI-tract or urogenital system.
Emesis has been observed in both the safety pharmacology and the repeated-dose toxicity studies.
Vomiting has also occurred rarely.
Vomiting may occur five to 10 minutes after injection or at the time of recovery.
One of the blister units should be separated from the blister card by tearing it apart at the perforations.
No such studies have been conducted with cattle.
Such macrocytosis should not be treated with folinic acid.
You may notice that you become tired and your skin tone becomes pale Very rarely, such changes in your blood can be permanent.
r ge Such allergic reactions have only been seen in a very few cases and the most extreme form, anaphylactic shock, is very rare.
Typically, such reactions have been observed within the first few weeks or months of initiation of CART.
Typically, such reactions have been observed within the first few weeks or months of initiation of CART.
Typically, such reactions have been observed within the first few weeks or months of 6 initiation of CART.
Typically, such reactions have been observed within the first few weeks or months of initiation of CART.
Typically, such reactions have been observed within the first few weeks or months of initiation of CART.
Typically, such reactions have been observed within the first weeks or months of initiation of CART.
Typically, such reactions have been observed within the first weeks or months of initiation of CART.
Typically, such reactions have been observed within the first few weeks or months of initiation of CART.
Such reactions may especially be seen, if the preparation is applied repeatedly, or administered to patients known to be hypersensitive to constituents of the product.
Such vaccinations should be postponed for at least 3 months after the last infusion of Privigen.
Such diet-related treatment effects may be a signal that you have eaten more fat than you should have done.
No such effects were observed in iron-preloaded rats.
These can usually be treated by your doctor.
Such patients are unresponsive to GONAL-f/ hCG therapy.
Such patients are unresponsive to GONAL-f/ hCG therapy.
These therapies should be directed by doctors with experience in the care of patients with haemophilia A.
These therapies should be directed by physicians with experience in the care of patients with haemophilia.
Marketing authorisation holder Fort Dodge Animal Health C. J. van Houtenlaan 36 1381 CP Weesp The Netherlands
Dose selection: see section 3 ‘How to use ORENCIA'of the Package Leaflet
Assay the [90Y]-radiolabelled Zevalin solution for its specific radioactivity
Determining Approximate Number of Doses Delivered
Establishment of the withdrawal period following consideration of all residue studies for pigs and cattle available With the submission of the new residue study for cattle the MAH proposed a withdrawal period of 96 days based on the statistical method.
EMEA/CPMP/PhvWP/BPWG/ 2231/99 EMEA/CPMP/BPWG/198/95 rev.
- determine how much Insuman Basal per day you will need,
- determine how much Insuman Comb 15 per day you will need,
- determine how much Insuman Comb 50 per day you will need,
- determine how much Insuman Rapid per day you will need,
- determine how much Optisulin per day you will need and at what time,
Applications for orphan medicinal product designation
17 Very rarely cases of colitis have been reported in patients taking lansoprazole.
26 Very rarely cases of colitis have been reported in patients taking lansoprazole.
Angle closure glaucoma has been reported very rarely following botulinum toxin treatment for blepharospasm.
Very rare cases of Progressive Multifocal Leukoencephalopathy (PML) have been reported during post-marketing use of MabThera in NHL and CLL (see section 4.8).
Very rare cases of Churg-Strauss Syndrome (CSS) have been reported during montelukast treatment in asthmatic patients (see section 4.4).
Your doctor will evaluate which cholesterol lowering regimen is best for your specific situation.
Discard any solution that is left in the vial after you give yourself the injection.
Danmark/ Norge/ Sverige/ Suomi/ Finland/ Ísland Genzyme A/ S, (Danmark/ Tanska/ Danmörk), Tlf/ Puh. / Sími: +45 32712600 Deutschland Genzyme GmbH, Tel: +49 610236740 Ελλάδα /Κύπρος Genzyme Hellas Ltd.
104 Deutschland MSD SHARP & DOHME GMBH Tel: +49 (0) 89 4561 2612 Infocenter@msd. de
112 Deutschland MSD SHARP & DOHME GMBH Tel: +49 (0) 89 4561 2612 Infocenter@msd. de
43 Deutschland MSD SHARP & DOHME GMBH Tel: +49 (0) 89 4561 2612 Infocenter@msd. de
51 Deutschland MSD SHARP & DOHME GMBH Tel: +49 (0) 89 4561 2612 Infocenter@msd. de
55 Deutschland MSD SHARP & DOHME GMBH Tel: +49 (0) 89 4561 2612 Infocenter@msd. de
61 Deutschland MSD SHARP & DOHME GMBH Tel: +49 (0) 89 4561 2612 Infocenter@msd. de
67 Deutschland MSD SHARP & DOHME GMBH Tel: +49 (0) 89 4561 2612 Infocenter@msd. de
67 Deutschland MSD SHARP & DOHME GMBH Tel: +49 (0) 89 4561 2612 Infocenter@msd. de
96 Deutschland MSD SHARP & DOHME GMBH Tel: +49 (0) 89 4561 2612 Infocenter@msd. de
Deutschland MSD SHARP & DOHME GmbH, Tel: +49 (0) 89 4561 2612 Infocenter@msd. de
Deutschland MSD SHARP & DOHME GMBH Tel: +49 (0) 89 4561 2612 Infocenter@msd. de
32 Deutschland Orphan Europe (Germany) GmbH Max-Planck Str.
Deutschland Wyeth Pharma GmbH Tel: +49 180 2 29 93 84 Fax: +49 251 204 1128
• Efficacy Working Party The Efficacy Working Party met 5 times in 2001 and was in charge of 37 guidance documents of which 15 were new and
- two packs containing 25 vials of 2.5 ml emulsion (adjuvant) for 10 doses
There are two scoops provided in the box, a white 1 gram scoop and a blue 5 gram scoop.
There are two scoops provided in the box, a white 1 gram scoop and a blue 5 gram scoop.
Two of three delavirdine-resistant clinical isolates examined were cross-resistant to efavirenz and contained
Two of three delavirdine-resistant clinical isolates examined were cross-resistant to efavirenz and contained the K103N substitution.
15 Systemic sclerosis with digital ulcer disease Two randomised, double-blind, multi-centre, placebo-controlled trials have been conducted in 122 (Study AC-052-401, RAPIDS-1) and 190 (Study AC-052-331, RAPIDS-2) adult patients with systemic sclerosis and digital ulcer disease (either ongoing digital ulcers or a history of digital ulcers within the last year).
33 Systemic sclerosis with digital ulcer disease Two randomised, double-blind, multi-centre, placebo-controlled trials have been conducted in 122 (Study AC-052-401, RAPIDS-1) and 190 (Study AC-052-331, RAPIDS-2) adult patients with systemic sclerosis and digital ulcer disease (either ongoing digital ulcers or a history of digital ulcers within the last year).
Two studies (1,363 patients) were carried out in nucleoside-naïve patients (these are patients who have not been treated with nucleoside analogues before).
The summary reasons for withdrawals in 2001 is published on the HEVRA website.
and authorised for radiolabelling
- breast overdevelopment in men
At a strategic level the EMEA will participate fully in the Telematics
– Revision of existing CPMP safety notes for guidance: • Update of Note for guidance on non-clinical local tolerance testing of medicinal products • Update of Note for guidance on carcinogenic potential • Update of Draft Note for guidance on non-clinical testing of substances with long-term marketing experience (‘old substances’)
Priorities for veterinary medicines in 2001-2002: • Finalise and adopt a Note for guidance on risk assessment in establishing maximum residue limits (MRL) to facilitate extrapolation of MRLs from major species'to minor species
Deputy Head of Sector for information technology David DRAKEFORD
Provision of improved offsite archiving facilities for the increasing number of files held by the EMEA, together with
development (pre-clinical) 22%
resistance build up to ivermectin in Parascaris equorum, however the highest number of P. equorum may be found in grazing horses 3-18 months old.
d) Adverse events applicable to all indications:
such as otitis media, because Turner syndrome patients have an increased risk of ear or other hearing disorders.
- in individuals with a known hypersensitivity to Clostridium botulinum type A neurotoxin
clinical verification of the neurotoxin effect on the injected muscle: e. g. an electromyographic investigation in a specialised facility
Unscrew the syringe from Bioset® and affix a needle for vaccine administration.
Unscrew the syringe to disconnect the vial (I).
Completely unscrew the injection needle assembly using an anti-clockwise turning motion as shown in Diagram R.
• Unscrew the vial adapter with the empty vial.
Twist off the needle and discard it properly.
Unscrew the needle all the way by giving the large needle cover 3 to 5 complete turns.
Unscrew the needle all the way by giving the needle cover 3 to 5 complete turns.
Insert needle into skin using injection technique recommended by your healthcare professional.
Insert needle into skin using injection technique recommended by your healthcare professional.
• Unscrew the needle. • Replace blue pen cap on pen before storage.
• your/ your child's (if he/ she is being treated) body surface area (which will be calculated by your doctor based on your height and weight). • the results of blood tests carried out before treatment
- Becoming knowledgeable about symptoms associated with infections, and
A single 40 mg dose of aprepitant, when co-administered with a single oral dose of dexamethasone 20 mg, increased the AUC of dexamethasone by 1.45-fold.
DEXDOMITOR contains the active substance dexmedetomidine, which belongs to a class of medicines having a psycholeptic (sedative) action.
DEXDOMITOR causes a decrease in heart rate and body temperature.
Dexdomitor is compatible with butorphanol and ketamine in the same syringe at least for two hours.
Benzoic Acid, Sucrose, Glycerin, Mint flavour (containing 0.23% alcohol) and Purified Water.
refers to the last day of the month.
Manufacturer of the biological active substance:
DG I and DG IA - External relations DG III - Industry DG V - Employment, Industrial Relations and Social Affairs DG VI - Agriculture DG IX – Personnel and Administration DG XII - Science, Research and Development Joint Research Centre DG XIX - Budgets DG XX - Financial Control DG XXIV - Consumer Policy and Consumer Health Protection
below the desired haemoglobin level may be observed.
below the desired haemoglobin level may be observed.
Viraferon is used in adult patients for the treatment of chronic hepatitis B or C, which are viral infections of the liver. no
Viraferon is used in adult patients for the treatment of chronic hepatitis B or C, which are viral infections of the liver. no
CONTACT their doctor IMMEDIATELY.
MUST CONTACT their doctor IMMEDIATELY.
New onset diabetes mellitus, hyperglycaemia or exacerbation of existing diabetes mellitus has been reported in patients receiving protease inhibitors.
diabetes mellitus, gout, anorexia, decreased appetite, decreased weight, increased weight, hyperglycaemia, insulin resistance, decreased high density lipoprotein, increased appetite, polydipsia, increased blood lactate dehydrogenase
There is a possibility of an increased risk of suicide related behaviour in young adults ages 18-29.
- diabetes, increased or decreased weight, increased appetite, increased thirst
For the treatment of adults, adolescents and children of 6 years or above with diabetes mellitus, where treatment with insulin is required.
decreased, blood glucose increased, blood uric acid increased, gout aggravated, blood cholesterol and/or triglycerides increased due to hydrochlorothiazide
Diacomit should only be administered under the supervision of a paediatrician / paediatric neurologist experienced in the diagnosis and management of epilepsy in infants and children.
Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.
Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.
Diacomit is used as an add-on to clobazam and valproate (other anti-epileptic medicines) to treat generalised tonic-clonic seizures (major fits, including loss of consciousness) when these are not adequately controlled with clobazam and valproate.
Protopy should not be used continuously.
diaphoresis, pemphigus, toxic epidermal necrolysis, Stevens-Johnson Syndrome, erythema multiforme.
thrush (a fungal infection in the mouth), sores in nose, bleeding from your nose, cold sores, loss of appetite, weight loss and tongue inflammation;
Very common side effects diarrhoea, usually mild and temporary.
Diarrhoea in calves of over one week of age and young, non-lactating cattle.
Keep the vial in the outer carton in order to protect from light.
Uncommon: hepatic enzymes increased, hepatic function abnormal Rare: bilirubinaemia
Diarrhoea** Stomatitis Dyspepsia Flatulence Skin and subcutaneous tissue disorders
Dicural 50 mg/ ml, solution for injection for cattle and dogs
Didanosine enteric-coated 400 mg SD (Indinavir 800 mg SD)
didanosine AUC ↔ 0.99 (0.79-1.25) didanosine Cmin ND didanosine Cmax ↔ 0.91 (0.58-1.42) etravirine AUC ↔ 1.11 (0.99-1.25) etravirine Cmin ↔ 1.05 (0.93-1.18) etravirine Cmax ↔ 1.16 (1.02-1.32)
Didanosine AUC ↔ 1.08 (0.92-1.27) Didanosine Cmin ND Didanosine Cmax ↔ 0.98 (0.79-1.21)
Didanosine/ Efavirenz Didanosine/ Emtricitabine
* EID50 = 50% Embryo infective dose: the virus titre required to produce infection in 50% of the embryos inoculated.
Mean Treatment Difference Compared with Placebo (SE)
- differences in maximum recommended daily dose.
Different end-filters can be used ranging in filter pore size from 0.2 microns up to 5 microns.
The use of both an in-line and end-filter is not recommended.
- various steroids (e.g. dexamethasone, ethinyl estradiol, fluticasone),
- difficulty sleeping, abnormal dreams, nightmares, sweating at night, difficulty concentrating,
- difficulty breathing, decrease in level of oxygen, choking, swelling of the airways, fluid in
- Difficulty in swallowing accompanied by earache and swollen glands, sore throat
digestion the use of BYETTA is not recommended.
- difficulty breathing, cough, nosebleed, running nose, throat irritation
difficulties in breathing, respiratory tract disorders, asthma acute breathlessness
- Difficulties in breathing, respiratory tract disorders, asthma
difficulty in breathing flushing of the skin (vasodilation) changes in fat distribution (see Side effects associated with combination antiretroviral therapy below)
er breathing (angioedema) • Shortness of breath (dyspnoea) ng • Skin rash • Hives (urticaria) lo
breathing difficulties (dyspnoea), double vision (diplopia), drooping eyelid (ptosis), voice alteration, fever
Released for consultation September 2001
Difloxacin (as the hydrochloride) Benzyl alcohol
In a study performed with 24 healthy subjects, when Pradaxa was coadministered with digoxin, no changes on digoxin and no clinical relevant changes on dabigatran exposure have been observed.
Digoxin (P-glycoprotein mediated transport):
- digoxin (used to treat heart problems)
dihydrate, disodium phospate dodecahydrate, calcium chloride dihydrate, glycine, L-Leucine, L-Isoleucine, L-Threonine, L-Glutamic acid, and L-Phenylalanine.
Dihydroergotamine, ergotamine, methylergometrine (dopaminergic vasoconstricteurs): risk of vasoconstriction and increase in blood pressure.
In homocystinuria, betaine reduces homocysteine levels in the blood by facilitating a reaction in the body called ‘ methylation’, which converts homocysteine back into methionine.
DILUTION OF CONCENTRATE WITH THE SUPPLIED DILUENT
Dilution prior to administration (optional)
Decreased total bilirubin, increased GGT, elevated plasma prolactin levels12.
Decrease of vitamin B 12 absorption and lactic acidosis*
of the gastrointestinal absorption of sparfloxacin.
Dose Reduction, treatment interruption and treatment discontinuation:
• Low blood pressure, coldness of hands and feet, high blood pressure • Cough, nasal congestion • Muscle damage • Breast pain, interruption in menstruation • High blood sugar • Increased sensitivity to noise
- low blood pressure (hypotension)
- A decrease in the proportion of red cells in the blood
- decreased blood pressure, decreased blood flow,
• Diminution of animal experiment- ation and control of veterinary vaccines
- white blood-cell depletion leading up to fever (febrile neutropenia), decreased levels of all blood
- decrease of red blood cells (anaemia, with symptoms such as skin pallor and fatigue), decrease
- Reduced blood flow in the heart vessels, faster heartbeat
You may be switched from the intravenous infusion to tablets once your condition improves.
reduction in blood cell counts (platelets, red or white blood cells), increase in white blood cell counts, changes in red blood cell counts
reduction in blood cell counts (platelets, red or white blood cells), inrease in white blood cell counts, changes in red blood cell counts
- Reduction in blood cell counts (platelets, red or white blood cells), increase in white blood cell
differences were observed between treated animals and controls, at 60 mg/ kg effects were still observed (decreased number of corpora lutea, implantations, total and viable fetuses).
- Reduced number of white blood cells (which help protect the body from infection) and blood platelets
- reduction in red blood cells (anaemia), increase in white blood cells (leucocytosis), alteration of the
which can make the skin pale and cause weakness or breathlessness) while undergoing treatment, please contact your doctor who will determine if it is necessary for you to stop using Raptiva.
• Decreased platelets (blood clotting cells) • Allergic reaction such as hives • Hallucinations • Problems with abnormal movements such as writhing, jerking movements and stiffness • Ringing in the ears • Racing heartbeat • Inflammation of the pancreas • Inflammation of the liver, yellowing of the skin and eyes • Severe skin reactions that require immediate medical attention, swelling of the lips and face, skin rash and redness, hair loss • Acute kidney failure
- low numbers of a particular type of white blood cell that fights infections (neutrophils),
corneal reflex decreased oxygen saturation decreased
- decreased sodium in the blood (hyponatraemia); increased potassium in the blood
P-value < 0.0001 for mean decrease in HIV-1 RN A; P-value = 0.0060 for mean change in CD4 cell count. d Confidence interval around observed difference of response rates; P-value < 0.0001 from logistic regression model, including stratification factors. e Confidence interval around observed difference of response rates; P-value = not significant. f Confidence interval around observed difference of response rates; P-value from CMH test controlling for stratification factors = 0.427 for de novo, and < 0.0001 for not de novo.
Sun/ Wed Mon/ Thu Tue/ Fri Wed/ Sat Thu/ Sun Fri/ Mon Sat/ Tue
- If you have any further questions, ask your doctor or your pharmacist.
The Board however also agreed to the release of information by the Agency during the evaluation phase in exceptional circumstances.
that you change the places where you inject, as you have been taught.
taking Viani unless they tell you to do so.
intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Diovan can also be available in the EU and the EEA under other trade names:
Each capsule contains topotecan hydrochloride equivalent to 0.25 mg or 1 mg of topotecan. • The other ingredients are: hydrogenated vegetable oil, glyceryl monostearate, gelatin, titanium dioxide (E171), and for 1 mg capsules only, red iron oxide (E172).
dipalmitoylphosphatidylglycerol, sodium chloride and water for injections.
premature luteinising
Honours degree and PhD in microbiology from University of Dublin, Trinity College.
Graduate in biochemistry and pharmacology from Leeds University.
Qualified chemist and pharmacist from the Free University of Berlin.
PhD in organic chemistry from the Free University of Berlin.
Qualified chemist and pharmacist from the Free University of Berlin.
Qualified chemist and pharmacist from the Free University of Berlin.
Qualified veterinary surgeon from the Faculty of Veterinary Science at Liverpool University and a Member of the Royal College of Veterinary Surgeons.
Qualified veterinary surgeon from the University of Giessen.
Qualified veterinary surgeon from the University of Hanover.
Qualified veterinary surgeon from the University of Hanover.
Qualified veterinary surgeon from University College Dublin.
1995, and was appointed Head of the Veterinary Unit in December of
Qualified as a veterinary surgeon from the Royal Veterinary College, London University.
Qualified as a veterinary surgeon from the Royal Veterinary College, London University.
Qualified veterinary surgeon from the Royal Veterinary College, London.
Qualified as a veterinary surgeon at the Veterinary College of Ireland, University College Dublin.
Qualified as a pharmacist from the University of Manchester in 1965.
Graduate of the Faculty of Veterinary Science at Liverpool University.
research fellow in the State University of Rome on projects in
Graduated in veterinary medicine from the Faculty of Veterinary Science at Liverpool University and is a Member of the Royal College of Veterinary Surgeons of the United Kingdom.
- Board-certification as neurosurgeon according to local, national requirements;
Qualified as a pharmacist from the University of Manchester in 1965.
Qualified as a pharmacist from Heriot-Watt University, Edinburgh.
Qualified as a pharmacist from Heriot-Watt University, Edinburgh.
Qualified pharmacist from the Free University of Brussels.
Qualified pharmacist from the Free University of Brussels.
Qualified Pharmacist from the Free University of Brussels.
Qualified pharmacist and Degree in medicine and surgery from the University of Barcelona, as well as Diploma in Pharmacology and Toxicology.
Qualified as a pharmacist, BSc (Pharm) and was granted a Masters degree in pharmaceutics in the research area of microencapsulation from Trinity College Dublin.
Qualified as a pharmacist, BSc (Pharm) and was granted a Masters degree in pharmaceutics in the research area of microencapsulation from Trinity College Dublin.
Graduated in pharmacology from Kings College, London University.
Graduated in pharmacology from Kings College, London University.
senior veterinary assessor in the pharmaceuticals and feed
Qualified veterinarian from the University of Giessen.
He is a graduate in business administration from the Institut Supérieur de Gestion in Paris.
research non-governmental organisations in France, Europe and the United States in the fields of cancer, AIDS and genetic diseases.
Law degree from the University of Dundee, UK.
Qualified pharmacist from the University of Strasbourg.
Qualified pharmacist from the University of Uppsala Faculty of Pharmacy.
Qualified Pharmacist and Degree in medicine and surgery from the University of Barcelona as well as postgraduate courses in pharmacology and toxicology, public health and
Qualified Pharmacist and Degree in medicine and surgery from the University of Barcelona as well as postgraduate courses in pharmacology and toxicology, public health and European
Veterinary medicine degree from the University of Milan.
Post-graduate qualifications in internal medicine, endocrinology, diabetology and cardiology.
Diplopia, blurred vision, dilated pupils, oculogyric crises.
dosing syringe from the bottle.
EXECUTIVE DIRECTOR EXECUTIVE DIRECTOR Thomas Lönngren Thomas Lönngren
The Council of the European Union has set the date of the proposed enlargement of the European Union as 1 May 2004.
enzyme replacement therapy is
disoproxil 245 mg (as fumarate)
- the availability of your insulin in the country you are visiting,
Each vial contains 5 ml solution (500 Units) or 10 ml solution (1000 Units) and they are available in packs of 1, 2, 5 and 10 vials of 5 ml or 1 vial of 10 ml.
Packs of 1, 3, 4, 5, 6, 8, 9 and 10 cartridges of 3 ml are available.
Each cartridge contains 3 ml solution (300 Units) and they are available in packs of 1, 3, 4, 5, 6, 8, 9 and 10 cartridges.
Packs of 1, 3, 4, 5, 6, 8, 9 and 10 cartridges are available.
Packs of 1, 3, 4, 5, 6, 8, 9 and 10 pre-filled pens of 3 ml are available.
Each pen contains 3 ml solution (300 Units) and they are available in packs of 1, 3, 4, 5, 6, 8, 9 and 10 pens.
Packs of 1, 3, 4, 5, 6, 8, 9 and 10 pre-filled pens of 3 ml are available.
Packs of 1, 3, 4, 5, 6, 8, 9 and 10 pens are available.
Packs of 3, 4, 5, 6, 9 or 10 cartridges are available.
Packs of 3, 4, 5, 6, 9 or 10 cartridges for OptiClik are available.
Iontophoretic transdermal system (ITS); one system + moisture absorber
Transdermal patch Novartis Pharma GmbH Roonstraße 25 D-90429 Nuremberg Germany
Dissolve the powder by gently swirling the vial.
The content of a 1 g vial is dissolved in 10 ml of water for injections by swirling.
Dissolve the product as described at 6.6.
Abdominal distension, fecal incontinence, gastrointestinal disorder (NOS), gastroenteritis, haemorrhoids
Birds should be deprived of water for two hours prior to vaccination.
Distribution The mean apparent volume of distribution of exenatide following subcutaneous administration of a single dose of exenatide is 28 l.
Rosuvastatin is taken up extensively by the liver which is the primary site of cholesterol synthesis and LDL-C clearance.
7 Distribution Autopsy data from patients show that mitotane is found in most tissues of the body, with fat as the primary site of storage.
Distribution: the apparent volume of distribution at steady state is 46±21 l.
The volume of distribution (Vss) of tolcapone is small (9 l).
Tell people that if you pass out (become unconscious), they should: turn you on your side and get no
Tell your doctor if you are or think you may be pregnant or if you are breast-feeding.
Potassium sparing diuretics, potassium supplements or potassium-containing salt substitutes:
tablets'), laxatives (e. g. castor oil), corticosteroids (e. g. prednisone), ACTH (a hormone),
Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, monitoring of potassium plasma levels is advised.
sparing diuretics, potassium supplements.
allergies and hormone imbalances
A number of substances affect glucose metabolism and may require dose adjustment of insulin glargine.
Various positions as a documentalist in several European countries, the latest from 1988 to 1995 setting up and running the Documentation Service at the European Commission Delegation in Norway.
Various positions as a documentalist in several European countries, the latest from 1988 to 1995 setting up and running the documentation service in the European Commission Delegation in Norway.
Division of Stryker Corporation Raheen Business Park Limerick Ireland
Division of Stryker Corporation Raheen Industrial Estate Raheen Limerick Ireland
Nineteen remaining topics are currently being examined by the CPMP Working Parties in preparation for the ICH4 meeting in July 1997 in Brussels.
BMD – mean change relative to baseline total hip at year 3
BMD – mean change relative to baseline total hip at year 3
Dña Ana Maria NAVEIRA NAVEIRA Directora General de Farmacia y Productos Sanitarios Ministerio de Sanidad y Consumo Paseo del Prado 18-20 E-2801 4 Madrid Tel: +34.1.227.6700 Fax: +34.1.596.1547
Docetaxel Winthrop 20 mg concentrate and solvent for solution for infusion
Docetaxel Winthrop 80 mg concentrate and solvent for solution for infusion
Docetaxel Winthrop 80 mg concentrate and solvent for solution for infusion
Docetaxel Winthrop 80 mg concentrate and solvent for solution for infusion
Docetaxel Winthrop 80 mg concentrate for solution for infusion docetaxel intravenous use
Qualified medical doctor from the Medical School of the University of Dublin.
Qualified medical doctor from the Medical School of the University of Dublin.
Doctorate in clinical pharmacology from the Autonomous University of Barcelona (UAB).
Doctor of Philosophy, degree in pharmaceutical microbiology from the University of Strathclyde, Glasgow.
Doctor of Philosophy, degree in pharmaceutical microbiology from the University of Strathclyde, Glasgow.
Docteur Maurice Donat – BP 442 F-06254 Mougins Cedex Tél: + 33 (0)4 92 92 44 00 E-mail: uk_medinfo@allergan. com
Doctor:...................... .……………………
Doctor:...................... .……………… Tel:.................. .……………………………………………..
Worked for the food industry (1976-1977), biological laboratory of the Free University of Amsterdam (1977-1978).
PhD in developmental cardiology at Leiden University.
PhD in developmental cardiology at Leiden University.
MSc in computer science and BSc in business administration and economics at the University of
PhD in organic chemistry from the Free University of Berlin.
PhD in organic chemistry from the Free University of Berlin.
PhD in pharmaceutical microbiology from the University of Strathclyde, Glasgow.
Doctorate in clinical pharmacology from the
Doctorate pharmacology from the Autonomous University of Barcelona (UAB).
Doctor of Sciences in physical sciences and qualification in management of research, PhD and MSc in physical organic chemistry, Degree in Biochemistry, from the University of Montpellier.
Doctorate of Science in physical sciences; qualification in research management; PhD in physical organic chemistry; Masters degree in physical organic chemistry; Degree in biochemistry.
DSc in physical sciences; qualification in research management; PhD in physical organic chemistry; Masters degree in physical organic chemistry; Degree in biochemistry.
Ms Fayl held various positions as a documentalist in several European countries, the latest from 1988 to 1995 setting up and running the documentation service in the European Commission Delegation in Norway.
Documentation and archiving Conference and linguistic support Information technology
Document management and publishing Conference services Information technology
the CHMP has recommended the granting of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Doxagamma 4 mg prolonged release tablets and associated names (see Annex I).
the documentation submitted, the scientific discussion within the Committee and the new wording proposed in the updated Guideline on SPC dated October 2005 and the latest QRD template, the CHMP has recommended the granting of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Doxastad 4 mg prolonged release tablets and associated names (see Annex I).
The sector’s mission is to provide reliable and robust IT
such as swollen face, tongue or pharynx, difficulty to swallow, hives and difficulties to breath.
Do I use a new needle for each injection? • Yes.
Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patients
To be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease, or epilepsy.
To be reconstituted with sodium pertechnetate (99mTc) solution for injection (not included in this kit).
a total haemoglobin concentration between 7 and 9 g/ dl. ed
(90% CI) (90% CI) (90% CI)
or any other medicinal product containing abacavir (Ziagen or Trizivir) again.
take Trizivir or any other medicinal product containing abacavir (i. e.
Ziagen or any other medicinal product containing abacavir (i. e.
PL-02-672 Warszawa Tel.: + 48 22 606-10-50
Domaniewska 50 C PL – 02 672 Warszawa Tel.: + 48-22 549 15 00
ActiTrak data for all EMEA in 2000
ActiTrak data for human medicines evaluation in 2000
Small, clinically insignificant, reversible elevations in serum creatinine levels have been observed in healthy subjects and patients treated with Ranexa.
CLINICAL PARTICULARS on 4.1 Therapeutic indications ol
Clinical data The efficacy and safety profile of < Invented Name > has been evaluated in more than 2,000 patients including infants (≥3 months), children, adolescents, and adults enrolled in phase II and III studies.
4.1 Therapeutic indications
Therapeutic indications
CLINICAL PARTICULARS Delete, where applicable, prevention and control of coccidiosis.
Treatment of adult patients with chronic hepatitis B associated with evidence of hepatitis B no
Long-Term efficacy data lon In a large study, 1,071 patients were enrolled after treatment in a prior non pegylated interferon alfa-2b or non pegylated interferon alfa-2b/ ribavirin study to evaluate the durability of sustained virologic response and assess the impact of continued viral negativity on clinical outcomes.
Long-Term efficacy data In a large study, 1,071 patients were enrolled after treatment in a prior non pegylated interferon alfa-2b or non pegylated interferon alfa-2b/ribavirin study to evaluate the durability of sustained virologic response and assess the impact of continued viral negativity on clinical outcomes.
Long-term efficacy data Two large long-term follow-up studies enrolled 1,071 patients and 567 patients after treatment in prior studies with nonpegylated interferon alfa-2b (with or without Rebetol) and pegylated interferon alfa- 2b (with or without Rebetol), respectively.
Long-term efficacy data Two large long-term follow-up studies enrolled 1,071 patients and 567 patients after treatment in prior studies with nonpegylated interferon alfa-2b (with or without ribavirin) and pegylated interferon alfa- 2b (with or without ribavirin), respectively.
Long-Term efficacy data A large long-term follow-up study enrolled 567 patients after treatment in a prior study with PegIntron (with or without ribavirin).
Long-Term efficacy data A large long-term follow-up study enrolled 567 patients after treatment in a prior study with ViraferonPeg (with or without ribavirin).
Post-marketing experience with saquinavir
Spontaneous data A reanalysis of spontaneous data reported to the MAH up to 30 September 2001 found 1579 confirmed cases of rhabdomyolysis amongst 7,620 reports.
6.1 List of excipients One 30 mg tablet contains:
6.1 List of excipients CPMP/ 255/ 98-EN One 60 mg tablet contains:
Pharmacokinetic data Cerivastatin is readily and completely (98%) absorbed from the gastrointestinal tract with plasma concentrations peaking within 2-3 hours of dosing and mono-exponential decay thereafter.
SUMMARY INFORMATION ON REFERRAL OPINION PURSUANT TO ARTICLE 30 OF COUNCIL DIRECTIVE 2001/ 83/ EC FOR
SUMMARY INFORMATION ON REFERRAL OPINION PURSUANT TO ARTICLE 30 OF COUNCIL DIRECTIVE 2001/ 83/ EC FOR
SUMMARY INFORMATION ON REFERRAL OPINION PERSUANT TO ARTICLE 6(13) OF COMMISSSION REGULATION (EC) No 1084/ 2003 FOR
SUMMARY INFORMATION ON REFERRAL OPINION
8 Additional data on effects of continuous oestrogen – progestogen combined products on emdometrial hyperplasia.
Dopharma also described the history of the product since 1987, the year of its first authorisation in the Netherlands.
Strength 75 mg 75 mg 75 mg 75 mg 75 mg 75 mg 75 mg 75 mg 75 mg 75 mg 75 mg 75 mg 75 mg 75 mg 300 mg 300 mg 300 mg 75 mg 75 mg
Dosing the oral solution Preparing the metering pump for dosing When the pump is pressed for the first time it will not discharge the correct quantity of oral solution.
Twice daily dose 300 mg/ m² 0.9 ml (75 mg) 1.9 ml (150 mg) 3.8 ml (300 mg) 4.7 ml (375 mg) 5.6 ml (450 mg)
Twice daily dose 350 mg/ m² 1.1 ml (87.5 mg) 2.2 ml (175 mg) 4.4 ml (350 mg) 5.5 ml (437.5 mg) 6.6 ml (525 mg)
Dose to be administered PegIntron should be administered as a once weekly subcutaneous injection.
Dose to be administered ViraferonPeg should be administered as a once weekly subcutaneous injection.
Dose after the first 24 hours (Maintenance Dose)
Dosage for adults The recommended dosage is approximately 47 micrograms depreotide (one vial) labelled with 555-740 MBq of technetium-99m.
The light dose (J/ cm)= power output from diffuser (W) x treatment time (sec) Diffuser length (cm)
The light dose (J/ cm) = power output from diffuser (W) x treatment time (sec) Diffuser length (cm)
Patients should be monitored for signs of withdrawal and their methadone dose increased as required to alleviate withdrawal symptoms.
Maintenance dose between 25 and 50 IU/ kg 2 times per week into 2 equal doses.
Maintenance dose between 25 and 50 IU/kg 2 times per week into 2 equal doses.
Usual maintenance dose 75 - 150 60 - 150 30 - 100
Maintenance The recommended maximum single dose is 4 mg taken with main meals.
Maintenance Dose (IU/hour) = [(100 – patient’s pre -treatment AT activity level in%) /10.22] x Body Weight in kg
Maintenance Dose (IU/ hour) = [(100 – patient's pre -treatment AT activity level in%) / 10.22] x Body Weight in kg
Dose of iloprost at
Dose of iloprost at mouthpiece
Dose of iloprost at mouthpiece 2.5 micrograms
patient's clinical response to methadone therapy.
Usual dose 5 mg once a day 7.5 mg once a day 10 mg once a day.
The usual dose The usual dose is about 14 ml injected over about 7 -14 seconds into a vein, usually a vein in an arm.
measuring spoonfuls)
measuring spoonfuls)
Recommended lopinavir/ ritonavir dosing (mg) twice daily.
3.5 mg* 3.3 mg* 3.0 mg*
Dose response In the fixed dose studies there is a flat dose response curve, providing no suggestion of advantage in terms of efficacy for using higher than the recommended doses.
Dose-response in monotherapy In a direct comparison with 90 micrograms, the 180 micrograms-dose was associated with superior sustained virological response in patients with cirrhosis, but in a study in non-cirrhotic patients very similar results were obtained with doses of 135 micrograms and 180 micrograms.
Dose recommendations for paediatric patients
Total dose (mg) = Dose (mg/ m2) x BSA (m2)
Total dose (mg) = Dose (mg/m2) x BSA (m2)
Doubling the darifenacin dose from 7.5 mg to 15 mg result in a 150% increase in steady-state exposure.
Abdominal pain, diarrhoea, constipation, nausea Mouth sores Inflammation of the pancreas
Abdominal pain, diarrhoea,
Intestinal perforation, gastrointestinal haemorrhage, intestinal stenosis Unknown:
Abdominal pain and gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal cramps and bloating
Abdominal pain and gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal cramps and bloating
Increased levels of substances that measure the function of the liver.
• Blood clots (thrombosis) • Pain around the area injected • Rash and/ or redness of the skin
- bruising, hair loss, changes to skin colour, increased sweating, dry skin, or other skin problems;
• pain in the tummy (abdomen) caused by inflammation of the pancreas
Abdominal pain/ discomfort Oily spotting from the rectum Flatus with discharge Faecal urgency Fatty/ oily stool Flatulence Liquid stools Oily evacuation Increased defecation
Musculoskeletal pain, muscular weakness
Urticaria, skin hyperpigmentation, allopecia, soft nails, rash, erythema
Joint swelling, Bone pain, Facial pain, Musculoskeletal stiffness, Muscular weakness
Joint swelling, Bone pain, Facial pain, Musculoskeletal stiffness, Muscular weakness,
Pharyngolaryngeal pain; Cough; Nasal dryness
Dyspnoea, epistaxis, cough Pleural effusion3, pharyngolaryngeal pain, pharyngitis Pleuritic pain, pulmonary fibrosis, pulmonary hypertension, pulmonary haemorrhage
Post-operative pain: single intravenous or subcutaneous injection.
Post-operative pain: single intravenous or subcutaneous injection.
Post-operative pain: single subcutaneous injection.
Periorbital oedema, dermatitis/ eczema/ rash Pruritus, face oedema, dry skin, erythema, alopecia, night sweats, photosensitivity reaction
tho • Fever (more than 37.5°C) • Irritability • Loss of appetite
Abdominal pain Dyspepsia Stomatitis Melaena Gastrointestinal bleeding Duodenal ulcer and perforation Gastric ulcer and perforation
- pain in and around the stomach (abdominal pain)
- pain in or around your stomach (abdominal pain)
• pain in the lower abdominal region, possibly in combination with nausea • vomiting and weight gain.
- Pain in joints, limbs or back, muscle cramps
pain in joints, limbs or back, muscle cramps joint disorders
• pain in the tummy (abdomen) caused by inflammation of the liver
product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you.
Vomiting Gastrointestinal and abdominal pains Dyspepsia Flatulence
- muscle pain, muscle cramps or weakness, stiffness of muscles or joints, joint pain with or
- muscle pain, inflammation of the joints, increased muscle tone, cramping, tendon rupture –
Musculoskeletal pain (mild or moderate)
Musculoskeletal pain (bone, muscle or joints)
General Disorders and Administration Site Conditions Fatigue (10.8%)
Musculoskeletal pain (mild to moderate, transient) Uncommon:
Musculoskeletal pain (mild to moderate) * see below
changes in blood test results (such as blood chemistry and blood count)
pain weight loss laboratory test results: changes in blood test results (such as blood chemistry and blood count)
- pain, flu-like symptoms, generally feeling unwell, swelling caused by build-up of fluid in the arms
Pain, flu-syndrome, asthenia, chills
Chest pain, asthenia, oedema, injection site pain
Chest pain, asthenia, oedema, injection site pain 15
Haematuria Urinary incontinence Urine flow decreased Polyuria Renal function abnormal
feet, dizziness, impaired writing ability, nervous system disorders
Twelve thousand two hundred and eighteen (12218) patients aged over 18 were randomised to perindopril 8 mg (n=6110) or placebo (n=6108).
liberación prolongada EEG
salaries interim and other support persons other staff-related expenditure total title 1
Dr Alexander JENTZSCH Ministerialrat Bundesministerium für Arbeit, Gesundheit und Soziales Stubenring 1 A-1010 Vienna Tel: +43.1.71172.4673 Fax: +43.1.714.9222
Dr André BROEKMANS Executive Director Medicines Evaluation Board P.O.
DRAXXIN is given as a single injection of 2.5 mg per kilogram body weight.
Dr Gerasimos KAVVADIAS President National Drug Organisation Mesogion 284 GR-15562 Holargos Tel: +30.1.652.5562 Fax: +30.1.654.5535
Dr Jacques BOISSEAU Directeur Agence Nationale du Médicament Vétérinaire La Haute Marche Javené F-35133 Fougères Tel: +33.2.99.94.78.72 Fax: +33.2.99.94.78.99
Dr Michael RUTTER Dr., Director and Chief Executive Veterinary Medicines Directorate Woodham Lane, New Haw UK- Addlestone KT15 3NB Tel: +01932.33 6.911 Fax: +01932.336.618/352.549
Dr Reddy's Laboratories (Uk) Limited 6 Riverview Road Beverley, E Yorks HU17 0LD United Kingdom
Dr Romano MARABELLI Direttore Generale Servizi Veterinari Ministero della Sanità Viale Civilità Romana 7 I-00144 Rome Tel: +39.6.5994.3945/6 Fax: +.39.6.5994.3190
Dublin, Ireland • Organon S. A., Usine Saint Charles, 60590 Eragny sur Epte, France
In vivo activity against HCMV was confirmed with controlled clinical studies of cidofovir for the treatment of CMV retinitis in patients with AIDS, which demonstrated statistically significant delays in time to CMV retinitis progression for patients on cidofovir when compared to control patients.
sympathomimetics, please see section "Taking other medicines"
damage and inflammation of the liver
- fosamprenavir (another medicine to treat HIV-infection)
(Measure once as spoonfuls or lumps of sugar or glucose tablets to see how much this means).
DUKORAL – 1 dose package, 2x1 dose package, 20x1 dose package (outer sleeve)
DUKORAL is indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children from 2 years of age who will be visiting endemic/ epidemic areas.
Dukoral is used in adults, adolescents and children from two years of age who will be visiting high-risk areas.
- lopinavir/ ritonavir (another medicine to treat HIV-infection)
DULOXETINE BOEHRINGER INGELHEIM increases the levels of serotonin and norepinephrine in the nervous system.
DULOXETINE BOEHRINGER INGELHEIM should not be used in combination with nonselective, irreversible Monoamine Oxidase Inhibitors - MAOIs (see section 4.5).
- a puncture-proof container (plastic container provided by the hospital or pharmacy) so you can
Generally, each fracture site is treated with the contents of one kit.
In general, the adverse event profile in children with pre-existing bronchial asthma was qualitatively similar to that of otherwise healthy children.
Reduced susceptibility for tylvalosin was generally noted in tylosin resistant strains.
• a new Neulasta pre-filled syringe; and
- an animal insulin (especially a bovine insulin) to human insulin,
- an animal insulin (especially a bovine insulin) to human insulin,
- one human insulin preparation to another,
From 1992 to 1993, Dr Duneton was technical advisor for public health in the Cabinet of the French Minister responsible for health and humanitarian action.
A new injection site should be used each day.
- that no more than two injections of hydroxocobalamin are to be administered,
The user should apply a new EVRA patch immediately.
From a microbiological point of view, the product should be used immediately.
From a microbiological safety point of view, the product is to be used immediately.
From a microbiological point of view, the product should be used immediately.
From a microbiological point of view, the product should be used immediately.
From a microbiological point of view, it should be used immediately.
From a microbiological point of view, the product should be used immediately after reconstitution.
From a microbiological point of view, the solution must be used immediately.
From a microbiological point of view, the product must be used immediately.
From a microbiological point of view, the product should be used immediately.
From a microbiological point of view, the product should be used immediately.
From a microbiological point of view, the diluted product should be used immediately.
From a microbiological point of view, the diluted product should be used immediately.
- From a microbiological point of view, the product should be used immediately.
From a microbiological point of view, the product should be used immediately.
12 From a microbiological point of view, the product should be used immediately.
From a microbiological point of view, the product should be used immediately after dilution.
17 From a microbiological point of view, the product should be used immediately.
8 From a microbiological point of view, the product should be used immediately.
From a microbiological point of view, the product should be used immediately.
From a microbiological point of view, the product should be used immediately after reconstitution.
From a microbiological point of view, the product should be used immediately after reconstitution (see section 6.3).
- From a microbiological point of view, the product is to be used immediately.
From a microbiological point of view, the product must be used immediately.
From a microbiological point of view the product, once dissolved, should be used immediately.
From a microbiological point of view the product should be used immediately.
From a microbiological point of view, the product should be used immediately.
10 From a microbiological point of view, the reconstituted product should be used immediately.
From a microbiological point of view, the reconstituted product should be used immediately.
From a microbiological point of view, the reconstituted and diluted solutions should be used immediately.
From a microbiological point of view, once reconstituted, the product may be stored for a maximum of 14 days at 2 C – 8 C.
From a microbiological point of view, the product should be used immediately.
- heart problems, which can cause symptoms such as chest pain (angina), particularly after any
Talk to your doctor if you have any of these conditions, or if they worsen whilst taking Avonex.
DuoTrav 40 micrograms/ ml + 5mg/ ml eye drops, solution
DuoTrav 40 micrograms/ ml + 5 mg/ ml eye drops, solution travoprost/ timolol
DuoTrav 40 micrograms/ ml + 5 mg/ ml eye drops, solution Travoprost/ Timolol
DuoTrav is a fixed dose combination of travoprost and timolol that can improve compliance in IOP control.
Since DuoTrav contains benzalkonium chloride, close monitoring is required with frequent or prolonged use.
21 • DuoTrav contains hydrogenated castor oil, which may cause skin reactions.
Therefore, care should be taken by people who wear soft contact lenses.
DuoTrav contains benzalkonium chloride which may cause irritation and is known to discolour soft contact lenses.
DuoTrav is used to reduce intraocular pressure (IOP, the pressure inside the eye).
• DuoTrav may increase the length, thickness, colour and/ or number of your eyelashes and may cause unusual hair growth on your eyelids.
Tell your doctor if your child is taking the following medicines before starting SINGULAIR: • phenobarbital (used for treatment of epilepsy) • phenytoin (used for treatment of epilepsy) • rifampicin (used to treat tuberculosis and some other infections)
From a microbiological point of view, if the product is diluted it should be transferred to the infusion pump immediately.
breakpoints relevant to the indications are acceptable.
During these trials less than 13% of patients in total discontinued treatment due to adverse events.
During this period when you have stored MIRCERA at a room temperature not above 25 °C you may not put MIRCERA back in the refrigerator before use.
Upon storage, a white deposit and clear supernatant can be observed.
Upon storage, a white deposit and clear supernatant may be observed.
Upon storage, a white deposit and clear supernatant may be observed.
Upon storage, a white deposit and clear supernatant can be observed.
Upon storage, a white deposit and clear supernatant may be observed.
During training of the patient for self- administration, special attention should be given to specific instructions for the use of the prefilled pen.
In clinical development, dizziness was commonly reported.
During the ‘ induction'phase, Vistide is given as a one-hour infusion of 5 mg per kilogram body weight once a week for the first two weeks.
During the 6 to 10 hour treatment period, showering or bathing should be avoided.
Translation Centre, will within the next year provide for a more adequate provision of translation facilities.
During clinical studies with ADVATE, a total of 56 adverse drug reactions (ADRs) were reported in 27 of 234 unique treated patients.
In the first few weeks after vaccination with Pandemrix the results of these tests may not be correct.
In the first few weeks after vaccination with Prepandrix the results of these tests may not be correct.
Upon storage, a white deposit and clear supernatant can be observed.
25 Upon storage, a fine white deposit with a clear colourless supernatant can be observed.
During therapy patient's weight should be monitored.
The patient's weight should be monitored during therapy with Prometax transdermal patches.
The patient's weight should be monitored during therapy with Exelon transdermal patches.
During treatment for hepatitis B or C the recommended testing schedule is at weeks 1, 2, 4, 8, 12, 16, and every other month, thereafter, throughout treatment.
During venipuncture, it is important to adhere to the instructions to limit the amount of blood entering the tubing.
Shelf-life after incorporation into feed:
Shelf life after first opening of the container:
Shelf life after first use of the pen:
Shelf-life after first opening of the container:
Shelf-life after first opening the bottle:
Shelf life after first opening the container:
Shelf-life after first opening the container:
Shelf-life after first use of the product:
Shelf-life after first opening the container:
Shelf-life after first opening the container:
Shelf life after first opening of the tube:
Shelf-life after first opening of the tube:
17 Shelf life after first use of the vial:
Shelf life after first use of the vial:
After reconstitution:
Shelf life after reconstitution After reconstitution:
26 Shelf life after first use of the cartridge:
46 Shelf life after first use of the cartridge:
Shelf life after first use of the cartridge:
Shelf life after first use of the cartridge:
Shelf life after first use of the vial:
Shelf life after first use of the vial:
Shelf life after first use of the pen:
Shelf life for pen in use:
Estimated inhalation time
Estimated Inhalation time
for type I variations 2001
During 2001 di scussions were held in different forums at the
The duration of immunity is up to 1 year.
Duration of treatment:
Duration of treatment: • Keppra is used as a chronic treatment.
Duration of treatment: • Keppra is used as a chronic treatment.
Maximum shelf-life for sterile products for human use after first opening or following reconstitution
Duration of treatment Continue to take Axura as long as it is of benefit to you.
Duration of treatment in combination with pegylated interferon alfa-2b
Duration of treatment: • Keppra is used as a chronic treatment.
How long to take SPRYCEL You should take SPRYCEL daily until your doctor tells you to stop.
Duration of treatment – Naïve patients Predictability of sustained virological response:
Duration of treatment A limited number of patients (50 patients) have received a second infusion for hypercalcaemia.
Mean EMEA Processing Time for Human Medicinal Products submitted 1995-1997 2
Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin)
Hypereosinophilic syndrome (HES) and/ or chronic eosinophilic leukaemia (CEL).
Photosensitivity reaction Alopecia
TOLTRAZURIL INTENDED FOR USE IN POULTRY SPECIES
amphotericin B or when amphotericin B has had to be stopped;
Dynastat had no effect on acetylsalicylic acid-mediated inhibition of platelet aggregation or bleeding times.
You will not be given Dynastat in the last three months of pregnancy.
Dynastat is not recommended for children or adolescents.
Leucopenia Lymphoma Like Reaction, Lymphadenopathy, Hypochromic Anaemia1,2,3, Blood Dyscrasia, Purpura, Coagulation Disorder, Coagulation Time Increased2,3, Anaemia1, Thrombocytopenia3, Thrombocythemia, Eosinophilia1, Leukocytosis2, Lymphocytosis
Sexual dysfunction Ejaculation disorder Ejaculation delayed Gynaecological haemorrhage
Erectile dysfunction, gynaecomastia, metrorrhagia, nipple pain
Sexual dysfunction Ejaculation disorder Ejaculation delayed Gynaecological haemorrhage
grand mal convulsion, syncope, dyskinesia, dizziness postural
grand mal convulsion, syncope, dyskinesia, dizziness postural,
grand mal convulsion, syncope, dyskinesia, dizziness postural,,
grand mal convulsion, syncope, dyskinesia,, dizziness postural,
Anorexia, constipation Dyspepsia, nausea, abdominal pain, gastroenteritis, stool abnormal
Dyspepsia, gastroesophageal reflux, stomatitis, ulcerative stomatitis, gingival bleeding, loose stools, constipation, flatulence, hemorrhoids, gingivitis, glossitis, dehydration, taste perversion
Palmar-plantar erythrodysaesthesia syndrome
disorders dysphagia diarrhoea, dry mouth, vomiting, colitis
High-grade dysplasia in Barrett's oesophagus of < 7 cm
Dyspnoea exertional, epistaxis, nasopharyngitis, sinus congestion, nasal congestion, rhinitis, sore throat
Dyspnoea, diplopia, fever, ptosis, voice alteration.
Hypertension Dyspnoea, Dysphonia, Cough, Rhinorrhoea, Throat tightness Salivary hypersecretion,,
Dyspnoea, increased sputum Gastrointestinal disorders:
Dyspnoea, nasal dryness Epistaxis, throat tightness, nasopharyngitis, cough, nasal congestion, rhinitis, snoring
Alopecia, rash Photosensitivity reaction, maculopapular rash, eczema, acne, skin disorder, nail disorder, skin discolouration, pruritus, dry skin, erythema, bruise, sweating increased
Dyspnoea, cough, hoarseness, pharyngolaryngeal pain, throat irritation, respiratory tract congestion, sinus congestion, post nasal drip, rhinorrhoea, snoring
Pneumonia, upper respiratory infection, nasal congestion
Renal and urinary disorders:
is 1 ml solution contains 100 IU (3.5 mg) of insulin human (rDNA).
uth Tel: + 34-91 848 85 00
Improvement in fatigue, as measured by the Functional Assessment of Cancer Therapy-fatigue (FACT-fatigue) scale, was also observed. ct
1 ml 1: cell culture infective dose 50% 2: egg infective dose 50%
Ebixa works by blocking special types of receptor called NMDA receptors to which the neurotransmitter glutamate normally attaches.
ECALTA has been studied primarily in patients with candidaemia and only in a limited number of patients with deep tissue Candida infections or with abscess-forming disease (see section 4.4 and section 5.1).
Do not store ECALTA above 25ºC.
ECALTA should be reconstituted with the solvent to a concentration of 3.33 mg/ ml and subsequently diluted to a concentration of 0.36 mg/ ml before use according to the instructions given in section 6.6.
ECALTA is given as an initial dose of 200 mg on day one, followed by 100 mg each day from day two.
ECALTA is prescribed to treat a type of fungal infection of the blood called candidaemia.
Patients with candida endocarditis, osteomyelitis or meningitis and known C. krusei infection have not been studied.
- ECF: epirubicin (50 mg/ m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/ m2 as a two
2.3.2 Exchange of documents/ information, in accordance with established procedures, and the documentation of such exchanges.
Post-test Breath Samples (3 Red Capped Tubes) Using the red-capped, take samples of your breath as before (see step 4).
Epworth Sleepiness Scale (ESS; range 0-24)
EDS – Excessive daytime sleepiness; ESS – Epworth Sleepiness Scale; MWT – Maintenance of Wakefulness Test; Naps – Number of inadvertent daytime naps; CGIc – Clinical Global Impression of Change; FOSQ – Functional Outcomes of Sleep Questionnaire
Scale of fees payable by the EMEA to national competent authorities
Functional Assessment of Cancer Therapy- Anaemia (FACT-An) general scale, FACT-An fatigue scale, and Cancer Linear Analogue Scale (CLAS).
Functional Assessment of Cancer Therapy-Anaemia (FACT-An) general scale, FACT-An fatigue scale, and Cancer Linear Analogue Scale (CLAS).
Spinal / Epidural anaesthesia In patients undergoing major orthopaedic surgery, epidural or spinal haematomas that may result in long-term or permanent paralysis cannot be excluded with the concurrent use of fondaparinux and
Echinococcus multilocularis (mature adult and immature) Echinococcus granulosus (mature adult and immature)
E. coli adhesin F4 (F4ab, F4ac, F4ad), at least … .2.1 SA. U* E. coli adhesin F5, at least……………………… 1.7 SA. U* E. coli adhesin F6, at least ……………………… 1.4 SA. U* E. coli adhesin F41, at least…………………… .1.7 SA. U* … *:
E. coli adhesin F4 (F4ab, F4ac, F4ad), at least … .2.1 SA. U* E. coli adhesin F5, at least……………………… 1.7 SA. U* E. coli adhesin F6, at least ……………………… 1.4 SA. U* E. coli adhesin F41, at least…………………… .1.7 SA. U* *:
E. coli adhesin F4 (F4ab, F4ac, F4ad), at least … .2.1 SA. U* E. coli adhesin F5, at least……………………… 1.7 SA. U* E. coli adhesin F6, at least ……………………… 1.4 SA. U* E. coli adhesin F41, at least…………………… .1.7 SA. U*
is the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
is the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
1 x 1 kg and 1 x 25 kg aluminium-lined plastic bags.
Econor has been developed especially for pigs and is not for use in humans.
Econor was used either to treat animals that were already affected by a disease or to prevent the outbreak of the disease in pigs in contact with diseased animals as well as on farms with a history of repeatedly re-occurring disease.
Econor improves the health and weight of the treated pigs, but may not eliminate completely the bacteria that caused lung infection.
- Abnormal flow of bile from the gallbladder into the intestine (cholestasis)
Application site discharge Application site hyperaesthesia Application site inflammation
- runny nose, cough, hoarseness due to infection of the upper respiratory tract
- runny nose, cough, hoarseness due to infection of the upper respiratory tract, sinusitis, cough
In subjects with type 1 or type 2 diabetes, inhaled human insulin has a faster onset of glucose pr
- ECX: epirubicin (50 mg/ m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/ m2 as a two
is swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
edetate disodium, sodium chloride, m -cresol, polysorbate 80 and water for injections.
monohydrate, edetate disodium, sodium chloride, m-cresol, polysorbate 80 and water for injections.
Disodium edetate (E386) Polysorbate 80 (E433) Lactose anhydrous Sodium hydroxide (E524) (for pH adjustment) and/ or Hydrochloric acid diluted (E507) (for pH adjustment)
The expiry date refers to the last day of that month.
The other ingredients are Total EDTMP (as EDTMP. H2O), calcium-EDTMP sodium salt (as Ca),
• Eduardo MARQUES FONTES (Portugal)
1) Description of post injection syndrome – Education about the 2 intramuscular formulations of olanzapine, including packaging differences – Description of reconstitution and proper administration technique – Recommendation for a 3-hour on-site observation period post injection – Recommendation that prior to giving the injection, the HCP should determine that the patient will not travel alone to their destination – Recommendation for informing patients that for the remainder of the day of the injection, they should not drive or operate machinery, should be vigilant for signs and symptoms of a post injection syndrome event, and should be able to obtain assistance if needed – Description of the most common symptoms reported with olanzapine overdose that represent the clinical manifestation in post injection syndrome events – Recommendation for appropriate monitoring until the event resolves if an event should occur 2) Recommendations for monitoring of patients for glucose, lipids, and weight. – Promote awareness of appropriate metabolic monitoring by distributing utilized published antipsychotic guidelines.
Eesti Allergan Ltd 1st Floor Marlow International The Parkway Marlow Bucks, SL7 1YL-UK Ühendkuningriik Tel: + 44 (0) 1628 494026 E-mail: uk_medinfo@allergan. com
Eesti Österreich Boehringer Ingelheim Pharma GmbH Eesti Filiaal Tel: +372 60 80 940
94 Eesti Österreich Boehringer Ingelheim Pharma GmbH Tel: + 37 2 60 80 940 Ελλάδα ΦΑΡΜΑΣΕΡΒ -ΛΙΛΛΥ Α .Ε .Β .Ε.
Eesti Österreich Boehringer Ingelheim Pharma GmbH Tel: + 37 2 60 80 940
Eesti Österreich BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT.
23 Tel: + 372 640 0007
182 Eesti Österreich Eli Lilly Holdings Limited Eesti filiaal Tel: +3726441100
29 Eesti Polska ESTOBIIN OÜ Udeselja 4-4 11913, Tallinn, Estonia Tel: +372 600 2996
Eesti Nederland GE Healthcare Estonia OÜ Mustamäe tee 46 EE - 10621 Tallinn Tel: +372 6260 061
Eesti Österreich GE Healthcare Estonia OÜ Mustamäe tee 46 EE – 10621 Tallinn Tel: + 372 6260 061
29 Eesti Österreich GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk .com
51 Eesti Österreich GlaxoSmithKline Eesti OÜ Tel: + 372 - 6 676 900 estonia@gsk.com
60 Eesti Österreich GlaxoSmithKline Eesti OÜ Tel: +372 6676900 Estonia@GSK. com
76 Eesti GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk. com
Eesti GlaxoSmithKline Eesti OÜ
Eesti GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900
Eesti GlaxoSmithKline - Eesti OÜ Tel: +372 667 6900 estonia@gsk.com
Eesti GlaxoSmithKline Eesti OÜ Tel: + 372 - 6 676 900 estonia@gsk.com
Eesti GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk. com
Eesti GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk.com
Eesti GlaxoSmithKline Eesti OÜ Tel: +372 667 6900 estonia@gsk. com
Eesti GlaxoSmithKline Eesti OÜ Tel: +372 667 6900 estonia@gsk.com
Eesti GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk. com
Eesti Österreich GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk.com
Eesti Österreich GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk.com
Eesti Österreich GlaxoSmithKline Eesti OÜ Tel: +372 667 6900 estonia@gsk.com
Eesti Österreich GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk. com
Eesti Österreich GlaxoSmithKline Eesti OÜ Tel: + 372 6676 979 estonia@gsk.com www.alli.gsk.ee
 443 Eesti Österreich Järvevana tee 9 EE-11314 Tallinn Tel: + 372 654 96 86
ed Järvevana tee 9 EE-11314 Tallinn Tel: + 372 654 96 86
Eesti Österreich Järvevana tee 9 EE-11314 Tallinn dic
Eesti Österreich Järvevana tee 9 EE-11314 Tallinn Tel: + 372 654 96 86
ge Eesti Österreich Järvevana tee 9 EE-11314 Tallinn
ra Järvevana tee 9 EE-11314 Tallinn Tel: + 372 654 96 86
uth Eesti Österreich Järvevana tee 9
Eesti Österreich KRKA, d.d., Novo mesto Eesti filiaal Tel: + 372 (0)6 597 365
234 Eesti Österreich Merck Serono Esindaja C/ o Ares Trading SA Baltic States Zamenhofo 11-3, LT-44287 Kaunas, Leedu Tel: +370 37320603
Eesti Österreich Merck Serono Esindaja C/o Ares Trading SA Baltic States Zamenhofo 11-3, LT-44287 Kaunas, Leedu Tel: +370 37320603
45 Eesti Österreich Merck Sharp & Dohme OÜ Tel.: +372 613 9750 msdeesti@merck. com
50 Eesti Österreich Merck Sharp & Dohme OÜ Tel.: +372 613 9750 msdeesti@merck. com
54 Eesti Österreich Merck Sharp & Dohme OÜ Tel.: +372 613 9750 msdeesti@merck. com
Eesti Merck Sharp & Dohme OÜ Tel: +372.613.9750 msdeesti@merck. com
Eesti Merck Sharp & Dohme OÜ Tel.: +372 613 9750 msdeesti@merck. com
Eesti Österreich Merck Sharp & Dohme OÜ Tel.: +372 613 9750 msdeesti@merck. com
Eesti Österreich Merck Sharp & Dohme OÜ Tel.: +372 613 9750 msdeesti@merck.com
Eesti Österreich Merck Sharp & Dohme OÜ Tel.: +372 613 9750 msdeesti@merck. com
Eesti Österreich Merck Sharp & Dohme OÜ Tel.: +372 6139 750 msdeesti@merck.com
ge Eesti Österreich Järvevana tee 9 EE-11314 Tallinn
140 Eesti Österreich BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT.
145 Eesti Österreich BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT.
150 Eesti Österreich BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT.
155 Eesti Österreich BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT.
Eesti BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT.
Eesti CentralPharma Communications OÜ Tel: +372 640 00 07
Eesti CSL Behring AB P.O.Box 712 S-182 17 Danderyd Tel: +46 8 544 966 70
EXUBERA Kliendi Tugikeskus Tel: + 372 6 405 328 ed
Eesti GE Healthcare Estonia OÜ Mustamäe tee 46 EE – 10621 Tallinn Tel: + 372 6260 061
Eesti GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk. com
Eesti GlaxoSmithKline Eesti OÜ Tel: +372 667 6900 estonia@gsk.com
Eesti GlaxoSmithKline Eesti OÜ Tel: +372 667 6900 estonia@gsk. com
Eesti GlaxoSmithKline Eesti OÜ Tel: +372 667 6900 estonia@gsk.com
Eesti GlaxoSmithKline Eesti OÜ Tel: +372 667 6900 estonia@gsk. com
Eesti Österreich GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk.com
Eesti Österreich GlaxoSmithKline Eesti OÜ Tel: +372 667 6900 estonia@gsk. com
Eesti Järvevana tee 9 EE-11314 Tallinn Tel: + 372 654 96 86
Eesti Merck Sharp & Dohme OÜ Tel: +372 613 9750 msdeesti@merck. com
Eesti Merck Sharp & Dohme OÜ Tel: +372.613.9750 msdeesti@merck. com
Eesti Merck Sharp & Dohme OÜ Tel: +372 613 9750 msdeesti@merck. com
Eesti Österreich Novartis Pharma Services Inc.
Eesti Orphan Europe AB Banérgatan 37 S-11522 Stockolm Rootsi Tel: + 46 8 545 80 230
Eesti Pfizer Luxembourg SARL Eesti filiaal Tel: + 372 6 405 328
Eesti Pfizer Luxembourg SARL Eesti filiaal Tel: +372 6 405 328
Eesti Pfizer Luxembourg SARL Eesti filiaal Tel: +372 6 405 328 Ελλάδα Pfizer Hellas A. E.
Eesti Roche Eesti OÜ Tel: + 372 - 6 112 401
75 Eesti Österreich Roche Eesti OÜ Tel: + 372 - 6 177 380
Eesti Roche Eesti OÜ Tel: + 372 - 6 177 380
Eesti Roche Eesti OÜ Tel: +372 - 6 177 380
Eesti Roche Eesti OÜ Tel: + 372 - 6 177 380
41 Eesti Österreich Pfizer Luxembourg SARL, Eesti filiaal Tel: +372 6 405 328
Eesti Österreich Pfizer Luxembourg SARL Eesti filiaal Tel.: +372 6 405 328
It has been shown that taking all doses at the appropriate times may greatly increase the effectiveness of your medicine.
Eesti Österreich sanofi-aventis Estonia OÜ Tel: +372 627 34 88
A dose adjustment is not needed when efavirenz is administered with VIRACEPT.
A dose adjustment is not needed when efavirenz is administered with VIRACEPT.
Efectin ER 75 mg Efectin ER 150 mg
Efectin ER 37,5 mg trde kapsules podaljšanim sproščanjem Efectin ER 75 mg trde kapsule s podaljšanim sproščanjem Efectin ER 150 mg trde kapsules podaljšanim sproščanjem
Efexor depot should be taken with food (see section 3 “ HOW TO TAKE EFEXOR DEPOT”).
Children and adolescents should be monitored every 3 months for evidence no
Antineoplastic effect: inhibition of topoisomerase II.
Effect of 6 months treatment on body weight measured at baseline
Effect of CHAMPIX on other drugs CHAMPIX is not expected to affect the way other drugs work.
Effect of ambrisentan on xenobiotic transporters
In a cross-over study in 22 HIV-infected patients treated with Invirase/ritonavir 1000 mg/100 mg twice daily and receiving three consecutive doses under fasting conditions or after a high-fat, high-calorie meal (46 g fat, 1,091 Kcal), the AUC0-12, Cmax and Ctrough values of saquinavir under fasting conditions were about 70 per cent lower than with a high-fat meal.
22 Effect of food: the bioavailability of a single 600 mg dose of efavirenz hard capsules in uninfected volunteers was increased 22% and 17%, respectively, when given with a meal of high fat or normal composition, relative to the bioavailability of a 600 mg dose given under fasted conditions (see section 4.4).
70 Effect of food: the bioavailability of a single 600 mg dose of efavirenz hard capsules in uninfected volunteers was increased 22% and 17%, respectively, when given with a meal of high fat or normal composition, relative to the bioavailability of a 600 mg dose given under fasted conditions (see section 4.4).
Effect of food: the bioavailability of a single 600 mg dose of efavirenz hard capsules in uninfected volunteers was increased 22% and 17%, respectively, when given with a meal of high fat or normal composition, relative to the bioavailability of a 600 mg dose given under fasted conditions (see section 4.4).
Effect of food: the administration of SUSTIVA with food may increase efavirenz exposure (see section 5.2) and may lead to an increase in the frequency of adverse reactions (see section 4.8).
Effect of food: the administration of SUSTIVA with food may increase efavirenz exposure (see section 5.2) and may lead to an increase in the frequency of adverse reactions (see section 4.8).
Effects of simvastatin on the pharmacokinetics of other medicinal products Simvastatin does not have an inhibitory effect on cytochrome P450 3A4.
Potential for RISPERDAL CONSTA to affect other medicinal products
Effect of other drugs on CHAMPIX Due to the way in which varenicline tartrate is removed from the body, it is not expected that other drugs will affect the way in which CHAMPIX works.
Amlodipine dilates peripheral arterioles, reducing the total peripheral resistance (afterload).
Convulsions or pronounced excitation: treat with benzodiazepines Respiratory insufficiency: treat with artificial respiration Tachycardia: treat with beta-blockers Urinary retention: treat with catheterisation Mydriasis: treat with pilocarpine eye drops and/ or place patient in dark room.
Effects of other medicinal products on glucuronidation of lamotrigine
Food effect The bioavailability of nilotinib is increased by food.
Effects of other medicinal products on posaconazole:
Effects of other medicinal products on ciprofloxacin:
Effects of other medicinal products on Ciprofloxacin:
HMG Co-A Reductase Inhibitors Atorvastatin, Fluvastatin, Lovastatin, Pravstatin, Rosuvastatin, Simvastatin
- combined effects of 5-ALA, anaesthesia, and tumour resection (= procedure-specific side effects).
Pain, oedema, inflammation, extravasation.
Abnormal vision such as blurry, hazy, fuzzy vision, or flashes of light, decreased vision, visual field defect such as grey or dark haloes, scotoma and black spots.
Common effects: means that between 1 in 10 and 1 in 100 people taking the medicine are affected.
Common effects: vomiting, mouth ulceration, swallowing difficult.
Affecting the body • Headaches • An increase in blood-test results that show how your liver is working • Increased blood pressure
Effects in the body: shortness of breath, increased allergic symptoms, facial swelling, drowsiness, generalized weakness, nausea, vomiting, sinus infection
Hormone effects • Subnormal activity of the thyroid gland (hypothyroidism): common • Breast enlargement (gynaecomastia): very rare (children); uncommon (adults)
ADVERSE EVENTS FROM PAEDIATRIC CLINICAL TRIALS In short-term (up to 10-12 weeks) clinical trials in children and adolescents, the following adverse events were observed in paroxetine treated patients at a frequency of at least 2% of patients and occurred at a rate at least twice that of placebo were: increased suicidal related behaviours (including suicide attempts and suicidal thoughts), self-harm behaviours and increased hostility.
Side effects before or after having a liver transplant
Cerebrovascular adverse reactions An approximately 3-fold increased risk of cerebrovascular adverse reactions have been seen in randomised placebo-controlled clinical trials in the dementia population with some atypical antipsychotics, including risperidone, aripiprazole, and olanzapine.
Undesirable effects in patients undergoing major orthopaedic
Undesirable effects in patients undergoing major orthopaedic surgery of lower limbs and/ or
Undesirable effects in patients undergoing major orthopaedic surgery of lower limbs and/ or abdominal surgery
Common: bleeding (gastrointestinal, haematuria, haematoma, epistaxis, haemoptysis, utero-vaginal haemorrhage, haemarthrosis, ocular, purpura, bruise) Uncommon: anaemia, thrombocytopaenia Rare: other bleeding (hepatic, retroperitoneal, intracranial/ intracerebral), thrombocythaemia
Adverse reactions in patients with recurrent or progressive malignant glioma Infections and infestations
- Common adverse events: urinary tract disorders (cystitis, urinary incontinence, urinary retention,
- Common adverse events: urinary tract disorders (such as bladder infections, irregular urination,
Side effects with unknown frequency include:
Very common ADRs in study BR.21
Very common ADRs in study BR.21
Very common ADRs in study PA.3 (100 mg cohort)
Very common ADRs in study PA.3 (100 mg cohort)
Adverse reaction elevations in ALT and/ or AST (consecutive, ≥ 3 X ULN), fasting glucose, uric acid (see below)
Commonly reported side effects (at least 1 in every 100 patients, but less than 1 in every 10 patients):
Commonly reported side effects (at least 1 in every 100 patients, but less than 1 in every 10 patients): pain at the place of injection, increased sweating, flushing, chest pain, fingers and toes very sensitive to cold, bruise, numbness or tingling feeling, shaky hands, increased or decreased sensitivity to touch, swelling due to a build-up of excess water, increase in muscle movement, changes in your voice, ear infection, abnormal vision, eye pain or infection, dry or teary eyes, nervousness, aggressive behaviour, wanting to harm yourself, lack of interest, feeling confused, feeling anxious or nervous, difficulty concentrating, behaviour disorder, weakness, feeling sleepy, unusual dreams, sleepwalking, trouble sleeping, change in thyroid gland activity (which may make you feel tired or, less commonly, energetic), pain on the right side around your ribs, abnormal liver function, sores in mouth, sore tongue, toothache, tooth disorder, tooth abscess, increased appetite, stomach upset, constipation, loose stools, acid reflux, gastroesophageal or rectal disorder, urinary tract infection, bedwetting, incontinence, urination disorders, difficult, irregular, or no menstrual period, abnormally heavy and prolonged menstrual periods, disorder of vagina, testis pain, fever blisters, fungal infections, bacterial infections, swollen glands, respiratory infections, sneezing, rapid breathing, nose bleed, cough, stuffy or runny nose, shortness of breath, nose irritation, skin sensitive to sunlight, pale skin, redness of skin or skin disorder, eczema (inflamed, red, itchy and dryness of the skin with possible oozing lesions), rash with raised spotted lesions, acne, itching, dry skin, skin discolouration, skin wound, nail disorder, tumor (unspecified), decrease in the number of blood clotting cells, excess of uric acid (as in gout) in the blood, inflammation of the membrane of the stomach and intestine, inflammation of the vagina, development of male body traits, and excess of triglycerides in the blood.
56 bruise, numbness or tingling feeling, feeling faint, shaky hands, increased or decreased sensitivity to touch, migraine, tense muscles, pain in joints, arthritis, unsteady when walking, vertigo (spinning feeling), changes in your hearing or voice, ringing in ears, ear infection, earache, blurred or abnormal vision, eye pain or infection, dry or teary eyes, agitation, nervousness, aggressive behaviour, mental disorder, wanting to harm yourself, lack of interest, abnormal crying, feeling confused, feeling sleepy, unusual dreams, trouble sleeping, change in thyroid gland activity (which may make you feel tired or, less commonly, energetic), pain on the right side around your ribs, enlarged liver, jaundice (yellow skin), change in taste, taste loss, bleeding gums or sores in mouth, sore tongue, inflamed gums, increased appetite, thirst, stomach upset, constipation, intestinal gas (flatus), irritated colon, loose stools, frequent need to urinate, passing more urine than usual, urinary tract infection, abnormal urine, difficult, irregular, or no menstrual period, abnormally heavy and prolonged menstrual periods, painful menstruation, disorder of ovary or vagina, breast pain, lack of interest in sex or inability to perform, irritation of prostate gland, fever blisters, fungal infections, swollen glands, respiratory infections, sinusitis, nose bleed, nonproductive cough, stuffy or runny nose, rapid or difficult breathing, abnormal hair texture, skin sensitive to sunlight, redness of skin or skin disorder, psoriasis, eczema (inflamed, red, itchy and dryness of the skin with possible oozing lesions), rash with raised spotted lesions, acne, tumour (unspecified), cardiac murmur (abnormal heart beat sounds), decrease in the number of blood clotting cells or decrease in certain white blood cells called lymphocytes that help fight infection, excess of sugar or uric acid (as in gout) in the blood, low calcium level in the blood, and water impairment.
Common side effects (occurring in less than 1 out of 10 patients) are bleeding from the stomach or the intestines and bleeding from the nose, and eye irritation due to keratitis.
Common side effects (these may affect up to 1 in 10 people)
Seeing flashes of light with floaters progressing to a loss of sight, decreased sharpness of vision, swelling of a section of the eye (uvea, cornea), clouding of the lens, small marks on the surface of the eye, bleeding in the eye, discharge from the eye with itching, redness and swelling (conjunctivitis), light sensitivity, eye discomfort, swelling of the eyelid, eyelid pain.
Common side effects (occurring in at least 1 in 100 patients) are:
Common side effects (affects 1 to 10 users in 100): • Restlessness, sleep disorder, dizziness, feeling dizzy when staying still, fatigue, drowsiness, sleepiness • Weight increased, toothache, weight decreased • Vomiting, diarrhea, constipation, nausea, dry mouth, abdominal pain or stomach discomfort, stomach infection • Difficulty breathing, lung infection (pneumonia), flu, infection of the breathing passages, urinary tract infection, increase in body temperature, urinary incontinence, sinus infection, viral infection, ear infection, nose congestion, sore throat, ‘ pink eye’, flu-like illness, cough • Blurred vision • Tremor, muscle weakness, fall, back pain, muscle spasm, pain in arms and legs, joint pain, involuntary movement of face or limb muscles, muscle pain, swelling of the arms and legs • Blood prolactin hormone level increased, liver enzymes increased, decrease in hemoglobin or red blood cell count (anemia), blood sugar increased • No menstruation, erectile dysfunction, breast discharge • Abnormal electrical conduction of the heart, high blood pressure, fast beating heart, chest pain, low blood pressure, abnormal electrical tracing of the heart (ECG) • Rash, injection site pain, skin redness.
Serious side effects It is not known how frequently these side effects occur
Serious side effects Tell your doctor immediately if you experience any of the following side effects – you may need medical attention:
Viral infection, pharyngitis Fungal infection, bacterial infection, pulmonary infection, otitis media, tooth abscess, herpes simplex, urinary tract infection,
Viral infection, pharyngitis Fungal infection, bacterial infection, pulmonary infection, otitis media, tooth abscess, herpes simplex, urinary tract infection,
Viral infection, pharyngitis Fungal infection, bacterial infection, pulmonary infection, otitis media, tooth abscess, herpes simplex, urinary tract infection,
Depression, emotional lability, insomnia Suicidal ideation, aggressive reaction, confusion, behaviour disorder, agitation, somnambulism, anxiety, nervousness, sleep disorder, abnormal dreaming, apathy
Viral infection, pharyngitis Fungal infection, bacterial infection, pulmonary infection, otitis media, tooth abscess, herpes simplex, urinary tract infection, vaginitis, gastroenteritis
- Very common adverse events: decreased appetite (including anorexia); lethargy.
- Very common adverse events: decreased appetite (including anorexia); lethargy (including calmness
The most common side effects (these may affect 10 in every 100 people or more)
25 Less common side effects (these may affect up to 9 in every 100 people)
NEUROLOGICAL ADVERSE EVENTS Severe neurological events have been reported with the use of nelarabine.
Side effects seen in clinical trials.
24 Side effects observed when Ceplene is used as described in this package leaflet
Very common adverse reactions ≥ 10% of patients
Very common adverse reactions ≥ 10% of patients
Very common adverse reactions ≥ 10% of patients
- Uncommon adverse events: weight loss/ loss of condition; dilation of the pupils of the eye
- Uncommon adverse events: weight loss/ loss of condition; mydriasis.
Uncommon side effects (affects 1 to 10 users in 1,000 patients):
Uncommon side effects (these may affect up to 1 in 100 people)
Uncommon side effects (occurring in more than 1 in 1000 patients) are:
Uncommon side effects: diverticulitis (fever, nausea, diarrhoea, constipation, stomach pain), red swollen (inflamed) areas in the mouth, high blood fat (triglycerides) and serious allergic (hypersensitivity) reactions.
Blindness, infection of the eye globe (endophthalmitis), inflammation and bleeding in the front part of the eye, sac of pus on the eye, changes of the central part of the eye surface, pain or irritation at the site of injection, abnormal sensation in the eye, irritation of the eyelid.
Uncommon These may affect up to 1 in 100 people − reduction in the number of platelets (blood cells necessary for blood clotting) − reduced blood flow to the brain
Your doctor should also monitor your liver function while you are being treated with VFEND by doing blood tests.  you are already being treated with phenytoin (used to treat epilepsy).
Uncommon side effects Interstitial pneumonitis (scarring of the air sacs of the lung) Spasm of the airways (wheeze) Abnormal chest X ray/scan (scarring of the lungs)
This will usually pass on its own but if it does not, tell your doctor.
Uncommon side effects • Allergic (hypersensitivity) reactions, including swelling of the face, lips, tongue and/ or throat • Vaginal bleeding, thick, whitish discharge and candidiasis (infection)
58 Uncommon side effects (affects 1 to 10 users in 1000): • Nervousness, poor attention, feeling very sleepy, exhausted, or weary, excessive sleep, elated mood (mania), feeling ‘ out of sorts’, sluggishness • Nasal congestion • Bladder infection, stomach and intestine infection, ear pain • Sudden swelling of lips and eyes along with difficulty breathing, allergy • Neck pain, buttock pain, musculoskeletal chest pain, pain during injection procedure, chest discomfort, swelling and thickening of skin at injection site • Decreased appetite, increased appetite • Sexual dysfunction, enlargement of breast in men, decreased sexual drive • Intense itching of the skin, reduced sensation of skin to pain and touch, a sensation of tingling, pricking, or numbness of skin, abscess under the skin, hair loss, acne, dry skin • Fainting, drop in blood pressure after standing, feeling dizzy after changing body position • Abnormal heart rhythm, awareness of heart beating, slow beating heart, • Body shakes rapidly and uncontrollably (convulsion) • Decrease in white blood cells that help against infection, decrease in platelets (blood cells that help you stop bleeding).
Uncommon side effects (likely to affect 1 to 10 in every 1000 patients) • anger, aggression, thoughts of suicide, suicide attempt. • vomiting. • gall bladder inflammation, gallstones. • urinary stones. • pneumonia and urinary tract infections. • low blood potassium levels, convulsions/ seizures.
Post-marketing adverse reactions reported for bivalirudin
of anaesthesia (= active substance-specific side effects)
41 Post marketing adverse events
93 Post marketing adverse events
Post marketing adverse events
ADRs reported in clinical trials or during postmarketing surveillance in patients with NHL and CLL disease treated with MabThera monotherapy/ maintenance or in combination with chemotherapy
Post-marketing experience
523 Side effects reported uncommonly (Seen in less than 1 in 100 but more than 1 in 1000 patients) • Severe allergic reaction with low blood pressure (shock) • Injection site urticaria (itchy rash)
550 Side effects reported uncommonly (Seen in less than 1 in 100 but more than 1 in 1000 patients) • Severe allergic reaction with low blood pressure (shock) • Injection site urticaria (itchy rash)
595 Side effects reported uncommonly (Seen in less than 1 in 100 but more than 1 in 1000 patients) • Severe allergic reaction with low blood pressure (shock) • Injection site urticaria (itchy rash)
605 Side effects reported uncommonly (Seen in less than 1 in 100 but more than 1 in 1000 patients) • Severe allergic reaction with low blood pressure (shock) • Injection site urticaria (itchy rash)
622 Side effects reported uncommonly (Seen in less than 1 in 100 but more than 1 in 1000 patients) • Severe allergic reaction with low blood pressure (shock) • Injection site urticaria (itchy rash)
632 Side effects reported uncommonly (Seen in less than 1 in 100 but more than 1 in 1000 patients) • Severe allergic reaction with low blood pressure (shock) • Injection site urticaria (itchy rash)
667 Side effects reported uncommonly (Seen in less than 1 in 100 but more than 1 in 1000 patients) • Severe allergic reaction with low blood pressure (shock) • Injection site urticaria (itchy rash)
677 Side effects reported uncommonly (Seen in less than 1 in 100 but more than 1 in 1000 patients) • Severe allergic reaction with low blood pressure (shock) • Injection site urticaria (itchy rash)
694 Side effects reported uncommonly (Seen in less than 1 in 100 but more than 1 in 1000 patients) • Severe allergic reaction with low blood pressure (shock) • Injection site urticaria (itchy rash)
739 Side effects reported uncommonly (Seen in less than 1 in 100 but more than 1 in 1000 patients) • Severe allergic reaction with low blood pressure (shock) • Injection site urticaria (itchy rash)
749 Side effects reported uncommonly (Seen in less than 1 in 100 but more than 1 in 1000 patients) • Severe allergic reaction with low blood pressure (shock) • Injection site urticaria (itchy rash)
766 Side effects reported uncommonly (Seen in less than 1 in 100 but more than 1 in 1000 patients) • Severe allergic reaction with low blood pressure (shock) • Injection site urticaria (itchy rash)
776 Side effects reported uncommonly (Seen in less than 1 in 100 but more than 1 in 1000 patients) • Severe allergic reaction with low blood pressure (shock) • Injection site urticaria (itchy rash)
Side effects reported uncommonly (Seen in less than 1 in 100 but more than 1 in 1000 patients) • Severe allergic reaction with low blood pressure (shock) • Injection site urticaria (itchy rash)
Rare side effects These may affect up to 1 in 1,000 people: • fluid in the lungs (pulmonary oedema) causing breathlessness • swelling of the retina at the back of the eye (macular oedema) • reduction in the number of red blood cells, or a type of white blood cell (granulocytopaenia) which can be severe (agranulocytosis), reduction in the number of all types of blood cells (pancytopaenia) • liver doesn't function as well as it should (increase in liver enzymes).
Rare side effects These may affect up to 1 in 1,000 people: • fluid in the lungs (pulmonary oedema) causing breathlessness • heart failure • swelling of the retina at the back of the eye (macular oedema) • liver doesn't function as well as it should (increase in liver enzymes).
A severe or life-threatening skin reaction (Stevens Johnson syndrome)
35 • Abnormal crying • Increased interest in sex • Blood clot in the lung • Inflammation of the gall bladder • Yellow-brown pigment spots on the face • Irregular periods • A bumpy rash (hives) where the patch has been on the skin • Rise in cholesterol levels.
Rare side effects (these can affect from 1 to 10 users in 10,000 patients treated) • Decrease of activity of the thyroid gland. • Dehydration. • Mania (a disorder which symptoms are over activity, racing thoughts and decrease need for sleep). • Bad breath. • Increased pressure in the eye. • Menopausal symptoms. • Contraction of the jaw muscle. • Increased level of cholesterol in the blood, low levels of sodium in the blood (the symptoms are feeling sick and unwell with weak muscles or confused), syndrome of inadequate secretion of anti-diuretic hormone (SIADH).
Rare side effects (these can affect from 1 to 10 users in 10,000 patients treated) • Decrease of activity of the thyroid gland. • Dehydration. • Mania (a disorder which symptoms are over activity, racing thoughts and decrease need for sleep), experiencing aggression and anger. • Bad breath. • Increased pressure in the eye. • Menopausal symptoms. • Contraction of the jaw muscle. • Increased level of cholesterol in the blood, low levels of sodium in the blood (the symptoms are feeling sick and unwell with weak muscles or confused), syndrome of inadequate secretion of anti-diuretic hormone (SIADH).
Gastrointestinal bleedings or perforation, circulatory failure, multiple sclerosis, lymphoma.
Adverse reactions possibly reflecting meningeal irritation in Phase II, III, and IV patients (n [%] of cycles* of therapy)
Selected treatment-emergent adverse reactions considered possibly or probably related to study drugs (efavirenz, emtricitabine and tenofovir disoproxil fumarate) in clinical study GS-01-934 over 144 weeks
Side effects reports on the marketed product (from spontaneous reporting):
side effects reports on the marketed product (from spontaneous reporting):
Side effects reports on the marketed product (from spontaneous reporting):
148 VERY COMMON side effects (affects more than 1 user in 10): − Diarrhoea; − Increased cholesterol; − Increased GGT (a type of liver enzyme); − Increased triglycerides (a form of fat).
VERY COMMON side effects (affects more than 1 user in 10): − Diarrhoea; − Increased cholesterol; − Increased GGT (a type of liver enzyme); − Increased triglycerides (a form of fat).
Inflammation of the eye, blurred vision, bleeding in the back of the eye (retinal bleeding), visual disturbances, eye pain, small particles or spots in your vision (floaters), bloodshot eye, eye irritation, a feeling of having something in the eye, increased tear production, inflammation or infection of the eyelid margins, dry eye, redness or itching of the eye.
Very common side effects: headache and runny nose.
Very common side effects (occurring in at least 1 in 10 patients) include: runny nose or sore throat, urinary infection (bladder infection), headaches, dizziness, nausea, diarrhoea, back pain, pain in joints, fever, and bruise.
Treatment-emergent events during concomitant and monotherapy treatment phases in patients with newly-diagnosed glioblastoma multiforme
Metabolic and endocrine effects Thiazide therapy may impair glucose tolerance.
Metabolic and endocrine effects: thiazide therapy may impair glucose tolerance.
Metabolic and endocrine effects Thiazide therapy may impair glucose tolerance.
As with others HMG-CoA Reductase inhibitors (statins), pravastatin has been associated with the onset of myalgia, myopathy and very rarely, rhabdomyolysis.
Very common side effects These may affect more than one person in every 10 people Affecting the eye • Longer eyelashes (up to 45% of people) • Slight redness (up to 44% of people) • Itchiness (up to 14% of people)
Effects in the eye: damage to the optic nerve, increased pressure in eye, deposits on the eye surface, corneal disorder, decreased eye sensation, inflammation or infection of the conjunctiva, abnormal, double or reduced vision, increased pigmentation of the eye, growth on surface of eye, increased tear production, eye swelling, sensitivity to light, decreased growth or number of eyelashes, drooping of the eyelids, inflammation of the eyelid glands
Effects in the eye: eyelid abnormality, decreased growth or number of eyelashes
General side effects: decreased or irregular heart rate, reduced heart function, chest pain, asthma, difficulty breathing, shortness of breath, decreased red blood cell count in blood, increased chlorine level in blood, dizziness, drowsiness, difficulty with memory, depression, difficulty sleeping, nervousness, irritability, fatigue, generalized weakness, feeling abnormal, pain, shaking, ringing in ears, decreased sex drive, male sexual difficulty, cold symptoms, chest congestion, cough, sinus infection, throat irritation, abnormal or decreased sensation in mouth, inflammation of the lining of the oesophagus, abdominal pain, nausea, upset stomach, frequent bowel movements, diarrhoea, intestinal gas, digestive disorder, kidney pain, muscle pain, muscle spasms, back pain, nose bleeds, dry nose, runny nose, stuffy nose, sneezing, rash, abnormal skin sensation, itching, loss of hair
Effects in the eye: eye pain, eye irritation, blurred vision, corneal staining, dry eye, itchy eye, eye redness
Effects in the eye: eye pain, eye irritation, blurred vision, corneal staining, dry eye, itchy eye, eye redness
Effects in the eye: inflammation inside the eye, eye pain and swelling, sensitivity to light, conjunctival bleeding, blurred vision, dry eye, itchy eye, eye allergy, increased tear production, eyelid irritation, itching, redness, pain and swelling; tired eyes, increased growth or number of eye lashes
Effects in the eye: inflammation inside the eye, eye pain or swelling, eye irritation, eye discharge, sensitivity to light, blurred, reduced or abnormal vision, dry eye, itchy eye, increased tear production, abnormal or decreased eye sensation; eyelid abnormality, irritation, itching, redness, pain, swelling or crusting; discolouration of the eyelashes, increased or decreased growth or number of eyelashes, changes in the colour of the iris.
Effects in the eye: inflammation of the coloured part of the eye (iritis), eye surface inflammation, deposits on the eye surface, fluid or swelling at the back of the eye, eye discharge, sensitivity to light, allergic conjunctivitis (eye allergy), eye irritation or pain, eyelid disorder (swelling) or drooping, increased tear production, eye redness
Effects in the eye: inflammation of the back of the eye.
23 Effects in the eye: eye surface inflammation with surface damage, inflammation inside the eye, red eye, itchy eye; eyelid itching, redness, swelling, or crusting; eye discharge, eye allergy, dry eye, tired eyes
Effects in the eye: eye surface inflammation with loss or damage of cells, eye pain, blurred vision, itchy eye, dry eye, foreign body sensation in the eyes, eyelid crusting
Effects in the eye: inflammation or infection of the conjunctiva, corneal disorder, eye allergy, tired eyes.
3 Ocular effects Travoprost may gradually change the eye colour by increasing the number of melanosomes (pigment granules) in melanocytes.
Ocular: corneal oedema, conjunctivitis, eye oedema, eye swelling, mydriasis, visual disturbance, eyelid margin crusting Systemic: hypersensitivity, dyspnea, somnolence, swelling face, dermatitis, erythema, nausea, vomiting, sinusitis, asthenia, malaise
Effects in the eye: corneal disorder, eye surface inflammation, swollen conjunctiva
Common side effects These may affect up to nine people in every 100 people Affecting the eye • An allergic reaction in the eye • Tired eyes • Sensitivity to light • Darker skin colour around the eye • Darker eyelashes • Pain • A feeling that something is in your eye • Sticky eyes • Darker iris colour • Difficulty in seeing clearly • Irritation • Burning • Inflamed, red and itchy eyelids • Tears • Dryness • Swelling of the see-through layer which covers the surface of the eye • Cataract • Small breaks in the surface of the eye, with or without inflammation
Effects in the eye: double vision, eyelid crusting, changes in the colour of the iris
23 Common side effects (1 to 10 users in 100) Effects in the eye: blurred vision, eye irritation, eye pain, eye discharge, itchy eye, dry eye, abnormal eye sensation, redness of the eye, eyelid itching, redness, or swelling.
18 Effects in the eye: blurred, reduced, or abnormal vision, corneal disorder, inflammation or infection of the conjunctiva, eye discharge, eye allergy, sensitivity to light, increased tear production, itchy eye, redness of the eye, eyelid abnormality, itching, redness, swelling, or crusting of the eyelid.
Retinal detachment (non-rhegmatogenous), subretinal/ retinal haemorrhage, vitreous haemorrhage.
Common effects: means that between 1 in 10 and 1 in 100 people taking the medicine are affected.
Uncommon effects: means that between 1 in 100 and 1 in 1000 people taking the medicine are affected.
Pharmacodynamic effects After administration of tenecteplase dose dependent consumption of α 2-antiplasmin (the fluid-phase inhibitor of plasmin) with consequent increase in the level of systemic plasmin generation have been observed.
Pharmacodynamic effects In studies using an initial dose of 0.7 mg/ kg followed by 11 weekly doses of 1.0 mg/ kg, efalizumab maximally reduced expression of CD11a on circulating T lymphocytes to approximately 15-30% of pre-dose baseline values and saturated CD11a to < 5% of baseline available CD11a binding sites.
Pharmacodynamic effects BYETTA improves glycaemic control through the immediate and sustained effects of lowering both postprandial and fasting glucose concentrations in patients with type 2 diabetes.
Pharmacodynamic effects FORSTEO is a bone formation agent to treat osteoporosis.
Pharmacodynamic effects Nicotinic acid causes a relative shift in the distribution of LDL subclasses from small, dense (most atherogenic) LDL particles to larger LDL particles.
Pharmacodynamic effects Laropiprant has been shown to be effective in reducing flushing symptoms induced by nicotinic acid.
Potential for other medicinal products to affect rimonabant: d
Potential for other medicinal products to affect RISPERDAL CONSTA
Possible Side Effects). • If you are taking other medicinal products which could interact with paclitaxel (see Using other medicines).
The carboxylic acid metabolite (fexofenadine) is detectable in human breast milk after terfenadine administration.
unless, in the physician's judgement, the potential benefit to the patient outweighs the potential risk to the infant.
EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
12 Effects on lipid metabolism and cardiovascular risk:
Effect on hip fractures Aclasta demonstrated a consistent effect over 3 years, resulting in a 41% reduction in the risk of hip fractures (95% CI, 17% to 58%).
Effect on skeletal muscle Rare cases of rhabdomyolysis have been associated with concomitant administration of lipid-altering doses (≥ 1000 mg/ day) of nicotinic acid and HMG-CoA reductase inhibitors (statins) (see section 4.8).
Effects on bone There are no long-term data on the effect of fulvestrant on bone.
Venous Thromboembolic Events Treatment-related venous thromboembolic events were reported in approximately 1.0% of patients with solid tumours who received SUTENT on clinical trials, including GIST and MRCC.
General disorders and administration site conditions Very common effects: injection site pain.
These effects usually wear off with continued treatment, however, if you have used larger doses for a long period of time, you should contact your doctor or pharmacist for advice.
Very Common effects: this means that more than 1 in 10 people taking the medicine are affected.
There have been no observed effects with Nespo on the ability to drive and use machines.
Vascular effects • High blood pressure (hypertension): rare (children); common (adults)
- All patients with PWS should have effective weight control before and during treatment with
Clinical efficacy The clinical studies comprised 3945 subjects (2997 treated with exenatide), 56% men and 44% women, 319 subjects (230 treated with exenatide) were ≥ 70 years of age and 34 subjects (27 treated with exenatide) were ≥ 75 years of age.
6 Efficacy against cholera Efficacy against cholera was assessed in three randomised double-blind placebo-controlled clinical trials conducted in Bangladesh (endemic region) and in Peru (non-endemic region).
Efficacy and safety of human plasma derived factor VIII. c and IX. c products in clinical trials in haemophiliacs before and after authorisation
Prophylactic efficacy in women naïve to HPV-16 and/ or HPV-18
Try to take the ABILIFY oral solution at the same time each day.
OLANZAPINE NEOPHARMA coated tablets are for oral use.
Pregnancy and breast-feeding Ask your doctor for advice before you are given METALYSE.
observed among patients treated with pravastatin;
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
You may need to read it again.
AstraZeneca Belgium Egide Van Ophemstraat 110 B-1180 Brussels Belgium
Egis Pharmaceuticals Plc Kereszturi Ut 30-38 H-1106 Budapest Hungary
is E2 glycoprotein of Classical Swine Fever (CSF) virus minimum 32 µg
the skin, very small cysts in the skin, dry and fragile skin
Einaudi 11, 00012 Guidonia Montecelio (Rome) Italy
Tel: + 44 (0) 208 600 1400 (Verenigd Koninkrijk)
Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Herts, AL10 9SN, UK
Sexual dysfunction (delayed or absent ejaculation, anorgasmia), priapism, galactorrhoea.
• To develop and validate an immunogenicity assay for assessing anti-IGF-I antibodies.
Elaprase is used as enzyme replacement therapy to treat Hunter syndrome (Mucopolysaccharidosis II) when the level of iduronate-2-sulfatase in the body is lower than normal.
It is designed for long-term use.
is the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
- cathode electrode: trilaminate of silver chloride composite material, silver foil, ECAT
- cathode electrode: trilaminate of silver chloride composite material, silver foil, ECAT.
This is part of a multipack and not for sale of individual vials ct
ris This document is a summary of the European Public Assessment Report (EPAR).
ra The fondaparinux clinical program in treatment of Venous Thromboembolism was designed to demonstrate the efficacy of fondaparinux for the treatment of deep vein thrombosis (DVT) and
ed Three 1 mg blisters should not be substituted for one 3 mg blister (see section 2, “Take special care with EXUBERA” and section 3, “How to take EXUBERA”).
Increased creatinine, BUN increased
Blood creatinine increased, Blood sodium decreased
Lipase increased Haemoglobin decreased
Lipase increase Haemoglobin decreased
Aspartate aminotransferase (AST) and blood uric acid increased (transient, minor) * see below
Elevations of CPK Muscle disorders, including myalgia, cramps and rhabdomyolysis
Hepato-biliary Increase in disorders liver enzymes (AST, ALT, alkaline phosphatase) Reproductive Vaginal system disorders Candida infection
Increase in liver enzyme levels (ASAT, ALAT, AP).
Increase in hepatic enzymes and bilirubin.
Raised blood levels of liver enzymes and bilirubin Rare:
Increased hepatic enzymes Hyperbilirubinaemia, hepatitis, jaundice Hepatic failure9, hepatic necrosis
hepatic enzyme increased (including GGT, ALAT, ASAT)
* Events identified during postmarketing surveillance
elevation of liver parameters (transaminases [especially ALT], less often gamma-GT, alkaline phosphatase, bilirubin)
Blood alkaline phosphatase, blood lactate dehydrogenase (LDH), gamma-glutamyltransferase (GGT) and blood uric acid increased (reversible, dose-dependent, mild or moderate) * see below
Blood alkaline phosphatase, LDH and blood uric acid increased (transient), blood glucose decreased (transient, moderate)
Blood alkaline phosphatase and LDH increased (transient, minor)
Elevation of liver function values including increase of serum bilirubin
Increased GGT, increased CPK, increased triglycerides, increased SGPT, increased SGOT, increased amylase, increased uric acid, decreased potassium, decreased free and total thyroxin
Elevated cholesterol, elevated blood sugar, elevated fat in the blood, low blood potassium, low blood phosphorus, elevated lactate dehydrogenase protein in the blood, elevated creatinine in the blood
Elevated cholesterol, elevated blood sugar, elevated fat in the blood, low blood potassium, low blood phosphorus, elevated lactate dehydrogenase protein in the blood, elevated creatinine in the blood
ALT elevation > 2x baseline and > 10x ULN
Increased gamma-glutamyl transferase (GGT)
- Pathologically (abnormally) elevated serum calcium levels (hypercalcaemia) as a result of
elevations in CK (≥ 10 X ULN), total bilirubin, reductions in phosphorus and platelet counts (see below)
Transient elevations in liver enzymes (AST, ALT).
Eli Lilly Danmark A/ S, Nybrovej 110, DK-2800 Kongens Lyngby Denmark
Eli Lilly Denmark, Nybrovej 110, 2800 Lyngby Denmark
Eli Lilly Holdings Limited, Kingsclere Road, Basingstoke, Hampshire, RG 216XA5 United Kingdom
Eli Lilly Holdings Linited, Kingsclere Road, Basingstoke, Hampshire, RG21 6XA United Kingdom
Eli Lilly Norge AS, Postboks 6090 Etterstad, N-0601 Oslo Norway
Disposing of used needles, syringes and vials
The plasma clearance of montelukast averages 45 ml/ min in healthy adults.
Elimination: the plasma elimination half-life of amprenavir ranges from 7.1 to 10.6 hours.
13 Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
13 The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
20 Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
20 The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
34 Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
55 Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
62 Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
69 Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
6 Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
76 Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
90 Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
97 Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
Elimination Unchanged rivastigmine is found in trace amounts in the urine; renal excretion of the metabolites is the major route of elimination after transdermal patch administration.
54 Excretion Unchanged rivastigmine is not found in the urine; renal excretion of the metabolites is the major route of elimination.
Excretion Unchanged rivastigmine is not found in the urine; renal excretion of the metabolites is the major route of elimination.
Disposal The syringe, needles and all injection materials are intended for single use and must be discarded after the injection.
Calcium is eliminated through faeces, urine and sweat.
Elimination 5-ALA is eliminated quickly with a terminal half-life of 1-3 hours.
Elimination Hepatic metabolism and renal excretion contribute significantly to the elimination of the active metabolite.
Disposal Pre-filled syringes are for single use only.
Elimination Ivabradine is eliminated with a main half-life of 2 hours (70-75% of the AUC) in plasma and an effective half-life of 11 hours.
Disposal Any unused product or waste material should be disposed of in accordance with local requirements.
Dispose of as radioactive waste in accordance with local law
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant or by appropriate channels approved for use by the competent authorities.
Dispose of waste material that has had contact with the active substance by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.
Discard any ampoules that have been accidentally thawed.
Elisabethhof 19 NL-2353 EW Leiderdorp
Tel: +31 (0)71 5455745
Attenuated Chlamydophila felis (905 strain).................................................................... ≥ 103.0 EID502 Excipient:
Attenuated Chlamydophila felis (905 strain).................................................................... ≥ 103.0 EID502 Attenuated feline panleucopenia virus (PLI IV)........................................................... ≥ 103.5 CCID501 Excipient:
Attenuated Chlamydophila felis (905 strain).................................................................... ≥ 103.0 EID502 Attenuated feline panleucopenia virus (PLI IV)............................................................ ≥ 103.5 CCID501 Excipient:
Chlamydophila felis (905 strain)......................................................................................... ≥ 103.0 EID50 FPV (PLI IV).................................................................................................................... ≥ 103.5 CCID50 Gentamicin, at most........................................................................................................................ .28 µg
Chlamydophila felis (905 strain)......................................................................................... ≥ 103.0 EID50 FPV (PLI IV).................................................................................................................... ≥ 103.5 CCID50 FeLV recombinant canarypox virus (vCP97).................................................................. ≥ 107.2 CCID50 Gentamicin, at most........................................................................................................................ .34 µg
Chlamydophila felis (905 strain)......................................................................................... ≥ 103.0 EID50 Gentamicin, at most........................................................................................................................ .28 µg
Attenuated feline panleucopenia virus (PLI IV)............................................................. ≥ 103.5 CCID501 Excipient:
Attenuated feline panleucopenia virus (PLI IV)............................................................  103.5 CCID 50 1 Excipient:
Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.
Before the treatment Atorvastatin should be prescribed with caution in patients with pre-disposing factors for rhabdomyolysis.
The safety profile of atorvastatin in the MIRACL study was consistent with what is described in Section 4.8.
The company also presented published information supporting the use of 90Y in radiolabelling other medicines.
It also presented the results of a clinical study in 668 kidney transplant patients comparing the use of Advagraf with that of Prograf/ Prograft or ciclosporin (another immunosuppressive medicine used in the prevention of rejection).
Censor Jurado de Cuentas and Member of the Registro Oficial de Auditores de Cuentas in Spain.
It has been observed both in patients receiving and not receiving enzyme replacement therapy.
Dr Papaluca has acted as EU rapporteur for an ICH efficacy topic and as a member of the International CIOMS Working Groups I and II on pharmacovigilance.
Dr Papaluca has acted as EU rapporteur for an ICH efficacy topic and as a member of the International CIOMS Working Groups I and II on pharmacovigilance.
Peripheral neuropathy was the cause of paclitaxel discontinuation in a few cases.
She joined the EMEA in November 1994 and was nominated as head of sector in November 2002.
After a three-year stay in Prague, Czech Republic,
The EMEA will liaise with EU medicines-enforcement officers on their work to investigate the incidence of counterfeit medicines.
Worked as a clinical endocrinologist in a French hospital until 1987 and then joined the Directorate of Pharmacy at the French Ministry of Health.
Worked as a clinical endocrinologist in a French hospital until 1987 and then joined the Directorate of Pharmacy at the French Ministry of Health.
It reaches well irrigated and peripheral tissues.
It blocks some receptors in the body, the muscarinic receptors, and in the bladder, this causes the muscles that push urine out of the bladder to relax.
It blocks a receptor in the body, the muscarinic M3 receptor, and in the bladder, this causes the muscles which pushes urine out of the bladder to relax.
See package leaflet for further information.
See package leaflet for further information.
It contains the active substance filgrastim (30 or 48 million units).
Therefore, it should be used with caution in these patients.
The patients then lose their ability to control their movements reliably.
It will be admin istered into a vein by a health care professional.
Infection with the hepatitis B virus may cause the liver to become swollen (inflamed).
It causes the liver to become swollen (inflamed).
It is currently authorised in the EU under the different names referred in Annex I.
This is given 3 times a week by injection into a vein or a tube that goes into a vein.
This is given twice a week by injection into a vein or a tube that goes into a vein.
However, it is inactivated by beta-lactamases that can efficiently hydrolyse cephalosporins, such as many of the extended-spectrum beta-lactamases and chromosomal cephalosporinases, such as AmpC type enzymes.
Galsulfase is comprised of 495 amino acids after cleavage of the N-terminus.
It is converted into homocysteine which is then normally converted into cysteine during digestion.
It is converted by thrombin/ thrombomodulin-complex on the endothelial surface to activated protein C (APC).
It is available in a vial, in cartridges (standard or OptiClick) or in a pre-filled pen (OptiSet or SoloStar).
She is also in charge of issues relating to medicines used in children.
This is produced by recombinant DNA technology, using a Chinese hamster ovary cell line transfected with the human FSH subunit genes.
It is supplied in packs of 1, 5 or 10 cartridges of 3 ml.
It is supplied in packs of 1, 5 or 10 cartridges of 3 ml.
It is supplied in packs of 1, 5 or 10 pre-filled pens of 3 ml.
It is supplied in packs of 5 or 10 pre-filled pens of 3 ml.
It is supplied of 1, 5 or 10 pre-filled pens of 3 ml.
It is supplied in packs of 1 or 5 vials of 10 ml or in a multipack of 5 x (1 x 10 ml) vials.
It is supplied in packs of 1 or 5 vials of 10 ml or in a multipack of 5 x (1 x 10 ml) vials.
It is supplied in packs of 1 or 5 vials of 10 ml or in a multipack of 5 x (1 x 10 ml) vials. not all packs may be marketed.
It is supplied in packs of 5 or 10 pre-filled pens of 3 ml.
It is available in a cartridge (PenFill) or in a prefilled pen (FlexPen and InnoLet).
It is available in a vial, a cartridge (PenFill) or in a prefilled pen (NovoLet, FlexPen or InnoLet).
It is available in a vial, cartridge (PenFill) or in a prefilled pen (NovoLet, FlexPen or InnoLet).
Further metabolism involves peptide hydrolysis and N-acetylation.
It is especially common in women after the menopause.
It is produced by switching on the gene for α -galactosidase A in cells.
It is rapidly and extensively hydrolysed by non-specific plasma esterases to the 5-hydroxymethyl derivative, its primary active metabolite, which is the main active pharmacological principle of fesoterodine.
It is often accompanied by symptoms affecting the eyes, such as irritation, watering or redness.
It is used for enzyme replacement therapy in Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome), a storage disorder where the level of N- acetylgalactosamine 4-sulfatase enzyme activity is absent or lower than normal.
It promotes growth during childhood and adolescence, and also acts on the way the body handles proteins, fat and carbohydrates.
The active ingredient in NutropinAq, somatropin, is identical to the human growth hormone.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
It weakly inhibits dopamine reuptake with no significant affinity for histaminergic, dopaminergic, cholinergic and adrenergic receptors.
It inhibits glycogenolysis and gluconeogenesis,
It limits thrombin formation by inactivating factors Va and VIIIa, thereby providing negative feedback regulation of coagulation.
It was not associated with any clinical symptoms, and none of these patients developed evidence of renal disease.
It does not stimulate insulin secretion and therefore does not produce hypoglycaemia or increased weight gain.
It is also responsible for provision of IT services for the EMEA.
Saquinavir concentrations may be increased.
- Dexamethasone induces CYP3A4 and may decrease saquinavir concentrations.
Ranolazine is a moderate to potent inhibitor of P-gp and a mild inhibitor of CYP3A4, and may increase plasma concentrations of P-gp or CYP3A4 substrates.
It may also be administered with a suitable auto-injector.
It may also cause inflammation in other areas of the body.
If this occurs it can result in severe anaemia, the symptoms of which are unusual tiredness, feeling dizzy or breathlessness.
It causes the liver to become swollen (inflamed).
It can be used in the following ways: • once a day as an add-on to oral anti-diabetes medicines.
It causes pain, stiffness, swelling, and increasing loss of movement in the joints it affects.
The Agency will conduct exercises and continually test its business-continuity plan, to ensure its proper functioning.
8 Sorivudine and analogues: a clinically significant drug-drug interaction between sorivudine and 5-FU, resulting from the inhibition of dihydropyrimidine dehydrogenase by sorivudine, has been described.
Sorivudine and analogues: a clinically significant drug-drug interaction between sorivudine and 5-FU, resulting from the inhibition of dihydropyrimidine dehydrogenase by sorivudine, has been described.
It is often accompanied by symptoms affecting the eyes, such as irritation, watering or redness.
Further, it comprises the running and management of the EMEA library as well as electronic archiving.
Nevirapine binds directly to reverse transcriptase and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site.
Common: myalgia, arthralgia.
It is available in a pre-filled syringe and in a vial (500 micromoles per millilitre).
The database will also be used in the generation of performance indicators on the centralised procedure.
They inhibit the activity of transpeptidase enzymes which catalyse cross- linkage of the glycopeptide polymer units that form the cell wall.
It is not for use in 1.5 ml pens.
Adverse reactions were usually mild, transient and rarely warranted the discontinuation of treatment with Lisonorm.
It will also roll out the first production version of the EU-wide database on manufacturing authorisations and GMP certificates.
It is also highlighted that Seretide is not appropriate as IMT in patients with mild and severe asthma and that in general inhaled corticosteroids remain the first line treatment for most patients.
It is also highlighted that Viani is not appropriate as IMT in patients with mild and severe asthma and that in general inhaled corticosteroids remain the first line treatment for most patients.
They can be flat and scaly, or raised, rough, hard and warty.
They can include acute chest syndrome, a life-threatening condition when the patient has sudden chest pain, fever, hard breathing or signs of fluid in the lungs on an X-ray.
They can then test this vaccine to see how people react to it, allowing them to predict how people will react when the flu strain causing the pandemic is included.
They can test this vaccine to see how people react to it, allowing them to predict how people will react when the flu strain causing a pandemic is included.
These in- cluded BEUC (Bureau Européen des Unions de Consommateurs), industry representative organisations (Associa- tion Européenne des Specialités
These will be given within a time period of 6 months.
They are sometimes called kilocalories or kcal.
Musculoskeletal pain is usually controlled with standard analgesics.
They are linked with a reduction in the effect of levodopa, when the patient experiences sudden switches between being ‘ on'and able to move, and being ‘ off 'and having difficulties moving about.
Arthralgia and/ or arthritis (usually transient and rarely chronic), and polyneuritis are features of infection with wild-type rubella and vary in frequency and severity with age and sex, being greatest in adult females and least in prepubertal children.
Following vaccination in children, reactions
They are assembled in ‘ virus-like particles'(structures that look like HPV, so that the body can 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The proposals are available on the web site of the European Commission Pharmaceuticals Unit: http: / /pharmacos. eudra. org/ F2.
These are very rare in people taking Avandamet.
These are very rare in people taking Avandia.
They are used together when treatment with just one did not work.
It states that “ for a new combination of oestrogen/ progestogen (e. g. new administration scheme or new strength) or a new progestogen in a fixed combination, endometrial data are required, except for a known progestogen, with the same administration route and the same progestogen dose as in known fixed combination with oestrogen, where data on endometrial safety can be extrapolated from the fixed combination if exposure to the oestrogen is similar or lower”.
It usually occurs in one part of the body and can last for several weeks.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
EMADINE 0.5 mg/ ml Eye Drops, solution Laboratoires Alcon, 23 Rue Georges Ferrenbach, F-68240 Kaysersberg France
EMADINE is supplied in 5 ml and 10 ml opaque plastic DROP-TAINER bottles.
EMADINE should not be used for longer than 4 weeks after first opening.
• EMADINE is not recommended for use in patients over 65 years of age, as it has not been studied in clinical trials in this age group.
• EMADINE is not recommended for use in patients over 65 years of age, as it has not been studied in clinical trials in this age group.
Requirements and controls applied to bovine serum (foetal or calf) used in the protection of immunological veterinary medicinal products Released for consultation October 2000
Note for Guidance on co-ordinating investigator signature of clinical study reports Released for consultation December 2000
In accordance with a decision by the heads of agencies, the operation of the EudraTrack procedure tracking system was
Note for Guidance on Medicinal Gases – Pharmaceutical Information Released for consultation July 2000
It is also worth noting that many of the applications are from companies who have already selected the centralised route for a previous submission and are expressing their satisfaction with the role played by the EMEA and CVMP.
Package containing one or four pre-filled pens of a 100 µg Aranesp solution for injection in 0.5 ml (200 µg/ ml).
Package containing one or four pre-filled pens of a 130 µg Aranesp solution for injection in 0.65 ml (200 µg/ ml).
Package containing one or four pre-filled pens of a 60 µg Aranesp solution for injection in 0.3 ml (200 µg/ ml).
Package of one vial of powder for solution for injection and one ampoule of water for injections.
Package containing one or four pre-filled pens of a 130 µg Nespo solution for injection in 0.65 ml (200 µg/ ml).
(OUTER CARTON / 30 AMPOULES WITH 1 ML 168 AMPOULES WITH 1 ML)
OUTER WRAP (containing 1 infusion bag of 200 mg / 100 mL solution for infusion)
OUTER WRAP (containing 1 infusion bag of 400 mg / 200 mL solution for infusion)
5 x 3 ml Liprolog cartridges for a 3 ml pen 2 x (5 x 3 ml) Liprolog cartridges for a 3 ml pen
5 x 3 ml Liprolog cartridges for a 3 ml pen 2 x (5 x 3 ml) Liprolog cartridges for a 3 ml pen
5 x 3 ml Liprolog Mix25 cartridges for a 3 ml pen 2 x (5 x 3 ml) Liprolog Mix25 cartridges for a 3 ml pen
2 x (5 x 3 ml) Liprolog Mix25 cartridges for a 3 ml pen.
2 x (5 x 3 ml) Liprolog Mix50 cartridges for a 3 ml pen.
5 x 3 ml Liprolog Mix50 cartridges for a 3 ml pen 2 x (5 x 3 ml) Liprolog Mix50 cartridges for a 3 ml pen
5 x 3 ml Humalog cartridges for a 3 ml pen 2 x (5 x 3 ml) Humalog cartridges for a 3 ml pen
5 x 3 ml Humalog BASAL cartridges for a 3 ml pen 2 x (5 x 3 ml) Humalog BASAL cartridges for a 3 ml pen
2 x (5 x 3 ml) Humalog Mix25 cartridges for a 3 ml pen.
5 x 3 ml Humalog Mix25 cartridges for a 3 ml pen 2 x (5 x 3 ml) Humalog Mix25 cartridges for a 3 ml pen
2 x (5 x 3 ml) Humalog Mix50 cartridges for a 3 ml pen.
5 x 3 ml Humalog Mix50 cartridges for a 3 ml pen 2 x (5 x 3 ml) Humalog Mix50 cartridges for a 3 ml pen
2 x (5 x 3 ml) Humalog Mix25 100 U/ ml Pens.
5 x 3 ml Liprolog Mix25 100 U/ ml KwikPens 2 x (5 x 3 ml) Liprolog Mix25 100 U/ ml KwikPens
2 x (5 x 3 ml) Liprolog Mix25 100 U/ ml KwikPens.
2 x (5 x 3 ml) Liprolog Mix25 100 U/ ml Pens.
5 x 3 ml Liprolog Mix25 100 U/ ml Pens 2 x (5 x 3 ml) Liprolog Mix25 100 U/ ml Pens
5 x 3 ml Liprolog Mix50 100 U/ ml KwikPens 2 x (5 x 3 ml) Liprolog Mix50 100 U/ ml KwikPens
5 x 3 ml Liprolog Mix50 100 U/ ml KwikPens 2 x (5 x 3 ml) Liprolog Mix50 100 U/ ml KwikPens.
5 x 3 ml Liprolog Mix50 100 U/ ml Pens 2 x (5 x 3 ml) Liprolog Mix50 100 U/ ml Pens
5 x (1 x 10 ml) Liprolog vials.
7 5 x (1 x 10 ml) Humalog vials.
This is a multipack and not for sale of individual vials no
Sealed pack Do not use if box has been opened
Sealed Pack Do not use if box has been opened
Sealed Pack Do not use if box has been opened
- pulmonary embolism, laboured breathing (dyspnoea), pulmonary oedema, nosebleed (epistaxis),
Applications received/ forecast Applications received/ forecast (veterinary medicines) (human medicines)
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. eu. int http: / /www. emea. eu. int ©EMEA 2006 Reproduction and/ or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Contents Introduction by the Executive Director
Why has Quadrisol been approved?
EMEA Heads of agencies for human medicines Heads of agencies for veterinary medicines Pan-European Regulatory Forum International Conference on Harmonisation Veterinary International Conference on Harmonisation
- 12.05.2000 - 15.06.2000 - 11.07.2000 - 27 days
EMEA/CVMP - Validation - Opinion - Active time - Clockstop
During pregnancy, methotrexate should only be administered on strict indications, where the benefits of the drug to the mother should be weighed against possible hazards to the foetus.
EMEA/CVMP (a) Validation (b) Opinion (c) Active time (d) Clockstop
18.12.1996 22.10.1997 198 days 95 days
DEUTSCHLAND Harald SCHWEIM Direktor BfArM Friedrich-Ebert-Allee 38 D – 53113 Bonn Tel.
EMEA/CPMP Validation Opinion Active time Clock stop
- Tablet - 0.5 mg, 1.0 mg, 2.0 mg, - 18 presentations
EMEA/CVMP a) Validation b) Opinion c) Active time d) Clockstop
EMEA/CVMP a) Validation b) Opinion c) Active time d) Clockstop
EMEA/CVMP a) Validation b) Opinion c) Active time d) Clockstop
Emulsion for injection E2 glycoprotein of Classical Swine Fever virus 4
EMEA Documentation service European Agency for the Evaluation of Medicinal Products 7 Westferry Circus Canary Wharf UK - London E14 4HB
The EMEA issues certificates of a medicinal product in conformity with the arrangements laid down by the World Health Organisation.
EMEA/MB/002/97 2.7 Information to health care professionals and public
EMEA/MB/002/97 3.3 Applications for establishment of maximum residue limits (MRLs)
Immunological Veterinary Medicinal Products
EMEA/MB/002/97 Sec tor for MRLs and pharmacovigilance
EMEA/MB/002/97 Improving support to the CPMP and its working parties
EMEND 80 mg is given as part of combination therapy (see section 4.2).
EMEND is taken just once a day for 3 consecutive days.
EMEND should be used with caution in these patients (see section 5.2).
EMEND should be used with caution in patients receiving concomitant orally administered active substances that are metabolised primarily through CYP3A4 (see section 4.5).
EMEND should be used with caution when taken with many other medicines.
EMEND should be used with caution when taken with some medicines.
EMEND is used in combination with other medicines to prevent nausea and vomiting caused by chemotherapy (cancer treatment).
EMEND is used to prevent nausea and vomiting after surgery.
EMEND can affect other medicines both during and after treatment with EMEND.
c - emerging genotypic ETVr
Emerging Genotypic Entecavir Resistance Through Year 5, Nucleoside-Naive Studies a
11 Genotypic Entecavir Resistance Through Year 5, Lamivudine-Refractory Studies
26 Genotypic Entecavir Resistance Through Year 5, Lamivudine-Refractory Studies
41 Genotypic Entecavir Resistance Through Year 5, Lamivudine-Refractory Studies
Manufacturer Roche Pharma AG, Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Germany.
ra Roche Pharma AG Emil-Barell-Strasse 1, D-79639 Grenzach-Wyhlen Germany
Do not allow treated animals to bathe in water courses until at least two hours after treatment administration.
Do not allow treated animals to bathe in water courses until at least two hours after treatment.
PRT Empreendimento Lagoas Park - Edifício 7 -
Emselex has been administered in clinical trials at doses up to 75 mg (five times maximum therapeutic dose).
Emselex should be used with caution in patients with risk of decreased gastrointestinal motility, gastro-oesophagal reflux and/ or who are concurrently taking medicinal products (such as oral bisphosphonates) that can cause or exacerbate oesophagitis.
Emselex should be taken with caution while breast-feeding.
Emselex should be taken once daily with liquid.
Emselex should be used with caution in patients being treated for narrow-angle glaucoma (see section 4.3).
Emselex is contraindicated in patients with:
Emselex is not recommended during pregnancy.
Emtriva is a treatment for Human Immunodeficiency Virus (HIV) infection in adults, children and infants above 4 months of age.
Emulsion to be exclusively mixed with suspension before administration
Emulsion to be exclusively mixed with suspension before administration
Emulsion for emulsion for injection 25 vials: emulsion
In 1976 he joined Organon International in the Netherlands, holding posts in neurophysiology, clinical research and clinical information management.
In 1976 he joined Organon International in the Netherlands, holding posts in research and clinical information management.
In 1979 he joined the European Commission in Brussels (ex-DG III) and in 1986 became Head of the Pharmaceuticals Unit.
Chargé de recherche 1st Class and became officer for European affairs in 1991.
In 1986 she joined the French National Scientific Research Centre (CNRS) as Chargé de recherche 1st Class and became officer for European affairs in 1991.
In 1986 he joined the University of Bordeaux and was involved in research areas in public health including epidemiology, clinical research, pharmacovigilance, tropical and infectious diseases, health economy and education.
In 1987 she joined the German Environmental Agency as scientific administrator.
In 1987 she joined the German Environmental Agency as scientific administrator.
joined the German Environmental Agency as scientific administrator.
In 1987, he joined Coopers & Lybrand where he was a senior management consultant specialising in the management and financial control of large primarily IT-related projects.
In 1987, he joined Coopers & Lybrand where he was a senior management consultant specialising in the management and financial control of large, primarily IT-related, projects.
In 1987, he joined Coopers & Lybrand where he was a senior management consultant specialising in the management and financial control of large, primarily IT- related, projects.
In 1987, he joined Coopers & Lybrand where he was a senior management consultant specialising in the management and financial control of large, primarily IT-related, projects.
In 1991 Mrs Mendosa was transferred to the London office of the European Commission Representation in the UK.
In 1992, he became Professor of Clinical Pharmacology and
In 1992, he became Professor of Clinical Pharmacology and Therapeutics and Director of the Masters/ Diploma course on European Registration of Medicinal Products (UAB).
In 1992, he became Professor of Clinical Pharmacology and Therapeutics and Director of the Masters/Diploma course on European Registration of Medicinal Products (UAB).
In 1993 he became Director of Information Systems/Information Technology at Astra AB in Greece.
In 1993 he became Director of Information Systems/Information Technology at Astra AB in Greece.
In 1993 he became Director of Information Systems/ Information Technology at Astra AB in Greece.
In 1993 he became Director of Information Systems/Information Technology at Astra AB in Greece.
In 1994, she joined the UK Veterinary Medicines Directorate as senior veterinary assessor in the pharmaceuticals and feed additives team.
In 1994, she joined the UK Veterinary Medicines Directorate as senior veterinary assessor in the pharmaceuticals and feed additives team.
In 1994, she joined the UK Veterinary Medicines Directorate as senior veterinary assessor in the pharmaceuticals and feed additives team.
In 1995 she joined the French Medicines Agency as Head of Unit for pharmaco-toxico-clinical assessment.
In 1995 she joined the French Medicines Agency as Head of Unit for pharmaco-toxico-clinical assessment.
In 1995, he was appointed Member of the CVMP and elected Chairman of the Working Group on Safety of Residues for the period 1996-1999.
The EMEA was also invited by international organisations to present its work at various meetings at which representatives of a large number of competent authorities for both human and veterinary medicines were present.
Particular emphasis was placed on the management of the pre-authorisation
All delegations were able to act as rapporteur or co-rapporteur in the centralised procedure in 1996.
In 1997, 31 new requests for scientific advice including 4 follow-ups were submitted by pharmaceutical companies.
In 1 997 he was appointed as Head of the pharmaceuticals assessment unit of the French veterinary agency (AFSSA-ANMV).
In 1997 he was appointed as Head of the pharmaceuticals assessment unit of the French veterinary agency (AFSSA-ANMV).
During 1997 management training courses were attended by the Executive Director, Heads of Unit and Heads of sector.
During 1997, the Working Party followed the developments of the VICH process with great interest and provided guidance when requested.
During 1997 the EMEA will also concern itself with focusing on its own technical role within the framework of international activities conducted under the auspices of the European Commission.
During 1997 the focus of interest for the sector for documentation and archiving moved towards document management and publishing.
In 1997 a total of 84 break-out sessions were organised by reference Member States and held at the EMEA.
During 1998 key initiatives will be completed in the areas of strategic business planning, information management, provision of scientific opinions, product information quality, EMEA quality manual and internal audits, scorecards, European partnerships, implementation of management actions, and training and appraisals.
0.3 mg/ kg/ day (once a day or two divided doses)
The second Pan-European Regulatory Forum on Management Board will continue to follow the preparations pharmaceuticals (PERF II) will begin in 2001.
In 2001 it is expected that work on the EC-USA MRA will increase and that the EC-Switzerland MRA will come into full operation.
Highlights in 2006 for initial evaluation of medicines for human use are expected in four main areas:
In 2006, development work on a number of EU telematics projects and sub-projects needs to be continued.
VCR 1.3 g/ m2 i. v., day 1; prednisolone 60 mg/ m2 oral, days 1-5
VCR 1.3 g/ m2 i. v., day 1; prednisolone 60 mg/ m2 oral, days 1-5
Assuming the MAH has a valid scientific point, and thus the method should have included an additional clean-up step to improve recovery, the weakness of this argument was that all sample results could therefore be understated.
Pressing the Dose Knob more slowly may make it easier.
• in combination with the PPARγ agonist when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control.
• in combination with the PPARγ agonist when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control.
• to improve glycaemic control in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
• to improve glycaemic control in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
The dosage of metformin or PPARγ agonist should be maintained, and sitagliptin administered concomitantly.
In combination with glimepiride, both 50 mg and 100 mg daily doses caused a reduction of around 0.6%.
- in combination with other medicines containing melphalan and prednisone, for patients who
In combination with capecitabine, for patients 60 years of age or more, a starting dose reduction of capecitabine to 75% is recommended (see capecitabine summary of product characteristics).
Adjunctively with chemotherapy, 5 million IU 3 times a week (every other day) injected subcutaneously (under the skin).
Adjunctively with chemotherapy, 5 million IU 3 times a week (every other day) injected subcutaneously (under the skin).
In combination with metformin, a daily dose of 100 mg Januvia reduced HbA1c by 0.70% (from 7.96 to 7.26%) after 24 weeks, compared to a fall of 0.08% in the patients adding placebo.
In combination with metformin, a daily dose of 100 mg TESAVEL reduced HbA1c by 0.70% (from 7.96 to 7.26%) after 24 weeks, compared to a fall of 0.08% in the patients adding placebo.
In combination with metformin, a daily dose of 100 mg Xelevia reduced HbA1c by 0.70% (from 7.96 to 7.26%) after 24 weeks, compared to a fall of 0.08% in the patients adding placebo.
- In combination with bortezomib for the treatment of progressive multiple myeloma in patients
cisplatin and 5-fluorouracil.
Dosage: In combination with oral antidiabetic agents it is recommended to initiate Levemir treatment with once daily administration at a dose of 10 U or 0.1-0.2 U/ kg.
In combination with oral antidiabetic agents it is recommended to initiate Levemir treatment with once daily administration at a dose of 10 U or 0.1-0.2 U/ kg.
In combination with oral antidiabetic agents it is recommended to initiate Levemir treatment with once daily administration at a dose of 10 U or 0.1-0.2 U/ kg.
Together with the pharmaceutical industry, an ongoing cycle of questionnaires is organised to assess the performance of the Agency and the centralised procedure.
Combination with insulin Metformin and insulin may be used in combination therapy to achieve better blood glucose control.
The concurrent use of BYETTA with insulin, D-phenylalanine derivatives(meglitinides), or alpha-glucosidase inhibitors has not been studied and cannot be recommended.
- In combination with irinotecan: for patients 65 years of age or more, a starting dose reduction of
Treatment in combination with other anti-epileptic drugs for patients with resistant partial epilepsy with or without secondary generalisation, that is where all other appropriate drug combinations have proved inadequate or have not been tolerated.
While waiting for the doctor, keep the person awake by talking to or shaking her/ him now and then.
Never inject it into a vein or muscle.
Never share needles and syringes.
Do not re-freeze under any circumstances.
Under no circumstances should Liprolog Mix25 be given intravenously.
Under no circumstances should Liprolog Mix50 be given intravenously.
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel.
Vildagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon.
By increasing endogenous GLP-1 levels, vildagliptin also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion.
By enhancing active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in a glucose- dependent manner.
By increasing the endogenous levels of these incretin hormones, vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
By blocking the receptors to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood pressure to drop, reducing the risk caused by high blood pressure, such as having a stroke.
Enbrel is reconstituted with 1 ml water for injections before use, and administered by subcutaneous injection.
Enbrel 25 mg powder for solution for injection Etanercept
Enbrel 25 mg solution for injection in pre-filled syringe Etanercept
Enbrel 41% and 40%, placebo 8% and 5% at months 3 and 6 respectively; p < 0.01 Enbrel vs placebo at all time points for both ACR 20 and ACR 50 responses).
Enbrel 41% and 40%, placebo 8% and 5% at months 3 and 6 respectively; p < 0.01 Enbrel vs Placebo at all time points for both ACR 20 and ACR 50 responses).
Enbrel 50 mg solution for injection in pre-filled syringe Etanercept
Enbrel 62% and 59%, placebo 23% and 11% at 3 and 6 months respectively:
Enbrel 62% and 59%, placebo 23% and 11% at 3 and 6 months respectively; ACR 50:
Enbrel has been studied in 2,680 patients with rheumatoid arthritis in double-blind and open-label trials.
Enbrel contains the ingredient benzyl alcohol, which may cause toxic and allergic reactions in infants and children up to 3 years old.
Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate.
Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.
Enbrel is also prescribed for the treatment of the following diseases in children and adolescents:
Enbrel is reconstituted with 1 ml bacteriostatic water for injections before use, and administered by subcutaneous injection.
Enbrel is reconstituted with 1 ml water for injections before use, and administered by subcutaneous injection.
Treatment with Enbrel may result in the formation of autoimmune antibodies (see section 4.8).
Enbrel must not be used in patients who have or are at risk of sepsis (serious blood infection), or in patients with infections.
Enbrel should not be used if all the powder in the vial is not dissolved within 10 minutes.
Enbrel is not effective in the treatment of Wegener's granulomatosis, a rare inflammatory disease.
Enbrel is not effective in the treatment of Wegener's granulomatosis, a rare inflammatory disease.
Enbrel is not recommended for the treatment of Wegener's granulomatosis.
56 x CHAMPIX 0.5 mg film-coated tablets.
56 x CHAMPIX 1 mg film-coated tablets.
In a meal-related treatment 50– 70% of this requirement may be provided by NovoRapid and the remainder by intermediate-acting or long-acting insulin.
During concomitant administration of a moderate CYP3A4 inhibitor, a dose increase to 8 mg should be preceded by an evaluation of the individual response and tolerability (see sections 4.4 and 4.5).
In the case of concomitant administration of these products, prothrombin time (PT) or other suitable coagulation tests should be monitored.
In the case of concomitant administration of these products, prothrombin time (PT) or other suitable coagulation tests should be monitored.
During concomitant use, it may be necessary to increase the dose of Calcichew-D3 (and associated names).
During concomitant use, it may be necessary to increase the dose of Calcichew-D3 (and associated names).
Careful monitoring of therapeutic and adverse effects is recommended when dexamethasone is concomitantly administered with indinavir.
If these substances are to be prescribed with the hydrochlorothiazide-telmisartan combination, monitoring of potassium plasma levels is advised.
If a bisphosphonate or sodium fluoride is used concomitantly, this preparation should be administered at least three hours before the intake of Calcichew-D3 (and associated names) since gastrointestinal absorption may be reduced.
If a bisphosphonate or sodium fluoride is used concomitantly, this preparation should be administered at least three hours before the intake of Calcitugg (and associated names) since gastrointestinal absorption may be reduced.
Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be
During concomitant use, it may be necessary to increase the dose of Calcitugg (and associated names).
If Effentora is administered, an antidote for the child should be readily available.
In combination with anaesthesia and tumour resection further side effects may occur:
If IONSYS is administered, an antidote for the child should be readily available.
When Kinzalmono is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended.
When Micardis is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended.
When Pritor is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended.
In cases of overdosage of radioactivity, frequent micturition and defaecation should be encouraged in order to minimise radiation dosage to the patient.
Daily serum exposure to nilotinib with 400 mg twice-daily dosing at steady state was 35% higher than with 800 mg once-daily dosing.
When these medications are administered to or withdrawn from a patient receiving repaglinide, the patient should be observed closely for changes in glycaemic control.
In the case of intravenous administration in cats, increased adverse reactions may be seen, e. g. hyperthermia, soft faeces, anorexia, decreased drinking or collapse.
13 administration, the average blood concentration of sirolimus is increased approximately 3-fold.
Upon repeated administration, the average blood concentration of sirolimus is increased approximately 3-fold.
The subcutaneous injection site should be alternated to prevent lipoatrophy.
If you get worse and your breathing is shallow and your skin gets pale, tell your doctor at once.
If you get worse and your breathing is shallow and your skin gets pale, tell your doctor at once.
- if you are allergic to rituximab, to other similar proteins, or to any of the other ingredients in the
When renal function is impaired, renal clearance is decreased in proportion to that of creatinine and thus the elimination half-life is prolonged, leading to increased levels of metformin in plasma.
If your renal function is decreased, the amount of product will be adapted.
In case of disorders of the blood in which red blood cells are abnormally broken down (haemolysis) or abnormal blood pigment levels (methaemoglobinaemia), your doctor will immediately and permanently discontinue treatment with Fasturtec.
Apnoea is treated with respiratory assistance.
Apnoea is treated with respiratory assistance.
If PRCA, a very rare condition, occurs, the Silapo therapy will be stopped and your doctor will determine the best course of action to treat the anaemia.
If this persists tell your doctor.
If visual symptoms develop, the patient should be referred to an ophthalmologist.
When during or after the treatment with ciprofloxacin or another fluoroquinolone severe and persistent diarrhoea occurs, pseudomembranous colitis must be taken into account (life-threatening with possibly fatal outcome).
If a patient develops a hypersensitivity reaction during the TORISEL infusion, despite the premedication, the infusion must be stopped and the patient observed for at least 30 to 60 minutes (depending on the severity of the reaction).
If accidentally applied to these areas, the cream should be thoroughly wiped off and/or rinsed off with water.
If accidentally applied to these areas, the cream should be thoroughly wiped off and/or rinsed with water.
105 If stopping treatment, as with other antiepileptic medicines, Keppra should be discontinued gradually to avoid an increase of seizures.
If stopping treatment, as with other antiepileptic medicines, Keppra should be discontinued gradually to avoid an increase of seizures.
When treatment with voriconazole is stopped, the initial dosage of efavirenz should be restored (see section 4.5).
When dosing is stopped, active drug substances will persist in the body for weeks.
If treatment is discontinued without regard to treatment response, the rate of post-treatment ALT flares could be higher.
Reduction of the pramipexole dose should be considered when these medicinal products are administered concomitantly with MIRAPEXIN.
Reduction of the pramipexole dose should be considered when these medicinal products are administered concomitantly with Pramipexole Teva.
Reduction of the pramipexole dose should be considered when these medicinal products are administered concomitantly with SIFROL.
Reduction of the pramipexole dose should be considered when these medicinal products are administered concomitantly.
If these medicinal products are to be prescribed with the hydrochlorothiazide-telmisartan combination, monitoring of potassium plasma levels is advised.
If there is a significant increase in the amount of this will let your doctor know that active H. pylori is present.
repeat testing, see For persistent increases > 3 x ULN, discontinue RoActemra section 4.4).
In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.
In the case of accidental self injection, seek medical advice immediately and show the package insert or label to a physician.
The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.
When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.
If it beeps at any other time, or more than once, tell your nurse or doctor.
In cases of severe or recurrent headache, visual problems, nausea, and/ or vomiting, a fundoscopy for papilloedema is recommended.
In case of severe or recurrent headache, visual problems, nausea and/ or vomiting, a fundoscopy for papilloedema is recommended.
13 Transferring a patient to another type or brand of insulin should be done under strict medical supervision.
27 Transferring a patient to a new type or brand of insulin should be done under strict medical supervision.
36 Transferring a patient to a new type or brand of insulin should be done under strict medical supervision.
Changes in strength, brand (manufacturer), type (fast-, dual-, long-acting insulin etc.), in
Transferring a patient to a new type or brand of insulin should be done under strict medical supervision.
Transferring a patient to another type or brand of insulin should be done under strict medical supervision.
Transferring a patient to another type or brand of insulin should be done under strict medical supervision.
Transferring a patient to another type or brand of insulin should be done under strict medical supervision.
Transferring a patient to another type or brand of insulin should be done under strict medical supervision.
In case of shock, standard medical treatment for shock should be implemented.
In case of shock, the current medical standards for shock treatment should be observed.
In case of shock, the current medical standards for shock treatment should be observed.
In the case of shock, the current medical standards for shock-treatment should be observed.
In the case of shock, the current medical standards for treatment of shock should be observed.
In case of shock, the current medical standards for shock treatment are to be observed.
In case of shock, the current medical standards for shock-treatment should be observed.
In case of shock, standard medical treatment for shock should be implemented.
5 In case of shock, standard medical treatment for shock should be implemented.
In case of shock, standard medical treatment for shock should be implemented.
In case of shock, standard medical treatment for shock should be implemented.
In case of shock, standard medical treatment should be administered.
91 When CRIXIVAN is used with ritonavir, please tell your doctor and refer to the package leaflet for ritonavir for more information.
When CRIXIVAN is used with ritonavir, please tell your doctor and refer to the package leaflet for ritonavir for more information.
When Telzir is co-administered with ritonavir, the half-life of amprenavir is increased to 15 – 23 hours.
In the event of haemorrhagic complications, treatment must be discontinued and the source of bleeding investigated.
If accidentally applied to these areas, the ointment should be thoroughly wiped off and/ or rinsed off with water.
If the ointment gets on any of these areas, it should be thoroughly wiped off and/ or rinsed off with water.
these areas, it should be thoroughly wiped off and/ or rinsed off with water.
these areas, it should be thoroughly wiped off and/ or rinsed off with water. ed
In case of accidental contact, rinse with abundant quantities of water.
62 If the product accidentally gets into eyes, they should be thoroughly flushed with plenty of water.
If the product accidentally gets into eyes, they should be thoroughly flushed with plenty of water.
If the product accidentally gets into eyes, they should be thoroughly flushed with plenty of water.
If the product accidentally gets into eyes, they should be thoroughly flushed with water.
If the product accidentally gets into eyes, they should be thoroughly flushed with water.
If any solution leaks from the injection site, insert the needle further.
When an EXUBERA treated patient becomes pregnant appropriate lo subcutaneous insulin should be substituted for inhaled insulin. o
If the patient becomes pregnant, you should consult the patient's doctor.
If you become pregnant, you should consult your doctor.
In case of persistent lack of antibody production, dosage of 0.5 g/ kg BW/ month is recommended until the antibody level returns to normal.
In case of persistent lack of antibody production, dosage of 0.5 g/ kg/ month is recommended until antibody level returns to normal.
Transfer to a therapy that is recommended at the severe stage of the disease (e. g., epoprostenol) should be considered if the clinical condition deteriorates (see section 4.2).
Transfer to a therapy that is recommended at the severe stage of the disease (e.g., epoprostenol) should be considered if the clinical condition deteriorates (see section 4.2).
In case of clinical deterioration in spite of Revatio treatment, alternative therapies should be considered.
It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy.
It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy.
5 It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy.
It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy.
If ILD is diagnosed, Tarceva should be discontinued and appropriate treatment initiated as necessary (see section 4.8).
If ILD is diagnosed, Tarceva should be discontinued and appropriate treatment initiated as necessary (see section 4.8).
In case PRCA is diagnosed, therapy with MIRCERA must be discontinued and patients should not be switched to another ESA.
32 If active tuberculosis is diagnosed, Humira therapy must not be initiated (see section 4.3).
If active tuberculosis is diagnosed, Humira therapy must not be initiated (see section 4.3).
ris If active tuberculosis is diagnosed, Trudexa therapy must not be initiated (see section 4.3).
tho If active tuberculosis is diagnosed, Trudexa therapy must not be initiated (see section 4.3).
If inactive (‘ latent’) tuberculosis is diagnosed, appropriate treatment for latent tuberculosis must be started with anti-tuberculosis prophylaxis therapy before the initiation of Humira, and in accordance with local recommendations.
If inactive (‘ latent’) tuberculosis is diagnosed, appropriate treatment for latent tuberculosis must be started with anti-tuberculosis prophylaxis therapy before the initiation of Humira, and in accordance with local recommendations.
If inactive (‘ latent’) tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis therapy before the initiation of Enbrel, and in accordance with local recommendations.
If latent tuberculosis is diagnosed, appropriate anti-tuberculosis prophylaxis in accordance with local recommendations must be initiated before starting treatment with Trudexa.
In the event of diarrhoea measures of rehydration should be instituted.
- if you develop severe or prolonged or bloody diarrhoea during or after taking Ketek tablets,
- if you develop severe or prolonged or bloody diarrhoea during or after taking Levviax tablets,
In case of any difficulty in isolating the individual muscles, injections should be made under electromyographic assistance.
In case of chest pain occurring during or after sexual activity you should NOT use nitrates but you should seek immediate medical assistance.
You should check with your child's doctor or pharmacist if you are not sure.
If in doubt, you should consult your doctor or pharmacist.
Your doctor will determine your dose depending on your weight and the type of infection you have.
If you are not certain, ask your doctor or pharmacist.
You should check with your doctor or pharmacist if you are not sure.
You should check with your doctor or pharmacist if you are unsure.
If in doubt ask your child's doctor.
You should check with your doctor or pharmacist if you are not sure.
If an acute attack occurs, a short-acting inhaled β -agonist should be used.
In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped.
5 In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped.
If any of these symptoms are severe or persist, you should contact your doctor.
In cases of internal fistula not arising in the GI tract, discontinuation of Avastin should be considered
- if you have a multiple pregnancy or a pregnancy between 24 and 27 weeks
Patients who develop increased transaminase levels should be monitored until the abnormality(ies) resolve.
These changes were usually mild, transient, and did not require interruption of treatment.
If there is a persistent and progressive increase in serum transaminase levels that cannot be attributed to other causes, EXJADE should be interrupted.
In the event of progressive elevation, or clinically significant elevation in association with clinical features of myopathy or rhabdomyolysis, discontinuation of ziconotide should be considered.
If you have a kidney problem, your dose may be altered.
If you are ill or have a major injury, then your blood sugar may increase (hyperglycaemia) or if you od
If there is a clinical need for immediate reversal following administration of rocuronium a dose of 16 mg/ kg sugammadex is recommended.
If re-administration of rocuronium or vecuronium is required a waiting time of 24 hours is recommended.
However, if treatment is to be continued, the dose of paclitaxel should be reduced for all subsequent courses of Paxene (see 4.2).
In the case of severe neutropenia (< 500 cells/ mm3 for seven days or more) during a course of docetaxel therapy, a reduction in dose for subsequent courses of therapy or the use of appropriate symptomatic measures are recommended (see section 4.2).
In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to the bacteria.
Popliteal and brachial perfusions may not need more than 1 litre.
Discard the reconstituted suspension if precipitates are observed.
If precipitates are observed, the reconstituted suspension should be discarded.
If precipitates or settling are visible, the vial should be gently inverted again to ensure complete resuspension prior to use.
If precipitates or settling are visible, the vial should be gently inverted again to ensure complete resuspension prior to use.
- When there are any tumours in the area of the non-union site.
In case of a recurrent moderate IAR or re-challenge after a single severe IAR, pre-treatment should be considered (antihistamines and paracetamol and/ or corticosteroids) and a reduction of the infusion rate to 50% – 25% of the rate at which the previous reaction occurred.
If a severe allergic reaction occurs, administration of Kineret should be discontinued and appropriate treatment initiated.
In case of an anaphylactoid reaction, adrenaline should be administered intramuscularly.
In case of anaphylactoid reaction, adrenaline should be administered intramuscularly.
In case of an anaphylactic-like reaction, treatment with azacitidine should be immediately discontinued and appropriate symptomatic treatment initiated.
If hypersensitivity reactions occur, the administration of the contrast medium must be discontinued immediately and intravenous treatment initiated, if necessary.
In the case of adverse reactions, doses might be reduced to once daily doses of 9 mg/kg bodyweight (range 7.5 – 10.5 mg/kg) or 6 mg/kg bw (range 4.5 – 7.5) according to the tables below.
If severe allergic (anaphylactic-type) reactions occur, your doctor will stop the infusion immediately, and start giving you suitable treatment.
If severe, requiring third party assistance, infusion of glucose may be necessary.
In case of a recurrent moderate IAR or re-challenge after a single severe IAR, pretreatment should be considered (antihistamines and paracetamol/ ibuprofen and/ or corticosteroids) and a reduction of the infusion rate to 1/ 2 – 1/ 4 the rate of the infusion at which the previous reaction occurred.
When substituting another ophthalmic antiglaucoma agent with AZARGA, the other agent should be discontinued and AZARGA should be started the following day.
When substituting another ophthalmic antiglaucoma agent with DuoTrav, the other agent should be discontinued and DuoTrav should be started the following day.
When substituting another ophthalmic antiglaucoma agent with TRAVATAN, the other agent should be discontinued and TRAVATAN should be started the following day.
Use this product under strict veterinary monitoring where there is a risk of gastro-intestinal bleeding, or if the animal previously displayed intolerance to NSAIDs.
When there is a risk of aspiration, induction of emesis is not recommended.
If there is redness, you should avoid direct sunlight for another 24 hours.
When the BBB is disrupted, the gadoversetamide molecules diffuse into the interstitial compartment thereby producing the characteristic paramagnetic effect of T1 and T2 shortening.
In case of severe bleeds NovoSeven will be administered by a doctor or nurse in the surgery or hospital.
If sensitivity to the accompanying solvent occurs, the vials should be reconstituted with water for injections and used as a single use vial.
If sensitivity to the accompanying solvent occurs, the vials should be reconstituted with water for injections and used as a single use vial (see section 6.3).
If sensitivity to the accompanying solvent occurs, the vials should be reconstituted with water for injections (see section 5 ‘ How to store Valtropin’).
- If sensitivity to solvent occurs, the vials should be reconstituted with water for injections
If sensitivity to the solvent occurs, the vials should be reconstituted with water for injections and used as a single use vial (see section 5 ‘ How to store Valtropin’).
If any signs or symptoms of extravasation occur (e. g., stinging, erythema) terminate the infusion immediately and restart in another vein.
In case of signs and symptoms of general central nervous system (CNS) overstimulation, careful symptomatic clinical treatment should be considered.
In case of signs and symptoms of general Central Nervous System (CNS) overstimulation, careful symptomatic clinical treatment should be considered.
In the event of any signs suggesting an allergic reaction (in particular difficulties in breathing, or swallowing, or swelling of the face, extremities, eyes, lips and/ or tongue) patients should discontinue treatment and contact the physician.
In the event of any signs suggesting an allergic reaction patients should discontinue treatment and contact the physician (see section 4.4).
In case of accidental overdosing, symptomatic therapy should be administered.
In case of chronic overdose where hypercalcaemia is present, the initial therapeutic step is hydration with saline solution.
In case of overdose, contact your doctor immediately.
In case of overdose typical oestrogen effects may occur.
In case of overdose, adverse reactions, as listed in Section "Adverse reactions", are expected to be more severe and more frequent.
Possible symptoms of lansoprazole overdose can be expected to be similar with adverse drug reactions listed in section 4.8.
In case of overdose, immediately stop the infusion (see section 5.2).
In the event of overdose occurring, the patient should be observed and treated symptomatically.
After an overdose, the side effects described below may occur with increased intensity.
In case of overdose with ADROVANCE, milk or antacids should be given to bind alendronate.
In case of overdose with FOSAVANCE, milk or antacids should be given to bind alendronate.
In the event of an overdose, it is recommended that appropriate supportive treatment should be initiated, as dictated by the patient's clinical status.
In the case of over dosage symptomatic treatment should be initiated.
In the case of overdose, symptomatic treatment should be initiated.
In cases of accidental overdose your veterinary surgeon should be consulted immediately and symptomatic therapy should be initiated.
In case of the following haemorrhagic events, the factor VIII activity should not fall below the given plasma activity level (in% of normal or IU/ dl) in the corresponding period.
If severe, sudden allergic reactions (anaphylactic) occur, the injection must be stopped immediately.
In the case of the following haemorrhagic events, the factor IX activity should not fall below the given plasma activity levels (in% of normal or in IU/ dl) in the corresponding period.
3 new infection while undergoing treatment with ORENCIA should be monitored closely.
If application site toxicity occurs, the application frequency can be reduced as described below.
If a complete response of a lesion occurs, no further application of Panretin gel should be made to the responding lesion.
Please consult your child's doctor in the event of any side effects as the doctor may have to adjust the dose of this medicine and the other antiepileptic medicine(s).
In this event, all antipsychotics, including RISPERDAL, should be discontinued.
If PML is suspected, further dosing must be suspended until PML has been excluded.
suspected, gallbladder studies are indicated.
If peripheral neuropathy is suspected, treatment with telbivudine should be reconsidered (see section 4.8).
If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be consulted.
If there is suspicion of extravasation by vesicant compounds other than anthracyclines through the same IV access, e. g. vincristine, mitomycin, and vinorelbine, Savene would not be effective against the reaction from these compounds.
If PML is suspected, further dosing must be suspended until PML has been excluded.
59 If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be consulted.
86 If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be consulted.
In case of any symptom indicating an exacerbation of myastenia gravis, you should therefore consult your doctor. • liver impairment in the past.
In case of concomitant therapy with other topical ocular medicines, an interval of five to ten minutes should be allowed between successive applications.
During long-term treatment, serum calcium levels should be followed and renal function should be monitored through measurements of serum creatinine.
You should stop taking OSSEOR if you have to take oral tetracyclines or quinolones (two types of antibiotics).
You should stop taking PROTELOS if you have to take oral tetracyclines or quinolones (two types of antibiotics).
It is recommended that antiarrhythmic therapy for bradycardia and/ or ventricular tachyarrhythmias (pacemaker, defibrillator) be available when Metalyse is administered.
For long term therapy, liver enzymes should be monitored at the start of therapy, e. g. after 2, 4 and 8 weeks.
In patients with impaired renal function, adjustment of the ceftriaxone dose is not necessary if the hepatic function is normal.
If the patient vomits, care must be taken to prevent aspiration of the vomitus.
- If the patient vomits during the test procedure, necessitating the repetition of the test, this should
However, maropitant can produce acute eye irritation and in the case of accidental eye exposure, flush the eyes with plenty of water and seek medical attention.
In the event of human exposure to the active ingredient of the vaccine, seek medical advice immediately and show the package leaflet i or the label to the physician.
In the event of human exposure to the active ingredient of the vaccine, seek medical advice immediately and show the package leaflet or the label to the physician.
In the event of human exposure to the active substance of the vaccine, seek medical advice immediately and show the package leaflet or the label to the doctor.
In case of inadvertent exposure during pregnancy, use of Livensa must be discontinued.
In case of inadvertent exposure during pregnancy, use of Intrinsa must be discontinued.
When exposed to any of these viruses and bacterium later in life, the cat will either not become infected or will have a much less serious infection.
If extravasation occurs, generally the infusion must be stopped immediately and started again in another blood vessel.
If serious bleeding occurs that is not controllable with pressure, immediately stop the INTEGRILIN infusion and any unfractionated heparin that is given concomitantly.
The enhanced increase in the insulin/ glucagon ratio during hyperglycaemia due to increased incretin hormone levels results in a decrease in fasting and postprandial hepatic glucose production, leading to reduced glycaemia.
The enhanced increase in the insulin/glucagon ratio during hyperglycaemia due to increased incretin hormone levels results in a decrease in fasting and postprandial hepatic glucose production, leading to reduced glycaemia.
If an interruption to insulin flow is suspected, follow the instructions in the product literature and if appropriate, notify your doctor or clinic.
If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly.
If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly.
If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacement given quickly.
The mean treatment duration was ng 5.5 days in the fondaparinux group and 5.2 days in the enoxaparin group.
Should your wound become infected during the use of REGRANEX,
Patients found to have a fungal infection should be treated for a minimum of 14 days and treatment should continue for at least 7 days after both neutropaenia and clinical symptoms are resolved.
In case of ocular infection, their use with anti-infectives should be undertaken with care.
In cases of heavy infestation prior to treatment, the dog's surrounding should be vacuumed and treated with a suitable insecticide.
In cases of heavy infestation with fleas prior to treatment, the dog's surrounding should be vacuumed and treated with a suitable insecticide.
In case of corneal infiltrates, the product should be discontinued and appropriate management should be implemented.
In case of accidental ingestion, seek medical advice immediately and show this package insert or the label to the physician.
In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.
If you are worried, talk to your doctor or pharmacist.
- in whom hypoglycaemia develops gradually,
also had decreased femur lengths compared with controls and skeletal muscle degeneration, necrosis and regeneration.
In cases of mild hepatic impairment no initial dosage adjustment is necessary at the recommended dose.
In cases of mild hepatic impairment no initial dosage adjustment is necessary at the recommended dose.
For severe hepatic impairment see section 4.3.
For severe hepatic impairment see section 4.3.
When renal or hepatic function is impaired, the effective dose and the radiation dose delivered to organs might be increased.
- with severe renal and hepatic impairment
23 If you have severe renal insufficiency you should take alternating daily doses of 800 mg (two tablets of 400 mg) and 400 mg (one tablet of 400 mg), starting with the 800 mg dose.
The dose may be adjusted, depending on body weight.
In case of intolerance to ribavirin, Pegasys monotherapy should be continued.
In case of surgery or anaesthesia, you should tell your doctor that you are taking Kinzalmono.
In case of surgery or anaesthesia, you should tell your doctor that you are taking Kinzalmono.
In case of surgery or anaesthesia, you should tell your doctor that you are taking Micardis.
In case of surgery or anaesthesia, you should tell your doctor that you are taking Pritor.
In case of parasitic otitis, an appropriate acaricidal treatment should be implemented.
In case a dose is missed, patients should be instructed to take one Bondenza 150 mg tablet the morning after the tablet is remembered, unless the time to the next scheduled dose is within 7 days.
If a dose is missed, the next schedule dose should be given as prescribed.
In case of combination it is advised that a doctor monitors your blood carefully.
NovoRapid should never be mixed with any other insulin when used in a pump.
If more than one topical ophthalmic medicinal product is being used, the medicines must be administered at least 5 minutes apart.
If more than one topical ophthalmic medicinal product is being used, the medicines must be administered at least 5 minutes apart.
When using 100 ml bags, the volume of Naglazyme may be added directly to the infusion bag.
If anthracyclines are used, the patient's cardiac function should be monitored carefully (see “ cardiotoxicity” section below).
If an alternative measuring device is used (e. g. a dispensing cup or teaspoon for larger doses) it is important that the device is rinsed to ensure complete removal of residual oral suspension.
If an infusion bag with a different volume is used, a proportional calculation should be made for the preparation.
If an infusion bag with a different volume is used, a proportional calculation should be made for the preparation.
In case of Uveitis/ Iritis cidofovir should be discontinued if there is no response to treatment with a topical corticosteroid or the condition worsens, or if iritis/ uveitis reoccurs after successful treatment.
In HIV Viread should always be used combined with other medicines to treat HIV infection.
In that case carry on with the next dose as normal.
In that case, the ciprofloxacin treatment must be discontinued, and medical treatment for shock should be given.
In this case you should immediately consult your doctor. • temporary pain and inflammation of the tendons, in particular of the Achilles tendon.
In this case you should immediately consult your doctor.
Nervous system disorders Encephalitis, encephalopathy, neuritis, neuropathy, paralysis, convulsions
Encephalitis and encephalopathy, excluding subacute sclerosing panencephalitis (SSPE), have been reported approximately once for every 3 million doses of the measles-containing vaccines manufactured by Merck & Co., Inc.
19 Encephalitis and encephalopathy (excluding subacute sclerosing panencephalitis [SSPE]) have been reported approximately once for every 3 million doses of the measles-containing vaccines manufactured by Merck & Co., Inc.
7 Encephalitis and encephalopathy (excluding subacute sclerosing panencephalitis [SSPE]) have been reported approximately once for every 3 million doses of the measles-containing vaccines manufactured by Merck & Co., Inc.
With regards to the prophylaxis in neutropenic patients, the studies submitted by the Applicant/ MAH showed comparable results between treatment groups.
For pancreatic cancer, the committee concluded that doctors and patients should take the patient 's chances of survival into account when prescribing Tarceva.
Concerning mixing or incompatibility with other insulins see section 6.6.
Care must be taken to ensure that no alcohol or other disinfectants enter the insulin solution.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. eu. int http: / /www. emea. eu. int  EMEA 2006 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged 10.6 (68%) or 12.5 (77%) less episodes of incontinence per week, respectively, when patients receiving placebo had 7 or 7.5 (54 or 58%) less episodes per week.
In comparison, those continuing to take Eprex/ Erypo had an increase of 0.063 g/ dl from a starting value of 12.0 g/ dl.
In comparison, those continuing to take Eprex/ Erypo had an increase of 0.063 g/ dl from a starting value of 12.0 g/ dl.
In comparison, those continuing to take Eprex/ Erypo had an increase of 0.063 g/ dl from a starting value of 12.0 g/ dl.
In addition to routine adverse event reporting, pre-specified event categories, adjudicated by an independent expert committee, were examined in two placebo- controlled safety studies in which patients received parecoxib sodium for at least 3 days and then were transitioned to oral valdecoxib for a total duration of 10-14 days.
Patients may need to continue to use a hair removal method (e. g. shaving or plucking) in conjunction with Vaniqa.
In conclusion, the benefit/ risk ratio is favourable for Crestor 5 or Crestor 10 mg as alternative start doses.
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
To avoid skin burns, Neupro should be removed if the patient has to have magnetic resonance imaging (MRI) or cardioversion (a process that restores the heart's normal rhythm).
Consequently no substantial delays were encountered in the Commission decision-taking process.
Therefore, Bondenza makes bones less likely to break.
Consequently, these 7 samples should have been excluded from the final calculation.
It follows that they are unlikely to present concerns during the proper clinical use of sibutramine.
Therefore a close safety monitoring is warranted in these patients.
In this context, this combination should not be used (see section 4.4).
Therefore, in acromegalic patients with diabetes mellitus, doses of insulin or hypoglycaemic medicinal products may need to be decreased (see also section 4.5).
It is important, therefore, for asthma patients that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control is maintained.
Based on these data Combivir may be administered with or without food.
Therefore in order to improve the margin of safety it is recommended that the Marketing Authorisation for 120 mg terfenadine tablet formulations should be withdrawn.
Therefore, concomitant use of Tracleer and tacrolimus or sirolimus is not advisable.
Therefore the use of< COVERSYL and associated names > is not recommended in women who are breast-feeding.
Therefore, caution is advisable in co-administering cimetidine and Sonata.
Therefore, caution is advisable in co-administering cimetidine and Zerene.
Therefore, caution should be exercised when OPTISON is administered to nursing women.
Therefore, caution should be exercised when OPTISON is administered to breast-feeding women.
99m Tc-depreotide is therefore contraindicated in pregnancy.
As a consequence, the CHMP has recommended the maintenance of the Marketing Authorisations for paroxetine containing medicinal products referred in Annex I as amended in accordance with the SPC set out in Annex III and under the conditions set out in Annex IV.
Therefore, the CHMP has recommended to maintain the Marketing Authorisations for all medicinal products and to grant Marketing Authorisations for all applications referred to in Annex I of the Opinion in accordance with the amendments to the relevant sections of the Summary of Product Characteristics and Package Leaflet, set out in Annex III of the Opinion.
Therefore the applicant performed another statistical evaluation using the original database.
Telbivudine is not a substrate, inhibitor or inducer of the cytochrome P450 (CYP450) enzyme system (see section 5.2). Therefore, the potential for CYP450-mediated drug interactions involving Sebivo is low.
Consequently, plasma concentrations of substances metabolised by these isoenzymes will be decreased when Tracleer is co-administered.
Women receiving caspofungin should not breast-feed.
Therefore, women on rivastigmine should not breast-feed.
As a result the metastases may become bigger.
Consequently newborns should be monitored carefully.
Consequently, newborns should be monitored carefully.
Therefore, patients should receive adequate antiemetic treatment and appropriate hydration prior to and/ or after receiving treatment.
Therefore, therapy with entecavir should not be used for HIV/ HBV co-infected patients who are not receiving HAART.
Therefore, concomitant use of potent CYP3A4 inducers with dasatinib is not recommended.
Therefore, the use of Aprovel is not recommended.
Therefore, the use of CoAprovel is not recommended.
Therefore, the use of Irbesartan BMS is not recommended.
Therefore, the use of Irbesartan Winthrop is not recommended.
Therefore, the use of Karvea is not recommended.
The use of Neoclarityn during pregnancy is therefore not recommended.
The use of {INVENTED NAME} during pregnancy is therefore not recommended.
Consequently the use of INTEGRILIN is not recommended in these circumstances.
As a result, the use of ORENCIA in children or adolescents is not recommended until further data become available.
Consequently, to preserve the efficacy of this drug:
Therefore, REGRANEX should not be used in nursing mothers.
The potential risk for humans is unknown.
Therefore, RISPERDAL CONSTA should not be used during pregnancy unless clearly necessary.
GANFORT has only been studied in adults and therefore its use is not recommended in children or adolescents.
LUMIGAN has only been studied in adults and therefore its use is not recommended in children or adolescents.
So any vaginal bleeding while you take OPTRUMA is unexpected.
Therefore, caution should be recommended when driving a car or operating machines.
Therefore, the interaction of Keppra with other substances, or vice versa, is unlikely.
8 The longer duration of action of insulin glargine is directly related to its slower rate of absorption and supports once daily administration.
The longer duration of action of insulin glargine is directly related to its slower rate of absorption and supports once daily administration.
Thiazide diuretic- associated azotaemia may occur in patients with impaired renal function.
Therefore, a 0.2 micron low protein binding in-line filter should be used for administration.
AS THE IMMUNOSUPRESSION CAUSED BY MABTHERA CAN LAST FOR SEVERAL MONTHS, SIDE EFFECTS MAY OCCUR EVEN AFTER YOU HAVE STOPPED TREATMENT.
Therefore, you should not take Tracleer if you are pregnant and you should also not become pregnant while taking Tracleer.
Keeping the plunger fully depressed, carefully lift the needle straight out from the injection site.
When in use, the pen must not be stored in the refrigerator.
28 During use: do not refrigerate.
35 During use: do not refrigerate.
42 During use: do not refrigerate.
During use: do not refrigerate.
When in-use, do not store in a refrigerator.
Through the visiting expert programme, officials from a number
- printing ink: titanium dioxide (E 171), indigo carmine (E 132) and iron oxide (E 172).
- printing ink: titanium dioxide (E 171), indigo carmine (E 132), and iron oxide (E 172).
Encysive (UK) Limited Alder Castle House 10 Noble Street London EC2V 7QJ United Kingdom
Encysive (UK) Limited Regus House Highbridge Industrial Estate Oxford Road Uxbridge UB8 1HR United Kingdom
This means that it is converted into amfenac in the eye.
Non-EU ADR reports (unexpected) Periodic safety update reports CPMP guidelines ICH-derived CPMP guidelines Meeting days
Keep the cap on the pen when NovoMix 30 FlexPen is not in use in order to protect from light.
Keep the cap on the pen when NovoMix 50 FlexPen is not in use in order to protect from light.
Keep the cap on the pen when NovoMix 70 FlexPen is not in use in order to protect from light.
In spite of this high protein binding, paclitaxel is widely distributed to tissues.
By lowering the blood pressure, the risk of damage caused by high blood pressure, such as having a stroke, is reduced.
By lowering the pressure, Azopt reduces the risk of damage.
Endophthalmitis, keratitis, conjunctivitis, periorbital oedema, hordeolum Cardiac disorders
These may affect the action of Combivir, or Combivir may affect their action.
The Agency’s communications and information technology networks are central to maintaining the relationship between itself and the 27 different competent authorities in the EU and EEA-EFTA Member States, the European Commission and the public.
* Maximum energies are listed for the beta emissions, the average beta particle energy is 233 keV.
you have an injury, operation, infection or fever,
have an injury, operation, infection or fever,
you have an injury, operation, infection or fever,
you have an injury, operation, infection or fever,
Different disease concepts for “symptomatic gastroesophageal reflux disease” and other “functional diseases” e.g. “dyspepsia”, are established throughout Europe and reflected in different labelling.
If you do you are more likely to cause irritation • Check each day to make sure the patch has not fallen off • Keep using the patches even if you do not have sex very often.
Paediatric > 5 mg/ dl (for > 4 weeks) Creatinine
Paediatric population There is no experience in children.
Children aged 12 - 23 months: two doses, each of 0.5 ml, with an interval of at least 2 months between doses.
Age less than 6 months (see sections 4.2 and 4.4).
Children: no data are available for paediatric cardiac transplant patients.
Children: no data are available for paediatric hepatic transplant patients.
No studies have been conducted to investigate the pharmacokinetics of sorafenib in paediatric patients.
Paediatric No studies with Januvia have been performed in paediatric patients.
Paediatric No studies with sitagliptin have been performed in paediatric patients.
Paediatric patients No studies have been performed in the paediatric population (see section 4.2).
Children 1 through 5 years of age: take 2.5 ml (½ of a 5 ml spoonful) of syrup once a day.
Children 1 through 5 years of age: take 2.5 ml (½ of a 5 ml spoonful) of oral solution once a day.
Children 6 through 11 years of age: take 5 ml (one 5 ml spoonful) of syrup once a day.
Children 6 through 11 years of age: take 5 ml (one 5 ml spoonful) of oral solution once a day.
39 Children and adolescents ADROVANCE should not be given to children and adolescents.
Children and adolescents ADROVANCE should not be given to children and adolescents.
Children and adolescents (3 months to 17 years of age)
Children and adolescents No formal clinical trials or pharmacokinetic studies have been conducted in children or adolescents.
Children and adolescents There is no experience in children.
Children and adolescents (see section 4.4 Special warnings and precautions for use):
Paediatric patients There is no experience in children or adolescents.
Children and adolescents The safety and efficacy of duloxetine in these age groups have not been studied.
Gemfibrozil therapy has not been investigated in children.
Gemfibrozil therapy has not been investigated in children.
Children and adolescents Treatment with MIRCERA is not recommended in children and adolescents as it has not been studied in these patients.
Children and adolescents In a single-dose pharmacokinetic study in 13 patients with type 2 diabetes and between the ages of 12 and 16 years, administration of exenatide (5µg) resulted in slightly lower mean AUC (16% lower) and Cmax (25% lower) compared to those observed in adults.
22 Children and adolescents (below 18 years of age) The use of Lucentis in children and adolescents has not been studied and is therefore not recommended.
Children and adolescents There are no data on the use of Bondronat in patients less than 18 years old.
No studies have been performed in paediatric patients.
Children and adolescents RISPERDAL CONSTA is not for people who are under 18 years old.
No studies have been performed in paediatric patients.
The pharmacokinetics of enfuvirtide have been studied in 37 paediatric patients.
Paediatric Patients The safety and effectiveness of SonoVue in patients under 18 years old has not been established and the product should not be used in these patients.
Celecoxib is not indicated for use in children.
Children: the pharmacokinetics of maraviroc in paediatric patients have not been established (see section 4.2).
The documentation on efficacy and safety in patients less than 18 years old is limited; therefore, the use of< (TRADENAME) > is not recommended in these patients.
The use of < Invented Name > in patients under 2 years of age is not recommended until further data become available.
At the end of the treatment you should return all unused capsules to the pharmacist.
It has seen the importance of identifying and focusing on core responsibilities; recognised the value of good communication systems; and become convinced of the need for performance goals and indicators and for transparency about that performance.
In Finland the product has been authorised for the indication: “ The treatment of fever and inflammation in cattle”.
Finally, members from Luxembourg and Portugal acted in 2 instances each, whereas a member from Greece was appointed in 1 case.
Finally, « Extrapyramidal symptoms » should be the grouped term in the subparagraph Nervous System Disorders and the single symptoms should be mentioned with an
Push the blunt filter needle into the centre of the vial stopper until the needle touches the bottom edge of the vial.
Albumin-corrected Serum calcium (mmol/ l)
According to the duration of infusion, two dosage regimes of Paxene are recommended:
The doctor will determine how many kits of InductOs you will receive, depending on the size and number of fractures.
By BSA using the Mosteller formula the recommended oral dose for paediatric patients of all ages is 150 mg/ m2 once daily for two weeks followed by 150 mg/ m2 twice daily thereafter.
Dosage Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will:
Dosage Based on your life -style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will
Dosage Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will:
Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will:
Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will determine how much Apidra you will need.
Dosage Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will:
Dosage Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will:
Dosage Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will:
Sustained virologic response rates with Viraferon + ribavirin (one year of treatment) by genotype and viral load
In general, these disappear within four days, but in rare cases they can persist for up to 14 days after the second injection.
In general, the adverse events seen in overdose cases involving PegIntron are consistent with the known safety profile for PegIntron; however, the severity of the events may be increased.
In general, the adverse events seen in overdose cases involving ViraferonPeg are
In general, the adverse events seen in overdose cases involving ViraferonPeg are consistent with the known safety profile for ViraferonPeg; however, the severity of the events may be increased.
In general, administration of somatropin to growth hormone deficient patients results in reduction in serum LDL and apolipoprotein B.
In general, the adverse events in paediatric patients were similar in frequency and type to those seen in adult patients.
General Nateglinide should not be used in monotherapy.
In general, the adverse event profile reported with overdose was comparable to recommended single doses of Gardasil.
5 In general, the adverse event profile reported with overdose was comparable to recommended single doses of Silgard.
In general, the adverse event profile reported with overdose was comparable to recommended single doses of Silgard.
In general, the adverse effects of overdose are consistent with those listed in section 4.8.
Patients should usually start with two doses of 2.25 g (4.5 ml) per day.
In general, patients infected with genotype 4 are considered harder to treat and limited study data (n=66) indicate they are compatible with a duration of treatment as for genotype 1.
In general, patients infected with genotype 4 are considered harder to treat and limited study data (n=66) indicate they are compatible with a duration of treatment as for genotype 1.
In general, patients infected with genotype 4 are considered harder to treat and limited study data (n=66) indicate they are compatible with a duration of treatment as for genotype 1.
In general, reported signs and symptoms have been those resulting from an exaggeration of the known pharmacological effects of risperidone.
6 In general sugammadex does not interfere with laboratory tests, with the possible exception of the serum progesterone assay and some coagulation parameters (activated partial thromboplastin time prothrombin time, prothrombin time (international normalized ratio)).
In general if the desired therapeutic effect cannot be achieved in a period of 2 to 4 weeks on a certain dose level, the dose can be further increased.
In general adequate follicular development is achieved on average by the tenth day of treatment (range 5 to 20 days).
Generally, one vial is sufficient, but a further vial can be used if necessary.
Your doctor will usually reduce your Advagraf dose once your condition has stabilised.
ENGERIX B is indicated for active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes in non immune subjects of all ages.
ENGERIX B should under no circumstances be administered intravenously.
ENGERIX B should not be administered to subjects with known hypersensitivity to any component of the vaccine, or to subjects having shown signs of hypersensitivity after previous ENGERIX B administration.
ENGERIX B should not be mixed with other vaccines.
- numbness, tingling sensation or sensation of weakness in the limbs
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
By inhibiting osteoclast activity via its specific receptors, salmon calcitonin decreases bone resorption.
By inhibiting osteoclast activity via its specific receptors, salmon calcitonin decreases bone resorption. ol In pharmacological studies, calcitonin has been shown to have analgesic activity in animal models.
By inhibiting osteoclast activity via its specific receptors, salmon calcitonin decreases bone resorption.
By inhibiting the DPP-4 enzyme, sitagliptin increases the levels of two known active incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Intent-to-treat: all confirmed events up to the end of the trial (included patients potentially exposed to non-study interventions following discontinuation of study medication).
By interfering with their function, bortezomib can kill cancer cells.
The sector provides secretarial support for the joint CPMP/CVMP Quality Working Party which met under the Chairmanship of Dr J-L Robert on three occasions during 1996.
If no clinical benefit is achieved within 9 weeks, treatment should be reconsidered.
The use of Agopton is not recommended in children as clinical data are limited (see also section 5.2).
The use of Agopton is not recommended in children as clinical data are limited (see also section 5.2.)
The use of Agopton is not recommended in children as clinical data are limited (see also section 5.2).
Co-administration of lamivudine with intravenous ganciclovir or foscarnet is not recommended until further information is available.
You must stop breast-feeding if you use Kineret.
You must stop breast-feeding if you use Kineret.
Because of the potential for serious adverse reactions in nursing infants, a decision should be made either to discontinue breast-feeding or AVONEX therapy.
There are no data available from patients with end-stage renal impairment on dialysis, and RELISTOR is not recommended in these patients (see section 4.4).
There is no data to recommend the use of sugammadex for immediate reversal following vecuronium induced blockade.
Zavesca should not be used during breast-feeding.
3 It is not known whether Kepivance is excreted in human milk, therefore Kepivance should not be administered to women who are breast-feeding.
The use of Kineret in women who are breast-feeding is not recommended.
It is not known whether filgrastim is excreted in human milk, therefore it is not recommended for use in breast-feeding women.
Because of the potential harm to the infant, mothers should be advised against breastfeeding while receiving Tarceva.
Because of the potential harm to the infant, mothers should be advised against breastfeeding while receiving Tarceva.
If the enzyme is not present, GAGs cannot be broken down and they build up in the cells.
The PSUR cycle of Docetaxel Winthrop is aligned with the cross-referred product, TAXOTERE, until otherwise specified.
3 the absence of a clear aetiology for the lymphadenopathy or in the presence of acute infectious mononucleosis, discontinuation of Protopy should be considered.
These events are not considered to be causally associated with tenofovir disoproxil fumarate therapy in the absence of proximal renal tubulopathy.
These events are not considered to be causally associated with tenofovir disoproxil fumarate therapy in the absence of proximal renal tubulopathy.
As there has been no experience with febuxostat, its use in these populations is not recommended.
If no safety box is available, the equipment should be supplemented with a mask and protective glasses.
In the absence of metabolic inhibitors, renal clearance accounts for less than 25% of total clearance of maraviroc and hence renal impairment is not expected to significantly alter maraviroc exposures.
Ensure that the tip seal has been properly removed.
This is just a precaution, since it is unlikely that the tip seal could be expelled from the tube while administering the vaccine.
At present it is not known how long treatment with Betaferon should last.
At present it is not known how long treatment with Extavia should last.
Withdraw air to equalize the pressure in the vial.
Remove the plastic flip-top cap from the BeneFIX vial to expose the central portion of the rubber stopper.
Remove the plastic flip-top cap from the ReFacto AF vial to expose the central portion of the rubber stopper.
In liaison with the Pharmacovigilance Working Party the involvement of the CPMP in the field of pharmacovigilance for centrally- authorised products increased significantly.
Holding the syringe barrels with one hand, aspirate both syringes slowly (vials facing up).
Holding the syringe barrels with one hand, loosen the syringe pistons by sliding them back and forth.
● When handling syringes, do not touch the needle.
At mid-cycle, high levels of LH trigger corpus luteum formation and ovulation.
In November 2007, the CHMP was concerned that there was insufficient evidence to show a benefit of CIMZIA.
During October the EMEA collaborated with EFPIA and other interested parties in a workshop to review the performance of the certification system 4 and identify areas for improvements.
d Name and address of the manufacturers responsible for batch release
is Name and address of the manufacturer(s) responsible for batch release
In addition, other amendments to the Summary of Product Characteristics, labelling and package leaflet not in relation with the outcome of the referral procedure were included in accordance with the Guideline on Summary of Product Characteristics, excipient guideline and the latest Quality Review of Document templates.
In addition, special precaution should be taken in patients with predisposition for development of deep vein thrombosis (DVTs).
The effects of recombinant salmon calcitonin on the body have also been shown to be equivalent to those of synthetic salmon calcitonin.
In addition, it noted that ECALTA has been studied mainly in patients with candidaemia (Candida sp. in the blood), and only in a limited number of patients with deep tissue infections or abscesses.
Furthermore, he shall focus his analysis on major issues and identify areas where clarification is needed.
It should also be included that the incorporation rate should be based on average food consumption at time of initiating treatment.
The ERG measures electrical currents in the retina.
In addition, there would seem to be no reason to mix these vaccines before administration to EU residents and the CHMP does not find any endorsement for mixing in the recommendations of WHO.
Furthermore, they had 25% higher risk of developing clinically significant cardiovascular disorders.
The high risk of precipitation is due to the low blood volume of the newborns.
Furthermore, ambrisentan does not induce MRP2, Pgp or BSEP.
In addition the CHMP identified the additional points to be harmonised in the various SPC sections.
In addition the COMP, through its Working Group with Interested Parties, will look at other initiatives to improve transparency.
• In addition the Working Party will conclude its work on
In addition, the clinical data support of the starting dose, the titration schedule, and the maximum total daily dosage of 3600 mg administered in three doses.
In addition, the recommended doses of Combivir in children produced similar levels of the two active substances as in adults.
Furthermore, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4% vs 1%) during treatment and during the 6 month lp
In general, the adverse event profile in the limited paediatric population studied was similar to that observed in adults, although there is a paediatric specific concern regarding growth inhibition as decrease in height (mean percentile decrease of growth velocity of 9%) and weight (mean percentile decrease of 13%) rod
Furthermore, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4% vs 1%) during treatment and during the 6 month follow-up after treatment.
Furthermore, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4% vs 1%) during treatment and during the 6 month follow-up after treatment.
The virus may then become harder to treat.
In addition hydroxycarbamide causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or protein.
In addition several initiatives have been taken to prepare for the im- plementation of a workflow based docu- ment management system at the EMEA.
Also, tell your doctor immediately if you experience any of the following side effects – you may need medical attention:
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
35 In addition, an updated RMP should be submitted: • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities; • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached; • At the request of the EMEA.
91 In addition, an updated RMP should be submitted: • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities; • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached; • At the request of the EMEA.
In addition, an updated RMP should be submitted: • When new information is received that may impact on the current Safety specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 says of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA.
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted: • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In parallel, there was a 62% reduction in vaccine type IPD in individuals over 5 years of age.
Alcohol was administered in a manner to maximize the rate of alcohol absorption (overnight fast with no food until 2 hours after alcohol).
In particular, no residues of the cell line used for the production are detectable at the concentrations of the active ingredient that are used in humans.
Especially in patients with serious heart diseases (e. g. severe heart failure, coronary artery disease) cardiovascular reactions may deteriorate.
In particular, they appeared less favourable in women and non-white subjects (see section 5.1).
In particular, the frequency of routine endoscopic surveillance should not be decreased and FAP-related surgery should not be delayed.
In particular, they appeared less favourable in women and non-white subjects (see section 5.1).
Particularly, a haemoglobin concentration above 12g/ dl should lead to discontinuation of erythropoietic agents.
Passing the column the separated gas species of breath are detected by an ionisation detector.
In HIV– infected paediatric patients, the pharmacokinetic parameters of indinavir in apple sauce were:
a 2 hour infusion on day 1 every three weeks), and 5-FU (200 mg/ m2 daily given by continuous infusion via a central line).
In addition to 33 core data elements, product information (SPC, PIL, labels) will be included in the database for a subset of centrally authorised products.
In addition to the maintenance and operational support of corporate and EU telematics applications — and the development of new EU telematics projects — the Agency's efforts and resources in the IT area will be applied to the operation, support, maintenance and development of a number of corporate and business-continuity projects.
In addition to imatinib, 35% of patients had received prior cytotoxic chemotherapy, 65% had received prior interferon, and 10% had received a prior stem cell transplant.
In addition to the clinical signs given under section 4.6, vaccination with a ten times overdose may induce an abscess in one of the submandibular lymph nodes.
In addition to the active metabolite, inactive metabolites are formed.
In addition to the active metabolite, inactive metabolites are formed, including two major metabolites formed by hydroxylation of the butyl side chain and a minor metabolite, an N-2 tetrazole glucuronide.
When it is locked, no liquid will come out.
In the locked position, the nozzle cannot be pressed down and no oral solution can be discharged.
Degarelix mimics a natural hormone (gonadotrophin-relasing hormone, GnRH) and directly blocks its effects.
In the presence of bacterial urease the ratio of the 13C/12C-carbon isotopes is significantly changed.
In the presence of bacterial urease the ratio of the 13C/ 12C-carbon isotopes is significantly changed.
In the presence of bacterial urease the ratio of the 13C/12C-carbon isotopes is significantly changed.
If there are particles in it, you must not use it. od
In the presence of metabolic inhibitors, renal clearance may account for up to 70% of total clearance of maraviroc and hence renal impairment may result in increased maraviroc exposures in this case (see sections 4.2 and 4.4).
In the presence of thyroid dysfunction, PegIntron treatment may be continued if TSH levels can be maintained in the normal range by medication.
- with active bleeding and/ or irreversible coagulation disorders
In the presence of herpes simplex skin infection, < Invented Name > treatment at the site of infection should be discontinued until the viral infection has cleared.
For motion sickness a light meal or snack before dosing is recommended; prolonged fasting before administration should be avoided.
As a result of these characteristics, the timing of the image acquisition after contrast administration is critical in liver imaging.
As a consequence of this biochemical activity, nilotinib selectively inhibits the proliferation and induces apoptosis in cell lines and in primary Philadelphia-chromosome positive leukaemia cells from CML patients.
Because there are no data available on effects in neonates exposed to alglucosidase alfa via breast milk, it is recommended to stop breast-feeding when Myozyme is used.
The lack of a definite mechanism means that it is difficult to predict how many other possible interactions there may be which could lead to an increased risk of rhabdomyolysis.
Because of co-administration with peginterferon alfa-2b or interferon alfa-2b:
Because of co-administration with peginterferon alfa-2b or interferon alfa-2b:
Theoretically, the effect of botulinum toxin may be potentiated by aminoglycoside antibiotics or spectinomycin, or other medicinal products that interfere with neuromuscular transmission (e. g. tubocurarine-type muscle relaxants).
In hip fracture patients, associated with their increased age, fondaparinux steady state plasma concentrations are:
In hip fracture patients, associated with their increased age, fondaparinux steady state plasma concentrations are:
Since some of these side effects are serious, ask your or your child's doctor to explain their warning signs.
In light of the popularity of the prototype CD-ROM (containing all documents issued by the EMEA to date), a new release will be issued during the first half of 1998.
There is increased risk of lactic acidosis in acute alcohol intoxication (particularly in the case of fasting, malnutrition or hepatic insufficiency) due to the metformin active substance of AVANDAMET (see section 4.4).
There is increased risk of lactic acidosis in acute alcohol intoxication (particularly in the case of fasting, malnutrition or hepatic insufficiency) due to the metformin active substance of Competact (see section 4.4).
There is increased risk of lactic acidosis in acute alcohol intoxication (particularly in the case of fasting, malnutrition or hepatic insufficiency) due to the metformin active substance of Glubrava (see section 4.4).
Due to increase of thrombotic risk in patients with malignant diseases, the use of anticoagulants treatment is frequent.
Because of possible excretion in human milk and because of the potential for serious adverse reactions in nursing infants, the use of DepoCyte is not recommended in breast-feeding women.
As anticipated due to the concomitant immunosuppression, the rate of emergence of YMDD variant HBV after 52 weeks treatment was higher (36% - 64%) in the liver transplant population than in the immunocompetent CHB patients (14% - 32%).
As anticipated due to the concomitant immunosuppression, the rate of emergence of YMDD variant HBV after 52 weeks treatment was higher (36% - 64%) in the liver transplant population than in the immunocompetent CHB patients (14% - 32%).
Due to limited documentation on potential drug interactions with glucosamine, one should generally be aware of altered response or concentration of concurrently used medicinal products.
Due to a potential for additive hepatotoxic effects, it is recommended that alcohol consumption be avoided during treatment with leflunomide.
Due to methodological limitations, a negative assay did not exclude the presence of antibodies to infliximab.
Because of its lipophilic nature, mitotane is not likely to be dialysable.
Due to its inhibition of TNFα, adalimumab administered during pregnancy could affect normal immune responses in the newborn.
111 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
123 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
135 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
147 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
15 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
160 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
172 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
184 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
196 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
208 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
220 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
232 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
244 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
256 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
268 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
27 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
280 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
292 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
304 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
39 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
3 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
51 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
63 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
75 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
87 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
99 of individual variability, titration to optimal therapeutic doses is expected for individual patients.
Because of individual variability, titration to optimal therapeutic doses is expected for individual patients.
those receiving r-HuEPO once weekly may be converted to once every other week Nespo.
Due to intra-patient variability, occasional individual haemoglobin values for a patient above and below the desired haemoglobin level may be observed.
Due to intra-patient variability, occasional individual haemoglobin values for a patient above and M
au Due to intra-patient variability, occasional individual haemoglobin values for a patient above and
Due to intra-patient variability, occasional individual haemoglobin values for a patient above and below the desired haemoglobin level may be observed.
Due to intra-patient variability, occasional individual haemoglobin values for a patient above and M
3 As the benefit of the vaccination is high in this group of infants, vaccination should not be withheld or delayed.
As the benefit of the vaccination is high in this group of infants, vaccination should not be withheld or delayed.
As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.
Based on minimal hepatic metabolism and the renal route of elimination for emtricitabine, it is unlikely that a dose adjustment would be required for Truvada in patients with hepatic impairment (see section 5.2).
Because the number of patients with soft tissue sarcoma is low, the disease is considered ‘ rare’, and Yondelis was designated an ‘ orphan medicine '(a medicine used in rare diseases) on 30 May 2001.
Because the number of patients with adrenal cortical carcinoma is low, the disease is considered ‘ rare’, and Lysodren was designated an ‘ orphan medicine '(a medicine used in rare diseases) on 12 June 2002.
Due to the unknown mechanism of deferiprone induced neutropenia, patients must not take medicinal products known to be associated with neutropenia or those that can cause agranulocytosis (see section 4.3).
Due to the potential for increased systemic absorption of pimecrolimus, < Invented Name > is not recommended in patients with Netherton's syndrome.
Luveris was used together with follitropin alfa – a follicle stimulating hormone preparation.
Because of the potential for adverse reactions in nursing infants, nursing must be discontinued prior to initiation of treatment.
Because of the potential for adverse effects on the nursing infant, losartan is contraindicated during breast-feeding (see section 4.3).
21 Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical evaluation (see section 4.4).
Because of the potential for serious adverse reactions in infants, breast-feeding must be discontinued while taking Siklos.
Because olanzapine may cause somnolence and dizziness, patients should be cautioned about operating machinery, including motor vehicles.
As olanzapine may cause somnolence and dizziness, patients should be cautioned about operating machinery, including motor vehicles.
Because olanzapine may cause somnolence and dizziness, patients should be cautioned about operating machinery, including motor vehicles.
Because of the potential risk of thrombotic complications, clinical surveillance for early signs of thrombotic and consumptive coagulopathy should be initiated with appropriate biological testing when administering this product to patients with liver disease, to patients post-operatively, to new-born infants, or to patients at risk of thrombotic phenomena or DIC.
5 clinical surveillance for early signs of thrombotic and consumptive coagulopathy should be initiated with appropriate biological testing when administering this product to patients with liver disease, to patients post-operatively, to neonates, or to patients at risk of thrombotic phenomena or DIC.
Because of the potential risk of thrombotic complications, clinical surveillance for early signs of thrombotic and consumptive coagulopathy should be initiated with appropriate biological testing when administering this product to patients with liver disease, to patients post-operatively, to neonates, or to patients at risk of thrombotic phenomena or DIC.
217 breast-feeding should be discontinued prior to initiation of treatment.
Because of the potential for adverse reactions in breast-fed infants, breast-feeding should be discontinued prior to initiation of treatment.
Because of the potential for adverse reactions in nursing infants, nursing should be discontinued prior to initiation of treatment.
Because of the potential for adverse reactions in nursing infants, nursing should be discontinued prior to initiation of treatment. t uc
Because of the potential for adverse reactions in nursing infants, nursing should be discontinued prior to initiation of t uc
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
electrical recording of the heart) changes,
as boluses divided between the three main meals. ed
All side effects were usually mild or moderate in intensity.
When the results of all four studies were taken together, the average growth rate was 2.8 cm per year before treatment.
When switching from an oral combined contraceptive
Consistent with the mechanism of action, rosiglitazone in combination with metformin reduced insulin resistance and improved pancreatic ß-cell function.
28 Consistent with the mechanism of action, rosiglitazone reduced insulin resistance and improved pancreatic ß-cell function.
Consistent with the mechanism of action, rosiglitazone reduced insulin resistance and improved pancreatic ß-cell function.
Consistent with the mechanism of action, rosiglitazone reduced insulin resistance and improved pancreatic ß-cell function.
However, exenatide does not impair the normal glucagon response and other hormone responses to hypoglycaemia.
In summary, trial 306 (EUCLID) was ill suited to provide the documentation to support the proposed claim in incipient nephropathy.
- by delaying intestinal glucose absorption
- by delaying intestinal glucose absorption.
However, given that the pharmacokinetic data allowed the optimisation of the dose (keeping overall exposure comparable between the two products), it was concluded that a bridge existed allowing well established use to apply to Dolovet.
In contrast, patients adding placebo had smaller changes in HbA1c levels, with a rise of 0.23% from a starting level of 8.30%.
Placebo treated patients, in contrast, experienced a gradual rise in serum creatinine.
Polyvinyl alcohol Titanium dioxide (E171) Macrogol 3000 Talc
Based on the proof-of-principle applied to all immunoglobulins, the BPWP considered that submitting a single PK study is acceptable.
By binding to the receptor, trastuzumab activates certain cells of the immune system (the body 's natural defences), which then kill the tumour cells.
By binding selectively to antithrombin, fondaparinux potentiates (about 300 times) the
By binding selectively to antithrombin, fondaparinux potentiates (about 300 times) the innate neutralization of Factor Xa by antithrombin.
By binding selectively to ATIII, fondaparinux potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII.
Together, these actions may prevent abnormal electrical activity spreading through the brain, reducing the chance of an epileptic fit happening.
All adverse reactions reported in patients in multiple clinical trials
All Skeletal Related Events (SREs) Placebo Bondronat 50 mg p-value n=277 n=287
Afterwards the ointment should be used once a day on each affected region of the skin until the eczema has gone away.
Afterwards the ointment should be used once a day on each affected region of the skin until the eczema has gone away.
The contents is poured into a drinking glass, the jar a second and third time filled with water and the contents transferred into the drinking glass, so that approximately 30 ml of test solution is obtained.
- then every year for the rhinotracheitis, calicivirosis and feline leukaemia components, and every
Afterwards gynaecological examination should be repeated at least once a year.
As a peptide, bivalirudin is expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acid in the body pool.
Taking these results into consideration, Humira is recommended for use in combination with MTX and for use as monotherapy in patients for whom MTX use is not appropriate (see section 4.2).
Holding onto the finger flange, slowly depress the plunger as far as it will go.
Hold the water-filled syringe by the barrel and push the needle through the rubber top of the Fuzeon vial at a slight angle.
● Hold the water-filled syringe by the barrel and push the needle through the rubber top of the vial at a slight angle.
Holding the syringe by the barrel, snap the syringe cap off the tip (D).
Holding the barrel of the pre-filled pen, press down slightly onto the injection site (holding in place without moving).
Holding the tube upright, firmly depress the cap to puncture the applicator seal, then remove the cap
Reaction with barium hydroxide results in a greater production of Compound A than does the reaction with soda lime.
In terms of total or partial tumour and/ or metastasis regression, eleven studies have shown some degree of improvement and sometimes occasional prolonged remissions.
Necrotizing enterocolitis, Intestinal perforation Uncommon:
Pseudomembranous enterocolitis (see section 4.4).
20 Meetings 1997 15 Meetings 1998 10
SVR after treatment of chronic HCV with non pegylated interferon alfa-2b (with or without ribavirin) results in long-term clearance of the virus providing resolution of the hepatic infection and clinical'cure 'from chronic HCV.
• Gastrointestinal disorders:
From 12-16 years of age, this magnitude of gaining 3 to 5 kg per year is maintained for girls, while boys gain approximately 5 kg per year.
Gallbladder disease, cholelithiasis, cholelithiasis aggravated, cholelithiasis re-occurrence
Mr Sauer held various positions in France as a hospital pharmacist and pharmaceutical inspector at the Ministry of Health.
Between 1992 and 1994, she was employed by the European Federation of Pharmaceutical Industries and Associations (EFPIA) as an Assistant in the Scientific, Technical and Regulatory Affairs, responsible for Quality and Biotechnology related matters.
Between 1 in 1000 and 1 in 10000 patients experience
Some 25-50% of the ingested dose of calcium is absorbed, predominantly in the proximal part of the small intestine, and delivered to the exchangeable calcium pool.
• Hepatobilitary disorders:
The syringe should be stored in the carton box in between uses.
After having taken Gliolan and before start of anaesthesia, the following side effects may occur:
An increase in serum exposure to nilotinib between the first dose and steady state was approximately 2-fold for daily dosing and 3.8-fold for twice-daily dosing.
Between infusions, the following may occur:
Enurace 50 was first authorised in The Netherlands on 15 September 2000.
Enurace has been officially authorised since 2000 (since 1995 available in the Netherlands).
When using the individual correction formulae, none of the values were out of the limit.
When using the individual correction formulae, none of the values were out of the limit.
Using sterile technique, place one syringe, one needle and the matrix inner package in the sterile field.
Based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e. g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).
Based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e. g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).
Combination studies looked at Enviage used with an angiotensin converting enzyme inhibitor (ramipril), an angiotensin receptor blocker (valsartan), a beta-blocker (atenolol), a calcium-channel blocker (amlodipine) and a 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
As we get older our skin makes less vitamin D.
Approximately 10% of patients treated with salmon calcitonin suffer from nausea, sometimes with vomiting.
About 14% of an intravenously- or orally-administered dose of losartan is converted to its active metabolite.
Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month 3 and month 6 compared to fewer than 5% of subjects in the placebo arm.
About 20% of the total quantity of perindopril absorbed is converted into perindoprilat, the active metabolite.
About 20% of the total quantity of perindopril absorbed is converted into perindoprilat, the active metabolite.
Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)].
Approximately 42% of patients had a femoral neck BMD T-score below -2.5 and approximately 45% of the patients had a femoral neck BMD T-score above -2.5.
About 5.7% of patients developed elevation in ALT during Raptiva therapy compared to 3.5% in placebo.
35%; however, LDL-C reduction was not altered.
Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites.
Approximately 70% of circulating inhibitory activity for HMG-oA reductase is attributed to active metabolites.
Systems and network administration and support, Helpdesk, application support
(Needles are not included). • Prime your Pen before each use.
(Needles are not included). • Prime your KwikPen before each use.
(Needles are not included). • Prime your KwikPen before each use.
(Needles are not included). • Prime your Pen before each use.
(Needles are not included). • Prime your KwikPen before each use.
- A measure of relative reporting rate of signals for each reported PT should be provided if
Furthermore, rufinamide does not inhibit the activity of cytochrome P450 enzymes (see Section 5.2).
Pericardial effusion*, tachycardia* Very common:
To help avoid skin irritation: • Stick the patch onto a different area of skin each day, for example on the right side of your body one day, then on the left side the next day; on your upper body one day, then on your lower body.
Epifarma S. R. L Via S. Rocco, 6 85033 Episcopia Pz Italy
149 Seizures: convulsions have been observed in patients receiving efavirenz, generally in the presence of known medical history of seizures.
- Epilepsy and/ or compromised central nervous system (CNS) function;
- Epilepsy and/or compromised central nervous system (CNS) function;
- Epilepsy and/ or compromised central nervous system (CNS) function (see section 4.4).
- Epilepsy and/or compromised central nervous system (CNS) function (see section 4.4).
- Severe renal or hepatic dysfunction; including that caused by metastases.
The starting dose is 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy (see section 5.1).
(N = 74) Median time to regression of symptoms, by patient (hours) All episodes
Dyspnoea*, coughing* Epistaxis, respiratory disorder, nasal congestion, rhinorrhea,
Dyspnoea*, coughing* Epistaxis, respiratory disorder, nasal congestion, rhinorrhea, cough nonproductive lon
Epistaxis, respiratory disorder, nasal congestion, rhinorrhea, cough nonproductive
Basal cell carcinoma, glioblastoma multiforme
Epivir can be taken with or without food.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Epoetin alfa HEXAL is a sterile but unpreserved product and is for single use only.
Epoetin alfa HEXAL is a sterile but unpreserved product and is for single use only.
Epoprostenol: limited data obtained from a study (AC-052-356, BREATHE-3) in which 10 paediatric patients received the combination of Tracleer and epoprostenol indicate that after both single- and multiple-dose administration, the Cmax and AUC values of bosentan were similar in patients with or without continuous infusion of epoprostenol (see section 5.1).
PPE (ileitis) & Swine Dysentery 4.25 mg/kg bodyweight
eptacog alfa (activated) 1 mg/ vial (50 KIU/ vial), 1 mg/ ml after reconstitution
eptacog alfa (activated) 2 mg/ vial (100 KIU/ vial), 1 mg/ ml after reconstitution
eptacog alfa (activated) 5 mg/ vial (250 KIU/ vial), 1 mg/ ml after reconstitution
Equilis Prequenza was also studied in pregnant mares.
Equilis Prequenza contains fragments (subunits) of the influenza virus against which the vaccine is indicated for.
Equilis Prequenza, suspension for injection, for horses
Equilis Prequenza, suspension for injection, for horses
Equilis Prequenza Te was also studied in pregnant mares.
Studies in pregnant mares were also performed.
Equilis Prequenza Te is a vaccine for use in horses.
Equilis Prequenza Te, suspension for injection, for horses
Equilis Prequenza Te, suspension for injection, for horses
Equimectin 12mg/ g oral gel for horses contains ivermectin.
EQUIOXX has been studied in laboratory animals, as well as in horses that were treated in various veterinary practices/ clinics across Europe (“ clinical studies”).
EQUIOXX is used to relieve the symptoms of osteoarthritis (swelling and pain in the joints) and reduce the lameness that is associated with the disease in horses.
EQUIOXX is presented as a paste with a special syringe that allows the right amount of medicine to be drawn and given directly into the horse's mouth.
(equivalent to 72.34 mg Fluoxetine hydrochloride)
- Eradication of Helicobacter pylori concurrently given with appropriate antibiotic therapy and
Erbitux 2 mg/ ml is compatible • with polyethylene, ethyl vinyl acetate or polyvinyl chloride bags, • with polyethylene, ethyl vinyl acetate, polyvinyl chloride, polybutadiene or polyurethane infusion sets, • with polyethersulfone, polyamide or polysulfone in-line filters.
Erbitux 5 mg/ ml is compatible • with polyethylene (PE), ethyl vinyl acetate (EVA) or polyvinyl chloride (PVC) bags, • with polyethylene (PE), polyurethane (PUR), ethyl vinyl acetate (EVA), polyolefine thermoplastic (TP) or polyvinyl chloride (PVC) infusion sets, • with polypropylene (PP) syringes for syringe pump.
Erbitux 5 mg/ ml solution for infusion Cetuximab
Erbitux contains cetuximab, a monoclonal antibody.
Erbitux must be administered under the supervision of a physician experienced in the use of antineoplastic medicinal products.
Erbitux is contraindicated in patients with known severe (grade 3 or 4) hypersensitivity reactions to cetuximab.
Erbitux is usually infused into a vein (given as a drip) once a week.
Erbitux is used in patients whose tumour cells have a protein on their surface called epidermal growth factor receptor (EGFR) and contain a ‘ wild-type'(non-mutated) gene called ‘ KRAS’.
Erbitux is used to treat two different types of cancer:
E Pull off the inner needle cap and dispose of it.
E Pull off the inner needle cap and dispose of it.
- ergotamine (used to treat migraine);
or Manufacturer responsible for batch release:
au E2 glycoprotein of Classical Swine Fever (CSF) virus minimum 32 µg
ed ris ho ut After the cloud appears, immediately turn the
corneal erosion, keratitis, eyelid pain, eye allergy, conjunctival oedema, eyelid oedema, eyelids pruritus
rash (9.0% vs 3.2%) swelling face (0.2% vs 0%), lipohypertrophy (0.3% vs 0.3%), night sweats (0.8% vs 0.8%), hyperhidrosis (0.5% vs 0.2%), prurigo (0.5% vs 0.5%), dry skin (0.3% vs 0.2%)
- rash with red (moist) irregular spots (erythema (exsudativum) multiforme), tender bluish red bumps in
- difficulty with breathing or light-headedness
Rash, scaling, irritation, redness Cracking, scabbing, crusting, draining, oozing Pain, burning, soreness Itching
Rash, pruritus Pigmentation disorder Leukocytoclastic vasculitis 1, urticaria 1 P P P
- maculo-papular rash (red skin reaction that can include pimples or spots)
- itchy rash (urticaria); itching; skin flushing (erythema)
99 Rash: mild-to-moderate rash has been reported in clinical studies with efavirenz and usually resolves with continued therapy.
Rash: mild-to-moderate rash has been reported in clinical studies with efavirenz and usually resolves with continued therapy.
• rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions, itching, changes in skin colour including darkening of the skin in patches
• rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions, itching, changes in skin colour including darkening of the skin in patches
rash, sweating increased, contusion
Urticaria, Rash, Pruritus, Alopecia
Anorexia Hypocalcaemia, dehydration, hyperuricemia, thirst Hyperglycaemia, hypertriglyceridaemia§, increased appetite
Sarcoidosis, exacerbation of sarcoidosis Systemic lupus erythematosus, vasculitis, rheumatoid no
Erythrocytes Haematocrit Mean corpuscular volume (MCV) Leucocytes Lymphocytes Monocytes Eosinophils Neutrophils Platelets
In case PRCA is diagnosed, therapy with Nespo must be discontinued and patients should not be switched to another recombinant erythropoietic protein (see section 4.4).
If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet.
• If you are a cancer patient you should be aware that Nespo may act as a blood cell growth factor and in some circumstances may have a negative impact on your cancer.
Esmeralda, 19 E-08950 Esplugues de Llobregat (Barcelona) Spain
GlaxoSmithKline SA Parque Tecnologico de Madrid Calle Severo Ochoa 2, 28760 Tres Cantos, Madrid Spain
Spain GlaxoSmithKline SA Parque Tecnologico de Madrid, Calle Severo Ochoa 2, 28760, Tres Cantos, Madrid Spain
Fernando de ANDRES-TRELLES
Josefa Valcárcel, 38 28027 Madrid Spain
Merck Sharp & Dohme de España, S. A., Josefa Valcárcel, 38 28027 Madrid Spain
Clinical trials in Lymphoid Blast Phase CML and Ph+ ALL:
11 Clinical trials Relapsing-remitting multiple sclerosis (RR-MS) One controlled clinical trial with Extavia in patients with relapsing-remitting multiple sclerosis and able to walk unaided (baseline EDSS 0 to 5.5) was performed.
Placebo-controlled trials in digital ulcers
Try to use Avonex at the same time on the same day each week.
Try always to keep familiar with your warning symptoms.
Wipe the inside and outside of the mouthpiece and the plastic casing with a dry cloth or tissue.
Wipe the mouthpiece of the Diskus with a dry tissue to clean it.
- Do not remove the metal can from the plastic casing during cleaning or at any other time.
- Wipe the inside and outside of the mouthpiece and the plastic casing with a dry cloth or tissue.
Do I need to do the New Pen Setup before every dose? • No.
- is of the Opinion that the benefit/ risk balance of Dynastat in the short-term treatment of
- is of the Opinion that the benefit/ risk balance of medicinal products containing celecoxib in
- is of the Opinion that the benefit/ risk balance of Onsenal in Familial Adenomatous Polyposis
The hepatic clearance of systemically available no
38 Pharmacokinetic parameter estimates for ReFacto in previously treated patients with haemophilia A
Pharmacokinetic parameter estimates for ReFacto in previously treated patients with haemophilia A PK parameter
Assessment of progenitor cell yields In assessing the number of progenitor cells harvested in patients treated with filgrastim, particular attention should be paid to the method of quantitation.
Gastro-intestinal: bleeding in the stomach and/or the gut.
Estrada do Rio da Mó n. º 8, 8A e 8B – Fervença 2705-906 Terrugem SNT Portugal Tel.: +351 219 608 410 Fax: +351 219 615 102 e-mail: geral@hikma. pt
Estrada do Rio da Mó n. º 8, 8A e 8B – Fervença 2705-906 Terrugem SNT Portugal Tel.: +351 219 608 410 Fax: +351 219 615 102 geral@hikma. pt
Estrada Nacional 249, Km 14,2 PT-2725-397 Mem Martins Codes Portugal Tel: +351 (21) 922 83 00 Fax: +351 (21) 920 22 31
oestrogens and progestagens, saluretics, thiazide diuretics, thyroid stimulating agents, glucocorticoids, phenothiazine derivatives, chlorpromazine, adrenaline and sympathicomimetics, nicotinic acid (high dosages) and nicotinic acid derivatives, laxatives (long term use), phenytoin, diazoxide, glucagon, barbiturates and rifampicin, acetozolamide.
This summary was last updated in 09-2007.
accordance with the 24 month shelf-life.
Opinions on establishment of old MRLs CVMP and VICH guidelines adopted Meeting days
Cats Vaccine against feline leukaemis (QJ57BA04)
and harmonisation of the pharmaceutical documentation – module 3 (quality)
Etanercept works by reducing the inflammation associated with certain diseases.
Etanercept works by reducing the inflammation associated with certain diseases.
Etanercept works by reducing the inflammation associated with the disease that the child under your care has.
Etanercept may also modulate biologic responses controlled by additional downstream molecules (e. g., cytokines, adhesion molecules, or proteinases) that are induced or regulated by TNF.
General disorders and administration site conditions Very common: pain, local weakness Common:
Treatment should be initiated only after a careful benefit/ risk evaluation, due to possible adverse events related to joints and/ or surrounding tissue.
Treatment should be initiated only after a careful benefit/ risk evaluation, due to possible adverse events related to joints and/ or surrounding tissue.
Due to the potential serious adverse reactions in the nursing child, breast-feeding is contraindicated during azacitidine therapy.
• Due to the protective safety cover it is not recommended to put the grey needle shield back on the used pre-filled pen.
Based on the minimal extent of pimecrolimus absorption after topical application of < Invented Name > (see Section 5.2 “Pharmacokinetic properties”), the potential risk for humans is considered limited.
Due to the potential risk of articular damage, ciprofloxacin should not be used during breast-feeding.
Due to the potential risk of articular damage, ciprofloxacin should not be used during breast-feeding.
Considering the grounds for referral, assessment of the withdrawal period is only consequential to an increment of the recommended dose.
For CLL patients similar results are assumable considering similarities between both diseases but that has not been investigated in clinical trials.
Based on the limited clinical experience in children from reports and studies covering 83 patients, dosing guidelines for adult subjects are considered valid for neonatal and paediatric patient population (see section 5.1).
No reproduction toxicity or carcinogenicity studies were performed due to testing being inappropriate as the intended clinical use of Beromun is in ILP for soft tissue sarcoma treatment.
Since this product contains sucrose, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
As LFA-1 is important in helping the lymphocytes to stick to cells in the skin, efalizumab reduces the inflammation in the skin that causes psoriasis.
Because factor VII acts directly on factor X, independently from factors VIII and IX, NovoSeven can be used in haemophilia patients who have developed inhibitors to factor VIII or IX.
Because the effect on the breast-fed infant is unknown, caution should be exercised when gabapentin is administered to a breast-feeding mother.
Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbit, Mycophenolate mofetil Teva film-coated tablets should not be crushed.
As all five original studies were carried out with a technique known as ‘ fundamental'ultrasound imaging, the company also presented the results of some studies to show that the results seen using fundamental imaging could also be obtained when using the imaging techniques known as ‘ harmonic'and ‘ non-linear’.
Since infertile women undergoing assisted reproduction, and particularly IVF, often have tubal abnormalities the incidence of ectopic pregnancies might be increased.
Because of an increased risk of meningitis, Soliris should not be given to people who are infected with Neisseria meningitidis, or who have not been vaccinated against this bacterium.
Taking into account that those with an impaired immune response due to congenital or acquired dysfunction or absence of the thymus could have a low immune response and so questionable protection from YF vaccination the warning statement regarding special populations is endorsed.
Since zonisamide and its metabolites are excreted renally, it should be discontinued in patients who develop acute renal failure or where a clinically significant sustained increase in serum creatinine is observed.
Patient's Name: ____________________ Doctor's Name: ____________________
As intranasal calcitonin is indicated for postmenopausal women, no studies have been carried out in pregnant women or nursing mothers.
Because there are strict laws covering the use, handling and disposal of radioactivity, YTRACIS will always be used in a hospital or a similar setting.
Because there are strict laws covering the use, handling and disposal of radiopharmaceuticals, Yttriga will always be used in a hospital or a similar setting.
Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
Based on its minimal extent of absorption, interactions of < Invented Name > with systemically administered medicinal products are unlikely to occur (see Section 5.2 “Pharmacokinetic properties”).
STEP 7 Store Pen for Next Dose
STEP E Complete New Pen Setup
- Severe, debilitating medical conditions, including patients with chronic renal failure, patients
anxiety (1.2% vs 1.7%), insomnia (1.8% vs 2.2%) confusional state (0.2% vs 0.2%), disorientation (0.2% vs 0.3%), nightmares (0.2% vs 0.2%), sleep disorders (0.5% vs 0.3%), nervousness (0.2% vs 0.2%), abnormal dreams (0.2% vs 0.2%)
Status epilepticus* Convulsion Coordination Abnormal*
Status epilepticus* Convulsion Coordination Abnormal* Nystagmus Psychomotor hyperactivity Tremor
Status epilepticus, extrapyramidal disorder, hemiparesis, ataxia, cognition impaired, dysphasia, gait abnormal, hyperesthesia, hypoesthesia, neurological disorder (NOS), peripheral neuropathy
Note for guidance on maximum shelf-life for sterile products for human use after f irst opening or following reconstitution
and CRP (mg/ dl) values) improved at 24 or 26 weeks compared to placebo.
changes in liver enzymes and function, yellowing of the skin due to liver problems, liver tissue damage and inflammation of the liver
Representatives of the European Commission also regularly participated in meetings of the group.
Cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including zaleplon.
ed baseline FEV1 < 70% predicted have not been established and the use of inhaled human insulin in this population is not recommended.
76 (60, 85) 60 (36, 76)
er predominantly reported in patients with CRF treated subcutaneously.
Ethanol (96 per cent), benzyl alcohol, benzyl benzoate and castor oil.
Ethanol (96 per cent) Benzyl alcohol Benzyl benzoate Castor oil
- 26.05.2000 - 31.07.2000 - 13.09.2000 - 45 days
PARTICULARS TO APPEAR ON THE OUTER PACKAGING FOR MONODOSE PRESENTATIONS
19 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
59 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS AMPOULE LABEL 5 mg/ ml CONCENTRATE FOR SOLUTION FOR INFUSION
LABEL ON THE ALUMINIUM FOIL (secondary packaging)
ed and Protopy 0.1% ointment).
treatment guidelines in Europe and North America
Dizziness, headache, concentration impaired, mouth dry Tremor, paresthesia, hypoesthesia, migraine, flushing,
dizziness* paraesthesia vertigo hot flush
is Any unused product or waste material should be disposed of in accordance with local requirements.
due to a nonspecific effect on the absorption capacity of the gastrointestinal tract.
• The needle may be clogged, bent, or incorrectly attached. • Attach a new needle.
predominantly depressive episodes (see section 5.1).
Protopy ointment should not be applied under occlusion (see section 4.4). a
All patients initiated on EXUBERA should have a baseline lung function examination (e. g. spirometry to measure FEV1).
Being overweight increases your risk of developing several serious health problems such as diabetes and heart disease.
Being overweight increases your risk of developing several serious health problems such as diabetes and heart disease.
as in the recommended immunisation schedule.
e of the needle should be inserted perpendicularly into a skin fold held between the thumb and the forefinger; the skin fold should be held throughout the injection.
disorders which may predispose to seizures or lower the seizure threshold.
and also on the EudraLex Internet site at http://pharmacos.eudra.org/eudralex/index.htm
Name and address of the manufacturer(s) of the biological active substance
--------Enbrel--------- --------Enbrel-------
--------Enbrel--------- --------Enbrel-------
DEX 10 mg/ m2 oral, days 1-5; CP 200 mg/ m2 i. v., days 3, 4, 5; MTX 12 mg intrathecal, day 1
Interaction study with Lopinavir/ ritonavir + rosuvastatin:
IHC3+ patient subset 3.
ADROVANCE studies The effect of ADROVANCE (alendronate 70 mg/ vitamin D3 2800 IU) on vitamin D status was demonstrated in a 15-week, multinational study that enrolled 682 osteoporotic post-menopausal women (serum 25-hydroxyvitamin D at baseline: mean, 56 nmol/ l [22.3 ng/ ml]; range, 22.5- 225 nmol/ l [9-90 ng/ ml]).
ADROVANCE studies The effect of the lower dose of ADROVANCE (alendronate 70 mg/ vitamin D3 2800 IU) on vitamin D status was demonstrated in a 15-week, multinational study that enrolled 682 osteoporotic post- menopausal women (serum 25-hydroxyvitamin D at baseline: mean, 56 nmol/ l [22.3 ng/ ml]; range, 22.5-225 nmol/ l [9-90 ng/ ml]).
Clinical studies In two phase III double-blind studies in a total of 376 patients with Parkinson's disease and end-of- dose motor fluctuations, entacapone or placebo was given with each levodopa/ dopa decarboxylase inhibitor dose.
Clinical studies in Alzheimer's dementia The efficacy of rivastigmine has been established through the use of three independent, domain specific, assessment tools which were assessed at periodic intervals during 6 month treatment periods.
Clinical studies in GIST One phase II, open-label, randomised, uncontrolled multinational study was conducted in patients with unresectable or metastatic malignant gastrointestinal stromal tumours (GIST).
No potentiation of the blood pressure lowering effect of sublingual nitroglycerin (0.4 mg) was observed when vardenafil (10 mg) was given at varying time intervals (1 h to 24 h) prior to the dose of nitroglycerin in a study in 18 healthy male subjects.
Pharmacological/Mechanistic Studies
Tolerability studies demonstrated that < Invented Name > has not shown contact sensitising, phototoxic or photosensitising potential, nor did they show any cumulative irritation.
Postgraduate diploma in industrial pharmaceutics, University of Brighton.
Post-graduate studies in pharmacology at the University of Melbourne and Auckland.
To investigate the tolerability of anagrelide and hydroxyurea in short and long term usage of up to three years.
CARTON CONTAINING 5 OR 20 HARD CAPSULES OF TEMODAL 140 mg INDIVIDUALLY SEALED IN SACHETS
The solvent is presented in a 2 ml ampoule, Type I flint glass.
EU/ 1/ 08/ 470/ 014 200 ml syrup EU/ 1/ 08/ 470/ 015 465 ml syrup
EU/0/00/000/000 – pack of 1 pre-filled oral applicator EU/0/00/000/000 – pack of 5 pre-filled oral applicators EU/0/00/000/000 – pack of 10 pre-filled oral applicators EU/0/00/000/000 – pack of 25 pre-filled oral applicators
EU/0/00/000/000 – pack of 1 tube EU/0/00/000/000 – pack of 10 tubes EU/0/00/000/000 – pack of 50 tubes
EU/0/00/000/000 EU/0/00/000/000 EU/0/00/000/000
EU/0/00/000/000 EU/0/00/000/000 EU/0/00/000/000 EU/0/00/000/000 EU/0/00/000/000 EU/0/00/000/000
EU/ 0/ 00/ 000/ 000 – pack of 1 EU/ 0/ 00/ 000/ 000 – pack of 10 EU/ 0/ 00/ 000/ 000 – pack of 100
EU/ 1/ 00/ 130/ 001 1 pre-filled syringe EU/ 1/ 00/ 130/ 002 5 pre-filled syringes
EU/1/00/131/001 (1 vial of powder, 1 ampoule of solvent) EU/1/00/131/002 (1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab) EU/1/00/131/003 (4 vials of powder, 4 ampoules of solvent) EU/1/00/131/004 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs) EU/1/00/131/005 (6 vials of powder, 6 ampoules of solvent) EU/1/00/131/026 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs)
EU/1/00/131/001 EU/1/00/131/002 EU/1/00/131/003 EU/1/00/131/004 EU/1/00/131/005 EU/1/00/131/026
EU/1/00/131/006 (1 vial of powder, 1 ampoule of solvent) EU/1/00/131/007 (1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab) EU/1/00/131/008 (4 vials of powder, 4 ampoules of solvent) EU/1/00/131/009 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs) EU/1/00/131/010 (6 vials of powder, 6 ampoules of solvent) EU/1/00/131/027 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs)
EU/1/00/131/006 EU/1/00/131/007 EU/1/00/131/008 EU/1/00/131/009 EU/1/00/131/010 EU/1/00/131/027
EU/1/00/131/011 (1 vial of powder, 1 ampoule of solvent) EU/1/00/131/012 (1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab) EU/1/00/131/013 (4 vials of powder, 4 ampoules of solvent) EU/1/00/131/014 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs) EU/1/00/131/015 (6 vials of powder, 6 ampoules of solvent) EU/1/00/131/028 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs)
EU/1/00/131/011 EU/1/00/131/012 EU/1/00/131/013 EU/1/00/131/014 EU/1/00/131/015 EU/1/00/131/028
EU/1/00/131/016 (1 vial of powder, 1 ampoule of solvent) EU/1/00/131/017 (1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab) EU/1/00/131/018 (4 vials of powder, 4 ampoules of solvent) EU/1/00/131/019 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs) EU/1/00/131/020 (6 vials of powder, 6 ampoules of solvent) EU/1/00/131/029 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs)
EU/1/00/131/016 EU/1/00/131/017 EU/1/00/131/018 EU/1/00/131/019 EU/1/00/131/020 EU/1/00/131/029
EU/1/00/131/021 (1 vial of powder, 1 ampoule of solvent) EU/1/00/131/022 (1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab) EU/1/00/131/023 (4 vials of powder, 4 ampoules of solvent) EU/1/00/131/024 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs) EU/1/00/131/025 (6 vials of powder, 6 ampoules of solvent) EU/1/00/131/030 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs)
EU/1/00/131/021 EU/1/00/131/022 EU/1/00/131/023 EU/1/00/131/024 EU/1/00/131/0 25 EU/1/00/131/030
EU/1/00/131/031 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/131/032 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/131/033 (6 pens, 6 injection needles and 12 cleansing swabs) EU/1/00/131/034 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/1/00/131/031 EU/1/00/131/032 EU/1/00/131/033 EU/1/00/131/034
EU/1/00/131/035 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/131/036 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/131/037 (6 pens, 6 injection needles and 12 cleansing swabs) EU/1/00/131/038 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/1/00/131/035 EU/1/00/131/036 EU/1/00/131/037 EU/1/00/131/038
EU/1/00/131/039 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/131/040 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/131/041 (6 pens, 6 injection needles and 12 cleansing swabs) EU/1/00/131/042 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/1/00/131/039 EU/1/00/131/040 EU/1/00/131/041 EU/1/00/131/042
EU/1/00/131/043 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/131/044 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/131/045 (6 pens, 6 injection needles and 12 cleansing swabs) EU/1/00/131/046 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/1/00/131/043 EU/1/00/131/044 EU/1/00/131/045 EU/1/00/131/046
EU/1/00/131/047 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/131/048 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/131/049 (6 pens, 6 injection needles and 12 cleansing swabs) EU/1/00/131/050 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/1/00/131/047 EU/1/00/131/048 EU/1/00/131/049 EU/1/00/131/050
EU/1/00/132/001 (1 vial of powder, 1 ampoule of solvent) EU/1/00/132/002 (1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab) EU/1/00/132/003 (4 vials of powder, 4 ampoules of solvent) EU/1/00/132/004 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs) EU/1/00/132/005 (6 vials of powder, 6 ampoules of solvent) EU/1/00/132/026 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs)
EU/1/00/132/001 EU/1/00/132/002 EU/1/00/132/003 EU/1/00/132/004 EU/1/00/132/005 EU/1/00/132/026
EU/1/00/132/006 (1 vial of powder, 1 ampoule of solvent) EU/1/00/132/007 (1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab) EU/1/00/132/008 (4 vials of powder, 4 ampoules of solvent) EU/1/00/132/009 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs) EU/1/00/132/010 (6 vials of powder, 6 ampoules of solvent) EU/1/00/132/027 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs)
EU/1/00/132/006 EU/1/00/132/007 EU/1/00/132/008 EU/1/00/132/009 EU/1/00/132/010 EU/1/00/132/027
EU/1/00/132/011 EU/1/00/132/012 EU/1/00/132/013 EU/1/00/132/014 EU/1/00/132/015 EU/1/00/132/028
EU/1/00/132/016 (1 vial of powder, 1 ampoule of solvent) EU/1/00/132/017 (1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab) EU/1/00/132/018 (4 vials of powder, 4 ampoules of solvent) EU/1/00/132/019 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs) EU/1/00/132/020 (6 vials of powder, 6 ampoules of solvent) EU/1/00/132/029 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs)
EU/1/00/132/016 EU/1/00/132/017 EU/1/00/132/018 EU/1/00/132/019 EU/1/00/132/020 EU/1/00/132/0 29
EU/1/00/132/021 (1 vial of powder, 1 ampoule of solvent) EU/1/00/132/022 (1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab) EU/1/00/132/023 (4 vials of powder, 4 ampoules of solvent) EU/1/00/132/024 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs) EU/1/00/132/025 (6 vials of powder, 6 ampoules of solvent) EU/1/00/132/030 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs)
EU/1/00/132/021 EU/1/00/132/022 EU/1/00/132/023 EU/1/00/132/024 EU/1/00/132/0 25 EU/1/00/132/030
EU/1/00/132/031 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/132/032 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/132/033 (6 pens, 6 injection needles and 12 cleansing swabs) EU/1/00/132/034 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/1/00/132/031 EU/1/00/132/032 EU/1/00/132/033 EU/1/00/132/034
EU/1/00/132/035 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/132/036 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/132/037 (6 pens, 6 injection needles and 12 cleansing swabs) EU/1/00/132/038 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/1/00/132/035 EU/1/00/132/036 EU/1/00/132/037 EU/1/00/132/038
EU/1/00/132/039 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/132/040 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/132/041 (6 pens, 6 injection needles and 12 cleansing swabs) EU/1/00/132/042 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/1/00/132/039 EU/1/00/132/040 EU/1/00/132/041 EU/1/00/132/042
EU/1/00/132/043 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/132/044 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/132/045 (6 pens, 6 injection needles and 12 cleansing swabs) EU/1/00/132/046 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/1/00/132/043 EU/1/00/132/044 EU/1/00/132/045 EU/1/00/132/046
EU/1/00/132/047 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/132/048 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/132/049 (6 pens, 6 injection needles and 12 cleansing swabs) EU/1/00/132/050 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/1/00/132/047 EU/1/00/132/048 EU/1/00/132/049 EU/1/00/132/050
EU/ 1/ 00/ 133/ 001 1 vial of 5ml EU/ 1/ 00/ 133/ 002 2 vials of 5ml EU/ 1/ 00/ 133/ 003 5 vials of 5ml EU/ 1/ 00/ 133/ 004 10 vials of 5ml
EU/ 1/ 00/ 134/ 001 1 vial of 5 ml EU/ 1/ 00/ 134/ 002 2 vials of 5 ml EU/ 1/ 00/ 134/ 003 5 vials of 5 ml EU/ 1/ 00/ 134/ 004 10 vials of 5 ml
EU/ 1/ 00/ 134/ 018 1 pen of 3 ml EU/ 1/ 00/ 134/ 008 3 pens of 3 ml EU/ 1/ 00/ 134/ 009 4 pens of 3 ml EU/ 1/ 00/ 134/ 010 5 pens of 3 ml EU/ 1/ 00/ 134/ 019 6 pens of 3 ml EU/ 1/ 00/ 134/ 020 8 pens of 3 ml EU/ 1/ 00/ 134/ 021 9 pens of 3 ml EU/ 1/ 00/ 134/ 011 10 pens of 3 ml
EU/ 1/ 00/ 134/ 022 1 cartridge of 3 ml EU/ 1/ 00/ 134/ 023 3 cartridges of 3 ml EU/ 1/ 00/ 134/ 024 4 cartridges of 3 ml EU/ 1/ 00/ 134/ 025 5 cartridges of 3 ml EU/ 1/ 00/ 134/ 026 6 cartridges of 3 ml EU/ 1/ 00/ 134/ 027 8 cartridges of 3 ml EU/ 1/ 00/ 134/ 028 9 cartridges of 3 ml EU/ 1/ 00/ 134/ 029 10 cartridges of 3 ml
EU/ 1/ 00/ 137/ 002 EU/ 1/ 00/ 137/ 003 EU/ 1/ 00/ 137/ 013 EU/ 1/ 00/ 137/ 016 EU/ 1/ 00/ 137/ 004
EU/ 1/ 00/ 137/ 005 EU/ 1/ 00/ 137/ 006 EU/ 1/ 00/ 137/ 007 EU/ 1/ 00/ 137/ 014 EU/ 1/ 00/ 137/ 017 EU/ 1/ 00/ 137/ 008 EU/ 1/ 00/ 137/ 009
EU/ 1/ 00/ 137/ 010 EU/ 1/ 00/ 137/ 011 EU/ 1/ 00/ 137/ 015 EU/ 1/ 00/ 137/ 018 EU/ 1/ 00/ 137/ 012
EU/ 1/ 00/ 146/ 001 20 tablets EU/ 1/ 00/ 146/ 002 30 tablets EU/ 1/ 00/ 146/ 003 50 tablets EU/ 1/ 00/ 146/ 004 60 tablets EU/ 1/ 00/ 146/ 005 100 tablets EU/ 1/ 00/ 146/ 029 200 tablets
EU/ 1/ 00/ 146/ 006 10 tablets EU/ 1/ 00/ 146/ 007 20 tablets EU/ 1/ 00/ 146/ 008 30 tablets EU/ 1/ 00/ 146/ 009 50 tablets EU/ 1/ 00/ 146/ 010 60 tablets EU/ 1/ 00/ 146/ 011 100 tablets EU/ 1/ 00/ 146/ 012 120 tablets EU/ 1/ 00/ 146/ 013 200 tablets
EU/ 1/ 00/ 146/ 014 20 tablets EU/ 1/ 00/ 146/ 015 30 tablets EU/ 1/ 00/ 146/ 016 50 tablets EU/ 1/ 00/ 146/ 017 60 tablets EU/ 1/ 00/ 146/ 018 80 tablets EU/ 1/ 00/ 146/ 019 100 tablets EU/ 1/ 00/ 146/ 028 200 tablets
EU/ 1/ 00/ 146/ 020 10 tablets EU/ 1/ 00/ 146/ 021 20 tablets EU/ 1/ 00/ 146/ 022 30 tablets EU/ 1/ 00/ 146/ 023 50 tablets EU/ 1/ 00/ 146/ 024 60 tablets EU/ 1/ 00/ 146/ 025 100 tablets EU/ 1/ 00/ 146/ 026 200 tablets
EU/ 1/ 00/ 150/ 007 14 tablets EU/ 1/ 00/ 150/ 001 28 tablets EU/ 1/ 00/ 150/ 016 30 tablets EU/ 1/ 00/ 150/ 002 50 tablets EU/ 1/ 00/ 150/ 009 56 tablets EU/ 1/ 00/ 150/ 017 84 tablets EU/ 1/ 00/ 150/ 018 90 tablets EU/ 1/ 00/ 150/ 003 98 tablets
EU/ 1/ 00/ 150/ 008 14 tablets EU/ 1/ 00/ 150/ 004 28 tablets EU/ 1/ 00/ 150/ 019 30 tablets EU/ 1/ 00/ 150/ 005 50 tablets EU/ 1/ 00/ 150/ 010 56 tablets EU/ 1/ 00/ 150/ 020 84 tablets EU/ 1/ 00/ 150/ 021 90 tablets EU/ 1/ 00/ 150/ 006 98 tablets
EU/ 1/ 00/ 150/ 011 14 tablets EU/ 1/ 00/ 150/ 012 28 tablets EU/ 1/ 00/ 150/ 022 30 tablets EU/ 1/ 00/ 150/ 013 50 tablets EU/ 1/ 00/ 150/ 014 56 tablets EU/ 1/ 00/ 150/ 023 84 tablets EU/ 1/ 00/ 150/ 024 90 tablets EU/ 1/ 00/ 150/ 015 98 tablets
EU/ 1/ 00/ 152/ 009 - 1 vial with bioset® and 1 pre-filled syringe without needle EU/ 1/ 00/ 152/ 010 - 10 vials with bioset® and 10 pre-filled syringes without needles EU/ 1/ 00/ 152/ 011 - 20 vials with bioset® and 20 pre-filled syringes without needles EU/ 1/ 00/ 152/ 012 - 50 vials with bioset® and 50 pre-filled syringes without needles EU/ 1/ 00/ 152/ 013 - 1 vial with bioset® and 1 pre-filled syringe with 1 needle EU/ 1/ 00/ 152/ 014 - 10 vials with bioset® and 10 pre-filled syringes with 10 needles EU/ 1/ 00/ 152/ 015 - 20 vials with bioset® and 20 pre-filled syringes with 20 needles EU/ 1/ 00/ 152/ 016 - 50 vials with bioset® and 50 pre-filled syringes with 50 needles EU/ 1/ 00/ 152/ 017 - 1 vial with bioset® and 1 pre-filled syringe with 2 needles EU/ 1/ 00/ 152/ 018 - 10 vials with bioset® and 10 pre-filled syringes with 20 needles
EU/ 1/ 00/ 152/ 009 EU/ 1/ 00/ 152/ 010 EU/ 1/ 00/ 152/ 011 EU/ 1/ 00/ 152/ 012 EU/ 1/ 00/ 152/ 013 EU/ 1/ 00/ 152/ 014 19 EU/ 1/ 00/ 152/ 015 EU/ 1/ 00/ 152/ 016 EU/ 1/ 00/ 152/ 017 EU/ 1/ 00/ 152/ 018
EU/ 1/ 00/ 153/ 001 - 1 pre-filled syringe without needle EU/ 1/ 00/ 153/ 002 - 10 pre-filled syringes without needles EU/ 1/ 00/ 153/ 003 - 20 pre-filled syringes without needles EU/ 1/ 00/ 153/ 004 - 50 pre-filled syringes without needles EU/ 1/ 00/ 153/ 005 - 1 pre-filled syringe with 1 needle EU/ 1/ 00/ 153/ 006 - 10 pre-filled syringes with 10 needles EU/ 1/ 00/ 153/ 007 - 20 pre-filled syringes with 20 needles EU/ 1/ 00/ 153/ 008 - 50 pre-filled syringes with 50 needles EU/ 1/ 00/ 153/ 009 - 1 pre-filled syringe with 2 needles EU/ 1/ 00/ 153/ 010 - 10 pre-filled syringes with 20 needles
EU/ 1/ 00/ 155/ 001 (1vial/ 1 ampoule) EU/ 1/ 00/ 155/ 002 (3 vials/ 3 ampoules) EU/ 1/ 00/ 155/ 003 (10 vials/ 10 ampoules) EU/ 1/ 00/ 155/ 004 (1 vial/ 1 vial) EU/ 1/ 00/ 155/ 005 (3 vial/ 3 vials) EU/ 1/ 00/ 155/ 006 (10 vials/ 10 vials)
EU/ 1/ 00/ 156/ 002 - Blister pack (60 Tablets) EU/ 1/ 00/ 156/ 003 -Bottle pack (60 Tablets)
EU/ 1/ 00/ 166/ 001 – 2500 U EU/ 1/ 00/ 166/ 002 – 5000 U EU/ 1/ 00/ 166/ 003 – 10,000 U
EU/ 1/ 00/ 167/ 001 EU/ 1/ 00/ 167/ 002 EU/ 1/ 00/ 167/ 005
EU/ 1/ 03/ 251/ 001 30 tablets EU/ 1/ 03/ 251/ 002 3 x 30 tablets
EU/1/03/262/007 1 hard capsule EU/1/03/262/008 5 x 1 hard capsule
EU/1/03/265/003 1 film-coated tablet EU/1/03/265/004 3 film-coated tablets
EU/1/03/266/003 1 film-coated tablet EU/1/03/266/004 3 film-coated tablets
EU/ 1/ 04/ 276/ 001 14 x 1 tablets EU/ 1/ 04/ 276/ 002 28 x 1 tablets EU/ 1/ 04/ 276/ 003 49 x 1 tablets EU/ 1/ 04/ 276/ 004 56 x 1 tablets EU/ 1/ 04/ 276/ 005 98 x 1 tablets
EU/ 1/ 04/ 276/ 011 14 x 1 tablets EU/ 1/ 04/ 276/ 012 28 x 1 tablets EU/ 1/ 04/ 276/ 013 49 x 1 tablets EU/ 1/ 04/ 276/ 014 56 x 1 tablets EU/ 1/ 04/ 276/ 015 98 x 1 tablets
EU/ 1/ 04/ 276/ 016 14 x 1 tablets EU/ 1/ 04/ 276/ 017 28 x 1 tablets EU/ 1/ 04/ 276/ 018 49 x 1 tablets EU/ 1/ 04/ 276/ 019 56 x 1 tablets EU/ 1/ 04/ 276/ 020 98 x 1 tablets
EU/ 1/ 04/ 276/ 024 14 x 1 orodispersible tablets EU/ 1/ 04/ 276/ 025 28 x 1 orodispersible tablets EU/ 1/ 04/ 276/ 026 49 x 1 orodispersible tablets
EU/ 1/ 04/ 276/ 027 14 x 1 orodispersible tablets EU/ 1/ 04/ 276/ 028 28 x 1 orodispersible tablets EU/ 1/ 04/ 276/ 029 49 x 1 orodispersible tablets
EU/ 1/ 04/ 276/ 030 14 x 1 orodispersible tablets EU/ 1/ 04/ 276/ 031 28 x 1 orodispersible tablets EU/ 1/ 04/ 276/ 032 49 x 1 orodispersible tablets
EU/1/04/279/017 – 019 EU/1/04/279/028 EU/1/04/279/040
EU/1/04/279/023 – 025 EU/1/04/279/029 EU/1/04/279/032 EU/04/279/043
EU/ 1/ 04/ 285/ 001 1 vial of 10ml EU/ 1/ 04/ 285/ 002 2 vials of 10ml.
EU/ 1/ 04/ 285/ 021 1 cartridge of 3ml EU/ 1/ 04/ 285/ 022 3 cartridges of 3ml EU/ 1/ 04/ 285/ 023 4 cartridges of 3ml EU/ 1/ 04/ 285/ 024 5 cartridges of 3ml EU/ 1/ 04/ 285/ 025 6 cartridges of 3ml EU/ 1/ 04/ 285/ 026 8 cartridges of 3ml EU/ 1/ 04/ 285/ 027 9 cartridges of 3ml EU/ 1/ 04/ 285/ 028 10 cartridges of 3ml
EU/ 1/ 04/ 287/ 004 56 sachets EU/ 1/ 04/ 287/ 005/ 84 sachets EU/ 1/ 04/ 287/ 006 100 sachets
EU/ 1/ 04/ 292/ 001 – carton of 14 tablets EU/ 1/ 04/ 292/ 002 – carton of 28 tablets EU/ 1/ 04/ 292/ 003 – carton of 84 tablets
EU/ 1/ 04/ 292/ 005 – carton of 14 tablets EU/ 1/ 04/ 292/ 006 – carton of 28 tablets EU/ 1/ 04/ 292/ 007 – carton of 84 tablets
EU/ 1/ 04/ 292/ 009 – carton of 14 tablets EU/ 1/ 04/ 292/ 010 – carton of 28 tablets EU/ 1/ 04/ 292/ 011 – carton of 84 tablets
EU/ 1/ 04/ 293/ 001 – carton of 14 tablets EU/ 1/ 04/ 293/ 002 – carton of 28 tablets EU/ 1/ 04/ 293/ 003 – carton of 84 tablets
EU/ 1/ 04/ 293/ 005 – carton of 14 tablets EU/ 1/ 04/ 293/ 006 – carton of 28 tablets EU/ 1/ 04/ 293/ 007 – carton of 84 tablets
EU/ 1/ 04/ 293/ 009 – carton of 14 tablets EU/ 1/ 04/ 293/ 010 – carton of 28 tablets EU/ 1/ 04/ 293/ 011 – carton of 84 tablets
EU/ 1/ 04/ 300/ 001 – 100 mg/ 4 ml vial EU/ 1/ 04/ 300/ 002 – 400 mg/ 16 ml vial
EU/ 1/ 04/ 305/ 001 30 film-coated tablets EU/ 1/ 04/ 305/ 002 3 x 30 film-coated tablets
EU/1/05/329/001 1 g / 10 ml EU/1/05/329/002 2.5 g / 25 ml EU/1/05/329/003 5 g / 50 ml EU/1/05/329/004 10 g / 100 ml EU/1/05/329/005 20 g / 200 ml
EU/1/05/329/003 5 g / 50 ml EU/1/05/329/004 10 g / 100 ml EU/1/05/329/005 20 g / 200 ml
EU/1/05/330/001 EU/1/05/330/002 EU/1/05/330/003 EU/1/05/330/004
EU/ 1/ 06/ 334/ 001 3 vials EU/ 1/ 06/ 334/ 002 4 vials EU/ 1/ 06/ 334/ 003 10 vials EU/ 1/ 06/ 334/ 004 20 vials
EU/ 1/ 06/ 337/ 003 EU/ 1/ 06/ 337/ 004 EU/ 1/ 06/ 337/ 005 EU/ 1/ 06/ 337/ 006 EU/ 1/ 06/ 337/ 007 EU/ 1/ 06/ 337/ 008 EU/ 1/ 06/ 337/ 009 EU/ 1/ 06/ 337/ 010 EU/ 1/ 06/ 337/ 011 EU/ 1/ 06/ 337/ 012 EU/ 1/ 06/ 337/ 013
EU/1/06/339/002 6 dual-chamber cartridges per pack.
EU/ 1/ 06/ 341/ 001 – pack of 1 EU/ 1/ 06/ 341/ 002 – pack of 10
EU/ 1/ 06/ 341/ 003 – pack of 1 EU/ 1/ 06/ 341/ 004 – pack of 10
EU/ 1/ 06/ 341/ 005 – pack of 1 EU/ 1/ 06/ 341/ 006 – pack of 10 EU/ 1/ 06/ 341/ 007 – pack of 20
EU/ 1/ 06/ 341/ 008 - pack of 1 EU/ 1/ 06/ 341/ 009 - pack of 10 EU/ 1/ 06/ 341/ 010 - pack of 20
EU/ 1/ 06/ 341/ 011– pack of 1 EU/ 1/ 06/ 341/ 012 – pack of 10 EU/ 1/ 06/ 341/ 013– pack of 20
EU/ 1/ 06/ 343/ 001 EU/ 1/ 06/ 343/ 002 EU/ 1/ 06/ 343/ 003 EU/ 1/ 06/ 343/ 004
EU/ 1/ 06/ 343/ 003 EU/ 1/ 06/ 343/ 006
EU/ 1/ 06/ 343/ 004 EU/ 1/ 06/ 343/ 007
MARKETING AUTHORISATION NUMBER(S) lon EU/ 1/ 06/ 344/ 001 EU/ 1/ 06/ 344/ 002 EU/ 1/ 06/ 344/ 003 EU/ 1/ 06/ 344/ 004 no
EU/ 1/ 06/ 345/ 001 EU/ 1/ 06/ 345/ 002 ol
EU/1/06/348/001 pack of 1 tube EU/1/06/348/002 pack of 10 tubes
EU/ 1/ 06/ 353/ 001 (14 film-coated tablets in blisters) EU/ 1/ 06/ 353/ 002 (28 film-coated tablets in blisters) EU/ 1/ 06/ 353/ 003 (56 film-coated tablets in blisters) EU/ 1/ 06/ 353/ 004 (84 film-coated tablets in blisters)
EU/ 1/ 06/ 354/ 001 14 tablets EU/ 1/ 06/ 354/ 002 28 tablets EU/ 1/ 06/ 354/ 003 30 tablets EU/ 1/ 06/ 354/ 004 50 tablets EU/ 1/ 06/ 354/ 005 56 tablets EU/ 1/ 06/ 354/ 006 60 tablets EU/ 1/ 06/ 354/ 007 90 tablets EU/ 1/ 06/ 354/ 008 98 tablets EU/ 1/ 06/ 354/ 009 180 tablets
EU/1/06/357/001 – pack of 1 EU/1/06/357/002– pack of 10 EU/1/06/357/018– pack of 20
EU/1/06/357/003 – pack of 1 EU/1/06/357/004 – pack of 10 EU/1/06/357/019 – pack of 20
EU/1/06/357/005 – pack of 1 EU/1/06/357/006 – pack of 10 EU/1/06/357/020 – pack of 20
EU/1/06/357/007– pack of 1 EU/1/06/357/008 – pack of 10 EU/1/06/357/021 – pack of 20
EU/1/06/357/009– pack of 1 EU/1/06/357/010 – pack of 10 EU/1/06/357/011 – pack of 20
EU/1/06/357/012– pack of 1 EU/1/06/357/013 – pack of 10 EU/1/06/357/014 – pack of 20
EU/1/06/357/015– pack of 1 EU/1/06/357/016 – pack of 10 EU/1/06/357/017 – pack of 20
EU/ 1/ 06/ 358/ 001 – pack of 1 EU/ 1/ 06/ 358/ 002– pack of 10 EU/ 1/ 06/ 358/ 018– pack of 20
EU/ 1/ 06/ 358/ 003 – pack of 1 EU/ 1/ 06/ 358/ 004 – pack of 10 EU/ 1/ 06/ 358/ 019 – pack of 20
EU/ 1/ 06/ 358/ 005 – pack of 1 EU/ 1/ 06/ 358/ 006 – pack of 10 EU/ 1/ 06/ 358/ 020 – pack of 20
EU/ 1/ 06/ 358/ 007– pack of 1 EU/ 1/ 06/ 358/ 008 – pack of 10 EU/ 1/ 06/ 358/ 021 – pack of 20
EU/ 1/ 06/ 358/ 009– pack of 1 EU/ 1/ 06/ 358/ 010 – pack of 10 EU/ 1/ 06/ 358/ 011 – pack of 20
EU/ 1/ 06/ 358/ 012– pack of 1 EU/ 1/ 06/ 358/ 013 – pack of 10 EU/ 1/ 06/ 358/ 014 – pack of 20
EU/ 1/ 06/ 358/ 015– pack of 1 EU/ 1/ 06/ 358/ 016 – pack of 10 EU/ 1/ 06/ 358/ 017 – pack of 20
EU/ 1/ 06/ 361/ 001 4 single-dose vials EU/ 1/ 06/ 361/ 002 1 single-dose vial
EU number EU/ 1/ 06/ 362/ 001 EU/ 1/ 06/ 362/ 002 EU/ 1/ 06/ 362/ 003 EU/ 1/ 06/ 362/ 004
EU/ 1/ 06/ 363/ 004 - 56 film-coated tablets (blisters) EU/ 1/ 06/ 363/ 007 - 60 x 1 film-coated tablets (unit-dose blisters) EU/ 1/ 06/ 363/ 001 - 60 film-coated tablets (bottle)
EU/ 1/ 06/ 363/ 005 - 56 film-coated tablets (blisters) EU/ 1/ 06/ 363/ 008 - 60 x 1 film-coated tablets (unit-dose blisters) EU/ 1/ 06/ 363/ 002 - 60 film-coated tablets (bottle)
EU/ 1/ 06/ 363/ 006 - 56 film-coated tablets (blisters) EU/ 1/ 06/ 363/ 009 - 60 x 1 film-coated tablets (unit-dose blisters) EU/ 1/ 06/ 363/ 003 - 60 film-coated tablets (bottle)
EU/ 1/ 06/ 363/ 011 - 30 x 1 film-coated tablets (unit-dose blisters) EU/ 1/ 06/ 363/ 010 - 30 film-coated tablets (bottle)
EU/ 1/ 06/ 364/ 001 (2 tablets) EU/ 1/ 06/ 364/ 002 (4 tablets) EU/ 1/ 06/ 364/ 003 (6 tablets) EU/ 1/ 06/ 364/ 004 (12 tablets) EU/ 1/ 06/ 364/ 005 (40 tablets)
EU/ 1/ 06/ 364/ 001 – 2 tablets EU/ 1/ 06/ 364/ 002 – 4 tablets EU/ 1/ 06/ 364/ 003 – 6 tablets EU/ 1/ 06/ 364/ 004 – 12 tablets EU/ 1/ 06/ 364/ 005 – 40 tablets
EU/ 1/ 06/ 364/ 001(2 tablets) EU/ 1/ 06/ 364/ 002 (4 tablets) EU/ 1/ 06/ 364/ 003 (6 tablets) EU/ 1/ 06/ 364/ 004 (12 tablets) EU/ 1/ 06/ 364/ 005 (40 tablets)
EU Number EU/ 1/ 06/ 364/ 001 EU/ 1/ 06/ 364/ 002 EU/ 1/ 06/ 364/ 003 EU/ 1/ 06/ 364/ 004 EU/ 1/ 06/ 364/ 005 EU/ 1/ 06/ 364/ 006 EU/ 1/ 06/ 364/ 007 EU/ 1/ 06/ 364/ 008 EU/ 1/ 06/ 364/ 009
EU/ 1/ 06/ 364/ 006 (2 tablets) EU/ 1/ 06/ 364/ 007 (4 tablets) EU/ 1/ 06/ 364/ 008 (12 tablets) EU/ 1/ 06/ 364/ 009 (40 tablets)
EU/ 1/ 06/ 364/ 006 – 2 tablets EU/ 1/ 06/ 364/ 007 – 4 tablets EU/ 1/ 06/ 364/ 008 – 12 tablets EU/ 1/ 06/ 364/ 009 – 40 tablets
EU/ 1/ 06/ 366/ 005 14 tablets EU/ 1/ 06/ 366/ 006 28 tablets EU/ 1/ 06/ 366/ 007 30 tablets EU/ 1/ 06/ 366/ 008 50 tablets EU/ 1/ 06/ 366/ 009 90 tablets EU/ 1/ 06/ 366/ 010 98 tablets
EU/ 1/ 06/ 366/ 011 14 tablets EU/ 1/ 06/ 366/ 012 28 tablets EU/ 1/ 06/ 366/ 013 30 tablets EU/ 1/ 06/ 366/ 014 50 tablets EU/ 1/ 06/ 366/ 015 90 tablets EU/ 1/ 06/ 366/ 016 98 tablets
EU/ 1/ 06/ 366/ 017 14 tablets EU/ 1/ 06/ 366/ 018 28 tablets EU/ 1/ 06/ 366/ 019 30 tablets EU/ 1/ 06/ 366/ 020 50 tablets EU/ 1/ 06/ 366/ 021 90 tablets EU/ 1/ 06/ 366/ 022 98 tablets
EU/ 1/ 06/ 367/ 001 30 capsules EU/ 1/ 06/ 367/ 002 60 capsules EU/ 1/ 06/ 367/ 003 90 capsules
EU/ 1/ 06/ 367/ 004 30 capsules EU/ 1/ 06/ 367/ 005 60 capsules EU/ 1/ 06/ 367/ 006 90 capsules
EU/ 1/ 06/ 368/ 001 (1 vial of 10 ml) EU/ 1/ 06/ 368/ 002 (5 vials of 10 ml)
EU/ 1/ 06/ 368/ 003 (1 vial of 10 ml) EU/ 1/ 06/ 368/ 004 (5 vials of 10 ml)
EU/ 1/ 06/ 368/ 007 (1 vial of 10 ml) EU/ 1/ 06/ 368/ 008 (5 vials of 10 ml)
EU/ 1/ 06/ 368/ 009 (1 vial of 10 ml) EU/ 1/ 06/ 368/ 010 (5 vials of 10 ml)
EU/ 1/ 06/ 368/ 011 (1 vial of 5 ml) EU/ 1/ 06/ 368/ 012 (5 vials of 5 ml)
EU/ 1/ 06/ 368/ 016 (3 pens of 3 ml) EU/ 1/ 06/ 368/ 017 (4 pens of 3 ml) EU/ 1/ 06/ 368/ 018 (5 pens of 3 ml) EU/ 1/ 06/ 368/ 103 (6 pens of 3 ml) EU/ 1/ 06/ 368/ 108 (9 pens of 3 ml) EU/ 1/ 06/ 368/ 019 (10 pens of 3 ml)
EU/ 1/ 06/ 368/ 025 (3 pens of 3 ml) EU/ 1/ 06/ 368/ 026 (4 pens of 3 ml) EU/ 1/ 06/ 368/ 027 (5 pens of 3 ml) EU/ 1/ 06/ 368/ 104 (6 pens of 3 ml) EU/ 1/ 06/ 368/ 109 (9 pens of 3 ml) EU/ 1/ 06/ 368/ 028 (10 pens of 3 ml)
EU/ 1/ 06/ 368/ 029 (1 vial of 5 ml) EU/ 1/ 06/ 368/ 030 (5 vials of 5 ml)
EU/ 1/ 06/ 368/ 034 (3 pens of 3 ml) EU/ 1/ 06/ 368/ 035 (4 pens of 3 ml) EU/ 1/ 06/ 368/ 036 (5 pens of 3 ml) EU/ 1/ 06/ 368/ 105 (5 pens of 3 ml) EU/ 1/ 06/ 368/ 110 (5 pens of 3 ml) EU/ 1/ 06/ 368/ 037 (10 pens of 3 ml)
EU/ 1/ 06/ 368/ 038 (1 vial of 5 ml) EU/ 1/ 06/ 368/ 039 (5 vials of 5 ml)
EU/ 1/ 06/ 368/ 043 (3 pens of 3 ml) EU/ 1/ 06/ 368/ 044 (4 pens of 3 ml) EU/ 1/ 06/ 368/ 045 (5 pens of 3 ml) EU/ 1/ 06/ 368/ 106 (6 pens of 3 ml) EU/ 1/ 06/ 368/ 111 (9 pens of 3 ml) EU/ 1/ 06/ 368/ 046 (10 pens of 3 ml)
EU/ 1/ 06/ 368/ 047 (1 vial of 5 ml) EU/ 1/ 06/ 368/ 048 (5 vials of 5 ml)
EU/ 1/ 06/ 368/ 005 (1 vial of 10 ml) EU/ 1/ 06/ 368/ 006 (5 vials of 10 ml)
EU/ 1/ 06/ 368/ 052 (3 pens of 3 ml) EU/ 1/ 06/ 368/ 053 (4 pens of 3 ml) EU/ 1/ 06/ 368/ 054 (5 pens of 3 ml) EU/ 1/ 06/ 368/ 107 (6 pens of 3 ml) EU/ 1/ 06/ 368/ 112 (9 pens of 3 ml) EU/ 1/ 06/ 368/ 055 (10 pens of 3 ml)
EU/ 1/ 06/ 368/ 058 (3 cartridges of 3 ml) EU/ 1/ 06/ 368/ 059 (4 cartridges of 3 ml) EU/ 1/ 06/ 368/ 060 (5 cartridges of 3 ml) EU/ 1/ 06/ 368/ 061 (6 cartridges of 3 ml) EU/ 1/ 06/ 368/ 062 (9 cartridges of 3 ml) EU/ 1/ 06/ 368/ 063 (10 cartridges of 3 ml)
EU/ 1/ 06/ 368/ 064 (3 cartridges of 3 ml) EU/ 1/ 06/ 368/ 065 (4 cartridges of 3 ml) EU/ 1/ 06/ 368/ 066 (5 cartridges of 3 ml) EU/ 1/ 06/ 368/ 067 (6 cartridges of 3 ml) EU/ 1/ 06/ 368/ 068 (9 cartridges of 3 ml) EU/ 1/ 06/ 368/ 069 (10 cartridges of 3 ml)
EU/ 1/ 06/ 368/ 070 (3 cartridges of 3 ml) EU/ 1/ 06/ 368/ 071 (4 cartridges of 3 ml) EU/ 1/ 06/ 368/ 072 (5 cartridges of 3 ml) EU/ 1/ 06/ 368/ 073 (6 cartridges of 3 ml) EU/ 1/ 06/ 368/ 074 (9 cartridges of 3 ml) EU/ 1/ 06/ 368/ 075 (10 cartridges of 3 ml)
EU/ 1/ 06/ 368/ 076 (3 cartridges of 3 ml) EU/ 1/ 06/ 368/ 077 (4 cartridges of 3 ml) EU/ 1/ 06/ 368/ 078 (5 cartridges of 3 ml) EU/ 1/ 06/ 368/ 079 (6 cartridges of 3 ml) EU/ 1/ 06/ 368/ 080 (9 cartridges of 3 ml) EU/ 1/ 06/ 368/ 081 (10 cartridges of 3 ml)
EU/ 1/ 06/ 368/ 082 (3 cartridges of 3 ml) EU/ 1/ 06/ 368/ 083 (4 cartridges of 3 ml) EU/ 1/ 06/ 368/ 084 (5 cartridges of 3 ml) EU/ 1/ 06/ 368/ 085 (6 cartridges of 3 ml) EU/ 1/ 06/ 368/ 086 (9 cartridges of 3 ml) EU/ 1/ 06/ 368/ 087 (10 cartridges of 3 ml)
EU/ 1/ 06/ 368/ 088 (3 cartridges of 3 ml) EU/ 1/ 06/ 368/ 013 (4 cartridges of 3 ml) EU/ 1/ 06/ 368/ 014 (5 cartridges of 3 ml) EU/ 1/ 06/ 368/ 093 (6 cartridges of 3 ml) EU/ 1/ 06/ 368/ 098 (9 cartridges of 3 ml) EU/ 1/ 06/ 368/ 015 (10 cartridges of 3 ml)
EU/ 1/ 06/ 368/ 089 (3 cartridges of 3 ml) EU/ 1/ 06/ 368/ 022 (4 cartridges of 3 ml) EU/ 1/ 06/ 368/ 023 (5 cartridges of 3 ml) EU/ 1/ 06/ 368/ 094 (6 cartridges of 3 ml) EU/ 1/ 06/ 368/ 099 (9 cartridges of 3 ml) EU/ 1/ 06/ 368/ 024 (10 cartridges of 3 ml)
EU/ 1/ 06/ 368/ 025 EU/ 1/ 06/ 368/ 026 EU/ 1/ 06/ 368/ 027 EU/ 1/ 06/ 368/ 104 EU/ 1/ 06/ 368/ 109 EU/ 1/ 06/ 368/ 028
EU/ 1/ 06/ 368/ 090 (3 cartridges of 3 ml) EU/ 1/ 06/ 368/ 031 (4 cartridges of 3 ml) EU/ 1/ 06/ 368/ 032 (5 cartridges of 3 ml) EU/ 1/ 06/ 368/ 095 (6 cartridges of 3 ml) EU/ 1/ 06/ 368/ 100 (9 cartridges of 3 ml) EU/ 1/ 06/ 368/ 033 (10 cartridges of 3 ml)
EU/ 1/ 06/ 368/ 091 (3 cartridges of 3 ml) EU/ 1/ 06/ 368/ 040 (4 cartridges of 3 ml) EU/ 1/ 06/ 368/ 041 (5 cartridges of 3 ml) EU/ 1/ 06/ 368/ 096 (6 cartridges of 3 ml) EU/ 1/ 06/ 368/ 101 (9 cartridges of 3 ml) EU/ 1/ 06/ 368/ 042 (10 cartridges of 3 ml)
EU/ 1/ 06/ 368/ 092 (3 cartridges of 3 ml) EU/ 1/ 06/ 368/ 049 (4 cartridges of 3 ml) EU/ 1/ 06/ 368/ 050 (5 cartridges of 3 ml) EU/ 1/ 06/ 368/ 097 (6 cartridges of 3 ml) EU/ 1/ 06/ 368/ 102 (9 cartridges of 3 ml) EU/ 1/ 06/ 368/ 051 (10 cartridges of 3 ml)
EU/ 1/ 06/ 368/ XXX (3 pens of 3 ml) EU/ 1/ 06/ 368/ XXX (4 pens of 3 ml) EU/ 1/ 06/ 368/ XXX (5 pens of 3 ml) EU/ 1/ 06/ 368/ XXX (6 pens of 3 ml) EU/ 1/ 06/ 368/ XXX (9 pens of 3 ml) EU/ 1/ 06/ 368/ XXX (10 pens of 3 ml)
EU/ 1/ 06/ 369/ 001 14 tablets EU/ 1/ 06/ 369/ 002 28 tablets EU/ 1/ 06/ 369/ 003 56 tablets EU/ 1/ 06/ 369/ 004 56 x 1 tablets EU/ 1/ 06/ 369/ 005 98 tablets
EU/ 1/ 06/ 369/ 006 14 tablets EU/ 1/ 06/ 369/ 007 28 tablets EU/ 1/ 06/ 369/ 008 56 tablets EU/ 1/ 06/ 369/ 009 56 x 1 tablets EU/ 1/ 06/ 369/ 010 98 tablets
EU/ 1/ 06/ 369/ 011 14 tablets EU/ 1/ 06/ 369/ 012 28 tablets EU/ 1/ 06/ 369/ 013 56 tablets EU/ 1/ 06/ 369/ 014 56 x 1 tablets EU/ 1/ 06/ 369/ 015 84 tablets EU/ 1/ 06/ 369/ 016 98 tablets
EU/ 1/ 06/ 369/ 017 14 tablets EU/ 1/ 06/ 369/ 018 28 tablets EU/ 1/ 06/ 369/ 019 56 tablets EU/ 1/ 06/ 369/ 020 56 x 1 tablets EU/ 1/ 06/ 369/ 021 84 tablets EU/ 1/ 06/ 369/ 022 98 tablets
EU/ 1/ 06/ 369/ 023 14 tablets EU/ 1/ 06/ 369/ 024 28 tablets EU/ 1/ 06/ 369/ 025 56 tablets EU/ 1/ 06/ 369/ 026 56 x 1 tablets EU/ 1/ 06/ 369/ 027 84 tablets EU/ 1/ 06/ 369/ 028 98 tablets
EU Number EU/ 1/ 06/ 371/ 001 EU/ 1/ 06/ 371/ 002 EU/ 1/ 06/ 371/ 003 EU/ 1/ 06/ 371/ 004 EU/ 1/ 06/ 371/ 005 EU/ 1/ 06/ 371/ 006 EU/ 1/ 06/ 371/ 007 EU/ 1/ 06/ 371/ 008 EU/ 1/ 06/ 371/ 009 EU/ 1/ 06/ 371/ 010 EU/ 1/ 06/ 371/ 011 EU/ 1/ 06/ 371/ 012 EU/ 1/ 06/ 371/ 013 EU/ 1/ 06/ 371/ 014 EU/ 1/ 06/ 371/ 015 EU/ 1/ 06/ 371/ 016 EU/ 1/ 06/ 371/ 017 EU/ 1/ 06/ 371/ 018 EU/ 1/ 06/ 371/ 019 EU/ 1/ 06/ 371/ 020 EU/ 1/ 06/ 371/ 021 EU/ 1/ 06/ 371/ 022 EU/ 1/ 06/ 371/ 023 EU/ 1/ 06/ 371/ 024 EU/ 1/ 06/ 371/ 025 EU/ 1/ 06/ 371/ 026 EU/ 1/ 06/ 371/ 027 EU/ 1/ 06/ 371/ 028 EU/ 1/ 06/ 371/ 029 EU/ 1/ 06/ 371/ 030 EU/ 1/ 06/ 371/ 031 EU/ 1/ 06/ 371/ 032 EU/ 1/ 06/ 371/ 033 EU/ 1/ 06/ 371/ 034 EU/ 1/ 06/ 371/ 035 EU/ 1/ 06/ 371/ 036
EU Number EU/ 1/ 06/ 372/ 001 EU/ 1/ 06/ 372/ 002 EU/ 1/ 06/ 372/ 003 EU/ 1/ 06/ 372/ 004 EU/ 1/ 06/ 372/ 005 EU/ 1/ 06/ 372/ 006 EU/ 1/ 06/ 372/ 007 EU/ 1/ 06/ 372/ 008 EU/ 1/ 06/ 372/ 009 EU/ 1/ 06/ 372/ 010 EU/ 1/ 06/ 372/ 011 EU/ 1/ 06/ 372/ 012 EU/ 1/ 06/ 372/ 013 EU/ 1/ 06/ 372/ 014 EU/ 1/ 06/ 372/ 015 EU/ 1/ 06/ 372/ 016 EU/ 1/ 06/ 372/ 017 EU/ 1/ 06/ 372/ 018 EU/ 1/ 06/ 372/ 019 EU/ 1/ 06/ 372/ 020 EU/ 1/ 06/ 372/ 021 EU/ 1/ 06/ 372/ 022 EU/ 1/ 06/ 372/ 023 EU/ 1/ 06/ 372/ 024 EU/ 1/ 06/ 372/ 025 EU/ 1/ 06/ 372/ 026 EU/ 1/ 06/ 372/ 027 EU/ 1/ 06/ 372/ 028 EU/ 1/ 06/ 372/ 029 EU/ 1/ 06/ 372/ 030 EU/ 1/ 06/ 372/ 031 EU/ 1/ 06/ 372/ 032 EU/ 1/ 06/ 372/ 033 EU/ 1/ 06/ 372/ 034 EU/ 1/ 06/ 372/ 035 EU/ 1/ 06/ 372/ 036
EU Number EU/ 1/ 06/ 373/ 001 EU/ 1/ 06/ 373/ 002 EU/ 1/ 06/ 373/ 003 EU/ 1/ 06/ 373/ 004 EU/ 1/ 06/ 373/ 005 EU/ 1/ 06/ 373/ 006 EU/ 1/ 06/ 373/ 007 EU/ 1/ 06/ 373/ 008 EU/ 1/ 06/ 373/ 009 EU/ 1/ 06/ 373/ 010 EU/ 1/ 06/ 373/ 011 EU/ 1/ 06/ 373/ 012 EU/ 1/ 06/ 373/ 013 EU/ 1/ 06/ 373/ 014 EU/ 1/ 06/ 373/ 015 EU/ 1/ 06/ 373/ 016 EU/ 1/ 06/ 373/ 017 EU/ 1/ 06/ 373/ 018 EU/ 1/ 06/ 373/ 019 EU/ 1/ 06/ 373/ 020 EU/ 1/ 06/ 373/ 021 EU/ 1/ 06/ 373/ 022 EU/ 1/ 06/ 373/ 023 EU/ 1/ 06/ 373/ 024 EU/ 1/ 06/ 373/ 025 EU/ 1/ 06/ 373/ 026 EU/ 1/ 06/ 373/ 027 EU/ 1/ 06/ 373/ 028 EU/ 1/ 06/ 373/ 029 EU/ 1/ 06/ 373/ 030 EU/ 1/ 06/ 373/ 031 EU/ 1/ 06/ 373/ 032 EU/ 1/ 06/ 373/ 033 EU/ 1/ 06/ 373/ 034 EU/ 1/ 06/ 373/ 035 EU/ 1/ 06/ 373/ 036
EU/ 1/ 06/ 375/ 006 14 tablets EU/ 1/ 06/ 375/ 007 28 tablets EU/ 1/ 06/ 375/ 008 56 tablets EU/ 1/ 06/ 375/ 009 56 x 1 tablets EU/ 1/ 06/ 375/ 010 98 tablets
EU/ 1/ 06/ 375/ 011 14 tablets EU/ 1/ 06/ 375/ 012 28 tablets EU/ 1/ 06/ 375/ 013 56 tablets EU/ 1/ 06/ 375/ 014 56 x 1 tablets EU/ 1/ 06/ 375/ 015 98 tablets
EU/ 1/ 06/ 375/ 016 14 tablets EU/ 1/ 06/ 375/ 017 28 tablets EU/ 1/ 06/ 375/ 018 56 tablets EU/ 1/ 06/ 375/ 019 56 x 1 tablets EU/ 1/ 06/ 375/ 020 84 tablets EU/ 1/ 06/ 375/ 021 98 tablets
EU/ 1/ 06/ 375/ 022 14 tablets EU/ 1/ 06/ 375/ 023 28 tablets EU/ 1/ 06/ 375/ 024 56 tablets EU/ 1/ 06/ 375/ 025 56 x 1 tablets EU/ 1/ 06/ 375/ 026 84 tablets EU/ 1/ 06/ 375/ 027 98 tablets
EU/ 1/ 06/ 375/ 028 14 tablets EU/ 1/ 06/ 375/ 029 28 tablets EU/ 1/ 06/ 375/ 030 56 tablets EU/ 1/ 06/ 375/ 031 56 x 1 tablets EU/ 1/ 06/ 375/ 032 84 tablets EU/ 1/ 06/ 375/ 033 98 tablets
EU/ 1/ 06/ 376/ 001 14 tablets EU/ 1/ 06/ 376/ 002 28 tablets EU/ 1/ 06/ 376/ 003 56 tablets EU/ 1/ 06/ 376/ 004 56 x 1 tablets EU/ 1/ 06/ 376/ 005 98 tablets
EU/ 1/ 06/ 376/ 006 14 tablets EU/ 1/ 06/ 376/ 007 28 tablets EU/ 1/ 06/ 376/ 008 56 tablets EU/ 1/ 06/ 376/ 009 56 x 1 tablets EU/ 1/ 06/ 376/ 010 98 tablets
EU/ 1/ 06/ 376/ 011 14 tablets EU/ 1/ 06/ 376/ 012 28 tablets EU/ 1/ 06/ 376/ 013 56 tablets EU/ 1/ 06/ 376/ 014 56 x 1 tablets EU/ 1/ 06/ 376/ 015 98 tablets
EU/ 1/ 06/ 376/ 016 14 tablets EU/ 1/ 06/ 376/ 017 28 tablets EU/ 1/ 06/ 376/ 018 56 tablets EU/ 1/ 06/ 376/ 019 56 x 1 tablets EU/ 1/ 06/ 376/ 020 84 tablets EU/ 1/ 06/ 376/ 021 98 tablets
EU/ 1/ 06/ 376/ 028 14 tablets EU/ 1/ 06/ 376/ 029 28 tablets EU/ 1/ 06/ 376/ 030 56 tablets EU/ 1/ 06/ 376/ 031 56 x 1 tablets EU/ 1/ 06/ 376/ 032 84 tablets EU/ 1/ 06/ 376/ 033 98 tablets
EU/ 1/ 06/ 377/ 001 14 tablets EU/ 1/ 06/ 377/ 002 28 tablets EU/ 1/ 06/ 377/ 003 56 tablets EU/ 1/ 06/ 377/ 004 56 x 1 tablets EU/ 1/ 06/ 377/ 005 98 tablets
EU/ 1/ 06/ 377/ 006 14 tablets EU/ 1/ 06/ 377/ 007 28 tablets EU/ 1/ 06/ 377/ 008 56 tablets EU/ 1/ 06/ 377/ 009 56 x 1 tablets EU/ 1/ 06/ 377/ 010 98 tablets
EU/ 1/ 06/ 377/ 011 14 tablets EU/ 1/ 06/ 377/ 012 28 tablets EU/ 1/ 06/ 377/ 013 56 tablets EU/ 1/ 06/ 377/ 014 56 x 1 tablets EU/ 1/ 06/ 377/ 015 84 tablets EU/ 1/ 06/ 377/ 016 98 tablets
EU/ 1/ 06/ 377/ 017 14 tablets EU/ 1/ 06/ 377/ 018 28 tablets EU/ 1/ 06/ 377/ 019 56 tablets EU/ 1/ 06/ 377/ 020 56 x 1 tablets EU/ 1/ 06/ 377/ 021 84 tablets EU/ 1/ 06/ 377/ 022 98 tablets
EU/ 1/ 06/ 377/ 023 14 tablets EU/ 1/ 06/ 377/ 024 28 tablets EU/ 1/ 06/ 377/ 025 56 tablets EU/ 1/ 06/ 377/ 026 56 x 1 tablets EU/ 1/ 06/ 377/ 027 84 tablets EU/ 1/ 06/ 377/ 028 98 tablets
EU/ 1/ 07/ 383/ 001 14 film-coated tablets EU/ 1/ 07/ 383/ 002 28 film-coated tablets EU/ 1/ 07/ 383/ 003 56 film-coated tablets EU/ 1/ 07/ 383/ 004 84 film-coated tablets EU/ 1/ 07/ 383/ 005 98 film-coated tablets EU/ 1/ 07/ 383/ 006 50 x 1 film-coated tablets
EU/ 1/ 07/ 383/ 013 14 film-coated tablets EU/ 1/ 07/ 383/ 014 28 film-coated tablets EU/ 1/ 07/ 383/ 015 56 film-coated tablets EU/ 1/ 07/ 383/ 016 84 film-coated tablets EU/ 1/ 07/ 383/ 017 98 film-coated tablets EU/ 1/ 07/ 383/ 018 50 x 1 film-coated tablets
EU/ 1/ 07/ 386/ 001 7 tablets EU/ 1/ 07/ 386/ 002 14 tablets EU/ 1/ 07/ 386/ 003 28 tablets EU/ 1/ 07/ 386/ 004 56 tablets EU/ 1/ 07/ 386/ 005 98 tablets EU/ 1/ 07/ 386/ 011 84 tablets
EU/ 1/ 07/ 386/ 006 7 tablets EU/ 1/ 07/ 386/ 007 14 tablets EU/ 1/ 07/ 386/ 008 28 tablets EU/ 1/ 07/ 386/ 009 56 tablets EU/ 1/ 07/ 386/ 010 98 tablets EU/ 1/ 07/ 386/ 012 84 tablets
EU/ 1/ 07/ 386/ 015 30 tablets EU/ 1/ 07/ 386/ 016 90 tablets
EU/ 1/ 07/ 387/ 001 30 capsules EU/ 1/ 07/ 387/ 002 50 capsules EU/ 1/ 07/ 387/ 009 100 capsules
EU/ 1/ 07/ 387/ 003 30 capsules EU/ 1/ 07/ 387/ 004 50 capsules EU/ 1/ 07/ 387/ 005 60 capsules EU/ 1/ 07/ 387/ 006 100 capsules
EU/1/07/390/002 5 g EU/1/07/390/003 10 g EU/1/07/390/004 15 g
EU/ 1/ 07/ 392/ 001 21 tablets EU/ 1/ 07/ 392/ 002 20 tablets
EU/ 1/ 07/ 398/ 001 (1 x 10 ml) EU/ 1/ 07/ 398/ 002 (10 x 10 ml) EU/ 1/ 07/ 398/ 003 (1 x 15 ml) EU/ 1/ 07/ 398/ 004 (10 x 15 ml) EU/ 1/ 07/ 398/ 005 (1 x 20 ml) EU/ 1/ 07/ 398/ 006 (10 x 20 ml)
EU/ 1/ 07/ 415/ 032 EU/ 1/ 07/ 415/ 033 EU/ 1/ 07/ 415/ 034 EU/ 1/ 07/ 415/ 035 EU/ 1/ 07/ 415/ 036
EU/ 1/ 07/ 415/ 042 EU/ 1/ 07/ 415/ 043 EU/ 1/ 07/ 415/ 044 EU/ 1/ 07/ 415/ 045 EU/ 1/ 07/ 415/ 046
EU/ 1/ 07/ 415/ 047 EU/ 1/ 07/ 415/ 048 EU/ 1/ 07/ 415/ 049 EU/ 1/ 07/ 415/ 050 EU/ 1/ 07/ 415/ 051
EU/ 1/ 07/ 415/ 052 EU/ 1/ 07/ 415/ 053 EU/ 1/ 07/ 415/ 054 EU/ 1/ 07/ 415/ 055 EU/ 1/ 07/ 415/ 056
EU/ 1/ 07/ 418/ 002 EU/ 1/ 07/ 418/ 003 EU/ 1/ 07/ 418/ 004 EU/ 1/ 07/ 418/ 005
EU/ 1/ 07/ 421/ 001 14 tablets EU/ 1/ 07/ 421/ 002 28 tablets EU/ 1/ 07/ 421/ 003 30 tablets EU/ 1/ 07/ 421/ 004 50 tablets EU/ 1/ 07/ 421/ 005 56 tablets EU/ 1/ 07/ 421/ 006 60 tablets EU/ 1/ 07/ 421/ 007 90 tablets EU/ 1/ 07/ 421/ 008 98 tablets EU/ 1/ 07/ 421/ 009 180 tablets
EU/1/07/425/001 EU/1/07/425/002 EU/1/07/425/003 EU/1/07/425/004 EU/1/07/425/005 EU/1/07/425/006
EU/1/07/425/007 EU/1/07/425/008 EU/1/07/425/009 EU/1/07/425/010 EU/1/07/425/011 EU/1/07/425/012
EU/1/07/425/013 EU/1/07/425/014 EU/1/07/425/015
EU/1/07/425/016 EU/1/07/425/017 EU/1/07/425/018
EU/ 1/ 07/ 426/ 001, 28 coated tablets EU/ 1/ 07/ 426/ 002, 56 coated tablets
EU/ 1/ 07/ 426/ 002 – Olanzapine Neopharma – 2.5 mg – coated tablets – 56 tablets per box
EU/ 1/ 07/ 426/ 003, 28 coated tablets EU/ 1/ 07/ 426/ 004, 56 coated tablets
EU/ 1/ 07/ 426/ 004 – Olanzapine Neopharma – 5 mg – coated tablets – 56 tablets per box
EU/ 1/ 07/ 426/ 005, 28 coated tablets EU/ 1/ 07/ 426/ 006, 56 coated tablets
EU/ 1/ 07/ 426/ 006 – Olanzapine Neopharma – 7.5 mg – coated tablets – 56 tablets per box
EU/ 1/ 07/ 426/ 007, 7 coated tablets EU/ 1/ 07/ 426/ 008, 28 coated tablets EU/ 1/ 07/ 426/ 009, 56 coated tablets
EU/ 1/ 07/ 426/ 010, 28 coated tablets EU/ 1/ 07/ 426/ 011, 56 coated tablets
EU/ 1/ 07/ 426/ 011 – Olanzapine Neopharma – 15 mg – coated tablets – 56 tablets per box
EU/ 1/ 07/ 430/ 001 30 film-coated tablets EU/ 1/ 07/ 430/ 002 3 x 30 film-coated tablets
MARKETING AUTHORISATION NUMBER(S) EU/ 1/ 07/ 431/ 017 EU/ 1/ 07/ 431/ 020 EU/ 1/ 07/ 431/ 021
EU/ 1/ 07/ 435/ 001 EU/ 1/ 07/ 435/ 002 EU/ 1/ 07/ 435/ 003 EU/ 1/ 07/ 435/ 004 EU/ 1/ 07/ 435/ 005 EU/ 1/ 07/ 435/ 006
EU/ 1/ 07/ 435/ 007 EU/ 1/ 07/ 435/ 008 EU/ 1/ 07/ 435/ 009 EU/ 1/ 07/ 435/ 010 EU/ 1/ 07/ 435/ 011 EU/ 1/ 07/ 435/ 012
EU/ 1/ 07/ 435/ 007 EU/ 1/ 07/ 435/ 008 EU/ 1/ 07/ 435/ 009 EU/ 1/ 07/ 435/ 010 EU/ 1/ 07/ 435/ 011 EU/ 1/ 07/ 435/ 012
EU/ 1/ 07/ 435/ 013 EU/ 1/ 07/ 435/ 014 EU/ 1/ 07/ 435/ 015 EU/ 1/ 07/ 435/ 016 EU/ 1/ 07/ 435/ 017 EU/ 1/ 07/ 435/ 018
EU/ 1/ 07/ 437/ 001 1 x 1 vial EU/ 1/ 07/ 437/ 002 1 x 10 vials
EU/ 1/ 07/ 438/ 001 (100 capsules) EU/ 1/ 07/ 438/ 002 (300 capsules)
EU/ 1/ 07/ 439/ 001 (100 capsules) EU/ 1/ 07/ 439/ 002 (300 capsules)
EU/1/08/464/001 14 tablets EU/1/08/464/002 14 tablets EU/1/08/464/003 28 tablets EU/1/08/464/004 28 tablets EU/1/08/464/005 30 tablets EU/1/08/464/006 30 tablets EU/1/08/464/007 50x1 tablets EU/1/08/464/008 50x1 tablets EU/1/08/464/009 84 tablets EU/1/08/464/010 84 tablets EU/1/08/464/011 90 tablets EU/1/08/464/012 90 tablets EU/1/08/464/013 100 tablets EU/1/08/464/014 100 tablets EU/1/08/464/018 7 tablets EU/1/08/464/019 7 tablets
EU/1/08/465/001 14 tablets EU/1/08/465/002 14 tablets EU/1/08/465/003 28 tablets EU/1/08/465/004 28 tablets EU/1/08/465/005 30 tablets EU/1/08/465/006 30 tablets EU/1/08/465/007 50x1 tablets EU/1/08/465/008 50x1 tablets EU/1/08/465/009 84 tablets EU/1/08/465/010 84 tablets EU/1/08/465/011 90 tablets EU/1/08/465/012 90 tablets EU/1/08/465/013 100 tablets EU/1/08/465/014 100 tablets EU/1/08/465/018 7 tablets EU/1/08/465/019 7 tablets
EU/1/08/484/001 EU/1/08/484/002 EU/1/08/484/003 EU/1/08/484/004 EU/1/08/484/005 EU/1/08/484/006
EU/1/08/484/007 EU/1/08/484/008 EU/1/08/484/009 EU/1/08/484/010 EU/1/08/484/011 EU/1/08/484/012
EU/1/08/484/013 EU/1/08/484/014 EU/1/08/484/015
EU/1/08/484/016 EU/1/08/484/017 EU/1/08/484/018
EU/ 1/ 95/ 001/ 001 1 ampoule of powder for solution for injection.
EU/ 1/ 95/ 001/ 003 5 ampoules of powder for solution for injection.
EU/ 1/ 95/ 001/ 004 10 ampoules of powder for solution for injection.
EU/ 1/ 95/ 001/ 005 1 vial of powder for solution for injection.
EU/ 1/ 95/ 001/ 009 1 ampoule of powder for solution for injection.
EU/ 1/ 95/ 001/ 012 10 ampoules of powder for solution for injection.
EU/ 1/ 95/ 001/ 025 1 vial of powder for solution for injection.
EU/ 1/ 95/ 001/ 026 5 vials of powder for solution for injection.
EU/ 1/ 95/ 001/ 027 10 vials of powder for solution for injection.
EU/ 1/ 95/ 001/ 028 1 vial of powder for solution for injection.
EU/ 1/ 95/ 003/ 005 EU/ 1/ 95/ 003/ 006 EU/ 1/ 95/ 003/ 007 EU/ 1/ 95/ 003/ 008 EU/ 1/ 95/ 003/ 010
EU/ 1/ 96/ 005/ 002 CellCept EU/ 1/ 96/ 005/ 004 CellCept
EU/ 1/ 96/ 011/ 001 (1 vial) EU/ 1/ 96/ 011/ 002 (10 vials)
EU/ 1/ 96/ 011/ 003 (1 vial) EU/ 1/ 96/ 011/ 004 (10 vials)
EU/ 1/ 96/ 015/ 001 (Bottle) EU/ 1/ 96/ 015/ 004 (Blister pack)
EU/ 1/ 96/ 015/ 003 (Bottle) EU/ 1/ 96/ 015/ 005 (Blister pack)
EU/ 1/ 96/ 022/ 002 28 coated tablets EU/ 1/ 96/ 022/ 023 35 coated tablets EU/ 1/ 96/ 022/ 019 56 coated tablets EU/ 1/ 96/ 022/ 029 70 coated tablets
EU/ 1/ 96/ 022/ 002 - ZYPREXA - 2.5 mg - coated tablets - 28 tablets, per box.
EU/ 1/ 96/ 022/ 004 28 coated tablets EU/ 1/ 96/ 022/ 024 35 coated tablets EU/ 1/ 96/ 022/ 020 56 coated tablets EU/ 1/ 96/ 022/ 030 70 coated tablets
EU/ 1/ 96/ 022/ 004 - ZYPREXA - 5 mg - coated tablets - 28 tablets, per box.
EU/ 1/ 96/ 022/ 008 7 coated tablets EU/ 1/ 96/ 022/ 009 28 coated tablets EU/ 1/ 96/ 022/ 026 35 coated tablets EU/ 1/ 96/ 022/ 010 56 coated tablets EU/ 1/ 96/ 022/ 032 70 coated tablets
EU/ 1/ 96/ 022/ 01128 coated tablets EU/ 1/ 96/ 022/ 025 35 coated tablets EU/ 1/ 96/ 022/ 006 56 coated tablets EU/ 1/ 96/ 022/ 031 70 coated tablets
EU/ 1/ 96/ 022/ 011 - ZYPREXA - 7.5 mg - coated tablets - 28 tablets, per box.
EU/ 1/ 96/ 022/ 012 28 coated tablets EU/ 1/ 96/ 022/ 027 35 coated tablets EU/ 1/ 96/ 022/ 021 56 coated tablets EU/ 1/ 96/ 022/ 033 70 coated tablets
EU/ 1/ 96/ 022/ 021 - ZYPREXA - 15 mg - coated tablets - 56 tablets, per box.
EU/ 1/ 96/ 022/ 014 28 coated tablets EU/ 1/ 96/ 022/ 028 35 coated tablets EU/ 1/ 96/ 022/ 022 56 coated tablets EU/ 1/ 96/ 022/ 034 70 coated tablets
EU/ 1/ 96/ 022/ 022 - ZYPREXA - 20 mg - coated tablets - 56 tablets, per box.
EU/ 1/ 96/ 022/ 016 Powder for solution for injection.
EU/ 1/ 96/ 022/ 002 EU/ 1/ 96/ 022/ 004 EU/ 1/ 96/ 022/ 006 EU/ 1/ 96/ 022/ 008 EU/ 1/ 96/ 022/ 009 EU/ 1/ 96/ 022/ 010 EU/ 1/ 96/ 022/ 011 EU/ 1/ 96/ 022/ 012 EU/ 1/ 96/ 022/ 014 EU/ 1/ 96/ 022/ 016 EU/ 1/ 96/ 022/ 017 EU/ 1/ 96/ 022/ 019 EU/ 1/ 96/ 022/ 020 EU/ 1/ 96/ 022/ 021 EU/ 1/ 96/ 022/ 022 EU/ 1/ 96/ 022/ 023 EU/ 1/ 96/ 022/ 024 EU/ 1/ 96/ 022/ 025 EU/ 1/ 96/ 022/ 026 EU/ 1/ 96/ 022/ 027 EU/ 1/ 96/ 022/ 028 EU/ 1/ 96/ 022/ 029 EU/ 1/ 96/ 022/ 030 EU/ 1/ 96/ 022/ 031 EU/ 1/ 96/ 022/ 032 EU/ 1/ 96/ 022/ 033 EU/ 1/ 96/ 022/ 034
EU/ 1/ 96/ 022/ 019 - ZYPREXA - 2.5 mg - coated tablets - 56 tablets, per box.
EU/ 1/ 96/ 022/ 020 - ZYPREXA - 5 mg - coated tablets - 56 tablets, per box.
EU/ 1/ 96/ 022/ 023 - ZYPREXA - 2.5 mg - coated tablets - 35 tablets, per box.
EU/ 1/ 96/ 022/ 024 - ZYPREXA - 5 mg - coated tablets - 35 tablets, per box.
EU/ 1/ 96/ 022/ 025 - ZYPREXA – 7.5 mg - coated tablets - 35 tablets, per box.
EU/ 1/ 96/ 022/ 027 - ZYPREXA - 15 mg - coated tablets - 35 tablets, per box.
EU/ 1/ 96/ 022/ 028 - ZYPREXA - 20 mg - coated tablets - 35 tablets, per box.
EU/ 1/ 96/ 022/ 029 - ZYPREXA - 2.5 mg - coated tablets - 70 tablets, per box.
EU/ 1/ 96/ 022/ 030 - ZYPREXA - 5 mg - coated tablets - 70 tablets, per box.
EU/ 1/ 96/ 022/ 031 - ZYPREXA – 7.5 mg - coated tablets - 70 tablets, per box.
EU/ 1/ 96/ 022/ 034 - ZYPREXA - 20 mg - coated tablets - 70 tablets, per box.
EU/ 1/ 96/ 024/ 001 180 hard capsules EU/ 1/ 96/ 024/ 002 270 hard capsules EU/ 1/ 96/ 024/ 003 360 hard capsules
EU/ 1/ 96/ 027/ 003 1 x 4 mg vial EU/ 1/ 96/ 027/ 001 5 x 4 mg vials
EU/ 1/ 96/ 027/ 005 1 x 1 mg vial EU/ 1/ 96/ 027/ 004 5 x 1 mg vials
EU/ 1/ 97/ 039/ 001 (100 hard capsules per bottle), EU/ 1/ 97/ 039/ 002 (500 hard capsules per bottle).
EU/ 1/ 97/ 039/ 003 (100 hard capsules per bottle), EU/ 1/ 97/ 039/ 004 (500 hard capsules per bottle).
EU/ 1/ 97/ 046/ 010 14 tablets EU/ 1/ 97/ 046/ 001 28 tablets EU/ 1/ 97/ 046/ 002 56 tablets EU/ 1/ 97/ 046/ 013 56 x 1 tablets EU/ 1/ 97/ 046/ 003 98 tablets
EU/ 1/ 97/ 046/ 011 14 tablets EU/ 1/ 97/ 046/ 004 28 tablets EU/ 1/ 97/ 046/ 005 56 tablets EU/ 1/ 97/ 046/ 014 56 x 1 tablets EU/ 1/ 97/ 046/ 006 98 tablets
EU/ 1/ 97/ 046/ 012 14 tablets EU/ 1/ 97/ 046/ 007 28 tablets EU/ 1/ 97/ 046/ 008 56 tablets EU/ 1/ 97/ 046/ 015 56 x 1 tablets EU/ 1/ 97/ 046/ 009 98 tablets
EU/ 1/ 97/ 046/ 026 14 tablets EU/ 1/ 97/ 046/ 027 28 tablets EU/ 1/ 97/ 046/ 036 30 tablets EU/ 1/ 97/ 046/ 028 56 tablets EU/ 1/ 97/ 046/ 029 56 x 1 tablets EU/ 1/ 97/ 046/ 033 84 tablets EU/ 1/ 97/ 046/ 039 90 tablets EU/ 1/ 97/ 046/ 030 98 tablets
EU/1/98/069/001a 28 tablets EU/1/98/069/001b 28 tablets EU/1/98/069/002a 50x1 tablets EU/1/98/069/002b 50x1 tablets EU/1/98/069/003a 84 tablets EU/1/98/069/003b 84 tablets EU/1/98/069/004a 100 tablets EU/1/98/069/004b 100 tablets EU/1/98/069/005a 30 tablets EU/1/98/069/005b 30 tablets EU/1/98/069/006a 90 tablets EU/1/98/069/006b 90 tablets EU/1/98/069/007a 14 tablets EU/1/98/069/007b 14 tablets EU/1/98/069/011a 7 tablets EU/1/98/069/011b 7 tablets
EU/1/98/070/001a 28 tablets EU/1/98/070/001b 28 tablets EU/1/98/070/002a 50x1 tablets EU/1/98/070/002b 50x1 tablets EU/1/98/070/003a 84 tablets EU/1/98/070/003b 84 tablets EU/1/98/070/004a 100 tablets EU/1/98/070/004b 100 tablets EU/1/98/070/005a 30 tablets EU/1/98/070/005b 30 tablets EU/1/98/070/006a 90 tablets EU/1/98/070/006b 90 tablets EU/1/98/070/007a 14 tablets EU/1/98/070/007b 14 tablets EU/1/98/070/011a 7 tablets EU/1/98/070/011b 7 tablets
EU/ 1/ 98/ 085/ 023 14 tablets EU/ 1/ 98/ 085/ 024 28 tablets EU/ 1/ 98/ 085/ 031 30 tablets EU/ 1/ 98/ 085/ 025 56 tablets EU/ 1/ 98/ 085/ 028 56 x 1 tablets EU/ 1/ 98/ 085/ 026 84 tablets EU/ 1/ 98/ 085/ 034 90 tablets EU/ 1/ 98/ 085/ 027 98 tablets
EU/ 1/ 98/ 086/ 023 14 tablets EU/ 1/ 98/ 086/ 024 28 tablets EU/ 1/ 98/ 086/ 031 30 tablets EU/ 1/ 98/ 086/ 025 56 tablets EU/ 1/ 98/ 086/ 028 56 x 1 tablets EU/ 1/ 98/ 086/ 026 84 tablets EU/ 1/ 98/ 086/ 034 90 tablets EU/ 1/ 98/ 086/ 027 98 tablets
EU/1/99/107/001 (84 hard capsules) EU/1/99/107/005 (112 hard capsules) EU/1/99/107/002 (140 hard capsules) EU/1/99/107/003 (168 hard capsules)
EU/1/99/107/001 EU/1/99/107/005 EU/1/99/107/002 EU/1/99/107/003
EU/1/99/116/001 1 vial 100 mg EU/1/99/116/002 2 vials 100 mg EU/1/99/116/003 3 vials 100 mg EU/1/99/116/004 4 vials 100 mg EU/1/99/116/005 5 vials 100 mg
EU/ 1/ 99/ 120/ 001 250 tablets EU/ 1/ 99/ 120/ 002 500 tablets
EU/1/99/127/001 1 vial of powder EU/1/99/127/040 12 vials of powder
EU/1/99/127/002 1 vial of powder EU/1/99/127/003 6 vials of powder
EU/1/99/127/011 EU/1/99/127/012 EU/1/99/127/013 EU/1/99/127/014
EU/1/99/127/015 EU/1/99/127/016 EU/1/99/127/017 EU/1/99/127/018
EU/1/99/127/023 1 multiple dose vial EU/1/99/127/024 1 multiple dose vial 6 injection syringes, 6 injection needles and 12 cle EU/1/99/127/025 2 multiple dose vials EU/1/99/127/041 2 multiple dose vials, 12 injection syringes, 12 injection needles and 24 cleansing swabs EU/1/99/127/026 12 multiple dose vials EU/1/99/127/042 12 multiple dose vials, 72 injection syringes, 72 injection needles and 144 cleansing swabs
EU/1/99/127/023 EU/1/99/127/024 EU/1/99/127/025 EU/1/99/127/026 EU/1/99/127/041 EU/1/99/127/042
EU/1/99/127/027 EU/1/99/127/028 EU/1/99/127/029 EU/1/99/127/030 EU/1/99/127/043 EU/1/99/127/044
EU/1/99/127/031 1 pen EU/1/99/127/032 2 pens EU/1/99/127/033 8 pens,
EU/1/99/127/031 EU/1/99/127/032 EU/1/99/127/033
EU/1/99/127/034 1 pen EU/1/99/127/035 2 pens EU/1/99/127/036 8 pens
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
EU/2/04/044/001 (42.5 mg/g – 20 kg) EU/2/04/044/002 (42.5 mg/g – 5 kg)
EU/2/05/054/018 2 tablets EU/2/05/054/019 4 tablets
EU/2/05/054/020 10 tablets EU/2/05/054/021 24 tablets EU/2/05/054/022 50 tablets
EU/2/05/054/023 2 tablets EU/2/05/054/024 4 tablets
EU/2/05/054/025 6 tablets EU/2/05/054/026 24 tablets EU/2/05/054/027 102 tablets
recent electrocardiography changes.
Dosage adjustment may be necessary when transferring patients from one insulin preparation to another (see section 4.4).
Improvement in fatigue, as measured by the Functional Assessment of Cancer Therapy-fatigue (FACT-fatigue) scale, was also observed. ct
European Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency
European Medicines Agency
European Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency
European Medicines Agency Veterinary Medicines
Topics discussed in 1996 fell into three broad categories: preparation of CPMP Guidelines on Pharmaco- vigilance, evaluation of product-related issues at the CPMP's request, and other inquiries at the request of national authorities.
156 Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
175 Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
118 Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
137 Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
or Agency (EMEA) http: / /www. emea. europa. eu
for Protopy to Astellas Pharma GmbH on 28 February 2002.
EU/ X/ XX/ XXX/ XXX 14 film-coated tablets EU/ X/ XX/ XXX/ XXX 28 film-coated tablets EU/ X/ XX/ XXX/ XXX 30x1 film-coated tablet EU/ X/ XX/ XXX/ XXX 56 film-coated tablets EU/ X/ XX/ XXX/ XXX 84 film-coated tablets EU/ X/ XX/ XXX/ XXX 90x1 film-coated tablet EU/ X/ XX/ XXX/ XXX 98 film-coated tablets
EU/ X/ XX/ XXX/ XXX 14 film-coated tablets EU/ X/ XX/ XXX/ XXX 28 film-coated tablets EU/ X/ XX/ XXX/ XXX 30x1 film-coated tablet EU/ X/ XX/ XXX/ XXX 56 film-coated tablets EU/ X/ XX/ XXX/ XXX 84 film-coated tablets EU/ X/ XX/ XXX/ XXX 90x1 film-coated tablet EU/ X/ XX/ XXX/ XXX 98 film-coated tablets
Critical Evaluation A number of areas of disharmony in the product information for Tritace have been evaluated by the CHMP and a revised product information was adopted.
Assessment of new data further to the request for re-consideration by the European Commission One new GLP-study in cattle and two complementary GLP-residue studies in pigs were submitted during the procedure for the reconsideration of the opinion.
Evaluation of the side effects is based on the following frequencies:
Evaluation of Medicines for Human Use
Benchmarking and development of performance indicators
Evaluation of anti-cancer medicinal products in man
Environmental risk assessment for veterinary medicinal
Physician's overall assessment of treatment effectiveness:
The decision to continue Xolair should be based on whether a marked improvement in overall asthma control is seen (see section 5.1; Physician's overall assessment of treatment effectiveness).
assessment Months (95% CI) Median Progression- Free
3 Members of the Committee for Veterinary Medicinal Products
Initial evaluation and specific post-marketing activities
Preclinical evaluation of anti-cancer medicinal products
Evaluate the effect of Naglazyme on pregnancy and lactation.
Evaluate the safety and efficacy of Naglazyme in 10 children less than 5 years of age will be treated with the 1 mg/ kg dose for at least one year.
Evaluate the safety and efficacy of Naglazyme in 10 children less than 5 years of age will be treated with the 1 mg/ kg dose for at least one year.
Confirmed Cardiac Events
Cardiovascular Cardiac events were observed in 11% patients in clinical studies with MabThera.
Events (deaths) n (%) Hazard ratiob (95% CI) c
Events (deaths) n (%) Hazard ratiob (95% CI) p-value c
Adverse reactionsa on ORACEA in pivotal placebo-controlled studies in rosacea:
• Adverse events in healthy volunteers
Adverse events in healthy volunteers
Grade 3 and 4 Adverse Events Carboplatin versus Gemcitabine plus carboplatin Number (%) of Patients
Confirmed Thrombotic Cardiovascular Serious Adverse Events
Serious suspected unexpected adverse events
141 Serious adverse events reported in clinical trials
Serious adverse events reported in clinical trials
Hepato-biliary disorders adverse events:
Events (%) in Bicalutamide patients
patient-years, diet alone 18 events/ 1,000 patient-years, (p=0.01).
5 Venous Thromboembolic Events:
Thromboembolic events, including pulmonary embolism
Confirmed Cerebrovascular Events
Confirmed Cerebrovascular Events
Per-protocol Intent-to-treat †
Single clinical event suggestive of MS:
Single clinical event suggestive of multiple sclerosis One controlled clinical trial with Extavia was performed in patients with a single clinical event and Magnetic Resonance Imaging (MRI) features suggestive of multiple sclerosis (at least two clinically silent lesions on the T2-weighted MRI).
patients undergoing major orthopaedic surgery
EVICEL is applied during surgical operations, to reduce bleeding and oozing during and after the operation.
2 x 1 ml, 2 x 2 ml and 2 x 5 ml.
Evicel is then dripped or sprayed on the surface of the wound until it forms a thin layer.
Evicel was more effective than the comparator treatments in reducing the bleeding at the site of application.
Evicel should only be used by an experienced surgeon.
EVISTA belongs to a group of non-hormonal medicines called Selective Oestrogen Receptor Modulators (SERMs).
Evista is used for the treatment and prevention of osteoporosis (a disease that makes bones fragile) in women who have been through the menopause.
There was no effect of Evista on hip fractures.
EVISTA may affect the development of the baby.
Avoid direct contact with treated animals until the application area is dry.
- Any pressure instability within the vial should be avoided since it may cause disruption of
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there may be potential risk of increased renal toxicity.
Avoid use in any dehydrated, hypovolaemic or hypotensive animals, as there is a potential risk of increased renal toxicity.
Avoid use in any dehydrated, hypovolaemic or hypotensive animals, as there is a risk of increased renal toxicity.
Avoid use of vaccination equipment with rubber parts.
Avoid freezing and excessive temperatures.
Avoid freezing or excessive temperatures
Avoid freezing or excessive temperatures.
Avoid the use in any dehydrated, hypovolaemic or hypotensive animals, as there may be potential risk of increased renal toxicity.
Avoid use in any dehydrated, hypovolaemic or hypotensive animals, as there may be potential risk of increased renal toxicity.
Avoid handling the product if hypersensitivity to tetracyclines exists.
Care should be taken that the contents of the pipette do not come into contact with the eyes or mouth of the recipient and/ or other animals.
Care should be taken that the contents of the pipette do not come into contact with the eyes or mouth of the recipient and/ or other animals.
Care should be taken that the contents of the pipette or the applied dose does not come into contact with the eyes or mouth of the recipient and/ or other animals.
Avoid areas with scars or stretch marks.
Avoid situations where OptiSet might be damaged.
Avoid situations where OptiSet might be damaged.
Avoid situations where SoloStar might be damaged.
19 Prophylactic use of corticosteroids to reduce stricture formation should be avoided during PDT as its use has shown not to reduce, and may worsen, stricture formation.
Prophylactic use of corticosteroids to reduce stricture formation should be avoided during PDT as its use has shown not to reduce, and may worsen, stricture formation.
Avoid contact with the eyes of the cat and avoid oral ingestion by the animal.
Avoid contact with the eyes, lips and nostrils.
Avoid skin contact with the pipette content.
Avoid touching the skin with the pipette's contents.
Skin contact with the pipette content should be avoided.
Avoid skin contact with infusion solution
Avoid contact between the product and your fingers.
- Avoid prolonged exposure of the treated area to sunlight or other ultraviolet (UV) light (such as
You need to avoid applying the gel to the healthy skin around the lesion.
Avoid covering the KS lesions treated with gel with any bandage or material other than loose clothing.
Avoid soaking in a hot bath for a long period of time, which can make the patch come off.
AVOID SHAKING TO PREVENT FOAM FORMATION.
Avoid excessive exposure to sunlight, sun lamps and tanning beds during treatment with < Invented Name >.
Do not get it in your eyes or inside your nose or mouth.
Avoid alcohol while taking Eucreas since alcohol may increase the risk of lactic acidosis (please see section “Possible side effects”).
Avoid alcohol while taking Icandra since alcohol may increase the risk of lactic acidosis (please see section “Possible side effects”).
Avoid alcohol while taking Zomarist since alcohol may increase the risk of lactic acidosis (please see section “Possible side effects”).
Avoid direct sunlight or strong indoor lighting.
- avoid tight fitting footwear or high-heeled shoes.
Avoid situations where OptiSet might be damaged.
Avoid situations where OptiSet might be damaged.
Avoid sunlight and solarium exposure on areas of skin showing any kind of skin reaction caused by Neupro.
Avoid repeated injections at the exact same spot previously used.
Avoid using the ointment inside your nose or mouth or in your eyes.
If the ointment gets on any of ic
Avoid contact with the skin, eyes or mucosa (moist body surfaces).
Avoid contact with any powder that spills out from damaged capsules.
ed including medicines obtained without a prescription.
Care should be taken not to bring the neonate into skin contact with areas to which Panretin gel has been recently applied.
Avoid direct exposure to bright indoor lights, including dental lamps, operating room lamps, unshaded light bulbs at close proximity or neon lights.
Avoid any unnecessary exercise as this might increase the risk of a tendon rupture.
Avoid any unnecessary exercise, as this might increase the risk of a tendon rupture.
However, do not scrub the area where the patch has been placed too hard.
Avoid forming bubbles during dissolution.
Avoid situations where SoloStar might be damaged.
Patients with signs or symptoms compatible with autoimmune disorders should be evaluated carefully, and the benefit-risk of continued interferon therapy should be reassessed (see also section 4.4 Chronic hepatitis C, Monotherapy (thyroid abnormalities) and section 4.8). no
Evoltra has been authorised under ‘ Exceptional Circumstances’.
Evoltra has been studied in patients less than 21 years old when they first became ill with ALL.
Evoltra was designated as an orphan medicine for this condition on 8 May 2003.
Evoltra is already used to treat children with acute lymphoblastic leukaemia (ALL, cancer of the lymphocytes, a type of white blood cell).
Evoltra may harm both male and female reproductive organs.
Evoltra is used to treat young patients with acute lymphoblastic leukaemia (ALL) when previous treatments have not worked or have stopped working.
Evoltra is used to treat children with acute lymphoblastic leukaemia (ALL), which is a cancer of the lymphocytes (a type of white blood cell).
MEAN (SE) ANNUALIZED CHANGE FROM BASELINE IN TOTAL SHARP SCORE
If you develop symptoms suggestive of infections, such as fever, persistent cough, weight loss, or listlessness, seek medical attention immediately.
EVRA transdermal patch Norelgestromin and ethinyl estradiol
EVRA should be applied to clean, dry, hairless, intact healthy skin on the buttock, abdomen, upper outer arm or upper torso, in a place where it will not be rubbed by tight clothing.
EVRA is intended for women of fertile age.
Evra is a transdermal patch (a patch that delivers a medicine across the skin).
EVRA has not been studied in women with hepatic impairment.
EVRA has not been studied in women with renal impairment.
EVRA should not be placed on the breasts or on skin that is red, irritated or cut.
- Hereditary dyslipoproteinemia
EVRA is not indicated during pregnancy (see section 4.6).
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Evropská 2590/ 33c
Tritace 1.25 Evropská 2590/ 33c Tritace 2.5 16000 Praha 6 Tritace 5 Czech Republic Tritace 10
Chronic suppurative otitis media
Adolescents and Children (age 5 – 17 years) Acute pulmonary exacerbation in paediatric cystic fibrosis patients:
Flares after treatment discontinuation:
Flares on treatment:
- Blood test showing increased levels of blood sugar, serum creatinine, myoglobin, or lactic
- Blood testing showing higher levels of liver enzymes or creatine phosphokinase (CPK).
Tests your doctor will do during treatment Some patients taking Tracleer were found to have abnormal liver function tests and anaemia (low haemoglobin).
The appearance of insulin should also be checked: the insulin solution must be clear, colourless, with no solid particles visible, and must have a water-like consistency.
The appearance of insulin should also be checked: the insulin solution must be clear, colourless, with no solid particles visible, and must have a water-like consistency.
- Carefully inspect the solution before injecting it and use only if clear and colourless.
Examine the solution prior to administration: it should be clear and colourless.
Examine the solution prior to administration: it should be clear and colourless.
Examine the reconstituted solution prior to administration: it should be clear and colourless.
The cartridges should be examined frequently and should not be used if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving a frosted appearance.
The cartridges should be examined frequently and should not be used if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
65 The cartridges should be examined frequently and should not be used if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving a frosted appearance.
The cartridges should be examined frequently and should not be used if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving a frosted appearance.
The cartridges should be examined frequently and should not be used if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving a frosted appearance.
The cartridges should be examined frequently and should not be used if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
The vials should be examined frequently and should not be used if clumps of material are present or if solid white particles stick to the bottom or wall of the vial, giving it a frosted appearance.
Inspect all new cartridges prior to use.
The deltoid muscle is the preferred site for injection in adults and adolescents.
H. pylori status: -< 3.5 excess δ13C = Negative > 3.5 excess δ13C = Positive
Too much fluid collecting in the tissues due to irregular lymph function
skin's immune system causes skin inflammation (itchiness, redness, dryness).
Excipient For a full list of excipients, see section 6.1
Excipients: glutamic acid, polysorbate 80, water for injections and sorbitol (E420) - see the package leaflet for further information.
Excipients: glutamic acid, polysorbate 80, water for injections and sorbitol (E420) - see the package leaflet for further information.
Excipients: sodium acetate, sorbitol (E420), polysorbate 20, water for injections.
is or Excipients: sodium acetate, sorbitol (E420), polysorbate 20, water for injections.
Benzyl alcohol, 1 mg/ ml butylhydroxytoluene (E 321; as antioxidant)
Excipients known to have a recognised action: sorbitol (E420), sodium acetate.
th Excipients known to have a recognised action: sorbitol (E420), sodium acetate.
Excipients known to have a recognised action: sorbitol E420, sodium acetate (see section 4.4).
is or Excipients known to have a recognised action: sorbitol E420, sodium acetate (see section 4.4).
This medicinal product contains 5.00 mmol sodium per dose (1 vial).
Excipients This medicinal product (concentrate-diluent mixture) contains 35% volume ethanol (alcohol); i. e., up to 693.5 mg per dose, equivalent to 17.6 ml beer, 7.3 ml wine per dose.
Excipients Each 150 mg film-coated tablet contains 0.84 mg of soya lecithin.
Excipients Each 300 mg film-coated tablet contains 1.68 mg of soya lecithin.
Excipients Each 200 mg vial contains 3.5 mg (< 1 mmol) sodium.
Each ml contains 376 mg of ethanol anhydrous and 560 mg of propylene glycol
Excipients: benzalkonium chloride 0.15 mg, polyoxyethylene hydrogenated castor oil 40 (HCO-40) 5 mg (see section 4.4.)
Excipients: zinc chloride, m-cresol, glycerol, hydrochloric acid, sodium hydroxide, water for injections
Excipients: zinc chloride, m-cresol, glycerol, hydrochloric acid, polysorbate 20, sodium hydroxide, water for injections
Excipients: zinc chloride, m-cresol, glycerol, hydrochloric acid, sodium hydroxide, polysorbate 20, water for injections
Excipients Benzalkonium chloride, which is commonly used as a preservative in ophthalmic products, has been reported to cause punctate keratopathy and/ or toxic ulcerative keratopathy.
Excipients: fosveset, sodium hydroxide, hydrochloride acid, water for injections
Excipients: glycine, disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate, and human albumin solution One ampoule of solvent contains 1 ml of water for injections.
Interferon alfa-2b has been shown to have abortifacient effects in Macaca mulatta (rhesus monkeys) at 90 and 180 times the recommended intramuscular or subcutaneous dose of 2 million IU/m2.
Excipients: aluminium hydroxide and a buffer solution of disodium phosphate, monopotassium phosphate, sodium carbonate, sodium bicarbonate, trometamol, sucrose, medium 199 (complex blend of amino acids, mineral salts, vitamins and other ingredients) and water for injections.
Excipients The reconstituted medicinal product contains approximately 425 mg sodium per dose.
Excipients: maltose, sodium dihydrogen phosphate monohydrate and sodium chloride
Excipients: mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol, polysorbate 80, glutathione (reduced).
Exipients: mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol, polysorbate 80, glutathione (reduced).
Excipients: metacresol, sodium dihydrogen phosphate dihydrate, glycerol, sodium hydroxide, hydrochloric acid (for pH adjustment), water for injections.
Excipients: phenol, zinc chloride, trometamol, glycerol, poloxamer 171, hydrochloric acid (for pH adjustment), water for injections.
Excipients: disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate, edetate disodium, sodium chloride, m-cresol, polysorbate 80 and water for injections
Excipients: sodium dihydrogen phosphate dihydrate, disodium phosphate dihydrate, sodium chloride, glycine, polysorbate 80, hydrochloric acid (for pH-adjustment), sodium hydroxide (for pH-adjustment), and water for injections
For a full list of excipients, see section 6.1.
For a full list of excipients, see section 6.1.
For a full list of excipients, see section 6.1.
Excipients: sucrose, polysorbate 80, monobasic sodium phosphate and dibasic sodium phosphate.
Excipients: α -(2-[1,2-distearoyl-sn-glycero(3)phosphooxy]ethylcarbamoyl)-ϖ - methoxypoly(oxyethylen)-40 sodium salt, fully hydrogenated soy phosphatidylcholine, cholesterol, ammonium sulphate, sucrose, histidine, water for injections, hydrochloric acid and sodium hydroxide.
Sodium (5.00 mmol per dose (1 vial))
Backing: polyester/ ethylene-vinyl acetate film; siliconised polyester film.
A 600 mg dose (30 ml) of oral solution contains approximately 47 mg sodium.
Also contains: α ,α -trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections.
Elimination Meloxicam is eliminated with a terminal half-life of 7.7 hours.
uncontrolled, repeated movements of the body);
ulcers, colitis associated with chemotherapy), as it is possible that Avastin may increase the risk of developing holes in the gut wall.
Example: for a 75 kg patient with a clearance of 3 ml/ h/ kg, the initial infusion rate would be 3 IU/ h/ kg to achieve a FVIII level of 100%.
Examples of symptoms that tell you that your blood sugar level is falling too much or too fast: sweating, clammy skin, anxiety, fast heart beat, high blood pressure, palpitations and irregular heartbeat,.
Examples of symptoms that tell you that your blood sugar level is falling too much or too fast: sweating, clammy skin, anxiety, fast heart beat, high blood pressure, palpitations and irregular heartbeat.
-In your body Examples of symptoms that tell you that your blood sugar level is falling too much or too fast: sweating, clammy skin, anxiety, fast heart beat, high blood pressure, palpitations and irregular heartbeat.
Skin exfoliation, photosensitivity reaction, pigmentation abnormal
- peeling or flaking of skin (exfoliative dermatitis)
Exforge 10 mg/ 160 mg film-coated tablets amlodipine/ valsartan
Exforge 10 mg/ 160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg alone or with Exforge 5 mg/ 160 mg.
Exforge 5 mg/ 160 mg film-coated tablets amlodipine/ valsartan
Exforge 5 mg/ 160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg alone.
Exforge 5 mg/ 80 mg film-coated tablets amlodipine/ valsartan
Exforge 5 mg/ 80 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg alone.
Exforge is taken by mouth as one tablet once a day with some water, with or without food.
Exforge has not been studied in any patient population other than hypertension.
Exforge has not been studied in any patient population other than hypertension.
Exforge can be used with or without food.
Stability testing requirements for new dosage forms (Q1C)
- ectoparasiticide testing requirements for sheep
Is there any reason for not being given Elaprase?
EXJADE induced similar responses in iron- overloaded patients with other anaemias.
EXJADE has not been studied in patients with hepatic impairment and must be used with caution in such patients.
EXJADE has not been studied in patients with renal impairment and is contraindicated in patients with estimated creatinine clearance < 60 ml/ min (see sections 4.3 and 4.4).
EXJADE is not recommended in patients with severe hepatic impairment as it has not been studied in such patients.
Use within 3 months of first opening.
EXP Shelf-life after first use:
• Clinical trials experience
Experience in patients with persistent viral replication:
Experience from rheumatoid arthritis
See also Post-marketing experience below.
The following additional laboratory abnormalities have been reported during post-marketing experience; they are derived from spontaneous reports for which precise incidences cannot be determined:
• Experience with hepatitis B vaccine:
Experience in patients with compensated liver disease and lamivudine-resistant HBV:
Experience in patients with decompensated liver disease and lamivudine-resistant HBV:
Experience in patients pre- and post-liver transplantation with lamivudine-resistant HBV:
Clinical experience Invasive aspergillosis Oral posaconazole 800 mg/ day in divided doses was evaluated for the treatment of invasive aspergillosis in patients with disease refractory to amphotericin B (including liposomal formulations) or itraconazole or in patients who were intolerant of these medicinal products in a non-comparative salvage therapy trial.
Clinical Experience in Non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
Clinical Experience in Non-Hodgkin's lymphoma and in chronic lymphocytic leukaemia
Post-marketing Experience Osteonecrosis of the jaw has been reported in patients treated by bisphosphonates.
Clinical trial experience with hard capsules
After a traineeship with the European Commission 1991-92, Martin Harvey Allchurch worked as a European affairs consultant in Brussels from 1992 to 1995.
Qualified as a pharmacist from Heriot-Watt University, Edinburgh.
From 1975 to 1990 Mrs Mendosa held a number of posts at the European Commission in Luxembourg, including the Conference Service, the Office for Official Publications and the Statistical Office.
From 1976 to 1978, lecturer at University of Uppsala.
From 1976 to 1987, Dr Grein held positions in Germany as scientific assistant at the Free University of Berlin and as pharmacist.
From 1977 to 1986, Dr Le Courtois worked as a general practitioner and as director of a medical centre in Paris.
From 1981 to 1983 Dr Abadie held a number of clinical and laboratory positions, before joining the pharmaceutical industry in 1983.
From 1981 to 1984, Dr Moulin worked in the Bovine Pathology Laboratory in Lyon.
From 1982 to 1986, Dr Bénéfice was a researcher at the University of Montpellier, France.
From 1988 to 1992, Dr Brosch worked as an assistant professor at the Department of Pharmacology and Toxicology at the University of Vienna, where she was specialised in electrophysiology.
Worked as a clinical endocrinologist in a French hospital until 1987 and then joined the Directorate of Pharmacy at the French Ministry of Health.
paediatrician in a teaching paediatric hospital in Paris, followed by a number of years working for a number of pharmaceutical companies.
Dr Wagner was a research and teaching assistant at Saarbruecken University from 1976 to 1981.
EU expert Dr Satu Pyörälü, Finland ⋅ Environmental Risk Assessment - EU expert Dr Carol Aldridge, UK ⋅ Efficiency Requirements for Anthelmintics Efficacy - EU Expert Prof.
EXP {month/ year} After dilution, the product should be used immediately.
"Month/ Year" After dilution, the product should be used immediately.
EXP {2 digits / year} Once opened use within 28 days.
EXP {2 digits/ year} Once opened use within 28 days.
EXP {month/ year} Once broached, use within 10 hours.
EXP {month/ year} Once opened use within 10 days.
EXP {month/year} Once broached, use within 28 days.
EXP {MM/ AA/ AA} Once opened, use by 6 months.
EXP {month/ year} Once opened use within 6 months.
< EXP {month/year} > Once broached, use within 8 hours.
EXP {month/ year} Once opened use within 6 months.
EXP {month/ year} Shelf-life after first use of the product:
EXP {month/ year} Shelf-life after first use of the product:
EXP {MM/ YYYY] In-use shelf life:
EXP {month/ year} Shelf-life after first opening the container:
EXP {month/ year} Shelf-life of broached vial:
{month/ year} Shelf-life of broached vial:
EXP {MM/ YYYY} Vial of suspension after reconstitution:
EXP {MM/ YYYY} Discard one month after first opening.
EXP {month/ year} Half tablets should be returned to the original market container and may be stored for up to 7 days
EXP {MM/ YYYY} The pen should be discarded 28 days after the first use.
EXP {month/ year} Once broached, use immediately
EXP {month/ year} Use immediately after opening.
EXP {month/ year} The product should be used immediately after reconstitution.
{MM-YYYY} Do not use after 2 months of first opening the bottle
EXP {MM/ YYYY} Discard pen 30 days after first use.
EXP {month/ year} Once broached, use by …
EXP {month/year} Once broached, use within 28 days
Once broached, use within 2 hours.
< EXP {month/year} > Once broached, use within 8 hours.
< EXP {month/year} > Once broached, use within 8 hours.
EXP {month/ year} Once broached, use within 8 hours
EXP month/ year Once opened, use immediately
- Limited exposure due to limited marketing.
Exp: xx/ xxxx Discard four weeks after first opening.
EXP: xx/ xxxx Discard four weeks after first opening.
Extavia is indicated for the treatment of • Patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis (see section 5.1). • Patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years. • Patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.
Extavia is a powder and solvent that are made up into a solution for injection.
Extremadura, 3, Poligono Industrial Allenduero, 09400 Aranda de Duero (Burgos), Spain. >
EXUBERA 1 mg inhalation powder pre-dispensed.
EXUBERA 1 mg inhalation powder pre-dispensed EXUBERA 3 mg inhalation powder pre-dispensed Insulin human
EXUBERA 1 mg inhalation powder pre-dispens ed Insulin human
EXUBERA 3 mg inhalation powder pre-dispensed.
EXUBERA 3 mg inhalation powder pre-dispensed
EXUBERA 3 mg inhalation powder pre-dispens ed Insulin human
Exubera has been studied in patients with type 2 or type 1 diabetes.
EXUBERA should only be breathed in through your mouth and should only be taken with your ic
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
EXUBERA can also be used to treat type 1 diabetes in adults whose level of blood sugar is not well- controlled by insulin injections.
EXUBERA is indicated for the treatment of adult patients with type 2 diabetes mellitus not adequately controlled with oral antidiabetic agents and requiring insulin therapy. uc
EXUBERA is used to reduce high blood sugar in adult patients with type 2 diabetes mellitus who ed
EXUBERA should not be taken during pregnancy.
Exubera is used only with its insulin inhaler.
Tel: + 371 670 35 775 pr
Eλληνικού 2 GR– 167 77 Eλληνικό - Aθήνα Tηλ: +30 2 10 89 06 300
F-92300 Levallois-Perret Tél: + 33-(0)1 41 06 35 00
FABLYN is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.
Fablyn is a medicine that contains the active substance lasofoxifene.
FABLYN is used to treat osteoporosis in women after the menopause (postmenopausal osteoporosis) who are likely to break bones, especially in the spine, hips and wrists.
Fablyn did not reduce the number of hip fractures to a level that would be relevant for patients.
Subjects with severe hepatic impairment have not been studied (see section 4.4).
It must not be used in women with unexplained bleeding from the womb.
Fablyn was more effective than placebo at reducing the number of new fractures.
Fabrazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α -galactosidase A deficiency).
Fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.
Fabrazyme is used as enzyme replacement therapy in Fabry disease, where the level of α - galactosidase enzyme activity is absent or lower than normal.
Fabrazyme is used as enzyme replacement therapy in Fabry disease, where the level of α- galactosidase enzyme activity is absent or lower than normal.
Aesica Queenborough Ltd Queenborough Kent ME11 5EL United Kingdom
Manufacturer Almac Pharma Services Limited, 20 Seagoe Industrial Estate, Craigavon, Co Armagh, BT63 5QD, United Kingdom.
Manufacturer Aventis Pharma, Dagenham Rainham Road South Dagenham Essex RM10 7XS United Kingdom
Manufacturer Axcan Pharma S.A., Route de Bû, 78550 Houdan, France
65 Manufacturer Biocodex 1 avenue Blaise Pascal - F-60000 Beauvais - France
Manufacturer Biocodex 1 avenue Blaise Pascal - F-60000 Beauvais - France
Manufacturer Bioglan AB Borrgatan 31 SE-211 24 Malmö Sweden
Manufacturer Brecon Pharmaceuticals Ltd Pharos House, Wye Valley Business Park Hay-on-Wye Hereford HR3 5PG United Kingdom
Manufacturer Catalent UK Packaging Ltd, Lancaster Way, Wingates Industrial Park, Westhoughton, Bolton, Lancashire, BL5 3XX, United Kingdom
Manufacturer CSL Behring GmbH, Emil-von-Behring-Straße 76, 35041 Marburg, Germany.
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
10 A MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
39 A MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
62 A MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
9 A MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
Defined as HCV-RNA below limit of detection using a research based RT-PCR assay at end of treatment and during follow-up period
MANUFACTURE OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE ANDMANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTUREROF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE ANDMANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION no
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE ng SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE lo o
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
18 A MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
CONDITIONS OF THE MARKETING AUTHORISATION tn uc od pr al in ic ed M A MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE AND MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE
16 A MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE no
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE no
Manufacturer Ferring AB Soldattorpsvägen 5 Box 30047 SE - 20061 Limhamn Sweden
Manufacturer Laboratoire Elaïapharm 2881 Route des Crêtes Z. I.
- Lilly S. A., Avda. de la Industria 30, 28108 Alcobendas (Madrid), Spain.
Manufacturer Mallinckrodt Medical Imaging Ireland Damastown Mulhuddart, Dublin 15 Ireland
Manufacturer medac Gesellschaft für klinische Spezialpräparate mbH Theaterstraße 6 D-22880 Wedel, Germany Tel. + 49 4103 8006 0 Fax: + 49 4103 8006 100
Manufacturer Novartis Pharma GmbH Roonstraße 25 D-90429 Nuremberg Germany
Manufacturer Novartis Pharma GmbH Roonstrasse 25 D-90429 Nuremberg Germany
Manufacturer Novartis Pharma GmbH Roonstraße 25 D-90429 Nuremberg Germany
Manufacturer Penn Pharmaceutical Services Limited Tafarnaubach Industrial Estate Tredegar Gwent NP22 3AA United Kingdom
Manufacturer Pfizer Ireland Pharmaceuticals Pottery Road Dun Laoghaire Co Dublin Ireland
(Manufacturer responsible for final filtration of monovalent pooled harvest):
Manufacturer for the batch release Pfizer PGM Z. I. d'Amboise F-37530 Pocé-sur-Cisse France
Manufacturer Responsible for Batch Release:
(Manufacturer responsible for monovalent pooled harvests, before final filtration):
Manufacturer Roche Pharma AG Emil-Barell-Strasse 1 D-79639 Grenzach-Wyhlen Germany
Manufacturer Sächsisches Serumwerk Dresden (SSW) Zirkusstraße 40 D-01069 Dresden Germany
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE ANDMANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE no
16 A MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
10 A MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
Manufacturer Wyeth Pharmaceuticals New Lane Havant Hants, PO9 2NG United Kingdom
Recombinant Factor IX Summary of Pharmacokinetic Parameters for Activity Data by Month in Previously Treated Patients
Weakness of the arms, pruritus, myalgia, joint disorder, arm pain
Muscle weakness, arthralgia, musculoskeletal pain, myalgia
weakness (see section 4 of this leaflet for more information).
- Persistent muscle weakness or muscle pain (myopathy/ myositis), muscle cramp
Sudden numbness or weakness of the arm, leg or face, especially if only on one side of
- low numbers of platelets (which help blood clotting) or bleeding disorders
From 1 965 to 1973, Mr Fairchild worked in a major pharmaceutical company setting up quality assurance systems and in production operations.
From 1965 to 1973, Mr Fairchild worked in a major pharmaceutical company setting up quality assurance systems and in production operations.
Take care to avoid penetrating the abdominal wall musculature or fat tissue.
Vials containing Humalog Mix25 should be rotated in the palms of the hands before use to resuspend the insulin until it appears uniformly cloudy or milky.
Vials containing Humalog Mix50 should be rotated in the palms of the hands before use to resuspend the insulin until it appears uniformly cloudy or milky.
The Pen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky.
Instructions for use and handling The KwikPen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky.
The KwikPen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky.
Rotate the inner part of the syringe assembly as shown below so that the label can be read in the viewing window.
147 Press down according to instructions on the cap while turning to the left.
167 Press down according to instructions on the cap while turning to the left.
As requested by the CHMP, the MAH agreed to submit the follow-up measures as listed below:
• Take care not to infect other people.
Take special care with Aldurazyme If you are treated with Aldurazyme, you may develop infusion-associated reactions.
Take special care with Bondronat: if you know or believe that you may have:
Take special care with Diacomit • if your child has kidney or liver problems. • if your child is using medicines containing:
Take special care with DULOXETINE BOEHRINGER INGELHEIM The following are reasons why DULOXETINE BOEHRINGER INGELHEIM may not be suitable for you.
Take special care with Gliolan After administration of this medicine, avoid that your eyes and skin are under strong light (for example operating illumination, direct sunlight or brightly focused indoor light) for 24 hours.
Take special care with Humalog BASAL KwikPen • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Humalog BASAL Pen • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Humalog BASAL • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Humalog KwikPen • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Humalog Mix25 KwikPen • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Humalog Mix25 Pen • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Humalog Mix25 • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Humalog Mix50 KwikPen • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Humalog Mix50 Pen • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Humalog Pen • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Humalog • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with IONSYS Tell your doctor or nurse
Take special care with Liprolog Basal KwikPen • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Liprolog Basal Pen • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Liprolog Basal • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Liprolog KwikPen • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Liprolog Mix25 Pen • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Liprolog Mix25 • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Liprolog Mix50 KwikPen • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Liprolog Mix50 Pen • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Liprolog Mix50 • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Liprolog Pen • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with Liprolog • If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low.
Take special care with ORACEA Inform your physician
Take special care with RISPERDAL CONSTA • If you have never taken any form of RISPERDAL, you should begin with oral RISPERDAL before beginning treatment with RISPERDAL CONSTA.
34 Take special care with STELARA Your doctor will assess your health before treatment.
44 Take special care with STELARA Your doctor will assess your health before treatment.
Take special care with Telzir Before you take Telzir your doctor needs to know: • If you have a known allergy to medicines containing sulphonamide.
Take special care with TESLASCAN if one of the following conditions exists:
22 Take special care with Thyrogen The injection with Thyrogen should never be injected into a vein.
Take special care with Trevaclyn Tell your doctor about all of your medical conditions.
Take care not to infect other people Sebivo does not reduce the risk of infecting others with hepatitis B virus (HBV) through sexual contact or exposure to contaminated blood or other body fluids.
Take care not to touch the end of the transfer needle.
Wilzin is usually not recommended for initial therapy of patients with signs and symptoms of Wilson's disease because of its slow onset of action.
Keep turning the cap until 6 is opposite the dosage indicator.
Slide the sleeve up the body of the syringe until it locks into position over the needle.
Do this in front of a mirror if it helps. • Do not touch your eye or eyelid, surrounding areas or other surfaces with the dropper.
Gently roll the Pen ten times
Cartridges containing Liprolog Basal should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky.
Cartridges containing Liprolog Mix25 should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky.
Cartridges containing Liprolog Mix50 should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky.
Cartridges containing Humalog BASAL should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky.
Cartridges containing Humalog Mix25 should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky.
Cartridges containing Humalog Mix50 should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky.
Take special care with Tritanrix HepB:
44 Take special care with Volibris: • if you have anaemia (a reduced number of red blood cells).
Turn the cap round 1 full turn, so 0 is opposite the dosage indicator again.
Turn the cap round 1 full turn, so 0 is opposite the dosage indicator again.
Turn the cap until 8 is opposite the dosage indicator; four clicks.
Turn the cap until 8 is opposite the dosage indicator; four clicks.
Turn the cap until 8 is opposite the dosage indicator; four clicks To select 26 units:
Are you exercising more than usual?
Importantly, 27.7% of patients also achieved a major cytogenetic response, which was complete in 20.4% (confirmed 16%) of patients.
expected that these improvements, together with increased staffing of the
Component of a multipack comprising 10 packs, each containing 1 bottle with 50 g oral drops, solution.
Component of a multipack comprising 10 packs, each containing 1 bottle with 50 g oral drops, solution.
Part of a pack containing 14 single packs in a 3-month pack of 3x14 single packs.
Part of a pack containing 15 single packs in a 3-month pack of 3x15 single packs.
Famar, 190 11 Avlona, Greece Catalent UK Packaging Limited, Sedge Close, Headway, Great Oakley, Corby, Northamptonshire NN18 8HS, United Kingdom.
Famar S. A., 49 KM Athens-Lamia, 190 11 Avlona, Greece
Fasturtec 1.5 mg/ ml powder and solvent for concentrate for solution for infusion
Fasturtec 1.5 mg/ ml powder and solvent for concentrate for solution for infusion rasburicase
Fasturtec 1.5 mg/ ml powder for concentrate for solution for infusion rasburicase Intravenous use
Fasturtec works by allowing uric acid to more easily be removed from the body by the kidneys.
1.5 mg rasburicase vial to be reconstituted with the 1 ml solvent ampoule; 7.5 mg rasburicase vial to be reconstituted with the 5 ml solvent ampoule).
Fasturtec is given at the start of chemotherapy.
Fasturtec is injected slowly into a vein, which should take about 30 minutes.
Fasturtec is a medicine containing the active substance rasburicase.
Fasturtec is used to treat and prevent acute (sudden) hyperuricaemia (increased levels of uric acid in the blood), in order to prevent kidney failure.
Fasturtec is not directly effective in the treatment of these abnormalities.
Fasturtec should not be used in patients with a deficiency in glucose-6-phosphate dehydrogenase (G6PD) or other metabolic disorders known to cause haemolytic anaemia (low red blood cell counts, caused by the cells being destroyed too soon).
Fasturtec is provided as a powder and solvent for concentrate for solution for infusion.
Common Pyrexia, Oedema, Oedema peripheral, Injection site reaction
Fatigue Fever, asthenia, rigors, malaise, pain, taste perversion
have discontinued Ziagen due to a hypersensitivity reaction, YOU MUST
have discontinued Ziagen due to a hypersensitivity reaction, YOU MUST NEVER
- severe tiredness or achiness or generally feeling ill
- severe tiredness or achiness or generally feeling ill
Maximum shelf-life for sterile medicinal products after first opening or following reconstitution Adopted July 2000
Note for guidance on quality of herbal medicinal products Released for consultation November 2000
Joint CPMP/CVMP Quality Working Party
In vitro fertilisation In single cases of in vitro fertilisation calcium antagonists like nifedipine have been associated with reversible biochemical changes in the spermatozoa's head section that may result in impaired sperm function.
European Public Assessment Report
Felodipine, nifedipine, nicardipine, diltiazem, nimodipine, verapamil, amlodipine, nisoldipine, isradipine (saquinavir/ritonavir)
26-Year-Old Females (Protocols 013 and 015) n GMT (95% CI)
When treatment with voriconazole is stopped, the initial dosage of efavirenz should be restored.
Premenopausal anovulatory women Premenopausal women have received rosiglitazone during clinical studies.
Fendrix has a minor or moderate influence on the ability to drive and use machine.
Fendrix should be injected intramuscularly in the deltoid region.
Fendrix is indicated for active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes for patients with renal insufficiency (including pre-haemodialysis and haemodialysis patients), from the age of 15 years onwards.
Fendrix is a vaccine which prevents hepatitis B disease in patients with renal insufficiency (including pre-haemodialysis and haemodialysis patients) from the age of 15 years onwards.
Fendrix should not be given to subjects with hypersensitivity to the active substance or to any of the excipients.
Norditropin Genotropin Salmeterol/fluticasone proprionate Fenofibrate Lisinopril Biochemie Lisinopril Cardiostat Somatropin Laurina Mononine
Fentanilo Matrix ratiomed 100 microgramos/ h parches
Close bottle using child resistant closure.
Close your Actraphane 10 NovoLet fully with 0 next to the dosage indicator.
Close your Actraphane 20 NovoLet fully with 0 next to the dosage indicator.
Close your Actraphane 30 NovoLet fully with 0 next to the dosage indicator.
Close your Actraphane 40 NovoLet fully with 0 next to the dosage indicator.
Close your Actraphane 50 NovoLet fully with 0 next to the dosage indicator.
Close your Mixtard 10 NovoLet fully with 0 next to the dosage indicator.
Close your Mixtard 20 NovoLet fully with 0 next to the dosage indicator.
Close your Mixtard 30 NovoLet fully with 0 next to the dosage indicator.
Close your Mixtard 40 NovoLet fully with 0 next to the dosage indicator.
Close your Mixtard 50 NovoLet fully with 0 next to the dosage indicator.
Close your NovoRapid NovoLet fully with 0 next to the dosage indicator.
Place the cap tightly over the top of the bottle, which now includes the bottle adapter.
Fernando de ANDRES- TRELLES
FERRING AB Soldattorpsvägen 5 SE-20061 Limhamn Sweden
Ferring Pharmaceuticals A/ S Kay Fiskers Plads 11 2300 Copenhagen S Denmark +45 88 33 88 34
Ferring Pharmaceuticals A/ S Kay Fiskers Plads 11 2300 Copenhagen S Denmark +45 88 33 88 34
Ferring Pharmaceuticals A/ S Kay Fiskers Plads 11 2300 København S Denmark
Ferring Pharmaceuticals A/ S Kay Fiskers Plads 11 DK-2300 Copenhagen S Denmark Tel. +45 8833 8834 38 Manufacturer:
Ferring Pharmaceuticals A/ S Kay Fiskers Plads 11 DK-2300 Copenhagen S Denmark Tel. +45 8833 8834 45 Manufacturer:
Ferring Pharmaceuticals A/ S Kay Fiskers Plads 11 DK-2300 Copenhagen S Denmark Tel: +45 88 33 88 34
Królowej Marysień ki 11 m.
Fertavid was studied in 172 anovulatory women, measuring how many cycles of treatment were needed for these women to ovulate.
Fertavid should not be used during breast-feeding.
No fertility data is available for humans.
Fertility No human data on the effect of etravirine on fertility are available.
Fertility Busulfan and DMA can impair fertility in man or woman.
Fertility: busulfan can impair fertility.
Fertility Formal studies of the potential effect of ORENCIA on human fertility have not been conducted.
Fevaxyn Pentofel has been studied against Feline Leukaemia, against respiratory diseases caused by Feline Rhinotracheitis virus, Feline Calicivirus and Feline Chlamydia psittaci, as well as against disease caused by Feline Panleukopenia virus.
Feline Panleukopenia Virus, Feline Rhinotracheitis Virus, Feline Calicivirus, Feline Leukaemia Virus, and the inactivated bacterium Feline Chlamydia psittaci.
Fevaxyn Pentofel is then given once every year.
Fevaxyn Pentofel is used to immunise healthy cats of 9 weeks or older against Feline Panleukopenia and Feline Leukaemia and against respiratory diseases caused by Feline Rhinotracheitis virus, Feline Calicivirus and Feline Chlamydia psittaci.
Fevaxyn Pentofel has been shown to be effective against Feline Leukaemia, against respiratory diseases caused by Feline Rhinotracheitis virus, Feline Calicivirus and Feline Chlamydia psittaci, as well as against disease caused by Feline Panleukopenia virus.
Fevaxyn Pentofel stimulates the development of active immunity against Feline Panleukopenia Virus, Feline Rhinotracheitis Virus, Feline Calicivirus, Chlamydophila felis and Feline Leukaemia Virus.
FGK Representative Service GmbH Heimeranstrasse 35 80339 München, Germany
FHV (F2 strain)................................................................................................................ ≥ 104.9 CCID50 FCV (431 and G1 strains).............................................................................................. ≥ 2.0 ELISA U.
FHV (F2 strain)................................................................................................................ ≥ 104.9 CCID50 FCV (431 and G1 strains).............................................................................................. ≥ 2.0 ELISA U.
FHV (F2 strain)................................................................................................................. ≥ 104.9 CCID50 FCV (431 and G1 strains)............................................................................................... ≥ 2.0 ELISA U.
FHV (F2 strain)................................................................................................................ ≥ 104.9 CCID50 FCV (431 and G1 strains).............................................................................................. ≥ 2.0 ELISA U.
FHV (F2 strain).................................................................................................................  104.9 CCID 50 FCV (431 and G1 strains)...............................................................................................  2.0 ELISA U.
Short (< 2.5 cm) fibre optic diffuser (50 J/ cm)
Short (< 2.5 cm) fibre optic diffuser (50 J/ cm)
Short fibre optic diffusers to be used without a centering balloon to deliver 50 J/ cm of diffuser length at a light intensity of 400 mW/ cm
Shock, Hypotension, Night sweats, Hypersensitivity reaction*
Blood lactate dehydrogenase increased Blood creatinine increased
Investigations Blood lactate dehydrogenase increased Blood creatinine increased
General disorders Pyrexia, and rigors*, administration pain*, site conditions asthenia, fatigue, injection site reaction*, irritability*
General disorders Pyrexia, and rigors*, administration pain*, site conditions asthenia, fatigue, injection site reaction*, irritability*
Fever, injection site mass, haematomas, oedema in legs Pain in legs, pain, abdominal and chest pain
Figure 1 Percent of Patients Receiving Highly Emetogenic Chemotherapy Who Remain Emesis Free Over Time – Cycle 1
Filgrastim HEXAL 30 MU/ 0.5 ml injection or infusion
Each pre-filled syringe contains 30 MU filgrastim in 0.5 ml, corresponding to 60 MU/ ml.
Filgrastim HEXAL 30 MU/ 0.5 ml solution for injection or infusion in pre-filled syringe
Filgrastim HEXAL 30 MU/ 0.5 ml solution for injection or infusion in pre-filled syringe
Filgrastim HEXAL 30 MU/ 0.5 ml solution for injection or infusion in pre-filled syringe Filgrastim HEXAL 48 MU/ 0.5 ml solution for injection or infusion in pre-filled syringe Filgrastim
Filgrastim HEXAL 48 MU/ 0.5 ml injection or infusion
Filgrastim HEXAL 48 MU/ 0.5 ml solution for injection or infusion in pre-filled syringe
Filgrastim HEXAL 48 MU/ 0.5 ml solution for injection or infusion in pre-filled syringe
Filgrastim HEXAL is available in strengths of 30 MU/ 0.5 ml and 48 MU/ 0.5 ml.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Filgrastim Hexal can also be used in people who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow.
Filgrastim ratiopharm 30 MIU/ 0.5 ml solution for injection or infusion
Filgrastim ratiopharm can also be used in patients who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow.
The MAH finally argued that the fluorimetric method used was capable of detecting residues of amoxicillin degradation products, and thus, the concentrations reported may have been overestimated.
– Further optimisation of a drug monitor scheme in order to antimicrobials provide a summary of all key and relevant pharmacovigilance
Finland GlaxoSmithKline Oy Piispansilta 9A, P. O.
Tel: + 386 1 580 2884 Suomi/ Finland Novartis Healthcare A/ S, Puh/ Tel: +45-39 16 84 00 Sverige Novartis Healthcare A/ S Tel: +45-39 16 84 00 United Kingdom Novartis Animal Health UK Ltd.
FIRMAGON 80 mg powder and solvent for solution for injection Degarelix
FIRMAGON 80 mg powder and solvent for solution for injection
FIRMAGON must be injected under the skin (subcutaneously) ONLY.
FIRMAGON is a powder for solution for injection.
Firmagon must not be injected into a vein or a muscle.
There is no relevant indication for use of FIRMAGON in women, children and adolescents.
For a full list of excipients, see section 6.1.
- Tracheo-oesophageal or broncho-oesophageal fistula.
Tracheo-oesophageal or broncho-oesophageal fistula.
Syringe containing your medicine being attached to a new needle
• Stick to realistic calorie and fat targets as this is a good way of maintaining your weight loss achievements in the long-term. • Write down what you eat in a food diary, including the calorie and fat content. • Try to be more physically active before you start taking the capsules.
Fit (by first pressing and then screwing) the adapter onto the open bottle neck
Open the bottle and fit (by first pressing and then screwing) the plastic adapter onto the open bottle neck.
Assemble the 5 µm filter needle (provided) onto the 1 ml syringe (provided) using aseptic technique.
Attach the actuator to the implanter using the Luer Lock connection.
The actuator is attached to the implanter using the Luer Lock connection.
Attach the longer needle to the syringe and remove the cover.
Put the needle on the syringe and remove the cover of the needle.
Put the short needle on the syringe and remove the cover.
Twist to lock the needle to the Luer connector.
Twist to lock the needle to the Luer connector.
• Always attach a new needle before each use.
Important information for use of OptiSet:
Set your calorie and fat targets
Vial A Pandemrix suspension for emulsion for injection
Single-use vial for intravitreal use only
Single-use vial for intravitreal use only.
Single use vial – discard any content remaining after first use.
Vial B Emulsion for emulsion for injection for Pandemrix
Vial B Emulsion for emulsion for injection for Prepandrix
9 Polysorbate 20, sodium hydroxide, water for injections
Zinc chloride, m-cresol, glycerol, hydrochloric acid, Polysorbate 20, sodium hydroxide, water for injections
Vial of 5 doses of emulsion Vial of 25 doses of emulsion
Vial of 5 doses of suspension Vial of 25 doses of suspension
Zinc chloride, m-cresol, glycerol, hydrochloric acid, sodium hydroxide, water for injections.
Docetaxel Winthrop 80 mg concentrate for solution for infusion vial
Polyethylene bottle containing 10, 32, 100 or 180 ml with a polyethylene dropper, a tamper proof child resistant closure and a polypropylene measuring syringe.
Polyethylene bottle containing 10, 32 or 100 ml with a polyethylene dropper, a tamper proof child resistant closure and a polypropylene measuring syringe.
Polyethylene bottle containing 15 ml with a polyethylene dropper, a tamper proof child resistant closure and a polypropylene measuring syringe.
Polyethylene bottle containing 15 or 30 ml with a polyethylene dropper, a tamper proof child resistant closure and a polypropylene measuring syringe.
42, 100 or 200 ml polyethylene terephthalate (PET) bottle with a tamper resistant child proof closure, and a 15 ml HDPE bottle with a tamper resistant child proof closure, and a polypropylene measuring syringe.
Vial for powder for suspension for injection (all packs)
ReFacto AF contains nominally 250, 500, 1000, or 2000 IU of moroctocog alfa.
High-density polyethylene (HDPE) bottles with child resistant screw cap (60 hard capsules per bottle), or
HDPE bottle with child resistant screw cap, fill mark (200 ml of solution after reconstitution) and measuring cup.
High-density polyethylene (HDPE) bottle with child-resistant closure.
bottle (HDPE) bottle (HDPE) bottle (HDPE) bottle (HDPE) without outer carton
bottle (HDPE) bottle (HDPE) blister (alu/ alu) 3 bottles (HDPE)
COLOURLESS TYPE-2 GLASS BOTTLE WITH GREY SILICONISED BROMOBUTYL STOPPER OR CHLOROBUTYL STOPPER
COLOURLESS TYPE-2 GLASS BOTTLE WITH GREY SILICONISED BROMOBUTYL STOPPER OR CHLOROBUTYL STOPPER.
White high-density polyethylene (HDPE) bottle with induction sealing and polypropylene child- resistant closure.
HDPE bottle with child resistant closure
Component of a multi-pack comprising 3 bottles, each containing 60 film-coated tablets.
8 Vials in use or carried as a spare:
Flatulence Skin and subcutaneous tissue disorders:
Flatulence, breathlessness, rash (red, raised or itchy), fever, general aches and pains and reduction in platelets (blood cells important for blood clotting).
Flebogammadif is usually given by intravenous infusion by a doctor or nurse, but patients (or their carers) may administer it themselves once they have been trained.
Since Flebogammadif might induce dizziness, patients should be cautioned when driving or operating machines.
Flemingweg 18 NL-2408 AV Alphen a/ d Rijn Netherlands
Flemingweg 18 NL-2408 AV Alphen a/ d Rijn Tel: + 31 172 449 494
Flexicam contains meloxicam which belongs to a class of medicines having anti- inflammatory action.
The FlexPen that is being used, about to be used or carried as a spare is not to be kept in a refrigerator.
FlexPen are pre-filled pens designed to be used with NovoFine short cap needles.
Proposal for a core-data for Lupuli flos (Hop strobile) (*)
Fluconazole/miconazole (saquinavir/ritonavir) Antimycobacterials
Belgium, France, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain, UK:
Fluvastatin Lovastatin Pravastatin Rosuvastatin Simvastatin
- fluvoxamine (used to treat depression and other psychiatric diseases)
[Calcium folinate/ 5-fluorouracil Calcium folinate may enhance the toxicity risk of 5-fluorouracil, particularly in elderly or debilitated patients.
Folliculitis, fungal infection, cold sores (non-herpetic), upper respiratory tract infection
Liver function Fluctuations in abnormalities of liver function tests are common in patients with chronic hepatitis C.
2.4 Operation of the Committee on Orphan Medicinal Products
2.1 Operation of the Committee for Proprietary Medicinal Products
Operation of the Committee for Proprietary Medicinal Products...... ..25 Performance indicators.................................................................................... .25 Centralised procedures.................................................................................... .26
Operation of the CVMP........................................................................ ..40 Performance indicators.................................................................................... .40 Rapporteurships................................................................................................ 42
2. maintenance and pharmacovigilance activities (Council Regulation (EEC) No 2309/93, Articles 15-25, Articles 37-47)
Fondaparinux should be used with care in these lo patients.
Fondaparinux should be used with care in these patients.
Renal impairment - Fondaparinux should be used with caution in patients with moderate renal ed
Renal impairment - Fondaparinux should be used with caution in patients with moderate renal impairment (see section 4.4). ed
significant reduction in the rate of symptomatic VTE (DVT, and / or PE) [1 (0.3%) vs 9 (2.7%) patients, respectively] including two fatal PE reported in the placebo group.
- clotting in vein at injection-site; inflammation at injection-site; pain at injection-site; collection of
Training in Administration
The initiative began by EMEA in 2001 on the organisation of training for assessors from national authorities within its premises continued in 2002 and the Agency contributed to the coordination of the programme with national competent authorities.
Qualified medical doctor from the Free University of Brussels.
Bachelor of Arts in languages and linguistics at the University of East Anglia and post-graduate degree in librarianship and information science at University of Wales.
Degree in medicine and surgery from the University of Rome.
Science at Liverpool University and is a Member of the Royal College of Veterinary Surgeons of the United Kingdom.
Qualified Pharmacist with Masters degree in Pharmaceutical Chemistry and Masters in Business Administration (MBA) from Trinity College Dublin.
Qualified pharmacist from the University of Uppsala Faculty of Pharmacy.
PhD in Microbiology from the University of Lyon.
Doctorate of Science in physical sciences; qualification in research management; PhD in physical organic chemistry; Masters degree in physical organic chemistry; Degree in biochemistry.
• Staff should be trained in how to handle and transfer the medicinal product. • Pregnant staff should be excluded from working with this medicinal product. • Personnel handling this medicinal product during handling/ transfer should wear protective clothing including mask, goggles and gloves. • All items for administration or cleaning, including gloves, should be placed in high-risk, waste disposal bags for high-temperature incineration.
MSc in computer science and BSc in business administration and economics at the University of Gothenburg.
science, history and English from the University of Hamburg.
hemifumarate) and 25 mg hydrocholorothiazide.
Powder for suspension for infusion One vial of 100 mg paclitaxel
Inhalation powder pre-dispensed
PHARMACEUTICAL FORM AND CONTENTS Inhalation powder pre-dispensed
Pharmaceutical Form Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard
Form a skin fold by pinching the skin between the thumb and the forefinger.
Form a skin fold by pinching the skin between thumb and forefinger.
Form a skin fold by pinching the skin between thumb and forefinger.
Formistin, Virlix, Zirtec 10 mg compresse rivestite con film Latvia:
Formistin, Virlix, Zirtec 10mg/ ml gocce orali soluzione Latvia:
Formistin, Virlix, Zirtec 10 mg compresse rivestite con film Latvia:
Zirtec 1mg/ ml soluzione orale Latvia:
All Treatment Initiation Forms should contain the following elements:
FORSTEO 20 micrograms/ 80 microliters solution for injection in pre-filled pen
FORSTEO increased BMD at the total hip (3.6%) compared with alendronate (2.2%) (p < 0.01), as well as at the femoral neck (3.7%) compared with alendronate (2.1%) (p < 0.05).
Forsteo reduced the risk of developing a new vertebral fracture over 19 months by 65% compared with placebo.
Forsteo contains the active substance teriparatide (one 2.4 ml prefilled pen contains 600 micrograms of teriparatide).
Forsteo is a prefilled pen that contains a solution for injection.
Forsteo is used for the treatment of osteoporosis (a disease that makes bones fragile) in the following groups:  women who have been through the menopause.
Forsteo FORSTEO, 20 microgram (µg) 80 microlitres solution for injection, in pre-filled pen
FORSTEO should not be used in paediatric patients (less than 18 years), or young adults with open epiphyses.
Forsteo must not be used in children or in young adults whose bones are not yet fully mature, or during pregnancy or breast- feeding.
FORSTEO may also cause an increase in an enzyme called alkaline phosphatase
Fort Dodge Charles City 2000 Rockford Road Charles City Iowa 50616 USA
Fort Dodge Animal Health Holland C. J. van Houtenlaan 36 1381 CP Weesp The Netherlands
Fort Dodge Animal Health Holland C. J. van Houtenlaan 36 1381 CP Weesp, The Netherlands
Fort Dodge Animal Health Holland CJ van Houtenlaan 36 1381 CP Weesp The Netherlands
Fort Dodge Animal Health Holland CJ van Houtenlaan 36 1381 CP Weesp, The Netherlands
Fort Dodge Laboratories Ireland Finisklin Industrial Estate Sligo Ireland
Fort Dodge Laboratories Ireland Finisklin Industrial Estate Sligo Ireland
FORZAAR 100 mg + 25 100 mg mg compresse rivestite con film
Fosavance 70 mg/ 5,600 IU is for use in patients who are not taking vitamin D supplements.
Fosavance (containing either 2,800 or 5,600 IU colecalciferol) is used to treat osteoporosis (a disease that makes bones fragile) in post-menopausal women at risk of low vitamin D levels.
FOSAVANCE has not been studied in children and adolescents and therefore should not be given to them.
FOSAVANCE is not recommended for patients with renal impairment where GFR is less than 35ml/ min (see section 4.2).
FOSAVANCE reduces the risk of vertebral and hip fractures.
Fosavance reduces the risk of vertebral (spine) and hip fractures (breaks).
Foscan 1 mg/ ml solution for injection Temoporfin Intravenous use
This product contains 48 vol% ethanol (alcohol), i. e up to 4.2 g per dose, equivalent to 84 ml of beer, 35 ml wine per dose.
Foscan must be administered intravenously via an in-dwelling cannula in a large proximal limb vein, preferably in the antecubital fossa.
Foscan is a porphyrin photosensitising medicine.
- tingling or numbness, pain, loss of reflexes, paralysis on a nerve route, itching and rash.
- pins and needles, unusual sensitivity to stimuli of the senses, decreased skin sensitivity, tremors,
Supplied with a rigid, transparent, polystyrene measuring spoon, calibrated at 2.5 ml and 5 ml.
Fournier Pharma 16b rue des Trois Arbres B-1180 Bruxelles Belgium
To provide final study reports for the following long-term trials APC/ Pre- SAP/ ADAPT in full, when available.
⋅ to provide efficient co-ordination and support on behalf of the EU delegation into VICH
Liisa KAARTINEN Immunologicals Working Party
Inactivated FPV (RP 9.50 - 12.25); FCV (RP 1.65 – 2.15); FVR (RP 1.60 – 2.10); Chlam (RP 2.00 – 2.30); FeLV (RP 1.45 – 2.0)
EN 6/ 8 The CVMP noted that the MAH excluded two observations as being outliers when calculating the withdrawal period.
The daily dosage is administered in equally divided doses 3 times a day.
inadequate blood supply at the non-union site.
Fractures of the shin bone If you have broken your shin bone, InductOs is used to increase the chance that your broken bone will heal, to help your fracture heal faster, and to reduce the need for additional surgeries to help your fracture heal.
Overheads - all sectors 17% Initial evaluation 20%
France 34 avenue Léonard de Vinci F-92400 Courbevoie
France - Activelle 0,5 mg/0,1 mg comprimé pelliculé Germany - Noviana Hungary - Noviana filmtabletta Iceland - Activelle® low 0.5 mg/0.1 mg tablets filmuhúðaðar töflur Ireland - Activelle low 0.5mg/0.1mg film-coated tablets Italy - Activelle® 0,5 mg/0,1 mg compresse film-rivestite Latvia - Noviana 0,5 mg/0,1 mg apvalkotās tabletes Lithuania - Activelle 0,5 mg / 0,1 mg plėvele dengtos tabletės Luxembourg - Activelle minor comprimés pelliculés The Netherlands - Activelle filmomhulde tabletten Norway - Noviana 0,5 mg/0,1 mg tablett filmdrasjert Portugal - 0,5mg Estradiol + 0.1 mg Acetato de Noretisterona Comprimidos revestidos por película Romania – Noviana comprimate filmate Slovenia - Noviana™ filmsko obložene tablete Slovakia - Noviana filmom obalené tablety Spain - Activelle 0,5 mg/ 0,1 mg comprimidos recubiertos de película Sweden - Activelle 0,5 mg/0,1 mg filmdragerade tabletter United Kingdom - Noviana film-coated tablets
100 France BRISTOL-MYERS SQUIBB SARL Tél: + 33 (0)810 410 500
106 France BRISTOL-MYERS SQUIBB SARL Tél: + 33 (0)810 410 500
112 France BRISTOL-MYERS SQUIBB SARL Tél: + 33 (0)810 410 500
30 France BRISTOL-MYERS SQUIBB SARL Tél: + 33 (0)810 410 500
48 France BRISTOL-MYERS SQUIBB SARL Tél: + 33 (0)810 410 500
88 France BRISTOL-MYERS SQUIBB SARL Tél: + 33 (0)810 410 500
94 France BRISTOL-MYERS SQUIBB SARL Tél: + 33 (0)810 410 500
Jean-Hughes TROUVIN
Box 24 FIN-02231 Espoo Finland
Box 24 FIN-02231, Espoo Finland
France Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 D-60318 Frankfurt
Frances NUTTALL Sara MENDOSA (acting) Gerard O'MALLEY
France Topotarget A/ S Fruebjergvej 3, DK – 2100 Copenhague Tél: + 45 39 17 83 92 Ireland TopoTarget A/ S Fruebjergvej 3 DK – 2100 Copenhagen Tel: + 45 39 17 83 92
31 France Wyeth Pharmaceuticals France Tél:+33 1 41 02 70 00 Fax:+33 1 41 02 70 10
France Wyeth Pharmaceuticals France Tél: +33 1 41 02 70 00 Fax: +33 1 41 02 70 10
In addition, a number of projects set out in the Work Programme have been completed:
Commonly some patients (4% or less) have experienced headache, uncommonly fevers and flu like symptoms joint and muscle pains; prolapse of the womb; pain on intercourse in females; erection difficulties; increase in sweating; feeling sick; stomach and bowel symptoms; ringing in the ears; flushing; tiredness; dizziness; migraine; pins and needles; insomnia; depression; loss of appetite; swollen glands; bacterial, viral and fungal infections (e.g. cold sores); vaginal infection including thrush; cough and colds with sore throat.
Common Application site: transient soreness, erythema, induration
*frequency is based only on reports in obese or overweight diabetic patients.
tissue disorders General disorders
pain at the extremities
Duration of therapy (days)
Between 1 in 100 and 1 in 1000 patients experience
Between 1 in 10 and 1 in 100 patients experience
Heart rate and rhythm disorders Uncommon: atrial fibrillation.
Not known Ear and labyrinth system disorders
Not known Skin and subcutaneous tissue disorders
Not known Metabolism and nutrition disorders
 Not known: excessive activation of white blood cells associated with inflammation (macrophage activation syndrome).
 Not known: excessive activation of white blood cells associated with inflammation (macrophage activation syndrome).
Not known Ear and labyrinth disorders
Bone marrow depression (granulocytopenia, agranulocytosis, aplastic anemia thrombocytopenia) Eosinophilia
Not known: erythema nodosum, skin ulcer, petechiae, photosensitivity.
Not known: hepatotoxicity, hepatomegaly, jaundice.
Not known: hypothyroidism, thyroiditis.
Frequency not known: myopathy, osteomalacia (both associated with proximal renal tubulopathy).
cystoid macular oedema (swelling of the retina within the eye leading to worsening vision)
Not known: cystoid macular oedema.
Not known: papilloedema, diplopia, vision blurred, photophobia, eye swelling, blepharitis, eye pain.
Skin and subcutaneous tissue disorders Common: rash morbilliform or other rash Uncommon: urticaria Not known: panniculitis, purpura, skin induration, Stevens-Johnson syndrome, pruritus
Not known: gastrointestinal ulcer perforation, retroperitoneal haemorrhage, haematemesis, gastric ulcer, oesophagitis ulcerative, subileus.
Skin and subcutaneous tissue disorders:
Not known: sepsis, bronchitis, herpes simplex, candidiadis.
Fanconi syndrome, proximal renal tubulopathy.
Not known: hearing impaired, ear pain.
Not known: motor weakness (most often reported in the setting of symptomatic hyperlactatemia or lactic acidosis syndrome)
Not known: motor weakness (most often reported in the setting of symptomatic hyperlactatemia or lactic acidosis syndrome)
Not known: liver failure, hepatitis and hepatic steatosis
Not known: liver failure, hepatitis and hepatic steatosis
Common (≥ 1/ 100 to < 1/ 10)
Common: alopecia, rash Uncommon: palmar-plantar erythrodysesthesia (PPE)
Common: asthenia, fever, infusion-associated acute reactions
common: headache, dizziness, somnolence
Itching, itching skin eruption (urticaria) and skin pain.
Common: abdominal pain, nausea, diarrhoea, vomiting
Gastrointestinal pain and presence of excessive amount of gas in the stomach or bowels (flatulence), mostly mild increases in liver laboratory values (bilirubin, transaminases) which will return to normal values once treatment is over.
Common: ecchymosis or swelling ‡ at the injection site, injection-site rash‡.
♦ Common (side effects which may occur in less than 1 per 10 but more than 1 per 100 doses of vaccine): • infection of the middle ear • bronchitis • sore throat and discomfort when swallowing • gastrointestinal symptoms such as vomiting and diarrhoea
♦ Common (side effects which may occur in less than 1 per 10 but more than 1 per 100 doses of vaccine): • infection of the middle ear • bronchitis • sore throat and discomfort when swallowing • gastrointestinal symptoms such as vomiting and diarrhoea
Common Uncommon Uncommon Uncommon
Common: rash, eczema, pruritus Post-marketing experience: alopecia: in several cases, recovery was observed when Keppra was discontinued
Common: rash, eczema, pruritus Post-marketing experience: alopecia: in several cases, recovery was observed when Keppra was discontinued.
Common: rash, itching, sweating
Common: blepharitis, blurred vision, eye irritation, eye pain, dry eye, eye discharge, eye pruritus, foreign body sensation in eyes, ocular hyperaemia Uncommon: corneal erosion, keratitis, punctate keratitis, keratopathy, deposit eye, corneal staining, corneal epithelium defect, intraocular pressure increased, optic nerve cup/ disc ratio increased, corneal oedema, conjunctivitis, meibomianitis, diplopia, glare, photophobia, photopsia, visual acuity reduced, allergic conjunctivitis, pterygium, scleral pigmentation, asthenopia, ocular discomfort, abnormal sensation in eye, keratoconjunctivitis sicca, hypoaesthesia eye, subconjunctival cyst, conjunctival hyperaemia, eyelids pruritus, eyelid margin crusting, lacrimation increased
common common common common common uncommon uncommon
Common Common Common Common Common
General disorders and administration site conditions: very common: pain, redness and swelling, fever (axillary ≥ 37.5°C; rectal ≥ 38°C) common: induration, fever (axillary > 39°C; rectal > 39.5°C) t uc
The lower number of platelets can cause unusual bleeding (for example nose or skin bleeds).
Common: myalgia, arthralgia, arthritis, bone pain
uncommon uncommon uncommon uncommon
Common Pneumonia Influenza Nasopharyngitis Ear infection Sinusitis Rhinitis
Side effects occured during clinical studies or routine use of the vaccine or with individual hepatitis A and hepatitis B vaccines or with the adult formulation of Twinrix include:
Skin and subcutaneous tissue disorders
Common Jarisch-Herxheimer reaction following cefuroxime axetil treatment of Lyme disease (see section 4.4).
Common (≥ 1/ 100 to < 1/ 10): superficial punctuate keratitis, corneal erosion, burning sensation, eye pruritus, stinging sensation in the eye, foreign body sensation, eye dryness, eyelid erythema, eye pain, photophobia, eye discharge, visual disturbance, eyelid pruritus.
Common: bleeding (gastrointestinal, haematuria, haematoma, epistaxis, haemoptysis, utero-vaginal haemorrhage, haemarthrosis, ocular, purpura, bruise)
Common: bleeding (gastrointestinal, haematuria, haematoma, epistaxis, haemoptysis, utero-vaginal haemorrhage, haemarthrosis, ocular, purpura, bruise) Uncommon: anaemia, thrombocytopaenia Rare: other bleeding (hepatic, retroperitoneal, intracranial/ intracerebral), thrombocythaemia
Rare: other bleeding (hepatic, retroperitoneal, intracranial/ intracerebral), thrombocythaemia ct
Common: headache, dizziness, paraesthaesia, hypoesthesia.
Therefore, they cannot be extrapolated to the lower dose strengths.
Common: constipation, flatulence, dyspepsia, nausea, diarrhoea.
In a compassionate-use study of 64 patients there were 46 patients for whom confirmed LDL receptor information was available.
EMEA/ CPMP/ 32703/ 03 Renal and urinary disorders:
Common: frequent desire to micturate, increased micturation, delayed ejaculation Uncommon: incontinence, micturation disturbances, dysuria Rare: impotence, priapism Very rare: increase of serum creatinine.
Common: abdominal pain, diarrhoea, dyspepsia, nausea, vomiting Post-marketing experience: pancreatitis
Common: abdominal pain, diarrhoea, dyspepsia, nausea, vomiting Post-marketing experience: pancreatitis
Common: abdominal pain, diarrhoea, dyspepsia, nausea, vomiting Post-marketing experience: pancreatitis
Post-marketing experience: pancreatitis
Common: dysarthria, amnesia, dysgeusia, tremor, balance impaired, ataxia, aphasia, burning sensation, sedation, paraesthesia, hypoaesthesia, disturbance in attention, speech disorder, areflexia, coordination abnormal, dizziness postural, cognitive disorder, hyperaesthesia, hyporeflexia, ageusia, depressed level of consciousness, dysaesthesia, parosmia, mental impairment
Common: - hypoaesthesia, disturbance in attention, tremor.
Common: -hypoaesthesia, disturbance in attention, tremor.
- common: as gastrointestinal (haematemesis, melena), gingival or genitourinary bleeding
Patients treated with REYATAZ have reported the following side effects:
Any Non-Bleeding Adverse Event
Adverse reactions reported with Abraxane at any dose in clinical trials.
Metabolism and nutrition disorders Common Psychiatric disorders
Eye irritation, eye pain, abnormal vision, reduced visual acuity, conjunctivitis, visual disturbance, eye pruritus Ear and labyrinth disorders:
Common: vertigo Uncommon: sudden hearing loss
Gastrointestinal disorders:
Fever, generalised pain and asthenia Rare: Chills, chest pain and influenza-like syndrome
Smoking is known to induce CYP1A2 metabolism, therefore if patients stop or start smoking during treatment with ropinirole, dose adjustment maybe required.
Cigarette smoking has been shown to reduce erlotinib exposure by 50-60%.
- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are
Fuzeon was originally authorised under ‘ Exceptional Circumstances’, because for scientific reasons it had not been possible to obtain complete information on the medicine.
Fuzeon is only to be administered by subcutaneous injection.
● The only recommended route of injection is subcutaneous (under the skin).
Fuzeon should be prescribed by a doctor who has experience in the treatment of HIV infection.
Fuzeon should be used with caution in these populations.
Fuzeon must only be reconstituted with 1.1 ml water for injections.
Fuzeon is a powder that is made up into a solution for injection.
Gadovist 1.0 mmol/ ml solution for injection Gadobutrol
Gadovist 1.0 mmol/ ml solution for injection Gadobutrol Intravenous use
Gadovist 1.0 mmol/ ml, solution for injection, prefilled syringe
Gadovist contains gadobutrol, a neutral macrocyclic gadolinium complex with contrast-enhancing properties, which is used for magnetic resonance imaging (MRI).
Gadovist consists of nonspecific, low-molecular-weight, extracellular gadolinium-chelates and is presented in the formulation l.0 mmol gadolinium/ ml and an osmolality of 1603 mosmol/ kg H2O at 37°C.
Gadovist is a contrast medium for magnetic resonance imaging (MRI) of the brain, spine, vessels, liver and kidneys.
Infliximab Naive Patients
Gallows Green Services Limited Cod Beck Blenders, Cod Beck Estate Dalton Lane, Dalton Thirsk, North Yorkshire YO7 3HR United Kingdom
Gallows Green Services Limited Cod Beck Blenders, Cod Beck Mill Dalton, Thirsk, North Yorkshire YO7 3HR United Kingdom
Slovenská republika Astellas Pharma s. r. o., organizač ná zlož ka Galvániho 15/ C SK-821 04 Bratislava 2 Tel: +421 2 4444 2157
GANFORT 300 micrograms/ ml + 5 mg/ ml eye drops, solution bimatoprost/ timolol
GANFORT contains benzalkonium chloride, and care should be taken by people who wear soft contact lenses as it can discolour them.
The preservative in GANFORT, benzalkonium chloride, may cause eye irritation.
GANFORT is prescribed to reduce high pressure in the eye.
The following eye side effects may be seen with GANFORT:
GANFORT has not been studied in patients with hepatic or renal impairment.
GANFORT may cause a darkening of the eyelid or of the iris of the eye.
Gloves: for hands, wrist and fingers.
⋅ to guarantee quality standards in scientific assessments, product literature and EPARs
Ensure the adequate provision of EU expertise into the VICH initiative at a critical time, with particular emphasis on finalising the pharmacovigilance, safety testing and environmental impact assessment guidelines, as well as full support of the VICH 2 conference in Japan in October 2002.
You may need to read it again.
Keep the mouth of the dog closed for a few seconds to ensure complete tablet wetting.
Keep the plunger fully depressed until after you have withdrawn the needle from the injection site.
Keep the syringes in the original container.
Keep the syringes in the outer carton.
Keep the pre-filled syringe in the outer carton.
Keep the pre-filled syringe in the outer carton.
Keep the pre-filled pen in the outer carton.
Keep the pre-filled pen in the outer carton.
Keep the pre-filled pen in the outer carton.
Keep the pre-filled pen in the outer carton.
Keep this card with you for 5 months after the
You may need to read them again.
- Keep this leaflet and the patient alert card.
- Keep this leaflet until your child has finished the complete vaccination course.
- If you have any further questions, ask your doctor or pharmacist.
You may need to read it again.
You may need to read it again.
Do not pass it on to others.
GENERAL CLASSIFICATION FOR SUPPLY
Metalyse 10,000 U Powder and solvent for solution for injection Tenecteplase
You may need to read it again. • If you have any further questions, ask your doctor or your pharmacist. • This medicine has been prescribed for you.
You may need to read it again
tho Keep the needle under your skin for at least 6 seconds to make sure the full dose has been delivered.
Keep it to use during needle removal.
- keep hands and feet uncovered (no gloves, socks, etc.);
(11.9%) Constipation (10.3%) Renals and Urinary Disorders
Flatulence Eructation Breath odour
Toxic epidermal necrolysis, erythema multiforme, discoid lupus erythematosis
Serious haemorrhage, haemorrhage of operative wound, vasculitis, hypotension
Gedeon Richter H-1103 Budapest, Gyomroi ut 19-21 Hungary
Michigan, USA or equivalent; dimensions:
Hard capsule White and light orange marked “Pfizer” on the cap and “PGN 225” on the body with black ink.
Hard capsule White and orange, marked “Pfizer” on the cap and “PGN 300” on the body with black ink.
Hard capsule White and orange, marked “Pfizer” on the cap and “PGN 75” on the body with black ink.
Hard capsule White, marked “Pfizer” on the cap and “PGN 150” on the body with black ink.
Hard capsule White, marked “ Pfizer ” on the cap and “ PGN 25 ” on the body with black ink.
Hard capsule White, marked “Pfizer” on the cap and “PGN 50” on the body with black ink.
Hard capsule White, opaque and imprinted with blue ink.
Size 1 hard capsule with aqua blue opaque cap and body, imprinted "93-376”.
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Opaque, white with two blue bands marked 7767 and 100 (INVENTED NAME 100 mg).
White, opaque capsules with two gold bands marked 7767 and 200.
White, opaque capsules with two gold bands marked 7767 and 400.
Opaque, yellow hard gelatine capsule, containing pellets with enteric coating.
Hard capsule Light orange, marked “Pfizer” on the cap and “PGN 200” on the body with black ink.
Hard capsule Orange, marked “Pfizer” on the cap and “PGN 100” on the body with black ink.
Opaque, white with two gold bands marked 7767 and 200 (INVENTED NAME 200 mg).
Hard Capsule White, opaque hard capsules with CYSTA 50 on the body and MYLAN on the cap.
Hard Capsule White, opaque hard capsules with CYSTAGON 150 on the body and MYLAN on the cap.
White opaque capsules marked “ Thalidomide 50 mg Celgene”.
White capsules marked “REV 25 mg”.
White capsules marked “ REV 5 mg”.
Pale blue/white capsules marked “REV 15 mg”.
Blue-green/pale yellow capsules marked “REV 10 mg”.
Opaque white cap and body.
- Garlic capsules (saquinavir/ritonavir)
White, opaque capsules marked “ NTBC 10mg” on one side of the capsule.
White, opaque capsules marked “ NTBC 2mg” on one side of the capsule.
gélules gastro-resistantes
Unused capsules Patients should be advised never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of the treatment.
Capsules are opaque with a white body and pink cap with “ 462” and “ 125 mg” printed radially in black ink on the body.
Capsules are opaque with a white body and cap with “ 461” and “ 80 mg” printed radially in black ink on the body.
Capsules have an opaque white hard shell with pink band, “ W” and the strength “ 10 mg”.
Oral use Oral use Oral use Oral use Oral use Oral use
Pharmaceutical Form Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard
Gemfibrozil Gemfibrozil increases the AUC of simvastatin acid by 1.9-fold, possibly due to inhibition of the glucuronidation pathway (see sections 4.2 and 4.4).
This should be taken into consideration by patients on a controlled sodium diet.
GEMZAR 1 g powder for 1g solution for infusion and intravesical instillation
Gemzar 1g Pulver zur Herstellung einer Infusionsloesung
such as easy bleeding from the gums, bruising or pinpoint red spots on the skin, please tell your doctor immediately.
Mail services during the year strongly increased with a two- to three-fold increase over the previous year, with over 26 500 items received and more than 7 500 items mailed out.
Usually, 7 to 14 days of treatment are sufficient.
at the start of treatment with somatropin and are dose-dependent.
Generally, these reactions were mild or moderate.
Typically, these lesions are mild and resolve without treatment, but oral lesions may be associated with salivation and labial and tongue oedema.
Generally, these symptoms are mild to moderate; however, in some patients they may be severe in intensity.
Blood cell counts normally return to normal within two weeks of stopping Siklos treatment.
7 In general, tigecycline is considered bacteriostatic.
The cough is usually mild and often gets better over time.
In general the safety profile of ISENTRESS in patients with hepatitis B and/ or hepatitis C virus co- infection was similar to that in patients without hepatitis B and/ or hepatitis C virus co-infection.
Usually, side effects are observed within the first week after treatment and are temporary in nature.
Usually, undesirable effects are observed within the first week after treatment and are temporary in nature.
Generally, patients who have rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis or psoriasis, already take several medicines to treat their disease such as methotrexate, azathioprine or 6-mercaptopurine.
Treatment usually lasts for approximately 3-6 months.
tho metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage destruction were also decreased after Trudexa administration.
General pharmacokinetic characteristics The pharmacokinetics of voriconazole have been characterised in healthy subjects, special populations and patients.
General The following additional information is based on publications on conventional preparations containing the Botulinum toxin type A complex.
General Patients must be assessed prior to administration of Zometa to ensure that they are adequately hydrated.
Generica Kg Südwestpark 50 D-90449 Nürnberg Germany
Generics Uk Limited Albany Gate, Darkes Lane, Potters Bar Herts EN6 1AG United Kingdom
Generics Uk Limited Albany Gate, Darkes Lane, Potters Bar Herts EN6 1AG United Kingdom
Generics [UK] Limited Potters Bar, Hertfordshire, EN6 1TL, UK
Generics [UK] LimitedPotters Bar, Hertfordshire, EN6 1TL, UK
Generics [UK] Limited, Station Close, Potters Bar, Hertfordshire, EN6 1TL, United Kingdom.
Station Close, Potters Bar, Tablets Herts, EN6 1TL.
Genotoxicity: a standard battery for genotoxicity testing of
Note for guidance on the Clinical investigation of recombinant factor VIII and IX products Released for consultation June 2000
Genzyme Corporation 500 Soldiers Field Road – Allston, MA 02134 – USA
Genzyme Europe BV Gooimeer 10 1411 DD Naarden Netherlands
Genzyme Europe BV, Gooimeer 10, 1411 DD Naarden, Netherlands
Genzyme Europe BV Gooimeer 10 1411DD Naarden The Netherlands
Genzyme Europe B. V., Gooimeer 10, NL-1411DD Naarden, The Netherlands
Č eská republika/ Slovenská republika/ Slovenija Genzyme Europe B. V. organizač ní slož ka (Č eská Republika) Tel: +420 227 133 665
Genzyme Limited, 12 Rookwood Way, Haverhill, Suffolk CB9 8PB, United Kingdom
_____________________ Georgette Lalis Director Directorate General for Enterprise and Industry European Commission
Christian FRIIS as of the 15 July 1997 meeting.
Rui MARQUES LEITÃO Director Geral Direcçao Geral de Veterinária Lg Academia Nacional de Belas Artes 2 P-1294 Lisboa Tel:
MANAGEMENT OF HAEMOLYTIC AND AREGENERATIVE ANAEMIA (haemoglobin, bilirubin, haptoglobin, reticulocytes) Contra-indication
MANAGEMENT OF HAEMOLYTIC AND AREGENERATIVE ANAEMIA (haemoglobin, bilirubin, haptoglobin, reticulocytes) Haemoglobin < 10g/ dL and either
MANAGEMENT OF NEUTROPENIA (Neutrophil counts) Contra-indication < 2000 / mm3
MANAGEMENT OF NEUTROPENIA (Neutrophil counts)
MANAGEMENT OF HEPATIC TOXICITY (ALT or AST) Contra-indication > 3 ULN
Clinical data safety management: data elements for transmission of individual case safety reports
MANAGEMENT OF PROTEIN-LOSS SYNDROME (Albuminemia and/ or UPC) Contra-indication
Document management and publishing • Document dissemination
Gianmartino BENZI, José-Luis VALVERDE LÓPEZ
GigaBecquerel, Becquerel is the unit in which radioactivity is measured).
spots or other skin blemishes.
Angle closure glaucoma, corneal ulceration.
GlaxoSmithkline Biologicals S. A., 89 rue de l'Institut, B-1330 Rixensart, Belgium
< GlaxoSmithKline EOOD, Gradinarska Street 5, Sofia 1510, Bulgaria. >
GlaxoSmithKline EOOD, Ivan Vazov complex Dimitar Manov street, bl.10, Sofia 1408 Bulgaria
Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 10 30 30 30 Finland.tuoteinfo@gsk.com
GlaxoSmithKline Oy, Piispansilta 9 A, 02230 Espoo, Suomi
Spain GlaxoSmithKline SA Parque Tecnologico de Madrid Calle Severo Ochoa 2, 28760 Tres Cantos, Madrid Spain
Spain GlaxoSmithKline SA Parque Tecnologico de Madrid, Calle Severo Ochoa 2, 28760 Tres Cantos, Madrid Spain
Spain GlaxoSmithKline SA Parque Tecnologico de Madrid, Calle Severo Ochoa 2, 28760, Tres Cantos, Madrid Spain
Glaxo Wellcome S. A., Avenida de Extremadura 3, 09400 Aranda de Duero, Burgos, Spain.
Glaxo Wellcome S.A., Avenida de Extremadura 3, 09400 Aranda de Duero, Burgos, Spain.
Glaxo Wellcome S. A., Avenida de Extremadura 3, 09400 Aranda de Duero, Burgos, Spain.
Glimepiride Absorption After oral administration, glimepiride is completely (100%) absorbed from the gastrointestinal tract.
- newly-diagnosed glioblastoma multiforme.
Gliolan contains a substance called aminolevulinic acid hydrochloride (5-ALA).
Gliolan should be used only by neurosurgeons who have attended a training course in accordance with the standards detailed below:
Gliolan should be used only by neurosurgeons who have attended a training course in accordance with the standards detailed below:
Gliolan is used in adult patients with malignant glioma (a type of brain tumour).
Gliolan has no influence on the ability to drive and use machines.
- malignant glioma, such as glioblastoma mult iforme or anaplastic astrocytoma.
- malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma.
The dosing button should be
Slide the needle in to pick it up and push the cap completely down over the needle.
Glivec was also better than standard chemotherapy in patients with ALL.
Glivec has been examined in 4 main studies involving 2133 adults and one study of 54 children with CML.
This means that some of their genes have re-arranged themselves to form a special chromosome called the Philadelphia chromosome.
Glivec is also indicated for the treatment of • adult patients with Kit (CD 117) positive unresectable and/ or metastatic malignant gastrointestinal stromal tumours (GIST). • adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/ or metastatic DFSP who are not eligible for surgery.
Glivec is indicated for the treatment of • adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. • adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. • adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. • adult patients with relapsed or refractory Ph+ ALL as monotherapy. • adult patients with myelodysplastic/ myeloproliferative diseases (MDS/ MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. • adult patients with advanced hypereosinophilic syndrome (HES) and/ or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.
Glivec is a treatment for adults and children for:
Glivec is used to treat adults with HES or CEL who have a specific re-arrangement of 2 genes called FIP1L1 and PDGFR α. • Gastrointestinal stromal tumours (GIST), a type of cancer (sarcoma) of the stomach and bowel, when there is uncontrolled growth of cells in the supporting tissues of these organs.
Glivec may do the same to some other medicines.
It can only be used to treat GIST that produce a specific protein called Kit. • Dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably.
or Global Evaluation § lower values = greater improvement
Overall, during the studies, 33% of patients had more lesions detected after TESLASCAN but 20% of patients had fewer lesions.
Patients were randomized to receive either pegylated interferon alfa-2b (1.5 µg/ kg/week) plus ribavirin (800 mg/day) or IntronA (3 MIU TIW) plus ribavirin (800 mg/day) for 48 weeks with a follow-up period of 6 months.
Patients were randomized to receive either pegylated interferon alfa-2b (1.5 µg/kg/week) plus ribavirin (800 mg/day) or IntronA (3 MIU TIW) plus ribavirin (800 mg/day) for 48 weeks with a follow-up period of 6 months.
Overall, the primary route of elimination for tigecycline is biliary excretion of unchanged tigecycline.
Overall, the reproductive and developmental effects observed in animals are consistent with the SERM class of compounds.
Overall, he results of the second study taken alone were insufficient to demonstrate a benefit of PROTELOS in preventing peripheral fractures.
Overall, the results of the second study taken alone were insufficient to demonstrate a benefit of OSSEOR in preventing peripheral fractures.
Overall it is estimated that, since authorization, more than 400,000 prescriptions for Oracea were filled at pharmacies in the USA up to November 2007 and the post-marketing experience identified no new safety concerns.
White cell and reticuloendothelial system disorders Rare: leucopoenia, eosinophilia, bone marrow hypoplasia.
GLUCOPH AGE/GLUCOPHAGE FORTE/DIANBEN/RISIDON may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.
Glustin 15 mg tablets can be taken with or without food.
Glustin 15 mg tablets may be used on their own or in combination with metformin and/ or a sulphonylurea which are also oral anti-diabetic medicines.
Glustin 15 mg tablets Pioglitazone (as HCl)
Glustin 15 mg tablets Pioglitazone (as hydrochloride)
Glustin 30 mg tablets can be taken with or without food.
Glustin 30 mg tablets may be used on their own or in combination with metformin and/ or a sulphonylurea which are also oral anti-diabetic medicines.
Glustin 30 mg tablets Pioglitazone (as hydrochloride)
Glustin 45 mg tablets can be taken with or without food.
Glustin 45 mg tablets may also be used in combination with insulin.
Glustin 45 mg tablets may be used on their own or in combination with metformin and/ or a sulphonylurea which are also oral anti-diabetic medicines.
Glustin 45 mg tablets Pioglitazone (as HCl)
Glustin 45 mg tablets Pioglitazone (as hydrochloride)
Glustin has been studied in clinical pharmacology studies and in clinical trials.
This means that it will start to lower your blood sugar about 2 ½ hours after you take it, and the effect will last for approximately 24 hours.
hydroxide, hydrochloric acid (for pH adjustment) and water for injections.
hydroxide, hydrochloric acid (for pH adjustment) and water for injections.
sodium hydroxide, hydrochloric acid (for pH adjustment) and water for injections.
sodium hydroxide, hydrochloric acid (for pH adjustment) and water for injections.
glycerol, phenol, metacresol, zinc (as chloride), sodium chloride, disodium phosphate dihydrate, protamine sulphate, sodium hydroxide, hydrochloric acid, water for injections
glycerol, phenol, metacresol, zinc (as chloride), sodium chloride, disodium phosphate dihydrate, protamine sulphate, sodium hydroxide, hydrochloric acid, water for injections
Glycine, sodium chloride, calcium chloride, histidine, polysorbate 80, sucrose.
E2 glycoprotein of Classical Swine Fever (CSF) virus minimum 32 µg
Gödecke GmbH Mooswaldallee 1 79090 Freiburg Germany
Gödecke GmbH (a pharma plant of Pfizer GmbH), Mooswaldallee 1, 79090 Freiburg, Germany.
GONAL-f 1050 IU/ 1.75 ml (77 micrograms/ 1.75 ml) must be reconstituted with the 2 ml solvent provided before use.
GONAL-f 1050 IU/ 1.75 ml (77 micrograms/ 1.75 ml) preparation must not be reconstituted with any other GONAL-f container.
GONAL-f 1050 IU/ 1.75 ml (77 micrograms/ 1.75 ml) preparation must not be reconstituted with any other GONAL-f containers.
GONAL-f 300 IU/ 0.50 ml (22 micrograms/ 0.50 ml) must be reconstituted with the 0.75 ml solvent provided before use.
GONAL-f 300 IU/ 0.50 ml (22 micrograms/ 0.50 ml) should not be mixed with other medicines in the same injection.
GONAL-f 300 IU/ 0.50 ml (22 micrograms/ 0.50 ml) preparation must not be reconstituted with any other GONAL-f containers.
GONAL-f 300 IU/ 0.5 ml (22 micrograms/ 0.5 ml) is not designed to allow the cartridge to be removed.
GONAL-f 900 IU/ 1.5 ml (66 micrograms/ 1.5 ml) is not designed to allow the cartridge to be removed.
GONAL-f 900 IU/ 1.5 ml (66 micrograms/ 1.5 ml) solution for injection in a pre-filled pen.
GONAL-f must be reconstituted with the solvent before use.
GONAL-f is given subcutaneously (under the skin).
• GONAL-f is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotrophin (hCG) therapy.
162 GONAL-f should not be administered as a mixture with other medicinal products in the same injection, except for lutropin alfa.
172 GONAL-f should not be administered as a mixture with other medicinal products in the same injection, except for lutropin alfa.
182 GONAL-f should not be administered as a mixture with other medicinal products in the same injection, except for lutropin alfa.
191 GONAL-f should not be administered as a mixture with other medicinal products in the same injection, except for lutropin alfa.
200 GONAL-f should not be administered as a mixture with other medicinal products in the same injection, except for lutropin alfa.
209 GONAL-f should not be administered as a mixture with other medicinal products in the same injection, except for lutropin alfa.
Gonazon contains azagly-nafarelin, which is an analogue of a natural hormone called gonadotrophin- releasing hormone (GnRH).
Gonazon contains the active substance azagly-nafarelin.
- Swelling of the palms of hands and soles of feet followed by the hands and feet becoming scaly
- breast swelling in males, impotence
menstrual disorder, priapism, retrograde ejaculation, sexual dysfunction, vaginal discharge
- swelling of the face, lips, tongue and/ or throat which may cause difficulty in swallowing.
- swelling of the face, lips or tongue
Facial swelling, dry skin, tendency to bruise, night sweats.
- general swelling, general pain, musculoskeletal chest pain, stiffness of joint, inflammation of the
Uncommon: localised swelling, seroma, product migration when mixed with synthetic bone void filler
legs, or shortness of breath.
and throat (signs of severe allergic reaction).
• tinnitus • syncope •
- uncomplicated gonorrhoea: urethritis and cervicitis
Gooimeer 10 1411 DD Naarden The Netherlands
harmless and lessen as treatment continues.
Gottlieb-Daimler-Strasse 19 891 50 Laichingen Germany
ringing, shakes, unsteadiness, prolonged sleep
GP-Pharm Polígon Industrial Els Vinyets - Els Fogars, Sector 2, Carretera Comarcal C244, km 22 08777 Sant Quintí de Mediona (Barcelona) Spain
This will further ensure that very little, if any, goes into your bodily circulation.
It could be shown with the aid of cell cultures of human bone marrow cells that epoetin alfa stimulates erythropoiesis specifically and does not affect leucopoiesis.
Owing to its primarily RXR-binding activity, bexarotene is less likely to cause mucocutaneous, nail, and hair toxicities; arthralgia; and myalgia; which are frequently reported with retinoic acid receptor (RAR) -binding agents.
The airless pump allows the product to be administered whatever the position of the bottle is.
The airless pump allows the product to be administered whatever the position of the bottle is.
The progress in standardisation at the EMEA allowed the use of templates for most scientific opinion documents.
10.5%c 19.4%d 0.2%e NA 4.7%g
23.8%c 43.5%d 29.1%e 3.9%f 8.7%g
Gramsci 731-733, 50019 Sesto Fiorentino, Florence, Italy
Gramsci 731-733, 50019 Sesto Fiorentino, Florence, Italy.
Luxembourg Mr Marc WIRTOR Dr Albert HUBERTY
Grand-Duché du Luxembourg Dr Jean-Louis ROBERT Ms Jacqueline GENOUX-HAMES
These include: − Angioneurotic oedema (swelling of the face, tongue and windpipe which can cause great difficulty in breathing), Stevens-Johnson syndrome (serious blistering condition of the skin, mouth, eyes and genitals), erythema multiforme (patchy red rash).
Considerable progress was made with several guideline documents being finalised.
15 Kaplan Meier Plots of Overall Survival by Histology
32 Kaplan Meier Plots of Overall Survival by Histology
during the treatment,
Severity of neuropathy Grade 1 (paraesthesia, weakness and/ or loss of reflexes) with no loss of function
Elevation of alkaline Phosphatase, Elevation of ALT
− Pregnancy − Breast-feeding − Hypersensitivity to the active substance or to any of the excipients.
Pregnancy The use of lumiracoxib, as with any drug to inhibit COX-2, is not recommended in women attempting to conceive.
Pregnancy :< COVERSYL and associated names > should not be used during the first trimester of pregnancy.
TESLASCAN must not be used during pregnancy (see section 4.3).
72 Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine during pregnancy and breast- feeding.
Pregnancy and breast-feeding 67 Ask your doctor or pharmacist for advice before taking any medicine during pregnancy and breast- feeding.
Pregnancy and breast-feeding 68 Ask your doctor or pharmacist for advice before taking any medicine during pregnancy and breast- feeding.
Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine during pregnancy and breast- feeding.
Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine during pregnancy and breast- feeding.
Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine during pregnancy or breast-feeding.
Pregnancy and breast-feeding Avoid becoming pregnant while being treated with Nexavar.
Pregnancy and breast-feeding Avoid pregnancy while being treated with Tarceva.
Pregnancy and breast-feeding Use in pregnancy It is not known whether Gliolan will harm an unborn baby.
Pregnancy and breast-feeding → Tell your anaesthetist if you are pregnant or might be pregnant.
Pregnancy and breast feeding Do not take Bondenza if you’re pregnant or breast feeding.
Pregnancy and breast-feeding Do not take Cardoreg 4 mg prolonged release tablets and associated names if you are pregnant or breast-feeding.
Pregnancy and breast-feeding Do not take Mycophenolate mofetil Teva if you are breast-feeding.
Pregnancy and breast-feeding Do not use AMMONAPS if you are pregnant, since this medicine could harm your unborn baby.
Pregnancy and breast-feeding • Do not use EVRA if you are pregnant or think you may be pregnant • Do not use EVRA if you are breast-feeding or planning to breast-feed.
278 Pregnancy and breast-feeding There is not much experience with NeoRecormon in pregnant women or women who are breast- feeding.
Pregnancy and breast-feeding There is not much experience with NeoRecormon in pregnant women or women who are breast- feeding.
Pregnancy and breast-feeding ORACEA must not be used during pregnancy since it may cause permanent discolouration of the teeth in the unborn child.
This is because MabThera is an antibody and can cross the placenta and affect your baby.
63 Driving and using machines ► If you drive or use tools or machines: watch out for signs of a hypo.
Pregnancy and breast-feeding ► If you are pregnant, planning a pregnancy or breast-feeding please contact your doctor for advice 73 Driving and using machines ► If you drive or use tools or machines: watch out for signs of a hypo.
You should not be given VISTIDE if you are pregnant.
- Pregnancy and lactation (see section 4.6).
Pregnancy and lactation (see sections 4.6 and 5.3).
Pregnancy and lactation (see sections 4.6 and 5.3).
Pregnancy You must avoid becoming pregnant for 3 months after Foscan treatment.
4.6 Pregnancy and lactation No clinical data on exposed pregnancies are available for celecoxib.
Pregnancy There are no adequate and well-controlled studies with etravirine in pregnant women.
Use during pregnancy There are no adequate and well-controlled studies in pregnant patients.
Use during pregnancy There are no adequate and well-controlled studies in pregnant patients.
Therefore, paroxetine should be used with caution in patients who are treated with oral anticoagulants.
Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be
Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be
Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be
Pregnancy During pregnancy, effective antiepileptic treatment must NOT be stopped.
Pregnancy You should not use CYSTAGON if you are pregnant.
Pregnancy You should not use Yondelis if you are pregnant or if you/ your partner are trying to become pregnant as Yondelis may harm the unborn baby.
Safety studies for gene therapy products.
CPMP Efficacy Working Party
The Joint CPMP/CVMP Quality Working Party met 4 times in 2002.
Safety Working Party 2 The Safety Working Party (SWP), chaired by Dr P.
were drafted by the Working Party and released for a six month consultation period by the CVMP.
group (29.8 events/ 1,000 patient-years) versus diet alone (43.3 events/ 1,000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/ 1,000 patient-years), p=0.0034
group (29.8 events/1,000 patient -ye ars) versus diet alone (43.3 events/1,000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1,000 patient-years), p=0.0034;
group (29.8 events/1,000 patient-years) versus diet alone (43.3 events/1,000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1,000 patient-years), p=0.0034;
group (29.8 events/ 1000 patient-years) versus diet alone (43.3 events/ 1000 patient-years), p=0.0023, and versus the combined sulfonylurea and insulin monotherapy groups (40.1 events/ 1000 patient-years), p=0.0034.
group (29.8 events/ 1,000 patient-years) versus diet alone (43.3 events/ 1,000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/ 1,000 patient-years), p=0.0034
It also made recommendations on the preparation of extemporaneous formulations of medicines frequently used in children in the EU following a survey of paediatric hospital pharmacies.
Specific patient groups No clinical studies have been conducted in patients with impaired hepatic function.
CPMP working groups COMP working groups
Gruppo Lepetit S. r. l., Località Valcanello, 03012 Anagni (FR), Italy.
Good manufacturing practices for medicinal products catalogue n˚ CO-71-91-760-EN-C, also available in ES, DA, DE, GR, FR, NL, PT
PREPARATION GUIDE FOR USE WITH Docetaxel Winthrop 20 MG CONCENTRATE FOR SOLUTION FOR INFUSION AND SOLVENT FOR Docetaxel Winthrop
PREPARATION GUIDE FOR USE WITH Docetaxel Winthrop 80 MG CONCENTRATE FOR SOLUTION FOR INFUSION AND SOLVENT FOR Docetaxel Winthrop
PREPARATION GUIDE FOR USE WITH TAXOTERE 20 MG CONCENTRATE FOR SOLUTION FOR INFUSION AND SOLVENT FOR TAXOTERE
PREPARATION GUIDE FOR USE WITH TAXOTERE 80 MG CONCENTRATE FOR SOLUTION FOR INFUSION AND SOLVENT FOR TAXOTERE
The following key elements should be included in the educational materials:
Gynaecomastia, erectile dysfunction, menorrhagia, menstruation irregular, sexual dysfunction, nipple pain, breast enlargement, scrotal oedema
H01AX (proposed) Treatment of patients with acromegaly who had an inadequte response to
H05B A01 Hypercalcaemia of malignancy and Paget's Disease
Malta V.J.Salomone Pharma Limited 79, Simpson Street, Marsa HMR 14, Malta.
Habilitation in pharmacology, toxicology and pharmacy, University of Munich.
Typically, these findings normalised, or appeared to be reversing, within two weeks following the end of treatment.
Usually, Humira is used with methotrexate.
Patients usually improve after tigecycline discontinuation.
Usually, the substitution therapy with KOGENATE Bayer 1000 IU is a life-time treatment.
Usually, the substitution therapy with KOGENATE Bayer 2000 IU is a life-time treatment.
Usually, the substitution therapy with KOGENATE Bayer 250 IU is a life-time treatment.
Usually, the substitution therapy with KOGENATE Bayer 500 IU is a life-time treatment.
Usually, the replacement therapy with ADVATE is a life-long treatment.
Many people with osteoporosis have no symptoms.
Hadovka Office Park Evropská 2590/ 33d
Hallucinations, manic reaction, confusion, agitation, anxiety and associated symptoms (e. g. nervousness), impaired concentration and thought process (e. g. depersonalisation), panic attacks, suicidal thoughts and behaviour (these symptoms may be due to the underlying disease), very rarely serotonin syndrome.
Suicide attempts Hallucination Suicide* Mental status change
Halocur is used in newborn calves to prevent or reduce diarrhoea due to an organism called Cryptosporidium parvum.
Halocur should not enter watercourses as this may be dangerous for fish and other aquatic organisms.
HALOCUR should not enter watercourses, as this may be dangerous for fish and other aquatic organisms.
Halocur can be used: • to prevent diarrhoea in farms with a history of cryptosporidiosis (infection with Cryptosporidium), when it is given to newborn calves in the first 24 to 48 hours of life, • to reduce diarrhoea, when it is given in the 24 hours after the onset of diarrhoea.
Halocur is presented as a clear, yellow solution for administration by mouth.
Halofuginone base (as lactate salt) Benzoic acid (E 210) Tartrazine (E 102)
Olanzapine also demonstrated comparable efficacy results to haloperidol in terms of the proportion of patients in symptomatic remission from mania and depression at 6 and 12 weeks.
Olanzapine also demonstrated comparable efficacy results to haloperidol in terms of the proportion of patients in symptomatic remission from mania and depression at 6 and 12 weeks.
Hälsa Pharma GmbH Immermannstraße 9 33619 Bielefeld GERMANY
Hälsa Pharma GmbH, Immermannstraße 9, 33619 Bielefeld, GERMANY
Hambros Plass 2C, 1 tr N-0164 OSLO Tlf: + 46 8 697 2000
recombinant human or humanised antibodies.
Hamwells Business Park Unit No.7, Hardicker Street M19 2rb Manchester United Kingdom
Handelsweg 25, P. O. Box 179, 5530 AD Bladel, The Netherlands
België/ Belgique/ Belgien Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 D-60318 Frankfurt Duitsland/ Allemagne/ Deutschland Tél/ Tel: +49 (0)69 1503 – 1
(applied physics and materials science) from Saarbruecken University, Diploma in physics from Tuebingen University, Master of Arts (mathematics) from the University of Cambridge, UK.
Hans-Peter HOFMANN 3, Gerhard Josef KOTHMANN, Vice-chairman
GERMANY Harald SCHWEIM Direktor BfArM Friedrich-Ebert-Allee 38 D - 53113 Bonn Tel.
GERMANY Harald SCHWEIM Direktor BfArM Friedrich-Ebert-Allee 38 D - 53113 Bonn Tel.
Harmire Road Barnard Castle Durham, DL12 8DT United Kingdom
• harmonisation of the content and standardisation of the presentation of medicinal product information documents.
Harmonisation and joint CPMP/CVMP Quality Working Party
• Euro consolidated into the financial and budgetary proceedings of the Agency • recruitment targets achieved • budget monitored and adjusted, particularly in response to increased revenues and the financing of new tasks such as orphan medicinal products and PERF II • preparation of organisational restructuring of the Unit for the Evaluation of Medicines for Human Use • restructuring and refurbishment of EMEA offices as part of building policy
Increased blood alkaline phosphatase, transaminases, bilirubin, uric acid, chloride, phosphate and sodium.
side up with the notch pointed towards the insulin inhaler, insert the blister. uc
HBVAXPRO is a vaccine, which is available as a suspension for injection in vials and pre-filled syringes.
HBVAXPRO is a vaccine inducing a specific humoral and cellular immune response against HBsAg, which results in an active immunisation against Hepatitis B virus infection.
HE Clissmann T/ A Schering 72 Heather Road Dublin 18
Help Aebe Valaoritou 10 Metamorfosi Attiki 14452 Greece
Pertussis toxoid1 Filamentous Haemagglutinin1 Pertactin1 Hepatitis B surface antigen2,3 Poliovirus (inactivated)
Haematemesis, mouth haemorrhage, abdominal pain, upper abdominal pain, gingival bleeding, mouth ulceration, proctalgia, stomatitis
Haematochezia Skin and subcutaneous tissue disorders:
Blood and the lymphatic system disorders U
heamaturia, proteinuria, polyuria, renal impairment
of white blood cells (agranulocytosis); a drop in the number of red and white blood cells and platelets (pancytopenia), which may be fatal; and bone marrow depression, which may also be fatal (see Section 2:
of white blood cells (agranulocytosis); a drop in the number of red and white blood cells and platelets (pancytopenia), which may be fatal; and bone marrow depression, which may also be fatal (see Section 2:
of white blood cells (agranulocytosis)
Haemophilia A or B with inhibitors or expected to have a high anamnestic response
Haemophilia: there have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophiliac patients type A and B treated with protease inhibitors.
haemoptysis, eye haemorrhage and ecchymosis were observed.
Haemoptysis*, pulmonary haemorrhage*, pulmonary infiltrates*, dyspnoea*, hypoxia*
Tumour-associated haemorrhage (see section 4.4).
Injection site haemorrhage, injection site pain, chest pain
Seizure (convulsion)*, peripheral neuropathy* Cerebrovascular haemorrhage*, cerebrovascular ischaemia*, encephalopathy*, polyneuropathy*
Seizure (convulsion)*, peripheral neuropathy* Cerebrovascular haemorrhage*, cerebrovascular ischaemia*, encephalopathy*, polyneuropathy*
Seizure (convulsion)*, peripheral neuropathy* Cerebrovascular haemorrhage*, cerebrovascular ischaemia*, encephalopathy*, polyneuropathy*
- recent gastrointestinal or genitourinary bleeding (within 10 days)
Gastrointestinal haemorrhage (such as gastric haemorrhage, gastric ulcer haemorrhage, haemorrhage rectum, haematemesis, melaena, mouth haemorrhage), nausea, vomiting
Serious haemorrhage, haemorrhage of operative wound, vasculitis, hypotension
Intraventricular haemorrhage, Periventricular leukomalacia
Retinal haemorrhage, visual disturbance NOS, blurred vision, photophobia, chromatopsia, cyanopsia, eye irritation, blood shot eyes/ red eyes
Retroperitoneal haemorrhage (such as retroperitoneal haematoma)
Retinal haemorrhages*, retinopathies (including macular oedema)*, retinal artery obstruction*, retinal vein obstruction*, optic neuritis*, papilloedema*, loss of visual acuity or visual field*, cotton wool spots*
Retinal haemorrhages*, retinopathies (including macular oedema)*, retinal artery obstruction*, retinal vein obstruction*, optic neuritis*, papilloedema*, loss of visual acuity or visual field*, cotton wool spots*
Peripheral neuropathy Cerebrovascular haemorrhage, cerbrovascular ischaemia, seizure, impaired consciousness, encephalopathy
hepatic, cardiac or renal function and haemorrhagic disorders
the blood (bilirubinaemia) and increased blood level of a certain enzyme (alkaline phosphatase)
hepatitis (0.2% vs 0.3%), hepatic steatosis (0.2% vs 0%), cytolytic hepatitis (0.3% vs 0%), hepatomegaly (0.2% vs 0.2%)
hepatitis10 impairment of liver function (e. g. with cholestasis and jaundice)
Hepatitis, impairment of liver function (with cholestasis and jaundice)
Chronic hepatitis C – treatment-experienced patients:
• chronic hepatitis C (a disease of the liver due to an infection by the hepatitis C virus).
- hepatitis, death of liver cells (liver necrosis) very rarely leading to life-threatening liver failure
Hepato-biliary disorders (see section 4.4) Uncommon: hepatitis, hepatic haemorrhage, hypoproteinaemia, hyperbilirubinaemia.
Skin and subcutaneous tissue disorders Very common:
Hepatomegaly, jaundice, hyperbilirubinemia* Hepatotoxicity (including fatalities)*
Commission - Opinion received - Date of Decision - Notification - Official Journal
Mr Heppell has worked in a number of Government Departments in t he United Kingdom and for the Government of Hong Kong.
Hermal Kurt Herrmann GmbH & Co OHG Scholtzstrasse 3 D-21465 Reinbek Germany
A survey in 2000 to measure the level of satisfaction of the delegates showed a high level of satisfaction with the level of service provided by the EMEA.
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)..................................... ≥ 104.9 CCID501 Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains).................... ≥ 2.0 ELISA U.
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)...................................... ≥ 104.9 CCID501 Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains)..................... ≥ 2.0 ELISA U.
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)..................................... ≥ 104.9 CCID501 Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains).................... ≥ 2.0 ELISA U.
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)......................................  104.9 CCID 50 1 Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains).....................  2.0 ELISA U.
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)..................................... ≥ 104.9 CCID501 Inactivated feline Calicivirosis antigens (FCV 431 and G1 strains)............................. ≥ 2.0 ELISA U.
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)...................................... ≥ 104.9 CCID501 Inactivated feline Calicivirosis antigens (FCV 431 and G1 strains).............................. ≥ 2.0 ELISA U.
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)..................................... ≥ 104.9 CCID501 Inactivated feline Calicivirosis antigens (FCV 431 and G1 strains)............................. ≥ 2.0 ELISA U.
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)......................................  104.9 CCID 50 1 Inactivated feline Calicivirosis antigens (FCV 431 and G1 strains)..............................  2.0 ELISA U.
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose Attenuated feline Chlamydophila felis (905 strain): at least 3.0 log 10 EID50 per dose
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose Attenuated feline Chlamydophila felis (905 strain): at least 3.0 log 10 EID50 per dose Attenuated feline panleucopenia virus (PLI IV): at least 3.5 log 10 CCID50 per dose
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per doses Attenuated feline Chlamydophila felis (905 strain): at least 3.0 log 10 EID50 per dose Attenuated feline panleucopenia virus (PLI IV): at least 3.5 log 10 CCID50 per dose FeLV recombinant canarypox virus (vCP97): at least 7.2 log 10 CCID50 per dose
Attenuated feline Rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose Attenuated feline Panleucopenia virus (PLI IV): at least 3.5 log 10 CCID50 per dose FeLV recombinant canarypox virus (vCP97): at least 7.2 log 10 CCID50 per dose
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose Attenuated feline panleucopenia virus (PLI IV): at least 3.5 log 10 CCID50 per dose
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose Attenuated feline Chlamydophila felis (905 strain): at least 3.0 log 10 EID50 per dose Attenuated feline panleucopenia virus (PLI IV): at least 3.5 log 10 CCID50 per dose
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per doses Attenuated feline Chlamydophila felis (905 strain): at least 3.0 log 10 EID50 per dose Attenuated feline panleucopenia virus (PLI IV): at least 3.5 log 10 CCID50 per dose FeLV recombinant canarypox virus (vCP97): at least 7.2 log 10 CCID50 per dose
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose Attenuated feline panleucopenia virus (PLI IV): at least 3.5 log 10 CCID50 per dose
Attenuated feline Rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose Attenuated feline Panleucopenia virus (PLI IV): at least 3.5 log 10 CCID50 per dose FeLV recombinant canarypox virus (vCP97): at least 7.2 log 10 CCID50 per dose
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose
Inactivated Feline Rhinotracheitis virus (605 strain):
Inactivated Feline Rhinotracheitis Virus (605 strain)
(eczema herpeticum), molluscum contagiosum, skin papilloma, application site disorders such as rash, pain, paraesthesia, desquamation, dryness, oedema, and condition aggravated.
Hexal AG, Industriestrasse 25, D-83607 Holzkirchen, Germany
HEXAL A/ S Kanalholmen 8-12, 2650 Hvidovre, Denmark
Hexal A/ S Kanalholmen 8-12 Dk-2650 Hvidovre Denmark
Method of administration HEXAVAC should be administered intramuscularly into the quadriceps or deltoid preferably at alternating sites for subsequent injections.
39 HEXAVAC is available in packs of 1, 10, 25 and 50 with or without neddles.
Suspension for injection in pre-filled syringe HEXAVAC is a slightly opaque white suspension
HEXAVAC must not be mixed in the same syringe with other vaccines or other parenterally administered drugs.
HEXAVAC should not be used as the birth dose or subsequent doses during the first year of life for children born to HbsAg- positive mothers.
HEXAVAC will not prevent hepatitis infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E or by other liver pathogens.
HEXAVAC - single dose pre-filled syringe with 1 separate needle - Pack of 10
HEXAVAC - single dose pre-filled syringe with 1 separate needle - Pack of 1
HEXAVAC - single dose pre-filled syringe with 2 separate needles - Pack of 1
HEXAVAC - single dose pre-filled syringe with attached needle - Pack of 10
HEXAVAC - single dose pre-filled syringe with attached needle - Pack of 1
HEXAVAC - single dose pre-filled syringe with attached needle - Pack of 25
HEXAVAC - single dose pre-filled syringe with attached needle - Pack of 50
HEXAVAC - single dose pre-filled syringe without needle - Pack of 10
HEXAVAC - single dose pre-filled syringe without needle - Pack of 1
HEXAVAC - single dose pre-filled syringe without needle - Pack of 25
HEXAVAC - single dose pre-filled syringe without needle - Pack of 50
* Hib PRP - Haemophilus influenzae type B polyribosylribitol phosphate TT - tetanus toxoid MenC PSC - Neisseria meningitidis serogroup C polysaccharide
HMG and FSH are hormones promoting egg maturation.
Hoechst Marion Roussel, Lda Estrada Nacional 249, Km 15 Apartado 39 2726 Mem Martins Codex
A/ S GEA Farmaceutisk Fabrik Holger Danskes Vej 89 DK-2000 Frederiksberg Denmark
Male: impotence, prostatitis Sexual dysfunction (not specified)*
Male: impotence, prostatitis Sexual dysfunction (not specified)*
AstraZeneca UK Limited Horizon Place, 600 Capability Green, Luton, Bedfordshire LU1 3LU England UK
either childhood or adult-onset etiology.
EMEA/MRFG secretariat (e-mail) email: mrp@emea.eu.int
Heads of agencies for medicines for veterinary use http: / /www. hevra. org
http://www.eudra.org/emea.org http://heads.medagencies.org http://www.hevra.org http://perf.eudra.org http://www.ifpma.org/ich1.html http://vich.eudra.org
The route of injection is the same as with r-HuEPO but your doctor will tell you how much you should take, and when, and may adjust your dose if necessary. ng If you are receiving chemotherapy lo
NETHERLANDS Huib van de DONK Directeur College ter Beoordeling van Geneesmiddelen Ministerie van V.W.S.
White Oil Sorbitan sesquioleate Polysorbate 80
Hydrogenated palm oil Lecithin Sodium acetate anhydrous
Hydrogenated vegetable oil Glyceryl monostearate
Hydrogenated vegetable oil, Glyceryl monostearate
Eight of 13 evaluable patients were shown to possess neutralizing antibodies.
Telematics, administration and other support activities are described in Chapters 5 and 6.
Eight metabolites of sorafenib have been identified, of which five have been detected in plasma.
Eight percent were severe, requiring multiple (6 - > 10) dilatations.
any of the other ingredients of Betaferon.
any of the other ingredients of Extavia.
Humalog BASAL is a white, sterile suspension.
Humalog is a replacement insulin which very similar to the insulin made by the pancreas.
Humalog Mix25 is a white, sterile suspension
Calcitonins Human coagulation factor VIII Loratadine Sibutramine Gatifloxacin Nimesulide COX-2-Inhibitors:
Human engineered monoclonal antibody specific for Transforming Growth Factor β2
Human Milk Fat Globule 1 / Human Milk Fat Globule 1-
Humira 40 mg solution for injection in vials Adalimumab
Humira 40 mg solution for injection in pre-filled pen Adalimumab
Humira 40 mg solution for injection in pre-filled pen
HUMIRA 40 mg solution for injection does not contain preservatives; therefore, any unused product or waste material should be disposed of in accordance with local requirements.
Humira is also available as a vial or a pre-filled pen.
Humira is also available as a pre-filled syringe or a pre-filled pen.
Humira has not been studiedin patients with hepatic or renal impairment.
Humira has not been studied in these patient populations.
Humira can also be used to treat severe, active and progressive rheumatoid arthritis without previous methotrexate treatment.
Since qualifying in 1983 Mr Humphreys has worked in the area of development pharmaceutics for a national branded generics manufacturer and an international research and development company.
Hunton House Highbridge Business Park, Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom
Hycamtin is available in packs containing 10 capsules of 0.25 mg or 1 mg topotecan.
Hydrochlorothiazide Adverse events (regardless of relationship to medicinal product) reported with the use of hydrochlorothiazide alone include:
Hydrocortisone aceponate Miconazole as nitrate Gentamicin as sulphate
Hydronephrosis Renal failure Urine abnormality
methyl-ethyl]phenoxy] methyl]phenyl]methoxy]- phenyl]iminomethyl]-
Hepatobiliary disorders Hyperbilirubinaemia Transaminases increased Aspartate aminotransferase increased
Blood calcium increased Uncommon
Hypercalcaemia Hydrochlorothiazide stimulates renal calcium reabsorption and may cause hypercalcaemia.
Hypercalcemia greater than 3.25 mmol/ L Vascular disorders Common:
Urine calcium/creatinine ratio increased Urine calcium increased
Hyperglycaemia/ glucose intolerance/ diabetes mellitus Patients should be advised that treatment with TORISEL may be associated with an increase in blood glucose levels in diabetic and non-diabetic patients.
fever, hyperhidrosis, bronchial constriction, impotence and angioedema.
hepatitis† hyperhidrosis, night sweats, pruritus, rash
Hyperhidrosis 2 General disorders and administrative site conditions
Mean number of new or newly-
Hyperkalaemia Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not recommended.
Hyperkalaemia Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (heparin, etc.) should be undertaken with caution and with frequent monitoring of potassium levels.
Headache, dizziness Hyperkinesia, tremor, dysphonia, paresthaesia, hypoaesthesia, hyperaesthesia, concentration impaired, somnolence no
Headache, dizziness Hyperkinesia, tremor, dysphonia, paresthaesia, hypoaesthesia, hyperaesthesia, concentration impaired, somnolence
Hyperkinesia, tremor, dysphonia, paresthaesia, hypoaesthesia, hyperaesthesia, concentration impaired, somnolence
Hyperkinesia, tremor, dysphonia, paresthaesia, hypoaesthesia, hyperaesthesia, concentration impaired, somnolence
Hyperkinesia, tremor, dysphonia, paresthaesia, hypoaesthesia, hyperaesthesia, concentration impaired, somnolence
Leucocytosis (WBC > 50 x 109/ l), thrombocytopenia (platelets < 100 x 109/ l; transient)
Hypersensitivity to other medicinal products of the echinocandin class.
Hypersensitivity to fluoxetine or to any of its excipients.
Hypersensitivity to fluoxetine or to any of the excipients.
- hypersensitivity to alemtuzumab, to murine proteins or to any of the excipients;
- Hypersensitivity to moxifloxacin, other quinolones or to any of the excipients.
Hypersensitivity to anagrelide or to any of the excipients of the medicinal product.
Hypersensitivity to the active substance Botulinum neurotoxin type A or to any of the excipients.
- Hypersensitivity to somatropin or to any of the excipients.
- Hypersensitivity to sparfloxacin or to drugs in the quinolone family.
Hypersensitivity to stavudine or to any of the excipients.
Hypersensitivity to the active substance or to peanuts or soya or to any of the excipients.
Hypersensitivity to the active substance (cidofovir) or to any excipients.
• Hypersensitivity to the active substance or to any of the excipients • Hypoglycaemia.
Hypersensitivity to the active substance or to any of the excipients.
• Hypersensitivity to the active substances or to any of the excipients. • Significant or unexplained hepatic dysfunction. • Active peptic ulcer disease. • Arterial bleeding.
Although the optimal (minimum) dose for full clinical benefit is unknown, patients must be treated at the recommended dose, with dose reduction for toxicity as described.
Hypersensitivity to the active substance or to any of the excipients of Avamys.
Hypersensitivity to the active substance or to any other excipients of the transdermal patch.
Hypersensitivity to the active substance or to any of the excipients.
• Hypersensitivity to the active substance or to any of the excipients. • Hypersensitivity to Chinese hamster ovary (CHO) cell products or other recombinant human or humanised antibodies. • Pregnancy (see section 4.6). • Avastin is contraindicated in patients with untreated CNS metastases (see sections 4.4 and 4.8).
Hypersensitivity to the active substance or any of the excipients.
Hypersensitivity to the active substance or any of the excipients.
Hypersensitivity to the active substance or excipient.
- hypersensitivity to the active substance or to any of the excipients
- Hypersensitivity to the active substance or to any of the excipients;
- Hypersensitivity to the active substance or to any of the excipients.
- Hypersensitivity to the active substance or to any of the excipients
• Hypersensitivity to the active substance or to any of the excipients.
Hypersensitivity to the active substance or to any of the excipients
Hypersensitivity to the active substance or to any of the excipients.
Hypersensitivity to the active substanceor to any of the excipients.
Hypersensitivity to the active substance or to any of the excipients.
Hypersensitivity to the active substance or to any of the excipients.
- Hypersensitivity to the the active substance or to any of the excipients.
Hypersensitivity to the active substance or to any of the excipients or to any bisphosphonates.
- Hypersensitivity to the active substance or to any of the excipients (e. g. metacresol) (see
Therefore, no adjustment is necessary for oral dosing for patients with mild to severe renal impairment (see section 5.2).
Hypersensitivity to the active substance or to any of the excipients (see section 4.4).
Hypersensitivity to the active substance or to any of the excipients (see section 4.8).
- Hypersensitivity to the active substance or to any interferon or to any of the excipients;
• Hypersensitivity to the active substance or any structural analogue of GnRH, extrinsic peptide hormones or to any of the excipients.
• Hypersensitivity to the active substance or any structural analogues of GnRH, extrinsic peptide hormones or to any of the excipients.
· Hypersensitivity to bovine or human thyroid stimulating hormone or to any of the excipients.
Hypersensitivity to eculizumab, murine proteins or to any of the excipients.
Hypersensitivity to efalizumab or to any of the excipients.
Hypersensitivity to emedastine or to any of the excipients.
- Hypersensitivity to ibritumomab tiuxetan, to yttrium chloride, to rituximab, to other murine
Hypersensitivity to human insulin or to any of the excipients (see section 6.1 List of excipients).
Hypersensitivity to any of the excipients< To be implemented nationally - in particular polyoxyethylene hydrogenated castor oil or structurally related compounds. >
Hypersensitivity to the active substances or to any of the excipients.
Hypersensitivity to the active substances or to any of the excipients or neomycin and polymyxin.
Hypersensitivity/ Angioedema Angioedema of the face, extremities, lips, mucous membranes, tongue, glottis and/ or larynx has been reported rarely in patients treated with ACE inhibitors, including< COVERSYL and associated names > (see 4.8 Undesirable effects).
Hypersensitivity to bortezomib, boron or to any of the excipients.
Hypersensitivity to cefuroxime, other cephalosporins or to any of the excipients.
• Hypersensitivity to 5-aminolevulinic acid hydrochloride or porphyrins. • Acute or chronic types of porphyria. • Pregnancy (see sections 4.6 and 5.3)
Hypersensitivity to the active substance or to any of the excipients.
Hypersensitivity to gadoversetamide or to any of the excipients or to other gadolinium containing products.
Hypersensitivity to levetiracetam or other pyrrolidone derivatives or any of the excipients.
Hypersensitivity to levetiracetam or other pyrrolidone derivatives or any of the excipients.
Hypersensitivity to pimecrolimus, other macrolactams or to any of the excipients.
Hypersensitivity to the active substance or to peanut or soya or to any of the excipients.
Hypersensitivity to the active substance or to any of the excipients.
Hypersensitivity to the active substance or to any of the excipients.
r ge Hypersensitivity to the active substance or to any of the excipients.
Hypersensitivity to the active substance or any of the excipients.
- Hypersensitivity to the active substance or to any of the excipients.
- Hypersensitivity to the active substance or to any of the excipients.
Hypersensitivity to the active substance or to any of the excipients
Hypersensitivity to the active substance or to any of the excipients.
Hypersensitivity to the active substance or to any of the excipients
Hypersensitivity to the active substance or to any of the excipients.
- Hypersensitivity to the active substances or to any of the excipients of the effervescent tablet
Hypersensitivity to the active substance or to any of the excipients (see section 6.1).
Hypersensitivity to the active substance or to any of the excipients.
Hypersensitivity to the active substance or to any of the excipients.
Hypersensitivity to tacrolimus or other macrolides.
Hypersensitivity to temsirolimus, its metabolites (including sirolimus), polysorbate 80, or to any of the excipients of TORISEL.
- Hypersensitivity to the active substance tenecteplase and to any of the excipients
- Hypersensitivity to toremifene or to any of the excipients.
Hypersensitivity to travoprost, timolol, or to any of the excipients.
Hypersensitivity to homologous immunoglobulins, especially in very rare cases of IgA deficiency, when the patient has antibodies against IgA.
Hypersensitivity to the active substances, to any of the excipients (see section 6.1), or to other sulfonamide-derived substances (hydrochlorothiazide is a sulfonamide-derived substance).
- Hypersensitivity to the active substances or to any of the excipients.
Hypersensitivity to the active substances or to any of the excipients.
Hypersensitivity to the active substances, or to any of the excipients.
Hypersensitivity to goat proteins or goat milk components.
Hypersensitivity to the active substances, to any of the excipients, to egg, chicken proteins, neomycin, formaldehyde and octoxinol 9.
Hypersensitivity to the active substances, to any of the excipients, to egg, chicken proteins, neomycin, formaldehyde and octoxinol 9.
Hypersensitivity to the active substances, to any of the excipients or to formaldehyde.
Hypersensitivity to the active substances, to dihydropyridine derivatives, or to any of the excipients.
Hypersensitivity to the active substance or to any of the excipients.
Hypersensitivity to the active substances or to any of the excipients.
Hypersensitivity to the active substances or to any of the excipients, or to diphtheria toxoid.
Patients with known hypersensitivity to lopinavir, ritonavir or any of the excipients.
Hypersensitivity to the active substances, including tetanus toxoid, or to any of the excipients (see sections 2 and 6.1).
Hypersensitivity to sulphonamides (see section 4.4).
Known hypersensitivity to glucosamine or to any of the excipients.
Hypersensitivity to nifedipine or other dihydropyridines, or to any of the excipients.
Hypersensitivity to the active substance or to any of the excipients.
Hypersensitivity to the active substance or to any of the excipients or to murine proteins.
- Hypersensitivity to the active substance or to any of the excipients (see section 6.1)
Viani is contraindicated in patients with hypersensitivity to any of the active substances or to the excipient.
History of hypersensitivity reaction to depreotide, any of the excipients of NeoSpect or sodium pertechnetate (99mTc) solution for injection.
- Known hypersensitivity to the active substance or to any of the excipients of this product.
Known hypersensitivity to the active substance or to any of the excipients.
Hypersensitivity to the active substances or to any of the excipients.
Known or suspected hypersensitivity to retapamulin or to the excipient.
The usual contraindications of MR examinations must be applied, such as exclusion of patients with infusion pumps, pacemakers, ferro-magnetic clips etc.  Hypersensitivity Allergoid and other idiosyncratic reactions may occur with all contrast media for intravenous application, also with gadoversetamide, which could become manifest in form of cardiovascular, respiratory and skin reactions.
The usual contraindications of MR examinations must be applied, such as exclusion of patients with infusion pumps, pacemakers, ferro-magnetic clips etc.  Hypersensitivity Allergoid and other idiosyncratic reactions may occur with all contrast media for intravenous application, also with gadoversetamide, which could become manifest in form of cardiovascular, respiratory and skin reactions.
 Hypersensitivity Allergoid and other idiosyncratic reactions may occur with all contrast media for intravenous application, also with gadoversetamide, which could become manifest in form of cardiovascular, respiratory and skin reactions (see section 4.8).
 Hypersensitivity Allergoid and other idiosyncratic reactions may occur with all contrast media for intravenous application, also with gadoversetamide, which could become manifest in form of cardiovascular, respiratory and skin reactions (see section 4.8).
Hepatobiliary disorders Reproductive system and breast disorders:
Hypersensitivity (anaphylactic reaction) to the active substance or to any of the excipients.
Severe hypersensitivity to erlotinib or to any of the excipients.
Hypersensitivity after previous administration of diphtheria, tetanus, pertussis, hepatitis B or polio vaccines.
Somnolence, insomnia, paraesthesia, hypersomnia, peripheral sensory neuropathy
Sweating (includin g night sweats) [12.2%]
hypertension (2.8% vs 2.2%) fatigue (3.3% vs 4.0%) sluggishness (0.2% vs 0%)
Hypertension :< COVERSYL and associated names > may be used in monotherapy or in combination with other classes of antihypertensive therapy.
Only 2 Member States have longer duration of titration (6 to 8 weeks) and 1 Member States has no proposal.
Pulmonary hypertension Pulmonary hypertension is a known complication of Gaucher disease.
Hypertension, flushing Hypotension, hot flush
Appetite decreased (anorexia), Constipation, Vomiting
Hypertension, Vasodilatation (mostly hot flashes/ flushes), Palpitations
- Overactive thyroid gland has been reported, abnormal development of secondary male sexual
Depression, emotional lability, insomnia Suicidal ideation, aggressive reaction, confusion, behaviour
Depression, emotional lability, insomnia Suicidal ideation, aggressive reaction, confusion, behaviour disorder, agitation, somnambulism, anxiety, nervousness, sleep
Hypertriglyceridemia§, hyperuricemia, increased appetite
Hypothyroidism§, Hyperthyroidism§, virilism
Skin hypertrophy, acrochordons*, abnormal hair texture*
Hypocalcaemia Bondenza, like other bisphosphonates administered intravenously, may cause a transient decrease in serum calcium values.
Hypocalcaemia Bonviva, like other bisphosphonates administered intravenously, may cause a transient decrease in serum calcium values.
Depression, irritability, insomnia, anxiety*, concentration impaired, emotional lability*
Hypersensitivity to human insulin or to any of the excipients (see section 6.1 List of excipients). uc
Hypoglycaemia Hypersensitivity to human insulin or to any of the excipients (see section 6.1 List of excipients).
Hypergonadism male, Cushing syndrome, hypothyroidism
Hypogonadism male, Cushing syndrome, hypothyroidism
Anorexia Hyperglycaemia, weight decreased Hypokalemia, alkaline phosphatase increased, weight increased
- Hypokaliemia: patients with a known history of hypokaliemia including that caused by
au Metabolism and nutrition disorders
r ge Metabolism and nutrition disorders
Hypokinesia, parosmia, dysgraphia Loss of consciousness, mental impairment, headache
Hyponatraemia Hypocalcaemia Weight decrease Dehydration Thirst
- Mirtazapine should not be administered concomitantly with MAO inhibitors or within two
Hypotension, hypertension, diastolic hypertension, blood pressure fluctuations
Hypotension, hypertension, syncope, flushing
Photosensitivity reaction, photodermatosis
Elevations in serum transaminase activities
Hypotension, thrombophlebitis, vasodilatation, flushing
- Underactive thyroid gland which can cause tiredness or weight gain
I-04010 Campoverde di Aprilia (Latina) Tel: + 39 06 92 8921
Pharmaceutiques Grand Public, Euro- pean Federation of Pharmaceutical In-
Ibaflin is available as tablets (30, 150, 300 and 900 mg) and as oral gels (3 and 7.5%).
Ibaflin is indicated for the treatment of the following conditions in dogs:
Ibraxion has been studied using the recommended dosing in all categories and age groups of animals.
Ibraxion contains a gene deleted IBR virus, which is inactivated.
Ibraxion is shaken before use and injected subcutaneously (under the skin) into the neck at the front of the shoulder.
Ibraxion is also intended to reduce the spread of the IBR virus by reducing the amount of virus excreted by the animals.
Ibraxion is an emulsion for injection.
Ibraxion is a gene specific deleted (gE), inactivated and adjuvanted (o/ w emulsion) vaccine which acts by the active immunisation of cattle characterised by the production of Infectious Bovine Rhinotracheitis (IBR) vironeutralising antibodies.
Ibraxion is used to immunise cattle to reduce the clinical signs of IBR and reduce field virus excretion (virus that is passed out of the animal).
Ibraxion may cause a slight rise in body temperature (less than 1°C) for less than 48 hours after injection.
CI = confidence interval, FOLFOX = oxaliplatin plus infusional 5-FU/ FA, ORR = objective response rate (patients with complete response or partial response), PFS = progression-free survival time
Cholestatic jaundice, AST and ALT increase, purpura, rash and pruritus.
IDA Industrial Park Old Kilmeaden Road Waterford Ireland
delusional ideas, states of excitement, asthenia, depression, anxiety, confusion, sexual dysfunction, withdrawal symptoms.
Aggressive behaviour
106 Thoughts of suicide and worsening of your depression If you are depressed you can sometimes have thoughts of harming or killing yourself.
85 Thoughts of suicide and worsening of your depression If you are depressed you can sometimes have thoughts of harming or killing yourself.
Thoughts of suicide and worsening of your depression If you are depressed you can sometimes have thoughts of harming or killing yourself.
Thoughts of suicide and worsening of your depression If you are depressed you can sometimes have thoughts of harming or killing yourself.
Depression, emotional lability, insomnia Suicidal ideation, aggressive reaction, confusion, behaviour disorder, agitation, somnambulism, anxiety, nervousness, sleep
highlighted for increased monitoring and follow-up should include:
(i) antibiotics in the last 28 days?
I Unscrew the vial adapter with the empty vial.
IDflu is given as one ‘ intradermal'injection into the upper layer of the skin, using a special micro-injection system.
- IDflu should under no circumstances be administered into a vein (intravascularly).
IDflu is administered to you by your doctor or nurse.
IgG/ IgA/ Light chain Median β 2-microglobulin (mg/ l) Median albumin (g/ l) Creatinine clearance ≤ 30 ml/ min [n (%)]
Identification and assay of active ingredients
II. E.2 Identification and assay of active ingredients
There have also been reports about severe vomiting that can lead to a rupture of the oesophagus.
It concluded that Gliolan increases the ability of the tumour to be distinguished from healthy brain tissue during surgery, and that it increases the proportion of patients whose tumours are completely removed and extends the time that patients survive without progression.
It activates another factor called factor X, which starts the coagulation process.
He was first appointed chairman of the Management Board at the April 1994 and stepped down in February 2000 after having served two terms of office.
They recommended that Rapilysin be given marketing authorisation (made available to doctors).
The Committee recommended that Equilis Prequenza Te should be given a marketing authorisation.
The MAH was also asked to justify the dosing in paediatric patients suffering from renal impairment and the dosing by weight in the 2-5 year age group and dosing by age groups 2-5, 6-11 and 12-18 as well as dosing for children less than 2 years old.
He was also Chairman of the French Medicines Registration Committee from 1985 to
He was also associated professor of medical physiology at the Technical University, Eindhoven.
They recommended that Nobilis IB 4-91 should be given a marketing authorisation.
It also reduced neuroendocrine activation.
There he was responsible for a number of groups in the technical support division of the Euratom Safeguards Directorate.
He was later appointed to the Pharmaceutical Inspectorate (Ministry of Social Affairs
He was later appointed to the Pharmaceutical Inspectorate (Ministry of Social Affairs and Public Health) in Brussels as a Chief Inspector, acting as the Secretary of the Belgian Medicines Commission.
He was later appointed to the Pharmaceutical Inspectorate (Ministry of Social Affairs and Public Health) in Brussels as a Chief Inspector, acting as the Secretary of the Belgian Medicines Commission.
Qualified as a pharmacist, BSc (Pharm) and was granted a Masters degree in pharmaceutics in the research area of microencapsulation from Trinity College Dublin.
He was appointed Director-General of the new Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS) in 1999.
He later joined the French Neuromuscular Diseases Association (AFM) as Special Advisor to stimulate public health policy on rare diseases, to create the French Alliance Maladies Rares, a national umbrella organisation of 70 patients associations, and to advise the European Organisation for Rare Disorders (Eurordis), based in Paris.
He then joined the European Centre for the Development of Vocational Training as Head of Administration, a position he held until April 1995 when he joined the EMEA.
He moved briefly to the pharmaceutical industry from 1 986 to 1987, before returning to clinical work at the Queen Fabiola Children’s University Hospital in Brussels as head of the nutrition and pharmacodynamics unit, a post he continues to hold today.
He moved briefly to the pharmaceutical industry from 1986 to 1987, before returning to clinical work at the Queen Fabiola Children's University Hospital in Brussels as head of the nutrition and pharmacodynamics unit, a post he continues to hold today.
He moved briefly to the pharmaceutical industry from 1986 to 1987, before returning to clinical work at the Queen Fabiola Children’s University Hospital in Brussels as head of the nutrition and pharmacodynamics unit, a post he continues to hold today.
It decided that Diacomit's benefits are greater than its risks for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalised tonic-clonic seizures in patients with SMEI (or Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.
It was first authorised in 1979 and is currently authorised in the EU in Belgium, France, Italy, Luxembourg and Portugal under the names Agreal and Agradil.
It was concluded that 160-320 mg of valsartan produced clinically relevant reductions in UAE in hypertensive patients with type 2 diabetes.
It is concluded that the safety of terfenadine was acceptable if used as recommended in the Summary of Product Characteristics (SPC).
The MAH was requested to report the results from the active monitoring program for IRREs in the USA.
Forcaltonin showed the same effectiveness and safety profile as synthetic salmon calcitonin.
As with other medicinal products in its class, ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature animals.
Treatment with the recommended dose of Halocur orally during 7 consecutive days, in calves aged from 4 to 10 days was shown to reduce diarrhoea compared to placebo.
One cartridge contains 60 million IU of recombinant interferon alfa-2b produced in E.coli by recombinant DNA technology, in 1.2 ml.
19 Tylvalosin has been shown to concentrate in phagocytic cells and gut epithelial cells.
It was demonstrated that the use of a 0.2 micron in-line filter removes visible particles and does not result in an apparent loss of protein or activity.
Mitochondrial dysfunction: nucleoside and nucleotide analogues have been demonstrated in vitro and in vivo to cause a variable degree of mitochondrial damage.
Nucleoside and nucleotide analogues have been demonstrated in vitro and in vivo to cause a variable degree of mitochondrial damage.
Mitochondrial dysfunction: nucleoside and nucleotide analogues have been demonstrated in vitro and in vivo to cause a variable degree of mitochondrial damage.
Nucleoside and nucleotide analogues have been demonstrated in vitro and in vivo to cause a variable degree of mitochondrial damage.
Serum antibodies have been shown to persist in chickens for at least 7 months.
It was demonstrated that the use of a 0.2 micron in-line filter removes visible particles and does not result in an apparent loss of protein or activity.
In the light of the experience gained in France particularly since 1992, and because of the seriousness of cardiac ADRs which included fatal cases, they considered that the safe use of terfenadine would not be sufficiently ensured by a more restrictive SPC and that the Marketing Authorisations for all terfenadine containing medicinal products must be withdrawn.
It has been considered that the risk-benefit of terfenadine 6 mg/ ml oral suspension formulations is acceptable and the Marketing Authorisations should be maintained provided that: -the Summaries of Product Characteristics (SPCs) are revised with emphasis on contraindications due to hepatic or cardiac diseases and pharmacokinetic or pharmacodynamic interactions between terfenadine and other substances as stated in Annex I.
Bass was both Head of Drug Toxicology at the Institute for Drugs at the Federal Health Office (BGA) in Berlin and Adjunct Professor of Pharmacology and Toxicology at the Free University of Berlin.
It has been considered that the risk-benefit of terfenadine 30 mg is acceptable and the Marketing Authorisation should be maintained provided that:
He is a former Belgian Member of both the CPMP and CVMP, and representative on the Pharmaceutical Committee, Standing Committee and Notice to Applicants working group.
He is a former Belgian Member of both the CPMP and CVMP, and representative on the Pharmaceutical Committee, Standing Committee and Notice to Applicants working group.
He is a former Belgian Member of both the CPMP and CVMP, and representative on the Pharmaceutical Committee, Standing Committee and Notice to Applicants working group.
He was later appointed to the Pharmaceutical Inspectorate (Ministry of Social Affairs and Public Health) in Brussels as a Chief Inspector, acting as the
AUCs of free and encapsulated cytarabine after ventricular injection of DepoCyte appeared to increase linearly with increasing dose, indicating that the release of cytarabine from DepoCyte and the pharmacokinetics of cytarabine are linear in human CSF.
Tacrolimus has been shown to increase the blood level of phenytoin.
Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.
Preotact has been shown to significantly reduce vertebral (spine) fractures, but not hip fractures.
Trudexa has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.
Trudexa has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. lP
Trudexa has been shown to slow down the damage to the cartilage and bone of the joints caused by the dic
Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.
Humira has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see Section 5.1) and to improve physical function.
Humira has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see Section 5.1) and to improve physical function.
Humira has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see Section 5.1) and to improve physical function.
Humira has been shown to slow down the damage to the cartilage and bone of the joints caused by the disease and to improve physical function.
He was nominated as press officer in September 2001.
He was nominated as head of the AIDS and drug addiction group of Paris public hospitals.
He was appointed Chief Veterinary Officer in 1991.
Infrequently, adult patients treated for chronic hepatitis C with Viraferon developed thyroid dic
Kaletra has been shown in vivo to induce its own metabolism and to increase the biotransformation of some medicinal products metabolised by cytochrome P450 enzymes and by glucuronidation.
Eight patients were retrospectively found to have dysbetalipoproteinemia, based on elevated cholesterol and triglycerides, the presence of the apolipoprotein E2/ 2 genotype, and a VLDL/ triglycerides ratio ≥ 0.25.
In rats, female reproductive function including birth was impaired at toxic dosages and the offspring showed reduced birth weights, viability and growth.
An increased chromosome fragility has been observed in one in vitro study on lymphocytes taken from patients after long term treatment with somatropin and following the addition of the radiomimetic medicinal product bleomycin.
A mean change from baseline of – 24.6 and – 30.6% at the 80 mg and 160 mg doses for LDL cholesterol, respectively, a mean change of -23.0% and -28.8% in total cholesterol and respectively, and a mean change of +7.4% and +4.7% 24.5% at the 80 mg and 160 mg, respectively, were found (see Table 3).
A relationship between active substance exposure at steady state (rivastigmine and metabolite NAP226-90) and bodyweight was observed in Alzheimer's dementia patients.
Inadvertent administration of up to 140 mg of caspofungin in one day has been reported.
Inadvertent administration of up to 140 mg of caspofungin in one day has been reported.
Patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES).
Bleeding or bruising more easily than normal due to a drop in a type of blood cell called platelets have been reported very rarely (less than 1 per 10,000 doses of vaccine) with the hepatitis B component of Quintanrix. t uc
A total of 3 substances were recommended for addition to Annex I (formal MRL fixed), 34 to Annex II (MRL not required), 13 to Annex III (provisional MRL) and 2 were placed in Annex IV (prohibited substances).
It was pointed out that treatment should be thought of as a package, which considers first- and second-line eradication therapies together.
It acts at the neuromuscular junction by stimulating presynaptic receptors belonging to the secretin receptor family which results in paralysis and death of the parasites.
It is active against the Human Immunodeficiency Virus (HIV) helping to reduce the number of HIV particles in blood.
It acts selectively on the receptor subtype AT1, which is responsible for the known actions of angiotensin II.
This means that it acts like somatostatin, and binds to the same receptors as somatostatin in the body.
It acts by reducing the amount of prostaglandins (chemical messengers) within cells.
Reproduction is authorised provided the source is acknowledged. the growth of blood vessels within tumours and also stimulates some of the specialised cells of the immune system to attack the cancerous cells.
< Invented Name > cream specifically treats an inflammation of the skin called atopic dermatitis (eczema).
It is active against the Human Immunodeficiency Virus (HIV) helping to reduce the number of HIV particles in blood.
As a result, it helps to clearly show abnormalities in the brain and spine, and in the liver.
It specifically helps to detect the loss of nerve cells that release dopamine, a chemical messenger.
It also improves survival and growth rate in the children treated.
It improves large artery elasticity and decreases the media: lumen ratio of small arteries.
There is increasing evidence that malfunctioning of glutamatergic neurotransmission, in particular at NMDA-receptors, contributes to both expression of symptoms and disease progression in neurodegenerative dementia.
It belongs to a group of medicines called bisphosphonates and is used to treat osteoporosis in post-menopausal women, osteoporosis in men and Paget's disease of the bone.
He joined the French medicines agency in 1994 as director of pharmacotherapeutic evaluation, a post he holds today.
He joined the EMEA in September 1997 and was appointed Head of Sector for New Chemical Substances in June 1998.
He joined the Secretariat of the European Parliament in 1989, serving on the secretariats of the Committee on Research, Technological Development and Energy, of the Committee on Budgets and latterly of the Parliament's Bureau and Conference of Presidents.
He joined the Secretariat of the European Parliament in 1989, serving on the secretariats of the Committee on Research, Technological Development and Energy, of the Committee on Budgets and latterly of the Parliament’s Bureau and Conference of Presidents.
Mr Pott joined the Secretariat of the European Parliament in 1989, serving on the secretariats of the Committee on Research, Technological Development and Energy, of the Committee on Budgets and latterly of the Parliament’s Bureau and Conference of Presidents.
He rejoined industry working for French and British multi-national pharmaceutical companies in international quality assurance before joining the EMEA in August 1995.
He rejoined industry working for French and British multi-national pharmaceutical companies in international quality assurance before joining the EMEA in August 1995.
Sometimes, the ovaries can over- respond to treatment (ovarian hyperstimulation syndrome), and both doctors and patients must be aware of this possibility.
It contains two active substances which work together to reduce pressure within the eye.
He served in the Cabinet of the French Secretary of State for health as public health adviser from 1997 to 1998, before being nominated as Secretary-General of the French Agence du Médicament in 1998.
It is purely provisional and can only be used after its transfer to other articles or items in this chapter in accordance with the Financial Regulation.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
It blocks an enzyme called integrase, which is involved in a step in the reproduction of HIV.
It blocks an enzyme (protease) that is involved in the reproduction of HIV.
It circulates bound to SHBG (37%) and to albumin (61%), while only approximately 1-2% is unbound.
In addition, he considers that since this is a generic, there will not be an additional risk to the environment.
It is a copy of a protein called osteogenic protein 1, also known as bone morphogenic protein 7 (BMP-7), which is produced naturally by the body and helps the formation of new bone tissue.
To be taken into consideration for patients on a controlled sodium diet.
It contains 50 mg or 100 mg of the active substance palivizumab.
It contains Doxazosin, which belongs to a group of medicines called alpha-blockers.
It contains 3.7 g sorbitol (E420) per dose (200 mg lacosamide), corresponding to a calorific value of 9.7 kcal.
It contains the active substance basiliximab.
It contains less than 23 mg (1 mmol) sodium in each weekly dose.
It contains multiple amines separated by one carbon from the polymer backbone.
It contains a protein (antigen) from the porcine circovirus type 2 virus (PCV2).
It contains a substance, ioflupane, that has been labelled with 123I (iodine-123), a radioactive form of the chemical element iodine.
It contains the active substance certolizumab pegol.
Together with the Safety Working Party it is expected to continue with the development of guidance for viral safety issues, DNA vaccines and gene therapy.
It also helps to reduce viral excretion in case of calicivirus infection.
This will also have to take into account the enlargement of the European Union and expected advances in medical science.
When these medicinal products are administered to or withdrawn from patients receiving nateglinide, the patient should be observed closely for changes in glycaemic control.
The bottle should be lightly shaken before opening.
The cream should be applied to the area twice daily for 7-14 days.
Sufficient cream should be applied to cover the treatment area, including one centimetre of skin surrounding the tumour.
If the patient fails to respond, for example a steady progression in Expanded Disability Status Scale (EDSS) for 6 months occurs or treatment with at least 3 courses of adrenocorticotropic hormone (ACTH) or corticosteroids during a one-year period is required despite Extavia therapy, treatment with Extavia should be stopped.
A decision on whether to continue/ discontinue breast-feeding or to continue/ discontinue therapy with RELISTOR should be made, taking into account the benefit of breast-feeding to the child and the benefit of RELISTOR therapy to the woman.
Panretin is applied twice a day to the skin lesions, avoiding healthy skin, using enough gel to cover each lesion with a generous coating, then left to dry for three to five minutes before covering with clothing.
The gel must be allowed to dry for three to five minutes before covering with clothing.
It should also not be used in patients who have diabetic ketoacidosis (high levels of ketones and acids in the blood), diabetic pre-coma, problems with their kidneys or liver, conditions that may affect the kidneys, or a disease that causes a reduced supply of oxygen to the tissues such as failure of the heart or lungs or a recent heart attack.
The dose should not be increased to the full twice-daily dose until any rash has cleared.
Fluticasone Furoate GSK should only be used for as long as the patient is exposed to the allergen, such as pollen, house dust mites or other animals.
The possibility of an increased risk of bleeding events should be borne in mind.
Healthcare professionals were to be reminded of these measures through a communication letter (Dear Healthcare Professional Letter).
Healthcare professionals were to be reminded of these measures through a communication letter (DHCP).
Healthcare professionals were to be reminded of these measures through a communication letter.
It must also be remembered that neutral regular insulin precipitates out at a pH of approximately 4.5 to 6.5.
It must also be remembered that neutral regular insulin precipitates out at a pH of approximately 4.5 to 6.5.
The treatment spot should cover all neovasculature, blood and/ or blocked fluorescence.
Its receipt, storage, use, transfer and disposal are subject to the regulations and/ or appropriate licenses of local competent official organisations.
Aseptic technique (meaning clean and germ-free) should be used during the reconstitution procedure.
The following instructions should be followed:
In these cases moxifloxacin should be discontinued and suitable treatment (e. g. treatment for shock) initiated.
As an alternative, patients requiring a long acting
Aggressive pelleting conditions such as temperatures in excess of 80oC, and the use of abrasive substances for pre- mixture should be avoided.
Avoid the use of other topical products on treated KS lesions.
Aggressive pelleting conditions such as temperatures in excess of 80oC, and the use of abrasive substances for pre- mixture should be avoided.
During this period, showering and bathing should be avoided.
should be reminded of the importance of removing the Alert Card included in the pack, and keeping it with them at all times.
They should be reminded of the importance of removing the Alert Card included in the pack, and keeping it with them at all times.
Physicians and patients should remain alert for signs and symptoms of gastrointestinal ulceration and haemorrhage during EXJADE therapy and promptly initiate additional evaluation and treatment if a serious gastrointestinal adverse event is suspected.
Recently treated animals should not be allowed to sleep in the same bed as their owners, especially children.
Therefore, dosages must be limited and this combination must be avoided in cases where there is a risk of misuse (see section 4.4).
Therefore, care should be taken by people who wear soft contact lenses.
Therefore, care should be taken by people who wear soft contact lenses.
Patients should be advised to avoid driving a car or operating hazardous machinery until they are reasonably certain that their performance is not affected.
Secondary infections are to be treated accordingly (see section 5.1).
Therefore, patients must be monitored closely.
The physician information about Thelin should contain the following key elements: • That Thelin is teratogenic o Use of effective contraception in women of child bearing age o Possible interaction with oral contraceptives and increased risk of thromboembolism o Need to advise female patients about teratogenicity, contraception, if necessary the need for pregnancy testing and what to do if they become pregnant o Referral of patients who become pregnant to a physician specialised or experienced in teratology and its diagnosis for evaluation and advice
A separate cannula should be used.
It should also not be used in patients with alcohol intoxication (excessive alcohol consumption) or alcoholism, or during breast- feeding.
It should also not be used in patients with alcohol intoxication (excessive alcohol consumption) or alcoholism, or during breast- feeding.
It should also not be used in patients who have had recent bleeding, who have severe high blood pressure or severe kidney problems, or a heart infection.
Therefore, contact with skin or eyes should be avoided.
It decay by emission of beta radiation of 2.281 MeV (99.98%) of maximal energy to stable Zirconium (90Zr).
Telmisartan displaces angiotensin II with very high affinity from its binding site at the AT1 receptor subtype, which is responsible for the known actions of angiotensin II.
Telmisartan does not exhibit any partial agonist activity at the AT1 receptor.
It should also be stated that it is advisable to limit treatment to about 10 days, as the activity of pseudoephedrine diminishes over time.
It reduces inflammation by reducing the production of immune cells called ‘ lymphocytes’, which are responsible for inflammation.
This usually disappears within one to four weeks.
On theoretical grounds, therefore, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
On theoretical grounds, therefore, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
On theoretical grounds, therefore, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley- Seegmiller syndrome.
VISTIDE must be administered by a health care professional.
Optisulin contains insulin glargine an insulin analogue with a prolonged duration of action. It should be administered once daily at any time but at the same time each day.
It should be dissolved with the solvent (solvent for parenteral use) -a clear, colourless solution- contained in a glass ampoule.
It should be dissolved with the solvent (solvent for parenteral use) -a clear, colourless solution-contained in a second glass ampoule.
It should be dissolved with the solvent (solvent for parenteral use)-a clear, colourless solution- contained in a second glass ampoule.
6 Consideration should be given to replacing zidovudine in a combination ART regimen if this is already established.
Consideration should be given to replacing zidovudine in a combination ART regimen if this is already established.
It must be mixed outside the body, usually in a laboratory, with the medicine that needs radiolabelling.
It must be taken with at least two other antiviral medicines that the patient has not taken before.
Your child should take SINGULAIR every evening. • It should be taken even when your child has no symptoms or if he/ she has an acute asthma attack. • Always have your child take SINGULAIR as your doctor has told you.
Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidality emerge.
A statement to highlight that tacrolimus should not be applied to lesions, which are considered to be potentially malignant or pre-malignant.
A statement reflecting the cases of malignancies reported in the post-marketing
It should be used with caution in patients who have problems with their liver.
It must only be used if the solution is clear, colourless, with no solid particles visible.
It should always be taken in combination with other prescribed antiepileptic medicines under the direction of a doctor.
He/ she will work out the correct dose of Binocrit for you to use and how long the treatment should continue.
It prevents a peptide (“ Substance P”) from binding to the NK1 receptors, which is involved in causing vomiting.
Valnemulin has been shown to interact with ionophores such as monensin, salinomycin and narasin and may result in signs indistinguishable from an ionophore toxicosis.
users of medicines, the pharmaceutical industry, health care
This results in an increase in blood pressure.
This increases the amount of oxygen carried in the blood in the arteries, helping to reduce the symptoms of anaemia.
This results in disproportionate increases in plasma concentrations of paroxetine and hence pharmacokinetic parameters are not constant, resulting in non-linear kinetics.
This makes the airways widen, allowing the air to flow more freely.
This results in an increase in blood pressure.
It is absorbed by cells in the body, where it is converted by enzymes into fluorescent chemicals, particularly protoporphyrin IX (PPIX).
It is currently marketed in the entire European Union and world-wide in more than 10 countries, including USA and Japan.
He is currently visiting Professor of Pharmacology at the School of Pharmacy University of London and has published widely.
It is used in healthy, sexually- mature dogs that have not been neutered.
It is used when the patient is ‘ Philadelphia chromosome positive'(Ph+), which means that some of the patient 's genes have re-arranged themselves to form a special chromosome called the Philadelphia chromosome.
It is used in patients who are at risk of fracture (bone breaks), including patients who have recently broken their hip in a minor trauma, such as a fall; • Paget's disease of the bone, a disease where the normal process of bone growth is changed.
It is administered into each of two sites in the medial and lateral heads of the affected gastrocnemius muscle.
It is given by injection into the upper arm muscle.
It is given to treat the non-neurological manifestations of the disease.
It is assumed that these effects are mediated by MTP inhibition at the level of the enterocyte.
It is acknowledge that the recommended dose did not result from a dose-finding study but rather from a confirmatory study (the pivotal trial).
It is thought that people who are depressed and/ or anxious have lower levels of serotonin and noradrenaline in the brain.
It is accepted that ACEi is established first-line therapy in patients with IDDM and any degree of hypertension.
It is therefore unlikely that you will receive more Temodal than you should.
It is advisable to use supplementary non-hormonal contraceptive measures other active substances like Probenecid.
It should be noted that stopping Cholestagel therapy will result in increased ciclosporin blood concentrations.
It should be noted that the Telzir oral suspension has not been evaluated clinically in adults and that the adverse reaction profile detailed in this section is based on the experience in adults with the Telzir film coated tablets.
It should be noted that GIST patients may have hepatic metastases which could lead to hepatic impairment.
It is noteworthy that among patients with a clinically suspected hypersensitivity reaction, a proportion did not carry HLA-B*5701.
It should be noted that a broader spectrum of symptoms are included, that do not necessarily have an extrapyramidal origin.
It should be noted that a broader spectrum of symptoms are included, that do not necessarily have an extrapyramidal origin.
It appeared that the receptor mediated clearance of efalizumab was saturated when plasma efalizumab concentrations were above 1 μ g/ ml.
The adverse reactions associated with overdose would be expected to be limited to photosensitivity reactions.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
It is anticipated that tenofovir exposure will be approximately 35% lower following administration of Atripla on an empty stomach as compared to the individual component tenofovir disoproxil fumarate when taken with food.
It is anticipated that tenofovir exposure will be approximately 35% lower following administration of Atripla on an empty stomach as compared to the individual component tenofovir disoproxil fumarate when taken with food (see section 5.2).
Dexamethasone is expected to decrease plasma concentrations of etravirine
St John's wort is expected to decrease the plasma concentrations of etravirine.
Not studied, etravirine is expected to increase plasma concentrations of diazepam.
Etravirine is expected to decrease plasma concentrations of cyclosporine, sirolimus or tacrolimus.
It is also important that you dispose of the syringe in a puncture-proof container.
The conclusion is that the benefit/ risk ratio is favourable for Crestor 5 mg or Crestor 10 mg as alternative start doses.
Do not pass it on dic
There are currently over 5 000 documents on the site.
Protaphane is supplied in vials, cartridges (Penfill), or pre-filled pens (InnoLet, NovoLet and FlexPen).
Women should be advised to use adequate birth control measures during treatment with hydroxycarbamide.
Patients experiencing xerostomia are advised to drink water to moisten the buccal cavity prior to administration of Effentora.
You should allow 15 to 30 minutes for the Enbrel solution in the syringe to reach room temperature.
It is advisable to determine the underlying cause and also treat the animal accordingly.
It is advisable to determine the underlying cause and treat the animal accordingly.
It is advisable to inject immediately after mixing.
It is advisable to rehydrate patients prior to starting therapy with etoricoxib.
The administration of Tritanrix HepB should be postponed in subjects suffering from acute severe febrile illness.
The administration of Tritanrix HepB should be postponed in subjects suffering from acute severe febrile illness.
It is advisable to determine the underlying cause and to treat the animal accordingly.
It is, therefore, advisable to determine the underlying cause and to treat the animal accordingly.
Use of rubber gloves and eye protection is recommended.
It should not be used in people who are taking a monoamine oxidase inhibitor (such as some medicines used to treat depression) or who have stopped taking one of these medicines within the last two weeks.
He is EU coordinator in the VICH.
It is current practice in paediatric vaccination to co-administer different vaccines during the same session with injectable vaccines being administered at separate injection sites.
Women taking Axura should not breast-feed.
Women taking memantine should not breast-feed.
Women taking Ebixa should not breast-feed.
It is not advisable to drink alcohol while you are being treated with Thymanax.
It is not advisable to drink alcohol while you are being treated with Valdoxan.
It is not recommended to chew, crush or split the tablets.
It is not recommended to take Circadin if you are breast feeding.
Ketek tablets are not recommended for use in children and adolescents less than 12 years old.
- Levviax tablets are not recommended for use in children and adolescents less than 12 years old.
From 1998 to present by Bureau Registratie Diergeneesmiddelen (BRD).
It is therefore advisable to use a flexible indwelling cannula for intravenous contrast medium administration.
Therefore, Annex III may not necessarily represent the current text.
It is used in patients who are undergoing magnetic resonance imaging (MRI), a special type of scan where images of the internal organs are taken.
It became evident during the course of the variation preceding this referral that an empirical therapy of PID with moxifloxacin should be avoided due to the high portion of N. gonorrhoeae being resistant to moxifloxacin and other quinolones.
It is not easy to mention the contributions of Fernand to the birth and development of the EMEA.
It is available in packs of 1, 3, 5 or 10 ampoules.
It is available as brown-orange tablets (200 mg).
It is available as pink, capsule-shaped tablets.
It is available as double-arrow- shaped tablets (yellow:
It is available as tablets (pale pink, square:
It is available as hexagonal tablets with 100 mg (pale yellow) or 200 mg (yellow-orange) of tolcapone.
It is available as yellow capsule-shaped tablets (300 mg) and as an oral solution (20 mg/ ml).
It is available as white capsules (200 and 400 mg).
It is available as a powder and solvent to be made up into a solution for injection, and as a single use pre-filled pen.
It is available in a pre-filled syringe and a pre-filled pen (SureClick), each containing 6 mg pegfilgrastim.
It is available as white, oval tablets (200 mg) and as an oral suspension (50 mg/ 5 ml).
It is available as blue, diamond- shaped tablets (25, 50 or 100 mg).
It is available as brown-orange tablets (200 mg).
It is available as tablets (round and white:
It is available as red, round tablets (200 mg).
It is available as a solution for injection in a vial, pre-filled syringe or pre-filled pen, all containing 40 mg of adalimumab.
It is available as a powder and solvent, which are made up into a solution for injection (1.3 or 5 mg/ ml), or as a ready-to-use solution in a cartridge (3.3 or 6.7 mg/ ml).
It is available as a solution for injection in a vial, pre-filled syringe or pre-filled pen, all containing 40 mg adalimumab.
It is available in ng a pre-filled syringe and a pre-filled pen (SureClick), each containing 6 mg pegfilgrastim. lo
It is, therefore, advisable to determine the underlying cause and to treat the animal accordingly.
It is therefore difficult to recommend an optimum method.
So it is important that you carefully read the side effects section of the leaflets that are provided with these other medicines.
Therefore, it is important to keep taking Emselex correctly, as described above.
It is therefore important that you carefully read the package leaflet provided with these medicines.
It is therefore important that you carefully read the package leaflet provided with these medicines.
It is therefore important that you carefully read the package leaflet that is provided with these medicines.
It is therefore important that you carefully read the Package Leaflet that is provided with these medicines.
It is therefore important that you commit to a lower-fat diet to manage these effects.
It is considered essential that monitoring recommendations are strictly adhered to.
Therefore, this SPC, labelling and package leaflet may not necessarily represent the current text.
3 antacids at least two hours after OSSEOR.
It is therefore preferable to take antacids at least two hours after PROTELOS.
It is recommended that the product is applied in the open air or in a well-ventilated room.
Therefore it is recommended that these medicines are not used together.
Therefore, appropriate laboratory testing to establish baseline renal or hepatic biochemistry parameters is recommended prior to and periodically during administration.
It is therefore recommended that mothers taking lamivudine do not breast feed their infants.
Also, you should know that patients under 18 have an increased risk of side-effects such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines.
Also, you should know that patients under 18 have an increased risk of side effects, such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when
Also, you should know that patients under 18 have an increased risk of side effects, such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines.
Also, you should know that patients under 18 have an increased risk of side-effects such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines.
Also, you should know that patients under 18 have an increased risk of side-effects such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines.
It is also important that you tell your doctor if any of the following circumstances apply to you:
He is also the Vice- Chairman of the International Alliance of Patients Organisations (IAPO) based in London.
He is also the Vice-Chairman of the International Alliance of Patients Organisations (IAPO) based in London.
He is also a member of the UK Broadcasting Standards Commission; Chairman of the Family Fund Trust; and Visiting Fellow of the London School of Economics.
Alternatively, 120 mg (20 ml) may be taken in the morning.
Tissue surrounding the tumour and normal brain may also be affected.
You may also have had one or more stents placed to keep open a blocked or narrowed artery supplying blood to the heart.
It is also used in adults and children in the ‘ chronic phase 'of the disease if it is not responding to interferon-alpha (another anti-cancer medicine), and in more advanced phases of the disease (‘ accelerated phase'and ‘ blast crisis’). • Ph+ acute lymphoblastic leukaemia (ALL), a type of cancer in which lymphocytes (another type of white blood cell) multiply too quickly.
It is also used in combination with an aromatase inhibitor for the treatment of patients with HER2-positive and hormone receptor-positive metastatic breast cancer.
Tenecteplase is cleared from circulation by binding to specific receptors in the liver followed by catabolism to small peptides.
It is then further converted in the kidneys to 1,25 hydroxycholecalciferol.
It is essential to follow strictly the once a day dosage during the 14-day ‘ lead in'period before rising to the twice daily dosage.
Neonates are known to have diminished MetHb reductase activity compared to adults.
It is extremely important that pregnant Wilson's disease patients continue their therapy during pregnancy.
If you or your doctor accidentally inject more than the recommended dose of FORCALTONIN, it is extremely unlikely to have any serious effects. lp
The EMEA participated in a range of activities with the World Health Organisation (WHO) in 2001 relating to medicines for both human and veterinary use.
Unchanged riluzole is the main component in plasma and is extensively metabolised by cytochrome P450 and subsequent glucuronidation.
It is common in adult patients, but uncommon in infants, children and adolescents.
It is common in adult patients, but uncommon in infants, children and adolescents.
It is common in adult patients, but uncommon in infants, children and adolescents.
with a history of chloasma gravidarum.
It is generally accepted that infection with PCV2 is essential but not sufficient to cause disease.
Patients must follow the Thalidomide Celgene Pregnancy Prevention Programme.
A reliable method of barrier contraception must be used in addition to oral contraceptives (see section 4.6).
You should check with your doctor or pharmacist if you are not sure.
It is important to apply the dose to an area where the dog cannot lick it off and to make sure that animals do not lick each other following treatment.
It is important to apply the dose to an area where the animal cannot lick it off and to make sure that animals do not lick each other following treatment.
Adequate intake of calcium and vitamin D is important in all patients.
Adequate intake of calcium and vitamin D is important in all patients.
The number will show through a window at the back of the plastic casing.
- It is important to continue taking Bondronat for as long as your doctor prescribes the medicine.
It is important to continue using Avonex regularly.
It’s important to keep taking Bondenza every month.
There are usually no symptoms of high blood pressure before damage occurs., Thus it is important to regularly measure blood pressure to verify if it is within the normal range.
Thus it is important to regularly measure blood pressure to verify if it is within the normal range.
Thus it is important to regularly measure blood pressure to verify if it is within the normal range.
It is important that you do not try to give yourself the injection unless you have received training from your doctor, nurse or pharmacist.
It is important that you do not try to give yourself the injection unless you have received special training
It is important not to miss a dose of Emtriva.
It is important not to miss a dose of Truvada.
Do not apply a patch to the same place on your body for at least 1 week.
It is important to complete the whole 5 day course, even if you start to feel better quickly.
It is important to take Atripla on a regular dosing schedule to avoid missing doses.
It is important that you take the tablets or liquid as the doctor tells you.
It is important that you take REYATAZ with food (a meal or a substantial snack) as this helps the body absorb the medicine.
It is important to keep taking Tarceva every day, as long as your doctor prescribes it for you.
It is important to take calcium and vitamin D supplements (for example tablets) as directed by your doctor.
It is important to apply the dose as indicated to minimise the quantity that the animal can lick off.
Care should be taken to ensure that the tablet is ingested.
It is important to note that CIALIS does not work if there is no sexual stimulation.
It is important to note that Tadalafil Lilly does not work if there is no sexual stimulation.
It is important to follow the instructions for use described in section 6.6 adequately, otherwise the validity of the test result will be questionable.
It is important to follow the instructions for use adequately (see section 6.6), otherwise the reliability of the outcome will become questionable.
It is important to follow the instructions for use adequately (see section 6.6), otherwise the reliability of the outcome will become questionable.
It is important that you follow the instructions of your doctor/health care professional regarding your child’s return visits for the follow-up doses.
It is important to follow the instructions from the doctor/ nurse so that your child completes the course of injections.
It is important to follow the instructions from the doctor/ nurse so that your child completes the course of injections.
It is important to follow the instructions for use exactly, otherwise the result may be questionable.
It is important to tell your doctor if you are taking fluticasone or budesonide (given by nose or inhaled to treat allergic symptoms or asthma).
Women using combined contraceptives should be emphatically advised to contact their physician in case of possible symptoms of thrombosis.
It is important for your child to continue taking SINGULAIR for as long as your doctor prescribes.
It is important that your child receives all 3 doses of the vaccine for protection against rotavirus.
It is important to keep your work area, your hands, and the injection site clean to lessen the risk of infection.
It is important to keep your work area, your hands, and the injection site clean to lessen the risk of infection.
It is important to drink plenty of water to avoid dehydration.
It is important that you read and understand the information about this serious reaction.
It is important that you take this medicine until you finish the prescribed course.
It is important that you take CHAMPIX regularly at the same time each day.
It is important to take Kivexa regularly because irregular intake may increase the risk of hypersensitivity reactions.
It is important that you take the number of 1 mg and 3 mg blisters that your doctor recommends in the combination that he or she recommends. lo
It is important that you carry on taking Olanzapine Teva for as long as your doctor tells you.
It is important that you carry on taking Olanzapine Teva for as long as your doctor tells you.
It is important to take Trizivir regularly because irregular intake may increase the risk of hypersensitivity reactions.
It is used together with low-dose ritonavir (another antiviral medicine) and other antiviral medicines to treat adults who are infected with human immunodeficiency virus (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used in combination with at least one other antiviral medicine to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used in combination with other antiviral medicines to treat adults and children infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used in combination with other antiviral medicines to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used together with other antiviral medicines to treat adults and children over two years of age who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used in combination with other antiviral medicines to treat adults who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is given into a vein (intravenously) as a single injection.
Dosage adjustment is not necessary in patients with renal insufficiency.
Frequent monitoring of blood cell counts should be performed during Abraxane therapy.
When preparing a stock solution the maximum concentration should be 40 g per 1500 ml or 400 g of product per 15 litres and it is necessary to mix the solution for 10 minutes.
A restriction regarding food intake is necessary, since effects of food consumption on the pharmacokinetic profile has been observed.
Previously akinetic or sedentary patients should be reminded to gradually resume activities following the injection of Xeomin.
Patients or their carers must be warned to take care to maintain hydration and avoid exposure to excessive temperatures.
It has to be ensured that the analysis is carried out by a qualified laboratory.
It has to be ensured that the analysis is carried out by a qualified laboratory.
It is necessary to consider the clinical condition of the patient when interpreting whole blood levels.
The generation of foam should be avoided.
You need to know about important signs and symptoms to look out for while you 're taking Telzir.
It is noted that a daily dose of 2 X 15 mg/ kg bw is recommended in several SPCs.
Ventilatory support is mandatory for patients until adequate spontaneous respiration is restored following reversal of neuromuscular block.
Therefore no special dosage regimen can be recommended.
Consequently it is expected that a fee will be introduced in the forthcoming fee reform.
The active substance in Cerenia, maropitant, is broken down via the liver and it is, therefore, recommended to use it with caution in dogs with liver disease.
It is therefore recommended that no other vaccines can be administered concurrently with the product. isa
When treatment with voriconazole is stopped, the initial dosage of efavirenz should be restored (see sections 4.4 and 4.5).
Sometimes it is necessary to adjust the dose or interrupt treatment.
It's especially important to mention:
It is especially important to tell your doctor or pharmacist if you are taking medicines containing any of the following substances as they may interact with ADENURIC and your doctor may wish to consider necessary measures: • Mercaptopurine (used to treat cancer) • Azathioprine (used to reduce immune response) • Theophylline (used to treat asthma) • Warfarin (used to thin your blood if you have a heart condition)
It is especially important that you tell your doctor or pharmacist if you are taking:
The relevance of this finding to humans is unlikely since it was not reported in short-term studies conducted with hydroxocobalamin.
This quantity is not likely to induce symptoms of lactose intolerance (milk intolerance).
The difference is unlikely to be of clinical relevance, though.
It is not expected that pseudoephedrine sulphate impairs psychomotor performance.
Rasilez HCT is unlikely to affect the ability to drive and use machines.
It is possible to change to Competact directly from metformin if appropriate.
It is possible to change to Glubrava directly from metformin if appropriate.
A glass of water may be taken after taking the dose.
Conversion to or from oral and i. v. administration can be done directly without titration.
It is possible to switch directly from oral administration to infusion and the other way around.
Once the infection has improved, the patient's treatment can be switched to an oral antibiotic.
Injection site reactions can be avoided by changing the injection site at each injection (injection site rotation).
Tissue distribution of drugs which are transported by P-gp may be increased.
Neulasta may be used if it is accidentally frozen for a single period of less than 24 hours.
Neulasta may be used if it is accidentally frozen for a single period of less than 24 hours.
Neupopeg may be used if it is accidentally frozen for a single period of less than 24 hours.
Very rarely will the patch come off completely.
Some settling of the reconstituted suspension may occur.
This adverse event may be related to treatment, injection technique, or both.
The clinical relevance of these findings may be limited.
The increase in digoxin exposure could be caused by competition between darifenacin and digoxin for P-glycoprotein.
It is possible that the risk of blood clots in the legs and/ or lungs with EVRA is more than the risk with combined birth control pills.
risk of side effects affecting the muscles may be higher when any of these medicines (and some others that can affect muscles) is taken during treatment with Cubicin.
In a study of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations.
The possibility exists for TNF-antagonists, including Enbrel, to affect host defences against infections and malignancies since TNF mediates inflammation and modulates cellular immune responses.
It is possible that prolonged exposure to light at the clinical research unit or accidental sunlight exposure after discharge may be responsible for the high frequency of photosensitivity reactions.
It is possible that concomitant use of other photosensitising agents (e. g. tetracyclines, sulphonamides, phenothiazines, sulfonylurea, hypoglycaemic agents, thiazide diuretics, and griseofulvin) could increase the potential for photosensitivity reactions.
The user may not be protected from pregnancy.
It is possible that Thyrogen may also cause tumour growth.
It may affect your heart rhythm.
- There is a possibility that ORACEA reduces the effectiveness of oral contraceptives, resulting
The powder should be mixed with the solvent provided just before use, and the contents of more than one vial of powder can be dissolved in on vial of solvent if needed.
The tablet should preferably be taken on the same date each month.
It is best to take Avaglim with food, or just before food, usually with your first main meal of the day.
It is best to take Avandamet with food, or just after food.
It is supplied in tubes containing 10, 30 or 60 grams of ointment.
The group is chaired by an EMEA representative and meets once a month in the margins of the CPMP plenary meetings.
It is expected that other medicinal products excreted by active tubular secretion could also reduce the renal clearance of the metabolite.
It is mainly active on the free stages of the parasite (sporozoïte, merozoïte).
No significant metabolites were detected in plasma samples after subcutaneous administration.
It is likely to be caused by passage of the eye drops in the nasopharynx via the nasolacrimal canal and is attributable to brinzolamide.
It is likely caused by passage of the eye drops in the nasopharynx via the nasolacrimal canal.
It is anticipated that progress at VICH will only advance during 2003.
In patients receiving chemotherapy 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
ed are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.
Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.
Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.
Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.
Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.
There are reports in the literature that, in both rodents and humans, the spatial distribution and density of CB1 receptors in the brain changes during development.
There are reports in the
Patients receiving nelarabine are recommended to receive intravenous hydration according to standard medical practice for the management of hyperuricemia in patients at risk of tumour lysis syndrome.
Patients receiving nelarabine are recommended to receive intravenous hydration according to standard medical practice for the management of hyperuricemia in patients at risk for tumour lysis syndrome.
It is recommended to administer the diluted solution through an in-line low protein-binding 0.2 µm filter to remove any protein particles which will not lead to any loss of agalsidase beta activity.
It is recommended to administer the diluted solution through an in-line low protein-binding 0.2 µm filter to remove any protein particles which will not lead to any loss of agalsidase beta activity.
It is recommended that the diluted Aldurazyme solution be administered to patients using an infusion set equipped with a 0.2 µm in-line filter.
It is recommended that the diluted Aldurazyme solution be administered to patients using an infusion set equipped with an 0.2 µm in-line filter.
It is recommended that the diluted Naglazyme solution be administered to patients using an infusion set equipped with a 0.2 µm in-line filter.
Oral use It is recommended that the gel is administered at the time of feeding.
The gel should be administered at the time of feeding.
It is advisable to administer the product before feeding.
IT IS RECOMMENDED THAT THE VACCINE BE ADMINISTERED IMMEDIATELY AFTER RECONSTITUTION, TO MINIMIZE LOSS OF POTENCY.
It is recommended that the vaccine be administered immediately after reconstitution or stored in the refrigerator and used within 8 hours to minimize loss of potency.
It is recommended that Yondelis be given through a central venous line (a thin tube leading from the skin into the large veins just above the heart).
Initial dose adjustment to alternate day dosing with 30 MU/ day (300 μ g/ day) is recommended.
Initial dose adjustment to alternate day dosing with 30 MIU (300 μ g)/ day by subcutaneous injection is recommended.
A dosing according to weight bands is recommended for Ziagen tablets.
It is not recommended to inject into areas where the skin is tender, bruised, red, or hard.
It is recommended that the system is primed before starting the infusion to the patient.
It is advisable to rehydrate patients prior to starting therapy with lumiracoxib.
It is recommended to apply the first transdermal patch on the day following the last oral dose.
It is recommended that Panretin gel should be applied for an initial treatment period of up to 12 weeks.
It is recommended that the application site should be rotated on a daily basis (e. g. from the right side to the left side and from the upper body to the lower body).
• Administration It is recommended to start the administration of the diluted solution within three hours.
It is recommended that the conduct of these tests should be recorded in the patient's alert card.
It is recommended that serum ferritin be monitored every month and that the dose of EXJADE be adjusted, if necessary, every 3 to 6 months based on the trends in serum ferritin.
Correction of this condition prior to administration of Copalia or close medical supervision at the start of treatment is recommended.
Correction of this condition prior to administration of Exforge or close medical supervision at the start of treatment is recommended.
Correction of this condition prior to administration of Imprida or close medical supervision at the start of treatment is recommended.
Doubling the daily dose to 5 mg TRITACE after one or two weeks and then to 10 mg TRITACE after a further two or three weeks is recommended.
Doubling the once daily dose to 2.5 mg after two weeks and then to 5 mg after a further two weeks is recommended.
Adequate monitoring of serum potassium in patients at risk is recommended.
Treatment for more than 10 days is not advisable, as the medicine 's effects on nasal congestion may wear off.
It is advisable to limit treatment to about 10 days, as during chronic administration the activity of pseudo-ephedrine diminishes with time.
It is advisable to limit treatment to about 10 days, as during chronic administration the activity of pseudoephedrine may diminish.
It is recommended that you limit sun exposure whilst receiving Vectibix and if you are experiencing skin reactions as sunlight can worsen these.
It is recommended to maintain this lower infusion rate in all subsequent infusions.
9 The measurement of protein C activity using chromogenic substrates is recommended for the determination of the patient's plasma level for protein C before and during treatment with CEPROTIN.
The measurement of protein C activity using chromogenic substrates is recommended for the
A change of therapy is recommended in this situation.
It is recommended that Mycophenolate mofetil Teva therapy should not be initiated until a negative pregnancy test has been obtained.
Do not mix NeoRecormon with other injections or infusion solutions.
The product should be used with the accompanying solvent only.
The use of latex gloves and safety glasses is recommended to avoid exposure in case of breakage of the ampoule or other accidental spillage.
The use of latex gloves and safety glasses is recommended to avoid exposure in case of breakage of the vial or other accidental spillage.
The use of latex gloves and safety glasses is recommended to avoid exposure in case of breakage of the vial or other accidental spillage.
It is recommended that treatment be continued until progression of the underlying disease.
It is recommended that a heaped measuring spoon is removed from the container and a flat surface, e. g. the blade of a knife, is drawn across the top of the measure.
It is recommended to take Copalia with some water.
It is recommended that< COVERSYL and associated names > is taken once daily in the morning before a meal.
It is recommended to take Exforge with some water.
It is recommended to take Imprida with some water.
It is recommended that TRITACE is taken each day at the same time of the day.
It is recommended that TRITAZIDE is taken once daily, at the same time of the day, usually in the morning.
It is recommended that the dosing spoon be rinsed with water after each daily dose.
It is recommended that the bag be labelled accordingly.
It is recommended that the bag be labelled accordingly.
It is recommended that< COVERSYL and associated names >, generally associated with a non- potassium-sparing diuretic and/or digoxin and/or a beta blocker, be introduced under close medical supervision with a recommended starting dose of 2 mg taken in the morning.
It is recommended that Cerezyme is used immediately after it has been mixed with sterile water.
It is recommended that two reliable forms of contraception be used together.
Use of intranasal calcitonin is recommended in conjunction with an adequate calcium and vitamin D intake.
It is recommended that Myozyme is used immediately after it has been mixed with sterile water.
- The use of a clean application aid is recommended and contact with other parts of the body should
An in-line polyethersulfone filter with a pore size of not greater than 5 microns is recommended for administration to avoid the possibility of particles bigger than 5 microns being infused.
It is recommended that a trough concentration be taken 1 or 2 weeks after switching formulations or tablet strength to confirm that the trough concentration is within the recommended target range.
It is recommended that the diet should be rich in fruit and vegetables.
As no data exist regarding the interchangeability of RotaTeq with another rotavirus vaccine, it is recommended that infants who receive RotaTeq for the first immunisation against rotavirus should receive this same vaccine for the subsequent doses.
Posology and method of administration It is recommended that treatment should be conducted under the care of physicians experienced in the treatment of obesity.
It is recommended that users visually check their patch daily to ensure continued proper adhesion.
It is recommended that all horses stabled together are vaccinated.
It is recommended that if a switch of formulations is required this is done under clinical supervision, in case of problems with tolerability (see section 5.2).
Adequate monitoring of serum potassium in patients at risk is recommended (see section 4.4).
It is expected to correct altered heartbeat by affecting the electrical activity of the heart muscle.
In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose.
In many cases, urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose.
Corrective treatment may often be required (see section 4.8).
Cysteamine mechanism of action by interfering with the cross-linking of collagen fibers has been postulated (see section 4.4).
It is quite normal to have a number of courses of Biograstim treatment.
It is quite normal to have a number of courses of Tevagrastim treatment.
Concurrent administration of agents likely to cause significant hypotension is not recommended.
It is very important that your child has immediate medical treatment for any severe allergic reaction.
It is used when the disease has not responded to, or has come back (relapsed), after at least two other treatments, and when no other treatment is expected to work.
It is used in children with a very rare type of epilepsy called ‘ severe myoclonic epilepsy in infancy'(SMEI), also known as Dravet 's syndrome.
It is used in adults and adolescents from 16 years of age who are not already immune to these two diseases and who are at risk of contracting both of them.
It is used to treat adults infected with human immunodeficiency virus-1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used during the patients'first ‘ remission'(a period without symptoms of the disease after the first course of treatment).
It is for the treatment of infection with the human immunodeficiency virus (HIV).
It is used to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used to treat the following groups of patients: • adults with moderate to severe active rheumatoid arthritis (an immune system disease causing inflammation of the joints) who have not responded adequately to other treatments, and adults with severe active rheumatoid arthritis that is progressive (getting worse) who have not taken methotrexate (another medicine that acts on the immune system) before.
It is used to treat the following diseases: • Chronic myeloid leukaemia (CML), a cancer of the white blood cells in which granulocytes (a type of white blood cell) start growing out of control.
It is used to treat patients with chronic lymphocytic leukaemia (CLL), a cancer of the lymphocytes (a type of white blood cell).
It is used to treat patients with the following diseases, when they cannot tolerate other antifungal medicines (amphotericin B, itraconazole or fluconazole) or have not improved after at least 7 days of treatment with other antifungal medicines: • invasive aspergillosis (a type of fungal infection due to Aspergillus), • fusariosis (another type of fungal infection due to Fusarium), • chromoblastomycosis and mycetoma (long-term fungal infections of the skin or the tissue just below the skin, usually caused by fungal spores infecting wounds due to thorns or splinters), • coccidioidomycosis (fungal infection of the lungs caused by breathing in spores).
It is used to treat patients with the following diseases, when they cannot tolerate other antifungal medicines (amphotericin B, itraconazole or fluconazole) or have not improved after at least 7 days of treatment with other antifungal medicines: • invasive aspergillosis (a type of fungal infection due to Aspergillus), • fusariosis (another type of fungal infection due to Fusarium), • chromoblastomycosis and mycetoma (long-term fungal infections of the skin or the tissue just below the skin, usually caused by fungal spores infecting wounds due to thorns or splinters), • coccidioidomycosis (fungal infection of the lungs caused by breathing in spores).
It is used in combination with other antiviral medicines to treat adults and children who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
It is used in conjunction with clobazam and valproate to treat a certain form of epilepsy called severe myoclonic epilepsy in infancy (Dravet's syndrome), which affects children.
It is used in combination with at least one other antiviral medicine to treat adults and adolescents over 12 years old who are infected with HIV (human immunodeficiency virus), the virus that causes acquired immune deficiency syndrome (AIDS).
It is used in combination with at least one other antiviral medicine to treat patients who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
It is used in combination with other antiviral medicines to treat adults and children who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
It is used in combination with other antiviral medicines to treat adults infected with human immunodeficiency virus (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used in combination with other antiviral medicines to treat adults, adolescents and children aged over four years who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used together with other antiviral medicines to treat adults and children aged three years or older infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used together with other antiviral medicines to treat adults and children aged three years or older infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used in combination with other antiviral medicines to treat adults and children infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
It is used in combination with other antiviral medicines for the treatment of patients infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used in combination with other antiviral medicines to treat patients infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used in combination with other antiviral medicines to treat adults, adolescents and children over three years of age who are infected with human immunodeficiency virus (HIV-1), the virus that causes acquired immune deficiency syndrome (AIDS).
It is used in combination with other antiviral medicines to treat adults and children over four years of age who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used in combination with other antiviral medicines to treat adults and children over two years of age who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used with cisplatin and 5-fluorouracil.
It is used in combination with ritonavir (another antiviral medicine) and other antiviral medicines to treat adults and children aged six years or above, who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used in combination with ritonavir (another antiviral medicine) and other antiviral medicines to treat adult patients with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used when treatment with anthracyclines and ifosfamide (other anticancer medicines) have stopped working, or in patients who cannot be given these medicines.
It is used when giving the original treatment again is not recommended.
It is used to treat adults who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
It is used to treat adults who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
It is used to maintain the remission (the period during which the disease is less severe or not detectable).
It is used to prevent painful vaso-occlusive crises that are recurrent (keep coming back).
Tumours can accelerate normal bone change in such a way that the release of calcium from bone is increased.
Tumours can accelerate normal bone change in such a way that the release of calcium from bone is increased.
It is used to treat adults, adolescents and children with: • invasive candidiasis (a type of fungal infection due to Candida); • invasive aspergillosis (another type of fungal infection due to Aspergillus) when the patient does not respond to or does not tolerate amphotericin B or itraconazole (other antifungal medicines); • suspected fungal infections (such as due to Candida or Aspergillus) when the patient is febrile (feverish) and neutropenic (lacking white blood cells).
It is much better to avoid these areas.
It is expected that abacavir will also be secreted into human milk, although this has not been confirmed.
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel.
It was evident that penicillin residues have caused allergic reactions in consumers and that some of these reactions have been serious.
It was evident that penicillin residues have caused allergic reactions in consumers and that some of these reactions have been serious.
Before you start treatment and regularly during treatment, your doctor will evaluate whether Activelle is a suitable treatment for you.
It has the ability to kill a wide range of bacteria (germs) that cause infections in various parts of the body.
It has potent neutralising and fusion-inhibitory activity against both RSV subtype A and B strains.
27 --------------------------------------------------------------------------------------------------------------------------- -------
There are many ways to solve this issue, however to balance the total regulatory system an executive body overlooking the whole system could be a major step forward.
There are limited data on patients with mild, moderate and non-dialysed severe renal impairment.
It concluded that terfenadine-pseudoephedrine tablet formulations should not be maintained on the market.
There are two types of CNV, known as classic CNV and occult CNV, which can be identified by fluorescein angiography.
This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are over-treated.
This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are over-treated.
There is also convincing evidence that UMAN BIG, along with active anti-HBV immunization, prevented transmission of HBV to newborns from anti- HBe+ mothers.
The 5′ -oxo analogues of 5-and 6-hydroxyemedastine and the N-oxide are also formed as minor metabolites.
It is supplied in packs containing 1, 3 or 10 vials of powder, together with the same number of solvent ampoules.
Postmarketing reports of suspected alopecia occurring during the treatment of sBCC and EGW have been received.
There are two isoforms of COX, COX-1, and COX-2.
One of the tasks of the CPMP and its Working
Four positional isomers, 1-O, 2-O, 3-O, 4-O-acylglucuronide exist, each accounts for less than 10% of total dabigatran in plasma.
Often, there are other medicines you can take instead.
There are nevertheless some studies which provide accurate information on tumour regression or disappearance and demonstrate that the threshold of 14 mg/ l appears necessary to induce an objective tumour regression.
Three simple ways to help reduce the impact of flu-like symptoms:
The rate of development of tolerance varies widely among individuals.
There is further increase in the risk of gastrointestinal adverse effects (gastrointestinal ulceration or other gastrointestinal complications) when celecoxib is taken concomitantly with acetylsalicylic acid (even at low doses).
There is further increase in the risk of gastrointestinal adverse effects (gastrointestinal ulceration or other gastrointestinal complications) when celecoxib is taken concomitantly with acetylsalicylic acid (even at low doses).
11 thromboembolic events in patients with cancer treated with recombinant human erythropoietin and a negative impact on overall survival cannot be excluded.
141 thromboembolic events in patients with cancer treated with recombinant human erythropoietin and a negative impact on overall survival cannot be excluded.
63 thromboembolic events in patients with cancer treated with recombinant human erythropoietin and a negative impact on overall survival cannot be excluded.
The re is an increased risk for thromboembolic events in patients with cancer treated with recombinant human erythropoietin and a negative impact on overall survival cannot be excluded.
There is an increased risk for thromboembolic events in patients with cancer treated with recombinant human erythropoietin and a negative impact on overall survival cannot be excluded.
- Occlusion in the connection between artery and vein (shunt thrombosis) may occur especially if
There is a theoretical risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to
It explains how the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
It explains how the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
It explains how the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
It explains how the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
is the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
is the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to
It explains how the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
It explains how the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
It explains how the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to
A decision on whether to continue/ discontinue breast-feeding or to continue/ discontinue therapy with CHAMPIX should be made taking into account the benefit of breast-feeding to the child and the benefit of CHAMPIX therapy to the woman.
In these clinical studies visual field examination under standardised, repeatable and comparable conditions (Goldmann kinetic perimetry, or Humphrey or Octopus static perimetry) should be performed.
At least 4 weeks'treatment is required to produce maximum effect.
However, it must be noted that the pharmacokinetics of insulin do not reflect its metabolic action.
Therefore, patients should not stay in a darkened room during this period and should be encouraged to expose their skin to ambient indoor light.
Therefore, administer the product with the syringe onto a portion of the food.
Avoid consumption of alcohol and medicinal products containing alcohol.
Therefore, pregnancy must be avoided for 3 months after treatment with temoporfin.
Therefore caution should be exercised if Cubicin is given to such patients.
Reapplication to the exact same skin location within 14 days should be avoided to minimise the potential risk of skin irritation.
Alcohol consumption must be avoided during treatment with Yondelis as this may harm the liver.
These medicines should be avoided during your treatment with Tasigna.
Avoid direct contact with the skin, mouth and nose when mixing Econor and handling the final feed.
A rise in haemoglobin of greater than 2 g/ dl (1.25 mmol/ l) over a four week period should be avoided.
Hypokaliemia should not be allowed to develop during sparfloxacin use.
The importance of concurrent dexamethasone administration should be emphasised at the initiation of each cycle of DepoCyte treatment.
Any breast milk produced during treatment or within 72 hours after the removal of the last patch should be discarded.
This is to be returned to the pharmacist for disposal.
It should be removed and a new system applied to a new skin site.
Clinical alertness to the possibility of co-incidental meningitis should be maintained.
The prolonged elimination of mitotane from the body after discontinuation of Lysodren should be considered.
The body part must not have been irradiated in connection with radiation therapy.
The system should be removed and a new system applied to a new skin site.
Complete resuspension should be ensured by mild agitation of the vial before use.
The patient should be followed closely, taking into account that impairment is reversible, but given the long half-life and the lipophilic nature of mitotane, it may take weeks to return to normal.
This system will provide a clear overview and understanding of the EMEA’s financial operations and the different stages involved in the processing of these operations.
It acts selectively on the AT 1 receptor subtype, which is responsible for the known actions of angiotensin II.
It also inhibits the Platelet Derived Growth Factor (PDGF) receptor and the Fibroblast Growth Factor Receptor (FGFR3).
It stops the action of the osteoclasts, the cells in the body that are involved in breaking down the bone tissue.
It stops the action of the osteoclasts, the cells in the body that are involved in breaking down the bone tissue.
It acts by interacting with ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma- aminobutyric acid (GABA), thereby blocking pre- and post-synaptic transfer of chloride ions across cell membranes.
He will immediately stop the infusion and restart it using another vein.
The office will play a role in increasing awareness of the EMEA and the work of its scientific committees among healthcare professionals, users of medicines, patients, learned societies and EU institutions and national authorities.
It is responsible for giving specialist technical assistance to the CPMP on manufacture and control of biotechnological and biological medicinal products including products derived from blood and plasma, and of immunological products.
Telmisartan does not exhibit any partial agonist activity at the AT1 receptor.
However, there was currently no animal model available to investigate SUDs.
Therefore pimecrolimus metabolism could not be determined after topical administration.
Note: short-term efficacy only has been demonstrated with regard to weight reduction.
There have not been any reported instances of systemic toxicity resulting from accidental injection of BOTOX.
Combining two NNRTIs has not been shown to be beneficial.
It only works when it is taken with levodopa, a copy of the neurotransmitter dopamine that can be taken by mouth.
It is not yet established whether or not treatment with gonadotrophins increases the baseline risk of these tumours in infertile women. • Women with generally recognised risk factors for thrombosis, such as a personal or family history, severe obesity (Body Mass Index > 30 kg/ m2) or thrombophilia, may have an increased risk of venous or arterial thrombo-embolic events, during or following treatment with gonadotrophins.
discussed above may apply to this patient population is unclear, specifically considering that the in
No carcinogenicity study has been conducted with carglumic acid.
There are no studies in pregnant women using TRISENOX.
Long-term animal carcinogenicity studies have not been performed.
Reproductive toxicity studies have not been performed with Pegasys.
No formal carcinogenicity studies of arsenic trioxide have been performed.
However, animal studies to evaluate this specific risk have not been conducted.
Specific in vivo drug interaction studies have not been performed.
No interaction studies have been performed.
Studies to assess the carcinogenic potential of pemetrexed have not been conducted.
Dose reduction or splitting the daily dose has not been shown to provide benefit.
It has not been demonstrated that the effect on HbA1c is independent from weight reduction.
A No Observed Effect Level (NOEL) was not established and the effect was not dose dependent.
- Although small increases of blood pressure have been reported in many women using hormonal
It is not known whether Aldurazyme appears in breast milk.
It is not known whether memantine is excreted in human breast milk but, taking into consideration the lipophilicity of the substance, this probably occurs.
It is not known whether amlodipine is excreted in human milk.
It is not known whether bortezomib is excreted in human milk.
There have been no therapeutic clinical trials conducted with Eucreas.
There have been no therapeutic clinical trials conducted with Icandra.
Studies in patients with pre-existing liver impairment have not been conducted.
No reproduction toxicity and carcinogenicity studies have been conducted.
There have been no studies of metformin added to vildagliptin.
Carcinogenicity studies with nilotinib have not been performed.
Specific dermal studies in pregnant animals have not been conducted.
Formal interaction studies between Thyrogen and other medicinal products have not been performed.
If pregnancy occurs during medication with Activelle, treatment should be withdrawn immediately.
There is no evidence of beneficial effects on the risks of cardiovascular disease with HRT in the menopause.
The frequency of bleeding events did not differ between iloprost and placebo-treated patients.
Sildenafil had no clinically significant impact on the plasma levels of oral contraceptives (ethinyloestradiol 30 μ g and levonorgestrel 150 μ g).
Single doses of antacid (magnesium hydroxide/ aluminium hydroxide) did not affect the bioavailability of sildenafil.
There was no change in Cmax or AUC for the active metabolite, n-desmethylsildenafil.
Sildenafil (50 mg) did not potentiate the hypotensive effects of alcohol in healthy volunteers with mean maximum blood alcohol levels of 80 mg/ dl.
Age and gender are not of clinical relevance to the pharmacokinetics of iloprost.
There was no evidence of a difference in risk between the different routes of administration.
44 There was no evidence that this finding was enhanced in the aliskiren/ hydrochlorothiazide combination as it was only apparent at a minimal severity in all animals.
There was no evidence that this finding was enhanced in the aliskiren/ hydrochlorothiazide combination as it was only apparent at a minimal severity in all animals.
It has not been shown that MIRCERA can be used to treat anaemia caused by other diseases.
There was no difference between FABLYN- and placebo-treated women in the incidences of endometrial carcinoma and endometrial hyperplasia.
Sildenafil (100 mg single dose) did not affect the steady state pharmacokinetics of the HIV protease inhibitor saquinavir, which is a CYP3A4 substrate/ inhibitor.
No adverse effects have been observed on male or female fertility.
There was no observed effect on the rate of rehospitalisation for unstable angina.
No evidence of cumulative myelosuppression was observed.
Acute, life-threatening toxicity has not been observed with gabapentin overdoses of up to 49 g.
No evidence for acute rebound has been observed.
It was not possible to detect stavudine in cerebrospinal fluid until at least 2 hours after oral administration.
A separate file for justification of exemption from phase II was not specifically given.
Dose adjustment of CellCept does not appear to be necessary.
Dose adjustment of Mycophenolate mofetil Teva does not appear to be necessary.
Dose adjustment of Myfenax does not appear to be necessary.
It should only be used once a flu pandemic has been officially declared by the World Health Organization (WHO) or European Union (EU).
Dose alteration of sulfamethoxazole/trimethoprim during concomitant ritonavir therapy should not be necessary.
Therefore, it must not be combined with other iron chelator therapies (see section 4.3).
It should only be used when other medicines are unsuitable.
It should only be used once a flu pandemic has been officially declared by the World Health Organization or European Union (EU).
It should only be used by qualified oncologists (cancer specialists) or other health professionals who are specialised in giving cytotoxic (cell-killing) medicines.
It must not be given to patients with severe liver disease, ‘ acute diffuse infiltrative pulmonary disease'(a severe lung problem) or pericardial disease (disease affecting the sac that surrounds the heart).
It should not be used in patients who have an active infection of the meninges.
Do not administer orally or parenterally.
In order for your medicine to work as intended, do not split, break, crush, or chew the tablet before you swallow it. • Avoid drinking alcohol or hot drinks near the time you take your dose of Pelzont.
In order for your medicine to work as intended, do not split, break, crush, or chew the tablet before you swallow it. • Avoid drinking alcohol or hot drinks near the time you take your dose of Tredaptive.
In order for your medicine to work as intended, do not split, break, crush, or chew the tablet before you swallow it. • Avoid drinking alcohol or hot drinks near the time you take your dose of Trevaclyn.
It should not be used concurrently with other biphosphonates if an interference is shown on the technetium [99mTc]-labelled biphosphonate bone scans.
It must not be used in patients in whom any previous HIV treatment combinations have failed to work or have stopped working.
It should not be used in patients who are taking St John's wort (a herbal preparation used to treat depression).
It should not be used in patients who have heart failure, problems with their liver, an ‘ acute coronary syndrome'such as unstable angina (a severe type of chest pain that changes in intensity) or certain types of heart attack, or complications of diabetes (diabetic ketoacidosis or diabetic precoma).
It must not be used in patients who have an active, severe infection.
It must not be used in patients who are severely allergic to other ‘ beta-lactam'antibiotics, such as penicillins or cephalosporins.
It must not be used in patients who have diabetic ketoacidosis (high levels of ketones and acids in the blood), diabetic pre-coma, problems with their kidneys or liver, conditions that may affect the kidneys, or a disease that causes a reduced supply of oxygen to the tissues such as failure of the heart or lungs or a recent heart attack.
It should not be used in patients who have severe problems with their liver.
It should not be used in patients who have heart failure, an ‘ acute coronary syndrome'such as unstable angina (a severe type of chest pain that changes in intensity) or certain types of heart attack, diseases that could affect the oxygen supply to the tissues (such as lung or heart problems, recent heart attack or shock), problems with their liver or kidneys, acute alcohol intoxication (excessive alcohol consumption), alcoholism, or complications of diabetes (diabetic ketoacidosis or diabetic coma).
It should also not be used in pregnant cows or heifers which are intended to produce milk for human consumption within 2 months of calving.
It should not be used in combination with other iron chelators.
It should not be used by anyone else as it could present a SERIOUS risk to their health, especially in children.
It should not usually be used on more than one occasion in any one patient.
It must also not be used in patients with ongoing major depression or who are being treated with antidepressants, since it can increase the risk of depression, including thoughts about suicide in a small minority of patients.
It should also not be used in patients with severe and uncontrolled infections, such as sepsis (serious blood infection) or ‘ opportunistic'infections (infections seen in patients with damaged immune systems).
It should also not be used in patients who have problems with their liver, an active stomach ulcer or bleeding from an artery.
It must also not be used in patients with alcohol intoxication (excessive alcohol consumption) or alcoholism, or during breast-feeding.
It should also not be used when there is ovarian enlargement or cyst not due to polycystic ovarian disease, or vaginal bleeding.
No more than two tablets should be used to treat any individual BTP episode, except when titrating using up to four tablets as described above.
Yondelis must not be administered as a mixture with other medicines in the same infusion apart from the diluent.
Optisulin must not be mixed with any other insulin or diluted.
It does not cure arthritis and will help you only as long as you continue to take it.
It cannot be excluded that the newborn may be affected.
It may not be excluded that the efficacy of oral contraceptives may be reduced during treatment.
It can only be used in children when invasive tests (taking a sample from the stomach using a probe) cannot be carried out or have given questionable results, or to check that H. pylori has been eliminated after a specific treatment to clear up the infection.
It will not protect against other infectious agents that can cause ear infections.
There is no further accumulation after 8 weeks of once weekly dosing.
Degarelix is not a substrate for the human CYP450 system and has not been shown to induce or inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4/ 5 to any great extent in vitro.
Iloprost is not a gene mutagen in bacterial and mammalian cells in vitro and is not clastogenic in human lymphocytes up to cytotoxic concentrations and in the micronucleus test in vivo.
It is not yet known whether other types of HRT increase the risk in the same way.
Therefore, taking aspirin to reduce flushing symptoms is not necessary.
Caution should be exercised when using Kentera when you are breast feeding.
Breast feeding while using oxybutynin is therefore not recommended.
The tissue around the eyes may be more sensitive, and therefore, it is not recommended that the face be used for testing.
Therefore the use of such combinations is not recommended.
Therefore, the use of such combinations is not recommended.
A starting dose higher than 6 g/ day is generally not recommended.
It is not known if somatropin is excreted into breast milk, but absorption of intact protein from the gastrointestinal tract of the infant is extremely unlikely.
It is not known whether the active substance in < Invented Name > passes into the milk after application to the skin.
It is not known whether efavirenz, emtricitabine or tenofovir are excreted in human milk.
It is not known whether pimecrolimus is excreted in the milk after topical application.
No interactions suceptible to have a noticeable impact have been observed between alcohol (at the blood level of 0.5 per mille corresponding to one glass of wine) and cetirizine used at the normal doses.
No interactions suceptible to have a noticeable impact have been observed between alcohol (at the blood level of 0.5 per mille corresponding to one glass of wine) and cetirizine used at the normal
It is not yet established whether or not treatment with gonadotrophins increases the baseline risk of these tumors in infertile women.
It is not yet established whether or not treatment with gonadotrophins increases the baseline risk of these tumours in infertile women.
It is not known whether the chance of developing an allergic reaction is increased if treatment with Fasturtec is repeated.
It is not known whether vildagliptin is excreted in human breast milk.
It is not known whether vildagliptin is excreted in human milk, but metformin is excreted in human milk in low amounts.
Nevertheless the risk of liver toxicity may be increased in this population.
No dose adjustment is required in patients with hepatic impairment (see sections 4.4 and 5.2).
6 It is not necessary to shake the vaccine before use.
It is not necessary to shake the vaccine before use.
No dose adjustment is required for patients with impaired renal function.
In case of impaired hepatic function it is not necessary to adjust the dosage.
There is no need for dose adaptation in patients with a creatinine clearance > 30 ml/ min (as determined from serum creatinine using the Cockroft and Gault formula).
You do not need to rub the gel into the lesion.
The dose does not need to be altered in patients with a liver disease provided that the renal function is normal (see section 4.8).
The dose does not need to be altered in patients with a liver disease provided that the renal function is normal (see section 4.8).
Hepatic impairment No dose adjustment is needed for patients with mild or moderate hepatic impairment (total score of 7 to 9 on the Child-Pugh scale).
It is not necessary to protect the diluted solution of Soliris from light during administration to the patient.
It is not necessary to protect the reconstituted medicinal product from light.
It is not necessary to blow hard into the tubes, just breathe normally and cap them quickly.
It is not necessary to overlay the contents of multiple kits to achieve the desired effect.
It is not possible to determine whether these events were directly related to CIALIS.
It is not possible to determine whether these events were directly related to tadalafil.
It is not possible to determine whether these events were directly related to VIAGRA.
It is not possible to determine whether these events are related directly to these factors or to other factors.
No dose recommendations can be made.
It is not recommended for children less than 4 years old.
It is not recommended for patients to apply Panretin gel concurrently with products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products.
It should be considered whether it is advisable to drive or operate machinery in these circumstances.
It is not recommended to use those together with Fentanyl-ratiopharm.
Doses of vildagliptin above 100 mg are not recommended.
The use of both an in-line and end-filter is not recommended.
DepoCyte is not recommended for use in children and adolescents until further data become available.
The use of mitotane in patients with severe hepatic impairment is not recommended.
A probenecid desensitisation program is not recommended for use.
It does not treat KS that is inside the body.
It is not expected that pseudoephedrine sulphate impairs psychomotor performance.
However, due to the low dose of protein administered and the short half-life of 99mTc, dosage adjustment is probably not necessary in such patients.
It is only used in calves and young cattle.
It is only used if the presence of a mutated form of the receptor protein c-kit in the tumours has been confirmed before the start of treatment.
it was not possible to establish a withdrawal period for cattle and pigs based on the data available;
There is no known specific treatment for extravasation reactions.
Pharmacokinetic data with ADVATE on previously untreated patients are currently not available.
Currently, there is no clinical evidence that these findings are of relevance to human use.
There are currently no data on overdose with Prometax transdermal patches.
There are currently no data on overdose with Exelon transdermal patches.
As far as is understood, there are no further ACEi trials focusing on retinopathy.
There is no antidote to this contrast medium.
No known antidote exists for Paxene overdose.
There are no clinical data of the effect of dabigatran on infants during breast feeding.
No data are available on the effects of vaccination with other inactivated antigens in patients receiving Kineret.
No formal assessments of pharmacokinetic interactions between TRISENOX and other therapeutic medicinal products have been conducted.
There is no experience on the effect of TRISENOX on the variant APL containing the t(11; 17) and t(5; 17) chromosomal translocations.
There is no experience of the treatment of previously untreated patients with Nonafact.
There is no evidence to suggest that any additional precautions are needed.
There is no evidence to suggest that any additional precautions are needed.
There is no evidence of an effect of Betaferon on the duration of relapses or on symptoms in between relapses, and no significant effect was seen on the progression of the disease in relapsing remitting multiple sclerosis.
There is no evidence of an effect of Extavia on the duration of relapses or on symptoms in between relapses, and no significant effect was seen on the progression of the disease in relapsing-remitting multiple sclerosis.
It has not been shown that a transdermal patch like EVRA is safer than a combined birth control pill taken by mouth.
There is no evidence that varicella vaccine virus is excreted in breast milk.
No curative or disease-modifying treatment exists, apart from surgery with arthroplasty.
There is no known antidote to Raptiva or any specific treatment for Raptiva overdose other than withholding treatment and patient observation.
No specific antidotes for venlafaxine are known.
There is no data on the use of Pradaxa in patients undergoing hip fracture surgery.
There is no data on the use of Pradaxa in patients undergoing hip fracture surgery.
No long term data are available on the use of AZOPT as adjunctive therapy to travoprost. (see section 5.1)
There are no data in patients with severe hepatic impairment.
There are no data on patients with severe hepatic impairment.
For celecoxib no clinical data on exposed pregnancies are available..
There is no clinical experience with CHAMPIX in patients with epilepsy.
No data are available on patients with severe hepatic impairment treated by Rasilez HCT.
There are no data on the effect of entecavir on transmission of HBV from mother to newborn infant.
It is not known if tenecteplase is excreted into breast milk.
For sugammadex no clinical data on exposed pregnancies are available.
Preclinical data about peri- and postnatal toxicity of etanercept and of effects of etanercept on fertility and general
Preclinical data about peri- and postnatal toxicity of etanercept and of effects of etanercept on fertility and general reproductive performance are not available.
There is no experience regarding the administration of< COVERSYL and associated names > in patients with a recent kidney transplantation.
There are no data on the effect of adefovir dipivoxil on transmission of HBV from mother to infant.
There are no data with regard to the efficacy and safety of simultaneous administration of Infanrix Penta and Measles-Mumps-Rubella vaccine.
It is not known whether ambrisentan is excreted in human breast milk.
No information is available on the treatment of overdose with Rasilez HCT.
Is not known if rufinamide is excreted in human breast milk.
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing major orthopaedic
Specific treatment is not available for {PRODUCT NAME} overdosage.
There are no adequate and well-controlled studies in pregnant women.
The re are no studies to demonstrate beneficial effects on survival of treatment with Tracleer.
There are no studies to demonstrate beneficial effects on survival of treatment with Tracleer.
No studies have been conducted that include patients with a history of malignancy or in whom treatment with Humira is continued following development of malignancy.
There are no studies on the carcinogenic potential of pegaptanib.
No formal interaction studies have been performed with Beromun.
There is no clinical experience of pioglitazone in triple combination with other oral antidiabetic agents.
There is no clinical trial experience of other oral anti-hyperglycaemic agents added to treatment with Tandemact or concomitantly administered glimepiride and pioglitazone.
It does not interfere with osteoclast recruitment.
So far there are no data from post-marketing experiences with Optaflu.
In vivo resistance (antiretroviral-naïve patients): extremely limited resistance data from patients treated with Atripla are currently available.
There is no known antidote to this contrast medium.
There is no difference in exposure among Chinese, Japanese, and Korean subjects.
There are no restrictions on the infant's consumption of food or liquid, either before or after vaccination.
There are no restrictions on the infant’s consumption of food or liquid, either before or after vaccination.
Therefore it is not expected to potentiate bradykinin- mediated adverse effects.
Therefore, it is not expected to potentiate bradykinin- mediated adverse effects.
There was no evidence that the antibodies detected represented a specific immune response to drotrecogin alfa (activated) therapy.
There was no pattern for the bleeding events and no difference between treatment groups in coagulation parameters.
There are currently no data available to support specific dosing recommendations for GIST patients based on prior gastrointestinal resection.
There is no basis for Mycophenolate mofetil Teva dose adjustment following cardiac transplant rejection.
There is no consensus as to whether the occurrence of these events is associated with the use of COCs.
There is no experience of overdose with ocular use.
The current paediatric indications are not disharmonised based on the indication itself but with regards to the definition of the paediatric age groups and with regards to the dosing for these groups.
There is no data on CellCept with phosphate binders other than sevelamer.
There is no data on mycophenolate mofetil with phosphate binders other than sevelamer.
There are no data available on adverse reactions in breast-feeding infants.
No data are available on male and female fertility as well as on peri- and postnatal development.
There are no data available on adverse effects in breast-feeding infants.
No specific information is available on the treatment of overdose with montelukast.
It is not known whether OPTISON is excreted in human milk.
There are no data on the long-term effects of fulvestrant on the postmenopausal endometrium.
There are no long-term data on the effect of fulvestrant on bone.
It is not known whether fulvestrant is excreted in human milk.
There are no additional precautions and warnings relevant to Kivexa.
There are no additional precautions or warnings relevant to the combination Trizivir.
There are no restrictions on taking food or liquid, including breast milk, either before or after vaccination with RotaTeq.
Patients with severe hepatic impairment have not been studied and therefore the use of Dynastat in patients with severe hepatic impairment is not recommended (see sections 4.2 and 4.3).
There is no experience with other anticonvulsant agents such as benzodiazepines (see sections 4.4 and 4.5).
There is no experience in children or adolescents with GIST and HES/ CEL.
There is no experience in children (under 18 years).
There is no therapeutic experience with losartan in patients with severe hepatic impairment.
There is no clinical experience in patients with severe hepatic impairment.
There is no therapeutic experience in patients with severe hepatic impairment.
There is no therapeutic experience with losartan in patients with severe hepatic impairment.
There is no experience of vildagliptin use in clinical trials in patients with NYHA functional class III-IV and therefore use is not recommended in these patients.
There is no experience with dose reduction/ increase or modification of the schedule in the treatment of extravasation.
There is no pharmacokinetic interaction with follitropin alfa when administered simultaneously.
There is no identified potential use of tolcapone in paediatric patients.
5.0 months) with cisplatin/ paclitaxel vs cisplatin/ tenoposide.
There was no increased benefit thereafter, up to 1 year.
There was no increased benefit thereafter, up to 1 year.
Montelukast should not be abruptly substituted for inhaled or oral corticosteroids.
There were no differences in terminal half-lives.
There was no dose- response effect for imaging efficacy (sensitivity or specificity) over antibody doses ranging from 0.1 mg to 1.0 mg.
This should lead to a reduction in liver damage and an improvement in your liver function.
This should lead to a reduction in liver damage and an improvement in your liver function.
your urine output to increase leading to a lowering of your blood pressure.
your urine output to increase, leading to a lowering of your blood pressure.
your urine output to increase leading to a lowering of your blood pressure.
The Committee for Medicinal products for Human Use (CHMP) decided that SonoVue's benefits are greater than its risks to enhance the echogenicity (ultrasound contrast) of the blood in echocardiography in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation, and in Doppler of macrovasculature (cerebral arteries, extracranial carotid or peripheral arteries and portal vein) or microvasculature (liver and breast lesions).
SonoVue is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.
However, the NovoMix 30 dosage may need to be adjusted.
However, the NovoMix 50 dosage may need to be adjusted.
However, the NovoMix 70 dosage may need to be adjusted.
However, the NovoRapid dosage may need to be adjusted.
It may become very severe, painful and disabling.
It may also be administered with a suitable auto-injector.
It may also be administered with a suitable auto-injector.
It can also be used in patients who do not have this abnormal reading on the ECG, if they have unstable angina (a severe type of chest pain) or have had a ‘ non-Q-wave'myocardial infarction.
It can also be used in patients who do not have this abnormal reading on the ECG, if they have unstable angina (a severe type of chest pain) or have had a non-Q-wave myocardial infarction.
There can also some be some local reaction (e. g. inflammation, hardening) for up to three months after implantation.
It may be mixed with water, milk, infant formula, applesauce, or yoghurt.
The tablet can either be mixed with a small amount of food offered prior to the main meal, or administered directly into the mouth after feeding.
Dose adjustments for these HMG Co-A reductase inhibitors may be necessary.
Dosage adjustment of antidiabetic agents, including insulin, may be required (see section 4.5).
Doses of sevoflurane may need adjustment for geriatric or debilitated dogs.
Doses required for maintenance anaesthesia may need to be reduced by approximately 0.5% in geriatric dogs (i. e.
It may be necessary to discontinue Raptiva treatment 8 weeks before a vaccination.
It may be necessary to initiate or increase treatment against high blood pressure.
The dosage of the anticoagulant may need to be reduced to maintain desired prothrombin time levels (see Section 4.5.)
Additional tapping may be required if clumps remain.
You may take it with or without food.
It may be useful to inform the patient when treatment is started that it will be of limited duration.
It can be used in patients also infected with human immunodeficiency virus (HIV).
It can be used in patients with liver cirrhosis (scarring) and in patients also infected with human immunodeficiency virus (HIV).
It may be used in combination with certain oral antidiabetic drugs.
It can be used on its own after other treatments have failed.
May cause toxic reactions and allergic reactions in infants and children up to 3 years old.
It may cause toxic reactions and anaphylactoid reactions in infants and children up to 3 years old.
You may be given other medicines (anti-emetics) to take before and/or after taking Temodal to prevent or control nausea and vomiting.
You may be given other medicines (anti-emetics) to take before and/or after taking Temodal to prevent or control nausea and vomiting.
You may be given other medicines (anti-emetics) to take before and/or after taking Temodal to prevent or control nausea and vomiting.
You may be given other medicines (anti-emetics) to take before and/or after receiving Temodal to prevent or control nausea and vomiting.
Because emesis may occur in the presence of impaired consciousness, appropriate posture (left lateral recumbent position) and protection of the airway by intubation may be warranted.
There may be a local reaction at the injection site, with slight pain on touching, itching or oedema (swelling), which disappears within one or two weeks.
There may be a local reaction at the injection site, with slight pain on touching, itching or oedema (swelling), which disappears within one or two weeks.
You may need to stop taking alli. • Successful weight loss is not just about eating differently for a short period of time before reverting to your old habits.
If you’re breast feeding, you may need to stop in order to take Bonviva.
He may also combine Diovan with an additional medicine (e. g. a diuretic).
Depending on the development of the workload in the Unit, re-structuring may have to be addressed in 1997 and 1998.
It could stop working or fall off.
You may notice a difference in the dose you receive if you are changing from a plasma-derived factor IX product to BeneFIX.
It has a primary amino acid sequence that is comparable to the Ala148 allelic form of plasma-derived factor IX, and some post-translational modifications of the recombinant molecule are different from those of the plasma-derived molecule.
It reduces the risk of spine and hip fractures.
It stays on while the medicine is being delivered.
Significant issues remain to be addressed in the mutual recognition procedure but good progress has been achieved during 1997.
It arises from uncontrolled cell growth of the supporting tissues of these organs.
These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 event per patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events per patient year).
Picture “ EWP” When acting as members of the scientific committees they act independently of their nominating authority.
They act by stimulating the dissociation of peptidyl-tRNA from the ribosome during the translocation process.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
This has involved co-ordination within the EU during the transitional phase (‘ confidence building ’) and providing secretarial support and joint chairmanship of the Joint Sectoral Group with Health Canada, the Canadian national authority.
- it is the second time it has become loose or has fallen off
These are types of cancer where T-lymphoblasts (a type of immature white blood cell) multiply too quickly.
The EMEA owes that to the public and it will enhance the credibility of the regulator.
The newly formed bone grows into the matrix, which then 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
It is a copy of protein called osteogenic protein 1, also known as bone morphogenetic protein 7 (BMP-7), that is produced naturally by the body and which helps the formation of new bone tissue.
They may happen any time after starting on Avonex.
This is inflammation of the nasal passages caused by an allergy, resulting in runny nose, blocked nose, itching and sneezing.
This is an acute disease that is characterised by inflammation of the peripheral nerves that causes severe muscle weakness mainly in the legs and upper limbs.
This is called acute painful neuropathy and it usually disappears.
This is called acute painful neuropathy and it usually disappears.
This is a procedure when one Member State (the ‘ reference Member State’, in this instance Sweden) assesses a medicine with a view of granting a marketing authorisation that will be valid in this country as well as in other member states (the ‘ concerned Member States’, in this instance Belgium, Denmark, Estonia, Finland, Germany, Greece, Hungary, Italy, Latvia, Lithuania, the Netherlands, Norway, Poland, Portugal, Slovenia, Spain and the United Kingdom).
It is an ear drop suspension for dogs, that is white in colour.
These are a group of blood diseases in which some blood cells start growing out of control.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
This is a serious type of lung infection that is caught outside of hospital.
This is the third mandate of the Board and members are appointed until the end of 2002.
It also includes patients whose lack of antibodies is due to a cancer of the blood (myeloma or chronic lymphoid leukaemia) or children born with acquired immune deficiency syndrome (AIDS), who suffer from frequent infections.
These include the morphine-substitute methadone and oral contraceptives.
They are usually only mild or moderate problems and they gradually diminish during the course of treatment.
This is a unique opportunity to integrate the planning and preparation processes for these two events and one the EMEA will not hesitate to grasp.
Other important and successful initiatives have included those on transparency of the Agency’s operations, enlargement of the Community, and review of the licensing process.
This is the third mandate of the Board and members are appointed until the end of 2002.
They usually occur within the first two weeks of the treatment and are usually temporary.
These certify the marketing authorisation and good manufacturing status of medicinal products in the EU and are intended for use in support of marketing authorisation applications in and export to non- EU countries.
Normally, these symptoms disappear if you continue treatment and keep to your recommended diet.
They will dissolve the powder before giving you the injection, and will inject the solution into a vein or a muscle.
Patients whose blood glucose control is greatly improved e. g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly (see section 4.8 Undesirable effects). i dic
They also need to take special care when switching a patient to Arava, or when switching a patient who is receiving Arava to another treatment.
They should also receive antibiotics and antiviral medicines during and after treatment.
The COMP is responsible for advising the European Commission on the development of an orphan drug policy and for providing assistance in liaison with international partners and patient organisations in this respect.
It attaches to the receptors for oestrogen on the surface of cells, where it blocks the effects of the hormone and causes the number of oestrogen receptors to fall.
It binds to the fibrin component of the thrombus (blood clot) and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus.
It seems intuitive that for good prognosis patients who have also received treatment of curative intent, the addition of bicalutamide might confer less benefit than in other patients.
The recommended anti-infective prophylaxis treatment appears to be effective in reducing the risk of PCP and herpes infections (see section 4.4).
Evidence exists indicating that efavirenz may have altered pharmacokinetics in very young children.
There are some indications that the Hep B vaccine currently produced is less immunogenic than the vaccine produced in the 1990's.
Interim results will be provided in the annual re-assessment reports.
This is followed by the fibrinogen- thrombin reaction which initiates the last phase of physiological blood coagulation.
In some cases you may have to stop taking one of the medicines.
Or you may have been prescribed Cardoreg 4 mg prolonged release tablets and associated names because you have enlargement of the prostate gland (prostatic hyperplasia).
Alternatively, your doctor may have prescribed CANCIDAS to treat a fungal infection in your nose, nasal sinuses, or lungs because other antifungal treatments have not been working as well as expected or because the other antifungal treatments are causing side effects.
It may be that women taking the combined hormonal contraceptive are examined more often.
Pedea may be less effective in very premature babies.
41 During your treatment with Yondelis you may feel tired and experience a loss of strength.
It is available as white, teardrop- shaped tablets.
It comes in two vials, one containing a suspension and the other containing an emulsion, and these need to be mixed before injection.
It is available as triangular tablets (pink:
It is available as turquoise capsules (120 mg).
It is presented in a pre-loaded applicator.
It is a powder and solvent to be made up into a suspension for injection.
It is a powder and solvent to be made up into a suspension for injection.
There is a significant first pass effect with an estimated first pass metabolism of 85%.
Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.
Consolidating the achievements of 1996 will be crucial over the next two years.
It will be necessary to ensure that the Agency’s partners in the European pharmaceutical approval system are in a similar position.
He undertook long term assignments as a management consultant until January 1997, when he joined the EMEA.
He has proved himself as an excellent manager as Deputy Director-General of the Medical Product Agency in Sweden.
283 Handling of the pen
Do not chew, crush or divide them.
The patches can be worn during bathing and hot weather.
Therefore the studies were performed as open-label studies.
A pilot procedure for the follow-up of testing results was also agreed upon in 2002.
12 moderate in intensity.
20 moderate in intensity.
28 moderate in intensity.
They were usually mild to moderate in intensity.
These may affect up to one in 100 people:
These may worsen kidney or nervous system problems when taken together with Advagraf.
They may lower the amount of Zavesca in your body.
They can produce adverse biological effects including hypokalaemia, haemolysis (glucose-6-phosphate dehydrogenase (G6PD) defect) and hypersensitivity due to sulphonamide properties.
They can easily be broken into two equal halves.
These can be unpleasant, but most of them disappear quickly.
The tablets may be taken with or without food.
They are derived from spontaneous reports for which the frequency cannot be estimated.
The most commonly expected adverse events are mainly gastrointestinal, including constipation, flatulence, dyspepsia, abdominal pain and usually ameliorate on continued treatment.
They bind to the donor site and prevent the translocation necessary for keeping the peptide chain growing.
Few cases of atosiban overdosing were reported, they occurred without any specific signs or symptoms.
Few cases of atosiban overdosing were reported, they occurred without any specific signs or symptoms.
Patients have experienced oedema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonary infiltrates, rash, vertigo, vomiting, increase in transaminases and weight decrease.
In dogs, these adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
They are common in adult patients, but uncommon in infants, children and adolescents.
They are more common when you first start using Avonex.
Alopecia, rash Photosensitivity reaction, maculopapular rash, eczema, acne, skin disorder, nail disorder, skin discolouration, pruritus, dry skin, erythema, bruise, sweating increased
These are used to treat Human Immunodeficiency Virus (HIV) infection.
It challenges the talents of the EMEA staff and will contribute to the quality of the performance of the EMEA.
It undergoes first-pass metabolism in the liver and other enteric organs, and reaches a peak plasma concentration of approximately 2.4 ng/ml CV 41% (after administration of two Activelle tablets) within 0.5 -1.5 hour.
It is subject to first-pass hepatic and intestinal metabolism and the metabolites do not contribute to fentanyl's therapeutic effects.
They will check that IONSYS is working.
Your doctor will note the expiry date on the pack.
You are also advised to pay particular attention to new onset of blisters or ulcers while taking Eucreas.
You are also advised to pay particular attention to new onset of blisters or ulcers while taking Galvus.
You are also advised to pay particular attention to new onset of blisters or ulcers while taking Icandra.
You are also advised to pay particular attention to new onset of blisters or ulcers while taking Jalra.
You are also advised to pay particular attention to new onset of blisters or ulcers while taking Xiliarx.
haemoglobin level between 10 and 12 g/ dl.
17 You will then drink the Pylobactell 13C-urea solution.
There are two caps – one is grey and labelled ‘1'and the other is plum and labelled ‘2’.
There were 114 out of 207 patients who continued on Humira 40 mg every other week for 60 months. na
were 114 out of 207 patients who continued on Humira 40 mg every other week for 60 months.
There were three septic episodes (2.8%) during Paxene administration related to the medicinal product that proved fatal.
There were sixteen cases of persistent HPV-16 infection, and five cases of persistent HPV-18 infection, all in the control group.
There were three treatment studies and one prevention study.
You should be screened for skin type Area in card for physician to record skin type and date of injection.
There is a window on each side of the pen through which you can see the Trudexa solution inside the na
There was, however, an increased infant mortality in the stavudine + didanosine (10%) treatment group compared to the stavudine (2%), didanosine (3%) or zidovudine (6%) groups, with a higher incidence of stillbirths in the stavudine + didanosine group.
There was, however, an increased infant mortality in the stavudine + didanosine (10%) treatment group compared to the stavudine (2%), didanosine (3%) or zidovudine (6%) groups, with a higher incidence of stillbirths in the stavudine + didanosine group.
There was an average decrease in susceptibility of 2-fold wild type (WT) for tipranavir, 12-fold WT for amprenavir, 55-fold WT for atazanavir, 41-fold WT for indinavir, 87-fold WT for lopinavir, 41- fold WT for nelfinavir, 195-fold WT for ritonavir, and 20-fold WT for saquinavir.
There was considerable overlap between the ranges of exposures seen in these two populations (see section 4.2).
Magnetic resonance imaging or cardioversion (see section 4.4).
agents) therapy or have stopped taking these types of medicines within the last 14 days.
Immediately after administration, take the dispenser apart and rinse both parts of the dispenser under running tap water.
After radiolabelling the antibody and diluting a 10 µl sample with 1.5 ml saline, immediately determine the radiochemical purity by Instant Thin Layer Chromatography on silica gel impregnated glass fiber strips, 1 × 9 cm using acetone as the solvent.
Active immunisation against avian Infectious Bronchitis virus variant strain IB 4-91 which causes infectious bronchitis in chickens.
Active immunisation of cattle to reduce the clinical signs of infectious bovine rhinotracheitis (IBR) and field virus excretion.
For the active immunization of chickens to provide passive immunisation against necrotic enteritis to their progeny, during the laying period.
• To prevent mortality and to reduce clinical signs and lesions of Infectious Bursal disease.
Concurrent active and passive immunisation (emergency vaccination)
Concurrent active and passive immunisation (emergency vaccination) The vaccine can be used together with Tetanus-Serum from Intervet for treatment of injured horses that have not been immunised against tetanus.
This is a disorder of the immune system where an abnormal protein is found in the blood.
Excessive immunosuppression with risk of lymphoproliferative disease.
Immunogenicity Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, patients may develop anti-exenatide antibodies following treatment with BYETTA.
Immunogenicity Antibodies to infliximab were detected in 3 (2.9%) paediatric patients.
Immunogenicity of ZOSTAVAX Within the Shingles Prevention Study (SPS), immune responses to vaccination were evaluated in a subset of the enrolled subjects (N=1395).
Immunogenicity The immunological mechanism by which RotaTeq protects against rotavirus gastroenteritis is not completely understood.
Immunogenicity Antibodies directed against the abatacept molecule were assessed by ELISA assays in rheumatoid arthritis patients treated for up to 3 years with abatacept.
Jean-Louis ROBERT Safety Working Party Christian FRIIS
Immunologicals for Equidae – Inactivated viral vaccines - West Nile Virus vaccine
Immunosuppressants (cyclosporin, tacrolimus, sirolimus):
Immunosupressants Cyclosporine Tacrolimus Sirolimus
Immunosuppressants Cyclosporin Tacrolimus Sirolimus CARDIOVASCULAR AGENTS Antiarrhythmics
- Immunosuppressants (tacrolimus, cyclosporine, sirolimus)
Number of 2.5 x 5 cm pieces of InductOs per LT-CAGE Lumbar Tapered Fusion Device
IMPORTANT - ALERT CARD Kivexa (abacavir sulfate / lamivudine) Tablets Carry this card with you at all times
IMPORTANT - ALERT CARD ZIAGEN (abacavir sulfate) Oral solution Carry this card with you at all times
Never store any granule/ food mixture for use at a later time.
Clinical Global Impressions of Change (CGI-c) Dose Group [g/ d (n)]
Imprida 10 mg/ 160 mg film-coated tablets amlodipine/ valsartan
Imprida 10 mg/ 160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg alone or with Imprida 5 mg/ 160 mg.
Imprida 5 mg/ 160 mg film-coated tablets amlodipine/ valsartan
Imprida 5 mg/ 80 mg film-coated tablets amlodipine/ valsartan
Strength 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 80 mg 5 mg/ 160 mg 5 mg/ 160 mg 5 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 10 mg/ 160 mg 5 mg/ 80 mg 5 mg/ 160 mg 10 mg/ 160 mg
Imprida 5 mg/ 80 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg alone.
Imprida has not been studied in any patient population other than hypertension.
Imprida has not been studied in any patient population other than hypertension.
Imprida can be used with or without food.
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders
Fracture incidence in postmenopausal women over 5 years
Incidence of new morphometric vertebral fractures
Incidence of patients with hip fracture and relative risk reduction in patients with BMD ≤ -2.4 SD (NHANES III) and age ≥ 74 years
Incidence of patients with vertebral fracture and relative risk reduction
Incidence of Non-CABG related bleedinga (% Patients) Event
(Note that numbers for Blood and Lymphatic System Disorders are described in a separate table of laboratory examinations) Adverse reactions described as very common were experienced in more than 1 in 10 patients (≥ 1/ 10).
Cardiac Adverse Event Incidence; n,% [95 %-confidence limits]
Fracture Incidence in Postmenopausal Women:
Incidence of less than 5% (Grade 3 or 4, possibly, probably, or definitely related):
Total rates of Alaninine aminotransferase increased 3 x ULN
Tilt your head back and look at the ceiling.
Includes: alcohol (42% v/ v see leaflet), high fructose corn syrup, propylene glycol, glycerol, polyoxyl 40 hydrogenated castor oil, potassium (as acesulfame potassium).
Incompatibilities No safety or efficacy information is available on the compatibility of this vaccine with any other vaccine.
Common: pain on urination Not known: infection of the kidneys, decreased kidney function, loss of renal function.
Very common: dry skin; rash Not known: severe skin reactions; hair loss; darkening skin colour; ingrown toenails with or without infection
- Overflow bladder, anuria or progressive renal insufficiency
- Incontinence, water retention, uncontrolled urination, abnormal menstruation, disorder of the
Urinary incontinence, Polyuria, Micturition urgency Skin and subcutaneous tissue disorders Common:
Proliferative Enteropathy (ileitis)
substance per kg feed with:
INCRELEX 10 mg/ml solution for injection Mecasermin
INCRELEX caused the speed of growth to increase significantly.
INCRELEX contains 9 mg/ ml benzyl alcohol as a preservative.
INCRELEX contains 9 mg per ml benzyl alcohol as a preservative.
INCRELEX is supplied as a sterile solution with preservative for multiple use.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
INCRELEX should not be used for growth promotion in patients with closed epiphyses.
please tell you doctor or pharmacist.
please tell you doctor or pharmacist.
please tell you doctor or pharmacist.
please tell your doctor or pharmacist.
please tell your doctor or pharmacist.
please tell your doctor or pharmacist.
this leaflet, please tell your doctor or pharmacist.
Joint CPMP/CVMP Quality Working Party
please tell your doctor or pharmacist.
leaflet, please tell your doctor or pharmacist.
reactions or illness, must be advised to contact their doctor before restarting.
events; eye disorders, flushing, bruising, menstrual irregularities, palpitations and tachycardia, as well as any signal of interaction with carbamazepine.
Also, the long-term safety effects concerning growth, maturation, and cognitive and behavioural development of ARICLAIM in this age group have not yet been demonstrated.
Adverse reactions (regardless of relationship to medicinal product) reported with the use of hydrochlorothiazide alone Investigations:
Intake of Lansoprazol-ratiopharm may mask the symptoms of a tumour and delay diagnosis of this condition
The effect of Lansoprazol-ratiopharm may be influenced by the following medicines or drug groups:
Therapeutic indications Optimark is indicated for use with magnetic resonance imaging (MRI) of the central nervous system (CNS) and liver.
Therapeutic indications Optimark is indicated for use with magnetic resonance imaging (MRI) of the central nervous system (CNS) and liver.
28 Indication Treatment of refractory Fungal Infections
The safety of this combination has not been established.
Indinavir / RTV (29%) Lopinavir / RTV (36%) Saquinavir / RTV(20%)
(declared on labelling as carrier)
You should tell your doctor or pharmacist if you are taking cimetidine (a stomach medicine) or erythromycin (an antibiotic).
Tell your doctor if you notice any side effects and they worry you.
InductOs is used together with a special metal cage that corrects the position of the spine.
5 InductOs may be placed into a void (loosely packed), folded, rolled, or wrapped, as the geometry of the fracture requires.
The EMEA provided a forum for the exchange of scientific information and the debate was the basis for the ongoing revision of gene therapy guidelines.
Industriepark 30-2220 Heist-op-den-Berg Belgium
Industriepark 30 B-2220 Heist-op-den-Berg Belgium
Infanrix Hexa is given by deep injection into a muscle.
Infanrix Hexa is a vaccine, which is available as a powder and suspension to be made up into a suspension for injection.
When an infant is given the vaccine, the immune system recognises the parts of the bacteria and viruses as ‘ foreign'and makes antibodies against them.
Infanrix Penta is given by deep injection into a muscle.
Infanrix Penta is a vaccine used in children to prevent five diseases: diphtheria, tetanus (lockjaw), pertussis (whooping cough), hepatitis B and poliomyelitis (Polio).
Infanrix Penta should under no circumstances be administered intravascularly or intradermally.
Acute Myocardial Infarction Short-term (6 weeks) treatment of haemodynamically stable patients within 24 hours of an acute myocardial infarction.
myocardial infarction (0.5% vs 0.2%), atrial fibrillation (0.2% vs 0%), angina pectoris (0.3% vs 0.2%)
- Acute infection of the sinuses (acute bacterial sinusitis)
Acute infection of the sinuses (acute bacterial sinusitis)
Due to its mechanism of action, the use of Soliris increases the patient’s susceptibility to meningococcal infection (Neisseria meningitidis).
genital herpes†, folliculitis, herpes simplex, herpes virus infection, herpes zoster, influenza, molluscum contagiosum
Immune system disorders
the bones around the nose) and chest infections in patients with long standing breathing difficulties and lung infection (pneumonia).
Hypersensitivity reaction*
Ear infection, flu, nasal congestion, chest infection.
- Infection of the lungs (pneumonia) acquired outside the hospital, except severe cases
Infection of the lungs acquired (pneumonia) outside the hospital, except severe cases
Adverse Reaction lower respiratory infections (including pneumonia, bronchitis), viral infections (including influenza, herpes infections), candidiasis, bacterial infections (including urinary tract infections), upper respiratory infection
herpes zoster, + respiratory tract infection, fungal infections, infections of unknown aetiology, +acute bronchitis, + sinusitis
Psychiatric disorders Nervous System Disorders
Sepsis, Urinary tract infection, Cellulitis, Tonsillitis, Pharyngitis, Oral candidiasis, Influenza, Gastroenteritis, Fungal infection, Infection, Tooth abscess
Sepsis, Urinary tract infection, Cellulitis, Tonsillitis, Pharyngitis, Oral candidiasis, Influenza, Gastroenteritis, Fungal infection, Infection, Tooth abscess
Bacterial and viral infections (including infection, cellulitis, herpes zoster, herpes simplex, bronchitis, abscess)
- fungal infection (mobilises)
Upper respiratory tract infection Nasopharyngitis
- -infection*, blood poisoning*, infection in the lungs which can lead to breathing difficulties
- infection, and in particular infection in the blood or bladder,
Febrile infection*, upper respiratory tract infection*, otitis media, otitis media serous, chronic otitis media serous *, otitis externa*, pharyngitis*, tonsillitis, ear infection, oral candidiasis*
Vascular disorders8
Viral infection, pharyngitis Fungal infection, bacterial infection, pulmonary infection, otitis
Viral infection, pharyngitis Fungal infection, bacterial infection, pulmonary infection, otitis media, tooth abscess, herpes simplex, urinary tract infection,
Fungal infection, bacterial infection, pulmonary infection, otitis media, tooth abscess, herpes simplex, urinary tract infection, vaginitis, gastroenteritis
Fungal infection, bacterial infection including sepsis, herpes simplex, otitis media
Fungal infection, bacterial infection including sepsis, herpes simplex, otitis media
• Infection/ inflammation ic
• Infection/ inflammation Occult blood loss ed
• Occult blood loss ed
• Infection of the intestine • Abscess under the skin, tingling pricking or numbness of skin, inflammation of the skin • Decrease in white blood cell counts that helps to protect you against bacterial infection • Depression • Convulsion • Eye blinking • Sensation of spinning or swaying • Slow beating heart, high blood pressure • Toothache, tongue spasm • Buttock pain • Weight decreased.
Related to surgery catheter-related infection, decreased red cell blood count, swelling of limbs and joints, prolonged bleeding after drain removal, decreased Factor VIII level and post-operative bruise.
Active or suspected ocular or periocular infection.
ed • Eating more than usual • Less exercise than usual.
• Having forgotten to take your insulin • Repeatedly taking less insulin than you need • An infection or a fever • Eating more than usual • Less exercise than usual.
Herpes viral infection, Nasopharyngitis, Lower respiratory tract infection
Herpes, viral infection, Nasopharyngitis, Lower respiratory tract infection
12-month persistent infection (secondary endpoint) HPV-16 and/ or 18* HPV-16 HPV-18
Nosocomial pneumonia including ventilator– associated pneumonia
Upper respiratory infection, bronchitis, oral candidiasis, herpes simplex, fungal, viral and bacterial infections
Herpes viral infections (herpes simplex dermatitis [eczema herpeticum], herpes simplex [cold sores], Kaposi's varicelliform eruption)
Herpes viral infections (herpes simplex dermatitis [eczema herpeticum], herpes simplex [cold sores], Kaposi's varicelliform eruption)
Skin infections such as impetigo (a bacterial skin infection), herpes simplex (cold sores), herpes zoster (shingles), herpes simplex dermatitis (eczema herpeticum), molluscum contagiosum (a viral skin infection), warts and furuncles (boils).
Infections In the REACH study, infections were reported in 56.3% of randomized subjects treated with infliximab.
Skin and soft tissue infections in dogs:
Skin and soft tissue infections in dogs:
Acute exacerbation of chronic sinusitis
Infections of the urinary system caused by Escherichia coli.
Application site pruritus, chest tightness, feeling hot, infusion site phlebitis, infusion site reaction, infusion site tenderness, malaise, peripheral oedema, swelling
(increased chance of bleeding or bruising)
Ear and labyrinth disorders: deafness Cardiac disorders: myocardial ischaemia, cardiovascular disorder, palpitations Vascular disorders: hypertension, lymphoedema, varicose veins Respiratory, thoracic and mediastinal disorders: lung oedema, stridor Gastrointestinal disorders: gastroenteritis, dysphagia, gastritis, mouth ulceration, cheilitis Hepato-biliary disorders: cholelithiasis Skin and subcutaneous tissue disorders: rash, alopecia Renal and urinary disorders: urinary retention, renal cyst Reproductive system and breast disorders: pelvic pain General disorders and administration site conditions: hypothermia Investigations: blood alkaline phosphatase increase, weight decrease Injury, poisoning and procedural complications: injury, injection site pain
6 Infections and Infestations: fever, Herpes Zoster, injection site infection, sepsis
Infections and infestations Common: sepsis (including fatal outcome), pneumonia (including bacterial, viral, and fungal), upper respiratory tract infection/ inflammation, herpes viral infection, enterocolitis infection
Viral infection, pharyngitis Fungal infection, bacterial infection, pulmonary infection, otitis
Herpes zoster, herpes simplex, nasopharyngitis, pneumonia7, sinusitis, cellulites, upper respiratory tract infection, influenza, urinary tract infection, gastroenteritis, sepsis
Herpes zoster, herpes simplex, nasopharyngitis, pneumonia7, sinusitis, cellulitis, upper respiratory tract infection, influenza, urinary tract infection, gastroenteritis, sepsis
Infections of the gastro-intestinal tract and intra- abdominal infections
• Infections of the gastro-intestinal tract (e. g. travellers ` diarrhoea)
• Infections of the gastro-intestinal tract (e. g. travellers'diarrhoea)
• Infections of the gastro-intestinal tract (e.g. travellers` diarrhoea)
• Infections of the gastro-intestinal tract (e. g. travellers'diarrhoea)
• serious infections such as pneumonia (a chest infection) or infections of the skin.
• Serious infections such as pneumonia (a chest infection) or infections of the skin.
Serious infections (including pneumonia, cellulitis, septic arthritis, sepsis)* Tuberculosis, opportunistic infections (including invasive fungal, protozoal, bacterial and atypical mycobacterial infections)*
Fungal, viral and bacterial infections.
- upper respiratory tract infections: acute otitis media, sinusitis, tonsillitis and pharyngitis
- Fungal infections (thrush) in your mouth or vagina
Children who suffer from inborn AIDS and get frequent infections.
Children with congenital AIDS and recurrent infections.
For upper respiratory tract infections such as tonsillitis, otitis media, sinusitis and pharyngitis:
Active, severe infections (see section 4.4).
Active, severe infections (see section 4.4).
Very common: infection (including herpes simplex, oral candidiasis, pharyngitis, rhinitis)
Infection* Metabolism and nutrition disorders
Herpes zoster, Urinary tract infection, Oral candidiasis, Upper respiratory tract infection, Rhinitis, Influenza, +Infection
Sepsis, tuberculosis, abscess, bacterial infection, fungal infection, cellulitis, candidiasis Unknown:
Viral infection, pharyngitis Fungal infection, bacterial infection, pulmonary infection, otitis media, tooth abscess, herpes simplex, urinary tract infection, vaginitis, gastroenteritis
Viral infection, pharyngitis Fungal infection, bacterial infection, pulmonary infection,
Viral infection, pharyngitis Fungal infection, bacterial infection, pulmonary infection, otitis media, tooth abscess, herpes simplex, urinary tract infection, vaginitis, gastroenteritis
Viral infection, pharyngitis Fungal infection, otitis media, herpes simplex, urinary tract infection
AUC) of tacrolimus from Protopy is approximately 30-fold less than that seen with oral immunosuppressive doses in kidney and liver transplant patients.
Below limit of quantitation* Below limit of quantitation* Below limit of quantitation* Below limit of quantitation* Below limit of quantitation*
problems caused by blood clots) in patients who are having major surgery to their legs, such as a hip replacement or surgery to repair a knee or hip fracture.
Pulmonary infiltrates*, pneumonitis*, interstitial pneumonitis*
Pulmonary infiltrates*, pneumonitis*, interstitial pneumonitis* 35
The transient false positive reactions could be due to the IgM response by the vaccine.
The transient false positive reactions may be due to the IgM response to the vaccine.
The transient false positive reactions could be due to the IgM response by the vaccine.
- Vein wall inflammation where the intravenous infusion (or “drip”) goes into your vein (phlebitis)
- inflammation in the mouth, fungal infection in the mouth (Candida infection)
- inflammation of the vein wall (at injection-site)
- Inflammation of the bowel with diarrhoea (Clostridium difficile colitis)
Mucosal inflammation Infusion site erythema Localised oedema Infusion site oedema Malaise
-Visual disturbances (change in vision) -Fever -Rash -Nausea, vomiting, diarrhoea -Headache -Swelling of the extremities -Stomach pains.
- inflamed, dry or scaly skin that sheds
diarrhoea, nausea gastrointestinal inflammatory conditions, gastrointestinal ulceration and perforation, gastrointestinal haemorrhages, stomatitis and ulceration, ascites, vomiting, gastrointestinal and abdominal pains, dyspeptic signs and symptoms, constipation, flatulence, bloating and distension, loose stools, gastrointestinal signs and symptoms
Additional information on special populations
Information about Tracleer Patient Information Booklet/Patient Reminder Card
INFORMATION FOR THE USER Aprovel 150 mg tablets irbesartan
INFORMATION FOR THE USER Aprovel 150 mg film-coated tablets irbesartan
INFORMATION FOR THE USER Aprovel 300 mg tablets irbesartan
INFORMATION FOR THE USER Aprovel 300 mg film-coated tablets irbesartan
INFORMATION FOR THE USER Aprovel 75 mg tablets irbesartan
INFORMATION FOR THE USER Aprovel 75 mg film-coated tablets irbesartan
Arava 100 mg film-coated tablets Leflunomide
Arava 10 mg film-coated tablets Leflunomide
Arava 20 mg film-coated tablets Leflunomide
INFORMATION FOR THE USER CoAprovel 300 mg/ 25 mg film-coated tablets irbesartan/ hydrochlorothiazide
INFORMATION FOR THE USER COMPETACT 15 mg/ 850 mg FILM-COATED TABLETS
INFORMATION FOR THE USER Corlentor 5 mg film-coated tablets Corlentor 7.5 mg film-coated tablets ivabradine
INFORMATION FOR THE USER Docetaxel Winthrop 20 mg concentrate and solvent for solution for infusion docetaxel
INFORMATION FOR THE USER Helicobacter Test INFAI 75 mg powder for oral solution 13 C-urea
INFORMATION FOR THE USER Helicobacter Test INFAI for children of the age 3-11 45 mg powder for oral solution 13 C-urea
INFORMATION FOR THE USER Irbesartan BMS 150 mg tablets irbesartan
INFORMATION FOR THE USER Irbesartan BMS 150 mg film-coated tablets irbesartan
INFORMATION FOR THE USER Irbesartan BMS 300 mg tablets irbesartan
INFORMATION FOR THE USER Irbesartan BMS 300 mg film-coated tablets irbesartan
INFORMATION FOR THE USER Irbesartan BMS 75 mg tablets irbesartan
INFORMATION FOR THE USER Irbesartan BMS 75 mg film-coated tablets irbesartan
INFORMATION FOR THE USER Irbesartan Hydrochlorothiazide BMS 300 mg/ 25 mg film-coated tablets irbesartan/ hydrochlorothiazide
INFORMATION FOR THE USER Irbesartan Hydrochlorothiazide Winthrop 300 mg/ 25 mg film-coated tablets irbesartan/ hydrochlorothiazide
INFORMATION FOR THE USER Irbesartan Winthrop 150 mg tablets irbesartan
INFORMATION FOR THE USER Irbesartan Winthrop 150 mg film-coated tablets irbesartan
INFORMATION FOR THE USER Irbesartan Winthrop 300 mg tablets irbesartan
INFORMATION FOR THE USER Irbesartan Winthrop 300 mg film-coated tablets irbesartan
INFORMATION FOR THE USER Irbesartan Winthrop 75 mg tablets irbesartan
INFORMATION FOR THE USER Irbesartan Winthrop 75 mg film-coated tablets irbesartan
INFORMATION FOR THE USER Karvea 150 mg tablets irbesartan
INFORMATION FOR THE USER Karvea 150 mg film-coated tablets irbesartan
INFORMATION FOR THE USER Karvea 300 mg tablets irbesartan
INFORMATION FOR THE USER Karvea 300 mg film-coated tablets irbesartan
INFORMATION FOR THE USER Karvea 75 mg tablets irbesartan
INFORMATION FOR THE USER Karvea 75 mg film-coated tablets irbesartan
INFORMATION FOR THE USER Karvezide 300 mg/ 25 mg film-coated tablets irbesartan/ hydrochlorothiazide
INFORMATION FOR THE USER LeukoScan (0.31 powder for solution for injection) (sulesomab)
LUMIGAN 0.3 mg/ ml, eye drops, solution bimatoprost
INFORMATION FOR THE USER Micardis 20 mg tablets Telmisartan
INFORMATION FOR THE USER Micardis 40 mg tablets Telmisartan
INFORMATION FOR THE USER Micardis 80 mg tablets Telmisartan
INFORMATION FOR THE USER NeuroBloc 5000 U/ ml Solution for Injection Botulinum Toxin Type B
INFORMATION FOR THE USER Rapilysin 10 U powder and solvent for solution for injection reteplase
INFORMATION FOR THE USER REVATIO 20mg film-coated tablets Sildenafil citrate
INFORMATION FOR THE USER Tandemact 30 mg/ 2 mg tablets
INFORMATION FOR THE USER Tandemact 30 mg/ 4 mg tablets
INFORMATION FOR THE USER Tandemact 45 mg/ 4 mg tablets
INFORMATION FOR THE USER TAXOTERE 20 mg concentrate and solvent for solution for infusion docetaxel
INFORMATION FOR THE USER TAXOTERE 80 mg concentrate and solvent for solution for infusion docetaxel
INFORMATION FOR THE USER Thyrogen 0.9 mg powder for solution for injection thyrotropin alfa
Vimpat 10 mg/ml solution for infusion Lacosamide
Important information about some of the ingredients of Yondelis
Important information about some of the ingredients of Kineret
Important information about some of the ingredients of Trevaclyn Trevaclyn contains a sugar called lactose.
Important information about some of the ingredients of SPRYCEL SPRYCEL contains lactose.
Important information about some of the ingredients of Tandemact:
Important information about some of the ingredients of TORISEL
Important information about some of the ingredients of Kineret
Important information for use of SoloStar:
Important information about some of the ingredients of Actos 15mg tablets:
Important information about some of the ingredients of Actos 30mg tablets:
Important information about some of the ingredients of Actos 45mg tablets:
Important information about some of the ingredients of Glustin 15 mg tablets:
Important information about some of the ingredients of Glustin 30 mg tablets:
Important information about some of the ingredients of Glustin 45 mg tablets:
Important information about some of the ingredients of KOGENATE Bayer 1000 IU This medicinal product contain less than 1 mmol sodium (23 mg) per vial, i. e. essentially “ sodium- free”.
Important information about some of the ingredients of KOGENATE Bayer 2000 IU This medicinal product contain less than 1 mmol sodium (23 mg) per vial, i. e. essentially “ sodium- free”.
Important information about some of the ingredients of KOGENATE Bayer 250 IU This medicinal product contain less than 1 mmol sodium (23 mg) per vial, i. e. essentially “ sodium- free”.
Important information about some of the ingredients of KOGENATE Bayer 500 IU This medicinal product contain less than 1 mmol sodium (23 mg) per vial, i. e. essentially “ sodium- free”.
Important information about some of the ingredients of Flebogammadif
Important information about some of the ingredients of Vimpat Vimpat contains soya-lecithin.
INFORMATION FOR THE USER Agenerase 150 mg soft capsules Amprenavir
INFORMATION FOR THE USER Agenerase 15 mg/ml oral solution Amprenavir
INFORMATION FOR THE USER Agenerase 50 mg soft capsules Amprenavir
INFORMATION FOR THE USER CEPROTIN 1000 IU powder and solvent for solution for injection Human Protein C
INFORMATION FOR THE USER CEPROTIN 500 IU powder and solvent for solution for injection Human Protein C
INFORMATION FOR THE USER ORENCIA 250 mg powder for concentrate for solution for infusion Abatacept
Information applicable to all indications:
Additional information on special population
Additional information on special populations
Additional information on special populations Patients co-infected with hepatitis B and/ or hepatitis C virus In the pooled analysis for DUET-1 and DUET-2, the incidence of hepatic events tended to be higher in co-infected subjects treated with INTELENCE compared to co-infected subjects in the placebo group.
Additional information on special populations Renally or hepatically impaired patients:
INFORMATION FOR THE USER Angiox 250 mg powder for concentrate for solution for injection and infusion bivalirudin
Health care Professional information The healthcare professional information regarding Volibris should contain the following key elements:
• Essential patient information
Information to appear on the inside of the flap
INFORMATION IN BRAILLE (this is only applicable to the outer pack)
Important information about some of the ingredients of ABILIFY Each ml of ABILIFY oral solution contains 200 mg of fructose and 400 mg of sucrose.
Important information about some of the ingredients of Aerius You should not take Aerius syrup if you are allergic to the colouring agent E110.
Important information about some of the ingredients of AMMONAPS Each AMMONAPS tablet contains 62 mg of sodium.
Important information about some of the ingredients of Atripla
Important information about some of the ingredients of Avamys Avamys contains benzalkonium chloride.
Important information about some of the ingredients of Neoclarityn You should not take Neoclarityn syrup if you are allergic to the colouring agent E110.
Important information about some of the ingredients of Sebivo Sebivo oral solution contains approximately 47 mg of sodium per 600 mg dose (30 ml).
Important information about some of the ingredients of REYATAZ
Important information about some of the ingredients of TRISENOX
ris This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium- free’.
For the constituted oral suspension:
Important information about some of the ingredients of Viread
Important information about some of the ingredients of Infanrix hexa Please tell your doctor if your child has had an allergic reaction to neomycin and polymyxin (antibiotics).
Important information about some of the ingredients of Infanrix Penta Please tell your doctor if your child has had an allergic reaction to neomycin and polymyxin (antibiotics).
Important information about some of the ingredients of Insuman Rapid
Important information about some of the ingredients of IntronA Your doctor may recommend that you consider vaccination against hepatitis A and B if you regularly/repeatedly receive human plasma-derived albumin.
Important information about some of the ingredients of IntronA Your doctor may recommend that you consider vaccination against hepatitis A and B if you regularly/repeatedly receive human plasma-derived albumin.
Important information about some of the ingredients of Irbesartan Krka This medicinal product contains castor oil which may cause stomach upset and diarrhoea.
Important information about some of the ingredients of Optisulin
Important information about some of the ingredients of ORACEA ORACEA contains sugar (sucrose).
Important information about some of the ingredients of TachoSil When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to the patients.
• Always attach a new needle before each use.
Important information for use of OptiSet:
Important information for use of OptiSet: • Always attach a new needle before each use.
Important information about some of the ingredients of CEPROTIN
Important information about some of the ingredients of CEPROTIN
322 IMPORTANT INFORMATION Always first attach a new needle before using OptiSet.
324 IMPORTANT INFORMATION Always first attach a new needle before using OptiSet.
342 IMPORTANT INFORMATION Always first attach a new needle before using OptiSet.
344 IMPORTANT INFORMATION Always first attach a new needle before using OptiSet.
385 IMPORTANT INFORMATION Always first attach a new needle before using OptiSet.
407 IMPORTANT INFORMATION Always first attach a new needle before using OptiSet.
409 IMPORTANT INFORMATION Always first attach a new needle before using OptiSet.
IMPORTANT INFORMATION Always first attach a new needle before using OptiSet.
Before your child receives Tritanrix HepB 3.
BEFORE YOU USE CEPROTIN
BEFORE YOU USE NONAFACT
FURTHER INFORMATION
FURTHER INFORMATION
FURTHER INFORMATION
FURTHER INFORMATION
Additional information on special populations
Additional information on special populations
FURTHER INFORMATION
ge Taking three separate 1 mg unit dose blisters delivers more insulin to your lungs than a single 3 mg unit dose blister does.
Further information on selected serious adverse drug reactions:
Additional information on hydrochlorothiazide interactions When administered concurrently, the following medicinal products may interact with thiazide diuretics:
Changes in body shape due to changes in fat distribution Combination antiretroviral therapy may cause changes in body shape due to changes in fat distribution.
What Viraferon contains
INFORMATION ON HOW TO SELF-INJECT Valtropin
ris information that you need to be aware of before you are given Trudexa and during treatment with Trudexa.
Please tell your doctor if your baby is taking or has recently taken any other medicines, including medicines obtained without a prescription.
Please also inform your doctor when it is planned to apply iodine contrast media about taking Cozaar Comp.
Always notify your doctor immediately if you have these symptoms or any side effects while taking SUSTIVA.
Tell your doctor immediately if you get any of these.
Tell your doctor immediately if you are having any thoughts or feelings about hurting yourself.
Tell your doctor immediately if you become pregnant.
Tell your doctor immediately if you experience • involuntary rhythmic movements of the tongue, mouth and face.
Tell your doctor immediately if you have the following symptoms during or after this treatment: • swelling around the eyes, lips, tongue, throat or hands • breathing difficulties, hoarseness, difficulty in speaking • skin redness, nettle rash (urticaria) or itching.
Tell the doctor requesting these tests that you have recently received CELVAPAN; • If you have a bleeding problem or bruise easily.
Side effects may occur at least up to 5 months after the last Humira injection.
Side effects may occur at least up to 5 months after the lastHumira injection.
− Tell your doctor or pharmacist if this side effect gets severe or troublesome.
Tell your doctor if any of these side effects get severe or troublesome.
- Tell your doctor if you get any of these symptoms.
Tell your doctor if any of these affect you.
 Tell your doctor if you are breast-feeding or about to start breast-feeding.
Take special care with Fendrix Tell your doctor if you have any known allergies.
Tell your doctor if you are pregnant, think you may be pregnant, or are planning to become pregnant.
Tell your doctor if you have any of the following and if they are too uncomfortable for you:
Mention any past or present serious illness to your doctor.
- if you are currently taking any products containing St John's wort (Hypericum perforatum) as
- if you are currently taking any products containing St John’s wort (Hypericum perforatum) as
This should reduce the volumes of documents photocopied and also the number of documents
Severe hypoglycaemia may lead to unconsciousness and/ or
Inhale your insulin dose Perform the following steps in immediate sequence.
Blood and lymphatic disorders Metabolism and nutrition disorders
HMG-CoA reductase inhibitors metabolised through CYP3A4 (e. g. simvastatin, lovastatin, and atorvastatin):
Monoamine Oxidase Inhibitors (MAOIs): due to the risk of serotonin syndrome, ARICLAIM should not be used in combination with nonselective irreversible monoamine oxidase inhibitors (MAOIs), or within at least 14 days of discontinuing treatment with an MAOI.
Monoamine oxidase inhibitors (MAOIs): due to the risk of serotonin syndrome, ARICLAIM should not be used in combination with nonselective, irreversible monoamine oxidase inhibitors (MAOIs), or within at least 14 days of discontinuing treatment with an MAOI.
Monoamine Oxidase Inhibitors (MAOIs): due to the risk of serotonin syndrome, CYMBALTA should not be used in combination with nonselective irreversible monoamine oxidase inhibitors (MAOIs), or within at least 14 days of discontinuing treatment with an MAOI.
Monoamine oxidase inhibitors (MAOIs): due to the risk of serotonin syndrome, DULOXETINE BOEHRINGER INGELHEIM should not be used in combination with nonselective, irreversible monoamine oxidase inhibitors (MAOIs), or within at least 14 days of discontinuing treatment with an MAOI.
Monoamine Oxidase Inhibitors (MAOIs): due to the risk of serotonin syndrome, XERISTAR should not be used in combination with nonselective irreversible monoamine oxidase inhibitors (MAOIs), or within at least 14 days of discontinuing treatment with an MAOI.
Monoamine oxidase inhibitors (MAOIs): due to the risk of serotonin syndrome, YENTREVE should not be used in combination with nonselective, irreversible monoamine oxidase inhibitors (MAOIs), or within at least 14 days of discontinuing treatment with an MAOI.
oxidase inhibitor - MAOI (see section below ‘ Taking other medicines’).
Monoamine Oxidase Inhibitors (MAOI): you should not take DULOXETINE BOEHRINGER INGELHEIM with an MAOI or within 14 days of stopping an MAOI.
42 Monoamine Oxidase Inhibitors (MAOI): you should not take YENTREVE with an MAOI or within 14 days of stopping an MAOI.
12 Medicinal product by therapeutic area (dose of Invirase used in study) Proton pump inhibitors
35 Medicinal product by therapeutic area (dose of Invirase used in study) Proton pump inhibitors
HMG-CoA reductase inhibitors which are highly dependent on CYP3A4 for metabolism, such as lovastatin and simvastatin, are expected to have markedly increased plasma concentrations when co-administered with Agenerase.
HMG Co-A Reductase Inhibitors
HMG Co-A Reductase Inhibitors Lovastatin Simvastatin
HMG-CoA reductase inhibitors Pravastatin Fluvastatin (saquinavir/ ritonavir)
HMG-CoA reductase inhibitors Pravastatin Fluvastatin (saquinavir/ritonavir)
Integrase Inhibitors Raltegravir 400 mg BID
Tumor Necrosis Factor alpha (TNF- α) inhibitors.
Tumor Necrosis Factor alpha (TNF-α) inhibitors.
Non-nucleoside reverse transcriptase inhibitors.
Non-nucleoside reverse transcriptase inhibitors (NNRTI) (CYP3A4 substrates, inhibitors or CYP450 inducers):
Nucleoside reverse transcriptase inhibitors (NRTIs) -
Nucleoside reverse transcriptase inhibitors:
Nucleoside / Nucleotide reverse transcriptase inhibitors
Nucleotide reverse transcriptase inhibitors:
P-gp potent inhibitors A single dose drug interaction study in healthy subjects has shown that ciclosporin (200 and 600 mg) increases Cmax of aliskiren 75 mg approximately 2.5-fold and AUC approximately 5-fold.
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
- 1,407 patients undergoing abdominal surgery treated up to 9 days
- 1407 patients undergoing abdominal surgery treated up to 9 days
Initially, it stimulates pituitary function and secretion of the gonadotrophins LH (luteinising hormone) and FSH (follicle stimulating hormone).
• Initiation of treatment in pregnancy (see section 4.6). • Hypersensitivity to natural or recombinant interferon-β, or to any excipients. • Current severe depression and/ or suicidal ideation (see sections 4.4 and 4.8).
- Initiation of treatment in pregnancy (see section 4.6).
syringe, 2 injection needles and 1 cleansing swab
syringe, 2 injection ne edles and 1 cleansing swab
Add the water for injections into the vial by pushing the syringe plunger down slowly to avoid foaming.
Administer Vial/Pen Once Weekly Strength
Your next injection will be on the Monday, 5 days later after
ADMINISTRATION OF CONCENTRATE-DILUENT MIXTURE IN SODIUM CHLORIDE INFUSION
ADMINISTRATION OF CONCENTRATE-DILUENT MIXTURE IN SODIUM CHLORIDE INFUSION • Withdraw the required amount of concentrate-diluent mixture (containing temsirolimus 10 mg/ ml) from the vial; i. e., 2.5 ml for a temsirolimus dose of 25 mg. • Inject the withdrawn volume rapidly into 250 ml of sodium chloride 9 mg/ ml (0.9%) solution for injection to ensure adequate mixing.
The needle should be removed after each injection and discarded.
INOmax should be used only after respiratory support has been optimised.
INOmax is not intended for adults.
INOmax should be used in ventilated infants expected to require support > 24 hours.
INOmax should be used only after respiratory support is optimised, including the use of surfactant.
Hepatic impairment No studies have been performed in patients with hepatic impairment and therefore Inovelon should not be administered to patients with severe hepatic impairment.
Write the date of reconstitution and expiry on the label (expiry is 1 month after reconstitution).
Carefully insert a pressure-venting device equipped with a hydrophobic filter.
Carefully insert a pressure-venting device equipped with a hydrophobic filter.
Gently insert the cannula into the teat canal; carefully infuse the product.
Put the needle through the rubber top of the Liprolog vial and inject the air into the vial.
Put the needle through the rubber top of the Humalog vial and inject the air into the vial.
Insert the reconstitution needle into the upright vial.
Insert the needle into the pinched skin at a 45° to 90° angle with a quick, firm motion.
Insert the reconstitution needle into the upright vial.
Insert the tip of the dispenser into the bottle adapter.
Insert a suitable in-line filter into the infusion line and prime it with Erbitux or sterile sodium chloride 9 mg/ ml (0.9%) solution before starting the infusion.
Insomnia, anxiety, headache, upper respiratory tract infection, parkinsonism, depression, and akathisia.
Insomnia, hallucinations, confusion, paroniria Agitation
Inspect the pre-filled syringe before use.
Inspect the suspension visually for foreign matter.
Inspections................................................................................................ 50
through your mouth in one breath. in
Starting Avonex If you are new to Avonex, your doctor may have advised that you start by taking a lower dose so that you can adjust to the effects of Avonex before increasing to the full dose.
Administer one dose (1 ml) of the product in each affected ear.
EUROPEAN UNION INSTITUTIONS EUROPEAN UNION INSTITUTIONS
Kövér Lajos utca 45-47.
21 Instructions for use, handling and disposal
Application Instructions – (Mon, Wed and Fri) 1.
7 SafetyGlide Information from Becton Dickinson WARNING: - Do not autoclave safety needle before use.
SafetyGlide Information from Becton Dickinson
Instructions for use These instructions are for both types of syringes (automatic and manual needle protection system).
Instructions for use These instructions are for both types of syringes (automatic and manual needle protection system).
Special handling instructions for SPRYCEL In the unlikely event of the tablets being broken, persons other than the patient are recommended to use gloves when handling SPRYCEL.
Special handling instructions For single use only.
Instructions for Needle-Free Vial Access Device
Instructions for determining the percent radioincorporation.
7 The vial should never be opened and must be kept inside its lead shielding.
INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS
INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS
INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
Directions for re-constituting suspension from sachets:
Instructions for mixing and administration of the vaccine:
Instructions for Needle-Free Vial Access Device RISPERDAL CONSTA extended release microspheres in the vial must be reconstituted only in the solvent in the syringesupplied in the dose pack, and must be administered only with the Needle-Pro safety needle supplied in the dose pack.
Instructions on the treatment of hypoglycaemia.
Instructions for preferr ed injection site
INSTRUCTIONS FOR INJECTING WITH THE ARANESP PRE-FILLED SYRINGE
INSTRUCTIONS FOR INJECTING WITH THE ARANESP PRE-FILLED PEN (SURECLICK)
INSTRUCTIONS FOR INJECTING WITH THE NESPO PRE-FILLED SYRINGE ro
INSTRUCTIONS FOR INJECTING WITH THE NESPO PRE-FILLED PEN (SURECLICK) ed
Before you use your new FORSTEO, please read the section Instructions for Use completely.
Directions for Use of safety needle Peel apart packaging of the safety needle, break the seal of the white plastic cover on the syringe Luer connector and attach the safety needle to the Luer Lock of the syringe by twisting.
Directions for Use of safety needle
For instructions for use and handling see section 6.6.
For instructions for use and handling see section 6.6.
INSTRUCTIONS FOR USE, HANDLING AND DISPOSAL
INSTRUCTIONS FOR USE, HANDLING AND DISPOSAL
Special Instructions for use (for infrared spectroscopy) The test is to be performed after instruction by a healthcare professional and under appropriate medical supervision.
INSTRUCTIONS ON HOW TO STORE AND DISPOSE OF ATRIANCE
3 Cardiac failure Experience with vildagliptin therapy in patients with congestive heart failure of New York Heart Association (NYHA) functional class I-II is limited and therefore vildagliptin should be used cautiously in these patients.
Cardiac failure Experience with vildagliptin therapy in patients with congestive heart failure of New York Heart Association (NYHA) functional class I-II is limited and therefore vildagliptin should be used cautiously in these patients.
Cardiac disorders congestive heart failure/ pulmonary oedema
Heart failure< COVERSYL and associated names > reduces cardiac work by a decrease in pre-load and after-load.
Heart failure :< COVERSYL and associated names > reduces cardiac work by a decrease in pre-load and after-load.
Heart failure Aliskiren should be used with caution in patients with serious congestive heart failure (New York Heart Association (NYHA) functional class III-IV).
cardiac or respiratory failure recent myocardial infarction shock
- Heart failure, palpitations (awareness of heart beat), fast heart rate
Symptomatic heart failure It is recommended that< COVERSYL and associated names >, generally associated with a non- potassium-sparing diuretic and/or digoxin and/or a beta blocker, be introduced under close medical supervision with a recommended starting dose of 2 mg taken in the morning.
- Transient or persistent heart failure post MI
 Not known: excessive activation of white blood cells associated with inflammation (macrophage activation syndrome).
- not enough c alcium and vitamin D in the diet
Renal failure and impairment, Elevation of serum creatinine
Hepatic impairment No dose adjustment is necessary for patients with mild hepatic impairment.
2 Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment (see section 5.2).
Hepatic impairment No adjustment to the recommended dose of Sebivo is necessary in patients with hepatic impairment (see section 5.2).
13 Hepatic impairment - No dosing adjustment is necessary in patients with either mild or moderate hepatic impairment.
25 Hepatic impairment - No dosing adjustment is necessary in patients with either mild or moderate hepatic impairment.
Hepatic impairment - No dosing adjustment is necessary in patients with either mild or moderate hepatic impairment.
35 Hepatic impairment - No dosing adjustment is necessary in patients with either mild or moderate hepatic impairment.
45 Hepatic impairment - No dosing adjustment is necessary in patients with either mild or moderate hepatic impairment.
See 4.4 Special warning and precautions for use and 5.2 Pharmacokinetic properties.
Hepatic impairment No pharmacokinetic and safety data in patients with hepatic impairment are available.
Hepatic and renal impairment RISPERDAL CONSTA has not been studied in hepatically and renally impaired patients.
Hepatic and renal impairment Studies have not been carried out in patients with hepatic or renal impairment.
Hepatic impairment Gemfibrozil is contraindicated in hepatic impairment (see section 4.3).
Hepatic insufficiency Anidulafungin is not hepatically metabolised.
Hepatic impairment: stavudine pharmacokinetics in patients with hepatic impairment were similar to those in patients with normal hepatic function.
The pharmacokinetics of enfuvirtide have not been studied in patients with hepatic impairment.
Hepatic impairment The pharmacokinetics of Pegasys were similar between healthy subjects and patients with hepatitis B or C.
Hepatic impairment - Fondaparinux pharmacokinetics has not been evaluated in hepatic impairment.
Hepatic impairment - Fondaparinux pharmacokinetics has not been evaluated in hepatic impairment. ici
The safety and efficacy of Soliris have not been studied in patients with hepatic impairment.
Mild to severe hepatic impairment (Child-Pugh Class A-C).
Hepatic impairment Thiazides should be used with caution in patients with impaired hepatic function.
Hepatic impairment: insufficient safety and efficacy data are available in patients with hepatic impairment to provide a dose adjustment recommendation.
Hepatic impairment Patients with known or suspected hepatic disorder have not been included in long-term clinical trials with degarelix.
Hepatic impairment: pharmacokinetic parameters in patients with moderate or severe hepatic impairment were similar to those in patients with normal hepatic function.
11 Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.
12 Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.
24 Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.
26 Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.
40 Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.
54 Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.
68 Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Hepatic impairment Toremifene should be used cautiously in patients with liver impairment (see section 5.2).
Hepatic impairment ORACEA should be administered with caution to patients with hepatic impairment or to those receiving potentially hepatotoxic medicinal products (see section 4.4)
Use in patients with hepatic or renal insufficiency Use of Pelzont in patients with hepatic or renal insufficiency has not been studied.
Use in patients with hepatic or renal insufficiency Use of Tredaptive in patients with hepatic or renal insufficiency has not been studied.
Use in patients with hepatic or renal insufficiency Use of Trevaclyn in patients with hepatic or renal insufficiency has not been studied.
Hepatic and renal impairment Specific studies have not been conducted in patients with hepatic and renal impairment (see section 4.2).
- hepatitis, death of liver cells (liver necrosis) very rarely leading to life-threatening liver failure
ra Severe hepatic impairment Dosing adjustment of fondaparinux is not necessary.
Severe hepatic impairment Dosing adjustment of fondaparinux is not necessary.
• Severe hepatic impairment (with or without cirrhosis) (see section 4.2).
Severe hepatic impairment (Child Pugh class C).
Patients with Heparin Induced Thrombocytopenia Fondaparinux does not bind to platelet factor 4 and does not cross-react with sera from patients with du
Severe hepatic impairment The use of fondaparinux should be considered with caution because of an increased risk of bleeding due to a deficiency of coagulation factors in patients with severe hepatic impairment (see section 4.2).
- Severe hepatic dysfunction or decompensated cirrhosis of the liver;
- Severe hepatic dysfunction or decompensated cirrhosis of the liver.
Severe hepatic impairment (see section 4.4).
Patients with hepatic impairment Tasigna has not been investigated in patients with hepatic impairment.
Hepatic impairment A study was performed to measure the PK of histamine in normal volunteers compared to patients with mild, moderate, and severe hepatic impairment.
- acute kidney failure, abnormal kidney function, vaginal secretion due to a fungal infection (vaginal
renal failure (acute and chronic), acute tubular necrosis, proximal renal tubulopathy including Fanconi syndrome, nephritis, acute interstitial nephritis, nephrogenic diabetes insipidus, increased creatinine, proteinuria
Retinal haemorrhage, optic atrophy, oculogyration, corneal opacity
Uncommon: renal failure acute, renal failure, oliguria, renal colic, haematuria, proteinuria, urinary retention, urinary frequency, difficulty in micturition, loin pain, urinary incontinence, micturition urgency.
Acute renal failure, interstitial nephritis, hyponatraemia
No dose adjustment is necessary for patients with renal impairment (see section 5.2).
Renal impairment Dose adjustment is not needed in patients with renal impairment (see section 5.2).
Renal insufficiency No dosage adjustment is necessary for patients with creatinine clearance ≥ 30 ml/ min (see section 5.2).
Renal impairment: no dose adjustment is considered necessary in patients with renal impairment (see section 5.2).
2 Renal insufficiency No dosage adjustment is necessary in patients with renal impairment or in patients undergoing haemodialysis (see section 5.2).
Renal impairment No dosage adjustment is required for patients with renal impairment (see section 5.2).
Renal impairment Degarelix has not been studied in patients with severe renal impairment and caution is therefore warranted.
Renal impairment: no clinical trials were conducted with SPRYCEL in patients with decreased renal function (trials excluded patients with serum creatinine concentration > 1.5 times the upper limit of the normal range).
Renal impairment - Fondaparinux should not be used in patients with creatinine clearance < 20 ml/ min (see section 4.3).
Impaired renal function: in healthy subjects, the renal elimination of unchanged atazanavir was approximately 7% of the administered dose.
Renal Insufficiency Renal insufficiency has been reported during treatment with Cubicin.
Renal impairment including acute renal failure
Renal impairment including acute renal failure
End-stage renal disease - Patients undergoing dialysis
Renal impairment and kidney transplantation When Rasilez HCT is used in patients with impaired renal function, periodic monitoring of potassium, creatinine and uric acid serum levels is recommended.
Renal impairment and kidney transplantation: when Aprovel is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended.
Renal impairment and kidney transplantation: when CoAprovel is used in patients with impaired renal function, a periodic monitoring of potassium, creatinine and uric acid serum levels is recommended.
Renal impairment and kidney transplantation: when Irbesartan BMS is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended.
Renal impairment and kidney transplantation: when Irbesartan Hydrochlorothiazide BMS is used in patients with impaired renal function, a periodic monitoring of potassium, creatinine and uric acid serum levels is recommended.
Renal impairment and kidney transplantation: when Irbesartan Hydrochlorothiazide Winthrop is used in patients with impaired renal function, a periodic monitoring of potassium, creatinine and uric acid serum levels is recommended.
Renal impairment and kidney transplantation: when Irbesartan Winthrop is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended.
Renal impairment and kidney transplantation: when Karvea is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended.
Renal impairment and kidney transplantation: when Karvezide is used in patients with impaired renal function, a periodic monitoring of potassium, creatinine and uric acid serum levels is recommended.
disorders Renal failure, haematuria Acute renal failure, urinary frequency, renal tubular necrosis, cystitis, urinary retention, dysuria, acquired Fanconi Syndrome, urinary incontinence, polyuria, increased blood urea, increased blood creatinine, nocturia
disorders renal impairment renal failure, renal failure acute, oliguria, renal tubular necrosis, nephropathy toxic, urinary abnormalities, bladder and urethral symptoms
renal impairment renal failure, renal failure acute, oliguria, renal tubular necrosis, nephropathy toxic, urinary abnormalities, bladder and urethral symptoms
Renal dysfunction Because nicotinic acid and its metabolites are excreted through the kidneys, Pelzont should be used with caution in patients with renal dysfunction.
Renal dysfunction Because nicotinic acid and its metabolites are excreted through the kidneys, Tredaptive should be used with caution in patients with renal dysfunction.
Renal impairment: the clearance of entecavir decreases with decreasing creatinine clearance (see section 5.2).
Renal impairment: entecavir clearance decreases with decreasing creatinine clearance.
Renal insufficiency Anidulafungin has negligible renal clearance (< 1%).
Renal impairment Renal clearance of unchanged medicinal product is a minor pathway of elimination.
Renal impairment The pharmacokinetics of a single 400 mg dose of rufinamide were not altered in subjects with chronic and severe renal failure compared to healthy volunteers.
The pharmacokinetics of tolcapone have not been investigated in patients with renal impairment.
The safety and efficacy of Soliris have not been studied in patients with renal impairment.
Renal impairment: the safety and efficacy of CELSENTRI have not been specifically studied in patients with renal impairment, therefore CELSENTRI should be used with caution in this population.
Renal impairment - Fondaparinux should be used with caution in patients with moderate renal impairment (see section 4.4).
Renal impairment: the pharmacokinetics of maraviroc have not been studied in patients with renal impairment.
• Renal impairment There are limited data in patients with moderate renal impairment and no data in patients with severe renal impairment.
Renal impairment: in patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered.
19 Renal impairment: in patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered.
29 Renal impairment: in patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered.
39 Renal impairment: in patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered.
49 Renal impairment: in patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered.
59 Renal impairment: in patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered.
9 Renal impairment: in patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Renal impairment: in patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Renal impairment: the following dosages are recommended:
Renal impairment The pharmacokinetics of etravirine have not been studied in patients with renal insufficiency.
Renal impairment The exposure of enalapril and enalaprilat is increased in patients with renal insufficiency.
Renal failure Oedema Chills Blood creatinine increased Weight increased
Renal and hepatic impairments No dosage adjustment is required in these patients.
Renal or hepatic impairment and liver fibrosis There are no data available on the use of deferiprone in patients with renal or hepatic impairment.
Renal or hepatic impairment and liver fibrosis There are no data available on the use of deferiprone in patients with renal or hepatic impairment.
Renal or hepatic impairment Dosage adjustment for patients with renal or hepatic impairment has not been studied in clinical trials.
myocardial infarction, severe arrhythmic disorders. lon Severe renal or hepatic dysfunction; including that caused by metastases.
- Severe renal or hepatic dysfunction; including that caused by metastases.
Hypersensitivity to the active substance or to any of the excipients Severe hepatic impairment Severe renal impairment Sleep apnoea syndrome Myasthenia gravis Severe respiratory insufficiency Children (under 18 years of age)
Renal impairment: dosage adjustment is recommended for patients with renal impairment (see section 4.2).
respiratory failures, respiratory tract disorders, asthma acute respiratory distress syndrome
respiratory failure, bronchospasm, dyspnoea, nasal congestion
10 Renal or hepatic impairment The pharmacokinetics of deferasirox have not been studied in patients with renal or hepatic impairment.
21 Renal or hepatic impairment The pharmacokinetics of deferasirox have not been studied in patients with renal or hepatic impairment.
32 Renal or hepatic impairment The pharmacokinetics of deferasirox have not been studied in patients with renal or hepatic impairment.
Patients with hepatic impairment: no dose adjustment is needed in patients with solely hepatic impairment.
Patients with hepatic impairment No dosage adjustment is necessary for patients with hepatic impairment (see section 5.2).
8 Patients with hepatic impairment There is no pharmacokinetic data in patients with hepatic impairment.
Patients with hepatic impairment There is no pharmacokinetic data in patients with hepatic impairment.
Patients with chronic liver diseases (hepatocellular, cholestatic, and biliary cirrhosis) given 10 or 20 mg of cetirizine as a single dose had a 50% increase in half-life along with a 40% decrease in clearance compared to healthy subjects.
Patients with chronic liver diseases (hepatocellular, cholestatic, and biliary cirrhosis) given 10 or 20 mg of cetirizine as a single dose had a 50% increase in half-life along with a 40% decrease in clearance compared to healthy subjects.
Patients with hepatic impairment Total plasma concentration of pioglitazone is unchanged, but with an increased volume of distribution.
Patients with hepatic impairment Pioglitazone should not be used in patients with hepatic impairment (see section 4.4).
Patients with hepatic impairment Rosiglitazone should not be used in patients with hepatic impairment.
2 Hepatic/ renal impairment: the safety and efficacy of Vaniqa in women with hepatic or renal impairment have not been established.
13 Patients with renal impairment No dosage adjustment is necessary in patients with impaired renal function (creatinine clearance > 4 ml/ min) (see section 5.2).
24 Patients with renal impairment No dosage adjustment is necessary in patients with impaired renal function (creatinine clearance > 4 ml/ min) (see section 5.2).
No dose adjustment is required in patients with Child Pugh A and B (mild to moderate) hepatic impairment.
Patients with hepatic impairment No dosage adjustment of BYETTA is necessary in patients with hepatic impairment (see section 5.2).
2 Patients with hepatic impairment No dose adjustment is required (see section 5.2).
Patients with hepatic impairment No dose adjustment is required (see section 5.2).
Patients with hepatic impairment: no dosage adjustment is required for patients with mild to moderate hepatic impairment.
Patients with hepatic impairment No dosage adjustment is required (see section 5.2).
Hepatic and Renal impairment Use EMADINE has not been studied in these patients and therefore, its use is not recommended in this population.
Hepatic impairment: the pharmacokinetics of amprenavir are significantly altered in patients with moderate to severe hepatic impairment.
Hepatic impairment: the use of< Nimesulide containing medicinal products > is contraindicated in patients with hepatic impairment (see section 5.2).
Hepatic impairment A single dose pharmacokinetic study was performed in 24 subjects with various degrees of hepatic impairment and 12 healthy subjects as controls.
No dose adjustment is required in patients with mild, moderate or severe renal impairment.
Patients with renal impairment: no dosage adjustment is required in patients with renal impairment.
Renal impairment: patients with renal impairment have not been specifically studied.
CRF following both intravenous and subcutaneous administration. a
In four Phase I clinical trials, steady state exposure to sorafenib was similar in patients with mild or moderate renal impairment compared to the exposures in patients with normal renal function.
Renal and hepatic impairment ORENCIA has not been studied in these patient populations.
Renal and/ or hepatic impairment A lower starting dose (5 mg) should be considered for such patients.
A lower starting dose (5 mg) should be considered for such patients.
Renal and/ or hepatic impairment A lower starting dose (5 mg) should be considered for such patients.
Patients with renal or hepatic impairment Gemcitabine should be used with caution in patients with hepatic or renal insufficiency as there is insufficient information from clinical studies to allow for clear dose recommendations for these patient populations (see sections 4.4 and 5.2).
Hepatic impairment: the use of< Nimesulide containing medicinal products > is contraindicated in patients with hepatic impairment (see section 5.2).
Hepatic impairment: the use of< Nimesulide containing medicinal products > is contraindicated in patients with hepatic impairment (see section 5.2).
Insulatard contains the active substance insulin human (rDNA).
Insulatard FlexPen 100 IU/ ml suspension for injection in a pre-filled pen.
105 Insulatard should not be disposed of via wastewater or household waste.
95 Insulatard should not be disposed of via wastewater or household waste.
Insulatard should not be disposed of via wastewater or household waste.
Insulatard should not be disposed of via wastewater or household waste.
Insulin aspart∗...........................................
Insulin with a rapid onset and moderately long duration of action.
0.25 Change from Baseline in FEV1 (L)
INH N= 236, 231, 233, 233, 235, 235, 226, 217, 208, 236.
Insulin Human Winthrop Basal contains 40 IU insulin per ml.
Insulin Human Winthrop Basal pre -filled pen, OptiSet, is not designed to allow any other insulin to be mixed in the cartridge.
Insulin Human Winthrop Basal pre-filled pen, SoloStar, is not designed to allow any other insulin to be mixed in the cartridge.
565 Insulin Human Winthrop Basal suspension for injection in a pre-filled pen.
Insulin Human Winthrop Comb 15 100 IU/ ml suspension for injection in a vial
Insulin Human Winthrop Comb 15 100 IU/ ml suspension for injection in a pre-filled pen
Insulin Human Winthrop Comb 15 100 IU/ ml suspension for injection in a pre-filled pen.
Insulin Human Winthrop Comb 15 contains 100 IU insulin per ml.
Insulin Human Winthrop Comb 15 contains 40 IU of insulin per ml suspension.
Insulin Human Winthrop Comb 15 contains 40 IU insulin per ml.
Insulin Human Winthrop Comb 15 in cartridges has been developed for use in the OptiPen series.
Insulin Human Winthrop Comb 15 is an insulin preparation with a gradual onset and long duration of action.
Insulin Human Winthrop Comb 15 (a biphasic isophane insulin suspension with 15% dissolved insulin) is an insulin with gradual onset and long duration of action.
Insulin Human Winthrop Comb 15, pre-filled pen, OptiSet, is not designed to allow any other insulin to be mixed in the cartridge.
Insulin Human Winthrop Comb 15, pre-filled pen, SoloStar, is not designed to allow any other insulin to be mixed in the cartridge.
637 Insulin Human Winthrop Comb 15 suspension for injection in a pre-filled pen.
Insulin Human Winthrop Comb 25 100 IU/ ml suspension for injection in a pre-filled pen
Insulin Human Winthrop Comb 25 contains 100 IU insulin per ml.
Insulin Human Winthrop Comb 25 contains 40 IU insulin per ml.
Insulin Human Winthrop Comb 25 is an insulin preparation with a gradual onset and long duration of action.
Insulin Human Winthrop Comb 25 (a biphasic isophane insulin suspension with 25% dissolved insulin) is an insulin with gradual onset and long duration of action.
Insulin Human Winthrop Comb 25, pre -filled pen, OptiSet, is not designed to allow any other insulin to be mixed in the cartridge.
Insulin Human Winthrop Comb 25, pre-filled pen, SoloStar, is not designed to allow any other insulin to be mixed in the cartridge.
709 Insulin Human Winthrop Comb 25 suspension for injection in a pre-filled pen.
Insulin Human Winthrop Comb 50 100 IU/ ml suspension for injection in a vial
Insulin Human Winthrop Comb 50 100 IU/ ml suspension for injection in a pre-filled pen
Insulin Human Winthrop Comb 50 100 IU/ ml suspension for injection in a pre-filled pen.
Insulin Human Winthrop Comb 50 contains 100 IU insulin per ml.
Insulin Human Winthrop Comb 50 contains 40 IU of insulin per ml suspension.
Insulin Human Winthrop Comb 50 contains 40 IU insulin per ml.
Insulin Human Winthrop Comb 50 is an insulin preparation with a rapid onset and moderately long duration of action.
Insulin Human Winthrop Comb 50 (a biphasic isophane insulin suspension with 50% dissolved insulin) is an insulin with rapid onset and moderately long duration of action.
Insulin Human Winthrop Comb 50, pre-filled pen, SoloStar, is not designed to allow any other insulin to be mixed in the cartridge.
781 Insulin Human Winthrop Comb 50 suspension for injection in a pre-filled pen.
Insulin Human Winthrop Rapid contains 40 IU insulin per ml.
Do not use this OptiSet if the insulin is cloudy, coloured or has particles.
Insulin Human Winthrop Rapid, OptiSet, is not designed to allow any other insulin to be mixed in the cartridge.
Insulin Human Winthrop Rapid, SoloStar, is not designed to allow any other insulin to be mixed in the cartridge.
Insuman Basal 100 IU/ ml suspension for injection in a vial
Insuman Basal 100 IU/ ml suspension for injection in a pre-filled pen
Insuman Basal 100 IU/ ml suspension for injection in a pre-filled pen.
Insuman Basal 40 IU/ ml suspension for injection in a vial
Insuman Basal contains 40 IU of insulin per ml suspension.
Insuman Basal in cartridges has been developed for use in the OptiPen series.
Insuman Basal, pre -filled pen, OptiSet, is not designed to allow any other insulin to be mixed in the cartridge.
Insuman Basal, pre-filled pen, SoloStar, is not designed to allow any other insulin to be mixed in the cartridge.
Insuman Basal is an insulin preparation with a gradual onset and long duration of action.
Insuman Basal (an isophane insulin suspension) is an insulin with gradual onset and long duration of action.
Insuman Basal is an isophane insulin suspension.
Insuman Basal is an isophane insulin suspension.
560 Insuman Basal suspension for injection in a pre-filled pen.
Insuman Comb 15 100 IU/ ml suspension for injection in a vial
Insuman Comb 15 100 IU/ ml suspension for injection in a pre-filled pen
Insuman Comb 15 100 IU/ ml suspension for injection in a pre-filled pen.
Insuman Comb 15 40 IU/ ml suspension for injection in a vial
Insuman Comb 15 contains 100 IU insulin per ml.
Insuman Comb 15 contains 40 IU of insulin per ml suspension.
Insuman Comb 15 in cartridges has been developed for use in the OptiPen series.
Insuman Comb 15 is an insulin preparation with a gradual onset and long duration of action.
Insuman Comb 15 (a biphasic isophane insulin suspension with 15% dissolved insulin) is an insulin with gradual onset and long duration of action.
Insuman Comb 15, pre-filled pen, OptiSet, is not designed to allow any other insulin to be mixed in the cartridge.
Insuman Comb 15, pre-filled pen, SoloStar, is not designed to allow any other insulin to be mixed in the cartridge.
630 Insuman Comb 15 suspension for injection in a pre-filled pen.
Insuman Comb 25 100 IU/ ml suspension for injection in a pre-filled pen
Insuman Comb 25 100 IU/ ml suspension for injection in a pre-filled pen.
Insuman Comb 25 contains 100 IU insulin per ml.
Insuman Comb 25 contains 40 IU of insulin per ml suspension.
Insuman Comb 25 is an insulin preparation with a gradual onset and long duration of action.
Insuman Comb 25 is an insulin preparation with a gradual onset and long duration of action.
Insuman Comb 25 (a biphasic isophane insulin suspension with 25% dissolved insulin) is an insulin with gradual onset and long duration of action.
Insuman Comb 25, pre -filled pen, OptiSet, is not designed to allow any other insulin to be mixed in the cartridge.
700 Insuman Comb 25 suspension for injection in a pre-filled pen.
Insuman Comb 50 100 IU/ ml suspension for injection in a vial
Insuman Comb 50 100 IU/ ml suspension for injection in a pre-filled pen
Insuman Comb 50 100 IU/ ml suspension for injection in a pre-filled pen.
Insuman Comb 50 40 IU/ ml suspension for injection in a vial
Insuman Comb 50 contains 100 IU insulin per ml.
Insuman Comb 50 contains 40 IU of insulin per ml suspension.
Insuman Comb 50 in cartridges has been developed for use in the OptiPen series.
Insuman Comb 50 is an insulin preparation with a rapid onset and moderately long duration of action.
Insuman Comb 50 (a biphasic isophane insulin suspension with 50% dissolved insulin) is an insulin with rapid onset and moderately long duration of action.
Insuman Comb 50, pre-filled pen, OptiSet, is not designed to allow any other insulin to be mixed in the cartridge.
Insuman Comb 50, pre-filled pen, SoloStar, is not designed to allow any other insulin to be mixed in the cartridge.
771 Insuman Comb 50 suspension for injection in a pre-filled pen.
Insuman contains the active substance insulin human.
Insuman is used in patients with diabetes who need treatment with insulin.
Insuman Rapid in cartridges has been developed for use in the OptiPen series.
Do not use this OptiSet if the insulin is cloudy, coloured or has particles.
Insuman Rapid is an insulin preparation with a rapid onset and short duration of action.
Insuman Rapid must not be mixed with any other insulin or with insulin analogues.
Insuman Rapid pre-filled pen, OptiSet, is not designed to allow any other insulin to be mixed in the cartridge.
Insuman Rapid pre-filled pen, SoloStar, is not designed to allow any other insulin to be mixed in the cartridge.
Intanza is given as one ‘ intradermal'injection into the upper layer of the skin, using a special micro-injection system.
- INTANZA should under no circumstances be administered into a vein (intravascularly).
INTANZA is administered to you by your doctor or nurse.
INTELENCE and lopinavir/ ritonavir can be used without dose adjustments.
INTELENCE should be used during pregnancy only if the potential benefit justifies the potential risk.
Intelence is only used in patients who have been treated for their HIV infection before.
To increase the interaction and discussions with all stakeholders in order to implement changes in the Agency’s
Last Observation Carried Forward 1 Based on ANCOVA with treatment and country as factors and baseline value as a covariate.
Important information about some of the ingredients of Lansoprazol-ratiopharm This medicine contains sucrose.
emtricitabine, or tenofovir disoproxil fumarate.
Interaction not studied with efavirenz, emtricitabine, or tenofovir disoproxil fumarate.
Food interactions: • Food delays the absorption of anagrelide but does not significantly alter systemic exposure. • The effects of food on bioavailability are not considered clinically relevant to the use of anagrelide.
4.5 Interactions with other medicinal products and other forms of interaction
40 Interaction with other medicinal products and other forms of interaction No formal interaction studies have been performed.
47 Interaction with other medicinal products and other forms of interaction No formal interaction studies have been performed.
Interaction with Other Medicinal Products and Other Forms of Interaction
INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION
Interactions with medicinal products It is not recommended to combine etravirine with tipranavir/ ritonavir, due to a marked pharmacokinetic interaction (76% decrease of etravirine AUC) that could significantly impair the virologic response to etravirine.
Interactions with other medicinal products Co-administration of REYATAZ with simvastatin or lovastatin is not recommended (see section 4.5).
P-glycoprotein interactions MDR1/ Mdr1a/ 1b (P-gp) was found to be the major efflux system involved in intestinal absorption and biliary excretion of aliskiren in preclinical studies.
The possibility of interactions with other medicinal products administered concurrently with Trizivir should be considered, particularly when the main route of elimination is active renal secretion especially via the cationic transport system e. g. trimethoprim.
Due to the interaction between high dose benserazide and tolcapone (resulting in increased levels of benserazide), the prescriber should, until more experience has been gained, be observant of dose-related adverse events (see 4.5).
Interactions affecting other medicinal products:
Interactions common to the combination No drug interaction studies were performed with Copalia and other medicinal products.
Interactions common to the combination No drug interaction studies were performed with Exforge and other medicinal products.
Interactions common to the combination No drug interaction studies were performed with Imprida and other medicinal products.
In urine glucose tests, nicotinic acid may also give false-positive reactions with cupric sulfate solution (Benedict's reagent).
Interactions and dose recommendations with other medicinal products
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal products by therapeutic areas ANTI-INFECTIVES Antiretrovirals NRTIs
Interactions involving other psychoactive agents
Interactions Do not combine with other veterinary medicinal products.
Medicinal products nteractions Indinavir should be used cautiously with other medicinal products that are potent inducers of CYP3A4.
Co-administration with CYP3A4 inducers is expected to lead to lack of efficacy.
Pharmacodynamic interactions Anticoagulant therapy should be monitored, particularly during the first few days after initiating Dynastat therapy in patients receiving warfarin or other anticoagulants, since these patients have an increased risk of bleeding complications.
Potential for other medicinal products to affect ABILIFY:
Interactions potentially affecting the efficacy of other medicinal products (see also section 4.4):
Interactions potentially affecting the efficacy of sugammadex (see also section 4.4):
swelling interfering with, but not precluding normal physical activities; small blisters or ulcerations less than 2 cm in diameter)
Interference with serological testing After injection of immunoglobulin the transitory rise of the various passively transferred antibodies in the patient's blood may result in misleading positive results in serological testing.
Interference with serological testing After infusion of immunoglobulin the transitory rise of the various passively transferred antibodies in the patients blood may result in misleading positive results in serological testing.
((Inside 1)) MONITORING YOUR WHITE BLOOD
If Yes, write the names of these here:
solution containing 3,000 IU (10,000 IU/ ml), 0.4ml of the solution containing 4,000 IU (10,000 IU/ ml), 0.5 ml of the solution containing 5,000 IU (10,000 IU/ ml), 0.3 ml of the a
substance insulin human.
Units) of the active substance insulin human.
Unconfirmed complete response 3 Estimated with observed range.
A manual on quality management at the EMEA was produced to help staff in their work and internal auditing procedures were put in place towards the end of 1998 to ensure that the progress made is continued in future.
Discontinue breast-feeding before starting to take Rebetol.
If no improvement or continued worsening of the neuropathy, discontinue treatment.
Interrupt RoActemra dosing until < 3 x ULN
95% Confidence Interval b
BSA range (m2) 0.08 – 0.25 0.25 – 0.42 0.42 – 0.58 0.58 – 0.75 0.75 – 0.92 0.92 – 1.08 1.08 – 1.25 1.25+
QT interval In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] 500 milliseconds [msec] at any time post baseline in patients with baseline QTcF < 500 msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo.
Surgery/ Anaesthesia In patients undergoing major surgery or during anaesthesia with agents that produce hypotension ,< COVERSYL and associated names > may block angiotensin II formation secondary to compensatory renin release.
Each IONSYS system is designed to deliver one on-demand dose of fentanyl over approximately 10 minutes.
Intervet Baltic States Vasario 16-osios 9-6A LT-Kauna 3000 Lithuania Tel: +370 373 216 60 Fax: +370 372 012 93
Intervet International BV, site De Bilt Ambachtstraat 4 3732 CN De Bilt The Netherlands
Intervet International Podruznica Krizna 10 SI-1000 Ljubljana Slovenija Tel: +386 (15) 417 567 Fax: +386 (15) 233 567
Vascular disorders General disorders and administration site conditions
History of hepatotoxic reactions to nimesulide Active gastric or duodenal ulcer, a history of recurrent ulceration or gastrointestinal bleeding, cerebrovascular bleeding or other active bleeding or bleeding disorders.
The forum will concentrate on the following priority action areas: • Implementation of Community pharmaceutical legislation and policy (‘ acquis communautaire’) • Good manufacturing practices • Pharmacovigilance
Alcohol intolerance (facial flushing or skin irritation after consumption of an lp
Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorbtion Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine.
Doctor's Phone: _____________________ uc
• Intra-operative photodynamic diagnosis of residual glioma
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
1.3 Review of the European marketing authorisation
procedures 4.2 Implementation of the clinical trials directive
Introduction and priority tasks for the EMEA..................................................
3/ 20 Introduce the atraumatic canula in the ear canal.
Introduce the atraumatic canula in the ear canal.
The needle of the syringe containing the 4 ml of water for injections should be inserted through the rubber top of the azacitidine vial followed by injection of the water for injections into the vial.
Insert the syringe firmly into the adapter.
Insert the syringe firmly into the adapter 4.
Insert the pipette into the bottle.
Insert the needle into the skin fold with a quick, firm action.
IntronA is used for the treatment of: • chronic (long-term) hepatitis B (a disease of the liver due to an infection by the hepatitis B virus) in adults, • chronic hepatitis C (a disease of the liver due to an infection by the hepatitis C virus).
IntronA 25 million IU/2.5 ml solution for injection or infusion Interferon alfa-2b
IntronA 25 million IU/2.5 ml solution for injection or infusion interferon alfa-2b
IntronA 3 million IU/0.5 ml solution for injection or infusion Interferon alfa-2b
IntronA 5 million IU/0.5 ml solution for injection or infusion Interferon alfa-2b
Please make sure to select an appropriate dosage form and strength.
IntronA, 60 million IU/pen, solution for injection:
As maintenance therapy in patients who have achieved objective remission (more than 50% reduction in myeloma protein) following initial induction chemotherapy.
IntronA is administered subcutaneously at a dose of 3 million IU three times a week (every other day) to adult patients, whether administered as monotherapy or in combination with
IntronA is administered subcutaneously at a dose of 3 million IU three times a week (every other day) to adult patients, whether administered as monotherapy or in combination with ribavirin.
IntronA is presented as a powder and solvent for solution for injection or infusion.
IntronA is presented as a powder and solvent for solution for injection or infusion.
IntronA is presented as a solution for injection or infusion.
Intussusception The risk of intussusception has been evaluated in a placebo-controlled study in infants.
INVANZ 1 g Powder for concentrate for solution for infusion Ertapenem
INVANZ 1 g Powder for concentrate for solution for infusion Ertapenem Intravenous use.
INVANZ is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery.
INVANZ is used when the bacteria (germs) that cause these infections are likely to be killed by the antibiotic.
INVANZ may be used for the treatment of infections in adult patients with renal insufficiency.
INVEGA contains a racemic mixture of (+)- and (-)-paliperidone.
Take special care with INVEGA -INVEGA has not been studied in elderly patients with dementia.
INVEGA should not be used while breast feeding.
Since INVEGA can lower blood pressure, care should be taken when INVEGA is taken with other medicines that lower blood pressure.
In the opposite way about two weeks should pass before patients treated with mirtazapine should be treated with MAO inhibitors (see section 4.3).
Invirase should only be given in combination with ritonavir (see section 4.2).
Invirase is always used in combination with ritonavir (another antiviral medicine) and other antiviral medicines.
Invirase may have a minor influence on the ability to drive and use machines.
Invirase may have a minor influence on the ability to drive and use machines.
In vitro, this metabolite shows minimal inhibition of acetylcholinesterase (< 10%).
In vitro, dasatinib is active in leukaemic cell lines representing variants of imatinib-sensitive and resistant disease.
Capecitabine was not mutagenic in vitro to bacteria (Ames test) or mammalian cells (Chinese hamster V79/ HPRT gene mutation assay).
In vitro the affinity binding of recombinant hLH to the LH/ CG receptor on Leydig tumour cells (MA-10) is between that for hCG and that of pituitary hLH, but within the same order of magnitude.
Their main modes of action are as chain terminators of viral reverse transcription.
Its main mode of action is as a chain terminator of viral reverse transcription.
Posaconazole is 40– 100 times more potent in vitro against Malassezia pachydermatis than clotrimazole, miconazole and nystatin.
In vitro, topotecan did not inhibit human P450 enzymes CYP1A2, CYP2A6, CYP2C8/ 9, CYP2C19, CYP2D6, CYP2E, CYP3A, or CYP4A nor did it inhibit the human cytosolic enzymes dihydropyrimidine or xanthine oxidase.
Exenatide has been shown to bind to and activate the known human GLP-1 receptor in vitro, its mechanism of action mediated by cyclic AMP and/ or other intracellular signaling pathways.
As for macrolides, H. influenzae is classified as intermediately susceptible.
In vitro, topotecan did not inhibit human P450 enzymes CYP1A2, CYP2A6, CYP2C8/ 9, CYP2C19, CYP2D6, CYP2E, CYP3A, or CYP4A nor did it inhibit the human cytosolic enzymes dihydropyrimidine or xanthine oxidase.
The toxicity of the free Yttrium (90Y) due to in-vivo release from the labelled biomolecule in the body during therapy could be reduced by post-administration of chelating agents
IONSYS 40 micrograms per dose iontophoretic transdermal system fentanyl
IONSYS 40 micrograms per dose iontophoretic transdermal system.
IONSYS delivers a nominal dose of 40 micrograms fentanyl over each 10-minute dosing period.
IONSYS should be applied to intact, non-irritated and non-irradiated skin on the chest or upper outer arm.
IONSYS should be used with caution in patients with paralytic ileus.
IONSYS is given to the patient after an operation.
IONSYS is an iontophoretic transdermal system (ITS).
Ipsen Pharma Biotech SAS Parc d'Activités du Plateau de Signes Chemin Départemental no 402 83870 Signes France
Safety studies for veterinary drug residues in human food:
Ireland Bayer Limited, Animal Health Division The Atrium Blackthorn Road IRL - Dublin 18
Ireland BRI STOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel: + 353 (1 800) 749 749
Ireland C & M Veterinary Distributors Limited IE-Limerick Tel:
(49-30) 45 48 33 32
31 Ireland Ferring Ireland Ltd United Drug House Magna Drive Magna Business Park Citywest Road IRL-Dublin 24 Tel: + 353-14637355
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited, Tel: +353 (0)1 2998771 medinfo_ireland@merck. com
Ireland Wyeth Pharmaceuticals Tel: +353 1 449 3500 Fax: +353 1 679 3773
I IntronA (3 MIU 3 times a week) I/R IntronA (3 MIU 3 times a week) + ribavirin (1,000/1,200 mg/day)
The response to treatment in both of these trials is presented in Table 4.
above address or from Direct telephone (44-20) 74 18 85 E-mail: subscriptions@emea. eu. int
Chest pain, asthenia, oedema, injection site pain
Conjunctival irritation Eyelid oedema Ear and labyrinth disorders:
Irritation, itching and reddening of the skin at the application site.
Eye irritation, eye pain, orbital oedema, scleral haemorrhage, retinal haemorrhage, blepharitis, macular oedema
I Viraferon (3 MIU 3 times a week) lon I/ R Viraferon (3 MIU 3 times a week) + ribavirin (1,000/ 1,200 mg/ day)
cerebral ischaemia, cerebrovascular accident, syncope,
myocardial ischaemia and infarction* congestive heart failure*
Iscover should be given as a single daily dose of 75 mg (one tablet) with or without food.
Iscover is used in adult patients to prevent atherothrombotic events (problems caused by blood clots and hardening of arteries).
Iscover is not intended for use in children or adolescents.
Iscover are pink tablets.
France 92 rue Baudin F-92300 Levallois-Perret
cough, nasopharyngeal pain
d Joint Space Narrowing
ed This alert card contains important safety information that you need to be aware of before you are given Trudexa and during treatment with
Because immunogenicity analyses are product-specific, comparison of antibody rates with those from no
You may have a very rare serious allergic reaction to Monotard or one of its ingredients (called a systemic allergic reaction).
You are advised to avoid becoming pregnant and must use adequate contraception while using Trudexa and for at least 5 months after the last Trudexa treatment.
In studies of interferon use in non-human primates, abnormalities of the menstrual cycle have been observed (see section 4.4). t uc
During treatment for hepatitis B or C the recommended testing schedule is at weeks 1, 2, 4, 8, 12, 16, and every other month, thereafter, throughout treatment.
E-2 8750 San Agustín de Guadalix – Madrid Tel: + 34-91 848 85 00 rod
E-28750 San Agustín de Guadalix – Madrid Tel: + 34-91 848 85 00 rod
Nacional I E-28750 San Agustín de Guadalix – Madrid Tel: + 34-91 848 85 00 rod lp i na dic Me
Due to its inhibition of TNFα, adalimumab administered during pregnancy could affect normal immune responses in the newborn.
with 1 injection syringe, 2 injection needles and 1 cleansing swab.
necrotising fasciitis, viral meningitis, diverticulitis
necrotising fasciitis, viral meningitis, diverticulitis
I Viraferon (3 MIU 3 times a week) I/ R Viraferon (3 MIU 3 times a week) + ribavirin (1,000/ 1,200 mg/ day) no
I Viraferon (3 MIU 3 times a week) lon I/ R Viraferon (3 MIU 3 times a week) + ribavirin (1,000/ 1,200 mg/ day)
ed This leaflet was last approved in {MM/ YYYY}
Telithromycin inhibits protein synthesis by acting at the ribosome level. t uc
Pharmaco-therapeutic group (ATC Code):
Isentress has been given ‘ Conditional Approval’.
ISENTRESS is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing anti-retroviral therapy.
Isentress is only used in patients who are already being treated for their HIV infection, if tests show that the virus is multiplying in the blood despite treatment.
Using Viraferon with food and drink While being treated with Viraferon, your doctor may want you to drink extra fluids to help prevent low blood pressure.
Using Viraferon with food and drink While being treat ed with Viraferon, your doctor may want you to drink extra fluids to help prevent low blood pressure.
Using Viraferon with food and drink While being treated with Viraferon, your doctor may want you to drink extra fluids to help prevent low blood pressure.
Urine levels of interferon were below the detection limit following each of the three routes of administration.
Urine levels of interferon were below the detection limit following each of the three routes of administration. lp
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
ed Preparation Collect nece ssary items before you begin:
Clinical trials, in general, support similar efficacy of telithromycin and comparators in the indications investigated (CAP not clinically serious enough to warrant parenteral therapy but efficacy has been demonstrated in a limited number of patients with risk factors such as pneumococcal bacteraemia or
If you are given glucagon you will need glucose or a sugary snack as soon as you are conscious.
Stevens Johnson syndrome, toxic epidermal necrolysis, erythema multiforme
ed Preparation Collect necessary items before you begin:
species (animal, human or analogue insulin) and/ or method of manufacture (recombinant DNA versus animal source insulin) may result in a change in dosage.
If an anaphylactic reaction or other serious allergic reaction occurs, administration of Trudexa should be discontinued immediately and appropriate therapy initiated.
1 Injection set = injection syringe + 2 injection needles + cleansing swab.
5/ 6 1 Injection set = injection syringe + 2 injection needles + cleansing swab.
cough, nasopharyngeal pain
15 ed ris tho r au ANNEX IIge lon A.
Pulmonary infiltrates§, pneumonitis§
If ALT flares during Viraferon therapy to greater than or equal to 2 times baseline, Viraferon therapy may be continued unless signs and symptoms of liver failure are observed.
ris Ultratard 100 IU/ ml Suspension for injection in a vial Suspension for injection in a vial.
ris Ultratard 40 IU/ ml Suspension for injection in a vial Suspension for injection in a vial.
ed Dosage adjustment may be necessary when transferring patients from one insulin preparation to another (see section 4.4 Special warnings and special precautions for use).
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
Box 509/ Gårdsvägen 8 S-169 29 Solna/ S-169 70 Solna Tel: + 46 (0) 8 5465 67 00
Ísland Actelion Pharmaceuticals Sverige AB Sími: +46-(0)8 544 982 50
83 Ísland Lundbeck Export A/ S, útibú á Íslandi Ármúla 1 IS-108 Reykjavík Tel: +354 414 7070
Ísland Lundbeck Export A/S, útibú á Íslandi Ármúla 1 IS-108 Reykjavík Tel: +354 414 7070
Ísland Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 D-60318 Frankfurt Þýskaland
19 Ísland Orphan Europe Nordic AB Banérgatan 37 S-11522 Stockholm Svíþjóð Tel: + 46 8 545 80 230
Additional office space of 1 460 m2 on the seventh floor of 7 Westferry Circus was occupied in 2000 to complement the existing three floors.
Virus wild-type CMV isolates ganciclovir-resistant CMV isolates foscarnet-resistant CMV isolates
Istituto Lusofarmaco Via Walter Tobagi 8 20068 Peschiera Borromeo (MI) Italy
Italia Luigi FRATI (6) Romano MARABELLI (Vice-Chairman)
Italia Luigi FRATI Romano MARABELLI
United Kingdom/ Ireland Genzyme Therapeutics (United Kingdom) Tel: +44 1865 405200
Italia Merck Sharp & Dohme (Italia) S. p. A., Tel: +39 06 361911 doccen@merck. com
Italia Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 D-60318 Frankfurt Germania Tel: +49 (0)69 1503 – 1
19/20 Italia Pfizer Italia S.r.l., Telefono: +39 06 3318 2933
Italia Pfizer Italia S.r.l., Telefono: +39 06 3318 2933
Itraconazole/ Efavirenz (200 mg q12h/ 600 mg once daily)
Antifungals Itraconazole/ Efavirenz (200 mg q12h/ 600 mg once daily)
*ITT = intention to treat. **Patients alive and in remission at the time of last follow up were censored at that time point for the analysis.
IVAX Pharmaceuticals UK (Runcorn, Cheshire), Aston Lane North Preston Brook Runcorn, Cheshire, United Kingdom
IVEMEND is incompatible with any solutions containing divalent cations (e. g., Ca2+, Mg2+), including Hartman's and Lactated Ringer's Solutions.
IVEMEND is used along with other medicines to prevent nausea and vomiting caused by chemotherapy treatment (e. g., cancer therapy).
Treatment and prevention of tick infestation (Ixodes ricinus, Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor reticulatus, Dermacentor variabilis, Amblyomma americanum) in dogs.
• J01DHXX • Parenteral treatment of moderate to severe infections caused by
J01 Treatment of community-acquired pneumonia, acute exacerbation
Jean-Michel ALEXANDRE 7 Gianmartino BENZI Mary TEELING 8
Tre atment of CMV renititis in patient with AIDS
Members of the Management Board
Nederland Dr Hans van BRONSWIJK Mr Willem van der GIESEN
Jalra should not be used during lactation.
Al. jana Pawla II 29 PL-00- 867 Warszawa Tel.: + 48 (0) 22 653 68 00
Jana Paw ł a II 29 PL-00- 867 Warszawa Tel.: + 48 (0) 22 653 68 00
Jansen-Cilag Oy Metsänneidonkuja 8 02130 Espoo
Janssen-Cilag AB Box 7073 192 07 Sollentuna Sverige
Janssen-Cilag AB, Box 7073 192 07 Sollentuna, Sverige
Janssen-Cilag AB Box 7073 192 07 Sollentuna Sweden
Janssen-Cilag AB Box 7073 192 07 Sollentuna Sweden
Janssen-Cilag AB, Box 7073 192 07 Sollentuna, Sverige
Janssen-Cilag AB, Box 7073 192 07 Sollentuna, Sverige
Janssen-Cilag AB c/ oVistor hf. Hörgatúni 2 Garðabær, Iceland
Janssen-Cilag Ltd Saunderton High Wycombe Buckinghamshire HP14 4HJ United Kingdom
Janssen-Cilag A/ S, Postboks 149, Hammerbakken 19, 3460 Birkerød, Denmark
Janssen-Cilag A/ S Postboks 149 Hammerbakken 19 3460 Birkerød
Janssen-Cilag GmbH 41457 Neuss
Janssen-Cilag GmbH 41457 Neuss or
Janssen-Cilag GmbH 41457 Neuss or Janssen-Cilag GmbH Raiffeisenstr.
Janssen-Cilag Pharmaceuticals
Janssen-Cilag Pharma GmbH Pfarrgasse 75, 1232 Wien, Austria
Janssen-Cilag Pharma GmbH Pfarrgasse 75 A-1232 Wien Austria
Janssen-Cilag Pharma GmbH Pfarrgasse 75 A-1232 Wien Austria
JANSSEN CILAG, SA Paseo de las 12 estrellas, 5-7 Madrid, Spain
Janssen Cilag, SA Paseo de las Doce Estrellas 5-7 28042 Madrid
Janssen Cilag, SA Paseo de las DoceEstrellas, 5-7 28042 Madrid, Spain
Januvia helps to improve the levels of insulin after a meal and decreases the amount of sugar made by the body.
Januvia has not been studied in patients with severe hepatic insufficiency.
13 - 14 - 15 10 - 11 - 12 10 - 11 - 12 7-8-9 5-6-7 9 - 10 - 11 7-8-9 8 - 9 - 10 13 - 14 - 15 10 - 11 - 12 8 - 9 - 10
January 14 - 15 - 16 February 11 - 12 - 13 March 11 - 12 - 13 April 8 - 9 - 10 May 6-7 June 10 - 11 - 12 July 15 - 16 - 17 September 9 - 10 - 11 October 14 - 15 - 16 November 11 - 12 - 13 December 9 - 10 - 11
The number of applications for authorisation of orphan medicines however rose as a proportion of total applications.
Jean-Hughes TROUVIN
Herbal Medicinal Products Working Party Konstantin KELLER
Jean-Hugues TROUVIN Barbara VAN ZWIETEN-BOOT Fernando GARCIA ALONSO Jean-Louis ROBERT Beatriz SILVA LIMA Markku TOIVONEN Manfred HAASE Konstantin KELLER
Jean-Michel ALEXANDRE Mary TEELING (January-September 2000) Hans van BRONSWIJK (September-December 2000)
Kjell STRANDBERG Generaldirektör Läkemedelsverket Husargatan 8, Box 26 S-751 03 Uppsala Tel:
I take this opportunity to thank them all for their hard work.
Many thanks also to the Agency and its staff for the great support of the work of the CVMP and myself.
130 10115 Berlin Germany.
I take this opportunity to thank both the staff who have worked so hard since the beginning of the Agency and newer staff who have adapted quickly during such a fast moving year.
I take this opportunity to thank all past and current staff members.
The important challenges of the future, against which the EMEA is determined to deliver, include enlargement of the Community, implementation of the 2001 Review, increasing clinical trials, pharmacovigilance and inspection functions, responsibility for Community pharmaceutical information management systems, extending the process of transparency to every aspect of its function, improving its ability to enforce regulation, and fulfilling its international role.
Discard the solvent vial, syringe, and needle as directed by your healthcare provider.
DISCARD IF RECONSTITUTED VACCINE IS NOT USED WITHIN 30 MINUTES.
DISCARD RECONSTITUTED VACCINE IF IT IS NOT USED WITHIN 30 MINUTES.
Any product where such defects are observed should be discarded.
62 ● Throw away the syringe into a dedicated waste container with a lid.
● Discard the syringe into a dedicated waste container with a lid.
Throw away the bottle 28 days after first opening it, but don't dispose of medicine in your waste water or your household waste.
• Throw away needles in a puncture-resistant container or as recommended by your healthcare professional.
● Discard used syringes into your dedicated container with a lid for the safe disposal of waste materials.
Discard the pre-filled pen and inject the full dose using a new pre-filled pen.
Throw away all used syringes directly into the dedicated waste container with a lid.
Jevany Bohumil 138 CZ-281 63 Kostelec nad Cernymi lesy Czech Republic
JO5AB06 Treatment of CMV renititis in patient with AIDS
João I – Piso 0 Ala A P-2770-203 Paço d’Arcos Tel: +351 21 00 45 900
Dr Jones is qualified in medicine and has held posts in clinical medicine and research at UK teaching hospitals.
All food-producing species All food-producing species All food-producing species
ongoing glimepiride + metformin therapy (N=115) Initial therapy (twice daily):
Capecitabine oral bid for 2 weeks (followed by 1 week off treatment)
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery (see section 5.1). ct
June 2002 July 2002 Ongoing Ongoing Ongoing Ongoing Ongoing Ongoing Ongoing Ongoing Ongoing
- Grapefruit juice (single dose) (unboosted saquinavir)
swirling until the contents are completely dissolved.
Repeat until the liquid appears uniformly white and cloudy.
Until June 2005, veralipride was authorised in Spain.
Just after starting to breathe in through their mouth, patients should press down on the top of the inhaler to release Seretide, while still breathing in steadily and deeply.
Just after starting to breathe in through their mouth, patients should press down on the top of the inhaler to release Viani, while still breathing in steadily and deeply.
The activity of 99mTc-depreotide administered to the patient should be measured using a suitably calibrated dose calibrator immediately prior to administration to the patient.
Just before withdrawing DepoCyte, gently invert the vial to mix the particles evenly.
Directly before the solution will be administered, invert the vial with the syringe still attached, so that the syringe is below the vial.
Just before use, roll the long-acting (cloudy) insulin between your hands until the liquid is uniformly white and cloudy.
DENMARK Jytte LYNGVIG Direktør Lægemiddelstyrelsen Frederikssundvej 378 DK - 2700 Brønshøj
K103N was the most frequently observed RT substitution in viral isolates from patients who experienced rebound in viral load during clinical studies of efavirenz.
KALETRA 133.3 mg/ 33.3 mg soft capsules lopinavir/ ritonavir
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Kaletra does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or CYP1A2 at clinically relevant concentrations (see section 4.3).
Kaletra contains polyoxyl 40 hydrogenated castor oil.
Kampenringweg 45 D-E (toren D en E) NL-2803 PE Gouda The Netherlands
Kapás utca 11-15., Buda Business Center H-1027 Budapest
Karadžičova 10 SK- 821 08 Bratislava 2 Tel: + 421 (0) 2 4445 4176
Karadžičova 10 SK-821 08 Bratislava 2 Tel: + 421 (0) 2 4445 4176
Karadž ič ova 10 SK 821 08 Bratislava 2 Tel: + 421 (0) 2 4445 4176
Karel de Neef Stephen Fairchild Beatrice Fayl post vacant post vacant
Karvea at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg.
Karvea is taken by mouth, with or without food.
Karvea should not be given to children and adolescents (under 18 years).
Karvea should not be given to children and adolescents (under 18 years).
Karvea does not usually interact with other medicines.
Kentera has been studied in a total of 881 patients, mostly elderly women, with overactive bladders in two main studies.
Kepivance contains the active substance palifermin which is a protein produced by biotechnology in a bacteria called Escherichia coli.
Kepivance is a sterile but unpreserved product and is intended for single use only.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Keppra 100 mg/ ml concentrate for solution for infusion Levetiracetam
Keppra 100 mg/ ml oral solution and Keppra 250 mg tablets are presentations more appropriate to young children.
Keppra 100 mg/ ml oral solution and Keppra 250 mg tablets are presentations more appropriate to young children.
keratitis, ectropion, diplopia, entropion, visual disturbance, blurred vision swelling of eyelid angle closure glaucoma, corneal ulceration
keratitis, keratopathy, increased optic nerve cup/disc ratio, corneal epithelium defect, corneal epithelium disorder, increased intraocular pressure, eye deposit, corneal staining, corneal oedema, conjunctivitis, meibomianitis, diplopia, glare, photophobia, photopsia, reduced visual acuity, pterygium, ocular discomfort, keratoconjunctivitis sicca, hypoaesthesia of the eye, scleral pigmentation, subconjunctival cyst, increased lacrimation, visual disturbance, eye swelling, eye allergy, madarosis, eyelid disorder, eyelid oedema
KGaA Eckenheimer Landstraße 100 60318 Frankfurt/ Main Germany Phone: +49-69/ 15 03-1 Fax: +49-69/ 15 03-200
KG Birkendorfer Strasse 65 D-88397 Biberach an der Riss Deutschland
KG Emil-von-Behring-Strasse 76 D-35041 Marburg
KG Emil-von-Behring-Strasse 76 D-35041 Marburg Germany
KG Emil-von-Behring-Strasse 76 D-35041 Marburg GERMANY
KG, Industriestrasse 32-36, 23843 Bad Oldesloe, Germany
Daily feed intake (kg) x Premix strength (mg/g)
KG Max-Planck-Ring 2 na
KG Tel: +49 (0) 69 50 50 83 09 Eesti Boehringer Ingelheim Pharma GmbH Tel: + 37 2 60 80 940 Ελλάδα ΦΑΡΜΑΣΕΡΒ -ΛΙΛΛΥ Α .Ε .Β .Ε.
KG Tel.: + 49 (0)89 36044 8701 produkt. info@gsk. com Eesti GlaxoSmithKline Eesti OU Tel: + 372 6676 900 estonia@gsk. com
KG Tel: + 49 (0)89 360448701 produkt.info@gsk.com
KG Tel.: + 49 (0)89 36044 8701 produkt.info@gsk.com
KG Tel.: + 49 (0)89 36044 8701 produkt. info@gsk. com
weight, or • 2.25 micrograms (once weekly) of Nespo per kilogram of your body weight. lp
Kineret 100 mg solution for injection in a vial Anakinra
Kineret 100 mg solution for injection in a vial Anakinra
Kineret 100 mg solution for injection in a pre-filled syringe Anakinra
Kineret 100 mg solution for injection in a pre-filled syringe.
Kineret is for use in adults only (age 18 years and over).
Kineret is a sterile unpreserved solution.
Kineret should not be used in patients who have severe problems with their kidneys.
Kineret is used to treat the signs and symptoms of rheumatoid arthritis in combination with another medicine called methotrexate.
It may contain some translucent- to-white particles of protein.
It may contain some translucent-to-white particles of protein.
KIOVIG 100 mg/ml solution for infusion Human Normal Immunoglobulin Intravenous use.
Kivexa should be prescribed by a doctor who has experience in the management of HIV infection.
Patients with severe hepatic impairment.
Kivexa is contraindicated in patients with severe hepatic impairment (see section 4.3).
Kivexa is a fixed-dose combination of two nucleoside analogues (abacavir and lamivudine).
Kivexa is a fixed-dose tablet and should not be prescribed for patients requiring dosage adjustments.
Kivexa, or any other medicinal product containing abacavir (Ziagen or Trizivir), MUST NEVER be restarted in patients who have stopped therapy due to a hypersensitivity reaction.
Kivexa can be taken with or without food.
Kivexa, Trizivir).
Kjell STRANDBERG Dr Per SJOBERG United Kingdom
Km 36 Carret Nacional 1 ES-28750 San Agustin de Guadalix Madrid, Spain
Marketing Authorisation Holder
KOGENATE Bayer 1000 IU is provided as a powder and solvent for solution for injection and is a dry white to slightly yellow powder or cake.
KOGENATE Bayer 2000 IU is provided as a powder and solvent for solution for injection and is a dry white to slightly yellow powder or cake.
KOGENATE Bayer 2000 IU must not be mixed with other infusion solutions.
KOGENATE Bayer 2000 IU Powder and solvent for solution for injection.
KOGENATE Bayer 2000 IU Powder for solution for injection
KOGENATE Bayer 250 IU is provided as a powder and solvent for solution for injection and is a dry white to slightly yellow powder or cake.
KOGENATE Bayer 250 IU must not be mixed with other infusion solutions.
KOGENATE Bayer 250 IU Powder and solvent for solution for injection.
KOGENATE Bayer 500 IU is provided as a powder and solvent for solution for injection and is a dry white to slightly yellow powder or cake.
KOGENATE Bayer has no influence on the ability to drive or to use machines.
KOGENATE Bayer has no influence on the ability to drive or to use machines.
KOGENATE Bayer is a powder and solvent that are mixed together to make a solution for injection.
Kohne Pharma Gmbh Schallbruch 1 D-42781 Haan Germany
After a period of general veterinary practice, Dr Kothmann joined the German Federal Research Centre for Animal Virus Diseases in 1970 and the veterinary administrative service for Lower Saxony in 1972.
in 1970 and the veterinary administrative service for Lower Saxony in 1972.
Krka, Tovarna Zdravil, D. D., Š marješ ka Cesta 6 Si-8501 Novo Mesto
Krka, Tovarna Zdravil, D. D., Š marješ ka Cesta 6 Si-8501 Novo Mesto Slovenia
4 PL – 02-954 Warszawa Tel.: + 48 22 842 71 00 ferring@ferringpl. com. pl
Kruczkowskiego 8 PL-00-380 Warszawa Tel.: + 48 22 4883 777
Clinical efficacy (with partial or complete response, see below under Clinical Experience) has been demonstrated for Aspergillus spp. including A. flavus, A. fumigatus, A. terreus, A. niger, A. nidulans, Candida spp., including C. albicans, C. glabrata, C. krusei, C. parapsilosis and C. tropicalis and limited numbers of C. dubliniensis, C. inconspicua, and C. guilliermondii, Scedosporium spp., including S. apiospermum, S. prolificans and Fusarium spp.
KURTH Paul-Ehrlich Institut Paul-Erlich Straße 51-59 D-63225 Langen Tel: +49.6103.770 Fax: +49.6103.770.123
Kuvan is intended for use in children with HPA due to PKU who are at least four years old.
KVP Pharma + Veterinär Produkte GmbH Projensdorfer Str.
24 Erlotinib is an epidermal growth factor receptor/human epidermal growth factor receptor type 1 (EGFR also known as HER1) tyrosine kinase inhibitor.
· Jean-Michel ALEXANDRE (France), Chairman
L03AA Adjunct to surgery for sarcoma of the limbs
• L03AB11 • Treatment of chronic hepatitis C in adults
J05AE05 Treatment of HIV infected adults and children
L04AA14 Treatment of the signs and symptoms of rheumatoid
L10, K20, L24, M46, I54, L63, I64, A71, V82, I84, and L90.
The mean absolute oral bioavailability is 41% (range 25-63%).
New clinical vertebral fracture over 3 years
The mean absolute oral bioavailability is 41% (range 25-63%).
The mean absolute oral bioavailability is 41% (range 25-63%).
Version 3.0 was introduced in October 1998 permitting a fully computer-based system superseding the previous fax-based procedure and enhancing operational transparency.
Abacavir maintains its antiretroviral activities against lamivudine- resistant HIV-1 harbouring only the M184V mutation.
Abacavir maintains its antiretroviral activities against lamivudine- resistant HIV-1 harbouring only the M184V mutation.
Abacavir is contraindicated in patients with severe hepatic impairment (see section 4.3 and 4.4).
Abacavir has no effect on the metabolism of ethanol.
Abacavir or lamivudine in Kivexa may interact with certain other medicines.
Abacavir has a weak potential to cause chromosomal damage both in vitro and in vivo at high tested concentrations.
The active substance abacavir in this medicine is likely to be found in human breast milk.
The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Diameter: about 8 mm The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
The Agency's personnel database will be further developed in 2002.
Abatacept has been designed to bind to two of these molecules (CD80 and CD86), preventing them from activating the T-cells.
Abatacept is produced by recombinant DNA technology in Chinese hamster ovary cells.
Abatacept is a fusion protein produced by recombinant DNA technology in Chinese hamster ovary cells.
Becaplermin acts like the natural growth factor, it stimulates cell growth and helps the growth of normal tissue for healing.
Becaplermin is produced by insertion of the gene for the B chain of human platelet derived growth factor into the yeast, Saccharomyces cerevisiae.
Becaplermin is a recombinant human Platelet Derived Growth Factor-BB (rhPDGF-BB).
Abetimus is a small piece of double-stranded DNA that has been designed to reduce circulating levels of these antibodies.
Abetimus, the active substance in Riquent, is a selective immunosuppressive agent (a compound that selectively dampens down the immune system).
BH4 is required by the body to use an amino acid called phenylalanine in order to build another amino acid called tyrosine.
Serum total bilirubin, gamma-glutamyl transferase, alkaline phosphatase, ALT and AST should be closely monitored during treatment if elevated values are observed.
affect lability, aggression, confusional state, euphoric mood, hallucination, mania, paranoia, suicide attempt, suicide ideation
Absolute bioavailability averaged 4% (CV 73%, range:
A study in normal healthy volunteers provided an estimate of the absolute bioavailability of 59%.
The absolute bioavailability after transdermal application is approximately 37%.
The absolute bioavailability of the film-coated tablets is around 40%, due to first-pass effect in the gut and liver.
The absolute bioavailability of dabigatran following oral administration of Pradaxa was approximately 6.5%.
The absolute bioavailability of dabigatran following oral administration of Pradaxa was approximately 6.5%.
Absolute bioavailability of a 500 mg metformin tablet is approximately 50-60% in healthy subjects.
The absolute bioavailability of saquinavir co-administered with ritonavir has not been established in humans.
The absolute bioavailability amounts to approximately 91%.
Absolute bioavailability or bioavailability for humans after oral administration is not known.
The bioavailability after per-oral dosing is about 76%.
The extent of absorption of cetirizine is not reduced with food, although the rate of absorption is decreased.
The bioavailability of desloratadine was dose proportional over the range of 5 mg to 20 mg.
Digoxin bioavailability may be slightly decreased by Riprazo.
Digoxin bioavailability may be slightly decreased by Sprimeo.
The bioavailability of loratadine and of the active metabolite is proportional to the administered dose.
The bioavailability parameters of loratadine and of the active metabolite are dose proportional.
The bioavailability of tulathromycin after intramuscular administration in pigs was approximately 88%.
The bioavailability of tulathromycin after subcutaneous administration in cattle was approximately 90%.
The bioavailability of the 2800 IU vitamin D3 in ADROVANCE is similar to 2800 IU vitamin D3 administered alone.
The bioavailability of the 5600 IU vitamin D3 in ADROVANCE is similar to 5600 IU vitamin D3 administered alone.
The bioavailability of deferasirox was increased to a variable extent when taken along with food.
Lansoprazole exhibits high (80-90%) bioavailability with a single dose.
The bioavailability of ropinirole varies greatly between individuals.
The bioavailability of rufinamide is dependent on dose.
The mean absolute oral bioavailability is 41% (range 25-63%).
124 administration has not been determined
138 administration has not been determined
Consistent with the limited oral bioavailability of tigecycline, there is little or no systemic exposure to tigecycline in the nursing pups as a result of exposure via maternal milk.
The systemic bioavailability of losartan tablets is approximately 33%.
The systemic bioavailability of robenacoxib tablets was 49% without food.
The systemic availability of sirolimus in combination with simultaneously administered ciclosporin (Sandimune) is approximately 14%.
The systemic availability and half-life in dialysis-dependent diabetic patients was comparable with healthy subjects.
Bivalirudin remains active and is not neutralised by products of the platelet release reaction.
Bleomycin belongs to the cytostatic antibiotics: it is a mixture of structurally related, alkaline, water soluble, glycopeptide antibiotics with a cytostatic effect.
The pack also contains a 30 ml polypropylene measuring cup with 1.0 ml graduations.
The box also contains 1 plastic measuring cup (52 ml), 1 plastic bottle adapter (to help get the drug into the dispenser) and 1 plastic oral dispenser (to give the correct amount of medicine via the mouth).
A filter with Luer lock connections for syringe and cannula is provided.
Three measuring spoons are enclosed in the carton to assist you in measuring out the dose prescribed by your doctor.
Your pack of Avonex already includes a needle for injection.
Vimpat treatment initiation pack contains 4 different packages (one for each tablet strength) with 14
The package must be sent to a qualified laboratory for analysis.
GlaxoSmithKline α .ε .β .ε, ADARTREL Κηφισίας 266, 152 32 Χαλάνδρι, Αθήνα, Ελλάδα
Laboratoire GlaxoSmithKline, 100 Route de Versailles, 78163 Marly-le-Roi Cedex,
António Loureiro Borges, n. º 3, Arquiparque - Miraflores, 1495-131 Algés
GlaxoSmithKline Oy, Piispansilta 9 A, 02230 Espoo, Suomi
Laboratoire GlaxoSmithKline, 100
Route de Versailles, 78163 Marly-le-Roi Cedex, France
Laboratoire Pharmy II 26 rue des Gaudines 78100 Saint-Germain-Laye France
Laboratorio Medinfar - Produtos Farmacêuticos, Lda Rua Manuel Ribeiro de Pavia, 1 - 1 Venda Nova 2700 Amadora
LABORATÓRIO MEDINFAR, Produtos Farmacêuticos, SA Rua Manuel Ribeiro de Pavia, 1-1° Venda Nova 2700-547 Amadora Portugal
Laboratorios faes Farma Sa maximo Aguirre, 14 48940 Lamiaco-Lejona Spain
Laboratorios Faes Farma Sa Maximo Aguirre, 14 48940 Lamiaco-Lejona Spain
Maximo Aguirre, 14 48940 Lamiaco-Lejona Spain Spain
Laboratorios Intervet SA Poligono El Montalvo Apartado 3006 Salamanca 37080 Spain
Laboratorios Intervet SA Poligono El Montalvo Apartado 3006 Salamanca 37080 Spain
Laboratórios Vitória Rua Elias Garcia, 28 Venda Nova 2700 Amadora
When reconstituted, Abraxane contains approximately 425 mg sodium per dose.
Key elements to be included in the educational brochure
Lack of effect on growth rate is also a benefit of montelukast.
The absorption of atazanavir may be reduced in situations where gastric pH is increased irrespective of cause.
The absorption of sparfloxacin is rapid with peak serum concentrations achieved 3 to 5 hours after the first dose.
It is likely that certain medicines or food additives may prevent the vitamin D in ADROVANCE from getting into your body, including artificial fat substitutes, mineral oils, orlistat and the cholesterol- lowering medicines, cholestyramine and colestipol.
Absorption of fentanyl from IONSYS is similar whether applied to the upper outer arm or chest.
Tylvalosin tartrate is rapidly absorbed after oral administration of Aivlosin.
Absorption and distribution of 13CO2 is faster than the urease reaction.
Oral absorption by the child is however unlikely.
Oral absorption by the child is however unlikely. no
Oral absorption by the child is however unlikely.
The rate and extent of absorption is unaffected by food intake, and thus Ketek tablets can be given without regard to food.
As buprenorphine is an opioid, pain as a symptom of a disease may be attenuated.
Buprenorphine is metabolised by 14-N-dealkylation and glucuroconjugation of the parent molecule and the dealkylated metabolite.
Buprenorphine and its metabolites are excreted in human breast milk.
Conventional long-term toxicity, reproduction, mutagenicity, and carcinogenicity studies have been performed in laboratory animals.
Salmon calcitonin is devoid of embryotoxic, teratogenic and mutagenic potential.
ed Forcaltonin has been compared with synthetic salmon calcitonin.
Salmon calcitonin may be administered at bedtime to reduce the incidence of nausea or vomiting lp
Salmon calcitonin may be administered at bedtime to reduce the incidence of nausea or vomiting which may occur, especially at the initiation of therapy.
Salmon calcitonin is a hormone which increases the amount of calcium and phosphate laid down in the bones and lowers the level of calcium circulating in the blood. ina
Calcitonin is also contra-indicated in patients with hypocalcaemia.
Calcitonin is also contraindicated in patients with hypocalcaemia.
• Prevention of acute bone loss due to sudden immobilisation such as in patients with recent osteoporotic fractures
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Human calcitonin is not directly mutagenic in bacterial or eukaryotic systems in vitro or in mammalian tests in vivo.
Injectable calcitonin may cause transient dizzines (see 4.8.
Injectable calcitonin may cause transient dizziness (see 4.8.
Intranasal calcitonin may cause transient dizziness (see section 4.8.
Calcitonin should be used during pregnancy only if treatment is considered absolutely essential by the physician.
In common with other inhalational anaesthetics, the MAC of sevoflurane is reduced by the concurrent administration of benzodiazepines and opioids.
Invasive candidiasis is a life-threatening disease..
The advisability of driving should be considered in these circumstances.
Placental transfer of mecasermin was not studied.
This leads to an increased capacity of the bladder, to changes in the way the bladder contracts, and to less bladder contractions.
The ability to induce protection against homologous and heterologous vaccine strains was assessed non-clinically using ferret challenge models.
Individual responsiveness must be considered when treatment is initiated.
Capecitabine is a ‘ prodrug 'that is converted to 5-fluorouracil (5-FU) in the body, but more is converted in tumour cells than in normal tissues.
Capsule contents: alcohol, butylated hydroxytoluene (E321), oleic acid, polyoxyl 35 castor oil.
- Carbamazepine and phenytoin, CYP3A4 inducers, increased mirtazapine clearance about
- When cimetidine (weak inhibitor of CYP1A2, CYP2D6 and CYP3A4) is administered with
Carbamazepine may make STOCRIN less likely to work.
Carbamazepine may make SUSTIVA less likely to work.
Both carbidopa and entacapone block some of the enzymes that are involved in the breakdown of levodopa in the body: carbidopa blocks the enzyme dopa decarboxylase, and entacapone blocks the enzyme catechol-O-methyl transferase (COMT).
Pregnancy and outcome Pulmonary oedema (associated with veno-occlusive disease) Suspected interactions Unexpected ADRs according to the SPC.
Patients who take Enbrel must be given the special alert card that summarises important safety information about the medicine.
The canister contains a white to off white suspension.
The insulin cartridge of the pump must be sterile and must be used once only.
The glass cartridge is irreversibly integrated in a transparent container and assembled to a plastic mechanism with a threaded rod at one extremity.
The metal can contains a pressurised liquid.
The container should not be punctured, broken or burnt even when apparently empty.
A cartridge that is in the pen should not be removed during injections.
Caspofungin has in vitro activity against Aspergillus species (Aspergillus fumigatus [N = 75], Aspergillus flavus [N = 111], Aspergillus niger [N = 31], Aspergillus nidulans [N = 8], Aspergillus terreus [N = 52], and Aspergillus candidus [N = 3]).
Caspofungin also has in vitro activity against Candida species (Candida albicans [N = 1032], Candida dubliniensis [N = 100], Candida glabrata [N = 151], Candida guilliermondii [N = 67], Candida kefyr [N = 62], Candida krusei [N = 147], Candida lipolytica [N = 20], Candida lusitaniae [N = 80], Candida parapsilosis [N = 215], Candida rugosa [N = 1], and Candida tropicalis [N = 258]), including isolates with multiple resistance transport mutations and those with acquired or intrinsic resistance to fluconazole, amphotericin B, and 5-flucytosine.
Cataplexy is a symptom of narcolepsy involving sudden muscle weakness in response to an emotional reaction such as anger, fear, joy, laughter or surprise.
Cataplexy is the onset of sudden muscle weakness or paralysis without losing consciousness, in response to a sudden emotional reaction such as anger, fear, joy, laughter or surprise.
The class “ disordered proliferative” used in study KLIM/ PD/ 7/ USA is not well defined and not usually recognized.
The cause and long-term health effects of these conditions are not known at this time.
The cause and long-term health effects of these conditions are not known at this time.
The exact cause of MS is unknown.
World Health Organization http: / /www. who. int European Commission Directorate-General for Research http: / /europa. eu. int/ comm
The catalogue is available on the on the Agency's web site and allows the public to search documents produced by the EMEA.
European Economic Area, central and eastern European countries and other European countries.
Approximate accumulation ranged from 1.4- to 8-fold following multiple as compared to single dose administration.
Ceftriaxon may adversely affect the efficacy of hormonal contraceptives Consequently, it is advisable to use supplementary non-hormonal contraceptive measures.
Ceftriaxone may precipitate in the gallbladder and kidneys and then be detectable as shadows on ultrasound (see section 4.8).
Cerivastatin effectively and dose-dependently (0.1-0.8mg/ day) reduces total cholesterol, LDL- cholesterol, triglycerides and increases HDL-cholesterol.
Lacer SA Sardenya 346 - 350 E - 08025 Barcelona Spain
Workload is expected to increase by 35% in 2000 for non-EU ADR reports (unexpected) and by another 25% in 2001, as
The workload of the Quality Review of Documents Working Group (QRD) will increase gradually, reflecting the trend in applications received.
Workload relating to variations (2000, 21%; 2001, 15%) and non-EU ADR reports (2000, 35%; 2001, 25%) will also increase.
treatment of chronic heptatitis C in naïve patients.
The chemotherapy should be given after the MabThera infusion.
The chemotherapy should be given after MabThera infusion.
Chorionic gonadotropin binds on the ovarian theca (and granulosa) cells to a transmembrane receptor shared with the luteinising hormone, the LH/ CG receptor.
19 consequently, sirolimus levels will decrease when ciclosporin is discontinued unless the sirolimus dose is increased.
35 consequently, sirolimus levels will decrease when ciclosporin is discontinued unless the sirolimus dose is increased.
Ciclosporin inhibits the metabolism of sirolimus, and consequently, sirolimus levels will decrease when ciclosporin is discontinued unless the sirolimus dose is increased.
- ciclosporin (used to prevent the body rejecting a transplanted organ or for other conditions, such
Benzoic acid is a mild irritant to the skin, eyes and mucous membrane.
Benzoic acid is a mild irritant to the skin, eyes and mucous membranes.
Carglumic acid has been shown in vitro to activate liver carbamoyl phosphate synthetase.
Gastric acid is central in the pathogenesis of gastroduodenal ulcers and acid inhibition has been shown to effectively heal NSAID-associated ulcers.
Gastric acid is central in the pathogenesis of gastroduodenal ulcers and acid inhibition has been shown to effectively heal NSAID induced ulcers.
Ibandronic acid was taken 60 minutes before the first food or drink of the day (post-dose fasting period).
Ibandronic acid selectively inhibits osteoclast activity, reducing bone resorption and thereby reducing skeletal complications of the malignant disease.
Nicotinic acid lowers the levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), very low density lipoprotein cholesterol (VLDL-C), apolipoprotein B (apo B, the major LDL protein), triglycerides (TG), and lipoprotein(a) (Lp(a), a modified LDL particle) and elevates the levels of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I (apo A-I, the major protein component of HDL).
Nicotinic acid also elevates the HDL2 subfraction to a greater extent than the HDL3 subfraction, thereby increasing the HDL2: HDL3 ratio, which is associated with decreased cardiovascular disease risk.
Zoledronic acid is eliminated by renal excretion.
Zoledronic acid is not systemically metabolised and does not affect human cytochrome P450 enzymes in vitro (see section 5.2).
Cimetidine and ranitidine increase the bioavailability of risperidone, but only marginally that of the active antipsychotic fraction.
Cimetidine and VIRAMUNE can be co-administered without dose adjustments.
20 Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by inhibition of the cationic secretory transport system of the renal tubules.
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by inhibition of the cationic secretory transport system of the renal tubules.
- cimetidine (to treat excess stomach acid and stomach ulcers);
- cimetidine (to treat excess stomach acid and stomach ulcers)
- cimetidine (used to treat gastrointestinal diseases)
Ciprofloxacin should be used with caution in patients with CNS disorders which may be predisposed to seizure.
22 Achilles tendon) has been reported, especially in elderly patients who were previously treated systemically with glucocorticoids.
191 Ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature animals.
Ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature animals.
Ciprofloxacin may cause an exacerbation of Myastenia gravis symptoms.
The blood circulation in the limb is then replaced by the ‘ perfusion 'of a special liquid and the limb is warmed to a temperature of between 38 and 39°C.
6 Cladribine induces a severe and prolonged reduction of CD4+ and CD8+ T-lymphocytes.
Cladribine is teratogenic in mice (at doses of 1.5 – 3.0 mg/ kg/ day, given on gestation days 6 – 15).
Mean steady state clearance is 24 ml/ kg/ day (range 5-76 ml/ kg/ day) at 1 mg/ kg/ week subcutaneous.
The CLcr (ml/ min) may be estimated from serum creatinine (mg/ dl) determination using the following formula:
is 0.56) and the volume of distribution (Vss) is approximately equal to plasma volume (50 ml/ kg).
is (SD 0.56) and the volume of distribution (Vss) is approximately equal to plasma volume (50 ml/ kg).
A half-life time of 7.7 hours has been observed.
The clearance of paclitaxel with Abraxane was larger (43%) than that following a solvent-based paclitaxel injection and its volume of distribution was also higher (53%).
The clearance of sirolimus may be reduced in patients with impaired hepatic function (see section 5.2).
Clearance also decreased in a corresponding manner to the AUC.
Estimated darifenacin clearance is 40 litres/ hour.
The estimated anakinra clearance increased with increasing creatinine clearance and body weight.
Both clearance and absolute bioavailability decrease with increasing dose.
The non-renal clearance is decreased as the dose is increased.
The mean intrinsic clearance was 0.016 l/ h/ m2 (range 0.008 - 0.027 l/ h/ m2), the mean central volume of distribution was 1.46 l/ m2 (range 1.10 - 1.64 l/ m2).
The mean intrinsic clearance was 0.021 l/ h/ m2 (range 0.009 – 0.041 l/ h/ m2), the mean central volume of distribution was 1.95 l/ m2 (range 1.67 – 2.40 l/ m2).
The metabolic clearance is much lower in patients with end-stage renal failure than in healthy subjects.
Therefore, the metabolic clearance is much lower in patients with end-stage renal failure than in healthy subjects.
2.5 l/hr/m2 (range 1-4 l/hr/m2).
Mean clearance in premature infants (gestational age approximately 26 weeks) is approximately 5-fold greater than in adults.
The concentration-dependent non-linear clearance plays a major role at low tocilizumab concentrations.
The renal clearance of sitagliptin was not meaningfully altered.
Renal clearance of zidovudine is estimated to be 0.34 l/ h/ kg, indicating glomerular filtration and active tubular secretion by the kidneys.
Renal clearance of ritonavir is also negligible; therefore the impact of renal impairment on amprenavir and ritonavir elimination should be minimal.
Renal clearance of unchanged zonisamide is relatively low (approximately 3.5 ml/ min); about 15 - 30% of the dose is eliminated unchanged.
Renal clearance is approximately 13% of total clearance.
Renal clearance is independent of dose and ranges between 360-471 ml/ min suggesting that entecavir undergoes both glomerular filtration and net tubular secretion.
Renal clearance accounts for approximately 23% of total clearance of maraviroc when maraviroc is administered without CYP3A4 inhibitors.
Renal clearance accounts for about 70% of lamivudine elimination.
The renal clearance occurs through glomerular filtration and active tubular secretion.
Clearance was 20.6 l/ h/ m2 (range 11 - 38) and the volume of distribution was 291 l/ m2 (range 121 - 638).
The total clearance of tocilizumab was concentration-dependent and is the sum of the linear and non-linear clearance.
Total clearance is around 2 l/ h, and less than 5% of the dose is excreted in the urine.
The Child-Pugh classification divides patients into groups A, B, and C, or "Mild", "Moderate" and "Severe" corresponding to scores of 5-6, 7-9 and 10-15, respectively.
The CLcr in ml/ min may be estimated from serum creatinine (mg/ dl) determination using the following formula:
The key to securing high quality performance lies in proper accountability.
If (Invented name)® treatment is started or stopped when you are taking warfarin, your doctor will need to perform certain tests. • You should not start to take the herbal remedy St John's wort while you are being treated with (Invented name)® since this may result in an increase of undesirable effects.
Cmax showed an increase over time.
The Cmax of sulfamethoxazole in pigs is approximately 6.2 µg/ g.
The mean Cmax (± standard deviation) was 185±55 microgram per ml.
At the Cmax, the plasma concentration represented only 1-2% of the applied dose.
Co-administration with systemic immunosuppressants should be done with caution because plasma concentrations of cyclosporine, sirolimus or tacrolimus may be affected when co-administered with INTELENCE.
Co-administration with REYATAZ/ ritonavir may cause a large increase in the concentration of these benzodiazepines.
Co-administration with a high-fat meal did not affect the AUC of atazanavir relative to fasting conditions and the Cmax was within 11% of fasting values.
Co-administration of amprenavir/ ritonavir and Atripla is not recommended.
Concomitant use of angiotensin II antagonists or diuretics and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function.
Co-administration of darifenacin 7.5 mg with the potent CYP3A4 inhibitor ketoconazole 400 mg resulted in a 5-fold increase in steady-state darifenacin AUC.
Co-administration of CELSENTRI with medicinal products that induce CYP3A4 may decrease maraviroc concentrations and reduce its therapeutic effects.
Co-administration of CELSENTRI with medicinal products that inhibit CYP3A4 may increase maraviroc plasma concentrations.
27 Co-administration of efavirenz with the fixed combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate, is not recommended.
3 Co-administration of efavirenz with the fixed combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate, is not recommended.
51 Co-administration of efavirenz with the fixed combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate, is not recommended.
Co-administration of efavirenz with the fixed combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate is not recommended.
Co-administration of efavirenz with the fixed combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate is not recommended.
Co-administration of efavirenz with the fixed combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate, is not recommended.
- Co-administration of the potent CYP3A4 inhibitor ketoconazole increased the peak plasma
Co-administration of lamivudine with intravenous ganciclovir or foscarnet is not recommended.
Co-administration of lamivudine with intravenous ganciclovir or foscarnet is not recommended.
Co-administration of lopinavir/ ritonavir and Atripla is not recommended.
Co-administration of lopinavir/ ritonavir with efavirenz resulted in a substantial decrease in lopinavir exposure, necessitating dosage adjustment of lopinavir/ ritonavir.
Co- administered of the mentioned medicines with nifedipine can be expected to lead to a substantial increase in bioavailability of nifedipine, due to a decreased first pass metabolism and decreased
Co- administered of the mentioned medicines with nifedipine can be expected to lead to a substantial increase in bioavailability of nifedipine, due to a decreased first pass metabolism and decreased elimination.
Co-administration with REYATAZ/ ritonavir has the potential to produce a decrease or, less often, an increase in INR (International Normalised Ratio).
Co-administration of proton pump inhibitors or other antiulcer medicinal products may increase plasma levels of raltegravir.
Blood clotting can be a problem when blood flow is disturbed in any way.
The regulatory and scientific consistency of scientific committees (CHMP and CVMP) opinions and assessment reports, and their quality, will be further improved.
The cohort comprised 68 374 patients with first-time recorded hyperlipidaemia.
Urine colouration may last up to 35 days after administration of Cyanokit.
European Parliament and Council of Ministers in 2001 reviewing the operation of the European marketing authorisation system.
The European Commission granted a marketing authorisation valid throughout the European Union, for Actraphane to Novo Nordisk A/ S on 7 October 2002.
The European Commission granted a marketing authorisation valid throughout the European Union for DEXDOMITOR on 30 August 2002.
The European Commission granted a marketing authorisation valid throughout the European Union, for Equilis Prequenza to Intervet International BV on 8 July 2005.
The European Commission granted a marketing authorisation valid throughout the European Union, for Equilis Prequenza Te to Intervet International BV on 8 July 2005.
The European Commission granted a marketing authorisation valid throughout the European Union for Nobivac Bb to Intervet International B. V. on 10 September 2002.
The European Commission granted a marketing authorisation valid throughout the European Union for Nobivac Piro to Intervet International B. V. on 2 September 2004.
The European Commission granted a marketing authorisation valid throughout the European Union for Porcilis AR-T DF to Intervet International B. V. on 16 November 2000.
The marketing authorisation holder is Roche Registration Limited.
The European Commission granted a marketing authorisation valid throughout the European Union for SOMAVERT to Pfizer Limited on 13 November 2002.
The European Commission granted a marketing authorisation valid throughout the European Union for Sprycel to Bristol-Myers Squibb Pharma EEIG on 20 November 2006.
The European Commission granted a marketing authorisation valid throughout the European Union for Wilzin to Orphan Europe SARL, on 13 October 2004.
The European Commission granted a marketing authorisation valid throughout the European Union for Yttriga to QSA Global GmbH on 19 January 2006.
The European Commission granted a marketing authorisation valid throughout the EU for Mycophenolate mofetil Teva to Teva Pharma B. V. on 21 February 2008.
The European Commission granted a marketing authorisation valid throughout the European Union to Orphan Europe SARL on 29 July 2004.
The European Commission granted a marketing authorisation valid throughout the European Union for Baraclude to BRISTOL-MYERS SQUIBB PHARMA EEIG on 26 June 2006.
The European Commission granted a marketing authorisation valid throughout the European Union for CHAMPIX to Pfizer Limited on 26th September 2006.
The European Commission granted a marketing authorisation valid throughout the European Union for CIALIS to Lilly ICOS Limited on 12 November 2002.
The European Commission granted a marketing authorisation valid throughout the EU for Clopidogrel BMS to Bristol Myers Squibb Pharma EEIG on 16 July 2008.
The European Commission granted a marketing authorisation valid throughout the European Union for CYSTAGON to Orphan Europe on 23 June 1997.
The European Commission granted a marketing authorisation, valid throughout the European Union for Halocur to Intervet International B. V. on 29 October 1999.
The European Commission granted a marketing authorisation valid throughout the European Union for Ibaflin to Intervet International B. V. on 13 June 2000.
The European Commission granted a marketing authorisation valid throughout the European Union for INVANZ to Merck Sharp & Dohme Limited on 18 April 2002.
The marketing authorisation holder is Bayer Healthcare AG.
The European Commission granted a marketing authorisation valid throughout the European Union for MabThera to Roche Registration Limited on 2 June 1998.
The European Commission granted a marketing authorisation valid throughout the European Union for MicardisPlus to Boehringer Ingelheim International GmbH on 19 April 2002.
The European Commission granted a marketing authorisation valid throughout the EU for Opgenra to Howmedica International S. de R.
The European Commission granted a marketing authorisation valid throughout the European Union for Protaphane to Novo Nordisk A/ S on 7 October 2002.
The European Commission granted a marketing authorisation valid throughout the European Union, for Pruban to Intervet International B. V. on 16 November 2000.
The European Commission granted a marketing authorisation valid throughout the European Union, for Quadrisol to Intervet International B. V. on 16 July 1997.
The European Commission granted a marketing authorisation valid throughout the European Union for Tamiflu to Roche Registration Limited on 20 June 2002.
The European Commission granted a marketing authorisation valid throughout the European Union for Zavesca on 20 November 2002.
The European Commission granted a marketing authorisation valid throughout the European Union for Zerit to BRISTOL-MYERS SQUIBB PHARMA EEIG on 8 May 1996.
system • Development and implementation of the electronic common technical document (eCTD) in the context of work done by the M2 Experts Working Group of the International Conference on Harmonisation The IT sector has played an active role at all levels in co- ordination and management of Eudra IT projects in the pharmaceutical sector, with regular participation and attendance at Telematics Management Committee and the Telematic Implementation Groups for all four major areas within this domain identified above.
The European Commission adopts its decision with the assistance of a standing committee composed of representatives of the Member States.
The European Commission will bring forward a proposal in 1997 for a new Council Fee Regulation.
The European Commission will shortly publish the post in the Official Journal of the European Communities .”
Comparison to exposure in historical controls suggests that CELSENTRI 300 mg twice daily and nevirapine can be co-administered without dose adjustment.
Comparison of survival curves from time of diagnosis versus the untreated historical cohort was made using a Cox proportional hazards regression analysis.
A comparison of XELOX plus bevacizumab versus FOLFOX-4 plus bevacizumab was a pre-specified exploratory analysis.
Compatibility with the following infusion sets has been verified:
Compatibility with ear cleaners has not been demonstrated.
Compatibility with a number of infusion sets has been verified.
The following have been shown to be compatible when added to Cubicin containing infusion solutions: aztreonam, ceftazidime, ceftriaxone, gentamicin, fluconazole, levofloxacin, dopamine, heparin and lidocaine.
The accounts are kept in accordance with the requirements of the Financial Regulation (as last amended on 5 February 1997, EMEA/MB/011/97).
In common with other inhalational anaesthetics, the minimum alveolar concentration (MAC) of sevoflurane is reduced by the concurrent administration of benzodiazepines and opioids.
Adalimumab concentrations in the synovial fluid from several rheumatoid arthritis patients ranged from 31-96% of those in serum.
- abnormal levels of a clotting factor (prothromibin) increased levels of the enzyme amylase
The level of cGMP is regulated by the rate of synthesis via guanylate cyclase and by the rate of degradation via cGMP hydrolysing phosphodiesterases (PDEs).
The concentration of the fully diluted ORENCIA solution in the infusion bag or bottle
Fluoride ion concentrations are influenced by the duration of anaesthesia and the concentration of sevoflurane.
The nitrogen dioxide (NO2) concentration and FiO2 must also be measured at the same site using calibrated and approved (CE-marked) monitoring equipment.
IGF-I was normal at the end of the study (week 12) in 38.5%, 75% and 82% of patients treated with 10, 15 or 20 mg/ day SOMAVERT, respectively, compared with 9.7% of the patients treated with placebo.
The concentration of PPIX is significantly lower in white matter than in cortex and tumour.
Intracellular concentration of cladribine exceeds plasma drug concentration by 128 to 375 times.
Maximum desloratadine concentration was about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours.
Antibodies to OP-1 and bovine bone collagen type 1 were found after both exposures; the antibody peak concentration was higher after the second implantation.
The mean concentration of toremifene at steady- state is 0.9 (range 0.6 - 1.3) µg/ ml at the recommended dose of 60 mg per day.
The target plasma mitotane concentration (14 mg/ l) was reached in all patients within 3 to 5 months and the total mitotane dose ranged between 283 and 387 g (median value:
3mg/l after repeated 75 mg oral doses) occurred approximately 1 hour after dosing.
The maximum measured plasma concentration of retapamulin was 10.7 ng/ ml in adults and 18.5 ng/ ml in paediatric patients.
The highest pimecrolimus blood concentration was 1.4 ng/ml in one patient.
The lowest tacrolimus blood concentration at which systemic
The design of the system allows separate disposal of the red fentanyl-containing bottom housing and the white electronic/ battery containing top housing.
The results of the two tests were compared to see if they were in agreement.
The clinical significance of these increases is unknown, and higher doses of PREMARIN were not studied in combination with etoricoxib.
Consumption of alcohol and medicinal products containing alcohol should be avoided.
Consumption of alcohol and medicinal products containing alcohol should be avoided.
Eating salty foods or drinking fluids before or after taking Norvir oral solution may help clear the aftertaste from your mouth.
Eating salty food or drinking fluids before or after taking Norvir oral solution can help clear the aftertaste from your mouth.
Eating food has no effect upon Emselex.
202 300 units (3 millilitres).
Each Liprolog KwikPen contains 300 units (3 millilitres).
Each Humalog KwikPen contains 300 units (3 millilitres).
Each Humalog Pen contains 300 units (3 millilitres).
Each Liprolog Pen contains 300 units (3 millilitres).
Contraception should be continued for at least 1 month after stopping treatment with isotretinoin, even in patients with amenorrhea.
- Contraception, pregnancy testing and visits should follow specific recommendation as described
Conversion of fibrinogen into fibrin occurs by the splitting of fibrinogen into fibrin monomers and fibrinopeptides.
Cooperation with the World Health Organisation continued and in particular the EMEA participated in an international training course on the registration of medicines held in Tunisia in September 1998.
The Agency will also offer substantial support to small and medium- sized enterprises (SMEs) through its new SME Office, and will work with academia, learned societies and industry on issues relating to new technologies.
Correction for anaemia may lead to increased appetite, and potassium and protein intake.
The adhesive/ drug layer contains oxybutynin and triacetin.
The backing layer of Neupro contains aluminium.
The colour of your iris may also go darker over time.
The injection button colour will vary based on the formulation of Insulin Human Winthrop insulin used.
The injection button colour will vary based on the formulation of Insulin Human Winthrop insulin used.
The injection button colour will vary based on the formulation of Insuman insulin used.
The injection button colour will vary based on the formulation of Insuman insulin used.
Weight is the most significant covariate affecting efalizumab clearance.
COX is a key enzyme in pathways of arachidonic acid metabolism.
Patients should have their serum creatinine level measured before receiving Aclasta.
⋅ creating the necessary templates for opinions, follow-up measures, obligations, variations, extensions, renewals
• Skeletal growth is accomplished at the epiphyseal plates at the ends of a growing bone.
Adequate follicular development is usually achieved on average by the tenth day of treatment (range 5 to 20 days).
Retinal haemorrhages§, retinopathies (including macular oedema), retinal artery or vein obstruction§, optic neuritis, papilloedema, loss of visual acuity or visual field, cotton- wool spots§
Further catalytic activation of 5'-DFUR then occurs by thymidine phosphorylase (ThyPase).
Excessive coagulation activation in the microcirculatory bed plays a significant part in the pathophysiology of severe sepsis.
99 The histamine H1-antagonistic activity of mirtazapine is associated with its sedative properties.
Antimuscarinic activity resides predominantly in the R-isomer.
19 The anti-tumour activity of topotecan involves the inhibition of topoisomerase-I, an enzyme intimately involved in DNA replication as it relieves the torsional strain introduced ahead of the moving replication fork.
31 The anti-tumour activity of topotecan involves the inhibition of topoisomerase-I, an enzyme intimately involved in DNA replication as it relieves the torsional strain introduced ahead of the moving replication fork.
7 The anti-tumour activity of topotecan involves the inhibition of topoisomerase-I, an enzyme intimately involved in DNA replication as it relieves the torsional strain introduced ahead of the moving replication fork.
The anti-tumour activity of topotecan involves the inhibition of topoisomerase-I, an enzyme intimately involved in DNA replication as it relieves the torsional strain introduced ahead of the moving replication fork.
The antiviral activity of maraviroc against HIV-2 has not been evaluated.
Dihydropyrimidine dehydrogenase (DPD) activity is the rate limiting step.
Valnemulin has little activity against Enterobacteriaceae, such as Salmonella spp. and Escherichia coli.
Osteoclastic activity is inhibited, but formation and binding of the osteoclasts is not affected.
21 The activity should be measured by a dose calibrator immediately before administration.
The activity should be measured by a dose calibrator immediately before administration.
Clopidogrel acts by irreversibly modifying the platelet ADP receptor.
The activity of GLP-1 and GIP is limited by the DPP-4 enzyme, which rapidly hydrolyzes the incretin hormones to produce inactive products.
the immune system (immunosuppressant) and to reduce inflammation.
Viral neuraminidase enzyme activity is important both for viral entry into uninfected cells and for the release of recently formed virus particles from infected cells, and for the further spread of infectious virus in the body.
Factor IX activity is absent or greatly reduced in patients with haemophilia B and substitution therapy may be required.
Factor VIII activity is greatly reduced in patients with haemophilia A, and, therefore, replacement therapy is necessary.
Reduced or absent α -L-iduronidase activity results in the accumulation of the GAGs, dermatan sulfate and heparan sulfate in many cell types and tissues.
Lactose Monohydrate 99.6 mgFor a full list of excipients, see section 6.1.
The graduated measuring spoon must be used for measuring the required prescribed amount of Ciprofloxacin oral suspension 100 mg/ mL.
The graduated measuring spoon must be used for measuring the required prescribed amount of Ciprofloxacin oral suspension 50 mg/ mL.
Patients had up to one prior PDT and baseline visual acuity in the study eye between 20/ 40 and 20/ 320.
For the 2.5 micrograms dose the medication chamber (350 microliter) with the red latch is used together with the red control disc.
For the 2.5 micrograms dose the medication chamber (350 microliter) with the red latch is used together with the red control disc.
32 For the 5 micrograms dose the medication chamber (650 microliter) with the purple coloured latch is used together with the purple control disc.
For the 5 micrograms dose the medication chamber (650 microliter) with the purple coloured latch is used together with the purple control disc.
For the 5 micrograms dose the medication chamber (650 microliter) with the purple coloured latch is used together with the purple control disc.
Cyanocobalamin is a stable, non-toxic compound that is excreted in the urine.
Cyclo-oxygenase-2 is an enzyme that increases at inflammatory sites and in abnormally growing cells.
Cyclooxygenase is responsible for generation of prostaglandins.
21 Cyclooxygenase is responsible for generation of prostaglandins.
Cyclooxygenase is responsible for generation of prostaglandins.
Cyclo-oxygenase produces prostaglandins, some of them being implicated in the development and maintenance of inflammation.
Cyclosporin A (an inhibitor of ABCB1, ABCC1 [MRP-1], and CYP3A4) administered with oral topotecan increased topotecan AUC to approximately 2 - 2.5-fold of control.
Cysteamine reacts with cystine to form the mixed disulfide of cysteamine and cysteine, and cysteine.
Cysteamine reduces cystine accumulation in some cells (e. g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.
Adalimumab has been designed to bind to a chemical messenger in the body called tumour necrosis factor (TNF).
Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 1-2 X 10-10 M).
This needs only to be done the first time that the bottle is opened.
Individual dose titration with the components (i. e. amlodipine and valsartan) is recommended before changing to the fixed dose combination.
Careful dose titration is recommended in debilitated or malnourished patients.
Gradual dose titration may help diminish these effects (see section 4.2).
Darbepoetin alfa stimulates erythropoiesis by the same mechanism as the endogenous hormone.
Darbepoetin alfa stimulates erythropoiesis by the same mechanism as the endogenous hormone.
(The quit date is the day in the second week of treatment when you will stop smoking, see Section 3.)
The date of transfer to room temperature and the end of the 9-month period should be recorded on the outer carton.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month. lo
The expiry date refers to the last day of the month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
121 The expiry date refers to the last day of the month.
The expiry date refers to the last day of the month.
The expiry date refers to the last day of the month.
Record date of transfer to room temperature and the end of the 9-month period on the outer carton.
The expiry date refers to the last day of that month.
The expiry date refers to the last date of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month. • Do not store above 30°C. • Store in the original package in order to protect from moisture. • Do not use any pack that is damaged or shows signs of tampering.
The expiry date refers to the last day of that month. • Store in the original package in order to protect from moisture. • Do not use any pack that is damaged or shows signs of tampering.
The expiry date refers to the last day of that month.  Store in the original package in order to protect from moisture.  Do not use any Jalra pack that is damaged or shows signs of tampering.
The expiry date refers to the last day of that month. • Store in the original package, in order to protect from light..
date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of the month concerned.
The expiry date refers to the last day of that month.  Do not use Diovan if you notice that the pack is damaged or shows signs of tampering.  Medicines should not be disposed of via wastewater or household waste.
The expiry data refers to the last day of that month.
The expiry date refers to the last date of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month. in
The expiry date refers to the last day of the month.
The expiry date refers to the last day of the month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The expiry date refers to the last day of that month.
The date the product is removed from the refrigerator and set at room temperature (not exceeding 25oC) and the date the bottle should be withdrawn should be noted on the outer carton.
The date the product is removed from the refrigerator and set at room temperature (not exceeding 25oC) and the date the bottle should be withdrawn should be noted on the outer carton.
The addition of concomitant TMZ to RT, followed by TMZ monotherapy in the treatment of patients with newly-diagnosed glioblastoma multiforme demonstrated a statistically significant improvement in overall survival (OS) compared with RT alone (Figure 1).
The clinical decision for use of Diacomit in children with SMEI less than 3 years of age needs to be made on an individual patient basis taking into consideration the potential clinical benefits and risks.
A Decision was issued by the European Commission on 11 July 2008.
A Decision was issued by the European Commission on 15 September 2008.
A Decision was issued by the European Commission on 28 November 2008.
A Decision was issued by the European Commission on 4 July 2006.
A Decision was issued by the European Commission on 6 October 2008.
A Decision was issued by the European Commission on 7 October 2008.
The advisability of driving should be considered in these circumstances.
A decision on whether to continue/ discontinue breast-feeding or to continue/ discontinue therapy with filgrastim should be made taking into account the benefit of breast- feeding to the child and the benefit of filgrastim therapy to the woman.
A decision on whether to continue/ discontinue breast-feeding or to continue/ discontinue therapy with Altargo should be made taking into account the benefit of breast-feeding to the child and the benefit of Altargo therapy to the woman.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with lansoprazole should be made taking into account the benefit of breastfeeding to the child and the benefit of lansoprazole therapy to the woman.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with lansoprazole should be made taking into account the benefit of breastfeeding to the child and the benefit of lansoprazole therapy to the woman.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with lansoprazole should be made taking into account the benefit of breastfeeding to the child and the benefit of lansoprazole therapy to the woman.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Mycamine should be made taking into account the benefit of breast-feeding to the child and the benefit of Mycamine therapy to the mother.
A decision on whether to continue/ discontinue breast-feeding or to continue/ discontinue therapy with NeuroBloc should be made taking into account the benefit of breast-feeding to the child and the benefit of NeuroBloc therapy to the women.
A decision on whether to continue or discontinue breast-feeding or to continue or discontinue therapy with MIRCERA should be made taking into account the benefit of breast-feeding to the child and the benefit of MIRCERA therapy to the woman.
A decision on whether to continue/ discontinue breast-feeding or to continue/ discontinue therapy should be made taking into account the benefit of breast-feeding to the child and the benefit of Pelzont to the woman.
A decision on whether to continue/ discontinue breast-feeding or to continue/ discontinue therapy should be made taking into account the benefit of breast-feeding to the child and the benefit of Tredaptive to the woman.
A decision on whether to continue/ discontinue breast-feeding or to continue/ discontinue therapy should be made taking into account the benefit of breast-feeding to the child and the benefit of Trevaclyn to the woman.
The necessity for and choice of premedication is left to the discretion of the veterinarian.
A decision on whether to discontinue breast-feeding or discontinue therapy with romiplostim should be made taking into account the benefit of breast-feeding to your child and the benefit of romiplostim therapy to you.
Immediate reversal in children and adolescents has not been investigated and is therefore not recommended until further data become available.
Deferiprone is the active substance in Ferriprox.
Deferiprone must not be used by breast-feeding mothers.
The definition of “ normotension” may be elusive in this population.
The secondary definition of response required a 4-point or greater improvement on the ADAS-Cog, no worsening on the CIBIC-Plus, and no worsening on the PDS.
Adefovir dipivoxil is a dipivaloyloxymethyl ester prodrug of the active substance adefovir.
As adefovir is structurally related to nucleoside analogues, this risk cannot be excluded.
Adefovir dipivoxil should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Adefovir dipivoxil should not be administered concurrently with tenofovir disoproxil fumarate (Viread).
Adefovir is excreted renally, by a combination of glomerular filtration and active tubular secretion.
Adefovir is excreted renally by a combination of glomerular filtration and active tubular secretion.
Adefovir is excreted renally, by a combination of glomerular filtration and active tubular secretion.
Degradation of insulin detemir is similar to that of human insulin; all metabolites formed are inactive.
The further degradation of M8 appears to be catalysed by CYP3A4.
The gE gene deletion allows differentiation between animals vaccinated with gE-negative vaccines (anti gE antibody negative, IBR vironeutralising antibody positive) and naturally infected animals (positive to both IBR vironeutralising antibody and anti gE antibody).
The application was withdrawn in the Netherlands and United Kingdom.
The half-life for desloratadine is 27.4 hours.
The half-life of amlodipine is prolonged in patients with hepatic impairment.
The elimination half life after per oral administration was about 4,5 hours.
The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.
The elimination half-life of gabapentin is independent of dose and averages 5 to 7 hours.
21% (9/43) 7% (2/27)
The half-life of reteplase was increased in patients with AMI as compared to healthy volunteers.
The effective half-life of enalaprilat following multiple doses of enalapril maleate is prolonged at this level of renal insufficiency and time to steady state is delayed.
The median half-life of Privigen in primary immunodeficiency patients was 36.6 days.
The mean half-life was estimated at 23 hours in infants younger than 26 months on enzyme-inducing therapy, 136 hours when co-administered with valproate and 38 hours in subjects treated without enzyme inducers/ inhibitors.
Mean half-life increased from 1.9 hours to 4.9 hours.
The plasma t1/ 2 of timolol is 4 hours after ocular administration of DuoTrav.
The mean elimination half-lives in healthy adult subjects were 8.4 hours (range = 3 to 20 hours) for loratadine and 28 hours (range = 8.8 to 92 hours) for the major active metabolite.
The mean elimination half-lives are 8.4 hours (range = 3 to 20 hours) for loratadine and 28 hours (range = 8.8 to 92 hours) for the active metabolite.
The terminal half-life after subcutaneous administration is determined by the rate of absorption from the subcutaneous tissue.
The terminal half-life of NET is about 9- 11 hours.
The longer terminal half-life of darbepoetin alfa administered subcutaneously compared to intravenously is due to subcutaneous absorption kinetics.
The longer terminal half-life of darbepoetin alfa administered subcutaneously compared to intravenously is due to subcutaneous absorption kinetics.
The longer terminal half-life of darbepoetin alfa administered subcutaneously compared to intravenously is due to subcutaneous absorption kinetics.
The terminal half-life ranged from approximately 9 to 13 hours.
The demonstration of the benefit of adefovir dipivoxil is based on histological, virological, biochemical, and serological responses in adults with:
Cardiovascular depression should be treated with plasma expanders, pressor agents, antiarrhythmic agents or other appropriate techniques.
Leaflet last approved on
This leaflet was last approved in (MM/ YYYY).
21 This leaflet was last approved on
37 This leaflet was last approved in.
49 INFORMATION FOR THE HEALTHCARE PROFESSIONALS
53 This leaflet was last approved in.
This leaflet was last approved in {MM/ YYYY}
This leaflet was last approved in {MM/ YYYY}.
This leaflet was last approved.
This leaflet was last approved in
This leaflet was last approved in.
This leaflet was last approved in. lp
This leaflet was last approved on
This leaflet was last approved on
This leaflet was last approved on ().
This leaflet was last approved on
This leaflet was last approved on
Lietuva Pfizer Luxembourg SARL, filialas Lietuvoje Tel: +3705 2514000
104 This leaflet was last approved in {MM/ YYYY}.
161 This leaflet was last approved in {MM/YYYY}
83 This leaflet was last approved in {MM/ YYYY}.
97 This leaflet was last approved in {MM/ YYYY}.
This leaflet was approved in {MM/ YYYY}
This leaflet was last approved in {MM/ YYYY}
This leaflet was last approved in {MM/ YYYY}.
This leaflet was last approved in {MM/YYYY}
This leaflet was approved on
This leaflet was last approved in 79 80 PACKAGE LEAFLET:
The terminal half-life in plasma was typically 3.5 to 5 hours.
The last study was conducted under “ field conditions ” in a large number of dogs that were treated for separation anxiety in various veterinary practices, or clinics, in two European countries.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
New born offspring of maternal animals exposed to MabThera were noted to have depleted B cell populations during the post natal phase.
Designation as an orphan medicinal product is the mechanism by which sponsors have access to various incentives designed to encourage the development of such medicines and their availability to patients.
Desirudin consists in a single chain polypeptide of 65 amino acid residues and 3 disulphide bridges.
Desirudin is contraindicated in patients:
Desirudin is contraindicated in severe hepatic impairment (see section 4.3).
Desirudin is a recombinant DNA product derived from yeast cells.
Desirudin should not be administered by intramuscular injection owing to the risk of local haematoma.
Desloratadine is excreted into breast milk, therefore the use of Aerius is not recommended in breast- feeding women.
Desloratadine is excreted into breast milk, therefore the use of Aerius is not recommended in breastfeeding women.
Desloratadine is excreted into breast milk, therefore the use of Azomyr is not recommended in breastfeeding women.
Desloratadine is excreted into breast milk, therefore the use of Neoclarityn is not recommended in breast-feeding women.
Desloratadine is excreted into breast milk, therefore the use of Neoclarityn is not recommended in breastfeeding women.
10 Desloratadine does not readily penetrate the central nervous system.
Desloratadine does not readily penetrate the central nervous system.
23 Desloratadine does not readily penetrate the central nervous system.
Desloratadine does not readily penetrate the central nervous system.
Structural joint damage (erosions and joint space narrowing) in both hands and feet was measured by the change from baseline in the total van der Heijde-modified Sharp score (0-440).
Immunohistochemical detection of EGFR expression was not performed since more than 90% of patients with squamous cell cancer of the head and neck have tumours that express EGFR.
During an initial open-label phase, patients were titrated to an effective dose of Effentora.
The second dose will be given between six and twelve months after the first dose.
The second study compared Emtriva with lamivudine (another antiviral medicine) in 468 treatment-naïve adults, in combination with stavudine and either efavirenz or nevirapine (other antiviral medicines).
The second study compared the same dose of Norvir taken alone, to zidovudine (another antiviral medicine) and to the combination of Norvir and zidovudine, in 356 treatment-naïve adults (who had not taken treatment for HIV infection before).
The second study showed that patients taking MIRCERA and those taking darbepoetin alfa had similar increases in haemoglobin levels (around 2 g/ dl).
The second study showed that the LDL cholesterol levels were further reduced when Trevaclyn was taken with simvastatin (48% reduction), compared with Trevaclyn alone (17% reduction) or simvastatin alone (37% reduction).
The second study showed that there is no difference between the two doses in terms of effectiveness.
The second study examined the effects of a combination of the 2 active substances in 683 patients with abnormal levels of glucose or fat in the blood.
The second study included a total of 119 patients whose disease was in the ‘ accelerated phase’, four fifths of whom had stopped responding to imatinib.
The second week 1 mg twice daily or 2 mg once daily can be given.
Dexamethasone is a weak to moderate enzyme inducer and its effect on warfarin is unknown.
In addition, dexamethasone did not affect protein binding of docetaxel.
Dibotermin alfa was not detectable in serum.
Didanosine should be taken at the fasted state 2 hours after
The treatment difference was -3.0% (Advagraf-ciclosporin) (95.2% confidence interval [-9.9%, 4.0%]) for Advagraf vs. ciclosporin and -1.9% (Prograf-ciclosporin) (95.2% confidence interval [-8.9%, 5.2%]) for Prograf vs. ciclosporin.
The between group difference in LS means for the percentage of days with β -agonist use was significant:
Difloxacin hydrochloride is bactericidal in activity and acts by inhibition of bacterial DNA gyrase.
Digoxin did not affect the pharmacokinetic profile of tigecycline.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Lowering the blood pressure to a normal level reduces the risk of developing these disorders.
The decrease in blood pressure occurs rapidly.
APTIVUS may be less effective due to decreased tipranavir plasma concentrations in patients taking these agents concomitantly.
Neutrophil and white cell count reductions at the end of week 4 correlated with the dose of Peg Intron.
Neutrophil and white cell count reductions at the end of week 4 correlated with the dose of PegIntron.
Neutrophil and white cell count reductions at the end of week 4 correlated with the dose of ViraferonPeg.
Reductions of plasma levels of plasminogen and α 2-antiplasmin normalise within 1 to 3 days.
The reduction in blood cell counts is usually short-lived.
The average reduction in daily levodopa dose was about 30% in those patients requiring a levodopa dose reduction.
The decrease seen in patients who received tolterodine was 1.69.
This allows a more focused discussion and hence improves the quality of scientific advice.
• drug distribution will only be possible after checking that the patient has effectively received a meningococcal vaccination with a written confirmation • prior to distribution, all health care professionals are provided with information on the following key safety concerns:
The distribution and clearance of cytarabine and of the predominant phospholipid component of the lipid particle (DOPC) following intrathecal administration of DepoCyte was evaluated in rodents.
The disposition and elimination of the albumin microspheres have not been studied in humans.
MTX) to tocilizumab monotherapy resulted in increased frequency of these elevations.
AS03 adjuvant composed of squalene (10.68 milligrams), DL-α -tocopherol (11.86 milligrams) and polysorbate 80 (4.85 milligrams)
The adjuvant includes also polysorbate 80 and sorbitan trioleate in a citrate buffer.
Long-term administration of buprenorphine during the last three months of pregnancy may cause a withdrawal syndrome in the neonate.
Co-administration with ciclosporin is not recommended.
Dosing continued for all patients through week 46.
Co-administration of amprenavir with methadone leads to a decrease of methadone concentrations.
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme responsible for the conversion of 3-hydroxy-3-methyl-glutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol.
Co-administration with other potentially phototoxic substances (e. g. tetracyclines, sulfonamides, fluoroquinolones, hypericin extracts) should be avoided (see also section 5.3).
Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been studied in healthy volunteers, and increased the AUC by 1.4-fold.
Co-administration of 10 mg adefovir dipivoxil with other medicinal products that are eliminated by tubular secretion or alter tubular function may increase serum concentrations of either adefovir or the co-administered medicinal product (see section 4.4).
Concurrent administration of bupropion with repeated doses of ritonavir is expected to decrease bupropion levels.
In case of concomitant administration of cephalosporins and aminoglycosides there has been reported an increased risk of oto- and nephrotoxicity.
Erectile dysfunction medicinal products: concomitant use is not recommended.
Co-administration of venlafaxine and weight loss agents is not recommended.
Darifenacin 30 mg once daily (two times greater than the recommended daily dose) co-administered with digoxin at steady state resulted in a small increase in digoxin exposure (AUC:
The concomitant use of Effentora with strong CYP3A4 inhibitors (e. g., ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate CYP3A4 inhibitors (e. g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious adverse drug reactions including fatal respiratory depression.
Coadministration of gabapentin with antacids containing aluminium and magnesium, reduces gabapentin bioavailability up to 24%.
Concomitant administration of nelarabine in combination with adenosine deaminase inhibitors, such as pentostatin is not recommended.
Concurrent administration of potentially nephrotoxic medicinal products should be avoided.
Co-administration of NeuroBloc and aminoglycosides or agents interfering with neuromuscular transmission (e. g. curare-like compounds) should be considered with caution.
Co-administration of nimesulide and furosemide results in a decrease (of about 20%) of the AUC and cumulative excretion of furosemide, without affecting its renal clearance.
Concurrent administration of ranitidine (300 mg single dose) with fosamprenavir (1400 mg single dose) decreased plasma amprenavir AUC by 30% and Cmax by 51%.
Concomitant administration of moxifloxacin with ranitidine or probenecid did not alter renal clearance of the parent drug.
Co- administration of Riprazo had no significant impact on atorvastatin, valsartan, metformin or amlodipine pharmacokinetics.
Rosiglitazone should be used with caution during concomitant administration of CYP2C8 inhibitors (e. g. gemfibrozil) or inducers (e. g. rifampicin).
Concomitant administration of erythropoietic agents or previous history of DVT may also increase thrombotic risk in these patients.
Concomitant use of sildenafil with ritonavir is contraindicated in pulmonary arterial hypertension patients.
Concurrent administration of SUTENT with the potent CYP3A4 inducer, rifampin, resulted approximately in 56% and 78% reduction in sunitinib Cmax and AUC0-∞, values respectively, after a single dose of SUTENT in healthy volunteers.
Co- administration of Tekturna had no significant impact on atorvastatin, valsartan, metformin or amlodipine pharmacokinetics.
Concomitant use of Telzir with simvastatin or lovastatin is not recommended due to an increased risk of myopathy, including rhabdomyolysis (see section 4.5).
The use of Telzir concomitantly with halofantrine or lidocaine (systemic) is not recommended.
The use of Telzir concomitantly with halofantrine or lidocaine (systemic) is not recommended (see section 4.5).
27 The use of Telzir concomitantly with PDE5 inhibitors (e. g. sildenafil and vardenafil) is not recommended (see section 4.5).
The use of Telzir concomitantly with PDE5 inhibitors (e. g. sildenafil and vardenafil) is not recommended (see section 4.5).
No clinically significant effect is anticipated when TORISEL is co-administered with agents that are metabolised by CYP2D6.
Co-administration of venlafaxine and weight loss agents is not recommended.
Coadministration of voriconazole and sirolimus is contraindicated, since voriconazole is likely to increase plasma concentrations of sirolimus significantly (see section 4.5).
Coadministration of voriconazole and sirolimus is contraindicated, since voriconazole is likely to increase plasma concentrations of sirolimus significantly (see section 4.5).
VFEND has been associated with elevations in liver function tests and clinical signs of liver damage, such as jaundice, and must only be used in patients with severe hepatic impairment if the benefit outweighs the potential risk.
The concomitant administration of EXJADE and vitamin C has not been formally studied.
The concomitant administration of EXJADE with anticoagulants may also increase the risk of gastrointestinal haemorrhage.
The concomitant administration of EXJADE with anticoagulants may also increase the risk of gastrointestinal haemorrhage.
Co-administration of potent CYP3A4 inhibitors (e. g. ketoconazole, itraconazole, ritonavir) with sildenafil for pulmonary arterial hypertension is contraindicated (see section 4.3).
Oral contraceptives Co-administration of rufinamide 800 mg b. i. d. and a combined oral contraceptive (ethinyloestradiol 35 μ g and norethindrone 1 mg) for 14 days resulted in a mean decrease in the ethinyl estradiol AUC0-24 of 22% and in norethindrone AUC0-24 of 14%.
Not studied, combined administration may result in increased warfarin levels.
It is recommended to avoid this combination (see section 4.4).
Simultaneous use of medicines enhancing the pH of the stomach is not recommended (see section 4.5).
Each administration of antibiotics can lead to multiplication of pathogens resistant to the active substance used.
Each administration of antibiotics can lead to multiplication of pathogens resistant to the active substance used.
6 Effect of food: the administration of Atripla with food may increase efavirenz exposure (see section 5.2) and may lead to an increase in frequency of adverse reactions (see section 4.8).
Use of AVAGLIM is contraindicated in patients with:
Administration of 300 mg/kg/day resulted in an increased incidence of thyroid follicular cell adenoma.
5-ALA HCl administration does not influence the function of the gastro-intestinal and central nervous systems.
Administration of fosamprenavir 700 mg twice daily with ritonavir 100 mg twice daily results in plasma amprenavir concentrations (data from study APV30003 in antiretroviral experienced patients) which results in protein adjusted median ratios of Cmin/ IC50 and Cmin/ IC95 of 21.7 (range 1.19-240) and 3.21 (range 0.26-30.0), respectively.
36 daily results in plasma amprenavir concentrations (data from study APV30003 in antiretroviral experienced patients) which results in protein adjusted median ratios of Cmin/ IC50 and Cmin/ IC95 of 21.7 (range 1.19-240) and 3.21 (range 0.26-30.0), respectively.
Giving many times the dose of Betaferon recommended for the treatment of multiple sclerosis has not led to life-threatening situations.
The administration of bleomycin almost always takes place in combination with other cytostatic drugs and/ or radiation therapy.
Administration of Cardoreg 4 mg prolonged release tablets and associated names in hypertensive patients causes a clinically significant reduction in blood pressure as a result of a reduction in systemic vascular resistance.
Caution is needed when administrating this vaccine to persons with a known hypersensitivity (other than anaphylactic reaction) to the active substance(s), to any of the excipients and to trace residues e. g. formaldehyde, benzonase, or sucrose.
CHAMPIX dosing should start 1-2 weeks before this date.
Then they begin treatment with CHAMPIX 1 to 2 weeks before that date.
Cidofovir administration is contraindicated in patients unable to receive probenecid or other sulfa- containing medication (see section 4.4 Prevention of nephrotoxicity).
Competact is contraindicated in patients with:
Cyanokit is given along with appropriate measures to decontaminate and support the patient, including providing oxygen for the patient to breathe.
Administration of oral cyclosporine A (15 mg/ kg), an inhibitor of transporters ABCB1 (P-gp) and ABCC1 (MRP-1) as well as the metabolising enzyme CYP3A4, within 4 hours of oral topotecan increased the dose normalised AUC0-24h of topotecan lactone and total topotecan approximately 2.0- and 2.5-fold respectively (see section 4.5).
Administration of oral cyclosporine A (15 mg/ kg), an inhibitor of transporters ABCB1 (P-gp) and ABCC1 (MRP-1) as well as the metabolising enzyme CYP3A4, within 4 hours of oral topotecan increased the dose normalised AUC0-24h of topotecan lactone and total topotecan approximately 2.0- and 2.5-fold, respectively (see section 4.5).
Multiple doses of ambrisentan resulted in slight increases in digoxin AUC0-last and trough concentrations, and a 29% increase in digoxin Cmax.
Multiple doses of lumiracoxib 1,200 mg once daily have been administered to patients with rheumatoid arthritis for 4 weeks without clinically significant adverse effects.
Repeat dose administration of oral posaconazole (400 mg twice daily for 16 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 6.7-fold and 8.9-fold (range 3.1 to 17.5-fold), respectively, in healthy subjects.
FIRMAGON is administered as a subcutaneous injection in the abdominal region.
Glivec administration to patients without the genetic translocation generally results in no improvement.
Administration of Gonazon at other stages of the cycle may induce heat that may be fertile.
The use of Kineret in pregnant women is not recommended.
Kivexa is contraindicated in patients with known hypersensitivity to the active substances or to any of the excipients.
Administration of the 60 mg prasugrel loading dose without concomitant use of proton pump inhibitors may provide most rapid onset of action.
The administration of the chelating treatment and Wilzin should be separated by at least 1 hour.
The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 and GIP.
7 The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).
The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).
The administration of medicinal products by the intrathecal (IT) route carries the risk of potentially serious infections, such as meningitis, which may be life threatening.
ge administered every other week as a single dose via subcutaneous injection.
Methotrexate should be continued during treatment with Trudexa.
Administration of Naglazyme should be carried out in an appropriate clinical setting where resuscitation equipment to manage medical emergencies would be readily available.
There are no restrictions on treatment with NovoMix 30 during lactation.
There are no restrictions on treatment with NovoMix 50 during lactation.
There are no restrictions on treatment with NovoMix 70 during lactation.
There are no restrictions on treatment with NovoRapid during lactation.
Administration of pemetrexed to pregnant mice resulted in decreased foetal viability, decreased foetal weight, incomplete ossification of some skeletal structures and cleft palate.
Therefore the use of Pradaxa is not recommended in this population (see sections 4.4 and 5.2).
Therefore the use of Pradaxa is not recommended in this population.
Therefore the use of Pradaxa is not recommended in this population.
CE marked pumps equivalent to the Synchromed and CADD-Micro pump should be used to deliver Prialt.
CE marked pumps equivalent to the Synchromed and CADD-Micro pump should be used to deliver ziconotide.
Difference between the recipient species and human Protein C will inevitably result in an immune response with antibody formation.
Use of rosiglitazone is contraindicated in patients with:
Administration of RotaTeq should be postponed in infants suffering from acute severe febrile illness.
Co-administration of robenacoxib non-flavoured tablets with food produced no delay in Tmax, but slightly lower values for Cmax (832 ng/ ml) and AUC (782 ng. h/ ml).
Administration of entitlements for existing, new and departing staff covers the major part of the work.
Infusions should be administered incrementally.
Tarceva dosing should be interrupted if changes in liver function are severe (see section 4.8).
Tarceva dosing should be interrupted if changes in liver function are severe (see section 4.8).
TMZ administration can be continued throughout the 42 day concomitant period (up to 49 days) if all of the following conditions are met:
Tracleer is contraindicated in pregnancy (see section 4.3).
Tritanrix HepB should be postponed in infants with a severe sudden fever, and it should not be given if the child has had encephalopathy (a brain disease) of unknown cause within seven days of a previous vaccination with a vaccine containing pertussis.
Trizivir is contraindicated in patients with end-stage renal disease (see section 4.3).
The exposure of human insulin following administration of three 1 mg blisters is significantly greater
The concomitant administration of EXJADE and aluminium-containing antacid preparations has not been formally studied.
ris Administration of EXUBERA 10 minutes prior to administration of salbutamol did not affect the bronchodilatory response to salbutamol in non-diabetic subjects with mild-moderate asthma.
Ziagen is contraindicated in patients with known hypersensitivity to the active substance or to any of the excipients.
Preclinical toxic effects related to ziconotide administration were observed only at exposures considered sufficiently in excess of the human exposure to indicate little risk in clinical use.
Prophylactic heparin increased the risk of non-serious bleeding (see section 4.8).
Serum levels of matrix metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage destruction were also decreased after Humira administration.
Dosing should begin at 0.5 mg once daily for the first 3 days then increased to 1 mg once daily.
Dosing should be delayed in the presence of elevated ciclosporin blood levels.
Use of filgrastim, either alone, or after chemotherapy, mobilises haematopoietic progenitor cells into peripheral blood.
Elderly patients are more likely to have decreased renal function, therefore caution should be exercised when treating elderly patients with tenofovir disoproxil fumarate (see below).
The administration of the chelating treatment and Wilzin should be separated by at least 1 hour.
A pneumococcal vaccine administered 6 weeks after discontinuation of Raptiva yielded normal results.
Administration of sugammadex to healthy volunteers resulted in increased renal elimination of rocuronium in complex.
11/ 24 With once daily dosing, clinically significant reductions in blood pressure are present throughout the day and at 24-hours post dose.
With once daily dosing, clinically significant reductions in blood pressure are present throughout the day and at 24-hours post dose.
Treatment with NRTIs should be discontinued if there is symptomatic hyperlactatemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
Administration of iodinated contrast agent The intravascular administration of iodinated contrast agents in radiological studies can lead to renal failure.
The intravascular administration of iodinated contrast agents in radiological studies can lead to renal failure.
The intravascular administration of iodinated contrast agents in radiological studies may lead to renal failure, resulting in metformin accumulation and a risk of lactic acidosis.
Intravascular administration is contraindicated.
The intravenous administration of CEPROTIN provides for an immediate but temporary increase in plasma levels of protein C.
Intravenous administration of the usual subcutaneous dose could result in severe hypoglycaemia.
Intravenous administration of tigecycline at a single dose of 300 mg over 60 minutes in healthy volunteers resulted in an increased incidence of nausea and vomiting.
Intravenous administration should not be protracted over more than 2 hours.
Intravenous administration should not be protracted over more than 2 hours.
Oral administration of pseudoephedrine at the recommended dose can cause other sympathomimetic effects, such as increased blood pressure, tachycardia or manifestations of central nervous system excitation.
The administration may last for up to 15-20 minutes.
The injection is given as a slow injection into a vein or a deep injection into a large muscle.
Once-a-day administration has not been evaluated in patients with hepatic insufficiency.
Multiple dosing of 7,200 mg/ day was associated with no major signs or symptoms.
Administration is by intramuscular (IM) or intravenous (IV) injection.
Simultaneous administration with cimetidine may lead to increased plasma levels of clomipramine.
Therefore, simultaneous administration of nucleoside analogues with cladribine is not advisable.
Simultaneous administration of five implants during a one- year period was well tolerated.
Simultaneous administration of ciprofloxacin with warfarin may augment its anti-coagulant effects.
Simultaneous administration of ciprofloxacin with warfarin may augment its anti-coagulant effects.
Concurrent use of Equilis Prequenza Te and Tetanus-Serum from Intervet may reduce active immunity against tetanus compared to horses vaccinated with Equilis Prequenza Te in the absence of tetanus antitoxin serum.
Subcutaneous administration of DRAXXIN to cattle frequently causes transient pain reactions and local swellings at the injection site that can persist for up to 30 days.
Total BMD also increased significantly.
Total body BMD also increased significantly.
The pharmaceutical documentation (module 3) as well as the pharmaceutical particulars of the SPC were harmonised, except the sections, which need to be introduced nationally by the Member States when implementing the harmonised SPC.
Dosing should be titrated as necessary to maintain the haemoglobin target. ct
Dosing should be titrated as necessary to maintain the haemoglobin target.
Dosing should be titrated as necessary to maintain the haemoglobin target.
The infusion should last 3 hours.
The dose for elderly FAP patients has not been established.
The highest cumulative dose administered to patients was 44,000 mg over a 20- week period and this dose did not result in any untoward acute effects.
The dose is 1 ml, which is given directly into the ear by one activation of the pump supplied with the bottle.
ABILIFY dose should be doubled when concomitant administration of ABILIFY occurs with carbamazepine.
The dose of acetylsalicylic acid given before Rapilysin should be at least 250 mg – 350 mg and should be followed by 75 – 150 mg/ day, at least until discharge from hospital.
The loading dose should be given as a 15 minute infusion immediately followed by initiation of the maintenance infusion.
The recommended dose of AVAMYS for adults and adolescents aged 12 years and over is two sprays in each nostril once a day.
The 40 mg dose is contraindicated in some of these patients (see Section 4.3 Contraindications).
The dose of 60 ml (one vial) may be given alone or dissolved in milk or milk substitute.
The recommended dosage of intranasal salmon calcitonin for the treatment of established post- menopausal osteoporosis is 200 I. U. once a day.
The recommended dosage of intranasal calcitonin for the treatment of established post-menopausal osteoporosis is 200 I. U. once a day.
The recommended dosage of intranasal calcitonin for the treatment of established post-menopausal osteoporosis is 80 I. U. once a day.
The dose of Cardoreg 4 mg prolonged release tablets and associated names is the same whether you are taking it for high blood pressure or to treat the symptoms of prostatic hyperplasia.
You should reduce the dose of these medicines to avoid damage to the penis.
The usual dose of Combivir for adults and adolescents weighing at least 30 kg is one tablet twice a day.
The starting dose of Pelzont is one tablet once a day for four weeks, after which the dose is increased to two tablets once a day.
The starting dose of Trevaclyn is one tablet once a day for four weeks, after which the dose is increased to two tablets once a day.
The dose of dexamethasone was chosen to account for active substance interactions.
The dose of dexamethasone was chosen to account for medicinal product interactions.
The recommended dosage of elcatonin for the treatment of established post-menopausal osteoporosis is 80 I. U. once a day.
The light dose administered will be 130 Joules/ cm (J/ cm) of diffuser length using a centring balloon.
Melphalan dosage should be calculated according to the litre-volume method of Wieberdink (Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthius GAA.
Metalyse should be administered on the basis of body weight, with a maximum dose of 10,000 units (50 mg tenecteplase).
The methadone dose was increased by a mean of 22% to alleviate withdrawal symptoms.
14 The 10 mg maintenance dose is not recommended.
2 The 10 mg maintenance dose is not recommended.
The daily maintenance dose is between 200 mg and 400 mg.
The maximum maintenance dose is 40 mg daily.
The recommended maintenance dose is 10 to 20 mg once a day in patients with rheumatoid arthritis, and 20 mg once a day in patients with psoriatic arthritis.
There is no dose adjustment recommended in patients with mild renal insufficiency.
Patients who experience severe neutropenia (neutrophils < 500 cells/ mm3 for a week or longer) or severe peripheral neuropathy during Paxene therapy should have their dosage reduced by 20% (NSCLC and first-line treatment of ovarian cancer) or 25% (MBC and MOC) for subsequent courses of Paxene.
Patients who experience severe neutropenia (neutrophils < 500 cells/ mm3 for a week or longer), severe peripheral neuropathy or mucositis (Grade 3 or worse) during Paxene therapy should have their dosage reduced by 25% to 75 mg/ m2 for subsequent courses of Paxene.
The dose of Sustiva needs to be reduced in patients taking voriconazole (used to treat fungal infections).
The recommended dose of Tyverb is five tablets once a day.
The dose should be given on Days 1, 8 and 15 of each 28-day cycle in combination with cisplatin.
The dose of exenatide can then be increased to 10 µg BID to further improve glycaemic control.
Radiolabelling of medicinal products, such as monoclonal antibodies, peptides or other substrates, with Yttrium (90Y) chloride is very sensitive to the presence of trace metal impurities.
The dose should be increased at every fourth injection in four steps (0.25 ml, 0.5 ml, 0.75 ml, 1.0 ml).
The sodium oxybate or placebo equivalent dose was 6g/ day for the first 4 weeks and was increased to 9g/ day for the remaining 4 weeks.
The effective dose of Clomicalm has been established in clinical studies in dogs.
The dose will be calculated according to your body weight.
The dose is determined using the following formula:
In cattle, it is injected under the skin, and the dose is divided in cattle weighing over 300 kg so that no more than 7.5 ml are injected at one site.
In pigs it is injected into a muscle, and the dose is divided in pigs weighing over 80 kg so that no more than 2 ml are injected at one site.
The dose is repeated every 4 weeks for as long as the disease does not progress and you are able to tolerate the treatment.
The usual way to take Mycophenolate mofetil Teva is as follows:
How much Sebivo to take The usual dose of Sebivo is one 600 mg tablet once a day.
How much Sebivo to take The usual dose of Sebivo is 30 ml of oral solution (600 mg telbivudine) once a day.
The usual dose is between 0.3 and 1.0 IU/ kg/ day.
The usual dose is 15 mg once a day.
The normal dose is 50 mg per kilogram body weight, divided into two or three doses during the day.
The usual dose is: − one 100 mg film-coated tablet − once a day − by mouth
The usual dose of Starlix to start with is 60 mg before the three main meals.
The usually effective dose is 40 mg once daily.
The usual dose when using the injection is 10 mg as a single injection into a muscle.
- The usual dose to treat an invasive Candida infection is 100 mg per day for patients weighing
The weekly dose can also be divided into daily doses.
27 The weekly dose can be given as one injection per week or in divided doses 3 to 7 times per week.
38 The weekly dose can be given as one injection per week or in divided doses 3 to 7 times per week.
49 The weekly dose can be given as one injection per week or in divided doses 3 to 7 times per week.
The weekly dose can be given as one injection per week or in divided doses 3 to 7 times per week.
The weekly dose can be given as one injection per week or in divided doses three or seven times per week.
The initial dose of acetylsalicylic acid prior to thrombolysis should be at least 250 mg (250 – 350 mg) followed by 75 – 150 mg/ day at least until discharge.
The starting dose of NeuroBloc is 10,000 U, divided into equal injections directly into the two to four muscles in the neck and shoulders that are most affected.
The initial dose should be given 6 hours following surgical closure provided that haemostasis has been established.
Depending on the clinical symptoms, the standard dosage should be gradually increased.
The initial dose by subcutaneous or intravenous administration is 0.45 µg/ kg body weight, as a single injection once weekly.
The initial dose is 10,000 U and should be divided between the two to four most affected muscles.
The initial dose is 150 IU/kg given subcutaneously 3 times per week.
The initial dose is 150 IU/ kg given subcutaneously 3 times per week.
Your initial dose is 1 microgram of Nplate per kilogram of your body weight once a week.
The recommended starting dose in adults is 2 to 3 g per day, divided into two or three doses, taken with meals containing fatty food.
The recommended starting dose of MIRCERA is 0.6 micrograms for every kilogram of your body weight.
The recommended starting dose of Invega is 6 mg once a day, taken in the morning.
The recommended starting dose is 25 mg RISPERDAL CONSTA every two weeks.
The recommended starting dose is 3 mg of infliximab for every kg of body weight.
The recommended initial daily dose is 50 mg in two divided doses.
The daily dose in adults, adolescents and children over 10 years of age is 6 g per day divided in 2 doses of 3 g per day.
The daily dose is 30 mg of combined actives per kg bodyweight by oral administration.
The paste is presented in a syringe of plastic with the dose to treat 50 kg of horse.
The first daily dose should be 100 mg per kilogram body weight, but up to 250 mg/ kg can be used if necessary.
- the initial daily dose is usually 100 mg per kilogram of body weight, up to a maximum of
The recommended initial daily dose of EXJADE is 20 mg/ kg body weight.
The maximum daily dose administered in clinical trials is 320 mg in divided doses.
The maximum daily dose reported is 1,200 µg for one day.
The maximum recommended daily dose of Onsenal is 800 mg.
The maximum recommended daily dose is 16 mg.
The maximum recommended daily dose is 20 mg.
The maximum recommended daily dose is 800 mg.
The maximum recommended daily dose is 400 mg for both indications.
The maximum daily single dose tested in humans is 1.5 mmol gadobutrol/ kg body weight.
The recommended daily dose of testosterone is 300 micrograms.
The recommended total daily dose in adult and paediatric patients over 10 years of age is 6 g per day administered orally in divided doses of 3 g two times per day.
The dose limiting adverse reaction was postural hypotension.
The highest dose of tolcapone administered to humans was 800 mg three times daily, with and without levodopa coadministration, in a one week study in healthy elderly volunteers.
The highest prior imatinib dose was ≥ 600 mg/ day in 75% of all patients, with 41% of patients receiving imatinib doses ≥ 800 mg/ day.
The median highest prior imatinib dose had been 600 mg/ day for CP patients and 800 mg/ day for AP patients.
The maximum total daily dose is 180 mg three times a day.
The maximum daily dose of olanzapine (including all formulations of olanzapine) is 20 mg.
The recommended maximum daily dose is 180 mg three times daily to be taken before the three main meals.
The recommended maximum daily dose is 6 mg twice a
The recommended maximum daily dose is 6 mg twice a day.
The maximum recommended daily dose is 800 mg.
The no observed adverse effect level (NOAEL) was considered to be less than 75 mg/kg/day, and is approximately 25-fold greater than the human daily exposure based on AUC exposure.
The maximum tolerated dose of Tarceva in NSCLC patients who currently smoke cigarettes was 300 mg.
The required dosage is determined using the following formula:
The required dosage is determined using the following formulae:
The dose should only be increased if the 5 mg dose is well tolerated.
The optimal dose has not been fully clarified.
The optimal dose has not been fully clarified.
The usual oral dexamethasone dose should be reduced by approximately 50% when co-administered with a regimen of fosaprepitant followed by aprepitant.
The recommended oral dose of EMEND is one 40 mg capsule within 3 hours prior to the start of anesthesia.
The dose can be taken regardless of mealtime.
The dose may be reduced to 0,25 mg. daily at the start of remobilisation.
The dose may be reduced to 50 I. U. daily at the start of remobilisation.
The dose for adults is 50 mg (one vial of DepoCyte).
- The dose to treat a Candida infection of the oesophagus is 150 mg for patients weighing more
When concomitant administration of ketoconozole with ABILIFY occurs, ABILIFY dose should be reduced to approximately one-half of its prescribed dose.
The prescribed dose of Siklos must be taken once daily, preferably in the morning before breakfast.
The prescribed dose should be administered orally with a meal and a large glass of water to minimise the risk of gastrointestinal irritations.
The prescribed dose should be administered orally with a meal and a large glass of water to minimise the risk of gastrointestinal irritations.
187 The dose for children and adolescents is based on body weight in kilograms.
The dose you receive is based on your body weight in kilograms.
The daily dose of AMMONAPS will be calculated from your protein tolerance, diet and body weight or body surface.
The daily dose is then maintained until pre-ovulatory conditions are reached.
The maximum daily dose administered in clinical trials is 320 mg in divided doses.
The maximum daily dose of aripiprazole is 30 mg (including all formulations of aripiprazole).
The maximum recommended daily dose is 8 mg/ 2,000 mg.
Maximum daily dose was not specified in some of the approved SPCs.
The maximum recommended daily dose is 8 mg rosiglitazone/ 4 mg glimepiride (given as one AVAGLIM tablet 8 mg/ 4 mg, once daily).
The recommended daily dose is 20 mg once a day.
This will be increased every 5 - 7 days as directed by your doctor until your symptoms are controlled (maintenance dose).
This will be increased every 5 – 7 days as directed by your doctor until your symptoms are controlled (maintenance dose).
The total daily dose of Ferriprox is 75 -100 mg per kilogram body weight given in three separate doses per day.
Your total daily dose and frequency of administration remain the same.
The recommended dose for adults and adolescents (12 years of age and over) is 5 mg once a day.
Therefore the Committee recommends maintaining the Marketing Authorisations for all veterinary medicinal products as referred to in Annex I and to vary the Marketing Authorisations in order to harmonise the indications and dosing regimens as described in the paragraph above.
The recommended dose in renal transplant patients is 1 g administered twice daily (2 g daily dose).
The recommended dose in renal transplant patients is 1 g administered twice daily (2 g daily dose).
The recommended dose of Adenuric is 80 mg once a day.
The recommended dose is 5, 7.5, 10 or 15 mg per kilogram of your body weight.
The recommended dose of Copalia is one tablet per day.
Dexamethasone should be taken at a dose of 40 mg once a day on days 1 to 4, 9 to 12 and 17 to 20 of the first four cycles, and on days 1 to 4 thereafter.
The recommended dose of dexamethasone is 40 mg orally once daily on days 1-4, 9-12, and 17-20 of each 28-day cycle for the first 4 cycles of therapy and then 40 mg once daily on days 1-4 every 28 days.
The recommended dose of filgrastim is 0.5 MU/ kg/ day (5 μ g/ kg/ day).
The recommended dose of Gliolan is 20 mg per kilogram body weight, taken two to four hours before the patient is anaesthetised.
The recommended dose of Levitra is 10 mg, taken with or without food, about 25 to 60 minutes before sexual activity.
The recommended dose of Rasilez HCT is one tablet per day.
The recommended dose of oral powder is 300 mg (6 level measuring spoons) once daily taken with ritonavir 100 mg once daily and with food.
The recommended dose of Riprazo is 150 mg once daily.
The recommended dose of Sebivo is one tablet once a day, with or without food.
The recommended dose of Sprimeo is 150 mg once daily.
The recommended dose of Sustiva for adults is 600 mg once a day.
The recommended dose of tadalafil is 10 mg, taken with or without food, ‘ on demand'at least 30 minutes before sexual activity.
The recommended dose of Tekturna is 150 mg once daily.
Limited data indicate that the dose should be reduced in patients with moderate renal impairment.
The recommended dose of Trudexa is 40 mg given every 2 weeks as a single subcutaneous injection (under the skin).
The recommended dose of Viread is one tablet taken once a day with food.
The recommended dose of Vivanza is 10 mg, taken with or without food, about 25 to 60 minutes before sexual activity.
The recommended dose of Exforge is one tablet per day.
The recommended dose is 0.5 to 3.0 ml per patient.
The recommended dose is 0.5 ml - 3.0 ml per patient.
The recommended dose is 10 mg taken as needed approximately 25 to 60 minutes before sexual activity.
The recommended dose is 2.5 or 5.0 micrograms.
The recommended dose is 8 mg per kilogram body weight.
The recommended dosage is one vial (approximately 47 micrograms of depreotide) labelled with 555-740 MBq of technetium-99m.
The recommended dose for each injection (1 ml) is 10 micrograms for adults and adolescents (16 years of age and older).
The recommended dose for closure of enterocutaneous f istulas is 5 mg of infliximab for every kg of body weight.
Dosing recommendations for patients receiving oral topotecan with Clcr less than 60 ml/ min have not been established.
The recommended dose for the treatment of HIV or for the treatment of chronic hepatitis B is 245 mg (one tablet) once daily taken orally with food.
The no-observed-effect-level for developmental effects was observed at 3- (valsartan) and 4- (amlodipine) fold the clinical exposure (based on AUC).
11-fold in AUC) in patients with chronic alcoholic liver disease (Childs-Pugh B).
The standard dose of Cystadane for patients aged over 10 years is 6 g a day, divided into two equal doses.
The total daily dose should be divided into equal amounts and given with each meal (e. g. three times per day).
The usual dose of Copalia is one tablet per day. − It is advisable to take your medicine at the same time each day, preferably in the morning. − Swallow the tablets with a glass of water. − You can take Copalia with or without food.
The usual dose of Dafiro is one tablet per day. − It is advisable to take your medicine at the same time each day, preferably in the morning. − Swallow the tablets with a glass of water. − You can take Dafiro with or without food.
The usual dose of Exforge is one tablet per day. − It is advisable to take your medicine at the same time each day, preferably in the morning. − Swallow the tablets with a glass of water. − You can take Exforge with or without food.
The usual dose of Imprida is one tablet per day. − It is advisable to take your medicine at the same time each day, preferably in the morning. − Swallow the tablets with a glass of water. − You can take Imprida with or without food.
The usual dose is 250 mg fulvestrant (one 5 ml injection) given once a month.
The usual dose is 9.75 mg (1.3 ml) for the first injection.
This is given twice a week by injection into a vein.
The usual dose fo r adults with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis is 40 mg adalimumab given every other week as
The usual dose for adults with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis is 40 mg adalimumab given every other week as
The usual dose for adults with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis is 40 mg adalimumab given every other week as a single dose.
The staffing of the Unit has been carried out carefully to match its major goals as well as the increasing workload.
Neuropathic pain is a medical condition in which the pain is commonly described as burning, stabbing, stinging, shooting or aching or like an electric shock.
Doxazosin has a beneficial effect on blood lipids with significant increase of HDL/ total cholesterol ratio (app.
Doxazosin works by relaxing muscle around the bladder exit and prostate gland so urine is passed more easily.
Doxazosin should be administered with caution in patients with signs of minor to moderate hepatic impairment.
Doxazosin is extensively metabolised with < 5% excreted as unchanged product.
Sympathomimetics may reduce the antihypertensive effect of doxazosin; doxazosin may reduce blood pressure and vascular reactions to dopamine, ephedrine, epinephrine, metaraminol, methoxamine and phenylephrine.
- Doxorubicin, docetaxel and irinotecan, which are other cancer treatments
Duloxetine is detected in breast milk, and steady-state concentrations in breast
Duloxetine is detected in breast milk, and steady-state concentrations in breast milk are about one-fourth those in plasma.
Duloxetine is a combined serotonin (5-HT) and noradrenaline (NA) reuptake inhibitor.
As a result, levodopa remains active for longer.
The duration of the perfusion including melphalan should be 60 minutes.
However, as long as the patient does not develop an infusion reaction (rash, itching, fever, headache, high blood pressure or flushing), the medicine can be infused more rapidly, by gradually reducing the duration of infusion to 1 hour.
The infusion time must not be less than 15 minutes.
The duration of protection was 5 months after primary vaccination and one year after the third vaccination.
The duration of protection was five months after primary vaccination and 12 months after the first revaccination.
Duration of useful contrast effect at the recommended dose is adequate to perform a complete echocardiographic examination including Doppler assessment.
The duration of the effect is approximately 24 hours and, therefore, tablets can be given the night before administration of an agent that may cause emesis (e.g. chemotherapy).
The effect duration is approximately 24 h and therefore treatment can be given the night before administration of an agent that may cause emesis e.g. chemotherapy.
The infusion time must not be less than 15 minutes.
The recommended infusion time is approximately 60 minutes.
Your doctor will decide on the speed at which the infusion should be given.
Follow-up time comprised at least 180 days after administration.
The median time of progression free survival (PFS) was 47.3 weeks (95% CI:
The duration of treatment with {PRODUCT NAME} 10 mg is determined by your doctor.
One hundred and nineteen patients received ≥ 14 days of anidulafungin.
15/ 18 The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis, calicivirus, Chlamydophila felis and feline leukaemia components, and 3 years for panleucopenia component
The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis, calicivirus, Chlamydophila felis and feline leukaemia components, and 3 years for panleucopenia component.
15/ 17 The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis, calicivirus, and Chlamydophila felis, and 3 years for panleucopenia component.
The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis, calicivirus, and Chlamydophila felis, and 3 years for panleucopenia component.
The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis, calicivirus and feline leukaemia components, and 3 years for panleucopenia component.
The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis and calicivirus, and 3 years for panleucopenia component.
The duration of immunity is 1 year after the last (re-)vaccination.
The duration of immunity is 1 year after the last (re-)vaccination.
The duration of immunity is one year after the last vaccination.
5 months after primary vaccination course and 1 year after the third vaccination.
The duration of immunity is not yet fully established in cattle or sheep, although interim results of ongoing studies demonstrate that the duration is at least 6 months after the primary vaccination course in sheep.
*Cycle length was 2 weeks during which the patient received either 1 dose of DepoCyte or 4 doses of cytarabine or methotrexate.
Duration of a complete washout is usually 11 days.
In the RE-MODEL trial (knee replacement) treatment was for 6 – 10 days and in the RE-NOVATE trial (hip replacement) for 28 – 35 days.
The duration of treatment in these studies ranged from 6 to 60 months.
Duration of treatment of invasive candidiasis should be based upon the patient's clinical and microbiological response.
The duration of treatment of early Lyme disease should be 20 days.
The duration of treatment depends on the severity of the disease and the patient's response.
Treatment should continue for as short a time as possible and should stop when symptoms, chiefly the congestion (blocked nose), have disappeared.
The duration of therapy is variable, but typically less than four days.
The duration of therapy was 48 weeks with a lp
follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load < 800,000 IU/ ml (Amplicor) who were treated for 24 weeks with a 6-month follow-up period.
Limited historical data indicate that treatment for 48 weeks might be associated with a higher sustained response rate (11/11) and with a lower risk of relapse (0/11 as compared to 7/96 following 24 weeks of treatment).
Predictability of sustained virological response – Naïve patients Virological reponse by week 12, defined as a 2-log viral load decrease or undetectable levels of HCV- RNA has been shown to be predictive for sustained response (Table 8).
The duration of therapy was 48 weeks with a follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load < 800,000 IU/ml (Amplicor) who were treated for 24 weeks with a 6-month follow-up period.
The duration of therapy was 48 weeks with a follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load < 800,000 IU/ml (Amplicor) who were treated for 24 weeks with a 6month follow-up period.
The duration of therapy was 48 weeks with a follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load < 800,000 IU/ ml (Amplicor) who were treated for 24 weeks with a 6 month follow-up period.
The duration of thera py was 48 weeks with a follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load < 800,000 IU/ml (Amplicor) who were treated for 24 weeks with a 6-month follow-up period.
The duration of therapy was 48 weeks with a follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load < 800,000 IU/ml (Amplicor) who were treated for 24 weeks with a 6-month follow-up period.
The duration of therapy was 48 weeks with a follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load < 800,000 IU/ml (Amplicor) who were treated for 24 weeks with a 6-month follow-up period.
The duration of therapy was 48 weeks with a follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load < 800,000 IU/ml (Amplicor) who were treated for 24 weeks with a 6month follow-up period.
Median overall survival time was 703 days (95% CI:
The median duration of treatment was 28.1 weeks (min:
The median duration of exposure to study treatment was significantly longer (44.0 weeks) in the lenalidomide/dexamethasone group as compared to placebo/dexamethasone (23.1 weeks).
Median duration of treatment was approximately 6 months (range < 1-16 months).
The median duration of exposure in days was 245 (1-502) for the CML-CP patients and 138 (2-503) for the CML- AP patients.
The median duration of therapy was 11 months (range 0.03 -31 months).
Daily ON time with and without entacapone was recorded in home-diaries by patients.
The total duration of fever was reduced by one day in the groups treated with oseltamivir.
Dysphagia can last for up to two to three weeks after injection, but a duration of up to five months has been reported in one case.
21 for two to three weeks after injection, but has been reported in one case to last five months.
PRCA means the inability to produce enough red blood cells in the bone marrow.
The inhaler has been designed for use in a vertical position.
The way Ferriprox causes neutropenia is not known.
The way it interacts with the receptor is slightly 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The small amount of BYETTA used in the New Pen Setup will not affect the 30-day supply of BYETTA.
Fatigue was reported following 29.2% doses of Ambirix, as compared to 19.3% doses of the three dose combined vaccine.
Fatigue, alopecia, pruritus, nausea, anorexia, weight decrease, irritability and insomnia occur at a notably lower rate in patients treated with PegIntron monotherapy compared to those treated with combination therapy (see Table 4).
Fatigue, alopecia, pruritus, nausea, anorexia, weight decrease, irritability and insomnia occur at a notably lower rate in patients treated with ViraferonPeg monotherapy compared to those treated with combination therapy (see Table 4).
Closure is critical for containment and maintenance of the product in the area of intended fusion.
Ferritin is a protein that stores iron in the body.
Fertility was not impaired either in male or in female rats.
The binding affinity of 4-hydroxymethyl ambrisentan for the human endothelin receptor is 65-fold less than ambrisentan.
Atrial fibrillation and flutter are very common conditions, particularly in people over 65 years of age.
Atrial fibrillation and atrial flutter are caused by problems in the conduction of electrical impulses in the upper chambers of the heart (atria).
Uptake in the brain is rapid, reaching about 7% of injected activity at 10 minutes post-injection and decreasing to 3% after 5 hours.
Free T3 resin uptake is decreased, reflecting the elevated TBG, free T4 concentration is unaltered.
Ritonavir and nelfinavir, although known as strong inhibitors, by contrast exhibit inducing properties when used concomitantly with steroid hormones.
If you are already taking St John's wort when you start on (Invented name)®, stop taking the St John's wort and tell your doctor at your next visit.
Fluoxetine should be avoided in patients with unstable seizure disorders/ epilepsy and patients with controlled epilepsy should be carefully monitored.
Fluoxetine is well absorbed from the gastrointestinal tract after oral administration.
Fluoxetine is well absorbed after oral administration (~72%) and the absorption is not affected by feeding.
Fluoxetine is metabolised to norfluoxetine, an equipotent SSRI that contributes to the efficacy the product.
Fluoxetine is a selective inhibitor of serotonin reuptake, and this probably accounts for the mechanism of action.
Fluoxetine and its active metabolite nor-fluoxetine have been shown to be highly selective inhibitors of serotonin uptake both in vitro and in vivo.
These symptoms may indicate either serotonergic effects
Fluoxetine inhibits catecholamine uptake only at high concentrations in vitro and has no effect on catecholamine uptake in vivo at doses that are used to inhibit serotonin uptake.
- fluoxetine (used to treat depression),
- fluoxetine (used to treat depression),
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Liver function should be monitored during treatment with Eucreas at three-month intervals during the first year and periodically thereafter.
Liver function should be monitored during treatment with Icandra at three-month intervals during the first year and periodically thereafter.
Liver function should be monitored during treatment with Jalra at three-month intervals during the first year and periodically thereafter.
Liver function should be monitored during treatment with Zomarist at three-month intervals during the first year and periodically thereafter.
The dog's cardiovascular functionality should be carefully assessed before the start of the treatment with Enurace 50 and it should be periodically monitored during the treatment.
Elderly patients (65-74 years) taking Eucreas should have their kidney function monitored regularly.
Elderly patients (65-74 years) taking Icandra should have their kidney function monitored regularly.
Elderly patients (65-74 years) taking Zomarist should have their kidney function monitored regularly.
This applies particularly when losartan is given in the presence of other conditions (fever, dehydration) likely to impair renal function.
Renal function should be monitored when celecoxib and any of these medicinal products are combined.
Renal function should be monitored through daily measurements of serum creatinine.
Renal function should be monitored when parecoxib sodium and any of these medicinal products are co-administered.
Renal function and serum potassium should be monitored.
ge Renal function evaluated by serum creatinine and GFR was similar in both groups at three years posttransplant. lon The beneficial effect of Zenapax prophylaxis upon the incidence of acute rejection after renal transplantation was not associated with adverse clinical sequelae, including the development of Post- Transplant Lymphoproliferative Disease (PTLD), at 3 years posttransplant. no
The US Food and Drug Administration is topic leader for mycoplasma testing, AHI is topic leader for formaldehyde and moisture testing, with FEDESA acting as topic leader for extraneous agents.
Anti-rasburicase antibodies have been detected in treated patients and healthy volunteers administered rasburicase.
Antibody formation was lower when Humira was given together with methotrexate in comparison with use as
Antibody formation was lower when Humira was given together with methotrexate in comparison with use as monotherapy.
Antibody formation was lower when Trudexa was given together with methotrexate in comparison with use as monotherapy.
Clots in arteries supplying blood to the heart may also reduce the blood supply, causing unstable angina (a severe chest pain).
The reduction to a putative amine, as well as the subsequent N-acetylation, occurs to a minor extent.
The study lasted from one to three years, and examined the rate of new ischaemic events (heart attacks, ischaemic strokes, and death).
When the blood clots, this is due to special cells in the blood, the platelets, sticking together (aggregating).
Training for the patients will be via a healthcare professional.
The training course will take place at qualified training centres using qualified trainers.
Formation of fluid collections (pseudocysts, localised oedema, implant site effusion), sometimes encapsulated, in some cases resulting in nerve compression and pain has been reported in patients undergoing spine surgery associated with the use of InductOs.
Consideration should be given to the prolonged-release nature of the product when assessing treatment needs and recovery.
Circulating vitamin D3 is bound to vitamin D-binding protein.
The infantile-onset form of Pompe disease is characterised by massive deposition of glycogen in the heart, and skeletal muscle always resulting in rapidly progressive cardiomyopathy, generalised muscle weakness and hypotonia.
Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation following ocular dosing.
The inorganic, lyophilized form of arsenic trioxide, when placed into solution, immediately forms the hydrolysis product arsenious acid (AsIII).
The {pharmaceutical form} may be taken without regard to mealtime.
The lyophilised powder form of IntronA is to be reconstituted by adding 1 ml of water for injections to the vial.
The wording of the proposal for Section 4.2 of the SPC is not supported.
The bottle form of Emadine contains benzalkonium chloride, which is known to discolour soft contact lenses.
Mavacoxib is 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide.
Significant resource has been directed to implementation of a new computerised system to improve the way the safety of medicines is monitored in the European Community.
The provision of information to third parties, the EMEA library, archiving and mailroom services fall within the Sector’s area of operation.
Providing targeted, understandable and accessible information to patients and healthcare professionals is an important element of that commitment, and will continue to be a priority for the Agency in 2006.
The protein fraction of the molecule contributes about 58% and consists of 165 amino acids.
France referred Lederfoline and associated names to the EMEA due to divergences of the nationally authorised summaries of product characteristics particularly with respect to the sections “ indications”, “ posology” and “ contra-indications” of the summary of product characteristics.
France considers that the dosing regime of the product is not correct.
Mirapexin must be given less frequently in patients who have problems with their kidneys.
Sifrol must be given less frequently in patients who have problems with their kidneys.
The application frequency can be increased stepwise to three or four times a day according to individual lesion tolerance, allowing no less than two weeks between dose increases.
The frequency of augmentation after longer use of MIRAPEXIN and the appropriate management of these events have not been evaluated in controlled clinical trials.
-5- augmentation after longer use of SIFROL and the appropriate management of these events have not been evaluated in controlled clinical trials.
The frequency of augmentation after longer use of SIFROL and the appropriate management of these events have not been evaluated in controlled clinical trials.
The frequency of these effects is reduced if the medicinal product is taken with food.
The frequency of these reactions decreased over time.
The frequency of augmentation after longer use of pramipexole and the appropriate management of these events have not been evaluated in controlled clinical trials.
The frequency of augmentation after longer use of pramipexole and the appropriate management of these events have not been evaluated in controlled clinical trials.
The incidence of bone marrow fibrosis was not increased in a study of haemodialysis patients who were treated with erythropoietin for 3 years compared to a matched control group of dialysis patients who had not been treated with erythropoietin).
Afterwards the frequency of application should be reduced to once a day until clearance of the lesion (see section 4.4).
ed Deaths occurring during the first 6 months post-transplant were reported in 3.4% of the placebo- and in 0.6% of the Zenapax-treated groups.
Dosing frequency should initially be every second hour until clinical improvement is observed.
Serious infections occurred in 0.01 per patient-year of follow-up in ustekinumab-treated patients (5 serious infections in 407 patient-years of follow-up) and 0.02 in placebo-treated patients (3 serious infections in 177 patient-years of follow-up) (see section 4.4).
The frequency of FVIII inhibitors detected so far is within the expected and previously observed range.
The occurrence of peripheral oedema can be related to the deterioration of the disease or insufficient effectiveness of the product.
The frequency of hypocalcaemia was much lower following subsequent infusions.
The incidence was 2/ 138 in patients not exposed to muromonab-CD3 (OKT3) and 4/ 34 in patients who received muromonab-CD3 concomitantly.
The overall frequency of discontinuations in sildenafil/ epoprostenol treated patients due to adverse events was 5.2% compared to 10.7% in the placebo/ epoprostenol treated patients.
No increase in the frequency or severity of adverse events was seen with subsequent doses.
NSF is a disease involving thickening of the skin and connective tissues.
Gabapentin is indicated for the treatment of peripheral neuropathic pain such as painful diabetic neuropathy and post-herpetic neuralgia in adults.
Gabapentin did not induce structural chromosome aberrations in mammalian cells in vitro or in vivo, and did not induce micronucleus formation in the bone marrow of hamsters.
Gabapentin does not interact with sodium channels in vitro and so differs from phenytoin and carbamazepine.
Gabapentin may have minor or moderate influence on the ability to drive and use machines.
Gabapentin partially reduces responses to the glutamate agonist N-methyl-D-aspartate (NMDA) in some test systems in vitro, but only at concentrations greater than 100 µM, which are not achieved in vivo.
Agalsidase beta is a protein and is expected to be metabolically degraded through peptide hydrolysis.
Galsulfase is a protein and is expected to be metabolically degraded through peptide hydrolysis.
Gamithromycin may cause irritation to eyes or/ and skin.
The age range will be modified considering that patients aged 12 years fall within the definition of adolescents.
Age (≥ 12 years) and gender, after adjustment for body weight effects, have no apparent effect on zonisamide exposure in epileptic patients during steady-state dosing.
Age (≥ 12 years) and gender, after adjustment for body weight effects, have no apparent effect on zonisamide exposure in epileptic patients during steady-state dosing.
Age (≥ 12 years) and gender, after adjustment for body weight effects, have no apparent effect on zonisamide exposure in epileptic patients during steady-state dosing.
The age range was 3–15 years.
The starting age for vaccination with YF vaccine is 9 months of age.
The capsule and liquid dosage forms are bioequivalent.
KG Max-Planck-Ring 2 65205 Wiesbaden
The capsule contains a white to off-white powder.
“Gemcitabine is indicated in the treatment of locally advance or metastatic bladder cancer in combination with cisplatin.”.
Gemcitabine should only be prescribed by a physician qualified in the use of anti-cancer chemotherapy.
The median age of treated patients (37 males, 24 females) was 12 years old.
Median age was 37 years, with a median disease duration of 5 years.
The median age was 62 years (range 27 to 83), and 99% were Caucasian.
Mean age was 75 years at inclusion and 23% of the patients enrolled were 80 to 100 years of age.
The study population had an average age of 62 years; the average duration of diabetes was 9.5 years.
The study population had an average age of 62 years; the average duration of diabetes was 9.5 years.
The mean age of patients was 32 years, 74% were male, 82% were Asian, 12% were Caucasian, and 6% had previously received alfa-interferon therapy.
The mean age of patients was 52.5 years, 13% were ≥ 65 years of age, and just 2% were ≥ 75 years of age.
The mean age of the paediatric patients was about six years and the mean dose of hydroxocobalamin was about 120 mg/ kg body weight.
The mean age (range) of patients who died was 86 years (range 67-100).
The mean age (range) of patients who died was 86 years (range 67-100).
Age had no clinically meaningful effect on the pharmacokinetics of laropiprant.
There are no apparent age-related effects on the pharmacok inetics of PegIntron.
There are no apparent age-related effects on the pharmacokinetics of PegIntron.
There are no apparent age-related effects on the pharmacok inetics of ViraferonPeg.
There are no apparent age-related effects on the pharmacokinetics of ViraferonPeg.
Elderly: age does not affect the pharmacokinetics of palonosetron.
Age does not affect the apparent clearance in heart failure patients.
The Agency worked in conjunction with the European Commission on the development of a Budget and Accounting system.
The Agency has put in place a robust structure for creating and maintaining electronic documents.
There are 14 pharmacists, 10 with medical degrees, 5 have degrees in veterinary medicine and 7 have other scientific backgrounds (chemistry, biochemistry, pharmacology).
The Agency will contribute as required to the work of the European Parliament and Council of the European Union as they begin their consideration of the proposals.
New therapies and advances in medical science will make demands on the Agency and its committees.
European Agency for the Evaluation of Medicinal Products Sector for Document management and publishing 7 Westferry Circus Canary Wharf UK - London E14 4HB
THEEUROPEANAGENCY FORTHEEVALUATIONOF MEDI NALPRODU
The Agency will progress its work on IP telephony, web-streaming, video-streaming and other audiovisual-meetings systems, to support the Agency's objectives in the area of meetings- management.
The Agency will advance the work on the new database for GMP certificates and manufacturing authorisations, and will complete the construction of an EU telematics data centre with high availability, high scalability and good performance.
The Agency occupies three floors of 7 Westferry Circus, covering an area of about 6 500 m 2, including three conference rooms with interpretation and facilities for national delegates attending
The Agency will also continue its work with the World Health Organization, Codex Alimentarius and OIE.
Age does not appear to affect temsirolimus and sirolimus pharmacokinetics significantly.
Age has no effect on the pharmacokinetics of nelarabine or ara-G.
There are no significant effects of age or weight on the pharmacokinetic properties of histamine.
Age alone causes a 7% reduction in clearance from the age of 30 to 70 years.
The prostate gland is just underneath the bladder in men.
Glucosamine is an endogenous substance, a normal constituent of the polysaccharide chains of cartilage matrix and synovial fluid glucosaminoglycans.
Glucosamine is not indicated for the treatment of acute painful symptoms.
The E2 glycoprotein is considered to be immunologically cross-reactive with all field strains.
Agomelatine increases noradrenaline and dopamine release specifically in the frontal cortex and has no influence on the extracellular levels of serotonin.
Agomelatine is metabolised mainly by cytochrome P450 1A2 (CYP1A2) (90%) and by CYP2C9/ 19 (10%).
Agomelatine is rapidly and well (≥ 80%) absorbed after oral administration.
Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist.
Agomelatine or its metabolites are excreted in the milk of lactating rats.
Agomelatine passes into the placenta and foetuses of pregnant rats.
Agomelatine resynchronises circadian rhythms in animal models of circadian rhythm disruption.
The drop will go in here (picture 1) • Bring the bottle tip close to the eye.
The drop will go in here (picture 2) • Bring the bottle tip close to the eye.
The drop will go in here. • Hold the container between your thumb and fingers with the open end pointing down. • Bring the container tip close to the eye.
An uncommon but serious side effect is agranulocytosis (very low levels of a type of white blood cell).
In patients who continue to take NSAID medication healing is delayed.
The eighth study looked at the effect of adding Abilify or placebo to existing treatment with lithium or valproate (another antipsychotic medicine) in 384 patients.
Needle may have been attached imprecisely (e.g. at a slant).
This will ensure that the full dose has been delivered.
This will ensure that the full dose has been delivered.
This will ensure that the full dose has been delivered.
The needle should be pushed into the extremity of the syringe and rotated a quarter of a turn (90°) to secure the connection.
d needle should be inserted perpendicularly into a skin fold held between the thumb and the forefinger;
The whole length of the needle should be inserted perpendicularly into a skin fold held between the thumb and the forefinger; the skin fold should be held throughout the injection.
The whole length of the needle should be inserted perpendicularly into a skin fold held between the thumb and the forefinger;
Insert the full le ngth of the needle at right angles into the skin
The needle must go all the way in.
The filter needle should be discarded after withdrawal of the vial contents and should not be used for the intravitreal injection.
The pack is supplied without a needle.
If this happens, do not use the syringe or vial.
2 The injection needle should be inserted 3.5-4.0 mm posterior to the limbus into the vitreous cavity, avoiding the horizontal meridian and aiming towards the centre of the globe.
The injection needle should be inserted 3.5-4.0 mm posterior to the limbus into the vitreous cavity, avoiding the horizontal meridian and aiming towards the centre of the globe.
The injection needle for intramuscular injection is provided.
The needle for intramuscular injection is provided.
Remove the needle after the injection and store the pen without the needle.
The needle will automatically retract from the skin and be capped.
For calibration and measurement necessary CO2-free air (zero-gas) will be produced via an integrated CO2-absorber in the analysator.
The AUC (SD) after 2 mg single dose exposure (4 mg in patients with hepatic insufficiency) was 31.4 ng/ ml x hr (28.3) in healthy volunteers, 304.9 ng/ ml x hr (228.0) in patients with hepatic insufficiency, and 117.9 ng/ ml x hr (83.8) in the elderly type 2 diabetic patients.
Dissolve the powder completely without shaking.
Allow the vial to cool to body temperature (about 15 minutes) at room temperature before proceeding.
Incubate the yttrium-90 chloride/ acetate/ ibritumomab tiuxetan solution at room temperature for five minutes.
Leave the adapter in the plastic packaging and do not touch the spike of the adapter.
Leave the blunt filter needle in the vial and disconnect the syringe from the blunt filter needle.
Allow the syringe to move up until the entire needle is guarded.
The diluted solution should be allowed to warm to room temperature prior to administration by exposure to ambient air.
Allow the solvent front to move to the top of the strip.
Nervous, aggressive or excited animals should be given the possibility to calm down before initiation of treatment.
Nervous, aggressive or excited animals should be given the possibility to calm down before initiation of treatment.
Equilibrate the refrigerated vial of CANCIDAS to room temperature.
Leave Aldara cream on the warts for 6 to 10 hours.
Leave Aldara cream on the skin for about 8 hours.
- Leave the cartridge in the pen, put the cap on the pen, and store it
- Leave the cartridge in the pen, put the cap on the pen, and store it
Leave the pre-filled syringe at room temperature for approximately 30 minutes.
- Allow the gel to dry for three to five minutes before covering a treated area with loose clothing.
The annual EMEA/EFPIA Info-day was held in October 2002.
The bronchodilation effect caused by a β -agonist was additive to that caused by montelukast.
Individual adjustment of dosage should be considered.
The justification was considered acceptable, but the dosing section of the SPC should be amended to better reflect the use as proposed and documented by the applicant.
Serum potassium levels should be monitored regularly during Aranesp therapy.
Periodic determinations of serum potassium to detect possible electrolyte imbalance should be performed in patients at risk at appropriate intervals (see sections 4.4 and 4.5).
Since lamivudine is dialysable, continuous haemodialysis could be used in the treatment of overdosage, although this has not been studied.
Since lamivudine is dialysable, continuous haemodialysis could be used in the treatment of overdose, although this has not been studied.
Lamivudine and zidovudine are well absorbed from the gastrointestinal tract.
Lamivudine-TP and carbovir-TP (the active triphosphate form of abacavir) are substrates for and competitive inhibitors of HIV reverse transcriptase (RT).
Lamotrigine is rapidly and completely absorbed from the gut with no significant first-pass metabolism.
Laronidase is comprised of 628 amino acids after cleavage of the N-terminus.
8 Laronidase is a protein and is expected to be metabolically degraded through peptide hydrolysis.
Albumin-corrected serum calcium (mg/ dl)
Benzyl alcohol must not be given to premature babies or neonates.
Benzyl alcohol may cause toxic reactions and anaphylactoid reactions in infants and children up to 3 years old.
Cetyl and stearyl alcohol may cause local skin reactions (e.g. contact dermatitis).
Alcohol should be avoided when taking ABILIFY.
Alcohol or other strong solvents may cause skin irritation and should not be used.
Alcohol may intensify and prolong the hypoglycaemic effect of insulin.
Alcohol may intensify and prolong the hypoglycaemic effect of insulin.
Alcohol may intensify and prolong the hypoglycaemic effect of insulin. uc
Alcohol can change the ability of NovoNorm to reduce the blood sugar.
Alcohol may upset the control of your blood sugar so you are advised to talk to your doctor about drinking alcohol while taking Starlix.
Alcohol may upset the control of your blood sugar so you are advised to talk to your doctor about drinking alcohol while taking Trazec.
yellow iron oxide (E 172), red iron oxide (E 172) and titanium dioxide (E 171).
A slight decrease in renal excretion of gabapentin that is observed when it is coadministered with cimetidine is not expected to be of clinical importance.
Alemtuzumab does not appear to damage haematopoietic stem cells or progenitor cells.
Alendronate belongs to a group of non-hormonal medicines called bisphosphonates.
Lepirudin specifically blocks one of the substances involved in the clotting process, thrombin.
Lepirudin is a highly specific direct inhibitor of thrombin.
(Lepirudin is a recombinant DNA product derived from yeast cells)
Lepirudin ([Leu1, Thr2]-63-desulfohirudin) is a recombinant hirudin derived from yeast cells.
The capsule(s) must be swallowed whole, and must not be chewed, crushed or divided.
The capsule(s) must be swallowed whole, and must not be chewed crushed or divided.
Acute lymphoblastic leukaemia is a form of leukaemia in which certain abnormal white cells (named “ lymphoblasts”) start growing out of control.
Acute lymphoblastic leukaemia is caused by abnormal growth of some types of white blood cells.
Levodopa increases the amount of dopamine and hence reduces the symptoms of Parkinson's disease.
Levodopa/ carbidopa may cause false positive result when a dipstick is used to test for urinary ketone and this reaction is not altered by boiling the urine sample.
Levodopa is converted into dopamine in the brain.
Levodopa is extensively metabolised to various metabolites, decarboxylation by dopa decarboxylase (DDC) and O-methylation by catechol-O-methyltransferase (COMT) being the most important pathways.
Levodopa and entacapone may form chelates with iron in the gastrointestinal tract.
Patients who did not have an assessment 12 weeks after EOT were counted as failures.
The binding of interferon beta-1b to these receptors induces the expression of a number of gene products that are believed to be the mediators of the biological actions of interferon beta-1b.
The binding of interferon beta-1b to these receptors induces the expression of a number of gene products that are believed to be the mediators of the biological actions of interferon beta-1b.
Based on the in vitro binding and the retinoid receptor activation profile of the metabolites, and on the relative amounts of individual metabolites in plasma, the metabolites have little impact on the pharmacological profile of retinoid receptor activation by bexarotene.
Binding of A771726 appeared slightly reduced and more variable in plasma from patients with rheumatoid arthritis or chronic renal insufficiency.
The median treatment duration was 15 days in both treatment arms.
The most commonly treated fungal infection was aspergillosis (43/ 61; 70%).
5.2: protein binding for TMP and SMX is not high (TMP 50, SMX 60), but the overall proposal of the MAH can be accepted.
Since histamine release is a causal factor in all urticarial diseases, desloratadine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria, as advised in clinical guidelines.
Since histamine release is a causal factor in all urticarial diseases, desloratadine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria, as advised in clinical guidelines.
Food, including a high-fat diet, has no clinically significant effect on gabapentin pharmacokinetics.
Application in feed Incorporation of 200 mg active substance per kg feed with:
substance per kg feed with:
18 *Lipoatrophy was observed in a long-term follow-up study of stavudine in combination with lamivudine and efavirenz (total follow-up: median 148 weeks ranging up to 207 weeks).
29 *Lipoatrophy was observed in a long-term follow-up study of stavudine in combination with lamivudine and efavirenz (total follow-up: median 148 weeks ranging up to 207 weeks).
40 *Lipoatrophy was observed in a long-term follow-up study of stavudine in combination with lamivudine and efavirenz (total follow-up: median 148 weeks ranging up to 207 weeks).
7 *Lipoatrophy was observed in a long-term follow-up study of stavudine in combination with lamivudine and efavirenz (total follow-up: median 148 weeks ranging up to 207 weeks).
51 *Lipoatrophy was observed in a long-term follow-up study of stavudine in combination with lamivudine and efavirenz (total follow-up: median 148 weeks ranging up to 207 weeks).
Aliskiren should be used with caution in patients with serious congestive heart failure (New York Heart Association [NYHA] functional class III-IV).
Aliskiren on its own has been authorised in the European Union (EU) since August 2007 as Rasilez, Enviage, Sprimeo, Tekturna and Riprazo.
For a full list of excipients see section 6.1
For a full list of excipients see section 6.1.
The List of Questions was sent to the Marketing Authorisation Holder.
The list of the medicinal product names concerned is given in Annex I.
The list of product names concerned is given in Annex I.
The list of the product names concerned is given in Annex I.
(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu The list of product names concerned is given in the Annex I.
The list of product names concerned is given in Annex I.
The list of product names concerned is given in the Annex I.
The list of the product names concerned is given in Annex I.
The list of product names concerned is given in Annex I.
The list of product names concerned is given in the Annex I.
The list of the product names concerned is given in Annex I.
The list of product names concerned is given in Annex I.
The list of product names concerned is given in Annex I.
The list of product names concerned is given in Annex I.
There was a total of 2 112 at the end of 1997, most of whom also work for the national agencies and are made available to the EMEA.
Membership of the Board in 1997 is given in Annex 1.
Membership of the CPMP and CVMP is given in Annexes 2 and 3.
The list of products which interact or may interact with Tritazide is acceptable.
The physician pre-prescription checklist will highlight the contraindications to the use of ambrisentan and important pre-prescription assessments including:
The following list of undesirable effects, considered related to treatment with Thyrogen have been reported in post-marketing experience:
The following list presents events seen at a higher rate among patients receiving Fuzeon+OB regimen than among patients on the OB alone regimen with an exposure adjusted increase of at least 2 patients with event per 100 patient-years.
Alitretinoin (9-cis-retinoic acid), a naturally- occurring endogenous hormone related to vitamin A, binds to and activates all known intracellular retinoid receptor subtypes (RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ).
Breast-feeding should be stopped if you are taking SPRYCEL.
Breast-feeding should be stopped during treatment with SPRYCEL.
Breast feeding must be discontinued in women who are receiving therapy with lapatinib.
Therefore, breast-feeding should be discontinued for the duration of Paxene therapy.
Breast-feeding is contraindicated while taking mitotane (see section 4.3) and after treatment discontinuation as long as mitotane plasma levels are detectable.
Breastfeeding is not recommended while taking ISENTRESS.
Breast-feeding should be stopped while taking Siklos.
Breast-feeding is not recommended during treatment with EXJADE.
Breast-feeding is not recommended during the use of Lucentis.
CLL affects a particular lymphocyte, the B cell, which originates in the bone marrow and develops in the lymph nodes.
Loratadine is a tricyclic antihistamine with selective, peripheral H1-receptor activity.
During long-term treatment there were no clinically significant changes in vital signs, laboratory test values, physical examinations or electrocardiograms.
Alglucosidase alfa may be excreted in breast milk.
L-proline is a physiological, non- essential amino acid.
The potential for displacement and its clinical relevance are unknown.
The reduced level of alertness can make driving and using machines hazardous.
Alteration in the transport system is produced by inducible proteins codified in plasmids and transposons.
sweating, itching and dry skin, skin and nail disorders
Lutropin alfa is a recombinant human luteinising hormone, a glycoprotein composed of non- covalently bound α - and β -subunits.
The majority of these reactions were mild or moderate in intensity.
but such cases have also been reported in patients treated for osteoporosis.
The majority of adverse reactions were mild to moderate in intensity.
Most of the undesirable effects were mild to moderate in intensity.
The majority of events were asymptomatic distal DVT.
The majority (70/ 80) of the recorded VTE events were venographically detected non-symptomatic cases of DVT.
Fondaparinux provided a significant reduction in the overall rate of VTE compared with placebo [3 patients (1.4%) vs 77 patients (35%), respectively].
The majority of patients presented with juvenile myoclonic epilepsy.
Furthermore, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4% vs 1%) during treatment and during the 6 month follow-up after treatment.
Most patients had other risk factors for cancer including 8 tobacco use, papillomavirus and active hepatitis B virus infection.
The majority of patients are controlled on the initial dose of 4 mg Cardoreg 4 mg prolonged release tablets and associated names.
including Crohn’s disease, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, Sjögren’s syndrome and dermatomyositis/ polymyositis.
Gaucher disease is an inherited metabolic disorder caused by a failure to degrade glucosylceramide resulting in lysosomal storage of this material and widespread pathology.
Subclinical means that the infection is present but not sufficiently developed to produce clear clinical signs in the cow.
The way it works in this disease is not completely understood.
How duloxetine works in SUI is not clear but it is thought that, by increasing the levels of 5-hydroxytryptamine and noradrenaline at the level of the nerves that control the muscle of the urethra (the tube that leads from the bladder to outside), duloxetine causes a stronger closure of the urethra during urine storage.
Handling of the solution for infusion should be done in a safety box and protective coats and gloves should be used.
- amantadine (which can be used to treat Parkinson's disease)
- amantadine (which can be used to treat Parkinson's disease).
The margin of safety for this product is considered to be low and has not been defined in patients with severe peripheral arterial occlusive disease.
The therapeutic margin of epoetin alfa is very wide.
The therapeutic margin of erythropoietin is very wide.
The therapeutic margin of NeoRecormon is very wide.
The collagen matrix is insoluble and consists of particles with a size range of 75-425µm.
The collagen matrix is insoluble and consists of particles with a size range of 75-425µm.
Ambrisentan is glucuronidated via several UGT isoenzymes (UGT1A9S, UGT2B7S and UGT1A3S) to form ambrisentan glucuronide (13%).
Ambrisentan is a non-sulphonamide (proprionic acid) ERA.
No evidence for mutagenic or genotoxic effects of ambrisentan were seen in bacteria or in two in vivo rodent studies.
Mecasermin is a recombinant DNA-derived human insulin-like growth factor-1(IGF-1) produced in Escherichia coli.
The median PFS was 167 days for patients randomised to Nexavar compared to 84 days for placebo patients (HR = 0.44; 95% CI:
The median survival time was 17.7 months versus 14.9 months for riluzole and placebo, respectively.
The median survival time approached 16.5 months versus 13.5 months for riluzole 100 mg/ day and placebo, respectively.
The median survival for patients treated with topotecan + BSC was 25.9 weeks [95% C. I.
The median survival was 30.3 weeks (95% CI:
Median overall survival was 20.6 weeks [95% CI:
This is best done by rolling the vial tilted between the palms of the hands.
This is best done by gently tilting the cartridge back and forth (at least ten times).
Melatonin is a naturally occurring hormone produced by the pineal gland and is structurally related to serotonin.
Improvement was seen as early as 8 weeks after initiation of treatment.
Clinical improvement generally occurs within the first week after injection.
Clinical improvement generally occurs within the first two weeks after injection.
Continuous improvement is the key to success of the quality management system of the EMEA.
Better provision of information to patients, users and health professionals will be a major objective in 1998-99.
Improvement in quality of life was measured up to Week 156 (36 months) and improvement was maintained through that time.
Improvement in quality of life was measured up to week 156 (36 months) and rod
Improvement in all three haematological variables (granulocyte count, platelet count and haemoglobin level) may require six months or more.
The improvement in glycaemic control observed with this agent may be mediated by enhancing the levels of active incretin hormones.
The global symptom score also improved more in the patients taking Prometax.
Improvement was defined as a reduction from baseline of two points or more in the Knodell necro-inflammatory score with no concurrent worsening in the Knodell fibrosis score.
The same publication reported long term follow-up data from 12 MDS/ MPD patients with PDGFR gene rearrangements (5 patients from study B2225).
Infectious meningitis may be associated with intrathecal administration.
The wording also indicates the importance for stepping down to inhaled corticosteroids alone once asthma control is attained.
Each patch surface is stamped with PG T001.
The radioincorporation assay for radiochemical purity, is performed by Instant Thin Layer Chromatography (ITLC) and should be carried out according to the following procedure.
124 electrolytes should be monitored in chronic renal failure patients.
No clinically significant differences were observed for QT, PR, QRS, or QTcB measurements between duloxetine- treated and placebo-treated patients.
No clinically significant differences were observed for QT, PR, QRS, or QTcB measurements between duloxetine- treated and placebo-treated patients.
No clinically significant differences were observed for QT, PR, QRS, or QTcB measurements between duloxetine-treated and placebo-treated patients.
The main measure of effectiveness was how many patients experienced an ‘ event'such as a blocked artery, another heart attack or death, during the study.
Metformin works mainly by inhibiting glucose production and reducing its absorption in the gut.
Metformin increases the transport capacity of specific types of membrane glucose transporters (GLUT-1 and GLUT-4).
Metformin increases the transport capacity of specific types of membrane glucose transporters (GLUT-1 and GLUT-4).
Metformin increases the transport capacity of all types of membrane glucose transporters (GLUT).
- metformin, in patients (particularly overweight patients) with insufficient glycaemic
- metformin, in patients (particularly overweight patients) with insufficient glycaemic
- metformin, in patients (particularly overweight patients) with insufficient glycaemic control
Metformin is excreted unchanged in the urine.
10 Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase.
Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase and increases the transport capacity of specific types of membrane glucose transporters (GLUT-1 and GLUT-4).
Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase.
Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase.
The correct method of releasing the tablet from the blister is:
The pooling method used and the addition of the spacer is likely to mask differences in quality between the two products.
Micafungin exhibits fungicidal activity against most Candida species and prominently inhibits actively growing hyphae of Aspergillus species.
Lamictal 100 mg Tabletten zur Herstellung einer 100 mg Suspension zum Einnehmen
Lamictal 200 mg Tabletten zur Herstellung einer 200 mg Suspension zum Einnehmen
Lamictal 25 mg Tabletten zur Herstellung einer 25 mg Suspension zum Einnehmen
Lamictal 50 mg Tabletten zur Herstellung einer 50 mg Suspension zum Einnehmen
Caution should be exercised when these medicinal products are prescribed together with mirtazapine.
QUALITATIVE AND QUANTITATIVE COMPOSITION
The availability of the sublingual tablet in doses of 2 mg and 8 mg allows for a downward titration of dosage.
Progress in the implementation of the veterinary aspects of the EudraVigilance project continued to be delayed pending finalisation of VICH guidelines on data elements for transmission of adverse event reports for veterinary medicines.
Tympanostomy tube placement was reduced by 24% (95% CI:
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components.
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and Chlamydophila felis components.
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components.
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis and calicivirus components.
Onsets of immunity have been demonstrated 1week after primary vaccination course for rhinotracheitis and calicivirus components.
Amitraz is a monoamine oxidase inhibitor (MOAI).
Amlodipine at this dose level prolonged both the gestation and labour duration.
Amlodipine should be used with caution in patients with severe renal insufficiency undergoing dialysis due to limited experience.
Amlodipine is extensively metabolized by the liver to inactive metabolites with 10% of the unchanged parent compound and 60% of metabolites are excreted in the urine.
concentration at least before each administration; it should normalise within a few hours after starting Carbaglu.
Dose modification in patients with AIDS-KS is addressed in 4.8.
Authorisations under the centralised procedure Reinhard Kroker A significant development in 1998 has been the change to Part B of the Annex to Council Regulation (EEC) No 2309/ 93 allowing applications to be lodged under the centralised system for new molecules intended to be used for companion (i. e. non-food-producing) animals as well as for food-producing animals.
The molecule contains 6 N-linked oligosaccharide modifications sites.
The molecule contains 6 N-linked oligosaccharide modification sites.
Moxidectin, 23-(O-methyloxime)-F28249 alpha is a second-generation macrocyclic lactone of the milbemycin family.
It is also active against gastrointestinal nematodes.
Moxifloxacin (400 mg) was included as an active internal control.
The mean age of the patients was 67 years, and approximately 60% were at least 65 years old.
The geometric mean fold- rise of immune response following vaccination as measured by gpELISA was 2.6-fold (95% CI:
The extent of this effect was dependent on the absolute degree of hyperhomocysteinemia, being higher in severe hyperhomocysteinemia.
The extent of absorption is dose-independent and is not altered by food.
The magnitude of the decrease in oral clearance is modest (20-40%) in patients with moderate renal impairment and therefore is unlikely to be of any clinical relevance.
The magnitude of changes in fasting total cholesterol, LDL cholesterol, triglycerides, and prolactin (see sections 4.4 and 4.8) were greater in adolescents than in adults.
The magnitude of changes in fasting total cholesterol, LDL cholesterol, triglycerides, and
The magnitude of changes in fasting total cholesterol, LDL cholesterol, triglycerides, and prolactin (see sections 4.4 and 4.8) were greater in adolescents than in adults.
The magnitude of these effects is small and has little clinical importance.
MPS I is a rare, inherited disease, where the level of α -L-iduronidase enzyme activity is much lower than normal.
The G48V mutation, previously identified in vitro as a saquinavir signature mutation, was present at baseline in virus from three patients, none of whom responded to therapy.
• The M184V/ I mutation developed in 2/ 19 (10.5%) isolates analysed from patients in the emtricitabine/ tenofovir disoproxil fumarate/ efavirenz group and in 10/ 29 (34.5%) isolates analysed from the lamivudine/ zidovudine/ efavirenz group (p-value < 0.05, Fisher's Exact test comparing the emtricitabine+tenofovir disoproxil fumarate group to the lamivudine/ zidovudine group among all subjects). • No virus analysed contained the K65R mutation. • Genotypic resistance to efavirenz, predominantly the K103N mutation, developed in virus from 13/ 19 (68%) patients in the emtricitabine/ tenofovir disoproxil fumarate/ efavirenz group and in virus from 21/ 29 (72%) patients in the comparative group.
V179F was never present without Y181C.
All adults and children achieved myeloablation.
Bone marrow suppression was the major dose-limiting toxicity of Paxene.
Anagrelide should be used with caution in patients of any age with known or suspected heart disease, and only if the potential benefits of therapy outweigh the potential risks.
The intention of the naloxone component is to deter intravenous misuse.
Care should be taken when using naloxone or other opioid antagonists to treat overdose in opioid- maintained patients, due to the risk of precipitating an acute withdrawal syndrome.
The analysis explored the effects of selected covariates including body weight, age, gender, hepatic and renal function, and presence of anti-natalizumab antibodies upon pharmacokinetics.
The pooled analysis of studies using the Arizona Sexual Experience Scale (ASEX) showed that Valdoxan was not associated with sexual dysfunction.
Analysis includes studies involving BM transplant during this period; some studies used GM-CSF b Analysis includes patients receiving BM transplant during this period
The PFS analysis was conducted at 342 events in 769 patients.
64 Based on the analysis of pooled placebo-controlled clinical trials comprising a total of 1,083 Neupro- and 508 placebo-treated patients, 73.0% of the patients on Neupro and 56.3% of patients on placebo reported at least one adverse reaction.
Based on the analysis of pooled placebo-controlled clinical trials comprising a total of 1,083 Neupro- and 508 placebo-treated patients, 73.0% of the patients on Neupro and 56.3% of patients on placebo reported at least one adverse reaction.
Based on the analysis of pooled placebo-controlled clinical trials comprising a total of 748 Neupro- and 214 placebo-treated patients, 65.0% of the patients on Neupro and 32.7% of patients on placebo reported at least one adverse reaction.
Analysis of the available pharmacokinetic data shows that following intrathecal DepoCyte administration in patients, either via the lumbar sac or by intraventricular reservoir, peaks of free cytarabine were observed within 5 hours in both the ventricle and lumbar sac.
Analysis of population-based pharmacokinetics of TMZ revealed that plasma TMZ clearance was independent of age, renal function or tobacco use.
13 Analysis of population-based pharmacokinetics of TMZ revealed that plasma TMZ clearance was independent of age, renal function or tobacco use.
Analysis of population-based pharmacokinetics of TMZ revealed that plasma TMZ clearance was independent of age, renal function or tobacco use.
Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:
Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:
Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:
When the results of all four studies were analysed together, Regranex was showed to heal about 10% more ulcers after 20 weeks than a placebo gel.
If the patient population was divided into 2 subgroups (those with and those without relapses in the 2-year period prior to study entry), there was no effect on disability in patients without relapses, but in patients with relapses, the proportion with progression in disability at the end of the study was reduced from 70% (placebo) to 57% (Rebif 22 micrograms and
The primary endpoint for CHAMPIX demonstrated statistical superiority to bupropion and placebo.
Analysis of cerebrospinal fluid did not reveal major signs of inflammation.
In a pooled follow-up analysis of studies MM-009 and MM-010 (N = 704), the median TTP was 48.3 weeks (95% CI:
The final efficacy analysis included all randomised patients (197 CHOP, 202 R-CHOP), and had a median follow-up duration of approximately 31 months.
HOMA analysis shows that pioglitazone improves beta cell function as well as increasing insulin sensitivity.
Based on the analysis of pooled placebo-controlled trials, comprising a total of 1923 patients on MIRAPEXIN and 1354 patients on placebo, adverse drug reactions were frequently reported for both groups.
Based on the analysis of pooled placebo-controlled trials, comprising a total of 1923 patients on MIRAPEXIN and 1354 patients on placebo, adverse drug reactions were frequently reported for both groups.
Based on the analysis of pooled placebo-controlled trials, comprising a total of 1,923 patients on pramipexole and 1,354 patients on placebo, adverse drug reactions were frequently reported for both groups.
Based on the analysis of pooled placebo-controlled trials, comprising a total of 1923 patients on SIFROL and 1354 patients on placebo, adverse drug reactions were frequently reported for both groups.
Based on the analysis of pooled placebo-controlled trials, comprising a total of 1923 patients on SIFROL and 1354 patients on placebo, adverse drug reactions were frequently reported for both groups.
The primary time point analysis after 3 years did not reach statistical significance for all pre-specified endpoints.
The principal analysis of the pivotal comparative study in 586 patients suffering from beta- thalassaemia and transfusional iron overload did not demonstrate non-inferiority of EXJADE to deferoxamine in the analysis of the total patient population.
Ultrastructural evidence suggests that these retinal changes may be secondary to phospholipidosis.
Nateglinide, the active ingredient in Starlix, stimulates the pancreas to produce insulin more quickly.
Nateglinide, the active ingredient in Trazec, stimulates the pancreas to produce insulin more quickly.
The quality management initiative begun in 1997 began to show tangible results during 1998.
Patients with concomitant acute pulmonary infections, COPD and severe asthma should be carefully monitored.
It stops after the pre-set dose has been administered.
They stop automatically after the pre-set dose has been delivered.
The need for treatment continuation should be reconsidered every 6 months.
The need for treatment should be reassessed regularly.
The necessity to address such pre-submission issues ensures a far more streamlined approach to the evaluation phase of the procedure.
The need to hold a similar meeting at the end of 1998 to measure progress will also be considered.
It is recognised that there is a need for close collaboration with the VICH activities and in particular with the Working Parties on Anthelmintic Efficacy and Good Clinical Practice which are priority topics.
Nelarabine is a pro-drug of the deoxyguanosine analogue ara-G.
Nelarabine has not been studied in patients with hepatic impairment.
Nelarabine has not been studied in individuals with renal impairment.
Among the opportunistic infections are BK virus associated nephropathy and JC virus associated progressive
NET binds to SHBG (36%) and to albumin (61%).
Peripheral neuropathy, characterised by paresthesia/ dysesthesia, is a common and well known effect of environmental arsenic.
Peripheral neuropathy is a very common, potentially severe, adverse reaction of treatment with thalidomide that may result in irreversible damage (see section 4.4).
Peripheral neuropathy is a very common, potentially severe, adverse reaction to treatment with thalidomide that may result in irreversible damage (see section 4.8).
Neurotoxicity is the dose limiting toxicity associated with nelarabine therapy (see section 4.4).
Receptor-bound Botulinum neurotoxin type A is endocytosed into the nerve terminal prior to reaching its target (SNAP 25) and will eventually be degraded intracellularly.
Febrile neutropenia and neutropenic infection occurred respectively in 12.1% and 3.4% of patients when patients received prophylactic G-CSF, in 15.6% and 12.9% of patients without prophylactic G-CSF (see section 4.2).
Your need for insulin may change if you also take: oral antidiabetic products; monoamine oxidase inhibitors (MAOI); beta-blockers; ACE-inhibitors; acetylsalicylic acid; anabolic steroids; sulphonamides; oral contraceptives; thiazides; glucocorticoids; thyroid hormone therapy; beta- sympathomimetics; growth hormone; danazol; octreotide or lanreotide.
Your need for insulin may change if you also take: oral antidiabetic products; monoamine oxidase inhibitors (MAOI); beta-blockers; ACE-inhibitors; acetylsalicylic acid; anabolic steroids; sulphonamides; oral contraceptives; thiazides; glucocorticoids; thyroid hormone therapy; beta- sympathomimetics; growth hormone; danazol; octreotide or lanreotide.
Your need for insulin may change if you also take: oral antidiabetic products; monoamine oxidase inhibitors (MAOI); beta-blockers; ACE-inhibitors; acetylsalicylic acid; anabolic steroids; sulphonamides; oral contraceptives; thiazides; glucocorticoids; thyroid hormone therapy; beta- sympathomimetics; growth hormone; danazol; octreotide or lanreotide.
Stable angina is a heart disease which happens when the heart does not receive enough oxygen.
Languages and Linguistics at the University of East Anglia and post-graduate degree in Librarianship and Information Science at University of Wales.
Languages and linguistics at the University of East Anglia and post- graduate degree in librarianship and information science at University of Wales.
Anidulafungin has shown fungicidal activity against Candida species and activity against regions of active cell growth of the hyphae of Aspergillus fumigatus.
Anidulafungin is a semi-synthetic echinocandin, a lipopeptide synthesised from a fermentation product of Aspergillus nidulans.
Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 isoenzymes.
Nitisinone is a competitive inhibitor of 4-hydroxyphenylpyruvate dioxygenase, an enzyme which precedes fumarylacetoacetate hydrolase in the tyrosine catabolic pathway.
The year 1996 has been of particular importance since it marks the shifting of the EMEA from its inauguration to its becoming a functional Agency.
In preparation for the series of expert working group meetings scheduled to begin in early 1997, the CVMP will adopt position papers on the following topics:-
Of particular importance was the implementation in 2001 of the common technical document (CTD) format for
applications and optional applications for innovative medicines where the applicant had a choice of procedure under Part B of the Annex to Council Regulation (EEC) No 2309/ 93.
If treatment with such medicinal product is discontinued, it may be necessary to reduce the mirtazapine dose.
An event that will have an important effect on the EMEA was the announcement by the European Commission of its proposals to reform the European system for the authorisation and supervision of medicines.
In addition ETOMEP has continued to provide a number of essential support services to EMEA comprising • Network publishing:
Food had a more significant effect on the active metabolite and decreased the Cmax by 29%, although it had no effect on the AUC.
Feed should be available when vaccinating.
Food may be given 4 hours or more after treatment.
The new expiry date at 2-8 C should be noted on the carton.
Re-injections should not occur before 12 weeks.
Lansoprazol TEVA 30 mg 30 mg enterokapsler
Dominating central serotonin antagonism may reduce the tendency of paliperidone to cause extrapyramidal side effects.
The antibody is able to bind to the surface of white blood cells which infiltrate the area of infection.
The antibody is an IgG1 kappa that contains human framework regions with the complementary-determining regions of a murine parent antibody that binds to IgE.
The antibody (IMMU-MN3) recognizes an antigenic structure shared by a surface glycoprotein (NCA-90) of granulocytes and the tumour marker, carcinoembryonic antigen (CEA).
The antigen has been found on a small percentage (< 5%) of granulocytes, but not on erythrocytes or platelets.
Antithrombin, a 58 kD, 432 amino-acid glycoprotein, belongs to the serpin (serine protease inhibitor) superfamily.
Lantus 100 Units/ml solution for injection in a pre-filled pen, SoloStar, is a clear and colourless solution.
Peripheral blood mononuclear cells (PBMC) from infliximab-treated patients showed undiminished proliferative responsiveness to stimuli compared with untreated patients, and no substantial changes in cytokine production by stimulated PBMC were observed following treatment with infliximab.
Blood counts should be assessed prior to starting treatment with Diacomit.
Paliperidone can have minor or moderate influence on the ability to drive and use machines due to potential nervous system and visual effects (see section 4.8).
Abdominal palpation should be sufficient to detect abnormal increases in splenic volume.
Abdominal palpation should be sufficient to detect abnormal increases in splenic volume.
Pancytopenia is normally reversible and the intensity of bone marrow aplasia is dose-dependent.
Endogenous 84-amino-acid parathyroid hormone (PTH) is the primary regulator of calcium and phosphate metabolism in bone and kidney.
Paroxetine is contraindicated in combination with monoamine oxidase inhibitors (MAOIs).
Pharmacodynamic Effects Paroxetine does not impair psychomotor function and does not potentiate the depressant effects of ethanol.
It is general clinical experience with all antidepressant therapies that the risk of suicide may increase in the early stages of recovery.
The Agency's involvement in this cycle will continue in 2006.
Collaboration with central and eastern European countries,
Section on undesirable effects was amended according to last post marketing surveillance information, and brought also in line with the guideline on summary of product characteristics.
26 The bottom of the device is covered by a protective film that is removed before use.
- the soluble insulin part precipitates out at a pH of approximately 4.5 to 6.5.
Desiccant should not be swallowed.
Desiccant should not be removed from the container.
New diagnosis of acute myelogenous leukemia was the most common underlying condition (435/ 602, [72%]).
APC is a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S.
APC exerts its effect by the inactivation of the activated forms of factors V and VIII which leads to a decrease in thrombin formation.
The periocular skin, eyelid and ocular surface should be disinfected and adequate anaesthesia and a broad-spectrum topical microbicide should be administered prior to the injection.
- you get reddening painful skin on your hands and feet,
The skin must be completely dry before applying the patch.
disorders nausea, oral dryness
Skin does not appear to metabolize fentanyl delivered transdermally.
The PEC in soil were calculated for intensively reared animals and pasture animals, according to the CVMP Guideline on Environmental Impact Assessment for Veterinary medicinal Products in Support of the VICH Guidelines GL6 and GL38 (EMEA/ CVMP/ ERA/ 418282/ 2005-corr).
The backing film provides the matrix system with occlusivity and physical integrity and protects the adhesive/ drug layer.
Continuous subcutaneous infusion eliminates some of the variations/ fluctuations inherent to injection therapy.
The infusion of cisplatin will last approximately 2 hours.
The infusion must be conducted according to standard medical practice.
Isolated limb perfusion allows the administration of high and fairly stable concentrations of tasonermin to the limb.
Continuous IV/ SC infusion of iloprost up to 26 weeks in rodents and non-rodents did not cause any organ toxicity at dose levels which exceeded the human therapeutic systemic exposure between 14 and 47 times (based on plasma levels).
Infusion with Yondelis should be delayed or the dose of Yondelis reduced if the patient 's blood counts are abnormal (such as low counts of white blood cells or platelets).
Infusion may be given through a peripheral vein.
The infusion may be given through a peripheral vein.
The infusion may be continued for up to 4 hours post-PCI as clinically warranted.
When these symptoms go away, or improve, the infusion can be continued.
The residual medicinal product must not be flushed in the administration tubing as rapid infusion of Busilvex has not been tested and is not recommended.
The infusion will be given every two weeks.
After the last administration of Novem cattle should not be slaughtered for 15 days, and pigs should not be slaughtered for 5 days.
Yttrium (90Y) has a half-life of 2.67 days (64.1 hours).
The washout period is up to 24 weeks (95% confidence interval, 18-24 weeks)
Loss of renal function may occur with only mild changes in serum creatinine.
Hand and foot, if not affected, should be protected by Esmarch (expulsion) bandages.
The clinical relevance of this finding is not known.
The clinical relevance of these differences is unknown.
The clinical relevance of these data in European populations has not been established.
The clinical relevance of these effects is unknown.
The clinical relevance of these interactions is unknown.
The clinical relevance of these potential interactions has not been studied but caution is advised especially with concomitant use of nilotinib and medicinal products with a narrow therapeutic index.
The clinical relevance of these findings is unknown.
The clinical relevance of this is unknown.
The clinical relevance of these findings is not established.
The clinical relevance of these observations has not been established.
The clinical relevance of these findings is unknown.
The clinical relevance of these reductions has not been established, but may decrease the efficacy of these antiretroviral agents.
The clinical relevance of these findings is uncertain as this has not been studied in patients.
The clinical relevance of these findings is unknown.
The clinical relevance of this effect has not been evaluated.
The clinical relevance of this increase has not been established.
The clinical relevance of this increase has not been established.
The clinical relevance of this decrease is unknown.
The clinical relevance of this finding has not been established.
CNS toxicity has not been established.
The clinical relevance of this finding in hypertensive patients is unknown.
The clinical relevance of this finding is minimal.
The clinical relevance of this observation has not been fully elucidated.
The clinical relevance of the finding is unknown.
The clinical relevance of this observation is not known.
However, the clinical relevance of this finding is not known (see section 5.2).
However, the clinical relevance of this finding is not known.
The clinical relevance of the reduction in didanosine levels has not been established.
The potential clinical relevance of neutralizing antibody formation is not known.
The clinical relevance of hOAT-3 in sitagliptin transport has not been established.
The relevance of these data for human exposure is unknown as these effects have been seen as related to well-known pharmacodynamic or species-specific actions.
A relevance of these findings to humans cannot be excluded.
The relevance of these findings to humans is unknown.
The relevance of these findings for humans is unknown.
The relevance of these pancreatic acinar cell tumors in male rats to carcinogenic risk in humans is unclear.
The human relevance of this finding is unknown.
The relevance of the uterine endometrial adenocarcinomas for humans is uncertain; however there is no evidence from clinical trials or marketed use to suggest that these findings are of clinical significance.
The in vivo relevance of these findings is unknown.
The relevance to humans is unknown.
Hepatic impairment: the pharmacokinetics of Atripla have not been studied in patients with hepatic impairment.
Anidulafungin pharmacokinetics were examined in subjects with Child-Pugh class A, B or C hepatic insufficiency.
Multiple dose pharmacokinetics are predictable from single-dose data.
The pharmacokinetics of icatibant has been extensively characterized by studies using both intravenous and subcutaneous administration to healthy volunteers and patients.
Elimination pharmacokinetics (pharmacokinetic parameters which do not include F such as CLr and T1/ 2), are best described by linear pharmacokinetics.
The pharmacokinetics of Liprolog Mix25 are representative of the individual pharmacokinetic properties of the two components.
The pharmacokinetics of Liprolog Mix50 are representative of the individual pharmacokinetic properties of the two components.
The pharmacokinetics of PegIntron have not been evaluated in patients with severe hepatic dysfunction.
The pharmacokinetics of Thyrogen were studied in patients with well-differentiated thyroid cancer following a single 0.9 mg intramuscular injection.
The pharmacokinetics of ViraferonPeg have not been evaluated in patients with severe hepatic dysfunction.
The pharmacokinetics of bevacizumab have been studied in a limited number of paediatric patients.
The pharmacokinetics of maraviroc have not been studied in subjects with severe hepatic impairment (see sections 4.2 and 4.4).
The pharmacokinetics of oral maraviroc are not dose proportional over the dose range.
Pegaptanib pharmacokinetics have not been studied in patients with hepatic impairment.
The pharmacokinetics of orally administered telmisartan are non- linear over doses from 20 – 160 mg with greater than proportional increases of plasma concentrations (Cmax and AUC) with increasing doses.
The pharmacokinetics of orally administered telmisartan are non- linear over doses from 20 – 160 mg with greater than proportional increases of plasma concentrations (Cmax and AUC) with increasing doses.
The pharmacokinetics of tenofovir have been studied in patients with hepatic impairment and no dose adjustment is required for tenofovir disoproxil fumarate in these patients.
The pharmacokinetics of tenofovir have been studied in patients with hepatic impairment and no dose adjustment is required in these patients.
The pharmacokinetics and safety of rimonabant have not been studied in patients with severe hepatic impairment; its use in these patients is not recommended.
The pharmacokinetics are not altered with repeat dosing.
Plasma pharmacokinetics and protein binding of gadofosveset were not significantly influenced by moderate hepatic impairment (Child Pugh B).
Pharmacovigilance is of especial importance to ensure that unexpected side effects are recognised rapidly and appropriate warnings given quickly to health professionals and patients.
The elimination phase is complete approximately 7 to 8 weeks after the last RISPERDAL CONSTA injection.
The initial pilot phase will see the creation of therapeutic advisory groups in three areas: anti-infectives, oncology and diagnostic agents
- phenytoin (used to prevent convulsions) and papaverine (used to relax the muscles)
The pathophysiology of the inflammatory lesions of rosacea is, in part, a manifestation of a neutrophil-mediated process.
IOP was measured in ‘ millimetres of mercury'(mmHg).
9 Pioglitazone effects may be mediated by a reduction of insulin resistance.
Pioglitazone effects may be mediated by a reduction of insulin resistance.
26 Pioglitazone should be used with caution during concomitant administration of cytochrome P450 2C8 inhibitors (e. g. gemfibrozil) or inducers (e. g. rifampicin).
Pioglitazone should be used with caution during concomitant administration of cytochrome P450 2C8 inhibitors (e. g. gemfibrozil) or inducers (e. g. rifampicin).
Pioglitazone tablets are taken orally once daily with or without food.
Pioglitazone is contraindicated in patients with:
Pioglitazone is indicated in the treatment of type 2 diabetes mellitus:
Pioglitazone should not be used in patients with hepatic impairment (see section 4.4).
Pioglitazone or placebo was added to existing antidiabetic and cardiovascular therapy for up to 3.5 years.
Pioglitazone or placebo was added to existing antidiabetic and cardiovascular therapy for up to 3.5 years.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree.
The dosing pipettes provided with the product show graduations corresponding to the correct body weight of the dog.
The pipette should be washed and dried and the cap should be screwed back on tightly.
Pirlimycin hydrochloride is a semi-synthetic lincosamide antibiotic.
The proposed dosage range from 20-50-80 mg/ kg/ day allows the continuation of long lasting therapeutic experience supported by the recommendations of learned societies.
• Availability of medicines task force continued to propose initiatives to the Commission – to be considered as part of the 2001 review of the European marketing authorisation system
Most of these combinations have not been studied in humans.
Most of these were mild or moderate, starting early in treatment and getting milder as treatment continued.
26 Many of the adverse reactions have not been treatment limiting.
Many of the adverse reactions have not been treatment limiting.
Most of these events are commonly observed in patients Stage 5 Chronic Kidney Disease and are not necessarily attributable to Renagel.
Almost all of these occurred during or just after the infusion.
Many of these patients reported concurrent peripheral oedema.
Many of these patients were also receiving chemotherapy and corticosteroids.
Most of these patients were adolescent or young adult males.
Many of these patients were also receiving chemotherapy and corticosteroids.
Most of these reactions occur within half an hour after administering the contrast medium.
Most of these adverse reactions were reported as mild in intensity.
Most post-treatment exacerbations of hepatitis were seen within 12 weeks of discontinuation of 10 mg adefovir dipivoxil.
Most cases of varicella reported in recipients of 1 dose or 2 doses of vaccine were mild.
Most data derives from the illicit use of GHB.
Most frequent side effects affect the stomach and intestine, the nervous system and the skin and connective tissue.
Most frequent adverse effects involve the gastro-intestinal tract and the central nervous system.
Most adverse drug reactions (ADRs) observed in the two clinical studies were mild to moderate in nature.
Most of the side effects that occurred during studies were mild.
Most of the adverse reactions reported were transient and of mild intensity.
Most of the adverse reactions reported were transient and of mild intensity.
Most studies involved patients with mild to moderate hypertension and one involved patients with severe hypertension.
Most of the above mentioned medicinal products are approved for the treatment of depression and anxiety in adults, but are not licensed Europe-wide for the treatment of these conditions in children or adolescents.
Most patients (97%, N=882) had neutropenia at baseline (< 200 neutrophils/µL).
Almost all patients (98%) who experienced ocular hyperaemia did not discontinue therapy as a result of this event.
Most of the patients in these two studies were infected with human immunodeficiency virus (HIV).
Most patients will already be receiving phosphate supplements and the dose of these may need to be altered when CYSTAGON is substituted for phosphocysteamine.
Most adverse reactions were of mild or moderate intensity.
Most minor reactions to insulins usually resolve in a few days to a few weeks.
Most minor reactions to insulins usually resolve in a few days to a few weeks.
Many of the protease amino acid substitutions reported to be associated with resistance to ritonavir and saquinavir were also associated with resistance to indinavir.
Most were ocular, mild to moderate, and none was serious:
Most had a signature mutation at amino acid 155 (N155 changed to H), amino acid 148 (Q148 changed to H, K, or R), or amino acid 143 (Y143 changed to H, C, or R), along with one or more additional integrase mutations.
The lower systemic exposure to timolol following AZARGA administration is not clinically relevant.
Lowest concentration, which completely inhibits visible growth of at least 50% of isolates 2 Lowest concentration, which completely inhibits visible growth of at least 90% of isolates 3 Some of these pathogens (e. g.
The PNEC for growth effects on terrestrial plants is 45 µg/ kg determined from the NOEC of 0.45 mg/ kg for P. trivialis and an assessment factor of 10.
Sleep apnoea should be assessed before onset of growth hormone treatment by recognised methods such as polysomnography or overnight oxymetry, and monitored if sleep apnoea is suspected.
The Agency 's orphan-medicines policy is designed to support innovation and research, including that conducted by small and medium-sized enterprises.
The ointment should be applied as a thin layer to affected areas of the skin.
The pump should be pressed onto the top of the bottle and screwed until it locks tightly on the bottle.
Oocyte retrieval is performed 34-35 hours later.
The trial population had evidence of coronary artery disease with no evidence of clinical signs of heart failure.
As the AIDS-KS population is very specific, safety data from a clinical study of 107 AIDS-KS patients are presented separately at the end of Section 4.8.
995 patients comprised the intent-to-treat population.
The study population consisted of 8,556 postmenopausal women with osteoporosis as defined by low BMD (vertebral or hip BMD at least 2.5 standard deviations below the mean value for healthy young women).
The population included in this study was moderately pretreated.
The population enrolled mainly consisted in na
The unused portion of Avonex must not be re-used.
The unlocked position is the normal position for discharging the oral solution.
The new dose will be determined by your Doctor.
Dosing in children with impaired renal and/ or hepatic function has not been studied.
Dosing in children with impaired renal and/or hepatic function has not been studied.
Dosing in patients under the age of 12 years should be adjusted on the basis of body surface area as illustrated below:
Dosing of BeneFIX may differ from that of plasma-derived factor IX products.
The subsequent dosage of< COVERSYL and associated names > should be adjusted according to blood pressure response.
GANFORT is given as one drop in the affected eye(s) once a day, in the morning.
In these Member States, the initial dose is 1mg/ day.
The dosage should be adjusted on the basis of laboratory measurements of antithrombin activity.
The dosage should be determined on the basis of laboratory measurements of the protein C activity.
109 The dosage must be determined by the surgical team individually for each patient as a function of the required amount of pre-donated blood and the endogenous red cell reserve:
121 The dosage must be determined by the surgical team individually for each patient as a function of the required amount of pre-donated blood and the endogenous red cell reserve:
133 The dosage must be determined by the surgical team individually for each patient as a function of the required amount of pre-donated blood and the endogenous red cell reserve:
145 The dosage must be determined by the surgical team individually for each patient as a function of the required amount of pre-donated blood and the endogenous red cell reserve:
157 The dosage must be determined by the surgical team individually for each patient as a function of the required amount of pre-donated blood and the endogenous red cell reserve:
73 The dosage must be determined by the surgical team individually for each patient as a function of the required amount of pre-donated blood and the endogenous red cell reserve:
85 The dosage must be determined by the surgical team individually for each patient as a function of the required amount of pre-donated blood and the endogenous red cell reserve:
97 The dosage must be determined by the surgical team individually for each patient as a function of the required amount of pre-donated blood and the endogenous red cell reserve:
The dosage must be determined by the surgical team individually for each patient as a function of the required amount of pre-donated blood and the endogenous red cell reserve:
The dose should be titrated to effect based on efficacy and tolerability (see Section 4.4) up to a maximum of 9 g/ day divided into two equal doses of 4.5g/ dose by adjusting up or down in dose increments of 1.5 g/ day (i. e.
The dosage should be determined by the physician, according to the requirement of the patient.
- The weekly dose can also be divided into daily doses.
The weekly dose can also be divided into daily doses.
The recommended starting dosage of anagrelide is 1mg/ day, which should be administered orally in two divided doses (0.5mg/ dose).
The initial dosage is 3 x 40 IU/ kg per week.
The recommended starting dose of immediate-release venlafaxine is 75 mg/ day in two or three divided doses taken with food.
15 ml solution/ day) administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see section 5.1).
The recommended starting dose for ABILIFY is 15 mg administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see section 5.1).
The total daily dose should be divided into
The total daily dose should be divided into three pre-meal doses.
The dose should only be increased to the higher dose (200 mg three times a day) if the increase in how your Parkinson's disease symptoms are controlled outweighs the expected increase in side effects.
The dosage can be increased to full dose for subsequent cycles if tolerated.
The label on the carton will tell you how many tablets you should take and when.
The maximum daily dose administered in clinical trials is 320 mg in divided doses.
In patients who do not develop rash within the first 4 – 8 weeks of treatment, further Tarceva treatment should be re-assessed (see section 5.1).
The recommended daily dose of Tarceva is 100 mg taken at least one hour before or two hours after the ingestion of food, in combination with gemcitabine (see the summary of product characteristics of gemcitabine for the pancreatic cancer indication).
The recommended dose of Fablyn is one tablet once a day.
The recommended dose of fondaparinux is 7.5 mg (patients with body weight ≥ 50, ≤ 100kg) once ct
The recommended dose of fondaparinux is 7.5 mg (patients with body weight ≥ 50, ≤ 100kg) once daily administered by subcutaneous injection.
Adults and adolescents (over 12 years of age): the recommended dose of Epivir is 300 mg daily.
Adults and adolescents over 12 years of age: the recommended dose of Epivir is 300 mg daily.
The recommended dose of Trudexa for patients with psoriatic arthritis and ankylosing spondylitis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection. t
The recommended dose of Trudexa for patients with psoriatic arthritis and ankylosing spondylitis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection. rod
The recommended dose of Trudexa for patients with psoriatic arthritis and ankylosing spondylitis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection. t
The recommended dose of YENTREVE is 40 mg twice daily without regard to meals.
57 The recommended dose of Humira for patients with psoriatic arthritis or ankylosing spondylitis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection.
The recommended dose of Humira for patients with psoriatic arthritis or ankylosing spondylitis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection.
The dosage must be strictly adhered to, especially the 14-days lead-in period (see section 4.2).
The recommended dosage is 40 IU per day administered intramuscularly, however, a minimum dosage regimen of 40 IU three times a week has achieved clinical and biochemical improvement.
The recommended dose is 800 mg once a day i. e. two 400 mg tablets once a day.
The recommended dose is one drop of GANFORT in the affected eye(s) once daily, administered in the morning.
Treatment of adult patients with Philadelphia chromosome or bcr/abl translocation positive chronic myelogenous leukaemia.
The selected dosage regimen for the approved indication is 400 mg as a single dose on the first day and 200mg/ day in a single daily dose thereafter.
The recommended dose of Humira for adult patients is an initial dose of 80 mg administered subcutaneously, followed by 40 mg subcutaneously given every other week starting one week after the initial dose.
Dosage should be individualized according to baseline LDL-C levels, the goal of therapy, and patient response.
Renal function and serum potassium should be monitored.
The usual dose is between 0.5 and 1.0 U per kilogram body weight per day.
The potential for absorption and harm to the
The possibility to consider shortening treatment duration to 24 weeks in genotype 1 and 4 patients was examined based on a sustained rapid virological response observed in patients with rapid virological response at week 4 in studies NV15942 and ML17131 (see Table 8).
The possibility to consider shortening treatment duration to 24 weeks in genotype 1 and 4 patients was examined based on a sustained rapid virological response observed in patients with rapid virological response at week 4 in studies NV15942 and ML17131 (see Table 8).
The possibility of shortening treatment duration to 16 weeks in genotype 2 or 3 patients was examined based on a sustained virological response observed in patients with rapid virological response by week 4 in study NV17317 (see Table 10).
The possibility of shortening treatment duration to 16 weeks in genotype 2 or 3 patients was examined based on a sustained virological response observed in patients with rapid virological response by week 4 in study NV17317 (see Table 10).
The potential for cross-resistance between efavirenz and NRTIs is low because of the different binding sites on the target and mechanism of action.
The possibility of experiencing gastrointestinal adverse reactions (see section 4.8) may increase when orlistat is taken with a diet high in fat (e. g. in a 2000 kcal/ day diet, > 30% of calories from fat equates to > 67 g of fat).
The possibility of experiencing gastrointestinal symptoms (see section 4.8) may increase when orlistat is taken with an individual meal or a diet high in fat.
The potential for interactions must be considered in patients receiving AZOPT.
The likelihood of metabolic drug interactions with lamivudine is low due to the small extent of hepatic metabolism (5 - 10%) and low plasma binding.
The possibility of sensitisation should be borne in mind.
It is unknown whether clofarabine or its metabolites are excreted in human breast milk.
In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of antihypertensive agents was examined.
injection, is also provided in the pack.
The powder has a white to off-white colour and comes in a glass vial.
The Cetrotide 0.25 mg powder in the vial and the solvent in the pre-filled syringe have the same expiry date.
a The white to off-white cake will dissolve completely.
The white to off-white cake will dissolve completely.
The white to off-white compact lyophilised powder will dissolve completely.
The powder should be mixed with water e. g. in a bottle using ½ litres of water, shaked well and administered immediately per orally to an animal.
The powder must be reconstituted with the solvent before use by gentle swirling.
The powder must be dissolved with the solvent before use.
The powder is white and the solvent is clear and colourless.
The powder is white to off-white.
The powder is provided in a vial as a dry white to slightly yellow powder or cake.
The powder is a white to off-white cake and the solvent is a colourless liquid.
Gliolan powder should be dissolved in 50 ml tap water by a nurse or pharmacist before the patient drinks the solution.
The oral powder may be mixed with water, milk, formula, soy formula, soy milk, dietary supplements, or pudding.
The oral powder is for use in individual pigs on farms where only a small number of pigs are to receive the medicine.
Unsuspended powder appears as light yellow, dry clumps clinging to the bottom of the vial.
Powder spilled from the broken tablet should be wiped up with a damp disposable towel which is thrown out.
The powder is a white to off-white cake.
Continued absorption of fentanyl from the skin accounts for a slower reduction in serum concentration than is seen after an intravenous infusion.
Continued administration of cidofovir to patients with persistent ≥ 2+ proteinuria following intravenous hydration may result in further evidence of proximal tubular injury, including glycosuria, decreases in serum phosphate, uric acid and bicarbonate, and elevations in serum creatinine.
Further intravenous administration is not contraindicated unless the reactions reoccur or worsen.
Continued safety and efficacy assessments will be included as well as further periodic neurological and neuropsychological evaluations.
Continued treatment may give further improvement and is necessary to maintain beneficial effects.
Continued treatment may result in further improvement and is necessary to maintain beneficial effects.
17 A decision on whether to continue/ discontinue breast-feeding or to continue/ discontinue therapy with romiplostim should be made taking into account the benefit of breast-feeding to the child and the benefit of romiplostim therapy to the woman.
5 A decision on whether to continue/ discontinue breast-feeding or to continue/ discontinue therapy with romiplostim should be made taking into account the benefit of breast-feeding to the child and the benefit of romiplostim therapy to the woman.
The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta-blockers.
be calibrated by spiking standardised human plasma with 0.15 μ g/ ml lepirudin (lower limit) and 1.5 μ g/ ml lepirudin (upper limit).
The appearance of the insulin should be checked: the insulin suspension must have an evenly milky white appearance.
The mixed appearance is a white, slightly milky liquid.
In these patients, physicians should be alert to the development of marked eosinophilia, vasculitic rash, worsening pulmonary symptoms, paranasal sinus abnormalities, cardiac complications, and/ or neuropathy.
Anti-degarelix antibody development has been observed in 10% of patients after treatment with FIRMAGON for one year.
The occurrence of neutralising antibodies (inhibitors) to factor VIII is well known in the treatment of patients with haemophilia A.
Of these, 1,110 were monitored for both serious and non-serious adverse experiences.
The oedema was delayed in onset and, in some cases, severe enough to result in airway compromise.
The lever will return to its original position
- To close the Diskus, slide the thumbgrip back towards you, as far as it will go.
Pseudomembranous colitis has been reported with almost all antibiotics, including ceftriaxone.
There is no clear evidence of gallstones or of acute cholecystitis developing in children or infants treated with ceftriaxone, and conservative management of Ceftriaxone precipitate in the gallbladder is recommended.
There is no clear evidence of gallstones or of acute cholecystitis developing in children or infants treated with ceftriaxone, and conservative management of Ceftriaxone precipitate in the gallbladder is recommended.
Formation of methaemoglobinaemia > 5% has been observed despite administration at appropriate concentrations.
Development of resistance to ciprofloxacin and other fluoroquinolones has been observed in staphylococci, especially methicillin- resistant S. aureus, P. aeruginosa, E. coli and E. faecalis (see the sensitivity table).
Patients using factor VIII replacement therapy are to be monitored for the development of factor VIII inhibitors.
Patients using factor-VIII replacement therapy are to be monitored for the development of factor VIII inhibitors.
Sarcoma was associated with the long-term presence of the heterotopic bone.
Sarcoma was associated with the long-term presence of the heterotopic bone.
A kidney disorder has been reported following high doses of plasma derived Factor IX to induce immune tolerance in haemophilia B patients with factor IX inhibitors and a history of allergic reactions (see also “ Take special care with BeneFIX ”).
Factor IX to induce immune tolerance in haemophilia B patients with factor IX inhibitors and a history of allergic reactions.
Nephrotic syndrome has been reported following attempted immune tolerance induction in haemophilia B patients with Factor IX inhibitors and a history of allergic reaction.
Nephrotic syndrome has been reported following high doses of plasma derived Factor IX to induce immune tolerance in haemophilia B patients with factor IX inhibitors and a history of allergic reactions.
The applicability of the following question of the VICH GL6 was considered:
The oral applicator containing the reconstituted vaccine should be shaken gently again before oral administration.
HCA applications on the skin lesions provide rapid reduction of the skin redness, irritation and scratching while minimising the general effects.
Care must be taken to avoid application of the gel to normal skin surrounding the lesions.
It takes 83 seconds to deliver the laser dose of 50 J/ cm2 required to activate Visudyne.
Immediate gentle pressure at the injection site can limit that risk.
Transdermal administration of oxybutynin bypasses the first-pass gastrointestinal and hepatic metabolism, reducing the formation of the N-desethyl metabolite.
The recommended intake of vitamin D is 400-800 IU daily.
Hepatic oxygen delivery and consumption were not significantly altered at concentrations up to 2.0 MAC.
Your daily intake of fat, carbohydrate and protein should be distributed over three meals.
The daily intake of fat, carbohydrate and protein should be distributed over three main meals.
The daily intake of fat, carbohydrate and protein should be distributed over three main meals.
The daily intake of fat should be distributed over three main meals.
Pravastatin is a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase, the enzyme catalysing the early rate-limiting step in cholesterol biosynthesis, and produces its lipid- lowering effect in two ways.
Pravastatin is a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme catalysing the early rate-limiting step in cholesterol biosynthesis, and produces its lipid- lowering effect in two ways.
The subcutaneous route is preferred in most cases.
The subcutaneous route is preferred in most cases.
Pregabalin should be used with caution in these patients.
Pregabalin is rapidly absorbed when administered in the fasted state, with peak plasma concentrations occurring within 1 hour following both single and multiple dose administration.
No specific pharmacodynamic interaction studies were conducted in elderly volunteers.
Because it is recommended that an H1 antihistamine be administered to patients before the start of the intravenous temsirolimus infusion, temsirolimus should be used with caution in patients with known hypersensitivity to the antihistamine or in patients who cannot receive the antihistamine for other medical reasons.
The first chamber contains the powder with the active substance and the second chamber contains the solvent.
The first dose of fondaparinux is administered intravenously and subsequent doses are administered by subcutaneous injection.
Take the first dose upon getting into bed and the second dose 2.5 to 4 hours later.
The first stage is the intravenous injection of PhotoBarr.
The first study compared the effects of Crixivan with those of zidovudine (another antiviral medicine) and the combination of both medicines.
The first study included 511 patients who were ‘ HBeAg positive '(infected with the common type of the hepatitis B virus) and the second included 184 patients who were ‘ HBeAg negative '(infected with a virus that has mutated [changed], leading to a form of chronic hepatitis B that is more difficult to treat).
The first study included 1,649 women with osteoporosis who already had vertebral fractures and the second included over 5,000 women whose osteoporosis affected the hip region in the thighbone.
The first study included 72 patients and the second included 78.
The first study included a total of 320 patients whose disease was in the ‘ chronic phase’, three quarters of whom had stopped responding to imatinib.
A rather sophisticated system was set up with the express mail service provider allowing ongoing trace of mail sent out up to confirmation of receipt by addressee.
The first time you use the nasal spray, you must test that it is working properly.
The first administration of Cetrotide should be performed under the supervision of a physician and under conditions where treatment of possible pseudo-allergic reactions is immediately available.
The first injection should be initiated 5 to 15 minutes before surgery but after induction of regional block anaesthesia, if used.
The first injection should be initiated 5 to 15 minutes before surgery but after induction of regional block anaesthesia, if used.
You will have the first infusion of Cyanokit over 15 minutes.
The first dose of the day of Tasmar should be taken together with the first dose of the day of a levodopa preparation, and the subsequent doses should be given approximately 6 and 12 hours later.
The first laser light session occurred 40-50 hours after injection and a second session, if indicated, occurred 96-120 hours after injection.
The first pathway results in the formation of nicotinamide adenine dinucleotide (NAD) and nicotinamide.
The preparation of VISTIDE diluted solution should be done in a laminar flow biological safety cabinet.
The New Pen Setup is done only once, just before each new pen is used for the first time. • The purpose of the setup is to make sure that your BYETTA pen is ready to use for the next 30 days. • If you repeat the New Pen Setup before each routine dose, you will not have enough BYETTA for 30 days.
For routine use, do not repeat the New Pen Setup.
For routine use, do not repeat the New Pen Setup.
• New Pen Setup is now done.
Aprepitant (125 mg/ 80 mg) is a substrate, a moderate inhibitor, and an inducer of CYP3A4.
Aprepitant was discontinued due to adverse reactions in 0.6% of patients treated with the aprepitant regimen compared with 0.4% of patients treated with standard therapy.
Therapy should be initiated by a physician experienced in the management of HIV infection.
The therapy should be initiated by a physician experienced in the management of HIV infection.
The presence of HACA may be associated with worsening infusion or allergic reactions after the second infusion of subsequent courses (see section 5.1).
Basic vaccination of fattening pigs and breeding pigs (gilts, sows and boars):
Samples with confirmed binding activity to CTLA-4 were assessed for the presence of neutralizing antibodies.
The presence of disinfectant and/ or antiseptic in water and material used for the preparation of vaccine solution is not compatible with an effective vaccination.
The presence of Tg autoantibodies can be expected in 18-40% of patients with differentiated thyroid cancer and may cause false negative serum Tg measurements.
The presence of free Yttrium (90Y) chloride in the body after an inadvertent administration of Yttriga will lead to increased bone marrow toxicity and haematopoetic stern cell damage.
The presence of the disease in the herd should be established before preventive treatment.
The presence of the disease in the herd should be established before preventative treatment.
The presence of the disease in the herd should be established before preventative treatment.
Presence of occult CNV lesions (fluorescence not well demarcated on the angiogram) was allowed.
If severe, persistent diarrhoea occurs during or after treatment, pseudomembranous colitis which is a serious, even life-threatening complication mostly caused by clostridium difficile, should be considered,.
Presentation of data will take into consideration the following recommendations:
The multi-dose presentation is licensed only in the Czech Republic, France and Latvia.
Facilities for artificial ventilation, oxygen enrichment and circulatory resuscitation should be immediately available.
Facilities for artificial ventilation, oxygen enrichment and circulatory resuscitation should be immediately available.
Pulmonary capillary wedge pressure was also reduced.
Pressure is applied with moistened gloves or a moist pad.
The provision of services by rapporteurs or experts is governed by a written contract between the EMEA and the national agencies concerned.
Viraemia was only prevented by two injections (as recommended in the vaccination schedule for
Prilocaine, whether administered as oral, parenteral, or topical formulations may cause methaemoglobinaemia.
The primary institutional partner of the EMEA is the European Commission, in particular Directorates-General III (Industry), VI (Agriculture), XII (Science, research and development), XXIV (Consumer policy and consumer health protection) and the Joint Research Centre.
The main measure of effectiveness was the number of patients whose infection was treated successfully and who did not need further treatment with any other antibiotics.
The main measure of effectiveness was how clear the images obtained in the test were.
The main measure of effectiveness was the time spent in the ‘ off'or in the ‘ on'state (the time when levodopa is not [off] or is [on] controlling the symptoms of Parkinson's disease).
The main measure of effectiveness was the time spent in the ‘ on'state (the time when levodopa is controlling the symptoms of Parkinson's disease) after the first levodopa dose of the morning in the first study, and over one day in the second study.
The main measure of effectiveness was the improvement in the eczema seen at the end of the study (3 or 12 weeks) using a scoring system (the modified Eczema Area and Severity Index) that looks at all the symptoms of atopic dermatitis.
The main measure of effectiveness was the improvement in symptoms between the start and end of the study, measured using two standard scales.
The main measure of effectiveness was the proportion of the dogs that developed antibodies against B. canis and B. rossi two weeks after the second injection.
The main measure of effectiveness was the proportion of neonates who needed ECMO.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The main measure of effectiveness was the proportion of patients with an increase in ‘ on 'time of one hour or more, over the three weeks following the switch.
The main measure of effectiveness was the reduction in the levels of HIV in the blood (viral load) after 24 weeks.
The main measure of effectiveness was how long the patients survived.
The main measure of effectiveness was the change in pain levels between the start of the study and the last four weeks on the stable dose.
The main measure of effectiveness was time until the disease got worse or, for Kaposi's sarcoma, the number of patients who responded to treatment.
The main measure of effectiveness was the number of women who became pregnant.
The main measure of effectiveness was the number of patients who ‘ responded 'after at least five weeks of treatment.
The main measure of effectiveness was the number of patients who went into ‘ remission'(clearance of leukaemia from the bone marrow and complete or partial recovery of blood cell counts to normal levels).
The main measure of effectiveness was the number of patients who had undetectable levels of HIV-1 in their blood (viral loads) after treatment.
The main measure of effectiveness was the number of patients who had a reduction in blood calcium levels of more than 1 mg per decilitre by the time a maintenance dose had been found (between two and 16 weeks after the start of the study).
The main measure of effectiveness was the number of serious bacterial infections over a year's treatment.
The main measure of effectiveness was the highest blood platelet level that was achieved during the three- month study.
The main measure of effectiveness was the change in the level of HIV in the blood (viral load), after 4 or 24 weeks of treatment.
The main measure of effectiveness was the change in symptoms over 26 weeks, as assessed on a standard scale (Unified Parkinson's Disease Rating Scale, UPDRS).
The main measure of effectiveness (complete response) was a reduction in platelet count of at least 50% from the start of treatment or to a count below 600 million/ ml.
The main measure of effectiveness was the number of patients with no bleeding at the site of application, 10 minutes after having received Evicel or Surgicel.
The main measure of effectiveness was the number of patients with no bleeding (haemostasis) at the site of application, four minutes after having received Evicel or manual compression.
The main measure of effectiveness was the change in the level of HIV in the blood (viral load) after 24 or 48 weeks of treatment.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The main measure of effectiveness was based on the change in the questionnaire score before the study began and after six months of treatment.
The main measure of effectiveness was the number of bleeding episodes.
The main measure of effectiveness was the change in the severity of pain each week, as recorded by the patients on an 11-point scale in daily diaries.
The main measure of effectiveness was the change in the severity of pain each week, as recorded by the patients on an 11-point scale in daily diaries.
The main objection relating to the identification of the patient population especially those patients who would respond to inhaled corticosteroids alone had not been adequately identified.
The primary efficacy outcome variable for both studies was the TWSTRS-Total score (range of possible scores is 0-87) at Week 4.
Securing an adequate funding basis for the future is therefore a major priority for 1997 and 1998.
Dosing at bedtime seems to improve the tolerability of these symptoms (see section 4.2).
Dosing with food (high fat meal) delays absorption by about 1 hour.
Taking ABILIFY with some medicines may need to change your dose of ABILIFY.
As ingestion of food decreases conversion to perindoprilat, hence bioavailability ,< COVERSYL and associated names > should be administered orally in a single daily dose in the morning before a meal.
As ingestion of food decreases conversion to perindoprilat, hence bioavailability ,< COVERSYL and associated names > should be administered orally in a single daily dose in the morning before a meal.
Food does not affect the rate and extent of absorption of ranolazine.
Food intake has no relevant influence on absorption, only absorption rate is slightly diminished.
Food delays and decreases the absorption of tolcapone, but the relative bioavailability of a dose of tolcapone taken with a meal is still 80% to 90%.
Food delays the time to reach the peak concentration from 6 to 10 hours and it marginally decreases the extent of absorption (approximately 11%).
Food delays the time to reach the peak concentration from 6 to 10 hours and it marginally decreases the extent of absorption (approximately 11%).
Food delays the time to reach the peak concentration from 6 to 10 hours and it marginally decreases the extent of absorption (approximately 11%).
Food delays the time to reach the peak concentration from 6 to 10 hours and it marginally decreases the extent of absorption (approximately 11%).
Food delays the time to reach the peak concentration from 6 to 10 hours and it marginally decreases the extent of absorption (approximately 11%).
Taking alli means your body will pass more fat through, and therefore may struggle to cope with eating as much fat as before.
The use of potassium supplements, potassium-sparing diuretics or potassium-containing salt substitutes, particularly in patients with impaired renal function, may lead to a significant increase in serum potassium.
The increasing awareness of the problems associated with antimicrobial resistance in human medicine is well recognised by the CVMP.
Rare cases of fainting (transient loss of consciousness), which may be preceded by a general feeling of being sick (e. g. nausea, stomach upsets) have been reported.
Lansoprazol ratiopharm has minor or moderate influence on the ability to drive and use machines.
Food intake has no influence on the pharmacokinetics of mirtazapine.
If you use more Preotact than you should:
5 The rate and extent of absorption is reduced when riluzole is administered with high-fat meals (decrease in Cmax of 44%, decrease in AUC of 17%).
Weight gain has been reported post-marketing among patients prescribed ABILIFY.
Breast- feeding while taking EXJADE is not recommended.
34 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
Use of anti-tuberculosis therapy should also be considered before the initiation of Remicade in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.
The management of such patients should be directed by physicians with experience in the care of patients with haemophilia (see section 4.4).
In managing overdosage, consider the possibility of multiple drug involvement.
Usual medical care for FAP patients should be continued while on celecoxib.
The usual medical care for FAP patients should be continued.
The optimal therapeutic management of patients with YMDD variant HBV has not yet been established (see section 4.4).
Evaluation by a cardiology specialist, performance of an echocardiogram and determination of serum troponin should therefore be considered in patients with HES/ CEL, and in patients with MDS/ MPD associated with high eosinophil levels before imatinib is administered.
Supportive care for gastrointestinal adverse events requiring treatment may include medication with an anti- emetic or anti-diarrhoeal medication.
105 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
20 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
27 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
35 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
41 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
48 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
65 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
78 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
93 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
Once a day dosing of CIALIS may be useful to men who anticipate having sexual activity two or more times per week.
Concomitant intake with alcohol is not recommended.
Food increases the bioavailability to 80 to 90%.
The Kaplan-Meier estimate for continued sustained response over 5 years is 97% (95% CI:
462 patients completed at least 5 years na
462 patients completed at least 5 years of long-term follow-up and only 12 sustained responders' out of 492 relapsed during this study. no
SVR after treatment of chronic HCV with non pegylated interferon alfa-2b (with or without ribavirin) results t
The Kaplan-Meier estimate for continued sustained response over 5 years for all patients is 97% with a 95% Confidence Interval of [95%, 99%].
The Kaplan-Meier estimate for continued sustained response over 5 years for all patients is 97% with a 95% Confidence Interval of [95%, 99%]. i dic
The Kaplan-Meier estimate for continued sustained response over 5 years for all patients is 99% (95% CI:
The Kaplan-Meier estimate for continued sustained response over 5 years is 97% (95% CI:
The chances of this happening may be higher in women taking Avandia for more than one year.
The chances of this happening may be higher in women taking rosiglitazone for more than one year.
The procedure was referred to the CHMP, who raised a number of issues through a List of Questions and a subsequent List of Outstanding Issues, which were addressed by the Applicant.
The procedure was therefore referred to the CHMP in October 2008.
The arbitration procedure started on 20 September 2007 with the adoption of a List of Questions.
The arbitration procedure started on 11 July 2007 with the adoption of list of questions.
The arbitration procedure started on 1 June 2006 with the adoption of a list of questions.
The arbitration procedure started on 26 April 2007 with the adoption of a list of questions.
The arbitration procedure started on 26 April 2007 with the adoption of a list of questions.
The arbitration procedure started on 27 April 2006 with the adoption of a list of questions.
The Decentralised Procedure, SE/ H/ 575/ 07/ DC, started on 1 September 2006.
The test procedure involves the following steps:
The procedure for reconstitution is described in section 6.6.
The referral procedure started on 19 September 2005.
The referral procedure started on 21 April 2005.
The referral procedure started on the 21 September 2006.
The referral procedure started 26 April 2002.
The arbitration procedure started on 27 April 2006.
The referral procedure started on 29 April 2005.
The referral procedure started on 21 October 1998.
The procedure for checking mock-ups and specimens within the EMEA will also be optimised.
The injection procedure should be carried out under aseptic conditions, which includes the use of surgical hand disinfection, sterile gloves, a sterile drape and a sterile eyelid speculum (or equivalent) and the availability of sterile paracentesis (if required).
This does not comply with the recommendations of the current guidance document (CVMP/ VICH/ 832/ 99), ‘ where pharmacokinetic parameters cannot demonstrate a relationship with effectiveness, two dose confirmation studies using the dose limiting parasite for therapeutic claims ….. will be needed .'For dose confirmation studies, ‘ at least two controlled or, where appropriate, critical dose confirmation studies ….. are recommended. 'Efficacy could be claimed if effectiveness against each parasite declared on the labelling was at 90% or above based on calculation of geometric means and there was a statistically significant difference in parasite numbers between control and treated horses.
The production of the medicine had moved from the factory that made the medicine used in the studies, to another factory that was to make the commercial product.
Antibody response to an experimental neo-antigen (∅ X174) was reduced during Raptiva therapy, but began to normalize 6 weeks after discontinuation of Raptiva therapy and did not demonstrate tolerance induction.
The generation of such antibodies with low binding capacity is unlikely to be clinically relevant.
Endogenous growth hormone production may also increase in some individuals with end-stage renal disease.
Excessive decreases in blood pressure or respiratory depression may be related to the depth of anaesthesia and may be corrected by decreasing the inspired concentration of sevoflurane.
Disability progression was measured as an increase in the Expanded Disability Status Scale (EDSS) of 1.0 point, sustained for at least six months.
Progression was defined as any of the following events: progression to accelerated phase or blast crisis, death, loss of CHR or MCyR, or in patients not achieving a CHR an increasing WBC despite
21 Cytomegalovirus (CMV) prophylaxis is recommended for 3 months after transplantation, particularly for patients at increased risk for CMV disease.
37 Cytomegalovirus (CMV) prophylaxis is recommended for 3 months after transplantation, particularly for patients at increased risk for CMV disease.
Cytomegalovirus (CMV) prophylaxis is recommended for 3 months after transplantation, particularly for patients at increased risk for CMV disease.
The proportion of affected patients decreases with subsequent infusions.
The proportion of patients with at least one SRE (excluding hypercalcaemia) was 29.8% in the Zometa-treated group versus 49.6% in the placebo group (p=0.003).
The proportion of patients who maintained CCyR for 1 year was 97% (95% CI:
The proportion of patients who maintained MCyR for 18 months was 90% (95% CI:
The proportion of patients healed after treatment with InductOs 1.5 mg/ ml was significantly higher at all visits from 10 weeks to 12 months post-operative, suggesting accelerated fracture healing.
The proportion of patients who experienced complete response, partial response or stable disease was 44.0% and 27.5%, respectively, for the Tarceva and placebo groups (p = 0.004).
The proportion of subjects achieving clinical remission at week 10 was 58.9% (66/ 112).
The proportion of subjects in clinical response at week 10 was 88.4% (99/ 112).
Dose-proportionality was not established for Cmax and C24hr (Cmax increased in a greater than dose-proportional manner and C24hr increased in a less than dose-proportional manner).
Dose-proportionality was not established for Cmax and C24hr (Cmax increased in a greater than dose-proportional manner and C24hr increased in a less than dose-proportional manner).
Dose proportionality has not been established in patients.
Protection against hepatitis B infections may not be obtained until after the second dose (see section 5.1).
The protection given by Ibraxion was measured by the reduction of clinical signs of IBR after the virus was introduced to the cattle.
Protein C contained in CEPROTIN is a normal constituent of human plasma and acts like endogenous protein C.
The protein product of the proto-oncogene KRAS (Kirsten rat sarcoma 2 viral oncogene homologue) is a central down-stream signal-transducer of EGFR.
Proteinuria ranged in severity from clinically asymptomatic, transient, trace proteinuria to nephrotic syndrome, with the great majority as Grade 1 proteinuria.
Caution must be exercised in patients with central or peripheral nervous system disease, e. g. brain metastasis or neuropathy (see section 4.8).
Potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes should be co-administered cautiously with Kinzalkomb (see section 4.5).
Potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes should be co-administered cautiously with MicardisPlus (see section 4.5).
Potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes should be co-administered cautiously with PritorPlus (see section 4.5).
Therefore, caution should be exercised in patients with cardiac dysfunction.
Therefore, caution should be exercised when driving or using machines.
Therefore, caution should be recommended when driving a car or operating machines.
Caution should also be exercised when duloxetine is used 3 with medicinal products that may impair its metabolism (see section 4.5).
Caution should also be exercised when duloxetine is used with medicinal products that may impair its metabolism (see section 4.5).
Care must be taken to avoid inadvertent injection of RISPERDAL CONSTA into a blood vessel.
Caution is required when co-administering potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes with Rasilez HCT (see sections 4.5 and 4.8).
Careful dose titration of Ranexa is recommended in patients treated with P-gp inhibitors.
Caution should be exercised when deferasirox is combined with strong UDP- glucuronosyl transferase (UGT) inducers, or CYP2C8 substrates (see section 4.5).
Caution should be exercised when < Invented Name > is administered to breastfeeding women.
Patients with hepatic impairment should be treated with caution (see section 4.4).
As a result, caution should be exercised when treating patients with these medicinal products as concomitant therapy since there is a potential for a significant interaction.
Dysphagia may persist for two to three weeks after injection, but has been reported to last up to five months post-injection.
Caution is advised during concomitant administration of fosaprepitant and CYP3A4 substrates.
Caution is advised during concomitant administration of EMEND and CYP3A4 substrates.
Caution should be exercised when these medicinal products are prescribed together with mirtazapine.
Caution should be exercised when ziconotide is administered to patients with impaired hepatic function.
Caution should be exercised when ziconotide is administered to patients with impaired renal function.
Pseudoephedrine is a nasal decongestant, which exerts its sympathomimetic effects indirectly, predominantly through release of adrenergic mediators from postganglionic nerve terminals.
Pseudo-ephedrine is a nasal decongestant, which exerts its sympathomimetic effects indirectly, predominantly through release of adrenergic mediators from postganglionic nerve terminals.
The advisability of driving should be considered in these circumstances.
The advisability of driving should be considered in these circumstances.
The publication of provisional rules on access to documents was welcomed at the workshop on transparency held at the EMEA on 30 October 1997, in particular by the European Ombudsman.
No more than 1.5 times the required diffuser power output should be needed from the laser.
PUVA is a type of treatment where the patient receives a medicine containing a compound called a ‘ psoralen 'before being exposed to ultraviolet light.
- Pyelonephritis is often associated with bacteraemia.
- Pyelonephritis is often associated with bacteraemia.
Quality of life was improved significantly with Circadin 2 mg compared to placebo.
The appropriate amount of powder is measured using the special scoops supplied in the pack, and the powder mixed with milk or formula.
The quantity of follitropin alfa per ml is 600 IU (equivalent to 44 micrograms).
The amount of levodopa available to the brain is increased.
Less NAP226-90 is formed following application of the transdermal patch, presumably because of the lack of presystemic (hepatic first pass) metabolism, in contrast to oral administration.
This should be taken into consideration by patients on a controlled sodium diet.
This should be taken into consideration by patients on a controlled sodium diet.
The amount of TESLASCAN in breast milk is not known.
The amount of Osigraft used should approximate the size of the bone defect.
The quantity of Ytracis needed for radiolabelling and the quantity of the radiolabelled medicine that is given will depend on the medicine that is radiolabelled and the disease that is being treated.
The quantity of YTRACIS required for radiolabelling and the quantity of Yttrium (90Y)-labelled medicinal product that is subsequently administered will depend on the medicinal product radiolabelled and its intended use.
The quantity of Yttriga required for radiolabelling and the quantity of Yttrium (90Y)-labelled medicinal product that is subsequently administered will depend on the medicinal product radiolabelled and its intended use.
If the same error occurs again, OptiSet may be damaged, use a new OptiSet.
The total amount of infliximab given to you is based on the dose and your body weight.
That adds up to 3500 fewer calories per week, about the number of calories in 0.5 kg (1 lb) of fat.
The activity administered must be such that the resulting radiation dose is as low as reasonably achievable bearing in mind the need to obtain the intended diagnostic result.
The reason for stage pooling is to become discriminative in terms of lung deposition and the measurement of particle size with an instrument such as an impactor is a way to obtain information on particle size of the aerosolized medication and the particle size distribution.
Rasburicase must be reconstituted with the entire volume of the supplied solvent ampoule (1.5 mg rasburicase vial to be reconstituted with the 1 ml solvent ampoule; 7.5 mg rasburicase vial to be reconstituted with the 5 ml solvent ampoule).
Acute GVHD was rated as serious in 3 patients.
The most frequent adverse reaction during treatment with epoetin alfa is a dose-dependent increase in blood pressure or aggravation of existing hypertension.
The most frequent adverse reaction during treatment with epoetin alfa is a dose-dependent increase in blood pressure or aggravation of existing hypertension.
The conduct of these tests should be recorded on your Patient Alert Card.
Research has shown an increased risk of birth defects in children of women taking anti-epileptic medicines.
Dose reductions were noted to slow or stop the progression of splenic enlargement and in 3% of patients a splenectomy was required.
Reduction of levodopa dosage decreases the severity and frequency of these reactions.
The reduction of urinary GAG excretion was somewhat less in patients for whom circulating anti-idursulfase antibodies were detected.
Reductions in pneumonia with abnormal chest radiograph were greatest in the first year of life (32.2%; 95% CI:
The reduction in flushing symptoms (assessed by patient questionnaires) was correlated with a reduction in nicotinic acid-induced vasodilatation (assessed by measurements of skin blood flow).
The deltoid region (shoulder) or the gluteal region (buttocks) may also be used.
The rules governing medicinal products for human use in the European Union catalogue n˚ CO-86-94-319-EN-C, also available in ES, DA, DE, GR, FR, IT, NL, PT
The rules governing veterinary medicinal products in the European Community catalogue n˚ CO-77-92-384-EN-C, also available in ES, DE, FR, IT
Recovery from methaemoglobinaemia is rapid; full recovery is recorded in less than 24 hours.
The relationship of these substitutions to in vivo effectiveness of enfuvirtide has not been established.
The relationship between concentration and effect has not been evaluated after administration of fosaprepitant.
The relationship between serum concentration and receptor saturation was assessed in 13 patients and was similar to that characterised in adult renal transplantation patients.
The relationship between in vitro anti-HIV-1 activity of amprenavir and the inhibition of HIV-1 replication in humans has not been defined.
Dose-dependency of the proliferative effect of unopposed oestrogens
Duration-dependency of the proliferative effect of unopposed oestrogens
The relationship of the infarct to prior administration of BeneFIX is uncertain.
The response after 6 months was similar to that seen with infliximab.
Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.
Response to treatment with Combivir varies between patients.
Response to treatment with Epivir varies between patients.
Response to treatment with Kivexa varies between patients.
Patients should be evaluated after 2 to 4 weeks of treatment with montelukast.
The response to treatment with Quadrisol was similar to the response to the other similar product.
Response to treatment with Trizivir varies between patients.
Response to treatment with Zerit varies between patients.
Response to treatment with Ziagen varies between patients.
Efficacy tended to be lower in patients positive for antibodies to ustekinumab; however, antibody positivity does not preclude a clinical response.
inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. t
response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.
response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. t uc
 the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.
The antibody response to HPV-16 and HPV-18 was measured using a type-specific ELISA which was shown to correlate with the pseudovirion-based neutralisation assay.
7 To address the heterogeneity in disease manifestation across patients, using a composite endpoint that summed up clinically significant changes across five efficacy variables (percent predicted normal FVC, 6MWT distance, shoulder flexion range of motion, AHI, and visual acuity) the global response was an improvement in 26 patients (58%), no change in 10 patients (22%), and a deterioration in 9 patients (20%).
The maximum response is usually achieved by 4 weeks and is maintained after that.
Transient platelet response was defined as weekly platelet count ≥ 50 x 109/ l for 4 or more times during study weeks 2-25 but without durable platelet response.
Virological response to APTIVUS/ ritonavir therapy has been evaluated using a tipranavir-associated mutation score based on baseline genotype in RESIST-1 and RESIST-2 patients.
Virological response should be frequently monitored in the lamivudine-refractory population and appropriate resistance testing should be performed.
SVR after treatment of chronic HCV with non pegylated interferon alfa-2b (with or without ribavirin) results in long-term clearance of the virus providing resolution of the hepatic infection and clinical'cure' from chronic HCV.
SVR after treatment of chronic HCV with non pegylated interferon alfa-2b (with or without ribavirin) results t
SVR after treatment of chronic HCV with PegIntron (with or without ribavirin) results in long-term clearance of the virus providing resolution of the hepatic infection and clinical “cure” from chronic HCV.
SVR after treatment of chronic HCV with ViraferonPeg (with or without ribavirin) results in long-term clearance of the virus providing resolution of the hepatic infection and clinical “cure” from chronic HCV.
Sustained Virologic Response (SVR) is defined as undetectable HCV-RNA at 24 weeks post-treatment (Table 10).
25 Resistance: resistance to efavirenz can be selected in vitro and resulted in single or multiple amino acid substitutions in HIV-1 RT, including L100I, V108I, V179D, and Y181C.
Resistance to thymidine analogues (of which zidovudine is one) is well characterised and is conferred by the stepwise accumulation of up to six specific mutations in the HIV reverse transcriptase at codons 41, 67, 70, 210, 215 and 219.
Resistance to cephalosporins results from enzymatic inactivation (β -lactamase production) or from other mechanisms.
Resistance against potentiated sulphonamides may vary.
Resistance against potentiated sulphonamides may vary.
Cross-resistance is frequent between tetracyclines.
HIV-1 resistance to lamivudine involves the development of a M184I or, more commonly, M184V amino acid change close to the active site of the viral RT.
HIV-1 resistance to lamivudine involves the development of a M184V amino acid change close to the active site of the viral reverse transcriptase (RT).
MLSB resistance may be constitutive or inducible.
Resistance is uncommon in Enterobacteriaceae and the drug is generally active against those with extended-spectrum beta-lactamases (ESBLs).
AmpC types) are present in conjunction with reduced permeability, arising by the loss of one or more outer membrane porins, or with up-regulated efflux.
Resistance may be chromosomal or plasmid-encoded and may be transferable if associated with transposons or plasmids.
Resistance may be chromosomal or plasmid-encoded and may be transferred if associated with transposons or plasmids.
Misuse of antibiotics increases resistance.
Solving issues relating to nationally approved medicines at Community level is important example of the role of the EMEA at the centre of the European medicines control system.
18/ 24 Sevoflurane causes dose-dependant respiratory depression, therefore respiration should be closely monitored during sevoflurane anaesthesia and the inspired concentration of sevoflurane adjusted accordingly.
Sevoflurane causes dose-dependant respiratory depression, therefore respiration should be closely monitored during sevoflurane anaesthesia and the inspired concentration of sevoflurane adjusted accordingly.
The wheezing observed in the younger age group could be attributed to a number of diagnoses (viral infection, RSV bronchiolitis, or early symptoms of classic asthma).
The rapid and complete recovery of haemodynamics and subsequently of blood gases, pH, and lactate after cyanide poisoning likely contributed to the better outcome of the hydroxocobalamin-treated animals.
Having all three substances in the same tablet can lower the number of tablets the patients have to take and help them stick to treatment.
Success of remnant ablation was assessed with radioiodine imaging and with serum thyroglobulin testing at 8 months after treatment.
The following revision to Section 4.2 of Singulair 4 mg OG SPC was finally accepted:
Ribavirin should be discontinued if either of the following apply:
Ribavirin therapy is contraindicated in women who are pregnant.
Ribavirin therapy is contraindicated in women who are pregnant.
Ribavirin therapy is contraindicated in women who are pregnant.
10 contraindicated in women who are pregnant.
148 contraindicated in women who are pregnant.
56 contraindicated in women who are pregnant.
79 contraindicated in women who are pregnant.
Ribavirin was active in the Balb/ 3T3 in vitro Transformation Assay.
Ribavirin was active in the Balb/3T3 in vitro Transformation Assay.
Rifabutin increases the Cmin of tipranavir by 16%.
Rifabutin is considered to be a weaker inducer than rifampicin.
Risperidone showed statistically significant and clinically important effectiveness in treating aggression and less consistently in treating agitation and psychosis in elderly dementia patients (as measured by the Behavioural Pathology in Alzheimer's Disease Rating Scale [BEHAVE-AD] and the Cohen-Mansfield Agitation Inventory [CMAI]).
Risperidone has no affinity for cholinergic receptors.
Rivastigmine may cause increased gastric acid secretions.
Rivastigmine is an acetyl- and butyrylcholinesterase inhibitor of the carbamate type, thought to
The increase in prothrombin time induced by warfarin is not affected by administration of rivastigmine.
Rivastigmine was not mutagenic in a standard battery of in vitro and in vivo tests, except in a chromosomal aberration test in human peripheral lymphocytes at a dose 104 times the maximum clinical exposure.
64 Rivastigmine was not mutagenic in a standard battery of in vitro and in vivo tests, except in a chromosomal aberration test in human peripheral lymphocytes at a dose exceeding 104 times the foreseen clinical exposure.
74 Rivastigmine was not mutagenic in a standard battery of in vitro and in vivo tests, except in a chromosomal aberration test in human peripheral lymphocytes at a dose exceeding 104 times the foreseen clinical exposure.
Rivastigmine was not mutagenic in a standard battery of in vitro and in vivo tests, except in a chromosomal aberration test in human peripheral lymphocytes at a dose exceeding 104 times the foreseen clinical exposure.
The increase in prothrombin time induced by warfarin is not affected by administration of oral rivastigmine.
Rivastigmine may exacerbate or induce extrapyramidal symptoms.
Consistent with the characteristics of a medicinal product that is primarily cleared by metabolism, moderate hepatic disease has a significant impact on laropiprant pharmacokinetics, with an increase in AUC and Cmax of approximately 2.8- and 2.2-fold respectively.
Rosiglitazone is indicated in the treatment of type 2 diabetes mellitus:
Rosiglitazone should therefore not be used in women who are breast-feeding.
13 Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.
Rosuvastatin (Crestor) 10 mg is currently authorised in the majority of MS as a start and maintenance dose with acceptable risk/ benefit ratio.
Rosuvastatin accounts for greater than 90% of the circulating HMG-CoA reductase inhibitor activity.
Because rotigotine is a dopamine agonist, it is assumed that dopamine antagonists, such as neuroleptics (e. g. phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of Neupro, and co-administration should be avoided.
Rotigotine may have major influence on the ability to drive and use machines.
Rotigotine may pass into your breast milk and affect your baby and is also likely to reduce the amount of milk you produce.
Rotigotine then stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the signs and symptoms of Parkinson's disease, such as stiffness and slowness of movement.
Stopping your treatment with Mycophenolate mofetil Teva may increase the chance of rejection of your transplanted organ.
Smoking should also be stopped as it could decrease the amount of medicine in the blood.
Treatment should be discontinued in these patients.
Consideration should be given to discontinuing treatment in patients who have shown no response up to 28 weeks of treatment.
The concomitant use of voriconazole with St John's Wort is contraindicated (see section 4.5).
Discontinuation of treatment does not lead to a rebound effect.
There should be no noticeable effects if you stop taking Rapinyl, but possible symptoms of withdrawal are anxiety, tremor, sweating, paleness, nausea and vomiting.
Discontinuation of treatment may result in a withdrawal syndrome that may be delayed.
Prevention of cardiovascular disease
SVR after treatment of chronic HCV with interferon alfa-2b (pegylated and nonpegylated,with or without Rebetol) results in long-term clearance of the virus providing resolution of the hepatic infection and clinical'cure' from chronic HCV.
SVR after treatment of chronic HCV with interferon alfa-2b (pegylated and nonpegylated, with or without ribavirin) results in long-term clearance of the virus providing resolution of the hepatic infection and clinical'cure 'from chronic HCV.
- The scope of the referral was to agree whether Cardoreg 4mg prolonged release tablets differ
Treatment of episodes of major depression.
The above mentioned referral has been administered as outlined below.
The reprographics room on the fourth floor was relocated to provide extra space for additional computer equipment as a result of the changeover to the new information technology architecture.
4 Sapropterin should be used with caution in patients who are receiving concomitant levodopa, as combined treatment with sapropterin may cause increased excitability and irritability.
Sapropterin was found to be weakly mutagenic in bacterial cells and an increase in chromosome aberrations was detected in Chinese hamster lung and ovary cells.
The AUC of FBAL increased with age (20% increase in age results in a 15% increase in the AUC of FBAL).
Planar imaging in all views necessary to adequately visualise the affected area at 1-8 h post-injection with at least 500 k counts or ten minutes per view should be made.
The plasma AUC of zonisamide was increased by 35% in subjects with creatinine clearance < 20 ml/ min (see also section 4.2.).
Bone changes including premature epiphyseal closure, hyperostosis, and calcification of tendons and ligaments have occurred after several years of administration at very high doses for treating disorders of keratinisation.
Dry eyes can be helped by the application of a lubricating eye ointment or by the application of tear replacement therapy.
The second chamber contains a sterile solvent for reconstitution.
The second dose should be given after an interval of at least three weeks after the first dose.
The second dose of the vaccine (V2) should be administered 4 weeks later.
The second study also looked at the number of patients whose bowels opened at least twice within four hours of the first four doses.
The second study showed that the LDL cholesterol levels were further reduced when Pelzont was taken with simvastatin (48% reduction), compared with Pelzont alone (17% reduction) or simvastatin alone (37% reduction).
The second study showed that the LDL cholesterol levels were further reduced when Tredaptive was taken with simvastatin (48% reduction), compared with Tredaptive alone (17% reduction) or simvastatin alone (37% reduction).
The second study looked at using Flebogammadif for immunomodulation in 20 patients with ITP.
Safety of Aerius syrup was demonstrated in three paediatric trials.
Safety of Azomyr syrup was demonstrated in three paediatric trials.
Security of information and of the EMEA premises remains a high
Long-term safety of inhaled human insulin has not been established in paediatric patients with diabetes and its use is therefore not recommended in patients under 18 years of age (see section 5.2).
The clinical safety during lactation has not been established, consequently use in nursing mothers is not recommended.
The safety of Convenia has not been assessed in animals suffering from severe renal dysfunction.
17 Pregnancy and breast-feeding The safety of OPTISON for use during human pregnancy has not been fully established.
The safety of posaconazole has been assessed in > 2,400 patients and healthy volunteers enrolled in clinical trials and from post-marketing experience.
Safety in malignant hypertension is not established.
The safety and efficacy of Atripla have not been studied for the treatment of chronic HBV infection.
The safety and efficacy of the dose interval adjustment guidelines provided in section 4.2 are based on pharmacokinetic modelling and have not been clinically evaluated.
Safety of Neoclarityn syrup was demonstrated in three paediatric trials.
The safety of Ribavirin capsules is evaluated from data from three clinical trials in patients with no previous exposure to interferon (interferon-naïve patients): two trials studied Ribavirin in combination with interferon alfa-2b, one trial studied Ribavirin in combination with peginterferon alfa-2b.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation, thus the use is not recommended during pregnancy and lactation.
The safe use of loratadine during pregnancy has not been established.
The safe use of {INVENTED NAME} during pregnancy has not been established.
3 The safety of OPTISON for use during human pregnancy has not been established.
The safety of sugammadex has been evaluated based on an integrated safety database of approximately 1700 patients and 120 volunteers.
The safety of the vaccine was studied in laboratory safety studies carried out with BTVPUR AlSap 8 in cattle and sheep.
Safety and effectiveness in women have not been established because of the paucity of clinical data.
The safety and efficacy in children and adolescents have not been studied in large controlled clinical trials.
The safety and efficacy of this combination have been established only using ribavirin capsules together with peginterferon alfa-2b or interferon alfa-2b solution for injection.
5 with pegylated or other forms of interferon (i. e. not alfa-2b) in these patients have not been evaluated.
The safety and efficacy of using BeneFIX for immune tolerance induction has not been established.
The safety and effectiveness of Protopic has been studied in more than 13,500 patients treated with tacrolimus ointment in clinical trials.
The safety and efficacy of Vaniqa was evaluated in two double-blind, randomised, vehicle- controlled clinical trials involving 594 women of skin types I-VI (393 on Vaniqa, 201 on vehicle) treated for up to 24 weeks.
Safety and efficacy in patients under the age of 12 years have not been substantially documented.
The safety and efficacy of PegIntron therapy has not been evaluated in patients with severe hepatic dysfunction, therefore PegIntron must not be used for these patients.
The safety and efficacy of ViraferonPeg therapy has not been evaluated in patients with severe hepatic dysfunction, therefore ViraferonPeg must not be used for these patients.
Selamectin activates special proteins called ‘chloride channels'on the surface of nerve and muscle cells, disrupting their normal electrical activity.
Selamectin has adulticidal, ovicidal and larvicidal activity against fleas.
There is an 80-fold selectivity over PDE1, and over 700-fold over PDE 2, 3, 4, 7, 8, 9, 10 and 11.
Thirteen isolates previously characterised as efavirenz-resistant were also resistant to nevirapine and delavirdine.
The sensitivity of the vaccine strain to antibiotics is listed below (SPC under section 4.8)
The sensitivity of the vaccine strain to antibiotics is listed above.
Prior to initiation of therapy, bacteriological sensitivity tests should be conducted.
The in vitro sensitivity to cidofovir is shown in the following table:
Sepsis related to leukopaenia was observed infrequently (< 1%).
The amino acid sequence of exenatide partially overlaps that of human GLP-1.
The full course of injections should be repeated for every pregnancy.
The plastic oral dosing syringe consists of two parts, an opaque barrel, and a white plunger rod that fits into the barrel.
The dosing syringe and cap are to be used once and then discarded.
 The syringe and needle should NEVER be re-used.
The syringe and needle should NEVER be reused.
The syringe and needle should NEVER be re-used.
The syringe and needle should NEVER be reused.
The syringe and needle should NEVER be reused.
 The syringe and needles should NEVER be re-used.
The dispenser provided with your medicine must always be used to measure to correct dose.
The syringe, needle and all injection materials are intended for single use and must be discarded after the injection.
The solvent pre-filled syringe provided should be used for reconstitution only and then disposed of in accordance with local requirements.
 The pre-filled syringe is for single-use administration only.
Dosing procedure using the measuring syringe:
The syringe fits onto the drop dispenser of the bottle and has a kg-body weight scale which corresponds to the maintenance dose.
The severity of vigabatrin attributed VFD could be determined for 92 patients.
Sibutramine is well absorbed and undergoes extensive first-pass metabolism.
Sibutramine and its active metabolites are eliminated by hepatic metabolism; the main enzyme involved is CYP3A4, and CYP2C9 and CYP1A2 can also contribute.
The clinical significance of these increases is unknown, and higher doses of PREMARIN< or local TRADEMARK > were not studied in combination with etoricoxib.
The clinical relevance of these findings is still uncertain.
This is not likely to be relevant for humans given recommended nasal doses which results in minimal systemic exposure (see section 5.2).
It cannot be excluded that sorafenib may increase the concentrations of concomitantly administered substrates of CYP2B6 (e. g. bupropion, cyclophosphamide, efavirenz, ifosfamide, methadone) and CYP2C8 (e. g. paclitaxel, amodiaquine, repaglinide).
The clinical relevance of this finding is unknown.
The clinical significance of this is unknown.
However, the clinical relevance of this finding is not known (see section 5.2).
However, the clinical relevance of this finding is not known.
The clinical significance of asymptomatic increases in serum amylase is unknown.
The relevance of these tumour findings in rodents in terms of human risk is unknown.
The significance of these findings for humans is unknown.
The relevance of this finding is unknown.
The significance of these findings is unknown, but they have been associated with delayed development.
The relevance of these findings to humans is not known.
The relevance of the osteodystrophy, the prolactin-mediated tumours and of the presumed rat substrain-specific renal tumours in terms of human risk is unknown.
side effects of the medicinal products could be increased.
Myopathy/ Rhabdomyolysis Simvastatin, like other inhibitors of HMG-CoA reductase, occasionally causes myopathy manifested as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times the upper limit of normal (ULN).
Simvastatin is an inactive lactone which is readily hydrolyzed in vivo to the corresponding beta-hydroxyacid, a potent inhibitor of HMG-CoA reductase.
Simvastatin and lovastatin are highly dependent on CYP3A4 for their metabolism and co-administration with REYATAZ/ ritonavir may result in increased concentrations.
- simvastatin (used to lower cholesterol),
Sitagliptin prevents the hydrolysis of incretin hormones by DPP-4, thereby increasing plasma concentrations of the active forms of GLP-1 and GIP.
As the company had supplied the additional information requested, the ‘ Exceptional Circumstances 'ended on 12 April 2002.
The company wanted the authorisation to be granted in Austria, Belgium, Bulgaria, the Czech Republic, Denmark, Estonia, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, Slovakia, Slovenia and Spain (the concerned Member States).
The company wanted the authorisation to be recognised in Austria, Denmark, Germany, Greece, Hungary, Poland, Portugal and Sweden (the concerned Member States).
ABILIFY oral solution may be used as an alternative to ABILIFY tablets for patients who have difficulty swallowing ABILIFY tablets (see section 5.2).
Oral solution is available to patients who have difficulty swallowing.
The oral solution can be considered for patients who have difficulty swallowing tablets.
Beromun should only be administered if leakage is less than 10%.
Pedea solution must not be in contact with any acidic solution such as certain antibiotics or diuretics.
Use the bar-code labels marked “30-minute- value” for these samples.
Dissolved Xeomin is intended for injections into the muscle.
The diluted solution should be taken immediately.
• The diluted solution must be mixed thoroughly by inverting several times
The diluted solution for injection should be used immediately.
The solution should be used immediately after preparation.
If refrigerated, the solution must be allowed to reach room temperature before administration.
- The solution is coloured or you can see particles floating in it.
Apidra 100 Units/ml, solution for injection in a pre-filled pen, SoloStar.It is a clear, colourless solution with no particles visible.
The solution for injection contains the active substance follitropin beta, produced by genetic engineering of a Chinese hamster ovary (CHO) cell line, in a concentration of 833 IU/ ml aqueous solution.
Ovitrelle 250 micrograms solution for injection may be stored at room temperature (at or below +25° C) for up to 30 days without being refrigerated again during this period, and must be discarded if not used during these 30 days.
The solution for injection form is also used in dogs to reduce post-operative pain and inflammation following orthopaedic and soft tissue surgery or in cats to reduce post-operative pain after ovariohysterectomy (spaying) and minor soft tissue surgery.
The solution for injection is for single use only.
Do not worry if the solution remains slightly hazy after mixing with water; this is normal.
There may be some translucent-to-white particles of protein in the solution.
The solution for injection is used for the treatment of pain and inflammation associated with orthopaedic (bone) or soft tissue surgery.
SOLUTION SHOULD NEVER BE ADMINISTERED BY RAPID OR BOLUS INTRAVENOUS INJECTION.
Infusion solutions should be used immediately after dilution.
391 Unless compatibility with other infusion solutions/drugs has been confirmed, the infusion solution must always be administered separately.
Unless compatibility with other infusion solutions/drugs has been confirmed, the infusion solution must
Unless compatibility with other infusion solutions/drugs has been confirmed, the infusion solution must always be administered separately.
Since the infusion solution is photosensitive, the infusion bags should be removed from the box only immediately before use.
The infusion solution can be infused either directly or after mixing with other compatible infusion solutions.
The solution (resulting volume 4.2 ml, concentration 238 mg/ ml) should be administered by deep intramuscular injection.
Somatropin has effects that are equivalent to human growth hormone of pituitary origin.
Somatropin also increases cardiac output, but the mechanism has yet to be clarified.
Somatropin also increases cardiac output, but the mechanism has yet to be clarified.
Somatropin is a potent metabolic hormone of importance for the metabolism of lipids, carbohydrates and proteins.
Somatropin should not be used for growth promotion in patients with closed epiphyses.
- Somatropin must not be used for growth promotion in patients with closed epiphyses.
Somatropin stimulates lipid metabolism; it increases plasma fatty acids and high-density lipoprotein (HDL)-cholesterols, and decreases total plasma cholesterol.
The live bacterium strain included in Nobivac Bb differs from other types of B. bronchiseptica because it is missing certain molecules and is therefore less likely to cause disease.
The feline leukaemia vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A.
The vaccine strain is resistant to aminoglycosides, sulphonamides, flumequine, and trimetroprim-sulfa combinations.
The vaccine strain is sensitive to penicillins, tetracyclines, macrolides and lincomycin.
The vaccine strain is sensitive to penicillins, tetracyclins, macrolides and lincomycin.
The vaccine strain is a deletion mutant with a limited growth potential in mammalian tissue.
The vaccine strain is a recombinant Herpesvirus of turkeys (HVT) expressing the protective antigen (VP2) of the Infectious Bursal Disease Virus (IBDV) strain Faragher 52/ 70.
The vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A.
The vaccine organism may establish a small suppurative inflammation locally at the injection site, leading to a disruption of the overlaying lip mucosa and subsequent discharge fluid and inflammatory cells.
The vaccine organism may establish a small suppurative inflammation locally at the injection site, leading to a disruption of the overlaying lip mucosa and subsequent discharge fluid and inflammatory cells.
PSUR submission when Prepandrix is used during the influenza pandemic:
Sparfloxacin, an aminodifluoroquinolone, is a synthetic antibiotic belonging to the quinolone family.
Sparfloxacin exhibits a spectrum of activity which is related to the therapeutic indication described in chapter 4.1 and focused on S. pneumoniae.
cytologic alteration of the hepatocytes, notably vacuolisation and multifocal or single cell liver necrosis;
There may also be a change in appearance of the fur (oily appearance and clumping or spiking of hair) at the application site.
There may be a change in appearance of the fur (oily appearance and clumping or spiking of hair) at the application site.
ibuprofen, diclofenac sodium and naproxen) may irritate the stomach and intestine.
As spironolactone has an antiandrogenic effect (acts against male hormones), it is not recommended to administer the product to growing dogs.
Spironolactone decreases digoxin elimination and hence raises digoxin plasma concentration.
Concomitant treatment with irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serotonin syndrome with symptoms such as agitation, tremor and hyperthermia.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The concurrent administration of Kineret and etanercept or other TNF antagonists is not recommended (see section 4.5).
The combination of losartan with a beta-blocker should be used with caution”.
Sirolimus in combination with other immunosuppressive agents has not been extensively investigated.
The combination of losartan with a beta-blocker should be used with caution (see section 5.1).
Potassium sparing diuretics, potassium supplements or potassium-containing salt substitutes:
ris combination therapy using the Mann-Whitney U test c. p-value is from the pairwise comparison of Trudexa monotherapy and methotrexate monotherapy using the Mann-Whitney U test
ris combination therapy using the Mann-Whitney U test c. p-value is from the pairwise comparison of Trudexa monotherapy and methotrexate monotherapy using the Mann-Whitney U test
Stavudine was carcinogenic in mice (liver tumours) and rats (liver tumours: cholangiocellular, hepatocellular, mixed hepatocholangiocellular, and/ or vascular; and urinary bladder carcinomas) at very high exposure levels.
CNS stimulation is particularly likely in children, as are atropine-like symptoms (dry mouth, fixed and dilated pupils, flushing, hyperthermia, and gastrointestinal symptoms).
Last Observation Carried Forward
on EMEA web site in 2001 and 2002.
The structure of the Unit remained stable with Dr Peter Jones as Head of Unit and the Heads of Sector, Dr Jill Ashley-Smith and Dr Kornelia Grein.
This work was carried out in collaboration with the Rapporteurs and Co- Rapporteurs for the products involved and the European Department for the Quality of Medicines.
Glycylcycline class antibiotics are structurally similar to tetracycline class antibiotics.
The staff structure of the Veterinary Medicines Unit has been assembled taking account of the likely workload forecasted in both MRL and CVMP/Procedures sectors.
The structure of the EMEA Secretariat became more stable by the end of 1996 and it is anticipated that it will remain largely unchanged during 1997 and 1998.
The active ingredient in Avonex is a protein called interferon beta-1a.
The active substance in Glivec, imatinib, is a protein-tyrosine kinase inhibitor.
The active substance in Glustin 30 mg tablets is pioglitazone.
The active substance in Glustin 45 mg tablets is pioglitazone.
The active ingredient of Lamictal passes into breast milk and may affect your baby.
The active substance is idursulfase, which is a form of the human enzyme iduronate-2-sulfatase.
- The active ingredient in MabThera is called rituximab.
< Invented Name > contains the active substance pimecrolimus, a calcineurin inhibitor.
The active substance of Prometax is rivastigmine.
The active ingredient in Telzir is fosamprenavir.
Eurican Herpes 205 contains the active substance canine herpes virus (F205 strain) antigens in a dose of 0.3 to 1.75 µg.
- The active substance of Zyrtec is cetirizine dihydrochloride.
- The active substance of Zyrtec Oral solution is cetirizine.
The active substance of Omnitrope is somatropin (1.3 mg) in a vial.
The active substance of Omnitrope is somatropin (3.3 mg/ ml) in a cartridge.
The active substance of Omnitrope is somatropin (5 mg/ ml) in a vial.
The active substance of Omnitrope is somatropin (6.7 mg/ ml) in a cartridge.
The active substance of FORCALTONIN is recombinant salmon calcitonin.
The active substance is cetrorelix acetate 0.26 – 0.27 mg, equivalent to 0.25 mg cetrorelix.
- The active substance is agalsidase beta, one vial contains 35 mg.
- The active substance is Yttrium (90Y) chloride.
The active substance is Yttrium (90Y) Chloride.
- The active substance is gadofosveset trisodium 244 mg/ millilitre corresponding to 0.25
- The active substance is moroctocog alfa (recombinant coagulation factor VIII).
- The active substance is mycophenolate mofetil
- The active substance is parecoxib (as parecoxib sodium).
- The active substance is peginterferon alfa-2b, 100 micrograms/0.5 ml.
- The active substance is peginterferon alfa-2b, 120 micrograms/0.5 ml.
- The active substance is peginterferon alfa-2b, 150 micrograms/0.5 ml.
- The active substance is peginterferon alfa-2b, 50 micrograms/0.5 ml.
- The active substance is peginterferon alfa-2b, 80 micrograms/0.5 ml.
- The active substance is peginterferon alfa-2b, 80 micrograms/0.5 ml.
- The active substance is sodium phenylbutyrate.
The active substance is eptotermin alfa (a recombinant human Osteogenic protein 1 produced in a recombinant Chinese hamster overy (CHO) cell line).
- The active substance is tolcapone (100 mg in each film- coated tablet)
- The active substance is tolcapone (200 mg in each film- coated tablet)
- The active substance is toremifene; each tablet contains 60 mg (as citrate).
- The active substance is arsenic trioxide 1 mg/ml
One ml of Insuman Rapid contains 100 IU (International
One ml of Insuman Rapid contains 40 IU of the active
- The other ingredients are disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate,
- The other ingredients are disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate,
- The other ingredients are disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate,
The active substance is olopatadine 1 mg/ ml (as hydrochloride).
The active substance is sulesomab Each 3 ml vial contains 0.31 mg sulesomab (IMMU-MN3 murine Fab′ -SH antigranulocyte monoclonal antibody fragments).
The active substance tipranavir is an antiretroviral agent used in the treatment of Human Immunodeficiency Virus (HIV) infection.
The active substance in Thyrogen is thyrotropin alfa.
Substance P is found in significant concentrations in the nuclei comprising the emetic centre and is considered the key neurotransmitter involved in vomiting.
The substance can be directly measured in the plasma up to approximately 2.5 months post implantation.
In NovoRapid substitution of amino acid proline with aspartic acid at position B28 reduces the tendency to form hexamers as observed with soluble human insulin.
Switching a patient to another type or brand of insulin should be done under strict medical supervision and may require change in dose.
The single substitution of chlorine for hydrogen at position 2 distinguishes cladribine from its natural counterpart 2'-deoxyadenosine and renders the molecule resistant to deamination by adenosine deaminase.
HER2 overexpression should be detected using an immunohistochemistry (IHC)-based assessment of fixed tumour blocks (see 4.4).
To the extent possible, the accessible surface area of the fracture (fracture lines and defects) should be covered with InductOs.
The area of the patch is 39 cm2 releasing a nominal 3.9 mg of oxybutynin per 24 hours.
The area of the patch is 39 cm2 releasing a nominal 3.9 mg of oxybutynin per 24 hours.
The area of the patch is 39 cm2, releasing a nominal 3.9 mg of oxybutynin per 24 hours.
Post-marketing surveillance of the more than 428 million doses that have been distributed worldwide (1978 to 2005) indicates that serious adverse events such as encephalitis and encephalopathy continue to be rarely reported.
Cardiac monitoring is not recommended except in patients with serious conduction abnormalities or arrhythmias.
Monitoring the level of active substance in the blood provides the most reliable basis for dose adjustment.
Cardiac function should be further monitored during treatment (e. g. every three months).
shows positive appreciation for the improvements introduced in the scientific advice procedure, another of the Agency’s priorities in 2002.
Periodic quantitative monitoring of urinary protein excretion is recommended.
The onset has typically been 1-5 days after administration of the first or subsequent injections, also after long duration of treatment.
These effects are much less likely to occur than with oral corticosteroids.
Pulmonary symptoms, such as cough and dyspnoea, may be a reason for discontinuation of the therapy and for further investigation, as appropriate.
In the event of elevated ALT and/ or AST during treatment, follow- up should be organised and dose reduction should be considered.
In the event of elevated ALT and/ or AST during treatment, follow- up should be organised and dose reduction should be considered.
In the event of elevated ALT and/ or AST during treatment, follow-up should be organised and dose reduction should be considered.
It can be expected that hepatitis D will also be prevented by immunisation with Fendrix as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
Pancytopenia has been uncommonly reported during clinical trials with pemetrexed.
If an allergic reaction to ertapenem occurs, discontinue the therapy immediately.
However, since a significant percentage of these patients were
The occurrence or aggravation of exertional dyspnea is usually the first clinical sign and requires treatment discontinuation and investigation in a specialised unit (see special warnings).
The occurrence or aggravation of exertional dyspnea is usually the first clinical sign and requires treatment discontinuation and investigation in a specialised unit (see special warnings).
Survival in the treated patients was compared to survival in a similar historical cohort of untreated subjects using a Cox proportional hazards regression analysis (See Table 3).
Survival and tumour progression have been examined in five large controlled studies involving a total ro
Survival and tumour progression have been examined in five large controlled studies involving a total ro
Survival and tumour progression have been examined in five large controlled studies involving a total of 2833 patients, of which four were double-blind placebo-controlled studies and one was an open- label study.
Survival and tumour progression have been examined in five large controlled studies involving a total of 2833 patients, of which four were double-blind placebo-controlled studies and one was an open- label study.
The overall survival is 65 months since diagnosis (range 25-234).
Median overall survival was 62 weeks for topotecan versus 53 weeks for paclitaxel (hazard ratio 0.9 [0.6, 1.3]).
Median overall survival had not yet been reached in either treatment arm at the time of analysis.
In-hospital and 3 month survival status was reported for 98% and 94% of the 1690 PROWESS subjects respectively.
The median survival of all patients enrolled was 17 months (range < 1 to 36+ months).
The 6-month event-free survival for the ITT population was 44% with a median event-free survival of 4.6 months, which was similar to the results for the progression-free survival.
Tracheostomy-free survival in patients treated with riluzole did not differ significantly from placebo.
The shaken suspension will appear as a turbid liquid with a slow settling white deposit
The shaken suspension will appear as a turbid liquid with a slow settling white deposit.
The oral suspension must be shaken well before use.
The oral suspension must be shaken well before use.
Oral suspension should be taken without food 6-17 years
Oral suspension can be taken independent of mealtimes.
As Ciprofloxacin Bayer 50 mg/ mL suspension contains 1.4 g sucrose per 5-mL measuring spoonful, this has to be taken into consideration in terms of daily intake.
The suspension should be administered immediately after complete disintegration of the tablet(s).
Once prepared, the suspension should be drunk within two hours.
The suspension should be given using the Metacam measuring syringe provided in the package.
There should be no noticeable effects on cessation of treatment with Rapinyl, but possible symptoms of withdrawal are anxiety, tremor, sweating, paleness, nausea and vomiting.
Suspension and emulsion to be mixed before administration
Suspension and emulsion to be mixed before administration
The suspension can be given using the measuring syringe provided in the package.
The suspension can be given using the Rheumocam measuring syringe provided in the package.
The suspension can be given using either of the two measuring syringes provided in the package.
The suspension can be given using either of the two measuring syringes provided in the package (depending on weight of dog).
The suspension can be given using the drop dispenser of the bottle for cats of any body weight.
The suspension can be given using either the drop dispenser of the bottle (for very small breeds) or the Metacam measuring syringe provided in the package.
The suspension can be given using either the drop dispenser of the bottle (for very small breeds) or the Metacam measuring syringe provided in the package.
The suspension can be given using either the drop dispenser (for very small breeds) or the Acticam measuring syringe provided in the package.
The suspension can be given using either the drop dispenser (for very small breeds) or the Acticam measuring syringe provided in the package (see below).
The suspension can be given using either the drop dispenser (for very small breeds) or the Flexicam measuring syringe provided in the package.
The suspension can be given using either the drop dispenser (for very small breeds) or the Flexicam measuring syringe provided in the package (see below).
The suspension has to be given with the measuring syringe provided in the package.
The suspension can be used by adults and adolescents instead of the capsule.
The vaccine suspension should be spread evenly over the correct number of chickens, at a distance of 30-40 cm using a coarse spray, preferably when the chickens are sitting together in dim light.
5-ALA synthesis is regulated by an intracellular pool of free heme via a negative feedback mechanism.
They have different sized lactone rings and due to the dimethylamino group, are basic.
Udder size, poor milk aspect, and pain also showed to be generally higher in the non-treated group.
Tasonermin is produced by recombinant DNA technology in E. coli.
Tasonermin is produced by recombinat DNA technology in E. coli
Tasonermin is a tumor necrosis factor alfa-1a; TNFα -1a, produced by recombinant DNA technology in E. coli.
Atazanavir has activity against HIV-2 isolates (EC50 of 1.9 to 32 nM).
Atazanavir has activity against HIV-1 Group M subtype viruses A, B, C, D, AE, AG, F, G, and J isolates in cell culture.
Telbivudine-5'-triphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate, thymidine 5'-triphosphate.
Telbivudine did not show any carcinogenic potential.
Telbivudine is not a substrate, inhibitor or inducer of the cytochrome P450 (CYP450) enzyme system.
Telithromycin inhibits protein synthesis by acting at the ribosome level.
Telithromycin displays moderate non-linear pharmacokinetics.
The tendency to develop tolerance varies considerably between individuals.
Photo- sensitivity reactions Increased tendency to bruise Dermatitis contact Urticaria Cold sweat
The blood pressure was measured in ‘ millimetres of mercury'(mmHg).
The blood pressure was measured in ‘ millimetres of mercury'(mmHg).
The preparation exhibits specific antagonistic actions on H1-receptors and affects histamine-induced skin wheals with a maximum effect reached after 4 hours.
(see attached SPC) was agreed upon this analysis.
3 The head of the cat should be held with its nose pointing upwards and its mouth closed, so that it is forced to breathe through its nostrils.
The head of the cat should be held with its nose pointing upward and its mouth closed, so that it is forced to breathe through its nostrils.
Bexarotene therapy should only be initiated and maintained by physicians experienced in the treatment of patients with CTCL.
Thrombin then converts fibrinogen into fibrin and a clot can be formed.
Thrombin then converts fibrinogen into fibrin and a clot is formed.
Thrombin then converts fibrinogen into fibrin and a clot can be formed.
Thrombin and fibrinogen are natural substances that are obtained from human blood.
Thrombin plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross- linked framework that stabilises the thrombus.
Thrombin plays a central role in the process of blood clotting.
Tigecycline may have adverse reactions similar to tetracycline class antibiotics.
Sixty-seven percent of the patients were able to be titrated to an effective dose.
In a clinical study with healthy subjects, there was an increase in serum tizanidine concentration (Cmax increase:
Tizanidine must not be administered together with Ciprofloxacin (see section 4.3).
Tolcapone blocks an enzyme that is involved in the breakdown of levodopa in the body called catechol-O-methyl transferase (COMT).
The long- term safety of Enbrel in combination with other disease-modifying antirheumatic drugs (DMARD) has not been established.
The long-term safety of Enbrel in combination with other disease-modifying antirheumatic drugs (DMARD) has not been established.
Tolerance to TMZ is similar to adults.
The safety of Vectibix in patients with mCRC who received at least one dose of Vectibix was evaluated in 920 patients.
The safety of anagrelide has been examined in 4 open label clinical studies.
The safety of EXJADE in combination with other iron chelators has not been established.
Safety of combination not established; combination not recommended.
Since tolcapone did not alter the tolerability of ephedrine, these drugs can be co-administered.
Specifically the safety of hydroxycarbamide had been examined retroactively from cohorts of 123 adults and 352 paediatric patients, over 13 years and up to 12 years respectively.
The safety of Neoclarityn syrup in children 2- to 11-years of age who are poor metabolisers is the same as in children who are normal metabolisers.
17 Safety of ReFacto AF was evaluated in previously treated children and adolescents (n=18, age 12-16 in a study and n=49, age 7-16 in a supporting study).
27 Safety of ReFacto AF was evaluated in previously treated children and adolescents (n=18, age 12-16 in a study and n=49, age 7-16 in a supporting study).
7 Safety of ReFacto AF was evaluated in previously treated children and adolescents (n=18, age 12-16 in a study and n=49, age 7-16 in a supporting study).
Safety of ReFacto AF was evaluated in previously treated children and adolescents (n=18, age 12-16 in a study and n=49, age 7-16 in a supporting study).
or uth ZIMULTI 20 mg has been evaluated for safety in approximately 2500 patients enrolled in studies that examined the metabolic and weight loss effects in overweight and obese patients and in approximately 3800 patients in other indications.
As the safety of < Invented Name > has not been established in erythrodermic patients, the use of the product in this patient population cannot be recommended.
The safety of fondaparinux 2.5 mg has been evaluated in 3,595 patients undergoing major orthopaedic surgery of the lower limbs treated up to 9 days, in 327 patients undergoing hip fracture surgery treated for 3 weeks following an initial prophylaxis of 1 week, 1,407 patients undergoing abdominal surgery treated up to 9 days, and in 425 medical patients who are at risk for thromboembolic complications treated up to 14 days.
No studies on the effect on the ability to drive and to use machines have been performed.
The safety of fondaparinux has been evaluated in 2,517 patients treated for Venous Thrombo-
The safety of fondaparinux has been evaluated in 2,517 patients treated for Venous Thrombo- Embolism and treated with fondaparinux for an average of 7 days.
The safety of fondaparinux has been evaluated in 2,517 patients treated for Venous Thrombo- Embolism and treated with fondaparinux for an average of 7 days.
The safety of sildenafil has not been studied in patients with known hereditary degenerative retinal disorders such as Retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases) and therefore its use is not recommended.
Safety and effectiveness in paediatric patients have not been established. – Elderly:
Safety and efficacy of CHAMPIX in combination with other smoking cessation therapies have not been studied.
Safety and efficacy of dasatinib have not yet been studied in paediatric patients.
The safety and efficacy of aripiprazole solution for injection has not been evaluated in patients with alcohol or medicinal product intoxication (either with prescribed or illicit medicinal products).
The safety and efficacy of erlotinib has not been studied in patients with renal impairment (serum creatinine concentration > 1.5 times the upper normal limit).
The safety and efficacy of erlotinib has not been studied in patients with renal impairment (serum creatinine concentration > 1.5 times the upper normal limit).
The safety and efficacy of erlotinib has not been studied in patients with severe hepatic impairment.
The safety and efficacy of erlotinib has not been studied in patients with severe hepatic impairment.
Safety and efficacy of MabThera have not been established in combination with other chemotherapies in diffuse large B cell non- Hodgkin's lymphoma.
The safety and efficacy of Myozyme in patients with renal or hepatic insufficiency have not been evaluated and no specific dosage regimen can be recommended for these patients.
The safety and efficacy of Myozyme have been primarily evaluated in children with ages ranging from infancy to adolescence.
The safety and efficacy of Neulasta have not been investigated in patients with myelodysplastic syndrome, chronic myelogenous leukaemia, and in patients with secondary Acute Myeloid Leukaemia (AML); therefore, it should not be used in such patients.
The safety and efficacy of Neulasta have not been investigated in patients receiving high dose chemotherapy.
The safety and efficacy of Neulasta have not been evaluated in patients receiving chemotherapy associated with delayed myelosuppression e. g., nitrosoureas.
The safety and efficacy of STELARA in combination with other immunosuppressants, including biologics, or phototherapy have not been evaluated (see section 4.4).
The safety and efficacy of Vectibix have not been studied in patients with renal or hepatic impairment.
Safety and effectiveness in paediatric patients under 5 years of age have not been studied.
The safety and efficacy have not been studied in patients with hepatic impairment.
The safety and efficacy have not been studied in patients with renal impairment.
Toltrazuril sulfone is slightly mobile in soil (mean Koc 616.5).
However, large quantities of grapefruit juice (over 1.2 l daily for 5 days) increased AUC of atorvastatin 2.5 fold and AUC of active (atorvastatin and metabolites) HMG-CoA reductase inhibitors 1.3 fold.
48 Atorvastatin reduces LDL production and the number of LDL particles.
62 Atorvastatin reduces LDL production and the number of LDL particles.
Prevention of cardiovascular disease
5.1 Pharmacodynamic properties
4.1 Therapeutic indications
It is not known whether this medicinal product or its metabolites are excreted in human milk.
There is evidence from animal studies that HMG-CoA reductase inhibitors may influence the development of embryos or foetuses.
LDL apheresis) in these patients or if such treatments are unavailable.
The entire contents of the vial should be withdrawn for a single administration.
The coughing is often accompanied by a “ whooping” sound, hence the common name “ whooping cough”.
The coughing is often accompanied by a “whooping” sound, hence the common name “whooping cough”.
Toxicity in animals upon repeated or continuous exposure (1 day to 4 weeks at exposure levels of up to 10 times the clinical steady state plasma concentration) was limited to exaggerated pharmacological effects.
Toxicity in animals was found at doses equivalent to human therapeutic doses.
The toxicity of the free Yttrium (90Y) due to in-vivo release from the labelled biomolecule in the body during therapy could be reduced by post-administration of chelating agents.
Dermal toxicity may become treatment-limiting, with intense erythema, oedema, and vesiculation.
Toxicity was not aggravated when juvenile animals were treated as compared with adult animals, but the data did indicate a steeper dose response.
Clostridium botulinum type A neurotoxin complex blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within the nerve endings.
Trabectedin has been administered for 6 or more cycles in 168 out of 569 (29.5%) patients treated with the proposed dose and schedule.
Trabectedin must not be used in patients with CPK > 2.5 ULN (see section 4.2).
The clinical relevance of these decreases is unknown.
The transparency of the Centralised system has been highly appreciated by all interested parties.
Transparency is an integral part of a good regulatory process.
Triple therapy allows the eradication of H. pylori in more than 85% of cases in patients with peptic ulcer.
Retinal atrophy occurred not until 18 months of treatment.
Patients with involvement of the tongue, glottis or larynx, are likely to experience airway obstruction, especially those with a history of airway surgery.
Autonomic neuropathy may be related to bortezomib or bortezomib may aggravate an underlying condition such as diabetic or amyloidotic neuropathy.
The IV line must be adequately flushed prior to and after Dynastat injection with a solution of known compatibility (see section 6.6).
A 0.2 or 0.22 micron low protein binding filter must be on line between the patient and the infusion port.
The tube from the injector to the patient (patient's tube) must be changed after every examination.
70 Latvija Bauskas 58a-401 Rī ga, LV-1004 Tel: + 371-7 21 38 25
Latvija Bauskas 58a -401 Rīga, LV-1004 Tel: + 371-7 21 38 25
Latvija Bauskas 58a -401 Rīg a, LV- 1004 Tel: + 371-7 21 38 25
Latvija Bauskas 58a -401 Rīg a, LV-1004 Tel: + 371-7 21 38 25
Latvija Bauskas 58a -401 Rīga, LV-1004 Tel: + 371-7 21 38 25
Latvija Bauskas 58a-401 Rī ga, LV-1004 Tel: + 371-7 21 38 25
Rīga, LV-1004 Tel: + 371-7 21 38 25
Latvija Boehringer Ingelheim Pharma GmbH Pā rstā vniecī ba Latvijā Brī vī bas iela 40-37 Rī ga, LV-1050 Tel: +371 7240 068
100 Latvija BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT.
Latvija Eli Lilly Holdings Limited pā rstā vniecī ba Latvijā Tel: + 371 67364000
200 Latvija Eli Lilly Holdings Limited pārstāvniecība Latvijā Tel: +371 7364000
222 Latvija Eli Lilly Holdings Limited pārstāvniecība Latvijā Tel: +371 7364000
289 Latvija Eli Lilly Holdings Limited pārstāvniecība Latvijā Tel: +371 7364000
Latvija Eli Lilly Holdings Limited p%rst%vniec & ba Latvij% Tel: +371 67364000
Latvija Janssen-Cilag Polska Sp. z o.o. filiāle Latvijā Tel: +371 678 93561
Latvija Merck Serono Pārstāvniecība C/o Ares Trading SA Baltic States Zamenhofo 11-3, LT-44287 Kauņa, Lietuva Tel: +370 37320603
Latvija Merck Serono Pā rstā vniecī ba C/ o Ares Trading SA Baltic States Zamenhofo 11-3, LT-44287 Kauņ a, Lietuva Tel: +370 37320603
Latvija Merck Serono Pārstāvniecība C/o Ares Trading SA Baltic States Zamenhofo 11 -3, LT-44287 Kauņa, Lietuva Tel: +370 37320603
Latvija OÜ ZOOVETVARU Pärnasalu 31 ET - 76505 Saue/ Harjumaa, ESTONIA Tel: + 372 6 709 006 E-mail: margus@zoovet. ee Lietuva OÜ ZOOVETVARU Pärnasalu 31 ET - 76505 Saue/ Harjumaa, ESTONIA Tel: + 372 6 709 006 E-mail: margus@zoovet. ee
26 Latvija Pfizer Luxembourg SARL, filiāle Latvijā Tel: +371 670 35 775
Latvija Pfizer Luxembourg SARL filiā le Latvijā Tel.: + 371 670 35 775
Latvija Pfizer Luxembourg SARL filiā le Latvijā Tel: +371 670 35 775
Latvija Pfizer Luxembourg SARL, filiāle Latvijā Tel: +371 670 35 775
Latvija Pfizer Luxembourg SARL filiā le Latvijā Tel: + 371 670 35 775
21 Latvija Veta Bauskas iela 58, LV-1004 Riga +371 7 610 001
Tylvalosin has been shown to cause hypersensitivity reactions in laboratory animals; therefore, people with known hypersensitivity to tylvalosin tartrate should avoid contact with the veterinary medicinal product.
Tylvalosin has been shown to cause hypersensitivity reactions in laboratory animals; therefore, people with known hypersensitivity to tylvalosin tartrate should avoid contact with the veterinary medicinal product.
Tylvalosin has activity against the following mycoplasma species found in chickens:
Tyrosine is broken down in the body by a number of enzymes.
Half-life was also similar between adult and paediatric patients with lp
Half-life was also similar between adult and paediatric patients with CRF following both intravenous and subcutaneous administration.
Half-life was also similar between adult and paediatric patients with lp
There was up to about 2.5-fold increase in AUC in subjects with hepatic impairment compared to healthy subjects.
AUC for L-5-formyl-THF and 5-methyl-THF were 28.4±3.5 mg. min/ l and 129±112 mg. min/ l after a dose of 25 mg.
Specific patient groups Elderly BYETTA should be used with caution and dose escalation from 5 µg to 10 µg should proceed conservatively in patients > 70 years.
Explanations for higher 5-ALA uptake include a disrupted blood-brain barrier, increased neo-vascularisation, and the overexpression of membrane transporters in glioma tissue.
This leads to insulin release through exocytosis.
Increased serum tizanidine concentration is associated with a potentiated hypotensive and sedative effect.
The increased digoxin levels may lessen over time (see section 4.5).
Uptitration to 80 mg and 160 mg twice daily should be done at intervals of at least two weeks to the highest dose, as tolerated by the patient.
Subsequent titration to a higher dose may be initiated as warranted clinically
Subsequent titration to a higher dose may be initiated as warranted clinically
Consideration has been given to increasing the frequency of the Working Party meetings.
Increasing the dose of Tarceva when co-administered with such agents is not likely to compensate for this loss of exposure.
Increasing the dose of Tarceva when co-administered with such agents is not likely to compensate for this loss of exposure.
Pressure build-up may require venting. • Shake well.
Pressure build-up may require venting. • Shake well.
The increase in digoxin exposure observed in the presence of multiple doses of ambrisentan was not considered clinically relevant, and no dose adjustment of digoxin is warranted (see section 4.5).
9 It must be considered that overdose of Busilvex will also increase exposure to DMA.
The increased exposure was likely at least partly due to immaturity of the drug-metabolising enzymes in juvenile animals.
There is no evidence of a reduction in tolerability associated with an increase in exposure.
Increased hostility occurred particularly in children with obsessive compulsive disorder, and especially in younger children less than 12 years of age.
Increased digoxin levels observed in patients receiving ritonavir may lessen over time as induction develops (see section 4.4).
Since increased concentrations of lovastatin and simvastatin may predispose patients to myopathies, including rhabdomyolysis, the combination of these medicinal products with ritonavir is contraindicated (see section 4.3).
Since increased concentrations of HMG-CoA reductase inhibitors may cause myopathy, including rhabdomyolysis, the combination of these medicinal products with VIRACEPT is not recommended.
Since increased concentrations of HMG-CoA reductase inhibitors may cause myopathy, including rhabdomyolysis, the combination of these medicinal products with VIRACEPT is not recommended.
Since increased concentrations of HMG-CoA reductase inhibitors may cause myopathy, including rhabdomyolysis, the combination of lovastatin or simvastatin with Telzir with ritonavir is not
Dose increases should be slower in these patients.
Elevations in liver aminotransferases, i.e., aspartate and alanine aminotransferases (AST and/or ALT), associated with bosentan are dose dependent.
11% of women at month 1, 15% of women at month 4 and 11% of women at the end of the 6 month trial reported bleeding or spotting.
submitted continue to be considered by the Committee.
The increased turnover causes accelerated bone loss because the compensatory increase in bone formation is not sufficient to offset increased bone resorption.
The excess risk gradually disappears during the course of the 10 years after cessation of COC use.
The increase is approximately 1.5- to 2-fold, corresponding to a 1.5-fold elevation of plasma AGP, to which imatinib binds strongly.
- Increase not thought to be clinically relevant.
Increase not thought to be clinically relevant.
- Increase not thought to be clinically relevant.
Increase not thought to be clinically relevant.
Marketing Authorisation Holder
Patient self-assessments were found to correlate with physician observations of efficacy.
Self-examination of the skin by the patient or the parents should also be advised.
If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package
Accidental injection/ self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Accidental injection/ self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Accidental injection/ self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Precipitations of ceftriaxone – calcium salt have been observed in lungs and kidneys of these dead preterm newborns.
Precipitations of ceftriaxone – calcium salt have been observed in lungs and kidneys of these dead preterm newborns.
However, blood glucose self-monitoring may become necessary to adjust the dose of sulphonylureas.
The other study (293 patients) was carried out in patients who had become refractory to lamivudine treatment.
Alternatively, a 1 ml syringe, graduated in ml, with pre-fixed needle for subcutaneous administration could be used.
Each ml of reconstituted solution contains 600 IU r-hFSH.
Vaccination with Nobilis IB 4-91 may induce mild respiratory signs of disease which may persist for a few days depending on the health and condition of the chickens.
Vaccination with Nobilis IB 4-91 may induce mild respiratory signs which may persist for a few days depending on the health and condition of the chickens.
Vaccination with Nobivac Piro does not prevent infection.
It is good clinical practice that vaccination should be preceded by a review of the medical history especially with regard to the contraindications and by a clinical examination.
Cat vaccination during and after VIRBAGEN OMEGA treatment is contra-indicated as both FeLV and FIV infections are known to be immunosuppressive.
This helps to reduce the symptoms of babesiosis.
Corresponding data based on whole blood averaged 47.6 l.
HbA1c was stable in both duloxetine-treated and placebo-treated patients.
The baseline median TSS was 31.7 in abatacept-treated patients and 33.4 in placebo-treated patients.
The median EC50 value for entecavir against LVDr HBV (rtL180M and rtM204V) was 0.026 µM (range 0.010-0.059 µM).
The validity of the test result may be affected if the patient is currently being treated with antibiotics or a proton-pump inhibitor or has completed a course of treatment with these medicinal products.
Valnemulin is well-accepted in feed, but administered at concentrations above 200 mg/ kg feed may result in transient reduction in food consumption associated with unpalatability during the first few days of feeding.
Valnemulin is well-accepted in feed, but administered at concentrations above 200 mg valnemulin / kg feed may result in transient reduction in food consumption associated with unpalatability during the first few days of feeding.
Valnemulin shows high activity against Mycoplasma spp. and spirochaetes such as Brachyspira hyodysenteriae and Brachyspira pilosicoli.
Valnemulin is an antibiotic belonging to the pleuromutilin group, which act by the inhibition of the initiation of protein synthesis at the level of the bacterial ribosome.
Valnemulin is an antibiotic belonging to the pleuromutilin group, which acts by the inhibition of the initiation of protein synthesis at the level of the bacterial ribosome.
Valnemulin has been shown to interact with ionophores such as monensin, salinomycin and narasin and may result in signs indistinguishable from an ionophore toxicosis.
Varenicline is highly selective and binds more potently to the α 4β 2 receptor subtype (Ki=0.15 nM) than to other common nicotinic receptors (α 3β 4 Ki=84 nM, α 7 Ki= 620 nM, α 1βγδ Ki= 3,400 nM), or to non-nicotinic receptors and transporters (Ki > 1µM, except to 5-HT3 receptors:
Varenicline undergoes minimal metabolism with 92% excreted unchanged in the urine and less than 10% excreted as metabolites.
The variability is increased with high fat food.
Inter-patient variability in nilotinib pharmacokinetics was moderate to high.
Inter-subject variability is high with a CV% of about 50% for CL and 60% for Vss
Venlafaxine also weakly inhibits dopamine uptake.
Venlafaxine is extensively metabolised, primarily to the active metabolite, O-desmethylvenlafaxine (ODV).
Venlafaxine and its metabolites are excreted primarily through the kidneys.
Venlafaxine and its active metabolite, O-desmethylvenlafaxine, are excreted in breast milk.
Venlafaxine and its active metabolite reduce β -adrenergic responsiveness after both acute (single dose) and chronic administration.
Venlafaxine was not mutagenic in a wide range of in vitro and in vivo tests.
⋅ revise consistency of texts within and across products, for EPARs, SPCs, package leaflets and labelling, and between language versions
Version 1 was available throughout the year and was successfully used by a small group of project managers.
It is used as a light-activated drug (photosensitiser).
Verteporfin at more than 5 times the expected maximum plasma concentration in treated patients, caused a low level of complement activation in human blood in vitro.
Skin that has been in contact with Aivlosin or medicated feed or drinking water should be washed.
Your bladder will need some time to adapt.
• Set up the following items on a clean surface
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Vildagliptin added to patients whose glycaemic control was not satisfactory despite treatment with metformin monotherapy resulted after 6-month treatment in additional statistically significant mean reductions in HbA1c compared to placebo (between group differences of -0.7% to -1.1% for vildagliptin 50 mg and 100 mg, respectively).
Vildagliptin on its own was approved by the European Union (EU) in September 2007 under the name Galvus, and metformin has been available in the EU since 1959.
Vildagliptin is indicated in the treatment of type 2 diabetes mellitus:
Vildagliptin does not work when the blood glucose is low.
Vildagliptin does not work when the blood glucose is low.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Vildagliptin was not mutagenic in conventional in vitro and in vivo tests for genotoxicity.
Vildagliptin on its own was approved by the EU in September 2007 under the name Galvus, and metformin has been available in the EU since 1959.
The final opinion was converted into a Decision by the European Commission on 14 July 2008.
The final opinion was converted into a Decision by the European Commission on 11/ 10/ 2006.
The final opinion was converted into a Decision by the European Commission on 15 September 2005.
The final opinion was converted into a Decision by the European Commission on 17 June 2008.
The final opinion was converted into a Decision by the European Commission on 21 August 2006.
The final opinion was converted into a Decision by the European Commission on 21 February 2006.
The final opinion was converted into a Decision by the European Commission on 22 May 2006.
The final opinion was converted into a Decision by the European Commission on 29 May 2006.
The final opinion was converted into a Decision by the European Commission on 5 September 2008.
The final opinion was converted into a Decision by the European Commission on 7 November 2005.
The final opinion was converted into a decision by the European Commission on 9 September 2008.
The final opinion was converted into a Decision by the European Commission on 03 April 2006.
The final opinion was converted into a Decision by the European Commission on 3 April 2006.
The final opinion was converted into a Decision by the European Commission on 22 July 2008.
The infusion flow rate should be controlled to equate a 2 hour period of administration.
The rate of infusion is 2 to 3 ml/ min for liver imaging and 4 to 6 ml/ min for imaging the pancreas.
The initial infusion rate should be no more than 0.25 mg/ min (15 mg/ hour) to minimise the potential occurrence of infusion-associated reactions.
The initial infusion rate should be no more than 0.25 mg/ min (15 mg/ hour) to minimise the potential occurrence of infusion-associated reactions.
The initial infusion rate should be no more than 0.25 mg/min (15 mg/hour) to minimise the potential occurrence of infusion -associated reactions.
The initial infusion rate should be no more than 0.25 mg/min (15 mg/hour) to minimise the potential occurrence of infusion-associated reactions.
The infusion rate may be increased gradually with further infusions.
The rate and extent of absorption of Rasilez HCT are equivalent to the bioavailability of aliskiren and hydrochlorothiazide when administered as individual monotherapies.
Both the rate and extent of absorption of Advagraf were reduced when administered with food.
The rate and extent of absorption of Copalia are equivalent to the bioavailability of valsartan and amlodipine when administered as individual tablets.
The rate and extent of absorption of Dafiro are equivalent to the bioavailability of valsartan and amlodipine when administered as individual tablets.
The rate and extent of absorption of Copalia are equivalent to the bioavailability of valsartan and amlodipine when administered as individual tablets.
The rate and extent of absorption of Dafiro are equivalent to the bioavailability of valsartan and amlodipine when administered as individual tablets.
The rate and extent of absorption of Exforge are equivalent to the bioavailability of valsartan and amlodipine when administered as individual tablets.
The rate and extent of absorption of Imprida are equivalent to the bioavailability of valsartan and amlodipine when administered as individual tablets.
The speed of the perfusor automate [ml per hour] is to be set in a body weight dependent fashion.
The route of injection is the same as with r-HuEPO but your doctor will tell you how much you should take, and when, and may adjust your dose if necessary. no
The route of injection is the same as with r-HuEPO but your doctor will tell you how much you should take, and when, and may adjust your dose if necessary.
The route of injection is the same as with r-HuEPO but your doctor will tell you how much you should take, and when, and may adjust your dose if necessary.
The major route of 14C elimination is renal.
The major route of 14C elimination is renal.
Warfarin did not affect the pharmacokinetic profile of tigecycline.
- Warfarin or phenprocoumon, anticoagulants used to prevent blood clots
Metabolism of azacitidine is by spontaneous hydrolysis and by deamination mediated by cytidine deaminase.
Azagly-nafarelin is rapidly absorbed after intraperitoneal treatment in rainbow trout.
Azagly-nafarelin is rapidly eliminated from plasma after IP treatment in rainbow trout.
Azagly-nafarelin is a peptide that is primarily degraded by peptidases and not by cytochrome P-450 enzymes.
Zidovudine and stavudine are phosphorylated by the cellular enzyme (thymidine kinase), which preferentially phosphorylates zidovudine, thereby decreasing the phosphorylation of stavudine to its active triphosphate form.
The red area will fade over the next few days.
The area treated may be covered with sterile bandage or gauze dressing.
A subgroup of 116 patients with isolated hypertriglyceridemia (Fredrickson's Type IV hyperlipidaemia) were identified by the following criteria: baseline LDL cholesterol< 130 mg/dL, as all patients in this study had baseline triglycerides > 200 mg/dl.
On 16 November 2006, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Mycograb 2 mg/ ml powder for solution for injection intended for the treatment of invasive candidiasis in adult patients, in combination with amphotericin B or a lipid formulation of amphotericin B.
1'-hydroxymidazolam is metabolised predominantly by uridine diphosphate-glucuronosyltransferases (UGT) 2B4 and 2B7.
On 20 April 2005, Pfizer presented data on serious skin reactions for valdecoxib during a hearing.
On 20 April 2005, Pfizer presented data on serious skin reactions for valdecoxib during a hearing.
On 20 April 2005, Pfizer presented data on serious skin reactions for valdecoxib during a hearing.
The European Commission granted a marketing authorisation valid throughout the European Union for Orfadin to Swedish Orphan International AB on 21 February 2005.
On 25 October 2006 the European Commission forwarded a draft decision to the Standing Committee on Veterinary Medicinal Products for adoption by written procedure.
On 25 October 2006 the European Commission forwarded a draft decision to the Standing Committee on Veterinary Medicinal Products for adoption by written procedure.
On 26 June 2008, the CHMP, having considered the data provided by the MAHs, recommended the granting of the variation to the marketing authorisations.
On 26 June 2008, the CHMP, having considered the data provided by the MAHs, recommended the granting of the variation to the marketing authorisations.
28 November 2005 EMEA/ CHMP/ 324332/ 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 31 REFERRAL
The European Commission granted a marketing authorisation valid throughout the European Union for Revatio to Pfizer Limited on 28 October 2005.
5-FU is further catabolised by the enzyme dihydropyrimidine dehydrogenase (DPD) to the much less toxic dihydro-5-fluorouracil (FUH2).
99m Tc-depreotide is administered intravenously in a single dose.
The benefit of treatment should be re-assessed at regular intervals.
Water should be withheld before vaccination to make the chickens thirsty.
There was no significant effect of cool water on these parameters.
Clinical benefit has been assessed at 24 and 36 months in 13 patients.
It is not known whether these findings translate into long-term clinical benefits.
INOmax has not been shown to be of benefit in premature (< 34 weeks) infants.
Patients who never smoked had a much greater benefit from erlotinib (survival HR = 0.42, CI 0.28-0.64) compared with current or ex-smokers (HR = 0.87, CI 0.71-1.05).
The benefit of further alterations in lipid levels by the combined use of gemfibrozil and HMG-CoA reductase inhibitors should be carefully weighed against the potential risks of such combinations and clinical monitoring is recommended.
The benefit of treatment should be re-assessed at regular intervals.
The benefit of the treatment on the criteria indicated above is not known in patients over the age of 65 years, who could not be included in the study.
The benefit of the treatment on the criteria indicated above is not known in patients over the age of 65 years, who were not included in the study.
The benefit of the treatment on the above criteria is not known in patients over the age of 75 years, who could not be included in the CARE and LIPID studies.
The potential benefit should be weighed against the risk in the treatment of patients with severe hepatic impairment.
The primary benefit was a 27.5% (95% CI:
2 The therapeutic benefit should regularly (at least every three months) be reassessed.
The therapeutic benefit should regularly (at least every three months) be reassessed.
Besilesomab is a monoclonal antibody (a type of protein that has been designed to recognise and bind to a specific structure called an antigen, that may be found on certain cells in the body).
2 The need for luteal phase support in cycles using Orgalutran has not been studied.
Bexarotene is a synthetic compound that exerts its biological action through selective binding and activation of the three RXRs: α, β, and γ.
Bexarotene should not be used in breast-feeding mothers.
Bimatoprost is moderately distributed into body tissues and the systemic volume of distribution in humans at steady-state was 0.67 l/ kg.
Bimatoprost is a prostamide, a substance related to prostaglandin F2 α that works by increasing the outflow of fluid from the eye.
Bimatoprost was not mutagenic or carcinogenic in a series of in vitro and in vivo studies.
Bimatoprost selectively mimics the effects of newly discovered biosynthesised substances called prostamides.
Bimatoprost then undergoes oxidation, N-deethylation and glucuronidation to form a diverse variety of metabolites.
9 enxyme inhibits the formation of the inflammation mediators PGE2 and PGI2.
The top housing is made of white plastic contains a lithium battery and electronics.
The nasal edge of the treatment spot must be at least 200 μ m from the temporal edge of the optic disc.
Bortezomib should be discontinued if serious reactions occur.
Bortezomib was positive for clastogenic activity (structural chromosomal aberrations) in the in vitro chromosomal aberration assay using Chinese hamster ovary cells (CHO) at concentrations as low as 3.125 μ g/ ml, which was the lowest concentration evaluated.
Bortezomib was positive for clastogenic activity (structural chromosomal aberrations) in the in vitro chromosomal aberration assay using Chinese hamster ovary (CHO) cells at concentrations as low as 3.125 μ g/ ml, which was the lowest concentration evaluated.
Botox [Clostridium botulinum toxin type A neurotoxin complex] inhibits the release of acetylcholine at the presynaptic membrane on cholinergic neurons.
- The vial should be vented with a sterile syringe needle or a sterile non-siliconised mini-spike before
- The vial should be vented with a sterile syringe needle or a sterile non-siliconised mini-spike before
Then the injection button should be held down 10 seconds before withdrawing the needle from the skin.
Then the injection button should be held down 10 seconds before withdrawing the needle.
It can only be pulled out as far as the mark (flat arrow) indicating the amount of medicine remaining in the reservoir.
Darifenacin hydrobromide is a substance which reduces the activity of an overactive bladder.
BTVPUR AlSap 8 contains bluetongue viruses of one type (‘ serotype 8’).
BTVPUR AlSap 8 contains bluetongue viruses that have been inactivated so that they cannot cause the disease.
BTVPUR AlSap 8 is used in cattle and sheep to protect them against bluetongue disease.
Cyclophosphamide or melphalan is then used to suppress the 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Busulfan was mutagenic in Salmonella typhimurium, Drosophila melanogaster and barley.
In addition, the BWP proposed a revision of the CPMP note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via medicinal products, which was released for consultation.
Calcium and vitamin D3 pass into breast milk.
Any calcium you take as part of a meal will not seriously affect uptake.
Any calcium you take as part of a meal will not seriously affect uptake.
Any calcium you take as part of a meal will not seriously affect uptake.
The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU
The PSUR cycle of Irbesartan BMS is aligned with the cross-referred product, KARVEA, until otherwise specified.
The PSUR cycle of Irbesartan Winthrop is aligned with the cross-referred product, APROVEL, until otherwise specified.
research non-governmental organisations in France, Europe and the United States in the fields of cancer, AIDS and genetic diseases.
Li-Fraumeni cancer is a type of cancer that occurs in patients with Li-Fraumeni syndrome, a condition where a gene called p53 is defective because of a mutation.
Butyl rubber, polyamide, and polyurethane should not be used.
Syringe tip cap and piston are made of bromobutyl rubber.
Syringe tip cap and piston are made of bromobutyl rubber.
The pen cap must be put back on the pen after each injection in order to protect from light.
The pen cap must be put back on the pen after each injection in order to protect from light.
The pen cap must be put back on the pen after each injection in order to protect from light.
The pen cap must put back on the pen after each injection in order to protect from light.
The pen cap must be put back on the pen after each injection in order to protect from light.
22 neurological disorders are transient or permanent is currently unknown.
Whether the neurological disorders are transient or permanent is currently unknown.
It is advisable to rehydrate patients prior to starting therapy with etoricoxib.
If needed (for example because of side effects), the dose may be reduced in 50 mg steps.
The infusion line should be flushed with sodium chloride solution before and after Vectibix administration to avoid mixing with other medicinal products or IV solutions.
3/20 Ceftiofur is particularly active against the following target pathogens causing respiratory and other diseases in pigs:
Ceftiofur inhibits the bacterial cell wall synthesis, thereby exerting bactericidal properties.
Cefuroxime does not interfere in the alkaline picrate assay for creatinine (see section 4.5).
Cefuroxime is widely distributed in the body including pleural fluid, sputum, bone, synovial fluid, and aqueous humour, but only achieves therapeutic concentrations in the CSF when the meninges are inflamed.
Celecoxib at daily doses of 200 mg – 400 mg provided pain relief within 24 hours of dosing.
Celecoxib is contraindicated in pregnancy and in women who can become pregnant (see 4.3 and 4.4).
Celecoxib is metabolised in the liver by hydroxylation, oxidation and some glucuronidation.
Celecoxib is mainly eliminated by metabolism.
Celecoxib is a diaryl-substituted pyrazole, chemically similar to other non-arylamine sulfonamides (e. g. thiazides, furosemide) but differing from arylamine sulfonamides (e. g. sulfamethoxizole and other sulfonamide antibiotics).
9 Celecoxib is an oral, selective cyclooxygenase-2 (COX-2) inhibitor.
No statistically significant inhibition of COX-1 (assessed as ex vivo inhibition of thromboxane B2 [TxB2] formation) was observed in healthy volunteers at the FAP therapeutic dose of 400 mg BID.
Celecoxib is an oral, selective, cyclooxygenase-2 (COX-2) inhibitor within the clinical dose range (200-400 mg daily).
Celecoxib may mask fever and other signs of inflammation.
Certolizumab has been designed to bind to a chemical messenger in the body called tumour necrosis factor-alpha (TNF-alpha).
Cetrorelix is a luteinising hormone releasing hormone (LHRH) antagonist.
Exchange of cerebrospinal fluid with isotonic saline has been carried out in a case of intrathecal overdose of free cytarabine and such a procedure may be considered in the case of DepoCyte overdose.
After discontinuation of GANFORT, pigmentation of iris may be permanent.
The change in iris pigmentation occurs slowly and may not be noticeable for several months.
The change may be more noticeable if you are only treating one eye.
The change may be more noticeable if you are only treating one eye.
The cat should be revaccinated for all components one year after the first vaccination course, then every year for rhinotracheitis and calicivirosis, and every three years for panleucopenia.
The cat should be revaccinated for all components one year after the first vaccination course, then every year for rhinotracheitis, calicivirosis and chlamydiosis.
The cat should be revaccinated for all components one year after the first vaccination course, then every year.
The cat should be revaccinated for all components one year after the first vaccination course, then every year for rhinotracheitis, calicivirosis and chlamydiosis, and every three years for panleucopenia.
The cat should be revaccinated for all components one year after the first vaccination course, then every year for rhinotracheitis, calicivirosis and feline leukaemia, and every three years for panleucopenia.
Cats are treated using the Profender spot-on solution range.
As Echinococcosis is a notifiable disease to the OIE, specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.
As Echinococcosis is a notifiable disease to the OIE, specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.
Benzalkonium chloride is known to discolour soft contact lenses.
The excipient benzalkonium chloride is an irritant and may cause irritation of the nasal mucosa (company-specific).
Benzalkonium chloride may be absorbed by soft contact lenses and is known to discolour soft contact lenses.
Yttrium (90Y) chloride is produced by decay of its radioactive precursor Strontium (90Sr).
The two main organs where Yttrium (90Y) chloride distributes are the liver and bones.
The CHMP acknowledged the data submitted, noting and assessing the data from the clinical studies EN3267-005 and EN3267-007.
The CHMP assessed the SPC wording proposed by the MAH and the submitted rationales for the proposal.
- the CHMP concluded that the Marketing Authorisation could be harmonised for Singulair 4mg
Authorisation Holders have been assessed based on the documentation submitted and the scientific discussion within the Committee,
- the CHMP concluded that the Marketing Authorisation could be harmonised on the following
The CHMP concluded, that the absolute risk was considered to be very small.
- the CHMP concluded that the data are not supportive of the following indications and therefore they
- the CHMP concluded that the products are bioequivalent and that the benefit-risk ratio is positive,
The CHMP concluded that the use of this vaccine will not pose an immediate risk to any of the target groups the vaccine is indicated for.
The CHMP decided to restrict the duration of the short-term therapy to 6 weeks, due to safety considerations.
The CHMP discussed the areas where there was a divergence identified in the dose recommendations.
The CHMP decided to limit the indication to AD, however the CHMP amended the warning in the SPC, regarding the magnitude of the risk for CVAEs in patients with MD/ VD to the following wording:
The CHMP therefore recommended the following wording to distinguish, by specific indications, the prophylactic and curative uses of ciprofloxacin in neutropenic patients with the following wording: -treatment of infections in neutropenic patients, -prophylaxis of infections in neutropenic patients.
The CHMP proposed the amendment of section 4.4 of the SPC, in order to minimise the risk for withholding treatment from patients with ocular rosacea.
The CHMP also noted that Tritace had an indication for nephroprotection in some countries.
The CHMP issued a positive opinion, on 21 April 2005, recommending the harmonisation of the SPC for Calcium Sandoz Effervescent tablets, 500/ 1000 mg and associated names for the following agreed therapeutic indications: -Prevention and treatment of calcium deficiency -Calcium supplement as an adjunct to specific therapy in the prevention and treatment of osteoporosis -Rickets and osteomalacia, in addition to vitamin D3 therapy
• the CHMP agreed that the benefits/ risk balance for fluoxetine in the treatment of moderate to severe major depressive episode in children and adolescents aged 8 to 18 is favourable,
The CHMP decided that Fabrazyme's benefits are greater than its risks for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.
24 the text within the SPC has been adjusted to indicate that caution (rather than “ not recommended”) is appropriate
The CHMP assessed the proposed wording provided by the MAH, and particular attention was given to the following issues:
The CHMP required the MAH to reflect the target population (patients with advanced/metastatic bladder cancer) and the combination treatment with cisplatin in the harmonized indication.
Prieto (ES) as Co- Rapporteur.
The CHMP recommended the granting of the variation of the Marketing Authorisations for which the summaries of product characteristics, labelling and package leaflets are set out in Annex III and under the conditions set out in Annex IV.
The CHMP has therefore recommended the granting of the Marketing Authorisation(s) and the amendment of the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State.
The CHMP fully endorses the development of a combined Guideline on specific immunoglobulins, in order to harmonise the requirements for granting marketing authorization.
The CHMP took note of the MAH's proposals, some of which had already been introduced in some countries, in an effort to limit these risks like:
The CHMP has recommended the granting of the Marketing Authorisation for which the Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure as mentioned in Annex III for Vantas.
22 the CHMP has recommended amendments of the Summary of Products Characteristic, Labelling and Package Leaflet, as set out in Annexe III of the CHMP opinion for Neurontin and associated names (see Annexe I of the opinion).
The CHMP has recommended the granting of the Marketing Authorisation(s), as well as the text to be included in the Summary of Product Characteristics, Package Leaflet and Labelling.
the CHMP has recommended the amendment of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Tritace and associated names (see Annex I).
the CHMP has recommended the amendment of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Diovan and associated names (see Annex I).
the CHMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Efexor and associated names (see Annex I).
the CHMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics is set out in Annex III of this opinion.
the CHMP has recommended the amendment of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Tritazide and associated names (see Annex I).
the CHMP has recommended the amendment of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Singulair and associated names (see Annex I).
Therefore, this SPC, labelling and package leaflet may not necessarily represent the current text.
the CHMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics, Labelling and Package Leaflet are set out in Annex III of the CHMP Opinion for Prograf and associated names (see Annex I).
the CHMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Efexor depot and associated names (see Annex I).
the CHMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Gemzar.
the CHMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Zyrtec and associated names (see Annex I).
the CHMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Risperdal Consta and associated names (see Annex I).
the CHMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Ciprofloxacin Bayer and associated names (see Annex I).
the CHMP has recommended the amendment of the Marketing Authorisations for which the Summaries of Product Characteristics, labelling and package leaflet are set out in Annex III for Risperdal and associated names (see Annex I).
43 the CHMP has recommended the amendment of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Lamictal and associated names (see Annex I).
The CHMP has recommended the variation (extension of indication) of the Marketing Authorisation in accordance with the Summary of Product Characteristics set out in Annex III for Gadovist (see Annex I).
The CHMP has recommended the granting of the variation of the Marketing Authorisations for which the Summary of Product Characteristics is set out in Annex III for Coversyl and related names (see Annex I).
As a consequence, the CHMP has recommended to maintain the Marketing Authorisations for all medicinal products and to grant Marketing Authorisations for all applications referred to in Annex I of the Opinion in accordance with the amendments to the relevant sections of the Summary of Product Characteristics, set out in Annex III of the Opinion.
The CHMP has recommended the removal of the therapeutic indication “ acute and chronic complicated pyelonephritis” for the medicinal products containing norfloxacin taken orally (referred to medicinal products listed in Annex I).
The CHMP has recommended the withdrawal of the Marketing Authorisations for the medicinal products containing veralipride referred to in Annex I.
The CHMP has recommended the granting of the variation of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III.
The CHMP recommended the granting of the variation of the Marketing Authorisations for which the Summaries of Product Characteristics, Labelling and Package Leaflets are set out in Annex III and under the conditions set out in Annex IV.
the CHMP has recommended the granting of the Marketing Authorisation for which the Summary of Product Characteristics, Labelling and Package Leaflet are set out in Annex III for Xeomin.
the CHMP has recommended granting the Marketing Authorisation for Menitorix, with amendments to the relevant sections of the PI and with commitments to be fulfilled.
the CHMP has recommended the granting of the Marketing Authorisation(s) and the amendment of the Summary of Product Characteristics, labelling and package leaflet which are set out in Annex III for Fentanyl-ratiopharm 25/ 50/ 75/ 100 µg/ h TTS and associated names (see Annex I).
the CHMP has recommended the granting of the Marketing Authorisation(s) and the amendment of the Summary of Product Characteristics, labelling and package leaflet which are set out in Annex III for Fentanyl-ratiopharm and associated names (see Annex I).
the CHMP has recommended the granting of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Activelle and associated names (see Annex I).
The CHMP has recommended the granting of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Ciprofloxacin Kabi and associated names (see Annex I).
the CHMP has recommended the granting of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet remain as per the final versions achieved during the Coordination Group procedure as mentioned in Annex III for Bleomycin Pharmachemie and associated names (see Annex I).
the CHMP has recommended the granting of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet remain as per the final versions achieved during the Coordination Group procedure as mentioned in Annex III for UMAN BIG.
the CHMP has recommended the granting of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Oracea.
the CHMP has recommended the granting of the Marketing Authorisations for which the valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure are set out in Annex III for Sabumalin and associated names (see Annex I).
the CHMP has recommended the granting of the Marketing Authorisations for which the valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure are set out in Annex III for Sanohex and associated names (see Annex I).
The CHMP has recommended the granting of the Marketing Authorisation(s) for which the Summaries of Product Characteristics, labelling and package leaflet are set out in Annex III for Nifedipinr Pharmamatch Retard 30/ 60 mg and associated names (see Annex I).
the CHMP has recommended the granting of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Doxazosin “ Arrow” 4 mg prolonged release tablets and associated names (see Annex I).
the CHMP has recommended the granting of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Lisonorm and associated names (see Annex I).
The CHMP has recommended the granting of the Marketing Authorisation(s).
The CHMP has recommended the variation of the Marketing Authorisations for PROCOMVAX in accordance with Article 5(2) of Regulation (EC) No 726/ 2004.
The CHMP highlighted that fact that the indication should be hypertension, and as add-on therapy when each monotherapy has failed.
The Committee noted that Stocrin has not been studied adequately in patients with advanced disease (CD4 cell counts below 50 cells/ mm3) or after treatment with protease inhibitors (another type of antiviral medicine) that was not working.
- The CHMP considers that the benefits of marketing a systemic drug such as Oracea in the present
The CHMP agreed also on the following changes to the SPC:
• the CHMP, as a consequence, considered the benefit/ risk balance for the above-mentioned extension of indication to be favourable,
The CHMP was of the opinion that the bioequivalence study (2207-59-DOS-5) demonstrated equivalency in safety profile when used without a spacer, as well as similar Cmax and Tmax values.
The CHMP was evaluating the initial documentation provided by the company and had not yet made any recommendations.
The CHMP was evaluating the initial documentation provided by the company.
The CHMP was concerned that the effectiveness of Diractin had not been sufficiently demonstrated in the single main study: compared with placebo, Diractin did not reduce pain levels to an extent that would be relevant for patients.
The CHMP was evaluating the initial documentation provided by the company.
The CHMP also agreed that the above-mentioned information with regards to long- term efficacy should be included in section 5.1 (Pharmacodynamic Properties) of the Summary of Product Characteristics (SPC).
The CHMP has recommended the suspension of the Marketing Authorisations for Hexavac.
The CHMP was concerned over the way the main clinical study was carried out.
The CHMP was concerned that only a modest benefit of NutropinAq in severe idiopathic short stature had been demonstrated, with an average gain in final adult height of around 6 to 7 cm in the main study.
The CHMP, taking into consideration the assessment of the studies and the recommendation of the SAG concluded that lamotrigine should be used for the prevention of depressive episode in patients with Bipolar I disorder who experience predominantly depressive episodes.
Ultrasound uses high-frequency sound waves to create images of certain areas inside the body.
Cholecalciferol is converted in the liver by hydroxylation to the active form 25- hydroxycholecalciferol.
Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the foetus, the potential risk from inhibition of HMG-CoA reductase outweighs the advantage of treatment during pregnancy.
Clopidogrel prolongs bleeding time and should be used with caution in patients who have lesions with a propensity to bleed (particularly gastrointestinal and intraocular).
Clopidogrel stops the platelets aggregating by blocking a substance called ADP from binding to a special receptor on their surface.
Clopidogrel is not intended for use in children or adolescents.
Clopidogrel may be taken with or without food.
Clopidogrel is not intended for use in children or adolescents.
- The colour coding strip blue and the push button are at the bottom of the pen as it is held cap up.
- The colour coding strip brown and the push button are at the bottom of the pen as it is held cap up.
- The colour coding strip pink and the push button are at the bottom of the pen as it is held cap
- The colour coding strip pink and the push button are at the bottom of the pen as it is held cap up.
Colecalciferol and some of its active metabolites pass into breast milk.
- The Committee concluded that the signal should be further investigated;
It concluded that terfenadine 120 mg tablet formulations should not be maintained on the market.
- The Committee concluded that the SMBR provides a robust signal that loratadine exposure
Therefore, the Committee decided that ReFacto AF's benefits are greater than its risks for the treatment and prevention of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
The Committee also concluded that the 320 mg dose provides a modest, but statistically significant additional reduction in blood pressure compared to 160 mg and a similarly modest increase in the rate of blood pressure control.
The Committee further considered that the benefit/ risk balance concerning the use of moxifloxacin up to 14 days in the PID indication remains positive, and that information and recommendations on the use of moxifloxacin, and the measures that should be taken before it is prescribed, are adequately addressed in the ‘ contraindications'and ‘ special warnings and precautions for use'sections of the EU SPC.
This pr ocedure will inv olve rem oving the following recommendations and indications for which no data were provided:
- The Committee considered that robust data is available showing the efficacy of Actira in the
- The Committee considered that robust data is available showing the efficacy of Avalox in the
The Committee decided that Aldurazyme's benefits are greater than its risks for long-term enzyme replacement therapy in patients with a confirmed diagnosis of MPS I.
The Committee decided that Tasigna's benefits are greater than its risks for the treatment of adults with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.
The Committee noted that evidence of Yondelis's effects is mainly based on the treatment of liposarcoma and leiomyosarcoma.
A pharmacovigilance workshop was jointly organised by the EMEA with interested parties in Madrid in May 2002.
The Committee noted that Sustiva has not been studied adequately in patients with advanced disease (CD4 cell counts below 50 cells/ mm3) or after treatment with protease inhibitors (another type of antiviral medicine) that was not working.
The Committee for Medicinal products for Human Use (CHMP) decided that Cerezyme gives effective control of the symptoms of types 1 and 3 Gaucher disease.
The Committee for Medicinal products for Human Use (CHMP) concluded that Cetrotide in a safe and effective alternative to existing treatments to prevent premature ovulation.
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Mycophenolate mofetil Teva has been shown to have comparable quality and to be bioequivalent to Cellcept.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Cyanokit appeared to be a well-tolerated and efficient cyanide antidote, based on its effects on survival and the prevention of brain damage.
The Committee for Medicinal Products for Human use (CHMP) concluded that DepoCyte has shown effectiveness in lymphomatous meningitis when compared with the standard formulation of cytarabine, and that its administration schedule, with fewer intrathecal injections, can be of benefit to the patient 's quality of life.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Diacomit had shown its effectiveness in SMEI, albeit in studies that were limited and did not last as long as the Committee expected.
The Committee for Medicinal Products for Human Use (CHMP) concluded that vildagliptin taken with metformin reduces blood glucose levels and the combination of the two active substances in one tablet may help patients to stick to their treatment.
The Committee for Medicinal Products for Human Use (CHMP) concluded that vildagliptin taken with metformin reduces blood glucose levels and the combination of the two active substances in one tablet may help patients to stick to their treatment.
The Committee decided that ACOMPLIA's benefits are greater than its risks when used, in addition to diet and ct
The Committee for Medicinal Products for Human Use (CHMP) concluded that the effectiveness of Busilvex had been shown, and that it provides an alternative to busulfan tablets, which have disadvantages such as the large number of tablets that need to be taken.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Tractocile has shown an effectiveness in delaying pre-term birth that is the same as seen with beta-agonists, and that the better outcome with Tractocile was due to the medicine being better tolerated.
The Committee for Medicinal Products for Human Use (CHMP) concluded that the effectiveness of Tysabri in MS, on both relapses and disability, had been clearly shown.
The Committee for Medicinal products for Human Use (CHMP) concluded that ZIMULTI had shown its no
The Committee for Medicinal Products for Human Use (CHMP) concluded that Thelin had shown its effectiveness, and that this effectiveness was as expected for this class of medicines.
The Committee for Medicinal Products for Human Use (CHMP) concluded that ECALTA's benefits are greater than its risks in the treatment of invasive candidiasis in adult non-neutropenic patients.
The Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Riprazo are greater than its risks for the treatment of essential hypertension.
The Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Sprimeo are greater than its risks for the treatment of essential hypertension.
The Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Tekturna are greater than its risks for the treatment of essential hypertension.
The Committee for Medicinal products for Human Use (CHMP) decided that TRISENOX's benefits are greater than its risks for induction of remission and consolidation in adult patients with relapsed/ refractory APL, characterised by the presence of the t(15; 17) translocation and/ or the presence of the Pro-Myelocytic Leukaemia/ Retinoic-Acid-Receptor-alpha (PML/ RAR-alpha) gene, when previous treatment has included a retinoid and chemotherapy.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Evoltra treatment may provide a way of obtaining remission, and of facilitating a stem cell transplant.
against erythropoietin (these antibodies may develop during treatment and can reduce its effectiveness).
The Committee for Medicinal Products for Human Use (CHMP) concluded that EMSELEX showed an effectiveness similar to that of other anticholinergic medicines used in overactive bladder syndrome.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Revatio provides an alternative treatment option for PAH.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Savene had shown its effectiveness in treating anthracycline extravasation, allowing patients to continue their anti-cancer treatment.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Telzir, which contains a prodrug of amprenavir, provides an advantage for patients, as the number of tablets they need to take is reduced when compared to the number of Agenerase capsules that they would need to take for the same dose of amprenavir.
The Committee for Medicinal products for Human Use (CHMP) decided that Betaferon's benefits are greater than its risks for the treatment of patients with relapsing remitting multiple sclerosis, secondary progressive multiple sclerosis, and in patients with a single episode of demyelination, severe enough to justify treatment with injected corticosteroids.
The Committee for Medicinal Products for Human Use (CHMP) decided that Aldurazyme gives effective control of the symptoms of MPS I.
The Committee for Medicinal products for Human Use (CHMP) concluded that CHAMPIX has shown its effectiveness in helping patients stop smoking, and that the risks of smoking outweigh the risks of the medicine.
The Committee for Medicinal Products for Human Use (CHMP) concluded that the effectiveness of pioglitazone and glimepiride in type 2 diabetes had been shown, and that Tandemact simplifies treatment and improves the ability of patients to stick to their treatment when a combination of the two active substances is needed.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Yondelis's benefits are greater than its risks for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.
The Committee for Medicinal Products for Human Use (CHMP) decided that OSSEOR's benefits are greater than its risks for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and hip fractures.
The Committee for Medicinal products for Human Use (CHMP) decided that Viread's benefits are greater than its risks in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected patients over 18 years of age.
The Committee for Medicinal Products for Human Use (CHMP) decided that Aclasta's benefits are greater than its risks for the treatment of osteoporosis in post-menopausal women and in men, at increased risk of fracture including those with a recent low-trauma hip fracture, and of Paget's disease of the bone.
The Committee for Medicinal Products for Human Use (CHMP) decided that Fablyn's benefits are greater than its risks for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Forsteo's benefits are greater than its risks for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture, and for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
The Committee for Medicinal Products for Human Use (CHMP) decided that Fosavance's benefits are greater than its risks for the treatment of postmenopausal osteoporosis in patients at risk of vitamin D insufficiency.
The Committee for Medicinal Products for Human Use (CHMP) decided that Myozyme's benefits are greater than its risks for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Pompe disease (acid alpha-glucosidase deficiency).
The Committee for Medicinal products for Human Use (CHMP) decided that Panretin's benefits are greater than its risks for the treatment of cutaneous lesions in patients with AIDS- related Kaposi's sarcoma.
The Committee for Medicinal Products for Human Use (CHMP) decided that Preotact's benefits are greater than its risks for the treatment of osteoporosis in postmenopausal women at high risk of fractures.
The Committee for Medicinal Products for Human Use (CHMP) decided that Stocrin's benefits are greater than its risks in antiviral combination treatment of HIV-infected adults, adolescents, and children three years of age and older.
The Committee for Medicinal Products for Human Use (CHMP) decided that Sustiva's benefits are greater than its risks in antiviral combination treatment of HIV-infected adults, adolescents and children three years of age and older.
The Committee for Medicinal Products for Human Use (CHMP) decided that Sutent's benefits are greater than its risks for the treatment of unresectable and/ or metastatic malignant GIST after failure of imatinib mesilate treatment due to resistance or intolerance, and for the treatment of advanced and/ or metastatic RCC.
The Committee for Medicinal Products for Human Use (CHMP) decided that Temodal's benefits are greater than its risks for treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment, and malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
The Committee for Medicinal Products for Human Use (CHMP) decided that Tracleer's benefits are greater than its risks for the treatment of patients with PAH and to reduce the number of new digital
The Committee for Medicinal Products for Human Use (CHMP) decided that Tritanrix HepB's benefits are greater than its risks for active immunisation against diphtheria, tetanus, pertussis and hepatitis B in infants from six weeks onwards.
The Committee for Medicinal Products for Human Use (CHMP) decided that Viracept's benefits are greater than its risks in antiretroviral combination treatment of HIV-1 infected adults, adolescents and children of three years of age and older.
The Committee for Medicinal Products for Human Use (CHMP) decided that Yentreve's benefits are greater than its risks for the treatment of moderate to severe SUI.
The Committee for Medicinal Products for Human Use (CHMP) decided that Ytracis's benefits are greater than its risks for the radiolabelling of carrier molecules which have been specifically developed and authorised for radiolabelling with this radionuclide.
The Committee for Medicinal products for Human Use (CHMP) decided that Yttriga's benefits are greater than its risks for the for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.
The Committee for Medicinal Products for Human Use (CHMP) noted that combining the two active substances in Azarga simplifies therapy and helps patients to stick to their treatment.
The Committee for Medicinal products for Human Use (CHMP) noted that psoriasis was more severe in ‘ high-need'patients, and that the effectiveness of Raptiva is relevant for these patients.
The Committee for Medicinal Products for Human Use (CHMP) noted that the risk of cholera for regular tourists is minor, but that Dukoral could be important for certain groups, such as healthcare workers in cholera epidemics.
The Committee for Medicinal Products for Human Use (CHMP) noted that surgical treatment for malignant glioma should aim to remove as much of the tumour as possible while sparing healthy brain tissue.
The Committee for Medicinal Products for Human Use (CHMP) noted that ReFacto AF was comparable to ReFacto, the original form of the medicine.
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Diovan in the European Union (EU) and the European Economic Area (EEA).
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Tritace in the European Union (EU) and the European Economic Area (EEA).
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Tritazide in the European Union and the European Economic Area (EEA).
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Nobivac Bb exceed the risks of its use.
Orphan Medicinal Products (COMP) on the designation of orphan medicines
The COMP is the first institutional committee of the European Union to have patient organisation representatives as full members.
The lyophilised Haemophilus influenzae type b (HIB) component is a white powder. rod
The major circulating component in plasma is ganirelix.
The most likely component involved in the reversible binding is hydroxy apatite, the inorganic matrix in these tissues.
The compound potentially induces photogenotoxicity after subsequent irradiation or light exposure which is obviously related to the induction of porphyrin synthesis.
The 4 mg tablet also contains purified talc and iron oxide yellow (E172).
The tablet has special score lines so that it can be easily divided into four equal parts.
The 100 microgram tablet is a white round tablet The 200 microgram tablet is a white oval-shaped tablet The 300 microgram tablet is a white triangle-shaped tablet The 400 microgram tablet is a white diamond-shaped tablet The 600 microgram tablet is a white “ D” -shaped tablet The 800 microgram tablet is a white capsule-shaped tablet
The Effentora tablet should not be sucked, chewed or swallowed, as this will result in lower plasma concentrations than when taken as directed.
The tablet must be used immediately once removed from the blister. • Separate one of the blister units from the blister card by tearing apart at the perforations. • Bend the blister unit along the line where indicated. • Peel the blister backing to expose the tablet.
The tablet and oral solution were bioequivalent in healthy subjects; therefore, both forms may be used interchangeably.
The tablet should not be stored once removed from the blister package as the tablet integrity can not be guaranteed and a risk of accidental exposure to a tablet can occur.
86 Olanzapine Teva Orodispersible Tablet should be placed in the mouth, where it will rapidly disperse in saliva, so it can be easily swallowed.
The product should be administered with food.
The tablet can be divided into equal halves.
The tablet can be divided into equal halves.
The tablet can be divided into equal halves.
The tablet can be divided into equal halves.
The tablet can be divided into four equal parts.
The tablet can be divided into four equal parts.
The tablet may be taken with or without food.
The dose can be taken regardless of mealtime.
The tablet may be taken with or without food.
Take the soluble tablets as a single daily dose with a meal to increase the absorption, and at the same time each day, preferably in the morning.
Take the soluble tablets as a single daily dose, with a meal to increase the absorption, and at the same time each day, preferably in the morning.
The tablet will disintegrate upon contact with moisture.
The tablet rapidly dissolves in the mouth, releasing microgranules which you should swallow without chewing.
The breath test concept relies on the administration of a specifically 13C-labelled urea whose metabolite utilisation is monitored by measuring 13CO2 in the expired breath gas.
Treatment initiation pack with 28 transdermal patches for a 4 week treatment schedule contains:
Advice for health care professionals on possible need to adjust dosages for patients normally treated outside Europe with Xyntha.
The Board also noted the Joint Action adopted by the EU Council of Ministers on 16 June 1997 on risk assessment of new synthetic drugs (OJ L 167, 26.6.1997).
The Management Board began a new mandate in 2000, electing André Broekmans as its new chairman and Gerhard Kothmann as vice-chairman.
The Board recognised that it must focus on its two main tasks:
The Agency’s many stakeholders, including the European institutions, the competent authorities of Member States, citizens of the European Community, patients, patient representatives and the pharmaceutical industry, will continue to have high expectations of this Agency, and the Agency is in my opinion, in a position to deliver against those expectations.
This has occurred globally and could have important implications.
The Management Board is the supervisory body of the EMEA.
The Management Board will in 2000 focus on:
The Board met four times in 1997 on 5 February, 4 June, 1 October and 3 December.
The Board considered two issues in particular.
The Management Board will follow closely preparations by the European Commission in 2000 and the proposals and discussions of the European Parliament and Council in 2001.
The Board must also be sure that the outcome of that performance measurement is published.
The Board will in particular review the scope of the special activities and projects for 2001.
Scientific advice is a priority area for the EMEA and is provided on any aspect of research and
The Board has set itself key objectives which focus on meeting these challenges successfully.
The contents of the pipette are squeezed onto the skin after parting the fur at the back of the head.
The content of the pipette is squeezed onto the skin after parting the fur between the shoulder blades of the cat.
The entire contents of the pipette should be applied evenly as 3 or 4 spots along the top of the back, from between the shoulders to the base of the tail.
The entire contents of the pipette should be applied evenly as 3 or 4 spots along the top of the back, from between the shoulders to the base of the tail.
The contents of the single dose syringe should be shaken well and administered aseptically by subcutaneous injection.
The contents of the prefilled syringe are shaken and given by subcutaneous (under the skin) injection.
The information package for certificates of medicinal products issued by the EMEA was updated in 2001.
EXUBERA is available in 1 mg and 3 mg unit dose blisters which are for administration via the lungs by oral inhalation only with the insulin inhaler. ed
The contents should be swirled gently during dissolution.
The contents of a vial should be used immediately after piercing the rubber stopper.
The contents of a vial should be used immediately after piercing the rubber stopper.
Once opened, the content of a vial should normally be used immediately (see section 6.3).
The content of the bottle should be used up within 45 days of opening.
The contents of a vial should be used immediately after piercing of the rubber stopper.
The content of a vial should be used immediately after reconstitution.
The contents of the OPTISON vial should be used within 30 minutes after the rubber stopper has been penetrated.
The content of the vial of YTRACIS is not to be administered directly to the patient but must be used for the radiolabelling of carrier molecules, such as monoclonal antibodies, peptides or other substrates.
The contents of the vial of Yttriga is not to be administered directly to the patient but must be used for the radiolabelling of carrier molecules, such as monoclonal antibodies, peptides or other substrates.
The unreconstituted contents of the vial before radiolabelling are not to be directly administered to patients.
For each inhalation session with the I-Neb AAD, the content of one 1-ml ampoule of Ventavis, showing three coloured rings (pink – red- red), will be transferred into the appropriate nebuliser medication chamber immediately before use.
For each inhalation session with the I-Neb AAD, the content of one 1-ml ampoule of Ventavis, showing three coloured rings (pink – red- red), will be transferred into the appropriate nebuliser medication chamber immediately before use.
The contents of one sachet should be reconstituted by stirring into 30 ml (two tablespoons) of tap water, and swallowed immediately.
The content of the tube of RotaTeq is given directly into the mouth of the baby.
The contents and management of the standard contract and the general principles governing the relationship between the EMEA and the national authority will be reviewed in 2002.
Draw 10 ml tap water into the syringe Invert the syringe and draw an additional 1 ml of air into it Shake the syringe gently for 10-20 seconds until the tablet is dispersed The contents can be emptied directly into the mouth Refill the syringe with 2-5 ml of tap water to flush the remnants out of the syringe into the mouth
The constant monitoring of the safety of medicines after authorisation (‘ pharmacovigilance’) is an important part of the work of the national competent authorities and EMEA.
The constant monitoring of the safety of medicines after authorisation (‘pharmacovigilance’) is an important part of the work of the national competent authorities and EMEA.
The constant monitoring of the safety of medicines after authorisation (‘ pharmacovigilance’) is an important part of the work of the national competent authorities and EMEA.
Patients should be periodically evaluated for their asthma control.
Glycaemic control should be monitored closely.
Particularly careful control of your diabetes, and prevention of hypoglycaemia, is important for the health of your baby.
Careful control of your diabetes, and prevention of hypoglycaemia, is important for the health of your baby.
Careful control of your diabetes, and prevention of hypoglycaemia, is important for the health of your baby.
The ICH co-ordinator for safety was Dr J.
- The body of published literature and resistance data presented provide adequate justification, both
- The body of published literature and resistance data presented provide adequate justification, both
The cortex of the adrenal gland produces steroid hormones.
The CPMP concluded that the signal should be further investigated.
The CPMP concluded that the three cited studies do not indicate an increased risk of congenital malformations with loratadine use.
The CPMP concluded that there was no indication of antiandrogenic effects in the studied endpoints.
The CPMP, having considered the grounds for appeal submitted on 21 March 1997, has concluded that its opinion of 22 January 1997 should not be revised and that the Marketing Authorisations for all medicinal products referred to in Annex A should be withdrawn.
the CPMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics is set out in Annex III of the CPMP Opinion for Pravachol and associated names (see Annex I).
the CPMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics is set out in Annex III of the Opinion for Lopid and associated names (see Annex I).
the CPMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics is set out in Annex III of the Opinion for Zocord and associated names (see Annex I).
The CPMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics is set out in Annex III of the Opinion.
the CPMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics is set out in Annex III of the Opinion.
EMEA/ CPMP/ 3736/ 03 9/ 21  EMEA 2003 the CPMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics is set out in Annex III for Lederfoline and associated names (see Annex I).
the CPMP has recommended the maintenance of the Marketing Authorisations for vigabatrin containing medicinal products (see Annex II) in accordance with the SPC set out in Annex III and under the conditions set out in Annex IV.
the CPMP has recommended the granting of the Marketing Authorisation for which the Summary of Product Characteristics is set out in Annex III for Botox (see Annex I).
The CPMP will continue to meet monthly under the chairmanship of Jean-Michel Alexandre and vice-chair Mary Teeling.
The CPMP will continue through its satellite groups (Invented Names Review Group, Organisational Matters Group, Meeting of the chairmen of the CPMP and working parties) to improve the functioning of the Committee and of the centralised procedure.
Composite mortality and morbidity risk was significantly reduced by 18.3% (95% CI:
The primary efficacy endpoint of the study was TTP, defined as the time from randomization to first documentation of objective tumour progression.
The primary endpoint at week 24 was the proportion of patients who achieved an ACR 20 response.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The primary efficacy endpoint in both studies was time to progression (TTP).
The primary endpoint was the proportion of patients who were alive and free of invasive ventilator support.
The primary adjudicated endpoint was a composite of death, myocardial infarction (MI) and refractory ct
The primary adjudicated endpoint was a composite of death, myocardial infarction (MI) and refractory ischaemia (RI) within 9 days of randomisation.
The main measure of effectiveness was the average survival time.
The primary evidence of efficacy was based on objective response rates.
The main measure of effectiveness was the number of days during which patients experienced severe oral mucositis.
The primary efficacy endpoint was CIN2+ associated with HPV-16 and/ or HPV-18.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The primary efficacy endpoint was progression free survival (PFS).
The primary efficacy endpoint was incident infection with HPV-16 and/ or HPV-18.
The main measure of effectiveness was based on the number of new digital ulcers developing during the studies.
The primary efficacy endpoint was the numbers of meters walked in 12 minutes at Week 24 compared to the number of meters walked at baseline.
The primary outcome assessment was the score for the Activities of Daily Living (ADL) component (Part II) plus the Motor Examination component (Part III) of the Unified Parkinson's Disease Rating Scale (UPDRS).
The primary endpoint was best tumour response.
Treatment with Tracleer resulted in fewer new digital ulcers for the duration of therapy, compared with placebo.
Composite of total VTE (including PE, proximal and distal DVT, whatever symptomatic or asymptomatic detected by routine venography) and all-cause mortality constituted the primary end-point for both studies.
Composite of total VTE (including PE, proximal and distal DVT, whatever symptomatic or asymptomatic detected by routine venography) and all-cause mortality constituted the primary end-point for both studies.
The main secondary endpoint of the study also showed comparable efficacy (non-inferiority) between the 100 mg total daily dose and the 140 mg total daily dose (difference in MCyR -0.8%; 95% confidence interval [-9.6% - 8.0%]).
Eculizumab preserves the early components of complement activation that are essential for opsonization of microorganisms and clearance of immune complexes.
Eculizumab binds to and inhibits a specific protein in the body that causes inflammation.
The CVMP concluded that the statistical method could not be used based on the data of the new study provided.
The CVMP concluded that the benefit - risk assessment for Bovilis BVD was favourable.
The CVMP has concluded that the risk/ benefit for Bovilis BVD is favourable.
The CVMP recommended varying the Marketing Authorisations of the concerned veterinary medicinal products in accordance with the conclusions where applicable.
The CVMP recommended the refusal of the granting of the Marketing Authorisation and the suspension of the Marketing Authorisation for Equimectin where appropriate.
The CVMP recommended the refusal of the granting of the Marketing Authorisation and the suspension of the Marketing Authorisation for Equimectin where appropriate.
The CVMP can accept the proposed revision of the indication:
The CVMP met 11 times under the chairmanship of Steve Dean.
Tylvalosin has a sixteen membered ring.
The PSUR cycle of ADROVANCE is aligned with the one of the product, FOSAVANCE, until otherwise specified.
The next cycle should begin on the usual “ Change Day”, which is the day after Day 28.
This helps the transplanted cells to ‘ engraft '(when they start to grow and produce normal blood cells).
CYP3A4 is a major enzyme responsible for the metabolism of dasatinib.
Since dabigatran is excreted predominantly by the renal route adequate diuresis must be maintained.
The Denmark referred the reasons for disagreement to the EMEA on 31 March 2006.
The Denmark referred the reasons for disagreement to the EMEA on 3 March 2006.
Darunavir in combination with ritonavir caused a reduction in the number of pups that exhibited the startle response on day 15 of lactation and a reduced pup survival during lactation.
Darunavir and ritonavir inhibit CYP3A4 and as a result can be expected to increase the plasma concentrations of calcium channel antagonists, which are CYP3A4 substrates.
Darunavir was not mutagenic or genotoxic in a battery of in vitro and in vivo assays including bacterial reverse mutation (Ames), chromosomal aberration in human lymphocytes and in vivo micronucleus test in mice.
The recommended infusion rate given under section 4.2 "Method of administration" must be followed closely.
The recommended infusion rate given under “4.2 Method of administration” must be closely followed.
Onset of antihypertensive activity was usually seen at one hour, with peak reduction of blood pressure achieved by 4 to 6 hours after administration.
The onset of drug effect may be faster when< INVENTED NAME > is administered without food.
The onset of the adverse event occurred after the sixth or greater dose in only 22 of these reports (15 after the sixth dose, 6 after the seventh doses and 1 after the eight dose).
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Deferasirox caused formation of micronuclei in vivo in the bone marrow, but not liver, of non-iron-loaded rats at lethal doses.
The level of efficacy for other species may differ from that observed in sheep and cattle.
The clinical relevance of these findings is still uncertain.
It took 47.3 weeks for the disease to get worse or the patient to die in the Sutent group, compared with 22.0 weeks in the group taking interferon alfa.
The withdrawal period of the product is zero days.
Time to first confirmation of normal levels of uric acid in hyperuricaemic patients is four hours for Fasturtec and 24 hours for allopurinol.
The time from start of administration of sugammadex or neostigmine to recovery of the T4/ T1 ratio to 0.9 was:
For skin carcinoma, the median time to first occurrence was significantly delayed.
The median time from diagnosis to start of treatment was 48 months.
The median time to death was 27.4months for patients treated with fulvestrant and 27.6 months for patients treated with anastrozole.
The median time to onset of response in the infliximab-treated group was 2 weeks.
The Applicant considered that the results from study 2007-59-DOS-5 demonstrate bioequivalence in terms of rate and extent of the total systemic absorption of inhaled salbutamol.
Extraneous agents testing of batches of finished product, if required.
Extraneous agents testing of raw materials 3.
• extraneous agents testing of raw materials are carried out according to the relevant requirements
Extraneous agents testing of raw materials 3.
DFSP is a cancer of the tissue beneath the skin in which some cells start growing out of control.
The front of the thigh is the preferred injection site.
The Marketing Authorisation Holder will provide the PSUR at 3-yearly intervals.
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
The Marketing Authorisation Holder for FORCALTONIN is Unigene UK Limited, 191 Sparrows Herne, Bushey Heath, Hertfordshire WD23 1AJ, UK. tn
The second Pan-European Regulatory Forum (PERF II) continues until July 2002.
The clinical development of DuoTrav included both patients naive and on therapy.
Antibody development has been observed with the use of Levemir.
Resistance development is beside absolute quantitative use of quinolone agents also driven by pharmacokinetic and pharmacodynamic (PK/ PD) factors.
Development of such antibodies is seen more commonly in patients treated with EXUBERA in
• Development progressed during 1997 on a time recording system (ActiTrak) for the EMEA Secretariat.
• Work also continued in 1997 on the development of a computerised accounting and budgetary system.
The development and resulting quality of these products has not been optimised in the normal way and is not state of the art.
Motor development is often completely arrested, or if motor milestones are achieved, they are subsequently lost.
By increasing levels of incretin hormones in the blood, vildagliptin stimulates the pancreas to produce more insulin 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The diagnosis was confirmed by objective testing (lung scan, pulmonary angiography or spiral CT scan).
The diagnosis of persistent asthma in very young children (6 months – 2 years) should be established by a paediatrician or pulmonologist.
The diagnosis of ovarian hyperstimulation may be confirmed by ultrasound examination.
The diagnosis and management of somatropin therapy should be initiated and monitored by adequately experienced physicians.
The diagnosis of gastroduodenal ulcers and reflux oesophagitis should be confirmed by endoscopy or other appropriate diagnostic means.
- diazoxide (used to treat high blood pressure),
- diazoxide (used to treat high blood pressure),
- diazoxide (used to treat high blood pressure),
- diazoxide (used to treat high blood pressure),
- diazoxide (used to treat high blood pressure),
- diazoxide (used to treat high blood pressure),
The Veterinary Dictionary of Defined Terms (Veddra) is now complete and incorporated in the EudraWatch system for communication of adverse reports between Member States, Commission and EMEA.
The diluent contains: polysorbate 80 (E 433), macrogol 400, anhydrous ethanol.
The Diskus releases a powder which is inhaled into the lungs.
- disopyramide (used to treat certain heart conditions),
The dosing-device is graded and each grade equals a dose for 50 kg bodyweight.
The device must be dry prior to use
The device is designed so that you can't use too much IONSYS, providing only you operate it, and only when you need pain relief.
Remove the IONSYS system before a magnetic resonance imaging (MRI) procedure, cardioversion, or defibrillation.
The IONSYS system will emit a single audio beep immediately.
The IONSYS system will stop working after 24 hours or after 80 doses have been delivered.
The system will then shut down and cannot deliver any additional doses.
The transdermal patch is composed of three layers: a backing film, an adhesive/ drug layer and a release liner.
The patch is designed to remain in place during these times.
The transdermal patch should not be applied to skin that is red, irritated or cut.
The used system should also be disposed of by medical staff.
DMA decreases fertility in male and female rodents (see sections 4.6 and 5.3)
Docetaxel belongs to the group of anti-cancer medicines called taxoids.
Docetaxel blocks the ability of cells to destroy the internal ‘ skeleton 'that allows them to divide and multiply.
Docetaxel blocks the ability of cells to destroy the internal ‘ skeleton 'that allows them to divide and multiply.
Docetaxel is a substance derived from the needles of yew trees.
Docetaxel has been shown to be mutagenic in the in vitro micronucleus and chromosome aberration test in CHO-K1 cells and in the in vivo micronucleus test in the mouse.
He is succeeded by Mr Gabriel Beechinor.
Dorzolamide led to decreases of between 4.3 and 4.9 mmHg.
The 320 mg strength was not available in all markets.
The dosage should be determined by the physician, according to the requirement of the patient.
Dosage will vary depending on your condition and your body weight.
The record of Savene's designation as an orphan medicine is available here
The physician information about INCRELEX should contain the following key elements:
The patient information pack should be provided and contain the following key messages: • Package leaflet • Contraindication in pregnancy and in breast-feeding women • Need for adequate calcium and vitamin D supplementation, appropriate physical activity, non- smoking and healthy diet • Key signs and symptoms of serious adverse events • When to seek attention from the health care provider
The patient information pack should be provided and contain the following key messages: • Package leaflet • Contraindication in pregnancy and in breast-feeding women • Need for adequate calcium and vitamin D supplementation, appropriate physical activity, non- smoking and healthy diet • Key signs and symptoms of serious adverse events • When to seek attention from the health care provider
Dr Abadie has been a consultant in cardiology and diabetology since 1984.
Dr Barbara van Zwieten-Boot was appointed Rapporteur and Dr Gonzalo Calvo Rojas, Dr Eric Abadie, Dr Karl Broich and Dr Julia Dunne were appointed Co-Rapporteurs.
Dr Jones joined the EMEA Management Board in 1995.
Dr Saint Raymond held a position as paediatrician in a teaching paediatric hospital in Paris, followed by a number of years working for a number of pharmaceutical companies.
Dr Wagner was appointed head of sector for IT in the same service in 1993.
The DSMB will be composed of independent physicians with expertise in Dermatology, Pediatric Medicine, Immunology, Epidemiology and Oncology.
Because EDMTP has a high affinity for bone tissue, it accumulates in the bone, especially in areas of rapid bone growth such as osteoblastic metastases.
- Co-administration of the potent CYP3A4 inhibitor ketoconazole increased the peak plasma
The manufacturer of VIAGRA is Pfizer PGM, Zone Industrielle, 29 route des Industries, 37530 Pocé- sur-Cisse, France.
77 The manufacturer is: < {Name and address} > < {tel} > < {fax} > < {e-mail} >
The manufacturer is: < {Name and address} > < {tel} > < {fax} > < {e-mail} >
er The manufacturer is Shire Human Genetic Therapies AB, Åldermansgatan 2, P. O.
The manufacturer responsible for batch release is:
The Manufacturer responsible for batch release is
Factor IX in this product therefore behaves like endogenous factor IX.
Factor IX is a normal constituent of human blood.
Platelet factor 4 does not inhibit lepirudin.
Activated Factor X converts prothrombin to thrombin.
Factor XIIIa, which is activated form Factor XIII by thrombin, crosslinks fibrin.
Lowering your blood pressure to normal reduces the risk of developing these disorders.
Delaying the first dose to midmorning or taking the dose with a little protein-containing food (e. g. meat) may help.
It is noted that there are no reports (PSURs) on lack of efficacy or developing resistance following use of TMP/ SDZ in horses.
Efalizumab has been designed to bind to part of a protein called LFA-1 on the surface of lymphocytes, a type of white blood cell that is involved in the inflammation process.
Efalizumab is an IgG1 kappa immunoglobulin, containing human constant region sequences and murine light- and heavy-chain complementary determining region sequences.
Therefore, voriconazole is likely to increase the plasma levels of benzodiazepines that are metabolised by CYP3A4 (midazolam and triazolam) and lead to a prolonged sedative effect.
Antiviral activity in vitro: efavirenz demonstrated antiviral activity against most non-clade B isolates (subtypes A, AE, AG, C, D, F, G, J, and N) but had reduced antiviral activity against group O viruses.
Efavirenz non-competitively inhibits HIV-1 reverse transcriptase (RT) and does not significantly inhibit human immunodeficiency virus-2 (HIV-2) RT or cellular deoxyribonucleic acid (DNA) polymerases (α, β, γ, and δ).
When treatment with voriconazole is stopped, the initial dosage of efavirenz should be restored (see sections 4.4 and 4.5).
Febuxostat should not be used while breast-feeding.
Fentanyl exhibits three compartment distribution pharmacokinetics.
Fentanyl, the active substance in IONSYS, can be abused.
The painkiller, fentanyl, slowly passes from the patch, through the skin and into the body.
Long term outcome was not studied (see section 4.4).
Long term outcome was not studied (see section 4.4). al
The anticonvulsant activity of zonisamide has been evaluated in a variety of models, in several species with induced or innate seizures, and zonisamide appears to act as a broad-spectrum anti-epileptic in these models.
The bactericidal effect of amoxicillin is neutralised by simultaneous use of bacteriostatic acting pharmaceuticals (macrolides, sulphonamides and tetracyclines).
The benefit of treatment should be re-assessed at regular intervals.
This is without prejudice to the obligations of confidentiality under Article 4 of the standard contract or professional gross negligence on the part of the rapporteur, co-rapporteur, expert or inspector.
Ultrasound imaging must be performed during injection of OPTISON as optimal contrast effect is obtained immediately after administration.
The effect of the HBsAg on foetal development has not been assessed.
The effect of ambrisentan on male human fertility is not known.
The effect of food on absorption is unknown.
The effect of food on the rate and extent of absorption was also studied.
The effect of stopping treatment after the achievement of a complete cytogenetic response has not been investigated.
The effect of stopping treatment after achieving a response has not been investigated.
The effect of stopping treatment after the achievement of a complete cytogenetic response (CCyR) has not been investigated.
The mechanism of the LDL-lowering effect of simvastatin may involve both reduction of VLDL cholesterol concentration and induction of the LDL receptor, leading to reduced production and increased catabolism of LDL cholesterol.
The effect of enzyme induction has not been studied.
The effect of orlistat in individuals with hepatic and/ or renal impairment has not been studied.
No studies on the effect of< Nimesulide containing medicinal products > on the ability to drive or use machines have been performed.
No studies on the effect of< Nimesulide containing medicinal products > on the ability to drive or use machines have been performed.
The effect of Enbrel on radiographic progression was maintained in patients who continued on treatment during the second year.
The effect of Enbrel on radiographic progression was maintained in patients who continued on treatment during the second year.
The effect of Pradaxa on the ability to drive and use machines is not known.
V08C A09 Paramagnetic contrast media The contrast-enhancing effect is mediated by gadobutrol, the nonionic complex consisting of gadolinium(III) and the macrocyclic ligand dihydroxy-hydroxymethylpropyl-tetraazacyclododecane- triacetic acid (butrol).
The effect of antacids on the absorption of erlotinib have not been investigated but absorption may be impaired, leading to lower plasma levels.
The effect of antibodies passed on by the mother was also investigated.
The effect of medicines containing phenytoin (for epilepsy) may be decreased if given together with Yondelis and this is therefore not recommended.
No studies on the effect of< Nimesulide containing medicinal products > on the ability to drive or use machines have been performed.
The effect of TRISENOX on your ability to drive is not known.
The effect of Volibris on the outcome of the disease is unknown.
The effect of bosentan on reduction of the number of new digital ulcers was more pronounced in patients with multiple digital ulcers.
The effect of the lower dose of ADROVANCE (alendronate 70 mg/ vitamin D3 2800 IU) plus an additional 2800 IU Vitamin D3 for a total of 5600 IU (the amount of vitamin D3 in the higher dose of ADROVANCE) once weekly was demonstrated in a 24-week, extension study that enrolled 619 osteoporotic post-menopausal women.
The effect of the lower dose of FOSAVANCE (alendronate 70 mg/ vitamin D3 2800 IU) plus an additional 2800 IU Vitamin D3 for a total of 5600 IU (the amount of vitamin D3 in the higher dose of FOSAVANCE) once weekly was demonstrated in a 24-week, extension study that enrolled 619 osteoporotic post-menopausal women.
The effect of glimepiride is dose- dependent and reproducible.
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the pharmacokinetics of repaglinide has been studied in healthy subjects.
The effect of renal or hepatic impairment on the pharmacokinetics of Effentora has not been studied.
The outcome of patients with bone marrow transplantation after dasatinib treatment has not been fully evaluated.
Free or biological active hormone concentrations are unchanged.
The effect of posaconazole on sirolimus in patients is unknown, but is expected to be variable due to the variable posaconazole exposure in patients.
Ritonavir effect on MDR-1 transport in renal tubuli has been a proposed mechanism for increased plasma concentrations of tenofovir.
The effect of sildenafil on mortality is unknown.
Likewise, the effect of stiripentol on their metabolism is not known.
The effect of teriparatide on human foetal development has not been studied.
A treatment effect was achieved after the first dose.
The effect of Fabrazyme treatment on the kidneys may be limited in patients with advanced renal disease.
The treatment effect of icatibant was confirmed by secondary efficacy endpoints.
The impact of treatment with Kineret on pre-existing malignancy has not been studied.
- The effect of treatment with Protopic on the developing immune system in children, especially
- The effect of treatment with Protopy on the developing immune system in children, especially
The treatment effect of the triglycerides-lowering response was significant between the placebo through simvastatin 40 mg (p=0.041).
The effect appears to be less pronounced than in patients with 1-3 positive nodes.
The blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.
The most commonly reported injection site related adverse event was pain (5%); some other injection site adverse events reported were (in decreasing frequency): nodule type reactions, erythema type reactions, non-specific injection site reactions, irritation, oedema type reactions, bruising, haemorrhage, and anesthesia.
The most frequent adverse reaction during treatment with NeoRecormon is an increase in blood pressure or aggravation of existing hypertension, especially in cases of rapid PCV increase (see section 4.4).
The most frequently reported treatment-related undesirable effect with TRAVATAN monotherapy was hyperaemia of the eye (22.3%), which included ocular, conjunctival, or scleral hyperaemia.
The inducing effect of St John's wort may persist for at least 2 weeks after cessation of treatment (see section 4.3).
John's wort may persist for at least 2 weeks after cessation of treatment.
John's wort may persist for at least 2 weeks after cessation of treatment (see section 4.3).
John's wort may persist for at least 2 weeks after cessation of treatment.
John’s wort may persist for at least 2 weeks after cessation of treatment.
John's wort may persist for at least 2 weeks after cessation of treatment (see section 4.3).
John’s wort may persist for at least 2 weeks after cessation of treatment (see section 4.3).
Ritonavir has been shown to induce metabolic enzymes, resulting in the induction of its own metabolism, and likely the induction of lopinavir metabolism.
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John's wort.
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John's wort (see section 4.3).
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John's wort (see section 4.3).
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John's wort (see section 4.3).
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John’s wort (see section 4.3).
The inducing effect may persist up to 2 weeks after cessation of treatment with St.
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John’s wort (see section 4.3).
The in vivo inhibitory effect on CYP2C8 has not been studied.
The enzyme-modulating effect of ritonavir may be dose dependent.
Relief of pain may persist for 4 weeks up to 4 months.
The potential effect of bevacizumab on the pharmacokinetics of cisplatin and gemcitabine was investigated in non-squamous NSCLC patients.
The effect of administering different botulinum neurotoxin serotypes concurrently is unknown.
Effect on hepatic clearance is less pronounced.
The effect on male human fertility is not known.
There was a significant and beneficial effect in quality of life (as assessed by PD-QUALIF scale).
The therapeutic effect is usually obtained within the first 24 hours of treatment.
The subsequent effect on efficacy is unknown.
The pulmonary vasodilatory effect of inhaled iloprost is of short duration (one to two hours).
Efficacy was also observed in more severely depressed patients (baseline HAM-D ≥ 25) in all positive placebo-controlled studies.
Efficacy has been demonstrated with or without concomitant use of methotrexate.
Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer's Disease Cooperative Study- Clinician 's Global Impression of Change).
Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer's Disease Cooperative Study- Clinician's Global Impression of Change).
Efficacy was established by the use of independent, domain-specific assessment tools which were applied at regular intervals during the 24-week treatment period.
Efficacy was established by the use of independent, domain-specific assessment tools which were applied at regular intervals during the 24-week treatment period.
Efficacy was based on 320 CP patients and 119 AP patients enrolled.
The efficacy was lower when no behavioural modification therapy was given.
Efficacy has only been demonstrated with regard to weight reduction.
efficacy of paroxetine in treating OCD was examined in three 24 week maintenance studies with relapse prevention design.
Long-term efficacy (more than 24 weeks) has not been demonstrated in OCD.
The antimicrobial effectiveness of valnemulin against bacteria causing the claimed diseases in pigs was studied in microbiological laboratories.
The antimicrobial effectiveness of tylvalosin against bacteria causing diseases was investigated in microbiological laboratories.
The effectiveness of Adenuric has been studied in two main studies involving a total of 1,834 patients with hyperuricaemia and gout.
Efficacy of Aerius syrup has not been investigated in paediatric trials in children less than 12 years of age.
Efficacy of Aerius syrup has not been investigated in separate paediatric trials.
The effectiveness of Arixtra has been studied for the prevention of and in the treatment of VTE.
Efficacy of Azomyr syrup has not been investigated in paediatric trials in children less than 12 years of age.
Efficacy of Azomyr syrup has not been investigated in paediatric trials in children less than 12 years of age.
Efficacy of Azomyr syrup has not been investigated in separate paediatric trials.
Efficacy of Azomyr oral solution has not been investigated in separate paediatric trials.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The efficacy of ARICLAIM is reinforced when combined with a training program called Pelvic Floor Muscle Training (PFMT).
The efficacy of ECALTA in neutropenic patients with candidaemia and in patients with deep tissue Candida infections or intra-abdominal abscess and peritonitis has not been established.
It is not known if CELSENTRI works in children.
The effectiveness of Ceplene has been studied in one main study involving 320 adults with AML who were in remission following leukaemia treatment.
The efficacy of Cerezyme on neurological symptoms of chronic neuronopathic Gaucher patients has not been established and no special dosage regimen can be recommended for these manifestations (see section 5.1).
The efficacy of Cervarix in the prevention of CIN2+ associated with HPV-16 and/ or HPV-18 as assessed up to 15 months after the last dose of vaccine or control and the rates of 12-month persistent infection in the TVC-1 cohort are presented in the table below:
The efficacy of CHAMPIX in smoking cessation was demonstrated in 3 clinical trials involving chronic cigarette smokers (≥ 10 cigarettes per day).
The effectiveness of Clopidogrel BMS as an anticoagulant was compared with that of aspirin in a study called CAPRIE including around 19,000 patients with atherothrombosis.
The effectiveness of Crixivan taken without ritonavir has been studied in three studies involving 524 patients infected with HIV.
The efficacy of DULOXETINE BOEHRINGER INGELHEIM is reinforced when combined with a training program called Pelvic Floor Muscle Training (PFMT).
Coadministration with agents that induce 3A4 activity may reduce the efficacy of Effentora.
- the efficacy of bleomycin can be considered as established through published literature and current
The efficacy of IT ziconotide was apparent in all groups.
The efficacy of lamivudine in patients co-infected with Delta hepatitis or hepatitis C has not been established.
Efficacy has been shown in studies in diabetic neuropathy, post herpetic neuralgia and spinal cord injury.
The efficacy of olanzapine was not established in these trials.
The efficacy of Masivet might be reduced in dogs previously treated with chemotherapy and/ or radiotherapy.
The efficacy of Masivet might be reduced in dogs previously treated with chemotherapy and/or radiotherapy.
Efficacy of Neoclarityn syrup has not been investigated in paediatric trials in children less than 12 years of age.
Efficacy of Neoclarityn syrup has not been investigated in separate paediatric trials.
Efficacy of Neoclarityn oral solution has not been investigated in separate paediatric trials.
In both studies, Nexavar was compared with placebo (a dummy treatment) in a double-blind manner 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The effectiveness of Nobivac Bb was investigated in three main studies involving cats of various breeds.
The effectiveness of Nobivac Piro has been studied in three laboratory studies in which dogs were vaccinated and then challenged (exposed to wild type Babesia).
6 Efficacy of OSSEOR to reduce the risk of new vertebral fracture was confirmed in the TROPOS study, including for osteoporotic patients without fragility fracture at baseline.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The effectiveness of Plavix as an anticoagulant was examined in a study (CAPRIE) of around 19,000 patients with atherothrombosis, where Plavix was compared with aspirin.
Efficacy of PROTELOS to reduce the risk of new vertebral fracture was confirmed in the TROPOS study, including for osteoporotic patients without fragility fracture at baseline.
The effectiveness of Equilis Prequenza has been studied in several trials under laboratory and field conditions.
The effectiveness of Equilis Prequenza Te has been studied in several trials under laboratory and field conditions.
The efficacy of Reconcile was higher when compared to placebo when behavioural modification therapy was also given to the dogs.
The efficacy of Revatio has not been established in patients with severe pulmonary arterial hypertension (functional class IV).
REYATAZ + ritonavir was similar (non-inferior) to lopinavir + ritonavir on this efficacy measure (time-averaged difference of 0.13, 97.5% confidence interval [-0.12, 0.39]).
Over time efficacy was maintained with RISPERDAL CONSTA (Figure 1).
Oral contraceptives may become less effective in patients taking Emend.
The efficacy of parenteral infusion of Naftidrofuryl (200mg/ 10ml) in the treatment of rest pain in patients with severe peripheral arterial occlusive disease had not been proven.
The once- and twice-daily doses of CELSENTRI were of similar effectiveness.
The herds of pigs were monitored for signs of infection with the type of Aujeszky's disease virus that is can be caught in the field.
The effectiveness of Targretin has been examined in two studies involving a total of 193 patients with CTCL who had failed on at least two previous treatments.
Telzir may be less effective due to decreased amprenavir plasma concentrations in patients taking these medicinal products concomitantly (see section 4.5).
The effectiveness of Tractocile as a treatment to delay pre-term birth was studied in 742 women who were 23 to 33 weeks pregnant in three main studies.
The effectiveness of Velcade has been studied in four main studies.
The efficacy of YENTREVE is reinforced when combined with a training program called Pelvic Floor Muscle Training (PFMT).
The protective efficacy of ZOSTAVAX against PHN was 67% (95% CI:
17 with < Invented Name > did not experience any flare compared with 24.0% of the patients randomized to the control group.
should not be taken until at least 2 hours after ORACEA.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The efficacy of prasugrel was independent of the ASA dose (75 mg to 325 mg once daily).
At 16 weeks after commencing Xolair therapy patients should be assessed by their physician for treatment effectiveness before further injections are administered.
The efficacy of the vaccine in cattle was studied in a laboratory trial using the vaccine in cattle from one month of age.
The estimate for vaccine efficacy against vaccine-serotype AOM, the primary endpoint of the trial, was 57% (95% CI:
The effect of zonisamide can be reduced by other medicines you are taking.
The effectiveness was determined based on examinations by a veterinarian and assessments by the animal's owner.
The efficacy and safety of inhaled human insulin in patients with
The efficacy and safety of inhaled human insulin in patients with
Efficacy and safety of Pelzont in combination with simvastatin > 40 mg were not included in this study.
Safety and efficacy of RILUTEK has only been studied in ALS.
Efficacy and safety of Trevaclyn in combination with simvastatin > 40 mg were not included in this study.
The safety and efficacy of Naglazyme in patients with renal or hepatic insufficiency have not been evaluated (see section 5.2).
The safety and efficacy of Naglazyme in patients with renal or hepatic insufficiency have not been evaluated.
< Invented Name > has not been evaluated for its efficacy and safety in the treatment of clinically infected atopic dermatitis.
The efficacy and safety of fondaparinux have not been formally studied in patients with HIT type II.
Luminity should not be used with fundamental imaging technique for stress echocardiography since efficacy and safety have not been established.
Protective efficacy against cholera in the Bangladesh study (per-protocol analysis) Protective efficacy,% (95% CI)
Protective efficacy has not been evaluated in males.
Protective efficacy has not been evaluated in males (see section 5.1).
Fibrinogen is a concentrate of clottable protein and Thrombin is an enzyme that causes clottable protein to coalesce.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Filgrastim is a protein produced by biotechnology in bacteria called Escherichia coli.
Therefore, filgrastim is not indicated for use in these conditions.
The release liner is two overlapped siliconised polyester strips that are peeled off and discarded by the patient prior to applying the patch.
The clear plastic liner covering the adhesive should be removed and discarded with care taken not to touch the gels.
The backing should be peeled off to remove the tablet from the blister.
Firocoxib is metabolised predominantly by dealkylation and glucuronidation in the liver.
The bottle also contains two sealed canisters containing silica gel desiccant.
The vial contains a dry white to slightly yellow powder or cake.
• The Docetaxel Winthrop 80 mg vial contains a solution of docetaxel in polysorbate 80 at a concentration of 40 mg/ ml.
Safely discard the 30 ml mixing vial.
The emulsion vial contains an ‘ adjuvant'(AS03).
The emulsion vial contains an ‘adjuvant'(AS03).
One vial of powder contains 150 IU follitropin alfa and 75 IU lutropin alfa.
One vial of powder contains 150 IU of follitropin alfa and 75 IU of lutropin alfa.
The vial of powder is designed to be reconstituted (mixed) with the solvent.
Prometax oral solution should be used within 1 month of opening the bottle.
The vial should be gently rotated until all of the powder is dissolved.
Shake well before you use.
The vial should be gently swirled until the medicine is dissolved.
The bottle should remain in an upright position when withdrawing the solution.
The vial should be shaken prior to each administration.
The vial is supplied in a lead pot of appropriate thickness.
The vial should not be cooled under running water, as this may impede labelling.
The vial should not be shaken or vigorously agitated.
If particles are observed and/ or the liquid in the vial is not colourless, clear to slightly opalescent, the vial must not be used.
The reconstituted vial should be for single patient use only.
The vial contains a white to off-white cake.
The empty, sterile vial is intended to be used for mixing the concentrate and solvent.
Fluconazole increases the AUC and Cmin of tipranavir by
of water for injections to the glass wall of the vial.
Calcium folinate should only be given by intramuscular or intravenous injection and must not be administered intrathecally.
The exact way bexarotene works in CTCL is not known.
This successful functioning of this network will permit the resolution of complex issues and cover the new summary of product characteristics guidance and legibility testing for patient information.
Fondaparinux should be used with care in these patients.
Neutralisation of Factor Xa interrupts the blood ng coagulation cascade and inhibits both thrombin formation and thrombus development.
Fondaparinux does not inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4) in vitro.
Fondaparinux does not inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, ici
ra Fondaparinux does not inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4) in vitro.
d Fondaparinux also significantly reduced the rate of adjudicated fatal PE [0 patients (0.0%) vs 5
Fondaparinux also significantly reduced the rate of adjudicated fatal PE [0 patients (0.0%) vs 5 patients (1.2%), respectively].
Fondaparinux also provided a significant reduction in the rate of symptomatic VTE (DVT, and / or PE) [1 (0.3%) vs 9 (2.7%) patients, respectively] including two fatal PE reported in the placebo group.
Fondaparinux also provided a significant reduction in the rate of symptomatic VTE (DVT, and / or PE) [1 (0.3%) vs 9 (2.7%) du
Fondaparinux provided a significant reduction in the overall rate of VTE compared with placebo [3 patients (1.4%) vs 77 patients (35%), respectively].
The format and means of dissemination, of this material should be discussed with the appropriate learned societies.
The format and means of dissemination, of this material should be discussed by the MAH with the appropriate learned societies.
The {pharmaceutical form} may be taken without regard to mealtime. >
These tissues were fixed in formalin or Bouin's fixative.
resource implications of any measures proposed by the
Fosaprepitant, a prodrug of aprepitant, when administered intravenously is rapidly converted to aprepitant.
The great success of the trial meant that this was continued as an established part of the procedure from November and at the same time an automatic validation procedure was introduced to cover all type II variations.
Fulvestrant blocks the trophic actions of estrogens without any partial agonist (estrogen-like) activity.
Very low density lipoprotein (VLDL), low 5 density lipoprotein (LDL), and high density lipoprotein (HDL) fractions are the major binding components.
Tenofovir disoproxil fumarate must be taken with food, as food enhances the bioavailability of tenofovir (see section 5.2).
Tenofovir disoproxil fumarate is a water soluble ester prodrug which is rapidly converted in vivo to tenofovir and formaldehyde.
Tenofovir disoproxil fumarate did not show any carcinogenic potential in a long-term oral carcinogenicity study in rats.
Tenofovir disoproxil fumarate has not been clinically evaluated in patients receiving medicinal products which are secreted by the same renal pathway, including the transport proteins human organic anion transporter (hOAT) 1 and 3 or MRP 4 (e. g. cidofovir, a known nephrotoxic medicinal product).
Tenofovir disoproxil fumarate has not been evaluated in patients receiving nephrotoxic medicinal products (e. g. aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2).
Tenofovir disoproxil fumarate should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Gadolinium is used as a ‘ contrast enhancer'to help obtain better images with MRI scans.
The breath from the bags will be introduced into the NDIR spectrometer using a variable gas pump.
G-CSF was used for secondary prophylaxis in 19.3% of patients (10.7% of the cycles).
Human G-CSF is a glycoprotein which regulates the production and release of functional neutrophils from the bone marrow.
Quadrisol oral gel improved the clinical scores for lameness and soft tissue injuries in horses.
Gemfibrozil increases the risk of myopathy when given concomitantly with some HMG-CoA reductase inhibitors.
Gemfibrozil increases the HDL2 and HDL3 subfractions as well as apolipoprotein A-I and A-II.
Gemfibrozil is a non-halogenated phenoxypentanoic acid.
Gemfibrozil potently inhibits CYP2C8, CYP2C9, CYP2C19, CYP1A2, UGTA1 and UGTA3 enzymes (see section 4.5)
The gene coding for the E2 glycoprotein (E2 gene) is a rather conserved region.
The gene coding for the E2 glycoprotein (E2 gene) is a rather conserved uc
The gene carried by the virus in Advexin is the normal (non-defective) p53 gene.
HCV genotype and baseline virus load are prognostic
HCV genotype and baseline virus load are prognostic factors which are known to affect response rates.
Glimepiride acts mainly by stimulating insulin release from pancreatic beta cells.
Glimepiride increases very rapidly the number of active glucose transport molecules in the plasma membranes of muscle and fat cells, resulting in stimulated glucose uptake.
Glimepiride should be used with caution during concomitant administration of CYP2C9 inhibitors (e. g. fluconazole) or inducers (see section 4.5).
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Glimepiride inhibits the glucose production in the liver by increasing the intracellular concentration of fructose-2,6-bisphosphate, which in turn inhibits the gluconeogenesis.
Glimepiride inhibits the hepatic glucose production by increasing the intracellular concentration of fructose-2,6 bisphosphate, which in turn inhibits gluconeogenesis.
The swelling should disappear within three weeks and should have no effect on the horse's appetite, nor cause it any discomfort.
Inflammation of the face, lips and eyes or respiratory difficulty are more severe signs that require urgent medical attention.
The swelling is expected to decrease within two days.
The bitter taste of Norvir solution may be lessened if mixed with chocolate milk.
The large number of designations granted in 2001 will result in a higher than anticipated number of orphan marketing applications in 2002.
Human granulocyte colony stimulating factor (G-CSF) is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow.
Human granulocyte colony stimulating factor (G-CSF) is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow.
The emphasis of the group will be on practical implementation of the procedures for GCP inspection in support of the centralised procedure.
The ad hoc influenza vaccine expert group, chaired by Dr J.
consultation (one of which concerned veterinary medicinal products only).
The ad hoc group on gene therapy, chaired by Dr Lincoln Tsang, held one meeting and focused on dose definition and standardisation of adenoviral vectors
The ad hoc group on pharmacogenetics, chaired by Dr Eric Abadie, held two meetings in 2001 and prepared a position paper on terminology in pharmacogenetics
In addition, the Working Party continued to work closely with members of the Biotechnology Working Party of the CPMP resulting in the revision of the Note for guidance on TSE.
The control group received < Invented Name > vehicle in order to maintain blinding.
The comparator group in all three studies was weekly methotrexate (10-25 mg weekly).
The VMRF interested parties liaison group met regularly during 2002.
The combined 150 mg and 300 mg/ 2 week treatment group was non inferior to the 405 mg/ 4 week treatment group (exacerbation rates 10% for each group) at 24 weeks after randomisation.
A rapporteur was also appointed to consider the annex to the VICH stability guideline for storage conditions for veterinary medicinal products.
In addition to members nominated by the Member States, the European Parliament representatives to the Management Board, the European Commission and observers from the European Pharmacopoeia also participate in the group.
A new e-mail address – mrp@emea.eu.int – was introduced at the EMEA to receive the notifications described in the Notice to
The Working Party continued the evaluation of the answers to the list of questions of old substances having provisional MRLs in Annex III of Council Regulation (EEC) No 2377/90.
The working group considered 19 issues at the request of the CPMP and 39 issues at the request of the Member States.
The Biotechnology Working Party (BWP), chaired by Professor G.
The Joint CPMP/ CVMP Quality Working Party met on three occasions during the year under the Chairmanship of Dr Jean-Louis Robert.
• The Working Party will monitor developments in ICH with a view to making similar recommendations for VICH guidelines
The Efficacy Working Party (EWP) met three times in 1998, chaired by Dr Lisa Kaartinen.
The Working Party was in charge of 13 guidelines of which 8 were new and 12 were published.
Other activities included the drafting of rules of procedure for the new Coordination Group and the monitoring of applications in the CTD format.
The Immunologicals Working Party (IWP) met three times in 1998, with Professor Paul-Pierre Pastoret as chairman.
The Immunologicals Working Party (IWP) met 4 times in 1997 under the chairmanship of Professor Paul-Pierre Pastoret.
The Pharmacovigilance Working Party (PhVWP), chaired by Dr S.
The Pharmacovigilance Working Party (PhVWP) chaired by Dr Susan Wood (†) held seven meetings in 1998.
The Working Party will also work in 1997 to develop guidelines on post marketing surveillance and the Secretariat will draft standard operating procedures for internal administration of pharmacovigilance within the Veterinary Unit.
The Safety of Residues Working Party will continue to process MRLs for old substances as outlined above.
The Safety Working Party provides a continuous support to the safety topics within the ICH process.
The Safety Working Party (SWP), chaired by Dr Per Sjöberg met twice in 1998.
The working party met once with Dr L.
Guidance was also provided to the topic group leader on VICH guidelines.
The Group will be given the possibility of access to additional scientific expertise where necessary to provide better advice in the areas of rare diseases.
The recommended dose group had the fewest number of patients who experienced ADRs and IARs.
Oral topotecan plus BSC group had a statistically significant improvement in overall survival compared with the BSC alone group (Log-rank p=0.0104).
Electromyographic guidance is not necessary.
The treatment guide for physicians should contain the following key elements: • The Summary of Product Characteristics • Need for periodic blood counts and dose adjustment • Need for contraception • Risk to male and female fertility, potential risk to foetus and breast feeding • Growth follow-up of treated children • Handling of broken tablets • Management of adverse drug reactions
the top of your thighs; and the abdomen, except for the area around the navel.
Change the place that you inject each time so you don't become sore in one area.
The hazard ratio of fulvestrant to anastrozole for time to death was 1.01 (95% CI 0.86 to 1.19).
The day I stop smoking will be ______________.
Just carry on with the next dose at the normal time.
Grapefruit juice may interact with Emselex.
Hudson (United Kingdom) as Co-rapporteur.
The development of standard templates will also be continued.
The company responded to these points on 30 November 2006.
Vimpat may have minor to moderate influence on the ability to drive and use machines.
The colostrum is collected and filtered and the lactoserum (the whey, the liquid part of milk) is concentrated to make Locatim.
Mother's milk should be thrown away during the first 24 hours after thrombolytic treatment.
Breast milk should be discarded within the first 24 hours after thrombolytic therapy.
Milk can be taken after zero days for both sheep and cattle.
Lansoprazol and ciclosporin may potentially inhibit CYP3A4-mediated metabolism of tacrolimus and thereby increase tacrolimus whole blood concentrations.
Therefore, laropiprant is not an inducer or inhibitor of CYP3A4.
Bioavailability following intramuscular injection in humans is high and similar to other calcitonins Elcatonin has short absorption and elimination half-lives of approx 4 hours.
Elcatonin is devoid of embryotoxic, teratogenic and mutagenic potential.
• Prevention of acute bone loss due to sudden immobilisation such as in patients with recent osteoporotic fractures
Elcatonin is an analog of eel calcitonin
Elcatonin should be used during pregnancy only if treatment is considered absolutely essential by the physician.
CTCL is a rare type of lymphoma (cancer of the lymph tissue) where some white blood cells (T-cells) grow in the skin.
Leflunomide is rapidly converted to the active metabolite, A771726, by first-pass metabolism (ring opening) in gut wall and liver.
Lenalidomide is produced as a racemic mixture.
Lenalidomide is not an enzyme inducer.
Lenalidomide may have minor or moderate influence on the ability to drive and use machines.
Lenalidomide has an asymmetric carbon atom and can therefore ex ist as the optically active forms S(-) and R(+).
Lenalidomide has an asymmetric carbon atom and can therefore exist as the optically active forms S(-) and R(+).
10 LeukoScan is reconstituted with 0.5 ml isotonic sodium chloride injection.
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl- estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified.
Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified.
53 Levetiracetam is excreted in human breast milk.
Levetiracetam is excreted in human breast milk.
Levetiracetam is rapidly absorbed after oral administration.
Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy.
Levetiracetam and related analogues show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy.
Levetiracetam is not extensively metabolised in humans.
Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion.
The excretion of Botulinum Toxin Type B in milk has not been studied in animals.
The disposition of orlistat appeared to be similar between normal weight and obese volunteers.
Elimination of fondaparinux decreases with weight.
Elimination was absorption rate limited (flip-flop kinetics), which explains the longer t½ after transdermal patch (3.4 h) versus oral or intravenous administrations (1.4 to 1.7 h).
Renal elimination of galsulfase is considered a minor pathway for clearance (see section 4.2).
Renal elimination of varenicline is primarily through glomerular filtration along with active tubular secretion via the organic cationic transporter, OCT2.
Renal elimination of rasburicase is considered to be a minor pathway for rasburicase clearance.
11 Ambrisentan does not undergo significant renal metabolism or renal clearance (excretion).
24 Ambrisentan does not undergo significant renal metabolism or renal clearance (excretion).
The renal clearance occurs through glomerular filtration and active tubular secretion.
Elimination is principally in the excreta (primarily the urine), with some biliary excretion also observed.
The distribution half-life was approximately 1.5 hours; the route of excretion is essentially renal with 41% of the radiolabel excreted in urine over the first 24 hours after administration.
The Liprolog Mix25 in your pre-filled pen is the same as the Liprolog Mix25, which comes in separate Liprolog Mix25 cartridges.
The Liprolog Mix25 in your Pen is the same as the Liprolog Mix25, which comes in separate Liprolog Mix25 cartridges.
The Liprolog Mix50 in your Pen is the same as the Liprolog Mix50, which comes in separate Liprolog Mix50 cartridges.
The Liprolog Mix50 in your pre -filled pen is the same as the Liprolog Mix50, which comes in separate Liprolog Mix50 cartridges.
The liquid in the glass will look cloudy. • Drink everything in the glass.
The resuspended liquid must appear uniformly white and cloudy.
Since lithium promotes the release of neutrophils, lithium is likely to potentiate the effect of filgrastim.
The Boehringer Ingelheim logo is printed on the cap and “ R110 ” on the body of the capsule.
The Boehringer Ingelheim logo is printed on the cap and “ R75 ” on the body of the capsule.
Therefore, losartan should be used with caution in these patient groups.
Therefore, losartan is contraindicated in patients with severe hepatic impairment (see sections 4.3 and 4.4).
Losartan is indicated for the treatment of hypertension.
Losartan is predominantly metabolised by cytochrome P450 (CYP) 2C9 to the active carboxy-acid metabolite.
Both biliary and urinary excretion contribute to the elimination of losartan and its metabolites.
Both losartan and its principal active metabolite have a far greater affinity for the AT1 receptor than for the AT2 receptor.
Therefore, losartan/ hydrochlorothiazide should not be administered to children and adolescents.
Because losartan decreases uric acid, losartan in combination with hydrochlorothiazide attenuates the diuretic- induced hyperuricemia.
Losartan selectively blocks the AT1 receptor.
There is no therapeutic experience with losartan in patients with severe hepatic impairment.
Losartan is also not recommended in children with hepatic impairment (see also section 4.4).
Losartan is also not recommended in children with hepatic impairment (see section 4.2).
Losartan is also not recommended in children with hepatic impairment (see also section 4.4).
Losartan is also not recommended in children with hepatic impairment (see section 4.2).
Losartan has been shown to have a mild and transient uricosuric effect.
Lymphoma is a recognised and listed adverse effect for systemically administered calcineurin inhibitor products.
Compatibility with both external as well as internal software under development might be difficult to maintain.
103 Maintenance of clinical remission was evaluated in CD Study III (CHARM).
A sustained haemoglobin level of greater than 12 g/ dl (7.5 mmol/ l) should be avoided; guidance for appropriate dose adjustment for when haemoglobin values exceeding 12 g/ dl (7.5 mmol/ l) are observed are described below.
A sustained haemoglobin level of greater than 12 g/ dl (7.5 mmol/ l) should be avoided; guidance for appropriate dose adjustment for when haemoglobin values exceeding 12 g/ dl (7.5 mmol/ l) are observed are described below.
A sustained haemoglobin level of greater than 12 g/ dl (7.5 mmol/ l) should be avoided; guidance for appropriate dose adjustments for when haemoglobin values exceeding 12 g/ dl (7.5 mmol/ l) are observed are described below.
Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin target range of 10 g/ dl ng (6.2 mmol/ l) to 12 g/ dl (7.5 mmol/ l).
The white ne edle sleeve will move down over the needle and lock into place over the needle tip.
The white needle sleeve will move down over the needle and lock into place over the needle tip.
The white needle sleeve is there to protect you from touching the needle.
Mangafodipir is a chelate containing the metal manganese - which has paramagnetic properties and is responsible for the contrast enhancement effect in MRI - and the ligand fodipir (dipyridoxyl diphosphate).
Mangafodipir and its metabolites are dialysable whereas manganese is not dialysable because of protein binding (see also section 5.2).
As a result of this interaction, the water molecules give a stronger signal, and this helps to obtain a brighter picture.
Maraviroc is the major circulating component (approximately 42% radioactivity) following a single oral dose of 300 mg.
Maraviroc may be given with ritonavir to increase the maraviroc exposure.
Maraviroc selectively binds to the human chemokine receptor CCR5, preventing CCR5-tropic HIV-1 from entering cells.
Maropitant is effective against vomiting.
Maropitant undergoes cytochrome P450 (CYP) metabolism in the liver.
Maropitant is metabolised in the liver and therefore should be used with caution in dogs with liver disease.
Maropitant is metabolised in the liver and therefore should be used with caution in patients with hepatic disease.
Maropitant is non-sedative and should not be used as a sedative in motion sickness.
Radiolabelling must take place immediately after reconstitution of product.
The capsule shell imprint contains shellac, propylene glycol, ammonium hydroxide, colouring agent (E 132).
The capsule shell imprint contains shellac, titanium dioxide (E171) and indigo carmine
Radiolabelling is a technique where a substance is tagged (labelled) with a radioactive compound.
Masitinib is metabolised predominantly by N-dealkylation.
Masitinib is a protein-tyrosine kinase inhibitor which, in vitro, potently and selectively inhibits the mutated form, in the juxtamembrane (JM) region, of the c-kit receptor.
Contaminated material must be disposed of as radioactive waste via an authorised route.
The Physician Information pack should contain the following key elements: • The Summary of Product Characteristics • Dose calculation, preparation of infusion and infusion rate • Risk of serious infections o The product should not be given to patients with active or suspected infection o The product may lessen signs and symptoms of acute infection delaying the diagnosis • Serious infusion reaction and their management • Serious hypersensitivity reactions and their management • Risk of gastrointestinal perforations especially in patients with history of diverticulitis or intestinal ulcerations • Reporting of serious adverse drug reactions • The Patient Information Packs (to be given to patients by healthcare professionals)
The Physician Information Pack should contain the following key elements: • The Summary of Product Characteristics • Dose calculation, preparation of infusion and infusion rate • Risk of serious infections o The product should not be given to patients with active or suspected infection o The product may lessen signs and symptoms of acute infection delaying the diagnosis • Serious infusion reaction and their management • Serious hypersensitivity reactions and their management • Risk of gastrointestinal perforations especially in patients with history of diverticulitis or intestinal ulcerations • Reporting of serious adverse drug reactions • The Patient Information Packs (to be given to patients by healthcare professionals)
The Patient Information Pack should contain the following key elements: • Patient Information Leaflet • Patient Alert Card
The Patient Information Pack should contain the following key elements: • Patient Information Leaflet • Patient Alert Card
The Nurse Information Pack should contain the following key elements: • Prevention of medical errors and infusion reactions o Preparation of infusion o Infusion rate • Monitoring of the patient for infusion reactions • Reporting of serious adverse drug reactions
Resources for the management of hypersensitivity reactions should be available.
• Appropriate administration materials must be composed of glass, polyolefin, or polyethylene to avoid excessive loss of medicinal product and to decrease the rate of DEHP extraction.
It is extensively distributed throughout the body and almost all the mavacoxib-related residues in plasma comprise parent drug.
5 x 3 ml Liprolog Basal cartridges for a 3 ml pen 2 x (5 x 3 ml) Liprolog Basal cartridges for a 3 ml pen
The inner sterile blister must be opened in a sterile operating room area.
The dose can then be inhaled and the device closed.
The EMEA hosted a meeting of the VICH Steering Committee on 27-28 June 2001 and also a number of VICH expert working groups during the course of the year.
The EMEA has also provided the Secretariat to support the MRFG.
The EMEA, as part of the EU delegation, continued its active participation in the VICH process in 2002 including at the second VICH conference held in Tokyo in October 2002.
The EMEA continued to receive information visits from national authorities of a number of non-EU countries.
The EMEA also provided the Secretariat to support the MRFG.
cause of delays in the transmission of EMEA documents to the Commission during the 30 day post-opinion period.
the EMEA has recommended the maintenance of the Marketing Authorisation for terfenadine 30 mg tablets in accordance with the draft SPC as stated in Annex I.
the EMEA has recommended the maintenance of the Marketing Authorisations for terfenadine 60 mg tablet formulations in accordance with the draft SPC as stated in Annex I.
the EMEA has recommended the maintenance of the Marketing Authorisations for terfenadine 6 mg/ ml oral suspension formulations in accordance with the draft SPC as stated in Annex I.
the EMEA has recommended the withdrawal of the Marketing Authorisations for terfenadine 120 mg tablet formulation.
The EMEA received a number of delegations from national authorities during the year, including from Australia, Canada, China, Hungary, Japan, Korea, New Zealand and Ukraine.
It faces several new challenges.
The EMEA expects to receive between 10 000 and 12 000 pieces of mail a year in 2001 and 2002 and send out about 20 000 pieces of mail.
Based in London, the EMEA is located in Canary Wharf, midway between the City of London and City Airport.
The EMEA continued its contacts with the European Parliament, in particular with the Committee on Environment, consumer protection and public health, and also the Committee on Budgets.
The EMEA participated in a WHO meeting on the quality of starting materials in July 2002.
The EMEA and its partners..................................................................... 15 European Union institutions........................................................................... .15 Cooperation with national competent authorities.......................................... .17
The EMEA will ensure adequate coordination and provision of expertise to the VICH process.
The EMEA issues plasma master file (PMF) and vaccine antigen master file (VAMF) certificates of a medicinal product in conformity with the arrangements laid down by Community legislation.
The EMEA participates in the work of the European Pharmacopoeia Commission as part of the EU delegation.
The EMEA will continue its analysis of the implications of the European Commission proposals for the revision of the European marketing authorisation system and they progress through the legislative process.
The EMEA is deeply committed to being a transparent, open and accessible organisation.
No functional or microscopic changes related to the periocular effects have been observed, and the mechanism of action for the periocular changes is unknown.
The mechanism behind these events is not known (see section 4.4).
The underlying mechanism and the clinical relevance are unknown.
The mechanism of action of glucosamine in humans is unknown.
The mechanism of action by which Botulinum neurotoxin type A exerts its effects on cholinergic nerve terminals can be described by a three-step sequential process which includes the following steps:
The exact way alitretinoin works in Kaposi's sarcoma is unknown.
The exact way halofuginone works is unknown.
The mechanism by which Intron A may alter thyroid status is unknown.
The mechanism by which IntronA may alter thyroid status is unknown.
The mechanism by which Viraferon may alter thyroid status is unknown.
The mechanism of the LDL-lowering effect of< Zocord > may involve both reduction of VLDL-cholesterol (VLDL-C) concentration and induction of the LDL receptor, leading to reduced production and increased catabolism of LDL-C.
The exact way that Extavia works in MS is not yet known but beta-interferon seems to calm down the immune system (the body 's natural defences) and prevents the relapses of MS.
The specific mechanism of action by which anagrelide reduces platelet count is not yet fully understood although it has been confirmed that anagrelide is platelet selective from in vitro and in vivo study information.
The mechanism of these interactions appears to be based on the hepatic enzyme inducing properties of these medicinal products.
The mechanism for this increased risk is not known.
The mechanism of vasculitis in patients receiving Neulasta is unknown.
The mechanism of vasculitis in patients receiving Neupopeg is unknown. od
The mechanism of antihypertensive effect of thiazide diuretics is not fully known.
The mechanism of this effect is unclear.
The mechanism is probably inhibition of disaccharidases in the gastrointestinal tract.
The mechanism and relevance of these findings in the rat carcinogenicity study for humans are not yet clarified.
The mechanism for this is not known, but as imiquimod has low systemic absorption from human skin, and is not mutagenic, any risk to humans from systemic exposure is likely to be low.
The mechanism by which Rebetol in combination with peginterferon alfa-2b or interferon alfa-2b exerts its effects against HCV is unknown.
The mechanism by which ribavirin in combination with peginterferon alfa-2b or interferon alfa-2b exerts its effects against HCV is unknown.
The principle mechanism of resistance is the acquisition of substitutions in the target protein, CYP51.
The mechanism for this effect is unknown.
No functional or microscopic changes related to the periocular effects have been observed, and the mechanism of action for the periocular changes is unknown.
The mechanism underlying the renal tumours in RISPERDAL CONSTA-treated male Wistar (Hannover) rats is unknown.
The underlying mechanism and the clinical relevance are unknown.
The doctor will give Infanrix hexa as an injection into the muscle.
20 The doctor will give Infanrix Penta as an injection into the muscle.
The doctor will give Tritanrix HepB as an injection into the thigh muscle.
The doctor will give Tritanrix HepB as an injection into the thigh muscle.
Your child's doctor has prescribed this medicine to help treat your child's epilepsy.
The physician was able to take into account PEF (peak expiratory flow), day and night time symptoms, rescue medication use, spirometry and exacerbations.
The physician was able to take into account PEF, day and night time symptoms, rescue medication use, spirometry and exacerbations.
Your child's doctor will tell you the new dose of the other antiepileptic medicine(s).
The physician should be particularly alert to symptoms suggestive of PML that the patient may not notice (e. g. cognitive, neurological or psychiatric symptoms).
The physician should be particularly alert to symptoms suggestive of PML that the patient may not notice (e. g. cognitive or psychiatric symptoms).
The physician should be alert to the temperature elevation that may occur following vaccination (see section 4.8).
The doctor should assess the patient's response to Tracleer and review the need for further treatment after eight weeks in patients with PAH who have not improved, and on a regular basis in patients with systemic sclerosis and ongoing digital ulcer 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Treatment initiation forms for male patients should also include:
The doctor or nurse will give Quintanrix as an injection into the muscle.
The doctor may decide to interrupt or stop treatment in patients experiencing certain side effects, especially those affecting the heart, lungs or liver.
The doctor may also advise you to take calcium and vitamin D supplements.
The doctor may interrupt treatment in patients who develop a serious infection.
After proper training in the reconstitution and injection technique, patients may self-inject with Raptiva, if their physician determines that this is appropriate.
The doctor will tell you the amount of liquids your child should drink.
The doctor will treat you, as appropriate, if you have any particular ill effects.
The medicine also produced an improvement in lung function, while the patients on placebo showed a slight worsening.
The product was accepted by the Belgium, Cyprus, Czech Republic, Denmark, Greece, Spain, Finland, France, Hungary, Italy, the Netherlands, Norway, Portugal, Sweden and the United Kingdom.
The medicine was effective in patients with all three types of homocystinuria.
The dose must be taken as soon as the blister has been opened.
It should be used with caution in patients who have severe problems with their liver.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The medicine can only be obtained with a prescription.
It may be taken with or without food.
The medicine can only be obtained with a prescription. t uc
The best place to give yourself an injection is the front of your thighs.
This is best done by rolling the vial at an oblique angle between the palms of the hands.
Mixing Liprolog Basal with insulins other than Liprolog has not been studied.
Mixing Liprolog Mix25 with other insulins has not been studied.
Mixing Liprolog Mix50 with other insulins has not been studied.
Mixing Humalog BASAL with insulins other than Humalog has not been studied.
Mixing Humalog Mix25 with other insulins has not been studied.
Mixing Humalog Mix50 with other insulins has not been studied.
The metabolism in horses has not been investigated.
The metabolism in horses was not investigated.
Metabolism of Glivec is mainly hepatic, and only 13% of excretion is through the kidneys.
Ethanol: the metabolism of abacavir is altered by concomitant ethanol resulting in an increase in AUC of abacavir of about 41%.
The HMG-CoA reductase inhibitors lovastatin and simvastatin are highly dependent on CYP3A4 for metabolism, thus concomitant use of Agenerase with simvastatin or lovastatin is not recommended due to an increased risk of myopathy, including rhabdomyolysis.
Metabolism of 17β-estradiol, occurs mainly in the liver and gut but also in target organs, and involves the formation of less active or inactive metabolites, including estrone, catecholestrogens and several oestrogen sulphates and glucuronides.
Metabolism of nilotinib is mainly hepatic.
The metabolism of arsenic trioxide involves oxidation of arsenious acid (AsIII), the active species of arsenic trioxide, to arsenic acid (AsV), as well as oxidative methylation to monomethylarsonic acid (MMAV) and dimethylarsinic acid (DMAV) by methyltransferases, primarily in the liver.
Metabolism and excretion of dabigatran were studied following a single intravenous dose of radiolabeled dabigatran in healthy male subjects.
Metabolism and excretion of dabigatran were studied following a single intravenous dose of radiolabeled dabigatran in healthy male subjects.
As a result, no pharmacokinetic metabolic drug interaction between stiripentol and levetiracetam is anticipated.
Liver metabolism is a minor route of elimination.
Intracellular metabolism of gemcitabine produces the gemcitabine mono, di and triphosphates (dFdCMP, dFdCDP and dFdCTP) of which dFdCDP and dFdCTP are considered active.
As metabolism is expected to occur by peptide hydrolysis, an impaired liver function is not expected to affect the pharmacokinetics.
A771726, the active metabolite of leflunomide, inhibits the human enzyme dihydroorotate dehydrogenase (DHODH) and exhibits antiproliferative activity.
A771726, the active metabolite of leflunomide, inhibits the human enzyme dihydroorotate dehydrogenase (DHODH) and exhibits antiproliferative activity.
The active metabolite is 10- to 40-times more active than losartan on a weight for weight basis.
The active metabolite is 10- to 40- times more active than Losartan on a weight for weight basis.
The active metabolite is further metabolised to two inactive compounds by S- methylation or conjugation with cysteine.
The active metabolite is eliminated entirely by renal excretion.
The active metabolite is further metabolised in the liver to its carboxy, carboxy-N-desisopropyl, and
The active metabolite, N-desethyloxybutynin, has pharmacological activity on the human detrusor muscle that is similar to that of oxybutynin in vitro studies, but has a greater binding affinity for parotid tissue than oxybutynin.
The most significant circulating metabolite in humans is a secondary amine (approximately 22% radioactivity) formed by N-dealkylation.
The major circulating metabolite is irbesartan glucuronide (approximately 6%).
The most abundant metabolite is a monohydroxylated derivative.
The most abundant metabolite is 8-hydroxy-ibafloxacin, which is also microbiologically active.
The monophosphate metabolite is subsequently converted to the active 5'-triphosphate form, ara-GTP.
The monophosphate metabolite is subsequently converted to the active 5'-triphosphate from, ara-GTP.
The N- desmethyl metabolite is approximately 50% less active than rosuvastatin whereas the lactone form is considered clinically inactive.
The ratios of the main metabolite M1 (des-(Orn8, Gly-NH29)-[Mpa1, D-Tyr(Et)2, Thr4]-oxytocin) to atosiban concentrations 13 in plasma were 1.4 and 2.8 at the second hour and at the end of the infusion respectively.
The ratios of the main metabolite M1 (des-(Orn8, Gly-NH29)-[Mpa1, D-Tyr(Et)2, Thr4]-oxytocin) to atosiban concentrations in plasma were 1.4 and 2.8 at the second hour and at the end of the infusion respectively.
The effect of Enbrel on the human pharmacokinetics of methotrexate has not been investigated.
- metoclopramide, used to treat nausea and vomiting
Miglustat is an inhibitor of glucosylceramide synthase, the enzyme responsible for the first step in the synthesis of most glycolipids.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
How duloxetine works in SUI is not clear but it is thought that, by increasing the levels of 5-hydroxytryptamine and noradrenaline at the level of the nerves that control the muscle of the urethra (the tube that leads from the bladder to outside), duloxetine causes a stronger closure of the urethra during urine storage.
The mode of administration of Livensa makes overdose unlikely.
The mode of administration of Intrinsa makes overdose unlikely.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The clearance model developed showed that body weight, gender, age, and serum creatinine were the main covariates.
Faecal excretion predominates with unchanged emodepside and hydroxylated derivatives as the major excretion products.
It activates the enzyme guanylate cyclase, resulting in an increased level of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum.
Montelukast also decreased "as-needed" β -agonist use and 23 corticosteroid rescue for worsening asthma compared with placebo.
Because montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment.
Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500 mg/ kg/ day (approximately > 200-fold based on systemic exposure).
Montelukast is not recommended as monotherapy in patients with moderate persistent asthma.
Montelukast sodium has been used for the add-on treatment (concomitantly with inhaled steroids) and to prevent exercise-induced bronchoconstriction.
The movement must always be repeated until the liquid appears uniformly white and cloudy • After resuspending, complete all of the following stages of injection without delay.
The concomitant use of Opgenra with a synthetic bone void filler is not recommended (see section 4.5).
The use of Osigraft with a synthetic bone void filler may lead to a risk of increase in local inflammation, infection and occasional migration of the implanted materials and is therefore not recommended.
The use of an anti-emetic may be necessary.
Repeat use of this bone morphogenetic protein (BMP) is not recommended.”
The MRFG met under the chairmanship of Dr David Jefferys of the United Kingdom from January to June 1998 and Dr Christa Wirthumer-Hoche of Austria from July to December 1998.
The MRFG has identified several areas where there is a need for existing CPMP guidelines to be updated or new guidance to be elaborated.
Emtricitabine did not inhibit the enzyme responsible for glucuronidation.
Also, emtricitabine did not inhibit uridine 5'-diphosphoglucuronyl transferase, the enzyme responsible for glucuronidation.
Also, emtricitabine did not inhibit uridine-5'-diphosphoglucuronyl transferase, the enzyme responsible for glucuronidation.
Mycophenolate mofetil is the 2-morpholinoethyl ester of MPA.
Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA).
Multiple myeloma is a cancer of the plasma cells in the bone marrow.
No clastogenic or mutagenic effects of natalizumab were observed in the Ames or human chromosomal aberration assays.
Nateglinide should be taken within 1 to 30 minutes before meals (usually breakfast, lunch and dinner).
Nateglinide is an amino acid (phenylalanine) derivative, which is chemically and pharmacologically distinct from other antidiabetic agents.
Nateglinide is a rapid, short-acting oral insulin secretagogue.
Nateglinide was not teratogenic in rats.
As patients with severe liver disease were not studied, nateglinide is contraindicated in this group.
According to the NCCLS (National Committee on Clinical Laboratory Standards) in 2001 the following breakpoints have been defined for cefuroxime axetil:
Activation of the protective mechanism may cause minimal splatter of fluid that may remain on the needle after injection.
Lendacin 1 g injektio-/ infuusiokuiva- aine, liuosta varten
Endothelin plays a significant role in the pathophysiology of PAH.
The area where the radioactive compound is collected, will light up on the picture and give information on the location of the tumour.
Children taking Combivir should be closely monitored for side effects.
conjunction with the commitment to carry out a post-marketing study as set out in Annex IV and the revision of the Summary of Product Characteristics as set out in Annex III,
Ernst LUSZCZAK Portugal José António ARANDA da SILVA Maria Armanda MIRANDA
Nilotinib is the main circulating component in the serum.
Nilotinib did not have effects on CNS or respiratory functions.
Nimesulide 3% gel / cream contains 3% w/ w nimesulide (1 g of gel / cream contains 30 mg of nimesulide) For excipients, see section 6.1
Nimesulide 3% gel / cream has not been studied in children.
Nimesulide 3% gel / cream should not be applied to skin wounds or open injuries.
Nimesulide should be used with caution in patients with gastrointestinal disorders, including history of peptic ulceration, history of gastrointestinal haemorrhage, ulcerative colitis or Crohn's disease.
Nimesulide is an inhibitor of the prostaglandin synthesis enzyme cyclo-oxygenase.
As nimesulide can interfere with platelet function, it should be used with caution in patients with bleeding diathesis (see also section 4.3).
The level of efficacy attained may vary depending on the degree of antigenic homology between the vaccine strain and circulating field strains.
The level of efficacy attained may vary depending on the degree of antigenic homology between the vaccine strain and circulating field strains.
The level of efficacy attained may vary depending on the degree of antigenic homology between the vaccine strain and circulating field strains.
The level of efficacy attained may vary depending on the degree of antigenic homology between the vaccine strain and circulating field strains.
The level of pharmacovigilance activities will intensify in 2002.
The level of work arising from MRAs is expected to rise by around 20%.
The degree of excretion of gadoversetamide in breast milk has not been studied in humans.
The degree of excretion of gadoversetamide in breast milk has not been studied in humans.
Mean levels of liver enzymes decreased with treatment with pioglitazone.
Mean levels of liver enzymes decreased with treatment with pioglitazone.
The very low level of arbitrations is another encouraging feature.
The appropriate number of vials should be opened under the water.
The appropriate number of vials should be opened under water.
The correct number of tablets or half tablets to use is calculated based on the dog's weight.
The number of non-EU ADRs has risen sharply in recent years and this is expected to continue in 2002.
The number of these reactions decreased the longer that patients were on Aldurazyme.
The number of horses with an adequate infection pretreatment is impossible to determine as no negative control group was included.
The prescribed number of tablets should be placed in a glass or cup of water and stirred until dissolved.
The number of repeat cycles used is at the discretion of the clinician.]
The number of applications for initial evaluation is expected to increase in 2001 and 2002.
Because the number of patients with primary IGF-1 deficiency is low, the disease is considered ‘ rare’, and INCRELEX was designated an ‘ orphan medicine '(a medicine used in rare diseases) on 22 May 2006.
There were too few women with a pregnancy at less than 28 weeks for the effectiveness of Tractocile in comparison to beta-agonists to be established in this group.
The number of InductOs kits to use and the volume of InductOs to be implanted are determined by the fracture anatomy and the ability to close the wound without overly packing or compressing the product.
The number of EMEA staff members grew from 208 to 248 at the end of 2002, an increase of 19%.
This is due to difficulties experienced by distributors gaining access to the most updated medicinal product labelling, requiring multiple exchanges of letters with EMEA to supply the correct mock-ups and specimens.
Several risk factors have been recognised which appear to predispose to cardiotoxicity with terfenadine.
The increase in some MS, since 1992, of spontaneous ADR- reports related to terfenadine (absolute and relative to sales figures) has not been seen with other NSAHs and is likely to indicate a reporting bias.
The number of elderly patients in whom the pharmacokinetics were determined was limited (over 65 years, N=3).
Because the number of patients with these diseases is low, the diseases are considered ‘ rare’, and Atriance was designated an ‘ orphan medicine '(a medicine used in rare diseases) on 16 June 2005.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2006 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Because the number of patients with these diseases is low, they are rare, and Glivec was designated an ‘ orphan medicine'(a medicine used in rare diseases) on various dates (see below).
Because the number of patients with these diseases is low, they are considered ‘ rare’, and mecasermin rinfabate was designated an ‘ orphan medicine'(a medicine used in rare diseases) on 20 June 2006.
Because the number of patients with malignant glioma is low, the disease is considered ‘ rare’, and Gliolan was designated an ‘ orphan medicine '(a medicine used in rare diseases) on 13 November 2002.
Caution should be exercised when ziconotide is administered to patients who are receiving systemic chemotherapy (see section 4.4).
Caution should be exercised when ziconotide is administered to patients who are receiving systemic chemotherapy (see section 4.5).
There were too few patients also receiving interferon-gamma to determine whether this improved the patients 'outcome further.
Cataplexy can sometimes cause a patient to collapse.
Because the number of patients with lupus nephritis is low, the disease is rare, and Riquent was designated an orphan medicine (a medicine used in rare diseases) on 20 November 2001.
The number of platelets can rise slightly to moderately during epoetin treatment, and this can cause changes in blood clotting.
The number of posts requested by the Agency is 220 in 2001 and 251 for 2002.
The number of case reports received or forecast by the EMEA is given below:
The number of severe adverse events, as well as the number of reported metabolism-related adverse events such as hypokalaemia, hyponatraemia and hyperuremia, was lower in the group treated with nifedipine.
The number of discontinuations due to hypertension-related events was also not significantly different between lumiracoxib (37) and NSAIDs (52).
The number of discontinuations in TARGET due to oedema was not significantly different between lumiracoxib (43) and NSAIDs (55).
The number of observed malignancies was consistent with that expected in an age- and gender-matched rheumatoid arthritis population (see section 4.4).
Extensions/modifications are expected to number 20.
The number of UC-related hospitalisations was significantly lower in the 5 and 10 mg/ kg infliximab treatment groups than in the placebo group (mean number of hospitalisations per 100 subject-years:
Three GMP workshops were held as part of the PERF II programme, as well as joint inspections in the accession candidate countries.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The median number of exposure days up to inhibitor development in these patients was 12 (range 3-49).
The total number of loratadine-exposed pregnancies worldwide is unknown, but is probably large.
The name of your medicine is EVRA transdermal patch.
Your concentrate for solution for infusion is called Paxene.
The name of the medicine was also changed from ReFacto to ReFacto AF.
The name of the medicine was changed to Thalidomide Celgene on 22 October 2008.
The enormous volume of “ acquis communautaire ” built up over the past twenty years now finds itself reinforced and clarified; by the same token, international harmonisation (ICH) has also benefited from this same dynamic action
Annex 4 Profiles of EMEA personalities
The new European system is based on co-operation between the national competent authorities of the Member States and the EMEA.
The new European system is based on cooperation between the national competent authorities of the Member States and the EMEA.
The new European system offers two routes for authorisation of medicinal products:
The costing exercise revealed the considerable resource contributions made by national authorities to the functioning of the EMEA.
With one hand grasp the product-side of the Mix2Vial set and with the other hand grasp the diluent-side of the Mix2Vial set and unscrew the set into two pieces.
The vial connector/vial/vial cup combination disconnects automatically.
Together, these actions are expected to prevent abnormal electrical activity in nerve cells, reducing pain due to nerve damage.
All 83 marketing authorisations for terfenadine 120 mg tablet formulations and terfenadine 60 mg + pseudoephedrine HCl 120 mg tablet formulations were withdrawn.
The patient information pack should be provided in both a form of patient information booklet and audio-CD that contain following key elements: • Patient information leaflet • How to prepare for Lucentis treatment • Which are the steps following treatment with Lucentis • Key signs and symptoms of serious adverse events • When to seek urgent attention from the health care provider
The corresponding suite for veterinary medicines will be rolled out in September 2006.
6 Entacapone belongs to a new therapeutic class, catechol-O-methyl transferase (COMT) inhibitors.
Entacapone belongs to a new therapeutic class, catechol-O-methyl transferase (COMT) inhibitors.
Entacapone blocks an enzyme that is involved in the break down of levodopa in the body called 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Entacapone blocks an enzyme that is involved in the breakdown of levodopa in the body called 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Entacapone inhibits the COMT enzyme mainly in peripheral tissues.
Entacapone may form chelates with iron in the gastrointestinal tract.
As entecavir is a nucleoside analogue, this risk cannot be excluded.
Entecavir is not a substrate, an inducer or an inhibitor of cytochrome P450 (CYP450) enzymes (see section 5.2).
Necrotising enteritis is a disease that causes damage to the gut.
The capsule shell contains gelatin, red iron oxide, propylene glycol, purified water, ‘ sorbitol special- glycerin blend'(d-sorbitol, 1,4 sorbitan, mannitol and glycerin) and titanium dioxide.
The capsule shell contains: gelatine, sodium laurilsulfate, titanium dioxide (E171) and silicon dioxide.
The capsule shell contains: gelatine, sodium laurilsulfate, yellow iron oxide (E172), titanium dioxide (E171) and silicon dioxide.
149 iron oxide, black iron oxide, yellow iron oxide, propylene glycol, indigocarmin (E132) and titanium dioxide (E171).
The capsule shell may also contain sodium laurilsulfate and silica colloidal anhydrous.
The capsule shell may also contain sodium laurilsulfate and silica colloidal anhydrous.
The capsule shell consists of gelatine, iron oxide black, red and yellow (E172), indigocarmine (E132), titanium dioxide (E171), and the printing ink contains titanium dioxide (E 171), shellac, soya lecithin, polydimethylsiloxane.
The capsule shell contains gelatin and titanium dioxide (E171).
The tablet shell, along with insoluble core components, is eliminated from the body; patients should not be concerned if they occasionally notice in their stool something that looks like a tablet.
The shell does not break down but passes through your body.
The environment has changed greatly since that time, with new workload demands made on the EMEA.
The enzyme CYP3A4 also contributes to the metabolism.
The enzyme CYUP3A4 also contributes to the metabolism.
ACE is identical to kininase II, an enzyme that degrades bradykinin.
The replacement enzyme helps to break down the Gb3 and stops it building up (accumulating) in the cells.
The treatment initiation pack contains 56 film-coated tablets in 4 packages: • the package marked ‘Week 1’contains 14 tablets of 50 mg, • the package marked ‘Week 2'contains 14 tablets of 100 mg, • the package marked ‘Week 3'contains 14 tablets of 150 mg, • the package marked ‘Week 4'contains 14 tablets of 200 mg.
The patient information pack should contain the following key elements: • Package leaflet • Handling of broken tablets • Need for periodic blood counts • Information on crisis or infections • Need for contraception • Risk to male and female fertility, potential risk to foetus and breast feeding • Key signs and symptoms of serious adverse reactions • When to seek urgent attention from the health care provider • Information on growth follow-up of treated children for their parents
The educational pack should contain the following • Summary of Product Characteristics and Patient Information Leaflet for ReFacto AF • The educational materials.
The educational materials for Healthcare professionals, patients and haemophiliac patients associations should include the following key elements:
Paclitaxel blocks the ability of cancer cells to break down their internal ‘ skeleton 'that allows them to divide and multiply.
Paclitaxel causes bone marrow suppression (particularly neutropenia).
Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation.
Therefore, paclitaxel is not recommended for paediatric use.
Paclitaxel has been shown to be clastogenic in vitro (chromosome aberrations in human lymphocytes) and in vivo (micronucleus test in mice).
10 in the Ames test or the Chinese hamster ovary/ hypoxanthine-guanine phosphoribosyl transferase (CHO/ HGPRT) gene mutation assay.
- paclitaxel (used in cancer treatment).
improve the service to delegates, new procedures were introduced in order to complete payments related to any meeting within 4 weeks after the meeting.
Palifermin is a 140 amino acid protein with a molecular weight of 16.3 kilodaltons.
Palifermin is a human keratinocyte growth factor (KGF), produced by recombinant DNA technology in Escherichia coli.
Palivizumab has been designed to bind to a protein called ‘ fusion protein A 'on the surface of RSV.
Panitumumab recognises and binds specifically to a protein known as epidermal growth factor receptor (EGFR), which is found on the surface of some cancer cells.
Pantoprazole and other proton- pump inhibitors were co-administered with Pradaxa in clinical trials and no effects on bleeding or efficacy were observed.
Section 4.5 of the draft Summary of Product Characteristics for terfenadine containing medicinal products should be amended as set out in Annex I.
The corresponding section of the PL was revised accordingly.
The path length of beta emission (χ 90) by yttrium-90 in tissue is 5 mm.
The European Parliament and Council of the European Union adopted codified Community rules on medicinal products for human and for veterinary use on 6 November 2001:
The partnership between the EMEA and national competent authorities is a vital part of the functioning of the centralised procedure.
The partnership between the EMEA, national authorities and the European Union institutions is central to the successful functioning of the European authorisation procedure.
Patients should be converted to oral therapy as soon as clinically practicable.
You are advised to stop breast-feeding if Tracleer is prescribed for you because it is not known if this medicine passes into the milk of women who are taking Tracleer.
It is not known whether Atriance is passed on through breast milk.
It is not known if BYETTA passes into your milk.
It is not known if SINGULAIR appears in breast milk.
It is not known whether becaplermin is excreted in human milk.
It is not known whether salmon calcitonin is excreted into human breast milk.
It is not known if InductOs passes into breast milk.
It is not known whether agomelatine is excreted into human milk.
The excretion of nelarabine in milk has not been studied in animals.
It is not known if the substance is excreted in human milk.
It is unknown whether varenicline is excreted in human breast milk.
Conversion to or from oral to intravenous administration can be done directly without titration.
It is not known whether elcatonin is excreted into human breast milk.
It is not known whether entecavir, the active ingredient in Baraclude, is excreted in human breast milk.
It is not known if< Etoricoxib > is excreted in human milk.
It is not known whether interferon beta-1b is excreted in human milk.
It is not known whether interferon beta-1b is excreted in human milk.
The excretion of MIRAPEXIN into breast milk has not been studied in women.
The excretion of SIFROL into breast milk has not been studied in women.
It is not known if Twinrix Adult passes into breast milk, however the vaccine is not expected to cause problems in breast-fed babies.
It is not known if Twinrix Adult passes into breast milk, however the vaccine is not expected to cause problems in breast-fed babies.
It is not known if Twinrix Paediatric passes into breast milk, however the vaccine is not expected to cause problems in breast-fed babies.
It is not known if Twinrix Paediatric passes into breast milk, however the vaccine is not expected to cause problems in breast-fed babies.
It is not known whether Tyverb passes into breast-milk.
When clinically appropriate, direct change from monotherapy to the fixed-dose combination may be considered.
When clinically appropriate, direct change from monotherapy to the fixed combination may be considered.
It is not known if bimatoprost is excreted in human breast milk but it is excreted in the milk of the lactating rat.
It is not known whether this product is present in human milk.
It is not known if paclitaxel passes into breast milk.
It is unknown whether panitumumab is excreted in human breast milk.
It is not known whether riluzole is excreted in human milk.
It is not known whether teriparatide is excreted in human milk.
It is not known whether this medicinal product is excreted in human milk.
It is not known whether this medicine is excreted in human milk.
It is not known whether atazanavir is excreted in human milk.
It is not known whether atazanavir is excreted in human milk.
Retrograde transsynaptic passage of active Botulinum neurotoxin type A into the central nervous system however has not been found.
The patch is applied to dry, clean skin on the lower abdomen (the tummy, below the waist).
The next EVRA patch should be applied on the usual “ Change Day”.
The patient received 12 Advexin injections into some of the tumours over a five-month period.
The patient developed diarrhoea, irritability and metabolic acidosis with hypokalaemia.
If fasting is a problem, for example for diabetic patients, please tell your doctor.
The test should be carried out after having fasted 6 hours before application, preferably overnight.
Patients should be instructed to seek medical attention if signs or symptoms of neurotoxicity develop, or if oral dexamethasone is not well tolerated.
Intravascular administration of contrast media should, if possible, be done with the patient lying down.
The patient must expire as the straw is slowly and completely withdrawn from the tube, which is then immediately capped.
Patients should remove the mouthpiece cover by gently squeezing the sides of the cover and check the mouthpiece inside and outside to see that it is clean.
Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites.
The patient or caregiver should stop using < Invented Name > when signs and symptoms resolve.
The patient usually remains conscious and breathing is not depressed.
Patients should continue holding their breath for as long as is comfortable.
This puts the patient at risk of developing blood clots or bleeding problems.
Pegaptanib 0.3mg showed treatment benefit regardless of baseline lesion subtype, lesion size and visual acuity as well as age, gender, iris pigmentation and prior and/ or baseline PDT usage.
Pegaptanib was studied in two controlled, double-masked, and identically designed randomised studies (EOP1003; EOP1004) in patients with neovascular AMD.
Pegaptanib is metabolised by nucleases and therefore cytochrome P450 mediated drug interactions are unlikely.
Pegaptanib has not been studied in pregnant women.
Pegaptanib does not accumulate in the plasma when administered intravitreally every 6 weeks.
Peginterferon alfa-2b and interferon alfa-2b are injected subcutaneously (under the skin).
The film-coating of each 7.5 mg tablet contains 0.18 mg soya lecithin
- The tablet coating contains hypromellose; titanium dioxide (E171); talc; macrogol and red (60
- The coating is composed of red iron oxide (E172), yellow iron oxide (E172), macrogol, talc and
16 Pemetrexed was not mutagenic in either the in vitro chromosome aberration test in Chinese hamster ovary cells, or the Ames test.
33 Pemetrexed was not mutagenic in either the in vitro chromosome aberration test in Chinese hamster ovary cells, or the Ames test.
Perindopril acts through its active metabolite, perindoprilat.
Perindopril acts through its active metabolite, perindoprilat.
Perindopril is active in all grades of hypertension: mild, moderate, severe; a reduction in systolic and diastolic blood pressures in both supine and standing positions is observed.
In addition there are 6 lawyers, 4 management or finance graduates and 6 staff members with other University degrees (IT, documentation, linguistics).
Since staff at the EMEA come from a wide range of backgrounds this training will contribute to the development of a common management approach.
The scientific and technical complement of staff has also been reinforced during the year.
Operational technical staff would be recruited thereafter.
The small bottle contains the active substance and the large bottle contains the solvent.
The very low level of arbitrations is another encouraging feature.
The updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR) or at the request of EMEA.
Also, urine pH may be elevated by states of renal tubulary acidosis (RTA) or severe infections of the urinary tract with Proteus bacteria.
Phenylacetate is a metabolically active compound that conjugates with glutamine via acetylation to form phenylacetylglutamine which is then excreted by the kidneys.
Sodium phenylbutyrate is a pro-drug and is rapidly metabolised to phenylacetate.
Carcinogenicity and fertility studies have not been conducted with sodium phenylbutyrate.
Gastric pH has been shown to be only a minor component in the large increase in bioavailability seen when given with food.
Serum phosphate should be tested every two to three weeks until a stable serum phosphate level is reached and on a regular basis thereafter.
Peak insulin concentration is reached generally by 45 minutes for inhaled ic
The peak is always well below the peak achieved using the intravenous route (approximately 1/ 20th of the value).
The peak is always well below the peak achieved using the intravenous route (approximately 1/20th of the value).
Rosiglitazone plasma concentrations peak at around 1 h after dosing.
Rosiglitazone plasma concentrations peak at around 1 h after dosing.
Rosiglitazone plasma concentrations peak at around 1 hour after dosing.
Epilepsy is caused by excessive electrical activity in the brain.
Epilepsy is caused by excessive electrical activity in the brain.
Epilepsy is a condition where the patients have repeated fits (seizures).
Pimecrolimus had no genotoxic, antigenic, phototoxic, photoallergenic or photocarcinogenic potential.
Epistaxis was generally mild to moderate in intensity.
Dimeticone or silicone emulsion may have been used to treat the cartridge plunger, and/ or the glass cartridge.
Dimeticone or silicone emulsion may be used to treat the cartridge plunger, and/ or the glass cartridge.
Dimeticone or silicone emulsion may be used to treat the cartridge plungers, and/ or the glass cartridges.
The yellow shaft is still showing after I push in the black injection button.
reached • At the request of the EMEA. ed M
Tend at steady state is 25 days (range 13-35 days).
The youngest horse included in the field trial was 16 months old.
Frequently, these will cease or decrease in intensity with continued use of the medicinal product, as the patient is titrated to the most appropriate dose.
Side effects will gradually disappear most probably as your body becomes used to the medicine.
In most cases side effects will gradually disappear as your body gets used to the medicine.
The weight of the offspring in the treated group was noted to be less than that of the control group during the observation period.
Epoetin delta is a hormone which stimulates the production of red blood cells in the bone marrow.
Epoetin delta, the active ingredient of Dynepo, is a copy of the human hormone, produced by a ic
The soaked sponge may then be placed where bone growth is desired.
Posaconazole increased the Cmax and AUC of rifabutin by 31% and 72%, respectively.
Posaconazole should be administered with food or a nutritional supplement (see section 4.2).
Posaconazole should be used with caution in patients with severe hepatic impairment.
Posaconazole is an inhibitor of CYP3A4 and should only be used under specific circumstances during treatment with other medicinal products that are metabolised by CYP3A4 (see section 4.5).
Posaconazole is a potent inhibitor of CYP3A4.
Posaconazole is not removed by haemodialysis.
Posaconazole may increase the plasma concentration of vinca alkaloids (e. g. vincristine and vinblastine), which may lead to neurotoxicity.
Posaconazole can increase the blood levels of
Treatment with these HMG-CoA reductase inhibitors
The carcinogenic potential of paclitaxel has not been studied.
Hydroxocobalamin has not been evaluated for carcinogenic potential.
The carcinogenic potential of docetaxel has not been studied.
The carcinogenic potential of methoxy polyethylene glycol-epetin beta has not been evaluated in long- term animal studies.
The carcinogenic potential of methoxy polyethylene glycol-epoetin beta has not been evaluated in long-term animal studies.
The carcinogenic potential of paclitaxel has not been studied.
The carcinogenic potential of parecoxib sodium has not been evaluated.
The carcinogenic potential of topotecan has not been studied.
4 The potential for inhibition of CYP2B6 has not been evaluated.
The potential for inhibition of CYP2B6 has not been evaluated.
The potential for pharmacokinetic or pharmacodynamic interactions is unknown.
The teratogenic potential of bortezomib has not been fully investigated.
The percent reduction at 12 weeks for sildenafil 20 mg in PVR (11.2%) was proportionally greater than the reduction in systemic vascular resistance (SVR) (7.2%).
The percentage of days with β -agonist use decreased from 38.0 to 15.4 in the montelukast group, and from 38.5 to 12.8 in the fluticasone group.
The percentage of days with β -agonist use decreased from 38.0 to 15.4 in the montelukast group, and from 38.5 to 12.8 in the fluticasone group.
The percentage of patients aged 65 or over was not significantly different between the lenalidomide/dexamethasone and placebo/dexamethasone groups.
The percent of patients alive at 12 months was 31.2% and 21.5%, for the Tarceva and placebo groups, respectively.
The percentage of patients who lost less than 1.5 lines was 72% for Visudyne and 44% for placebo (p=0.003).
The proportion of patients with CMV viraemia/ syndrome was 13.5%.
A higher proportion of patients receiving the original rituximab/ MTX treatment also had no erosive progression over 56 weeks (Table 8).
A higher proportion of patients receiving the original rituximab/ MTX treatment also had no erosive progression over 56 weeks (Table 8).
The percent of Humira-treated patients achieving ACR 20, 50 and 70 responses was consistent across RA studies I, II and III.
The percent of Trudexa-treated patients achieving ACR 20, 50 and 70 responses was consistent across
The percent of Trudexa-treated patients achieving ACR 20, 50 and 70 responses was consistent across
The percentage of IgG subclasses is approximately 66.6% IgG1, 28.5% IgG2, 2.7% IgG3 and 2.2% IgG4.
PPE is characterised by painful, macular reddening skin eruptions.
Renal excretion of unchanged pramipexole is the major route of elimination.
Prasugrel was associated with a 50% reduction in stent thrombosis through the 15 month follow-up period.
Prasugrel stops the platelets aggregating by blocking a substance called ADP from binding to a receptor on their surface.
Prasugrel must not be used in patients with severe hepatic impairment (see section 4.
Praziquantel is a pyrazinoisoquinoline derivative effective against tapeworms such as Dipylidium caninum, Echinococcus multilocularis, and Taenia taeniaeformis.
Praziquantel is a pyrazinoisoquinoline derivative effective against tapeworms such as Dipylidium caninum, Taenia spp., Echinococcus multilocularis and Echinococcus granulosus.
The first EMEA workshop on gene therapy was held on 23 April 1998.
The EMEA Financial Controller, Birgit Snoeren, left the Agency midway through 1997.
The first was the forthcoming review of the system by the European Commission, as is required by Regulation (EEC) No 2309/ 93.
The day the first patch is applied (Day 1/ Start Day) determines the subsequent Change Days.
On the first day of treatment, start with Neupro 2 mg (package marked “Week 1)“, and use one Neupro 2 mg transdermal patch daily.
On the first day of treatment take 200 mg (one 5 ml spoonful) once.
The primary objective was to evaluate the triglycerides lowering response across placebo, 20, 40, and 80 mg doses of simvastatin after a 6-week treatment period in patients with hypertriglyceridemia.
Already in 1975 the first scientific body was created, the ‘ old CPMP’.
The first patient will be enrolled by April 2005 the latest.
The first EMEA Internet web site was launched in September 1995.
The prescriber should advise the patient to scoop an overfilled spoon of loose powder from the bottle using the measuring spoon provided.
ed This document is a summary of the European Public Assessment Report (EPAR).
EPAR summary for the public This document is a summary of the European Public Assessment Report (EPAR).
This document is a summary of the European Public Assessment Report.
This document is a summary of the European Public Assessment Report (EPAR).
This document is a summary of the European Public Assessment Report (EPAR).
This document is a summary of the European Public Assessment Report (EPAR).
This document is a summary of the European Public Assessment Report.
The main measure of the immune response was the level of antibodies against PCV2 in the piglets'blood.
The main measure of effectiveness was the change in each of the nine different behaviours recognised as characteristic indicators of separation anxiety in dogs.
The main measure of effectiveness was the proportion of patients who were cured at the end of treatment as determined by a reduction in symptoms, or who had ‘ satisfactory'reductions in the amount of bacteria detected in samples.
The main measure of effectiveness was based on the number of new bone complications.
The main measure of effectiveness was the number of patients whose symptoms returned during 24 to 26 weeks of treatment.
The main measure of effectiveness was the number of patients whose final three blood uric acid levels were below 6 mg/ dl.
The main measure of effectiveness was the number of patients whose treatment was successful after two years.
The main measure of effectiveness was the level of antibodies in the blood against the viruses in the vaccine.
The main measure of effectiveness was the level of antibodies in the blood against the viruses and bacteria in the vaccine.
The main measure of effectiveness was the level of antibodies in the blood against the viruses and bacteria in the vaccine.
The main measure of effectiveness in these five studies was the change in symptoms after six weeks, as measured on a standard scale for depression called the Hamilton Depression Rating Scale (HAM-D).
The main measure of effectiveness was whether the treatment had worked after a week.
The main measure of effectiveness was the reduction in blood levels of methotrexate.
The main measure of effectiveness was how long the patients survived.
The main measure of effectiveness was the time taken before the disease started to get worse or the patient died.
The main measure of effectiveness was the change in symptoms after three to four months.
The main measure of effectiveness was the change in the levels of haemoglobin between the start of the study and the evaluation period, between weeks 25 and 29.
The main measure of effectiveness was the change in the levels of haemoglobin between the start of the study and the evaluation period, between weeks 25 and 29.
The main measure of effectiveness 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The main measure of effectiveness was the proportion of patients who responded to treatment, defined as no evidence of disease and recovery of blood cell counts, within a month of starting Atriance treatment.
The main measure of effectiveness was the reduction in intraocular eye pressure (IOP).
The main measure of effectiveness was whether patients had adequate control of copper levels.
The main measure of effectiveness was the number of women who had a new fracture in the spine as seen on X-rays.
The main measures of effectiveness were the number of patients who survived and the number who did not need a ventilator.
The main measure of effectiveness was the number of patients whose bleeding had stopped after three minutes.
The main measure of effectiveness was the number of patients whose tumours responded to treatment.
The main measure of effectiveness was the number of relapses that the patients had.
The main measure of effectiveness was the percentage of patients with low vitamin D levels after 15 weeks.
The main measure of effectiveness was the percentage of patients with low vitamin D levels.
This was measured using various means, such as visual or descriptive scales, analgesic (painkiller) use, and assessment by the doctor.
The main measure of effectiveness was response rates.
The main measure of effectiveness was the level of hepatitis C virus RNA circulating in the blood before and during treatment, and at ‘ follow-up’, 24 weeks later.
The main measure of effectiveness was the level of hepatitis C virus RNA circulating in the blood before and during treatment, and at ‘ follow-up’, 24 weeks later.
The main measure of effectiveness was the time taken to fall asleep.
The main measure of effectiveness was the change in the levels of HIV in the patients'blood (viral load).
The primary endpoint was the proportion of patients who experienced a clinical response, defined as a decrease in CDAI by ≥ 70 points from baseline at the 4-week evaluation and without an increase in the use of medicinal products or surgery for Crohn's disease.
The primary endpoint was the proportion of patients who experienced a clinical response, defined as ≥ 50% reduction from baseline in the number of fistulae draining upon gentle compression on at least two consecutive visits (4 weeks apart), without an increase in the use of medicinal products or surgery for Crohn's disease.
A key secondary endpoint was the continuous abstinence (CA) rate for week 13 through week 52.
The main secondary endpoint was MCyR by total daily dose level in the imatinib-resistant patients.
The main benefit is that Orfadin has been shown to greatly extend life.
The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism.
The major circulating metabolite is the methylcatechol glucuronide.
The major circulating metabolite results from N-demethylation of sildenafil.
The principle metabolites are hexafluoroisopropanol (HFIP) with release of inorganic fluoride and CO2.
The primary metabolite resulting from the cleavage of Arg3-Pro4 bond of the N-terminal sequence by thrombin is not active because of the loss of affinity to the catalytic active site of thrombin.
The main safety concern discussed was visual field defects (VFD).
The major degradation product of pravastatin is the 3-α- hydroxy isomeric metabolite.
Clinical signs of Cryptosporidium parvum infection are seen mainly as diarrhoea.
The active substance in DaTSCAN, ioflupane (123I), is a radiopharmaceutical.
Actraphane contains the active ingredient insulin human (rDNA).
Actrapid contains the active substance insulin human (rDNA).
The active substance in Adenuric, feboxustat, reduces the formation of uric acid.
The active substance in Advexin, contusugene ladenovec, is a ‘ viral vector’.
The active ingredient in Aldurazyme, laronidase, is a copy of the human enzyme α -L-iduronidase.
Ammonaps contains the active substance sodium phenylbutyrate.
The active ingredient in Arixtra, fondaparinux sodium, stops one of the substances (factors) that are involved in the clotting of blood, Factor Xa.
The active substance in Byetta, exenatide, is an ‘ incretin mimetic’.
It contains the active substance human protein C.
Cetrotide contains the active substance cetrorelix, either 0.25 mg or 3 mg per vial.
The active substance in Cetrotide, cetrorelix, blocks the effects of a natural hormone, called luteinising hormone releasing hormone (LHRH).
The active substance in CHAMPIX, varenicline, can bind to some of these receptors, the α 4β 2 nicotinic acetylcholine receptors.
The active substance in Cholestagel, colesevelam, is not absorbed by the body, but stays in the gut, where it attaches to substances called bile acids and carries them out of the body in the faeces.
The active substance in CIMZIA, certolizumab pegol, is an immunosuppressant medicine.
The active substance in Convenia is cefovecin which belongs to a class of antibiotics called third generation cephalosporins.
The active substance in Cyanokit, hydroxocobalamin, reacts with cyanide in the body.
The active ingredient of DepoCyte, cytarabine, was mutagenic in in vitro tests and was clastogenic in vitro (chromosome aberrations and sister chromatid exchange in human leukocytes) and in vivo (chromosome aberrations and sister chromatid exchange assay in rodent bone marrow, mouse micronucleus assay).
The active substance in Dicural, difloxacin, belongs to a group of antibiotics called ‘ fluoroquinolones’.
The active substance in Dynastat, parecoxib, is a ‘ prodrug 'of valdecoxib.
The active substance in Fareston, toremifene, is an anti-oestrogen.
The active substance in Faslodex, fulvestrant, is an anti-oestrogen.
The active substance in Fasturtec, rasburicase, is an enzyme called urate oxidase, which is able to transform uric acid into another chemical called allantoin.
The active substance in Ferriprox, deferiprone, is an ‘ iron chelator’.
Halocur contains the active substance halofuginone lactate, which is used against parasitic diseases caused by protozoa.
The active substance in INCRELEX, mecasermin, is a copy of the human hormone IGF-1.
Vildagliptin does 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The active substance in Keppra, levetiracetam, is an anti-epileptic medicine.
The active substance in Kineret, anakinra, is a copy of a natural human protein called ‘ human interleukin-1 receptor antagonist’.
The active substance in Kuvan, sapropterin dihydrochloride, is a synthetic copy of BH4.
The active ingredient in Elaprase, idursulfase, is a copy of the human enzyme iduronate-2-sulfatase.
The active substance in LeukoScan, sulesomab, is a monoclonal antibody.
Luveris contains the active substance lutropin alfa.
The active substance in Luveris, lutropin alfa, is a copy of the natural luteinising hormone (LH).
The active substance in MabCampath, alemtuzumab, is a monoclonal antibody.
The active substance in MabThera, rituximab, is a monoclonal antibody.
The active substance of Masivet can cause skin sensitisation. • Avoid skin contact with faeces, urine, and vomit of treated dogs. • Wear protective gloves while disposing of vomit, urine or faeces of treated dogs. • If broken tablets, vomit, urine or faeces of treated dogs come into contact with the skin, rinse immediately with plenty of water.
Metalyse contains the active substance tenecteplase.
Mixtard contains the active substance insulin human (rDNA).
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The active substance in Naglazyme, galsulfase, is a copy of the human enzyme arylsulfatase B.
The active substance in Enbrel, etanercept, is a protein that has been designed to block the activity of a chemical messenger in the body called tumour necrosis factor (TNF).
The active substance in NEVANAC, nepafenac, is a ‘ prodrug 'of amfenac.
NovoRapid contains the active ingredient insulin aspart.
The active substance in Paxene, paclitaxel, belongs to the group of anticancer medicines known as the taxanes.
The active substance in Posaconazole SP, posaconazole, is an antifungal medicine that belongs to the triazoles group.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Previcox contains the active substance firocoxib, which belongs to a class of medicines having anti- inflammatory action.
Protaphane contains the active substance insulin human (rDNA).
The active substance in Erbitux, cetuximab, is a monoclonal antibody.
The active substance in RoActemra, tocilizumab, is a monoclonal antibody.
SCINTIMUN contains the active substance besilesomab.
The active substance of Siklos passes into human breast-milk.
The active substance in Stelara, ustekinumab, is a monoclonal antibody.
The active substance in Stocrin, efavirenz, is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
The active substance in Synagis, palivizumab, is a monoclonal antibody.
The active substance in Tarceva, erlotinib, is an anti-cancer medicine that belongs to the group ‘ epidermal growth factor receptor (EGFR) inhibitors’.
The active substance in Tygacil, tigecycline, belongs to the group of antibiotics called ‘ glycylcyclines’, which are similar to tetracycline.
The active substance in Valdoxan/ Thymanax, agomelatine, is a ‘ melatonergic agonist'and a ‘ 5-HT2C antagonist’.
The active substance in Vectibix, panitumumab, is a monoclonal antibody.
It contains the active substance insulin human ng (rDNA). lo
The active substance in Veraflox, pradofloxacin, belongs to a class of antibiotics called third generation fluoroquinolones.
The active substance in Vimpat, lacosamide, is an anti-epileptic medicine.
The active substance in ViraferonPeg, peginterferon alfa-2b, belongs to the group ‘ interferons’.
The active substance in Viread, tenofovir disoproxil, is a ‘ prodrug 'that is converted into tenofovir in the body.
The active substance in Voraxaze, glucarpidase, is a copy of the naturally-occurring enzyme carboxypeptidase G2.
The active ingredient in Wilzin is the zinc cation (positively charged zinc), which blocks the absorption of copper from the diet.
The active substance in Xarelto, rivaroxaban, is a ‘ factor Xa inhibitor’.
Yarvitan contains the active substance mitratapide which helps to reduce weight in dogs.
The active substance in Zonegran, zonisamide, is an anti-epileptic.
The active substance in Hepsera, adefovir dipivoxil, is a ‘ prodrug 'that is converted into adefovir in the body.
The active substance in Humira, adalimumab, is a monoclonal antibody.
The active substance in Inovelon, rufinamide, is an anti-epileptic medicine.
The active substance in Intelence, etravirine, is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
IONSYS contain the active ingredient fentanyl, which is a strong painkiller.
The active substance in IVEMEND, fosaprepitant, is a ‘ prodrug 'of aprepitant.
The active substance in Orgalutran, ganirelix, blocks the effects of a natural hormone, called gonadotrophin-releasing hormone (GnRH).
Ultratard contains the active ingredient insulin human (rDNA).
The active substance in Zenapax, daclizumab, is a monoclonal antibody.
The active substance is contained within a non absorbable shell designed to release the active substance at a controlled rate.
- The active substance is icatibant 30 milligrams (as acetate) in 3 ml solution for injection in each
The drug substance and the drug product have been appropriately described and generally satisfactory documentation has been provided.
The fentanyl is contained inside a reservoir.
The active substance in Ammonaps, sodium phenylbutyrate, is transformed by the body into another compound, phenylacetate.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against a disease.
Probenecid interferes with renal secretion of ciprofloxacin.
Probenecid is only taken on the same day that VISTIDE is administered.
Probenecid may also cause other side effects including loss of appetite, sore gums, flushing, hair loss, dizziness, reduced red blood cell count and increased frequency to urinate.
Probenecid may interact with other medicines commonly used in the treatment of AIDS and AIDS- related illnesses, such as zidovudine (AZT).
The product was accepted by the Czech Republic, Italy and Spain.
The compound has a cryptosporidiostatic effect on Cryptosporidium parvum.
The product when kept in its outer carton may be stored at ambient room temperature (< 25°C) for a single period of up to 3 months; note the new expiry date on the top of the carton.
The product when kept in its outer carton may be stored at ambient room temperature (< 25°C) for a single period of up to 3 months; note the new expiry date on the carton.
The product when kept in its outer carton may be stored at ambient room temperature (up to 25°C) for a limited period of 3 months.
The product contains the inactivated whole cells of Ornithobacterium rhinotracheale serotype A, strain B3263/ 91 mixed with an oil adjuvant.
The product as presented allows treating a dog suffering from bilateral otitis.
The product of radioactive decay is stable zirconium-90.
A horizontal ribbon mixer should be used to incorporate the product into the feeding stuff.
The product should be discarded before use if it contains particulate matter or is discoloured.
The product should be used within 6 months of opening.
The product should be used immediately after dilution.
1 year After first opening, the product should be used immediately.
The product should have a malleable, coherent putty-like consistency
The product is supplied in packs of 1 vial of powder, 1 pre-filled syringe of solvent, 1 EasyMIX adapter for reconstitution, 1 needle for injection; in packs of 4 vials of powder, 4 pre-filled syringes of solvent, 4 EasyMIX adapters for reconstitution, 4 needles for injection and in packs of 12 vials of powder, 12 pre-filled syringes of solvent, 12 EasyMIX adapters for reconstitution and 12 needles for injection.
The product is recommended for 30mg the treatment of bacterial diseases in horses including: - Alimentary tract infections.
The physical product manufactured for sale in the various markets appears to be identical.
The product under referral is intended for horses only.
The compound selectively inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukaemic cells from Philadelphia chromosome positive CML and acute lymphoblastic leukaemia (ALL) patients.
The product may not be returned to refrigerated storage after storage at room temperature.
The product may not be returned to refrigerated storage again.
The product may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.
Shelf life after first use of the cartridge The product may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.
Shelf life after first use of the pen The product may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.
Shelf life after first use of the vial The product may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.
Shelf-life after first use of the vial The product may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.
The product can be re-activated up to 48 hours after initial activation and used up to 12 hours after the second activation, whether stored under refrigeration or at room temperature.
The product can be re-activated up to 48 hours after initial activation and used up to 12 hours after the second activation.
The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes.
The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes.
The reconstituted product will appear clear or slightly opaque.
Do not open before use The reconstitued product should be used immediately
Reconstituted product should be used immediately after preparation.
Do not open before use The reconstitued product should be used immediately
The reconstitued product should be used immediately.
The reconstituted product should be used immediately.
The reconstituted product is a homogeneous, cloudy suspension, free of agglomerates.
Alexandre was Head of the Pharmacology Department at the Broussais Hospital and Professor of Pharmacology at UFR Broussais-Hôtel Dieu, Paris.
Alexandre was Head of the Pharmacology Department at the Broussais Hospital and Professor of Pharmacology at UFR Broussais-Hôtel Dieu, Paris.
Professor Jean-Michel Alexandre was re-elected Chairman and Dr Mary Teeling was elected Vice-Chairman of the CPMP for the period 1998-2000.
The benefit/ risk of the systemic treatment with the combination of loratadine and pseudoephedrine versus treatment with loratadine and a topical application of pseudoephedrine was discussed.
The adverse event profile in adolescents and patients with chronic cardiac and/ or respiratory disease was qualitatively similar to those of healthy young adults.
The concentration-time profile following intravenous administration is well described by a two-compartment model.
The reactogenicity profile of Fendrix in healthy subjects was generally comparable to that seen in pre- haemodialysis and haemodialysis patients.
The reactogenicity profile of Fendrix in a total of 82 pre-haemodialysis and haemodialysis patients was generally comparable to that seen in healthy subjects.
The adverse experience profile for pediatric patients is not different from that seen in adult patients.
The side effect profile was also similar at the lower incidences.
The adverse event profile reported in the ACS program is consistent with the adverse drug reactions identified for VTE prophylaxis.
The adverse reactions profile appears similar for adults and adolescents.
A similar safety profile has been observed in subjects with prior or current HPV infection as compared to subjects negative for oncogenic HPV DNA or seronegative for HPV-16 and HPV-18 antibodies.
The overall safety profile of MabThera in rheumatoid arthritis is based on data from patients from clinical trials and from post-marketing surveillance.
The overall safety profile of MabThera in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia is based on data from patients from clinical trials and from post-marketing surveillance.
The pharmacokinetics of bosentan have not been studied in patients with Child- Pugh class B or C hepatic impairment and Tracleer is contra-indicated in this patient population (see section 4.3).
EDQM will also participate in a number of EMEA working parties.
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing major orthopaedic surgery of the lower limbs treated up to 9 days The fondaparinux clinical program was designed to demonstrate the efficacy of fondaparinux for the prevention of venous thromboembolic events (VTE), i. e. proximal and distal deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery.
The fondaparinux clinical program in treatment of Venous Thromboembolism was designed to demonstrate the efficacy of fondaparinux for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
The clinical development program was composed by 5 studies provided in the following table:
The programme shall convey the following key messages:
A total of 29 applications for designation were withdrawn in 2001 since the sponsors were not able to fully justify their requests.
The application should cover the best support work processes and also document archiving in order to allow for cost effective access to any document at any time.
The educational programme for laboratories should inform about the following key elements:
The amended draft Summary of Product Characteristics is set out in Annex I.
Prozac is currently approved for the treatment of major depressive episodes, obsessive-compulsive disorder and bulimia nervosa, in adults.
< Invented Name > had a sparing effect on the use of topical corticosteroids: more patients treated with < Invented Name > did not use corticosteroids in 12 months [children (57% < Invented Name > vs 32% control), infants (64% < Invented Name > vs 35% control)].
10 Eptifibatide, a synthetic cyclic heptapeptide containing six amino acids, including one cysteine amide and one mercaptopropionyl (desamino cysteinyl) residue, is an inhibitor of platelet aggregation and belongs to the class of RGD (arginine-glycine-aspartate)-mimetics.
24 Eptifibatide, a synthetic cyclic heptapeptide containing six amino acids, including one cysteine amide and one mercaptopropionyl (desamino cysteinyl) residue, is an inhibitor of platelet aggregation and belongs to the class of RGD (arginine-glycine-aspartate)-mimetics.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Avamys nasal spray is a predominantly off-white plastic device with a dose indicator window, light blue side actuated lever and lid which contains a stopper.
The intranasal device should be shaken before use.
QUADRAMET is delivered frozen in dry ice.
QUADRAMET is used only as a palliative agent and should not be used concurrently with myelotoxic chemotherapy as this may enhance myelotoxicity.
QUADRAMET may be given subsequent to either of these treatments after allowing for adequate marrow recovery.
Balanced central serotonin and dopamine antagonism may reduce extrapyramidal side effect liability and extend the therapeutic activity to the negative and affective symptoms of schizophrenia.
This changes the body's hormonal balance and help to prevent ovulation.
The hospital staff will store IONSYS.
The equivalence of intake of 2800 IU of vitamin D3 weekly in ADROVANCE to daily dosing of vitamin D 400 IU has not been studied.
The equivalence of intake of 5600 IU of vitamin D3 weekly in ADROVANCE to daily dosing of vitamin D 800 IU has not been studied.
The equivalent of one marking is sufficient to treat 50 kg of bodyweight.
Suppression of H. pylori might give false negative results.
The suppression of Helicobacter pylori might give false negative results.
The imaging agent, technetium-99m LeukoScan [technetium-99m sulesomab] is formed by reconstitution of the contents of the LeukoScan vial with 0.5 mL sodium chloride for injection followed by the addition of 1100 MBq of sodium pertechnetate [99mTc] in 1 mL of Sodium Chloride for Injection.
Raloxifene has the same effect as oestrogen in the bone, but it does not have an effect in the breast or the womb.
Raltegravir is not an inhibitor of the UDP-glucuronosyltransferases (UGTs) 1A1 and 2B7, and raltegravir does not inhibit P-glycoprotein-mediated transport.
Ranibizumab has been designed to block a substance called vascular endothelial growth factor A (VEGF-A).
Therefore in such patients, the benefit/ risk ratio of FIRMAGON must be thoroughly appraised (see sections 4.5 and 4.8).
Therefore in such patients, the benefit/ risk ratio of FIRMAGON must be thoroughly appraised (see sections 4.5 and 4.8).
A careful risk/ benefit assessment should be made, taking into consideration that the liver toxicity is dose dependent (see sections 4.4 and 5.1).
The benefit/ risk of lamotrigine as add-on treatment in primary generalised tonic clonic seizures in children is also considered favourable.
The risk-benefit ratio of mycophenolate mofetil in combination with tacrolimus or sirolimus has not been established (see also section 4.5).
The risk-benefit balance should be considered in patients at risk of venous thromboembolic events of any aetiology (see sections 4.3 and 4.8).
The risk-benefit balance should be considered in patients at risk of venous thromboembolic events of any aetiology.
The risk-benefit profile for romiplostim has not been established in MDS or other non-ITP patient populations.
Cancer patients receiving treatment with erythropoietin have an increased risk of blood clots/ blood clotting disorders (thrombotic vascular events).
Cancer patients receiving treatment with erythropoietin have an increased risk of blood clots/ blood clotting disorders (thrombotic vascular events).
This risk should be carefully weighted against the benefit to be derived from treatment with epoetin alfa, particularly if you have an increased risk of thrombotic vascular events, e. g. if you are obese or have a history of thrombotic vascular events (e. g. deep vein thrombosis or pulmonary embolism).
products is favourable and the Marketing Authorisations should be maintained provided that:
The benefit/ risk ratio was not defined fully in patients with 4 and more positive nodes at this analysis stage.
This 1996 Activity Report is the first one covering a full year of operations.
The hazard ratio for the treatment effect was 0.58 (95% CI:
The hazard ratio for overall survival was 0.96 (95% CI:
The metabolite-to-parent AUC∞ ratio was around 0.7 after transdermal patch versus 3.5 after oral administration, indicating that much less metabolism occurred after dermal compared to oral treatment.
Peak/ trough ratio of Cardoreg 4 mg prolonged release tablets and associated names is less than half that of immediate release doxazosin tablets.
The relationship between tacrolimus trough levels (C24) and systemic
The Rapporteur was Dr Hudson and Co-Rapporteur(s) was Dr Ljungberg.
The Rapporteur was Dr Ian Hudson and Co-Rapporteur was Dr Michał Piroż ynski.
The Rapporteur was Dr Ian Hudson and Co-Rapporteur was Dr Pierre Demolis.
The Rapporteur was Dr Jean-Louis Robert and Co- Rapporteur was Dr Janos Borvendeg.
The Rapporteur was Dr Karl Broich and Co-Rapporteur was Dr Eric Abadie.
The Rapporteur was Dr Karl Broich and Co-Rapporteur(s) was Dr Pierre Demolis.
The Rapporteur was Dr Ondř ej Slanař (CZ) and Co-Rapporteur(s) was Prof János Borvendég (HU).
The Rapporteur was Dr Ondrej Slanar and Co-Rapporteur was Dr Matthew Thatcher.
The Rapporteur was Dr Pierre Demolis (FR) as Rapporteur and Co-Rapporteur(s) was Dr Ingemar Persson (SE).
Salmonson and the Co-Rapporteur was Dr Abadie.
The Rapporteur was Dr Tomas Salmonson (SE) and Dr Pierre Demolis (FR) was Co-Rapporteur.
The Rapporteur was Dr Tomas Salmonson (SE) and Co-Rapporteur was Dr Ian Hudson (UK).
Dr Barbara van Zwieten-Boot and Dr Tomas Salmonson, respectively.
Dr P Neels and Dr T Salmonson, respectively.
The Rapporteur and Co-Rapporteur appointed were:
The Rapporteur and Co-Rapporteur appointed were:
The Rapporteur and Co-Rapporteur appointed were Dr D Lyons and Dr G Calvo Rojas, respectively.
The Rapporteur and Co-Rapporteur appointed were Dr P.
The Rapporteur and Co-Rapporteur appointed were Dr Rossi and Dr Calvo-Rojas respectively.
The Rapporteur and Co-Rapporteur appointed were Tomas Salmonson and Eric Abadie, respectively.
The mean metabolite: parent plasma AUC ratio was less than 10% for both total topotecan and topotecan lactone.
The mean metabolite: parent AUC ratio was less than 10% for both total topotecan and topotecan lactone.
The risk/ benefit of further treatment with RISPERDAL CONSTA should be assessed if clinically relevant orthostatic hypotension persists.
The blood to plasma ratio (B/ P) of 36 indicates that sirolimus is extensively partitioned into formed blood elements.
51 approximately 1 measured in rat lymph nodes suggests that ritonavir distributes into lymphatic tissues.
Tissue to plasma ratios of approximately 1 measured in rat lymph nodes suggests that ritonavir distributes into lymphatic tissues.
Rash, erythema and pruritus will usually disappear within one day after the patch has been removed.
The ratio of 5-FU concentration in tumour to plasma was 21.4 (ranged from 3.9 to 59.9, n=8) whereas the ratio in healthy tissues to plasma was 8.9 (ranged from 3.0 to 25.8, n=8).
Rats appear to be particularly sensitive to oncogenic effects of TMZ, with the occurrence of first tumours within 3 months of initiating dosing.
The SPC is amended in section 4.1, 4.2, 4.3 and 4.4 in section 4.4. to reflect the lower age limit for vaccination with STAMARIL.
- The SPC, labelling and package leaflet proposed by the applicant has been assessed based on
- The SPC, labelling and package leaflet proposed by the applicant has been assessed based on the
The epidermal growth factor receptor (EGFR) is involved in foetal development.
Both < Invented Name > and topical corticosteroids were used without restrictions.
Heavy reliance on a single class of antibiotics may result in the induction of resistance in a bacterial population.
The grounds were on the wording of the excerpt of the Summary Product Characteristics in the special warnings and undesirable effects sections, objecting to the statement of causality.
Study recruitment was initiated during September 2006.
Recruitment to the Agency follows the rules and practices of the EU institutions.
Survival continued to be followed after the interim analysis.
Diet and other non-pharmacological treatments (e. g. exercise, weight reduction) should be continued during therapy with Pelzont.
Diet and other non-pharmacological treatments (e. g. exercise, weight reduction) should be continued during therapy with Tredaptive.
Diet and other non-pharmacological treatments (e. g. exercise, weight reduction) should be continued during therapy with Trevaclyn.
Council Regulation (EEC) No 2309/ 93 sets out the main objectives for the EMEA as follows:
The Regulation and three Directives creating the centralised and decentralised procedures can be found in the EC Official Journal No L.214 of 24.8.93.
The calculation of travel reimbursements for 2 024 delegate visits was processed within the target time of two weeks.
The replacement of the European Commission’s financial control by a decentralised structure based on internal audits within the individual Directorates-General has been publicly announced.
The JICS representative also advised and lectured on multilingualism, interpreting and communication at Universities in Ireland and the UK.
Human and veterinary medicinal products Official batch release excluded 4.4 Certification of medicinal products The demand for certificates was uneven during 2002, with
For the remainder of the day after injection, patients should be advised to be vigilant for signs and symptoms of overdose secondary to post injection adverse reactions, be able to obtain assistance if needed and should not drive or operate machinery (see section 4.7).
The remains of the tumour should be removed whenever this is possible, usually after several weeks.
Any remaining contents should be discarded after use.
- The outcome of the 4th analysis of the EPC data should be provided to the RMS and the NCAs where
The in vivo micronucleus test was negative.
The result is a reduction in intraocular pressure (IOP) which is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss.
The net result is the inhibition of lymphocyte activation, which results in immunosuppression.
- The Summary of Products Characteristic, labelling and package leaflet proposed by the
The Summary of Product Characteristics is set out in Annex III for Isotretinoin / Lurantal / Trivane / Rexidal / Scheritonin (see Annex I).
The valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved at day 90 during the Coordination group procedure.
The Summary of Product Characteristics, labelling and package leaflet are set out in Annex III of the opinion for Glucomed and associated names (see Annex I).
The valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination Group procedure with the following amendment:
been assessed based on the documentation submitted including the proposal for a pregnancy prevention programme and the scientific discussion within the Committee, the CPMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics is set out in Annex III for Roaccutane and associated names (see Annex I).
- the Summary of Product Characteristics is amended as stated in Annex I
The valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure as mentioned in Annex III.
The Scientific Conclusions and the grounds for amendment of the Summary of Product Characteristics are set out in Annex B.
The Scientific Conclusions and the grounds for withdrawal are set out in Annex B.
The consequence of this for the clinical use of the drug is unknown.
Water withholding should be kept as short as possible with a minimum of half an hour.
Riluzole stops the release of glutamate and this may help in preventing the nerve cells being damaged.
19 out as the potential for local immunosuppression with the long-term use of pimecrolimus cream is unknown.
There is increased risk of lactic acidosis in acute alcohol intoxication (particularly in the case of fasting, malnutrition or hepatic insufficiency) due to the metformin active substance of Efficib (see section 4.4).
Metformin-related lactic acidosis increases with the degree of impairment of renal function, therefore, serum creatinine concentrations should be determined regularly:
The risk of malignancy, particularly lymphoproliferative disorders, is increased with use of some immunosuppressive agents.
The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.
The thyroid tumorigenic potential is regarded to be species-specific.
The risk of fracture should be considered in the care of patients, especially female patients, treated with rosiglitazone.
The risk of fractures should be considered in the long term care of women treated with pioglitazone.
The risk of fractures should be considered in the long term care of women treated with pioglitazone.
The risk of birth defects is increased by a factor of 2 – 3 in the offspring of mothers treated with an antiepileptic medicinal product.
For selective, reversible MAOIs, like moclobemide, the risk of serotonin syndrome is lower.
The risk of CVAEs was significantly higher in patients with mixed or vascular type of dementia when compared to Alzheimer's dementia.
The risk of hypokalaemia is greater in patients with cirrhosis of liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or Adrenocorticotropic hormone (ACTH) (see section 4.5).
The risk of hypokalaemia is greater in patients with cirrhosis of liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or Adrenocorticotropic hormone (ACTH) (see section 4.5).
The risk of hypokalaemia is greater in patients with cirrhosis of the liver, patients experiencing brisk diuresis, patients with inadequate oral electrolyte intake and patients receiving concomitant therapy with corticosteroids or adrenocorticotropic hormone (ACTH) (see sections 4.5 and 4.8).
The risk of inducing a fertile heat is low in metoestrus (5%).
The estimated risk of a second event was 50% in three years and 39% in two years in the placebo group and 35% (three years) and 21% (two years) in the AVONEX group.
The risk of using venlafaxine in combination with other CNS-active substances has not been systematically evaluated.
The risk associated with combination therapy, in particular in long-term treatment, is unknown.
Tracleer is contraindicated in pregnancy (see section 4.3).
The potential risk for humans is unknown.
The potential risk for humans is unknown.
The potential risk for humans is unknown.
As the benefit of the vaccination is high in this group of infants, vaccination should not be withheld or delayed. t
The potential risk with the combination of AZA or 6-MP and Remicade should be carefully considered.
Possible risk connected with the use of ephedrine in this group of animals can be reduced by appropriate management measures.
The potential risk for humans is unknown.
The potential risk for humans is unknown.
potential risk for humans is unknown.
The potential risk for humans is unknown.
The potential risk for humans is unknown.
The risk for humans cannot be completely ruled out as the potential for local immunosuppression with the long-term use of tacrolimus ointment is unknown.
The risk for humans cannot be completely ruled out as the potential for local immunosuppression with the long-term use of tacrolimus ointment is unknown.
The relative risk compared to placebo for a similar composite endpoint (CV death, MI, stroke) was 1.14 (95% CI 0.61 - 2.12) with celecoxib 200 mg twice daily.
29/ 30 vitamin D and calcium alone) in all patients treated with daily doses of 200 I. U. was 0.67 (95% CI:
The relative risk of developing vertebral fractures, compared to placebo (treatment with vitamin D and calcium alone) in all patients treated with daily doses of 200 I. U. was 0.67 (95% CI:
A risk for transmission of Creutzfeld-Jacob disease (CJD) cannot be excluded.
This allows a lower dose of Telzir to be used for the same antiviral effect.
Ritonavir induces CYP3A4, CYP1A2, CYP2C9 and glucuronosyl transferase.
Ritonavir inhibits the metabolism of saquinavir, thereby increasing ("boosting") the plasma levels of saquinavir.
- ritonavir (used in the treatment of HIV infection),
- ritonavir (used to treat AIDS)
39 Erlotinib is an epidermal growth factor receptor/human epidermal growth factor receptor type 1 (EGFR also known as HER1) tyrosine kinase inhibitor.
9 Erlotinib is an epidermal growth factor receptor/ human epidermal growth factor receptor type 1 (EGFR also known as HER1) tyrosine kinase inhibitor.
Erlotinib potently inhibits the intracellular phosphorylation of EGFR.
Erlotinib potently inhibits the intracellular phosphorylation of EGFR.
Erlotinib binds to serum albumin and alpha-1 acid glycoprotein (AAG).
Erlotinib binds to serum albumin and alpha-1 acid glycoprotein (AAG).
The role of Ceplene is to protect lymphocytes, in particular NK cells and T cells, which are responsible for the immune- mediated destruction of residual leukaemic cells.
The role of transporters (for example p-glycoprotein) in the disposition of tadalafil is not known.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against diseases.
However, the role of EXJADE as a contributing or aggravating factor cannot be excluded (see section 4.8).
United Kingdom referred the reasons for disagreement to the EMEA on 5 May 2006.
Rufinamide has demonstrated little or no significant capacity in-vitro to act as a competitive or mechanism-based inhibitor of the following human P450 enzymes:
Rufinamide was evenly distributed between erythrocytes and plasma.
Skin rash most commonly occurred on the face, upper chest, and back, but could extend to the extremities.
It can be treated with antihistamines.
The rate at which the dose of sirolimus is increased should correspond to the rate of ciclosporin elimination.
PRCA means that the body has stopped or reduced the production of red blood cells which causes severe anaemia.
PRCA means that the body stopped or reduced the production of red blood cells.
PRCA means that the body has stopped or reduced the production of red blood cells which causes severe anaemia.
PRCA means that the body has stopped or reduced the production of red blood cells which causes severe anaemia.
Erythropoietin is a glycoprotein that stimulates, as a mitosis-stimulating factor and differentiating hormone, the formation of erythrocytes from precursors of the stem cell compartment.
Erythropoietin is a glycoprotein that stimulates the formation of erythrocytes from precursors of the stem cell compartment.
Erythropoietin is a glycoprotein that stimulates, as a mitosis-stimulating factor and differentiating hormone, the formation of erythrocytes from precursors of the stem cell compartment.
Erythropoietin is a glycoprotein that stimulates the formation of erythrocytes from its committed progenitors.
A hormone called erythropoietin stimulates the production of red blood cells from the bone marrow.
of 2833 patients, of which four were double-blind placebo-controlled studies and one was an open- label study.
Human erythropoietin is an endogenous glycoprotein hormone that is the primary regulator of erythropoiesis through specific interaction with the erythropoietin receptor on the erythroid progenitor cells in the bone marrow.
Human erythropoietin is an endogenous glycoprotein hormone that is the primary regulator of erythropoiesis through specific interaction with the erythropoietin receptor on the erythroid progenitor cells in the bone marrow.
The 19 isolates demonstrated a 4.3-fold increase in IC50 compared to baseline isolates (from 6.2- to 43-fold, compared to wild-type virus).
All 28 patients (100%) treated after withdrawal of THST and all 32 patients (100%) treated after Thyrogen administration had either no visible uptake of radioiodine in the thyroid bed or, if visible, thyroid bed uptake < 0.1% of the administered activity of radioiodine.
All breath bags should be placed back into the original packaging.
All breath samples containers should be placed back into the original packaging.
All 65 FIP1L1-PDGFRα fusion kinase positive patients achieved a CHR sustained for months (range from 1+ to 44+ months censored at the time of the reporting).
Chromosomal aberrations were categorized according to Döhner's hierarchical model.
The amino acids at positions 1, 2, 3, 6, 8 and 10 of the natural GnRH decapeptide have been substituted resulting in N-Ac-D-Nal(2)1, D- -pClPhe2, D-Pal(3)3, D-hArg(Et2)6, L-hArg(Et2)8, D-Ala10]-GnRH with a molecular weight of 1570.4.
Trends: • Level of international activities is expected to remain strong,
The activities of the network are co-ordinated by the European Department for the Quality of Medicines (EDQM) Council of Europe) and the EMEA.
Improvement teams will continue to work in the area of the Agency's partnerships with stakeholders and support the product information management project.
Implementation of the database is to be undertaken by the EMEA and the tracking Telematics Implementation Group (TIG) is chaired by Portugal.
EMEA website, library and mailroom The EMEA Internet website, main- tained and managed in London by the ETOMEP team from JRC, enjoyed great popularity and was visited from almost all points of the globe during
Adjuvants are used to improve the body’s response to the vaccine.
The cDNAs encode for an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites, and a beta subunit of 118 residues containing one N-linked glycosylation site.
The conditions studied were severe pneumonia, neutropenia, acute bacterial exacerbations of chronic bronchitis, complicated, community-acquired skin and skin structure infections, infections in cancer patients and bacteraemia,.
Bone disorders reported were genu valgum, leg pain and hyperextensive joints, osteopenia, compression fractures, and scoliosis.
Anticonvulsants (carbamazepine, phenobarbital) should be used with caution.
Cationic agents that are eliminated by renal tubular secretion (e. g., cimetidine) may interact with metformin by competing for common renal tubular transport systems.
Dopamine agonists are known to impair the systemic regulation of the blood pressure resulting in postural/ orthostatic hypotension.
Used needle and syringe should be placed in a sharps container (such as a biohazard container), hard plastic container (such as a detergent bottle), or metal container (such as an empty coffee can).
Tacrolimus Interaction with indinavir/ ritonavir not studied Indinavir and ritonavir inhibit CYP3A4 and as a result are expected to increase the plasma concentrations of tacrolimus.
Salbutamol is a beta2-adrenergic receptor agonist.
Food and/ or drink will increase acid production in the stomach and the effect of the vaccine may be impaired.
Α lpha-2-agonists have an anaesthetic sparing effect and therefore the dose of sevoflurane should be reduced accordingly.
Α lpha-2-agonists have an anaesthetic sparing effect and therefore the dose of sevoflurane should be reduced accordingly.
Alterations in calcium metabolism have not been examined in human clinical studies.
Samarium-153 emits both medium-energy beta particles and an imageable gamma photon, and has a period of 46.3 hours (1.93 days).
The nucleoside analogues (e. g. didanosine and zalcitabine) like zidovudine, are not eliminated by this mechanism and are unlikely to interact with lamivudine.
The nucleoside analogues (e. g. didanosine and zalcitabine) like zidovudine, are not eliminated by this mechanism and are unlikely to interact with lamivudine.
Nucleoside analogues (e. g. zidovudine, didanosine and zalcitabine) and other medicinal products (e. g. ranitidine, cimetidine) are eliminated only in part by this mechanism and were shown not to interact with lamivudine.
Nucleoside analogues (e. g. zidovudine, didanosine and zalcitabine) and other medicinal products (e. g. ranitidine, cimetidine) are eliminated only in part by this mechanism and were shown not to interact with lamivudine.
The nucleoside analogues (e. g. zidovudine and didanosine) are not metabolised by this mechanism and are unlikely to interact with lamivudine.
Cognitive investigations in clinical pharmacology studies demonstrated that rimonabant is devoid of
frequency, urinary incontinence, urinary urgency
Halogenated volatile anaesthetics can react with desiccated carbon dioxide (CO2) absorbents to produce carbon monoxide (CO) that may result in elevated levels of carboxyhaemoglobin in some dogs.
When the blood clots, this is due to special cells in the blood, the platelets, sticking together (aggregating).
If agglutination of red blood cells in the tubing/ syringe is observed, discard all this material (tubing, syringe and BeneFIX solution) and resume administration with a new package.
Blood must be collected into pre-chilled tubes containing heparin anticoagulant.
Severely diseased animals can have a decreased appetite and water consumption.
After the last administration of Zactran, cattle should not be slaughtered for 64 days.
The animals may also show some signs of slight pain for one day.
Animals showing a polyuria-polydipsia should not be treated with Incurin.
Animals showing a polyuria-polydipsia (excessive water intake and consequent excretion of a large volume of urine) should also not be treated with this product.
Treated animals should have free access to water.
In a photocarcinogenicity study, albino hairless mice were chronically treated with tacrolimus ointment and UV radiation.
Vaccinated animals can spread the vaccine strain of Bordetella bronchiseptica for six weeks, and there may be intermittent shedding for at least one year.
Vaccinated animals can spread the Bordetella bronchispetica vaccine strain for six weeks; in individual cases for at least one year.
Recently treated animals should not be allowed to sleep in the same bed as their owners, especially children.
Recently treated animals should not be allowed to sleep in the same bed as their owners, especially children.
Cytogenetic abnormalities were evaluated in 117 of the total population of 176 patients.
CNS anomalies (exencephaly/ encephalocele), limb anomalies (micromelia, club foot, syndactyly, oligodactyly) and others (micrognathia, gastroschisis, oedema, and rib abnormalities).
Mostly this resolves upon discontinuation of the treatment with cetirizine dihydrochloride.
Transient abnormalities include elevated values of blood urea, AST (SGOT), ALT (SGPT), LDH, bilirubin, and alkaline phosphatase.
Antacids and sucralfate may decrease the bioavailabilty of lansoprazole.
Antacids and sucralfate may reduce the bioavailability of lansoprazole.
Single doses of antacid (magnesium hydroxide/ aluminium hydroxide) did not affect the bioavailability of sildenafil.
Antacids can interfere with gastro-intestinal absorption of quinolones.
Anti-acids can interfere with gastro-intestinal absorption of quinolones.
Anti-acids can interfere with gastro-intestinal absorption of quinolones.
Antiacids can interfere with gastro-intestinal absorption of quinolones.
Antacids may interfere with gastro-intestinal absorption.
Anti-androgens act against the effects of androgens (male sex hormones).
Cephalosporin and penicillin antibiotics can cause allergies in humans, and sometimes these allergies can be very serious.
Cephalosporin and penicillin antibiotics can cause allergies in humans, and sometimes these allergies can be very serious.
- Streptogramin antibiotics such as quinupristin/ dalfopristin inhibit CYP3A4.
- Streptogramin antibiotics such as quinupristin/dalfopristin inhibit CYP3A4.
Macrolide antibiotics are the metabolites or semi-synthetic derivatives of metabolites of soil organisms obtained by fermentation.
β -lactam antibiotics prevent the bacterial cell wall synthesis by interfering with the final stage of peptidoglycan synthesis.
- anticoagulants: ibuprofen may increase the effect of anticoagulants and enhance the risk of
Anticonvulsants, cimetidine and thiazides may increase the catabolism of vitamin D.
Anti-OP-1 antibodies have the ability to neutralise the in vitro biological activity of at least BMP-6.
Anti-OP-1 antibodies have the ability to neutralize the in vitro biological activity of at least BMP-6.
The antibodies help to block the virus from infecting cells in the body.
The antibodies help to block the virus from entering cells in the body.
Antibodies to eptotermin alfa were also found in sera from pooled foetal and umbilical cord blood, at levels that correlated to that of the maternal blood.
Antibodies to eptotermin alfa were found in sera from pooled foetal and umbilical cord blood at levels that correlated to that of the maternal blood.
Antibodies against all four HPV types were transferred to the offspring during gestation and possibly during lactation.
The antibodies in Flebogammadif help to stop infections and help to stop your body rejecting the new cells.
Human antibodies are predominately catabolized by lysosomal enzymes to small peptides and amino acids.
The anti-toxin intestinal antibodies prevent the cholera toxin from binding to the intestinal mucosal surface thereby preventing the toxin-mediated diarrhoeal symptoms.
Monoclonal antibodies are proteins which specifically recognise and bind to other unique proteins in the body.
Monoclonal antibodies are proteins which specifically recognise and bind to a unique other protein called an antigen.
Monoclonal antibodies are proteins which specifically recognise and bind to a unique other protein called an antigen.
Antibodies may reduce the therapeutic effectiveness of the product.
The antibodies then protect the offspring against infection with this type of bacterium.
Specific humoral antibodies against hepatitis B were observed in 70% of the adults after the first dose and approximately 99% after the third dose.
Serum antibodies could be expected to persist for at least 12 months after administration of two doses of vaccine.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The antigens are adjuvanted with 150 mg dl-α -tocopherol acetate per dose.
Antithrombotics are medicines to prevent formation of blood clots (thrombosis).
The baits are distributed by land or by air within the framework of vaccination campaigns against rabies.
Discontinuations or virological failures considered as failures.
Discontinuations due to other specific adverse reactions among patients taking Pelzont were infrequent (< 1%).
Discontinuations due to other specific adverse reactions among patients taking Tredaptive were infrequent (< 1%).
Discontinuations due to other specific adverse reactions among patients taking Trevaclyn were infrequent (< 1%).
Discontinuations or virological failures considered as failures.
The following combinations are not recommended: • bromocriptine • cabergoline • lisuride, pergolide: risk of vasoconstriction and increase in blood pressure.
The following combinations are not recommended:
Combination antiretroviral therapy may cause changes in body shape due to changes in fat distribution.
The risk is increased in case of the above-mentioned treatment combinations.
Bilirubin increases to > 3 × ULN were associated with aminotransferase increases (> 3 × ULN) in 2 of 658 (0.3%) of patients treated with bosentan.
30 reductase inhibitors may cause myopathy, including rhabdomyolysis, the combination of these medicinal products with Kaletra is not recommended.
Since increased concentrations of HMG-CoA reductase inhibitors may cause myopathy, including rhabdomyolysis, the combination of these medicinal products with Kaletra is not recommended.
The mean increases from baseline in lumbar spine BMD at one year were 5.1% (95% CI:
The mean BMD increases were 2.3% and 2.9% at the femoral neck and 2.9% and 3.1% at the total hip in the 70 mg once weekly and 10 mg daily groups, respectively.
The marketing authorisations for Type II-containing medicinal products, categorised as anorectic agent, should be maintained provided that • the Summary of Product Characteristics is amended as stated in Annex I.
The marketing authorisations for Type III-containing medicinal products, categorised as anorectic agent, should be maintained provided that • the Summary of Product Characteristics is amended as stated in Annex I.
The marketing authorisations for Type I-containing medicinal products, categorised as anorectic agent, should be maintained provided that • the Summary of Product Characteristics is amended as stated in Annex I.
Marketing Authorisations for veterinary medicinal products containing toltrazuril and intended for use in poultry species were previously granted to Bayer HealthCare and/ or Ceva Santé Animale in Austria, Belgium, Bulgaria, Cyprus, Czech republic, France, Germany, Greece, Hungary, Ireland, Italy, Poland, Portugal, Romania, Slovakia, Slovenia, the Netherlands and the United Kingdom following national marketing authorisation procedures.
Other causes of frequent urination (heart failure or renal disease) should be assessed before treatment with Emselex.
Other causes of frequent urination (heart failure or renal disease) should be assessed before treatment with Kentera.
Other causes of frequent urination (treatment of heart failure or renal disease) should be assessed before treatment with fesoterodine.
Other causes of PRCA should be excluded, and appropriate therapy initiated.
This medicinal product is authorised in the Member States of the EEA under the following names:
Other ingredients in the capsule shell are:
The other ingredients in the tablet coat are methacrylic copolymer, silica colloidal anhydrous, macrogol and titanium dioxide (E-171)).
- The other ingredients in Infanrix Penta are: sodium chloride (NaCl), medium 199 containing
- The other ingredients of Optisulin are: zinc chloride, m-cresol, glycerol, sodium hydroxide,
- The other ingredients in the tablet are croscarmellose sodium, hydroxypropylcellulose,
- The other ingredients in the tablet core are microcrystalline cellulose, croscarmellose sodium,
- The other ingredients in the tablet core are croscarmellose sodium, magnesium stearate, maize
- The other ingredients in the tablet core are maize starch, pregelatinised starch, sodium starch
- The other ingredients of the solvent are: poloxamer 188, water for injection.
- The other ingredients in Tritanrix HepB are: thiomersal, sodium chloride and water for injections.
- The other ingredients in the tablet core are croscarmellose sodium, magnesium stearate, maize
- The other ingredients are glutamic acid, sorbitol (E420), polysorbate 80 and water for
- The other ingredients are calcobutrol sodium, trometamol, hydrochloric acid and water for
The other ingredients are: benzalkonium chloride, carbomer 974P, edetate disodium, mannitol, purified water, sodium chloride, tyloxapol.
The other ingredients are: benzalkonium chloride, trometamol; sodium chloride; hypromellose; purified water.
- Other ingredients of Lantus are: zinc chloride, m-cresol, glycerol, sodium hydroxide,
• The other ingredients are poly(dimethylsiloxane, trimethylsilyl silicate)-copolymerisate, povidoneK90, sodium metabisulphite (E223), ascorbyl palmitate (E304) and DL-α-tocopherol (E307).
• The other ingredients are: disodium edetate (E386), polysorbate 80 (E433), lactose anhydrous, sodium hydroxide (E524) (for pH adjustment) and/ or hydrochloric acid diluted (E507) (for pH adjustment).
- The other ingredients are fosveset, sodium hydroxide, hydrochloric acid, and water for injections.
The other ingredients are glucose anhydrous, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water.
- The other ingredients are glycine, disodium phosphate anhydrous, sodium dihydrogen phosphate
- The other ingredients are glycine, disodium phosphate anhydrous, sodium dihydrogen phosphate
The other ingredients are sodium acetate, sorbitol (E420), polysorbate 20 and water for injections.
The other ingredients are sodium acetate, sorbitol (E420), polysorbate 20 and water for injections.
acid (for pH adjustment) and water for injections.
- The other ingredients are isostearic acid, benzyl alcohol, cetyl alcohol, stearyl alcohol, white soft
- The other ingredients are: glycine, sodium chloride, sodium citrate
The other ingredients are glycine, sodium chloride, calcium chloride, histidine, polysorbate 80, and sucrose.
- The other ingredients are white soft paraffin and butylated hydroxytoluene (E321), a
- The other ingredients are benzalkonium chloride (preservative), sodium chloride, sodium
- The other ingredients are: sodium chloride, disodium phosphate dodecahydrate, potassium
- The other ingredients are sodium chloride, sucrose, histidine and water for injections.
- The other ingredients are dimethylacetamide and macrogol 400
- The other ingredients are: potassium dihydrogen phosphate; disodium phosphate, anhydrous;
- The other ingredients are sucrose, polysorbate 80, disodium phosphate dodecahydrate, sodium
- The other ingredients are sucrose, histidine, histidine hydrochloride monohydrate and
The other ingredients are lactic acid (E270), sodium chloride, hydrochloric acid (E507) for pH adjustment and water for injections.
- The other ingredients are protamine sulphate, m-cresol, phenol, glycerol, dibasic sodium
The other ingredients are triacetin, acrylic adhesive solution (containing 2-ethylhexyl acrylate, N- vinyl pyrrolidone and hexamethyleneglycol dimethacrylate polymer domains), clear backing film of polyester/ ethylene vinyl acetate (PET/ EVA), and siliconised polyester release liner (PET).
The other ingredients are: macrogol 4000, distearoylphosphatidylcholine, dipalmitoylphosphatidylglycerol sodium, palmitic acid.
- The other ingredients are: metacresol, sodium chloride, trometamol, polysorbate 20,
- The other ingredients are: phenol, zinc chloride, trometamol, poloxamer 171, glycerol,
- The other ingredients are: phenol, zinc chloride, trometamol, poloxamer 171, glycerol, hydrochloric
edetate disodium, sodium chloride, m-cresol, polysorbate 80 and water for injections.
- The other ingredients are disodium phosphate anhydrous, sodium dihydrogen phosphate
- The other ingredients are disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate,
- The other ingredients are disodium phosphate anhydrous, sodium dihydrogen phosphate
- The other ingredients are disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate,
- The other ingredients are disodium phosphate anhydrous, Sodium dihydrogen phosphate monohydrate,
191 The other ingredients are disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, calcium chloride dihydrate, polysorbate 20, glycine, leucine, isoleucine, threonine, glutamic acid, phenylalanine, water for injections, sodium hydroxide (pH adjuster), hydrochloric acid (pH adjuster).
The other ingredients are disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, calcium chloride dihydrate, polysorbate 20, glycine, leucine, isoleucine, threonine, glutamic acid, phenylalanine, water for injections, sodium hydroxide (pH adjuster), hydrochloric acid (pH adjuster).
The other ingredients are sucrose, glycine, glutamic acid, sodium chloride, sodium hydroxide and polysorbate 80, water for injections, and bovine Type I collagen.
- The other ingredients are sorbitol (E420), sodium dihydrogen citrate (E331[a]), xanthan gum
The other layers of retina were not affected.
The other layers of retina were not affected.
Other androgenic effects commonly reported were acne, voice deepening and alopecia.
Other effects should be treated symptomatically.
The additional adverse reactions in Table 2 have been reported from postmarketing surveillance or no
The other major class of adverse reactions are gastrointestinal symptoms, including nausea, vomiting, abdominal pain, constipation and diarrhoea.
Other undesirable effects seen include splenic enlargement, which may be progressive in a minority of cases and thrombocytopenia.
Other side effects include irritability, sleepiness, fever, diarrhoea, vomiting, loss of appetite, middle ear infection, and unusual high-pitched crying.
The following other side effects have been reported in very few patients treated with Tasigna: • confusion, disorientation • sensation of numbness or tingling in fingers and toes • increased sensitivity of the eyes or the skin to light • eye pain or redness, pain, swelling and itching of the eyelids • difficulty hearing, ear pain • joint stiffness, muscle weakness • unconsciousness • blood in urine • weight gain, tiredness, hair loss, muscle weakness, feeling cold If any of these affects you severely, tell your doctor.
Further rare cases with fatal outcome, reported in association with LITAK chemotherapy, were second malignancy, cerebro- and cardiovascular infarctions, graft-versus-host disease caused by multiple transfusions of non-irradiated blood, as well as tumour lysis syndrome with hyperuricaemia, metabolic acidosis, and acute renal failure.
Other less frequently reported serious adverse reactions (< 2%) included neutropenic sepsis, pneumonia, thrombocytopenia and haemorrhagic events (e. g. cerebral haemorrhage).
Other local reactions included erythema, pain/ tenderness, itching, discharge, and a burning sensation.
Other sections of the SPC which were not harmonised and which need to be introduced nationally by the Member States when implementing the harmonised SPC are the following:
Other frequently observed signs or symptoms of the hypersensitivity reaction may include lethargy or malaise and musculoskeletal symptoms (myalgia, rarely myolysis, arthralgia).
Other frequently observed signs or symptoms of the hypersensitivity reaction may include lethargy or malaise and musculoskeletal symptoms (myalgia, rarely myolysis, arthralgia).
Other routine reversal situations have not been investigated and are therefore not recommended until further data become available.
Other symptoms may include: • acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating, muscle stiffness, and drowsiness or sleepiness; slower breathing, aspiration, high or low blood pressure, abnormal rhythms of the heart.
Other symptoms that affect the entire body include loss of appetite, fever, loss of energy and anemia (lack of red blood cells).
- the obvious benefits are the long duration of use and the lack of compliance problems
Soap, alcohol, or other solvents should not be used to remove the gel because they may enhance the active substances'ability to penetrate the skin.
This stops the bacteria growing, resulting in their death.
Bacteria can develop resistance to antimicrobial substances.
Bacteria can be responsible for 60-70% of clinical episodes of AOM.
In patients with hepatic or renal impairment insulin requirements may be diminished.
The individual insulin requirement in adults and children is usually between 0.5 and 1.0 U/ kg/ day.
The individual insulin requirement is usually between 0.3 and 1.0 IU/ kg/ day.
The individual insulin requirement is usually between 0.5 and 1.0 Units/ kg/ day in adult patients and this may be fully or partially supplied with NovoMix 50.
The individual insulin requirement is usually between 0.5 and 1.0 Units/ kg/ day in adult patients and this may be fully or partially supplied with NovoMix 70.
Beta-blockers and other anti-hypertensive agents should be used with caution during treatment with Ceplene.
Beta-blockers can mask the signs and symptoms of hypoglycaemia (see section 4.4).
4 Beta-blockers may increase the hypoglycaemic effect of antidiabetic agents.
Beta-blockers may increase the hypoglycaemic effect of antidiabetic agents.
Beta-blockers can mask the signs and symptoms of hypoglycaemia (see section 4.4).
Beta-blockers may also mask the signs of hyperthyroidism and cause worsening of Prinzmetal angina, severe peripheral and central circulatory disorders and hypotension.
tho Wounds that are especially prone to infection are burns, fractures, deep wounds or wounds contaminated with soil, dust, horse manure/ dung or wood splinters.
Wounds that are especially prone to infection are burns, fractures, deep wounds or wounds contaminated with soil, dust, horse manure/ dung or wood splinters.
Wounds that are especially prone to infection are burns, fractures, deep wounds or wounds contaminated with soil, dust, horse manure/dung or wood splinters.
Alcohol and some medicines can affect your blood sugar levels.
Alcohol and some medicines can affect your blood sugar levels.
Dimeticone or silicone emulsion may have been used to treat the vial stoppers.
Dimeticone or silicone emulsion may be used to treat the vial stoppers.
The bubbles act as a reflector of the ultrasound beam and provide a better echo than the tissues of the body.
The shields are optional to help you administer your injection.
The relative egg reductions calculations do not reflect these findings, particularly regarding P. equorum.
31 Calories are a measurement of the energy your body needs.
The capsules and oral solution must be taken with food, but the tablets can be taken with or without food.
Baseline demographic and disease characteristics of the patients were similar between the 2 treatment groups, 100 mg Tarceva plus gemcitabine or placebo plus gemcitabine, except for a slightly larger proportion of females in the erlotinib/ gemcitabine arm compared with the placebo/ gemcitabine arm:
• The following minimum yttrium-90 characteristics are recommended:
The pharmacokinetics of sildenafil in patients with severely impaired hepatic function have not been studied.
Vardenafil pharmacokinetics has not been studied in patients requiring dialysis (see section 4.3).
Fertavid cartridges are not designed to allow any other drug to be mixed in the cartridges.
Puregon cartridges are not designed to allow any other drug to be mixed in the cartridges.
Insulin Human Winthrop Basal cartridges for OptiClik are not designed to allow any other insulin to be mixed in the cartridge for OptiClik.
Insulin Human Winthrop Comb 15 cartridges are not designed to allow any other insulin to be mixed in the cartridge.
163 Insulin Human Winthrop Comb 15 cartridges for OptiClik are not designed to allow any other insulin to be mixed in the cartridge for OptiClik.
Insulin Human Winthrop Comb 25 cartridges are not designed to allow any other insulin to be mixed in the cartridge.
221 Insulin Human Winthrop Comb 25 cartridges for OptiClik are not designed to allow any other insulin to be mixed in the cartridge for OptiClik.
Insulin Human Winthrop Comb 50 cartridges are not designed to allow any other insulin to be mixed in the cartridge.
279 Insulin Human Winthrop Comb 50 cartridges for OptiClik are not designed to allow any other insulin to be mixed in the cartridge for OptiClik.
Insulin Human Winthrop Rapid cartridges are not designed to allow any other insulin to be mixed in the cartridge.
Insulin Human Winthrop Rapid cartridges for OptiClik are not designed to allow any other insulin to be mixed in the cartridge for OptiClik.
Insuman Basal cartridges are not designed to allow any other insulin to be mixed in the cartridge.
Insuman Basal cartridges for Opticlik are not designed to allow any other insulin to be mixed in the cartridge for Opticlik.
Insuman Comb 15 cartridges are not designed to allow any other insulin to be mixed in the cartridge.
Insuman Comb 15 cartridges for OptiClik are not designed to allow any other insulin to be mixed in the cartridge for OptiClik.
Insuman Comb 25 cartridges are not designed to allow any other insulin to be mixed in the cartridge.
Insuman Comb 25 cartridges for OptiClik are not designed to allow any other insulin to be mixed in the cartridge for OptiClik.
Insuman Comb 50 cartridges are not designed to allow any other insulin to be mixed in the cartridge.
Insuman Comb 50 cartridges for OptiClik are not designed to allow any other insulin to be mixed in the cartridge for OptiClik.
Insuman Rapid cartridges are not designed to allow any other insulin to be mixed in the cartridge.
Insuman Rapid cartridges for OptiClik are not designed to allow any other insulin to be mixed in the cartridge for OptiClik.
21 Cartridges should only be used in combination with products that are compatible with them and allow the cartridge to function safely and effectively.
Cartridges should only be used in combination with products that are compatible with them and allow the cartridge to function safely and effectively.
38 Acute cases and severely diseased pigs with reduced food and water intake should be treated with a suitable injectable product.
Acute cases and severely diseased pigs with reduced food and water intake should be treated with a suitable injectable product.
Acute cases and severely diseased pigs with reduced food and water intake should be treated with a suitable injectable product.
Acute cases and severely diseased pigs with reduced food or water intake should be treated with a suitable injectable product.
Acute cases and severely diseased pigs with reduced food or water intake should be treated with a suitable injectable product.
This is most likely to occur within the first few weeks of treatment.
The incidence of lactic acidosis can and should be reduced by also assessing other associated
Fatality attributed to overdose of fluoxetine alone has been extremely rare.
The most serious were reported in patients taking other drugs or who were suffering from diseases that can affect the liver (e.g. alcohol abuse, severe infection).
The most serious were reported in patients taking other medicines or who were suffering from diseases that can affect the liver (e.g. alcohol abuse, severe infection).
The most serious were reported in patients taking other drugs or who were suffering from diseases that can affect the liver (e.g. alcohol abuse, severe infection).
The reported lack of effect with ReFacto has been described as bleeding into target joints, bleeding into new joints or a subjective feeling by the patient of new onset
Agranulocytosis (uncommon) and neutropenia have been reported; therefore regular monitoring of patients taking Mycophenolate mofetil Teva is advised (see section 4.4).
The cause and long-term health effects of these conditions are not known at this time.
The cause and long-term health effects of these conditions are not known at this time.
The cause and long-term health effects of these conditions are not known at this time.
The cause and the long-term effects of these changes are not yet known.
The cause and long-term health effects of these conditions are not known at this time.
Bacterial and fungal otitis is often secondary in nature and appropriate diagnosis should be used to determine the primary factors involved.
CCR consisted of BSC alone (n = 105), low-dose cytarabine plus BSC (n = 49) or standard induction chemotherapy plus BSC (n = 25).
• the blister sealing is broken or the blister is damaged in any way • the liquid is coloured or you can see particles floating in it • any liquid has leaked out of the pre-filled syringe or condensation is visible within the sealed blister • you know or think it may have been accidentally frozen
This avoids that the DNA breaks, which would damage the cells.
The cells are only stained in part of their membrane.
cells possibly leading to tiredness, frequent infections, bleeding and fever (pancytopenia)*; lower number of lymphocytes (lymphocytopenia),
Induced heat is not observed if treatment is started before puberty.
Changes identified and agreed will be systematically implemented.
The cats were vaccinated with Nobivac Bb before being challenged by being exposed to wild-type B. bronchiseptica.
Cats are vaccinated by giving a 0.2-ml dose into one nostril.
The usual administration schedule is one single dose every other day.
The accelerated immunisation schedule should be advised.
The dosing schedule can be more flexible, please speak to your doctor for more information.
The recommended vaccination schedule for Fendrix is four doses.
The recommended vaccination schedule for Twinrix Adult is three doses, with a gap of one month between the first two doses and a gap of five months between the second and third.
The recommended vaccination schedule for Twinrix Paediatric is three doses with a gap of one month between the first two doses and a gap of five months between the second and third.
The schedule is two injections with an interval of one month followed by a third injection 6 months after the first administration (0,1,6 months).
The optimum regimen for safe administration of gemcitabine with therapeutic doses of radiation has not yet been determined in all tumour types.
This dosing regimen for paediatric patients weighing 14-30 kg is based primarily on pharmacokinetic modelling.
The recommended dosing regimen is described in the following diagram:
The recommended dosage regimen of Aldurazyme is 100 U/ kg body weight administered once every week as an intravenous infusion.
The typical activity profile following subcutaneous injection is illustrated below.
A commonly used regimen for superovulation involves the administration of 150-225 IU of GONAL-f daily, commencing on days 2 or 3 of the cycle.
The following dosing regimen should be used:
Horses developed protection two weeks after primary vaccination.
Dogs should be treated for as long as is needed.
Sick and debilitated dogs and cats should only be premedicated with dexmedetomidine before induction and maintenance of general anaesthesia based on a risk-benefit assessment.
Sick and debilitated dogs and cats should only be premedicated with dexmedetomidine before induction and maintenance of general anaesthesia based on a risk-benefit assessment.
Dogs should not be allowed to swim in ditches, ponds or streams for 4 days after treatment.
Dogs should not be bathed or shampooed from 48 hours before treatment.
Numbers in bold font are the results of primary endpoints. b Haematologic response criteria (all responses confirmed after 4 weeks):
The figures are based on how many people said they'd had them.
The figures are based on how many people said they’d had them.
3 Conditions which may make the early warning symptoms of hypoglycaemia different or less pronounced include long duration of diabetes, intensified insulin therapy, diabetic nerve disease, medicinal products such as beta blockers or after transfer from animal-source insulin to human insulin.
The Cmin, Cmax and AUC0-24 were all significantly higher with the BID regimen compared with the TID regimen.
8 hydroxocobalamin are termed free cobalamins-(III); the sum of free and protein-bound cobalamins is termed total cobalamins-(III).
Fibrin sealants/ haemostatics are metabolised in the same way as endogenous fibrin, by fibrinolysis and phagocytosis.
The inhibitor-coagulation enzyme complexes are removed by the reticulo-endothelial system.
12 in addition to the characteristic progressive hepatosplenomegaly.
5 in addition to the characteristic progressive hepatosplenomegaly.
The primary complications of overdose are anticipated to be bone marrow suppression and mucositis.
The acellular pertussis components (pertussis toxin:
The ingredients may pass into breast milk and so may harm your baby.
The ingredients may pass into breast milk and so may harm your baby.
The ingredients may pass into breast milk and so may harm your baby.
The 10 mg tablets have a special score line that enables them to be easily broken in two.
See package leaflet for further information.
The tablets contain either 2 mg buprenorphine and 0.5 mg naloxone, or 8 mg buprenorphine and 2 mg naloxone.
AMMONAPS tablets should be taken with a large volume of water.
AMMONAPS tablets should not be given to children who are not able to swallow tablets.
Avaglim tablets come in different strengths.
Cerenia tablets are available in 16 mg, 24 mg, 60 mg and 160 mg strength.
Circadin tablets should not be crushed or cut in half.
Ketek tablets are presented in blister packs.
Levviax tablets are presented in blister packs.
Therefore, the use of Cozaar Comp tablets is not recommended.
Olanzapine Teva tablets break easily, so you should handle the tablets carefully.
Probenecid tablets are given to minimise the potential for kidney damage.
Starlix tablets start to act quickly after you take them and are eliminated from the body rapidly.
Telzir tablets can be taken with or without food.
Telzir tablets can be taken with or without food.
Telzir tablets may be taken without regard to food intake.
Tracleer tablets are also indicated in digital ulcers (ulcers of the fingers) in people with a condition called scleroderma.
Vimpat tablets and oral syrup are bioequivalent.
Ibaflin tablets were at least as effective as the comparator antibiotics in treating skin, urinary tract and upper tract respiratory infections in dogs.
The tablets must be administered whole and should not be divided, broken or ground up.
The tablets must be administered as a whole and should not be divided, broken or ground.
INFORMATION FOR THE USER VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets Voriconazole
Do not break or crush tablets.
Do not chew, divide or crush the tablets.
The tablets should not be chewed, divided or crushed.
Pale orange tablet The tablets have a score line on both sides allowing the tablet to be halved.
24 The orodispersible tablets can be dispersed in a small amount of water and administered via a naso- gastric tube or oral syringe.
The orodispersible tablets, which can be used as an alternative to the tablets, are taken by being placed on the tongue, where they disintegrate quickly in the saliva, or by mixing them in water before swallowing.
The orodispersible tablets are taken by being placed on the tongue, where they disintegrate quickly in the saliva, or by mixing them in water before swallowing.
The orodispersible tablets are taken by being placed on the tongue, where they disintegrate quickly in the saliva, or by mixing them in water before swallowing.
- Immediate release film-coated tablets:
- CHAMPIX 0.5 mg film-coated tablets are white, film-coated, modified capsular shaped tablets,
- CHAMPIX 1 mg film-coated tablets are light blue film-coated, modified capsular shaped
{Invented Name} film- coated tablets can be administered without regard to timing of meals.
{Invented Name} film-coated tablets are administered orally and may be taken with or without food.
Sebivo film-coated tablets are supplied in packs of 28 or 98 tablets.
The film- coated tablets can be taken with or without food.
The film-coated tablets can be taken with or without food.
The film- coated tablets can be taken with or without food.
Viread 245 mg film-coated tablets are almond-shaped and light blue in colour.
The tablet can be divided into equal halves.
The tablet can be divided into equal halves.
The tablets can either be taken all at once, or split into two doses during the day.
The tablets may come in calendar packs.
Reconcile tablets should be administered orally with or without food.
Reconcile tablets should not be given concomitantly with veterinary medicinal products that lower the seizure threshold (e. g. phenothiazines such as acepromazine or chlorpromazine).
Reconcile tablets may be given with or without food and are flavoured so that most dogs will consume the tablet when offered by the owner.
Reconcile tablets may be given with or without food.
Reconcile tablets are used as an aid in the treatment of separation-related disorders in dogs, such as destruction and vocalisation and inappropriate defaecation and/ or urination.
The tablets are pale-orange and have a score line on both sides so that they can be halved.
The tablets are fragile and should not be pushed through the blister.
The tablets are provided in blister packs containing 2, 4, 8 or 12 tablets in a carton or card packaging.
The 50 microgram strength sublingual tablet may be used for an intermediate dose-titration step.
The analytical accounts are facilitated by the ActiTrak system that records time spent by staff of the Agency on their different responsibilities.
12/ 21 that reaches in lung are always higher than in plasma.
Encapsulated cytarabine concentrations and the counts of the lipid particles in which the cytarabine is encapsulated in DepoCyte followed a similar distribution pattern.
John's wort and the dose of efavirenz may need adjusting.
Cyclosporine A (CsA) levels markedly increase in patients on PIs, including indinavir.
John's wort, and the dose of saquinavir may need adjusting.
The concentration of sevoflurane necessary to maintain anaesthesia is much less than that required for induction.
Sirolimus concentrations should be measured upon initiation, during co-administration, and at discontinuation of posaconazole treatment, with sirolimus doses adjusted accordingly.
Sirolimus concentrations were measured in concentration-controlled trials of paediatric renal-transplant patients who were also receiving ciclosporin and corticosteroids.
Concentrations of warfarin may be affected.
Concentrations of the metabolite 14-OH-clarithromycin were not detectable.
Steady state plasma gabapentin concentrations are predictable from single-dose data.
Posaconazole plasma concentrations (Cmax and AUC) were reduced by 39% when posaconazole was administered with cimetidine (400 mg twice a day) due to reduced absorption possibly secondary to a decrease in gastric acid production.
Therefore, the plasma concentrations of the substances metabolised via cytochrome P450 may be modified.
The plasmatic concentrations of halofuginone after repeated oral administrations are comparable to the pharmacokinetic pattern after single oral treatment.
The plasma concentrations decrease with increasing weight.
The plasma concentrations of bosentan were also decreased by 29%.
In elderly hypertensive patients the plasma concentrations of losartan and its active metabolite do not differ essentially from those found in young hypertensive patients.
The peak plasma concentrations of tolcapone at this dose were on average 30 µg/ ml (compared to 3 and 6 µg/ ml with 100 mg tid and 200 mg tid of tolcapone respectively).
Due to the very low plasma concentrations achieved after inhaled dosing clinically significant drug interactions are in general unlikely.
Therapeutic plasma concentrations remain until 4 to 6 weeks after the last RISPERDAL CONSTA injection.
Whole blood trough sirolimus concentrations, as measured by LC/ MS/ MS, were significantly correlated (r2 = 0.85) with AUC , ss.
Suggested ciclosporin trough concentration ranges for the first 2-3 months after transplantation are 150 - 400 ng/ ml (monoclonal assay or equivalent technique).
Sirolimus levels should be monitored and appropriate dose reductions of both medications should be considered.
Serum levels of ritonavir may be affected by select co-administered medicinal products (eg delavirdine, efavirenz, phenytoin and rifampicin).
Betaferon serum levels were followed in patients and volunteers by means of a not completely specific bioassay.
Extavia serum levels were followed in patients and volunteers by means of a not completely specific bioassay.
The scientific conclusions are provided in Annex II, together with the Summary of Product Characteristics, labelling and package leaflet in Annex III.
(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail@emea. eu. int http: / /www. emea. eu. int EMEA 2004 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged The final opinion was converted into a Decision by the European Commission on 28 April 2004. * Notes:
Starter packs containing 21 or 42 tablets are also available for use during the first few weeks of treatment when the dose is being slowly increased.
Starter packs containing 21 or 42 tablets are available for use during the first few weeks of treatment when the dose is being slowly increased.
Starter packs containing 42 tablets are also available for use during the first few weeks of treatment when the dose is being slowly increased.
Starter packs containing 42 tablets are available for use during the first few weeks of treatment when the dose is being slowly increased.
The conditions of the Marketing Authorisation are set out in Annex IV.
Conditions of the Marketing Authorisation are set out in Annex IV.
The conditions of the Marketing Authorisation are provided in Annex IV.
The conditions of the Marketing Authorisation are listed in Annex IV.
11/ 21 conditions involve preconditioning ingredients with steam at 55-65ºC and 10% moisture.
Conferences activity at the EMEA expanded in 1997 to reach a total of 173 statutory meetings carried out over 292 days.
The long-term consequences 6 of these events are currently unknown.
The long-term consequences of these events are currently
The long term consequences of these events are currently unknown.
The long-term consequences of these events are currently unknown.
The long-term consequences of these events are currently unknown.
The long-term consequences of these reactions are currently unknown.
The clinical implications of these findings are not known.
The clinical consequence of osteoporosis is fractures.
The clinical consequences of overdosing with Luminity are not known.
The relevance of these findings for humans is not known.
It is not known whether REYATAZ administered to the mother during pregnancy will exacerbate physiological hyperbilirubinaemia and lead to kernicterus in neonates and infants.
The effect of hepatic impairment on the pharmacokinetics of buprenorphine and naloxone is unknown.
As the effect of clofarabine treatment on human fertility is unknown, reproductive planning should be discussed with patients as appropriate.
The safety of reinitiating Avastin therapy in patients previously experiencing RPLS is not known.
The regular nature of contacts with interested parties at scientific commit- tee level continued in 1996.
Such containers should be sealed and disposed of properly.
- Contra-indication in patients with hepatic impairment (i. e. cirrhosis or active liver disease);
The HZ pain severity-by-duration score was 89 (95%CI:
Scores were around 23 points at the start of the study.
- corticosteroids (such as "cortisone" used to treat inflammation),
- corticosteroids (such as "cortisone", used to treat inflammation),
- corticosteroids (such as "cortisone" used to treat inflammation),
- corticosteroids (such as "cortisone" used to treat inflammation),
Topical corticosteroids are also known to slow or delay healing.
The mother-infant pairs were randomised to receive either stavudine (N= 91), didanosine (N= 94), stavudine + didanosine (N= 88) or zidovudine (N= 89).
Coxibs therefore display analgesic, anti-inflammatory, and antipyretic properties.
Pruritus, erythema,
HAE attacks are accompanied by an increased release of bradykinin, which is the key mediator in the development of the clinical symptoms.
The clinical end points were ” Time to clinical cure” and ” overall clinical cure”.
Inclusion criterias were; women between 55 and 85 years of age with BMD T-scores below -2.5 or below -2 and at least one additional risk factor for fracture.
Fetal and maternal outcome did apparently not differ between the atosiban and the β -agonist group, but the clinical studies were not powered enough to rule out a possible difference.
6 The secondary measures of efficacy included global assessments of improvement by the examiner, Activities of Daily Living (ADL) subscale scores when OFF and UPDRS motor while ON.
It could be shown with the aid of cell cultures of human bone marrow cells that erythropoietin stimulates erythropoiesis specifically and does not affect leucopoiesis.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Waste materials should be disposed of in accordance with local requirements.
Waste material should be disposed of safely.
The following definitions apply to the frequency terminology used hereafter:
The median time to onset of rash and diarrhoea was 10 days and 15 days, respectively.
Cooperation with the major European pharmaceutical trade associations has allowed close monitoring of our performance in 2002 together with EFPIA and FEDESA, although no performance survey was
Applications for variations will be processed within the legislative time frame.
Requests may be made either in writing to the EMEA or sent to the following e-mail addresses:
The Technical Coordination Unit provides logistical support
Applications are submitted directly to the EMEA.
The Agency’s personnel database was further developed, in particular to improve the provision of management information.
This opportunity is often taken by applicants to avoid a possible negative opinion.
Itching will usually disappear within one day after the patch has been removed.
An unused half tablet should be returned to the opened blister and kept within the cardboard outer.
3 years 5/ 33 Half tablets should be returned to the original market container and may be stored for up to 7 days
Do not use after the expiry date stated on the label Half tablets should be returned to the original market container and may be stored for up to 7 days
Mean plasma half-lives were 42.9 hours (chronic renal failure), 57.4 hours (between hemodialysis) and 13.0 hours (during hemodialysis), compared with 26.2 hours in healthy volunteers.
As a result, planned expenditure has been cut in several parts of the budget.
- phenothiazine derivatives (used to treat psychiatric disorders),
- phenothiazine derivatives (used to treat psychiatric disorders),
- phenothiazine derivatives (used to treat psychiatric disorders),
- phenothiazine derivatives(used to treat psychiatric disorders),
- phenothiazine derivatives (used to treat psychiatric disorders),
Sulphone, sulphide and 5-hydroxyl derivatives of lansoprazole have been identified in plasma.
Thiazide diuretics may increase serum calcium levels due to the decreased excretion.
It is forwarded to the European Parliament, Council, Commission and Member States.
Both antibiotics were given for up to two weeks.
The other two studies showed that Kineret was more effective than placebo when used as an add-on to methotrexate.
The other two studies compared Dukoral (containing recombinant cholera toxin) with placebo in over 22,000 people in Peru.
The two ingredients work together to reduce pressure within the eye.
Both components must be mixed together before your child receives the vaccine.
Both compounds are chemically related NMDA-antagonists.
Both topical corticosteroids induced a significant reduction in skin thickness measured by echography, as compared to < Invented Name > and vehicle, which did not induce a reduction of skin thickness.
The two most commonly reported undesirable effects in clinical studies among patients with prior Botulinum Toxin Type A exposure were dry mouth and dysphagia, which were reported at a frequency of 41% and 29%, respectively.
Both studies were similarly designed.
The two formulations were bioequivalent in terms of AUC but not in terms of Cmax.
The two foreseeable impurities are referred to by the names:
The two powders are made up into a ‘ suspension'(a liquid with solid particles in it) with a putty-like consistency, which is implanted in the body.
The first two years of activities are described in the 1995 and 1996 Annual Reports of the EMEA (published by the Office for Official Publications of the European Communities, ISBN 92-827-7491-0 and 92-9155-002-7).
The two mains studies of the effectiveness of CHAMPIX in smoking cessation involved 2,052 patients (average age:
The two main metabolites are the pyridine-3-carbonic acid metabolite and a 2-hydroxymethyl- pyridine-3-carbonic acid metabolite or, depending on the pH, its lacton form.
The two main organs where Yttrium (90Y) chloride distributes are the liver and bones.
The two active substances in Advocate interact with receptors in the parasites.
Both active substances in Combivir, lamivudine and zidovudine, are nucleoside reverse transcriptase inhibitors (NRTIs).
The two active substances in Pelzont, nicotinic acid and laropiprant, have different modes of action.
The two active substances in Tredaptive, nicotinic acid and laropiprant, have different modes of action.
The two active substances in Trevaclyn, nicotinic acid and laropiprant, have different modes of action.
The releases and meeting reports for the first time Committee’s two rapporteurs for the review, Rosemary Müller and Françoise Grossetête, also visited the Agency during the year.
The two active substances work together to lower your blood pressure.
The two active substances have inverse effects on plasma potassium.
Physical, cognitive, or sexual developments in the offspring of mothers receiving methoxy polyethylene glycol-epetin beta during gestation and lactation were not affected.
Physical, cognitive, or sexual developments in the offspring of mothers receiving methoxy polyethylene glycol-epoetin beta during gestation and lactation were not affected.
The most frequent diagnoses were bloodstream infections (candidaemia) (77%, n=186) and Candida peritonitis (8%, n=19); patients with Candida endocarditis, osteomyelitis, or meningitis were excluded from this study.
Diarrhoea associated with Tasmar usually began 2 to 4 months after initiation of therapy.
Diarrhoea associated with Tasmar usually began 2 to 4 months after initiation of therapy.
Diarrhoea responds well to proactive management (see section 4.4).
Diarrhoea or vomiting with blood were uncommon..
- differences in maximum recommended daily dose.
Demographic differences between the adolescents and adults include a lower average body weight and fewer adolescents were smokers.
Demographic differences between the adolescents and adults include a lower average body weight and fewer adolescents were smokers.
The differences in TSS and JSN were not statistically significant between methotrexate and Enbrel 25 mg.
The differences in the new laboratory standard for ReFacto AF as compared to the laboratory standard for ReFacto and instructions on when to change to using the ReFacto AF laboratory standard.
2 • Additional messages regarding the transition plan for replacement of ReFacto with ReFacto AF in the Member State(s)
Treatment differences (BYETTA minus comparator) were -4.1 kg in the 26-week study and – 5.4 kg in the 52-week study.
The maximum mean (95% upper confidence bound) differences in QTcF from placebo were 3.6 (6.3) and 13.1(15.8) for 400/ 100 mg twice daily and supratherapeutic 800/ 200 mg twice daily LPV/ r, respectively.
Structural differences of the recombinant Factor IX molecule compared with plasma derived Factor IX appear to contribute to the different recovery compared to plasma derived Factor IX.
The use of various assays to detect serum antibodies and differing definitions of antibody positivity limits the ability to compare antigenicity among different products.
Differences in sustained virological response (SVR) based on treatment duration, demographics and best responses to previous treatment are displayed in Table 12.
Differences in sustained virological response (SVR) based on treatment duration, demographics and best responses to previous treatment are displayed in Table 12.
In this case the vaccines should be injected into separate limbs.
Different injectable vaccines should always be given at different injection sites.
Different injectable vaccines should always be given at different injection sites.
Difficulties in making comparisons among the different trials are recognised as they include a different population and use different endpoints.
Swallowing difficulties may persist for two to three weeks after injection, but has been reported in one case to last five months.
Consensus treatment guidelines identify ACEi as established therapy in the setting of acute myocardial infarction.
Discussions began on how best to make this model application tracking system freely available to regulatory authorities not only in the European region and throughout the world.
Rivastigmine transdermal patches were not phototoxic.
The transdermal patches are equipped with a blue imprint with the strength.
The existing business-continuity arrangements will be improved to support a range of disaster- recovery scenarios.
Loop diuretics are preferred to thiazides in this population.
Potassium-sparing diuretics (e. g. spironolactone, amiloride, and triamterene), potassium supplements, or potassium-containing salt substitutes and other substances that may increase potassium levels (e. g. heparin) can lead to hyperkalaemia in combination with ACE inhibitors, particularly in patients with renal impairment and other pre-existing conditions (see section 4.4).
Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered cautiously with CoAprovel (see section 4.5).
Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered cautiously with Irbesartan Hydrochlorothiazide BMS (see section 4.5).
Potassium-sparing diuretics, potassium supplements or potassium- containing salts substitutes should be co-administered cautiously with Irbesartan Hydrochlorothiazide Winthrop (see section 4.5).
Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered cautiously with Karvezide (see section 4.5).
amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
Potassium sparing diuretics (e. g. spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
The concomitant use of potassium sparing diuretics, potassium supplements and potassium containing salt substitutes with losartan/ hydrochlorothiazide is not recommended (see section 4.5).
The concomitant use of potassium sparing diuretics, potassium supplements and potassium containing salt substitutes with losartan is not recommended (see section 4.5).
Potassium sparing diuretics (e. g. spironolactone, triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
Thiazides pass into human milk and may inhibit lactation.
Thiazide diuretics may increase serum calcium levels due to decreased excretion.
The divergences identified at the start of the referral were resolved.
The divergences identified at the start of the referral have been resolved.
The following documents are intended to be finalised or released for consultation in 2002.
CPMP position statements/ position papers are scientific statements aimed at communicating the current state-of-the-art EU-wide scientific position on a specific topic.
Adequate pharmacovigilance and pharmacokinetic data are not available for other fibrates.
Since there are very limited data in patients with hepatitis B/ C co-infection, special caution should be exercised when treating these patients with CELSENTRI.
There are limited data in patients with severe hepatic impairment (see section 4.2).
RISPERDAL CONSTA clinical data in elderly are limited.
Clinical safety data suggest that the incidence of minor mucocutaneous haemorrhage (e. g. epistaxis) may be dose-dependent.
Sibutramine has shown potential antidepressant activity in animal studies
The chronic phase data include patients treated with any dose of SPRYCEL.
EXUBERA should not be used in patients with lung disease such as asthma and COPD, as there are ed
Limited safety data (N= 51) are available in co- infected patients with CD4+ cell counts < 200/ µl.
Limited safety data (N= 51) are available in co- infected patients with CD4+ cell counts < 200/ µl.
Limited safety data (N= 51) are available in co- infected patients with CD4+ cell counts < 200/ µl.
There are limited data from this study in patients with Child Pugh B liver impairment and only one patient with Child Pugh C had been included.
21 Only limited experience with overdose is available from clinical studies and post-marketing experience.
Only limited experience with overdose is available from clinical studies and post-marketing experience.
Data from ActiTrak (the EMEA activity and time tracking system) for the Agency as a whole and for different areas of activity in 2000 are presented in the relevant chapters of this annual report.
Of some relevance is the interim analysis data from the ongoing case-control study of the progestogen releasing contraceptive IUD (Mirena) (ICPE meeting report, 2008).
Other data sets have not confirmed this finding.
The data described below reflect exposure to SPRYCEL in 2,182 patients in clinical trials (starting dose 100 mg once daily, 140 mg once daily, 50 mg twice daily, or 70 mg twice daily).
102 Data on clinical efficacy in patients with glioblastoma multiforme (Karnofsky performance status [KPS] ≥ 70), progressive or recurrent after surgery and RT, were based on two clinical trials with oral TMZ.
Data on clinical efficacy in patients with glioblastoma multiforme (Karnofsky performance status [KPS] ≥ 70), progressive or recurrent after surgery and RT, were based on two clinical trials with oral TMZ.
Efficacy information in tibia fracture is available only from controlled clinical trials in which open tibial fractures were treated using intramedullary nail fixation (see section 5.1).
Efficacy data, both overall and by various subgroups, are presented below in Table 1.
Efficacy data are connected to several shortcomings and the amount of data available is sparse.
There are limited pharmacokinetic data in patients with severe gastrointestinal dysfunction (such as severe diarrhoea).
The data on the safety of repeated dosing are limited and based on compassionate use of the product.
Safety data were reviewed in detail by a Data Safety Monitoring Committee, which concluded that celecoxib 16 mg/ kg/ day was a safe dose to recommend for further studies in juvenile FAP patients.
The preclinical safety data satisfy the requirements of the WHO.
Post market surveillance data has signaled that the use of Osigraft in combination with a synthetic bone void filler may lead to an increase in local inflammation infection and occasional migration of the implanted materials.
The overall survival (OS) data were not mature at the time of the interim analysis.
35 human clinical trials which now provide safety data of more relevance to the patient population (see section 4.8).
Pregelatinised starch (maize) Povidone K-30 Croscarmellose sodium Magnesium stearate
The nonclinical toxicity profile of mycophenolate mofetil appears to be consistent with adverse events observed in human clinical trials which now provide safety data of more relevance to the patient population (see section 4.8).
The clinical safety data available with abacavir in hepatically impaired patients is very limited.
The safety data described below summarise all procedure and drug potentially related adverse events in the 295 patients in the 0.3 mg treatment group.
Safety and immunogenicity data are not yet available for children in other specific high-risk groups for invasive pneumococcal disease (e. g. children with another congenital or acquired splenic dysfunction, HIV-infected, malignancy, nephrotic syndrome).
Safety and immunogenicity data are not yet available for children in other specific high-risk groups for invasive pneumococcal disease (e. g. children with another congenital or acquired splenic dysfunction, HIV-infected, malignancy, nephrotic syndrome).
Safety and immunogenicity data are not yet available for children in other specific high-risk groups for invasive pneumococcal disease (e. g. children with another congenital or acquired splenic dysfunction, HIV- infected, malignancy, nephrotic syndrome).
There are limited data from clinical trials to fully assess the safety of the sequential use of other DMARDs (including TNF inhibitors and other biologics) following MabThera (see section 4.5).
Limited safety data (N= 25) are available in co-infected patients with CD4+ cell counts < 200/µl (see section 4.4).
Limited safety data (N = 25) are available in co-infected patients with CD4+ cell counts < 200/µl (see section 4.4).
Limited safety data (N = 25) are available in co-infected patients with CD4+ cell counts < 200/ µl (see section 4.4).
Safety and efficacy data are available which demonstrate that this vaccine can be administered the same day but not mixed with Merial adjuvanted vaccines (various combinations of feline viral rhinotracheitis, calicivirosis, panleukopenia and rabies components).
Safety and efficacy data are available which demonstrate that this vaccine can be administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Merial non-adjuvanted vaccine range (various combinations of feline viral rhinotracheitis, calicivirosis, panleukopenia and chlamydiosis components) and/ or administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Merial non-adjuvanted vaccine against feline leukaemia and/ or administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
Since limited data are available across all hepatic impairment groups and across all renal impairment groups, caution is advised in the use of TRISENOX in patients with hepatic and/ or renal impairment.
The data available did not allow establishing a reliable withdrawal period based on residues in kidney by either the statistical or the alternative method.
There are limited data available on overdose with RoActemra.
Information obtained from a preclinical study in rats with 125I-labelled albumin microspheres indicated that microspheres were rapidly cleared from the circulation, and radio-labelled microspheres, albumin
The data in Table 1 is based on the controlled Studies (I− IX, CLASSIC I, GAIN AND CHARM) (described in section 5.1) involving 3271 patients receiving Trudexa and 1809 patients receiving placebo or active comparator
Data from patients treated up to two years with AVONEX suggests that approximately 8% develop neutralising antibodies.
The data was similar when re-analysed to include only those patients age 55 or older.
Experimental data suggest that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites.
The data generated from these studies however, did not allow, at that stage, to establish withdrawal periods for cattle or pigs with the desired level of reliability.
Thus the data indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-mediated glucuronidation.
Initial safety data will be submitted when available (anticipated 2010), final data will be submitted when available (anticipated 2016).
The data of more than 400 patients have confirmed that over a wide range of creatinine clearance values (30-130 mL/ min) the pharmacokinetics of tolcapone are unaffected by renal function.
Data from clinical studies support intermittent treatment with < Invented Name > for up to 12 months.
Data from a third long-term study, ADAPT (The Alzheimer's Disease Anti-inflammatory Prevention Trial), did not show a significantly increased cardiovascular risk with celecoxib 200mg BID compared to placebo.
153 obtained from ongoing clinical studies on the treatment of previously untreated patients (PUPs), with BeneFIX.
Sufficient data have not been obtained from ongoing clinical studies on the treatment of previously untreated patients (PUPs), with BeneFIX.
Sufficient data have not been obtained from ongoing clinical studies on the treatment of previously untreated patients (PUPs), with BeneFIX.
Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e. g., dry eye syndrome), rheumatoid arthritis or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse reactions which may become sight threatening.
Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e. g., dry eye syndrome), rheumatoid arthritis or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse reactions which may become sight threatening.
The CHMP therefore recommended the strengthening of the contraindication in 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel.
The pharmaceutical particulars of the SPC were harmonised, except the sections, which need to be introduced nationally by the Member States when implementing the harmonised SPC (section 6).
The pharmaceutical particulars of the SPC were harmonised, except the sections, which need to be introduced nationally by the Member States when implementing the harmonised SPC (section 6).
The pharmaceutical particulars of the SPC were harmonised, except the sections, which need to be introduced nationally by the Member States when implementing the harmonised SPC (section 6).
Pharmacokinetic data from over 2,000 postmenopausal women including patients in selected osteoporosis clinical trials contributed to a population pharmacokinetic analysis.
Race had no clinically meaningful effect on the pharmacokinetics of laropiprant based on a composite analysis of pharmacokinetic data including subjects of White, Hispanic, Black, Asian, and Native American racial groups.
Race has no clinically meaningful effect on the pharmacokinetics of nicotinic acid (prolonged-release formulation) based on pharmacokinetic data including subjects of Hispanic, White, Black, and Native American racial groups.
The pharmacokinetics of single and multiple doses of simvastatin showed that no accumulation of medicinal product occurred after multiple dosing.
Prasugrel's pharmacokinetics are similar in healthy subjects, patients with stable atherosclerosis, and patients undergoing percutaneous coronary intervention.
Pharmacokinetic data indicated that no dose adjustment is necessary for elderly patients (see section 5.2).
Pharmacokinetic data indicated that no dose adjustment is necessary for elderly patients (see section 5.2).
Pharmacodynamic data suggest that at a dose of 0.2 mg/ kg Replagal, the reductions in plasma Gb3 are more or less comparable between adolescents and young children (see section 5.1).
Pharmacoepidemiological evidence and spontaneous reports suggest that in spite of restrictions and repeated provision of information on the risks associated with terfenadine, coprescription with contraindicated drugs and misuse in the form of overdose occur.
Preclinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeated dose toxicity, toxicity to reproduction or genotoxicity.
This finding is based on conventional safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenicity, and reproduction toxicity studies.
This was based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenicity, and fertility.
The data submitted by the Marketing Authorisation Holders was only for chickens and turkeys.
Post-marketing data revealed very rare cases of erythema multiforme.
The residue data provided was inadequate and the withdrawal period is therefore inadequately supported.
The residue data provided was inadequate and the withdrawal period is therefore inadequately supported.
The data resulting from this study should be provided to the relevant national competent authorities for assessment.
er Data presented from controlled studies included 1357 patients, 766 who received Nespo and 591 ng patients who received r-HuEPO.
The data submitted builds on clinical data from 221 volunteers and 41 patients.
Data to support dose titration in rheumatoid arthritis come from ATTRACT, ASPIRE and the START study.
The data suggest that beneficial effects were greater among those patients with higher levels of overexpression of HER2 (3+).
There is a suggestion in the data that responses in combination with enzyme inducers is less than in combination with non-enzyme inducing antiepileptic agents.
Beyond the reported ALT findings the following laboratory chemistry data had been measured in phase 3 studies as presented in table 3.
17 Information about the pharmacokinetics of somatropin in geriatric and paediatric populations, in different races and in patients with renal, hepatic or cardiac insufficiency is either lacking or incomplete.
Information about the pharmacokinetics of somatropin in geriatric and paediatric populations, in different races and in patients with renal, hepatic or cardiac insufficiency is either lacking or incomplete.
13 concomitant antiepileptic medicinal products once seizure control has been achieved with the addition of Inovelon.
There are insufficient data on the withdrawal of concomitant antiepileptic medicinal products once seizure control has been achieved with the addition of Inovelon.
Currently there is only limited experience in combining oral topotecan with other chemotherapy agents.
Paediatric hypertension There are limited data on the efficacy and safety of losartan in children and adolescents aged 6-16 years old for the treatment of hypertension (see 5.1:
There are insufficient data available with regard to the use of ciprofloxacin in children and adolescents.
There is only limited experience with the use of sugammadex in infants (30 days to 2 years), and term newborn infants (less than 30 days) have not been studied.
Common ≥1/100; < 1/10 Vulvovaginal mycotic infection, see also “Reproductive system and breast disorders
Doses administered should be titrated to the patient's clinical response.
13 parameters such as half-life and recovery, as well as the clinical situation into consideration in order to adjust the dose as appropriate.
35 parameters such as half-life and recovery, as well as the clinical situation into consideration in order to adjust the dose as appropriate.
Cumulative doses ranged from 20 mg up to 60 mg.
Doses of 500, 750, 1,000, and 1,250 mg/m2 (total dose per cycle over 5 days) have been evaluated clinically in patients.
Doses of 500, 750, 1,000, and 1,250 mg/m2 (total dose per cycle over 5 days) have been evaluated clinically in patients.
Each dose of Combivir should be taken approximately 12 hours apart.
Preanaesthetic doses for premedicants may be lower than the label directions for their use as a single medication.
The infusion doses need to be reduced in patients with kidney problems who are undergoing PCI.
Ritonavir doses higher than 100 mg twice daily have not been studied with darunavir.
Ritonavir doses higher than 100 mg twice daily have not been studied with darunavir.
Ritonavir doses higher than 100 mg twice daily have not been studied with fosamprenavir.
Ritonavir doses higher than 100 mg twice daily have not been studied with fosamprenavir.
The doses of Zonegran were increased gradually over six weeks before an 18-week period on a stable dose.
Doses below 1025 mg of this medicinal product contain less than 1 mmol sodium (23 mg), i.e. essentially ‘sodium free’.
These findings are not likely to be relevant for humans given recommended nasal doses which results in minimal systemic exposure.
Doses are calculated based on the patient's weight.
Doses above 1.4 mg/ kg (or in excess of 100 mg) daily have not been studied in pediatric patients.
Musculoskeletal pain is usually controlled with standard analgesics.
*Induction and Maintenance cycle lengths were 2 and 4 weeks, respectively, during which the patient received either 1 dose of DepoCyte or 4 doses of cytarabine.
Deviations from the dosage regimen indicated above are not advised (see Section 4.9 Overdose).
The breath samples, collected in 100 ml breath bags, are analysed by non-dispersive infrared spectrometry (NDIR).
The breath samples, collected in 10 ml glass- or plastic sample tubes, are analysed by isotope ratio mass spectrometry (IRMS).
The breath samples, collected in breath bags are analysed by non-dispersive infrared spectroscopy (NDIR).
The breath samples, collected in 10 l glass, plastic sample tubes are analysed by isotope ratio mass spectrometry (IRMS).
The Secretariat of the Agency is primarily responsible for providing administrative and technical support to the Management Board, scientific committees and their working parties.
The EMEA secretariat provided increasing assistance to this group; all parties concerned accepted that the procedure should be more transparent as described in the Best Practice guide.
Nevertheless there are three main goals for the EMEA Secretariat:
The Secretariat will have to assure a high standard of translations and the development of acceptable and understandable package leaflets.
The Secretariat of the Management Board is provided by staff from the Directorate.
The secretariat of the Management Board is provided by staff of the Directorate.
The Secretariat remains prepared to upgrade this service when requested by national authorities.
The sector provides support to the CPMP, its working parties and the other sectors within the Human Medicines Unit.
The sector will continue to help in setting up and operating the Agency’s quality management system, being responsible for the quality manual and internal quality system audits.
The sector will also contribute to the ongoing supervision and management of the site.
The sector is in charge of the secretariat of the Efficacy and Safety CPMP Working Parties.
The effects of desloratadine in poor metabolizers < 2 years of age have not been studied.
Long-term effects of losartan on growth, puberty and general development have not been studied.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/ day and serum creatinine ranging from 1.0-3.0 mg/ dl, the long-term effects (mean 2.6 years) of Aprovel on the progression of renal disease and all-cause mortality were examined.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/ day and serum creatinine ranging from 1.0-3.0 mg/ dl, the long-term effects (mean 2.6 years) of Aprovel on the progression of renal disease and all-cause mortality were examined.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/ day and serum creatinine ranging from 1.0-3.0 mg/ dl, the long-term effects (mean 2.6 years) of Irbesartan BMS on the progression of renal disease and all-cause mortality were examined.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/ day and serum creatinine ranging from 1.0-3.0 mg/ dl, the long-term effects (mean 2.6 years) of Irbesartan BMS on the progression of renal disease and all-cause mortality were examined.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/ day and serum creatinine ranging from 1.0-3.0 mg/ dl, the long-term effects (mean 2.6 years) of Irbesartan Winthrop on the progression of renal disease and all-cause mortality were examined.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/ day and serum creatinine ranging from 1.0-3.0 mg/ dl, the long-term effects (mean 2.6 years) of Irbesartan Winthrop on the progression of renal disease and all-cause mortality were examined.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/ day and serum creatinine ranging from 1.0-3.0 mg/ dl, the long-term effects (mean 2.6 years) of Karvea on the progression of renal disease and all-cause mortality were examined.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/ day and serum creatinine ranging from 1.0-3.0 mg/ dl, the long-term effects (mean 2.6 years) of Karvea on the progression of renal disease and all-cause mortality were examined.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/ day and serum creatinine ranging
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/ day and serum creatinine ranging from 1.0-3.0 mg/ dl, the long-term effects (mean 2.6 years) of irbesartan on the progression of renal
There are no data on long term effects on growth and development and on sexual maturation.
There are no data on long term effects on growth and development and lon on sexual maturation.
The biological effects of somatropin are equivalent to those of human growth hormone of pituitary origin.
Cardiovascular effects seen in animals (dogs) at exposure levels similar (0.25 mmol/ kg) and higher (1.25 mmol/ kg), respectively, to maximum clinical exposure levels were a dose dependent transient increase in blood pressure (5% and 10%, above saline control) and myocardial contractility (5% and 16%, above saline control).
The cognitive effects of ziconotide are typically reversible within 1 - 4 weeks after discontinuation of the medicinal product, but may persist in some cases.
The skin effects of burning, stinging, tingling, rash and erythema were reported at higher levels in Vaniqa treated patients compared to vehicle, as indicated by the asterisk (*).
The effects of Aerius syrup in poor metabolisers < 2 years of age have not been studied.
The effects of Aerius syrup in poor metabolizers < 2 years of age have not been studied.
The effects of Azomyr syrup in poor metabolisers < 2 years of age have not been studied.
The effects of Azomyr syrup in poor metabolizers < 2 years of age have not been studied.
No studies on the effects on the ability to drive and use machines have been performed.
The effects of repeat dosing of ambrisentan (10 mg) on the pharmacokinetics of single dose digoxin were studied in 15 healthy volunteers.
No data exist on the effects of injectable calcitonin on the ability to drive and use machines.
tho No data exist on the effects of injectable calcitonin on the ability to drive and use machines.
No data exist on the effects of intranasal calcitonin on the ability to drive and use machines.
The effects of concomitant administration of erlotinib with H2 antagonists and antacids are unknown; however, reduced bioavailability is likely.
The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.
The effects of stopping smoking The effects of changes in your body resulting from stopping smoking, with or without treatment with CHAMPIX, may alter the way other drugs work.
The effect of hepatic impairment on the absorption of inhaled human insulin has not been studied (see section 4.2).
The effect of renal impairment on the absorption of inhaled human insulin has not been studied (see section 4.2).
The effect of hepatic impairment on the absorption of inhaled human insulin has not been studied (see section 4.2).
The effects of Neoclarityn syrup in poor metabolisers < 2 years of age have not been studied.
The effects of Neoclarityn syrup in poor metabolizers < 2 years of age have not been studied.
Warfarin The effects of Rasilez on warfarin pharmacokinetics have not been evaluated.
The effects of this medicine in pregnant women are not known.
No studies on the effects of EXJADE on the ability to drive and use machines have been performed.
The effect of renal or hepatic impairment on the pharmacokinetics of efalizumab has not been studied.
The effects of overdose of lansoprazole in humans are not known (although the acute toxicity is likely to be low) and, consequently, instructions for treatment cannot be given.
Most notably the effects of the quality management system and an industry standard IT architecture will start to benefit the organisation.
The effect of tolcapone on the pharmacokinetics of other drugs metabolised by COMT such as α -methyldopa, dobutamine, apomorphine, adrenaline and isoprenaline have not been evaluated.
The effects were more pronounced in female rats.
Common effects include pain, burning, irritation or redness.
Common effects include: pins and needles, small swollen areas in the skin, pain, burning, irritation, bleeding, redness or rash.
Musculoskeletal pain is usually controlled with standard analgesics.
128 Cardiovascular (CVS) adverse events, particularly arrhythmia, appeared to be correlated mostly with pre-existing CVS disease and prior therapy with cardiotoxic agents (see section 4.4).
The side effects caused by Emselex are usually mild and temporary.
The above side effects may require medical intervention and some may be life-threatening or fatal.
The following additional adverse reactions have been reported during post– marketing experience; they are derived from spontaneous reports for which incidences cannot be determined:
Adverse drug reactions (ADRs) reported in more than 10% of patients treated with Neupro transdermal patch are nausea, dizziness, somnolence and application site reactions.
The side effects described below have been experienced by patients given VIRAMUNE:
80 Side effects of unknown frequency may include:
Side effects of unknown frequency may include:
The most frequent adverse reactions reported for loratadine in excess of placebo were somnolence, headache, increased appetite and insomnia.
The side effects at the higher dose can often be severe and affect your liver.
These were reported during the Phase 3 clinical development programme, which included a total of 1,030 chronic angina patients treated with Ranexa.
Events noted as having Unknown frequency were identified via post-marketing surveillance.
Adverse drug reactions (ADRs) reported in more than 10% of patients treated with Neupro are nausea, application site reactions, fatigue and headache.
There were fewer reactions after the second dose of the vaccine compared with the first dose.
Any side effects that occur may be more severe.
Common side effects may include:
Common side effects (occurring in at least 1 in 100 patients) are:
The rare side-effects (reported in at least 1 in 10,000 patients) are: • Lung infection • Skin reaction to another agent following radiation • Blood clot
The most frequent reported or observed serious adverse drug reactions were: • Infusion-related reactions (including cytokine-release syndrome, tumour-lysis syndrome), see section 4.4. • Infections, see section 4.4. • Cardiovascular events, see section 4.4.
The most frequently reported serious related adverse events included nausea, vomiting, diarrhoea, pyrexia, and increased bilirubin.
The most common side effects with Infanrix Penta (seen in more than 1 in 10 doses of the vaccine) are loss of appetite, fever of 38ºC or more, local swelling, pain and redness at the injection site, fatigue (tiredness), abnormal crying, irritability and restlessness.
The most common side effects with Tritanrix HepB (seen in more than 1 in 10 doses of the vaccine) are drowsiness, feeding problems, fever, redness, swelling, pain, unusual crying and irritability.
The most commonly reported adverse drug reactions occurring in ≥ 10% of patients are headache and flushing.
The commonly reported side effects include: headache; nausea; pain, burning, bruising or numbness where the injection was given.
The most common side effect in patients receiving Paxene on its own is bone marrow suppression, which results in severe neutropenia (low white blood cells count), thrombocytopenia (low platelets count), and anaemia (low red blood cells count).
5 Adverse reactions more commonly associated with DepoCyte are headache, arachnoiditis and confusion.
The most common side effects seen with Gliolan are due to a combination of the medicine itself, as well as anaesthesia and the removal of the tumour.
The most commonly reported adverse reactions are headache and dyspepsia.
The most commonly reported adverse reactions were headache and dyspepsia.
The most frequent reported adverse drug reactions are amnesia, paraesthesia, somnolence and dysmenorrhea.
The most frequent adverse reactions reported in excess of placebo were somnolence, headache, increased appetite and insomnia.
The most frequent (≥ 2%) of those were diarrhoea (3.9%), hypertriglyceridaemia (3.8%), rash (2.8%), nausea (2.6%), hypercholesterolaemia (2.5%) and headache (2.0%).
The more common side effects of ADARTREL can happen when some patients first start their therapy and/ or when the dose is increased.
The most common adverse reactions were diarrhoea, rash, alopecia and hand-foot syndrome (corresponds to palmar plantar erythrodysaesthesia syndrome in MedDRA).
The most frequently observed adverse reactions which occurred significantly more frequently in the lenalidomide/dexamethasone group compared to the placebo/dexamethasone group were neutropenia (39.4%), fatigue (27.2%), asthenia (17.6%), constipation (23.5%), muscle cramp (20.1%), thrombocytopenia (18.4%), anaemia (17.0%), diarrhoea (14.2%) and rash (10.2%).
The most common side effects of < Invented Name > are reactions (e.g. discomfort) at the application site.
The most common undesirable effects were dysgeusia, feeling hot, headache and dizziness.
The most common undesirable effects were a strange taste in the mouth, feeling hot, headache and dizziness.
The most commonly reported adverse reactions in patients treated with ORACEA, ie those which occurred with ≥ 3% frequency on ORACEA and with a frequency at least 1% higher than on placebo, were nasopharyngitis, diarrhoea and hypertension.
The most notable adverse reactions associated with efavirenz are rash and nervous system symptoms.
The most notable adverse reactions associated with efavirenz are rash and nervous system symptoms (see section 4.4).
The most notableadverse reactions associated with efavirenz are rash and nervous system symptoms (see section 4.4).
The most notable adverse reactions that have been reported in clinical studies with efavirenz are rash and nervous system symptoms.
The most serious adverse reactions include anaemia (which may require transfusions), neutropenia and leucopenia.
The most commonly reported adverse drug reactions (ADRs) are nausea and diarrhoea.
The most commonly reported adverse drug reactions (ADRs) are nausea and diarrhoea.
The most commonly reported adverse drug reactions (ADRs) are nausea, diarrhoea, vomiting, transient increase in transaminases, rash, and injection and infusion site reactions.
Side-effects listed have a rate equal or greater than placebo, and the discontinuation rate due to side effects was 7.1% in patients receiving celecoxib and 6.1% in patients receiving placebo.
The following adverse drug reactions (ADRs) have been reported during the treatment with lisinopril and amlodipine independently:
The reported adverse events following the use of OPTISON in Phase III human clinical studies have been mild to moderate with subsequent full recovery.
The undesirable effects observed during treatment with elcatonin are similar to dose reported after administration of salmon calcitonin Frequency estimates:
Side effects observed with Fendrix were generally comparable to those seen in pre-haemodialysis and haemodialysis patients.
An increase in plasma volume accompanied by decrease in red cell parameters and increase in heart weight.
Adverse events observed in patients after a sixth or greater dose were similar in character and frequency to those after the initial 5 doses.
Side effects seen in clinical trials with Efient include:
Side effects reported in clinical studies for patients treated with Rasilez HCT were:
Adverse reactions are alos included that have been reported from postmarketing surveillance in patients taking CIALIS on demand.
Adverse reactions are also included that have been reported from postmarketing surveillance in patients taking CIALIS on demand.
Adverse reactions are also included that have been reported from postmarketing surveillance in patients taking tadalafil on demand.
The observed undesirable effects were generally of a mild severity.
The adverse drug reactions that occurred more frequently on bosentan than on placebo (≥ 3% of bosentan-treated patients, with ≥ 2% difference) were headache (15.8% vs 12.8%), flushing (6.6% vs 1.7%), abnormal hepatic function (5.9% vs 2.1%), leg oedema (4.7% vs 1.4%), and anaemia (3.4% vs 1.0%), all of which were dose related.
The adverse reactions were similar in all indications, with two exceptions.
The side effects only rarely resulted into having to stop taking VIRACEPT.
Uncommon side effects (affecting between 1 in 100 and 1 in 1000 patients) of RILUTEK are:
Uncommon side effects (affects 1 to 10 users in 1000) are: • Increased risk of blood clots in the legs (deep vein thrombosis) • Increased risk of blood clots in the lungs (pulmonary embolism) • Increased risk of blood clots in the eyes (retinal vein thrombosis) • Skin around the vein is red and painful (superficial vein thrombophlebitis)
Uncommon side effects may include:
Uncommon side effects (likely to occur in 1 to 10 patients in 1000) include: vomiting,, skin rash, bleeding at the back of the eye, eye irritation, bloodshot eyes / red eyes, eye pain, double vision, abnormal sensation in the eye, irregular or rapid heartbeat, muscle pain, feeling sleepy, reduced sense of touch, vertigo, ringing in the ears, nausea, dry mouth, chest pain and feeling tired.
Uncommon side effects are experienced in less than 1 in 100 patients but in at least 1 per 1,000 patients.
Uncommon side effects that may occur (in between 1 in 100 people and 1 in 1000 people) are:
Side effects thought to be caused by Zeffix are listed below:
The main adverse events reported are haematological disorders (anaemia, neutropenia), metabolic disorders (hyperlactataemia, hyperlipasaemia).
The main adverse events reported are haematological disorders (anaemia, neutropenia), metabolic disorders (hyperlactatemia, hyperlipasemia).
Adverse drug reactions that led to Doribax discontinuation were nausea (0.1%), diarrhoea (0.1%), pruritus (0.1%), vulvomycotic infection (0.1%), hepatic enzyme increased (0.2%) and rash (0.2%).
Adverse events following such surgery and not specifically associated with the product may include wound infection, osteomyelitis (infection of the bone), complications of mechanical support (such as the metal rod or plate used for stabilisation), bleeding at the wound site, failure of the wound to heal, nausea, fever and pain.
Side effects reported in clinical studies for patients treated with Aprovel were:
Side effects reported in clinical studies for patients treated with Irbesartan BMS were:
Side effects reported in clinical studies for patients treated with Karvea were:
Adverse drug reactions (ADRs) reported in the prophylactic paediatric studies were similar in the placebo and palivizumab groups.
Adverse reactions reported with the use of irbesartan alone include:
Those reported in at least 10% of patients with a hypersensitivity reaction are in bold text.
Side effects reported in clinical studies for patients treated with CoAprovel were:
Side effects reported in clinical studies for patients treated with Karvezide were:
Adverse reactions are listed according to the following frequency.
Rare side effects These may affect up to 1 in 1,000 people: • fluid in the lungs (pulmonary oedema) causing breathlessness • heart failure • swelling of the retina at the back of the eye (macular oedema) • liver doesn’t function as well as it should (increase in liver enzymes).
49 Rare side effects (affecting less than 1 in 1000 people) include:
56 Rare side effects (affecting less than 1 in 1000 people) include:
Rare side effects include: numbness or tingling sensations, involuntary muscle contractions or transient thrombocytopenia (a low platelet count in the blood which can result in bleeding or bruising).
Constipation, flatulence, nausea, abdominal pain, and diarrhoea.
Side effects with Dukoral are not common.
Side effects with Kinzalmono are not common.
The following undesirable effects cover adverse reactions from post-marketing experience: the types of adverse reactions reported during post-marketing with mycophenolate are similar to those seen in the controlled renal, cardiac and hepatic transplant studies.
Adverse reactions of unknown frequency reported with the use of telmisartan alone include:
Adverse reactions of unknown frequency reported with the use of telmisartan alone include:
23 Adverse reactions of unknown frequency reported with the use of hydrochlorothiazide alone include:
35 Adverse reactions of unknown frequency reported with the use of hydrochlorothiazide alone include:
37 Adverse reactions of unknown frequency reported with the use of hydrochlorothiazide alone include:
Adverse reactions of unknown frequency reported with the use of hydrochlorothiazide alone include:
Adverse reactions of unknown frequency reported with the use of hydrochlorothiazide alone include:
The following additional adverse reactions were seen:
The following side effects have been observed commonly:
The following side effects have been reported in patients taking Cholestagel:
The following side effects were reported in clinical studies with the use of RotaTeq:
The following adverse reactions listed below were observed in clinical studies or with post marketing experience.
The following side effects have been reported after taking medicines containing oestrogen/progestagens.
The following adverse reactions have been reported during clinical studies and/ or post-marketing use with alendronate.
The following side effects have been reported in patients taking Renagel:
Patients treated with REYATAZ have reported the following side effects:
The following adverse reactions have been reported during post-marketing experience:
The following adverse reactions have been reported during post-marketing experience: a
The following adverse events were reported more commonly in paediatric Crohn's disease patients in the REACH study (see section 5.1) than in adult Crohn's disease patients: anaemia (10.7%), blood in stool (9.7%), leukopenia (8.7%), flushing (8.7%), viral infection (7.8%), neutropenia (6.8%), bone fracture (6.8%), bacterial infection (5.8%), and respiratory tract allergic reaction (5.8%).
The following side effects can be seen after the use of Gardasil:
The following side effects can be seen after the use of Silgard:
Pancytopenia, Bone marrow depression, Anaphylactic shock, Psychotic reactions, Migraine, Olfactory nerve disorders, Hearing impaired, Vasculitis, Pancreatitis, Liver necrosis, Petechiae, Tendon rupture
The following side effects are rare (occur in less than 1 in 1000 patients):
• Post marketing experience The following additional undesirable effects have been reported following the widespread use of HEXAVAC.
The following additional adverse reactions have been reported during post– marketing experience; they are derived from spontaneous reports and therefore, the frequency of these adverse reactions is not known:
The following additional adverse reactions have been reported during post– marketing experience; they are derived from spontaneous reports and therefore, the frequency of these adverse reactions is not known:
Adverse events occurring with a frequency of ≥ 2% in patients in either group during the first 3 months post-transplant are listed below. t uc
Side effects that occurred during a clinical trial with Fendrix in pre-haemodialysis and haemodialysis patients were as follows:
Adverse reactions reported in a clinical trial following primary vaccination with Fendrix and considered as being at least possibly related to vaccination have been categorised by frequency.
39 Side effects that occurred during clinical trials with Tritanrix HepB were as follows:
Side effects reported in clinical studies for patients treated with irbesartan were:
The most commonly reported events are headache and rhinorrhoea.
Clinical experience with epoetins M
Clinical experience with epoetins suggest hypertension and thrombosis risk may be reduced by titrating the dose to maintain M
common are hypertension, access related thrombosis and headache.
The most common are hypertension, access related thrombosis and headache.
Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.
Effects in non-clinical studies were generally observed at exposures in excess of the maximum human exposure.
The observed reactions were inappetence, emesis, diarrhoea and anal irritation.
The observed reactions were inappetence, emesis, diarrhoea, and anal irritation.
The pharmacodynamic effects of bivalirudin may be assessed using measures of anticoagulation including the ACT.
The following pharmacological effects have been observed in vitro:
The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolised via CYP3A4 (alprazolam, triazolam) should be considered when co- administering these agents with EMEND (125 mg/ 80 mg).
The effects of overdose that might be expected include delayed hypercalcemia, nausea, vomiting, dizziness and headache.
Potential rebound effects following cessation of treatment with AZOPT have not been studied; the IOP-lowering effect is expected to last for 5-7 days.
Expected respiratory events are bradypnoea, intermittent respiratory patterns, hypoventilation, and apnoea.
Infrequent adverse reactions include paddling, retching, salivation, cyanosis, premature ventricular contractions and excessive cardiopulmonary depression.
Most frequent side effects affect the stomach and intestine, the nervous system and the skin and connective tissue.
Following side effects are rare (affect less than 1 in 1000 people).
Sensory symptoms have usually improved or resolved within months of paclitaxel discontinuation.
These are the side effects reported by people taking Seretide.
These are the side effects reported by people taking Viani.
The following effects have been reported in clinical studies with Thyrogen:
The following are all ADRs that were reported in INVEGA-treated subjects in clinical trials.
No studies on the effects on the ability to drive and use machines have been performed.
uth No studies on the effects on the ability to drive and use machines have been performed.
Whether this affected respiration during the night is unknown.
Teratogenic effects included exencephaly or encephalocele, absent/ reduced frontal and absent parietal bones.
The clinical effects of Botulinum neurotoxin type A can increase or decrease by repeated injections.
This was done in order to increase the consistency of the operation of the centralised procedure both from a procedural and a scientific viewpoint.
The most frequent ADRs in these patient populations were nausea and vomiting.
ADRs are added to the appropriate category in the tables according to the pooled analysis from clinical trials.
The following are all the ADRs that were reported in clinical trials and postmarketing.
10 increases gastric counts of bacteria normally present in the gastrointestinal tract.
Asymptomatic elevations of GGT levels are the most frequent.
Pack sizes are 24 (1 x 24), 100 (2 x 50) and 180 (1 x 180) tablets.
Emollients can be applied together with < Invented Name > (see Section 4.2 “Posology and method of administration”).
- Mineral oil may be used between Panretin applications in order to help prevent excessive
Mineral oil may be used between Panretin gel applications in order to help prevent excessive dryness or itching.
Children under 18 years of age must not take Zerene.
26 during the two-week lead-in dosing period, until the rash resolves.
Treatment should not be used in paediatric patients with a growth velocity less than 1 cm per year and near closure of epiphyses.
- Children and growing adolescents except for the treatment of acute pulmonary exacerbations of
Children should not have contact with the product or with animals during treatment.
Children should not have contact with the product or with animals during treatment.
Children were followed until 3.5 years of age.
In post-marketing experience with Ferriprox, neurological disorders (such as tremors, walking disorders, double vision, involuntary muscle contractions, problems with movement coordination) have been reported in children who had been voluntarily prescribed more than double the maximum recommended dose of 100 mg/ kg/ day for several years.
The records of Vidaza's designations as an orphan medicine are available here (myelodysplastic syndromes) and here (AML).
The records of Zavesca's designation as an orphan medicine are available here (type 1 Gaucher disease) and here (Niemann-Pick type C disease).
The P450 enzymes tested for inhibition were:
The full EPARs for the reference medicines can also be found on the EMEA's website.
The 4-oxo and 4-hydroxymetabolite epimeric pair are the major metabolites with
The 4-oxo and 4-hydroxymetabolite epimeric pair are the major metabolites with antiviral activity, but comprise only minute amounts of total plasma radioactivity.
PPE infrequently resulted in permanent treatment discontinuation (3.7% - 7.0%).
Trained hospital staff will ensure the correct storage of NeoSpect.
Skin rashes (2 - 31%) are mainly described in patients with other concomitant medications known to cause rash (antibiotics and/ or allopurinol).
The skin rashes led to the withdrawal of lamotrigine treatment in 2% of patients.
Rashes are usually mild to moderate, maculopapular erythematous cutaneous eruptions, with or without pruritus, located on the trunk, face and extremities.
Skin rash and skin reddening will usually disappear within one day after the patch has been removed.
The service has a number of projects in 2002, including Develop and implement a business continuity plan Acquisition and refurbishment of the 6th floor at the EMEA offices, together with associated works elsewhere in the EMEA offices Develop an archive database for files stored offsite from the EMEA Installation of a digital photocopying network Installation of digital closed-circuit television
The Joint Interpreting and Conference Service of the European Commission is the largest in the world with some 500 staff interpreters and over 1 600 freelance interpreters.
The subscription service offers a second language version of documents free of charge where they are available.
The help desk became fully operational in May 1997 and is accessible via phone, fax, e-mail and through a Web-based form.
The Support service is also responsible for the physical and accounting control of the Agency’s inventory of equipment.
The red blood cells most likely represent a secondary compartment of distribution.
The most frequent species isolated at baseline were C. albicans (63.8% anidulafungin, 59.3% fluconazole), followed by C. glabrata (15.7%, 25.4%), C. parapsilosis (10.2%, 13.6%) and C. tropicalis (11.8%, 9.3%) - with 20, 13 and 15 isolates of the last 3 species, respectively, in the anidulafungin group.
Phase III clinical trials (CAP-001 studies) include data from 742 women who were diagnosed with pre-term labour at 23– 33 weeks of gestation and were randomised to receive either atosiban (according to this labelling) or β -agonist (dose-titrated).
Patients with a creatinine clearance of ≤ 30 ml/ min were not investigated in the clinical trials.
Clinical studies have demonstrated that adult patients receiving r-HuEPO one, two or three times weekly may be converted to once weekly or once every other week Aranesp.
Clinical studies have demonstrated that adult patients receiving r-HuEPO one, two or three times weekly may be converted to once weekly or once every other week Nespo.
Conjugated oestrogens are excreted with the bile, where they are hydrolysed and reabsorbed (enterohepatic circulation), and mainly in urine in biologically inactive form.
The dose titration steps and target dose are based on the result of the AIRE study.
Procedural steps for any post-marketing situations will have to be incorporated into the software (follow-up measures/specific obligations, variations, extensions, pharmacovigilance).
The Reference Member States were Germany, Hungary, Norway, Poland, Slovakia, Spain, United Kingdom.
The Reference Member State were Estonia, Latvia, Lithuania, Netherlands, Spain, United Kingdom.
The Member States must ensure that the Marketing Authorisation Holder will provide healthcare professionals with educational materials for healthcare professionals and patients.
The Member States shall ensure that the following key elements are included in the appropriate material:
The Member States must ensure that the education plans for physicians, health care providers, and patients contain the measures a) to m) as detailed below, and are suitable for the purpose of minimising adverse events associated with the intravitreal injection procedure (e. g. endophthalmitis) prior to marketing.
The Member States must ensure that all conditions with regard to the safe and effective use of the medicinal products described below are implemented:
The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented:
The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented.
The Member States who raised concerns regarding the potential risk to animal health were Belgium, Denmark, France, Germany, Ireland, Italy, Portugal and Spain.
The intravenous infusion set provided in the kit must then be used as it includes an appropriate filter 10 and is to be primed with the reconstituted solution.
The intravenous infusion set provided in the kit must then be used as it includes an appropriate filter and is to be primed with the reconstituted solution.
The bar-code labels marked “30-minute-value” must be used for these samples.
The studies looked at the 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The studies in pigs were carried out either in pigs already affected by the disease or in pigs who had been in contact with diseased animals on the same farm and, therefore, likely to develop the disease as well.
Clinical studies with < Invented Name > did not include a sufficient number of patients in this age range to determine whether they respond differently from younger patients.
Clinical trials in patients with type 1 and type 2 diabetes have demonstrated reduced postprandial hyperglycaemia with Liprolog Mix25 compared to human insulin mixture 30/ 70.
In clinical studies there was no age-related difference in the efficacy or safety profiles of alendronate.
In clinical trials there was no age-related difference with regard to efficacy or safety profiles of alendronate.
Clinical trials confirmed the safety and efficacy of 300 mg atazanavir once daily with ritonavir 100 mg once daily in treatment experienced patients.
Clinical studies have demonstrated the wide margin of safety for gamithromycin injection in cattle.
The clinical studies have been conducted in a patient population with a mean age > 65 years.
Clinical studies demonstrated that the immune responses and the safety profiles of the administered vaccines were unaffected.
ed in treatment, occurs in approximately 20% of well-controlled patients.
The pivotal clinical studies did not include children below 3 years old.
Preclinical absorption studies through full-thickness wounds were conducted in rats with a wound area of 1.4 - 1.6 cm².
Carcinogenicity studies have not been performed.
Carcinogenicity studies did not reveal special hazards for humans.
Carcinogenicity studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel due to the development of neutralising antibodies in rodents.
Cystometric studies performed with darifenacin in patients with involuntary bladder contractions showed increased bladder capacity, increased volume threshold for unstable contractions and diminished frequency of unstable detrusor contractions.
Classic kinetic and distribution studies cannot be conducted with Botulinum neurotoxin type A because the active substance is applied in such small quantities (picograms per injection), and because it binds so rapidly and irreversibly to cholinergic nerve terminals.
In laboratory studies, maropitant has been shown to be a potential eye irritant.
In vitro metabolism studies suggest that methylnaltrexone does not inhibit the activity of CYP1A2, CYP2E1, CYP2B6, CYP2A6, CYP2C9, CYP2C19 or CYP3A4, while it is a weak inhibitor of the metabolism of a model CYP2D6 substrate.
Safety pharmacology studies did not reveal any adverse effects on central nervous, respiratory or cardiovascular function.
Safety pharmacology studies have shown that Carbaglu administered orally at doses of 250, 500, 1000 mg/ kg had no statistically significant effect on respiration, central nervous system and cardiovascular system.
It is estimated that, on average, increasing the oral dose from 200 mg twice daily to 300 mg twice daily leads to a 2.5-fold increase in exposure (AUCτ).
Studies in the rat on fertility and general reproductive performance and on pre- and postnatal development were uneventful except for a minor reduction in the survival of pups nursed by mothers exhibiting toxic responses to stiripentol at a dose of 800 mg/ kg/ day (See, section, 4.6).
Long-term follow up studies of children with therapy resistant epilepsy have generally demonstrated adequate control of partial epilepsies with or without secondary generalization.
11 Single-dose and repeated-dose toxicity and local tolerance studies revealed no special hazards to humans.
23 Single-dose and repeated-dose toxicity and local tolerance studies revealed no special hazards to humans.
Single-dose and repeated-dose toxicity and local tolerance studies revealed no special hazards to humans.
Toxicokinetic studies showed no interaction of the antibodies with the measured concentrations.
Safety margins from the toxicology studies are small due to the dose-limiting hypocalcaemia observed in the animal models.
In teraction studies have only been performed in adults.
Interaction studies have only been performed in adults.
Interaction studies were conducted with 10 mg and/ or 20 mg tadalafil, as indicated below.
Interaction studies have only been performed in adults.
Interaction studies have only been performed in adults.
Interaction studies have only been performed in adults.
Interaction studies have only been performed in adults.
Interaction studies have only been performed in adults.
Drug-drug interaction studies have established that CYP3A4 inhibitors increase ivabradine plasma concentrations, while inducers decrease them.
Interaction studies have only been performed in adults
Interaction studies have only been performed in adults.
Interaction studies have only been performed in adults.
Interaction studies were performed with oral RISPERDAL.
Interactions studies have only been performed in adults.
Interaction studies have only been performed in adults.
Studies with vigabatrin revealed no evidence of mutagenic or carcinogenic effects.
Electrophysiology studies in vitro and neurochemical studies in vivo have shown that varenicline binds to the α 4β 2 neuronal nicotinic acetylcholine receptors and stimulates receptor-mediated activity, but at a significantly lower level than nicotine.
Therefore the combination product of terfenadine-pseudoephedrine has an unacceptable risk/ benefit balance.
The studies were still ongoing at the time of the medicine's assessment and are scheduled to last for up to five years.
The studies were still ongoing at the time of the medicine's assessment.
In vitro and in vivo studies with etravirine revealed no evidence of a mutagenic potential.
In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2(COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
In vitro studies indicate that lenalidomide has no inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A.
In vitro investigations have shown that interactions are unlikely with medications that are metabolised by cytochrome P450 or glucuronised or conjugated in some other way.
Nateglinide has shown a low potential for protein displacement in in vitro studies.
Nateglinide has shown a low potential for protein displacement in in vitro studies.
In vivo studies in dogs demonstrated the anti-emetic efficacy of maropitant against central and peripheral emetics including apomorphine, cisplatin and syrup of ipecac.
The studies supporting its use in other cancers involved over 1,300 patients (metastatic breast cancer:
They underwent a TESLASCAN-enhanced MRI scan.
The studies were still ongoing at the time of the medicine's assessment.
The studies showed that IntronA is effective in the diseases for which it can be used.
Studies demonstrated that its effects are mediated by a mechanism that is different from that of ciclosporin, tacrolimus, and other immunosuppressive agents.
The studies demonstrated that Vaxxitek HVT+IBD is effective in the active immunisation of chickens and chicks in the egg against Infectious Bursal disease.
The studies measured how many patients had a ‘ complete response’, which was defined as no vomiting and no need for any other medication to control nausea and vomiting in the 24 hours after the operation.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The studies lasted between six and 52 weeks and the main measure of effectiveness was the change in blood pressure during either the resting phase of the heartbeat (diastolic) or when the chambers of the heart are contracting (systolic).
The studies lasted for between eight weeks and a year, and the main measure of effectiveness was the change in blood pressure either during the resting phase of the heartbeat (diastolic) or when the chambers of the heart were contracting (systolic).
Studies have established the pathway of active tubular secretion of tenofovir to be influx into proximal tubule cell by the human organic anion transporters (hOAT) 1 and 3 and efflux into the urine by the multidrug resistant protein 4 (MRP 4).
The studies examined how long it took for atrial fibrillation or flutter to return.
The studies either recruited patients who were being treated with chemotherapy (two studies) or used patient populations in which erythropoiesis stimulating agents are not indicated: anaemia in patients with cancer not receiving chemotherapy, and head and neck cancer patients receiving radiotherapy.
The studies measured how many patients developed DVT (deep vein thrombosis: formation of a clot in the vessels of the leg) up to 30 days after treatment.
The studies measured how long it would take before the disease would progress.
The studies demonstrated that the 50 mg dose did not have a relevant benefit and the 300 mg dose did not show better efficacy than the 100 mg dose.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The trials showed that vaccination of pigs with Porcilis PCV helps to reduce the amount of virus in the animal's blood and lymphoid tissues and to reduce weight loss associated with PCV2 infection occurring during the fattening period.
The studies showed that pigs treated with Aivlosin lost less weight during the infection and showed less severe signs of disease than untreated animals.
The studies showed that Levemir controls HbA1c in a similar manner to insulin NPH, with less risk of low blood glucose level during the night and no associated weight gain.
The studies demonstrated that Equilis StrepE is effective in the active immunisation of horses from 4 months of age against Streptococcus equi to reduce clinical signs and occurrence of lymph node abscesses.
The studies looked at the kidney function, the survival and the growth rate of the patients.
The studies involved over 10,000 infants, about three quarters of whom received Infanrix Penta, given according to various time schedules.
The studies either recruited patients who were being treated with chemotherapy (two studies) or used patient populations in which erythropoiesis stimulating agents are not indicated: anaemia in patients with cancer not receiving chemotherapy, and head and neck cancer patients receiving radiotherapy.
Studies examining administration of Cholestagel as a single dose with breakfast, a single dose with dinner, or as divided doses with breakfast and dinner did not show significant differences in LDL-C reduction for different dosing schedules.
The shorter studies in kidney and liver transplant patients showed that Advagraf and Prograf/ Prograft have comparable absorption in the body.
The maintenance studies showed that long-term treatment with Rapamune was effective in helping the new kidney to survive, with an improvement in how well the new kidney worked and an improvement in blood pressure when ciclosporin treatment was stopped.
Preclinical studies have shown that venlafaxine and its major metabolite, O-desmethylvenlafaxine (ODV), are inhibitors of serotonin and noradrenaline reuptake.
The main studies showed that Nobivac Bb was effective in reducing the symptoms caused by B. bronchiseptica.
Studies in animals have indicated that cetrorelix exerts a dose related influence on fertility, reproductive performance and pregnancy.
Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/ 9 and 3A4.
Based on in vitro studies, saquinavir is rapidly metabolised to a range of mono- and di-hydroxylated inactive compounds.
The studies examined death, amputations, and new thromboembolic (clotting) complications.
The studies in women with severe LH/ FSH deficiency and in men with hypogonadotrophic hypogonadism had low numbers of patients but were acceptable because these are rare conditions.
Toxicological animal studies reveal no special hazards for humans regarding safety pharmacology, genotoxicity, carcinogenicity and studies with repeated dosing.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The only adverse reaction reported in this trial was one case of mild sunburn occurring in a patient treated with the highest dose.
The only pharmacodynamic effect was a small (3.5 bpm) increase in heart rate.
The only plasma-radiolabelled metabolite detected was A771726.
Patient evaluations continued for 16 weeks post injection.
Baseline assessments, including TWSTRS and VAS pain evaluation by patient and investigator, were repeated at 4, 8 and 12 weeks after treatment.
Cardiovascular events can be life-threatening or cause death.
Pre-specified events that occurred with the highest incidence in all three treatment groups involved the category of surgical wound complications, including deep surgical infections and sternal wound healing events.
Common events have a frequency of more than 1 in 100.
The haemorrhagic events that have been observed in clinical studies were predominantly tumour- associated haemorrhage (see below) and minor mucocutaneous haemorrhage (e. g. epistaxis).
21 The dose dependent adverse events of hydrochlorothiazide (particularly electrolyte disturbances) may increase when titrating the hydrochlorothiazide.
37 The dose dependent adverse events of hydrochlorothiazide (particularly electrolyte disturbances) may increase when titrating the hydrochlorothiazide.
51 The dose dependent adverse events of hydrochlorothiazide (particularly electrolyte disturbances) may increase when titrating the hydrochlorothiazide.
9 The dose dependent adverse events of hydrochlorothiazide (particularly electrolyte disturbances) may increase when titrating the hydrochlorothiazide.
The side effects were generally similar to those observed in adults.
Gastrointestinal and hepatic adverse events were observed significantly more frequently with diclofenac than etoricoxib.
Serious adverse events related to the injection procedure included endophthalmitis, rhegmatogenous retinal detachment, retinal tear and iatrogenic traumatic cataract (see section 4.4).
The most commonly reported adverse events were nausea, vomiting, headache and pruritus.
9 (medicine-related treatment-emergent) adverse events in combination therapy (Caelyx + bortezomib) were nausea (40%), diarrhoea (35%), neutropaenia (33%), thrombocytopaenia (29%), vomiting (28%), fatigue (27%), and constipation (22%).
The most common adverse reactions in pivotal study PA.3 in pancreatic cancer patients receiving Tarceva 100 mg plus gemcitabine were fatigue, rash and diarrhoea.
The most frequent adverse events were peripheral oedema (31%), headache (19%), abnormal liver function (13%), muscle cramps (13%), fluid retention (13%) and vomiting (13%).
The most common adverse events were application site reactions which were reported by approximately 19% of the patients treated with < Invented Name > and 16% of patients in the control groups.
83 The most common side effects are:
The most frequently observed side effects are:
In view of these conclusions the CHMP considered that guidance with regards to the discontinuation of paroxetine (down titration), as well as a warning and a description of the withdrawal symptoms seen on discontinuation of paroxetine should be included in the respective sections of the SPC and suitable pharmaceutical forms/ strengths need to be available in order to facilitate titration.
18 The most commonly reported ADRs (investigator assessment) are liver function abnormalities (3.5%), diarrhoea (2.7%), headache (1.8%), nausea (1.7%), rash (1.5%).
The most commonly reported ADRs (investigator assessment) are liver function abnormalities (3.5%), diarrhoea (2.7%), headache (1.8%), nausea (1.7%), rash (1.5%).
Adverse reactions to OPTISON are rare and usually of a non-serious nature.
Serious ocular Adverse Events reported in Macugen treated patients included endophthalmitis (12 cases, 1%), retinal haemorrhage (3 cases, < 1%), vitreous haemorrhage (2 cases, < 1%) and retinal detachment (4 cases, < 1%).
Adverse events were similar to those seen at lower doses.
Adverse events (regardless of relationship to medicinal product) reported with the use of hydrochlorothiazide alone include:
Severe adverse events reported included varicella with signs and symptoms of aseptic meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis, depression/ personality disorder, cutaneous ulcer, oesophagitis/ gastritis, group A streptococcal septic shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.
Severe adverse events reported included varicella with signs and symptoms of aseptic meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis, depression/ personality disorder, cutaneous ulcer, oesophagitis/ gastritis, group A streptococcal septic shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.
The following adverse reactions have been observed in patients who received Tarceva administered as single agent and patients who received Tarceva concurrently with chemotherapy.
The following adverse events have been reported during post-marketing surveillance.
The above events were not cumulative, were typically reversible and generally did not result in treatment discontinuation.
The above events were not cumulative, were typically reversible and generally did not result in treatment discontinuation.
The reported events were mostly transient, of mild to moderate intensity and led to very few discontinuations (< 1%).
The following events were reported during post-marketing experience of palivizumab:
The following events have been reported in post-marketing experience:
The following events have been mentioned: insomnia, headache, nausea, diarrhoea, flu syndrome, nervousness, depression, pain, sweating and dizziness.
The following events have been: insomnia, headache, nausea, diarrhoea, flu syndrome, nervousness, depression, pain, sweating and dizziness.
The following events have been mentioned: insomnia, headache, nausea, diarrhoea, flu syndrome, nervousness, depression, pain, sweating and dizziness.
The following events have been mentioned: insomnia, headache, nausea, diarrhoea, flu syndrome, nervousness, depression, pain, sweating, and dizziness.
The following events have been reported spontaneously during postmarketing experience:
Sevoflurane is compatible with phenothiazines and alpha-2-agonists commonly used in veterinary practice.
Sevoflurane may be used for maintenance anaesthesia following mask induction with sevoflurane or following induction with injectable agents.
Smoking cessation with or without treatment is associated with various symptoms.
Smoking cessation itself may result in changes to warfarin pharmacokinetics (see section 4.4).
MRI evaluations for T1-weighted gadolinium (Gd)-enhancing lesions and T2-hyperintense lesions were performed annually.
Specific ophthalmoscopic examinations in clinical studies with memantine did not disclose any ocular changes.
Conditions which need supervision If any of the following conditions are present, have occurred previously, and/or have been aggravated during pregnancy or previous hormone treatment, the patient should be closely supervised.
The excipients used in the formulations of the drug product and manufacturing processes are standard for the proposed pharmaceutical forms.
The excipients used in the formulations of the drug product and manufacturing processes are standard for the proposed pharmaceutical forms.
Gender, weight and ethnicity have no clinically relevant influence on aliskiren pharmacokinetics.
Gender has no clinically meaningful effect on pharmacokinetics of nicotinic acid (prolonged-release formulation).
8 Gender: gender does not affect the pharmacokinetics of palonosetron.
Clinical requirements for combined vaccines and gene therapy/ DNA vaccines were shared with the Biotechnology Working Party.
The budget and resource demands for 2002 were put together early in 2001 for submission to the EU institutions.
- requirements for combined veterinary vaccines
Preclinical requirements for Osteoporosis were discussed with the Safety Working Party.
Since clinical experience in elderly is limited, caution should be exercised .”
In vitro and ex vivo experiments showed a protein binding of approximately 40 - 42% independent of the concentration of the drug.
Systemic exposures (daily AUC and Cmax) in plasma from the twice daily regimen appeared equivalent to those from the same total daily dose given in three divided doses [Bergshoeff, 2004].
The maternal systemic exposures after 500 and 2000 mg/ kg/ day were twenty five times and seventy times the expected human exposure.
Defined as HCV-RNA below limit of detection using a research based RT-PCR assay at end of treatment and during follow-up period
The response to treatment in both of these trials is presented in Table 4.
Factors increasing the susceptibility to hypoglycaemia require particularly close monitoring and may necessitate dose adjustment.
Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of Zometa and other bisphosphonates as well as use of other nephrotoxic drugs.
The following factors were pre-specified in the statistical analysis plan for inclusion in the model: age, time from surgery to randomization, gender, CEA levels at baseline, lymph nodes at baseline, and country.
Women with the highest baseline cholesterol levels had the greatest decreases.
Pregnant staff should not handle Paxene.
Pregnant women should avoid contact with the medicinal product.
Pregnant women should take special care to avoid self- injection.
- Pregnant staff should be excluded from working with this medicine
Pregnant women should not administer the product.
Pregnant staff must be excluded from working with this medicinal product.
Pregnant women should not take INTELENCE unless specifically directed by the doctor.
Pregnant and breast-feeding women should not have any contact with the product and should also avoid operating rooms and animal recovery areas where the product is being, or has recently been, used.
(see section 4.4 Special Warnings and Special Precautions for use)
Women (N=1,113) were vaccinated in study 001 and evaluated for efficacy up to month 27.
Women should not use Vaniqa whilst breast-feeding.
9 For women on long-term therapy with hepatic enzyme inducers, another method of contraception should be considered.
Breastfeeding mothers may use < Invented Name > but should not apply < Invented Name > to the breast in order to avoid unintentional oral uptake by the newborn.
Dietary fibres and some dairy products, in particular, delay the absorption of zinc salts.
Short fibre optic diffusers (< 2.5 cm) are to be used to pretreat nodules with 50 J/ cm diffuser length prior to regular balloon treatment in the first laser light session or for the retreatment of "skip" areas after the first light session.
Diagrams A and B show you all the different parts of the pen and the injection needle.
Filters may occasionally clog up during the infusion.
Vials containing VASOVIST are not intended for the withdrawal of multiple doses.
The vials of Fuzeon and water for injections should only be used once.
The vials of Fuzeon are intended for single use only.
The suspension and emulsion vials once mixed form a multidose container.
TESLASCAN vials should be visually inspected for particulate matter and for the integrity of the container prior to use.
HYCAMTIN 4 mg vials must be reconstituted with 4 ml water for injections.
2-8°C (refrigerator): vials thaw within 1 day, or 20-25°C (room temperature): vials thaw within 1 hour, or 37ºC (e. g. water bath, using aseptic technique, or by warming vials in the hand): vials should be thawed within 10 minutes and must not be left at this temperature for longer than 10 minutes or until fully thawed.
2-8°C (refrigerator): vials thaw within 1 day, or 20-25°C (room temperature): vials thaw within 1 hour, or 37ºC (e.g. water bath, using aseptic technique, or by warming vials in the hand): vials should be thawed within 10 minutes and must not be left at this temperature for longer than 10 minutes or until fully thawed.
Vials should be allowed to warm to room temperature (18°C -22°C) for a minimum of 30 minutes and be gently inverted to resuspend the particles immediately prior to withdrawal from the vial.
The vials should be gently swirled and not shaken.
Vials should be visually inspected prior to use.
Vials in use should be stored below 30°C.
17 The closed vials are equipped with a tamper-evident snap-off cap which is made of polypropylene.
26 The closed vials are equipped with a tamper-evident snap-off cap which is made of polypropylene.
8 The closed vials are equipped with a tamper-evident snap-off cap which is made of polypropylene.
The closed vials are equipped with a tamper-evident snap-off cap which is made of polypropylene.
The NovoSeven package contains Type I glass vials closed with a chlorobutyl rubber stopper, covered with an aluminium cap. The closed vials are equipped with a tamper-evident snap-off cap which is made of polypropylene.
1 x 10 ml This is part of a multipack and not for sale of individual vials
5 x (1 x 10 ml) This is a multipack and not for sale of individual vials
Suspension for injection 5 x (1 x 10 ml) This is a multipack and not for sale of individual vials
Suspension for injection 1 x 10 ml This is part of a multipack and not for sale of individual vials
Vials are intended for single use only.
The bottles are equipped with child resistant caps.
There are arrows to show the next tablet to be taken according to your treatment schedule.
The arrows mean you are ready for the next step.
Fluctuations are when the effects of the medicines wear off and symptoms re-emerge.
Fluctuations happen when the effects of the medication wear off and symptoms re-emerge.
Fluctuations happen when the effects of the medication wear off and symptoms re-emerge.
Renal and hepatic function should be monitored in this patient population during deferiprone therapy.
Severe hypothyroidism has to be treated prior to start of NutropinAq therapy. • Since somatropin therapy following renal transplantation has not been adequately tested, growth hormone treatment should be terminated after that surgery. • Adrenocorticotrophic Hormone (ACTH) -deficient patients should consult the doctor regularly during growth hormone therapy.
Abacavir, lamivudine and zidovudine triphosphates show significantly less affinity for host cell DNA polymerases.
Abacavir and lamivudine triphosphates show significantly less affinity for host cell DNA polymerases.
Gastroresistant formulations containing substances sensitive for degradation in the stomach, such as proton pump inhibitors, should be taken at least 1 hour before or more than 4 hours after BYETTA injection.
The following oral and intravenous formulations are currently approved and marketed in different EU countries:
Solid dosage forms of the tetracyclines may cause oesophageal irritation and ulceration.
Broken bones can happen during normal, everyday activity, such as lifting, or from minor injury that would not generally break normal bone.
Broken bones can happen during normal, everyday activity, such as lifting, or from minor injury that would not generally break normal bone.
Broken bones usually occur at the hip, spine, or wrist and can lead not only to pain but also to considerable problems like stooped posture (‘ dowager's hump’) and loss of mobility.
Broken bones usually occur at the hip, spine, or wrist and can lead not only to pain but also to considerable problems like stooped posture (‘ dowager's hump’) and loss of mobility.
The patients'heart rates were measured when they were resting.
Frequencies of adverse drug reactions from clinical trials that are considered related to Actraphane are listed below.
Frequencies of adverse drug reactions from clinical trials that are considered related to Actraphane are listed below.
Frequencies of adverse drug reactions from clinical trials that are considered related to Actraphane are listed below.
Frequencies of adverse drug reactions from clinical trials that are considered related to Actrapid, are listed below.
Frequencies of adverse drug reactions from clinical trials that are considered related to Actrapid, are listed below.
Frequencies of adverse drug reactions from clinical trials that are considered related to Insulatard are listed below.
Frequencies of adverse drug reactions from clinical trials that are considered related to Insulatard are listed below.
Frequencies of adverse drug reactions from clinical trials, which by an overall judgement are considered related to insulin aspart are listed below.
Frequencies of adverse drug reactions from clinical trials that are considered related to Mixtard are listed below.
Frequencies of adverse drug reactions from clinical trials that are considered related to Mixtard are listed below.
Frequencies of adverse drug reactions from clinical trials that are considered related to Protaphane are listed below.
Frequencies of adverse drug reactions from clinical trials that are considered related to Protaphane are listed below.
Frequencies of adverse drug reactions from clinical trials, which by an overall judgement are considered related to Levemir are listed below.
Frequencies given are based on the observations during the pivotal clinical study or two supporting clinical studies.
The reported frequencies for these events as well as the rates of discontinuation due to any adverse reactions were similar in patients receiving CELSENTRI 300 mg twice daily + OBT (Optimised Background Therapy) compared to those receiving OBT alone.
Smokers must have stopped smoking for at least 6 month before they can take Exubera.
Future layers and breeders should not be vaccinated before 3 weeks of age.
Arterial sheaths may be removed when coagulation has returned to normal (e. g., when activated clotting time [ACT] is less than 180 seconds (usually 2-6 hours after discontinuation of heparin).
Emend capsules should be swallowed whole, with or without food.
Prometax 3.0 mg hard capsules, which contain an off-white to slightly yellow powder, have an orange cap and orange body, with a red imprint “ ENA 713 3 mg” on the body.
Prometax 4.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and red body, with a white imprint “ ENA 713 4,5 mg” on the body.
Prometax 6.0 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and orange body, with a red imprint “ ENA 713 6 mg” on the body.
Prometax capsules have also been studied in 541 patients with dementia due to Parkinson's disease.
Sonata 10 mg hard capsules, which contain an intensely dark blue powder, have a white cap, with pink imprint “ W”, and white body, with pink imprint “ 10 mg”.
Thalidomide Celgene are white hard capsules marked “Thalidomide 50 mg Celgene”.
Exelon 3.0 mg hard capsules, which contain an off-white to slightly yellow powder, have an orange cap and orange body, with a red imprint “ EXELON 3 mg ” on the body.
Exelon 4.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and red body, with a white imprint “ EXELON 4,5 mg ” on the body.
Exelon 6.0 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and orange body, with a red imprint “ EXELON 6 mg ” on the body.
Zerene 10 mg hard capsules, which contain an intensely dark blue powder, have a white cap, with pink imprint “ W”, and white body, with pink imprint “ 10 mg”.
- Zonegran 25 mg hard capsules have a white opaque body and a white opaque cap and are
Hycamtin 1 mg capsules are pink and imprinted with ‘ Hycamtin'and ‘ 1 mg’.
HYCAMTIN capsules should not be broken or crushed.
Hycamtin capsules must not be opened or crushed.
Capsules should be taken immediately following removal from the blister.
The capsules may be opened and their contents mixed in a small amount of water or formula diet just before swallowing.
There has been no experience with the effects of lansoprazole overdose in humans.
The capsules are semi– translucent white and coded CRIXIVAN™ 100 mg in green.
The capsules are semi-translucent white and coded CRIXIVAN TM 100 mg in green.
The capsules are semi– translucent white and coded CRIXIVAN™ 200 mg in blue.
The capsules are semi-translucent white and coded CRIXIVANTM 200 mg in blue.
The capsules are semi– translucent white and coded CRIXIVAN™ 400 mg in green.
The capsules are semi-translucent white and coded CRIXIVANTM 400 mg in green.
The capsules are provided in carton packs.
The capsules are opaque pink and imprinted with ‘ HYCAMTIN'and ‘ 1 mg’.
HIV genomes that fail to integrate cannot direct the production of new infectious viral particles, so inhibiting integration prevents propagation of the viral infection.
White blood cells are uc
Sex hormone-binding globulins (SHBG) are increased and result in elevated levels of total circulating endogenous sex steroids.
Fasting plasma glucose levels were significantly lower in patients treated with EXUBERA regimens
Fasting plasma glucose levels were significantly lower in patients treated with EXUBERA regimens compared with those treated with subcutaneous insulin.
Any swelling or local reaction resolves naturally.
AMMONAPS granules contain 124 mg (5.4 mmol) of sodium per gram of sodium phenylbutyrate, corresponding to 2.5 g (108 mmol) of sodium per 20 g of sodium phenylbutyrate, which is the maximum daily dose.
AMMONAPS granules can be removed from the refrigerator for one single period of maximum 3 months and stored at a temperature not above 25°C, after which the product must be discarded.
The granules should be dissolved in a glass of water and mixed with the vaccine.
The effervescent granules, supplied in a sachet, are white.
The actual groups of pigs studied were all showing clinical signs.
The CPMP working parties (Pharmacovigilance Working Party, Biotechnology Working Party, Efficacy Working Party and Safety Working Party), as well as the joint CPMP/ CVMP Quality Working Party continued to meet in 1997 at regular intervals.
issues including biological threats, and transparency and communication expectations of citizens and interested parties
There were 59% males and 41% females; 89.9% caucasian and 4.7% black patients.
Haemophiliacs may bleed more In patients with haemophilia type A and B, there have been reports of increased bleeding while taking protease inhibitors.
Haemophiliacs may bleed more In patients with haemophilia type A and B, there have been reports of increased bleeding while taking protease inhibitors.
Males who are taking ribavirin should not have unprotected sex.
- thyroid hormones (used to treat the thyroid gland disorders),
thyroid hormones (used to treat the thyroid gland disorders), protease inhibitors (used to treat HIV),
- thyroid hormones (used to treat thyroid gland disorders),
Sildenafil (100 mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates.
Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by acetyl salicylic acid (150 mg).
Sildenafil (50 mg) did not potentiate the hypotensive effects of alcohol in healthy volunteers with mean maximum blood alcohol levels of 80 mg/ dl.
Sildenafil has no effect on visual acuity or contrast sensitivity.
Sildenafil is a potent and selective inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5), the enzyme that is responsible for degradation of cGMP.
Therefore sildenafil should be administered to these patients only after careful benefit-risk assessment.
Abnormal images are either asymmetric or symmetric with unequal intensity and/ or loss of crescent.
Normal images are characterised by two symmetrical crescent-shaped areas of equal intensity.
This is possibly because antibodies against these infections are also present in immunoglobulins.
Immunoglobulins are normal constituents of the human body.
Immunoglobulins are a normal constituent of the human body.
Immunosuppressants may affect response to vaccination.
Immunosuppressants like STELARA decrease the activity of the immune system.
The metal cages fix the position of the vertebrae, and InductOs encourages bone to grow between the two vertebrae to join them permanently in the correct position.
The clinical relevance of these findings is unknown.
Exposures of ambrisentan as measured by AUC(0-inf) and Cmax were increased by 35% and 20%, respectively.
The corresponding incidences in patients receiving the recommended regimen of enoxaparin in the treatment of DVT were 2.3% (13/ 559), 4.6% (17/ 368), 9.7% (14/ 145) and 11.1% (2/ 18) respectively, and in patients receiving the recommended regimen of unfractionated heparin in the treatment of PE were 6.9% (36/ 523), 3.1% (11/ 352), 11.1% (18/ 162) and 10.7% (3/ 28), respectively.
e regimen in the treatment of DVT or PE with normal renal function, mild renal impairment, moderate renal impairment and severe renal impairment were 3.0% (34/ 1132), 4.4% (32/ 733), 6.6% (21/ 318),
26 corresponding incidences in patients receiving the recommended regimen of enoxaparin in the treatment of DVT were 2.5%, 3.6% and 8.3% respectively, while the incidences in patients receiving the recommended regimen of UFH in the treatment of PE were 5.5%, 6.6% and 7.4%, respectively.
The corresponding incidences in patients receiving the recommended regimen of enoxaparin in the
The corresponding incidences in patients receiving the recommended regimen of enoxaparin in the treatment of DVT were 2.5%, 3.6% and 8.3% respectively, while the incidences in patients receiving
36 corresponding incidences in patients receiving the recommended regimen of enoxaparin in the treatment of DVT were 2.5%, 3.6% and 8.3% respectively, while the incidences in patients receiving the recommended regimen of UFH in the treatment of PE were 5.5%, 6.6% and 7.4%, respectively.
46 corresponding incidences in patients receiving the recommended regimen of enoxaparin in the treatment of DVT were 2.5%, 3.6% and 8.3% respectively, while the incidences in patients receiving the recommended regimen of UFH in the treatment of PE were 5.5%, 6.6% and 7.4%, respectively.
The corresponding incidences in patients receiving the recommended regimen of enoxaparin in the treatment of DVT were 2.3% (13/ 559), 4.6% (17/ 368), 9.7% (14/ 145) and 11.1% (2/ 18) respectively, and in patients receiving the recommended regimen of unfractionated heparin in the treatment of PE were 6.9% (36/ 523), 3.1% (11/ 352), 11.1% (18/ 162) and 10.7% (3/ 28), respectively.
The corresponding incidences in patients receiving the recommended
The corresponding incidences in patients receiving the recommended regimen of enoxaparin in the treatment of DVT were 2.3% (13/ 559), 4.6% (17/ 368), 9.7% (14/ 145) and 11.1% (2/ 18) respectively, and in patients receiving the recommended regimen of unfractionated heparin in the treatment of PE were 6.9% (36/ 523), 3.1% (11/ 352), 11.1% (18/ 162) and 10.7% (3/ 28), respectively.
The corresponding incidences in patients receiving the recommended
The incidences of acute rejection were numerically lower with tacrolimus in all three studies and one of the studies reported a significantly lower incidence of bronchiolitis obliterans syndrome with tacrolimus.
The effects on the incidence of MI and RI were not statistically different between the fondaparinux and enoxaparin treatment groups.
Placebo rates in PROWESS 0.4% vs 1.2% respectively).
The following indications must be deleted from this section:
The following indications are currently approved for Gemzar and were assessed by the CHMP:
The Pearl Indices for the oral contraceptives were 0.57 (monophasic) and 1.28 (triphasic).
John's wort, rifampicin) might therefore decrease the bioavailability of Riprazo.
John's wort, rifampicin) might therefore decrease the bioavailability of Sprimeo.
CYP3A4 inducers seemed to have a substantial impact on the pharmacokinetics of sildenafil in pulmonary arterial hypertension patients, which was confirmed in the in-vivo interaction study with CYP3A4 inducer bosentan.
Ear infections in dogs can be caused by bacteria or fungi.
- Serious infections, including salmonella infections, TB, and non-tuberculous mycobacterial
- Serious infections including salmonella, TB, and non-tuberculous mycobacterial infections-
Serious infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia, cholecystitis, osteomyelitis, gastritis, appendicitis, Streptococcal fasciitis, myositis, septic shock, diverticulitis and abscess.
Reported serious infections included pneumonia, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis and bacterial arthritis.
The most commonly reported infections were upper respiratory tract infection and pharyngitis, and the most commonly reported serious infection was abscess.
Infections that may be treated include impetigo (which causes crusting scabs on infected areas), cuts, grazes and stitched wounds.
The infections observed consisted primarily of bacterial events such as cellulitis, pneumonia, and bone and joint infections.
Serious infections reported in at least one patient treated with abatacept (0.05% of patients) included the following: pneumonia; bronchitis; cellulitis; acute pyelonephritis; urinary tract infection; diverticulitis, intestinal abscess; localised infection; skin abscess; musculoskeletal infections; sepsis; empyema; hepatitis E; and tuberculosis (see section 4.4).
Three 1 mg unit dose blisters should not be substituted for one 3mg blister (see n section 2, “Take special care with EXUBER A”, section 3, “How to take EXUBERA” and section 6 “Further information”). lo
Since clinical information is limited regarding the combination of warfarin and tolcapone, coagulation parameters should be monitored when these drugs are co-administered.
The healthcare professional information regarding Volibris should contain the following key elements:
The information in this section is based on binding affinity between sugammadex and other medicinal products, non-clinical experiments and simulations using a model taking into account the pharmacodynamic effect of neuromuscular blocking agents and the pharmacokinetic interaction between neuromuscular blocking agents and sugammadex.
Information in this leaflet is organised under the following 7 sections:
The physician information about Exjade should contain the following key elements:
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
Insufficient information is available regarding the use of ramipril during breast-feeding and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
The data available on stavudine excretion into human breast milk are insufficient to assess the risk to the infant.
Information and recommendations regarding taking measures before prescribing moxifloxacin are adequately addressed in the ‘ contraindications'and ‘ warnings-precaution of use'sections of the SPC and PL.
The information supplied by the company shows the utility of Yttriga as a precursor to radiolabel medicines with 90Y.
The data presented did not show a definite association with lymphoma or any malignancy.
Information on the prescription status of this product may be found on the label/ outer package.
The following drug interaction information is based on Geometric Mean values; the effect for an individual patient cannot be predicted precisely.
--------------------------------------------------------------------------------------------------------------------------- -- The following information is intended for medical or healthcare professionals only:
THE FOLLOWING INFORMATION IS INTENDED FOR MEDICAL OR HEALTHCARE PROFESSIONALS ONLY
Singlet oxygen causes damage to biological structures within the diffusion range, leading to local vascular occlusion, cell damage and, under certain conditions, cell death.
Inhibitors of ABCB1 and ABCG2 administered with oral topotecan have been shown to increase topotecan exposure.
CYP3A4 inhibitors include ketoconazole, itraconazole, erythromycin, clarithromycin, troleandomycin and cyclosporin.
The DPP-4 inhibitors are a class of agents that act as incretin enhancers.
The DPP-4 inhibitors are a class of agents that act as incretin enhancers.
Inhibitors of the P- glycoprotein (e. g. ciclosporin) can increase the bioavailability of atorvastatin.
Inhibitors of P-gp may decrease the efflux of sirolimus from intestinal cells and increase sirolimus levels.
Reversible and irreversible MAO inhibitor(s) may cause: risk of vasoconstriction and increased blood pressure.
• MAO-inhibitors (used to treat depression).
- monoamine axydase (MAO) inhibitors (used to treat depression),
Monoamine oxidase inhibitors, anti-malarial, and anti-trypanosomal active substances may alter the metabolism of Ceplene and should be avoided (see section 4.4).
HMG-CoA reductase inhibitors which are highly dependent on CYP3A4 metabolism, such as lovastatin and simvastatin, are expected to have markedly increased plasma concentrations when co-administered with VIRACEPT.
HMG-CoA reductase inhibitors which are highly dependent on CYP3A4 metabolism, such as lovastatin and simvastatin, are expected to have markedly increased plasma concentrations when co-administered with VIRACEPT.
HMG-CoA reductase inhibitors which are highly dependent on CYP3A4 for metabolism, such as lovastatin and simvastatin, are expected to have markedly increased plasma concentrations when co-administered with Telzir with ritonavir.
Co-administration with ciclosporin A, a potent OATP inhibitor, resulted in a 6-fold increase in Cmin and a 67% increase in AUC of sitaxentan therefore the use of Thelin in patients receiving systemic ciclosporin A is contraindicated (see section 4.3).
Factor VIII inhibitors are antibodies in the blood which block the factor VIII you are using.
Factor VIII inhibitors are antibodies in the blood which block the factor VIII you are using.
Factor VIII inhibitors are antibodies in the blood which block the factor VIII you are using.
Factor VIII inhibitors are antibodies in the blood which block the factor VIII you are using.
The injections of epoetin beta will increase the amount of blood that can be taken from your body before surgery and given back during or after the operation (this is an autologous transfusion).
If convenient, the front of your waist (abdomen), your buttocks or the front of your upper arms may be used. no
The thigh, the gluteal region or the deltoid region may also be used.
If convenient it may also be given in the abdominal wall (tummy), the buttocks or the deltoid region (shoulder).
If convenient it may also be given in the abdominal wall (tummy), the gluteal region (buttocks) or the deltoid region (shoulder).
If convenient it may also be given in the gluteal region (bottom) or the deltoid region (shoulder).
If convenient it may also be given in the gluteal region (buttocks) or the deltoid region (shoulder).
The injections should be preferably administered on the alternate sides of the neck.
The injections should be preferably administered on the alternate sides of the neck.
The injections are administered subcutaneously in the deltoid region of the arm or the thigh.
The injections are administered subcutaneously in the deltoid region of the arm or the thigh.
In some cases, however, your doctor may decide to use another dose or another frequency of dosing.
The injections are administered subcutaneously in the deltoid region of the arm.
Additional injections, when indicated, should be conservative in such patients.
Subsequent injections of Ceplene may be self-administered at home by a patient who demonstrates a good understanding of necessary precautions and who has demonstrated adequate injection skills.
database for GMP was made available through EudraNet to a number of Member States in April 2002.
The COMP held two workshops with interested parties in 2002.
The instructions for reconstitution must be followed carefully.
Detailed instruction accompanying NovoMix 50 FlexPen must be followed.
Detailed instructions for preparation and administration are contained in the user package leaflet provided with BeneFIX.
The instructions for use of this device should be strictly followed.
58 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using SoloStar.
Before using SoloStar, the Instructions for Use included in the Package Leaflet must be read carefully.
Before using SoloStar, the Instructions for Use included in the Package Leaflet must be read carefully.
The Instructions for Use included in the Package Leaflet must be read carefully before using SoloStar.
Before using SoloStar, the Instructions for Use included in the Package Leaflet must be read carefully (see section 6.6).
151 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
152 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
209 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
210 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
266 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
268 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
Before using OptiSet, the Instructions for Use included in the Package Leaflet must be read carefully.
Before using OptiSet, the Instructions for Use included in the Package Leaflet must be read carefully
Before using OptiSet, the Instructions for Use included in the Package Leaflet must be read carefully.
Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
Before using OptiSet, the Instructions for Use included in the Package Leaflet must be read carefully (see section 6.6)
Before using OptiSet, the Instructions for Use included in the Package Leaflet must be read carefully (see section 6.6).
ra Instruction for self-administration is mentioned in the Package Leaflet.
ra Instruction for self-administration is mentioned in the Package Leaflet.
Instructions for the preparation of Revasc are provided in section 6.6.
The instructions for using OptiClik, the insulin pen, are provided with your OptiClik.
The instructions for using OptiClik, the insulin pen, are provided with your OptiClik.
The instructions for using OptiClik, the insulin pen, are provided with your OptiClik.
The instructions for using OptiClik, the insulin pen, are provided with your OptiClik.
The instructions for using the pen must be followed carefully.
11 The instructions for using the pen, included with the leaflet, must be followed carefully.
22 The instructions for using the pen, included with the leaflet, must be followed carefully.
The instructions for use and handling are given in section 6.6.
Anaemia symptoms and sequelae may vary with age, gender, and overall burden of disease; a a
The instructions for use, handling and disposal are given in section 6.6.
Instructions for use are included in the pack.
The separate instructions for using the pen must be followed carefully.
Specific instructions regarding the proper monitoring of ReFacto AF.
The following instructions explain how to inject PegIntron yourself.
Instruments must be linear over a wide range of CO2 concentrations typically 1.0 - 6.0%.
Taking Replagal with food and drink Interactions with food or drink are unlikely.
No interaction studies have been performed.
The pharmacokinetic interaction of Pelzont with statins has been studied only with simvastatin (see section 4.4).
The pharmacokinetic interaction of Trevaclyn with statins has been studied only with simvastatin (see section 4.4).
A potential interaction between vaccination and application of Protopy ointment has not been lp
Because of the potential risk of vaccination failure, vaccination should be administered no
Potential interactions between < Invented Name > and other medicinal products have not been systematically evaluated.
Amenorrhea, breast pain, dysmenorrhea, menorrhagia, menstrual disorder, vaginal disorder
 9 Interferons may affect the oxidative metabolic process.
Interferons may affect the oxidative metabolic process.
Interferons are natural substances produced by the body to help it fight against attacks such as infections caused by viruses.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
• damage to kidney tubule cells
• damage to kidney tubule cells
• blister-like lesions on the skin (pustular rashes).
Injury, poisoning and procedural complications
hyperintense lesion volume
37 conditions Injury, poisoning and procedural complications
Injury, poisoning and procedural complications a
Injury, poisoning, and procedural complications Common:
Injury, poisoning, and procedural complications Common: contusion
Injury, poisoning and procedural complications
Injury, poisoning and procedural complications common:
Injury, poisoning and procedural complications Common:
Haematocrit decreased Laboratory test abnormal Injury, poisoning and Post procedural procedural complications complication
- Injury, poisoning and procedural complications
- Injury, poisoning and procedural complications
Injury, poisoning and procedural complications +
Injury, poisoning and procedural complications †
Injury, poisoning and procedural complications:
Injury, poisoning and procedural complications
Injury, poisoning and procedural complications Common
Injury, poisoning and procedural complications Uncommon:
Injury, poisoning, and procedural complications Uncommon
Injury, poisoning and procedural complications Radiation recall
Injury, poisoning and procedural complications Very rare:
Injury, poisoning and procedural complications * see section 4.4
Sirolimus is also a substrate for the multidrug efflux pump, P-glycoprotein (P-gp) located in the small intestine.
Sirolimus is also a substrate for the multidrug efflux pump, P-glycoprotein (P-gp) located in the small intestine.
Sirolimus is extensively metabolised by the CYP3A4 isozyme in the intestinal wall and liver.
Sirolimus is extensively metabolized by the CYP3A4 isozyme in the intestinal wall and liver.
Sirolimus is the major component in human whole blood and contributes to greater than 90% of the immunosuppressive activity.
Sirolimus is extensively metabolised by O-demethylation and/ or hydroxylation.
Sirolimus was not mutagenic in the in vitro bacterial reverse mutation assays, the Chinese hamster ovary cell chromosomal aberration assay, the mouse lymphoma cell forward mutation assay, or the in vivo mouse micronucleus assay.
Les Isnes Rue Louis Genonceau, 13 BE-5023 Gembloux Belgium
Isolates with baseline fold change of > 0 to 3 are considered susceptible; isolates with > 3 to 10 fold changes have decreased susceptibility; isolates with > 10 fold changes are resistant.
Clinical isolates of HIV-2 demonstrated EC50 values in the range of 0.3-2.4 nM.
Clinical isolates of HIV-2 demonstrated EC50 values in the range of 0.3-2.4 nM.
Of these, isolates from 96 nelfinavir-treated subject and 51 lopinavir/ ritonavir-treated
Group O and HIV-2 isolates have reduced susceptibility in vitro to tipranavir with EC50 values ranging from 0.164-1 µM and 0.233- 0.522 µM, respectively.
The recommended site of administration is the region of the deltoid.
The site should not be oily, damaged, or irritated.
It has been shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule.
The most common site of spontaneous bleeding was the gastrointestinal tract (1.7% rate with prasugrel and 1.3% rate with clopidogrel); the most frequent site of provoked bleeding was the arterial puncture site (1.3% rate with prasugrel and 1.2% with clopidogrel).
The site of injection should be rotated daily to help prevent lipohypertrophy.
The injection site must be firm for the device to work properly.
The usual injection site is the back of your hand or just in front of your elbow.
Occasionally, the injection site can become infected; the skin may become swollen, tender and hard and the whole area could be very painful.
The preferred injection site for using the Aranesp pre-filled pen is the front of the thigh.
Young children may not develop jaundice.
Let them dry completely before you use them again.
LDL is formed from very-low-density protein (VLDL) and is catabolised predominantly by the high affinity LDL receptor.
The GDH-PQQ based glucose monitoring systems may react with the maltose present in ORENCIA, resulting in falsely elevated blood glucose readings on the day of infusion.
Contact lenses should be removed prior to instillation and may be reinserted 15 minutes following administration.
Intracranial lesions must be inactive and anti-tumour
- pre cancerous cervical lesions (changes in cells of the cervix that have a risk of turning into
- precancerous cervical lesions (changes in cells of the cervix that have a risk of turning into
- precancerous cervical lesions (changes in cells of the cervix that have a risk of turning into
Tissue damage also results from ischaemia secondary to vasoconstriction, platelet activation and aggregation and clotting.
Leukotrienes cause narrowing and swelling of airways in the lungs.
EU expert - Dr J-L Robert, Luxembourg ⋅ ICH Safety Guidelines related to genotoxicity - EU expert Dr Derek Renshaw, UK ⋅ ICH Safety Guidelines on reproduction toxicity - EU expert Dr Susan Barlow, UK ⋅ Good Clinical Practice:
Low- density lipoprotein (LDL) is formed from VLDL and is catabolized primarily through the receptor with high affinity to LDL (LDL receptor).
Macrolides are bacteriostatic acting antibiotics and inhibit essential protein biosynthesis by virtue of their selective binding to bacterial ribosomal RNA.
Macrolides are metabolites or derivatives of metabolites of soil organisms obtained by fermentation.
Concomitant illness, especially infections, usually increases the patient's insulin requirements.
23 Concomitant illness, especially infections and feverish conditions, usually increases the patient's insulin requirement.
Concomitant illness, especially infections and feverish conditions, usually increases the patient's insulin requirement.
Pain sensations may be described as hot, burning, throbbing, shooting, stabbing, sharp, cramping, aching, tingling, numbness, pins and needles etc.
Pain sensations may be described as hot, burning, throbbing, shooting, stabbing, sharp, cramping, aching, tingling, numbness, pins and needles.
The neurological manifestations are considered secondary to the abnormal accumulation of glycosphingolipids in neuronal and glial cells.
Severe and serious liver toxicities will be assessed through the PSUR but also through analysis of these events in the CSP database.
Operators should wear gloves when mixing the concentrate solution with the solvent.
The mechanisms of these toxicities are not completely understood.
The underlying mechanisms are not fully understood, but because of the high doses employed and since Aloxi is intended for single application in humans, these findings are not considered relevant for clinical use.
Clinicians should be aware of the possible emergence of significant depressive symptomatology in patients undergoing a smoking cessation attempt, and should advise patients accordingly.
Physicians and parents should be alert to the development of a limp or complaints of hip or knee pain in patients treated with NutropinAq.
Doctors and patients must be aware of this possibility.
Doctors should only prescribe Viracept to patients who have already taken medicines in the same class as Viracept (protease inhibitors) once they have looked at the antiviral medicines the patient has taken before and the likelihood that the virus will respond to the medicine.
Prescribing physicians should ensure that patients with IgE below 76 IU/ ml have unequivocal in vitro reactivity (RAST) to a perennial allergen before starting therapy.
Medicines should not be disposed of via wastewater or household waste.
Medicinal products added to the insulin suspension may cause degradation of the insulin, e. g. if the medicinal products contain thiols or sulphites.
Drugs which decrease renal calcium excretion, e. g. thiazide diuretics, may increase the risk of hypercalcaemia.
Diuretic agents such as the hydrochlorothiazide contained in CoAprovel may have an effect on other medicines.
Diuretic agents such as the hydrochlorothiazide contained in Irbesartan Hydrochlorothiazide BMS may interact with other medicines.
Diuretic agents such as the hydrochlorothiazide contained in Irbesartan Hydrochlorothiazide Winthrop may interact with other medicines.
Diuretic agents such as the hydrochlorothiazide contained in Karvezide may have an effect on other medicines.
The medicines were taken alone or in combination with another anti-inflammatory medicine such as methotrexate.
Immunomodulatory medicinal products may increase the risk of malignancy.
Medicinal products added to the insulin solution may cause degradation of the insulin, e. g. if the medicinal products contain thiols or sulphites.
The above-mentioned substances are converted by a specific enzyme (CYP1A2).
Medicines should not be disposed of via wastewater or household waste.
Medicines should not be disposed of via wastewater or household waste.
Medicines should not be disposed of via wastewater (do not flush it down the toilet).
Medicines must not be disposed of via wastewater or household waste.
Medicines should not be disposed of via wastewater or household waste.
104 Medicines should not be disposed of via wastewater or household waste.
106 Medicines should not be disposed of via wastewater or household waste.
111 Medicines should not be disposed of via wastewater or household waste.
111 The usual dose for adults (including elderly patients) is as follows:
118 Medicines should not be disposed of via wastewater or household waste.
157 Medicines should not be disposed of via wastewater or household waste.
206 Medicines should not be disposed of via wastewater or household waste.
215 Medicines should not be disposed of via wastewater or household waste.
21 Medicines should not be disposed of via wastewater or household waste.
234 Medicines should not be disposed of via wastewater or household waste.
243 Medicines should not be disposed of via wastewater or household waste.
243 Medicines should not be disposed of via wastewater or household waste.
24 Medicines should not be disposed of via wastewater or household waste.
252 Medicines should not be disposed of via wastewater or household waste.
262 Medicines should not be disposed of via wastewater or household waste.
287 Medicines should not be disposed of via wastewater or household waste.
32 Medicines should not be disposed of via wastewater or household waste.
32 Medicines should not be disposed of via wastewater or household waste.
346 Medicines should not be disposed of via waster water or household waste.
34 Medicines should not be disposed of via wastewater or household waste.
350 Medicines should not be disposed of down the drain or with household rubbish.
35 Medicines should not be disposed of via wastewater or household waste.
37 Medicines should not be disposed of via wastewater or household waste.
40 Medicines should not be disposed of via wastewater or household waste.
47 Medicines should not be disposed of via wastewater or household waste.
48 Medicines should not be disposed of via wastewater or household waste.
51 Medicines should not be disposed of via wastewater or household waste.
52 Medicines should not be disposed of via wastewater or household waste.
54 Medicines should not be disposed of via wastewater or household waste.
56 Medicines should not be disposed of via wastewater or household waste.
57 Medicines should not be disposed of via wastewater or household waste.
57 Medicines should not be disposed of via wastewater or household waste.
72 Medicines should not be disposed of via wastewater or household waste.
81 Medicines should not be disposed of via wastewater or household waste.
81 Medicines should not be disposed of via waste water or household waste.
86 Medicines should not be disposed of via wastewater or household waste.
8 Medicines no longer required should not be disposed of via wastewater or the municipal sewage system.
90 Medicines should not be disposed of via wastewater or household waste.
91 Medicines should not be disposed of via wastewater or household waste.
92 Medicines should not be disposed of via wastewater or household waste.
97 Medicines should not be disposed of via wastewater or household waste.
Do not store above 30°C Medicines should not be disposed of via wastewater or household waste.
Medicinal products should not be disposed of via wastewater or household waste.
Medicine should not be disposed of via wastewater or household waste.
Medicines must not be disposed of via wastewater or household waste.
Medicines should not be disposed of down the drain or in household rubbish.
Medicines should not be disposed of down the drain or with household rubbish.
Medicines should not be disposed of in wastewater or household waste.
Medicines should not be disposed of via via wastewater or household waste.
Medicines should not be disposed of via waster water or household waste.
Medicines should not be disposed of via wastewater of household waste.
Medicines should not be disposed of via wastewater of household waste.
• Medicines should not be disposed of via wastewater or household waste.
Medicines should not be disposed of via wastewater or household waste.
Medicines should not be disposed of via waste water or household waste.
Medicines should not be disposed of via waste water or household waste.
Medicines should not be disposed of via wastewater or household waste.
Medicines should not be disposed of via waste water or household waste.
Medicines should not be disposed of via wastewater or household waste.
Medicines should not be disposed of via wastewater or house hold waste.
Medicines should not be disposed of via wastewater or household waste.
Medicines should not be disposed of via wastewater or house hold waste.
Medicines should not be disposed of via wastewater or household waste.
Medicines should not be disposed of via wastewater or household waste.
Medicines should not be disposed of via wastewater or household waste – this helps protect the environment.
Medicines should not be disposed of via wastewater or in household waste.
Medicines should not be disposed via wastewater or household waste.
Medicines should not be disposed via wastewater or household waste.
ra Medicines should not be disposed of via wastewater or household waste.
This medicinal product does not require any special storage conditions dic
This medicine does not require any special storage conditions.
What (Invented name)® looks like and contents of the pack< [To be completed nationally] >
You should not throw away any medicine through wastewater or household waste.
Medicines should not be disposed of via wastewater or household waste.
Medicines should not be disposed of via waste water or household waste.
Medicines should not be disposed of via wastewater or household waste.
Medicines should not be disposed of via wastewater or household waste.
Medicines should not be disposed of via wastewater or household waste.
Medicines should not be disposed of via waste water or household waste.
Medicines should not be disposed of via wastewater or household waste.
Medicines should not be disposed of via wastewater or household waste.
Medicines that neutralise stomach acids (antacids such as aluminium hydroxide/ magnesium hydroxide) may be taken up to 2 hours before or 2 hours after taking SPRYCEL.
Medicines no longer required should not be disposed of via wastewater or the municipal sewage system.
Medicines that may cause your blood sugar level to rise (hyperglycaemia) include:
Medicines that may cause your blood sugar level to rise (hyperglycaemia) include:
Medicines that may cause your blood sugar level to fall (hypoglycaemia) include:
Medicines that may cause your blood sugar level to fall (hypoglycaemia) include:
Medicines that may cause your blood sugar level to fall (hypoglycaemia) include:
ut Medicines that may cause your blood sugar to rise include corticosteroids (used to treat inflammatory
- medicines which need a certain liver enzyme system (known as cytochrome P450 system) for
Medicines shown during clinical trials not to interfere with DaTSCAN imaging include amantadine, trihexyphenidyl, budipine, levodopa, metoprolol, primidone, propranolol and selegiline.
The following medicines may also interact with Efexor depot and should be used with caution.
Medicines known as “ statins” and “ fibrates” used to treat elevated cholesterol and triglycerides have been associated with an increased risk of muscle breakdown (rhabdomyolysis).
Agents for the treatment of erectile dysfunction, including sildenafil, should not be used in men for whom sexual activity is inadvisable (e. g. patients with severe cardiovascular disorders such as unstable angina or severe cardiac failure).
The best places to give yourself an injection are: the front of your thighs; the front of your waist (abdomen), or the upper arm.
74 yourself an injection are: the front of your waist (abdomen); your buttocks; the front of your thighs or upper arms.
The best places to give yourself an injection are: the front of your waist (abdomen); your buttocks; the front of your thighs or upper arms.
The best place to give yourself an injection are: the front of your waist (abdomen); your buttocks; the front of your thighs or upper arms.
The best place to give yourself an injection are: the front of your waist (abdomen); your buttocks; the front of your thighs or upper arms may be used.
The best place to give yourself an injection are: the front of your waist (abdomen); your buttocks: the front of your thighs or upper arms may be used.
Your insulin will work more quickly if you inject it around the waist.
Your insulin will work more quickly if you inject it around the waist.
The best places to give yourself an injection are: the front of your ic
The limbs affected by the disease may be painfully deformed.
In 9 cases, CPMP members from Germany and Finland were designated rapporteur or co-rapporteur, with the members from Denmark and Ireland designated in 8 instances.
Members from Belgium and Spain were designated in 4 instances.
Members of the Management Board and scientific committees were able to see the result of the teams 'work in a display arranged near to the meeting rooms at the EMEA.
CPMP members from the Netherlands were
Measurements of ADP-induced ex vivo platelet aggregation at physiologic calcium concentrations (D-phenylalanyl-L- prolyl-L-arginine chloromethyl ketone [PPACK] anticoagulant) in patients presenting with unstable angina and Non Q-Wave Myocardial Infarction showed a concentration-dependent inhibition with an IC50 (50% inhibitory concentration) of approximately 550 ng/ ml and an IC80 (80% inhibitory concentration) of approximately 1,100 ng/ ml.
AUC0-24hr measurements were not performed in this study due to the sparse plasma sampling.
The usual safety requirements for magnetic resonance imaging, especially the exclusion of ferromagnetic materials, also apply when using Gadovist.
Objective measurements of driving ability, sleep latency and assembly line performance have not demonstrated any clinically relevant effects at the recommended dose of 10 mg.
The measures taken in the manufacture of Fibrinogen and Thrombin are considered effective for lipid coated viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus and the non- enveloped virus, hepatitis A.
The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19.
The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19.
The measures taken may be of limited value against parvovirus B19.
The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV and for the non-enveloped virus HAV.
The measures taken for the manufacture of KIOVIG are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non- enveloped hepatitis A virus and parvovirus B19.
Your doctor may recommend that you consider vaccination against hepatitis A and B if you regularly/ repeatedly receive human plasma-derived coagulation factor IX
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A and B19 viruses.
The measures taken are considered effective for enveloped viruses such as HIV, HBV, and HCV, and for the non-enveloped viruses HAV and B19V.
The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV, and for the non-enveloped viruses HAV and parvovirus B19.
The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19.
Specific measures which have been already taken in order to minimise the risk of visual disorders in vigabatrin receiving patients and what was their impact.
Deboronated-bortezomib metabolites are inactive as 26S proteasome inhibitors.
Identified metabolites (includes 17-ketone, sulphone, 3-sulphate, 3- and 17-glucuronide metabolites) are either less active or exhibit similar activity to fulvestrant in anti-estrogen models.
The metabolites lack the specific biological activity of calcitonin.
The metabolites lack the specific biological activity of elcatonin.
The pentavalent metabolites, MMAV and DMAV, are slow to appear in plasma (approximately 10-24 hours after first administration of arsenic trioxide), but due to their longer half-life, accumulate more upon multiple dosing than does AsIII.
The main metabolites are monohydroxycyclohexyl derivatives of praziquantel.
The metabolites, which could not be detected in plasma, are devoid of anticonvulsant activity.
The metabolites are eliminated from plasma and urine in 2 phases, for which half-lives of about 2 and 5 hours (plasma) and 2 and 18 hours (urine) have been calculated.
Elimination is by renal excretion of metabolites, 89% as sulphated and glucoronide conjugates of 6-hydroxymelatonin and 2% is excreted as melatonin (unchanged drug).
Metabolites are excreted in urine and via biliary excretion in faeces.
Your normal dialysis routine will not affect the ability of Nespo to treat your anaemia.
The microbubbles have a mean diameter of about 2.5 µm, with 90% having a diameter less than 6 µm and 99% having a diameter less than 11 µm.
RISPERDAL CONSTA extended release microspheres in the vial must be reconstituted only in the solvent in the syringe supplied in the dose pack, and must be administered only with the Needle-Pro safety needle supplied in the dose pack.
The microspheres have a mean diameter of 2.5 - 4.5 microns and concentrations of 5-8 x 108 microspheres/ ml.
As OPTISON consists of microspheres that are stable and small enough for transpulmonary passage, it will also give enhanced echo signals in the left heart cavities.
Updates to the database will continue in 2002.
Dose modifications applied should be applied for the precipitating adverse event as necessary (see section 4.2).
Changes in plasma concentration of amlodipine are not related to the degree of renal impairment.
- a low number of white blood cells or platelets, which can cause an increased risk of infection,
Changes to your mood, thoughts about suicide, feeling unusually sad, anxious or worthless, should be reported to your doctor immediately.
As part of the modifications to the fourth floor a security office within the reception area was installed to provide better security coverage of visitors and for staff working on this floor.
The most important changes included cardiac hypertrophy and dilatation, leading to signs of cardiac insufficiency in some animals.
The changes observed at the low dose of the 13 week studies can be classified as minimal and fully reversible.
Peripheral nerve changes were characterised by minimal to slight axonal degeneration and were frequently accompanied by functional changes.
The circulatory changes included decreased blood pressure and, in some studies, increased heart rate and decreased contractility.
Free circulating Botulinum neurotoxin type A molecules which have not bound to presynaptic cholinergic nerve terminal receptors will be phagocytosed or pinocytosed and degraded like any other free circulating protein.
The fibrin monomers aggregate and form a fibrin clot.
The reasons for referral concerned the risk of gastrointestinal and skin reactions.
The grounds for the referral were that Germany was not in a position to accept some of the anti-cancer indications because they were not recognised as acceptable for bleomycin in the country.
Mean daily blood glucose values were similar between BYETTA and insulin.
Facilities for the treatment of such reactions should be immediately available.
Tylvalosin is included in Annex I of Council Regulation (EEC) No.
Mutations at position 82 occur via two pathways: one from pre-existing mutation 82A selecting to 82T, the other from wild type 82V selecting to 82L.
Nausea, vomiting, flushing and dizziness are known to be dose dependent when calcitonin is administered parenterally.
Nausea, vomiting, flushing and dizziness are known to be dose dependent when calcitonin is administered parenterally.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
That much has been achieved in 1996 was indeed confirmed at the second audit of the European registration system chaired by Dr Martin Bangemann, and by the declarations made by representatives of consumers, pharmaceutical industry and other interest groups at that meeting.
These findings were based on a rather limited
Hyperbilirubinaemic newborns and preterm newborns should not be treated with ceftriaxone.
Premature infants who have already been transfused by the start of treatment with NeoRecormon are not likely to benefit as much as untransfused infants.
- The new evidence from the GPRD studies is more vulnerable to various biases, e. g.
Peripheral blood B cell counts begin to increase from week 24 and evidence for repopulation is observed in the majority of patients by week 40, whether MabThera was administered as monotherapy or in combination with methotrexate.
Objectives 7 and 8 address harmonisation and specific activities not covered currently by fees.
The objectives set for the forum in 1999 remain the same:
The goals of iron chelation therapy are to remove the amount of iron administered in transfusions and, as required, to reduce the existing iron burden.
The overall objectives for 2002 will be to structure and proceed with the projects, both new and old, for which it will have responsibility.
The primary objectives of the open label study were to evaluate the safety, immunogenicity and effect of repeat doses of NeuroBloc in subjects with CD who were already resistant to Botulinum Toxin Type A compared to subjects who were responsive to Botulinum Toxin Type A..
Objectives of therapy are stated in the pharmacodynamic section of the summary of product characteristics.
The objections raised by France and Sweden should not prevent the granting of a marketing authorisation for Compagel gel for horses.
In the acute and chronic toxicity studies most of the findings are related to the hormonal effects of toremifene.
Observations included transient and reversible neurological effects consisting of tremors, uncoordinated movements and hyper- and hypoactivity.
Peripheral oedema was reported more frequently with 10 mg ambrisentan (see section 4.8).
Peripheral oedema is a very common symptom of the disease itself, but can also occur under therapy.
Extra body fluid can make some existing heart problems worse or lead to heart failure.
Birds with the disease fail to thrive.
The solvent in this product may stain certain materials including leather, fabrics, plastics and finished surfaces.
The solvent in Advocate may stain certain materials including leather, fabrics, plastics and finished surfaces.
The solvent in Advocate may stain certain materials including leather, fabrics, plastics and finished surfaces.
The solvent dimethylacetamide (DMA) may also impair fertility.
The solvent should not be used if it is discoloured or cloudy.
The core and key support processes of the Agency were identified and mapped.
Opioids, also known as narcotic drugs, are drugs such as heroin or morphine.
Sorafenib is a multikinase inhibitor which has demonstrated both anti-proliferative and anti- angiogenic properties in vitro and in vivo.
Since sorafenib is mainly eliminated via the hepatic route exposure might be increased in patients with severe hepatic impairment (see section 4.2 and 5.2).
Target organs for neoplastic changes were the kidneys, urinary bladder, urethra, preputial and clitoral gland, small intestine, parathyroid glands, adrenal glands and non- glandular stomach.
Gradually, the bones become thin and fragile, and more likely to break.
Bacterial and fungal otitis is often secondary in nature.
As regards the relief of symptoms, this was examined in both studies through the use of diary cards and investigator interviews.
Administrative support will be provided by the Secretariat of the Veterinary Medicines Evaluation Unit.
support while introducing new services and improvements to the infrastructure as required from the business and the users.
Waste paper and used wipes can be put in an ordinary rubbish bin.
The parameters of capecitabine, 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR) measured on days 1 and 14 were similar.
The pharmacokinetic parameters based on pharmacokinetic modelling in typical elderly and/ or renally impaired patients are presented below:
Gabapentin pharmacokinetics in children were determined in 50 healthy subjects between the ages of 1 month and 12 years.
Emtricitabine and tenofovir pharmacokinetics are similar in male and female patients.
The pharmacokinetics of etravirine have not been studied in patients with severe hepatic impairment (Child-Pugh Class C).
The pharmacokinetics of A771726 in CAPD subjects appeared to be similar to healthy volunteers.
The sugammadex pharmacokinetic parameters were calculated from the total sum of non-complex- bound and complex-bound concentrations of sugammadex.
This will involve using vials of original BeneFIX product along with the appropriate use of accompanying original BeneFIX sterile water solvent. • Instructions that patients should not mix vials of current and reformulated product for a given dose prior to transition to the new reformulated BeneFIX, and necessity not to mix up these two products.
The pharmacokinetic parameters obtained in studies comparing recombinant Factor IX to plasma derived Factor IX were similar to those obtained in human studies.
The capsule shell contains gelatine, titanium dioxide.
Particles > 4.5 µm are swallowed and contribute by negligible amount to the early systemic bioavailability (as Cmax) and peak adverse events of inhaled salbutamol.
Irradiation by the emitted beta particles from yttrium-90 occurs in a radius of 5 mm around the isotope.
The resulting immature particles are non– infectious and are incapable of establishing new cycles of infection.
The most important parts to note are as follows:
Used patches should be discarded carefully in accordance with the instructions given in section 6.6.
36 Used patches should not be flushed down the toilet or placed in liquid disposal systems.
Disease of the thymus gland has also been recognised as a potential risk factor (see section 4.3 and section 4.8).
Subjects with severe hepatic impairment (Child-Pugh class C) were not evaluated.
Patients with malabsorption may not adequately absorb vitamin D3.
Patients should be instructed to consult their physician immediately should pregnancy occur.
Patients should be instructed that if they miss a dose of ADROVANCE they should take one tablet on the morning after they remember.
Patients should be instructed that if they miss a dose of FOSAVANCE they should take one tablet on the morning after they remember.
Patients in the Vitamin D3 2800 group received ADROVANCE (70 mg/ 2800 IU) (n=299) and patients in the Vitamin D3 5600 group received ADROVANCE (70 mg/ 2800 IU) plus an additional 2800 IU vitamin D3 (n=309) once a week; additional vitamin D supplements were allowed.
Patients planning pregnancy Lisonorm should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.
Patients should not chew or suck the tablet, because of a potential for oropharyngeal ulceration.
Patients received the lower strength (70 mg/ 2800 IU) of ADROVANCE (n=350) or FOSAMAX (alendronate) 70 mg (n=332) once a week; additional vitamin
Patients received the lower strength (70 mg/ 2800 IU) of ADROVANCE (n=350) or FOSAMAX (alendronate) 70 mg (n=332) once a week; additional vitamin D supplements
Management of elevated serum calcium Patients with persistent elevated serum calcium (above the upper normal level) should be evaluated for underlying disease (e. g. hyperparathyroidism).
Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.
Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.
Since patients with osteoporosis may not get enough vitamin D3 through exposure to sunlight, it is included in ADROVANCE.
Since patients with osteoporosis may not get enough vitamin D3 through exposure to sunlight, it is included in Fosavance.
Women who take celecoxib should not breastfeed.
Patients using oral contraceptives were excluded.
Patients undergoing ovarian stimulation are at an increased risk of developing ovarian hyperstimulation syndrome (OHSS) due to multiple follicular development
Patients undergoing ovarian stimulation are at an increased risk of developing ovarian hyperstimulation syndrome (OHSS) due to multiple follicular development.
Improvement in bridging fibrosis occurred in 19/ 30 (63%) patients without YMDD variant and 22/ 44 (50%) patients with the variant.
Improvement in bridging fibrosis occurred in 19/ 30 (63%) patients without YMDD variant and 22/ 44 (50%) patients with the variant.
In patients with YMDD variant HBV, 41/ 82 (50%) patients had improvement in liver inflammation and 40/ 56 (71%) patients without YMDD variant HBV had improvement.
Elderly patients receiving Mycophenolate mofetil Teva as part of a combination immunosuppressive regimen, may be at increased risk of certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared to younger individuals.
Patients allergic to tetracycline antibiotics may also be allergic to Tygacil.
Patients hypersensitive to tetracycline class antibiotics may be hypersensitive to tigecycline.
Patients who are allergic to peanut or soya must not take these tablets.
Patients who are allergic to peanut or soya must not take these tablets.
The patients in the weekly treatment group experienced a clinically significant 15% mean improvement in FEV1 at the end of the study.
The patients at risk of tumour lysis syndrome are those with high tumour burden prior to treatment.
Patients at risk for the development of hyperkalaemia include those with renal impairment, diabetes mellitus, acute cardiac decompensation, dehydration, metabolic acidosis, or concomitant use of potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes, or any medicinal products associated with increases in potassium serum levels (e. g. heparin).
Patients at increased risk must be followed closely.
Asthmatic patients starting on glucosamine should therefore be aware of potential worsening of symptoms.
Cancer patients receiving treatment with erythropoietin have an increased risk of blood clots/ blood clotting disorders (thrombotic vascular events).
This enzyme normally breaks down a fatty substance called globotriaosylceramide (Gb3).
This enzyme normally breaks down a fatty substance called globotriaosylceramide (GL-3).
Patients with CLL have too many abnormal lymphocytes, which accumulate mainly in the bone marrow and blood.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Patients with APL are normally treated with retinoids (substances derived from vitamin A).
Patients who have problems with their liver (including hepatitis B or C infection) may be at an elevated risk of liver damage when taking Kaletra.
Patients with secondary MDS were excluded from the study.
Olanzapine Teva orodispersible tablet contains D-glucose: patients with rare glucose- galactose malabsorption should not take this medicine.
Patients with Turner syndrome should be evaluated carefully for otitis media and other ear disorders since these patients have an increased risk of ear or hearing disorders.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose- isomaltase insufficiency should not take this medicine.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Patients with haemophilia A may develop neutralising antibodies (inhibitors) to factor VIII.
Patients with haemophilia B (Christmas disease) are deficient in coagulation factor IX.
Haemophilia B patients may develop antibodies (inhibitors) to factor IX.
Patients with haemophilia B may develop neutralising antibodies (inhibitors) to factor IX.
Patients with haemophilia B may develop neutralising antibodies (inhibitors) to factor IX.
Patients with hepatic impairment might therefore have increased exposure to nilotinib and should be treated with caution (see section 4.2).
Patients with duodenal ulcers (n=3) were treated for 6 weeks and patients with gastric ulcers (n=42) or multiple ulcers (n=5) for 8 weeks.
A clinically relevant, low responding inhibitor was detected in 1 out of 65 BeneFIX patients who had previously received plasma derived products.
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse events.
Telzir with ritonavir should be used with caution and at reduced doses in adults with mild, moderate or severe hepatic impairment (see section 4.2). Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse events.
AIDS patients with Kaposi's sarcoma were not included.
Patients received meningococcal vaccination prior to receipt of Soliris.
Gilbert's disease) may exhibit increased serum concentrations of bilirubin and must be treated with caution.
Gilbert’s disease) may exhibit increased serum concentrations of bilirubin and must be treated with caution.
Responses for patients with baseline Knodell Fibrosis Scores of 4 (cirrhosis) were comparable to overall responses on all efficacy outcome measures (all patients had compensated liver disease).
Patients with antibodies to r-hα GAL have a greater potential to experience infusion-associated reactions (IARs), which are defined as any related adverse event occurring on the infusion day.
Patients who experience erections lasting 4 hours or more should be instructed to seek immediate medical assistance.
Patients with rare hereditary problems of fructose intolerance, glucose- galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Patients with rare hereditary problems of fructose intolerance, glucose- galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Patients experiencing signs of hepatic insufficiency during or post-treatment should be monitored more frequently as appropriate.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption syndrome or sucrase-isomaltase insufficiency should not take this medicine.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine.
Patients with pre-existing liver dysfunction, including chronic active hepatitis, can have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
45 Patients with pre-existing liver dysfunction including chronic hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be
Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Patients with pre- existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Patients with pre-existing liver dysfunction, including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy, and should be monitored according to standard practice.
Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy, and should be monitored according to standard practice.
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Patients with pre-existing liver dysfunction including chronic hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Patients requiring rescue medicinal products were not considered for durable platelet response.
- patients with unstable angina or angina occurring during sexual intercourse,
Patients who had received 2 to 3 prior therapeutic regimens had a response rate of 32% (10/ 32) and patients who received greater than 7 prior therapeutic regimens had a response rate of 31% (21/ 67).
Patients receiving Angiox without GPI also had a lower rate of bleeding after 30 days and after a year.
Patients who responded at week 4 were followed to week 12.
Sixty-nine percent of the patients underwent surgery for cancer.
Patients with diabetes or glucose intolerance should be monitored closely during somatropin therapy.
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination therapy and should be monitored according to standard practice.
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Patients with pre-existing liver dysfunction including chronic hepatitis have an increased frequency of liver function abnormalities during combination anti-retroviral therapy and should be monitored according to standard practice.
Patients with chronic hepatitis B or C and treated with antiretroviral agents are at increased risk of severe and potentially fatal liver adverse events and may require blood tests for monitoring of liver function.
Patients with chronic hepatitis B or C and treated with antiretroviral agents are at increased risk of severe and potentially fatal liver adverse events and may require blood tests for monitoring of liver function.
Patients with chronic hepatitis B or C and treated with antiretroviral agents are at increased risk for severe and potentially fatal liver adverse events and may require blood tests for control of liver function.
Patients with chronic hepatitis B or C and treated with antiretroviral agents are at increased risk of severe and potentially fatal liver adverse events and may require blood tests for monitoring of liver function.
- infected with hepatitis B or C
Patients with unstable coronary artery disease or recent myocardial infarction were excluded from these studies.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Responses for patients with baseline Knodell Fibrosis Scores of 4 (cirrhosis) were comparable to overall responses on all efficacy outcome measures (all patients had compensated liver disease).
Cancer patients on erythropoietin should have haemoglobin (the part of a red blood cell that carries oxygen) levels measured on a regular basis until a stable level is achieved, and periodically thereafter.
Patients adding vildagliptin had falls in HbA1c levels of 0.88% after 24 weeks from a starting level of 8.38%.
Patients who have detectable virus at week 12 should stop therapy.
Patients who develop a new infection while undergoing treatment with Trudexa should be monitored closely.
Patients co-infected with hepatitis C and treated with alpha interferon and ribavirin may constitute a special risk.
Patients co-infected with hepatitis C and treated with alpha interferon and ribavirin may constitute a special risk.
Patients co-infected with hepatitis C and treated with alpha interferon and ribavirin may constitute a special risk.
Patients known to be CYP2C9 poor metabolisers should be treated with caution.
Patients known to be CYP2C9 poor metabolisers should be treated with caution (see 5.2.).
Patients in the TMZ + RT arm received concomitant TMZ (75 mg/m2) once daily, starting the first day of RT until the last day of RT, for 42 days (with a maximum of 49 days).
Patients in this study (n=1,927) received open-label CHAMPIX 1 mg twice daily for 12 weeks.
Patients who were in the non-MTX stratum were either naïve to or had been withdrawn from MTX at least two weeks prior to study drug administration.
Patients who were in the non-MTX stratum were either naïve to or had been withdrawn from MTX at least two weeks prior to study drug administration.
Patients in the single centre study had relapsed following 1-6 prior therapy regimens and 2 patients had relapsed following stem cell transplantation.
Patients in Arms A and B were also randomised to receive a GPIIb/ IIIa inhibitor either upfront at the time of randomization (prior to angiography) or at the time of PCI.
The patients had to present with unprovoked partial seizures or with generalized tonic-clonic seizures only.
Patients developing an infection during treatment with Raptiva should be monitored and according to severity Raptiva should be discontinued.
Patients should have their serum creatinine levels assessed prior to each dose of Zometa.
Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter.
14 consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.
24 consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.
4 consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.
Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.
Patients should be monitored closely to ensure that the lowest approved dose of Aranesp is used to provide adequate control of the symptoms of anaemia.
provide adequate control of the symptoms of anaemia. ed
Patients should be instructed accordingly.
Patients should be monitored closely to ensure that the lowest approved dose of Dynepo is used to provide adequate control of the symptoms of anaemia.
Patients should be closely monitored and all cases of IARs, delayed reactions and possible immunological reactions should be reported.
The patients differed significantly in age, body weight and plasma volume.
Patients should be monitored with regard to electrocardiogram (ECG) and serum calcium levels.
Patients should then hold their breath for 5 seconds and exhale normally.
Patients should start a cholesterol-lowering diet before treatment and continue it through treatment.
Patients should be aware of circumstances where warning symptoms of hypoglycaemia are diminished.
Patients should be started on dexamethasone 4 mg twice daily orally or intravenously for 5 days beginning on the day of injection of DepoCyte.
In addition, patients should be alerted to the risk of hypoglycaemia when Efficib is used in combination with other sulfonylurea agents.
Therefore, patients should consult their physician as to whether driving or use of machines is permitted.
9 advised of the importance of taking Kivexa regularly.
Consequently, patients should be advised of the importance of taking Ziagen regularly.
Therefore patients should remain under close clinical observation by physicians experienced in the treatment of these associated HIV diseases.
This can happen during the treatment, or after it has been stopped.
Patients must be instructed to remove contact lenses prior to application of DuoTrav and wait 15 minutes after instillation of the dose before reinsertion.
Patients should be warned of the possibility of long term side effects, especially photosensitivity, and the need to seek medical assistance if they arise.
Patients should be warned about the potential for central nervous system effects, and advised not to drive or operate machinery whilst taking sparfloxacin.
Patients must be educated to use the proper injection techniques.
Patients must be educated to use proper injection techniques.
Patients should be evaluated after 2 to 4 weeks for response to montelukast.
3 should have examinations periodically and at the occurrence of clinical symptoms to rule out such potential complications or to initiate appropriate treatment.
Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.
Patients should be warned about the potential for dizziness or vertigo, and advised not to drive or operate machinery if these symptoms occur.
Patients should be cautioned about the potential effects of these events on the ability to
Patients must be instructed to remove contact lenses prior to the application of EMADINE and wait 15 minutes after instillation of the dose before reinsertion.
To reduce the risk of photosensitivity, patients should be warned against exposure to direct and solarium sunlight.
Patients should be observed by the physician for immediate toxic reactions.
Patients should be observed by the physician for immediate toxic reactions.
Patients should be under close medical supervision during the Visudyne infusion and caution should be exercised when Visudyne treatment under general anaesthesia is considered.
Patients must have adequate fluids before and after treatment.
Patients should be monitored for the development of factor VIII inhibitors.
37 cough, fever, dyspnoea and/ or hypoxia), and topotecan should be discontinued if a new diagnosis of ILD is confirmed.
Patients should be monitored for seizure control.
Patients should be treated with CHAMPIX for 12 weeks.
106 Patients should be monitored closely to ensure that the lowest approved dose of MIRCERA is used to provide adequate control of the symptoms of anaemia.
114 Patients should be monitored closely to ensure that the lowest approved dose of MIRCERA is used to provide adequate control of the symptoms of anaemia.
122 Patients should be monitored closely to ensure that the lowest approved dose of MIRCERA is used to provide adequate control of the symptoms of anaemia.
146 Patients should be monitored closely to ensure that the lowest approved dose of MIRCERA is used to provide adequate control of the symptoms of anaemia.
162 Patients should be monitored closely to ensure that the lowest approved dose of MIRCERA is used to provide adequate control of the symptoms of anaemia.
58 Patients should be monitored closely to ensure that the lowest approved dose of MIRCERA is used to provide adequate control of the symptoms of anaemia.
66 Patients should be monitored closely to ensure that the lowest approved dose of MIRCERA is used to provide adequate control of the symptoms of anaemia.
74 Patients should be monitored closely to ensure that the lowest approved dose of MIRCERA is used to provide adequate control of the symptoms of anaemia.
82 Patients should be monitored closely to ensure that the lowest approved dose of MIRCERA is used to provide adequate control of the symptoms of anaemia.
90 Patients should be monitored closely to ensure that the lowest approved dose of MIRCERA is used to provide adequate control of the symptoms of anaemia.
98 Patients should be monitored closely to ensure that the lowest approved dose of MIRCERA is used to provide adequate control of the symptoms of anaemia.
Patients should be monitored closely to ensure that the lowest approved dose of NeoRecormon is used to provide adequate control of the symptoms of anaemia.
Patients should be monitored closely to ensure that the lowest approved dose of Retacrit is used to provide adequate control of the symptoms of anaemia.
Patients should be monitored closely to ensure that the lowest approved dose of Retacrit is used to provide adequate control of the symptoms of anemia.
Patients should be monitored closely to ensure that the lowest approved dose of Silapo is used to provide adequate control of the symptoms of anaemia.
Patients should be monitored closely to ensure that the lowest approved dose of Silapo is used to provide adequate control of the symptoms of anemia.
Patients should be monitored closely to ensure that the lowest approved dose of Epoetin alfa is used to provide adequate control of anaemia and of the symptoms of anaemia.
Patients should be monitored closely to ensure that the lowest approved dose of Epoetin alfa is used to provide adequate control of the symptoms of anaemia.
Patients should take the medicine regularly and avoid missing doses.
Patients should be given an antihistamine and a painkiller before each infusion.
Patients should be premedicated with anti-emetics for nausea and vomiting.
Head and neck cancer Patients must receive premedication with antiemetics and appropriate hydration (prior to and after cisplatin administration).
Patients should receive adequate anti-convulsant prophylaxis.
Prior to re-treatment, patients must fulfil the baseline criteria defined above.
Patients should not get the IONSYS system wet.
There are limited clinical data available from patients with creatinine clearance less than
In order to be able to take action immediately, patients should carry glucose with them at all times. i dic
Patients whose blood glucose control is greatly improved e. g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised i dic
3 Patients, whose blood glucose control is greatly improved, e. g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia, and should be advised accordingly.
Patients whose blood glucose control is greatly improved e. g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.
Patients, whose blood glucose control is greatly improved, e. g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia, and should be advised accordingly.
Studies in cancer patients have excluded patients with ALT or AST > 2.5 x ULN (Upper Limit of Normal) or, if due to liver metastasis, > 5.0 x ULN.
No clinical studies have been performed in patients with impaired renal function Studies excluded patients with serum creatinine > 2.0 x ULN.
Patients whose IgE level is below 76 IU/ ml are less likely to benefit from the medicine.
Patients in the placebo/dexamethasone (placebo/dex) group took 1 placebo capsule on Days 1 to 28 of each 28-day cycle.
In the pramipexole group, patients received 0,375 mg in the first week, 0.75 mg in the second week and were titrated further in weekly increments of 0.75 mg to their optimal dose up to a maximum of 4.5 mg/ day.
Patients of advanced age have an increased risk of bleeding complications with anticoagulation.
Overweight patients should continue their energy-restricted diet.
Overweight patients should continue their energy-restricted diet.
Patients were between 18 and 70 years of age and had active psoriatic arthritis ( 3 swollen joints and  3 tender joints) in at least one of the following forms:
Patients were randomised to continued treatment with sodium oxybate at their stable dose or to placebo.
Patients were randomized to receive either Ribavirin (800-1,200 mg/ day based on weight) plus peginterferon alfa-2b (100 or 150 µg/ week based on weight) or Ribavirin (800- 1,200 mg/ day based on weight) plus interferon alfa-2b (3 MIU TIW).
Patients were randomized to receive either Ribavirin (800 mg/ day) plus peginterferon alfa-2b (1.5 µg/ kg/ week) or Ribavirin (800 mg/ day) plus interferon alfa-2b (3 MIU TIW) for 48 weeks with a follow-up period of 6 months.
Patients were randomized to receive either Rebetol (800 mg/day) plus peginterferon alfa-2b (1.5 µg/kg/week) or Rebetol (800 mg/day) plus interferon alfa-2b (3 MIU TIW) for 48 weeks with a follow-up period of 6 months.
or 150 µg / week based on weight) plus ribavirin (800-1,200 mg/ day based on weight) or Viraferon (3 MIU TIW) plus ribavirin (800-1,200 mg/ day based on weight).
Patients were randomized to receive either pegylated interferon alfa-2b (100 or 150 µg / week based on weight) plus ribavirin (800-1,200 mg/ day based on weight) or Viraferon (3 MIU TIW) plus ribavirin (800-1,200 mg/ day based on weight).
The duration of therapy was 48 weeks with a follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load na
Patients were randomized to receive either pegylated interferon alfa-2b (1.5 µg/kg/ week) plus ribavirin (800 mg/day) or IntronA (3 MIU TIW) plus ribavirin (800 mg/day) for 48 weeks with a follow-up period of 6 months.
Patients were randomized to receive either pegylated interferon alfa-2b (1.5 µg/kg/week) plus ribavirin (800 mg/day) or IntronA (3 MIU TIW) plus ribavirin (800 mg/day) for 48 weeks with a follow-up period of 6 months.
Limited historical data indicate that treatment for 48 weeks might be associated with a higher sustained response rate (11/11) and with a lower risk of relapse (0/11 as compared to 7/96 following 24 weeks of treatment).
Patients were randomized to receive either PegIntron (1.5 µg/kg/week) plus ribavirin (800 mg/day) or interferon alfa-2b (3 MIU TIW) plus ribavirin (800 mg/day) for 48 weeks with a follow-u p period of 6 months.
Patients were randomized to receive either PegIntron (1.5 µg/kg/week) plus ribavirin (800 mg/day) or interferon alfa-2b (3 MIU TIW) plus ribavirin (800 mg/day) for 48 weeks with a follow-up period of 6 months.
The high sustained response rate in this subgroup of patients was identified in an interim analysis (n=49) and prospectively confirmed (n=48).
Patients were randomized to receive either ViraferonPeg (1.5 µg/kg/week) plus ribavirin (800 mg/day) or interferon alfa-2b (3 MIU TIW) plus ribavirin (800 mg/day) for 48 weeks with a follow-up period of 6 months.
Patients were randomised to either 0.4mg or placebo with optional titration to 0.8mg.
Patients were treated twice daily with < Invented Name >.
Patients and/ or parents or the legal responsible person must be able to follow directions regarding the administration of this medicinal product, their monitoring and care.
Patients/ caregivers should be cautioned to immediately report signs and symptoms of potential CVAEs such as sudden weakness or numbness in the face, arms or legs, and speech or vision problems.
The patients studied had an MMSE (Mini-Mental State Examination) score of 10– 24.
Patients involved should be preferably naïve to the history of thalidomide.
Patients involved should be preferably naïve to the history of thalidomide.
Patients involved in this study had an MMSE (Mini-Mental State Examination) score of 10– 20.
Patients involved in this study had an MMSE (Mini-Mental State Examination) score of 10– 24.
The patients included in the pharmacokinetic studies were mainly children and adolescents.
Patients had to be either refractory to (disease progression or failure to improve with other antifungal therapies given for at least 7 days) (84% of the enrolled patients) or intolerant of (16% of enrolled patients) other standard antifungal therapies.
Chronic renal failure patients on erythropoietin should have their haemoglobin (the part of a red blood cell that carries oxygen) levels measured on a regular basis until a stable level is achieved, and periodically thereafter to minimise the risk of an increase in blood pressure.
Hepato-biliary disorders Common Uncommon
Patients with renal failure were excluded from this study.
Mildly anaemic patients (haematocrit of 33-39%) requiring predeposit of ≥ 4 units of blood should be treated with Silapo at a dose of 600 IU/ kg body weight 2 times weekly for 3 weeks prior to surgery.
Mildly anaemic patients (haematocrit of 33-39%) requiring predeposit of ≥ 4 units of blood should be treated with Silapo at a dose of 600 IU/kg body weight 2 times weekly for 3 weeks prior to surgery.
Patients, carers and doctors need to be aware that Tysabri can be associated with infections, including PML.
Patients who are known or suspected to be CYP2C9 poor metabolizers based on previous history/ experience with other CYP2C9 substrates should be administered celecoxib with caution (see Section 4.2).
Patients who are known or suspected to be CYP2C9 poor metabolizers based on genotyping or previous history/ experience with other CYP2C9 substrates should be administered celecoxib with caution, as the risk of dose-dependent adverse effects is increased.
Naïve patients also received nucleoside reverse transcriptase inhibitors.
Patients who did not have a virologic response were offered alternative treatment.
Patients should not drive or use machines as long as these symptoms persist.
Patients must not smoke while taking Exubera.
- Patients should not chew or suck the tablet because of a potential for oropharyngeal ulceration.
Patients should not get the IONSYS system wet.
From the first week of treatment, onset of sleep and the quality of sleep were significantly improved without daytime clumsiness as assessed by patients.
Patients also received mycophenolate mofetil (another medicine used in the prevention of rejection).
Patients were randomised to once daily losartan 50 mg or once daily atenolol 50 mg.
Patients were randomised to once daily Losartan 50 mg or once daily atenolol 50 mg.
Patients were randomised to receive the LT-CAGE Lumbar Tapered Fusion Device filled with either InductOs or autogenous bone graft taken from the iliac crest.
Patients were randomized to one of 3 doses of valsartan (160, 320 and 640 mg/ od) and treated for 30 weeks.
or non-myeloid malignancies receiving multi-cycle chemotherapy.
or non-myeloid malignancies receiving multi-cycle chemotherapy.
Patients were randomised to receive sham or 0.3 mg, 1 mg or 3 mg pegaptanib administered as intravitreal injections every 6 weeks for 48 weeks.
The patients were randomised with a 2:1 ratio to receive TYSABRI 300 mg (n = 627) or placebo (n = 315) every 4 weeks for up to 30 infusions.
Patients were followed up for up to 4.6 years (3.4 years on average).
Doses of 20 or 40 mg of Trudexa were given by subcutaneous injection every other week with placebo on no
Acute coronary syndrome
Patients received either 100 U/ kg of Aldurazyme or placebo every week for a total of 26 weeks.
Patients were titrated from 75 mg to a maintenance dose of 300 mg Aprovel, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated.
Patients were titrated from 75 mg to a maintenance dose of 300 mg Irbesartan BMS, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated.
Patients were titrated from 75 mg to a maintenance dose of 300 mg irbesartan, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated.
Patients were titrated from 75 mg to a maintenance dose of 300 mg Irbesartan Winthrop, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated.
Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated.
The patients received calcium and vitamin D supplements.
Patients received either ADROVANCE or alendronate only once a week.
Patients were nephrectomised for primary renal cell carcinoma.
Patients were treated with anti-hypertensive therapy (either amlodipine or atenolol-based regimen) and either atorvastatin 10 mg daily (n=5,168) or placebo (n=5,137).
Patients or their carers can give injections of ReFacto AF, provided that they have been trained appropriately.
Treatment should not be used in paediatric patients with a growth velocity less than 1 cm per year and near closure of epiphyses.
The patients then lose their ability to control their movements reliably.
The patients then lose their ability to control their movements reliably.
Patients who weighted > 20kg to< 50 kg received either 2.5, 25 or 50 mg of losartan daily and patients who weighted > 50 kg received either 5, 50 or 100 mg of losartan daily.
Patients can also develop a severe allergic reaction to Luminity, and must be closely monitored.
Patients may inject themselves once they have been trained, if their doctor thinks that this is appropriate.
Patients may inject themselves once they have been trained.
Patients may present clinically with predominantly hepatic, neurologic, or psychiatric symptoms.
The patients can inject Betaferon themselves, provided that they have been trained.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Patients who did not have an assessment 12 weeks after EOT were counted as failures.
Patient may not have a weekly response within 8 weeks after receiving any rescue medicinal products. c Number of weeks with platelet response is defined as number of weeks with platelet counts ≥ 50 x 109/ l during study weeks 2-25.
116 Patients taking Kaletra must not take products containing St John’s wort (Hypericum perforatum) as this may stop Kaletra from working properly.
Patients taking placebo showed a reduction of 9.0 m after 12 weeks.
Patients taking Ziagen may develop a hypersensitivity reaction (serious allergic reaction) which can be life-threatening if treatment with Ziagen is continued.
Patients taking Ziagen may develop a hypersensitivity reaction (serious allergic reaction) which can be life-threatening if treatment with Ziagen is continued.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Patients who experience mucositis (Grade 2 or worse) during Paxene therapy should have their dosage reduced by 25% for subsequent courses of Paxene.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Patients predisposed to the development of autoimmune disorders may be at increased risk.
Patients with signs or symptoms compatible with autoimmune disorders should be evaluated carefully, and the benefit-risk of continued interferon therapy should be reassessed (see also section 4.4 Thyroid changes and 4.8).
Patients with signs or symptoms compatible with autoimmune disorders should be evaluated carefully, and the benefit-risk of continued interferon therapy should be reassessed (see also section 4.4 Chronic hepatitis C, Monotherapy (thyroid abnormalities) and section 4.8).
Patients predisposed to the development of autoimmune disorders may be at increased risk. lon Patients with signs or symptoms compatible with autoimmune disorders should be evaluated carefully, and the benefit-risk of continued interferon therapy should be reassessed (see also section 4.4 Chronic hepatitis C, Monotherapy (thyroid abnormalities) and section 4.8).
Patients developing signs/ symptoms of a systemic hypersensitivity reaction should discontinue enfuvirtide treatment and should seek medical evaluation immediately.
Patients who have problems with their liver (including hepatitis B or C infection) may be at an elevated risk of liver damage when taking Ziagen.
- Patients with endocrine (hormonal) disorders are more likely to have problems with their hips.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Patients with preexisting ophthalmologic disorders (eg, diabetic or hypertensive retinopathy) should receive periodic ophthalmologic exams during Pegasys therapy.
In patients with these conditions, serum calcium and symptoms of hypocalcaemia should be monitored during treatment with alendronate.
Patients with growth hormone failure secondary to CRI should be examined periodically for evidence of progression of renal osteodystrophy.
Those who could not progress (levels 4 and 5) were excluded from the analyses.
Patients with mild, moderate or severe liver dysfunction should be given the minimum recommended dose of 400 mg daily.
Patients with anorexia, asthenia, nausea, vomiting or diarrhoea may rapidly become dehydrated.
Patients exhibiting depression should be monitored closely during therapy with Betaferon and treated appropriately.
Patients exhibiting depression should be monitored closely during therapy with Betaferon and treated appropriately.
[Patients with Candida endocarditis, osteomyelitis or meningitis, or those with infection due to C. krusei, were specifically excluded from the study].
Patients hypersensitive to Insulin Human Winthrop Basal for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Patients hypersensitive to Insulin Human Winthrop Basal for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Patients hypersensitive to Insulin Human Winthrop Comb 15 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Patients hypersensitive to Insulin Human Winthrop Comb 25 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Patients hypersensitive to Insulin Human Winthrop Comb 50 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Patients hypersensitive to Insulin Human Winthrop Infusat for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Patients hypersensitive to Insulin Human Winthrop Rapid for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Patients hypersensitive to Insuman Basal for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti- allergic treatment.
Patients hypersensitive to Insuman Comb 15 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti- allergic treatment.
Patients hypersensitive to Insuman Comb 25 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti- allergic treatment.
Patients hypersensitive to Insuman Comb 50 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti- allergic treatment.
Patients hypersensitive to Insuman Infusat for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti- allergic treatment.
Patients hypersensitive to Insuman Rapid for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti- allergic treatment.
Patients with renal impairment:
Patients with severe liver impairment have not been studied (see section 4.3).
Patients with renal impairment may be more sensitive to the blood pressure lowering effects of Ceplene.
Patients with single lesions may continue provided that the necrosis is not too extensive.
Patients with glucose-galactose malabsorption should not take this medicine.
Patients with evidence of corneal epithelial breakdown should immediately discontinue use of NEVANAC and should be monitored closely for corneal health.
FAP patients carrying an ileorectal anastomosis or ileo pouch-anal anastomosis can develop anastomotic ulcerations.
Patients experiencing a mucocutaneous reaction should not receive any further component of the Zevalin regimen.
Patients with latent TB should be treated with standard anti-mycobacterial therapy before initiating RoActemra.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Patients at risk for the development of hyperkalaemia include those with renal insufficiency, uncontrolled diabetes mellitus, or those using concomitant potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes; or those patients taking other drugs associated with increases in serum potassium (e. g. heparin).
Patients with elevated bilirubin must not be treated with Yondelis (see section 4.4).
Patients who discontinue immunosuppressants prior to or during Remicade treatment are at greater risk of developing these antibodies.
Patients developing a serious infection should stop Enbrel treatment.
Patients without this disease may use sildenafil under their doctor’s supervision (see the section on Taking other medicines);
Subjects who had been treated with growth hormone during childhood, until final height was attained, should be re-evaluated for growth hormone deficiency after epiphyseal closure before replacement therapy is commenced at the doses recommended for adults.
Patients who have been receiving one of these medicines need to receive MIRCERA once a month, with the dose ranging between 120 and 360 micrograms.
Patients who weighted > 20kg to< 50 kg received either 2.5, 25 or 50 mg of losartan daily and patients who weighted > 50 kg received either 5, 50 or 100 mg of losartan daily.
Patients who take Kivexa must be given the special alert card that summarises the key safety information about the medicine.
Patients with rare hereditary problems of fructose intolerance, glucose- galactose malabsorption or sucrase-isomaltase insufficiency should not take this vaccine.
Patients with IgE lower than 76 IU/ ml were less likely to experience benefit (see section 5.1).
Patients who have broken their hip should receive Aclasta at least two weeks after the operation to repair the fracture.
Patients who were randomized to the placebo maintenance group and then later crossed over to infliximab are included in the infliximab group in the ALT analysis.
Patients randomised to receive placebo at Weeks 0 and 4 crossed over to receive ustekinumab (either 45 mg or 90 mg) at Weeks 12 and 16.
Patients randomised to receive placebo at Weeks 0 and 4 crossed over to receive ustekinumab (either 45 mg or 90 mg) at Weeks 12 and 16 followed by dosing every 12 weeks.
Patients receiving methadone and Atripla concomitantly should be monitored for signs of withdrawal and their methadone dose increased as required to alleviate withdrawal symptoms.
Patients receiving DepoCyte should be concurrently treated with corticosteroids (e. g. dexamethasone) to mitigate the symptoms of arachnoiditis (see section 4.8), which is a common adverse reaction.
Patients who receive anthracyclines after stopping Herceptin may possibly be at increased risk of cardiotoxicity.
Patients receiving DMARDs, NSAIDS, or corticosteroids could continue them on stable doses.
Patients receiving montelukast had more days without asthma than those receiving placebo.
Patients receiving STELARA may receive concurrent inactivated or non-live vaccinations.
Female (79%) and male (21%) patients with a mean age of 58 years (range 19-91 years) were included.
Patients responding to 8/ 10-weeks of acute treatment with open-label Valdoxan 25-50 mg once daily were randomised to either Valdoxan 25-50 mg once daily or placebo for further 6-months.
Patients who were re-randomized to discontinue pegaptanib after one year, lost visual acuity during the second year.
Eligible patients were randomised to 1 of 4 treatments (ratio 1:1:1:1); placebo, simvastatin 20, 40, or 80 mg.
Patients with these rare disorders lack certain liver enzymes and are therefore not able to get rid of nitrogen waste, which builds up after eating protein.
Patients with underlying neurological disorders including swallowing difficulties are at increased risk of these side effects.
Haemophilia A patients may develop antibodies (inhibitors) to factor VIII.
Haemophilia A patients may develop antibodies (inhibitors) to factor VIII.
Haemophilia B patients may develop antibodies (inhibitors) to factor IX.
Patients with hepatic impairment should be observed carefully for signs of fentanyl toxicity.
Patients with renal insufficiency may develop hypocalcaemia or hypercalcaemia.
Patients taking amlodipine alone had a fall of 10.0 mmHg, compared with 11.8 mmHg in the patients adding 160 mg valsartan.
Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided.
Cytarabine patients not completing all 4 doses within a cycle are counted as a complete cycle.
Patients taking Inovelon had a 35.8% reduction in the total number of seizures, falling from an average of 290 seizures in the 4-week period before Inovelon was started.
Patients adding Inovelon also had a 42.5% reduction in the number of ‘ tonic-atonic'seizures (a common type of fit in patients with Lennox-Gastaut syndrome that often involves the patient dropping to the floor), compared to a 1.9% increase in those adding placebo.
Placebo patients received methotrexate while infliximab patients received both infliximab and methotrexate.
Patients who are given Ranexa must also be given a ‘ patient alert card 'that summarises the key safety information about the medicine.
Patients on a low potassium diet should be cautioned.
Patients who receive RoActemra should be given the special alert card that summarises the safety information about the medicine.
Patients on sildenafil achieved a statistically significant reduction in mean Pulmonary Arterial Pressure (mPAP) compared to those on placebo.
Patients who take Trizivir must be given the special alert card that summarises the key safety information about the medicine.
Patients who take Ziagen must be given the special alert card that summarises the key safety information about the medicine.
Patients who are stable on a once weekly dosing regimen may be switched to once every two weeks administration.
To be taken into consideration by patients on a controlled sodium diet.
Patients treated with ATryn should be monitored for possible clinical immunological reactions.
Patients on Dynepo therapy can experience increase in blood pressure or aggravation of existing hypertension.
Patients treated with immediate release doxazosin tablets against hypertension can be transferred to Cardoreg 4 mg prolonged release tablets and associated names and the dose titrated upwards as needed, while maintaining effect and tolerability.
Patients treated with Aldurazyme may develop infusion-associated reactions (IARs), defined as any related adverse event occurring during the infusion or until the end of the infusion day (see section 4.8).
Patients treated with Avastin have an increased risk of haemorrhage, especially tumour-associated haemorrhage.
Patients being treated with Byetta should continue to follow their diet and exercise plans.
Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided.
Patients treated with immunosuppressants, including Mycophenolate mofetil Teva, are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal), fatal infections and sepsis (see section 4.8).
Diacomit may cause dizziness and ataxia that may affect ability to drive and use machines and patients should not drive or use machinery whilst on Diacomit therapy.
16 Patients in the Enbrel in combination with methotrexate therapy group had significantly higher ACR 20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and 52 weeks than patients in either of the single therapy groups (results shown in table below).
170 Patients in the Enbrel in combination with methotrexate therapy group had significantly higher ACR 20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and 52 weeks than patients in either of the single therapy groups (results shown in table below).
43 Patients in the Enbrel in combination with methotrexate therapy group had significantly higher ACR 20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and 52 weeks than patients in either of the single therapy groups (results shown in table below).
70 Patients in the Enbrel in combination with methotrexate therapy group had significantly higher ACR 20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and 52 weeks than patients in either of the single therapy groups (results shown in table below).
Patients in the Enbrel in combination with methotrexate therapy group had significantly higher ACR 20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and 52 weeks than patients in either of the single therapy groups (results shown in table below).
Patients treated concurrently with erlotinib and gemcitabine should be monitored carefully for the possibility to develop ILD-like toxicity.
Patients treated concurrently with erlotinib and gemcitabine should be monitored carefully for the possibility to develop ILD-like toxicity.
Patients treated with Humira usually experienced improvement in haematological signs of chronic inflammation.
Alzheimer´s disease assessment scale (ADAS-cog) (p=0.003) -and CIBIC-plus (p=0.004) at week 24 last observation carried forward (LOCF).
Patients treated with ribavirin and zidovudine are at increased risk of developing anaemia; therefore, the concomitant use of ribavirin with zidovudine is not recommended (see section 4.5).
Patients treated with PegIntron and ribavirin combination therapy and zidovudine are at increased risk of developing anaemia and therefore the concomitant use of this combination with zidovudine is not recommended (see section 4.5).
Patients treated with Lucentis in PIER received a mean of 10 total treatments out of possible 13 from day 0 to month 24.
Patients treated with nelarabine are potentially at risk of suffering from somnolence during and for several days after treatment.
Patients treated with Remicade should be given the package leaflet and the special Alert card.
Patients treated with ribavirin and zidovudine are at increased risk of developing anaemia; therefore, the concomitant use of ribavirin with zidovudine is not recommended (see section 4.5).
Patients who receive Tysabri must be given a special alert card that summarises the key safety information about the medicine.
Patients treated with TYSABRI must be given the patient alert card.
Patients treated with a dosage of 4 mg or less oral risperidone should receive 25 mg RISPERDAL CONSTA, while patients treated with higher oral doses should be considered for the higher RISPERDAL CONSTA dose of 37.5 mg.
Patients treated with a dosage of 4 mg or less oral risperidone should receive 25 mg RISPERDAL CONSTA, while patients treated with higher oral doses should be considered for the higher RISPERDAL CONSTA dose of 37.5 mg.
Valnemulin has activity against a range of bacteria including those responsible for enteric and respiratory disease in pigs.
The spectrum of activity of thalidomide is not fully characterised.
The IRMS must possess a triple collector to allow the simultaneous detection of the ions at mass/ charge ratio 44, 45 and 46 fluctuations in the oxygen isotope content.
Infrared spectrometers for breath analysis must comply with the following specifications:
Normal saline is given to minimise the potential for kidney damage.
Infusions should be carried out in a specialised cancer ward.
Older adults may be more sensitive to the effects of this
In people with CML, white cells called granulocytes start growing out of control.
Individuals with haemophilia B may develop antibodies (inhibitors) against factor IX.
Therefore, care should be taken by people who wear soft contact lenses.
Persons with known hypersensitivity to the active substance or any of the excipients should administer the product with caution.
6 mg/ kg dose (number of vials) - - - - 18.0 ml (1) 21.0 ml (2) 24.0 ml (2) 27.0 ml (2) 30.0 ml (2) 33.0 ml (2) 36.0 ml (2) 39.0 ml (2) 42.0 ml (3) 45.0 ml (3) 48.0 ml (3) 51.0 ml (3) 54.0 ml (3) 57.0 ml (3) 60.0 ml (3)
Discrete nodules will receive an initial light application of 50 J/ cm (using short diffuser) before the balloon light application.
- phenothiazine derivatives (used to treat psychiatric disorders),
- phenothiazine derivatives (used to treat psychiatric disorders),
Phosphenes were generally reported to be of mild to moderate intensity.
The blisters are then packed in cardboard boxes.
Bags/ containers that come in contact with TORISEL must be made of glass, polyolefin, or polyethylene.
- Hair at the application site should be clipped (not shaved) before system application.
Hair at the application site should be clipped (not shaved) before system application.
Use of injection sites should be rotated so that the same site is not used more than approximately once a month.
When an infant is given the vaccine, the immune system recognises the parts of the bacteria and viruses as ‘ foreign'and makes antibodies against them.
Laying and breeder stock should get a second vaccination 6-10 weeks after the first vaccination.
Both patient populations presented a median age of 63 years, with a comparable male to female ratio.
Affected pigs are pyrexic, exhibit inappetence, and in severe cases become incoordinated, ataxic and may become recumbent.
Affected pigs are pyrexic (have a high temperature), have a lack of appetite; in severe cases they might become uncoordinated and remain lying down.
Breeding boars (male pigs) should be revaccinated every six months.
The pigs should be vaccinated in time before the expected exposure to the field virus, preferably prior to housing (crowding) or transfer to new groups.
Severely affected pigs should be removed to clean dry pens and given symptomatic treatment, including treatment for concurrent disease.
Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated.
Recommended dose for 5 days
The travel and accommodation options available to delegates will be increased through a revision of the terms on which the EMEA purchases from its suppliers.
The percentages were 15% in the patients treated with Prograf/ Prograft, and 17% in those treated with ciclosporin.
The usual safety precautions for magnetic resonance imaging must be observed, e. g., exclusion of cardiac pacemakers and ferromagnetic implants.
Premature infants who have been transfused before the start of treatment with NeoRecormon are not likely to benefit as much as untransfused infants.
Applications for variations to marketing authorisations granted under the centralised procedure essentially began in the latter half of 1996.
The first of these are transient and their cause should be investigated if symptoms persist.
España Federico PLAZA PIÑOL Quintiliano PÉREZ BONILLA (3)
The first summaries of COMP opinions were published on the EMEA web site in March 2002.
Alcohol and some medicines can affect your blood sugar levels.
First symptoms of ovarian hyperstimulation are pain in the lower abdominal region, possibly in combination with nausea, vomiting and weight gain.
First symptoms of OHSS are pain in the lower abdominal region, possibly in combination with nausea, vomiting and weight gain.
482 The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if
661 The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if
681 The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if
795 The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if
The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if
The first symptoms which alert you to hypoglycaemia (“warning symptoms”) may change, be weaker or may be missing altogether if
The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if
The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if
The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if:
The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if:
It is unclear whether or not there is a direct association between pioglitazone and macular oedema but prescribers should be alert to the possibility of macular oedema if patients report disturbances in visual acuity; an appropriate ophthalmological referral should be considered.
Multidose presentations must be for individual patient use only.
No individual sale of single packs.
Evidence of efficacy with chlormezanone is limited and of poor quality.
The main activities of the sector are to ensure the continuation of the co- ordination of quality management of routine operations in support of the Agency's functioning in the areas of product information quality, translations, coherence of regulatory documents (templates and opinions), document management, document dissemination (production and distribution), library services, mail services and archiving.
The instructions include the following main steps:
The main measures of effectiveness were the length of the endocardium (inner surface) of the left ventricle of the heart that could be seen before and after injection of OPTISON and the reference medicine, and the observer's assessment of the change in the ability to see the endocardium of the left ventricle before and after each injection.
The main measures of effectiveness were the number of eggs that could be harvested and the ongoing pregnancy rate.
The study looked at the ability of two 7.5-microgram doses of Celvapan, given 21 days apart, to trigger the production of antibodies (‘ immunogenicity’). The main measures of effectiveness were the levels of antibodies against the flu virus in the blood before vaccination, on the day of the second injection (day 21), and 21 days after the second vaccination (day 42).
The main measures of effectiveness were the response rates (percentage of patients whose cancer responded to treatment), the time taken for the disease to progress and the increase in survival.
The major dose limiting toxicities of lenalidomide include neutropenia and thrombocytopenia.
The main areas for harmonisation were: the sections 4.1, 4.2, 4.3, 4.4 and 4.6 of the summary of product information (SPC).
The main sections to be harmonised were the sections Therapeutic indications, Posology and method of administration, Contraindications, Special warning and special precaution for use, Undesirable effects.
The main excretory route is via urine and faeces.
The main excretory routes are via urine and faeces.
The main measures of effectiveness were the number of exacerbations and number of patients with exacerbations of asthma, the patients'quality of life (assessed using standard questionnaires), and the reduction in the amount of inhaled corticosteroid that the patients needed to take.
The main measures of effectiveness were the change in the severity of hayfever symptoms reported by the patients between before treatment started, and over the entire 15 days of treatment.
The main measures of effectiveness were the number of relapses, and the changes in the patients'level of disability, measured using a standard scale (the Expanded Disability Status Scale).
The main measures of effectiveness were the response rates (percentage of patients whose cancer responded to treatment), the time taken for the disease to progress and the increase in survival time.
The main measure of effectiveness were the response rates (percentage of patients whose cancer responded to treatment), the time taken for the disease to progress and the increase in survival time.
The main measures of effectiveness were response rates in the hepatitis studies and survival time in the cancer studies.
The main measures of effectiveness were changes in pain scores as rated by the patients.
The key elements that need to be covered in training hospital personnel are as follows.
The main risk factors for hyperkalaemia to be considered are:
The major metabolites, hydroxylated and demethylated agomelatine, are not active and are rapidly conjugated and eliminated in the urine.
Main human metabolites are N-3,5-dimethyl-gludantan, the isomeric mixture of 4- and 6-hydroxy-memantine, and 1-nitroso-3,5-dimethyl-adamantane.
The major circulating metabolites are inactive.
The main metabolites identified are the N-desmethyl and lactone metabolites.
The major metabolites found in all species were the 5-hydroxy- and 5-carboxy-metabolites and the oxalyl-metabolite.
The main metabolites are hydrolysable conjugates of difloxacin, the other metabolites are proportionally minor ones.
The most important metabolites are isomers of 5α-dihydro-NET and of tetrahydro-NET, which are excreted mainly in the urine as sulfate or glucuronide conjugates.
Electronic submission
The principal objectives for 2003 are:
The main areas for harmonisation were as follows.
The main symptoms are itching, rash, wheals (slightly elevated, itchy skin patches that are paler or redder than surrounding skin), severe difficulty in breathing, nausea, vomiting and
The main sites of surgery were colonic/ rectal, gastric, hepatic, cholecystectomy or other biliary.
The active substances in Tritanrix HepB have been available in the European Union (EU) for a number of years in other vaccines.
The active substances and other ingredients in Tritanrix HepB are listed at the end of the leaflet.
Problems with overdosage with this medicine are unlikely.
The normal procedures for proper handling and disposal of anticancer medicinal products should be adopted, namely: − Personnel should be trained to reconstitute the medicinal product. − Pregnant staff should be excluded from working with this medicinal product. − Personnel handling this medicinal product during reconstitution should wear protective clothing including mask, goggles and gloves. − All items for administration or cleaning, including gloves, should be placed in high-risk, waste disposal bags for high-temperature incineration.
As anaesthetic drugs may affect renal perfusion, the use of parenteral fluids during surgery should be considered to decrease potential renal complications when using NSAIDs peri-operatively.
As anaesthetic drugs may affect renal perfusion, the use of parenteral fluid therapy during surgery should be considered to decrease potential renal complications when using NSAIDs peri-operatively.
Agents that may enhance the risk of haemorrhage should not be administered concomitantly or should be administered with caution with Pradaxa (see section 4.5).
Agents that may enhance the risk of haemorrhage should not be administered concomitantly or should be administered with caution with Pradaxa (see section 4.5).
When given concurrently, the following drugs may interact with thiazide diuretics:
The expected degradation products are small peptides and individual amino acids which are eliminated by glomerular filtration.
Factor IX products rarely require to be administered more than once daily.
Any unused product or waste material should be disposed of in accordance with local requirements.
Any unused product or waste materials should be disposed of in accordance with local requirements.
Health care professionals, relatives and other carers must follow general precautionary measures for removal and disposal of needles to eliminate the risk of unintended needle penetration.
Cross-resistance profiles for efavirenz, nevirapine and delavirdine in vitro demonstrated that the K103N substitution confers loss of susceptibility to all three NNRTIs.
Therefore, the benefit and the risk of concurrent treatment should be carefully weighed (see section 4.4).
The pharmacokinetic profiles of transdermal and oral combined hormonal contraceptives are different and caution should be exercised when making a direct comparison of these PK parameters.
Good progress in the VICH initiative in 1997 bodes well for further progress in 1998.
• Publication of summaries of opinions from the Committee for The European Commission proposals for the revision of European pharmaceutical legislation (OJ C 75 E, 26.3.2002, pp.
Desloratadine has demonstrated antiallergic properties from in vitro studies.
ed The pharmacokinetics of darbepoetin alfa has been studied clinically in chronic renal failure patients following intravenous and subcutaneous administration.
The pharmacokinetics of darbepoetin alfa has been studied clinically in chronic renal failure patients following intravenous and subcutaneous administration.
The pharmacokinetic properties of doxazosin in Cardoreg 4 mg prolonged release tablets and associated names lead to a minor variation in plasma levels.
The pharmacokinetic properties of lamivudine and abacavir are described below.
The pharmacokinetic properties of lepirudin following intravenous administration are well described by a two-compartment model.
The pharmacokinetics of Ribavirin and interferon alfa-2b (dose- normalized) are similar in adults and children or adolescents.
The pharmacokinetic properties of etravirine have been evaluated in adult healthy subjects and in adult treatment-experienced HIV-1 infected patients.
The pharmacokinetic properties of imiquimod following single and multiple topical application in paediatric patients with molluscum contagiosum (MC) have been investigated.
The pharmacokinetics of NovoMix 30 has not been investigated in children or adolescents.
The pharmacokinetics of NovoMix 70 has not been investigated in elderly, children or patients with impaired renal or liver function.
Using the FVIIa assay, the pharmacokinetic properties of NovoSeven were studied in 12 paediatric (2 - 12 years) and 5 adult patients in non bleeding state.
Using the FVII clotting assay, the pharmacokinetics of NovoSeven were investigated in 35 healthy Caucasian and Japanese subjects in a dose-escalation study.
The pharmacokinetic properties of NutropinAq have only been investigated in healthy adult males.
The pharmacokinetics of Rebetol and interferon alfa-2b (dose-normalized) are similar in adults and children or adolescents.
The pharmacokinetics of Rebetol and interferon alfa-2b (dose-normalized) are similar in adults and children or adolescents.
The pharmacokinetics of Viraferon and ribavirin (dose-normalized) are similar in adults and children or adolescents. t
The pharmacokinetics of IntronA and ribavirin (dose-normalized) are similar in adults and children or adolescents.
Using the FVIIa assay, the pharmacokinetic properties of rFVIIa were studied in 12 paediatric (2 - 12 years) and 5 adult patients in non bleeding state.
Using the FVII clotting assay, the pharmacokinetics of rFVIIa were investigated in 35 healthy Caucasian and Japanese subjects in a dose-escalation study.
The pharmacokinetic and pharmacodynamic properties of NovoRapid were investigated in children (6– 12 years) and adolescents (13– 17 years) with type 1 diabetes.
The following properties have been demonstrated in preclinical studies:
The ultrasonic properties of the product are very different from those of soft tissue and will generate strong echoes.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Anaesthetic regimens that include opioid, alpha-2-agonist, benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance concentrations.
The following complete feeding stuffs for pigs can be used for the manufacturing of medicated feeds:
101 carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein.
114 carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein.
23 carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein.
36 carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein.
75 carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein.
88 carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein.
The four carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the
The four carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein.
The four carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein.
The issues identified by the MRFG for further work include the areas of hormone replacement therapy, paediatric medicines, oncology products, anti- infectives and revision of the guidance on bioequivalence testing.
The issues discussed included the efficacy data provided in the clinical trials, particularly in the subset of patients having a functional impact and the long-term efficacy and safety as well as the benefit-risk ratio.
Quinolone class drugs have been associated with cartilage erosions in weight-bearing joints and other forms of arthropathy in immature animals of various species.
Radiographs of hands/ wrists and feet were read at baseline and 6, 12, and 24 months.
RAF kinases are serine/ threonine kinases, whereas c-KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß are receptor tyrosine kinases.
The reason for this difference is unclear and possibly related to an increased hepatic metabolism and excretion.
Final study reports will be shared with Agencies when available.
The reports suggest that CEPROTIN is well tolerated in children and small infants.
The rash associated with the efavirenz component usually resolves with continued therapy.
Serious allergic reactions are uncommon.
Infusion associated reactions consisted most often of fever and chills.
The most common of these infusion-related reactions included cutaneous reactions (rash, pruritus, urticaria), pyrexia, headache, and hypertension.
Reactions at an individual injection site usually last for equal to or less than 7 days.
Injection site reactions generally did not necessitate discontinuation of the medicinal product.
Infusion site reactions were generally mild and consisted of hyper pigmentation, inflammation, redness or dryness of the skin, phlebitis or extravasation and swelling of the vein.
Injection site reactions occurred frequently after administration of Betaferon.
Injection site reactions occurred frequently after administration of Betaferon.
Inflammation of a vein.
The following local reactions may be observed at the application site: fur discoloration, local alopecia or pruritus.
Subsequent free radical reactions can form superoxide and hydroxyl radicals.
12 General reactions that may occur in temporal association with Tritanrix HepB vaccination are listed below.
General reactions that may occur in temporal association with Tritanrix HepB vaccination are listed below.
Most frequent adverse reactions involve the gastro-intestinal tract and the central nervous system.
Post-Marketing Experience The following additional serious adverse reactions have been identified during post-marketing exposure:
The following additional serious adverse reactions have been identified during post-marketing exposure:
Serious adverse reactions reported during the post-marketing period include: – Arterial thrombotic events such as myocardial infarctions or ischaemia, cerebrovascular disorders and bowel infarction.
Serious adverse reactions reported during the post-marketing period include: – Arterial thrombotic events such as myocardial infarctions or ischaemia, cerebrovascular disorders and bowel infarction.
The adverse reaction most often reported (30.4%) was application site reactions.
Most commonly reported adverse reactions are of gastrointestinal character and are seen in approximately 7% of the patients.
The most commonly reported adverse reactions are headache, nasopharyngitis, nausea, pyrexia, myalgia, fatigue, and herpes simplex, each occurring in 5 or more out of 100 patients.
The local adverse reactions are characteristic of an acute tissue inflammatory response induced by photoactivation.
Adverse reactions were generally mild or moderate in intensity.
Patient reported adverse reactions from 2292 patients treated with imiquimod cream in placebo controlled and open clinical studies are presented below.
Those serious adverse reactions attributed to TRISENOX included APL differentiation syndrome (3), leukocytosis (3), prolonged QT interval (4, 1 with torsade de pointes), atrial fibrillation/ atrial flutter (1), hyperglycaemia (2) and a variety of serious adverse reactions related to haemorrhage, infections, pain, diarrhoea, nausea.
7 2 cycles and tended to decrease with subsequent cycles.
The following adverse reactions have been observed:
The following additional adverse reactions have been reported during post– marketing experience; they are derived from spontaneous reports and therefore, the frequency of these adverse reactions is not known:
The following adverse reactions have been report:
The adverse reactions occurring in at least 5% of patients considered at least possibly related to the treatment of low-dose IL-2 with Ceplene in AML studies (n=196 for the IL-2 and Ceplene treatment arm) are listed below by body system organ, class and frequency.
The most commonly reported reactions were hyperglycaemia, hypokalaemia, neutropenia, and increased alanine amino transferase (ALT).
These reactions are mainly fever and chills.
The most commonly 38 reported reactions are listed in section 4.8.
The most commonly reported reactions are listed in section 4.8.
Infusion related reactions may occur as a result of hypersensitivity and/ or to the mechanism of action.
Infusion reactions rarely recur after the first treatment cycle.
Commonly reported post-vaccination reactions are a diffuse swelling and/ or hardened nodule, accompanied by pain, at the site of vaccination.
Adverse reactions are often dose related and occur most frequently in the first couple of weeks after initiation of therapy.
Australia, China, Columbia, Cuba, Japan, Lithuania, Namibia, Russia, Singapore, South Africa and Thailand.
Dimeric soluble receptors such as etanercept possess a higher affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of TNF binding to its cellular receptors.
Oestrogen receptors can be found in the urethral sphincter, where oestrogens induce a full response, this way improving urethral closure and bladder storage.
Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative.
Dose adjustment guidelines should be followed (see section 4.2).
Dosing recommendations for patients receiving oral topotecan with Clcr less than 60 ml/ min have not been established (see section 4.4).
Dose modification guidelines for patients who use PegIntron monotherapy are shown in Table 3a.
Dose modification guidelines for patients who use ViraferonPeg monotherapy are shown in Table 3a.
A new Unit was created in October 2001 with responsibility for facilitating communications and networking between the
Official recommendations on HER2 testing may also apply.
Specific recommendations for management of treatment-emergent anaemia are as follows: ribavirin should be reduced to 600 milligrams/ day (200 milligrams in the morning and 400 milligrams in the evening) if either of the following apply:
However, decreases in exposure were as much as 56% and 66%, respectively, in individual subjects.
reinforced throughout the year, not only with the different services of the European Commission (in particular Directorates-General III - Industry affairs, XII - Science, research and technology, and the EC Joint Research Centre), but also with the European Parliament and its Committee on the Environment, Public Health and Consumer Protection.
Meals rich in large neutral amino acids may delay and reduce the absorption of levodopa.
ACR 20 and 50 responses were higher in patients treated with Enbrel at 3 and 6 months than in patients treated with placebo (ACR 20:
The ACR responses in Study V were consistent with the DAS28 score.
ACR responses were maintained in the open-label extension study for up to 136 weeks.
- the responses provided by the Applicant, in particular the additional clinical data submitted during
However, the response from commercial suppliers was disappointing and expensive and did not meet the Agency’s needs in complying with the financial regulations.
Responses were also determined by a composite score of five clinical signs (surface area, erythema, plaque elevation, scaling and hypo/ hyperpigmentation) which also considered all extracutaneous CTCL manifestations.
The responses were submitted to the EMEA on 12 September 2006.
Serologic responses obtained with the Hemagglutination Inhibition (HI) assay showed that 92% of subjects achieved seroprotection and 75% seroconverted after two 7.5 μ g injections.
approximation of the laws of Member States relating to veterinary medicinal products, as amended (OJ L 317, 6.11.1981, p.
Media and press contacts Representatives of the media should contact the following people for information:
Residues at the injection sites were high and still up to 5 times above the muscle MRL at the latest time point.
Residues in the injection sites were high and still up to 5 times above the muscle MRL at the latest time point.
Residues in muscle, fat and liver were below the MRL at all time points.
Residues in muscle, fat, liver and kidney were below the MRL at all time points.
Mannose-6-phosphate (M6P) residues on the oligosaccharide chains allow specific binding of the enzyme to the M6P receptors on the cell surface, leading to cellular internalization of the enzyme, targeting to intracellular lysosomes and subsequent catabolism of accumulated GAG.
The additional sugar residues are molecularly indistinct from those on the endogenous hormone.
Zidovudine resistance emerged as more frequent after 30 – 60 weeks, especially in patients receiving double combination therapy.
Cross-resistance among the currently registered NNRTIs is broad.
Cross-resistance among the currently registered NNRTIs is broad.
Heads of national agencies who are not members of the Board will be invited to attend when issues of common interest are discussed.
Heads of national agencies who are not members of the Board will be invited to attend when issues of common interest are discussed.
SBA-MenC results are available for 177 subjects, anti-PRP results for 178 subjects.
The cardiorenal results for EDGE and EDGE II were consistent with those described for the MEDAL Study.
The following results of the effects of FABLYN on the endometrium through 5 years of exposure are reported from the PEARL study.
The results below are pooled data from the two trials.
Key results from all four studies are summarized in table 3.
Key efficacy results for IMPACT and IMPACT 2 are shown in Table 8 below:
Key results are presented in Table 9.
The combined results of these two trials are presented below:
The vardenafil results showed an increase in QTc (Fridericia) of 8 msec (90% CI:
The results of the two studies taken together showed that, on average, it took 48.3 weeks for the disease to get worse in patients taking Revlimid, compared with 20.1 weeks in those taking placebo.
Results from other supportive studies using MabThera in combination with other chemotherapy regimens (including CHOP, FCM, PC, PCM) for the treatment of CLL patients have also demonstrated high overall response rates with promising PFS rates without adding relevant toxicity to the treatment.
Results of these analyses subsequently led to an unblinding in both studies, in order to allow patients in the placebo/dexamethasone group to receive treatment with the lenalidomide/dexamethasone combination.
The results of these fed studies demonstrate that Lansoprazole's bioavailability is not only markedly reduced when taken with food, but that its absorption, in the presence of food, can be very erratic.
The results of these tests allow your doctor to choose the correct dose of Fertavid from day to day.
The results of these tests allow your doctor to choose the correct dose of Puregon from day to day.
Study results were obtained with the 80 mg dose strength.
The results for efficacy of Eqvalan measured this way were also below 90%.
Efficacy findings were consistent, independent of the infective Candida species, primary site of infection and neutropenic status (see Table).
The outcome of the revision of the current regulatory framework will impact on the tasks and functions of the EMEA.
The PFS results are given again below:
Results of P907 showed efficacy over placebo.
Study results are summarized in Table 11.
Virological response in previously untreated paediatric patients
The results of the trials showed that vaccination by Ibraxion of calves either not less than 3 to 4 months of age (if they have antibodies to IBR that have been passed on from their mother) or from 2-week of age (if they have no maternal antibodies). provided protection from IBR for six months.
Results from the 2- and 4- week studies showed that no pharmacological tolerance developed with any dose of Zerene.
Results of individual studies support the results from the combined analysis.
104 Results of the Ames/salmonella and Human Peripheral Blood Lymphocyte (HPBL) chromosome aberration tests showed a positive mutagenicity response.
Results of the Ames/salmonella and Human Peripheral Blood Lymphocyte (HPBL) chromosome aberration tests showed a positive mutagenicity response.
Looking at the results of the three studies in which Cholestagel was used with a statin, there was a further reduction of 8% in LDL cholesterol levels with 2.3 g Cholestagel (about four tablets), and of 16% with 3.8 g Cholestagel (about six tablets).
Safety results in paediatric patients were consistent with the safety profile of levetiracetam in adults except for behavioural and psychiatric adverse events which were more common in children than in adults (38.6% versus 18.6%).
Safety results in paediatric patients were consistent with the safety profile of levetiracetam in adults except for behavioural and psychiatric adverse events which were more common in children than in adults (38.6% versus 18.6%).
Safety results on 246 patients were consistent with the adverse events profile in the overall population.
The present results of Raptiva versus placebo over 12 weeks of treatment with different populations indicate a PASI 75 response to Raptiva in 22% to 39% of patients (see Table 2).
Results from a mass balance study with radioactive 14C-etravirine showed that < 1.2% of the administered dose of etravirine is excreted in the urine.
The results of the pilot project, which will be carried out with the help of the European Commission, will be carefully evaluated before further proposals are made.
The results were again similar to patients with non-laryngeal attacks of HAE with a median time to start of regression of symptoms of 0.6 - 1.0 hours (controlled phase).
In study I, daily ON time (hours) was measured from home diaries and in study II, the proportion of daily ON time.
From the results it can be concluded that efficacy results of the 20 mg maintenance dose were more favourable, on the other hand, the safety results favoured the 10 mg daily maintenance dose.
The results indicate that the drug substance and drug product can be reproducibly manufactured.
Results indicate that sodium phenylbutyrate did not induce any mutagenic effects in the Ames test with or without metabolic activation.
The results indicate that the drug substance and drug product can be reproducibly manufactured.
The results indicate that XELOX is equivalent to FOLFOX-4 in terms of overall survival (see Table 8).
A dose of 75 IU r-hLH daily (in combination with 150 IU follitropin alfa (r-hFSH)) resulted in adequate follicular development and oestrogen production.
The interim results (results calculated before the study was finished) were sufficiently good for the study to be stopped early and for the patients who were receiving placebo to be switched to Sutent.
Results showed no meaningful effect of hepatic impairment on the AUC or Cmax of methylnaltrexone.
The results obtained with Noxafil were compared with the records of 218 patients who were treated with other antifungal medicines.
In pravastatin -tre ated patients, results showed:
In pravastatin-treated patients, results showed:
The results in the treatment of other types of clotting disorders, and of patients with other protein C deficiencies, were not sufficient to assess completely the use of CEPROTIN in these groups.
The results obtained in populations with different characteristics (e. g. unstable angina or non-Q-wave MI, low to high risk levels, diabetes, need for revascularisation, age, gender, etc.) were consistent with the results of the primary analysis.
The results obtained in populations with different characteristics (e.g. unstable angina or non-Q-wave MI, low to high risk levels, diabetes, need for revascularisation, age, gender, etc.) were consistent with the results of the primary analysis.
The results were also calculated separately between ‘ HBeAg-positive'patients (infected with the common hepatitis B virus) and ‘ HBeAg-negative 'patients (infected with a virus that has mutated, leading to a form of chronic hepatitis B that is more difficult to treat).
The results were also considered acceptable on clinical grounds as lansoprazole's efficacy is largely independent of dose at this therapeutic dose range.
The results were confirmed in the other study, which involved children aged between six months and three and a half years.
The results showed roughly similar pharmacokinetic parameters of losartan following oral administration in infants and toddlers, preschool children, school age children and adolescents.
The results showed that the active metabolite is formed from losartan in all age groups.
MabCampath pharmacokinetics followed a 2-compartment model and displayed non-linear elimination kinetics.
The results showed roughly similar pharmacokinetic parameters of losartan following oral administration in infants and toddlers, preschool children, school age children and adolescents.
The pharmacokinetic results reflect the slightly different in vitro characteristics of these nebulizers (see Section 4.2).
The results for these subjects were not different from the results in the study as a whole.
Key results of studies 2, 3 and 4 are shown below.
Key results of studies 2, 3 and 4 are shown below.
Results are from a Cox proportional hazards regression analysis which includes treatment as a time-varying covariate, and also includes age of diagnosis and age at symptom onset.
Serology results for the efficacy study carried out in chickens by Katsma et al. should be provided.
The results will be compared and a significant increase in the amount of 13 Carbon in the second set of samples will suggest your doctor that Helicobacter pylori are present.
Results continuously improved with increasing experience over the course of 11 years.
The results reported indicated residue values below the muscle MRL at all time points except for 1 animal at the last time point, which had a concentration of 6 times above the muscle MRL.
The results are difficult to interpret due to various reasons such as differences in effect on systolic blood pressure and discontinuation of diuretics in the doxazosin-treated group prior to commencement of the treatment.
Secondary efficacy outcomes were generally consistent with the primary outcome.
The summaries of opinion of the Committee for Orphan Medicinal Products for Tracleer are available here (PAH) and here (systemic sclerosis).
- the Summaries of Products Characteristic, labelling and package leaflet proposed by the Marketing
- the Summaries of Products Characteristic, labelling and package leaflet proposed by the Marketing
- The Summaries of Products Characteristic, labelling and package leaflet proposed by the Marketing
- the Summaries of Products Characteristic, labelling and package leaflet proposed by the Marketing
- the Summaries of Products Characteristic, labelling and package leaflet proposed by the Marketing
- the Summaries of Products Characteristic, labelling and package leaflet proposed by the Marketing
- The Summaries of Products Characteristic, labelling and package leaflet proposed by the Marketing
- the Summaries of Products Characteristic, labelling, package leaflet proposed by the Marketing
Adults The effective daily dose is usually between 15 and 45 mg; the starting dose is 15 or 30 mg.
Mrs Genoux-Hames, Prof Trouvin, Dr Abadie:
Meetings in 1998 were held with representatives of authorities from Belgium, Germany, France, Austria, Sweden and UK.
They will be responsible for the operation and future development of the system.
Issues already identified include transparency issues, including post-marketing and pharmacovigilance communication, and readability of patient leaflets
SIRS, capillary leak syndrome or tumour lysis syndrome were reported as an adverse event in 10% (13/ 132) of patients (see section 4.4).
The risks to be expected are associated with the inadvertent administration of excess radioactivity.
In the following conditions the risks of reteplase therapy may be increased and should be weighed against the anticipated benefits:
In the following conditions, the risk of Metalyse therapy may be increased and should be weighed against the anticipated benefits:
Because the potential interaction of efavirenz, a component of Atripla, with oral contraceptives has not been fully characterised, a reliable method of barrier contraception must be used in addition to oral contraceptives
All part of the sections for 4 and 5 of the summary of product characteristics has been harmonised during the procedure.
Sachets should not be re-used once opened.
The pivotal clinical trial supporting the approval of Osigraft did not include the use of synthetic bone void fillers.
Bleeding events were reported at 48 hours and non bleeding events are reported at 30 days.
Referrals to the CPMP now constitute a significant allocation of the Agency’s resource both in terms of scientific evaluation and discussion during CPMP plenary meetings.
The 18 week STRIDE-2 trial, conducted in 246 patients, included 4 treatment arms: placebo once daily, Thelin 50 mg once daily, Thelin 100 mg once daily, and open-label bosentan twice daily (efficacy-rater blinded, administered according to the approved package insert).
The following diagrams indicate the possible injection sites:
Quality of life scores were measured using the Juniper Asthma-related Quality of Life Questionnaire.
Mean baseline NAPSI scores were 4.6 and 4.3 in infliximab and placebo group.
Symptom scores were around 100 points at the start of the study, but had fallen by around 25 points in the patients receiving Zypadhera after eight weeks, compared with around 9 points in the patients receiving placebo.
The dose per inhalation session should be administered 6 to 9 times per day according to the individual need and tolerability.
The period between each treatment session should be at least 10 weeks.
Sections 4.5, 4.6, 4.7, 4.8 and 4.9 were also harmonised.
T1 -weighted scanning sequences are particularly suitable for contrast-enhanced examinations.
Syringes must be disposed in a puncture-proof container.
Polycarbonate syringes must not be used with Busilvex.
Polycarbonate syringes must not be used with Busilvex.
Syringes and needles must be sterile before use.
The syringes may be presented in either blistered (1- & 4-pack) or non-blistered packaging (1-pack only).
The syringes may be presented in either blistered (1- & 4-pack) or non-blistered packaging (1-pack only).
The syringes may be presented in either blistered (1- & 4-pack) or non-blistered packaging (1-pack only).
The syringes may be presented in either blistered (1- & 4-pack) or non-blistered packaging (1-pack only).
The syringes may be presented in either blistered (1- & 4-pack) or non-blistered packaging (1-pack only).
The services of the Commission continued to be represented at the EMEA through both the European Technical Office for Medicinal Products (ETOMEP) of the Joint Research Centre and the Anglo-Irish Desk of the Joint Interpretation and Conference Service.
Network services (domain name management and Internet access) are operated by ETOMEP as well as electronic mail services (X.400 and SMTP).
Acute signs of overdose may include nausea, vomiting, headache and diarrhoea.
ris Patients whose blood glucose control is greatly improved e. g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised
Treatment- related clinical signs were mainly related to sedation, reduced food consumption and secondary changes in body weight, body weight gain and organ weights.
Signs include: • raised and itchy rash (hives) • swelling, sometimes of the face or mouth (angioedema), causing difficulty in breathing • collapse.
These may be signs of liver problems: • nausea and vomiting • stomach (abdominal) pain 105 • loss of appetite • dark-coloured urine.
These may be signs of liver problems: • nausea and vomiting • stomach (abdominal) pain • loss of appetite • dark-coloured urine.
ris • if your child has previously had an allergic reaction to any vaccine against diphtheria, tetanus, pertussis (whooping cough), hepatitis B or Haemophilus influenzae type b diseases. • if your child experienced problems of the nervous system (such as repetitive fits, decrease of
Signs of acute toxicity in animals included ataxia, laboured breathing, ptosis, hypoactivity, or excitation.
Acute (single-dose) toxicity Signs of oral toxicity in rodents were characteristic of potent neuroleptic compounds: hypoactivity, coma, tremors, clonic convulsions, salivation, and depressed weight gain.
The adverse clinical signs observed in dogs included salivation, emesis and diarrhoea/ abnormal stool.
Signs of this condition can be pain in the mouth, teeth and/ or jaw, swelling or sores inside the mouth, numbness or a “ heavy jaw feeling”, or loosening of a tooth.
IH-associated signs and symptoms resolved after interruption of dosing.
The signs and symptoms of this hypersensitivity reaction are listed below.
Signs and symptoms of overdose (duloxetine alone or in combination with other medicinal products) included somnolence, coma, serotonin syndrome, seizures, vomiting and tachycardia.
Signs and symptoms of overdose (duloxetine alone or with mixed drugs) included somnolence, coma, serotonin syndrome, seizures,, vomiting andtachycardia.
Signs and symptoms of overdose (duloxetine alone or with mixed medicinal products) included somnolence, coma, serotonin syndrome, seizures, vomiting and tachycardia.
Signs and symptoms of overdose (duloxetine alone or with mixed medicinal products) included somnolence, coma, serotonin syndrome, seizures,, vomiting and tachycardia.
Common signs and symptoms of cyanide poisoning include: nausea, vomiting, headache, altered mental status (e. g. confusion, disorientation), chest tightness, dyspnoea, tachypnoea or hyperpnoea (early), bradypnoea or apnoea (late), hypertension (early) or hypotension (late), cardiovascular collapse, seizures or coma, mydriasis, and plasma lactate concentration > 8 mmol/ l.
Signs are usually transitory and generally resolved without treatment within 24 hours.
Transferring a patient to another type or brand of insulin should be done under strict medical a
Usual warning symptoms may disappear in patients with longstanding diabetes.
Simulations suggest that the prolonged dose interval is not optimal and could result in increased toxicity and possibly inadequate response.
The site(s) of application should then be covered by a moist saline gauze dressing that maintains a moist wound-healing environment.
The preferred sites are anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in young children.
Under no circumstances must ceftriaxone solutions be mixed with solutions containing calcium.
Solutions of reconstituted gemcitabine should not be refrigerated, as crystallisation may occur.
Only clear solutions free of visible particles should be used.
The reconstituted solutions should be used immediately.
Reconstituted solutions should be diluted in sodium chloride 9 mg/ ml (0.9%) solution immediately after preparation.
The reconstituted solutions should be inspected visually for particulate matter and discolouration prior to administration, whenever the container permits.
The reconstituted solutions are isotonic for parenteral administration.
The reconstituted solutions are isotonic for parenteral administration.
Bacterial strains of both Inaba and Ogawa serotypes and of El Tor and 5 Classical biotypes are included in the vaccine.
• Infrared spectrometers for breath analysis must comply with the following specifications:
Methicillin-resistant staphylococci (MRS) are resistant to all currently available β -lactam antibiotics including cefuroxime.
Stimulants (analeptics) must not be used.
70 Pens should only be used in combination with products that are compatible with them and allow the pens to function safely and effectively.
Pens should only be used in combination with products that are compatible with them and allow the pens to function safely and effectively.
• The Aranesp pre-filled pen should NEVER be reused. • NEVER put the grey needle cap back into the used pre-filled pen. • The used pre-filled pen should be disposed of in accordance with local requirements.
The Trudexa pre-filled pen is available in packs containing 1, 2, 4, and 6 pre-filled pens.
The Humira pre-filled pen is available in packs containing 1, 2, 4, and 6 pre-filled pens.
In use pens Pre-filled pens in use or carried as a spare may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.The pen in use must not be stored in the refrigerator Do not use it after this time period.
• The used pre-filled pen should be disposed of in accordance with local requirements.
Cationic active substances that are eliminated by renal tubular secretion (e.g. cimetidine) may interact with metformin by competing for common renal tubular transport systems and hence delay the elimination of metformin, which may increase the risk of lactic acidosis.
The active substances Each 0.5 ml dose contains:
The active substances of Eucreas belong to a group of medicines called “oral antidiabetics”.
The active substances in EVRA are norelgestromin 6mg and ethinyl estradiol 600 micrograms.
The active substances of Icandra belong to a group of medicines called “oral antidiabetics”.
The active substances of Zomarist belong to a group of medicines called “oral antidiabetics”.
Remaining hormonal active ingredients of the patch may have harmful effects if reaching the aquatic environment.
The active substances are split Influenza virus*, inactivated, containing antigens equivalent to the following strains:
The active substances are split Influenza virus*, inactivated, containing antigens equivalent to the following strains:
- The active substances are efavirenz, emtricitabine and tenofovir disoproxil.
- The active substance is buprenorphine and naloxone.
- The active substances are desloratadine and pseudoephedrine (as sulphate)
The active substances are alendronate sodium trihydrate and colecalciferol (vitamin D3).
Substances in food, especially phytates and fibres, bind zinc and prevent it from entering the intestinal cells.
Oral contraceptives, thiazides, glucocorticoids, thyroid hormones and beta-sympathomimetics, growth hormone and danazol.
Thiazides, glucocorticoids, thyroid hormones and beta-sympathomimetics, growth hormone and danazol.
Oral hypoglycaemic agents (OHA), monoamine oxidase inhibitors (MAOI), non-selective beta- blocking agents, angiotensin converting enzyme (ACE) inhibitors, salicylates, alcohol, anabolic steroids and sulphonamides.
Oral hypoglycaemic agents (OHA), monoamine oxidase inhibitors (MAOI), non-selective beta- blocking agents, angiotensin converting enzyme (ACE) inhibitors, salicylates, alcohol, anabolic steroids and sulphonamides.
Substances that may enhance the blood-glucose-lowering activity and increase susceptibility to hypoglycaemia include oral antidiabetic agents, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamide oxidase inhibitors (MAOIs), pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics.
The above-mentioned substances are converted by a specific enzyme (CYP1A2).
Amino acid substitutions that developed in 10 to 20% of the isolates were V11I, I13V, L33F, I50V and F53L.
Amino acid substitutions that developed in 5 to 10% of isolates were L10F, I15V, M36L, K43T, M46I, I47V, A71I, G73S, T74P, L76V, V82I and I84V.
Specific single substitutions at these residues in gp41 each resulted in a range of decreases from baseline in recombinant viral susceptibility to enfuvirtide.
The single substitutions which led to the highest resistance to efavirenz in cell culture correspond to a leucine-to-isoleucine change at position 100 (L100I, 17 to 22-fold resistance) and a lysine-to-asparagine at position 103 (K103N, 18 to 33-fold resistance).
A second dose may be given at least 4 weeks after the first dose.
Subjects with renal failure necessitating dialysis treatment were not investigated.
Subjects in the untreated historical cohort were born in 1993 or later.
Subjects in the untreated historical cohort were born in 1995 or later.
- special care should be taken with patients below 50 kg weight;
Subjects with diabetes had significant reductions in the primary and all secondary composite endpoints.
15 Other Individuals who are known to be infected with human immunodeficiency viruses and are not immunocompromised may be vaccinated.
4 Other Individuals who are known to be infected with human immunodeficiency viruses and are not immunocompromised may be vaccinated.
Black patients may have up to a 31% lower Cmax and a 43% lower AUC than patients of other races.
Black patients may have up to a 31% lower Cmax and a 43% lower AUC than patients of other races.
Subjects were seen daily in the clinic (Monday through Friday) for dosing and efficacy assessments.
Persons with a history of severe hypoglycemia should have glucagon available.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this vaccine.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this vaccine.
Subjects treated with Peg Intron showed mild dose-related elevations in body temperature.
Subjects treated with PegIntron showed mild dose-related elevations in body temperature.
Subjects treated with ViraferonPeg showed mild dose-related elevations in body temperature.
Overdose is unlikely to occur in the intended clinical circumstances.
7 Insulin suspensions should not be used if they do not appear uniformly white and cloudy after resuspension.
Insulin suspensions should not be used if they do not appear uniformly white and cloudy after resuspension.
Sympathomimetics may reduce the antihypertensive effect of doxazosin; doxazosin may reduce blood pressure and vascular reactions to dopamine, ephedrine, epinephrine, metaraminol, methoxamine and phenylephrine.
Nervous system symptoms usually begin during the first one or two days of therapy and generally resolve after the first 2 - 4 weeks.
Nervous system symptoms usually begin during the first one or two days of therapy and generally resolve after the first two to four weeks.
Nervous system symptoms associated with efavirenz usually begin during the first one or two days of therapy and generally resolve after the first two to four weeks.
Symptoms include swollen face, tongue or throat, difficulty swallowing,
The symptoms of this allergic reaction can occur at any time during treatment with Ziagen.
Some of the signs of lactic acidosis are:
This helps to reduce the symptoms of allergy, such as asthma attacks.
Angina symptoms (chest, arm or jaw pain) are caused by the heart not receiving enough oxygenated blood.
Most patients had relief of symptoms after stopping treatment.
- difficulty in thinking and concentrating, depression.
Coughing, wheezing, and chest tightness.
Symptoms of hypercalcaemia may include: nausea, vomiting, thirst, polydipsia, polyuria, dehydration and constipation.
Hypoglycaemia Symptoms of hypoglycaemia usually occur suddenly.
Symptoms of overdose are not immediately apparent post-injection and may include general weakness, ptosis, diplopia, swallowing and speech difficulties or paralysis of the respiratory muscles resulting in an aspiration pneumonia.
Symptoms of overdose may include dizziness, tremor, headaches, tiredness, seizures, hallucinations, confusion, gastrointestinal upset, liver and kidney abnormalities, crystalluria, haematuria.
Symptoms of the overdoses included dizziness, double vision, slurred speech, drowsiness, lethargy and mild diarrhoea.
Symptoms of venous or arterial thrombosis can include:
The symptoms related to this hypersensitivity reaction worsen with continued therapy and can be life- threatening.
Manifestations of acute vitamin A toxicity include severe headache, nausea or vomiting, drowsiness, irritability and pruritus.
The signs and symptoms of salmeterol overdose are tremor, headache and tachycardia.
Symptoms of active psoriatic arthritis include inflammation of joints, swelling, difficulty moving, pain and patches of red, scaly skin (skin lesions).
Symptoms of active psoriatic arthritis include inflammation of joints, swelling, difficulty moving, pain and patches of red, scaly skin (skin lesions).
In addition, as with SSRIs, co-administration with other serotonergic active substances (L- tryptophan, triptans, tramadol, linezolid, SSRIs, venlafaxine, lithium and St.
The symptoms of GAD are prolonged excessive anxiety and worry that are difficult to control.
Common symptoms of overdosage are nausea, vomiting, diarrhoea, severe bone marrow depression (including anaemia, thrombocytopenia, leukopenia, and agranulocytosis), acute renal insufficiency as well as irreversible neurologic toxicity (paraparesis / quadriparesis), Guillan-Barré syndrome, and Brown-Séquard syndrome.
Symptoms have included altered mental states (e. g. tiredness), effects on your nervous system (e. g. convulsions, feelings of numbness or tingling, weakness and paralysis).
The most commonly reported symptoms were gastro-intestinal (e. g., nausea, vomiting, diarrhoea) and renal (e. g., nephrolithiasis, flank pain, haematuria).
The non-neurological symptoms of MPS I can be an enlarged liver, stiff joints which make moving more difficult, less lung volume, heart disease and eye disease.
Symptoms resolved with conservative management.
Symptoms may disappear completely or partly.
Symptoms can include yellow skin and eyes, itching, stomach pain and liver tenderness.
The symptoms may be delayed for up to 24 hours after ingestion.
Symptoms may include lower stomach (abdominal) pain, particularly on the left side, possibly with fever and constipation • Skin blistering (including blisters that burst) • Severe stomach pain caused by gallstones • Hepatitis (inflammation of the liver).
They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentration, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation.
Usual warning symptoms may disappear in patients with longstanding diabetes.
Usual warning symptoms may disappear in patients with longstanding diabetes.
The most commonly reported flu-like symptoms are myalgia, fever, chills, sweating, asthenia, headache and nausea.
Symptoms that you should look out for are rash, a high temperature or chill, feeling sick or being sick and sweating and shaking.
The symptoms you might experience are described in Section 2 of this leaflet ("Take special care with Macugen").
Examples of symptoms that tell you that your blood sugar level is falling too much or too fast: sweating, clammy skin, anxiety, fast heart beat, high blood pressure, palpitations and irregular heartbeat.
The symptoms worsen with continued treatment and may be life-threatening if treatment is continued.
Your symptoms will then usually improve gradually (this is called a remission).
Sensory symptoms have usually improved or resolved within months of paclitaxel discontinuation.
Symptoms started from a few days to several months after initiating Tarceva therapy.
Symptoms started from a few days to several months after initiating Tarceva therapy.
This causes a wide range of symptoms, particularly difficulty breathing and difficulty walking.
Symptoms suggestive of serum sickness include arthritis/ arthralgias, rash (urticaria or other forms), fever and lymphadenopathy.
Myelodysplastic/ myeloproliferative diseases with PDGFR gene re-arrangements could be associated with high eosinophil levels.
Ulcer status was determined by endoscopy at week 4, 8, and 12.
Antibody status should be regularly monitored.
The HIV status for the newborns and infants ≤ 3 months of age was negative, for older infants it tended to be positive.
Cumulative rates for this composite endpoint over 3 years were 2.3% (21/ 933 subjects) and 1.9% (12/ 628 subjects), respectively.
Cumulative rates for this composite endpoint over 3 years were 3.0% (20/ 671 subjects) and 2.5% (17/ 685 subjects), respectively, compared to 0.9% (6/ 679 subjects) for placebo.
The rates of discontinuation due to any adverse reaction were 5.8% in patients receiving INTELENCE and 4.5% in patients receiving placebo.
Prothrombin activation fragment 1 levels and thrombin-antithrombin III-complexes increase during thrombolysis indicating thrombin production of which the clinical relevance is unknown.
Maintenance of remission and response rates are presented in Table 12.
B-type natriuretic peptide (BNP) levels were reduced by 25% in the aliskiren arm compared to placebo.
B-type natriuretic peptide (BNP) levels were reduced by 25% in the Rasilez arm compared to placebo.
B-type natriuretic peptide (BNP) levels were reduced by 25% in the Riprazo arm compared to placebo.
B-type natriuretic peptide (BNP) levels were reduced by 25% in the Sprimeo arm compared to placebo.
B-type natriuretic peptide (BNP) levels were reduced by 25% in the Tekturna arm compared to placebo.
Alkaline phosphatase (AP), aspartate transaminase (AST or SGOT) and alanine transaminase (ALT or SGPT) should be ≤ 3 times upper limit of normal.
APTIVUS/ ritonavir response rates in the RESIST studies were assessed by baseline tipranavir genotype and phenotype.
The response rates in all patients were 39.5% (95% CI:
Clinical response rates (50% or greater improvement in pain) were analysed according to whether or not the patient experienced somnolence during treatment.
Response rates in these trials were increased with compliance.
Response rates in these trials were increased with compliance.
Rates of complete haematological response, major cytogenetic response and complete cytogenetic response on first-line treatment were estimated using the Kaplan-Meier approach, for which non- responses were censored at the date of last examination.
The response rates (measuring how the immune system had responded to the viruses) were:
Response rates were analysed both by the patient as the unit of analysis and by the lesion.
The response rates (measuring how the immune system had responded to the viruses) were:
The response rates at month 6 were comparable to the 3-month results.
The response rate was similar for both genders.
Responder rates were highest in patients who switched NRTIs.
Sustained virological response rates in children and adolescents were similar to those in adults.
Sustained virological response rates in children and adolescents
Sustained virological response rates in children and adolescents were similar to those in adults.
Sustained virological response rates in children and adolescents were similar to those in adults.
Sustained virological response rates in children and adolescents were similar to those in adults.
The rates of confirmed lower GI clinical events (small or large bowel perforation, obstruction, or hemorrhage, (POBs)) were not significantly different between etoricoxib and diclofenac.
Haemoglobin levels should be measured on a regular basis until a stable level is achieved and periodically thereafter.
Haemoglobin levels should be measured on a regular basis until a stable level is achieved and periodically thereafter.
CD study I and CD study II induction of remission and response rates are presented in Table 11.
Doxycycline blood levels in patients treated with ORACEA are lower than in those treated with conventional antimicrobial formulations of doxycycline.
In addition, serum levels of matrix metalloproteinase-3, which produces cartilage destruction and tissue remodelling, were decreased.
Fundamental and non-linear imaging techniques (second harmonic, multipulse phase and/ or amplitude modulation) using both continuous and triggered acquisition were utilised in clinical studies with Luminity.
The structure at the end of 1996 w as therefore:
Tendinitis and/ or tendon rupture (particularly affecting the Achilles tendon) occurs in association with quinolone antibiotics.
The following terms have been combined: a Anorexia and decreased appetite b Dysgeusia, ageusia and taste disturbance c Abdominal pain and abdominal pain upper d Oedema, oedema peripheral and oedema face e White blood cell count decreased, neutrophil count decreased, and leukocyte count decreased
Acceptance testing together with Member States was completed.
- field efficacy testing of veterinary vaccines
Reproductive toxicity testing showed no evidence of effects on fertility, embryofetal, or postnatal development.
Mutagenicity Lepirudin was not mutagenic or clastogenic in standard assays for such effects.
CYP1A, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, none of these were inhibited by dexrazoxane.
Thiazides should be used with caution in patients with impaired hepatic function.
Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia.
The current estimate of the median survival of the previously untreated and treated patients was 7.7 and 4.7 months, respectively.
The estimate of vaccine serotype specific efficacy was 94% (95% CI:
Stiripentol enhances the central depressant effect of chlorpromazine.
Stiripentol is extensively metabolized, 13 different metabolites having been found in urine.
The surrounding soft tissues are then closed around the implant.
The surrounding soft tissues are then closed around the implanted material.
Patients were randomized to receive either pegylated interferon alfa-2b (1.5 µg/kg/week) plus ribavirin (800 mg/day) or IntronA (3 MIU TIW) plus ribavirin (800 mg/day) for 48 weeks with a follow-up period of 6 months.
Intentions to appeal were notified by marketing authorisation holders on 23, 26, 28 and 29 June and 4 July 1995.
Storage is supervised by the specialists at the hospital.
Agents for the treatment of erectile dysfunction, including CIALIS, must not be used in men with cardiac disease for whom sexual activity is inadvisable.
Smoking cessation therapies are more likely to succeed for patients who are motivated to stop smoking and who are provided with additional advice and support.
Changes in body fat have been seen in some patients taking antiretroviral therapy.
Combination antiretroviral therapy (CART), including REYATAZ (with or without ritonavir)-based CART, is associated with dyslipidaemia.
Combination antiretroviral therapy may cause changes in body shape due to changes in fat distribution.
Thiazide therapy may impair glucose tolerance.
The transporters MRP2 and MXR (BCRP) are involved in the biliary excretion of deferasirox.
The works were completed in June and approximately 80 staff moved to their
with the EU and EEA-EFTA Member States.
Estriol is a short-acting natural oestrogen.
Oestriol is a short-acting natural oestrogen.
The other three main studies involved patients with malignant glioma that had come back or got worse after previous treatment.
The three clinical studies performed with Naglazyme focused on assessing the systemic manifestations of MPS VI such as endurance, joint mobility, joint pain and stiffness, upper airway obstruction, manual dexterity and visual acuity.
The three additional studies also showed that adding MabThera to other types of chemotherapy also improved the patients'outcome.
All three studies compared the effectiveness of Emend, taken in combination with dexamethasone and ondansetron, with that of the standard combination of dexamethasone and ondansetron.
All three active substances are already available in the European Union (EU): efavirenz has been approved as Sustiva and Stocrin since 1999, emtricitabine has been approved as Emtriva since 2003, and tenofovir disoproxil has been approved as Viread since 2002.
Cognitive impairment typically appears after several weeks of treatment.
Rashes are usually mild to moderate, maculopapular erythematous cutaneous eruptions, with or
Mucopolysaccharide storage disorders are caused by the deficiency of specific lysosomal enzymes required for the catabolism of glycosaminoglycans (GAGs).
Mucopolysaccharide storage disorders are caused by the deficiency of specific lysosomal enzymes required for the catabolism of glycosaminoglycans (GAGs).
The neurological disorders progressively regressed after deferiprone discontinuation.
Tubings in which the inner surface materials are made of polyethylene or polyolefin have been evaluated and found compatible with pump use.
Tumour types included were Ewing's Sarcoma/ primitive neuroectodermal tumour, neuroblastoma, osteoblastoma, and rhabdomyosarcoma.
Liver tumours are most likely related to enzyme induction specific to rodents.
The observed hepatocellular and thyroid tumours in rodents are considered to be of limited relevance to humans.
Malignant tumours occurred in the preputial gland of males and the clitoral gland of females of both species, and in rats in the thyroid gland of males and in the liver, urinary bladder, lymph nodes and the subcutis of females.
Malignant tumours occurred in the preputial gland of males and the clitoral gland of females of both species, and in rats in the thyroid gland of males and the liver, urinary bladder, lymph nodes and the subcutis of females.
Malignant tumours occurred in the preputial gland of males and the clitoral gland of females of both species, and in rats in the thyroid gland of males and and in the liver, urinary bladder, lymph nodes and the subcutis of females.
The pen in use must not be stored in a refrigerator.
The Preotact pen and needles are not included.
The KwikPen is designed for ease of use.
The KwikPen has to be used as recommended in the user manual.
The KwikPen has to be used as recommended in the user manual.
The prefilled pen can be used until it is empty.
The prefilled pen can be used until it is empty.
Sucralfate/Antacids may decrease the bioavailability of lansoprazole.
For the peadiatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents.
It forms a complex with the neuromuscular blocking agents rocuronium or vecuronium in plasma and thereby reduces the amount of neuromuscular blocking agent available to bind to nicotinic receptors in the neuromuscular junction.
Sugammadex has not been investigated in patients receiving rocuronium or vecuronium in the ICU setting.
Sugammadex should only be administered by, or under the supervision of an anaesthetist.
Sugammadex should not be used to reverse block induced by nonsteroidal neuromuscular blocking agents such as succinylcholine or benzylisoquinolinium compounds.
Sugammadex is not metabolised nor excreted by the liver; therefore dedicated studies in patients with hepatic impairment have not been conducted.
Sugammadex can be used during breast-feeding.
Sugammadex can be used to reverse different levels of rocuronium or vecuronium induced neuromuscular blockade:
Monitoring the level of active substance in the blood provides the most reliable basis for dose adjustment.
Follow-up should be arranged under supervision of a specialist in epileptology, neurology or paediatric neurology.
Consumption of a diet low in fat will decrease the likelihood of experiencing adverse gastrointestinal reactions (see section 4.4).
This can help the patients stick to their treatment.
Post-marketing experience revealed no different or new safety signals for Xeomin compared to other Botulinum toxin containing medicinal products.
Ulcers with a suspicious appearance should be biopsied to exclude malignancy.
Sulesomab has been designed to target an antigen called NCA90, which is present on the surface of granulocytes (a type of white blood cell).
Pseudoephedrine sulfate provides a nasal decongestant effect after oral administration due to its vasoconstrictive action.
Pseudoephedrine sulphate provides a nasal decongestant effect after oral administration due to its vasoconstrictive action.
Pseudoephedrine sulfate undergoes incomplete hepatic metabolism by N- demethylation to an inactive metabolite.
Sunitinib was identified as an inhibitor of platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET).
Sunitinib was identified as inhibitor of platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET).
Sunitinib was not mutagenic in bacteria using metabolic activation provided by rat liver.
Sunitinib did not induce structural chromosome aberrations in human peripheral blood lymphocyte cells in vitro.
The multivitamin should contain vitamins A, D, E and K.
Overdosage of Cetrotide 0.25 mg may result in a prolonged duration of action but is unlikely to be associated with acute toxic effects.
Overdose with 40 mg/ kg (20 times the recommended dose) of Clomicalm produced hunched posture, tremors, flushed abdomen and decreased activity in dogs.
Overdose of erythropoietin may produce effects that are extensions of the pharmacological effects of the hormone.
Overdose with INOmax will be manifest by elevations in methaemoglobin and NO2.
The highest overdose has been approximately 1.5 grams.
Bladder catheterisation should be undertaken in patients with urinary obstruction.
Urine may be discoloured reddish-brown by entacapone, but this is a harmless phenomenon.
Urine may be discoloured reddish-brown by entacapone, but this is a harmless phenomenon.
Reporting is available to EudraNet users on the Intranet Web pages.
Users should avoid skin and eye contact with the product and if such contact happens, they should wash the exposed area thoroughly with clean water.
Therefore blind users will be able to double check the information written on the cardboard wallets (Braille text) with the information obtained from a physician (during the visit).
Users are able to obtain documents systematically either through the Internet (immediate access) or in paper format (monthly mailings).
- Chloasma may occasionally occur with the use of hormonal contraception, especially in users
Users who choose not to breast-feed should start contraceptive therapy with EVRA no sooner than 4 weeks after child-birth.
Concomitant vaccines should always be administered at separate injection sites and preferably into different limbs.
Vaccines work by ‘ teaching'the immune system how to defend itself against diseases.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against diseases.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against diseases.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against diseases.
The polysaccharides are chemically attached (conjugated) to tetanus toxoid as a carrier protein because this improves the response to the vaccine.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against diseases.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against a disease.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against diseases.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against diseases.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against a disease.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against a disease.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against diseases.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against a diseases.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against diseases.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against a disease.
Vaccines against B. bronchiseptica that are administered through the nose are also used in dogs.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against a disease.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against a disease.
Unused vaccine and other waste material should be disposed of in compliance with local rules for the disposal of products of this nature.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against a disease.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against a disease.
Tetravalent vaccines against serotypes A, C, Y and W135 are strongly recommended, preferably conjugated ones.
Live vaccines should not be given concurrently with STELARA (see section 4.4).
Cows with subclinically infected udders were treated with Pirsue (once daily for 8 days) or with another antibiotic, authorised in the EU to treat these infections.
The corresponding values after oral single and multiple dose administration are 34±5% and 40±12%, respectively.
The corresponding values in patients with moderate hepatic impairment were 41% and 146% respectively.
PegIntron Cmax and AUC measurements increase in a dose-related manner.
ViraferonPeg Cmax and AUC measurements increase in a dose-related manner.
Lapatinib AUC values were approximately 3- and 4-fold higher (Cmax approximately 2.5 and 3– fold higher) when administered with a low fat (5% fat [500 calories]) or with a high fat (50% fat [1,000 calories]) meal, respectively.
Irbesartan AUC and Cmax values were also somewhat greater in elderly subjects (≥ 65 years) than those of young subjects
Irbesartan AUC and Cmax values were also somewhat greater in elderly subjects (≥ 65 years) than those of young subjects (18 - 40 years).
Irbesartan AUC and Cmax values were also somewhat greater in elderly subjects (≥ 65 years) than those of young subjects (18-40 years).
Irbesartan AUC and Cmax values were also somewhat greater in elderly subjects (≥ 65 years) than those of young subjects (18-40 years).
peak plasma concentration (mean Cmax = 0.34 mg/ l) is obtained 2 hours post-dosing.
The INR values increased on average by 13% [CI90 6– 19%].
The values for the comparator treatments were slightly higher (buserelin:
Median Cmax and AUC0-∞ values were 16.70 (9.66-30.56) ng/ ml and 204.40 (109.75-356.05) ng·h/ ml, respectively.
The observed values of the peak concentrations are 9 fold greater than the IC50 of abacavir of 0.08 µg/ ml or 0.26 µM when abacavir is given at 600 mg twice daily.
The observed values of the peak concentrations are 9 fold greater than the IC50 of abacavir of 0.08 µg/ ml or 0.26 µM when abacavir is given at 600 mg twice daily.
The values obtained in the studies are comparable to parameters reported for other human immunoglobulins.
The respective values for anaerobes are 16 µg/ ml (sensitive), 32 µg/ ml (intermediate) and 64 µg/ ml (resistant).
All values were between 1.5 fold and 3 fold the ULN, and returned to baseline levels after therapy discontinuation.
All values were between 2.5 fold and 3.5 fold the ULN (Upper Limit of Normal).
The canarypox viruses do not spread or multiply in the cat but they do produce proteins from the FeLV genes.
23-50-fold) harboured 2 to 4 amino acid substitutions in the protease gene.
Biotransformation Seven major metabolites were identified and the metabolic pathways were identified as glucuronidation at the pyridine nitrogen, pyridine– N– oxidation with and without 3’– hydroxylation on the indane ring, 3’– hydroxylation of indane, p– hydroxylation of phenylmethyl moiety, and N– depyridomethylation with and without the 3’– hydroxylation.
Injection volumes ranged from 15.0 to 25.9 ml.
Injection volumes ranged from 2.88 to 5.52 ml.
Vomiting can be associated with serious, severely debilitating conditions and the cause should be investigated.
Vomiting may be reduced by co-administration of Clomicalm with a small quantity of food.
Vomiting may be reduced by co-administration with a small quantity of food.
Vomiting may be reduced by giving the tablets with a small quantity of food.
True hypersensitivity reactions are rare.
The SWP, in cooperation with the BWP, was involved in the preparation of the DNA vaccine and gene therapy related notes for guidance.
The eyes should be protected by a suitable lubricant.
The eyes should be rinsed immediately and thoroughly with water.
Acute coronary syndrome is a group of conditions that includes unstable angina (a severe type of chest pain) and heart attack.
Ovarian Hyperstimulation Syndrome (OHSS) is a medical event distinct from uncomplicated ovarian enlargement.
Ovarian hyperstimulation syndrome (OHSS) may occur during or following ovarian stimulation.
Post marketing studies Between 1998 and 1999 several Post-marketing observational (PMO) studies were performed in Germany.
The fibrin adhesion system initiates the last phase of physiological blood coagulation.
During 1997 the distribution of EPARs and other key EMEA documents will be re-examined to enhance their availability, including increased active distribution through the creation of a subscription service for all documents and better use of dissemination points.
The outcome of these discussions at EMEA will compliment the elaboration of a European Risk Management Strategy initiated by the Heads of Agencies.
If you experience difficulties choose a more firm injection site
The Quixidar pre-filled syringe has been designed with an automatic needle protection system to
The Quixidar pre-filled syringe has been designed with an automatic needle protection system to
The application tracking system developed jointly by the World Health Organisation (WHO) and the EMEA – SIAMED – will be further developed for general use at the EMEA in 2002.
Video-conferencing was increasingly introduced for routine consultations with the European Commission and for small meetings with industry and other partners of the EMEA.
The endocannabinoid system is a physiological system present in brain and peripheral tissues ct
The European system for the authorisation and supervision of medicines, and the EMEA as part of that system, enters 2002 with a number of challenges ahead of it, building on initiatives begun in 2001 and on new enterprises to be undertaken in 2002.
The immune system will be able to produce antibodies more quickly when it is exposed to flu virus of the same strain.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to B. canis.
Areas with scars or stretch marks should be avoided.
Active smoking greatly enhances whereas passive exposure to tobacco smoke in non-smokers decreases the rate and extent of absorption of EXUBERA (see sections 4.3 and 5.2).
Smoking appears to increase the rate at which you lose bone and, therefore, may increase your risk of broken bones.
10 Table 1 lists the adverse reactions based on experience from clinical studies as well as adverse reactions, some with fatal outcome, reported from post-marketing experience.
Table 1 shows the changes in lipid parameters at 8 weeks.
Table 1 summarises key efficacy results of the pooled follow-up analyses of studies MM-009 and MM-010.
Table 1 summarises response rates based on the best response assessments for studies MM-009 and MM-010.
Table 1 summarizes efficacy data from this study.
21 Table 2 summarises the primary efficacy endpoint results:
Table 2 summarises the primary efficacy endpoint results:
Response data are shown in Table 3.
A tabular summary of the secondary efficacy results is presented in Table 3.
Chest pain, asthenia, oedema, injection site pain
The response to treatment in both of these trials is presented in Table 4.
The response to treatment in both of these trials is presented in Table 4. uc
The response to treatment in both of these trials is presented in Table 4.
The response to treatment in both of these trials is presented in Table 4.
Table 4 provides treatment-emergent adverse events in patients with newly-diagnosed glioblastoma multiforme during the concomitant and monotherapy phases of treatment.
Table 4 provides treatment-emergent adverse events in patients with newly-diagnosed glioblastoma multiforme during the concomitant and monotherapy phases of treatment.
Table 5 includes adverse reactions reported during clinical trials for recurrent or progressive malignant glioma and following the marketing of Temodal.
Table 5 includes adverse reactions reported during clinical trials for recurrent or progressive malignant glioma and following the marketing of Temodal.
Table 5 includes adverse reactions reported during clinical trials for recurrent or progressive malignant glioma and following the marketing of Temodal.
Table 5 includes results in the study 1 population.
The response to treatment in both of these trials is presented in Table 9.
The following table has been worked out so that it gives you a calorie target that’s about 500 calories fewer per day than your body needs to maintain your current weight.
ADRs that occurred in post-myocardial infarction and/ or heart failure patients are listed below:
The table below lists adverse reactions on ORACEA in the pivotal clinical trials, ie adverse reactions for which the frequency on ORACEA was greater than the frequency on placebo (by ≥ 1%).
The table below summarises the key efficacy results for this study.
The following chart shows how to set your fat target based on the amount of calories you are allowed per day.
studies in patients treated for weight loss and related metabolic disorders when these incidences were statistically significantly greater than the corresponding placebo rate (for events ≥ 1%) or considered clinically relevant (for events < 1%). du
Tacrolimus is extensively distributed in the body.
12 Tacrolimus is extensively metabolised in the liver and although blood concentrations are low following topical therapy, the ointment should be used with caution in patients with hepatic failure (see section 5.2).
Tacrolimus is extensively metabolised in the liver and although blood concentrations are low following topical therapy, the ointment should be used with caution in patients with hepatic failure (see section 5.2).
The efficacy and safety of Protopy was assessed in
Tacrolimus ointment does not affect collagen synthesis in humans.
Tacrolimus calms down the immune system, and this helps relieve the skin inflammation and the itch.
Tacrolimus has been used since the mid-1990's to help prevent rejection in transplant patients (when the immune system attacks the transplanted organ).
Tacrolimus suppresses T-cell activation and T-helper-cell dependent B-cell proliferation, as well as the formation of lymphokines (such as interleukins-2, -3, and γ -interferon) and the expression of the interleukin-2 receptor.
Tadalafil at doses of 2.5, 5, and 10 mg taken once a day has been evaluated in 3 clinical studies involving 853 patients of various ages (range 21-82 years) and ethnicities, with erectile dysfunction of various severities (mild, moderate, severe) and etiologies.
8 Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).
Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).
The MAH proposed a withdrawal period of 5 days in pigs and 6 days in broilers.
The MAH submitted its response to the CHMP List of Questions on 29 September 2006.
The MAH wished to maintain that all MAOIs should be contraindicated whereas the CHMP considered that only non-selective, irreversible MAOIs should be contraindicated and that a strong warning in Section 4.5 of the SPC should be sufficient for the reversible MAOIs.
The MAH suggested the involvement of fluoxetine-induced inhibition of GnRH, so that fluoxetine would act as an endocrine disrupter.
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market.
The MAH was of the view that all MAOIs should be contraindicated with venlafaxine.
Etanercept is a competitive inhibitor of TNF-binding to its cell surface receptors and thereby inhibits the biological activity of TNF.
Steady state is achieved after 4-7 days of dosing.
Steady state is achieved after 4– 7 days of dosing.
Steady state is reached after 2 weeks of treatment.
Steady-state conditions are reached during the second application of the transdermal patch.
Lumiracoxib does not accumulate in plasma under once or twice daily administration and steady state is achieved on the first day of administration with no increase in Cmax or AUC after extended dosing.
Steady-state is generally achieved following 4 days of repeat dosing.
Steady state pharmacokinetics was attained by the fourth treatment in most animals.
In the MRP Sweden is the Reference Member State (RMS) and Austria, Belgium, Finland, France, Germany, Italy, Ireland, Luxembourg, Portugal, Spain and the United Kingdom are Concerned Member States (CMS).
In the MRP Sweden is the Reference Member State (RMS) and Austria, Belgium, Denmark, Finland, France, Greece, Germany, Italy, Ireland, Luxembourg, The Netherlands, Portugal, Spain and the United Kingdom are Concerned Member States (CMS).
In the MRP United Kingdom is the Reference Member State (RMS) and Austria, Belgium, Finland, France, Germany, Italy, Ireland, Luxembourg, Portugal, Spain and Sweden are Concerned Member States (CMS).
In the MRP United Kingdom is the Reference Member State (RMS) and Austria, Belgium, Denmark, Finland, France, Greece, Germany, Italy, Ireland, Iceland, Luxembourg, The Netherlands, Portugal, Spain and Sweden are Concerned Member States (CMS).
The Reference Member State was France and the Concerned Member States were Belgium, the Czech Republic, Germany, Italy, Spain and the United Kingdom.
The Reference Member State was France and the Concerned Member States were Belgium, the Czech Republic, Germany, Italy, Spain, and the United Kingdom.
The Reference Member State was Hungary and the Concerned Member States were Czech Republic, Estonia, Hungary, Lithuania, Latvia, Poland, Romania and Slovak Republic.
The Reference Member State was Germany and the Concerned Member States were Austria, Denmark, Spain, Finland, France, Italy, Luxembourg, Norway, Poland, Portugal, Sweden and United Kingdom.
The Reference Member State was Czech Republic and the Concerned Member States were Austria, Denmark, Germany, Estonia, Greece, France, Hungary, Italy, Latvia, Lithuania, the Netherlands, Norway, Poland, Portugal, Sweden, Slovenia, Slovak Republic and the United Kingdom.
The Reference Member State was Sweden and the Concerned Member States were Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, Slovak Republic, Slovenia, Spain and United Kingdom.
The Reference Member State was Sweden and the Concerned Member States were Austria, Belgium, Bulgaria, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Latvia, Netherlands, Norway, Portugal, Romania, Slovenia, Slovak Republic and United Kingdom.
The Reference Member State was Sweden and the Concerned Member States were Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Germany, Greece, Spain, Finland, France, Hungary, Ireland, Italy, Latvia, Lithuania, Luxemburg, The Netherlands, Poland, Portugal, Slovakia and United Kingdom and Norway and Iceland.
The Reference Member State was the United Kingdom and the Concerned Member States were Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, the Netherlands, Norway, Poland, Portugal, the Slovak Republic, Spain and Sweden.
The Reference Member State was Netherlands and the Concerned Member States were Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and United Kingdom.
The Reference Member State was Netherlands and the Concerned Member States were Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain and Sweden.
The Reference Member State was Ireland and the Concerned Member States were Belgium, Cyprus, Czech Republic, Germany, Denmark, Greece, Spain, Finland, France, Hungary, Italy, the Netherlands, Norway, Portugal, Sweden and the United Kingdom.
In the MRP Sweden is the Reference Member State and Austria, Belgium, Denmark, Finland, France, Greece, Germany, Italy, Ireland, Luxembourg, The Netherlands, Portugal, Spain and the UK are Concerned Member States.
In the MRP the United Kingdom is the Reference Member State and Austria, Belgium, Finland, France, Germany, Italy, Ireland, Luxembourg, Portugal, Spain and Sweden are Concerned Member States.
In the MRP the United Kingdom is the Reference Member State and Austria, Belgium, Denmark, Finland, France, Greece, Germany, Italy, Ireland, Iceland, Luxembourg, The Netherlands, Portugal, Spain and Sweden are Concerned Member States.
The Reference Member State for this MRP was Ireland with Austria, Belgium, Denmark, Germany, Greece, Finland, Iceland, Italy, Luxembourg, Norway, Portugal, Spain, and Sweden as Concerned Member States.
ratios for overall survival ranged between 1.25 and 2.47 in favour of controls.
The cumulative HIV-1 infant infection rate at 14-16 weeks was 13.1% (n = 310) in the VIRAMUNE group, versus 25.1% (n = 308 in the ultra-short zidovudine group (p = 0.00063).
The extent of absorption of cetirizine is not reduced with food, although the rate of absorption is decreased.
41 The extent of absorption of cetirizine is not reduced with food, although the rate of absorption is decreased.
ALT should be measured as part of the standard pre-operative evaluation (see section 4.4).
The rate of study drug discontinuation due to adverse events was 7.2% for prasugrel and 6.3% for clopidogrel.
20 discontinuation rate due to adverse events in these studies was 5.0% for patients receiving Dynastat and 4.3% for patients receiving placebo.
34 discontinuation rate due to adverse events in these studies was 5.0% for patients receiving Dynastat and 4.3% for patients receiving placebo.
47 discontinuation rate due to adverse events in these studies was 5.0% for patients receiving Dynastat and 4.3% for patients receiving placebo.
The discontinuation rate due to adverse events in these studies was 5.0% for patients receiving Dynastat and 4.3% for patients receiving placebo.
Bilirubin peaks approximately a week after onset and resolves approximately two weeks after onset.
The total bilirubin should be ≤ 1.5 times upper limit of normal.
The ciprofloxacin level in the blood can be increased. • phenytoin (used to treat epilepsy).
The ciprofloxacin level in the blood can be increased. • phenytoin (used to treat epilepsy).
The rate of deterioration of HbA1c during the second year was less with pioglitazone than with gliclazide.
This suggests a higher pregnancy rate for the comparators.
The dialyser extraction efficiency is 60% for levetiracetam and 74% for the primary metabolite.
The renal elimination rate of memantine under alkaline urine conditions may be reduced by a factor of 7 to 9 (see section 4.4).
The renal elimination rate of memantine under alkaline urine conditions may be reduced by a factor of 7 to 9 (see section 4.4).
Mannitol content is below the threshold of the Excipient guideline's annex.
Steady state cutaneous penetration of eflornithine in women from Vaniqa on facial skin of shaving women was 0.8%.
Platelet counts and haemoglobin level should also be monitored at regular intervals in cancer patients.
The rate of overall disease progression in the lamivudine group was higher for subjects with detectable YMDD variant HBV DNA (23/ 209, 11%) compared to those without detectable YMDD variant HBV (11/ 221, 5%).
The event rate for biopsy-confirmed acute rejection within the first 24 weeks after transplantation was 18.6% in the Advagraf group (N=331) and 14.9% in the Prograf group (N=336).
64 response was also higher in the patients treated at 600 mg (33%) as compared to the patients treated at 400 mg (16%, p=0.0220).
The response rate in these patients was about 52%.
The complete response rate after cycle 8 was 76.2% in the R-CHOP group and 62.4% in the CHOP group (p=0.0028).
The response rate of other acute myelogenous leukaemia subtypes to TRISENOX has not been examined.
The overall response rate according to this composite assessment was 31% (19/ 61) with a clinical complete response rate of 7% (4/ 61).
The objective response rate for fulvestrant was 19.2% compared with 16.5% for anastrozole.
The objective response rate by RECIST in the Tarceva group was 8.9% (95% CI, 6.4 to 12.0).
Response rate (investigator assessment) in patients that crossed over to panitumumab after progression on BSC alone was 22% (95% CI:
Objective response rate and progression free survival time were significantly improved with cetuximab.
Important information about some of the ingredients of PegIntron This medicinal product contains less than 1 mmol sodium (23 mg) per 0.7 ml, i.e., essentially "sodium-free".
Important information about some of the ingredients of PegIntron This medicinal product contains less than 1 mmol sodium (23 mg) per 0.7 ml, i.e., essentially "sodium-free".
Important information about some of the ingredients of ViraferonPeg This medicinal product contains less than 1 mmol sodium (23 mg) per 0.7 ml, i.e., essentially "sodium-free".
Important information about some of the ingredients of ViraferonPeg This medicinal product contains less than 1 mmol sodium (23 mg) per 0.7 ml, i.e., essentially "sodium-free".
This medicinal product contains less than 1 mmol sodium (23 mg) per 0.7 ml, i.e., essentially "sodium-free".
The survival rate of 41% depended very much on the clinical situation.
Of the 213 patients in whom the outcome was known the survival was 58%.
The overall survival (OS) in the pooled studies at one year after the start of treatment was 82% in patients treated with lenalidomide/dexamethasone versus 75% in patients treated with placebo/dexamethasone, with a median follow-up duration of 98.0 weeks (min:
(N=370) was half that in patients treated with a standard dose of unfractionated heparin (N=396) (p < 0.0001); the rate of proximal deep venous thrombosis was only one fifth that observed with the heparin (p < 0.0001).
The exposure-adjusted rate was 0.06 events per 100 patient-years.
- Haemoglobin reaches ≥ 12 g/ dl or
The hip fracture event rate was 1.44% for Aclasta-treated patients compared to 2.49% for placebo-treated patients.
The helminth infection rate in the overall clinical programme, which was not designed to detect such infections, was less than 1 in 1,000 patients.
Discontinuation due to undesirable events was 7% for the patients treated with Zerit.
The high rate of CHR is accompanied by the development of a complete cytogenetic response (CCyR) of 65% which is comparable to the results observed in adults.
The protein binding of paclitaxel following Abraxane administration is estimated at about 90%.
The estimated rate of patients free of progression to accelerated phase or blast crisis at 60 months was significantly higher in the Glivec arm compared to the IFN arm (92.9% versus 86.2%, p < 0.001).
The overall neutralizing antibody rate was 11/ 108 patients (10%).
9 Technetium [99mTc] disintegrates with the emission of gamma radiation with an energy of 140 keV and a half life of 6 hours to technetium [99Tc] which can be regarded as quasi stable.
Telmisartan does not show affinity for other receptors, including AT2 and other less characterised AT receptors.
Telmisartan does not show affinity for other receptors, including AT2 and other less characterised AT receptors.
Telmisartan does not inhibit angiotensin converting enzyme (kininase II), the enzyme which also degrades bradykinin.
Telmisartan may be taken with or without food.
Telmisartan displaces angiotensin II with very high affinity from its binding site at the AT1 receptor subtype, which is responsible for the known actions of angiotensin II.
Telmisartan selectively binds the AT1 receptor.
Temozolomide is a triazene, which undergoes rapid chemical conversion at physiologic pH to the active monomethyl triazenoimidazole carboxamide (MTIC).
Temozolomide is a triazene, which undergoes rapid chemical conversion at physiologic pH to the active monomethyl triazenoimidazole carboxamide (MTIC).
The withdrawal period for both sheep and cattle is zero days.
The withdrawal period is zero days.
The withdrawal period of the product is zero days.
The withdrawal period for milk was 2.5 days.
The median time to disease progression was 5.3 months (175 mg/ m2; 95% CI:
Prothrombin time (INR) was not affected by varenicline.
These were requested by 15 marketing authorisation holders for 115 countries.
The mean residence time is approximately 5 hours.
The mean residence time of saquinavir was 7 hours (n = 8).
The median survival for patients treated with topotecan + BSC was 25.9 weeks [95% C. I.
12 The estimated time to first emesis in the study is depicted by the Kaplan-Meier plot in Figure 2.
20 The estimated time to first emesis in the study is depicted by the Kaplan-Meier plot in Figure 2.
34 The estimated time to first emesis in the study is depicted by the Kaplan-Meier plot in Figure 2.
48 The estimated time to first emesis in the study is depicted by the Kaplan-Meier plot in Figure 2.
The duration of the useful imaging time is 2.5 - 4.5 minutes for a dose of 0.5 - 3.0 ml.
The median time to onset of rash was 10 days.
The time to Absolute Neutrophil Count (ANC) greater than 0.5x109 / l was 13 days (range 9-29 days) in allogenic patients (OMC-BUS 4), and 10 days (range 8-19 days) in autologous patients (OMC-BUS 3).
The time to Absolute Neutrophil Count (ANC) greater than 0.5x109/ l was 21 days (range 12-47 days) in allogenic patients, and 11 days (range 10-15 days) in autologous patients.
Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-temsirolimus complex binds and inhibits the activity of mTOR that controls cell division.
The extent of percutaneous absorption of topical medications is determined by many factors including the integrity of the epidermal barrier.
Tenofovir displayed antiviral activity against HIV-1 clades A, B, C, D, E, F, G, and O.
Tenofovir is also active against HIV-1 subtypes A, C, D, E, F, G, and O and against HIVBaL in primary monocyte/ macrophage cells.
Tenofovir is excreted renally, both by filtration and active secretion via the human organic anion transporter 1 (hOAT1).
Tenofovir is structurally related to nucleoside analogues hence the risk of lipodystrophy cannot be excluded.
Tenofovir shows activity in vitro against HIV-2, with an EC50 of 4.9 µmol/ l in MT-4 cells.
Tepoxalin is extensively converted to its acid metabolite.
Tepoxalin and its metabolites are excreted in the faeces (99%).
Teriparatide, rhPTH(1-34), produced in E. coli, using recombinant DNA technology, is identical to the 34 N-terminal amino acid sequence of endogenous human parathyroid hormone.
CEPROTIN proved to have no mutagenic potential in the Ames test performed.
CEPROTIN proved to have no mutagenic potential in the Ames test performed.
In the iloprost group, the mean change from baseline after 12 weeks of treatment in the 6 minute walking distance was an increase of 22 meters (-3.3 meters in the placebo group, no data imputation for death or missing values).
The trend test was significant in the triglycerides response over the range of doses from placebo through simvastatin 80 mg (p=0.001).
Ethinyl estradiol is also metabolised to various hydroxylated products and their glucuronide and sulfate conjugates.
Only the ethinyloestradiol component of oral contraceptives has been studied.
Venous thromboembolism HRT is associated with a higher relative risk of developing venous thromboembolism (VTE), i.e. deep vein thrombosis or pulmonary embolism.
Timolol does appear in human breast milk.
Timolol and its metabolites are primarily excreted by the kidneys.
There are no known adverse reactions of ocular timolol on liver function.
Tipranavir demonstrates antiviral activity in vitro against a broad panel of HIV-1 group M non-clade B isolates (A, C, D, F, G, H, CRF01 AE, CRF02 AG, CRF12 BF).
Tipranavir should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
The corresponding bar-code label must be put on the data sheet for patient documentation.
The corresponding bar-code label must be put on the data sheet for patient documentation.
The bar-code labels marked “30-minute-value” must be used for these samples.
The surrounding muscle tissue is then closed around the implanted medicine as is the skin on top of the muscle.
Antibody titers should be regularly monitored.
- at the request of the EMEA
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
The MAH shall set up a surveillance programme/registry to collect information on the demographics, safety and outcome data from patients prescribed Tracleer to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market and for as long as the marketed product remains in use.
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market.
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market. ct
The MAH must ensure that the system of pharmacovigilance is in place and functioning prior to placing the product on the market.
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market.
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the tn
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market.
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market and for as long as the marketed product remains in use.
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market.
The MAH must ensure that the system of pharmacovigilance, as described in the document “ Description of the PharmacoVigilance system” submitted on 16 November 2005, and any subsequent updates, is in place and functioning before and whilst the product is on the market.
The MAH also considered that the limited data available does not permit any dose modifications to be suggested in the SPC for patients with renal or hepatic impairment and that the precautions already adequately reflect the information available.
The MAH created a single table containing all relevant ADRs from all three indications: hypertension, post- MI, and CHF.
The MAH stated that the clinical benefit/ risk ratio of cetirizine has not been specifically evaluated in patients with renal impairment and that the dose is therefore based on pharmacokinetic calculations only.
The Marketing Authorisation Holder provided written explanations on 21 September 2006.
The Marketing Authorisation Holder provided an updated environmental risk assessment.
The Marketing Authorisation Holder (MAH) shall ensure that, at launch, all physicians who are expected to prescribe/ use Lucentis are provided with a physician information pack containing the following: • Physician information • Intravitreal injection procedure video • Intravitreal injection procedure pictogram • Patient information pack
The Marketing Authorisation Holder (MAH) shall ensure, at launch, all physicians who are expected to prescribe/ use Lucentis are provided with a physician information pack containing the following: • Physician information • Intravitreal injection procedure video • Intravitreal injection procedure pictogram • Patient information pack
The Marketing Authorisation Holder (MAH) should ensure that, at launch, all Healthcare Professionals who are expected to prescribe/ use ReFacto AF, all laboratories that are expected to monitor patients receiving ReFacto AF and all EU Haemophiliac patients associations are provided with Educational packs.
The MAH further argued that the method used was probably not robust enough and cited a recent publication that mentions the need for deproteinization steps to improve method recovery.
The marketing authorisation holder of Ketek is:
The marketing authorisation holder of Levviax is:
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market and for as long as the marketed product remains in use.
The Marketing Authorisation Holder must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market and for as long as the marketed product remains in use.
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market and for as long as the marketed product remains in use.
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
The Marketing Authorisation Holder must implement nationally, prior to marketing, and as agreed with the competent authorities in the Member States:
The Marketing Authorisation Holder must ensure that the system of pharmacovigilance is in place and functioning prior to placing the product on the market.
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market.
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market and for as long as the marketed product remains in use.
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market and for as long as the marketed product remains in use.
The Marketing Authorisation Holder must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market.
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market.
56 Marketing Authorisation Holder is:
The marketing authorisation holder is Bayer Healthcare AG.
The marketing authorisation holder is Bayer HealthCare AG.
The marketing authorisation holder is Beaufour Ipsen Pharma.
The marketing authorisation holder is Biovitrum AB (publ).
The marketing authorisation holder is Boehringer Ingelheim International GmbH.
The marketing authorisation holder is CIS bio international.
The marketing authorisation holder is Daiichi Sankyo Europe GmbH.
The marketing authorisation holder is Ferring Pharmaceuticals A/ S.
The marketing authorisation holder is Genzyme Europe BV.
The marketing authorisation holder is INO Therapeutics AB.
The marketing authorisation holder is Janssen-Cilag International NV.
The marketing authorisation holder is LEO Pharma A/ S.
Marketing Authorisation Holder is:
The marketing authorisation holder is Meda AB.
The marketing authorisation holder is: < {Name and address} > < {tel} > < {fax} > < {e-mail} >
is Norton Healthcare Limited, Albert Basin, Royal Docks, London E16 2QJ, United Kingdom.
The marketing authorisation holder is Orion Corporation.
The marketing authorisation holder is Pacira Limited
The marketing authorisation holder is Pfizer Limited.
The marketing authorisation holder is Pfizer Limited. ed
The marketing authorisation holder is Swedish Orphan International AB.
The marketing authorisation holder is:
The marketing authorisation holder is:
The Marketing Authorisation Holder is:
The marketing authorisation holder is Valeant Pharmaceuticals Ltd.
The MAH must ensure that the system of pharmacovigilance, as described in version DescPhSys000001/ 4 dated 12/ 12/ 2006– Updated:
26 TMZ was administered as salvage therapy in the follow-up phase in 161 patients of the 282 (57%) in the RT alone arm, and 62 patients of the 277 (22%) in the TMZ + RT arm.
41 TMZ was administered as salvage therapy in the follow-up phase in 161 patients of the 282 (57%) in the RT alone arm, and 62 patients of the 277 (22%) in the TMZ + RT arm.
56 TMZ was administered as salvage therapy in the follow-up phase in 161 patients of the 282 (57%) in the RT alone arm, and 62 patients of the 277 (22%) in the TMZ + RT arm.
71 TMZ was administered as salvage therapy in the follow-up phase in 161 patients of the 282 (57%) in the RT alone arm, and 62 patients of the 277 (22%) in the TMZ + RT arm.
86 TMZ was administered as salvage therapy in the follow-up phase in 161 patients of the 282 (57%) in the RT alone arm, and 62 patients of the 277 (22%) in the TMZ + RT arm.
TMZ was administered as salvage therapy in the follow-up phase in 161 patients of the 282 (57%) in the RT alone arm, and 62 patients of the 277 (22%) in the TMZ + RT arm.
14 TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on cross-linking of cell surface TNFRs.
168 TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on cross-linking of cell surface TNFRs.
41 TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on cross-linking of cell surface TNFRs.
TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on cross-linking of cell surface TNFRs.
Tocilizumab has been designed to bind to the receptor for a messenger molecule (cytokine) in the body called interleukin-6.
Plasma levels of 3- OMD were markedly and dose-dependently decreased by tolcapone when given with levodopa/ AADC-I (aromatic amino acid decarboxylase - inhibitor) (benserazide or carbidopa).
6 Toremifene is eliminated mainly as metabolites to the faeces.
Toremifene is a nonsteroidal triphenylethylene derivative.
Driving and using machines Toremifene has no influence on the ability to drive and use machines.
Toremifene has no influence on the ability to drive and use machines.
Toremifene can be taken with or without food.
All three doses must be administered to complete the vaccination regimen.
The toxoid is a toxin processed in order to remove its toxic effect, but retain its antigenic properties.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Naglazyme treatment should be supervised by a doctor who has experience in the management of patients with MPS VI or similar diseases.
Treatment was most commonly associated with a rise in body temperature.
Treatment continued whilst clinical benefit was noted.
Long term treatment should be intermittent and not continuous.
Treatment with Aranesp is divided into two stages – correction and maintenance phase.
Treatment with Copalia is not recommended during breast- feeding.
Treatment with Exforge is not recommended during breast- feeding.
Treatment with Imprida is not recommended during breast- feeding.
This will be followed by a daily dose of 100 mg (maintenance dose).
Humira in combination with methotrexate, is indicated for:
the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the no
the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been no
the treatment of severe, active and progressive rheumatoid arthritis in adults not previously t
Trudexa can be given as monotherapy in case of intolerance to methotrexate or when continued uc
The treatment for the prevention of peptic ulceration of patients in need of continuous NSAID treatment should be restricted to high risk patients (e.g. previous gastrointestinal bleeding, perforation 35 or ulcer, advanced age, concomitant use of medication known to increase the likelihood of upper GI adverse events [e.g. corticosteroids or anticoagulants], the presence of a serious co-morbidity factor or the prolonged use of NSAID maximum recommended doses).
The treatment for the prevention of peptic ulceration of patients in need of continuous NSAID treatment should be restricted to high risk patients (e.g. previous gastrointestinal bleeding, perforation or ulcer, advanced age, concomitant use of medication known to increase the likelihood of upper GI adverse events [e.g. corticosteroids or anticoagulants], the presence of a serious co-morbidity factor or the prolonged use of NSAID maximum recommended doses).
The treatment for the prevention of peptic ulceration of patients in need of continuous NSAID treatment should be restricted to high risk patients (e.g. previous gastrointestinal bleeding, perforation or ulcer, advanced age, concomitant use of medication known to increase the likelihood of upper GI adverse events [e.g. corticosteroids or anticoagulants], the presence of a serious co-morbidity factor or the prolonged use of NSAID maximum recommended doses).
Treatment for CMV retinitis is necessary to reduce the potential for blindness.
Treatment of rosacea is mainly aimed at reducing the papulopustular lesions while the erythema and telangiectasia components are difficult to alleviate.
Secondary organic causes of obesity must be excluded by diagnosis before prescribing this agent.
The management of obesity should be undertaken using a global approach and should include dietary, medical and psychotherapeutic methods.
The management of obesity should be undertaken using a global approach, and should include dietary, medical and psychotherapeutic methods.
13 Maintenance treatment can be continued for as long as a therapeutic benefit for the patient exists.
24 Maintenance treatment can be continued for as long as a therapeutic benefit for the patient exists.
2 Maintenance treatment can be continued for as long as a therapeutic benefit for the patient exists.
35 Maintenance treatment can be continued for as long as a therapeutic benefit for the patient exists.
Maintenance treatment can be continued for as long as a therapeutic benefit for the patient exists.
The treatment of animals weighing less than 1 kg should be based on a risk-benefit assessment.
Treatment of animals weighing less than 1 kg should be based on a risk-benefit assessment.
Treatment of animals weighing less than 1 kg should be based on a risk-benefit assessment.
Data processing by filtered backprojection and reconstruction in three planes (transaxial, coronal, and sagittal) is recommended.
Second-line therapy with quadruple therapy using proton pump inhibitor combined with bismuth subcitrate (subsalicylate) and metronidazole, and tertacycline for a minimum of 7 days has been recommended.
Treatment of paediatric patients younger than 1 year of age has not been studied:
Treatment of nausea with antiemetics is usually not necessary.
Treatment of patients with end-stage renal disease should be made with caution as there is little clinical experience and accumulation of a metabolite (with no known pharmacological activity).
Treatment of any overdose will be performed at the hospital.
Treatment should be discontinued after 10 days if no clinical improvement is apparent.
Treatment should be discontinued after 10 days if no clinical improvement is apparent.
The treatment should be re-considered if at 5 days no improvement in the clinical condition is observed.
The treatment should be reconsidered if at 5 days no improvement in the clinical condition is observed.
In these patients, treatment should be started under close medical supervision with low doses and careful dose titration.
Care should be taken to avoid treatment of animals that might not tolerate prolonged NSAID exposure.
Therapy should be initiated by a physician experienced in the management of HIV infection.
Therapy should be initiated by a physician experienced in the management of HIV infection.
Therapy should be initiated by a physician experienced in the diagnosis and the treatment of patients with CML.
Treatment should be initiated only by a physician experienced in the treatment of patients with hepatitis B or C.
Protopy should not be used in immunocompromised adults or children.
The treatment should be intermittent and not continuous.
Treatment should be intermittent and not continuous.
A major cytogenetic response is defined by < 34% Ph+ leukaemic cells in the bone marrow, whereas a minor response is  34%, but < 90% Ph+ cells in the marrow.
Treatment should be dis continued in case of severe leukopaenia (< 1,200/mm3), severe neutropaenia (< 750/mm3) or severe thrombocytopaenia (< 70,000/mm3).
Treatment should be discontinued in case of severe leukopaenia (< 1,200/ mm3), severe neutropaenia (< 750/ mm3) or severe thrombocytopaenia (< 70,000/ mm3).
Treatment should be discontinued in case of severe leukopaenia (< 1,200/mm3), severe neutropaenia (< 750/mm3) or severe thrombocytopaenia (< 70,000/mm3).
Treatment should continue for five weeks in patients who have had hip replacement surgery, and for two weeks in patients who have had knee replacement surgery.
Treatment should be reassessed regularly, on a case-by-case basis.
Treatment should only be initiated and monitored by a physician experienced in the treatment of pulmonary arterial hypertension.
Treatment should be directed at the major anticipated toxicities, which are bone marrow suppression, mucositis and peripheral neuropathy.
Patients should be advised to adhere strictly to a calorie- controlled diet.
Patients should be advised to adhere strictly to a calorie-controlled diet.
Treatment of cyanide poisoning must include immediate attention to airway patency, adequacy of oxygenation and hydration, cardiovascular support, and management of seizures.
Treatment of latent tuberculosis infection should be initiated prior to administering STELARA.
- Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal
If the overdose results in loss of consciousness, intravenous glucose or parenteral glucagon may be required to reverse the hypoglycaemic effects.
Treatment in proestrus will not suppress that particular heat (proestrus and oestrus).
Treatment will usually be every day for 7 days.
Treatment will usually be every day for 7 days.
The treatment will usually be given over a period of approximately 60 minutes.
Treatment is continued for as long as recommended in local guidelines on the management of HIV-infected patients.
Treatment is prescribed and monitored by physicians who are specialists in the treatment of drug dependence.
The treatment is an initial measure in an obesity management programme; it has to be combined with changes in diet, which must be continued after treatment is finished.
After intravenous initiation of treatment, the treatment can be continued orally as well.
The laser treatment induces a photochemical, not a thermal, effect.
The most effective method to remove lactate and metformin is haemodialysis.
Myocet (60 mg/ m2) + CPA (600 mg/ m2) was compared with conventional doxorubicin + CPA (at the same doses) and Myocet (75 mg/ m2) + CPA (600 mg/ m2) was compared to epirubicin + CPA (at the same doses).
Treatment must be initiated by a physician experienced in the treatment of PAH.
Treatment with Sutent should only be initiated by doctors who have experience in the treatment of GIST or RCC.
Treatment should only be resumed after consideration of risk – benefit to the patient.
Patients should not be switched to another medicinal product as anti-erythropoietin antibodies cross-react with other erythropoietins.
Treatment is not recommended in patients with relapsing-remitting multiple sclerosis who have experienced less than 2 relapses in the previous 2 years or in patients with secondary-progressive multiple sclerosis who have had no active disease in the previous 2 years.
Treatment is not recommended in patients with relapsing-remitting multiple sclerosis who have experienced less than 2 relapses in the previous 2 years or in patients with secondary-progressive multiple sclerosis who have had no active disease in the previous 2 years.
Treatment with Advagraf should only be prescribed by doctors who have experience in the management of transplant patients.
5 Treatment with nucleoside analogues should be discontinued in the setting of symptomatic hyperlactatemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
Treatment with nucleoside analogues should be discontinued if there is symptomatic hyperlactatemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
Treatment with nucleoside analogues should be discontinued in the setting of symptomatic hyperlactatemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
The TNF antagonist therapy was discontinued prior to randomisation.
Aranesp treatment should be initiated by physicians experienced in the above mentioned indications.
Treatment with Atripla should be started by a doctor who has experience in the management of HIV infection.
Betaferon therapy should not be started if you are pregnant (see also ‘Do not use Betaferon’).
Betaferon treatment should not be started if you are pregnant (see also ‘Do not use Betaferon’).
Carbaglu treatment should be initiated under the supervision of a physician experienced in the treatment of metabolic disorders.
Carbaglu treatment should be started by a doctor who has experience in treating patients with metabolic diseases.
Treatment with CELSENTRI should be initiated by a doctor who has experience in the management of HIV infection.
Treatment with CEPROTIN should be initiated under the supervision of a physician experienced in substitution therapy with coagulation factors/ inhibitors where monitoring of protein C activity is feasible.
CEPROTIN treatment should only be started by a doctor who has experience in this type of therapy and where it is possible to measure protein C activity.
Treatment with Cetrotide should be carried out by a doctor who has experience in this type of fertility treatment.
Treatment with Cetrotide is not advised in women with severe allergic conditions.
Since treatment with Cetrotide is not advised in women with severe allergic conditions it is important that you inform your doctor of any allergies.
COVERSYL should be introduced at a dose of 4 mg once daily for two weeks, then increased to 8 mg once daily, depending on renal function and provided that the 4 mg dose is well tolerated.
Stable coronary artery disease :< COVERSYL and associated names > should be introduced at a dose of 4 mg once daily for two weeks, then increased to 8 mg once daily, depending on renal function and provided that the 4 mg dose is well tolerated.
Treatment with Crixivan should be given by doctors who have experience in the treatment of HIV infection.
CYSTAGON treatment should be started by a doctor who has experience in the treatment of cystinosis.
30 Treatment with CYSTAGON should continue indefinitely, as instructed by your doctor.
Treatment with anti-TNFα antibodies is not recommended.
Since treatment with diuretics may be a contributory factor to the above, they should be discontinued and renal function should be monitored during the first weeks of< COVERSYL and associated names > therapy.
Treatment with thiazide diuretics, lithium, vitamin A, vitamin D and cardiac glycosides must also be discontinued.
Treatment with ECALTA should be initiated by a doctor who has experience in the management of invasive fungal infections.
Careful consideration should be given to patients with hypovolaemia and hypotension.
Treatment with Epivir should be initiated by a doctor who has experience in the management of HIV infection.
Treatment with Filgrastim HEXAL should be maintained until the last stem cell collection.
Gemfibrozil therapy should be terminated if abnormalities persist.
Side effects in men Men may experience some breast development, acne or weight gain due to treatment with hCG.
Some men undergoing treatment with GONAL-f may experience local reactions at the injection site (pain,
Treatment with Humira may result in the formation of autoimmune antibodies.
Treatment with INOmax should not be stopped suddenly, so that the circulation in your baby's lungs is able to adjust to oxygen/ air without INOmax.
Treatment with Inovelon should be initiated by a physician specialised in paediatrics or neurology with experience in the treatment of epilepsy.
Treatment with Inovelon should be initiated by a paediatrician (a doctor specialised in treating children) or a neurologist (a doctor who treats brain disorders).
Treatment with NRTIs should be discontinued if there is symptomatic hyperlactatemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
Therapy with Invirase should be initiated by a physician experienced in the management of HIV infection.
Therapy with Invirase should be initiated by a physician experienced in the management of HIV infection.
Treatment with Invirase should be started by a doctor who has experience in the treatment of HIV infection.
Treatment with Isentress should be started by a doctor who has experience in the management of HIV infection.
Kineret treatment should not be initiated in patients with neutropenia (ANC < 1.5 x 109/ l).
Treatment with nicotinic acid reduces the risk of death and cardiovascular events, and slows progression or promotes regression of atherosclerotic lesions.
Fluoxetine should be discontinued in any patient entering a manic phase.
Therefore, treatment via feed with Aivlosin is not recommended for these animals.
Anidulafungin treatment prolonged survival and also reduced the organ burden of Candida spp., when determined at intervals from 24 to 96 hours after the last treatment.
Nitisinone treatment should be initiated and supervised by a physician experienced in the treatment of HT-1 patients.
Lapatinib treatment should only be initiated by a physician experienced in the administration of anti- cancer agents.
Pioglitazone may be initiated at 15 mg or 30 mg once daily.
12 Rosiglitazone was associated with increases in weight.
Rosiglitazone was associated with increases in weight.
Somatropin therapy should be continued in children and adolescents until their epiphysis are closed.
Treatment with somatropin is a long-term treatment.
Because mycophenolate has been associated with an increased incidence of digestive system adverse events, including infrequent cases of gastrointestinal tract ulceration, haemorrhage and perforation, Mycophenolate mofetil Teva should be administered with caution in patients with active serious digestive system disease.
Treatment with nucleoside analogues should be discontinued when rapidly elevating aminotransferase levels, progressive hepatomegaly or metabolic/ lactic acidosis of unknown aetiology occur.
Treatment with nucleoside analogues should be discontinued when rapidly elevating aminotransferase levels, progressive hepatomegaly or metabolic/ lactic acidosis of unknown aetiology occur.
Treatment with nucleoside analogues must be discontinued in the setting of symptomatic hyperlactataemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
Treatment with nucleoside analogues should be discontinued in the setting of symptomatic hyperlactataemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
Treatment with nucleoside analogues should be discontinued in the setting of symptomatic hyperlactataemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
Treatment with nucleoside analogues should be discontinued in the setting of symptomatic hyperlactatemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
Treatment with orlistat may potentially impair the absorption of fat-soluble vitamins (A, D, E and K) (see section 4.5).
Treatment with Lucentis is for intravitreal injection only.
Treatment with Lysodren should be continued as long as clinical benefits are observed.
Treatment with Macugen is for intravitreal injection only and should be administered by ophthalmologists experienced in intravitreal injections.
As fibrin is lysed during Metalyse therapy, bleeding from recent puncture site may occur.
Treatment is therefore not recommended in these patient groups.
Treatment should be reserved for patients in whom it is considered of particular importance to avoid homologous blood transfusion taking into consideration the risk/ benefit assessment for homologous transfusions.
Nespo treatment should be initiated by physicians experienced in the above mentioned indications. du
Treatment with Norvir should be given by a doctor who has experience in the treatment of HIV infection.
Treatment with Orfadin should be started and monitored by doctors who are experienced in the treatment of hereditary tyrosinemia type 1 (HT-1) patients.
With additional Orfadin treatment, the survival rate increases to 82%.
Treatment with orlistat may potentially impair the absorption of fat-soluble vitamins (A, D, E and K).
Treatment with Ovitrelle may increase your risk of developing a condition called ovarian hyperstimulation syndrome (OHSS) (see also ‘ Possible side effects’).
Panretin treatment should be initiated and maintained by a doctor experienced in the treatment of patients with Kaposi's sarcoma.
Treatment with Paxene has been shown to improve the response rate of various tumours.
Treatment with Paxene should be given by an oncologist (cancer specialist) in a specialised cancer ward.
Treatment should normally not be initiated if ALT is > 10 times the upper limit of normal.
Placebo/ valdecoxib treatment was also associated with a higher incidence of CV thromboembolic events versus placebo treatment, but this difference did not reach statistical significance.
Treatment with Prezista should be started by a doctor who has experience in the management of HIV infection.
A statement to highlight that tacrolimus should not be applied to lesions, wh ich
Treatment with Protopy may be associated with an increased risk of herpes viral infections (herpes simplex dermatitis [eczema herpeticum], herpes simplex [cold sores], Kaposi's varicelliform no
Treatment with Protopy may be associated with an increased risk of herpes viral infections (herpes simplex dermatitis [eczema herpeticum], herpes simplex [cold sores], Kaposi's varicelliform lp
Treatment with Protopy may be repeated if symptoms reappear.
Raptiva should be discontinued if a malignancy develops while the patient is on treatment (see sections 4.3 and 4.8).
The need for an increased dose relative to that used for adults and older children should be anticipated when treating younger children with ReFacto AF.
Treatment initiation with Refludan should be undertaken only in a setting where medical assistance is readily available and where there is access to treatment for anaphylactic reactions. – Patients should be informed that they have received Refludan. – In case of renal impairment relative overdose may occur even under a standard dosage regimen.
Patients with fistulising Crohn's disease with acute suppurative fistulas must not initiate Remicade therapy until a source for possible infection, specifically abscess, has been excluded (see section 4.3).
Treatment initiation with Revasc should be undertaken only in a setting where medical assistance is readily available and where there is access to treatment for anaphylactic reactions.
Treatment with Sebivo should be started by a doctor who has experience in the management of chronic hepatitis B.
Treatment with Siklos should be discontinued if bone marrow function is markedly depressed.
Treatment with Siklos should be initiated by a doctor who has experience in the management of sickle cell syndrome.
There were fewer thrombotic events with Soliris treatment than during the same period of time prior to treatment.
Soliris therapy must not be initiated without prior vaccination against Neisseria meningitidis at least 2 weeks prior to initial administration.
For further information please ask the doctor.
Since somatropin therapy following renal transplantation has not been adequately tested, NutropinAq treatment should be terminated after that surgery.
SOMAVERT treatment should be initiated by a doctor who has experience in the treatment of acromegaly.
Discontinue SUTENT in patients with nephrotic syndrome.
Treatment with Tarceva should be supervised by a doctor who has experience of the use of anticancer medicines.
Treatment with Targretin should only be initiated and maintained by a doctor who has experience in the treatment of patients with CTCL.
Treatment with Tasigna should be initiated by a doctor who has experience in the diagnosis and treatment of CML.
Tasmar therapy should only be initiated by physicians experienced in the management of advanced Parkinson's disease, to ensure an appropriate risk-benefit assessment.
Treatment with Telzir should be started by a doctor who has experience in the management of HIV infection.
Treatment with higher doses of tetracyclines is associated with emergence of resistant intestinal bacteria, such as enterococci and enterobacteria.
Tevagrastim treatment will last for up to 2 weeks and in exceptional cases longer.
Treatment with TORISEL should continue until the patient does not benefit any more or has unacceptable side effects.
In study AC-052-401, during 16 weeks of double-blind therapy, patients in the bosentan group developed a mean of 1.4 new digital ulcers vs.
Treatment with Tractocile should be carried out by a doctor who has experience in the treatment of pre-term labour.
TRISENOX treatment should be supervised by a doctor who has experience in the management of patients with acute leukaemias.
Tritazide and associated names should be started at the lowest available dosage.
Treatment with Trizivir should be initiated by a doctor who has experience in the management of HIV infection.
Treatment with Trudexa must be discontinued in patients who develop new or worsening symptoms of congestive heart failure.
treatment of the diseases that Trudexa is used to treat.
Treatment with Trudexa may result in the formation of autoimmune antibodies.
Treatment with Tysabri should be started and supervised by a doctor who is experienced in treating diseases of the nervous system, and who has access to a type of scanning machine called a magnetic resonance imaging (MRI) machine.
Tyverb should only be initiated by a doctor who has experience in giving anticancer medicines.
Combination antiretroviral therapy may cause changes in body shape due to changes in fat distribution.
72 Combination antiretroviral therapy may cause changes in body shape due to changes in fat distribution.
Combination antiretroviral therapy may cause changes in body shape due to changes in fat distribution.
Combination antiretroviral therapy may cause changes in body shape due to changes in fat distribution.
Combination antiretroviral therapy may cause changes in body shape due to changes in fat distribution.
Combination antiretroviral therapy may cause changes in body shape due to changes in fat distribution.
After an initial dose of 20 mg twice daily, valsartan should be titrated to 40 mg, 80 mg, and 160 mg twice daily over the next few weeks.
Treatment with Velcade should only be started and given under the supervision of a doctor who has experience in the use of cancer chemotherapy.
Therapy with VIRACEPT should be initiated by a physician experienced in the management of HIV infection.
Treatment with Viracept should be initiated by a doctor who has experience in the treatment of HIV infection.
Treatment with Viraferon should be initiated by a doctor who has experience in the management of lp
Treatment with Viread should be initiated by a doctor who has experience in the treatment of HIV infection.
Wilzin treatment should be started by a doctor who has experience in the treatment of Wilson's disease.
Wilzin treatment should be initiated and monitored by a physician experienced in the treatment of Wilson's disease.
Wilzin treatment should be initiated under the supervision of a physician experienced in the treatment of Wilson's disease (see section 4.4).
Xolair treatment should be initiated by physicians experienced in the diagnosis and treatment of severe persistent asthma.
Xolair therapy has not been studied in patients with autoimmune diseases, immune complex-mediated conditions, or pre-existing renal or hepatic impairment.
Xolair treatment should only be considered for patients whose asthma is caused by IgE (immunoglobulin E, an antibody).
Xolair treatment should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma (see section 4.2).
Treatment with Yondelis should be discontinued until the patient fully recovers.
The following criteria are required to allow treatment with Yondelis:
Treatment with ziconotide should only be undertaken by physicians experienced in intrathecal (IT) administration of medicinal products.
Thereafter, treatment can be resumed as appropriate at a reduced dose depending on the initial severity of the event.
The treatment may vary, depending on the results of your regular blood tests.
Treatment may be delayed to allow sufficient time for recovery.
Treatment can be continued once blood pressure has been stabilised.
Pharmacological treatment should be an integral part of a more comprehensive treatment programme, including psychosocial and educational intervention.
Daily treatment with 2.5 mg resulted in progressive increases in BMD at vertebral and nonvertebral sites of the skeleton.
A recommended regimen commences with one vial of Pergoveris daily.
Treatment then continues with two 110 mg capsules (220 mg) once a day for 28 to 35 days after hip replacement and for 10 days after knee replacement.
Treatment is continued for two to three weeks after the operation.
Nplate will be given under the direct supervision of your doctor, who will closely control the amount of Nplate given to you.
IntronA is generally given three times per week (every other day) but the injection can be given more frequently in some diseases (CML and melanoma).
The glucocorticoid replacement therapy may require adjustment after NutropinAq therapy has been started.
Document transfer to key EMEA partners like the Commission, national authorities and the Luxembourg Translation Centre would also need to be included.
Transferring a patient to another type or brand of insulin should be done under strict medical supervision.
HER2, a receptor for epidermal growth factor, which is found on the surface of certain tumour cells.
Trastuzumab is a recombinant humanised IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2).
Trastuzumab binds selectively to an antigen called human epidermal growth factor 2 (HER2).
The work continued on the implementation of the common technical document and collaboration with the European Pharmacopoeia in the framework of the Certification of Suitability scheme. • Herbal Medicinal Products Working Party The Herbal Medicinal Products Working Party was established in 2002 as a working party of the CPMP with a new composition, mandate and work programme approved by the EMEA Management Board.
Preparatory work on a second series of topics, including testing of biologicals, and pharmacovigilance is now well under way.
The work already underway on strict monitoring of time and cost for these activities will be continued.
• Provision of information and assistance to new staff and the organisation and co-ordination of training programmes for all staff
Work on the contract between the EMEA and the Italian Ministry of Health to assist Italy in training of inspectors and joint inspections will continue in 2002.
Etravirine demonstrates activity against HIV-1 group M (subtypes A, B, C, D, E, F, and G) and HIV-1 group O primary isolates with EC50 values ranging from 0.3 to 1.7 nM and from 11.5 to 21.7 nM, respectively.
Etravirine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site.
Travoprost is a prodrug that undergoes rapid ester hydrolysis in the cornea to the active free acid.
• Travoprost may be absorbed through the skin and therefore should not be used by women who are pregnant or are attempting to become pregnant.
The teat end should be cleaned until no more dirt appears on the swab.
Arsenic trioxide also causes damage or degradation of the fusion protein Pro-Myelocytic Leukaemia/ Retinoic Acid Receptor-alpha (PML/ RAR alpha).
The viral tropism cannot be safely predicted by treatment history and assessment of stored samples.
The viral tropism cannot be predicted by treatment history or assessment of stored samples.
The pump tubing should be attached to the bag, the tubing purged and then capped.
Study 001/ 007, which included women from 15 to 25 years of age at the time of vaccination, evaluated the immune response against HPV-16 and HPV-18 up to 76 months post dose 1.
101 Study 1 was a Phase 2 study in patients with active but clinically stable plaque psoriasis involving  10% of the body surface area that were  18 years old.
126 Study 1 was a Phase 2 study in patients with active but clinically stable plaque psoriasis involving  10% of the body surface area that were  18 years old.
176 Study 1 was a Phase 2 study in patients with active but clinically stable plaque psoriasis involving  10% of the body surface area that were  18 years old.
202 Study 1 was a Phase 2 study in patients with active but clinically stable plaque psoriasis involving  10% of the body surface area that were  18 years old.
49 Study 1 was a Phase 2 study in patients with active but clinically stable plaque psoriasis involving  10% of the body surface area that were  18 years old.
76 Study 1 was a Phase 2 study in patients with active but clinically stable plaque psoriasis involving  10% of the body surface area that were  18 years old.
Study 1 was a Phase 2 study in patients with active but clinically stable plaque psoriasis involving  10% of the body surface area that were  18 years old.
Study 2 assessed the efficacy and safety of Xolair in a population of 312 severe allergic asthmatics which matched the population in study 1.
after IntronA in combination with combination with ribavirin in
Stu dy 2 (P02080) was a randomized, single centre study that enrolled 95 previously untreated adult patients with chronic hepatitis C who were co- infected with HIV.
Study 2 (P02080) was a randomized, single centre study that enrolled 95 previously untreated adult patients with chronic hepatitis C who were co- infected with HIV.
Study 2 (P02080) was a randomized, single centre study that enrolled 95 previously untreated adult patients with chronic hepatitis C who were co-infected with HIV.
Study 2 (P02080) was a randomized, single centre study that enrolled 95 previously untreated adult patients with chronic hepatitis C rod
The study compared the effects of either Viread with those of stavudine (another antiviral medicine) when they were taken together with lamivudine and efavirenz (other antiviral medicines).
The study confirmed the relationship between the use of anorectic agents and the occurrence of primary pulmonary hypertension.
The study showed that Aldurazyme had improved both the FVC and the walking ability of patients at 26 weeks.
The study was double blinded (neither the doctor nor the patient knew which treatment the patient was receiving), and it measured the time taken for the disease to get worse.
The study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least one but no more than four disease-modifying antirheumatic drugs (DMARDs).
The AIRE study included more than 2,000 patients with transient/ persistent clinical signs of heart failure after documented myocardial infarction.
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinican´s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer´s disease cooperative study – activities of the daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
The study showed that Elaprase improved both lung function and the walking ability of the patients.
The study investigated a) the effect of simvastatin on mortality, b) the effect of simvastatin on major coronary events, and c) the effect of simvastatin on any coronary event.
The study measured the number of children who developed an S. pneumoniae invasive disease during the 3.5 years of the study.
The study is a randomized, double-blind, placebo- controlled dose-finding study, in the indication of acquired protein C deficiency due to meningococcal sepsis (IMAG 112).
The pivotal clinical trial for Unstable Angina (UA)/ Non-Q Wave Myocardial Infarction (NQMI) was PURSUIT.
The study of VFEND in invasive aspergillosis involved 277 immunocompromised patients (their immune system was not working properly).
The carcinogenicity study in the rat did not reveal any effect which may be relevant for humans.
The EPC study was an empirical design, that is to say, it generally compared Casodex (bicalutamide) to the standard of care in each region involved.
Study III evaluated 623 patients who had an inadequate clinical response to MTX.
M98-940 is an open-label study of a liquid formulation of Kaletra in 100 antiretroviral naïve (44%) and experienced (56%) paediatric patients.
M98-940 is an open-label study of a liquid formulation of Kaletra in 100 antiretroviral naïve (44%) and experienced (56%) paediatric patients.
The adverse event profile was generally similar in the MERLIN-TIMI 36 study.
The single institution study included 2 paediatric patients (< 18 years old), both of whom achieved CR.
The study was not powered to show a reduction in clinical fractures in men; the incidence of clinical fractures was 7.5% in men treated with Aclasta versus 8.7% for placebo.
The study was still ongoing at the time of assessment.
The study included 107 patients with aspergillosis, 18 patients with fusariosis, 11 with chromoblastomycosis or mycotema, and 16 with coccidioidomycosis.
The main study looked at the effectiveness and safety of Rotarix, and it involved over 63,000 infants.
Psoriasis Study 1 (PHOENIX 1) evaluated 766 patients.
In the study of induction treatment, CIMZIA showed only marginal effectiveness, which was too low to be relevant for patients.
Study S2 (105) evaluated patients who were splenectomised and continued to have thrombocytopenia.
The additional study confirmed the improvement in symptoms with ORENCIA in patients who had not responded adequately to methotrexate.
The study of Betaferon in patients with a single demyelinating event involved 487 patients, who received either Betaferon or a placebo for two years.
The study in children showed that the medicine produced similar levels of the active substance in the blood in children and adults, with similar side effects and effectiveness.
The VIO study included patients with occult with no classic subfoveal CNV with a visual acuity score of 73-34 letters (20/ 40-20/ 200), and patients with lesions > 4 MPS disc areas were to have baseline visual acuity < 65 letters (< 20/ 50).
The VIP-AMD included patients with occult with no classic subfoveal CNV with a visual acuity score of > 50 letters (20/ 100).
Study WV16240 recruited patients who were positive for HBeAg, while study WV16241 recruited patients who were negative for HBeAg and positive for anti-HBe.
Study WV16240 recruited patients who were positive for HBeAg, while study WV16241 recruited patients who were negative for HBeAg and positive for anti-HBe.
prothrombin (coagulation factor) values, reduction in blood platelets (thrombocytopenia) with bruises and tendency to bleed, increase in blood platelets (thrombocytosis)
decreased amounts of a blood clotting factor (thrombocytes)
Leukocytosis White blood cell counts of 100 x 109/ l or greater have been observed in less than 5% of patients receiving filgrastim at doses above 0.3 MIU/ kg/ day (3 μ g/ kg/ day).
Leucocytosis White blood cell counts of 100 x 109/ l or greater have been observed in less than 5% of patients receiving filgrastim at doses above 0.3 MU/ kg/ day (3 μ g/ kg/ day).
Leukopenia, thrombocytopenia, anaemia Pancytopenia, leukocytosis
Skin cancer, benign neoplasm of skin Leucopenia, thrombocytopenia, anaemia Pancytopenia, leucocytosis
LeukoScan is radiolabelled by mixing it with a solution of radioactive technetium (99mTc).
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The frequency as reported in clinical trials was 9.4% following multiple injections of 0.25 mg cetrorelix.
The ir activities cover such key areas as security, switchboard/reception, restaurant, building and equipment, maintenance, and cleaning and office supplies.
Quixidar is used to treat patients with a blood clot in the blood vessels of their legs (deep vein thrombosis) and/or lungs (pulmonary embolism). ro
The eyes should be protected by a suitable eye lubricant.
The vaccine has been developed to provide protection against this strain, so that it can be used before or during a flu pandemic.
The vaccine acts by inducing antibodies against both the bacterial components and CTB.
The vaccine helps to reduce the symptoms of the diseases and also helps to reduce viral excretion in case of calicivirus infection.
The vaccine helps to reduce the symptoms of the diseases and helps to reduce viral excretion in case of calicivirus infection.
The vaccine helps to reduce the symptoms of the diseases.
The vaccine CELVAPAN may be used during lactation.
Vaccines work by ‘ teaching'the immune system (the body's natural defences) how to defend itself against diseases.
The vaccine confers 6-month protection against rabies.
The vaccine also contains ‘ adjuvants '(a compound containing aluminium as well as mineral oil, an emulsifier and a detergent) to stimulate a better response.
The vaccine also contains an ‘ adjuvant '(a compound called saponin) to stimulate a better response.
Vaccines work by ‘ teaching'the immune system how to defend itself against diseases.
The vaccine also contains an ‘ adjuvant'(liquid paraffin) to stimulate a better response.
The vaccine helps to reduce the symptoms of the diseases.
The product should only be used after it has been established that IBV variant strain 4-91 is epidemiologically
The product should only be used after it has been established that IBV variant strain 4-91 is epidemiologically relevant in the area.
The vaccine is to be administered orally without mixing with any other vaccines or solutions.
The vaccine is to be administered orally without mixing with any other vaccines or solutions.
The vaccine should be allowed to reach room temperature before use.
The preferred injection sites are the anterolateral area of the thigh in younger children and the deltoid area in older children, adolescents, and adults.
The vaccine is to be injected intramuscularly (IM) or subcutaneously (SC).
The vaccine should be allowed to reach room temperature before use.
The vaccine should be used immediately after opening.
The vaccine should be used as supplied; no reconstitution is necessary.
The vaccine is administered directly from the tip of the syringe onto the opening of the nostril and enters the nasal cavity during inhalation.
The vaccine is given by injection into a muscle.
The vaccine is given as an injection into a muscle.
The vaccine is an emulsion (a mixture of oil- and water-based liquids) for injection.
The vaccine IDflu may be used during breast-feeding.
The vaccine induces an active immunity and a serological response against Infectious Bursal Disease and Marek's Disease in chickens.
The vaccine INTANZA may be used during breast-feeding.
The vaccine does not provide complete protection and it is important to adhere to standard protective measures to avoid cholera.
The vaccine should never be given into a vein.
The vaccine should not be used if foreign particles are present in the suspension.
Under no circumstance should this vaccine be administered by injection.
The vaccine should under no circumstances be administered intravascularly or subcutaneously.
The vaccine should never be injected into a vein.
The vaccine should never be given into a vein.
The vaccine should never be given into a vein.
The vaccine should never be given into a vein or into the skin.
The vaccine should never be given into a vein.
Why has Purevax RCPCh been approved?
The vaccine should not be mixed in the same syringe with any other vaccines and solutions.
The vaccine should not be used if foreign particles are present in the suspension.
Discard the product if particulates are present or if it appears discoloured.
The vaccine does not provide complete protection and it is important to adhere to dietary and hygiene advice to avoid diarrhoeal diseases.
The vaccine may be administered by veterinarians only.
The vaccine will not prevent infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E or other pathogens known to infect the liver.
The vaccine will not prevent infection caused by other agents such as hepatitis C and hepatitis E and other pathogens known to infect the liver.
The vaccine will not prevent infection caused by other agents such as hepatitis C and hepatitis E and other pathogens known to infect the liver.
The vaccine will not prevent infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E and other pathogens known to infect the liver.
The vaccine will not prevent infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E and other pathogens known to infect the liver.
Nobilis IB 4-91 vaccine has also been compared with controls, i. e. chickens that were not vaccinated.
The vaccine can be administered to future layers and breeders from three weeks of age onwards via intranasal/ ocular route, coarse spray or drinking water.
Daronrix may be used during lactation.
The vaccine can be given without regard to food, liquid, or breast milk.
The vaccine can be used during pregnancy and lactation.
The vaccine may be used during lactation.
The vaccine may not prevent hepatitis B in these individuals.
It may also cause a temporary increase in body temperature.
The poliomyelitis vaccine is obtained from the propagation of poliomyelitis viruses types 1, 2 and 3 on Vero cells, purified, then inactivated by formaldehyde.
The reconstituted vaccine contains an inactivated porcine circovirus type 2 (PCV2) in an oily adjuvant (o/ w).
5/ 23 Reconstituted vaccine should be used within 4 hours.
2 years Reconstituted product should be used immediately.
Reconstituted vaccine should be used immediately.
The reconstituted vaccine is slightly more turbid than the solvent and is milky white in appearance.
54 The reconstituted vaccine is slightly more turbid than the solvent and is milky white in appearance.
The mixed vaccine is a whitish emulsion.
The vaccine is an off-white, opalescent, translucent suspension.
The vaccine is a homogeneous white suspension.
The vaccine is a whitish suspension supplied in a single-dose glass vial.
Stimulates active immunity against feline rhinotracheitis herpesvirus and feline calicivirus.
Stimulates active immunity against feline rhinotracheitis herpesvirus, feline calicivirus, Chlamydophila felis, feline panleucopenia virus and feline leukaemia virus.
Stimulates active immunity against feline rhinotracheitis herpesvirus, feline calicivirus and Chlamydophila felis.
Stimulates active immunity against feline rhinotracheitis virus, feline calicivirus, and feline panleucopenia virus.
Stimulates active immunity against feline rhinotracheitis virus, feline calicivirus, feline panleucopenia virus and feline leukaemia virus.
Valdecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor within the clinical dose range.
Valsartan also demonstrated beneficial effects on signs and symptoms of HF.
Valsartan was as effective as captopril in reducing all-cause mortality after myocardial infarction.
Valsartan has been studied in patients with post myocardial infarction and heart failure.
There is currently no experience on the safe use in patients with a creatinine clearance < 10 ml/ min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients (see sections 4.2 and 5.2).
Valsartan does not exhibit any partial agonist activity at the AT1 receptor and has much (about 20,000-fold) greater affinity for the AT1 receptor than for the AT2 receptor.
Valsartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.
Valsartan is not known to bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.
Valsartan does not undergo any noteworthy biotransformation.
Valsartan does not inhibit ACE, also known as kininase II, which converts angiotensin I to angiotensin II and degrades bradykinin.
Safety evaluation of Tarceva is based on the data from 759 patients treated with at least one 150 mg dose of Tarceva monotherapy during Phase III NSCLC study BR.21, Phase II NSCLC study A248-1007, and three Phase II studies in populations other than NSCLC:
Assessment of the change in fibrosis after 48 weeks treatment using the Knodell scores confirms that patients treated with adefovir dipivoxil 10 mg had more regression and less progression of fibrosis than patients treated with placebo.
The evaluation of the goals for distribution of educational materials should also be considered.
An assessment of renal function should be included in the evaluation of patients post-myocardial infarction.
Vardenafil 20 mg potentiated the blood pressure lowering effect of sublingual nitroglycerin (0.4mg) taken 1 and 4 hours after vardenafil administration to healthy middle aged subjects.
Single and multiple oral doses of vardenafil up to 40 mg produced no clinically relevant changes in the ECGs of normal male volunteers.
Vedaprofen contains an asymmetric carbon atom and, therefore, is a racemic mixture of a (+) enantiomer and a (-) enantiomer.
Levemir should not be disposed of via waste water or household waste.
Levemir which has been frozen must not be used.
10 Levemir should not be used if it does not appear clear and colourless.
30 Levemir should not be used if it does not appear clear and colourless.
Levemir should not be used if it does not appear clear and colourless.
The most frequent adverse reaction is an increase in blood pressure or aggravation of existing hypertension.
The most common adverse reaction reported at a greater incidence in patients treated with aprepitant (1.1%) than with ondansetron (1.0%) was ALT increased.
Twenty six events in 24/ 132 patients were considered to be related to clofarabine, the most frequently reported being flushing (15 events; not serious) and hypotension (5 events; one of which was considered to be serious; see section 4.4).
The event may be self limited, but ziconotide should be discontinued until the event resolves.
It is not known whether rFVIIa is excreted in human milk.
Until June 2005, veralipride was also marketed in Spain.
Veralipride is a benzamide neuroleptic medicine indicated in the treatment of vasomotor symptoms associated with the menopause.
The glass should be rinsed with water several times and each rinse completely swallowed to ensure the entire dose is consumed.
The measuring cup provided has been especially designed to give you the right dose of Norvir oral solution.
The dosing cup is not dishwasher-safe.
The dosage cup or oral syringe should be cleaned immediately with hot water and dish soap after use.
The use of the product in dogs of less than 10 kg or more than 40 kg bodyweight, therefore, should be subject to a risk/ benefit assessment performed by the veterinarian.
The use of the product in dogs of less than 10 kg or more than 40 kg bodyweight, therefore, should be subject to a risk/ benefit assessment performed by the veterinarian.
The Vialmix is not included in the Luminity pack but will be provided to healthcare professionals upon ordering the pack.
Vigabatrin is an antiepileptic drug with a clearly defined mechanism of action.
This is because vigabatrin was designed rationally as a selective irreversible inhibitor of GABA-transaminase, the enzyme responsible for the breakdown of GABA.
Both HIV and the ingredients of Atripla may pass through breast milk and cause serious harm to your baby.
The human immunodeficiency virus (HIV-1) encodes an aspartyl protease that is essential for the cleavage and maturation of viral protein precursors.
The HIV virus in your blood may eventually become resistant to Fuzeon and your blood levels of virus begin to rise.
The virus may then become harder to treat.
The bottle is inverted and the correct volume withdrawn.
The volume after mixing 1 vial of suspension (2.5 ml) with 1 vial of emulsion (2.5 ml) corresponds to 10 doses of vaccine (5 ml)
The volume after mixing 1 vial of suspension (2.5 ml) with 1 vial of emulsion (2.5 ml) corresponds to 10 doses of vaccine (5 ml).
The volume of distribution decreased with continued treatment, possibly related to antibody formation and/ or decreased liver volume.
Ciprofloxacin is present in plasma largely in a non- ionised form and has a large steady state distribution volume of 2-3 L/kg body weight.
Ciprofloxacin is present in plasma largely in a non- ionised form and has a large steady state distribution volume of 2-3 L/kg body weight.
Apparent volume of distribution averaged 415 litres (%CV= 50) at steady-state.
The volume of distribution at steady state for somatropin in healthy adult males is about 50 ml/ kg bodyweight, approximating the serum volume.
The volume of distribution of the peripheral compartment was 47.4 l/m2.
The volume of distribution of maraviroc is approximately 194 L.
The steady-state volume of distribution of sugammadex is approximately 11 to 14 litres.
Mean apparent volume of distribution is 0.99 l/kg.
Mean volume of distribution of central compartment:
The mean Vd ranged between 63-276 L
The mean Vd ranged between 63 – 276 l.
The volume of distribution (Vd, area) is 1.1 l x kg-1.
The volume of the syringe should be small enough so that the prescribed dose can be given with reasonable accuracy.
The volume of diluted sodium pertechnetate (99mTc) solution for injection, added to the vial must be 1 ml.
The volume of Naglazyme is to be slowly added to the sodium chloride 9 mg/ ml (0.9%) solution for infusion.
The volume of Pandemrix (5 ml) after mixing corresponds to 10 doses of vaccine.
The volume of the central compartment (Vc) and clearance correspond to an initial half-life of 1.4 days and a terminal half-life of about 20 days.
The theoretical specific activity is 20 GBq/ microgram of Yttrium (90Y) (see section 6.5).
150 l/m2 (range 96-228 l/m2).
The volume required to administer the correct dose can be calculated from the following scheme:
The reconstituted volume allows accurate withdrawal of 10.0 ml (equal to 50 mg) from each vial.
The reconstituted volume allows accurate withdrawal of 10.0 ml (equal to 400 units) from each vial.
The reconstituted volume allows accurate withdrawal of 10.0 ml (equal to 400 units) from each vial.
The reconstituted volume allows accurate withdrawal of 5.0 ml (equal to 200 units) from each vial.
The reconstituted volume allows accurate withdrawal of 5.0 ml (equal to 200 units) from each vial.
The total volume after reconstitution is 5.26 ml (200 mg vial) or 26.3 ml (1000 mg vial) respectively.
Fill the 13C-urea jar to the brim with water for a second and third time and add these contents to the drinking glass (total volume of tap water should be approximately 30 ml).
Fill the 13C-urea jar to the brim with water for a second and third time and add these contents to the drinking glass (total volume of tap water should be approximately 30 ml).
The natural course of peripheral neuropathy to resolution to baseline due to cumulative toxicity of Abraxane after > 6 courses of treatment was not evaluated and remains unknown.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The course of pre- existing infections may be aggravated.
Progression to cirrhosis occurred in 4/ 68 (6%) patients with the YMDD variant, whereas no patients without the variant progressed to cirrhosis.
Approximate number of doses delivered.
The red light comes on when you start a dose.
VZV was not detected in any of these specimens.
Wild-type VZV was detected in 25 (5 for ZOSTAVAX, 20 for placebo) of these specimens.
Clinical examination should include evaluation for physical signs of fat
Clinical examination should include evaluation for physical signs of fat redistribution.
Clinical examination should include evaluation for physical signs of fat redistribution.
Clinical examination should include evaluation for physical signs of fat redistribution (see section 4.8).
Investigations in cell cultures of human bone marrow cells showed that epoetin beta stimulates erythropoiesis specifically and does not affect leucopoiesis.
In vitro examinations of emedastine's affinity for histamine receptors (H1, H2, and H3) demonstrate 10,000-fold selectivity for the H1 receptor, Ki's = 1.3 nM, 49,064 nM and 12, 430 nM, respectively.
In vitro examinations of emedastine's affinity for histamine receptors (H1, H2, and H3) demonstrate 10,000-fold selectivity for the H1 receptor, Kis = 1.3 nM, 49,064 nM and 12, 430 nM, respectively.
Meticulous expert scrutiny of individual reports of all known cases (3 cases from Germany and 1 case from Austria) of SUD in the 2nd year of life did not reveal any circumstantial evidence of a biological and causal link between Hexavac and the occurrence of SUD.
Examination revealed no reports of hypospadias associated with maternal loratadine use and no evidence of an increased rate of major congenital abnormalities among offspring of mothers exposed to loratadine during the first trimester.
Imaging can start immediately after the injection, and VASOVIST allows to take images up to one hour.
Scanning may start immediately after the VASOVIST injection.
Biliary excretion of the unchanged drug was the major route of elimination.
Biliary excretion may also contribute to the elimination.
Biliary excretion accounts for approximately 50% of the total tigecycline excretion.
It is not known whether this medicinal product or its metabolites are excreted in human milk.
It is not known whether this medicinal products or its metabolites are excreted in human milk.
It is not known whether galsulfase is excreted in milk, therefore breast-feeding should be stopped during Naglazyme treatment.
The excretion of ambrisentan in milk has not been studied in animals.
The excretion of emodepside has not been investigated in dogs.
It is not known whether Macugen is excreted in human milk.
The main route of excretion of zonisamide metabolites and unchanged drug is via the urine.
The excretion of histamine in milk has not been studied in animals, but at maternotoxic doses in rats, offspring showed slight toxicity during early lactation (see Section 5.3).
Renal excretion of deferasirox and its metabolites is minimal (8% of the dose).
Renal excretion plays a minor role in the elimination of paclitaxel, less than 10% of the dose has been reported to be excreted in the urine as unchanged drug.
The cumulative renal excretion of total orlistat-related materials was < 2% of the given dose.
Viral shedding into the upper respiratory tract was also reduced in vaccinated animals relative to controls, suggesting a reduced risk of viral transmission.
Exenatide suppresses glucagon secretion which is known to be inappropriately elevated in type 2 diabetes.
The costing exercise is carried out at the request of the European Parliament and of the European Court of Auditors.
Pregnancy must be excluded before start of treatment with leflunomide,
Pregnancy must be excluded before start of treatment with leflunomide,
The experience gained served as a starting point for this first public formal work programme for 1997 and 1998.
Clinical trial experience with daily doses greater than 20mg is minimal.
Experience with other contrast media shows that the risk of hypersensitivity reactions is higher in those patients.
The experience with Glivec in patients with MDS/ MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1).
There is currently limited experience of patients receiving more than 3 treatment cycles (see section 4.4).
- Experience in patients with Silver-Russell syndrome is limited.
Experience in patients with Silver-Russell syndrome is limited.
The experience in patients who are severely immunocompromised, receiving immunosuppressive therapy, and patients with severe neutropenia is limited since this population was excluded from phase 3 trials.
Human experience of acute overdose with ritonavir is limited.
Clinical experience shows that host defence against infection is compromised in some patients treated with infliximab.
There is limited clinical experience with NovoMix 70 in pregnancy.
The experience of OPTISON in severely ill patients is limited.
The clinical experience in patients > 75 years is very limited.
The clinical experience in patients with moderate renal impairment is very limited.
The clinical experience in patients > 65 years of age is very limited.
- Experience in patients above 60 years of age is limited.
Limited information is available in patients with moderate hepatic impairment.
It is general clinical experience that the risk of suicide may increase in the early stages of recovery.
It is general clinical experience that the risk of suicide may increase in the early stages of recovery.
The experience with cefuroxime axetil in limited numbers of patients with uncomplicated anorectal gonorrhoea or pharyngeal gonorrhoea is not sufficient and the efficacy is not established and therefore not acceptable and should not be included in the product information.
Based on the experience with the use of other medicinal products that blunt the renin- angiotensin system, concomitant use of the above medicinal products may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).
Your doctor will check your levels of the red blood pigment (haemoglobin) regularly
Experience of somatropin treatment in patients above 60 years of age is limited.
Experience with concomitant administration of anti-fibrinolytics and NovoSeven treatment is however limited.
Experience with concomitant administration of anti-fibrinolytics and rFVIIa treatment is however limited.
Human experience of acute overdose with REYATAZ is limited.
- Experience with prolonged treatment in patients with PWS is limited.
Experience of overdose with amlodipine is limited.
- Experience in patients above 60 years of age is limited.
There is limited experience in non-Caucasian patients and patients at elevated immunological risk (e. g. retransplantation, evidence of panel reactive antibodies (PRA)).
Post-marketing experience has not identified any new safety concerns.
Post-marketing experience of infusion associated reactions revealed reporting of pyrexia, chills and vomiting, mostly mild to moderate in intensity.
Relations with EU institutions were also
The aetiology of the allergic reactions to BeneFIX has not yet been elucidated.
The exposure at this dose level corresponded to 39-fold the estimated free clinical AUC for a 300 mg twice daily dose.
Exposure to the pro-drug is less than 5% relative to the active metabolite.
Patients with moderate renal impairment have an increased exposure to dabigatran.
Ritonavir exposure (AUC12h) was decreased by 49%.
Exenatide exposure increased proportionally over the therapeutic dose range of 5 µg to 10 µg.
Median exposure in the PREZISTA/ritonavir group was 56.3 weeks.
32 can increase the incidence of adverse events associated with oral contraceptives (e. g., venous thrombo- embolic events in women at risk).
An 15 increase in EE exposure can increase the incidence of adverse events associated with oral contraceptives (e. g., venous thrombo-embolic events in women at risk).
An increase in EE exposure can increase the incidence of adverse events associated with oral contraceptives (e. g., venous thrombo-embolic events in women at risk).
Prenatal exposure of rat pups to phenylacetate (the active metabolite of phenylbutyrate) produced lesions in cortical pyramidal cells; dendritic spines were longer and thinner
Prenatal exposure of rat pups to phenylacetate (the active metabolite of phenylbutyrate) produced lesions in cortical pyramidal cells; dendritic spines were longer and thinner than normal and reduced in number.
C5 expression in the human tissue panel examined in this study is consistent with published reports of C5 expression, as C5 has been reported in smooth muscle, striated muscle, and renal proximal tubular epithelium.
The extension of the European registration system to the whole of European Economic Area (Iceland and Norway) and general depreciation since 1995, place additional demands on the resources of the Agency.
You can clean the outside of your OptiSet by wiping it with a damp cloth.
Zaleplon is a pyrazolopyrimidine hypnotic that is structurally different from benzodiazepines and other hypnotics.
Because zaleplon is excreted in the breast milk, Sonata should not be administered to breast-feeding mothers.
Because zaleplon is excreted in the breast milk, Zerene should not be administered to breast-feeding mothers.
Ziconotide is contraindicated in combination with IT chemotherapy (see section 4.3).
Ziconotide is contraindicated in combination with IT chemotherapy (see section 4.5).
Ziconotide is indicated for the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia.
7 Ziconotide is a synthetic analogue of a ω -conopeptide, MVIIA, found in the venom of the Conus magus marine snail.
Ziconotide is a synthetic analogue of a ω -conopeptide, MVIIA, found in the venom of the Conus magus marine snail.
Ziconotide is a peptide consisting of 25 naturally-occurring amino acids of the L-configuration, and does not appear to be appreciably metabolised in the CSF.
Ziconotide is a relatively small molecular weight peptide (MW = 2,639) and is filtered by the kidney glomerulus, but only minimal amounts of ziconotide (< 1%) are recovered in human urine following intravenous infusion.
Ziconotide did not induce bacterial gene mutation and was not
< Zocord > is effective alone or in combination with bile acid sequestrants.
It may lead to severe and long-lasting pain and scarring.
There is no evidence that zonisamide induces its own metabolism.
Zonisamide prevents maximal electroshock seizures and restricts seizure spread, including the propagation of seizures from cortex to sub-cortical structures and suppresses epileptogenic focus activity.
- and the harmonisation of the Summary of Product Characteristics, labelling and package leaflet,
Haemoglobin is the protein in red blood cells that carries oxygen around the body.
Haemoglobin is the protein in red blood cells that carries oxygen around the body.
HbF interferes with the polymerisation of HbS and thus impedes the sickling of red blood cell.
Natural hirudin is produced in trace amounts as a family of highly homologous iso-polypeptides by the leech Hirudo medicinalis.
Histamine is rapidly absorbed after subcutaneous injection.
Histamine is a substance in the body that causes allergic symptoms.
Histopathology revealed brain lesions that were consistent with cyanide-induced hypoxia.
A hormone called erythropoietin stimulates the production of red blood cells from the bone marrow. in
Luteinising hormone binds on the ovarian theca (and granulosa) cells and testicular Leydig cells, to a receptor shared with human chorionic gonadotrophin hormone (hCG).
Hydrogenated castor oil may cause stomach upset or diarrhoea.
The Humalog BASAL in your KwikPen is the same as the Humalog BASAL, which comes in separate Humalog BASAL cartridges.
The Humalog BASAL in your Pen is the same as the Humalog BASAL, which comes in separate Humalog BASAL cartridges.
The Humalog Mix25 in your KwikPen is the same as the Humalog Mix25, which comes in separate Humalog Mix25 cartridges.
The Humalog Mix50 in your KwikPen is the same as the Humalog Mix50, which comes in separate Humalog Mix50 cartridges.
Hydrochlorothiazide is excreted in human milk.
Hydrochlorothiazide is one of a group of medicines (called thiazide diuretics) that causes increased urine output and so causes a lowering of blood pressure.
Hydrochlorothiazide may attenuate the effect of antidiabetic medicines.
Hydrochlorothiazide may cause or exacerbate hypovolaemia which could lead to electrolyte imbalance (see section 4.4).
Hydrochlorothiazide can reduce plasma volume as well as the uteroplacental blood flow.
Hydrochlorothiazide may reduce both plasma volume and uteroplacental blood flow.
Hydrochlorothiazide also accumulates in erythrocytes at approximately 3 times the level in plasma.
Hydrocortisone aceponate is a glucocorticosteroid, which is a type of substance that helps to reduce inflammation and itching.
tartrate corresponding to rivastigmine base 2.0 mg.
Hydroxocobalamin may interfere with all urine colorimetric parameters.
Hydroxocobalamin (vitamin B12a) has been used as a vitamin supplement since the 1950s.
Hydroxycarbamide is excreted in human milk.
Hydroxycarbamide is presumed to be a transspecies carcinogen.
Hydroxynimesulide, the main metabolite is found only as a glucuronate.
Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D.
Homozygous familiar hypercholesterolemia was defined by an LDL cholesterol level ≥ 500 mg/ dl and the presence of at least 2 of the following: tendinous xanthoma, both parents with a diagnosis of familial hypercholesterolemia or an LDL-receptor genotype indicating the presence of a mutation in both LDL receptor genes.
Severe hyperglycaemia or ketoacidosis must always be treated by a doctor, normally in a hospital.
Severe hyperglycaemia or ketoacidosis must always be treated by a doctor, normally in a hospital.
Severe hyperglycaemia or ketoacidosis must always be treated by a doctor, normally in a hospital.
The biliary hyperplasia regressed upon cessation of dosing.
Pulmonary arterial hypertension is the term used when the heart struggles to pump blood to the lungs.
Pulmonary artery hypertension is a severe and often fatal disease.
The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta-blockers.
hypertension Pharmacodynamic section of the SPC for anti-bacterial
For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.
The hepatocellular centrilobular hypertrophy was consistent with rodent specific enzyme induction.
Hypoglycaemia may be associated with listlessness, confusion, palpitations, headache, sweating and vomiting.
Hypoglycaemia may occur as a result of an excess of insulin acitivity relative to food intake and energy expenditure.
Hypoglycaemia may occur as a result of an excess of insulin activity relative to food intake and energy expenditure.
Hypoglycaemia may be associated with listlessness, confusion, palpitations, headache, sweating and vomiting.
Severe hypoglycaemia may lead to loss of consciousness, and in extreme cases, death.
Although hypokalaemia may develop with the use of thiazide diuretics, concurrent therapy with irbesartan may reduce diuretic-induced hypokalaemia.
Hypomagnesaemia is reversible following discontinuation of cetuximab.
(see section 4.2 Posology and Method of Administration)
It is postulated that Myozyme will restore lysosomal GAA activity resulting in stabilisation or restoration of cardiac and skeletal muscle function (including respiratory muscles).
croscarmellose sodium, silica colloidal anhydrous, sodium stearyl fumarate.
Ibafloxacin and 8-hydroxy-ibafloxacin act synergystically.
The most abundant metabolite is 8-hydroxy-ibafloxacin, which is also microbiologically active. lbafloxacin and 8- hydroxy-ibafloxacin act synergistically.
The most abundant metabolite is 8-hydroxy-ibafloxacin, which is also microbiologically active. lbafloxacin and 8-hydroxy-ibafloxacin act synergistically.
16.5 mg/ 30 cm² which release 100 µg fentanyl per hour
which release 100 µg fentanyl per hour
4.125 mg/ 7.5 cm² which release 25 µg fentanyl per hour
12.375 mg/ 22.5 cm² which release 75 µg fentanyl per hour
MANUFACTURER FOR THE BATCH RELEASE MERIAL Laboratoire Porte des Alpes Rue de l'Aviation F-69800 SAINT PRIEST FRANCE
Let go of the plunger allowing the syringe to move up inside the device until the entire needle is guarded.
Ibritumomab has been designed to target an antigen, CD20, which is present on the surface of all B-lymphocytes.
Ibuprofen is a NSAID that possesses anti-inflammatory, analgesic and antipyretic activity.
Ibuprofen is a racemic mixture of S(+) and R(-) enantiomers.
As a NSAID, ibuprofen may interact with the following medicinal products:
increase the anti-clotting effect of this product.
BSc in Public Administration and an MSc in Economics from Trinity College Dublin.
Bachelor of Arts in languages and linguistics at the University of East Anglia and post- graduate degree in librarianship and information science at University of Wales.
Bachelor of Arts in languages and linguistics at the University of East Anglia and post-graduate degree in librarianship and information science at University of Wales.
Lilly France S. A. S 13 rue Pagès 92158 Suresnes Cedex, FRANCE
The best places for injections are where the skin is loose and soft, and away from joints, nerves, bones, for example the abdomen, arm, thigh or buttocks.
The best places for injections are where the skin is loose and soft, and away from joints, nerves, bones, for example the abdomen, arm, thigh or buttocks.
Iduronate-2-sulfatase functions to catabolize the glycosaminoglycans (GAG) dermatan sulfate and heparan sulfate by cleavage of oligosaccharide-linked sulfate moieties.
Idursulfase is secreted as a 525 amino acid glycoprotein and contains 8 N-linked glycosylation sites that are occupied by complex, hybrid, and high-mannose type oligosaccharide chains.
Lietuva Allergan Ltd 1st Floor Marlow International The Parkway Marlow Bucks, SL7 1YL-UK Jungtinė Karalystė Tel: + 44 (0) 1628 494026 E-mail: uk_medinfo@allergan. com
Lietuva Austrijos bendroves "Nycomed Osteuropa Marketing Service GmbH" atstovybe Seimyniskiu 3 LT-09312 Vilnius Tel: +370 521 09 070 Infor@nycomed.lt
73 Lietuva BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT.
Lietuva BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT.
Lietuva Beaufour Ipsen Pharma Lietuvos filialas Betygalos g.
207 Lietuva Eli Lilly Holdings Limited atstovybė Tel. +370 (5) 2649600
23 Lietuva Eli Lilly Holdings Limited atstovybė Tel. + 370 (5) 2649600
Eli Lilly Sweden AB Tel: + 46-(0)8 7378800 United Kingdom Eli Lilly and Company Limited Tel: + 44 (0) 1256 315999
Lietuva Eli Lilly Holdings Limited atstovyb 'Tel. +370 (5) 2649600
Lietuva GlaxoSmithKline Lietuva U AB Tel: +370 5 264 90 00 info.lt@gsk.com
Lietuva IVAX Pharmaceuticals s.r.o Tel: +370 525 26490
96 C/o Ares Trading SA Baltic States Zamenhofo 11 -3, LT-44287 Kaunas Tel: +370 37320603
Lietuva Orphan Europe AB Banérgatan 37
29 Lietuva Oy SWEDISH ORPHAN Ab Tel: + 358 201 558 840
- Anxiety, depression, tingling, confusion, dizziness, agitation, trembling, hallucinations and
Lietuva Pfizer Luxembourg SARL, filialas Lietuvoje Tel. +3705 2514000
Lietuva Pfizer Luxembourg SARL Filialas Lietuvoje Tel. +3705 2514000
Lietuva UAB „GlaxoSmithKline Lietuva“ Tel: +370 5 2 649000 info.lt@gsk.com
Lietuva UAB sanofi -aventis Lietuva Tel: +370 5 2755224
Circulating IGF-1 plays an important role in the acquisition and maintenance of bone mass.
Insulin-like growth factor-1 (IGF-1) is the principal hormonal mediator of statural growth.
IGF-I is regulated by human growth hormone and causes growth in the body.
As human IgG is secreted into human milk, and the potential for harm to the infant is unknown, women should not breast-feed during Osigraft therapy (see Section 5.3).
Because human IgG is secreted into human milk, panitumumab might also be secreted.
Karel de NEEF Stephen FAIRCHILD Beatrice FAYL Sylvie BÉNÉFICE
In addition to its support function, the sector undertook the development and implementation of a number of new mainstream projects, including an EMEA internal web-based news and alert channel called Ticker.
Guidelines for the testing of veterinary medicinal products catalogue n˚ CO-86-94-383-EN-C
studies to assess the potential for resistance resulting from the use of antimicrobial veterinary medicinal products and the second concerns antimicrobials for general veterinary
Liisa KAARTINEN David MACKAY Cornelia IBRAHIM Jean-Louis ROBERT Christian FRIIS Margarita ARBOIX
Multiple non-overlapping fields may be illuminated.
Avda de la Industria 30 28108 Alcobendas (Madrid) Spain
De la Industria, 30,28108 Alcobendas, Madrid, Spain.
Lilly S. A., Avda de la Industria 30, 28108 Alcobendas (Madrid), Spain
Lilly S. A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain
Lilly S. A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain
Lilly S. A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain.
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain.
Lilly S. A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain
Iloprost is extensively metabolised principally via ß-oxidation of the carboxyl side chain.
No unchanged substance is eliminated.
Steady state imaging can begin after the dynamic scan has been completed.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular events.
23 BMI is a way to find out if you have a healthy weight, or are overweight, for your height.
Imidacloprid has minimal pharmacological activity in mammals.
Imidacloprid is effective against larval flea stages and adult fleas.
Imidacloprid is effective against larval flea stages and adult fleas.
Imidacloprid is effective against larval flea stages and adult fleas.
Imidacloprid has a high affinity for the nicotinergic acetylcholine receptors in the post-synaptic region of the central nervous system (CNS) of the flea.
Imiglucerase (recombinant macrophage targeted β -glucocerebrosidase) catalyses the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide following the normal degradation pathway for membrane lipids.
-Restriction of the treatment duration to 3 months in combination with monthly examination in an effort to limit the psychiatric and neurological adverse events.
Restricted to duly designated competent administrative authorities.
Immunisation against FeLV sub-group A provides full protection against all three sub-groups of the virus:
Immunisation of progeny from vaccinated birds should therefore be delayed until such antibodies have declined.
Immunisation does not protect against V. cholerae serogroup O139 or other species of Vibrio.
The impact of long-term treatment with Enbrel on the development of autoimmune diseases is unknown.
The clinical impact of these QT changes is unknown (see section 5.1).
The actual clinical impact of these QT changes is unknown.
The surveillance of the safe use of medicines – ‘pharmacovigilance'– was highlighted as the Agency’s major priority for the year.
The impact of these changes on ovarian ovulatory activity is unknown.
The relevance of these findings for ritonavir boosted indinavir is unknown.
The impact of the co-administration of Volibris with inducers of CYP3A4 and 2C19 is unknown.
The effect of food on absorption of raltegravir is uncertain (see section 5.2).
Amyloidosis The impact of proteasome inhibition by bortezomib on disorders associated with protein accumulation such as amyloidosis is unknown.
The impact of scientific advice on the outcome of the scientific evaluation at the stage of marketing authorisation was assessed
The impact of long- term treatment with Humira on the development of autoimmune diseases is unknown.
The impact of long- term treatment with Trudexa on the development of autoimmune diseases is unknown.
The impact of the vaccine on total number of episodes of otitis media regardless of etiology was a 7% reduction (95% CI:
Gonazon implant is a solid, off white, 14x3x1 mm implant.
The clinical relevance of these findings is unknown.
The increasing importance of the partnership between national authorities and the EMEA has led to an increasing number of briefing and exchange visits between officials from national authorities and the EMEA on a broad range of subjects.
The relevance of this to the safety of Firazyr is unknown (see section 5.2).
The relevance of these data for humans is unknown.
The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced.
The importance of collaboration with respect to the European Department for the Quality of Medicines Certification of Suitability scheme will be recognised by the routine inclusion of this item in the agendas of the Quality Working Party in 2002.
The magnitude of the effect was dependent on the dose of benserazide.
The extent and duration of interference in cyanide-poisoned patients may differ according to the severity of intoxication.
What is important for the future is to have in place mechanisms to ensure that performance continues to improve.
This could mainly be attributed to the increased incidence of peripheral oedema.
18 risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any conditions associated with hypoxia.
3 risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any conditions associated with hypoxia.
The incidence of lactic acidosis can and should be reduced by also assessing other associated
The incidence of these events in clinical studies was > 10%.
The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors, such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any conditions associated with hypoxia (see also sections 4.3 and 4.5).
The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors such as poorly controlled diabetes, ketosis,
The incidence of lactic acidosis can and should be reduced by assessing also other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any condition associated with hypoxia.
The incidence of bone marrow fibrosis was not increased in a study of haemodialysis patients who were treated with epoetin alfa for 3 years compared to a matched control group of dialysis patients who had not been treated with epoetin alfa.).
The incidence of death/ re-MI at Day 30 was significantly reduced from 11.1% for the control group to 9.7% for the fondaparinux group (hazard ratio 0.86, 95% CI, 0.77, 0.96, p = 0.008).
The incidence of death/ re-MI at Day 30 was significantly reduced from 11.1% for the control group to 9.7% for the fondaparinux group (hazard ratio 0.86, 95% CI, 0.77, 0.96, p = 0.008).
The incidence of resistance to caspofungin by various clinical isolates of Candida and Aspergillus is unknown.
However, there were no differences in the incidence of these adverse events compared with patients who received bone autograft (transplanted bone) instead of Osigraft, except in the case of osteomyelitis (infection of the bone) for which the incidence of osteomyelitis was statistically higher in the autograft group.
The incidence in clinical trials of thrombotic / thromboembolic complications.
The incidence of serious adverse events was significantly lower in the palivizumab group compared to the placebo group.
The subject incidence of serious adverse events at the recommended dose of Kineret (100 mg/ day) is comparable with placebo (7.1% compared with 6.5% in the placebo group).
Consequently the incidence of the undesirable effects listed in section 4.8 might be increased.
The incidence of adverse reactions possibly reflecting meningeal irritation determined from all the patients treated with 50 mg DepoCyte in the Phase II-IV clinical trials is given in Table 1 below:
The incidence of medication errors in clinical trials.
The incidence of symptomatic VTE, including PE was not significantly different between treatment groups.
A significantly (p=0.033) greater incidence of events in the cardiovascular/ thromboembolic category was detected in the parecoxib / valdecoxib treatment group (2.0%) compared to the placebo/ placebo treatment group (0.5%).
The incidence of serious bleeding events in the PROWESS and ENHANCE studies is provided below.
The incidence of adverse reactions has been evaluated in approximately 5,000 subjects 18 years old and above who received formulations containing at least 3.75 microgram HA/ AS03.
The incidence of adverse reactions has been evaluated in approximately 5,000 subjects 18 years old and above who received formulations containing at least 3.75 microgram HA/ AS03.
0.94% for tenecteplase and alteplase, respectively.
A small (n=83), Phase II, randomised, double-blind study in patients receiving chemotherapy for od
The incidence of severe skin rash was independent of the duration of treatment (10% in both cases).
The incidence of injection site reactions may be reduced by the use of an autoinjector.
The SRE rate (events/ person year) was 0.628 for Zometa and 1.096 for placebo.
ut but the incidence of proximal DVT was also significantly reduced.
The incidence of all adverse reactions occurring in > 10% of cycles in either treatment group in Phase 1-4 studies in patients with lymphomatous meningitis receiving DepoCyte or cytarabine is given in Table 2 below:
FABLYN-treated and placebo-treated groups had similar incidences of endometrial hyperplasia and endometrial cancer (see section 5.1).
The incidence of new retinopathy was examined in those who had no retinopathy at baseline.
13%) at prolonged treatment of 20 days of early Lyme disease.
The incidence was 1.4 fold (95% CI 0.9-2.3) increased in women with or without other risk factors for VTE and 1.5 fold (95% CI 0.8-2.7) increased in women with no other risk factors for VTE.
Incidence and severity of CNS and gastrointestinal (GI) adverse reactions usually decreased over time.
The overall incidence of PPE reported was 44.0% - 46.1%.
The overall incidence of adverse events in children 2 through 11 years of age was similar for the Aerius syrup and the placebo groups.
The overall incidence of adverse events in children 2 through 11 years of age was similar for the Neoclarityn syrup and the placebo groups.
There was an overall higher incidence of non-serious ocular adverse events, mainly related to signs of local irritation, in the brinzolamide/ travoprost groups.
For atrial fibrillation serious adverse events the pooled incidences were 1.3% for Aclasta and 0.8% for placebo.
Considering the higher incidence of serious and even life-threatening risks in the treatment of an infection which has a high spontaneous resolution rate without antibiotics was considered of concern.
The significantly lower incidence of this event with celecoxib was maintained with or without acetylsalicylic acid use.
Enrollment in Arm 3 was discontinued, as pre-specified, once safety of Avastin with the IFL regimen was established and considered acceptable.
and ≥ 2 x baseline value *Each patient may be represented in one or more category. †
Incorporation of telbivudine-5'-triphosphate into viral DNA causes DNA chain termination, resulting in inhibition of HBV replication.
The Pearl Index is a standard way of measuring the effectiveness of contraceptives, which measures how many unwanted pregnancies occur in 100 woman-years (corresponding to 1,300 cycles).
An indication for Zocord  in homozygous familial hypercholesterolaemia (FH) was granted by 11 Member States (Austria, Belgium, Luxembourg, France, Greece, UK, Ireland, the Netherlands, Portugal, Spain, and Iceland.).
The indication applied for was the treatment of patients with advanced or metastatic pancretic cancer.
The amended indication for the treatment of gastrointestinal endoparasitic infections in horses had not been demonstrated by the data provided.
Indinavir alone or in combination with nucleoside analogues (zidovudine/ stavudine and lamivudine) has been shown to delay clinical progression rate compared with nucleoside analogues and to provide a sustained effect on viral load and CD4 count.
Indinavir and cimetidine can be co-administered without dose adjustment.
Indinavir and methadone can be co-administered without dose adjustment.
Interaction with indinavir/ ritonavir not studied Indinavir and ritonavir inhibit CYP3A4 and as a result are expected to increase the plasma concentrations of carbamazepine.
Interaction with indinavir/ ritonavir not studied Indinavir and ritonavir inhibit CYP3A4 and as a result are expected to increase the plasma concentrations of erythromycin and itraconazole.
Interaction with indinavir/ ritonavir not studied Indinavir and ritonavir inhibit CYP3A4 and as a result are expected to increase the plasma concentrations of fentanyl.
Interaction with indinavir/ ritonavir not studied Indinavir and ritonavir inhibit CYP3A4 and as a result are expected to increase the plasma concentrations of ketoconazole.
Buspirone Interaction with indinavir/ ritonavir not studied Indinavir and ritonavir inhibit CYP3A4 and as a result are expected to increase the plasma concentrations of buspirone.
Indinavir inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of these anticonvulsants.
Indinavir inhibits CYP3A4 and as a result is expected to markedly increase the plasma concentrations of these HMG-CoA reductase inhibitors, which are highly dependent on CYP3A4 metabolism.
Indinavir binds reversibly to the protease active site and inhibits competitively the enzyme, thereby preventing cleavage of the viral precursor polyproteins that occurs during maturation of the newly formed viral particle.
Anaesthetic induction is correspondingly rapid and the depth of anaesthesia changes rapidly with changes in anaesthetic concentration.
Maximal enzyme induction is generally not seen for 2-3 weeks but may be sustained for at least 4 weeks after cessation of therapy.
The potential for ambrisentan to induce CYP3A4 activity was explored in healthy volunteers with results suggesting a lack of inductive effect of ambrisentan on the CYP3A4 isoenzyme.
The pharmacokinetics of ropinirole are linear overall (Cmax and AUC) in the therapeutic range between 0.25 mg and 4 mg, after a single dose and after repeated dosing.
Linezolide: risk of vasoconstriction and increase in blood pressure.
Infection was seen from four weeks in non-vaccinated animals.
Clinical Experience Succesful outcome in this section is defined as complete or partial response.
The most commonly treated fungal infection was aspergillosis (43/ 61; 70%).
Parvovirus B19 infection may be serious for pregnant women (fetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e. g. haemolytic anaemia).
Infection with O. rhinotracheale can cause respiratory diseases and death.
Infertility is achieved from 6 weeks up to at least 6 months after initial treatment.
Paronychial inflammation was associated with swelling of the lateral nail folds of the toes and fingers.
Inflammation can increase the percutaneous absorption of veterinary medicinal products.
Infliximab has been designed to bind to a chemical messenger in the body called tumour necrosis factor-alpha (TNF-alpha).
Infliximab prevented disease in transgenic mice that develop polyarthritis as a result of constitutive expression of human TNFα and when administered after disease onset, it allowed eroded joints to heal.
The influence of this combined administration has not yet been investigated systemically.
The influence of this combined administration has not yet been investigated systemically.
Ciprofloxacin Kabi has minor or moderate influence on the ability to drive and use machines.
The effect of food on the rate and extent of absorption was also studied.
The influence of food has not been investigated because this medicinal product is generally given on empty stomach prior to induction of anaesthesia.
No data on the influence of maternal antibodies on the effect of vaccination with Nobivac Bb for cats are available.
The influence of different injection sites on the absorption of NovoMix 70 has not been investigated.
The influence of TRISENOX on the efficacy of other antileukaemic medicinal products is unknown.
Renal clearance of ritonavir is also negligible, therefore the impact of renal impairment on amprenavir and ritonavir elimination should be minimal
The information provided about Tracleer shall contain the following key elements:
The improvement of information for users of medicines and health professionals is one of the priority tasks of the EMEA.
---------------------------------------------------------------------------------------------------------------------
The following information is intended for medical or healthcare professionals only:
The physician information should contain the following key elements: • Clear demarcation of the new formulation of NovoSeven from original NovoSeven, with clear descriptions of any differences in the vial sizes, colour codes and dosing and reconstitution instructions • Clear information about their difference in concentration. • Information about the potential safety risks of errors in dosing calculation resulting from the confusion between the two formulations and its possible clinical consequences (e. g. potential for thrombotic risk if overdose). • Encouragement to report medications errors and their causes and consequences.
The physician information should contain the following key elements:
The physician information should contain the following key elements: • The Summary of Product Characteristics • Sterile techniques, including periocular and ocular disinfection, to minimise risk of infection • Use of antibiotics • Use of povidone iodine or equivalent • Techniques for the intravitreal injection • Key signs and symptoms of IVT injection related adverse events • Management of IVT injection related adverse events
The physician educational material should contain the following key elements: • The Summary of Product Characteristics • Reminder card with the following key messages: o Need to measure serum creatinine before treatment with Aclasta o Recommendation not to use Aclasta in patients with creatinine clearance < 35 ml/ min o Contraindication in pregnancy and in breast-feeding women due to potential teratogenicity o Need to ensure appropriate hydration of the patient o Need to infuse Aclasta slowly over a period of no less than 15 minutes o One-yearly dosing regime o Adequate calcium and vitamin D intake are recommended in association with Aclasta administration o Need for appropriate physical activity, non-smoking and healthy diet • Patient information pack
The physician information about TYSABRI shall contain the following key elements: • Restricted indication • Atypical/ opportunistic infections in particular PML including:
The following information is intended for medical or healthcare professionals only:
Food may increase the amount of loratadine absorbed, but without clinically significant results.
Food had no effect on the bioavailability (Cmax and AUC) of desloratadine or pseudoephedrine.
Consecutive inhalation of three 1 mg unit dose blisters causes a significantly higher insulin exposure in
During nebulisation sessions a facial mask must be avoided and only a mouthpiece should be used.
COMT inhibition in red blood cells closely follows the plasma concentrations of entacapone, thus clearly indicating the reversible nature of COMT inhibition.
Inhibition of mTOR activity results in a G1 growth arrest in treated tumour cells resulting from selective disruption of translation of cell cycle regulatory proteins, such as D-type cyclins, c-myc, and ornithine decarboxylase.
Prasugrel-mediated inhibition of platelet aggregation exhibits low between-subject (12%) and within-subject (9%) variability with both 5 µM and 20 µM ADP.
The ensuing inhibition of cholinergic transmission in insects results in paralysis and death.
The inhibition of lipo-oxygenase enzyme reduces the synthesis of leucotriens.
Inhibition of CYP3A4 by both CRIXIVAN and ritonavir could result in elevated plasma concentrations of these medicines, potentially causing serious or life-threatening reactions.
Inhibition of CYP3A4 by both CRIXIVAN and ritonavir could result in elevated plasma concentrations of these medicines, potentially causing serious or life-threatening reactions.
e innate neutralization of Factor Xa by antithrombin.
Neutralisation of Factor Xa interrupts the blood coagulation cascade and inhibits both thrombin formation and thrombus development.
Neutralisation of Factor Xa interrupts the blood coagulation cascade and inhibits both thrombin formation and thrombus development.
Inhibition of the proteasome results in cell cycle arrest and apoptosis.
In vitro, inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin.
The maximum inhibition by prasugrel of ADP-induced platelet aggregation is 83% with 5 µM ADP and 79% with 20 µM ADP, in both cases with 89% of healthy subjects and patients with stable atherosclerosis achieving at least 50% inhibition of platelet aggregation by 1 hour.
Accidental injection/ self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Accidental injection/ self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Accidental injection/ self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Accidental injection/ self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Accidental injection is dangerous.
Accidental injection is dangerous – see package insert before use
Accidental injection is dangerous – read the package leaflet before use.
Accidental injection is dangerous – see package insert before use.
Accidental injection is dangerous – see package leaflet before use.
Accidental injection is dangerous – read package leaflet before use.
Accidental injection is dangerous – read package leaflet before use.
Accidental injection/ self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Accidental injection/ self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Accidental injection can cause severe pain and swelling, particularly if the vaccine is injected into a joint or finger.
Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger, which can in rare cases lead to the loss of the finger.
If the yellow shaft does not show, you have completed the injection steps correctly.
au Injection into a lifted skin fold minimises the risk of unintended intramuscular injection.
Injection into a lifted skin fold minimises the risk of unintended intramuscular injection.
ge Keep the needle under the skin for at least 6 seconds to make sure the entire dose is injected.
Keep the needle under the skin for at least 6 seconds to make sure the entire dose is injected.
Injection of Avonex into the buttocks is not recommended. • Use a different injection site each week.
The solution for injection can also cause pain on injection.
Silapo must not be shaken or mixed with any other liquid.
The injection of Ibraxion may cause a temporary tissue reaction at the site of injection, which may last for three weeks and rarely up to five weeks.
Injection should be made with an infusion solution compatible with tigecycline and any other medicinal product(s) via this common line.
Injection should be made with an infusion solution compatible with tigecycline and any other medicinal product(s) via this common line (see section 6.2)
Injection should be given immediately after mixing.
The injection should be given subcutaneously and the site varied to prevent lipoatrophy.
Cold insulin is more painful to inject.
Cold insulin is more painful to inject.
Cold insulin is more painful to inject.
Click Injection is considered successful whether or not the presence of a wheal is observed.
The injection is given to you by a doctor or nurse, usually in a hospital or clinic, such as after an operation.
The injection is given once a month in the first 3 months.
The injection is complete when the yellow indicator stops moving.
Intravascular administration of iodinated contrast agents in radiological studies may lead to renal failure, resulting in metformin accumulation and risk of lactic acidosis.
Intravascular administration of iodinated contrast media may lead to renal failure, resulting in metformin accumulation with the risk of lactic acidosis.
Intravascular administration of iodinated contrast agents may lead to renal failure, resulting in metformin accumulation and a risk of lactic acidosis.
An intravenous injection should be administered over at least 2 – 4 minutes directly into the vein or via the tubing of an intravenous infusion.
The injection should be administered over at least 2 – 4 minutes directly into the vein or via the tubing of an intravenous infusion (see section 4.2).
The IV bolus injection may be given rapidly and directly into a vein or into an existing IV line.
If accidentally injected paravenously there may be damage to paravenous tissue.
The injection may be given rapidly and directly into a vein or into an existing intravenous line (a thin tube running into a vein), or it can be given slowly and deeply into a muscle.
The subcutaneous injection of DRAXXIN to cattle often causes temporary pain and swelling at the injection site, which can last up to 30 days.
The safety of gamithromycin during pregnancy and lactation has not been evaluated in cattle.
Safety throughout pregnancy in cows is not yet fully established however interim results demonstrate safety in at least the last trimester of pregnancy in cows.
Safety throughout pregnancy in cows is not yet fully established however interim results demonstrate safety in at least the last trimester of pregnancy in cows.
Incorporation of additional ETVr amino acid changes rtT184, rtS202 or rtM250 decreases entecavir susceptibility in cell culture.
Impaired liver function was associated with higher exposure to M1 in plasma, whereas exposure to parent drug was comparable to exposure in healthy volunteers.
Patients with an impaired liver function have an increased renal excretion of ceftriaxone.
Insulin helps to lower the level of sugar in the blood, especially after meals.
The replacement insulin acts in same way as naturally produced insulin and helps glucose enter cells from the blood.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The insulin should be mixed by turning OptiSet slowly up and down at least 10 times.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Insulin is a substance which helps to lower the level of sugar in the blood, especially after meals.
Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.
Cold insulin is more painful to inject.
Cold insulin is more painful to inject.
Insulin glargine is produced by recombinant DNA technology in Escherichia coli.
Insulin glulisine is produced by recombinant DNA technology in Escherichia coli.
Human insulin is produced by recombinant DNA technology in Escherichia coli.
Human insulin is produced by recombinant DNA technology in Escherichia coli.
Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis and enhances protein synthesis.
Insulin that you inject in such a site may not work very well.
(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail@emea. eu. int http: / /www. emea. eu. int ©EMEA 2006 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged quickly (more or less immediately after injection), and as Humalog NPL in the protamine suspension form which is absorbed much more slowly during the day; and give a longer duration of action.
Insulin that you inject in such a site may not work very well.
Insulin that you inject in such a site may not work very well.
Insulin treatment of the nursing mother presents no risk to the baby.
Insulin treatment of the breast-feeding mother presents no risk to the baby.
Insulin treatment of the nursing mother presents no risk to the baby.
The contents of a full pipette is applied onto the animal's skin, after parting the fur.
Integration of these services with the new IT architecture (based on WinNT) is going on and will be fully available by the completion of the migration period.
The interfering effect of some of these medicines can last for up to 28 days after you have stopped taking them.
Interaction with indinavir/ ritonavir not studied
Interaction with indinavir/ ritonavir not studied Indinavir and ritonavir inhibit CYP3A4 and as a result are expected to increase the plasma concentrations of loratidine.
Interaction with indinavir/ ritonavir not studied Trazodone AUC:
Interaction will continue with the Office for Harmonization in the Internal Market (Trade marks and Designs) based in Alicante.
4 The interaction of Rebif with corticosteroids or adrenocorticotropic hormone (ACTH) has not been studied systematically.
The interaction of Rebif with corticosteroids or adrenocorticotropic hormone (ACTH) has not been studied systematically.
The interaction of immunoglobulin (IG) with YF vaccine was investigated in 160 healthy subjects in the US.
The interaction of AVONEX with corticosteroids or adrenocorticotropic hormone (ACTH) has not been studied systematically.
ng The potential for interaction with lithium, which also promotes the release of neutrophils, has not been specifically investigated.
The potential for interaction with lithium, which also promotes the release of neutrophils, has not been specifically investigated.
Although the exact antiviral t uc
Interferon beta is produced by various cell types including fibroblasts and macrophages.
Interferon does not act directly and specifically on the pathogenic virus, but exerts its effect by inhibition of the internal synthesis mechanisms of the infected cells.
Interferon may impair fertility (see section 4.6 and section 5.3).
Interferon beta-1b both decreases the binding affinity and enhances the internalisation and degradation of the interferon-gamma receptor.
Interferon beta-1b both decreases the binding affinity and enhances the internalisation and degradation of the interferon-gamma receptor.
The inside of the ear should be cleaned and dried before treatment.
The inside of the ear should be cleaned and dried before treatment and any excess hair cut away.
Interleukin-1 (IL-1) is a pivotal pro-inflammatory cytokine mediating many cellular responses including those important in synovial inflammation.
The interpretation of sequential determinations of the PT and/ or APTT should take these variables into consideration.
Interruption of breast-feeding during the treatment period is recommended.
Abrupt withdrawal of Copalia has not been associated with a rapid increase in blood pressure.
Temporarily stopping the infusion usually resolves these symptoms without further therapy.
4 those measured in healthy adults, even in newborn infants.
The sampling interval and wash-out period were considered long enough and the statistical evaluation was also appropriate.
The range of observed apparent half-lives is broad, the apparent terminal half-life is generally in the range of 10 - 72 hours.
The range of observed apparent half-lives is broad, the apparent terminal half-life is generally in the range of 10-72 hours.
The time period between the first and the second injection must be at least three weeks.
2 There should be intervals of at least 4 weeks between doses.
The interval between two doses should not be shorter than 1 month.
The interval between injections must be at least one month.
If a repeat course of treatment is considered it should not be given at an interval less than 16 weeks.
There should be an interval of at least 4 weeks between doses.
The dosage interval when steady state has been reached varies from 2 - 4 weeks.
The dosage interval when steady state has been reached varies from 2 to 4 weeks.
The initial dose interval should be 2 - 3 hours.
Thereafter, dosing intervals may be shortened cautiously based on individual tolerability.
In no case should there be more than 7 consecutive patch-free days.
QT interval was corrected for heart rate by Fridericia's method.
The heart rate-corrected QT interval in duloxetine-treated patients did not differ from that seen in placebo-treated patients.
The heart rate-corrected QT interval in duloxetine-treated patients did not differ from that seen in placebo-treated patients.
The heart rate corrected QT interval in fesoterodine treated patients did not differ from that seen in placebo treated patients.
The heart rate-corrected QT interval in duloxetine-treated patients did not differ from that seen in placebo-treated patients.
The heart rate-corrected QT interval in duloxetine-treated patients did not differ from that seen in placebo-treated patients.
Introducing appropriate lifestyle changes (e. g. increased exercise), in conjunction with this weight management programme, may provide additional benefits.
The addition or withdrawal of these drugs or adjusting of the dose of these drugs during Inovelon therapy may require an adjustment in dosage of Inovelon.
Ioflupane also binds to the serotonin transporter on 5-HT neurons but with lower (approximately 10-fold) binding affinity.
Ionisation, beam formation and acceleration all occur in the source, magnetic deflection takes place in the flight tube and detection takes place in the collector.
Ionisation, beam formation and acceleration all occur in the source, magnetic deflection takes place in the flight tube and detection takes place in the collector.
Acquired lipodystrophy, alopecia, dry skin, eczema, lipoatrophy, pruritus, rash
Lipomed GmbH Schönaugasse 11 D-79713 Bad Säckingen
Lipomed GmbH Schönaugasse 11 D-79713 Bad Säckingen Germany
Liprolog Basal is a white, sterile suspension.
Liprolog Basal is a white, sterile suspension.
The Liprolog in your pre -filled pen is the same as the Liprolog, which comes in separate Liprolog cartridges.
Liprolog is used to treat adults and children who have diabetes and need insulin to keep their blood glucose (sugar) level controlled, including patients whose diabetes has just been diagnosed.
Liprolog Mix25 is a white, sterile suspension
Liprolog Mix25 is a white, sterile suspension.
Liprolog Mix25 is a white, sterile suspension
Liprolog Mix50 is a white, sterile suspension.
Liprolog Mix50 is a white, sterile suspension.
Pale yellow clear liquid that may have a pink tint
Bodyweight (kg) Metalyse (U)
Irbesartan and its metabolites are eliminated by both biliary and renal pathways.
Irbesartan on its own has been approved in the EU since 1997 under the names Karvea and Aprovel.
Irbesartan on its own has been approved in the EU since 1997 under the names Karvea and Aprovel.
Please read these instructions carefully so that you know how to use the solution correctly.
Please read the instructions carefully and follow them step by step.
Read complete directions thoroughly before starting the preparation procedure.
Read the package leaflet fully before using OptiSet for the first time
Read the package leaflet fully before using OptiSet for the first time.
Read the package leaflet before use for directions on reconstitution and dilution.
Read the package leaflet before use for correct administration, disposal of waste materials and special warnings for immunecompromised humans.
See leaflet for further information.
during treatment with MABTHERA. • Show this card to any doctor involved
Read the package leaflet enclosed in the vaccine vial.
Read the package leaflet enclosed in the vaccine vial before use.
Read package leaflet and instructions for use of the inhaler before use. ic
Read the enclosed package leaflet before reconstitution and use.
Read the leaflet for the shelf life of the diluted product.
Read the leaflet for the shelf life of the reconstituted product
MRI is an imaging method that relies on the tiny magnetic fields produced by water molecules in the body.
MRI is an imaging method that uses magnetic fields and radio waves.
MRI is an imaging method that relies on the tiny magnetic fields produced by water molecules in the body.
Please read the instructions carefully and follow them step by step.
Please read the instructions carefully and follow them step by step.
Plea se read the instructions carefully and follow them step by step.
Please read the instructions carefully and follow them step by step.
Please read the instructions carefully and follow them step by step.
Please read all of the instructions carefully before attempting to use the pen and follow them step by step.
Please read all of the instructions carefully before attempting to use the pen and follow them step by step.
Also read the BYETTA Package leaflet that comes with the BYETTA pen carton.
Also read the BYETTA Package leaflet that comes with the BYETTA pen carton.
Follow the directions carefully when using the FORSTEO.
Read and follow carefully the instructions that accompany your insulin pump.
Read and follow the instructions that accompany your insulin infusion pump.
Read and follow the directions in this section only after you’ve read Section 1-What You Need To Know About Your BYETTA Pen.
Read and follow the directions in this section only after you’ve read Section 1-What You Need To Know About Your BYETTA Pen.
Please read the instructions carefully and follow them step by step.
Please read the instructions carefully and follow them step by step.
Read the following information before you use < Invented Name > cream.
Iceland and Norway completed their first year as members of the CPMP and CVMP.
Isotretinoin is contraindicated in women of childbearing potential unless all of the following conditions of the Pregnancy Prevention Programme are met:
As at the end of 2002, only 2 national competent authorities and 1 pharmaceutical company were systematically using
- Pre-use check list procedure (a series of steps required immediately prior to each patient initiation
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS
This can reduce your responsiveness when driving a vehicle or operating machinery.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
STATEMENT OF THE ACTIVE SUBSTANCES AND OTHER INGREDIENTS
Contains ≥ 106,3 and ≤ 108,3 CFU of live Bordetella bronchiseptica strain B-C2, per 0.2 ml dose of reconstituted suspension.
STATEMENT OF THE ACTIVE AND OTHER SUBSTANCE(S)
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
QUANITITY OF THE ACTIVE SUBSTANCE(S)
STATEMENT OF ACTIVE AND OTHER SUBSTANCE(S)
STATEMENT OF THE ACTIVE AND OTHER SUBSTANCES
STATEMENT OF THE ACTIVE AND OTHER SUBSTANCE(S)
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENT(S)
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
CPMP/3256/03 • Nephrolithiasis
Pregnancy and lactation (See section 4.3 “ Contraindications” and section 4.6 “ Pregnancy and lactation”).
Lithuania Luxembourg Luxembourg Luxembourg Luxembourg Malta
Ivabradine is the S-enantiomer with no bioconversion demonstrated in vivo.
Ivabradine is therefore not recommended in patients with atrial fibrillation or other cardiac arrhythmias that interfere with sinus node function.
17 Ivabradine can interact also with the retinal current Ih which closely resembles cardiac If.
18 Ivabradine can interact also with the retinal current Ih which closely resembles cardiac If.
7 Ivabradine can interact also with the retinal current Ih which closely resembles cardiac If.
Livensa is used to treat HSDD.
Livensa has no influence on the ability to drive and use machines.
• Educational leaflet • Summary of product characteristics (SPC) and Package Leaflet and Labelling
Awarene ss sessions were held for all staff and
The purpose of the studies was to evaluate the durability of sustained virologic response (SVR) and assess the impact of continued viral negativity on clinical outcomes.
The purpose of the studies was to evaluate the durability ofsustained virologic response (SVR) and assess the impact of continued viral negativity on clinicaloutcomes.
The purpose of the study was to determine the optimal dose of valsartan for reducing UAE in hypertensive patients with type 2 diabetes.
The purpose of the study was to evaluate the durability of sustained virologic response (SVR) and assess the impact of continued viral negativity on clinical outcomes.
The purpose of the study was to evaluate the durability of sustained virologic response (SVR) and assess the impact of continued viral negativity on clinical outcomes.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
The aim is to restore, for the time when the patient is at risk, a level of antithrombin activity that is normal.
The objective is to expose and treat all areas of HGD and the entire length of BO.
The objective was to demonstrate the long-term efficacy and safety of photodynamic therapy with verteporfin in limiting the decrease in visual acuity in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration.
It examined the effect of adding fenofibrate to the patients ’
The internal target of dealing with 85 per cent of routine transactions within one day was attained and surpassed within the first quarter of the year.
The primary endpoint was progression free survival (PFS).
The scope of the referral was to discuss the benefit/ risk of glucosamine hydrochloride in the proposed indication The Summary of Products Characteristic, labelling and package leaflet proposed by the applicant has been assessed based on the documentation submitted and the scientific discussion within the Committee.
The scope of the referral was to discuss the benefit/ risk of the different dosage recommendations for newborns, especially regarding the differentiation of newborns up to 14 days of age and from 15 up to 27 days of age and regarding the use of dose in excess of 50 mg/ kg/ day The Summary of Products Characteristic, labelling and package leaflet proposed by the applicant has been assessed based on the documentation submitted and the scientific discussion within the Committee. the CHMP has recommended by majority the granting of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Ceftriaxone Tyrol Pharma and associated names (see Annex I).
Other side effects are uncommon or rare.
(Invented) Name Strength
Loc Ai Conti 55051 Castelvecchio Pascoli, Barga (Lucca) - ITALY
Locate a suitable site, and slowly inject NovoSeven into a vein over a period of 2 - 5 minutes without removing the needle from the injection site.
Locatim thereby provides additional protection against deaths due to enterotoxicosis caused by E. coli.
Locatim oral solution for neonatal calves less than 12 hours of age
Locatim oral solution for neonatal calves less than 12 hours of age
Locatim, oral solution for neonatal calves less than 12 hours of age
Hire of hardware and software for specified projects
Hire of hardware and software for the operation of the Agency
Hire of furniture Maintenance, use and repair of furniture
Blockage of the dialysis system is possible if heparinisation is not optimum.
Occlusion of the dialysis system is possible if heparinisation is not optimum.
Nasolacrimal occlusion or gently closing the eyelid after instillation may help reduce the incidence of this effect (see also 4.2 Posology and method of administration).
Nasolacrimal occlusion or gently closing the eyelid after instillation may help reduce the occurrence of this effect (see section 4.2).
145/200 (73%) 135/200 (68%) 114/164 (70%)
LOCF = last observation carried forward.
ITT = Intention to Treat NC = F: non-completers = failures
Octreotide/ laneotide may both decrease and increase insulin requirement. t
The odds ratio (95% exact confidence interval) was 1.21 (0.7, 2.1).
The odds ratio (95% exact confidence interval) was 2.96 (1.34, 7.50).
As cerebral oedema has also been reported in patients with hypermethioninemia, secondary hypermethioninemia due to betaine therapy has been postulated as a possible mechanism of action.
Logomed Pharma GmbH Eckenheimer Landstrasse 100- 104 D-60318 Frankfurt
Lokalne telefoniczne centrum informacyjne dla
Olanzapine also demonstrated comparable efficacy results to haloperidol in terms of the proportion of patients in symptomatic remission from mania and depression at 6 and 12 weeks.
Olanzapine also demonstrated comparable efficacy results to haloperidol in terms of the proportion of patients in symptomatic remission from mania and depression at 6 and 12 weeks.
Olanzapine also demonstrated comparable efficacy results to haloperidol in terms of the proportion of patients in symptomatic remission from mania and depression at 6 and 12 weeks.
In a co-therapy study of patients treated with lithium or valproate for a minimum of 2 weeks, the addition
Olanzapine also demonstrated comparable efficacy results to haloperidol in terms of the proportion of patients in symptomatic remission from mania and depression at 6 and 12 weeks.
Olanzapine is indicated for the treatment of moderate to severe manic episode.
Olanzapine is indicated for the treatment of moderate to severe manic episode.
Olanzapine is metabolised in the liver by conjugative and oxidative pathways.
Oral olanzapine also demonstrated comparable efficacy results to haloperidol in terms of the proportion of patients in symptomatic remission from mania and depression at 6 and 12 weeks.
16 Olanzapine can be given without regards for meals as absorption is not affected by food.
2 Olanzapine can be given without regards for meals as absorption is not affected by food.
30 Olanzapine can be given without regards for meals as absorption is not affected by food.
44 Olanzapine can be given without regards for meals as absorption is not affected by food.
58 Olanzapine can be given without regards for meals as absorption is not affected by food.
72 Olanzapine can be given without regards for meals as absorption is not affected by food.
It has the same dosage and frequency of administration as olanzapine tablets.
Olanzapine can be given without regards for meals as absorption is not affected by food.
34 Omalizumab is a recombinant DNA-derived humanised monoclonal antibody that selectively binds to human immunoglobulin E (IgE).
46 Omalizumab is a recombinant DNA-derived humanised monoclonal antibody that selectively binds to human immunoglobulin E (IgE).
Omalizumab is a recombinant DNA-derived humanised monoclonal antibody that selectively binds to human immunoglobulin E (IgE).
Patients whose blood glucose control is greatly improved e. g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised ro
A16AB04 (temporary) Long-term replacement therapy in patients with a confirmed
Mr Lönngren was with the National Board of Health and Welfare, Sweden, from 1978 to 1990 during which time he was responsible for herbal medicines, cosmetics, medical devices, narcotics and contraceptives.
Mr Lönngren was with the National Board of Health and Welfare, Sweden, from 1978 to 1990 during which time he was responsible for herbal medicines, cosmetics, medical devices, narcotics and contraceptives.
with updated instructions and training materials,
Lopid as an adjunct to diet and other non-pharmacological treatment (e. g. exercise, weight reduction) for the following:
< (LOPID and associated names) > < (strength) > mg< tablets > < capsules > < granules > < film-coated tablets > < coated tablets >
Lopid should not be used when breast feeding.
Lopid should not be used in patients with severely impaired renal function (see section 4.3).
Kit for radiopaharmaceutical preparation
Lopinavir/ ritonavir 400/ 100 mg bid (saquinavir/ ritonavir 1000/ 100 mg bid in combination with 2 or 3 NRTIs)
lopinavir/rtv 800/200 mg per day N=346
It should be considered whether it is advisable to drive or operate machinery in these circumstances.
during pregnancy increases the risk of hypospadia.
pregnancy increases the risk of hypospadia.
therapeutic areas (dose)
Patients with homocystinuria cannot convert homocysteine into cysteine, so homocysteine builds up in the blood and urine.
The aetiology of the allergic reactions to BeneFIX has not yet been elucidated.
The effect of orlistat results in an increase in faecal fat as early as 24 to 48 hours after dosing.
Orlistat, M1 and M3 are all subject to biliary excretion.
Orlistat, M1 and M3 are all subject to biliary excretion.
Orlistat has no influence on the ability to drive and use machines.
However, orlistat may indirectly reduce the availability of oral contraceptives and lead to unexpected pregnancies in some individual cases.
When gemcitabine is administered daily, high mortality among the animals but minimal antitumoural activity is observed.
The dose limiting toxicity in these studies was essentially haematological.
The main measure of effectiveness was the 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
(Invented name)®, at a dose of 20mg, has been shown to be significantly more effective than placebo in two short-term pivotal studies, as measured by the reduction of Childhood Depression Rating Scale-Revised (CDRS-R) total scores and Clinical Global Impression of Improvement (CGI-I) scores.
At slaughter, the left (first) injection site was taken for local tolerance assessment.
When driving vehicles or operating machines, it should be taken into account that occasionally dizziness or weariness may occur during treatment of hypertension.
At the last observation at 12 weeks, 13/ 27 (48%) of infliximab- treated patients were still responding.
When concomitant administration of potent CYP3A4 inducers with aripiprazole occurs, the aripiprazole dose should be increased.
Patients should avoid exposing the product to high moisture or relative humidity conditions e. g. a steamy bathroom, when taking their dose. od
Patients should avoid exposing the product to high moisture or relative humidity conditions e. g. a tn
In an interim analysis based on 947 randomized patients, shortened progression free survival time and increased deaths were observed in the patients receiving Vectibix in combination with bevacizumab and chemotherapy.
To open for the first time, use the pointed portion of the cap to puncture the metal safety seal.
The first time you use NovoMix 50 Penfill roll the cartridge between your palms 10 times – it is important that the cartridge is kept horizontal (see picture A).
The first time you use NovoMix 70 Penfill roll the cartridge between your palms 10 times – it is important that the cartridge is kept horizontal (see picture A).
When prescribing Tarceva, factors associated with prolonged survival should be taken into account (see section 4.2 and 5.1).
The open label extension study showed improvement and/ or maintenance of these effects up to 208 weeks in the Aldurazyme/ Aldurazyme group and 182 weeks in the Placebo/ Aldurazyme group as indicated in the table below.
If side effects occur, Econor containing food should be immediately removed; severely affected pigs should be moved to clean, dry pens and given appropriate treatment.
In the case of an adverse reaction, immediate withdrawal of medication is recommended.
In a French compassionate use program for Diacomit, topiramate was added to Diacomit, clobazam and valproate in 41% of 230 cases.
Multinucleated cells were seen in the liver in the absence of other histopathological changes in the rat carcinogenicity study.
Multinucleated cells were seen in the liver in the absence of other histopathological changes in the rat carcinogenicity study.
In the pancreatic cancer study in combination with gemcitabine, the incidence of ILD-like events was 2.5% in the Tarceva plus gemcitabine group versus 0.4% in the placebo plus gemcitabine treated group.
In the pancreatic cancer study in combination with gemcitabine, the incidence of ILD-like events was 2.5% in the Tarceva plus gemcitabine group versus 0.4% in the placebo plus gemcitabine treated group.
When injected, this exposure helps the calf's immune system to recognise and fight the IBR virus.
When injected, this small exposure helps the cat's immune system to recognise and attack the viruses and bacterium.
Under field conditions, sporadic local and systemic clinical reactions have been reported.
The content, upon storage may present a fine white deposit with a clear colourless supernatant.
During their November 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Menitorix, that the objections raised by Greece, Poland and Spain should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
During their 16-19 July 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Xeomin, that the objections raised by Finland, France and Italy, should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
During their 18 – 21 June 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Lansoprazole and associated names, that the objections raised by the Czech Republic, Spain and Portugal should not prevent the granting of a Marketing Authorisation and that the valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure.
This study was not available to CMD(v).
In trials where the application sites were rotated as reflected in the instructions provided in the SPC and package leaflet, 34.2% of 748 patients using Neupro, experienced application site reactions.
In clinical studies no overall differences in safety or efficacy were observed between patients aged ≥ 65 years and younger patients.
In clinical studies, dosing with 30 MIU (300 μ g)/ day on 1 to 7 days per week was required to maintain the ANC
In clinical trials involving 414 adults the most frequent of adverse events reported were insomnia (8.9%), dry mouth (7.2%) and headache (3.1%).
Allergic reactions associated with administration of Kineret during clinical trials were rare.
Changes to the liver function values occurred in patients treated with Betaferon during clinical studies.
In clinical trials, an increased risk of death and serious cardiovascular events was observed when erythropoiesis stimulating agents (ESAs) were administered to target a haemoglobin of greater than 12 g/ dl (7.5 mmol/ l).
In clinical trials, an increased risk of death and serious cardiovascular events was observed when erythropoiesis stimulating agents (ESAs) were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l).
In trials where the application sites were rotated as reflected in the instructions provided in SPC and package leaflet, 35.7% of 830 patients using the Neupro transdermal patch, experienced application site reactions.
Erythrocytes are a primary target of toxicity for ribavirin in animal studies.
During clinical studies 128 children (98 children with growth hormone deficiency and 30 with Turner syndrome) were exposed to Valtropin.
In clinical trials with Ribavirin used in combination with peginterferon alfa-2b or interferon alfa-2b, the maximum overdose reported was a total dose of 10 g of Ribavirin (50 x 200 mg capsules) and 39 MIU of interferon alfa-2b (13 subcutaneous injections of 3 MIU each) taken in one day by a patient in an attempt at suicide.
In clinical trials C95-132 and I95-143, Ribavirin + interferon alfa-2b combination therapy proved to be significantly more effective than interferon alfa-2b monotherapy (a doubling in sustained response).
In clinial studies, serious bacterial, fungal, and viral infections have been observed in patients receiving STELARA (see section 4.8).
In clinical trials in a paediatric population, Aerius syrup was administered to a total of 246 children aged 6 months through 11 years.
In clinical trials in a paediatric population, the desloratadine syrup formulation was administered to a total of 246 children aged 6 months through 11 years.
In clinical trials in a paediatric population, Neoclarityn syrup was administered to a total of 246 children aged 6 months through 11 years.
In clinical trials that assessed the driving ability, no impairment occurred in patients receiving desloratadine.
In clinical studies, the effective dose of Effentora for BTP was not predictable from the daily maintenance dose of opioid.
Lenalidomide has been used in clinical trials in multiple myeloma patients up to 86 years of age (see section 5.1).
In clinical studies Xolair was commonly used in conjunction with inhaled and oral corticosteroids, inhaled short-acting and long-acting beta agonists, leukotriene modifiers, theophyllines and oral antihistamines.
Status epilepticus cases have been observed during clinical development studies, under rufinamide whereas no such cases have been observed under placebo.
In the fertility studies the NOAEL was 300 U/ kg/ day for general toxicity in both males and females and 1000 U/ kg/ day for fertility and reproductive performance.
In clinical trials with Botulinum toxin type A complex it was reported that dysphagia occurs less frequently with total doses below 200 U per treatment session.
In clinical trials with Botulinum toxin type A complex, it was reported that swallowing difficulties occur less frequently with low doses.
In objective tests no adverse effects of terfenadine on the central nervous system have been detected.
False positive urine cannabinoid test results have been reported in uninfected volunteers who received efavirenz.
In controlled clinical studies involving approximately 1400 patients, the following adverse reactions were reported in patients given Cholestagel.
11 In pharmacokinetic studies that compared the absolute and relative bioavailability of Effentora and oral transmucosal fentanyl citrate (OTFC), the rate and extent of fentanyl absorption in Effentora demonstrated exposure that was between 30% to 50% greater than that for oral transmucosal fentanyl citrate.
24 In pharmacokinetic studies that compared the absolute and relative bioavailability of Effentora and oral transmucosal fentanyl citrate (OTFC), the rate and extent of fentanyl absorption in Effentora demonstrated exposure that was between 30% to 50% greater than that for oral transmucosal fentanyl citrate.
37 In pharmacokinetic studies that compared the absolute and relative bioavailability of Effentora and oral transmucosal fentanyl citrate (OTFC), the rate and extent of fentanyl absorption in Effentora demonstrated exposure that was between 30% to 50% greater than that for oral transmucosal fentanyl citrate.
50 In pharmacokinetic studies that compared the absolute and relative bioavailability of Effentora and oral transmucosal fentanyl citrate (OTFC), the rate and extent of fentanyl absorption in Effentora demonstrated exposure that was between 30% to 50% greater than that for oral transmucosal fentanyl citrate.
63 In pharmacokinetic studies that compared the absolute and relative bioavailability of Effentora and oral transmucosal fentanyl citrate (OTFC), the rate and extent of fentanyl absorption in Effentora demonstrated exposure that was between 30% to 50% greater than that for oral transmucosal fentanyl citrate.
In the pivotal placebo-controlled studies with ORACEA in rosacea, 269 patients were treated with ORACEA 40 mg once daily and 268 patients were treated with placebo for 16 weeks.
When mixing Aivlosin into feed or drinking water or handling the medicated feed or water, direct contact with eyes, skin and mouth should be avoided and protective equipment should be worn, e. g. overalls, gloves and face masks (respirator).
22 Upon multiple dosing, ribavirin accumulates extensively in plasma with a six-fold ratio of multiple- dose to single-dose AUC12hr.
Upon multiple dosing, ribavirin accumulates extensively in plasma with a six-fold ratio of multiple-dose to single-dose AUC12hr.
Upon multiple dosing, ribavirin accumulates extensively in plasma with a six-fold ratio of multiple-dose to single-dose AUC12hr.
When administered with irinotecan, whose active metabolite SN-38 is further metabolised by the UGT1A1 pathway, there was a 67 - 120% increase in the AUC of SN-38 and a 26 - 42% increase in the AUC of irinotecan.
Sixty-eight percent (136 of 200) of patients in a population pharmacokinetic analysis had renal impairment (46.5% mild [50-80 ml/ min], 20% moderate [30-50 ml/ min], and 1.5% severe [< 30 ml/ min]).
For post-operative pain relief in cats, safety has only been documented after thiopental/ halothane anaesthesia.
When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.
With efavirenz, an increase of the lopinavir/ ritonavir soft capsule or oral solution doses
In a standard battery of in vitro and in vivo tests icatibant was not genotoxic.
In a placebo-controlled clinical trial (n = 126), no difference was detected in anti-tetanus antibody response between the Kineret and placebo treatment groups when a tetanus/ diphtheria toxoid vaccine was administered concurrently with Kineret.
In a clinical pharmacology trial, in adults and adolescents, in which desloratadine was
4/ 33 In a 21 day study, fluoxetine was administered daily at a dose of 0.75, 1.5 and 3.0 mg/ kg to laboratory Beagles.
13 A two-year mouse carcinogenicity study by dermal administration on three days a week did not induce tumours at the application site.
In a dermal fertility study in rats, no adverse effects on fertility were observed at up to 180 times the human dose.
In an open label pharmacokinetic study, all 24 healthy subjects experienced photosensitivity reactions, which were characteristically represented by erythematous rash and oedema and were mild to moderate in intensity.
Improvement in fatigue, as measured by the Functional Assessment of Cancer Therapy-fatigue (FACT-fatigue) scale, was also observed. ct
In a prospective, randomised double-blind, placebo-controlled study conducted in 344 anaemic patients with lymphoproliferative malignancies receiving chemotherapy there was a significant reduction in transfusion requirements and an improvement in haemoglobin response (p < 0.001).
When maternal exposure to the antibody occurred during organogenesis, two cases of retinal dysplasia and one case of umbilical hernia were observed among 230 offspring born to mothers exposed to the higher antibody dose (approximately 4 times the
In the future, the immune system will be able to react against the virus more quickly when it is exposed to the virus.
In the future, the immune system will be able to make antibodies more quickly when it is exposed to the viruses.
In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to the viruses.
This means that the viruses and surface antigens are fixed onto aluminium compounds, to stimulate a better response.
In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to the viruses or bacteria.
In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to the viruses or bacteria.
In the future, the immune system will be able to make the antibodies more quickly when it is exposed to the bacteria again.
When Riquent is injected, the levels of these antibodies in the blood are lowered and this is expected to help reduce the patient's likelihood of experiencing a ‘ flare’.
During an operation, the surgeon applies Opgenra directly along each side of the two vertebrae to help new bone develop and to make the vertebrae fuse together.
In a clinical study with healthy subjects, there was an increase in serum tizanidine concentration (Cmax increase:
In a clinical study with healthy subjects, there was an increase in serum tizanidine concentration (Cmax increase:
In a clinical study with healthy subjects, there was an increase in serum tizanidine concentration (Cmax increase:
In a clinical trial where Pedea was administered prophylactically during the first 6 hours of life, severe hypoxemia with pulmonary hypertension was reported in 3 newborn infants less than 28 weeks of gestational age.
In a clinical study of the medicinal product, antibodies to the protein eptotermin alfa were detected in 194 out of 207 (94%) patients treated with it and 18 out of 86 (21%) treated with autograft bone (control group).
While transitioning from TNF blocking agent therapy to ORENCIA therapy, patients should be monitored for signs of infection.
Ensure that the plunger rod is drawn sufficiently back when emptying the vial in order to completely empty the filter needle.
During the pre-licensure clinical development program, a total of 1,737 pregnancies were reported including 870 in women who had received Cervarix.
Upon storage, a white deposit and clear supernatant can be observed.
For the purpose of ambulatory use, Cyanokit may be exposed during short periods to the temperature variations of • usual transport (15 days submitted to temperatures ranging from 5 to 40°C) • transport in the desert (4 days submitted to temperatures ranging from 5 to 60°C) and • freezing/ defrosting cycles (15 days submitted to temperatures ranging from -20 to 40°C).
For the purpose of ambulatory use, Cyanokit may be exposed during short periods to the temperature variations of usual transport (15 days submitted to temperatures ranging from 5°C to 40°C), transport in the desert (4 days submitted to temperatures ranging from 5°C to 60°C) and freezing/ defrosting cycles (15 days submitted to temperatures ranging from -20°C to 40°C).
In the treatment of HIV, combination antiretroviral therapy may also cause increased fats in the blood (hyperlipaemia) and resistance to insulin.
Whenever possible, the BO segment selected for treatment should include normal tissue margins of a few millimetres at the proximal and distal ends.
Where this is not possible, the EMEA is called on to prepare a binding arbitration.
When this is not possible, or when dogs resist having the product placed directly into the mouth, put the tablet immediately before administration into a small amount of moistened food, or in a moist treat.
Where this is not possible, the EMEA is called on to arbitrate.
When this happens in the joints and causes pain, it is known as ‘ gout’.
When Ceplene is first given, the patient 's blood pressure, heart rate and lung function must be monitored.
When a dog is given the vaccine, the immune system recognises the antigens as ‘ foreign'and makes antibodies against them.
When CRIXIVAN is used with ritonavir, consult the Summary of Product Characteristics of ritonavir for additional contraindications.
When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients.
When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients.
When medicines are made from human blood or plasma, a number of measures are put in place to prevent infections being passed on to patients.
When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients.
When patients with blood cancers start chemotherapy, they are at risk of developing hyperuricaemia.
If you are prescribed IntronA in combination with ribavirin, ribavirin can be very damaging to an unborn baby, thus both female and male patients must take special precautions in their sexual activity if there is any chance for pregnancy to occur:
If you are prescribed IntronA in combination with ribavirin, ribavirin can be very damaging to an unborn baby, thus both female and male patients must take special precautions in their sexual activity if there is any chance for pregnancy to occur:
When IONSYS is applied without activating the current, the average absorption rate of fentanyl over 24 hours was 2.3 micrograms fentanyl/ hour, indicating minimal passive delivery.
When the cartridge is inserted in the special injection pen and the pen screwed together, the powder and solvent mix to make up the solution for injection.
- When cimetidine (weak inhibitor of CYP1A2, CYP2D6 and CYP3A4) is administered with
When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP.
When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells.
325  When the needle is completely inserted into the skin, release the skin that you are holding.
 When the needle is completely inserted into the skin, release the skin that you are holding.
When the needle is completely inserted into the skin, release the skin that you are holding.
Once the needle has been inserted completely, release your grasp of the skin.
73 When the needle is in, release the skin, and using the same hand, hold on to the syringe barrel to help steady it and prevent shifting.
When the needle is in, release the skin, and using the same hand, hold on to the syringe barrel to help steady it and prevent shifting.
Bioavailability decreased to an estimated 0.46% and 0.39% when alendronate was given an hour or half an hour before a standardised breakfast.
Bioavailability was decreased similarly to an estimated 0.46% and 0.39% when alendronate was administered one hour or half an hour before a standardised breakfast.
Bioavailability was decreased similarly to an estimated 0.46% and 0.39% when alendronate was administered one hour or half an hour before a standardised breakfast.
When administered concomitantly with alcohol loratadine has no potentiating effects as measured by psychomotor performance studies.
1000 patient-years, diet alone 18 events/ 1000 patient-years (p=0.01) For metformin used as second-line therapy, in combination with a sulfonylurea, benefit regarding clinical outcome has not been shown.
Methadone AUC may be decreased when co-administered with VIRACEPT; therefore upward adjustment of methadone dose may be required during concomitant use with VIRACEPT (see section 4.5).
Methadone AUC may be decreased when co-administered with VIRACEPT; therefore upward adjustment of methadone dose may be required during concomitant use with VIRACEPT (see section 4.5).
When myelin is damaged, the messages between the brain and other parts of the body are disrupted.
When administered orally or sublingually in usual doses to patients experiencing opioid withdrawal, naloxone exhibits little or no pharmacological effect because of its almost complete first pass metabolism.
When the radioactive antibody binds to the white blood cells, your doctor can determine where the infection is located by using a special imaging camera that reveals areas of radioactivity.
When paroxetine is to be co-administered with a known drug metabolising enzyme inhibitor, consideration should be given to using paroxetine doses at the lower end of the range.
When intraocular pressure is raised, it causes damage to the retina (the light-sensitive membrane at the back of the eye) and to the optic nerve that sends signals from the eye to the brain.
Where feed intake is reduced, use the following formula:
In rheumatoid factor (RF) positive patients, marked decreases were observed in rheumatoid factor concentrations following treatment with rituximab in all three studies (range 45-64%).
When the response has been obtained, the minimal effective dose to maintain this level should be established.
When the response has been obtained, the minimal effective dose to maintain this level should be established.
When a solution of the radioactive substance sodium pertechnetate (99mTc) is added to the vial, 99mTc-depreotide is formed.
When substance P attaches to these receptors, it causes nausea and vomiting.
When substance P attaches to these receptors, it causes nausea and vomiting.
When toxicity is controlled, doses may be carefully readjusted upward.
When the sow is injected, this small exposure helps the pig's immune system to recognise and attack the bacteria.
Where the original national authorisation cannot be recognised, the points in dispute are submitted to the EMEA for arbitration.
When the Committee appoints one of its members to act as rapporteur or co-rapporteur, he shall provide the Committee with a draft assessment report.
As depreotide binds to the receptors, it carries the radioactivity with it, and this can be detected using special imaging equipment, such as scintigraphy or single photon emission computed tomography (SPECT).
When the solvent front is within 1 cm of the top of the strip, remove it, cut it in half and place each into a glass tube.
When used to prevent bone complications, the infusion can be repeated every three to four weeks, and patients should also take supplements of calcium and vitamin D.
When energy absorbed by the porphyrin is transferred to oxygen, highly reactive short-lived singlet oxygen is generated.
Where the number of chickens is between the standard dosages, the next higher dosage should be used.
When the enzyme is blocked, the DNA strands break.
When rituximab binds to the surface of this cell it causes the cell to die.
When rituximab binds to the antigen, this causes lysis (cell death).
When IPSS cytogenetic subgroups were analysed, similar findings in terms of median overall survival were observed in all groups (good, intermediate, poor cytogenetics, including monosomy 7).
When these enzymes are blocked, they cannot digest some fats in the diet, and this allows about a quarter of the fat eaten in the meal to pass through the gut undigested.
In patients with compromised renal function, clearance of gadoversetamide will be slowed and the interference with calcium determination by OCP prolonged.
When sildenafil is taken with food, the rate of absorption is reduced with a mean delay in tmax of 60 minutes and a mean reduction in Cmax of 29%.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
When given 2 hours before CsA administration, sirolimus Cmax and AUC were not affected.
Where patients are not currently taking oral risperidone, the recommended dose is 25 mg RISPERDAL CONSTA every two weeks.
In patients with renal impairment in which Mycophenolate mofetil Teva and ganciclovir or its prodrugs, e. g. valganciclovir, are co-administered the dose recommendations for ganciclovir should be observed and patients monitored carefully.
When the receptors are blocked, histamine cannot have its effect, which leads to a decrease in the symptoms of allergy.
As the foxes or raccoon dogs eat the bait, they get exposed to the viruses and make antibodies against them.
After signs and symptoms of invasive candidiasis have improved and cultures have become negative, a switch to oral antifungal therapy may be considered.
Where full study reports are not available to the MAH, it agrees to provide publications/ manuscripts in lieu of the study report(s).
38 When administration is halted, the eyrthropoietic parameters return toward baseline levels within the recovery period of 1-3 months.
46 When administration is halted, the eyrthropoietic parameters return toward baseline levels within the recovery period of 1-3 months.
When administration is halted, the eyrthropoietic parameters return toward baseline levels within the recovery period of 1-3 months.
When treatment with voriconazole is stopped, the initial dosage of efavirenz should be restored.
When a cat is given the vaccine, the immune system recognises the bacteria as ‘ foreign'and makes a special type of antibodies against them.
When a cat is given the vaccine, the immune system recognises the FeLV proteins as ‘ foreign'and makes antibodies against them.
When a horse is given the vaccine, the immune system recognises the bacteria as ‘ foreign'and makes antibodies against them.
When a person is given the vaccine, the immune system recognises the virus fragments as ‘ foreign'and makes antibodies against them.
When a person is given the vaccine, the immune system recognises the parts of the flu virus it contains as ‘ foreign'and makes antibodies against them.
The immune system will then be able to produce antibodies more quickly when it is exposed to the virus again.
When a breeder is given the vaccine, the immune system recognises the killed bacteria as ‘ foreign'and makes antibodies against them.
When a pig is given the vaccine, the pig's immune system recognises the protein as ‘ foreign'and reacts by building up an active immune response.
When a patient is given the vaccine, the immune system makes antibodies against the L1 proteins.
When an infant is given the vaccine, the immune system recognises the parts of the bacteria and viruses as ‘ foreign'and makes antibodies against them.
When imiquimod is applied to the skin, it acts locally on the immune system to trigger the release of cytokines, including interferon.
When indinavir is administered as monotherapy resistant viruses rapidly emerge (see section 5.1).
When illuminated under blue light of a specific wavelength, the PPIX in the tumour glows an intense red, while the normal brain tissue appears blue.
When implanted, eptotermin alfa stimulates the formation of new bone, helping to repair the broken bone.
Dose escalation, when indicated, should be conservative in such patients.
108 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
108 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
134 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
134 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
17 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
17 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
30 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
30 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
4 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
56 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
56 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
95 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
95 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
When treating HIV infection, it is not always possible to tell whether some of the undesirable effects that occur are caused by Agenerase, by other medicines taken at the same time or by the HIV disease.
When MabThera is given in combination with CHOP or CVP (cyclophosphamide, vincristine, and prednisone) chemotherapy, regular full blood counts should be performed according to usual medical practice.
When Menitorix was administered as a 3-dose primary vaccination course, a DTPa- HBV-IPV* vaccine (N=796) or a DTPa-IPV vaccine* (N=375) was administered concomitantly.
In case the product is mixed with food, it should be added to a small quantity of food, prior to feeding.
When NeoSpect is radiolabelled, the radioactive element technetium-99m (99mTc) is attached to depreotide.
When OPTISON is injected, it travels in the veins to the heart.
When paclitaxel was given after cisplatin, patients showed a more profound myelosuppression and an approximately 20% decrease in paclitaxel clearance.
When paclitaxel is given before cisplatin, the safety profile of paclitaxel is consistent with that reported for single-agent use.
When Pegasys is used in combination with ribavirin, both male and female patients must take special precautions in their sexual activity if there is any chance for pregnancy to occur as ribavirin can be very damaging to an unborn baby:
In combination therapy with ribavirin, ribavirin can be very damaging to an unborn baby, thus both female and male patients must take special precautions in their sexual activity if there is any chance for pregnancy to occur:
In combination therapy with ribavirin, ribavirin can be very damaging to an unborn baby, thus both female and male patients must take special precautions in their sexual activity if there is any chance for pregnancy to occur:
When given in combination with behavioural modification therapy, approximately 42% of dogs given Reconcile improved within one week, compared to only 17% of the dogs given placebo (plus the behavioural modification therapy).
When reconstituted with 1 ml solvent, provides 20 mg/ ml of parecoxib.
When reconstituted with 2 ml solvent, provides 20 mg/ ml of parecoxib.
When REYATAZ and ritonavir are co-administered, the metabolic drug interaction profile for ritonavir may predominate because ritonavir is a more potent CYP3A4 inhibitor than atazanavir.
When only 1 or 2 cakes are required the volume may be reduced to 0.5 ml.
When only 1 or 2 cakes are required the volume may be reduced to 0.5 ml.
When only 1 or 2 lyospheres are required the volume may be reduced to 0.5 ml.
When treatment with SINGULAIR is used as add-on therapy to inhaled corticosteroids, SINGULAIR should not be abruptly substituted for inhaled corticosteroids (see section 4.4).
When Thyrogen is given, it acts like TSH and stimulates all leftover cells in the thyroid, including cancer cells.
When Tritanrix HepB is given according to the 6-10-14 weeks schedule, it is recommended to administer a dose of HBV vaccine at birth to improve protection.
In combination therapy with ribavirin, ribavirin can be very damaging to an unborn baby, thus both female and male patients must take special precautions in their sexual activity if there is any chance for pregnancy to occur:
In combination therapy with ribavirin, ribavirin can be very damaging to an unborn baby, thus both female and male patients must take special precautions in their sexual activity if there is any chance for pregnancy to occur:
When your persistent pain is controlled again, your doctor may need to change your dose of Effentora.
- if your child has any present or past medical problems after any dose of Prevenar.
- if your child is allergic (hypersensitive) to the active substances, to any other ingredients or to
- if your child has any bleeding problems.
- if your child has any bleeding problems.
When an infant is given the vaccine, the immune system (the body’s natural defences) will make antibodies against the most commonly occurring types of rotavirus.
Once you have opened the syrup bottle, you must not use it longer than 4 weeks.
When you have finished, the black injection button should be all the way in.
When starting on glucosamine, you should be aware of potential
When you first start your insulin treatment, it may disturb your vision, but the reaction usually disappears.
When you first start your treatment, it may disturb your vision, but the reaction
When you first start your treatment, it may disturb your vision, but the reaction usually disappears.
When you first start your treatment, it may disturb your vision, but the reaction usually disappears.
When you first start your insulin treatment, it may disturb your vision, but the condition usually disappears.
When you first start your insulin treatment, it may disturb your vision, but the disturbance is usually temporary.
When you first start your insulin treatment, it may disturb your vision, but the reaction usually disappears.
Wait for several seconds to let the powder dissolve.
If you come back to an area after one Rotation Cycle choose the most distant injection site within this area.
If you come back to an area after one Rotation Cycle choose the most distant injection site within this area.
When taking Pradaxa capsules out of the blister pack, please observe the following instructions
When taking Pradaxa capsules out of the blister pack, the following instructions should be followed:
When you have some types of operation, your muscles must be completely relaxed.
When using alternate injection sites, it is particularly important to create enough surface tension on the site to be able to successfully complete the injection.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
When it is given to birds, the animals'immune systems (their natural defences) learn how to make antibodies (a special type of protein) to fight the virus.
When it is given to chickens, the birds'immune system (their natural defence mechanism) learns how to make antibodies (a special type of protein) to fight the disease.
When it is given to a chicken, its immune system recognises the toxoid as ‘ foreign'and makes antibodies against it.
Pedea, when given to your baby, can help to close the ductus arteriosus.
When it is given to cattle and sheep, the animals'immune systems recognise the viruses as ‘ foreign 'and make antibodies against the virus.
When it is combined to the radioactive technetium isotope and injected into your vein, it finds an abnormal accumulation of white blood cells and attaches to them.
When the gilt or sow is injected, the pig's immune system recognises the inactivated virus as ‘ foreign'and reacts to this by producing antibodies to destroy it.
When combination with long-acting insulin is necessary it is only possible to mix Velosulin with isophane or premixed insulin products.
If filled to the brim the measuring device provides 50 ml.
When reconstituted in water Agopton is a pink suspension with a strawberry flavour.
When used to prevent blood clots in patients undergoing PCI, a higher dose of Angiox is used, and the infusion may be continued for up to four hours after the procedure.
When it binds to these receptors, 5HT normally causes nausea and vomiting.
Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, emergency therapy should be administered promptly.
When a dose adjustment is necessary, this should be done in steps of 25 IU/ kg, 3 times per week at intervals of at least 4 weeks until the desired goal is achieved.
When a dose adjustment is necessary, this should be done in steps of 25 IU/kg, 3 times per week at intervals of at least 4 weeks until the desired goal is achieved.
Once a syringe is opened it should only be used to continue the treatment course in the same animal.
Once a syringe is opened it should only be used to continue the treatment course in the same animal.
When a cat is given the vaccine, the immune system recognises the weakened or killed viruses as ‘ foreign'and makes antibodies against them.
When a cat is given the vaccine, the immune system recognises the weakened or killed viruses and the weakened bacteria as ‘ foreign'and makes antibodies against them.
When a cat is given the vaccine, the immune system recognises the weakened or killed viruses and the FeLV proteins as ‘ foreign'and makes antibodies against them.
When a cat is given the vaccine, the immune system recognises the weakened or killed viruses, the FeLV proteins, and the weakened bacteria as ‘ foreign'and makes antibodies against them.
Patients should not consume any food and drink when a tablet is in the buccal cavity.
If an oral total daily dose of at least 2 mg is well tolerated, an injection of 25 mg RISPERDAL CONSTA can be administered every 2 weeks.
When a side effect is described as “ common” this means that it has been reported in at least 1 in every 100 patients but less than 1 in every 10 patients.
If a capsule is damaged, avoid contact of the powder
When pregnancy is detected, enalapril treatment should be discontinued as soon as possible (see 4.6 Pregnancy and lactation).
When a child is given the vaccine, the immune system recognises the viruses and surface antigens as ‘ foreign'and makes antibodies against them.
If exposed to the viruses in the future, the immune system will be able to make antibodies more quickly.
When a person is given the vaccine, the immune system recognises the viruses and surface antigens as ‘ foreign'and makes antibodies against them.
The antibodies will help to protect against diseases caused by these viruses.
When it is given to a cow, the animal's immune system recognises the bacteria as ‘ foreign 'and makes antibodies against them.
When a person is given the vaccine, the immune system recognises the weakened viruses as ‘ foreign'and makes antibodies against them.
This helps to protect against the diseases that these bacteria and viruses cause.
Where a patient requires administration by tube, it is possible to re-constitute AMMONAPS in water prior to use (solubility for sodium phenylbutyrate is up to 5 g in 10 ml water).
When a patient is given the vaccine, the immune system recognises the surface antigens as ‘ foreign'and makes antibodies against them.
When patients receive repeated transfusions, the transfused red cells bring iron.
When a pig is given the vaccine, the pig's immune system recognises the protein as ‘ foreign'and reacts by building up an active immune response.
34 In patients who are already taking ritonavir when digoxin is introduced, digoxin should be introduced more gradually than usual.
In patients who are already taking ritonavir when digoxin is introduced, digoxin should be introduced more gradually than usual.
When treatment with somatropin is started this deficit is rapidly corrected.
Losartan Following oral administration in patients with mild to moderate alcoholic cirrhosis of the liver, plasma concentrations of losartan and its active metabolite were, respectively, 5-fold and 1.7-fold greater than those seen in young male volunteers.
Losartan Following oral administration, losartan is well absorbed and undergoes first-pass metabolism, forming an active carboxylic acid metabolite and other inactive metabolites.
Losartan About 14% of an intravenously- or orally-administered dose of losartan is converted to its active metabolite.
Losartan-Hydrochlorothiazide The plasma concentrations of losartan and its active metabolite and the absorption of hydrochlorothiazide in elderly hypertensives are not significantly different from those in young hypertensives.
Osteonecrosis of the jaw is generally associated with tooth extraction and/ or local infection (including osteomyelistis).
Osteoporosis is a thinning and weakening of the bones, which is common in women after the menopause.
Osteoporosis is a disease that causes your bones to become thin and fragile - this disease is especially common in women after the menopause.
Osteoporosis can be treated and it is never too late to begin treatment.
Osteoporosis can be treated and it is never too late to begin treatment.
11/ 17 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Acute otitis media (AOM) is a common childhood disease with different aetiologies.
A hole should be clearly visible at the tip of the tube and the tip seal should be inside the top of the tube cap.
Lovett House, Lovett Road Staines Middlesex TW18 3AZ United Kingdom
Oxybutynin is transported across intact skin and into the systemic circulation by passive diffusion across the stratum corneum.
Oxybutinin has been available as a tablet for the treatment of overactive bladder since the 1970's.
Oxybutynin is a racemic (50:50) mixture of R- and S-isomers.
Oxybutynin, the active substance in the patch, is dissolved in the thin layer of adhesive, which is used to stick the patch to your skin.
- nitric oxide: since both medicinal products inhibit platelet function, their combination may in
other capital expenditure
LPV/ r 400/ 100 mg bid (n=358), IDV/ r 800/ 100 mg bid (n=23), SQV/ r 1000/ 100 mg bid or 800/ 200 mg bid (n=162), APV/ r 600/ 100 mg bid (n=194) ENF Enfuvirtide; FAS Full Analysis Set; PP Per Protocol; APV/ rtv Amprenavir/ ritonavir; IDV/ rtv Indinavir/ ritonavir; LPV/ rtv Lopinavir/ ritonavir; SQV/ rtv Saquinavir/ ritonavir
The Internet address remains the same (http: / /www. eudra. org/ emea. html).
This plan shall consist of measures to provide adequate education on: l) Key signs and symptoms of serious adverse events associated with the intravitreal injection procedure m) When to seek urgent attention from the health care provider
25, The Courtyard Kilcarbery Business Park Nangor Road Clondalkin IRL-Dublin 22 Tel: +353 (0)1 4671555
Triq tat-Torba Attard BZN 12
Lucentis 10 mg/ ml solution for injection Ranibizumab Intravitreal use
Lucentis must be administered by a qualified ophthalmologist experienced in intravitreal injections.
Lucentis must be administered by a qualified ophthalmologist experienced in intravitreal injections.
Lucentis is a solution for injection into the eye.
Lucentis is used to treat patients with the ‘ wet'form of age-related macular degeneration (AMD).
Lucentis has not been studied in patients who have previously received intravitreal injections.
3 Lucentis should not be administered concurrently with other anti-VEGF agents (systemic or ocular).
This helps to reduce the pressure inside the eye and the risk of damage.
LUMIGAN contains benzalkonium chloride, which is known to discolour soft contact lenses.
LUMIGAN contains the preservative benzalkonium chloride, which may be absorbed by soft contact lenses.
Luminity is used in adults to obtain a clearer scan of the chambers of the heart, especially of the left ventricle, during echocardiography (a diagnostic test where an image of the heart is obtained using ultrasound).
As Luminity is only intended for administration by healthcare professionals no information will be included in Braille.
enhanced brightness in a limited area of the visual field.
MON 1 MON 2 TUE 1 TUE 2 WED 1 WED 2 THU 1 THU 2 FRI 1 FRI 2 SAT 1 SAT 2 SUN 1 SUN 2
Lundbeck A/ S Ottiliavej 9 DK-2500 Valby Denmark.
Lundbeck A/ S Ottiliavej 9 DK-2500 Valby Denmark
Lundbeck A/ S Ottiliavej 9, DK-2500 Valby Denmark
other ingredients of Mycophenolate mofetil Teva.
other ingredients of Mycophenolate mofetil Teva.
One of the most important areas of activity in 2002 was the acquisition and refurbishment of the sixth floor at the EMEA headquarters building at 7 Westferry Circus.
If such inhibitors occur, a sign may be an increase in the amount of ReFacto AF typically required to treat a bleed and/or continued bleeding after a treatment.
One of these studies involved 16 patients who were treated for an average of 15.5 months.
One of these studies contained only diabetic men.
One study also compared the effects of adding Revatio or placebo to epoprostenol in 267 patients.
One of the studies also looked at the effect of Tracleer on healing in 190 patients, by measuring the time taken for one selected digital ulcer in each patient to heal completely.
One of the studies in adults was carried out in patients after they had received antibiotics to treat their infection.
procedure shows that we have improved the service and I hope to build on this progress.
One involves mutations in ribosomal protein L3, the other is a non- specific efflux mechanism (ABC transporter vgaAv).
The Pharmacopeia secretariat and experts similarly participate in meetings of the European Commission Pharmaceutical Committee and also in a number of EMEA working groups.
The Unit intends to contribute to the Agency’s objective of improving transparency, both for the general public and for patient, consumer, health care professionals, learned societies and pharmaceutical representative groups.
These changes are intended to facilitate the efficient handling of tasks, while maintaining support to the Committee for Proprietary Medicinal Products (CPMP), its working parties and to the Committee for Orphan Medicinal Products (COMP).
One was obtained by hydroxylation of the pyrrolidone ring (1.6% of the dose) and the other one by opening of the pyrrolidone ring (0.9% of the dose).
Urea is rapidly absorbed from the gastro-intestinal tract and distributed into extracellular and intracellular fluids including lymph, bile, cerebrospinal fluid and blood.
Urea is one metabolite of hydroxycarbamide.
Hypomagnesaemia, hypokalaemia Hyperkalaemia, hypernatraemia
Chronic idiopathic urticaria was studied as a clinical model for urticarial conditions, since the underlying pathophysiology is similar, regardless of etiology, and because chronic patients can be more easily recruited prospectively.
Chronic idiopathic urticaria was studied as a clinical model for urticarial conditions, since the underlying pathophysiology is similar, regardless of etiology, and because chronic patients can be more easily recruited prospectively.
No studies on the effects on the ability to drive and use machines have been performed.
Dizziness, headache, concentration impaired, mouth dry Tremor, paresthesia, hypoesthesia, migraine, flushing, somnolence, taste perversion
The use of antibiotics may promote the overgrowth of non-susceptible micro-organisms.
However, this does not preclude the occurrence of hepatic events in patients with cirrhosis (including hepatocarcinoma). rod
ris If active tuberculosis is diagnosed, Trudexa therapy must not be initiated (see section 4.3).
ge Excipients: glycine, disodium phosphate anhydrous sodium dihydrogen phosphate monohydrate, and human albumin solution
ge Excipients: glycine, disodium phosphate anhydrous, Sodium dihydrogen phosphate monohydrate, and human albumin solution
ge Excipients: glycine, disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate, and human albumin solution lon One ampoule of solvent contains 1 ml of water for injections.
ge Excipients: disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate, edetate disodium, sodium chloride, m-cresol, polysorbate 80 and water for injections lon 4.
ge clearance is much lower in patients with end-stage renal failure than in healthy subjects.
ed fast heart rate (tachycardia); bleeding (haemorrhage); blood clot (thrombosis); low blood pressure (hypotension); accumulation of lymph fluid in one part of the body (lymphocele); severe shortness of breath, including when laying flat at night (pulmonary oedema); fluid on the lungs (pleural effusion);
ed in treatment, occurs in approximately 20% of well-controlled patients.
Treatment with Trudexa may result in the formation of autoimmune antibodies.
42 The vaccine should never be given into a vein.
Metabolism Human insulin is reported to be degraded by insulin protease or insulin-degrading enzymes and possibly protein disulfide isomerase.
After doses of 0.5 mg/ kg (~40 mg), clearances ranged from 11 to 15 ml/ hour, the distribution volume (Vss) ranged from 5 to 6 litres and the mean terminal phase half- life was approximately two weeks.
Study 2 (P02080) was a randomized, single centre study that enrolled 95 previously untreated adult patients with chronic hepatitis C who were co-infected with HIV.
6 No gross changes to circulating lymphocyte numbers or cell phenotypes were observed by fluorescence-activated cell sorter (FACS) analysis other than the expected transient decrease in Tac+ cells.
During treatment for hepatitis B or C the recommended testing schedule is at weeks 1, 2, 4, 8, 12, 16, and
România GlaxoSmithKline (GSK) SRL Tel: +40 (0)21 3028 208
Ustekinumab has been designed to bind to a protein called ‘ IL-12/ 23p40’.
Ustekinumab prevents IL-12 and IL-23 contributions to immune cell activation, such as intracellular signaling and cytokine secretion.
Ustekinumab inhibits the activity of human IL-12 and IL-23 by preventing these cytokines from binding to their IL-12Rβ 1 receptor protein expressed on the surface of immune cells.
Ustekinumab cannot bind to IL-12 or IL-23 that is pre-bound to IL-12Rβ 1 cell surface receptors.
Marketing Authorisation Holder and Manufacturer
ed term treatment with Trudexa on the development of autoimmune diseases is unknown.
The impact of long- term treatment with Trudexa on the development of autoimmune diseases is unknown.
In addition, rare cases of transient loss of consciousness, which may be preceded by vagal symptoms, have been reported (see section 4.8).
Dizziness, headache, concentration impaired, mouth dry Tremor, paresthesia, hypoesthesia, migraine, flushing,
Micturition frequency Renal failure, renal insufficiency, nephrotic syndrome
Renal failure, renal insufficiency, nephrotic syndrome
Hypothyroidism§, hyperthyroidism§ Diabetes, aggravated diabetes
Trudexa is also available as a pre-filled syringe or a pre-filled pen.
No dose recommendations can be made.
r ge latent disease.
ris Malignancies and lymphoproliferative disorders
tho Malignancies and lymphoproliferative disorders
The operator should be careful to protect the eyes while inspecting the solution for clarity.
The approved use in The Netherlands was a 5 mg start dose for patients with predisposing factors to myopathy, and 10 mg as the recommended start dose for patients without these predisposing factors.
Use during anaesthesia with halothane and oxygen has not been studied.
Use in these dogs is therefore not recommended.
Use in these dogs is therefore not recommended.
Paediatric patients Use in the paediatric patient population is not recommended.
Use in children and adolescents is therefore not recommended.
Use is not recommended in newborns, infants, children and adolescents.
Therefore, use in patients with severe hepatic impairment is not recommended.
The clinical use of TESLASCAN has been investigated at field strengths from 0.5 to 2.0 Tesla.
Concomitant use of anagrelide with other PDE III inhibitors such as milrinone, amrinone, enoximone, olprinone and cilostazol is not recommended.
The concomitant use of partial opioid agonists/ antagonists (e. g. buprenorphine, nalbuphine, pentazocine) is not recommended.
Concurrent use of antibiotics with oral contraceptives may render oral contraceptives less effective.
It is possible that concomitant use of other photosensitising agents (e. g., tetracyclines, sulphonamides, phenothiazines, sulphonylurea hypoglycaemic agents, thiazide diuretics, griseofulvin and fluoroquinolones) could increase the photosensitivity reaction.
Simultaneous use of different NSAIDs is not recommended.
Simultaneous use of different NSAIDs is not recommended.
Concomitant use of those drugs with toremifene should be carefully considered.
If these medicinal products are used concomitantly care is advised, and close clinical and virological monitoring should be performed since it is difficult to predict the effect of the combination of amprenavir and ritonavir on delavirdine.
The concomitant use of deferasirox with aluminium-containing antacid preparations is not recommended.
9 ribavirin with zidovudine is not recommended due to an increased risk of anaemia (see section 4.4).
The concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia (see section 4.4).
The concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia (see section 4.4).
The concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia (see section 4.4).
The concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia (see section 4.5).
The concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia (see section 4.5)
The concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia (see section 4.5).
Concomitant use of indinavir with lovastatin or simvastatin is not recommended due to an increased risk of myopathy including rhabdomyolysis.
Concomitant use with nitroglycerin and other nitrates, or other vasodilators, may further reduce blood pressure.
Concomitant use with nitroglycerine and other nitrates, or other vasodilators, may further reduce blood pressure.
The comcomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia (see section 4.5).
The concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia (see section 4.5).
Concomitant use of ritonavir (400 mg twice daily and more) and voriconazole is contraindicated due to a reduction in voriconazole plasma concentrations and possible loss of effect (see section 4.5)
Concomitant use of ritonavir (400 mg twice daily and more) and voriconazole is contraindicated due to a reduction in voriconazole plasma concentrations and possible loss of effect (see section 4.5)
Tetracyclines used concurrently with oral contraceptives have in a few cases resulted in either breakthrough bleeding or pregnancy.
The concomitant use of venlafaxine with serotonin precursors (such as tryptophan supplements) is not recommended (see section 4.4).
The concomitant use of venlafaxine with serotonin precursors (such as tryptophan supplements) is not recommended (see section 4.4).
Concomitant use of losartan and ACE-inhibitors has shown to impair renal function.
Continually using it may lead to further improvement.
Abatacept is not recommended for use in combination with TNF blocking agents.
Agopton should not be given to children.
The use of heavier animals would have given extra assurance about residues levels at the injection site and would have made all studies homogenous.
The use of oral anticoagulants, non-study antiplatelet medicinal products and chronic NSAIDs was not allowed in TRITON.
Use of Atripla should be avoided with concurrent or recent use of a nephrotoxic medicinal product.
Other HMG-CoA reductase inhibitors should be considered such as pravastatin, fluvastatin or rosuvastatin.
Other HMG-CoA reductase inhibitors should be considered such as pravastatin, fluvastatin or rosuvastatin.
therefore, use of BYETTA is not recommended in this age group.
Therefore, the use of BYETTA is not recommended in patients with severe gastrointestinal disease.
Using this Tg criterion, 18/ 21 patients (86%) and 23/ 24 patients (96%) had thyroid remnants successfully ablated in the THST withdrawal group and the Thyrogen treatment group, respectively.
The use of this medicinal product is contraindicated in patients with
Cerezyme (imiglucerase) is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease and who exhibit clinically significant non-neurological manifestations of the disease.
Combivir is therefore contra- indicated in these patients (see section 4.4).
The use of Copalia in children and adolescents is not recommended.
The use of Crixivan with ritonavir is based on limited evidence.
The use of higher ritonavir doses might alter the safety profile of the combination and therefore is not recommended.
The use of higher ritonavir doses might alter the safety profile of the combination and therefore is not recommended.
The use of higher ritonavir doses might alter the safety profile of the combination and therefore is not recommended.
The use of Duvaxyn WNV reduces the number of animals with viraemia after natural infection, but may not systematically prevent it.
Therefore filgrastim is not indicated for use in these conditions.
Therefore, the use of Galvus is not recommended in these patients.
Use of gloves and other protective clothing to prevent skin contact is recommended.
Therefore, the use of Jalra is not recommended in these patients.
Therefore, use of Januvia is not recommended in this patient population (see section 5.2).
The use of Kineret with tumour necrosis factor (TNF) antagonists (other medicines used in rheumatoid arthritis) is not recommended.
- Due to adverse effects on the cartilage in juvenile animals (see section 5.3) the use of
The use of amprenavir in combination with ritonavir has not been studied in patients with hepatic impairment.
Ribavirin clinical trials in adults The use of Ribavirin in combination treatment with peginterferon alfa-2b or interferon alfa-2b was evaluated in a number of clinical trials.
The use of sitagliptin in combination with insulin has not been adequately studied.
The combination product is not recommended for use in patients with impaired renal or hepatic function.
The use of tigecycline may result in overgrowth of non-susceptible organisms, including fungi.
Zidovudine is therefore not recommended to be used in combination with stavudine.
Use of enalapril is not recommended during breast feeding.
Enfuvirtide use in OBT in enfuvirtide-naïve patients was counted as one active drug in OBT.
Thus the data on a limited number of exposed pregnancies indicate no adverse effects on pregnancy or on the health of the foetus/ newborn.
The use of losartan is not recommended in patients with severe hepatic impairment (see section "Do not take losartan").
The use of< Nimesulide-containing medicinal products > may impair female fertility and is not recommended in women attempting to conceive.
Anti-peristaltic drugs are contraindicated in this situation.
The use of glucose oxidase methods may give false negative results for glycosuria.
Therefore, the use of MicardisPlus is not recommended.
The use of MIRAPEXIN has not been studied in hemodialysis patients, or in patients with severe renal impairment.
Co-administration of the combination oral contraceptive containing norethindrone and 17 α-ethinylestradiol with VIRACEPT resulted in a decrease in AUC of the contraceptive drug; therefore alternative contraceptive measure should also be considered (see section 4.5).
The use of Mycophenolate mofetil Teva is not recommended during pregnancy and should be reserved for cases where no more suitable alternative treatment is available.
The use of Enbrel is not expected to affect the ability to drive or use machines.
The use of Enbrel is not expected to affect the ability to drive or use machines.
The use of {INVENTED NAME} during pregnancy is therefore not recommended .”
The use of NutropinAq in patients with chronic renal insufficiency receiving glucocorticoid therapy has not been evaluated.
Occlusive dressings are not recommended.
Epivir is not recommended for use as monotherapy.
The use of Privigen in pregnant or breast-feeding women has not been studied separately.
The use of prostacyclin, prostacyclin analogues and endothelin receptor antagonists was not permitted as add-on therapy, and neither was arginine supplementation.
The use of Protopy ointment in patients with genetic epidermal barrier defects such as Netherton's syndrome is not recommended due to the potential for permanently increased systemic absorption of tacrolimus.
is The use of Protopy ointment in patients with genetic epidermal barrier defects such as Netherton's
The use of Rapamune may lead to increased blood concentrations of cholesterol and triglycerides that may require treatment.
The use of Rapamune may lead to increased blood concentrations of cholesterol and triglycerides that may require treatment.
The use of Ribavirin in combination with peginterferon alfa-2b had no observable negative impact on the control of HIV viraemia during therapy or follow-up.
The use of RILUTEK is not recommended in children
The use of Riprazo in children and adolescents is not recommended.
The use of AIIRAs is contraindicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).
The use of SIFROL has not been studied in hemodialysis patients, or in patients with severe renal impairment.
The use of Sprimeo in children and adolescents is not recommended.
Use of Tarceva in patients with severe hepatic impairment is not recommended (see section 5.2).
Use of Tarceva in patients with severe hepatic impairment is not recommended (see section 5.2).
Use of Tarceva in paediatric patients is not recommended.
Use of Tarceva in paediatric patients is not recommended.
Use of Tarceva in patients with severe renal impairment is not recommended.
Use of Tarceva in patients with severe renal impairment is not recommended.
The use of Tekturna in children and adolescents is not recommended.
The use of Thyrogen should be supervised by a doctor with expertise in thyroid cancer.
The use of Thyrogen allows for radioiodine imaging while patients are euthyroid on thyroid hormone suppression treatment.
Use of TMZ in combination with other myelosuppressive agents may increase the likelihood of myelosuppression.
19 The use of etoricoxib, as with any drug substance known to inhibit COX-2, is not recommended in women attempting to conceive.
The use of etoricoxib, as with any drug substance known to inhibit COX-2, is not recommended in women attempting to conceive.
The use of other topical products on treated KS lesions should be avoided.
The use of any combined hormonal contraceptive, including EVRA, carries an increased risk of venous thromboembolism (deep vein thrombosis, pulmonary embolism) compared to no use.
Use of any thienopyridine within 5 days before enrolment was an exclusion criterion.
Wherever possible, the use of electronic versions will be encouraged, reducing not only the volumes required of the centralised reprographics facility, but also mailing volumes and the number of physical documents transported by delegates attending meetings.
The use of Xeomin in children and adolescents has not yet been investigated and is therefore not recommended.
if you/your child has finished growing (the bone growth plates are closed). the use of INCRELEX has not been studied in children under 2 years of age and is therefore not recommended.
The use of Incurin is contraindicated during pregnancy and in animals younger than 1 year.
The use of Internet technology to give the widest possible access to documents of the EMEA is an important aspect of the Agency's work.
The use of Kentera in patients with hepatic impairment should be carefully monitored.
Kentera is not recommended for use in children or adolescents.
Use of < Invented Name > may cause mild and transient reactions at the site of application, such as a feeling of warmth and/or burning sensation.
The use of < Invented Name > under occlusion has not been studied in patients.
Use of Opgenra does not guarantee fusion; additional surgeries may be required.
The use of Optisulin may be considered in pregnancy, if necessary.
- Using ORACEA with the general anaesthetic methoxyfluorane may cause serious harm to the
Use of 5-ALA under conditions other than the ones used in the clinical trials entail an undetermined risk.
The use of basiliximab does not preclude subsequent treatment with murine antilymphocyte antibody preparations.
Use of filgrastim, either alone or after chemotherapy, mobilises haematopoietic progenitor cells into peripheral blood.
It is not recommended to use FORCALTONIN in children. ina
Use of lisinopril is not recommended during breast-feeding.
Use of the veterinary medicinal product should be based on susceptibility testing and take into account official and local policies on the use of antimicrobials in farm animals.
Using a larger diameter needle will make it easier to push the Dose Knob during your injection.
For administration the use of a luer-lock syringe is required.
The use in such animals is not recommended.
Use of the product should be based on susceptibility testing and take into account offical and local antimicrobial policies.
Use of the product should be based on susceptibility testing and take into account official and local antimicrobial policies.
Use of the product should be based on susceptibility testing and take into account official and local antimicrobial policies.
The use is not recommended during pregnancy and lactation.
Use in pregnancy is, therefore, not recommended.
The use of sugammadex in patients with severe renal impairment is not recommended.
Toremifene is recommended for postmenopausal patients.
The use of ziconotide in combination with morphine or baclofen, rescue medication, the evaluation of health related quality of life, and the analysis of adverse events will also be taken into account.
Use only according to the risk/ benefit assessment of the responsible veterinarian.
The use is not recommended during lactation.
Do not use during pregnancy and lactation.
Pre-emptive use of Effentora for predictable pain episodes was not investigated in the clinical trials.
CIALIS 10 mg and 20 mg is intended for use prior to anticipated sexual activity and is not recommended for continuous daily use.
Simultaneous use of ceftriaxone and bacteriostatic antibiotics is, therefore, not recommended..
Simultaneous use of loop- diuretics (for example furosemid) may decrease the effect of the diuretic.
Simultaneous use of loop-diuretics (for example furosemid) may decrease the effect of the diuretic.
Simultaneous use of glucocorticoids may add undesirable effects on GI-canal.
Simultaneous use of NovoSeven and coagulation factor concentrates should be avoided.
Subsequent intravenous administration is not contraindicated unless the reactions recur or worsen.
The user should apply the first patch of the new cycle as soon as remembered.
user should stop the current contraceptive cycle and start a new four-week cycle immediately by putting on a new EVRA patch.
Luveris 75 IU, powder and solvent for solution for injection Lutropin alfa
Luveris 75 IU, powder and solvent for solution for injection.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Luveris has been studied in two studies in a total of 81 patients, where the effect of different doses of Luveris was studied.
It is given by subcutaneous injection (under the skin).
Luveris is used together with FSH (another hormone that stimulates ovulation).
Luveris has no influence on the ability to drive and use machines.
Luveris should not be mixed with other medicinal products in the same injection, except for follitropin alfa.
België/ Belgique/ Belgien Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 D-60318 Frankfurt Duitsland/ Allemagne/ Deutschland Tél/ Tel: +49 (0)69 1503 – 1
Luxembourg/ Luxemburg SWEDISH ORPHAN INTERNATIONAL SARL Tél/ Tel: + 33 1 41 92 18 01
Luxembourg/Luxemburg Orphan Europe Benelux Koning Albert I, Iaan 48 bus 3 B-1780 Wemmel (Brussels) Belgique/Belgien Tél/Tel: +32 2 4 6101 36
Lymphadenopathy localised to the region of the injection site
Psychiatric disorders Nervous system disorders Cardiac disorders
development and post-marketing experience in association with the use of Protopy.
Non-Hogkin's lymphoma and chronic lymphocytic leukaemia
White lyophilisate and clear, colourless solvent.
LYRICA 25, 50, 75, 100, 150, 200, 225 and 300mg hard capsules (Pregabalin)
Lyrica may have minor or moderate influence on the ability to drive and use machines.
Taking Lysodren with food and drink Lysodren should preferably be taken during meals containing fat-rich food such as milk, chocolate, oil.
90Y, yttrium-90, is a radioactive form of the chemical element yttrium.
The 90Y contained in Ytracis then attaches itself to the carrier medicine and the resulting mixture is given according to the instructions in the Package Leaflet of the carrier medicine.
The yttrium-90 contained in Yttriga then attaches itself to the carrier medicine and the resulting mixture is given according to the Package Leaflet of the carrier medicine.
M1 and M2 are the only metabolites relevant in humans, both are microbiologically inactive.
MabThera in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-
MabThera is an infusion (“drip”) which is given directly into your veins.
MabThera is used in combination with methotrexate (a medicine that acts on the immune system) in patients who cannot take or have not responded adequately to other treatments, including treatment containing a tumour necrosis factor (TNF) inhibitor (a type of medicine for rheumatoid arthritis).
MabThera is usually taken together with another medicine called methotrexate.
Macrogol 4000, distearoylphosphatidylcholine, dipalmitoylphosphatidylglycerol sodium, palmitic acid.
Macugen 0.3 mg should be administered once every six weeks (9 injections per year) by intravitreal injection into the affected eye.
Macugen 0.3 mg solution for injection pegaptanib sodium
Macugen 0.3 mg solution for injection Pegaptanib sodium
Macugen 0.3 mg solution for injection pegaptanib sodium Intravitreal use
Macugen should be discarded if kept at room temperature for more than two weeks.
Macugen is an ophthalmic product, which means it is for eye treatment only.
ge oedema), retinal artery or vein obstruction§, optic neuritis, papilloedema, loss of visual acuity or visual field, cotton- wool spots§ lon Ear and labyrinth Common:
Now that you have done the New Pen Setup, follow Section 3 for all of your injections.
Do maintain pressure on the skin during the injection
Maintain this dose (200 mg/ day) (two divided doses)
Maintain target dose achieved in dose escalation (200 mg/ day; two divided doses) (dose range 100 - 400 mg/ day)
Maintain target dose achieved in dose escalation (200 mg/ day; dose range 100-400 mg/ day)
Hold the syringe with the needle in the vial pointing up.
• Wear protective gloves and spectacles during the ampoule thawing and opening operations. • Remove from the liquid nitrogen container only those ampoules which are to be used immediately. • Thaw rapidly the contents of the ampoules by agitation in water at 25-30°C.
104 Table 12 Maintenance of Clinical Remission and Response (Percent of Patients)
23 Table 12 Maintenance of Clinical Remission and Response (Percent of Patients)
50 Table 12 Maintenance of Clinical Remission and Response (Percent of Patients)
77 Table 12 Maintenance of Clinical Remission and Response (Percent of Patients)
Maintenance of Clinical Remission and Response (Percent of Patients) no
However, you should seek immediate treatment in any event.
Master of Science in economics and Bachelor of Science in public administration from Trinity College Dublin.
Master of Science in economics and Bachelor of Science in public administration from Trinity College Dublin.
Service, serving in the Departments of Health, Finance and the Office of Public Works.
Masters Degree in pharmacy and Doctor of Natural Sciences Degree in pharmacology from the University of Vienna.
MSc in computer science and BSc in business administration and economics at the University of Gothenburg.
MSc in computer science and BSc in business administration and economics at the University of Gothenburg.
MSc in Computer Science and BSc in Business Administration and Economics at the University of Gothenburg.
Master of Science in economics and Bachelor of Science in public administration from Trinity College Dublin.
Masters Degree in political science, history and English from the University of Hamburg.
Masters Degree in political science, history and English from the University of Hamburg.
The safety of fondaparinux 2.5 mg has been evaluated in 3,595 patients undergoing major orthopaedic surgery of the lower limbs treated up to 9 days, in 327 patients undergoing hip fracture surgery treated for 3 weeks following an initial prophylaxis of 1 week, 1407 patients undergoing abdominal surgery
Cough increased Dyspnea * Gastrointestinal disorders
Sinusitis Cough increased Dyspnoea * Gastrointestinal disorders
- Anaemic patients with chronic renal failure
Kawasaki disease 1.6 to 2.0 g/kg bw should be administered in divided doses over two to five days or 2.0 g/kg bw as a single dose.
Gall bladder disease Gall bladder disease has been reported after treatment with oestrogen/progestagen.
cabergoline, lisuride and pergolide (for Parkinson's disease).
Parkinson's disease and dementia with Lewy bodies Physicians should weigh the risks versus the benefits when prescribing antipsychotic medicinal products, including INVEGA, to patients with Parkinson's Disease or Dementia with Lewy Bodies (DLB) since both groups may be at increased risk of Neuroleptic Malignant Syndrome as well as having an increased
Parkinson's disease and dementia with Lewy bodies Physicians should weigh the risks versus the benefits when prescribing antipsychotic medicinal products, including INVEGA, to patients with Parkinson's Disease or Dementia with Lewy Bodies (DLB) since both groups may be at increased risk of Neuroleptic Malignant Syndrome as well as having an increased sensitivity to antipsychotics.
Parkinson's disease Based on the analysis of pooled placebo-controlled clinical trials comprising a total of 1,083 Neupro- and 508 placebo-treated patients, 73.0% of the patients on Neupro and 56.3% of patients on placebo reported at least one adverse reaction.
Parkinson's disease The daily dose is to be taken divided into 3 equal doses.
Parkinson's disease Dosing in patients with early-stage Parkinson's disease:
Liver disease resulting in hepatic impairment (see section 5.2).
- Serious illness with blistering of skin, mouth, eyes and genitals; increased hairiness
Liver disease resulting in hepatic impairment (see section 5.2).
Hepatic disease or baseline transaminases greater than 3 times the upper limit of normal.
• Cancers, other than lymphoma, have been reported in patients with a specific type of lung disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.
Patients predisposed to the development of autoimmune disorders may be at increased risk.
Congenital jaw malformation, pigmented naevus*
Notwithstanding the expected further growth of the Agency increases in the volume of transactions will be met as far as is possible from the allocated staffing.
Notwithstanding the MAH proposals, the CHMP considered that the applicability of the MAH proposals need to be substantiated by data, which validity needs to be determined.
Mallinckrodt Medical Imaging Ireland Damastown Mulhuddart Dublin 15 Ireland
Malta 168 Christopher Street MT-VLT02 Valletta Tel: + 356 21 23 21 75
168 Christopher Street MT-VLT02 Valletta Tel: + 356-21 23 21 75
Malta 168 Chri stopher Street MT-VLT02 Valletta Tel: + 356-21 23 21 75
Tel: +356 25 442600 medinfo_mt@merck. com
Malta A.M.Mangion Ltd Triq Ġdida fi Triq Valletta Luqa LQA 6000 Malta tel:+356 2397 6000
Malta 168 Christopher Street MT-VLT02 Valletta Tel: + 356-21 23 21 75
Č eská republika sanofi-aventis, s. r. o.
Č eská republika sanofi-aventis, s. r. o.
Česká republika sanofi-aventis, s.r.o.
Malta Cherubino Ltd Delf Building Sliema Road MT-GZR 06 Gzira Malta Tel: +356-21-343270/1/2/3/4
Malta Cherubino Ltd Delf Building Sliema Road MT-GZR 06 Gzira Malta Tel: +356-21-343270/ 1/ 2/ 3/ 4
Malta Merck Sharp & Dohme (Middle East) Limited Tel: +357 22866700 info_cyprus@merck. com
Tel: +356 2540 2600 medinfo_mt@merck. com
Malta Nycomed Langebjerg 1 DK-4000 Roskilde Denmark Tel: +45 46 77 11 11 info@nycomed.com
Malta V.J.Salomone Pharma Limited 79, Simpson Street, Marsa HMR 14, Malta.
Malta V. J. Salomone Pharma Limited 79, Simpson Street, Marsa HMR 14, Malta.
V. J. Salomone Pharma Limited 79, Simpson Street, Marsa HMR 14,
V. J. Salomone Pharma Limited 79, Simpson Street, Marsa HMR 14,
Then eat something that has a long-acting effect in raising your blood sugar (e.g. bread).
Mangion Buildings New Street in Valletta Road MT-LQA 6000 Luqa Tel: +356 2397 6000
General Disorders and Administration Site Conditions
… []… “ Gastrointestinal (GI) Effects, Risk of GI Ulceration, Bleeding, and Perforation.
General disorders and reactions at the injection site
reactions at the injection site
Before using SoloStar, the Instructions for Use included in the Package Leaflet must be read carefully.
Handling of the pen Before using SoloStar, the Instructions for Use included in the Package Leaflet must be read carefully.
Before using OptiSet, the Instructions for Use included in the Package Leaflet must be read carefully.
Handling of the pen Before using OptiSet, the Instructions for Use included in the Package Leaflet must be read carefully.
Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
95 Handling of the pre-filled pen Before using the KwikPen the user manual included in the package leaflet must be read carefully.
68 • Pregnant staff should be excluded from working with this medicinal product. • Staff handling this medicinal product during reconstitution should wear protective clothing including mask, goggles and gloves. • All items for administration or cleaning, including gloves, should be placed in high-risk, waste disposal bags for high-temperature incineration. • Liquid waste may be flushed with large amounts of water. • Accidental contact with the skin or eyes should be treated immediately with copious amounts of water.
Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patients
Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patients lp
Handle the used system carefully and only by the sides and top housing.
Handle this product with care to avoid exposure, taking all recommended precautions.
General disorders and reactions at the injection site
Mannitol (E421) Sodium acetate (E262) Hydrochloric acid (E507) (for pH adjustment) Sodium hydroxide (E524) (for pH adjustment)
Mannitol (E421), sucrose, l-histidine, hydrochloric acid (for pH adjustment) and polysorbate 20.
Mannitol (E421) Sucrose L-histidine Hydrochloric acid (for pH adjustment) Polysorbate 20
Mannitol (E421) Threonine Polysorbate 80 Sodium citrate (for pH adjustment) Hydrochloric acid concentrated (for pH adjustment)
– Mannitol – Sodium hydroxide for adjustment to pH 7
- increased shortage of oxygen in the heart, including a heart attack
Manuel I - Piso 2 Rua Dos Malhões Nº 1 2770-071 Paço De Arcos Portugal
Mare de Déu de Montserrat, 221 hydrochloride 08041 Barcelona Spain
María de Molina, 40 E-28006 Madrid Línea de Información:
Marinopoulou Str., 174 56 Alimos, Athens, Greece. uc
España Ms Carmen COLLADO ALVAREZ Prof.
Malta Allergan Ltd 1st Floor Marlow International The Parkway Marlow Bucks, SL7 1YL-UK United Kingdom/ Renju Unit Tel: + 44 (0) 1628 494026 E-mail: uk_medinfo@allergan. com
Biochemical markers of bone turn-over Clinically meaningful reductions in serum CTX levels were observed at all time points measured, i. e. months 3, 6, 12 and 24.
Masters degree in European and international law from the Vrije Universiteit Brussel, Belgium.
Agence Française de Sécurité Sanitaire des Aliments 23, avenue du Général de Gaulle B.P.
Directeur Général Agence Française de Sécurité Sanitaire des Aliments 23, avenue du Général de Gaulle B.P.
Maš era – Spasić eva ul.10 SI-1000 Ljubliana Tel: +386 1 5372866 E-mail: uk_medinfo@allergan. com
Masitinib 150 mg (equivalent to masitinib mesylate 178.9 mg)
Masitinib 50 mg (equivalent to masitinib mesylate 59.6 mg).
Masivet is used to treat dogs with mast-cell tumours (a type of cancer).
Masivet might extend the time before the tumours progress.
The cream should be rubbed into the treatment area until 3 the cream vanishes.
The cream should be rubbed into the treatment area until the cream vanishes.
Apply a thin layer of Aldara cream onto clean, dry wart area and rub gently into the skin until cream vanishes.
Rub gently into the area until the cream vanishes.
Rub gently into the skin until the cream vanishes.
• Physician Information Pack • Nurse Information Pack • Patient Information Pack
Physician Information Pack Nurse Information Pack Patient Information Pack
Special library, documentation and reproduction equipment
The main priorities for 2006 are: continued development and modification of systems to implement the new legislation; reliable operation of the EU telematics systems and related services; and continued analysis and development of the EU telematics IT projects.
Palatable matrix (bait) containing a tetracycline biomarker
Palatable matrix (bait) containing a tetracycline biomarker
Sixth General Report on the Activities of the European Agency for the Evaluation of Medicinal Products
Headache Thromboembolism, usually associated with severe OHSS
These are likely to affect more than 10 in every 100 people Headache, nausea, vomiting, diarrhoea, indigestion, rash, muscle cramps, pain in the muscles and bones, and swelling (including puffy eyes and ankle swelling), joint pain, tiredness, increased weight.
For those entering with VL > 200 copies/ml, VF defined as any increase > 0.5 logs and/or VL > 50,000 copies/ml at week 4, > 5,000 copies/ml at week 12, or > 200 copies/ml at week 24 or thereafter.
For those entering with VL > 200 copies/ml, VF defined as any increase > 0.5 logs and/or VL > 50,000 copies/ml at week 4, > 5,000 copies/ml at week 12, or > 200 copies/ml at week 24 or thereafter.
- 327 patients undergoing hip fracture surgery treated for 3 weeks following an initial prophylaxis
MDA Blood Bank Sheba Hospital Ramat Gan 52621 POB 888 Kiryat Ono 55000 Israel
• Medac Gesellschaft fuer klinische Spezialpräparate mbH
medac Gesellschaft für klinische Spezialpräparate mbH Fehlandtstraße 3 D-20354 Hamburg Germany
medac Gesellschaft für klinische Spezialpräparate mbH Fehlandtstraße 3 D-20354 Hamburg, Germany Tel. + 49 4103 8006 0 Fax: +49 4103 8006 100
In children, only the lowest strength Protopy 0.03% should be used.
abacavir (Kivexa, Ziagen), lamivudine or zidovudine, or any of the other ingredients found in Trizivir
Products 1995 (ISBN 92-827-7491-0, Office for Official Publications of the EU)
Medicinal Products 1996 (ISBN 92-9155-002-7, Office for Official Publications of the EU)
Medicinal Products 1997 (ISBN 92-9155-010-8, Office for Official Publications of the EU)
Since tolcapone interferes with the metabolism of catecholamines, interactions with other drugs affecting catecholamine levels are theoretically possible.
VIGABATRIN CONTAINING MEDICINAL PRODUCTS WITH MARKETING AUTHORISATION IN THE EU
Medicinal products whose plasma levels may be increased when co-administered with Telzir
Medicinal products whose plasma levels may be decreased when co-administered with Telzir
CNS medicinal products: the risk of using duloxetine in combination with other CNS-active medicinal products has not been systematically evaluated, except in the cases described in this section.
medicinal products New medicinal substances
- Heart medicines (e. g. digoxin) or medicines to control the rhythm of your heart (e. g. quinidine,
- Heart medicines (e. g. digoxin) or medicines to control the rhythm of your heart (e. g. quinidine,
- medicines for heart disease;
significantly induce glucuronidation of lamotrigine Phenytoin Carbamazepine Phenobarbitone Primidone Rifampicin Lopinavir/ ritonavir Ethinyloestradiol/ levonorgestrel combination*
careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, uc
Medicinal products that may reduce plasma amprenavir concentrations when co-administered with Telzir
Medicines used to lower blood fats (also called statins): atorvastatin, pravastatin, simvastatin.
- Medicines used to lower blood fats (also called statins): atorvastatin, pravastatin, simvastatin.
- Heart medicines (e. g. digoxin) or medicines to control the rhythm of your heart (e. g. quinidine,
- Medicines used to treat bacterial infections, including tuberculosis and AIDS-related
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. od
Medice Arzneimittel Pütter GmbH & Co KG Kuhloweg 37 D-58638 Iserlohn
Medice Arzneimittel Pütter GmbH & Co KG Kuhloweg 37 D-58638 Iserlohn Germany
Medice Arzneimittel Pütter GmbH & Co KG, Kuhloweg 37, D-58638 Iserlohn, Germany
Mediplus This UK database was examined for first time cases of myopathy, myositis or renal failure subsequent to any statin prescription.
______________________ Meena Ballantyne Assistant Deputy Minister Health Products and Food Branch Health Canada
Best response according to ACTG criteria for vehicle controlled phase
Mixing with other solutions: see sections 6.2 and 6.6.
1:1 Methanol / 1M Ammonium Acetate (MAM) - Carefully mix one part methanol with one part 1M Ammonium Acetate.
Mix by inversion, rolling the container, avoid foaming or agitating the solution.
Mix the measured dose of powder with water, juice, milk, formula or food until completely dissolved and ingest immediately after mixing.
Stir the mixture and give the entire contents of the bowl to the patient.
Always mix NovoRapid and long-acting insulin in the same sequence.
Sheila KENNEDY (acting) The annual report for inspection activities is given in
Graduate in biochemistry and pharmacology from Leeds University.
Miss Leivers worked for the Milk Marketing Board for England and Wales (MMB) as a Liaison Chemist for 5 years prior to being appointed Assistant Director of the MMB/ Federation of Agricultural Cooperatives office in Brussels, representing all sectors of agricultural cooperation to the European institutions.
Boehringer Ingelheim International GmbH
- skin adhesive: polybutene, resin ester
- skin adhesive: polybutene, resin ester.
appointed rapporteur or co-rapporteur in 6 cases, whereas members from Austria and Italy were appointed in 5 cases.
Hypersensitivity/ angioedem Alopecia, Rash, Purpura, a of the face, extremities, Skin discolouration, lips, tongue, glottis and/ or Diaphoresis, Pruritus larynx (see section 4.4), Rash, Pruritus
Membership of the Committee for Veterinary Medicinal Products
EMEA staff members by nationality in 2002
It may harm them, even if their symptoms are the same.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please
Even the trials in liver and kidney transplantation were of only moderate size.
Even the amended indication for the treatment of gastrointestinal endoparasitic infections in horses has not been demonstrated by the data provided.
Although this effect is minor and was of no clinical significance in this study, it should be considered when co-administering these medicines.
Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit.
Although deferasirox has a lower affinity for aluminium than for iron, it is not recommended to take EXJADE tablets with aluminium-containing antacid preparations (see section 4.4).
Although the CI for the fed study results (CI for AUCinf.
Although etravirine demonstrates in vitro activity against wild type HIV-2 with median EC50 values ranging from 5.7 to 7.2 µM, treatment of HIV-2 infection with etravirine is not recommended in the absence of clinical data.
Even if you have used Avonex before, some of the information may have changed.
Even if you are not being treated with RISPERDAL Oral but you experience any of the following, talk to your doctor: • Bed wetting, difficulty in urination, urination at short intervals, vaginal discharge • Tonsillitis, eye infection, skin infection, fungal infection of nails • Lack of emotion, confusion, poor attention, loss of consciousness, balance disorder • Unresponsive to stimuli, stroke, decreased blood supply to the brain, brain blood vessel disorder, sudden weakness or numbness of the face, arms, or legs, especially on one side, or instances of slurred speech that last for less than 24 hours (these are called mini-strokes or strokes) • Eye discharge, eye rolling, eye swelling, ringing in the ears, nose bleeding, dry eye, increased tears, painful oversensitivity to light, increased pressure within the eyeball, reduced visual clarity • Wheezing, pneumonia caused by inhaling food, hoarseness, cough with sputum, lung congestion, breathing passage congestion, crackly lung noise, breathing passage disorder, fast shallow breathing • Very hard feces, fecal incontinence, abdominal discomfort, thirst, lip swelling, inflammation of the colon, reduced saliva • Skin discoloration, skin lesion, skin disorder, thickening of the skin
Even if small amounts have been injected, accidental injection with
To conduct physician surveys to monitor appropriate use.
Aseptic meningitis*, Severe infections*, JC virus infection resulting in progressive multifocal leukoencephalopathy*
Menitorix will only confer protection against Haemophilus influenzae type b and Neisseria meningitidis group C.
Menitorix is a freeze-dried vaccine preparation consisting of 5µg of the purified H. influenzae type b capsular polysaccharide, polyribosylribitol phosphate (PRP) and 5µg of the meningococcal capsular polysaccharide of group C (PSC) both directly conjugated to tetanus toxoid (TT) carrier protein.
Menitorix should under no circumstances be administered intravascularly, intradermally or subcutaneously.
Amenorrhea, breast pain, dysmenorrhea, menorrhagia, menstrual disorder, vaginal disorder
During 1996 the number of e-mail messages exchanged by EMEA with the outside world averaged approximately 2 000 per month (1 40 Mbytes).
It may harm them, even if their symptoms are the same as yours. − If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
It may harm them, even if their symptoms are the same as yours. − If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
leaflet, please tell your doctor or pharmacist.
please tell your doctor or pharmacist
please tell your doctor or pharmacist.
please tell your doctor or pharmacist
please tell your doctor or pharmacist.
please tell your doctor or pharmacist.
please tell your doctor or pharmacist.
please tell your doctor or your pharmacist
please tell your doctor or your pharmacist.
tell your doctor or pharmacist.
please tell your doctor/health care professional.
ed please tell your doctor or pharmacist.
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
It may harm them, even if their symptoms are the same as yours.  If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell you doctor or pharmacist.
It may harm them, even if their symptoms are the same as yours. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
leaflet, please tell your doctor or pharmacist.
please tell you doctor or pharmacist.
please tell your doctor of pharmacist.
please tell your doctor or pharmacist.
please tell your doctor or pharmacist
please tell your doctor or pharmacist.
please tell your doctor or pharmacist.
please tell your doctor or pharmacist.
please tell your doctor or pharmacist.
please tell your doctor or pharmacist.
please tell your doctor or your pharmacist.
please tell your doctor or your pharmacist.
tell your doctor or pharmacist.
tell your doctor or pharmacist.
tell your doctor or pharmacist.
tell your doctor or pharmacist.
your doctor or pharmacist.
your doctor or pharmacist.
please tell your doctor or radiologist.
please tell your doctor or pharmacist.
please tell your doctor or pharmacist.
please tell your doctor or pharmacist.
please tell your doctor or health care professional.
please tell your doctor or pharmacist.
tell your doctor or pharmacist.
PARTICULARS TO APPEAR ON THE INNER SIDE OF THE LID OF THE CARTON IN FORM OF A PICTOGRAMM
66 PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING
85 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
MINIMUM PARTICULARS TO APPEAR ON AMPOULES
STATEMENT OF THE MRLs
STATEMENT OF THE MRLs
STATEMENT OF THE MRLs gA tin ker Ma
STATEMENT OF THE MRLs od Pr al
STATEMENT OF THE MRLs
STATEMENT OF THE MRLs
Please read the instructions carefully and follow them step by step.
Merck AB S-195 87 Stockholm Tel: +46-8-562 445 00
Merck AB Strandvejen 102 B, 4th DK-2900 Hellerup Tlf: +45 35253550
Merck NM AB Ynglingagatan 14 11347, Post Box 23033 SE-10435 Stockholm
Merck NM AB Ynglingagatan 14 11347, Post Box 23033 SE-10435 Stockholm Sweden
Dunajska cesta 119 SI-1000 Ljubljana Tel: +386 1 560 3 800
Merck Sharp & Dohme Bulgaria EOOD 55 Nikola Vaptzarov blvd.
Merck Sharp & Dohme BV - Chaussée de Waterloo 1135 - B-1180 Brussels Belgium
Merck Sharp & Dohme BV - Chaussée de Waterloo 1135 - B-1180 Brussels, Belgium
Merck Sharp & Dohme BV - Chaussée de Waterloo 1135 - B-1180 Brussels Belgium
Merck Sharp & Dohme BV - Chaussée de Waterloo 1135 - B-1180 Brussels, Belgium
Merck Sharp & Dohme BV - Chaussée de Waterloo 1135 B-1180 Brussels Belgium
Merck Sharp & Dohme BV PO Box 581 NL-2003 PC Haarlem The Netherlands
Merck Sharp & Dohme BV, Postbus 581, 2003 PC, Haarlem The Netherlands
Merck Sharp & Dohme BV, Postbus 581, 2003 PC, Haarlem The Netherlands
BOX 581, 2003 PC Haarlem The Netherlands
Merck Sharp & Dohme B. V Arcoxia Waarderweg 39 Post Bus 581 2003 PC Haarlem The Netherlands
Merck Sharp & Dohme B. V Waarderweg 39 Post Bus 581 2003 PC Haarlem The Netherlands
Merck Sharp & Dohme (Middle East) Limited., Tel: +357 22866700Nederland:
Merck Sharp & Dohme OÜ Peterburi tee 46, Tallinn 11415, Estonia
Merck Sharp & Dohme OÜ Peterburi tee 46, Tallinn 11415, Estonia
Merck Sharp & Dohme OÜ Peterburi tee 46 11415 Tallinn Estonia
Merck Sharp & Dohme OÜ Peterburi tee 46 11415 Tallinn Estonia
Merck Sharp & Dohme PO Box 581 2003 PC Haarlem The Netherlands
Merck Sharp & Dohme PO Box 581 2003 PC Haarlem The Netherlands
MSD BV Waarderweg 39 2031 BN Haarlem The Netherlands
The Merck Sharp & Dohme Netherlands PO Box 581 2003 PC Haarlem The Netherlands
Merck Sharp & Dohme Romania S. R. L., Tel: + 4021 529 29 00 Slovenija:
Merck Sharp & Dohme Romania S. RL., Tel: + 4021 529 29 00 Slovenija:
Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 (0) 8 626 1400 medicinskinfo@merck. com
Merck Sherp & Dohme Chaussée de Waterloo 1135 B-1180 Brussels Belgium
Thiomersal................................................................................................................................. ..0.20 mg Adjuvant:
Thiomersal................................................................................................................................. ..0.20 mg Adjuvant:
MERIAL, 29 avenue Tony Garnier, 69007 Lyon, France.
MERIAL 29 avenue Tony Garnier FR-69007 Lyon France.
MERIAL, 29 avenue Tony Garnier, FR-69007 Lyon, France.
4 Chemin de Calquet 31300 Toulouse France
Merial, Laboratory of Lyon Gerland 254, Avenue Marcel Mérieux, 69007 Lyon, France
Merial, Laboratory of Lyon Gerland 254, Avenue Marcel Mérieux, 69007 Lyon, France
Merial Laboratory of Lyon Porte des Alpes Rue de l'aviation 69800 SAINT-PRIEST France
MERIAL Laboratory of Lyon Porte des Alpes Rue de l'Aviation, 69800 Saint-Priest France
MERIAL Laboratory of Lyon Porte des Alpes Rue de l'Aviation, 69800 Saint-Priest France
Name and address of the manufacturer(s) of the biological active substance(s) Merial Laboratory of Lyon Porte des Alpes Rue de l'aviation 69800 SAINT-PRIEST France
Merial Laboratoire Porte des Alpes Rue de l'Aviation F-69800 Saint Priest France
Merial, Laboratoire Porte des Alpes Rue de l'Aviation, F-69800 Saint Priest, France
MERIAL, Laboratoire Porte des Alpes, Rue de l'Aviation, F-69800 Saint Priest, France
MERIAL, Laboratoire Porte des Alpes, Rue de l'Aviation, F-69800 Saint Priest, France
Mérial Laboratoire Lyon Gerland, 254 rue Marcel Merieux 69007 Lyon France
Mérial Laboratoire Porte des Alpes Rue de l'Aviation 69800 Saint Priest France
{Name and Address }< {tel }> < {fax }> < {e-mail }>
Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 60318 Frankfurt/ Main
Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 60318 Frankfurt/ Main Germany
{Name and address }< {tel }> < {fax }> < {e-mail }>
Measuring the dose of IntronA Remove the cap from the vial.
Blood glucose testing Parenteral medicinal products containing maltose can interfere with the readings of blood glucose monitors that use test strips with glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ).
As measured by immersing the diffuser into the cuvette in the power meter and slowly increasing the laser power.
Creatine kinase measurement and interpretation:
measures and specific obligations 2000-2002
Measure 23 ml of water by filling the measuring cup (included in the carton) to the top of the
Caution: please remember that artificial sweeteners and foods with artificial sweeteners (e.g. diet drinks) are of no help in hypoglycaemia.
Human antibodies undergo endocytotic digestion in the cells of the reticuloendothelial system.
No dose adjustment is necessary in patients known to be CYP2C9 poor metabolisers (see section 5.2).
Metabolism After a single dose of 5 g of sodium phenylbutyrate, in the form of granules, measurable plasma levels of phenylacetate and phenylacetylglutamine are detected 30 and 60 minutes respectively after dosing.
Metabolism The main circulating metabolite in humans is the N-demethylated piperazine derivative, which shows similar in vitro potency to the parent.
Metabolism Degarelix is subject to common peptidic degradation during the passage of the hepato-biliary system and is mainly excreted as peptide fragments in the faeces.
Connective tissue metabolism Somatropin stimulates the synthesis of chondroitin sulphate and collagen as well as the urinary excretion of hydroxyproline.
As a peptide, enfuvirtide is expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool.
Nutrition Disorders
Metabolism: capecitabine is first metabolised by hepatic carboxylesterase to 5'-DFCR, which is then converted to 5'-DFUR by cytidine deaminase, principally located in the liver and tumour tissues.
24 Metabolism Metformin is excreted unchanged in the urine.
This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree.
This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser
21 Metabolism Aprepitant undergoes extensive metabolism.
Metabolism: entecavir is not a substrate, inhibitor or inducer of the CYP450 enzyme system.
Metabolism Prasugrel is not detected in plasma following oral administration.
27 Human insulin is reported to be degraded by insulin protease or insulin-degrading enzymes and possibly protein disulfide isomerase.
27 Metabolism Human insulin is reported to be degraded by insulin protease or insulin-degrading enzymes and possibly protein disulfide isomerase.
34 Human insulin is reported to be degraded by insulin protease or insulin-degrading enzymes and possibly protein disulfide isomerase.
34 Metabolism Human insulin is reported to be degraded by insulin protease or insulin-degrading enzymes and possibly protein disulfide isomerase.
41 Human insulin is reported to be degraded by insulin protease or insulin-degrading enzymes and possibly protein disulfide isomerase.
41 Metabolism Human insulin is reported to be degraded by insulin protease or insulin-degrading enzymes and possibly protein disulfide isomerase.
Metabolism Human insulin is reported to be degraded by insulin protease or insulin-degrading enzymes and possibly protein disulfide isomerase.
Metabolism Human insulin is reported to be degraded by insulin protease or insulin-degrading enzymes and Me
Metabolism: bexarotene metabolites in plasma include 6- and 7-hydroxy-bexarotene and 6- and 7-oxo- bexarotene.
Metabolism A small amount of entacapone, the (E)-isomer, is converted to its (Z)-isomer.
- 24.09.1999 - 21.09.2000 - 176 days - 215 days
Metacresol, sodium dihydrogen phosphate dihydrate, glycerol, sodium hydroxide, hydrochloric acid (for pH adjustment), water for injections.
Metacresol, sodium dihydrogen phosphate dihydrate, glycerol, sodium hydroxide, hydrochloric acid (for pH adjustment), water for injections.
Metalyse 10,000 units 1 vial contains 10,000 units (50 mg) tenecteplase.
Metalyse 8,000 U Powder and solvent for solution for injection Tenecteplase
Metalyse 8,000 U Powder for solution for injection.
Metalyse 6,000 units 1 vial contains 6,000 units (30 mg) tenecteplase.
Metalyse 6,000 U Powder and solvent for solution for injection Tenecteplase
Metalyse 8,000 units 1 vial contains 8,000 units (40 mg) tenecteplase.
Metalyse caused significantly less non-intracranial (non-brain) major bleedings than alteplase, which meant that there was less need for blood transfusions.
METALYSE is given by a single injection into a vein by a doctor who is experienced in the use of this type of drug.
Metalyse is incompatible with dextrose solution.
Metalyse is incompatible with dextrose infusion solutions.
METALYSE is a powder and solvent for solution for injection.
Metalyse is used within 6 hours of the first symptoms of the heart attack.
Metformin Combinations not recommended There is increased risk of lactic acidosis in acute alcohol intoxication (particularly in the case of fasting, malnutrition or hepatic insufficiency) due to the metformin active substance of Icandra (see section 4.4).
Metformin Combinations not recommended There is increased risk of lactic acidosis in acute alcohol intoxication (particularly in the case of fasting, malnutrition or hepatic insufficiency) due to the metformin active substance of Zomarist (see section 4.4).
In patients with chronic hepatitis C that were on stable methadone maintenance therapy and naïve to peginterferon alfa-2b, addition of 1.5 microgram/kg/week of PegIntron subcutaneously for 4 weeks increased R-methadone AUC by approximately 15% (95% Cl for AUC ratio estimate 103 – 128%).
In patients with chronic hepatitis C that were on stable methadone maintenance therapy and naïve to peginterferon alfa-2b, addition of 1.5 microgram/kg/week of PegIntron subcutaneously for 4 weeks increased R-methadone AUC by approximately 15% (95% Cl for AUC ratio estimate 103 – 128%).
In patients with chronic hepatitis C that were on stable methadone maintenance therapy and naïve to peginterferon alfa-2b, addition of 1.5 microgram/kg/week of ViraferonPeg subcutaneously for 4 weeks increased R-methadone AUC by approximately 15% (95% Cl for AUC ratio estimate 103 – 128%).
Methadone, stable maintenance dose (atazanavir 400 mg QD) SEDATIVES Benzodiazepines
Methadone/ Emtricitabine HERBAL PRODUCTS
Co-administration of nelfinavir 1250 mg BID with methadone 80 +/ - 21 mg once a day in HIV negative methadone maintenance patients resulted in a 47% decrease in methadone AUC.
Co-administration of nelfinavir 1250 mg BID with methadone 80 +/- 21 mg once a day in HIV negative methadone maintenance patients resulted in a 47% decrease in methadone AUC.
Method of administration The total daily dose may be divided in two or three doses according to patient's convenience.
Method and route of administration of Ceftriaxone Tyrol Pharma 1g powder for solution for injection/ infusion
contraindicated Remicade has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see Section 5.1).
As to where Methoxasol-T is also authorised in Austria, Poland, Hungary, and Lithuania, these marketing authorisations have been included in the scope of the procedure.
Methoxasol, oral solution for pigs and broilers.
Methylhydroxypropylcellulose, Talc Yellow iron oxide (E 172) Ethylcellulose Titanium dioxide (E 171) Triacetin Sodium lauryl sulfate
Metoprolol Concomitant administration of venlafaxine and metoprolol to healthy volunteers in a pharmacokinetic interaction study for both medicinal products resulted in an increase of plasma concentrations of metoprolol by approximately 30-40% without altering the plasma concentrations of its active metabolite, α -hydroxymetoprolol.
Par- and Dysaesthesia Hypoaesthesia Tremor Seizures (see section 4.4) Vertigo
• put in place effective monitoring so that the Board is well informed about the performance of the Agency and the system as a whole
Mexiletine Simultaneous administration of ciprofloxacin and mexiletine can lead to increased plasma concentrations of mexiletine.
Mexiletine Simultaneous administration of ciprofloxacin and mexiletine can lead to increased plasma concentrations of mexiletine.
There were also concerns with regards to psychiatric reactions and bleeding disorders related to the use of sibutramine.
10.0 10.3 10.0 9.8 9.7 9.6 9.5 9.5 9.4 9.4 9.4 9.3
MicardisPlus 80 mg/ 25 mg tablets telmisartan/ hydrochlorothiazide
MicardisPlus 80 mg/ 25 mg tablets telmisartan/ hydrochlorothiazide
MicardisPlus is not indicated in patients with severe hepatic impairment.
cancer, gout, or arthritis, and vitamin D supplements.
Michael RUTTER Director and Chief Executive Veterinary Medicines Directorate Woodham Lane New Haw, Addlestone Surrey KT15 3LS United Kingdom Tel.
A detailed review of training needs and the provision of training was undertaken during the year to improve the opportunities available to staff members.
Perflutren -containing microspheres, 5-8 x 108/ ml with a mean diameter range of 2.5 - 4.5 µm.
microspheres and loss of contrast effect.
- Painful urination with blood in the urine
discomfort in passing urine); central nervous system signs (incoordination, disorientation)
Micturition frequency, polyuria Renal failure*, renal insufficiency* Nephrotic syndrome*
Midazolam 7.5 mg Single Dose (maraviroc 300 mg BID) HERBAL PRODUCTS
Midazolam and other benzodiazepines metabolised by CYP3A4:
Eagles Earles Minimal Essential Medium with Hepes buffer and Lactalbumin hydrolysate
John's wort (Hypericum perforatum):
John's wort (Hypericum perforatum)/ Emtricitabine
John's wort (Hypericum perforatum)/ Tenofovir disoproxil fumarate
John's wort (unboosted saquinavir) Other potential interactions
John’s wort (unboosted saquinavir) Other potential interactions
Mimpara brought about a 42% reduction in PTH levels compared with an increase of 8% in patients taking placebo.
Mimpara is used in patients with serious kidney disease who need dialysis to clear their blood of waste products.
Minor, including tooth extraction
pharmaceuticals Minimising the risk of transmitting animal spongiform
The effect of renal impairment on the absorption of inhaled human insulin has not been studied (see section 4.2).
3 tablets MIRAPEXIN 0.18 mg OR 6 tablets MIRAPEXIN 0.088 mg
What MIRAPEXIN looks like and contents of the pack MIRAPEXIN 0.18 mg tablets are white, oval, flat, embossed with a code.
MIRAPEXIN can be taken with or without food.
tablets (see Section 6, “ Further information”).
MIRCERA 1000 micrograms/ml solution for injection methoxy polyethylene glycol-epoetin beta
MIRCERA 200 micrograms/ml solution for injection methoxy polyethylene glycol-epoetin beta
MIRCERA 400 micrograms/ml solution for injection methoxy polyethylene glycol-epoetin beta
MIRCERA 600 micrograms/ml solution for injection methoxy polyethylene glycol-epoetin beta
MIRCERA should be used with caution in patients who have severe problems with their liver.
MIRCERA is indicated to treat only the symptomatic anaemia caused by chronic kidney disease.
MIRCERA is not approved for the treatment of anaemia in patients with cancer.
MIRCERA stimulates erythropoiesis by interaction with the erythropoietin receptor on progenitor cells in the bone marrow.
Pregnancy warning Lenalidomide is structurally related to thalidomide.
METHOD AND ROUTE(S) OF ADMINISTRATION od
Shake the closed bottle of constituted suspension for approximately 10 seconds before each use.
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovenia and Slovak Republic), the purpose of PERF II is help candidate countries prepare their regulatory systems before
Management and organisation of the CPMP Provision is made for the Committee for Proprietary Medicinal
implications: • Continuation of the overhaul of human resource management at the EMEA, including rules regarding part-time working,
Safety of medicinal products for human and veterinary use
Implement upgrades to customised applications as required by new releases of the underlying proprietary applications
Read the package insert before use.
4.4 Special warnings
4.4 Special warnings and precautions for use
Reversible Posterior Leukoencephalopathy Syndrome (rare) (see also section 4.4 Special warnings and precautions for use)
Special Warnings and Special Precautions for Use - "Malignancies").
Hypersensitivity to the active substance or to any of the excipients
To contribute to the protection and promotion of public and animal health by:
Invented Names Review Group The group was established in November 1999 upon request of the CPMP and is composed of representatives of the Member States, the European Commission and EMEA.
Mitratapide 5 mg/ ml Butylated hydroxyanisole (E 320) Yarvitan is a colourless to slightly yellow solution.
Mixtard 10 NovoLet is a simple, compact pre-filled pen.
Mixtard 30 FlexPen 100 IU/ ml suspension for injection in a pre-filled pen.
Mixtard is supplied in vials, cartridges (PenFill) or pre-filled pens (NovoLet, FlexPen or InnoLet).
Mixtard is a mixture of fast-acting insulin and long- acting insulin.
Mixtard is a mixture of dissolved insulin and isophane (NPH) insulin.
Mixtard should not be disposed of via wastewater or household waste.
Ms Nuttall then served with the Food and Agriculture Organisation of the United Nations for five years before joining the EMEA in May 1995.
{MM/ YYYY} This leaflet is changed from time to time.
Ms Fayl held various positions as a documentalist in several European countries, the latest from 1988 to 1995 setting up and running the documentation service in the European Commission Delegation in Norway.
Mme Mariette BACKES-LIES Inspecteur Chef de Division Laboratoire Nationale de Santé 10 rue C.M.
Bachelor of Commerce from University College Dublin.
Ms Nuttall held several posts in the Irish Civil Service, serving in the Departments of Health, Finance and the Office of Public Works.
Ms Nuttall held several posts in the Irish Civil Service, serving in the Departments of Health, Finance and the Office of Public Works.
Ms Nuttall then served with the Food and Agriculture Organisation of the United Nations from 1990 to 1995.
Mrs Saara REINIUS Director-General Ministry of Agriculture and Forestry, Veterinary and Food Department P.O.
- peripheral blood stem cell mobilisation.
- Mobilisation of peripheral blood progenitor cells (PBPC).
Peripheral blood stem cell mobilisation
Mobilisation of PBPC
In case of administration by a non health care professional appropriate training is needed.
Method of administration Aprovel is for oral use.
Method of administration The vaccine is intended for oral use.
Method of administration CoAprovel is for oral use.
Administration Dissolve the preparation as described in section 6.6.
Method of administration It is recommended that the oral daily dose of Advagraf be administered once daily in the morning.
Method of administration It is recommended that the oral daily dose be administered in two divided doses (e. g. morning and evening).
Method of administration It is recommended that Atripla be swallowed whole with water.
Method of administration It is recommended that you take the tablets with some water.
Method of administration Directly after removal from the pack and the release liner, the patch is applied to a non-hairy area of skin on the upper body (chest, back, upper arm).
2 Method of administration The hard capsule should be swallowed whole.
Method of administration The hard capsule should be swallowed whole.
Method of administration Cholestagel tablets should be taken orally with a meal and liquid.
Method of administration Transdermal patches should be applied once a day to clean, dry, hairless, intact healthy skin on the upper or lower back, upper arm or chest, in a place which will not be rubbed by tight clothing.
Method of administration
Method of administration Raptiva is for subcutaneous injection.
Administration Reconstitute the preparation as described in section 6.6.
Method of administration STELARA is for subcutaneous injection.
Method of administration Tasmar is administered orally three times daily.
INSTRUCTIONS FOR USE/ HANDLING
Instructions for use You must not use the bottle if the tamper-proof seal on the bottle neck is broken before you first use it.
METHOD AND, IF NECESSARY, ROUTE(S) OF ADMINISTRATION ct
METHOD AND, IF NECESSARY, ROUTE(S) OF ADMINISTRATION ct du
Method and route of administration 2 For epilesional use.
Method and route of administration Swallow your capsules whole with a glass of water.
Method and route of administration Raptiva is injected just under the skin (subcutaneous).
Method of administration Yttriga is intended for radiolabelling of medicinal products to treat specific diseases, which are subsequently administered by approved route.
METHOD AND ROUTE(S) OF ADMINISTRATION
Packaging: • 5-dose bottle, box of 1 bottle. • 5-dose bottle, box of 10 bottles. • 10-dose bottle, box of 1 bottle. • 10-dose bottle, box of 10 bottles. • 25-dose bottle, box of 1 bottle. • 25-dose bottle, box of 10 bottles
The website, which can be found at http://www.eudra.org/emea.html, was widely used for dissemination purposes in 1996 contained over 200 documents covering general EME A information, scientific committee press releases, SOPs, guidelines, EPARs and newsletters.
Dose modification of gemcitabine within a cycle for bladder cancer, NSCLC and pancreatic cancer, given in monotherapy or in combination with cisplatin
Dose adjustment for adverse reactions
Insulin that you inject in such a site may not work very well.
Modification of dose and regimen Continue to monitor the patient with clinical examination.
- changes in the blood cell count (which may result in symptoms such as tiredness, fainting,
Currently paroxetine is not authorised for use in
Mean1/ Median2 percent change from baseline
* Mean change from baseline to last assessment.
These can be seen in the results of
These can be seen in the results from
- changes in heart rate (e. g. slow beating) or abnormality of electrocardiogram (ECG),
Modif ied release oral and transdermal dosage forms:
No changes in methadone dosage were required based on clinical status during or after the period of INTELENCE co-administration.
Selective Oestrogen Receptor Modulator.
example through incorrect storage,
example through incorrect storage,
< EXP {month/year} > Once broached, use within 3 hours.
EXP {month/ year} Once broached, use within 3 hours.
< EXP {month/year} > Once broached, use within 3 hours. tin
EXP: month/ year Once broached, use within 6 months.
Month/ Year Once broached, use within 8 weeks
Month\Year Once broached, use within 8 weeks
EXP {month/ year} Once broached, use within 3 hours.
Moisés ABASCAL ALONSO, Yann LE CAM, Vice-chairman, Alastair KENT
Mommaertslaan, 14 1831 Machelen (Diegem)
BM = bone marrow, PB = peripheral blood 2 Cytogenetic response criteria:
• Product information • Physician information about Tysabri • Patient alert card
edetate disodium, sodium chloride, m-cresol, polysorbate 80 and water for injections. no
monohydrate, edetate disodium, sodium chloride, m-cresol, polysorbate 80 and water for injections.
What Viraferon looks like and contents of the pack t uc
What Viraferon looks like and contents of the pack t uc
dihydrogen phosphate dihydrate, glycerol, sodium hydroxide, hydrochloric acid (for pH adjustment) and water for injections.
phosphate dihydrate, glycerol, sodium hydroxide, hydrochloric acid (for pH adjustment) and water for injections.
Attach the reconstitution needle to the syringe, with the syringe in
 Show this card to any doctor involved in your treatment.  See the Enbrel package leaflet for more information.
Prior to Humira treatment: • Humira should not be used if you have moderate to severe heart failure.
Moraxella catarrhalis * Neisseria meningitidis Pasteurella spp.
Equianalgesic doses (mg) Active substance Parenteral (im) Oral Morphine Hydromorphone Oxycodone Methadone Levorphanol Oxymorphine Diamorphine Pethidine Codeine Buprenorphine Ketobemidone
Overall study mortality Mortality during study therapy Mortality attributed to Candida infection
high levels of sugar in the blood
reaction including blisters (Stevens Johnson syndrome)
5 GROUNDS FOR AMENDMENT OF THE PRODUCT INFORMATION
Grounds for amendments of the Summaries of Products Characteristics, labelling and Package leaflet
The Summary of Products Characteristic, labelling and package leaflet proposed by the applicant has been assessed based on the documentation submitted and the scientific discussion within the Committee. the CHMP has recommended the granting of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Lansoprazol ratiopharm and associated names (see Annex I).
Reasons for rejection of financial transactions 1997-2000
GROUNDS FOR MAINTAINING THE MARKETING AUTHORISATION OF HEXAVAC
GROUNDS FOR THE REMOVAL OF THE THERAPEUTIC INDICATION “ ACUTE AND CHRONIC COMPLICATED PYELONEPHRITIS”
This finding is maintained even when reports with interacting drugs are excluded.
GROUNDS FOR WITHDRAWAL OF THE MARKETING AUTHORISATIONS Whereas,
This will usually pass on its own but if it does not, tell your doctor.
- uncontrolled movements (dyskinesias), worsening of Parkinson's symptoms
MRCVS, studied for MSc at the Veterinary School of the University of Edinburgh.
MRLs for old substances........................................................................ ..44
MSD Magyarország Kft, Tel: + 36.1.888.5300 Malta:
Norge MSD (Norge) AS, Tlf: +47 32 20 73 00 msdnorge@msd. no
MSD Sharp & Dohme GmbH Lindenplatz 1 85540 Haar Germany
Deutschland MSD SHARP & DOHME GmbH, Tel: +49 (0) 89 4561 2612 Infocenter@msd. de
Deutschland MSD SHARP & DOHME GMBH Tel: +49 (0) 89 4561 2612 Infocenter@msd. de
• Mucopolysaccharidosis type VI (Maroteaux-Lamy Syndrome)
Treatment of acute promyelocytic leukaemia
Specific operational objectives for 2003 include:
- Musculoskeletal: muscle or joint pain, tendinitis, ruptured tendon (see “ Contra-
Events of special clinical interest Skeletal muscle: effects on the skeletal muscle, e.g. musculoskeletal pain including arthralgia, muscle cramps, myalgia, muscle weakness and elevated CK levels have been reported in clinical trials.
Musculo- skeletal pain Muscle tightness Muscle spasm
Syncope2 Orthostatic hypotension2 Blood pressure increase Peripheral coldness
The blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.
Injury, Poisoning and procedural ina
Mutagenicity In vitro and in vivo tests did not indicate a genotoxic potential of tacrolimus.
Mutagenicity and carcinogenic potential Zoledronic acid was not mutagenic in the mutagenicity tests performed and carcinogenicity testing did not provide any evidence of carcinogenic potential.
MVB, admitted to membership of the Royal College of Veterinary Surgeons.
Myalgia Arthralgia Joint disorder Osteoarthritis General disorders:
Myalgia Arthralgia, back pain (e. g. sciatica), muscle cramps, pain in limb, weakness
Myalgia Muscle twitching Muscular weakness Back pain
Myalgia, rarely myolysis, arthralgia, elevated creatine phosphokinase
back pain, pain in extremities such as fingers and toes
Mycograb was to be used together with amphotericin B (another antifungal medicine) to treat adult patients with invasive candidiasis.
Mycophenolate mofetil Teva 250 mg hard capsules are available in PVC/ PVdC -aluminium blisters in pack sizes of 100 or 300 capsules per carton.
Mycophenolate mofetil Teva 250 mg hard capsules Mycophenolate mofetil
Mycophenolate mofetil Teva 250mg hard capsules Mycophenolate mofetil
Mycophenolate mofetil Teva 500 mg film-coated tablets Mycophenolate mofetil
Mycophenolate mofetil Teva 500mg film-coated tablets Mycophenolate mofetil
Mycophenolate mofetil Teva 500mg film-coated tablets Mycophenolate mofetil
Mycophenolate mofetil Teva is a medicine that is used to suppress immune activity.
Mycophenolate mofetil Teva tablets should only be prescribed to patients with a body surface area greater than 1.5 m2, at a dose of 1 g twice daily (2 g daily dose).
Mycophenolate mofetil Teva film-coated tablets should be handled with care.
Mycophenolate mofetil Teva is contraindicated in women who are breast-feeding (see section 4.6).
Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, Mycophenolate mofetil Teva is contraindicated in breast-feeding mothers (see section 4.3).
Mycophenolate mofetil Teva is an inosine monophosphate dehydrogenase (IMPDH) inhibitor.
Mycophenolate mofetil Teva is a ‘ generic medicine’.
Mycophenolate mofetil Teva is used to prevent the body from rejecting a transplanted kidney, heart or liver.
Mycophenolate mofetil Teva is used to prevent your body rejecting a transplanted kidney, heart or liver.
Mycophenolate mofetil Teva capsules should be handled with care.
Mycophenolate mofetil Teva should be used in pregnant women only if the potential benefit outweighs the potential risk to the foetus.
Mycophenolate mofetil Teva reduces your body's defence mechanism.
Myeloma IgG Myeloma IgA Myeloma light chain Median duration since diagnosis (yrs) Chromosome 13 abnormalities
• Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. • Children with congenital AIDS and recurrent infections.
Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.
Myeloma or chronic lymphocytic leukaemia (CLL) with severe secondary hypogammaglobulinemia and recurrent infections.
Bone marrow depression, Agranulocytosis, Leucopenia, Neutropenia, Thrombocytopenia, Haemolytic anaemia Anaemia, Lymphadenopathies
Myfenax 500 mg film-coated tablets Mycophenolate mofetil
Myfenax 500mg film-coated tablets Mycophenolate mofetil
Mylan BV Dieselweg 25, 3752 LB, Bunschoten The Netherlands
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
Myocet can not be used in pregnancy and women receiving Myocet should not breast-feed.
Skeletal muscle relaxants, nondepolarizing (e. g., tubocurarine) Possible increased responsiveness to the muscle relaxant.
Myozyme has been studied in two main studies involving a total of 39 babies and infants with Pompe disease.
Myozyme is indicated for long-term enzyme replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid α -glucosidase deficiency).
Enzyme replacement therapy provides patients with the enzyme they are lacking.
Myozyme is used to treat patients who have a confirmed diagnosis of Pompe disease.
As Myozyme does not contain a preservative, each vial of Myozyme is for single use only.
As Myozyme does not contain a preservative, each vial of Myozyme is for single use only.
2 Replaced Dietrich HENSCHLER as of the 22 February 2000 meeting.
N03AX17 In animal models, stiripentol antagonizes seizures induced by electric shock, pentetrazole and bicuculline.
N03AX17 In animal models, stiripentol antagonizes seizures induced by electric shock, pentetrazole and bicuculline.
n=123; Mean=100.0; Median=58.0; Range=9-1192
(N=18) 18 (100)* 18 (100)*
N ≥ 90% improvement ≥ 75% improvement ≥ 50% improvement PGA of cleared (0) or minimal (1) PGA of cleared (0), minimal (1), or mild (2) All nails cleared c
E-28750 San Agustín de Guadalix – Madrid Tel: + 34-91 848 85 00 t
E-28750 San Agustín de Guadalix – Madrid Tel: + 34-91 848 85 00 t
E-28750 San Agustín de Guadalix – Tel: + 34-91 848 85 00
Nacional I E-28 750 San Agustín de Guadalix - Madrid Tel: + 34-91 848 85 00
Under no circumstances should Liprolog Mix25 be given intravenously.
Naglazyme 1 mg/ ml concentrate for solution for infusion Galsulfase
Naglazyme 1 mg/ ml concentrate for solution for infusion Galsulfase
Naglazyme 1 mg/ ml concentrate for solution for infusion.
Naglazyme has been authorised under ‘ Exceptional Circumstances’.
Naglazyme helps to break down the GAGs and stop them building up in the cells.
Naglazyme is given as a four-hour infusion once a week.
Naglazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis VI (MPS VI; N-acetylgalactosamine 4-sulfatase deficiency).
Naglazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis VI (MPS VI; N-acetylgalactosamine 4-sulfatase deficiency; Maroteaux-Lamy syndrome) (see section 5.1).
Naglazyme is an enzyme replacement therapy.
Naglazyme is used to treat patients who have mucopolysaccharidosis VI (MPS VI or Maroteaux-Lamy syndrome).
Naglazyme should not be mixed with other medicinal products in the same infusion, except for those mentioned below.
Naglazyme was more effective than placebo.
(NaH2PO4.2 H2O) and water for injections.
No other medicines should be added to the solution containing Raptiva and Raptiva should not be reconstituted with other solvents. • Turn the vial upside down, with the syringe still attached.
Do not add any other insulin to the cartridge.
Do not breast-feed if you are receiving Cubicin, because it may pass into your breast milk and could affect the baby.
- has not been gaining weight and growing as expected.
Do not apply other ointments, creams or lotions to the area being treated with Altargo unless specifically instructed to do so by your doctor.
Do not apply the cream more than once per day.
Do not push in the injection button while setting your dose.
Do not stop Apidra without speaking to a doctor, who will tell you what needs to be done.
Do not stop Apidra without speaking to a doctor, who will tell you what needs to be done.
Don’t stop taking Hepsera without your doctor’s advice.
• Don’t stop taking Viread without your doctor’s advice.
Do not stop Insulin Human Winthrop Basal without speaking to a doctor, who will tell you what needs to be done.
Do not stop Insulin Human Winthrop Comb 15 without speaking to a doctor, who will tell you what needs to be done.
Do not stop Insulin Human Winthrop Comb 25 without speaking to a doctor, who will tell you what needs to be done.
Do not stop Insulin Human Winthrop Comb 50 without speaking to a doctor, who will tell you what needs to be done.
Do not stop Insulin Human Winthrop Infusat without speaking to a doctor, who will tell you what needs to be done.
Do not stop Insulin Human Winthrop Rapid without speaking to a doctor, who will tell you what needs to be done.
Do not stop Insulin Human Winthrop Rapid without speaking to a doctor, who will tell you what needs to be done.
Do not stop Insuman Basal without speaking to a doctor, who will tell you what needs to be done.
Do not stop Insuman Comb 15 without speaking to a doctor, who will tell you what needs to be done.
Do not stop Insuman Comb 25 without speaking to a doctor, who will tell you what needs to be done.
Do not stop Insuman Comb 50 without speaking to a doctor, who will tell you what needs to be done.
Do not stop Insuman Infusat without speaking to a doctor, who will tell you what needs to be done.
Do not stop Insuman Rapid without speaking to a doctor, who will tell you what needs to be done.
Do not stop Insuman Rapid without speaking to a doctor, who will tell you what needs to be done.
Do not stop Lantus without speaking to a doctor, who will tell you what needs to be done.
Do not stop Lantus without speaking to a doctor, who will tell you what needs to be done.
Do not stop treatment with Zeffix without your doctor’s advice.
Do not stop Optisulin without speaking to a doctor, who will tell you what needs to be done.
Do not stop using ReFacto AF without consulting your doctor.
Do not stop your Avonex treatment without speaking to your neurologist.
Do not stop your Avonex treatment without speaking to your neurologist.
Do not stop taking your medicine without first talking to your doctor.
Do not stop taking your medicine unless you have discussed this with your doctor first.
Hepatobiliary disorders
NA-Salicylaat, 100%, powder for solution for oral administration
NA-SALICYLAAT, 100%, powder for solution for oral administration
nationally - in particular polyoxyethylene hydrogenated castor oil or similar substances. >
Gastrointestinal disorders Nausea, constipation, upper abdominal pain, vomiting, dyspepsia and diarrhoea
Nausea; Diarrhoea; Vomiting; Constipation; Stomatitis; Dyspepsia; Abdominal pain
- nausea, vomiting, diarrhoea, stomach pain
Nausea Vomiting Anorexia Constipation Stomatitis/ pharyngitis
Nausea, vomiting, diarrhoea, dyspepsia, abdominal pain Gastric ulcer
Nausea, vomiting, abdominal pain, abnormal stools, dyspepsia, flatulence, gastrointestinal disorder
Naxcel has the benefit of a long duration of activity.
Abbreviations: # subj: number subjects; SC: seroconversion; SN: sero-neutralisation; No sAE: no serious AE; (*) tested in 322 subjects
NC = F, noncompleter = failure. b EFV, efavirenz; ZDV, zidovudine; 3TC, lamivudine; IDV, indinavir; NRTI, nucleoside reverse transcriptase inhibitor; NFV, nelfinavir. c C. I., confidence interval for proportion of patients in response. d S. E. M., standard error of the mean. ---, not performed.
NC = F, noncompleter = failure. b C. I., confidence interval. c S. E. M., standard error of the mean. d EFV, efavirenz; ZDV, zidovudine; 3TC, lamivudine; IDV, indinavir.
S. E. M., standard error of the mean. d EFV, efavirenz; ZDV, zidovudine; 3TC, lamivudine; IDV, indinavir.
ZDV + 3TC a NC = F, noncompleter = failure. b C. I., confidence interval. c
However findings were only seen at exposure levels considered being higher than the maximum human exposure, indicating limited relevance to clinical use.
However, in one of these trials, a fixed-dose trial, there was a significant dose response relationship for cerebrovascular adverse events in patients treated with aripiprazole.
However, large quantities of grapefruit juice (over 1.2 l daily for 5 days) increased AUC of atorvastatin 2.5 fold and AUC of active (atorvastatin and metabolites) HMG-CoA reductase inhibitors 1.3 fold.
However, because of its safety profile, the medicine should only be used in patients who have a real need for the medicine.
However, growth hormone treatment has not been shown to increase the incidence or severity of scoliosis.
There have been no therapeutic clinical trials conducted with Competact tablets however bioequivalence of Competact with co-administered pioglitazone and metformin has been demonstrated (see section 5.2).
However, bivalirudin was not mutagenic or clastogenic in standard assays for such effects.
However, the majority of common adverse drug reactions were mild to moderate, they usually start early in therapy, and most tended to disappear even as therapy was continued.
However, the majority of common adverse drug reactions were mild to moderate, they usually start early in therapy, and most tended to disappear even as therapy was continued.
However, the majority of common adverse reactions were mild to moderate, they usually start early in therapy, and most tended to disappear even as therapy was continued.
No significant increase in overall survival has been observed in this study, however, the trial was not powered to detect such a difference.
Nevertheless, the solution must be filtered with an in-line filter of 0.2 micrometer or 0.22 micrometer nominal pore size during administration.
Nevertheless, there is a possibility that ovarian hyperstimulation syndrome (OHSS) may result from an overdosage of Ovitrelle (see section 4.4).
Of these 7 patients, 3 had eye, 1 had sinus, and 3 had disseminated infection.
Nevertheless the CHMP noted that consideration should be given to the precautions of use in ciprofloxacin treatment of such infections.
Notwithstanding, the new proposed model will have only predictive value once it has been fully validated and has shown to be able to discriminate batches of HBVAXPRO that have elicited a high vs. a low immune response during clinical trials.
Nevertheless the product should be used immediately.
However, the study had to be stopped early because of side effects (kidney and lungs problems).
This should be taken into account when treating infections caused by H. influenzae.
• Never drink alcohol while you are being treated with Zerene.
vaccination until recovery.
The need to refer patients who become pregnant to a physician specialised or experienced in teratology and its diagnosis for evaluation and advice.
If you are pregnant do not start using Avonex.
If you are pregnant, do not start using Avonex.
Do not drive to the hospital, get somebody else to take you or call for an ambulance.
Do not store Viani Evohaler in a cold place, as your medicine may not work as well.
Do not crush or chew these capsules or the content of an emptied capsule because this will stop them from working properly.
Damastown, Mulhuddart
Nederland Pfizer Animal Health B .V., Tel: +31 (0)10 4064 600
Jean-Hughes TROUVIN
drive or use any tools or machines (see also section'Driving and using machines')
Must be administered by authorised personnel only
Do not give Bondenza to children or adolescents.
IT IS NOT SUBSEQUENTLY MAINTAINED OR UPDATED BY THE EMEA, AND THEREFORE MAY NOT NECESSARILY REPRESENT THE CURRENT TEXT.
Do not “save up” fat and calorie allowances and then splurge on a high-fat meal or dessert, as you may have done on other weight loss programmes. • Most users who experience these effects find that they can manage and control them by adjusting their diet.
- nefazodone or selective serotonin re-uptake inhibitors used to treat depression
- Nefazodone (unboosted saquinavir) Antihistamines
Do not use too much force as the needle may loosen.
Under no circumstances should Liprolog Mix25 be given intravenously.
Under no circumstances should Liprolog Mix50 be given intravenously.
For instructions on how to use the Preotact pen, please read the User Manual of the Preotact pen.
Thyrogen solution should never be injected into a vein.
Do NOT inject Optisulin in a vein, since this will change its action and may cause hypoglycaemia.
- Never put the syringes that you have used into your normal household rubbish bin.
Do not mix NeoRecormon with other injections or infusion solutions.
Never recap a needle.
No alcohol or other solvents must be used for cleaning, as these may penetrate the skin due to the effect of the patch.
Medicines should not be disposed of via wastewater or household waste.
Keep out of the reach and sight of children
Do not keep your pen or the cartridges you are using in the fridge.
Avoid places where the patch can be rubbed off by tight clothing.
Do not use it in your nose, eyes or mouth.
It may harm them, even if their symptoms are the same as yours or those of the child you are caring for.  If you are concerned about any side effect, or if you notice any side effects that are not listed in this leaflet, please tell your doctor or pharmacist.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
It may harm them, even if their symptoms are the same as yours. – If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, diabetes nurse or your pharmacist.
It may harm them, even if their symptoms are the same as yours. – If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, diabetes nurse or your pharmacist.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
It may harm them, even if their symptoms are the same as your child's. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
It may harm them, even if their symptoms are the same than yours. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, tell your
It may harm them, even if their symptoms are the same as yours – If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, diabetes nurse or your pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your child's doctor or pharmacist.
- If any of the side effects become serious, or if you notice any side effects not listed in this
It may harm them, even if their symptoms appear to be the same as yours.  If any of the side effects become serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
- If any of the side effects gets serious, or if you notice any side effects not listed in this
It may harm them, even if their symptoms are the same as yours. – If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, diabetes nurse or your pharmacist.
It may harm them, even if their symptoms are the same as yours. – If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, diabetes nurse or your pharmacist.
It must only be used if the cartridge is intact and the solution is clear, colourless, with no solid particles visible, and if it is of water-like consistency.
It must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of water-like consistency.
It must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of water-like consistency.
It must only be used if the cartridge is intact and the solution is clear, colourless, with no solid particles visible.
Do not use it if the date has passed the last day of the month shown
Do not use it if the date has passed the last day of the month shown
Do not mix any other insulin in a Liprolog Basal cartridge.
Do not mix any other insulin in a Liprolog cartridge.
Do not mix any other insulin in a Liprolog Mix25 cartridge.
Do not mix any other insulin in a Liprolog Mix50 cartridge.
Do not mix any other insulin in a Humalog BASAL cartridge.
Do not mix any other insulin in a Humalog cartridge.
Do not mix any other insulin in a Humalog Mix25 cartridge.
Do not mix any other insulin in a Humalog Mix50 cartridge.
● Never mix your medicine with tap water.
Do not mix with any liquid prior to dispensing.
Do not mix Optisulin with any other insulins or medicines.
Do not add any other insulin to the cartridge.
Cerezyme should not be given as a mixture with other medicinal products in the same infusion (drip).
Step by step instructions Do not mix Telzir with any other medicines in the bottle or the syringe.
Neoclarityn 2.5 mg orodispersible tablets desloratadine
Neoclarityn 2.5 mg orodispersible tablet is indicated for adults and children (6 years of age and older).
Neoclarityn 5 mg orodispersible tablets desloratadine
Neoclarityn 5 mg orodispersible tablet is indicated for adults and adolescents (12 years of age and older).
Neoclarityn is indicated for adults and adolescents (12 years of age and older).
Neoclarityn is used to relieve the symptoms of allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) or urticaria (a skin condition caused by an allergy, with symptoms including itching and hives).
Neoclarityn oral lyophilisate is indicated for adults and adolescents (12 years of age and older).
Neoclarityn syrup contains sucrose and sorbitol.
Neoclarityn syrup is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy).
Neoclarityn syrup is indicated for children 1 through 11 years of age, adolescents (12 years of age and older), and adults, including the elderly.
Neoclarityn syrup is an antiallergy medicine that does not make you drowsy.
Neoclarityn syrup relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites).
Neocolipor is administered to female pigs – both sows and gilts - in order to immunise their offspring against neonatal enterotoxicosis.
Neocolipor Suspension for injection Pigs (sows and gilts)
- Neoplasm with increased bleeding risk
NeoRecormon 30,000 IU injection IV/SC use
Under no circumstances should more than one dose be administered per syringe; the medicinal product is for single use only.
NeoSpect 47 micrograms, kit for radiopharmaceutical preparation.
Do not share personal items that could have blood or body fluids on them, such as toothbrushes or razor blades.
Do not go unaccompanied to seek medical help.
Do not use in puppies under 7 weeks of age.
It should not be administered in a line containing dextrose.
Do not use in case of hypersensitivity to ceftiofur or other β-lactam antibiotics.
Do not use on an empty stomach.
Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.
Do not use in animals suffering from alimentary tract disorders, impaired heart, liver and kidney function.
Do not administer the product to pigs receiving ionophores.
Do not administer the product to pigs receiving ionophores.
59 Do not use in puppies under 7 weeks of age.
Do not use in puppies under 7 weeks of age.
Do not administer in conjunction with bactericidal antibiotics like beta-lactames.
Do not administer in conjunction with bactericidal antibiotics like beta-lactames.
Do not use antibiotics within one week after vaccination.
For in vitro radiolabelling.
Do not use if the eardrum is perforated.
2 Do not administer as an intravenous push or bolus injection.
Do not administer intramuscularly in chickens less than 2 weeks old.
- Do not add any other insulin to the cartridge.
- Do not add any other insulin to the cartridge.
Do not add any other insulin to the cartridge.
Do not apply directly to the ear canal.
Do not apply the ointment to infected lesions.
- on KS lesions close to any other skin complaint
Do not apply the veterinary medicinal product to the surface of the cat's hair coat.
Do not apply the medicine to the surface of the dog's hair coat.
Patches should not be applied to the breasts or other body regions.
Protopy ointment should not be applied under occlusion (see section 4.4). lp
492 • Do not push the injection button while turning, as insulin will come out.
496 • Do not push the injection button while turning, as insulin will come out.
563 • Do not push the injection button while turning, as insulin will come out.
568 • Do not push the injection button while turning, as insulin will come out.
633 • Do not push the injection button while turning, as insulin will come out.
640 • Do not push the injection button while turning, as insulin will come out.
703 • Do not push the injection button while turning, as insulin will come out.
774 • Do not push the injection button while turning, as insulin will come out.
784 • Do not push the injection button while turning, as insulin will come out.
• Do not push the injection button while turning, as insulin will come out.
Leave 2 to 3 hours after your daily dose of ORACEA before drinking or eating dairy products.
Do not combine with other veterinary medicinal products.
Do not initiate Soliris therapy in patients:
Ultratard vials that are being used or about to be used are not to be kept in the fridge.
Do not freeze, in order to prevent damage to the prefilled syringe.
For intravenous use, single use administration only.
Do not store above 30°C.
Do not store above 25ºC.
Do not store above 30ºC.
Discard open tubes 7 days after opening.
Opened tubes of Panretin gel must not be stored above 25°C, and should be protected from exposure to strong light and heat (e. g., direct sunlight).
The transdermal patch should not be cut, since no information is available on the quality, efficacy and safety of such divided patches.
Do not cut the Neupro patches into pieces.
• Do not give Viread to children and adolescents under 18 years of age.
No attempt should be made to remove the tablet by pushing it through the blister backing as this will damage both the tablet and blister.
Do not expose to excessive heat or direct sunlight.
Do not expose to excessive heat or direct sunlight.
Do not expose to excessive heat or direct sunlight.
Do not expose the patch to the sun.
Do not administer orally or parenterally.
Do not smoke when applying this product.
Do not inject in an area where the skin is reddened, bruised, or hard.
This may mean there is an infection.
Avoid areas with scars or stretch marks.
Avoid areas with scars or stretch marks.
Do not inject into areas where the skin is tender, bruised, red, or hard.
Do not inject into areas where the skin is tender, bruised, red, or hard.
Do NOT inject Insulin Human Winthrop Comb 15 into a vein.
Do not inject Insulin Human Winthrop Comb 15 into a vein (blood vessel).
Do NOT inject Insulin Human Winthrop Comb 25 into a vein.
Do not inject Insulin Human Winthrop Comb 25 into a vein (blood vessel).
Do NOT inject Insulin Human Winthrop Comb 50 into a vein.
Do not inject Insulin Human Winthrop Comb 50 into a vein (blood vessel).
Do not inject Insuman Basal into a vein (blood vessel).
Do not inject Insuman Comb 15 into a vein (blood vessel).
Do not inject Insuman Comb 25 into a vein (blood vessel).
Do not inject Insuman Comb 50 into a vein (blood vessel).
Do not inject intravenously, intradermally, or subcutaneously
Do not use an area that has a rash or broken skin, or is bruised or lumpy.
Do not stop taking TRAVATAN without speaking to your doctor.
Do not insert a needle through the stopper.
Do not get the inside of the IRU wet. uc
Once InductOs and the LT-CAGE device are implanted, do not irrigate the wound region.
Do not throw the vial away because the pharmacy may request that you return it.
Do not throw the vial away because the pharmacy may request that you return it.
Medicines should not be disposed of via waste water or household waste.
Medicines should not be disposed of via wastewater or household waste.
Do not flush used or unused patches down the toilet.
Recently treated animals should not be allowed to sleep with the owners, especially children.
Dogs should not be allowed to swim in surface waters for 4 days after treatment.
Dogs should not be allowed to swim in surface waters for 4 days after treatment.
Do not allow the sides of the strip to contact the side of the tank.
Children should not have access to used pipettes.
Do not use it if the date has passed the last day of the month shown.
63 Do not eat, drink or smoke during application.
Do not eat, drink or smoke during application.
Do not eat, drink or smoke while treating a dog.
Do not mix with any other vaccine/ immunological product.
Do not mix with any other vaccine/ immunological product, except the solvent supplied for use with the product.
Do not mix with any other medicinal product.
Do not mix with any other medicinal product.
Do not mix with any other veterinary medicinal product.
Do not mix with any other medicinal product.
Do not mix with any other veterinary medicinal products except the solvent supplied for use with the vaccine.
Do not mix with any other veterinary medicinal products except the solvent supplied for use with the vaccine.
Do not mix with any other veterinary medicinal product.
16/ 17 Do not mix with any other veterinary medicinal products.
Do not mix with any other medicinal product.
Do not mix with any other vaccine or immunological product.
Do not mix with any other veterinary medicinal product.
Do not mix with any other vaccine or immunological product except Merial non-adjuvanted vaccine range.
Do not mix with any other vaccine or immunological product, except those mentioned below.
Do not mix with any other vaccine or immunological product, except those mentioned in section “ Interactions”.
Do not mix with any other vaccine/ immunological product.
Do not mix with any other vaccine or immunological product.
Do not mix DepoCyte with any other medicinal products (see section 6.2).
Do not mix the solution with other injectable medicines.
Do not mix the Enbrel solution with any other medicine.
Do not mix the Enbrel solution with any other medicine.
Do not mix or administer with other products.
Do not mix Thyrogen with other medicines in the same injection.
Do not put Apidra next to the freezer compartment or a freezer pack.
Do not put Insulin Human Winthrop Basal next to the freezer compartment or a freezer pack.
Do not put Insulin Human Winthrop Comb 15 next to the freezer compartment or a freezer pack.
Do not put Insulin Human Winthrop Comb 25 next to the freezer compartment or a freezer pack.
Do not put Insulin Human Winthrop Comb 50 next to the freezer compartment or a freezer pack.
Do not put Insulin Human Winthrop Rapid next to the freezer compartment or a freezer pack.
Do not put Insuman Basal next to the freezer compartment or a freezer pack.
Do not put Insuman Comb 15 next to the freezer compartment or a freezer pack.
Do not put Insuman Comb 25 next to the freezer compartment or a freezer pack.
Do not put Insuman Comb 50 next to the freezer compartment or a freezer pack.
Do not put Insuman Infusat next to the freezer compartment or a freezer pack.
Do not put Insuman Rapid next to the freezer compartment or a freezer pack.
Do not put Lantus next the freezer compartment or a freezer pack.
Do not put Lantus next to the freezer compartment or a freezer pack.
Do not put Optisulin next to the freezer compartment or a freezer pack.
Do not forget to mark the date on the bottle, when removed from the refrigerator.
Do not put the metal container in water.
- Replace the mouthpiece cover.
Do not shower or bathe during this time.
This can usually be avoided if you remain inactive for at least 4 hours after taking Zerene. • There is a chance that you may experience somnambulism (sleepwalking), including eating or driving while not fully awake with no memory of the event.
Do not overheat > 37° C.
- Do not put the cover back on used needles.
Do not remove the pipette from the packaging until ready to use.
Do not remove the adapter housing at this step.
- the pressure regulator should not be tightened with pliers, at the risk of crushing the gasket
Do not touch the needle or push the plunger.
Do not touch the syringe tip with your hand or any surface.
Do not use Apidra if it does not appear clear and colourless.
111 The expiry date refers to the last day of the month.
Do not use Aranesp if you think it has been frozen.
Do not use within 14 days of onset of the laying.
Do not use BeneFIX if the solution is not clear and colourless.
Do not use BeneFIX if the solution is not clear or colourless.
Do not use Biograstim if you notice it is cloudy or there are particles in it.
Do not use Bondronat if you notice that the solution is not clear or contains particles.
Do not use this SoloStar if insulin is cloudy, coloured or has particles. • The insulin suspensions (Insulin Human Winthrop Basal or Insulin Human Winthrop mixtures) should be mixed by turning SoloStar up and down at least 10 times to resuspend the insulin.
Do not use this SoloStar if insulin is cloudy, coloured or has particles. • The insulin suspensions (Insuman Basal or Insuman mixtures) should be mixed by turning SoloStar up and down at least 10 times to resuspend the insulin.
Do not use this OptiSet if the insulin is cloudy, coloured or has particles.
You should not use Cetrotide 0.25 mg if you are already pregnant, or suspect that you might be pregnant, or if you are breast-feeding.
You should not use Cetrotide 3 mg if you are already pregnant, or suspect that you might be pregnant, or if you are breast-feeding.
Do not use in animals less than 10 weeks.
Do not use in animals previously treated with Oxyglobin.
Do not use in animals suffering from gastrointestinal bleeding, blood dyscrasia or haemorrhagic disorders.
Do not use in dogs with a known or suspected genetic susceptibility to malignant hyperthermia.
Do not use in dogs during pregnancy and lactation.
Do not use in dogs during pregnancy and lactation.
Do not use in dogs in which overweight or obesity is caused by a concomitant systemic disease such as hypothyroidism or hyperadrenocorticism.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of individual hypersensitivity to the product.
Not for use in animals from which eggs are produced for human consumption
Not for use in pregnant cows or heifers, which are intended to produce milk for human consumption, within 2 months of expected parturition.
Do not use in animals previously treated with Oxyglobin.
Do not use in animals with cardiovascular disorders.
Do not use in animals suffering from gastrointestinal ulceration.
Do not use in animals with severe systemic disease or in animals that are moribund.
Do not use in case of hypersensitivity to the active substance or to any of the excipients Do not use in case of known hypersensitivity to sulphonamides.
Do not use in animals suffering from alimentary tract disorders, impaired heart, liver and kidney function.
Do not use in animals suffering from gastrointestinal disorders and haemorrhage, impaired hepatic, cardiac or renal function and bleeding disorders.
Do not use in animals suffering from gastrointestinal ulceration.
13/ 24 Do not use in dogs less than 12 weeks of age.
Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in animals suffering from Cushing's syndrome.
Do not use in animals suffering from Cushing's syndrome.
Do not use in puppies under 6 months of age.
Do not use in dogs suffering from gastrointestinal ulceration or with hepatic disease.
Do not use in dogs suffering from stomach ulcer or with liver disease.
Do not use in puppies below 6 months of age or in kittens below 5 months of age.
Do not use in small herbivores (including guinea pigs and rabbits).
Do not use in pregnant cows or heifers, which are intended to produce milk for human consumption, within 2 months of expected parturition.
Do not use filter needles and avoid foaming.
Do not use filter needles and avoid foaming.
Do not use scissors as you may accidentally damage the patch.
Do not use any Starlix pack that is damaged or shows signs of tampering.
- Do not use insect repellents containing DEET (N, N-diethyl-m-toluamide) or other products
Do not use polycarbonate syringes with Busilvex.
Do not use with glucose-containing solutions.
Do not use with glucose-containing solutions (see 6.2).
Do not use solutions containing visible particles or that are cloudy.
Do not use solutions containing visible particles or that are cloudy.
Do not use solutions that contain visible particles or that are cloudy (G).
Do not use solutions which are cloudy or contain particles.
Do not use solutions that are cloudy or have deposits.
Do not use solutions that are cloudy or have particulate matter.
Do not use solutions that are cloudy or have deposits.
Do not use during pregnancy and lactation because the safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Do not use during pregnancy and lactation because the safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Do not use during pregnancy and lactation.
Do not use concurrently with substances known to cause ototoxicity.
Do not use Enbrel if you notice the solution is not clear or contains particles.
Do not use Enbrel if you notice the solution is not clear or contains particles.
Do not use if you notice the solution is not clear or contains particles.
Do not use in case of hypersensitivity to robenacoxib or to any ingredients of the solution.
Do not use if the eardrum is perforated.
Do not use in case of known resistance to amoxicillin.
Do not use solutions that are cloudy or have deposits.
Do not use in the case of hypersensitivity to the active substances or to any of the excipients.
Do not use in the case of hypersensitivity to the active substances or to any of the excipients.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in case of known hypersensitivity to the active substance or to any of the excipients.
Do not use in the case of hypersensitivity to the active substance or to any of the excipients.
Do not use in case of hypersensitivity to the active substance or to any of the excipients, to corticosteroids, to other azole antifungal agents and to other aminoglycosides.
Do not use in case of hypersensitivity to macrolide antibiotics or to any of the excipients.
Do not use in case of hypersensitivity to the active substances or to any of the excipients.
Do not use in case of hypersensitivity to the active substances or to any of the excipients.
Do not use in the case of hypersensitivity to the active substances or to any of the excipients.
Do not use in case of known hypersensitivity to phenylpyrazole class compounds or any of the excipients.
Do not use Extavia if you notice it contains particles or is discoloured.
Do not use Fasturtec if you notice that the solution is unclear and/ or contains particles.
Do not use Flebogammadif if you notice that the solution is cloudy or has deposits.
Do not use Flebogammadif if you notice that the solution is cloudy or has deposits.
FORSTEO should not be used if the solution is cloudy, coloured or contains particles.
Do not use FORSTEO if it is, or has been, frozen.
Do not use Humalog BASAL KwikPen, if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
Do not use Humalog BASAL Pen, if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
Do not use Humalog BASAL, if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
Do not use Humalog Mix25 Pen, if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
Do not use Humalog Mix25, if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
Do not use Humalog Mix25, if clumps of material are present or if solid white particles stick to the bottom or wall of the vial, giving it a frosted appearance.
Do not use Humalog Mix50 KwikPen, if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
Do not use Humalog Mix50 Pen, if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
Do not use Humalog Mix50, if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
Do not use Humalog Mix50, if clumps of material are present or if solid white particles stick to the bottom or wall of the vial, giving it a frosted appearance.
198 Do not use Humalog, if it is coloured or it has solid pieces in it.
Do not use Insulin Human Winthrop Rapid if you notice particles in it.
Do not use Insuman Rapid if you notice particles in it.
Do not use Iscover if you notice any visible sign of deterioration.
Do not use ISENTRESS with medicinal products that increase gastric pH unless this is unavoidable.
201 Do not use KOGENATE Bayer 2000 IU if you notice any particles or the solution is cloudy.
177 Do not use KOGENATE Bayer 250 IU if you notice any particles or the solution is cloudy.
Do not use epinephrine, dopamine, or other sympathomimetic agents with beta-agonist activity since beta stimulation may worsen hypotension.
Do not use epinephrine, dopamine, or other sympathomimetic agents with beta agonist activity since beta stimulation may worsen hypotension.
Do not use epinephrine, dopamine, or other sympathomimetic agents with beta- agonist activity since beta stimulation may worsen hypotension.
Do not use epinephrine, dopamine, or other sympathomimetic agents with beta-agonist activity since beta stimulation may worsen hypotension.
Do not use Lantus if you notice particles in it.
Do not use the Trudexa pre-filled syringe after the expiry date stated on the label/ blister/ carton after
Do not use Forcaltonin if you notice the solution is not completely clear and colourless.
Do not use Liprolog Pen if it appears cloudy, thickened, or slightly coloured or if solid particles are visible.
Do not use Liprolog if it appears cloudy, thickened, or slightly coloured or if solid particles are visible.
Do not use Liprolog KwikPen if it appears cloudy, thickened, or slightly coloured or if solid particles are visible.
Do not use Humalog Pen if it appears cloudy, thickened, or slightly coloured or if solid particles are visible.
Do not use Humalog if it appears cloudy, thickened, or slightly coloured or if solid particles are visible.
Do not use the diluted infusion solution if it is cloudy or precipitated.
Do not use if the solution is cloudy or has precipitated.
Do not use if you notice that the solution is not clear or contains particles.
Do not use Clopidogrel BMS if you notice any visible sign of deterioration.
Do not use clopidogrel if you notice any visible sign of deterioration.
Do not use Clopidogrel Winthrop if you notice any visible sign of deterioration.
Do not use the Trudexa vial after the expiry date stated on the label/ blister/ carton after EXP:.
Do not use the medicine if it has been shaken strongly.
Do not use EXUBERA if you notice that a blister is not properly sealed or damaged.
Do not use in conjunction with other serotonergic agents (e. g. sertraline) and monoamine oxidase inhibitors (MAOIs) [e. g., selegiline hydrochloride (L-deprenyl), amitraz] or tricyclic amines (TCAs) (e. g. amitriptyline and clomipramine).
Do not use vials exhibiting foreign particles or discoloration.
Do not use vials exhibiting foreign particles, cloudiness or discoloration.
Do not use vials exhibiting foreign particles, cloudiness or discoloration.
Do not use sodium salicylates in neonates or calves less than 2 weeks of age.
Do not use solutions that are cloudy or have deposits.
Do not use Liprolog Basal KwikPen, if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
Do not use Liprolog Basal Pen, if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
Do not use Liprolog Basal, if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
Do not use Liprolog Mix25, if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
Do not use Liprolog Mix50 Pen, if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
Do not use Liprolog Mix 50, if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving it a frosted appearance.
181 Do not use Liprolog, if it is coloured or it has solid pieces in it.
Do not use this OptiSet if insulin is cloudy, coloured or has particles.
Do not use Naglazyme if it contains visible particles.
Do not use Nespo if you think it has been frozen. a
Do not use Neulasta if you notice it is cloudy or there are particles in it.
Do not use Neupopeg if you notice it is cloudy or there are particles in it.
Do not use Neupopeg if you notice it is cloudy or there are particles in it.
Do not use Betaferon if you notice it contains particles or is discoloured.
Do not use Plavix if you notice any visible sign of deterioration.
Do not use Privigen if you notice that the solution is cloudy or has particles.
Do not use Ratiograstim if you notice it is cloudy or there are particles in it.
Do not use Savene if you notice that the vial is damaged or show signs of tampering.
DO NOT USE if it is broken or if the liquid looks cloudy or contains particles.
Do not use if moisture absorber is missing or not intact.
do not use if the solution is not totally clear or if the powder is not totally reconstituted
Do not use if cloudy.
Do not use if you notice any damage to the capsules, blister or carton or any visible signs of deterioration in the medicine.
Do not use this SoloStar if the insulin is cloudy, coloured or has particles.
Do not use SoloStar if you notice particles in it.
Do not use in cats that are suffering from concomitant disease, or are debilitated and underweight (for size and age).
Do not use Tevagrastim if you notice it is cloudy or there are particles in it.
Do not use TYSABRI if you notice particles in the liquid and/ or the liquid in the vial is discoloured.
- Do not use any pack that is damaged or shows signs of tampering.
- a gas cylinder whose valve is not protected by a cap or a shell should not be used
Do not use the solution if foreign particles are observed or if the solution is discoloured.
Do not use your medicine after the expiry date (MM/ YY) as indicated on the tube and the outer carton.
Nephritis interstitial, renal dysfunction, glycosuria
Renal and urinary disorders: interstitial nephritis, renal dysfunction
Skin and subcutaneous tissue disorders:
Do not inject Bondenza yourself.
Do not take any medicine to treat diarrhoea without first checking with your doctor.
Never take two Bondenza tablets within the same week.
Do not take CELSENTRI if you are allergic (hypersensitive) to maraviroc or to peanut or soya or to any of the other ingredients of CELSENTRI (see section 2, Important information about some of the ingredients of CELSENTRI).
Do not take Hycamtin: • if you are allergic (hypersensitive) to topotecan or any of the other ingredients of Hycamtin. • if you are breast feeding. • if your blood cell counts are too low.
Do not take RISPERDAL CONSTA • If you are allergic (hypersensitive) to risperidone or any of the other ingredients of RISPERDAL CONSTA (listed in Section 6 below).
Do not take Arava when you are breast feeding, as leflunomide passes into the breast milk.
If you are allergic to peanut or soya do not use this medicinal product.
Do not bath, shower or swim right after applying < Invented Name >.
Do not take two doses in one day.
Do not put the metal container in water.
Do not take two doses in one day.
Do not take the strong pain killer, pethidine, while taking AZILECT.
Do not take Exforge − if you are allergic (hypersensitive) to amlodipine or other medicines of the dihydropyridine type, − if you are allergic (hypersensitive) to valsartan or any of the other ingredients of Exforge.
Do not take more than the daily amount of Efexor depot that has been prescribed for you in one day.
Do not take more than the daily amount of Efexor that has been prescribed for you in one day.
Do not take SPRYCEL if you are allergic (hypersensitive) to dasatinib or any of the other ingredients of SPRYCEL.
Do not take Tarceva with food.
Do not take your tablet at bedtime or before you get up for the day.
Do not cover the treated area with bandages or other dressings after you have applied Aldara cream.
- Do not put the cover back on used syringes.
Do not refill NovoMix 50 Penfill cartridges.
Do not refill NovoMix 70 Penfill cartridges.
Rockspring Healthcare Ltd Nerin House 26 Bridgeway Street Douglas IM1 1EL – Isle of Man UK
dizziness, orthostatic dizziness*
Restlessness, light-headedness, vertigo, paraesthesia, dizziness
- Do not remove the metal can from the plastic casing during cleaning or at any other time.
Do not be concerned if you do not experience any of these problems.
Nespo 15 micrograms solution for injection in a vial Darbepoetin alfa
Nespo 15 micrograms solution for injection in a vial Nespo 25 micrograms solution for injection in a vial Nespo 40 micrograms solution for injection in a vial Nespo 60 micrograms solution for injection in a vial darbepoetin alfa
Nespo 40 micrograms solution for injection in a vial Darbepoetin alfa
Nespo is a solution for injection in a vial, a pre-filled syringe or a pre-filled pen.
Nespo is a sterile but unpreserved product.
Nespo is used to treat anaemia (fewer red blood cells in the blood than normal) in two groups of patients: • adults and children over one year of age with anaemia caused by long-term kidney failure, when ct
Nespo is supplied ready for use in a pre-filled syringe or pre-filled pen, which can be used by the patient or their carer.
au Food and drink do not affect Nespo.
Nespo SureClick Pre-filled pen - Read package leaflet before use ENGLISH
OptiSet has been dropped or subjected to impact.
OptiSet has been dropped or subjected to impact.
Do not touch the spike tip of the access device at any time.
11-fold in AUC) in patients with chronic alcoholic liver disease (Childs-Pugh B).
1) Put the large needle cover on the needle.
Cleaning and storing the syringe:
Swab the injection site with a disinfectant (for example alcohol) to remove any surface bacteria.
Cleanse the area for injection thoroughly with an alcohol swab in a circular motion, working outward.
Nine of these patients developed malignancies, including 1 lymphoma.
Neulasta 6 mg solution for injection in a pre-filled pen.
Neulasta 6 mg solution for injection in a pre-filled pen pegfilgrastim
Neulasta 6 mg solution for injection in a pre-filled pen Pegfilgrastim
Neulasta contains the active substance pegfilgrastim.
Neulasta is a solution for injection that contains the active ingredient pegfilgrastim.
Neupopeg 6 mg solution for injection in a pre-filled pen.
Neupro 1 mg/24 h transdermal patch Rotigotine
Neupro 1 mg/24 h transdermal patch Rotigotine Transdermal use.
Neupro 2 mg/24 h 4 mg/24 h 6 mg/24 h 8 mg/24 h
Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h, 8 mg/24 h
Neupro 2 mg/24 h Each patch releases 2 mg of rotigotine per 24 hours.
Neupro 2 mg/24 h transdermal patch Rotigotine
Neupro 2 mg/24 h transdermal patch Rotigotine Transdermal use.
Neupro 2 mg/24 h Neupro 4 mg/24 h Neupro 6 mg/24 h Neupro 8 mg/24 h Transdermal patch Rotigotine
Neupro 3 mg/24 h transdermal patch Rotigotine
Neupro 3 mg/24 h transdermal patch Rotigotine Transdermal use.
Neupro 4 mg/24 h Each patch releases 4 mg of rotigotine per 24 hours.
Neupro 4 mg/24 h transdermal patch Rotigotine
Neupro 4 mg/24 h transdermal patch Rotigotine Transdermal use.
Neupro 6 mg/24 h Each patch releases 6 mg of rotigotine per 24 hours.
Neupro 6 mg/24 h transdermal patch Rotigotine
Neupro 6 mg/24 h transdermal patch Rotigotine Transdermal use.
Neupro 8 mg/24 h Each patch releases 8 mg of rotigotine per 24 hours.
Neupro 8 mg/24 h transdermal patch Rotigotine Transdermal use.
Neupro is used for to treat the symptoms of the following diseases in adults: • Parkinson's disease.
Neupro was not investigated in patients with severe hepatic impairment.
been observed rarely in patients with Parkinson's disease.
Neurontin Neurontin Neurontin Neurontin Neurontin Neurontin Neurontin Neurontin Neurontin Neurontin Neurontin Neurontin
cranial neuropathy, peripheral neuropathy facial nerve palsy4, loss of other senses4
84 Painful neuropathy (nerve related pain).
Painful neuropathy (nerve related pain).
Optic neuropathy, papilledema, retinal vascular disorder, retinopathy, corneal ulcer
Optic neuropathy, papilledema, retinal vascular disorder, retinopathy, corneal ulcer
Optic neuropathy, Papilledema, retinal vascular disorder, retinopathy, corneal ulcer
Optic neuropathy, papilloedema, retinal vascular disorder, retinopathy, corneal ulcer
peripheral neuropathy (2.8% vs 1.8%), headache (2.7% vs 4.1%) convulsion (0.3% vs 0.5%), syncope (0.3% vs 0.3%), amnesia (0.2% vs 0.2%), tremor (0.2% vs 0.3%), somnolence (0.7% vs 0.5%), paraesthesia (0.7% vs 0.7%), hypoaesthesia (0.3% vs 0.2%), hypersomnia (0.2% vs 0%)
Peripheral neuropathy Lenalidomide is structurally related to thalidomide, which is known to induce severe peripheral neuropathy.
Peripheral neuropathy, paraesthesia, somnolence, dizziness, tremor
Peripheral neuropathy: patients with a history of peripheral neuropathy are at increased risk for development of neuropathy.
Neurotoxicity, Consciousness decreased, Headache
cardiac arrhythmias aplastic anaemia, bone marrow depression, neutropenia/ agranulocytosis, haemolytic anaemia, leucopenia, thrombocytopenia
vertigo, paraesthesia, light-headedness, restlessness
13  EMEA 2005 Neutropenia/ Agranulocytosis/ Thrombocytopenia/ Anaemia:
24  EMEA 2005 Neutropenia/ Agranulocytosis/ Thrombocytopenia/ Anaemia:
25 Neutropenia/ agranulocytosis Neutropenia/ agranulocytosis, as well as thrombocytopenia and anaemia, have been rarely seen and bone marrow depression has also been reported.
Congenital neutropenia The recommended starting dose is 1.2 MU/ kg/ day (12 μ g/ kg/ day) as a single dose or in divided doses.
Paresthesia; Headache; Dysgeusia; Hypoaesthesia
Idiopathic or cyclic neutropenia The recommended starting dose is 0.5 MU/ kg/ day (5 μ g/ kg/ day) as a single dose or in divided doses.
Neutropenia, lymphopenia, leucopenia, thrombocytopenia, anaemia
• Only healthy animals should be vaccinated. • Do not mix with any veterinary medicinal product. • In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. • Can be used during pregnancy and lactation. • No interaction has been observed when the vaccine was administered simultaneously, but at a separate site, with MERIAL 's inactivated vaccine against rabies. • Following the administration of overdoses of vaccine, no side-effects other than those described under “ Adverse reactions” have been observed.
• Only healthy animals should be vaccinated. • Do not mix with any veterinary medicinal product. • In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. • Can be used during pregnancy and lactation. • No interaction has been observed when the vaccine was administered simultaneously, but at a separate site, with MERIAL 's inactivated vaccine against rabies. • Following the administration of overdoses of vaccine, no side-effects other than those described under “ Adverse reactions” have been observed.
Since NEVANAC contains benzalkonium chloride, close monitoring is required with frequent or prolonged use.
NEVANAC contains benzalkonium chloride, which is known to discolour soft contact lenses.
NEVANAC contains benzalkonium chloride which may cause irritation and is known to discolour soft contact lenses.
NEVANAC is a yellow eye drop suspension that contains the active substance nepafenac.
Nevirapine 200 mg BID (maraviroc 300 mg Single Dose) PIs
Nevirapine Cmin ↑ 1.07 ANTITHROMBOTICS Warfarin
- Nevirapine (unboosted saquinavir)
Do not make yourself vomit, and do not lie down — this could cause Bondenza to irritate your oesophagus.
Do not make yourself vomit, and do not lie down — this could cause Bonviva to irritate your oesophagus.
75 Don't worry if a little Norvir oral solution is left in the measuring cup after you've taken your dose.
Neuralgia, convulsions, transient thrombocytopenia.
16 Neuralgia, paraesthesia, convulsions, transient thrombocytopenia.
Neuralgia, paraesthesia, convulsions, transient thrombocytopenia.
Retinal haemorrhages§, retinopathies (including macular oedema), retinal artery or vein obstruction§, optic neuritis, papilloedema, loss of visual acuity or visual field, cotton- wool spots§
New e-mail addresses for the EMEA staff members were introduced with effect from 1 November 2001 with the introduction of the ‘ emea. eu. int 'domain for e- mail:
Nexavar may increase the effects and, in particular, the side effects of these medicines.
- You are advised to share the information in this leaflet with relatives or other relevant persons.
Nicobrand Limited 189 Castleroe Road, Coleraine BT51 3RP Northern Ireland
Nicobrand Limited 189 Castleroe Road Coleraine Northern Ireland BT51 3RP
The statistical nor the alternative method could be used as at the last time point residues at the injection site were up to 6 times the MRL for muscle.
Incidences (%) Risk ratio over
Incidences (%) Risk ratio over enoxaparin
Incidences (%) Risk ratio over enoxaparin
N Incidences (%) Risk ratio over
● Never inject your medicine with other injectable medicines.
Under no circumstances should Humalog Mix25 be given intravenously.
Under no circumstances should Humalog Mix50 be given intravenously.
Never inject your insulin directly into a vein or muscle.
Never inject your insulin directly into a vein or muscle.
Do not inject into this site; withdraw the needle and repeat the procedure.
Do not inject into this site; withdraw the needle and repeat this step.
Do not inject but withdraw the needle and repeat the injection procedure.
Do not inject MIRCERA into an area that is tender or healing
Do not inject PegIntron into an area where the skin is irritated, red, bruised, infected, or has scars, stretch marks, or lumps.
428 Do not inject into areas where the skin is tender, bruised, red, or hard.
Do not inject ViraferonPeg into an area where the skin is irritated, red, bruised, infected, or has scars, stretch marks, or lumps.
Do not stop using DuoTrav without speaking to your doctor.
37 Do not stop your treatment without contacting your doctor.
and the liver, and improves pyruvate utilisation.
the liver, and improves pyruvate utilisation.
Before commencing treatment with Protopy ointment, clinical infections at treatment sites should be cleared.
Nobilis IB 4-91 given at day-old can adversely affect the efficacy of Turkey Rhinotracheitis (TRT) vaccine given within 7 days.
Nobilis IB 4-91 given at day-old can adversely affect the efficacy of Turkey Rhinotracheitis (TRT) vaccine given within 7 days; therefore this vaccination scheme is contraindicated.
There was a clear immune response to Nobilis IB 4-91.
Nobilis IB 4-91 is intended to protect chickens against respiratory signs of disease caused by IBV variant strain 4-91 only and should not be used as a replacement for other IBV vaccines.
Nobilis IB 4-91 can cause mild respiratory signs of disease which may last for a few days depending on the health and condition of the chickens.
Nobilis IB 4-91 is used to immunise chickens to reduce the respiratory signs of Infectious Bronchitis caused by the variant strain IB 4-91, which causes infectious bronchitis in chickens.
Nobilis IB 4-91 can be given to 1-day-old chicks and older chickens by coarse spray or by intranasal (breathed in through the nose) or ocular (absorbed by the eyes) administration.
Nobilis IB 4-91 is a lyophilised (freeze dried) vaccine pellet which is made into a solution for dosing.
Nobilis Influenza H5N6 emulsion for injection for chickens
Nobilis OR Inac contains small amounts of a killed bacterium called O. rhinotracheale serotype A, strain B3263/ 91.
Nobilis OR inac emulsion for injection for chickens
Nobilis OR inac emulsion for injection for chickens
Nobilis OR Inac is an emulsion (a mixture of oil- and water-based liquids) for injection.
Nobivac Bb was the first live B. bronchiseptica vaccine licensed for use in cats.
Nobivac Bb contains a type of live B. bronchiseptica called strain B-C2.
Nobivac Bb is a dry substance and solvent that are made up into a suspension, which is given via the nose.
Nobivac Piro is a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection.
Nobivac Piro is a vaccine that contains antigens (proteins) from the parasites Babesia canis and Babesia rossi.
sweats, +skin disorder hypertonia, myalgia, arthralgia, back pain, neck pain, pain
number of animals in the house X mean weight of individual animal (kg) X 100 ----------------------------------------------------------------------------------------------------- total water consumption of the house on the previous day (litres)
82% 86/9/1 39 32% 28% 41% 4.0 (1.7-5.1) 272 (135-420)
of film-coated tablets twice daily*
Number of film-coated tablets three times daily*
Translations of the agreed SPC, labelling
Number of variations + annual fee for maintenance of marketing authorisation
have used Protopy ointment have had malignancies (for example, skin or lymphoma).
(which help the blood to clot) may fall,
Number of meetings and reimbursed delegates 2000-2002
Operate, support and maintain all existing hardware and
Number of subjects with ≥ 1 Thymidine Analogue Mutations (TAMs).
Number of payments received and made
Number of videoconferences and reimbursed meetings
Number (proportion) with moderate or marked improvement
Number (proportion) with ≥ 1 hour ON time response Secondary Outcome
numbers 1 to 14 numbers 1 to 28 sun as symbol moon as symbol
Numbers 1 to 14 sun as symbol moon as symbol
Numbers 1 to 28 sun as symbol moon as symbol
< INVENTED NAME > is administered orally and may be taken with or without food.
Vehicle p-value < Invente Vehicle
{INVENTED NAME} 100 mg film-coated tablets {INVENTED NAME} 200 mg film-coated tablets {INVENTED NAME} 400 mg film-coated tablets
< Invented Name > contains cetyl alcohol and stearyl alcohol which may cause local skin reactions. < Invented Name > also contains propylene glycol, which may cause skin irritation.
< Invented Name > Cream is only to be used for atopic dermatitis.
It works in the cells in the skin that cause the inflammation and characteristic redness and itching of eczema. < Invented Name > cream is available in tubes of 15 g, 30 g, 60 g and 100 g.
Do not use for other skin conditions. < Invented Name > cream is for external use only.
< Invented Name > Cream is for use only after other prescription medicines or emollients have not worked for you or if your Doctor recommends that other prescription medicines should not be used.
Emollients can be applied immediately after using < Invented Name >.
Treatment should be intermittent, short-term and not continuous. < Invented Name > should be applied thinly to the affected areas twice daily.
< Invented Name > should be initiated by physicians with experience in the diagnosis and treatment of atopic dermatitis.
{INVENTED NAME} should be administered with caution in patients with severe liver impairment (see 4.2).
{INVENTED NAME} {Strength} {Pharmaceutical form}
{Invented Name} has not been studied in children and thus is contraindicated in children under 18 years of age.
{INVENTED NAME} is contraindicated in patients who are hypersensitive to the active substance or to any of the excipients in these formulations.
{INVENTED NAME} is excreted is breast milk, therefore the use of {INVENTED NAME} is not recommended in breast-feeding women.
< Invented Name > was used at first signs of itching and redness to prevent progression to flares of atopic dermatitis.
{INVENTED NAME} {pharmaceutical form} must not be used during pregnancy (see section 4.6).
Invented name Iscover Iscover Iscover Iscover Iscover Iscover Iscover Iscover Iscover Iscover Iscover Iscover Iscover Iscover Iscover Iscover Iscover Iscover Iscover
< Invented Name > has no photocarcinogenic potential in animals (see section 5.3. “Preclinical Safety Data”).
< Invented Name > has not been studied in patients with Netherton’s syndrome.
12 < Invented Name > may be used on all skin areas, including the head and face, neck and intertriginous areas, except on mucous membranes. < Invented Name > should not be applied under occlusion (see Section 4.4 “Special warnings and precautions for use”).
< Invented Name > should not be applied to areas affected by acute cutaneous viral infections (herpes simplex, chicken pox).
Long-term effect on the local skin immune response and on the incidence of skin malignancies is unknown. < Invented Name > should not be applied to potentially malignant or pre-malignant skin lesions.
< Invented Name > cream should not be used in patients with congenital or acquired immunodeficiencies or in patients on therapy that causes immunosuppression.
< Invented Name > has no known effect on the ability to drive and use machines.
Treatment with < Invented Name > should be discontinued until the infection has cleared. < Invented Name > may cause reactions at the application site such as a feeling of warmth and/or a burning sensation.
Taking (Invented name)® with food or drink • You can take (Invented name)® with or without food, whichever you prefer. • You should avoid alcohol while you are taking this medicine.
< {INVENTED NAME }< syrup > < oral solution > < oral suspension > contains … g of sucrose per … ml.
Manufacturer AstraZeneca UK Limited Silk Road Business Park Macclesfield Cheshire SK10 2NA United Kingdom
Patient’s Name: __________________ Doctor’s Name: __________________ Doctor’s Phone: __________________
Patient’s Name: _____________________ Doctor’s Name: _____________________ Doctor’s Phone: _____________________
“{Patient Name} was implanted with a medicinal product containing eptotermin alfa on {dd/mm/yyy}.
{PRODUCT NAME} is used to lower lipids known as cholesterol and triglycerides in the blood when a low fat diet and life style changes on their own have failed.
Product name, MAH, MA number, date of first authorisation/ renewal of authorisation, Date of revision of the text.
NAME OF THE MARKETING AUTHORISATION HOLDER a
NAME OF THE MARKETING AUTHORISATION HOLDER a
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
NAME OF MARKETING AUTHORISATION HOLDER
NAME OF MARKETING AUTHORISATION HOLDER
NAME OF THE MARKETING AUTHORISATION HOLDER a
Name and address of the manufacturer of the biological active substance
Name and address of the manufacturer(s) of the biological active substance
Name and address of the manufacturer(s) of the biological active substance(s)
Name and address of the manufacturers responsible for batch release in the EEA
Names and addresses of the manufacturer(s) responsible for batch release
Name and address of the manufacturer responsible for batch release for syrup
Name and address of the manufacturer(s) of the biological active substance
Name and address of the manufacturer(s) of the biological active substance(s)
Name and address of the manufacturer(s) of the biological active substance(s)
Name and address of the manufacturer(s) of the biological active substance
Name and address of the manufacturer(s) of the biological active substance(s)
Name and address of the manufacturer(s) of the biological active substance(s)
Name and address of the manufacturer(s) of the biological active substance
Name and address of the manufacturer(s) of the biological active substance
Name and address of the manufacturer(s) of the biological active substance(s)
Merial Laboratory of Lyon Porte des Alpes Rue de l'aviation 69800 SAINT-PRIEST France
Name and address of the manufacturer(s) of the biological active substance(s)
Name and address of the manufacturer(s) of the biological active substance
Name and address of the manufacturer(s) of the biological active substance(s)
Name and address of the manufacturer(s) of the biological active substance
Name and address of the manufacturer(s) responsible for batch release
Name and address of the manufacturer(s) of the biological active substance(s) Boehringer Ingelheim Vetmedica Inc.
Name and address of the manufacturer(s) of the biological active substance(s)
Name and address of the manufacturer(s) responsible for batch release
Mérial, Laboratoire Porte des Alpes Rue de l'Aviation 69800 Saint Priest France
Name and address of the manufacturer of the biological active substance
Name and address of the manufacturer(s) of the biological active substance(s)
Name and address of the manufacturer(s) of the biological active substance(s)
Name and address of the manufacturer(s) of the biological active substance
Name and address of the manufacturers of the biological active substances Fort Dodge Animal Health Holland C. J. van Houtenlaan 36 1381 CP Weesp The Netherlands
MERIAL Laboratoire de Toulouse 4 Chemin du Calquet 31300 TOULOUSE FRANCE
Name and address of the manufacturer of the biological active substance(s) MERIAL Laboratoire Porte des Alpes Rue de l'Aviation F-69800 SAINT PRIEST FRANCE
Name and address of the manufacturer(s) of the biological active substance(s)
Name and address of the manufacturer(s) of the biological active substance
Name and address of the manufacturer(s) responsible for batch release Fort Dodge Animal Health Holland C. J. van Houtenlaan 36 1381 CP Weesp The Netherlands
Laboratoires BIOCODEX 1 avenue Blaise Pascal, 60000 Beauvais FRANCE
MERIAL Laboratoire Porte des Alpes Rue de l'Aviation F-69800 SAINT PRIEST
Name and address of the manufacturer responsible for batch release U U
Name and address of the manufacturer(s) responsible for batch release
Name and address of the manufacturer(s) responsible for batch release
Pfizer (Heinrich Mack Nachf) Heinrich-Mack-Str.
The pharmacokinetics of IntronA and ribavirin (dose-normalized) are similar in adults and children or adolescents.
Name and address of the Manufacturing Authorisation Holder responsible for batch release Intervet GesmbH Siemensstrasse 107 A-1210 Wien Austria
Name and address of the Manufacturing Authorisation Holder responsible for batch release Intervet International B. V.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER uc
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
11 NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Date of first authorisation:
GENERAL CLASSIFICATION FOR SUPPLY
Name and address of the Marketing Authorisation Holder Intervet International B. V.
MARKETING AUTHORISATION HOLDER
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
NAME AND ADDRESS OF THE MARKETING AUTORISATION HOLDER
NAME OF THE MARKETING AUTHORISATION HOLDER
or Shire Pharmaceutical Contracts Ltd
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER no
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
{Name and address} < {tel} > < {fax} > < {e-mail} >
{Name and Address }< {tel }> < {fax }> < {e-mail }>
390 {Name and address} < {tel} > < {fax} > < {e-mail} >
398 {Name and address} < {tel} > < {fax} > < {e-mail} >
414 {Name and address} < {tel} > < {fax} > < {e-mail} >
{Name and address} < {tel} > < {fax} > < {e-mail} >
{Name and address} < {tel} > < {fax} > < {e-mail} >
{Name and Address} < {tel} > < {fax} > < {e-mail} >
NAME OR CORPORATE NAME AND ADDRESS OR REGISTERED PLACE OF BUSINESS OF THE MARKETING AUTHORISATION HOLDER
Names and addresses of the manufacturers of the biological active substance
Names and addresses of the manufacturers responsible for batch release
Names and addresses of the manufacturer(s) of the biological active substance(s)
Nonafact is a powder and solvent that are mixed together to form a solution for infusion (drip into a vein).
Nonafact is presented as a powder and a solvent for solution for injection (vial of 5 ml or 10 ml)
Orphan medicinal product designation date:
Not known* Skin and subcutaneous tissue disorders:
ge Oral hypoglycaemic agents (OHA), monoamine oxidase inhibitors (MAOI), non-selective beta- blocking agents, angiotensin converting enzyme (ACE) inhibitors, salicylates and alcohol.
Oral hypoglycaemic agents (OHA), monoamine oxidase inhibitors (MAOI), non-selective beta- blocking agents, angiotensin converting enzyme (ACE) inhibitors, salicylates and alcohol.
Norbitec GmbH Pinnauallee 4 D-25436 Uetersen Germany
Norge Allergan Norden AB Johanneslundsvägen 3-5 S-194 81 Upplands Väsby Sverige Tlf: + 46 (0)8 594 100 00 E-mail: uk_medinfo@allergan. com
Tel: +31 30 6 02 59 14 Norge Boehringer Ingelheim Norway KS Tlf: +47 66 76 13 00
Tlf: +47 66 76 13 00
Norge CSL Behring AB P.O.Box 712 S-182 17 Danderyd
Norge Biovitrum AB (publ) C. J.
Deutschland BRISTOL-MYERS SQUIBB GMBH & CO.
Norge Wyeth Tlf: +47 40 00 23 40 Fax: +47 40 00 23 41
1384 Asker Tlf: +47 66 75 33 00
Norge MSD (Norge) AS Tlf: +47 32 20 73 00 msdnorge@msd.no
Norge MSD (Norge) AS Tlf: +47 32 20 73 00 msdnorge@msd. no
Norge MSD (Norge) AS Tlf: +47 32 20 73 00 msdnorge@msd. no
Nederland Merck Sharp & Dohme BV Tel: +31 (0) 23 5153153 msdbvnl@merck.com Norge MSD (Norge) AS Tlf: +47 32 20 73 00 msdnorge@msd.no
Norge MSD (Norge) A/ S Tlf: +47 32 20 73 00 msdnorge@ msd. no
Norge MSD (Norge) AS Tlf: +47 32 20 73 00 msdnorge@msd.no
Norge MSD (Norge) AS Tlf: +47 32 20 73 00 msdnorge@msd. no
Norge MSD (Norge) AS, Tlf: +47 32 20 73 00 msdnorge@msd. no
Norge Nycomed Pharma AS Drammensveien 852 NO-1372 Asker Tlf: +47 6676 3030 infonorge@nycomed.no
Norge Sandoz AS Jernbaneveien 4 N-1400 Ski Tlf: + 47 64 91 30 00
Norge Aventis Pharma Norge AS Tlf: +47 67 10 71 00
Norge Aventis Pharma Norge AS Tlf: +47 67 10 71 00
Norge Aventis Pharma NorgeAS Tlf: +47 67 10 71 00
Österreich Orphan Europe (Germany) GmbH Max-Planck Str.
Norge Wyeth Tlf: + 47 40 00 23 40 Fax: +47 40 00 23 41
Norge Wyeth Tlf: +47 40 00 23 40 Fax: +47 40 00 23 41
Norge Wyeth Tlf: +47 40 00 23 40 Fax: +47 40 00 23 41
Normally, no additional benefit is conferred by treating more frequently than every three months.
You will usually be observed during the whole infusion and for at least 20 minutes thereafter.
should be evaluated and treated, if appropriated: ic
should be evaluated and treated, if appropriated: in
should be evaluated and treated, if appropriated: • Infection/ inflammation ic
Norton Healthcare Gemini House Flex Meadow, Harlow Essex CM19 5TY UK
Norton Healthcare Limited Albert Basin Royal Docks London E16 2QJ United Kingdom
Norge Meda A/ S Askerveien 61 N-1384 Asker Tlf: +47 66 75 33 00
Norvir contains polyoxyl 35 castor oil which may cause stomach upset and diarrhoea.
Children under 2 years of age should not take Norvir.
and increased sleeping)
Michel CHOJNOWSKI Danmark Ib VALSBORG Ib Bo LUMHOLTZ
CPMP Note for Guidance on Inclusion of antioxidants and anti- microbial preservatives in medicinal products
Note for guidance on xenogenic cell therapy products (jointly with Efficacy and Safety Working Parties)
Concept paper on requirements for evaluation of new immunological ’adjuvants'in vaccines
used as excipients in medicinal products
Note for guidance on requirements and controls of bovine serum used during the manufacture of medicinal products
Note for guidance on comparability r-DNA-derived medicinal products (joint with Efficacy and Safety Working Parties)
NOTE: do not use any areas in which you feel lumps, firm knots, or pain; talk to your doctor or healthcare professional about anything you find. • The instruction manual provided with the RebiSmart autoinjector device and your doctor will tell you how to choose the correct dose of 22 micrograms.
NOTE: do not use any areas in which you feel lumps, firm knots, or pain; talk to your doctor or healthcare professional about anything you find. • The instruction manual provided with the RebiSmart autoinjector device and your doctor will tell you how to choose the correct dose of 44 micrograms.
Record the date of treatment in the clinical records of the animals.
Note time patient drinks test meal
Note that the injection button only goes out as far as the amount of insulin that is left in the reservoir.
Guidelines on the quality, safety and efficacy of medicinal products for human use catalogue n˚ CO-55-89-843-EN-C, also available in ES, DE, FR, IT Addenda volumes published in July 1990 (n˚ CB-59-90-936- EN-C, also in ES, DE, FR), May 1992 (n˚ CO-75-92-558- EN-C, also in ES, DE, FR, IT) and January 1995 (III/5415/95, not yet published)
• Note the figure on the cap next to the dosage indicator • Note the highest figure you can see on the push-button scale • Add the two together to show the dose you set • If you have set a wrong dose, simply turn the cap forwards or backwards until you set the right number of units.
Record the patient’s skin type and the date of injection on the patient alert card
Remember that AMMONAPS must be taken with the special protein reduced diet.
Note that it is acceptable for a small amount of fluid to remain in the solvent vial after transfer.
Keep a record of what you are eating in a food diary.
Notice to marketing authorisation holders - pharmacovigilance guidlines
Read all of this leaflet carefully before your child is vaccinated.
Summary of the EMEA work programme 2006 EMEA/ 62913/ 2006 Parallel-distribution notifications validated (Input)
Proportional reporting ratio [PRR], Information Component [IC)] or the Empirical Bayesian Geometric Mean [EBMG]; this is not mandatory as all MAHs do not yet have this capability.
Education and sharing regulatory expertise is also a priority.
[Not required on the immediate label]
After an increase in dose, an additional test will be done after 2 weeks.
In particular, tell your doctor if you have: • diabetes • high blood pressure • history of vascular disease or thrombosis • overweight • blood volume decrease • diseases which increase blood viscosity • advanced age
Remember to avoid direct sunlight coming through the window or direct light from household appliances such as reading lamps.
Subjects with congenital malformation of the gastrointestinal tract that could predispose to intussusception.
We have also worked closely with partners elsewhere in the world, both through the ICH and VICH initiatives and bilaterally.
There are a number of challenges that we will need to analyse and plan for their consequences.
In patients with severe hepatic impairment clinical experience is lacking and therefore the use of doxazosin is not recommended.
We suggest you write the date of your most recent test and also of your next test (ask your doctor for the date) on the patient reminder card, to help you remember when your next test is due.
We also suggest you consult your doctor or nurse for a demonstration.
• new IT architecture; • office system; 8 • development environment; • corporate database; • document management and work flow;
New IT architecture
stomach) or vomiting that is new or worsened.
of suspected adverse reactions to veterinary medicines • In accordance with its guideline on extrapolation of MRLs
New applications under the centralised system and scientific advice
The assessment report from rapporteurs was received by day 70 for 94% of the products, which was an improvement on the 78% in 2000
New applications (by medicinal product) New applications (by active substance)
New pharmacovigilance guidelines
Chapter 1 EMEA in the European system
Chapter 1 EMEA in the European system New issues to be faced in 2003 with workload implications:
Contribution to the activities of the EMCDDA in Lisbon through contribution to EU Joint Actions and the Trend project
increasing need for re-inspections of authorised sites
Maintenance of the office and public areas
Objectives: • To streamline the current procedure taking into account experience thus far in particular by identifying a pragmatic
personnel data and management system
Do not open or crush the capsules unless you have difficulty in swallowing (e. g. in children).
Novaris Healthcare A/ S, Lyngbyvej 172 DK-2100 København Ø, Denmark
Novartis Farmaceutica, S. A Gran Via de les Corts Catalanes, 764 08013 Barcelona Spain
Novartis Healthcare A/ S, Lyngbyvej 172, 2100 Kobenhavn, Denmark Attn:
Novartis Healthcare A/ S, Lyngbyvej 172, 2100 København Ø Denmark
Novartis Pharma GmbH, Roonstrasse 25, D-90420 Nüremberg, Germany.
Novartis Sanidad Animal, S. L., Tel: +34-93 306 4700 France:
Novem 5 mg/ ml solution for injection for cattle and pigs Meloxicam
Novem 5 mg/ ml solution for injection for cattle and pigs
Novem is a solution for injection, which comes in two strengths:
NovoMix 30 FlexPen 100 U/ ml, suspension for injection in a pre-filled pen.
NovoMix 30 FlexPen in use or carried as a spare: can be kept at ambient temperature (below 30°C) for up to 4 weeks, but any remainder must then be discarded.
NovoMix 30 should not be disposed of via wastewater or household waste.
NovoMix 30 which has been frozen must not be used.
NovoMix 50 and NovoMix 70 injected three times a day have been compared in 664 patients (with type 1 or type 2 diabetes) to human insulin 30 injected twice a day.
NovoMix 50 and NovoMix 70 gave better overall control of blood glucose than human insulin 30.
NovoMix 50 FlexPen 100 U/ ml Suspension for injection in a pre-filled pen Insulin aspart
NovoMix 50 FlexPen 100 U/ ml, suspension for injection in a pre-filled pen.
40 NovoMix 50 FlexPen in use or carried as a spare: can be kept at ambient temperature (below 30°C) for up to 4 weeks, but any remainder must then be discarded.
NovoMix 50 FlexPen that is being used or about to be used is not to be kept in the refrigerator.
NovoMix 50 should never be administered intravenously.
NovoMix 50 should not be disposed of via wastewater or household waste.
NovoMix 50 which has been frozen must not be used.
NovoMix 70 is a mixture of rapid-acting insulin analogue (70%) and long-acting insulin analogue (30%).
NovoMix 70 FlexPen 100 U/ ml Suspension for injection in a pre-filled pen Insulin aspart
NovoMix 70 FlexPen 100 U/ ml, suspension for injection in a pre-filled pen.
NovoMix 70 FlexPen in use or carried as a spare: can be kept at ambient temperature (below 30°C) for up to 4 weeks, but any remainder must then be discarded.
NovoMix 70 FlexPen that is being used or about to be used is not to be kept in the refrigerator.
NovoMix 70 FlexPen is for use by one person only.
NovoMix 70 should never be administered intravenously.
NovoMix 70 should not be disposed of via wastewater or household waste.
NovoMix 70 which has been frozen must not be used.
NovoMix is a range of white suspensions for injection.
Manufacturer The manufacturer can be identified by the batch number printed on the slip of the carton and on the label:
NovoNorm 0.5 mg tablets 1 mg tablets 2 mg tablets
NovoRapid 100 U/ ml, solution for injection in a vial.
NovoRapid is administered subcutaneously in the abdominal wall, the thigh, the deltoid region or the gluteal region.
NovoRapid is administered subcutaneously (under the skin) by injection in the abdominal wall (tummy), the thigh, the deltoid region (shoulder) or the gluteal region (buttocks).
NovoRapid is a clear colourless solution for injection.
NovoRapid FlexPen 100 U/ ml, solution for injection in a pre-filled pen.
NovoRapid FlexPen should only be used in combination with products that are compatible with them and allow the pens to function safely and effectively.
NovoRapid FlexPen in use or carried as a spare:
NovoRapid FlexPen is for use by one person only.
NovoRapid FlexPen is for use by one person only
NovoRapid InnoLet 100 U/ ml, solution for injection in a pre-filled pen.
NovoRapid InnoLet should only be used in combination with products that are compatible with them and allow the pens to function safely and effectively.
NovoRapid InnoLet in use or carried as a spare:
NovoRapid should not be disposed of via waste water or household waste.
NovoRapid should not be used if it does not appear clear and colourless.
NovoRapid NovoLet 100 U/ ml, solution for injection in a pre-filled pen.
NovoRapid NovoLet should only be used in combination with products that are compatible with them and allow the pens to function safely and effectively.
NovoRapid NovoLet that is being used or about to be used is not to be kept in the refrigerator.
NovoRapid NovoLet is a simple, compact pre-filled pen.
NovoRapid Penfill should only be used in combination with products that are compatible with them and allow the Penfill to function safely and effectively.
NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection eptacog alfa (activated)
NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection
NovoSeven 1 mg (50 KIU) powder for injection eptacog alfa (activated) IV
NovoSeven 2.4 mg (120 KIU) Powder for injection eptacog alfa (activated) IV
NovoSeven 2.4 mg (120 KIU) Powder and solvent for solution for injection
NovoSeven has also been studied in patients with Glanzmann's thrombasthenia who could not receive platelets.
NovoSeven must not be mixed with infusion solutions or be given in a drip.
NovoSeven can be used during breast-feeding.
NovoSeven reconstituted product is a clear, colourless solution.
NovoSeven is presented as powder and solvent for solution for injection containing 1 mg eptacog alfa (activated) per vial (corresponds to 50 KIU/ vial).
NovoSeven is presented as powder and solvent for solution for injection containing 2 mg eptacog alfa (activated) per vial (corresponds to 100 KIU/ vial).
Nowogrodzka PL – 02- 014 Warszawa LENGYELORSZÁG Tel: +48(0)22 50 40 890
Nowogrodzka 68 PL - 02- 014 Warszawa POLIJA Tel: +48(0)22 50 40 890
Nowogrodzka 68 PL - 02- 014 Warszawa POLJSKA Tel: +48(0)22 50 40 890
Nowogrodzka PL – 02- 014 Warszawa POLSKA Tel: +48(0)22 50 40 890
Nowogrodzka PL – 02- 014 Warszawa POOLA Tel: +48(0)22 50 40 890
Nowogrodzka PL – 02- 014 Warszawa Tel: +48(0)22 50 40 890
Nowogrodzka 68 PL - 02- 014 Warszawa POLIJA Tel: +48(0)22 50 40 890
Noxafil also successfully treated 11 of 24 patients who had proven or probable fusariosis, 9 of 11 patients with chromoblastomycosis or mycetoma, and 11 of 16 patients with coccidioidomycosis.
Noxafil must only be used as directed by your doctor.
Noxafil is also used to treat patients with oropharyngeal candidiasis or ‘ thrush’, a fungal infection of the mouth and throat due to Candida.
- No. patients with event - No. patients without event
- No. patients with event - No. patients without event Distant disease-free survival
Nplate should be injected once per week in order to keep your platelet counts up.
Nplate should be administered once weekly as a subcutaneous injection.
Nplate should be used with caution in these populations.
Nplate is indicated for adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) splenectomised patients who are refractory to other treatments (e. g. corticosteroids, immunoglobulins).
Nplate is a protein used to treat low platelet counts in patients with immune (idiopathic) thrombocytopenic purpura (called ITP).
Nplate is a sterile but unpreserved product and is intended for single use only.
Nplate is a sterile but unpreserved product and is intended for single use only.
N Proportion of patients with SREs (%)
Su 50 ml (25 doses) – 100 ml (50 doses) – 250 ml (125 doses)
Su Manufacturer responsible for batch release
nd Do not mix with any other vaccine or immunological product.
nd Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
monoclonal antibody (Cotara)
nuclitec GmbH Gieselweg 1 38110 Braunschweig Germany
nuclitec GmbH Gieselweg 1 D-38110 Braunschweig Germany
nuclitec GmbH Gieselweg 1, D-38110 Braunschweig Germany Tel +49- 05307-932262 Fax +49- 05307-932337 e-mail
absolute neutrophil count decreased, blood amylase increased, blood cholesterol increased, blood creatinine increased, blood glucose increased, blood urea nitrogen increased, fasting blood glucose increased, glucose urine present, high density lipoprotein increased, low density lipoprotein increased, platelet count decreased, red blood cells urine positive, weight increased, white blood cell count decreased
patients with 150,000 platelets per mm3 and more:
patients with 150,000 platelets per mm³ and more:
Blood cell counts Platelet counts should be monitored closely, especially during the first few weeks of filgrastim therapy.
Blood cell counts ANC should be monitored closely, especially during the first few weeks of filgrastim therapy.
MARKETING AUTHORISATION NUMBERS
MARKETING AUTHORISATION NUMBER(S)
MARKETING AUTHORISATION NUMBERS
MARKETING AUTHORISATION NUMBER(S
MARKETING AUTHORISATION NUMBER(S)
MARKETING AUTORISATION NUMBER(S)
NUMBER IN THE COMMUNITY REGISTER OF MEDICINAL PRODUCTS
NUMBER(S) IN THE COMMUNITY REGISTER OF MEDICINAL
NUMBER(S) IN THE COMMUNITY REGISTER OF MEDICINAL PRODUCTS
NUMBER(S) IN THE COMMUNITY REGISTER OF MEDICINAL PRODUCTS
NUMBERS IN THE COMMUNITY REGISTER OF MEDICINAL PRODUCTS
EU/ 1/ 06/ 368/ 088 EU/ 1/ 06/ 368/ 013 EU/ 1/ 06/ 368/ 014 EU/ 1/ 06/ 368/ 093 EU/ 1/ 06/ 368/ 098 EU/ 1/ 06/ 368/ 015
EU/ 1/ 07/ 427/ 001 EU/ 1/ 07/ 427/ 002 EU/ 1/ 07/ 427/ 003 EU/ 1/ 07/ 427/ 038 EU/ 1/ 07/ 427/ 048
MARKETING AUTHORISATION NUMBER(S)/ MRP PROCEDURE NUMBER
EU Number EU/ 1/ 00/ 151/ 001 EU/ 1/ 00/ 151/ 002 EU/ 1/ 00/ 151/ 003 EU/ 1/ 00/ 151/ 004 EU/ 1/ 00/ 151/ 005 EU/ 1/ 00/ 151/ 006 EU/ 1/ 00/ 151/ 007 EU/ 1/ 00/ 151/ 008 EU/ 1/ 00/ 151/ 009 EU/ 1/ 00/ 151/ 010 EU/ 1/ 00/ 151/ 011 EU/ 1/ 00/ 151/ 012 EU/ 1/ 00/ 151/ 013 EU/ 1/ 00/ 151/ 014 EU/ 1/ 00/ 151/ 015 EU/ 1/ 00/ 151/ 016 EU/ 1/ 00/ 151/ 017 EU/ 1/ 00/ 151/ 018 EU/ 1/ 00/ 151/ 019 EU/ 1/ 00/ 151/ 020 EU/ 1/ 00/ 151/ 021 EU/ 1/ 00/ 151/ 022 EU/ 1/ 00/ 151/ 023 EU/ 1/ 00/ 151/ 024
EU Number EU/ 1/ 06/ 347/ 001 EU/ 1/ 06/ 347/ 002 EU/ 1/ 06/ 347/ 003 EU/ 1/ 06/ 347/ 004 EU/ 1/ 06/ 347/ 005 EU/ 1/ 06/ 347/ 006
EU Number EU/ 1/ 06/ 380/ 001 EU/ 1/ 06/ 380/ 002 EU/ 1/ 06/ 380/ 003
No other solutions should be used for reconstitution (see section 6.2).
Do not use TRAVATAN. • if you are allergic to travoprost or any of the other ingredients of TRAVATAN.
Only a clear and colourless solution should be used.
Do not use ReFacto AF if you notice that it is cloudy or contains visible particles.
Only use needles that have been approved for use with OptiSet.
230 Only needles that are compatible for use with SoloStar should be used.
Only needles that are compatible for use with SoloStar should be used.
Only use needles that are compatible for use with SoloStar.
that are compatible for use with SoloStar should be used.
Only use needles that are compatible for use with SoloStar (see “SoloStar Instructions for Use”).
Use only clear and colourless solutions.
17 Use only clear solutions and undamaged containers.
Use only clear solutions and undamaged containers.
Do not use Aldurazyme If you are allergic (hypersensitive) to any of the ingredients of Aldurazyme or if you have experienced a severe allergic reaction to laronidase.
Do not use any Neulasta that is left in the syringe.
Do not use OPATANOL • If you are allergic (hypersensitive) to olopatadine or any of the other ingredients of OPATANOL.
Do not use Optimark if you are allergic (hypersensitive)  to the active substance gadoversetamide or  to any of the other ingredients of Optimark, or  to other gadolinium contrast agents
Do not use STELARA • If you are allergic (hypersensitive) to ustekinumab or to any of the other ingredients of STELARA (listed in section 6 ‘ What STELARA contains’). • If you have an active infection which your doctor considers important (see also below ‘ Take special care with STELARA’).
Do not use TESLASCAN if one of the following conditions exists:
● Never use a syringe with a bent or damaged needle.
Use syringes and needles only once.
► In insulin infusion pumps ► If NovoLet is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Actraphane) ► If it's not uniformly white and cloudy when it's resuspended.
Do not use Altargo if you are breast-feeding a baby.
Do not use AMMONAPS if you are breast-feeding, since this medicine could pass into the breast-milk and harm your baby.
Do not use this OptiSet if the insulin is cloudy, coloured or has particles.
Do not use sunlamps or tanning beds, and avoid sunlight as much as possible during treatment with Aldara cream.
Do not use any Neulasta that is left in the syringe.
Do not use FORSTEO if solid particles appear or if the solution is cloudy or coloured.
Do not use Fuzeon if you notice any particles in the powder or the solution once the water for injection has been added.
Do not use Fuzeon if you notice any particles in the powder or the solution once the water for injections has been added.
 Do not use the syringe if this perforation is already broken.
You must not use any Kineret that is left in the vial.
Do not use the drops while your contact lenses are in your eyes.
Do not store above 25 °C Do not use the bottle more than 6 weeks after opening.
Do not use after the expiry date or if it is cloudy or if you see particles.
► In insulin infusion pumps ► If Penfill or the device containing Penfill is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Mixtard) ► If it's not uniformly white and cloudy when it's resuspended.
► In insulin infusion pumps ► If NovoLet is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn't been stored correctly or been frozen (see 6 How to store Mixtard) ► If it's not uniformly white and cloudy when it's resuspended.
Do not use Optisulin if you notice particles in it.
Do not use SoloStar if it is damaged or not working properly, it has to be discarded and a new SoloStar has to be used.
Do not use SoloStar if it is damaged or not working properly (due to mechanical defects), it has to be discarded and a new SoloStar has to be used.
Do not use SoloStar if it is damaged or not working properly, it has to be discarded and a new SoloStar has to be used.
Do not use SoloStar if it is damaged or not working properly (due to mechanical defects), it has to be discarded and a new SoloStar has to be used.
If it is not, do not use.
DO NOT USE your Pen if any part appears broken or damaged.
Once the KwikPen is empty, do not use it again.
Only use needles that have been approved for use with SoloStar.
Only use needles that have been approved for use with SoloStar.
Only use needles that are compatible for use with SoloStar (see “SoloStar Instructions for Use”).
Only use SoloStar if the solution is clear, colourless and waterlike.
NutropinAq 10 mg/ 2 ml (30IU) solution for injection Somatropin
NutropinAq 10 mg/ 2 ml (30IU), solution for injection Somatropin
NutropinAq has been studied in children who had growth failure cause by lack of growth hormone (230), Turner syndrome (117), or kidney disease (195).
NutropinAq is intended for use only with the NutropinAq Pen.
NutropinAq is used to treat children in the following situations: • children who fail to grow because of a lack of growth hormone. • children who are short because of Turner syndrome (a rare genetic disorder affecting girls), confirmed by chromosome analysis (DNA testing). • children before puberty, who fail to grow because of longstanding kidney disease, (chronic renal insufficiency) up to the time when they receive a kidney transplant.
NutropinAq is a solution for subcutaneous use.
NutropinAq is a solution for injection in a cartridge.
The NutropinAq is designed to withstand a nominal (one hour maximum) period of time outside of the refrigerator on a daily basis.
Variety of posts in the Irish Civil Service, serving in the Departments of Health, Finance and the Office of Public Works.
Key objectives for financial and administrative support..............................
Key objectives for technical co-ordination 1997-1998
Key objectives for administrative support 1997-1998
Key objectives for technical co-ordination.....................................................
Key objectives for medicinal products for human use..................................
Key objectives for medicines for human use
Key objectives for medicinal products for human use 1997-1998
Key objectives for medicines for veterinary use
Key objectives for medicinal products for veterinary use............................
Goals and objectives of the Unit for the Evaluation of Medicines for Human Use............................................................... .21
Secondary endpoints: secondary efficacy parameters included the proportion of women remaining undelivered within 48 h of treatment initiation.
Chapter 4 Key objectives for veterinary medicines and information technology.............................................................................. ..27
Oblong, opaque, off-white to cream coloured, printed with ‘ GX CC1’.
Oblong, opaque, off-white to cream coloured, printed with ‘ GX CC2’.
Aseptic technique must be strictly observed throughout handling of Myocet since no preservative is present.
Follow them exactly and visit your diabetes clinic regularly. • If you change the type of insulin you use (for example from a human or animal insulin to a Humalog product), you may have to take more or less than before.
Follow them exactly and visit your diabetes clinic regularly. • If you change the type of insulin you use (for example from a human or animal insulin to a Humalog product), you may have to take more or less than before.
Follow them exactly and visit your diabetes clinic regularly. • If you change the type of insulin you use (for example from a human or animal insulin to a Liprolog product), you may have to take more or less than before.
Follow them exactly and visit your diabetes clinic regularly. • If you change the type of insulin you use (for example from a human or animal insulin to a Humalog product), you may have to take more or less than before.
Follow them exactly and visit your diabetes clinic regularly. • If you change the type of insulin you use (for example from a human or animal insulin to a Liprolog product), you may have to take more or less than before.
210 • If you change the type of insulin you use (for example from a human or animal insulin to a Humalog product), you may have to take more or less than before.
225 • If you change the type of insulin you use (for example from a human or animal insulin to a Humalog product), you may have to take more or less than before.
Follow them exactly and visit your diabetes clinic regularly. • If you change the type of insulin you use (for example from a human or animal insulin to a Humalog product), you may have to take more or less than before.
Follow them exactly and visit your diabetes clinic regularly. • If you change the type of insulin you use (for example from a human or animal insulin to a Humalog product), you may have to take more or less than before.
This might just be for the first injection or it may be a gradual change over several weeks or months.
178 • If you change the type of insulin you use (for example from a human or animal insulin to a Liprolog product), you may have to take more or less than before.
192 • If you change the type of insulin you use (for example from a human or animal insulin to a Liprolog product), you may have to take more or less than before.
Follow them exactly and visit your diabetes clinic regularly. • If you change the type of insulin you use (for example from a human or animal insulin to a Liprolog product), you may have to take more or less than before.
Follow them exactly and visit your diabetes clinic regularly. • If you change the type of insulin you use (for example from a human or animal insulin to a Liprolog product), you may have to take more or less than before.
Obtaining probenecid Probenecid is not supplied with VISTIDE and should be obtained via the Marketing Authorisation Holder of probenecid.
19 Trudexa 80/ 40 mg and 160/ 80 mg compared to placebo and was seen at weeks 26 and 56 in CHARM as well among the adalimumab treatment groups compared to the placebo group.
s ori Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients, including those treated with Viraferon.
- Obstruction of the gut, increased blood level of the enzyme amylase, reflux of stomach content
Pulmonary embolism Dyspnoea Hypoxia Epistaxis
Very common (≥ 1/ 10) Very Rare (≤ 1/ 10 000) Ear and labyrinth disorders:
Eye Disorders Ear and Labyrinth Disorders
Increase in transaminases Increased bilirubin
Eye Disorders Ear and Labyrinth Disorders
Hepatobiliary Disorders
Increase in transaminases Increased bilirubin
P-value (stratified Cochran-Mantel-Haenszel test) = 0.002.
The following side effects are important and will require immediate action if you experience them: − Angioneurotic oedema (swelling of the face, tongue and windpipe which can cause great difficulty in breathing).
Angioedema, bronchial constriction, fever.
oedema lower limb, pyrexia, weakness, asthenia, feeling abnormal, impaired healing, peripheral oedema
Aspartate aminotransferase increased Alanine aminotransferase increased
face oedema, dry skin, contusion, tendency to bruise, night sweats
macular oedema, iritis, conjunctivitis, eyelid ptosis, corneal disorder
Oedema, pitting oedema, facial oedema, oedema peripheral, fatigue, flushing, asthenia, hot flush
Oedema, pitting oedema, facial oedema, oedema peripheral, fatigue, flushing, asthenia, hot flush 6
Papilloedema, reduced visual acuity*, myopia*
peripheral oedema, flushing (facial reddening).
- Very common: peripheral oedema, flushing (facial reddening).
Peripheral Oedema Haemorrhage, Hypertension, Oedema3, Vasodilatation1,2,3, Varicose Vein
Pericardial effusion Pulmonary oedema Pulmonary hypertension Haemorrhage
Pulmonary oedema*, interstitial pneumonia*, pulmonary infiltrates*
Also reported in patients with invasive aspergillosis were pulmonary oedema, adult respiratory distress syndrome (ARDS), and radiographic infiltrates.
Rare (occur in more than 1 in 10000 patients but less than 1 in 1000 patients)
Peripheral oedema Peripheral oedema-worsening Fatigue Investigations
Erectile dysfunction, vaginitis conditions Oedema peripheral, asthenia, face oedema, oedema
Oedema peripheral Chest pain Oedema Investigations
Congestive heart failure/ cardiac dysfunction
Superficial oedema Pleural Effusion Generalised oedema Congestive heart failure/ cardiac dysfunction
watery eyes, swollen or painful eyelids, tired eyes, in-growing eyelashes, headache, runny nose, hair growing around the eye
Mouth ulceration, esophagitis, nausea and vomiting, gastritis, dysphagia, dry mouth, flatulence, gingivitis, taste perversion
oestrogens and progestagens, saluretics, thiazide diuretics, thyroid stimulating agents, glucocorticoids, phenothiazine derivatives, chlorpromazine, adrenaline and sympathicomimetics, nicotinic acid (high dosages) and nicotinic acid derivatives, laxatives (long-term use), phenytoin, diazoxide, glucagon, barbiturates and rifampicin. acetozolamide
The EudraVigilance database management system (DBMS) and the EudraVigilance gateway are operational at the EMEA since December 2001.
Office for Official Publications of the EC, 2, rue Mercier, L - 2985 Luxembourg Tel:
Office for Official Publications of the European Communities 2, rue de Mercier L -2985 Luxembourg
Office for Official Publications of the European Communities 2, rue de Mercier L - 2985 Luxembourg The texts will also be available in 1998 on the EudraLex Internet site at http://www.eudra.org 7 b) EMEA documents
Office for Official Publications of the European Communities, 1999
Office for Official Publications of the European Communities, 2000
Office for Official Publications of the European Communities 2, rue de Mercier – L - 2985 Luxembourg
Office for Official Publications of the European Communities 2, rue de Mercier L - 2985 Luxembourg
Office for Official Publications of the European Communities 2, rue Mercier L - 2985 Luxembourg The texts will also be available in 1998 on the EudraLex Internet site at http://dg3.eudra.org
Office for Official Publications of the European Communities
OFFICE FOR OFFICIAL PUBLICATIONS OF THE EUROPEAN COMMUNITIES
Prescriber guide and Prescriber slide kit − The educational tools are designed to aid physicians in optimising the benefit-risk ratio of porfimer treatment. − Patients should NOT be treated with porfimer if: o they have severe hepatic disease. o they have trachea or broncho-oesophageal fistulas. o they have suspected erosions of major blood vessels.
Olanzapine Mylan is also used to treat moderate to severe manic episodes (extremely high mood) in adults.
Olanzapine Neopharma is also used to treat moderate to severe manic episodes (extremely high mood) in adults.
Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva
Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva
Olanzapine Teva belongs to a group of medicines called antipsychotics.
Olanzapine Teva is also used to treat moderate to severe manic episodes (extremely high mood) in adults.
Sorbitan oleate, 2-Ethylhexylacrylate – 1-Vinyl-2-pyrrolidone co-polymer.
Sorbitan oleate, 2-Ethylhexylacrylate – 1-Vinyl-2-pyrrolidone copolymer, E110, E180, copper phthalocyanine blue pigment, polyethylene, siliconised polyester.
From 1971 to 1974, Mr O'Malley completed articles in Dublin.
Rifabutin (CYP450 inducer):
GENERAL CLASSIFICATION FOR SUPPLY
Marketing authorisation holder Omnipharm Ltd The Spire Egypt Road Nottingham NG7 7GD UK
Omnipharm Limited, The Spire, Egypt Road, Nottingham NG7 7GD United Kingdom
Omnipharm Ltd The Spire Egypt Road Nottingham NG7 7GD UK
Neisseria meningitidis OMPC (outer membrane protein complex of the B11 strain of Neisseria meningitidis subgroup B)
Neisseria meningitidis OMPC (outer membrane protein complex of the B11 strain of Neisseria meningitidis subgroup B)
OMRIX Biopharmaceuticals Ltd Plasma Fractionation Institute Sheba Hospital, Tel Hashomer Ramat Gan 52621, Israel Att:
Resolution was seen in approximately 30% of the patients within four months.
Sevoflurane degradation in soda lime has been shown to increase with temperature.
Milk or antacids should be given in order to bind alendronate.
Malignant glioma tissue (WHO-grade III and IV, e. g. glioblastoma multiforme, gliosarcoma or anaplastic astrocytoma) has also been demonstrated to synthesise and accumulate porphyrins in response to 5-ALA administration.
There was also a continued level of improvement in the quality of financial transactions submitted in 2000, with an average of 1.05% of submissions requiring revision (1.37% in 1999).
It was also active against quiescent lymphocytes and macrophages.
They also had fewer abscesses and fewer lymph nodes affected.
Humira has been shown to slow down the damage to the cartilage and bone of the joints caused by the disease and to improve physical function.
In total 43,366 hypercholesterolaemic patients, average age 59 years, were treated with cerivastatin.
The restructuring has allowed for an improved handling of safety-related issues by the new therapeutic teams.
One hundred and seventy two of these patients (0.4%) experienced at least one adverse event indicative of myopathy (CPK increased, myopathy, myositis, myalgia, myasthenia, arthralgia).
There was a decrease in the ratio of VLDL cholesterol to serum triglycerides and in the apolipoproteins B and E, suggesting a reduction in the amount of circulating atherogenic remnant particles.
There is evidence that the concentration of macrolides is higher at the site of infection than in plasma, in particular in neutrophils, alveolar macrophages and alveolar epithelial cells.
One to two weeks should elapse between titration steps (as determined by blood glucose response).
Once-Daily Fleroxacin Versus Twice-Daily Ciprofloxacin in the Treatment of Complicated Urinary Tract InfectionsJ Urol 1997; 158:
The injection site should be alternated to prevent lipoatrophy.
The injection site should be alternated to prevent lipoatrophy.
Very few medicinal products are known to be metabolised predominantly by UGT2B4 or UGT2B7.
This is considered a species-specific effect and of no clinical relevance.
This is considered a species-specific effect and of no clinical relevance.
Patients should be monitored carefully for dose-related adverse reactions, especially nervous system symptoms (see sections 4.3 and 4.4).
There are follow-up data under controlled clinical conditions for patients with relapsing-remitting MS for up to 5 years and for patients with secondary progressive MS for up to 3 years.
There are follow-up data under controlled clinical conditions for patients with relapsing-remitting MS for up to 5 years and for patients with secondary progressive MS for up to 3 years.
There are follow-up data under controlled clinical conditions for patients with relapsing-remitting multiple sclerosis for up to 5 years and for patients with secondary progressive multiple sclerosis for up to 3 years.
There are limited data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment.
There are limited data on the safety and efficacy of tenofovir disoproxil fumarate in patients with impaired renal function.
Periodic monitoring is necessary to detect inadequate lowering of blood glucose at the recommended maximum dose level (i. e. primary failure) and to detect loss of adequate blood glucose- lowering response after an initial period of effectiveness (i. e. secondary failure).
A clicking sound can be heard, which will stop when the injection button has been pressed in completely.
It is estimated that the frequency of the homozygous *3/ *3 genotype is 0.3-1.0% among different ethnic groups.
Therefore, the concomitant use of toremifene with such drugs should be avoided.
It is not known whether Beromun is excreted in human milk.
It is not known whether topical administration to humans could result in sufficient systemic absorption to produce detectable quantities in breast milk.
It is not known whether Herceptin can cause foetal harm when administered to a pregnant woman or whether it can affect reproductive capacity.
It is not known whether Botulinum neurotoxin type A is excreted into the breast milk.
It is unknown whether rasburicase is excreted in human milk.
It is not known whether sapropterin or its metabolites are excreted in human breast milk.
It is not known whether somatropin is excreted in human milk.
It is not known whether somatropin is excreted in human milk.
It is not known whether this active substance is excreted in human milk, however, the enzyme is likely to be digested in the child 's gastrointestinal tract
It is unknown whether Botulinum Toxin Type B is excreted in human breast milk.
It is not known whether Cerezyme passes via the placenta to the developing foetus.
It is unknown whether gadofosveset trisodium is excreted in human breast milk.
It is not known if emtricitabine is excreted in human milk.
It is not known whether the active ingredient in CELSENTRI can pass into your breast milk.
It is not known whether valdecoxib is excreted in human milk.
It is unknown whether histamine is excreted in human breast milk.
It is not known whether Sebivo reduces the risk of passing your hepatitis B virus on to your unborn baby.
It is also available as a solution for injection in a vial or a cartridge.
Children under treatment for tuberculosis have not experienced exacerbation of the disease when immunized with live measles virus vaccine.
Children under treatment for tuberculosis have not experienced exacerbation of the disease when immunized with live measles virus vaccine.
There are no known side effects on the fetus or new-born baby.
There are no known side effects on the fetus or newborn baby.
No specific antidote for duloxetine is known but if serotonin syndrome ensues, specific treatment (such as with cyproheptadine and/ or temperature control) may be considered..
No specific antidote for duloxetine is known but if serotonin syndrome ensues, specific treatment (such as with cyproheptadine and/ or temperature control) may be considered..
No specific antidote is known for duloxetine but if serotonin syndrome ensues, specific treatment (such as with cyproheptadine and/ or temperature control) may be considered.
No specific antidote is known for duloxetine but if serotonin syndrome ensues, specific treatment (such as with cyproheptadine and/ or temperature control) may be considered.
No specific antidote is known for duloxetine but if serotonin syndrome ensues, specific treatment (such as with cyproheptadine and/ or temperature control) may be considered.
It is not known exactly how long protection against infection with hepatits A and B viruses will last, although protection against hepatitis A virus probably lasts about 10 years.
The effect of renal and hepatic dysfunction on pharmacokinetics of tenecteplase in humans is not known.
The potential for human risk in pregnancy is unknown.
The effects of an overdose on the duration of photosensitivity are unknown.
There are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh class C).
No data are available in patients with severe hepatic insufficiency (Child-Pugh Class C).
No such data exist for cerivastatin.
No specific information is available on the treatment of overdose with EMEND.
No information on the tolerability of tolcapone in these populations is available (see 5.2).
No studies are available in children and adolescents in the other currently approved indications for adults.
There is only experience in the treatment of patients with previous history of transfusions.
There is no specific information available with regard to overdosage with alendronate.
No specific information is available on the treatment of overdose with alendronate.
It is not known whether emtricitabine or tenofovir are excreted in human milk.
It is not known whether tenofovir is excreted in human milk.
Insufficient evidence has been made available concerning the efficacy of paroxetine for the treatment of obsessive compulsive disorder and social anxiety/ social phobia.
Patients with severe hepatic impairment have not been studied; therefore, no dosing recommendations can be made (see section 4.4).
Patients with severe hepatic impairment have not been studied.
No specific information is available on the treatment of over dosage with Bondenza.
No specific information is available on the treatment of overdosage with Bondenza.
No specific information is available on the treatment of overdosage with Bondronat.
No specific information is available on the treatment of over dosage with Bonviva.
No specific information is available on the treatment of overdosage with Bonviva.
There are only limited data in patients with liver impairment and on the effects of medicinal products known to influence hepatic metabolism (e. g. cimetidine).
No more than 200 U total should be injected for the first course of therapy, with adjustments made in subsequent courses dependent on the initial response.
CPMP/ 4260/ 03 treatment, initial dosing in a naïve patient should U should be given at any one site.
It cannot be excluded that stronger inhibitors of CYP3A4 (i. e. ketoconazole, itraconazole, ritonavir) increase the plasma concentration of amlodipine to a greater extent than diltiazem.
It cannot be excluded that the effect of nilotinib is greater at steady state.
It is not known if ADENURIC may pass into human breast milk.
It is not known whether this finding was due to effects on the males and/ or the females.
It is not known if Efficib passes into human breast milk.
It is not known whether it is excreted in human milk.
It is not known if Galvus passes into breast milk.
It is not known whether adalimumab passes into breast milk.
It is not known if Jalra passes into breast milk.
It is not known if Janumet passes into human breast milk.
It is not known if Januvia passes into breast milk.
It is not known whether abatacept, the active ingredient, passes into human milk.
It is not known whether cytarabine is excreted in human milk following intrathecal administration.
It is not known whether daptomycin is excreted in human milk.
It is not known whether adefovir is excreted in human milk.
It is not known whether the free fraction in the maternal and fetal compartments differs substantially.
It is not known whether alendronate is excreted into breast milk in humans.
It is not known whether breast-feeding will lead to exposure of the infant to medicinal product.
It is not known whether memantine is excreted in human breast milk but, taking into consideration the lipophilicity of the substance, this probably occurs.
It is not known whether micafungin is excreted in human breast milk.
It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.
It is not known whether sitagliptin is excreted in human milk.
It is not known whether sitagliptin passes into human milk.
It is not known if somatropin is excreted into breast milk, but absorption of intact protein from the gastrointestinal tract of the infant is extremely unlikely.
It is not known whether the active substance in this medicine passes into breast milk.
It is not yet known whether the active substance in this medicine passes into human breast milk.
It is not known if temoporfin is excreted in human milk.
It is not known if deferasirox is secreted into human milk.
It is unknown whether doripenem is excreted in human breast milk.
It is not known whether Tarceva has a different effect if your liver or kidneys are not functioning normally.
It is unknown whether filgrastim is excreted in human breast milk.
It is unknown whether filgrastim passes over to the breast milk.
It is not known whether this medicinal product is excreted in human milk.
It is unknown whether methoxy polyethylene glycol-epoetin beta is excreted in human breast milk.
It is not known if montelukast is excreted in human milk.
It is not yet known whether the active substances in this medicine pass into human breast milk.
It is unknown whether sugammadex is excreted in human breast milk.
It is not known whether etanercept is excreted in human milk.
It is unknown whether temsirolimus is excreted in human breast milk.
It is not known whether measles or mumps vaccine virus is secreted in human milk.
It is not known whether VZV is secreted in human milk.
It is not known whether Interferon beta-1b passes into human breast milk.
It is not known whether ioflupane (123I) is excreted in human milk.
Aprovel is contraindicated (see section 4.3) during breast-feeding. It is not known whether irbesartan is excreted in human milk.
It is not known whether irbesartan is excreted in human milk.
Karvea is contraindicated (see section 4.3) during breast-feeding. It is not known whether irbesartan is excreted in human milk.
It is not known whether omalizumab is excreted in human breast milk.
It is not known whether oseltamivir or the active metabolite are excreted in human milk.
It is not known if ustekinumab is absorbed systemically after ingestion.
- It is not known if MIRCERA has a different effect in patients with haemoglobinopathies
It is not known if Norvir p asses into breast milk.
It is not known if Norvir passes into breast milk.
It is not known whether OPTISON passes into human milk.
It is not known if Pelzont will pass into your breast milk.
It is not known if Pelzont will harm your unborn baby. • You are breast-feeding or plan to breast-feed.
It is not known if SOMAVERT passes into breast milk.
It is not known if TESAVEL passes into breast milk.
It is not known if Tredaptive will pass into your breast milk.
It is not known if Tredaptive will harm your unborn baby. • You are breast-feeding or plan to breast-feed.
It is not known if Trevaclyn will pass into your breast milk.
It is not known if Trevaclyn will harm your unborn baby. • You are breast-feeding or plan to breast-feed.
It is not known whether adalimumab passes into breast milk.
It is not known if Tygacil passes into breast milk in humans.
It is not known if Velmetia passes into human breast milk.
Because many medicines are excreted in human milk, nursing mothers should discontinue VISTIDE or stop nursing if they continue to receive VISTIDE.
It is not known if Xiliarx passes into breast milk.
It is not known if Zenapax is
CYSTAGON excretion in human's milk is unknown.
There was no relevant increase in exposure to nilotinib when the dose was increased from 400 mg twice daily to 600 mg twice daily.
There was no change in the infection rates in the pigs that were not vaccinated.
Destruction of sebaceous cells, focal epidermal necrosis with a transient acute inflammation and diffuse reactive changes in the keratinocytes as well as transient secondary oedema and inflammation of dermis are observed.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
It is thought that the destruction of nerve cells in motor neurone disease may be caused by too much glutamate, a neurotransmitter (chemical messenger).
This is thought to be due to differences in parental characteristics (e. g. maternal age, sperm characteristics) and multiple pregnancies.
This is thought to be due to differences in parental characteristics (e. g. maternal age, sperm characteristics) and multiple pregnancies.
This effect is thought to be mediated by the immunosuppression caused as a result of systemic treatment with the product.
Aripiprazole is thought to act mainly by being a ‘ partial agonist 'for the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin).
It is thought that olanzapine's beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytrypamine (also called serotonin) and dopamine.
The mechanism of action of Botox in hyperhidrosis is thought to be the inhibition of cholinergically-induced excessive sweating by blockage of autonomic sympathetic nerve fibres innervating sweat glands.
Soluble TNFRs are thought to regulate TNF biological activity.
RNA, which are needed for viruses to survive and multiply.
It is generally believed that paclitaxel promotes the assembly of microtubules from tubulin dimer and prevents depolymerisation.
An abnormal response by the body's immune system is thought to play an important part in the process which damages the CNS.
Increased exposure to nilotinib might also be expected with moderate CYP3A4 inhibitors.
TESLASCAN can also be used with MRI to investigate lesions of the pancreas.
Mild episodes of hypoglycaemia can usually be treated with oral carbohydrates.
The product may be mixed directly into the drinking water system or first mixed as a stock solution into a smaller amount of water, which is then added into the drinking water system.
Luveris may be mixed with follitropin alfa and co-administered as a single injection.
The capsule may be opened and the content suspended in a small amount of water or formula diet immediately before intake.
Excessive doses of amlodipine can be expected to cause peripheral vasodilation with marked hypotension.
The following side effects may be expected:
These and other documents are available:
180 disease-modifying medicines, such as methotrexate.
You may first be given other 146 disease-modifying medicines, such as methotrexate.
You may first be given other disease-modifying medicines, such as methotrexate.
The expected adverse events would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hyperkinesia, hallucinations, agitation and hypotension.
The expected adverse reactions would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hyperkinesia, hallucinations, agitation and hypotension.
33 The necessity of resuspending the NovoMix 30 suspension immediately before use is to be stressed to the patient.
9 The necessity of resuspending the NovoMix 30 suspension immediately before use is to be stressed to the patient.
The necessity of resuspending the NovoMix 50 suspension immediately before use is to be stressed to the patient.
The necessity of resuspending the NovoMix 70 suspension immediately before use is to be stressed to the patient.
A rinse of the infusion line must be performed between each product administration (see section 6.6).
Nausea, vomiting, flushing and dizziness are known to be dose dependent when calcitonin is administered parenterally.
It is known that the virus can be passed to the baby in breast milk.
Onsenal should be used along with the usual care for FAP patients such as surgery and endoscopic surveillance.
Onsenal is used to reduce the number of polyps in patients with familial adenomatous polyposis (FAP).
Onsenal is used to reduce the number of gastrointestinal polyps in patients with Familial Adenomatous Polyposis (FAP).
This is thought to be achieved by a gastrointestinal dialysis mechanism and/ or by interrupting enterohepatic recycling.
Transient events reported have included nausea, weakness/ lethargy and hypotension.
The data presented did not show a definite association with lymphoma or any malignancy.
ra decrease in rate of linear growth, of whom 5 (6%) children had a > 30 percentile decrease despite being off treatment for more than 1 year.
Unchanged insulin glargine and degradation products are also present in the plasma.
have inadequate skin coverage and vascularity of the non-union site;
have active infection at the site of non-union or active systemic infection;
have any tumour in the vicinity of the non-union site;
Under these circumstances treatment should be immediately discontinued and the patient referred to a specialist unit for investigation.
You have been prescribed Clopidogrel BMS to help prevent blood clots and reduce the risk of these severe events because:
You have been prescribed Clopidogrel Winthrop to help prevent blood clots and reduce the risk of these severe events because:
You have been prescribed Iscover to help prevent blood clots and reduce the risk of these severe events because:
You will be asked to lie down on the MRI scanning bed.
8 wise addition of the water for injection down the inside of the vial and not directly onto the lyophilized cake.
This is done by slow drop- wise addition of the water for injection down the inside of the vial and not directly onto the lyophilized cake.
17 wise addition of the water for injection down the inside of the vial and not directly onto the lyophilized cake.
OPATANOL 1 mg/ ml eye drops, solution Olopatadine
OPATANOL was as effective as cromolyn sodium and as levocabastine.
OPATANOL was compared with cromolyn sodium (another anti-allergy medicine), with levocabastine (another antihistamine) and, in two studies, with placebo (a dummy treatment).
Since OPATANOL contains benzalkonium chloride, close monitoring is required with frequent or prolonged use in dry eye patients, or in conditions where the cornea is compromised.
OPATANOL contains benzalkonium chloride, which is known to discolour soft contact lenses.
OPATANOL is used in adults and children aged three years and older.
OPATANOL is a clear eye drop solution, which contains the active substance olopatadine.
OPATANOL is a medicine for treatment of allergic conditions of the eye.
Opgenra should be used immediately after reconstitution.
Opgenra is contraindicated in children, adolescents and the skeletally immature (see section 4.3).
Opgenra is an osteoinductive and osteoconductive medicinal product.
2/ 25 Opgenra must not be used in patients who:
Ophthalmologicals-antiglaucoma preparations and miotics-beta-blocking agents-timolol, combinations.
BAMALITE BAMALITE OPIREN Frash OPIREN Frash BAMALITE Frash BAMALITE Frash
Oprymea is not recommended during breast-feeding.
Oprymea can have a major influence on the ability to drive and use machines.
Oprymea can have a major influence on the ability to drive and use machines.
Oprymea can be taken with or without food.
"Further information").
Optimark should only be administered by physicians experienced in clinical MRI practice.
Optimark is indicated for use with magnetic resonance imaging (MRI) of the central nervous system (CNS) and liver.
Optimark should not be used during pregnancy except in cases where a contrast enhanced MR scan is determined to be critical, with no acceptable alternative imaging examination.
OptiSet has to be used as recommended in these Instructions for Use (see section 6.6).
OptiSet is damaged, use a new OptiSet.
Needle may have been attached imprecisely (e.g. at a slant).
OPTISON 0.19 mg/ ml dispersion for injection Perflutren-containing microspheres
OPTISON 0.19 mg/ ml dispersion for injection Perflutren-containing microspheres
OPTISON improves the visualization of the inner cardiac walls in patients where the walls are difficult to see.
OPTISON contains microspheres (tiny gas bubbles) that after injection travel through the veins to the heart and fill the left heart chambers, allowing the doctor to visualise and asses the function of the heart.
OPTISON contains gas-filled albumin microspheres (tiny bubbles) that generate echoes very differently from the surrounding tissues when used during an ultrasound scan.
OPTISON should only be used in patients where the study without contrast enhancement is inconclusive.
OPTISON consists of perflutren -containing microspheres.
OPTISON is slowly injected into a vein, usually in the right arm.
OPTISON is an ultrasound contrast agent that helps to obtain clearer pictures (scan) of the heart during an echocardiography (a procedure where an image of the heart is obtained by using ultrasound).
OPTISON is used to obtain a clearer scan of the chambers of the heart, especially of the left ventricle, during echocardiography (a diagnostic test where an image of the heart is obtained using ultrasound).
OPTISON must not be mixed with other medicinal products.
OPTISON should only be used by doctors who have experience in diagnostic ultrasound imaging.
- OPTISON will segregate in an undisturbed syringe and must be resuspended before use.
OPTISON in the non-resuspended form has a white layer of microspheres on top of the liquid phase that requires resuspension before use.
Optisulin contains insulin glargine an insulin analogue with a prolonged duration of action.
Optisulin is given by injection under the skin in the abdominal wall (tummy), the thigh, or the deltoid region (shoulder).
Optisulin is a clear solution for injection containing the active substance insulin glargine.
Only use Optisulin if the solution is clear, colourless and waterlike.
Optruma is used for the treatment and prevention of osteoporosis (a disease that makes bones fragile) in women who have been through the menopause.
OPTRUMA has no known effects on driving or using machines.
OPTRUMA has no effect on the risk of ER negative breast cancers.
There was no effect of Optruma on hip fractures.
OPTRUMA should not be used in patients with hepatic impairment (see section 4.3).
OPTRUMA may affect the development of the baby.
OPTRUMA mimics some of the helpful effects of oestrogen after the menopause.
Porcilis Pesti is an emulsion for injection.
ORACEA contains doxycycline in a formulation designed to yield plasma levels below the antimicrobial threshold.
ORACEA should be used with caution in patients with a history of predisposition to candidiasis overgrowth.
ORACEA is indicated to reduce papulopustular lesions in adult patients with facial rosacea.
ORACEA is a medicine for use in adults to reduce the pimples or red bumps on the face caused by a condition called rosacea.
ORACEA and certain other medications may not work properly when taken together.
ORACEA should not be used in patients with ocular manifestations of rosacea (such as ocular rosacea and/ or blepharitis/ meibomianitis) as there are limited efficacy and safety data in this population.
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Route of Administration Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Orbifloxacin 8.5 mg/ ml Ear drops, Mometasone furoate (as suspension monohydrate) 0.9 mg/ ml Posaconazole 0.9 mg/ ml
Orbifloxacin 8.5 mg/ ml Mometasone furoate (as monohydrate) 0.9 mg/ ml Posaconazole 0.9 mg/ ml
Orbifloxacin Mometasone furoate (as monohydrate) Posaconazole
Ear (no effects were found to be common or uncommon); rare: ear pain.
cheekbone (acromegaly), high blood sugar (hyperglycaemia) and presence of sugar in the urine (glucosuria).
ORENCIA and children / adolescents ORENCIA has not been studied in patients under 18 years of age, therefore ORENCIA is not recommended in this patient population.
ORENCIA contains maltose, which is a type of sugar that can give falsely high blood glucose readings with certain types of blood glucose monitors.
ORENCIA should NOT be used with siliconised syringes (see section 6.6).
Orfadin 2 mg hard capsules Orfadin 5 mg hard capsules Orfadin 10 mg hard capsules nitisinone
Orfadin is a hard white capsule for oral use.
Orfadin is used to treat hereditary tyrosinemia type 1 (HT-1), a rare childhood disease.
Orfadin is used for treatment of a disease called hereditary tyrosinemia type I.
Orgalutran contains ganirelix, which antagonises the actions of the natural gonadotrophin releasing hormone (GnRH).
Orgalutran is a clear and colourless aqueous solution for injection.
Orgalutran is used to prevent the premature LH surge that might cause such a premature release of egg cells.
Refurbishment plans for the third floor, EMEA offices
12 Organigram of the European Agency for the Evaluation of Medicinal Products
Head of Unit Inspections Document management & publishing Conference services Information technology Total Additional posts in reserve
The EMEA continued its active support of the International Conference on Harmonisation of Technical Requirements for Registration of Veterinary Products (VICH) and the VICH secretariat.
Organon Kloosterstraat 6 PO Box 20 5349 AB, Oss The Netherlands
Organon Laboratories Ltd Cambridge Science Park Milton Road Cambridge CB4 0FL United Kingdom
Organon S. A., Usine Saint Charles, 60590 Eragny sur Epte France.
Organon S. A., Usine Saint Charles 60590 Eragny sur Epte France.
Point the tip of the oral syringe towards the inside of the cheek.
Ethnicity Anidulafungin pharmacokinetics were similar among Caucasians, Blacks, Asians, and Hispanics.
e Race - Pharmacokinetic differences due to race have not been studied prospectively.
e Race - Pharmacokinetic differences due to race have not been studied prospectively.
Race - Pharmacokinetic differences due to race have not been studied prospectively.
Ethnicity Experience with treatment is limited in groups other than Caucasians.
Suomi/Finland Orion Oyj ORION PHARMA ELÄINLÄÄKKEET Tengströminkatu 8, PL/PB 425 FIN-20101 Turku/Åbo Puh/Tel: +358 10 4261
Orlistat blocks gastrointestinal lipases (enzymes that digest fat).
The effect of orlistat results in an increase in faecal fat as early as 24 to 48 hours after dosing.
Orphan Europe, Immeuble ‘ Le Wilson’, 70 avenue du Général de Gaulle, F-92800 Puteaux, France
Immeuble "Le Wilson" 70 avenue du Général de Gaulle F-92800 Puteaux France
Orphan Europe SARL Immeuble "Le Wilson" 70 avenue du Général de Gaulle F-92800 Puteaux France
Orphan Europe S. A. R. L., Immeuble “ Le Wilson” 70 avenue du Général de Gaulle F- 92800 Puteaux, France
Orphan Europe SARL Immeuble “ Le Wilson” F-92058 Paris La Défense France
Orphan Europe SARL Immeuble “ Le Wilson” F - 92058 Paris-La Défense France
Orphan Europe SARL Immeuble “ Le Wilson” F-92058 Paris La Défense - France
Orphan Europe SARL Immeuble “ Le Wilson” F-92058 Paris-La-Défense - France
Orphan Europe SARL, Immeuble “ Le Wilson”, F-92058 Paris La Défense, France
primary dysmenorrhoea
primary dysmenorrhoea
Osigraft does not aid in the support of weight and does not stabilise the fracture.
Replace the needle and repeat
Osmolality (mosmol/ kg H2O) at 37 °C Viscosity (mPa. s) at 20 °C Viscosity (mPa. s) at 37 °C Density (g/ ml) at 20 °C
OSSEOR works by reducing bone breakdown and stimulating rebuilding of bone and therefore reduces the risk of fracture.
OSSEOR should be used with caution in patients at increased risk of VTE, including patients with a past history of VTE.
OSSEOR is used to treat osteoporosis (a disease that makes bones fragile) in postmenopausal women to reduce the risk of vertebral (spine) and hip fractures.
Osteonecrosis, muscle atrophy, amyotrophy, pain in foot, muscle spasms, musculoskeletal pain, night cramps, groin pain, pain in jaw, neck pain, spondylitis, joint stiffness, joint swelling, musculoskeletal stiffness, limb discomfort, toe deformities, local swelling
Osteoporosis in men with increased risk of fracture The efficacy of alendronate 10 mg once daily in men (31-87 years, mean age 63 years, n=241) with osteoporosis was evaluated in a two-year study.
Glucocorticoid-induced osteoporosis Long-term use of steroids is often associated with the development of osteoporosis accompanied by fractures.
Badener Strasse 23 A-2514 Traiskirchen
Badener S trasse 23 A-2514 Traiskirchen lon
Badener Strasse 23 A-2514 Traiskirchen Tel: + 43-(0)2252 502-0
Badener Strasse 23 A-2514 Traiskirchen Tel: + 43-(0)2252 502-0
BRISTOL-MYERS SQUIBB GESMBH Tel: + 43 1 60 14 30
Eesti GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk. com
Eesti GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk. com
126 Eesti Österreich Novartis Pharma Services Inc.
Eesti Novartis Pharma Services Inc.
Eesti PharmaSwiss Eesti OÜ Sepise 18 EE-11415 Tallinn Tel: + 372 6401 301
Eesti Österreich Roche Eesti OÜ Tel: + 372 - 6 112 401
Österreich SWEDISH ORPHAN INTERNATIONAL GmbH Tel: +49 6103 20 26 90
Dr O’Sullivan was in general veterinary practice in the UK and Ireland from 1972 to 1976, then in service as Veterinary Officer with Overseas Development in Botswana and North Yemen until 1982.
Remove as much as possible of the amount administered before the next instillation.
Otorrhoea, ear disorder*, middle ear disorder*, tympanic membrane disorder*, ear pain, ear congestion*, fluid in middle ear
1, 2, 3 or 10 x Diskus each containing 60 inhalations
or 1, 2, 3 or 10 x Diskus each containing 60 inhalations
other ingredients of Aerinaze.
33 Causes of a hyperglycaemia • Having forgotten to take your insulin • Repeatedly taking less insulin than you need • An infection or a fever
• Having forgotten to take your insulin • Repeatedly taking less insulin than you need • An infection or a fever • Eating more than usual • Less exercise than usual.
• Having forgotten to take your insulin • Repeatedly taking less insulin than you need • An infection or a fever • Eating more than usual • Less exercise than usual.
• Having forgotten to take your insulin • Repeatedly taking less insulin than you need • An infection or a fever • Eating more than usual • Less exercise than usual.
• Having forgotten to take your insulin • Repeatedly taking less insulin than you need • An infection or a fever
• Having forgotten to take your insulin • Repeatedly taking less insulin than you need • An infection or a fever • Eating more than usual
• Having forgotten to take your insulin • Repeatedly taking less insulin than you need • An infection or a fever • Eating more than usual • Less exercise than usual.
• Having forgotten to take your insulin • Repeatedly taking less insulin than you need • An infection or a fever • Eating more than usual • Less exercise than usual.
• Having forgotten to take your insulin • Repeatedly taking less insulin than you need • An infection or a fever • Eating more than usual • Less exercise than usual.
Retinal haemorrhages§, retinopathies (including macular oedema), retinal artery or vein obstruction§, optic neuritis, papilloedema, loss of visual acuity or visual field, cotton- wool spots§
Vertigo, tinnitus Hearing loss, hearing disorder
If a patient receiving Trudexa shows prolonged/ atypical symptoms/ signs of infections or general deterioration, prevalent opportunistic conditions must be considered.
dehydrogenase (LDH), or imbalance of salts.
a new EVRA patch immediately.
- or alone in patients who show intolerance to methotrexate or for whom methotrexate is
Low- density lipoprotein (LDL) is formed from VLDL and is catabolized primarily through the receptor with high affinity to LDL (LDL receptor).
• Improved tables summarising marketing authorisations granted under the centralised procedure were constantly updated and published every month in 1997.
In addition to Members of the European Parliament, the EMEA also received delegations from the Belgian, Italian and UK parliaments.
In addition to the obligations set out in Council Regulation (EEC) No 2309/ 93 and the EMEA Code of Conduct, individual confidentiality undertakings will be concluded with each European expert.
In addition to the assessment of the satisfaction of eculizumab information provided, the proposed questionnaire will investigate other methods for assessing the effectiveness of the risk minimisation program (e. g. surveys to follow compliance to vaccination).
In addition to the assessment of the satisfaction of eculizumab information provided, the proposed questionnaire will investigate other methods for assessing the effectiveness of the risk minimisation program (e.g. surveys to follow compliance to vaccination).
Open the childproof cap by pushing down on it with your palm and twisting it anti-clockwise, or in the direction of the arrow.
Open the inner sterile package and remove the sponge.
Open the prefilled syringe by breaking the seal of the closure and remove the white cap together with the rubber tip cap inside.
Open the prefilled syringe by breaking the seal of the closure and remove the white cap together with the rubber tip cap inside
Open the prefilled syringe by breaking the seal of the closure and remove the white cap together with the rubber tip cap inside.
Open Syringe Packages and Remove Vial Caps
Or Wyeth Pharmaceuticals New Lane Havant Hants, PO9 2NG United Kingdom
Or Wyeth Pharmaceuticals New Lane Havant Hants, PO9 2NG United Kingdom
Proposal for a core-data for Calendula flos (Calendulae flower) (*)
OVITRELLE 250 MICROGRAMS, POWDER AND SOLVENT FOR SOLUTION FOR INJECTION, SOLVENT IN AMPOULES
OVITRELLE 250 MICROGRAMS, POWDER AND SOLVENT FOR SOLUTION FOR INJECTION, SOLVENT IN VIALS
Ovitrelle is a powder and solvent to be made up into a solution for injection.
inhibitors (e. g. phenelzine, tranylcypromine).
Oxyglobin contains bovine haemoglobin glutamer-200 (at a strength of 130 mg/ ml), which belongs to a class of medicines having an oxygen-carrying action.
Oxyglobin is intended for a single use only.
Oy Eli Lilly Finland, Ab Rajatorpantie 41 C, PL 16, 01641 Vantaa Finland
Ribavirin (800 mg) + peginterferon alfa-2b (1.5 micrograms/ kg) Ribavirin (1,000/ 1,200 mg) + peginterferon alfa-2b (1.5 to 0.5 microgram/ kg) Ribavirin (1,000/ 1,200 mg) + interferon alfa-2b (3 MIU)
It decays by emission of beta radiation of 2.281 MeV (99.98%) of maximal energy to stable Zirconium (90Zr).
14 tablets + 14 tablets + 14 tablets + 14 tablets
Paclitaxel blocks the cell's ability to break down the ‘ skeleton 'that allows cells to divide and multiply.
In the context of this Implementation Plan, the term “ therapeutic products” (Canada) includes pharmaceuticals, radiopharmaceuticals and human biologics, and the term “ medicinal product authorised in the European Union” refers to products subject to evaluation or authorised under the centralised procedure as well as medicinal products
Why has Naxcel been approved?
Why has Equilis Prequenza been approved?
Why has Masivet been approved?
Why has Nobilis OR Inac been approved?
Payment for administrative assistance from the Community institutions
Adverse reactions or in combination with OBT)
Olanzapine pamoate monohydrate equivalent to 405 mg olanzapine.
pancreatitis (0.7% vs 0.2%), haematemesis (0.2% vs 0%), stomatitis (0.2% vs 0.2%), constipation (0.3% vs 0.5%), abdominal distension (0.7% vs 1.0%), dry mouth (0.2% vs 0%), retching (0.2% vs 0%)
Blood bilirubin increased, Gamma-glutamyl- transferase increased, Hepatitis
Ischaemic colitus*, ulcerative colitus* Periodontal disorder, dental disorder
Pancreatitis* Ischaemic colitus*, ulcerative colitus* Periodontal disorder, dental disorder
Pancytopenia, bone marrow depression, leukopenia, thrombocytopenia, purpura, anaemia
Rare: pancytopenia (probably by antiproliferative mechanism), leucopenia (leucocytes < 2 G/ l), eosinophilia
Pandemrix has been authorised under ‘ Exceptional Circumstances’.
Pandemrix contains small amounts of haemagglutinins (proteins from the surface) of a virus called H5N1.
Pandemrix may be used during lactation.
When a person is given the vaccine, the immune system recognises the virus as ‘ foreign'and makes antibodies against it.
Panretin is used when: • the lesions are not ulcerated or lymphoedematous (the skin has not broken and the lesions are not swollen with fluid), and • they have not responded to the antiretroviral treatment the patient is already receiving, and • radiotherapy or chemotherapy is not appropriate, and • the patient does not need treatment for visceral (internal) Kaposi's sarcoma.
- Do not apply the gel on or near sensitive parts of your body such as eyes, nostrils, mouth, lips,
Long trousers: for lower body/ legs.
Paracetamol Paracetamol was used as a model medicinal product to evaluate the effect of exenatide on gastric emptying.
Light liquid paraffin Dl-alpha-tocopherol acetate
Pharmacologically active substance Light liquid paraffin Polysorbate 80 Sorbitan mono oleate (E494) Glycine
Pharmacologically active substance Light liquid paraffin Polysorbate 80 Sorbitan mono oleate (E494) Glycine
Pharmacologically active substance Light liquid paraffin Polysorbate 80 Sorbitan mono oleate (E494) Glycine
Liquid paraffin..............................................................................
In another trial, one patient with Crohn's disease, who had a long history of treatment with immunosuppressants and associated lymphopenia also developed PML and died.
In addition, a number of recommendations stemming from the Agency's work with patients'and consumers'organisations will be implemented, contacts with patients and healthcare professionals will be strengthened through development of specific frameworks, and a new working group with healthcare professionals will be established.
5 Catechols and other drugs metabolised by catechol-O-methyltransferase (COMT):
In addition, an updated RMP should be submitted: • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
In addition, an updated RMP should be submitted: • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimization Activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA.
facial paralysis, facial muscle weakness, inflammation of the cornea (keratitis), everted margin of the lid (ectropion), double vision (diplopia), inverted margin of the lid (entropion), visual disturbance, blurred vision, dizziness, inflammatory skin reaction (dermatitis), tiredness
68 Quality of life parameters Patients treated with TPF experienced significantly less deterioration of their Global health score compared to those treated with PF (p = 0.01, using the EORTC QLQ-C30 scale).
Quality of life parameters Patients treated with TPF experienced significantly less deterioration of their Global health score compared to those treated with PF (p = 0.01, using the EORTC QLQ-C30 scale).
Pharmacokinetic Parameters at Multiple Dose Levels after a Single Infusion of Oxyglobin
Pharmacokinetic Parameters at Multiple Dose Levels after a Single Infusion of Oxyglobin
Pharmacokinetic Parameters in Caelyx-Treated AIDS-KS
Pharmacokinetic Parameters* in Adult Subjects Receiving Effentora
Duration of action (hr) GIRmax (mg/ kg/ min) † estimated values
Pharmacodynamic Parameters for Levemir and NPH Glucose infusion rate (mg/ kg/ min)
PK Parameters of sugammadex in typical paediatric patients PK Parameter Elimination Half-Life (h) Volume of Distribution at Steady State (l)
Number of Patients
Parameter Survival at Hour 4, N (%) Survival at Day 14, N (%)
- Paranoia (e. g. excessive fear for one's own well-being)
- Paranoia (e. g. excessive fear for one's own well-being)
Parascaris equorum should have been selected as the dose limiting parasite.
Because the use of BeneFIX by continuous infusion has not been evaluated, BeneFIX should not be mixed with infusion solutions or be given in a drip.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
AUCs of doripenem and of the microbiologically inactive ring-opened metabolite are substantially increased in patients who require haemodialysis compared with healthy subjects.
This compares with 5 to 10 cases per 100,000 women-years for non-users and 60 cases per 100,000 pregnancies.
Therefore, following HBeAg seroconversion, patients should be periodically monitored to determine that serologic and clinical responses are being maintained.
As a result no dose adjustment for Riprazo or these co-administered medicinal products is necessary.
As a result no dose adjustment for Sprimeo or these co-administered medicinal products is necessary.
Hence, no dose-adjustments are necessary in younger patients.
Therefore no conclusions on the effect of enzyme replacement therapy on the neurological manifestations of the disease can be drawn.
Consequently, no meaningful change in AUC of methylnaltrexone, in addition to Cmax, was observed before and after multiple-dose administration of cimetidine.
Therefore, at the time of the withdrawal, the CHMP was of the opinion that any benefits of Diractin did not outweigh the identified risks.
Therefore at concentrations observed in the plasma (approximately 4% relative to parent ambrisentan), 4-hydroxymethyl ambrisentan is not expected to contribute to pharmacological activity of ambrisentan.
Therefore, in patients with a known cardiac history, the risk of cardiovascular complications resulting from infusion reactions should be considered before treatment with MabThera and patients closely monitored during administration.
The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore it should only be given with caution to pregnant women and breast-feeding mothers.
The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding mothers.
Therefore, this medicinal product should be used with caution in such patients.
Therefore, this wording may not necessarily represent the current text.
Rarely (likely to occur in fewer than 1 in 1000 patients) blood clots in blood vessels (abnormal blood clottings) have been seen to occur with similar medicines. Therefore, this could possibly occur with Pergoveris / hCG therapy.
As a result, these substances do not get broken down and processed by the body as they should.
Therefore, Annex III may not necessarily represent the current text.
Therefore, treatment is not recommended in these patient groups.
Additional monitoring of vitamins and folic acid is recommended in patients receiving peritoneal dialysis, since in the clinical study, vitamin A, D, E and K levels were not measured in these patients.
Therefore, in patients receiving dasatinib, systemic administration of a potent CYP3A4 inhibitor is not recommended.
Therefore, as with other antidepressants, fluoxetine should be introduced cautiously in patients who have a history of seizures.
Therefore, as with any agent acting on the RAS, routine monitoring of electrolytes and renal function is indicated in patients with diabetes mellitus, kidney disease, or heart failure.
Therefore, because some viruses are secreted in human milk, caution should be exercised if ZOSTAVAX is administered to a breast-feeding woman.
Therefore, if you are pregnant or breast-feeding consult your doctor before using this product.
Therefore, Cozaar Comp should not be given to children.
Because 14-OH-clarithromycin has reduced activity against Mycobacterium avium complex (MAC), overall activity against this pathogen may be altered; therefore alternatives to clarithromycin should be considered for the treatment of MAC.
Therefore, such combinations should be avoided in children.
Thus, after you give yourself the injection, discard the PegIntron pre-filled pen with any solution that is left in it.
Thus, after you give yourself the injection, discard the ViraferonPeg pre-filled pen with any solution that is left in it.
Clinically significant interaction resulting from an increase in the stomach pH due to the didanosine antacid component is unlikely and no dose separation or adjustment is considered necessary when fosamprenavir and didanosine are administered concomitantly (see chapter, Antacids).
Epivir is therefore not recommended to be used in combination with zalcitabine.
Consequently, because of the potential for adverse reactions in nursing infants, breast feeding must be discontinued for the duration of docetaxel therapy.
Therefore, EXUBERA should be used with caution in patients of low body weight.
Therefore, EXUBERA should not be used during pregnancy.
Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/ or suicidal ideation or behaviour emerge.
Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/ or suicidal ideation or behaviour emerge.
Therefore, care should be taken by people who wear soft contact lenses.
Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/ or suicidal ideation or behaviour emerge.
Therefore, this medicine should be used with caution in such patients.
Therefore a hepatic tumour should be considered in the differential diagnosis when severe upper abdominal pain, liver enlargement or signs of intra-abdominal haemorrhage occur in women using EVRA.
Hence, no dose adjustment is required in these patients.
Whether this affected respiration during the night is unknown.
Kivexa is therefore not recommended to be used in combination with zalcitabine.
Epivir is therefore not recommended to be used in combination with zalcitabine.
Co-administration of Tarceva with CYP3A4 inducers should therefore be avoided.
Therefore, the different cloud size/ shape or the humid environment that exists in the respiratory tree may be relevant.
Therefore use in patients with severe hepatic impairment is not recommended.
Therefore, concomitant administration of these medicinal products is not recommended.
Therefore concomitant administration of Norvir with disulfiram or medicines with disulfiram-like reactions (eg metronidazole) should be avoided.
The HMG-CoA reductase inhibitors simvastatin and lovastatin are highly dependent on CYP3A for metabolism, thus concomitant use of ritonavir with simvastatin or lovastatin is not recommended due to an increased risk of myopathy including rhabdomyolysis.
The HMG-CoA reductase inhibitors simvastatin and lovastatin are highly dependent on CYP3A for metabolism, thus concomitant use of ritonavir with simvastatin or lovastatin is not recommended due to an increased risk of myopathy including rhabdomyolysis.
Therefore, treatment with acetylsalicylic acid to alleviate flushing symptoms is not necessary (see section 5.1).
Therefore, administration of OSSEOR and such products should be separated by at least two hours (see section 5.2).
Therefore the use of Pradaxa is not recommended in patients undergoing anaesthesia with post-operative indwelling epidural catheters.
Therefore the use of Pradaxa is not recommended in patients undergoing anaesthesia with post-operative indwelling epidural catheters.
Therefore the administration of a bolus dose of sugammadex is considered to be equivalent to one missed daily dose of oral contraceptive steroids (either combined or progestogen only).
Therefore, gabapentin should be used with caution in patients with mixed seizures including absences.
As a result, levodopa remains active for longer.
The dosage should therefore be reduced in these patients (see section 4.2).
Therefore, the main measure of effectiveness was based on the experts'assessment of the outcome of these 145 patients, in comparison with the outcome that would be expected without using Beromun.
Therefore, caution should be used in these patients.
Therefore, caution should be exercised when driving or using machines.
Therefore, simvastatin is not expected to affect plasma concentrations of substances metabolised via cytochrome P450 3A4.
Therefore the combination product should be used with caution in patients above 60 years of age.
4.6 Pregnancy and lactation
The combination product should not be used in patients above 60 years of age.
The combination product should not be used in patients with impaired renal or hepatic function.
Therefore, routine measurement of coagulation parameters is not currently indicated in the management of patients on APTIVUS.
Therefore, resection of fluorescing tissue should be weighed up carefully against the neurological function of fluorescing tissue.
Therefore, the benefit and the risk of concurrent treatment should be carefully weighed (see section 4.4).
Significant and relevant results were obtained in the short-term but not in the long- term studies and therefore the CHMP concluded that the long-term efficacy has not been sufficiently demonstrated.
Significant and relevant results were obtained in the short-term studies but not in the long-term studies and therefore the CHMP concluded that the long-term efficacy has not been sufficiently demonstrated.
Therefore, the CHMP concluded that the products should be considered as interchangeable.
Therefore the CHMP considered that the benefit/ risk balance of paroxetine containing medicinal products in the agreed indications is favourable and the Marketing Authorisations should be maintained in accordance with the:
Therefore, the CHMP decided that Cyanokit's benefits are greater than its risks for the treatment of known or suspected cyanide poisoning.
- The CHMP, as a consequence, recommended the amendment of the Summary of Product
Therefore, the CHMP recommended the withdrawal of all Marketing Authorisations for medicinal products containing veralipride throughout Europe.
Therefore the Committee recommended maintaining the Marketing Authorisations for all veterinary medicinal products containing toltrazuril intended for use in chickens and turkeys.
Therefore, efficacy of Thyrogen with doses of 131I < 100 mCi has not been established.
Therefore, mixing of rapid acting insulin with Levemir should be avoided.
Therefore, mixing of rapid acting insulin with Levemir should be avoided.
Therefore, prasugrel should be used with caution in these patients.
Consequently, the time-action profile of an insulin preparation is determined solely by its absorption characteristics.
Consequently, the time-action profile of an insulin preparation is determined solely by its absorption characteristics. ic ed
Consequently, the time-action profile of an insulin preparation is determined solely by its absorption characteristics. lP
Consequently, the time-action profile of an insulin preparation is determined solely by its absorption characteristics. rod
insulin preparation is determined solely by its absorption characteristics.
Consequently, the Summary of Product Characteristics and package leaflet should be amended as set out in Annex III.
Therefore, the potential risk for humans is unknown.
Therefore, ertapenem should not be used in these patients.
Therefore, ertapenem should not be used in these patients.
Thus, antacids may be administered up to 2 hours prior to or 2 hours following SPRYCEL (see section 4.4).
Therefore, it is recommended that the tablets should be taken after an overnight fast (minimum 6 hours) and fasting should continue for at least 30 minutes after the dose has been taken (see Section 4.2).
Therefore, both medicinal products can be administered concomitantly.
Breast-feeding women must, therefore, not receive leflunomide.
Patients receiving TYSABRI should not breastfeed their infants.
Therefore medicinal products that are inducers, inhibitors or substrates of CYP3A4 must be used with caution when administered concurrently with Telzir with ritonavir (see sections 4.3 and 4.5).
Therefore the CHMP members recommended follow-up measures to further investigate the known cases and to initiate further studies
Therefore, patients must be instructed to wait 15 minutes after instillation of AZOPT before inserting contact lenses.
Consequently affected persons should avoid these tasks until their faculties are fully recovered.
Therefore the pleuromutilins appear to inhibit bacterial protein synthesis by multiple mechanisms.
Herbal preparations containing St John's wort should therefore not be combined with Agenerase.
12 that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as cimetidine and amantadine, may interact with pramipex ole resulting in reduced clearance of either or both medicinal products.
28 that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as cimetidine and amantadine, may interact with pramipex ole resulting in reduced clearance of either or both medicinal products.
36 that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as cimetidine and amantadine, may interact with pramipexole resulting in reduced clearance of either or both medicinal products.
4 that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as cimetidine and amantadine, may interact with pramipexole resulting in reduced clearance of either or both medicinal products.
Therefore, medicinal products that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as cimetidine and amantadine, may interact with pramipexole resulting in reduced clearance of either or both medicinal products.
Therefore, medicinal products that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as cimetidine and amantadine, may interact with pramipexole resulting in reduced clearance of either or both medicinal products.
Consequently, the study results could not be considered reliable and could not be used for the evaluation of the vaccine.
The interactions for the first two sections are presented in the following order: contraindications, those requiring dosage adjustment and careful clinical and/ or biological monitoring and finally those that have no significant pharmacokinetic interaction but may be of clinical interest in this therapeutic field.
Therefore there is potential for voriconazole to increase the plasma levels of substances metabolised by these CYP450 isoenzymes.
Therefore, voriconazole is likely to increase the plasma levels of benzodiazepines that are metabolised by CYP3A4 (midazolam and triazolam) and lead to a prolonged sedative effect.
Therefore, voriconazole is likely to increase the plasma levels of benzodiazepines that are metabolised by CYP3A4 (e. g. midazolam and triazolam) and lead to a prolonged sedative effect.
Therefore, voriconazole is likely to increase plasma levels of statins that are metabolised by CYP3A4.
Voriconazole inhibits the activity of cytochrome P450 isoenzymes, CYP2C19, CYP2C9 and CYP3A4.
Hence, hydroxyurea should not be used in the treatment of HIV infection.
The CHMP also considered that the survey referred to by the Applicant, showing that papulopustular lesions are readily recognized and rated by dermatologists providing a qualitative as well as quantitative measurement, was relevant; therefore the currently proposed indication was considered clinically applicable and practical.
Therefore, the combined use of APTIVUS/ ritonavir with either omeprazole or esomeprazole is not recommended.
Therefore, concomitant use is not recommended.
23 The absorption of nelfinavir may be reduced in conditions where gastric pH is increased, therefore concomitant use of VIRACEPT with Proton Pump Inhibitors is not recommended (see section 4.4), except for omeprazole which is contra-indicated (see section 4.3).
7 The absorption of nelfinavir may be reduced in conditions where gastric pH is increased, therefore concomitant use of VIRACEPT with Proton Pump Inhibitors is not recommended (see section 4.4), except for omeprazole which is contra-indicated (see section 4.3).
Therefore, concurrent therapy with ORENCIA and a TNF blocking agent is not recommended.
Therefore Cetrotide 0.25 mg should be used in repeated cycles only after a careful risk/ benefit evaluation.
2 Paediatric population The safety and efficacy of Cholestagel have not been established in children and adolescent patients; therefore, the use of Cholestagel in these patient populations is not recommended.
Consequently, use of enalapril is not recommended if breast-feeding.
Therefore, the use of EVRA is not to be recommended until the breast-feeding mother has completely weaned her child.
Therefore, the use of sildenafil is not recommended in these patients.
Therefore the use in this species is not recommended during pregnancy and lactation.
Therefore, do not breast-feed an infant if you are taking PegIntron.
ra It is not known whether this product is present in human milk.
Therefore OPTISON should not be used in pregnancy unless benefit outweighs risk and it is considered necessary by the physician.
Therefore, please discard unused reconstituted concentrate immediately.
Therefore, RILUTEK should not be used in patients with any other form of motor neurone disease.
Therefore, if symptoms occur after discontinuing Tasmar, physicians should consider increasing the patient's levodopa dose (see 4.2).
Therefore, if paroxetine is co-administered with Telzir and ritonavir, the recommended approach is a dose titration of paroxetine based on a clinical assessment of antidepressant response.
If pregnancy is detected during therapy, Sprimeo should be discontinued accordingly.
Therefore the use of the product during pregnancy and lactation is not recommended.
Yet, Telzir should be used with caution in patients with a known sulphonamide allergy.
Therefore, a decision to continue/ discontinue breast-feeding or to continue/ discontinue therapy with Efexor depot should be made, taking into account the benefit of breast-feeding to the child and the benefit of Efexor depot therapy to the woman.
Therefore, a decision to continue/ discontinue breast-feeding or to continue/ discontinue therapy with Efexor should be made, taking into account the benefit of breast-feeding to the child and the benefit of Efexor therapy to the woman.
The induction of drug metabolizing enzymes cannot therefore be excluded.
The induction of metabolizing enzymes cannot therefore be excluded.
Therefore, a teratogenic effect of lenalidomide is expected and lenalidomide is contraindicated during pregnancy (see section 4.3).
Therefore dose modification is not required for patients with renal function impairment.
Therefore, a rapid imaging sequence should be initiated 20 seconds after bolus injection of the contrast agent when the agent is predominately in the hepatic arteries and then again at 60 seconds after injection during the dominant portal venous phase.
Therefore sexual stimulation is required in order for sildenafil to produce its intended beneficial pharmacological effects.
Therefore, an additional check of the AT activity level should be done after the surgery.
Therefore, a 0.2 micron low protein binding in-line filter should be used for administration.
Therefore, steroid replacement may be necessary in these patients.
Consequently you should avoid driving and operating machinery until your faculties are fully recovered.
If you have stopped treatment due to hypersensitivity syndrome, it should be permanent and you should not re-start therapy with OSSEOR.
Therefore, you should employ an alternative, effective and safe contraceptive method if you are taking APTIVUS.
Therefore do not have unprotected intercourse. • Pregnancy and any exposure during pregnancy must be avoided.
Therefore you should use Cetrotide 0.25 mg in repeated cycles only after a careful risk/ benefit evaluation by your doctor.
Therefore you should use Cetrotide 3 mg in repeated cycles only after a careful risk/ benefit evaluation by your doctor.
In contrast to long-term administration of ritonavir, there was no significant interaction with bupropion after short-term administration of low doses of ritonavir (200 mg twice daily for 2 days), suggesting reductions in bupropion concentrations may have onset several days after initiation of ritonavir co-administration.
In contrast, patients adding placebo had smaller changes in HbA1c levels, with a rise of 0.23% from a starting level of 8.30%.
10 compared with healthy subjects; however there were no changes in Cmax and AUC of rivastigmine in subjects with severe renal impairment.
21 compared with healthy subjects; however there were no changes in Cmax and AUC of rivastigmine in subjects with severe renal impairment.
32 compared with healthy subjects; however there were no changes in Cmax and AUC of rivastigmine in subjects with severe renal impairment.
32 Subjects with renal impairment Cmax and AUC of rivastigmine were more than twice as high in subjects with moderate renal impairment compared with healthy subjects; however there were no changes in Cmax and AUC of rivastigmine in subjects with severe renal impairment.
43 compared with healthy subjects; however there were no changes in Cmax and AUC of rivastigmine in subjects with severe renal impairment.
Subjects with renal impairment Cmax and AUC of rivastigmine were more than twice as high in subjects with moderate renal impairment compared with healthy subjects; however there were no changes in Cmax and AUC of rivastigmine in subjects with severe renal impairment.
EXUBERA is also indicated for the treatment of adult patients with type 1 diabetes mellitus, in addition to long or intermediate acting subcutaneous insulin, for whom the potential benefits of od
1 2 injection syringes, 24 injection needles and 12 cleansing swabs.
12 injection syringes, 24 injection needles and 12 cleansing swabs.
syringes, 24 injection needles and 12 cleansing swabs.
syringe, 2 injection needles and 1 cleansing swab;
syringes, 8 injection needles and 4 cleansing swabs;
syringe, 2 injection needles and 1 cleansing swab;
syringes, 8 injection needles and 4 cleansing swabs;
Lacrimation increased; Conjunctivitis
Headache Oral/ perioral paraesthesia, tremors, sleep disorders
Paraesthesias and dysaesthesias (hyperaesthesia, burning sensation)
For example, following two weeks of treatment with an agonist, 150-225 IU GONAL-f are administered for the first 7 days.
some antibiotics (Bactrim and Septra used in combination with sulfamethoxole and trimethoprim), which can be used to treat infections
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel.
For example, in generic applications, a preclinical bridge is made that allows extrapolation to the field situation.
This may lead to acute symptoms, which depend on the anatomical location of the tissue e. g. hemiplegia, hemiparesis, loss of vision have occurred in patients with CNS metastases.
For example, following two weeks of treatment with an agonist, 150-225 IU GONAL-f are administered for the first 7 days.
For example, always take your tablet one hour before breakfast.
For example, if you weigh 60 kg your daily dose will be 30 million international units (MIU).
For example, if you weigh 60 kg your daily dose will be 60 million international units (MIU).
For example, a dose of 140 mg docetaxel would require 14 ml docetaxel premix solution.
For example, a dose of 140 mg docetaxel would require 14 ml docetaxel premix solution.
Sometimes you may need to stop taking your medicine for a short time.
Changes in this area of the brain occur in: • Parkinsonism (including Parkinson's disease) and • dementia with Lewy bodies.
Thereafter tests will be taken if the doctor finds it necessary.
Thereafter, each pump will give the correct dose (1 ml containing 15 mg of the active substance mirtazapine).
Subsequently national Marketing Authorisations have been granted in all EU Member States for the treatment of various psychiatric disorders.
Then, during the ‘ maintenance'phase, it is given once every two weeks.
Thereafter, penicillamine at a daily dose ≤ 1 gm per day may be given.
Thereafter, it is recommended that the ANC is measured at least twice weekly for the first two weeks and subsequently once per week or once every other week during maintenance therapy.
Thereafter, it is recommended that the ANC is measured at least twice per week for the first 2 weeks and subsequently once per week or once every other week during maintenance therapy.
Following this, the usual daily dose of SOMAVERT is 10 mg, which is given by subcutaneous injection (just under the skin).
Thereafter, the recommended dose is 30 mg daily administered 3 times weekly on alternate days up to a maximum of 12 weeks.
Thereafter, feeding should be in accordance with energy requirements for maintenance (to be calculated by the veterinarian).
Subsequently, Section 4.4 of Singulair 4mg OG SPC was revised to include the following wording:
During the following time the sponge will dissolve and disappear completely.
This will be followed up by regular reviews with interested parties of the performance of the system.
In the future, the immune system will be able to produce these antibodies more quickly when it is again exposed to the bacteria.
In the future, the immune system will be able to produce antibodies more quickly when it is exposed to the FeLV.
In the future, the immune system will be able to produce antibodies more quickly when it is exposed to any of these virus strains.
Later on, the insulin must be resuspended again prior to each injection.
When exposed to IBR virus later in life, the calf will either not become infected or have a much less serious infection.
The European Parliament has indicated that it wishes to look at the regulation again in 2001, including further data from the EMEA and national authorities on the costs associated with the operation of the European procedures.
European Parliament Gianmartino BENZI Dietrich HENSCHLER Alternates
European Parliament Gianmartino BENZI Dietrich HENSCHLER Alternates
Thus, an in-line filter must be used as a precautionary measure and is provided in the package.
17 (≥ 75 years of age) than younger patients (< 75 years of age): constipation (8% versus 5%), nausea (6% versus 3%), hypotension (5% versus 1%), and vomiting (4% versus 1%).
Of the 36 subjects, 12 (33%) had a history of hypoglycaemia prior to beginning treatment.
In vitro activity against the following pathogens has been shown, but the clinical significance is unknown:
Of these 7 patients, 3 had eye, 1 had sinus, and 3 had disseminated infection.
Some of these cases may have resulted from unrecognized measles in the first year of life or possibly from the measles vaccination.
In these cases, possible mechanisms have not been established, but they are probably not directly related to antiandrogenic activity.
Among the latter, three studies find such an increase only in patients in whom mitotane plasma is above 14 mg/ l.
Survival and tumour progression have been examined in five large controlled studies involving a total of 2833 patients, of which four were double-blind placebo-controlled studies and one was an open- label study.
Survival and tumour progression have been examined in five large controlled studies involving a total of 2'833 patients, of which four were double-blind placebo-controlled studies and one was an open- label study.
Survival and tumour progression have been examined in five large controlled studies involving a total of 2833 patients, of which four were double-blind placebo-controlled studies and one was an open- label study.
These medicines include hypnotics and tranquilisers (e. g. benzodiazepines), fluvoxamine, thioridazine and imipramine (used to treat depression or psychiatric problems), oestrogen (contraceptives or hormone replacement therapy), cimetidine and psoralens (used to treat skin problems e. g. psoriasis).
Of these patients, 2,264 patients received vildagliptin as monotherapy and
Of these patients, 2,264 patients received vildagliptin as monotherapy and 1,520 patients received vildagliptin in combination with another medicinal product.
Of these patients 30/ 36 (83%) were treatment resistant not intolerant.
This includes 427 patients who received the recommended dose 300 mg twice daily and a further 401 patients who received 300 mg once daily for at least 24 weeks.
Of these, 581 patients received a fixed 300 mg dose as monotherapy.
Among those, 66 patients showed no progression of structural damage defined by a change in the TSS of zero or less..
Among those, 66 patients showed no progression of structural damage defined by a change in the TSS of zero or less.
progression of structural damage defined by a change in the TSS of zero or less.
Of these patients, 76% had associated diffuse peritonitis (surgically-apparent peritonitis).
Among those, 86, 72, and 41 patients had ACR 20/ 50/ 70 response, respectively at month 60.
Among those, 86, 72, and 41 patients had ACR 20/ 50/ 70 response, respectively at Month 60.
Among those, 86, 72, and 41 patients had ACR 20/ 50/ 70 response, respectively at Month 60.
Among those, 86, 72, and 41 patients had ACR 20/ 50/ 70 response, respectively at month 60.
Many of these patients reported concurrent peripheral oedema.
Many of these patients reported concurrent peripheral oedema.
Many of these patients reported concurrent peripheral oedema.
Among those patients with elevated uric acid levels, very few patients treated with the combination developed clinical gout, none of which required treatment modification or discontinuation from the clinical trials.
Of these, 185 (98.9%) env genes carried specific substitutions in region of aa 36 - 45 of gp41.
Of these, 64.3% were major malformations.
Of these, 37 had invasive candidiasis, 10 had invasive aspergillosis, and 1 patient had esophageal candidiasis.
Out of the 12 patients enrolled, 9 responded, one completely and 8 partially.
Among the 15 cases, the severity was recorded as mild in 11 cases, moderate in one case and not recorded in 3 cases.
Of the 16 patients with high titres, 15 received immune tolerance (IT) treatment.
Among the 176 patients who received Vectibix after progression on BSC alone, the response rate (investigator assessment) was 11.4% (95% CI:
Of the 22 patients stable at week 8, 6 improved at week 12/16 and 4 deteriorated compared with baseline.
Out of 353 patients in the MM-009 and MM-010 studies who received lenalidomide/dexamethasone, 45.6% were aged 65 or over.
Of the 39 patients who had received two or more prior induction regimens, 5 (13%) [95% CI:
In a large study, 1,071 patients were enrolled after treatment in a prior non pegylated interferon alfa-2b or non pegylated interferon alfa-2b/ ribavirin study to evaluate the durability of sustained virologic response and assess the impact of continued viral negativity on clinical outcomes.
Long-Term efficacy data lon In a large study, 1,071 patients were enrolled after treatment in a prior non pegylated interferon alfa-2b or non pegylated interferon alfa-2b/ ribavirin study to evaluate the durability of sustained virologic response and assess the impact of continued viral negativity on clinical outcomes.
of long-term follow-up and only 12 sustained responders' out of 492 relapsed during this study.
The Kaplan-Meier estimate for continued sustained response over 5 years for all patients is 97% with a 95% Confidence Interval of [95%, 99%].
Of the 669 patients enrolled, 245 (37%) were 65 years of age or older.
Of the 908 participants, 239 thereof experienced adverse events (AEs).
The EMEA is aware of the international context in which it operates and is increasingly active with the European Union’s international partner organisations and countries.
Among eighteen patients who were intolerant or had infections refractory to amphotericin B or itraconazole, seven patients were classed as responders.
Of the circulating metabolites, the majority are glucuronide conjugates of posaconazole with only minor amounts of oxidative (CYP450 mediated) metabolites observed.
of long-term follow-up and only 12 sustained responders' out of 492 relapsed during this study.
New activities and EU initiatives with significant impact on the workload include:
0%), including COPD exacerbation (1 of 37 patients [2.7%]) and bronchitis (1 of 37 patients [2.7%]).
163 placebo-controlled trials, serious adverse events occurred at a frequency of 4% in 349 patients treated with Enbrel compared with 5% of 152 placebo-treated patients.
9 placebo-controlled trials, serious adverse events occurred at a frequency of 4% in 349 patients treated with Enbrel compared with 5% of 152 placebo-treated patients.
Among patients with psoriatic arthritis who received Enbrel, the clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.
Among patients with extrapulmonary disease, 2 of 8 patients who also had definite, probable, or possible CNS involvement had a favourable response.
Of patients in the teriparatide trials, 82.8% of the FORSTEO patients and 84.5% of the placebo patients reported at least 1 adverse event.
Among patients initially not reperfused, the incidence of death/ re-MI at Day 30 was significantly reduced from 15% for the control group to 12.1% for the fondaparinux group (hazard ratio 0.79, 95% CI, 0.65; 0.97, p = 0.023).
Among imatinib-intolerant patients, the estimated rate of PFS was 98% (95% CI:
Among entecavir-treated nucleoside naive patients, post-treatment exacerbations had a median time to onset of 23-24 weeks, and most were reported in HBeAg negative patients (see section 4.8).
Among entecavir-treated nucleoside-naive patients, ALT elevations had a median time to onset of 23-24 weeks, and 86% (24/ 28) of ALT elevations occurred in HBeAg negative patients.
Anaemia (haemoglobin < 10g/ dL) was reported in 7% and 14% of patients treated with Pegasys monotherapy or in combination therapy, respectively.
Anaemia (haemoglobin < 10g/ dL) was reported in 7% and 14% of patients treated with Pegasys monotherapy or in combination therapy, respectively.
Among imatinib-resistant patients, the estimated rate of PFS was 88% (95% CI:
325 (92%) of the patients in the lenalidomide/dexamethasone group experienced at least one adverse reaction compared to 288 (82%) in the placebo/dexamethasone group.
Among entecavir-treated patients on-treatment exacerbations had a median time of onset of 4-5 weeks.
Among entecavir-treated patients, on-treatment ALT elevations had a median time to onset of 4-5 weeks, generally resolved with continued treatment, and, in a majority of cases, were associated with a ≥ 2 log10/ ml reduction in viral load that preceded or coincided with the ALT elevation.
For those patients who received more than 7 days of therapy with caspofungin, 50% (26/ 52) had a favourable response.
Reasons for not receiving ERT included the burden of intravenous infusions and difficulties in venous access.
Symptoms of homocystinuria include thrombosis (formation of blood clots in the blood vessels), weakness of the bones, abnormalities of the skeleton, ectopia lentis (a disorder where the lens of the eye is in the wrong position) and mental retardation.
Themes under consideration include medicines information.
Parnassustoren / Locatellikade 1 NL- 1076 AZ Amsterdam
- capsule shell: gelatin, titanium dioxide (E 171), sodium lauril sulfate
- capsule shell: gelatin, titanium dioxide (E 171), sodium lauril sulfate, indigo carmine (E 132),
Capsule shell: gelatin, titanium dioxide (E 171), sodium lauril sulfate, indigo carmine (E 132),
In contrast, there were 155 (28.0%) events in the IFN+Ara-C arm, of which 128 occurred during first-line treatment with IFN+Ara-C.
60 n Inha le d Ins ulin Concentration (uU/ ml)
Inha le d Ins ulin Concentration (uU/ ml)
The bioavailability of a 200 I. U. dose relative to parenteral administration is between 2 and 15%.
The bioavailability of a 40 I. U. dose relative to parenteral administration is between 45 and 53%.
Compared to a patient with a body weight of 65 kg, the rivastigmine steady-state concentrations in a patient with a body weight of 35 kg would be approximately doubled, while for a patient with a body weight of 100 kg the concentrations would be approximately halved.
The average survival time was significantly longer for patients who received RILUTEK compared with patients who received placebo.
Compared with pharmacokinetic data from adults with CRF where the same sampling duration was used, the ct
Compared with pharmacokinetic data from adults with CRF where the same sampling duration was used, the ct
comparison showed that the pharmacokinetics of darbepoetin alfa were similar for paediatric and adult patients with CRF.
comparison showed that the pharmacokinetics of darbepoetin alfa were similar for paediatric and adult patients with CRF.
Compared with pharmacokinetic data from adults with CRF where the same sampling duration was used, the comparison showed that the pharmacokinetics of darbepoetin alfa were similar for paediatric and adult patients with CRF.
baseline to 4 hours Difference
Upon release of the plunger, the plastic cylinder will rapidly move to cover the needle.
of tuberculosis before starting RoActemra.
Via its binding to a specific cytoplasmic immunophilin (FKBP12), tacrolimus inhibits calcium-
• Increased number of delegates and meetings in 2003 will result in increased number of transactions to be executed 30 EMEA Work Programme 2003
- Previous successful participation at a training course, or equivalent course during the phase
place in the main conference rooms.
precipitates before resuspension.
Uncommon effects: means that between 1 in 100 and 1 in 1000 people taking the medicine are affected.
you have low blood pressure or if your arteriovenous fistula has complications.
transplant and are taking medicines that suppress the immune system, • children and adolescents with a history of severe mental illness, particularly severe depression, suicidal thoughts or suicide attempts. ina
Stretch Injection site must be firm and tight
For intramuscular use of 1 dose (2 ml) per pig
-PPV inducing a HIA titre of at least 160 (in rabbits). - E. rhusiopathiae:
Patients developing dyspnoea while treated with EXUBERA should be examined for pulmonary or
No special requirements for disposal.
Astellas Pharma S. A Paseo del Club Deportivo n°1, Bloque 14 28223 Pozuelo de Alarcón (Madrid) Spain
Paseo del Club Deportivo n° 1 Bloque 14-2a E-28223 Pozuelo de Alarcón, Madrid Tel: + 34 91 4952700
not less than 106.0 CCID50
It should also not be used in patients with diabetic ketoacidosis (high levels of ketones [acids] in the blood), in patients with severe liver problems or in patients also taking gemfibrozil (a medicine used to reduce blood fat levels).
Switching from Pradaxa treatment to parenteral anticoagulant:
57 Switching from capsules or oral solution to transdermal patches Based on comparable exposure between oral and transdermal rivastigmine (see section 5.2), patients treated with Prometax capsules or oral solution can be switched to Prometax transdermal patches as follows: • A patient on a dose of 3 mg/ day oral rivastigmine can be switched to 4.6 mg/ 24 h transdermal patches. • A patient on a dose of 6 mg/ day oral rivastigmine can be switched to 4.6 mg/ 24 h transdermal patches. • A patient on a stable and well tolerated dose of 9 mg/ day oral rivastigmine can be switched to 9.5 mg/ 24 h transdermal patches.
67 Switching from capsules or oral solution to transdermal patches Based on comparable exposure between oral and transdermal rivastigmine (see section 5.2), patients treated with Prometax capsules or oral solution can be switched to Prometax transdermal patches as follows: • A patient on a dose of 3 mg/ day oral rivastigmine can be switched to 4.6 mg/ 24 h transdermal patches. • A patient on a dose of 6 mg/ day oral rivastigmine can be switched to 4.6 mg/ 24 h transdermal patches. • A patient on a stable and well tolerated dose of 9 mg/ day oral rivastigmine can be switched to 9.5 mg/ 24 h transdermal patches.
3 Switching from parenteral anticoagulants treatment to Pradaxa:
It is not known if rimonabant is excreted in human milk.
Complete the other stages of injection without delay.
Complete the other stages of injection without delay.
To measure the dose: • Shake the bottle lightly before opening • Use the correct spoon:
The safety and efficacy of enfuvirtide has not been specifically studied in patients with significant underlying liver disorders.
- Diseases and/ or conditions resulting in hypercalcaemia and/ or hypercalciuria
Diseases and/or conditions resulting in hypercalcaemia and/or hypercalciuria Nephrolithiasis Hypervitaminosis D Hypersensitivity to the active substances or to any of the excipients
Diseases and/or conditions resulting in hypercalcaemia and/or hypercalciuria
4.4 Special warnings and precautions for use
4.4 Special warnings and precautions for use
is permitted to take fluids and medicinal products by mouth.
22 using duloxetine considered their symptoms of stress incontinence to be improved with treatment compared with women using placebo (64.6% versus 50.1%, p < .001).
Using a global improvement scale (PGI), significantly more women using duloxetine considered their symptoms of stress incontinence to be improved with treatment compared with women using placebo (64.6% versus 50.1%, p < .001).
Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment.
Patients ≥ 75 years old The use of Efient in patients ≥ 75 years of age is generally not recommended.
Adult patients with psoriatic arthritis
Adult patients with psoriatic arthritis
Adult patients with newly -diagnosed glioblastoma multiforme
Adult patients with newly-diagnosed glioblastoma multiforme
Patients with recurrent or progressive malignant glioma
Adult patients with newly -diagnosed glioblastoma multiforme
Adult patients with newly-diagnosed glioblastoma multiforme
3 Adult and paediatric patients 3 years of age or older with recurrent or progressive malignant glioma:
Adult and paediatric patients 3 years of age or older with recurrent or progressive malignant glioma:
Adult and paediatric patients 3 years of age or older with recurrent or progressive malignant glioma:
− Adult patients with renal insufficiency not yet undergoing dialysis
Adult patients with renal insufficiency not yet undergoing dialysis
Adult patients with renal insufficiency not yet undergoing dialysis:
Adults with kidney disease not yet receiving dialysis
Elderly No dose adjustment is necessary for elderly patients.
No dose adjustment is necessary for elderly patients.
There is no dose adjustment necessary in these patients unless there are predisposing risk factors (see section 4.4 Muscle disorders).
There is no dose adjustment necessary in these patients unless there are predisposing risk factors (see section 4.4 Muscle disorders).
Elderly patients No dose adjustment is recommended based on age (see section 5.2).
Elderly patients No specific dose adjustment is necessary.
Based on the population pharmacokinetic analysis, which included patients with a wide range of ages (27 to 86 years) and included 234 (46%) patients greater or equal to 65, age has no influence on the pharmacokinetics of 5'-DFUR and 5-FU.
Elderly patients with dementia INVEGA has not been studied in elderly patients with dementia.
Elderly patients with dementia RISPERDAL CONSTA has not been studied in elderly patients with dementia, hence it is not indicated for use in this group of patients.
Elderly patients The recommended doses should be used in elderly patients except those with severe renal insufficiency (see above and section 4.4).
Elderly Data in elderly are limited, but suggest no marked changes in exenatide exposure with increased age up to about 75 years old.
29 Elderly patients: insufficient numbers of elderly patients have been evaluated in clinical studies to determine whether they respond differently than younger patients.
53 Elderly patients: insufficient numbers of elderly patients have been evaluated in clinical studies to determine whether they respond differently than younger patients.
5 Elderly patients: insufficient numbers of elderly patients have been evaluated in clinical studies to determine whether they respond differently than younger patients.
Elderly patients: insufficient numbers of elderly patients have been evaluated in clinical studies to determine whether they respond differently than younger patients.
Alemtuzumab does not appear to damage haematopoietic stem cells or progenitor cells.
First Line B-CLL Patients
Patients with tumours that have returned or worsened (malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma) taking Temodal only:
Patients with tumours that have returned or worsened (malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma) taking Temodal only:
32 Patients with hepatic impairment In patients with compensated cirrhosis (eg, Child-Pugh A), Pegasys has been shown to be effective and safe.
58 Patients with hepatic impairment In patients with compensated cirrhosis (eg, Child-Pugh A), Pegasys has been shown to be effective and safe.
84 Patients with hepatic impairment In patients with compensated cirrhosis (eg, Child-Pugh A), Pegasys has been shown to be effective and safe.
Patients with moderate or severe hepatic impairment.
Patients with hepatic or renal impairment
Patients with renal impairment and elderly patients:
6 Patients with renal or hepatic impairment:
Patients with diabetes mellitus: caution should be exercised when administering bexarotene in patients using insulin, agents enhancing insulin secretion (e. g. sulfonylureas), or insulin-sensitisers (e. g. thiazolidinediones).
Patients with hepatic or renal impairment
End-stage renal disease patients For patients with ESRD, Sebivo should be administered after haemodialysis (see section 5.2).
Patients with a disease that is associated with multiple inflammations of the nerves in the whole body (Guillain Barré syndrome).
Patients with newly-diagnosed glioblastoma multiforme:
Patients with Prior Cisplatin Chemoradiotherapy
Patients with ACR20 response/ Patients evaluated (%)c
Patients with known hypersensitivity to trastuzumab, murine proteins, or to any of the excipients.
Patients with renal or hepatic impairment Studies of filgrastim in patients with severe impairment of renal or hepatic function demonstrate that it exhibits a similar pharmacokinetic and pharmacodynamic profile to that seen in normal individuals.
Patients with recurrent or progressive malignant glioma
Patients with a history of hypersensitivity to infliximab (see section 4.8), to other murine proteins, or to any of the excipients.
- Patients with a history of hypersensitivity to natural or recombinant interferon -ß, human
Patients with coexisting conditions There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophiliac patients type A and B treated with PIs.
- patients who have received prior bone marrow transplant or stem cell support,
- patients with liver cirrhosis and/ or ascites
- patients with liver cirrhosis and/or ascites
Patients with moderate or severe (Child-Pugh B or C) hepatic impairment.
Patients with renal impairment Daily dose in patients with renal impairment should be based on creatinine clearance (see section 5.2):
- patients with haemodynamically relevant left ventricular inflow or outflow impediment
- patients with haemodynamically relevant left ventricular inflow or outflow impediment (e. g.
15 Patients with Heparin Induced Thrombocytopenia Fondaparinux should be used with caution in patients with a history of HIT.
Patients with Heparin Induced Thrombocytopenia Fondaparinux should be used with caution in patients with a history of HIT.
6 Patients with growth failure associated with chronic renal insufficiency Common: renal failure, peritonitis, osteonecrosis, blood creatinine increase.
Patients undergoing major orthopaedic or abdominal surgery The recommended dose of fondaparinux is 2.5 mg once daily administered post-operatively by subcutaneous injection. na
Patients undergoing major orthopaedic or abdominal surgery The recommended dose of fondaparinux is 2.5 mg once daily administered post-operatively by subcutaneous injection.
10 HIV/ HBV co-infected patients not receiving concomitant HAART: entecavir has not been evaluated in HIV/ HBV co-infected patients not concurrently receiving effective HIV treatment.
25 HIV/ HBV co-infected patients not receiving concomitant HAART: entecavir has not been evaluated in HIV/ HBV co-infected patients not concurrently receiving effective HIV treatment.
HIV/ HBV co-infected patients not receiving concomitant HAART: entecavir has not been evaluated in HIV/ HBV co-infected patients not concurrently receiving effective HIV treatment.
4 Patients with HIV and hepatitis B or C virus co-infection:
Patients co-infected with hepatitis B and/or hepatitis C virus Among 1,968 treatment-experienced patients receiving PREZISTA co-administered with ritonavir 600/100 mg b.i.d., 236 patients were co-infected with hepatitis B or C.
Patients co-infected with hepatitis B virus (HBV):
Patients co-infected with hepatitis C virus:
34 Human immunodeficiency virus (HIV)/ HBV co-infected patients not receiving concomitant antiretroviral therapy: entecavir has not been evaluated in HIV/ HBV co-infected patients not concurrently receiving effective HIV treatment.
Human immunodeficiency virus (HIV)/ HBV co-infected patients not receiving concomitant antiretroviral therapy: entecavir has not been evaluated in HIV/ HBV co-infected patients not
Patients co-infected with hepatitis B and/ or hepatitis C virus Among 1,151 patients receiving atazanavir 400 mg once daily, 177 patients were co-infected with chronic hepatitis B or C, and among 655 patients receiving atazanavir 300 mg once daily with ritonavir 100 mg once daily, 97 patients were co-infected with chronic hepatitis B or C.
Patients < 30 kg also receiving valproate medication:
103 Patients developing Factor VIII inhibitors If your plasma Factor VIII fails to reach expected levels with ADVATE, or if bleeding is not adequately controlled, it could be due to the development of Factor VIII inhibitors.
113 Patients developing Factor VIII inhibitors If your plasma Factor VIII fails to reach expected levels with ADVATE, or if bleeding is not adequately controlled, it could be due to the development of Factor VIII inhibitors.
123 Patients developing Factor VIII inhibitors If your plasma Factor VIII fails to reach expected levels with ADVATE, or if bleeding is not adequately controlled, it could be due to the development of Factor VIII inhibitors.
133 Patients developing Factor VIII inhibitors If your plasma Factor VIII fails to reach expected levels with ADVATE, or if bleeding is not adequately controlled, it could be due to the development of Factor VIII inhibitors.
93 Patients developing Factor VIII inhibitors If your plasma Factor VIII fails to reach expected levels with ADVATE, or if bleeding is not adequately controlled, it could be due to the development of Factor VIII inhibitors.
Patients developing Factor VIII inhibitors If your plasma Factor VIII fails to reach expected levels with ADVATE, or if bleeding is not adequately controlled, it could be due to the development of Factor VIII inhibitors.
Patients in whom the blood supply to the extremity distal to the tumour is suspected to be highly dependent on tumour associated blood vessels.
11 Medical patients who are at high risk for thromboembolic complications based on an individual risk assessment The recommended dose of fondaparinux is 2.5 mg once daily administered by subcutaneous injection.
12 Medical patients who are at high risk for thromboembolic complications based on an individual risk assessment The recommended dose of fondaparinux is 2.5 mg once daily administered by subcutaneous injection.
Medical patients who are at high risk for thromboembolic complications based on an individual risk assessment The recommended dose of fondaparinux is 2.5 mg once daily administered by subcutaneous injection.
There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophiliac patients type A and B treated with protease inhibitors.
There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophiliac patients type A and B treated with protease inhibitors.
Haemophiliac patients There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthrosis in patients with haemophilia type A and B treated with PIs.
Haemophiliac patients There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthrosis in patients with haemophilia type A and B treated with PIs.
Patients with high blood pressure and type 2 diabetes Treatment usually starts with 50 mg losartan (one tablet Cozaar 50 mg) once a day.
Patients with High Blood Pressure Treatment usually starts with 50 mg losartan (one tablet Cozaar 50 mg) once a day.
dose recommendations cannot be given.
Patients with HIV-1 harbouring mutations:
Patients with hepatic impairment No dose adjustment is required (see section 5.2).
Patients with hepatic impairment No adjustments of the starting dose nor of the dose modification rules are required in patients with hepatic impairmented patients (see section 5.2).
Patients with hepatic impairment No adjustments of the starting dose nor of the dose modification rules are required in patients with hepatic impairment (see section 5.2).
Treatment naïve patients The resistance profile in treatment-naïve patients has not been characterized.
Naïve patients Three trials examined the use of interferon in naïve patients, two with Ribavirin + interferon alfa-2b (C95-132 and I95-143) and one with Ribavirin + peginterferon alfa-2b (C/ I98-580).
YMDD variant HBV status HBeAg seroconversion
- patients with active second malignancies;
Patient with pre-existing risk factors
pulmonary embolism) or severe myelosuppression.
congenital agammaglobulinemia or hypogammaglobulinemia, common variable immunodeficiency, severe combined immunodeficiencies, Wiskott Aldrich syndrome.
Patients with known hypersensitivity to lopinavir, ritonavir or any of the excipients.
• Patients with high disease activity despite treatment with a beta-interferon (see section 5.1);
• patients with severe hypoproteinaemia, e. g. in nephrotic syndrome,
Patients with active or suspected ocular or periocular infections.
The pharmacokinetics of zonisamide in patients with impaired liver function have not been adequately studied.
Patients with severe (Child-Pugh Class C) hepatic impairment.
No change in dosage is required for renal impairment.
Patients with renal impairment: no dosage adjustment is needed (see section 5.2).
Patients with chronic renal insufficiency (CRI)
Patients with chronic renal insufficiency (CRI)
Patients with renal/ hepatic impairment Studies of filgrastim in patients with severe impairment of renal or hepatic function demonstrate that it exhibits a similar pharmacokinetic and pharmacodynamic profile to that seen in normal individuals.
Patients with renal or hepatic impairment There have been no studies on the effect of impaired renal or hepatic function on the pharmacokinetics of Xolair.
Patients with impaired hepatic or renal function
Patients with diseases of the blood that lead to a lack of antibody production and recurrent infections (myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinemia).
Patients with clinically significant response (%)
Patients with Clinically Significant Response (%)
• Patients with rapidly evolving severe relapsing remitting multiple sclerosis (see section 5.1).
• Patients with rapidly evolving severe relapsing remitting multiple sclerosis, defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.
Post-surgical patients with an increased risk for bleeding:
Patients with Prader-Willi syndrome (PWS)
Patients with Prader-Willi syndrome (PWS)
and keeping it with them at all times.
Patients who for any reason cannot receive adequate antithrombotic prophylaxis.
If PCI was performed, patients received either intravenous fondaparinux (fondaparinux patients) or weight adjusted intravenous UFH (enoxaparin patients) as adjunctive therapy, dependent on the timing of the last lo subcutaneous dose and planned use of GP IIb/ IIIa inhibitor.
Resistant Intolerant without MCyR time of imatinib treatment in
Patients without Prior Cisplatin Chemoradiotherapy
Patients with renal or hepatic impairment:
Patients with hepatic impairment:
Patients with renal impairment:
- patients undergoing major surgery or during anaesthesia with agents that produce
Patients on a controlled sodium diet:
Patients treated and monitored for b resistance Patients in specific year with:
Diuretic-treated patients In patients concurrently treated with diuretics, as hypotension may occur following initiation of the treatment, caution is recommended.
Patients taking levodopa (advanced stage of Parkinson’s disease) You will start by using one Neupro 4 mg/24 h patch daily.
- patients with current concomitant therapy with oral anticoagulants (e. g. warfarin sodium)
Patrick Le Courtois, Head of Unit, b.
Marketing Authorisation Holder
André PAUWELS, Frans GOSSELINCKX
a pause in breathing or other breathing difficulties.
Sverige Pfizer AB Tel: +46 (0)8 550 520 00
Paxene 6 mg/ml concentrate for solution for infusion (paclitaxel)
Paxene has also been shown to improve the survival time for some types of cancer.
Paxene has been studied in 107 patients with Karposi's sarcoma.
Paxene contains polyoxyl castor oil, which can cause an allergic reaction.
Paxene should be administered via an infusion control device (pump) using non-PVC tubing and connectors.
Paxene should be administered through an in-line filter with a microporous membrane not greater than 0.22 µm.
Paxene should be given before cisplatin when used in combination (see 4.5).
Paxene is very similar to another authorised medicine containing paclitaxel (Taxol) and the studies supporting the use of Taxol were used to support the use of Paxene.
Pregnant staff should not handle Paxene.
The Netherlands, Belgium, Germany, France, Italy, Spain and the United Kingdom.
Netherlands Netherlands Netherlands Poland Poland Portugal Portugal Portugal Portugal Portugal Romania Romania Slovenia Slovenia Spain Spain Sweden Sweden
Pc-Fice 20 Mg Granulat Zur Herstellung Einer Lösung Zum Einnehmen 28887.00.01
Skin and subcutaneous tissue disorders
• yellow skin or eyes, itching, or pain in the abdomen (tummy) caused by inflammation of the liver
PECSOIL- Intensively reared animals = 1.036 µg. kg-1 PECSOIL- Pasture animals = 0.48 µg. kg-1 For two soil exposure scenarios the PECSOIL values did not exceed the 100 µg/ kg threshold value as stated in the VICH Guideline for Phase I assessments of veterinary medicines.
Pedea is contraindicated in neonates with:
Pedea is supplied in packs of 4 x 2 ml ampoules.
Pedea should not be used prophylactically (used before there is a proof of a patent ductus arteriosus).
Pedea is a solution for injection available in cartons of four 2 ml ampoules.
Pedea should be carefully administered to your baby by the healthcare professional, to avoid damage to the skin and surrounding tissues.
Paediatric population There are no data on the use of Bondenza in these age groups.
Paediatric patients - Fondaparinux has not been investigated in this population.
ut Paediatric patients - Fondaparinux has not been investigated in this population.
Pegasys 360/ 180 or Pegasys 360/ 180 or 180 μ g 180 μ g & & Ribavirin 1000/ 1200 Ribavirin mg 1000/ 1200 mg 72 or 48 Weeks 72 Weeks (N = 942) (N = 473) Pts with SVR in Pts with VR at Wk 12 a VR at Wk 12 b (N = 876) (N = 100)
Pegasys 360/ 180 or 180 μ g & Ribavirin 1000/ 1200 mg 48 Weeks (N = 469) SVR in Pts with VR at Wk 12 b (N = 57)
Low viral load= ≤ 800,000 IU/ mL; High viral load= > 800,000 IU/ mL RVR = rapid viral response (HCV RNA undetectable) at week 4
Pegasys has a minor or moderate influence on the ability to drive and use machines.
Pegasys has a minor or moderate influence on the ability to drive and use machines.
to 135/ 90/ 45 micrograms
Pegasys is used to treat adult patients with the following diseases: • chronic (long-term) hepatitis B (a disease of the liver due to infection with the hepatitis B virus).
Pegasys is used for the treatment of chronic hepatitis B or C, which are viral infections of the liver.
Pegasys has not been evaluated in patients with decompensated cirrhosis (eg, Child-Pugh B or C or bleeding oesophageal varices) (see section 4.3).
Pegfilgrastim is a protein produced by biotechnology in bacteria called E. coli.
Pegfilgrastim is a protein produced by biotechnology in bacteria called E. coli.
peginterferon alfa-2a*.................................................................................... .135 micrograms Each vial of 1 ml solution contains 135 micrograms peginterferon alfa-2a*.
peginterferon alfa-2a*.................................................................................... .180 micrograms Each vial of 1 ml solution contains 180 micrograms peginterferon alfa-2a*.
PegIntron monotherapy As monotherapy the PegIntron regimen is 0.5 or 1.0 microgram/k g/week.
PegIntron monotherapy As monotherapy the PegIntron regimen is 0.5 or 1.0 microgram/kg/week.
PegIntron is indicated for the treatment of chronic hepatitis C only in patients 18 years of age or older.
Birgitta BRATTHALL, Anders BROSTRÖM
Film coat Polyvinyl alcohol (Partially Hydrolyzed) Talc (E553b) Titanium dioxide (E171) Macrogol / PEG 3350 Allura red AC Aluminium Lake (E129) Lecithin (Soya) (E322)
Film coat Polyvinyl alcohol (Partially Hydrolyzed) Talc (E553b) Titanium dioxide (E171) Macrogol / PEG 3350 Lecithin (Soya) (E322) Allura red AC Aluminium Lake (E129)
Polyvinyl alcohol-part. hydrolyzed Titanium dioxide (E171) Macrogol 3350 Talc
Talc (E553b) hypromellose (E464) titanium dioxide (E171) macrogol 8000
Talc (E553b) hypromellose (E464) titanium dioxide (E171) macrogol 8000.
● Pelzont (1000 mg/ 20 mg to 2000 mg/ 40 mg at week 5) ▲ Nicotinic acid (prolonged-release 1000 mg to 2000 mg at week 5) ○ Placebo *Includes patients with moderate, severe, or extreme flushing symptoms † Dose advancement at Week 5
Pelzont Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure, indicating little relevance to human use.
Therefore, Pelzont should be used with caution in patients with or predisposed to gout.
Pelzont should be used in patients in combination with HMG-CoA reductase inhibitors (statins), when the cholesterol lowering effect of HMG-CoA reductase inhibitor monotherapy is inadequate.
It does this by lowering the levels of total cholesterol, LDL cholesterol, fatty substances called triglycerides and apo B (a part of LDL) in the blood; • to raise levels of ‘ good'cholesterol (HDL cholesterol) and apo A-I (a part of HDL).
It can be used as monotherapy only in patients in whom HMG-CoA reductase inhibitors are considered inappropriate or not tolerated.
During that period, patients should avoid exposure of unprotected skin, eyes or other body organs to direct sunlight or bright indoor light such as tanning salons, bright halogen lighting, or high power lighting in surgery operating rooms or dental surgeries.
During cutting and handling, avoid excessive fluid loss from InductOs.
The overall mortality (death rate) during the study period was 9%.
During handling, avoid excessive fluid loss from InductOs.
During the randomised period of the EUROPA study, only serious adverse events were collected.
There were no events of bone crisis, avascular necrosis or fracture during the treatment period.
A lower incidence of acute rejection episodes for tacrolimus- versus ciclosporin- treated patients (11.5% versus 22.6%) and a lower incidence of chronic rejection, the bronchiolitis obliterans syndrome (2.86% versus 8.57%), was reported within the first year after transplantation.
A lower incidence of acute rejection episodes for tacrolimus- versus ciclosporin-treated patients (11.5% versus 22.6%) and a lower incidence of chronic rejection, the bronchiolitis obliterans syndrome (2.86% versus 8.57%), was reported within the first year after transplantation.
If you experience muscle pain, severe and persistent stomach pain with nausea and vomiting, severe and persistent trouble breathing and tiredness while taking Sebivo, call your doctor immediately.
During post marketing surveillance, the following adverse reactions have been reported in patients treated with pemetrexed:
During normal digestion, bile acids are secreted into the intestine.
Within 24 hours after having taken Gliolan, avoid any other medicines that may harm the liver.
For 30 days following Foscan treatment, avoid eye tests that use bright lights.
First 4 treatment cycles: • On days 1-4, 9-12 and 17-20: take 40 mg dexamethasone once per day • On days 21-28: do NOT take dexamethasone
During the second half of 1997, discussions started between EudraNet users about the improvement of the communication layer from ISDN to Frame Relay services provided by a single character (GlobalOne) within the framework of the TESTA (Trans-European Services for Telematics between Administrations) initiative, managed by DG III/IDA.
In clinical trials involving 442 patients, no patients have developed antibodies to thyrotropin alfa either after single or repeated limited (27 patients) use of the product.
In the first few weeks after vaccination with CELVAPAN the results of these tests may not be correct.
During treatment with Advocate no other antiparasitic macrocyclic lactone should be administered.
During therapy and until healed, affected skin is likely to appear noticeably different from normal skin.
Therapy with simvastatin should be temporarily stopped a few days prior to elective major surgery and when any major medical or surgical condition supervenes.
treatment (median) Transfusion Avoidance during
- During treatment with Velmetia, your doctor will check your kidney function at least once a
You should continue your diet during treatment with Velmetia and take care that your carbohydrate intake is equally distributed over the day.
In use Store below 25 ºC.
- for less than one day (up to 24 hours): it should be re-applied to the same place or replaced with
During or after treatment with MABTHERA If you develop symptoms suggestive of infections, such as fever, persistent cough, weight loss, or listlessness, seek medical attention immediately.
- for more than one day (24 hours or more) or if the user is not aware when the patch has lifted or
reading, or listening to the radio);
Hold your breath, take the inhaler from your mouth and your finger from the top of the inhaler.
During a short break in taking the medicine the amount of virus in your blood may increase.
During a mean of 53 weeks of treatment with Volibris, none of the patients enrolled had a confirmed serum ALT > 3xULN that required permanent discontinuation of treatment.
No metabolic effects, e. g. on plasma lipids or glucose metabolism, have been seen during treatment with amlodipine.
While being treated with PegIntron Your doctor may want you to drink extra fluids to help prevent low blood pressure.
While being treated with ViraferonPeg Your doctor may want you to drink extra fluids to help prevent low blood pressure.
Penicillin: hydrochlorothiazide is excreted in the distal tubulus, and reduces excretion of penicillin.
Penn Pharmaceutical Services Limited Tafarnaubach Industrial Estate Tredegar Gwent NP22 3AA United Kingdom
Penn Pharmaceutical Services Limited Tafarnaubach Industrial Estate Tredegar, Gwent NP2 3AA United Kingdom
Penn Pharmaceutical Services Ltd Units 23-24 Tafarnaubach Industrial Estate Tredegar Gwent NP22 3AA UK
Penn Pharmaceutical Services Ltd Units 23-24 Tafarnaubach Industrial Estate Tredegar Gwent NP22 3AA UK
Pentagon Park Boundary Way Hemel Hempstead Herts HP2 7UD United Kingdom
Pentagon Park Boundary Way Hemel Hempstead Herts HP2 7UD United Kingdom.
Pentagon Park Boundary Way Hemel Hempstead Herts., HP2 7UD United Kingdom.
Pentagon Park Boundary Way Hemel Hempstead Herts., HP2 7UD United Kingdom
Losing weight may mean you need adjustments to the dose of these medicines.
Dysphonia (common) * if specified, the frequency has been derived from clinical trial data
gastro-intestinal perforation6
PERF II, which ran from July 2001, was closed in September 2002.
Each priority action area involves a programme of practical workshops with the involvement of experts from the competent authorities of the EU and accession candidate countries.
is infused continuously ("basal rate") and how much and when you need additional insulin as an "insulin boost" ("bolus dose"),
Intravenous infusion using non-linear contrast imaging technique (rest and stress) or fundamental imaging technique at rest:
Following infusions: _______________________ _______________________ _______________________
Pergoveris contains potent gonadotrophic substances capable of causing mild to severe adverse reactions, and should only be used by physicians who are thoroughly familiar with infertility problems and their management.
Pergoveris must be reconstituted with the solvent before use.
Pergoveris should be given as a course of daily injections.
Pergoveris should not be administered as a mixture with other medicinal products, in the same injection, except follitropin alfa.
hypesthesia, arthralgia, asthenia, pain, bursitis, dermatitis, headache, injection site hypersensitivity, malaise, nausea, paresthesia, postural hypotension, pruritus, rash, in coordination, amnesia, circumoral paresthesia, depression, insomnia, peripheral oedema, vertigo (some of the uncommon events may be disease related)
thrombosis, cardiac tamponade, myocardial rupture
If the product is not lon reconstituted during the four-week period, it cannot be put back in the refrigerator for a new storage period and must be discarded.
Periodic Safety Update Reports for Marketed Drugs – Addendum to ICH-E2C (CPMP/ICH/4679/02)
Periodically you will have samples of your blood taken to evaluate your kidney and liver function.
hot, oedema peripheral, pain, asthenia, chest pain, face oedema, hyperthermia
Neuropathy peripheral, neuropathy, paraesthesia, polyneuropathy, dizziness, dysgeusia
Recruitment is carried out through open selection and follows the rules and practices of the EU institutions.
Elderly patients (≥ 65 years) The recommended starting dose for the elderly is 7.5 mg daily.
12 Elderly Plasma concentrations following a 1 g and 2 g intravenous dose of ertapenem are slightly higher (approximately 39% and 22%, respectively) in healthy elderly adults (≥ 65 years) relative to young adults (< 65 years).
Elderly Population No dose adjustment is required (see section 5.2).
No clinically significant differences were observed in the pharmacokinetics between young (aged 21-40 years) and elderly (65-75 years).
Geriatrics No differences in FORSTEO pharmacokinetics were detected with regard to age (range 31 to 85 years).
Elderly No dose adjustment is necessary.
Elderly No dose adjustment is required.
12 Elderly Population In a multivariate analysis, age was not found to be an independent factor of any of the pharmacokinetic parameters studied.
Elderly In a multivariate analysis, age was not found to be an independent factor of any of the pharmacokinetic parameters studied.
Elderly Population In a multivariate analysis, age was not found to be an independent factor of any of the pharmacokinetic parameters studied.
Older people and SPRYCEL SPRYCEL can be used by people over 65 at the same doses as other adults.
Elderly When advanced age is associated with decrease in renal function Lisonorm dose adjustments for patients with renal impairment apply (see section 4.2).
Loss of < 15 letters in visual acuity (%)a (maintenance of vision)
- Loss/impairment of hearing, ringing in the ears, earache
- loss of appetite, weight loss or gain, bleeding in the gut, ulcers
Appetite decreased (anorexia), Constipation, Vomiting
Lost ≥ 10% of baseline body weight (%) Placebo Orlistat 60 mg
Lost ≥ 5% of baseline body weight (%) Placebo Orlistat 60 mg a
Common − injection site swelling, node and hardness − chills, fever or influenza-like illness after the injection − trouble sleeping, tiredness, weakness, dizziness, headache − increased weight, nausea, elevated levels of some liver enzymes − excessive sweating (including night sweats)
Investigations Common: weight decreased, blood lactate dehydrogenase increased.
Weight increase Creatine phosphokinase increased
Peseri Trading Limited El Greco House
Merck Sharp & Dohme OÜ Peterburi tee 46 11415 Tallinn Estonia
Infected small lacerations, abrasions, or sutured wounds.
- small, pin-point bleeding under the skin (petechiae); various skin eruptions or rashes (for
Few cases of rash or pruritus have been observed (below 1%).
There are limited reports of overdose with Agenerase.
There is limited clinical data on the safety of CIALIS in patients with severe hepatic insufficiency (Child-Pugh
There is limited clinical data on the safety of CIALIS in patients with severe hepatic insufficiency (Child-Pugh Class C).
There is limited clinical data on the safety of tadalafil in patients with severe hepatic insufficiency (Child- Pugh Class C).
There is limited clinical experience with OPTISON in patients with certain severe states of cardiac, pulmonary, renal and hepatic disease.
There are few data available on patients of African origin.
Few patients (1.1%; 0.4% serious) discontinued treatment due to a hepatic event.
Few patients (1.1%; 0.4% serious) discontinued treatment due to a hepatic event.
Few patients experienced serious adverse events:
Few patients experienced serious adverse events:
Few subjects (0.2%) discontinued due to adverse reactions.
Shortly after mixing the LeukoScan with the radioactive technetium isotope, the doctor will inject it into your vein.
♦ Uncommon (less than 1 per 100 but more than 1 per 1000 doses of vaccine): • Sore nose and throat and discomfort when swallowing, runny nose • Itching at the injection site
Hypotension, orthostatic hypotension, flushing, hypertension, phlebitis
Uncommon Arthralgia, arthritis, myalgia, muscle cramp, musculoskeletal pain
Uncommon Blood amylase increase, platelet count decrease, blood creatinine increase, haemoglobin decrease, blood urea increase, LDH increase, triglycerides increase
Uncommon: blood lactate dehydrogenase increased, blood glucose decreased, blood creatinine increased, blood urea increased.
17 Common: oedema/ fluid retention Uncommon: appetite increase or decrease, weight gain.
Common: oedema/ fluid retention Uncommon: appetite increase or decrease, weight gain.
Common: at least 1 in 100 and less than 1 in 10 patients Uncommon: at least 1 in 1000 and less than1 in 100 patients
Uncommon: abdominal distention, acid reflux, bowel movement pattern change, constipation, dry mouth, gastroduodenal ulcer, irritable bowel syndrome, oesophagitis, oral ulcer, vomiting, gastritis.
Respiratory, thoracic and mediastinal disorders:
Oral candidiasis, nasopharyngitis, cellulitis, herpes simplex, viral infection, pneumonia, catheter-related infection, fungal infection, herpes zoster, injection site infection Uncommon:
Infections Common: influenza like symptoms, respiratory tract infection (e. g bronchitis), urinary tract infection Uncommon: candidiasis, ear infection, herpes simplex, tooth infection
Uncommon: muscular cramp/ spasm, musculoskeletal pain/ stiffness.
200 Uncommon: reduced blood cell counts (pancytopenia, anaemia, leukopenia).
Uncommon: reduced number of blood cell counts (pancytopenia, anaemia, leukopenia).
Uncommon: • Pain, swelling, itching, hardness, bleeding, bruising and irritation where the injection is given.
Uncommon: muscular pain, swelling of joints/ arthralgia, muscle weakness
Uncommon: abdominal pain, dry mouth, dyspepsia, flatulence, stomach discomfort.
Uncommon: muscular pain, swelling of joints/ arthralgia, muscle weakness
Uncommon: chest pain, face oedema, gravitational oedema, influenza-like illness, chills, malaise.
Dysphagia, flatulence, glossodynia, dry mouth, gingival pain, loose stools, oesophagitis, lower abdominal pain, mouth ulceration, oral pain, rectal haemorrhage Renal and urinary disorders:
Respiratory disorders Common: cough, pharyngitis Uncommon: dyspnoea, epistaxis, rhinitis, sinus congestion, asthma
Uncommon: decreased blood pressure Uncommon: chronic obstructive pulmonary disease, pharyngolaryngeal pain, rhinorrhoea, cough Uncommon: hair disorder, lichen planus
♦ Uncommon (side effects which may occur in less than 1 per 100 but more than 1 per 1,000 doses of vaccine): • pneumonia (serious lung infection) • respiratory disorder
Uncommon: insomnia Common: dysgeusia Common: blurred vision, eye pain, eye irritation, foreign body sensation in eyes Uncommon: corneal erosion, punctate keratitis, dry eye, eye discharge, eye pruritus, ocular hyperaemia, blepharitis, allergic conjunctivitis, corneal disorder, anterior chamber flare, conjunctival hyperaemia, eyelid margin crusting, astenopia, abnormal sensation in eye, eyelids pruritus, allergic blepharitis, erythema of eyelid
Uncommon: hepatic enzymes increased (ALAT, ASAT), lipase increased, liver function test abnormal (ALAT, ASAT), weight decreased.
Uncommon Uncommon Uncommon Uncommon
Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon
Uncommon Uncommon Uncommon Uncommon
Uncommon Uncommon Uncommon Uncommon
Uncommon: apathy, depression, depressed mood, libido decreased, nightmare, insomnia, nervousness
Genital pain male Penile disorder Dyspareunia Erectile dysfunction Uterovaginal prolapse Vaginal pain Vaginitis atrophic Vulval disorder
Uncommon: euphoria, amnesia, insomnia, hallucinations, agitation.
Uncommon: gastroenteritis, upper respiratory infection, urinary tract infection.
Uncommon: eye haemorrhage, visual acuity reduced, periorbital oedema, conjunctivitis, eye irritation, dry eye.
Joint hyperextension, leg pain, genu valgum, osteopenia, compression fracture, scoliosis.
Uncommon: ear infection, gastroenteritis, nasopharyngitis, otitis media, pharyngitis, roseola, viral infection, viral rash.
Uncommon: upper respiratory tract infection
Uncommon: changes in nail pigmentation or discoloration of nail bed
Immune system disorders Uncommon - Urticaria, rash Very rare - Anaphylactic reactions
Uncommon - Oedema Oedema may occur upon initiation of insulin therapy.
Uncommon - Oedema Oedema may occur upon initiation of insulin therapy.
Uncommon: weight decreased, blood pressure increased
Common Common Uncommon Uncommon Uncommon Uncommon
Common Common Uncommon Uncommon Uncommon Uncommon
Uncommon Uncommon Uncommon Uncommon
Uncommon Uncommon Uncommon
Uncommon: pneumonia, urinary tract infection, gastroenteritis, pharyngitis.
Uncommon (≥ 1/ 1000 to < 1/ 100): iritis, eye irritation, conjunctival oedema, blepharitis, epiphora, eyelid oedema, eyelid pain, visual acuity worsened, asthenopia, trichiasis.
Uncommon: agitation, nausea, tremor, confusion, sweating, emotional instability, visual disturbances, palpitations, diarrhoea, irritability.
Uncommon: alopecia, oedema of the face/ general oedema Rare: rash, pruritus, purpura
Uncommon (affects 1 to 10 users in 1000):
Uncommon: muscular pain, arthralgia, muscle weakness
Adverse reactions reported with the use of irbesartan alone General disorders and administration site conditions:
sexual dysfunction, libido changes
Uncommon: dysponea, asthma, respiratory disorder, pharyngolaryngeal pain, cough, dysphonia, nasal congestion, throat irritation
Uncommon: dry eyes, amblyopia, visual field defect
♦ Uncommon (side effects which may occur in less than 1 per 100 but more than 1 per 1,000 doses of vaccine): • upper respiratory tract infection (infection of the nose, throat or trachea) • dizziness • other injection site reactions such as hard lump, tingling or numbness.
♦ Uncommon (side effects which may occur in less than 1 per 100 but more than 1 per 1,000 doses of vaccine): • upper respiratory tract infection (infection of the nose, throat or trachea) • dizziness • other injection site reactions such as hard lump, tingling or numbness.
♦ Uncommon (side effects which may occur in less than 1 per 100 but more than 1 per 1,000 doses of vaccine): • upper respiratory tract infection (infection of the nose, throat or trachea) • dizziness • other injection site reactions such as hard lump, tingling or numbness.
Uncommon: sepsis, bacteraemia, pneumonia pneumococcal, bronchopneumonia, upper and lower respiratory tract infection, catheter related infection, pleural infection, haemophilus infection, cytomegalovirus infection, influenza, infectious mononucleosis, varicella, urinary tract infection, gastroenteritis, candidal infection, fungal infection, post herpetic neuralgia, oral candidiasis, blepharitis, infection.
Reproductive system and breast disorders:
uncommon: hypertension
Uncommon: incoherence, loss of consciousness, coma, stupor, convulsions, cerebrovascular accident, encephalopathy
Uncommon Nausea Vomiting irritation or inflammation of the gullet (oesophagus - the tube that connects your mouth with your stomach) or stomach black or tarlike stools rash itching redness of the skin
Uncommon: thirst, hypokalaemia, gout Rare: hypoglycaemia Very rare: increase in serum urea.
Uncommon: rash, acne, photosensitivity, hyperhidrosis, oily skin, pruritus, skin lesion.
Uncommon: thirst, hypokalaemia, gout Rare: hypoglycaemia Very rare: increase in serum urea.
Uncommon: gastro-intestinal symptoms (such as nausea, vomiting, diarrhoea and upper abdominal pain)
Uncommon: thrombophlebitis, hypertension, thrombosis
Productive cough, exertional dyspnoea, sinus congestion, decreased breath sounds, pleural effusion, allergic rhinitis, hoarseness, nasal congestion, nasal dryness, wheezing
Dyspnoea Pharyngolaryngeal pain
May occur in more than one person in every 10 people Occurs in up to nine people in every 100 people Occurs in up to nine people in every 1000 people Cannot be estimated from the available data
types of blood cells in your body.
May cause toxic reactions and allergic reactions in infants and children up to 3 years old
May cause toxic reactions and allergic reactions in infants and children up to 3 years old.
Can be used during pregnancy and lactation.
necessary to adapt the dose of Advagraf that you receive.
Can be used during pregnancy and lactation.
Can be used during pregnancy and lactation.
Can be used during pregnancy and lactation.
Can be used during pregnancy and lactation.
73 Are there any interactions with an influenza vaccination?
87 Are there any interactions with an influenza vaccination?
May cause toxic reactions and allergic reactions in infants and children up to 3 years old.
May cause toxic reactions and allergic reactions in infants and children up to 3 years old.
May cause toxic reactions and anaphylactoid reactions in infants and children up to 3 years old.
Nausea, vomiting, dizziness, and headache can also occur.
blood does not contain enough red blood cells and the symptoms may be fatigue, weakness and shortness of breath.
Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.
Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.
Additi onal signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.
Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.
Severe granulocytopenia, thrombocytopenia, anaemia, or any combination thereof may develop.
Pfizer Europe MA EEIG Ramsgate Road Sandwich Kent CT 13 9 NJ United Kingdom
Pfizer Europe Ma Eeig Ramsgate Road Sandwich Kent Ct13 9nj United Kingdom
Pfizer Europe MA EEIG Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom
I. de Pocé 29 route des Industries F-37530 Pocé sur Cisse France
Pfizer GmbH Arzneimittelwerk, Gödecke, Mooswaldallee 1, D-79090 Freiburg, Germany
Pfizer GmbH Arzneimittelwerk, Gödecke, Mooswaldallee 1, D-79090 Freiburg, Germany.
Pfizer Ireland Pharmaceuticals Pottery Road Dun Laoghaire Co Dublin Ireland
Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom
Marketing authorisation holder Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom.
Marketing Authorisation Holder Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ UK
Marketing authorisation holder Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ UK.
Marketing Authorisation Holder Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ UK
Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ UK
Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ UK
Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ UK.
Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom
Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ UK
Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ UK
Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom
Pfizer Limited Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom
Marketing Authorisation Holder Pfizer Limited Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom
Pfizer Limited, Sandwich, Kent CT13 9NJ United Kingdom Manufacturer:
Pfizer Limited, Sandwich, Kent CT13 9NJ United Kingdom Manufacturer:
Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom
Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom
Pfizer Luxembourg SARL, 283, route d'Arlon, L-8011 Strassen, Luksemburg
67 Ελλάδα Pfizer Hellas A. E.
Pfizer PGM, Zone Industrielle, 29 route des Industries, 37530 Poce-sur-Cisse, France.
Pfizer PGM, Zone Industrielle, 29 Route des Industries, 37530 Pocé-sur-Cisse, France.
Pfizer S. A., Boulevard De La Plaine 17 B-1050 Brussels Belgium
Tel: +40 (0)21 207 2800
N ≥ 90% improvement ≥ 75% improvement ≥ 50% improvement PGA of cleared (0) or minimal (1) PGA of cleared (0), minimal (1), or mild (2) Week 50
where she worked as a consultant on European pharmaceutical matters as well as continuing her work with EFPIA, she joined the Pharmaceuticals Unit of the European Commission in September 1998.
Pharmachemie B. V (PCH) Swensweg 5 Haarlem The Netherlands
Swensweg 5 2031 GA Haarlem The Netherlands
Pharmacia Ireland Limited Airways Industrial Estate Dublin 17 Ireland
Pharmacia NV/ SA Rijksweg 12 B-2870 Puurs Belgium
Renal/ hepatic impairment Impaired hepatic or renal function could cause increased serum concentrations.
Pharmacodynamics Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.
THE AMENDMENTS OF THE
Secondary pharmacology Travoprost significantly increased optic nerve head blood flow in rabbits following 7 days of topical ocular administration (1.4 micrograms, once-daily).
Committee recently decided to further explore the way to optimise the provision of scientific advice by taking into account the advances in the biomedical knowledge together with the European regulatory requirements.
The listings below are all based on post-marketing experience and is subject to underreporting and should be interpreted in that light.
Pharmacovigilance Plan or risk minimisation activities
http://www.ifpma.org/ich1.html
Pharma Pack Kft 2040 Hungary, Budaörs, Vasút u.13 Hungary
Pharmapartner Nv Kolonel Begaultlaan 16 B-3012 Leuven Belgium
Dr. Gerhard Mann Chem. - pharm. Fabrik GmbH Brunsbuetteler Damm 165-173 D-13581 Berlin Germany
Dr. Gerhard Mann Chem. - pharm. Fabrik GmbH Brunsbuetteler Damm 165-173, D-13581 Berlin Germany
Pharos House Wye Valley Business Park Hay-on-Wye Hereford HR3 5PG United Kingdom
pharyngitis, sneezing, cough, postnasal drip, throat irritation
Rhinitis Nasal congestion Pharyngo laryngeal pain
Pharyngitis Rhinitis Pneumonia Upper respiratory tract infection Folliculitis
Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention” in Atherosclerosis 140 (1998) 199-270.
Phenol, zinc chloride, trometamol, poloxamer 171, glycerol, hydrochloric acid (for pH adjustment), water for injections.
35 D-89257 Illertissen Germany
Philippe DUNETON Directeur Général Agence Française de Sécurité Sanitaire des Produits de Santé 143-147, boulevard Anatole France F - 93285 Saint-Denis CEDEX Tel.
Philippe DUNETON Directeur Général Agence Française de Sécurité Sanitaire des Produits de Santé 143-147, boulevard Anatole France F - 93285 Saint-Denis CEDEX Tel.
Philippe DUNETON, Martin HIRSCH
(blood clots in the leg) may be increased in the event of lengthy immobilisation.
- blistering of the skin when exposed to sunlight (phototoxicity)
Phosphate Uric acid Aspartate aminotransferase (AST) Creatine kinase (CK) Creatinine kinase isoenzym MB (CKMB) Lactate dehydrogenase
disodium hydrogen phospate, calcium chloride, glycine, L-Leucine, L-Isoleucine, L-Threonine, L-Glutamic acid, and L-Phenylalanine.
dodecahydrate, sodium hydroxide, potassium dihydrogen phosphate, potassium chloride, pentetic acid, hydrochloric acid (diluted), water for injection
Disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, calcium chloride dihydrate, polysorbate 20, glycine, leucine, isoleucine, threonine, glutamic acid, phenylalanine, water for injections, sodium hydroxide (pH adjuster), hydrochloric acid (pH adjuster).
dihydrogen phosphate dihydrate, glycerol, sodium hydroxide, hydrochloric acid (for pH adjustment) and water for injections.
phosphate dihydrate, glycerol, sodium hydroxide, hydrochloric acid (for pH adjustment) and water for injections.
dihydrogen phosphate dihydrate, glycerol, sodium hydroxide, hydrochloric acid (for pH adjustment) and water for injections.
phosphate dihydrate, glycerol, sodium hydroxide, hydrochloric acid (for pH adjustment) and water for injections.
oligodeoxynucleotide (Oncomun)
Photo Strachan Heppell Chairman of the Management Board
Photosensitivity Ciprofloxacin has been shown to cause photosensitivity reactions.
- Phototoxicity including manifestations of sunburn, erythema and severe bullous lesions.
- standard phrases for summaries of product characteristics
pain, swelling or reddening)
- Tingling or numbness feeling, flushing (becoming red in the skin), impaired concentration,
Pierre Fabre Médicament 45, place Abel Gance F-92654 Boulogne Billancourt cedex France
Oral mucosa pigmentation, taste perversion and dyspepsia.
Nail and skin pigmentation, urticaria and sweating
Presentation - Form - Dosage - Number of presentations
Vaccine against neonatal diarrhoea
Pimozide (saquinavir/ritonavir) Oral contraceptives
- Enlarged liver, hepatitis, liver failure, gallbladder disease, gallstones
Form a skin fold by pinching the skin between the thumb and the forefinger.
Squeeze a big skin fold between your thumb and index finger.
Form a skin fold by pinching the skin between thumb and forefinger.
Form a skin fold by pinching the skin between thumb and forefinger.
Pinch up a large area of skin between finger and thumb.
PIOGLITAZONE IN COMBINATION THERAPY WITH SULPHONYLUREA
19 PIOGLITAZONE IN TRIPLE ORAL COMBINATION THERAPY WITH METFORMIN AND SULPHONYLUREA
PIOGLITAZONE IN TRIPLE ORAL COMBINATION THERAPY WITH METFORMIN AND SULPHONYLUREA
Pioglitazone (as HCl) metformin hydrochloride
Pioglitazone (as HCl) Metformin hydrochloride
Pioglitazone (as hydrochloride) metformin hydrochloride
Pioglitazone (as hydrochloride) Metformin hydrochloride
PIRES Director-General DgV Lg Academia Nacional de Belas Artes 2 P-1294 Lisbon Tel: +351.1.323.9500 Fax: +351.1.346.3518
Pirlimycin hydrochloride equivalent to 50 mg pirlimycin per 10 ml syringe
Pirlimycin hydrochloride equivalent to 50 mg pirlimycin per 10 ml syringe
Commission - Opinion received - Date of Decision - Notification - Official Journal
e Follow-up therapy with another anticoagulant medicinal product
14 PACKAGE LEAFLET PIRSUE 5 mg/ ml intramammary solution for cattle
PIRSUE 5 mg/ ml intramammary solution for cattle
Rua João Chagas, no 53 Piso 3 P– 1499-040 Cruz Quebrada-Dafundo Tel: + 351 21 414 83 00
Turn the bottle right way up and w ith a tw isting m ovem ent separate the dosing syringe from the bottle.
drop dispenser of the bottle by gently pushing.
ed weight), or • 2.25 micrograms (once weekly) of Nespo per kilogram of your body weight.
Suomi/Finland PL 86/PB 86 FIN-02151 Espoo/Esbo Puh/Tel: + 358-(0)20-7570 300
Treatment Group Placebo Cerivastatin 0.1mg Cerivastatin 0.2mg Cerivastatin 0.3mg Cerivastatin 0.4mg Cerivastatin 0.8mg
Mean baseline (SD) Mean change (SD) P-value (vs, Placebo) Diff. of LS Means (SE)
R076477-SCH-304 Mean baseline (SD) Mean change (SD) P-value (vs, Placebo) Diff. of LS Means (SE)
Median attacks/ week Placebo 3.0 g/ day 6.0 g/ day 9.0 g/ day
Apply the tip of the STRONGHOLD tube directly to the skin without massaging.
Place InductOs so that it bridges the fracture region and makes good contact with the major proximal and distal fragments.
Place the syringe in front of one of the nostrils and carefully administer the whole contents of the syringe into the nasal cavity via this nostril.
Place the absorbed toxin in an autoclave bag, seal it and process as Medical Biohazardous Waste in accordance with local requirements.
Place the absorbed toxin in an autoclave bag, seal it and process as Medical Biohazardous Waste in accordance with local requirements.
Place the tip of the pipette on the skin and squeeze the pipette to empty the entire contents.
Place the tip of the pipette on the skin and squeeze it gently several times at one or two spots to empty the contents onto the skin.
Place the tip of the pipette on the skin and squeeze the pipette gently several times at 2-3 spots down the back-line of large dogs to prevent runoff.
Place the tip of the pipette on the skin and squeeze the pipette gently several times at one or two spots to empty the contents onto the skin.
Place the tip of the pipette on the skin and squeeze it gently several times at one or two spots to empty the contents onto the skin.
Place the tip of the pipette on the skin and squeeze the pipette to empty the entire contents.
Place the tip of the pipette on the skin and gently squeeze the pipette to expel a portion of its contents directly onto the skin.
Place the tip of the pipette on the skin and gently squeeze the pipette to expel a portion of its contents directly onto the skin.
Place the developing tanks behind a lead shield.
PLEASE PLACE BAR-CODE LABEL ON PATIENT RECORDS, IF APPLICABLE
Place the tip of the pipette on the skin and squeeze firmly several times to empty the contents directly onto the skin.
Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin.
Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin.
Put the used syringe in the puncture-proof container.
Put the tip of the syringe just inside the mouth, pointing it towards the cheek.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
Place the tablet on your tongue and suck gently.
Place the mouthpiece in your mouth between your teeth and close your lips around it.
Put the mouthpiece to your lips; breathe in steadily and deeply through the Diskus, not through your nose.
Place the measuring cup on a flat surface at eye-level.
Set the tip of the pen on the prepared injection site and press the needle into the skin by pushing the pen downward until the shield is totally depressed.
Quickly form a seal with your lips around the uc
Place your thumb on the Dose Knob and push firmly until the Dose Knob stops moving.
Place your thumb on the Dose Knob and push firmly until the Dose Knob stops moving.
Change to a new FORSTEO to take your dose as directed by your healthcare professional.
AUC(0-∞) was similar between adult and paediatric patients with CRF following subcutaneous administration.
Skin and soft tissue abscesses and wounds in cats:
Skin and soft tissue abscesses and wounds in cats:
IMPLEMENTATION PLAN FOR REGULATORY CO-OPERATION ON MEDICINAL PRODUCTS APRIL 2, 2009
Pharmacovigilance Plan or risk minimisation activities,
Planta de Producción Ronda de Santa Maria 158 E-08210 Barberà del Vallès, Barcelona Spain
approximately 17 and 30%, respectively (see section 4.5). od
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Wait until ANC ≥ 1,500 and platelets ≥ 75,000; redose with no dose reduction.
Platelets In clinical trials few patients had platelet counts below the lower limit of the normal laboratory range.
Blister Pack of 10 x 300 mg maraviroc film-coated tablets
FOIL LABEL, 15 mg (ALL PACK SIZES)
FOIL LABEL, 30 mg (ALL PACK SIZES)
FOIL LABEL, 45 mg (ALL PACK SIZES)
FOIL LABEL, 60 mg (ALL PACK SIZES)
bottle (HDPE) bottle (HDPE) blister (Aclar/ PVC/ alu) in a card
10 Aclar / PVC / blisters with aluminium foil backing containing one clear blister of 11 x 0.5 mg and 14 x 1 mg film-coated tablets and a second clear blister of 28 x 1 mg film-coated tablets in secondary heat sealed card packaging.
20 Aclar / PVC / blisters with aluminium foil backing containing one clear blister of 11 x 0.5 mg and 14 x 1 mg film-coated tablets and a second clear blister of 28 x 1 mg film-coated tablets in secondary heat sealed card packaging.
Blisters Store in original package in order to protect from moisture.
Alu/ Alu blisters (calendar blisters and unit dose blisters) and high-density polyethylene (HDPE) bottle with child resistant closure of polypropylene.
Alu/ Alu blisters (unit dose blisters) and high-density polyethylene (HDPE) bottle with child resistant closure of polypropylene.
BLISTER OF 5 mg FILM-COATED TABLETS
(PVC/ CTFE/ alu blisters) (PVC/ PVDC/ alu blisters)
7 TABLET OPA-ALU-PVC/ ALU BLISTER
7 TABLET OPA-ALU-PVC/ ALU BLISTER
7 TABLET OPA-ALU-PVC/ ALU BLISTER
BLISTER FOR THE CARMELLOSE POWDER VIAL
7 & 10 TABLET PVC-PCTFE/ ALU BLISTER (for white and clear blister)
PVC/ polychlorotrifluoroethylene (PCTFE) – Alu blisters:
7 & 10 TABLET PVC-PCTFE/ ALU BLISTER (for white and clear blister)
7 & 10 TABLET PVC-PTFE/ ALU BLISTER (for white and clear blister)
The syringes may be presented in either blistered (1- & 4-pack) or non-blistered packaging (1-pack only).
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
coated tablets and 1 clear blister of 14 x CHAMPIX 1 mg film-coated tablets in a carton.
coated tablets and 1 clear blister of 14 x CHAMPIX 1 mg film-coated tablets in card packaging.
Fondaparinux does not bind
{PRODUCT NAME} is contraindicated in pregnancy and while breast feeding.
ratios for overall survival ranged between 1.25 and 2.47 in favour of controls.
Plavix is not intended for use in children or adolescents.
er This medicine has been prescribed for you.
er 1 single use pre-filled pen This box containing 1 pre-filled pen, is part of a 4-multipack ng SureClick x4 4 single use pre-filled pens lo
Application site warmth, application site erythema, application site pain, application site irritation, application site paraesthesia, application site rash
au Hampshire, RG24 8EP United Kingdom
er Británie/ Storbritannien/ Ühendkuningriik/ Hνω µέυο Βασίλειο / United Kingdom/ Bretland/ ng Lielbritā nija/ Jungtinė Karalystė / Nagy- Britannia/ Verenigd Koninkrijk/ lo Storbritannia/ Wielka Brytania/ Marea Britanie / Velika Britanija/ Vel'ká Británia/ Iso- no
INH and INH washout N=158, 155, 143, 139, 123.
Pliva Pharma Limited Vision House, Bedford Road Petersfield, Hampsire GU32 3QB United Kingdom
comparison showed that the pharmacokinetics of darbepoetin alfa were similar for paediatric and adult patients with CRF.
Administration of salbutamol prior to EXUBERA may result in increased insulin absorption (see section 5.2).
Human erythropoietin is an endogenous glycoprotein hormone that is the primary regulator of erythropoiesis through specific interaction with the erythropoietin receptor on the erythroid progenitor cells in the bone marrow.
Human erythropoietin is an endogenous glycoprotein hormone that is the primary regulator of erythropoiesis through specific interaction with the erythropoietin receptor on the erythroid progenitor cells in the bone marrow.
The needle protection system of the Quixidar pre-filled syringe has been designed with an automatic safety system to protect from needle stick injuries following injection.
Nespo is a sterile but unpreserved product.
au Food and drink do not affect Nespo.
is Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines,
comparison showed that the pharmacokinetics of darbepoetin alfa were similar for paediatric and adult patients with CRF.
ed The pharmacokinetics of darbepoetin alfa has been studied clinically in chronic renal failure patients following intravenous and subcutaneous administration.
is Improvement ≥ 90% in Physician's
CRF following both intravenous and subcutaneous administration. a
ed Results from clinical studies in patients The efficacy and safety of Protopy was assessed in more than 13,500 patients treated with tacrolimus ointment in Phase I to Phase III clinical trials.
th Hampshire International Business Park Chineham, Basingstoke
ra EU/ 1/ 06/ 344/ 007 EU/ 1/ 06/ 344/ 008 EU/ 1/ 06/ 344/ 009
ra THE MARKETING AUTHORISATION HOLDER
Over 1,500 of these patients were treated with < Invented Name > and over 500 were treated with control treatment i.e. either < Invented Name > vehicle and/or topical corticosteroids.
GENERAL CLASSIFICATION FOR SUPPLY
Over 4874 patients were studied in controlled Phase II and III clinical studies. na
Treatment of Deep Venous Thrombosis
Greater than 70% of patients enrolled exhibited 3+ overexpression.
7 90% of cytarabine was excreted by day 4 and an additional 2.7% by 21 days.
Over 4 million ‘ hits'(requests for information) were recorded and some 120 000 documents were downloaded in total, of which EPARs and guidelines were the most frequently demanded.
The heads of national competent authorities meeting in November 2001 endorsed this proposal and it is expected to become operational during 2002.
During titration, multiple tablets may be used: up to four 100 micrograms or up to four 200 micrograms tablets may be used to treat a single episode of BTP during dose titration according to the following schedule: • If the initial 100 micrograms tablet is not efficacious, the patient can be instructed to treat the next episode of BTP with two 100 micrograms tablets.
They then performed a number of field trials which further confirmed the safety of Duvaxyn WNV and proved its efficacy in reducing the number of viraemic horses and thereby protecting against the disease.
Martinez and Suissa and Garcia Rodriguez).
The re are multiple mechanisms responsible for resistance development to macrolide compounds.
Several metabolites have been detected, but only three of them have been identified:
Several metabolites were identified in urine and faeces.
rheumatoid arthritis patients ranged from 31-96% of those in serum.
Several patients have received their total dose of Naglazyme at approximately twice the recommended infusion rate without apparent adverse events.
Many had signs of local infection including osteomyelitis.
A number of organisational issues were discussed and resolved.
revision of the performance evaluation system and the rules regarding internal transfer of staff • Finalisation of the implementation of the computer-based
Several sectors in different units used the application to determine the default task patterns to be loaded to the system.
A number of cleavage (hydrolysis) sites on the human insulin
A number of cleavage (hydrolysis) sites on the human insulin molecule have been proposed; none of the metabolites formed following the cleavage are active.
Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
The AUC of metabolites increased with decreased renal function.
The smaller the injection volume the less pressure sensation and less spread of Botulinum neurotoxin type A in the injected muscle occurs.
The smaller the injection volume the less pressure sensation and the less spread of Botulinum neurotoxin type A in the injected muscle occurs.
Plynárenská 7/B SK-824 78 Bratislava Tel: +421 233 552 600
Swine Enzootic Pneumonia 2.125 mg/kg bodyweight
- Pneumonia (a serious type of chest or lung infection) that you catch in a hospital or similar setting.
Pneumonitis Fungal infection Candidiasis Herpes zoster Abscess Urinary tract infection Sinusitis Bronchitis Upper respiratory tract infection Pharyngitis Infection
Pneumonia, respiratory infection, urinary tract infection, infection, otitis media
Pneumonia, nasopharyngitis, upper respiratory tract infection, oral candidiasis
- Community acquired pneumonia, except severe cases
- Community acquired pneumonia, except severe cases
ori Infectious episodes, including viral infections, fungal infections, bacteraemia and septicaemia, and pneumonia, were reported in 72% of the placebo-treated patients and in 68% of Zenapax-treated
Pneumonia, influenza, respiratory tract infection, respiratory moniliasis, gastrointestinal infection, candidiasis, gastroenteritis, infection, bronchitis, pharyngitis, sinusitis, fungal skin infection, skin candida, vaginal candidiasis, rhinitis
Pneumonia, influenza, respiratory tract infection, respiratory moniliasis, gastrointestinal infection, candidiasis, gastroenteritis, infection, bronchitis, pharyngitis, sinusitis, fungal skin infection, skin candida, vaginal candidiasis, rhinitis
Sepsis, gastrointestinal candidiasis, urinary tract infection, herpes simplex, herpes zoster Pneumonia, influenza, respiratory tract infection, respiratory moniliasis, gastrointestinal infection, candidiasis, gastroenteritis, infection, bronchitis, pharyngitis, sinusitis, fungal skin infection, skin candida, vaginal candidiasis, rhinitis
Acute diffuse infiltrative pulmonary and pericardial disease.
Pulmonary embolism, Pneumothorax, Haemoptysis, Asthma, Dyspnoea exertional
ANC ≥ 1.5 x 109/l and platelet count ≥ 100 x 109/l.
FLEXIBLE PO/PVC BAG (200 mg / 100 mL solution for infusion)
FLEXIBLE PO/PVC BAG (400 mg / 200 mL solution for infusion)
Bags made of polyolefin/ polyamide co-extruded plastic and over wrapped with a protective plastic bag composed of polyamide/ polypropylene.
Baseline weight(kg) Change of weight from baseline(kg)
Weight Although weight was identified as a source of variability in clearance in the population pharmacokinetic analysis, weight has little clinical relevance on the pharmacokinetics of anidulafungin.
Number of VIRACEPT 250 mg film-coated tablets per dose*
(Dogs and Cats) 2.5 kg 5 kg 10 kg 20 kg 40 kg 60 kg
this many kg 10-12 13-14 15-17 18-20 21-22 23-25 26-28 29-31 32-33 34-36 37-39 40-41 42-44 45-47
10-12 13-14 15-17 18-20 21-22 23-25 26-28 29-31 32-33 34-36 37-39 40-41 42-44 45-47
amending Council Regulation (EC) No 297/95 on fees
Point the end of the nozzle toward the outside of your nose, away from the centre ridge of your nose.
EMEA contact points and reference documents.................................... .61 EMEA budgets for 1999 to 2001............................................................ ..64 Members of the Management Board...................................................... ..65 Members of the Committee for Proprietary Medicinal Products......... ..66 Members of the Committee for Veterinary Medicinal Products............ 67 Members of the Committee for Orphan Medicinal Products............... ..68 National competent authority partners................................................... .69 CPMP opinions in 2000 on medicinal products for human use............ .73 CVMP opinions in 2000 on medicinal products for veterinary use...... ..78
Poleczki 21 PL-02-822 Warszawa
Polígono Industrial La Mina Avda. de los Reyes, 1 E-28770 Colmenar Viejo Madrid Spain
Polígono Levante Can Guasch, 2 E-08150 Parets del Vallès Barcelona, Spain
Polígono Levante Can Guasch, 2, E-08150 Parets del Vallès Barcelona, Spain
Musculoskeletal pain, muscular weakness
Ελλάδα GlaxoSmithKline A. E. B. E.
greater than its risks for treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in adults when other treatments have been inadequate.
ge Rheumatoid arthritis lon Trudexa in combination with methotrexate, is indicated for:
Rheumatoid arthritis lon Trudexa in combination with methotrexate, is indicated for:
The initial recommended daily dose is 200 mg taken in two divided doses.
Rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
poly(butylmethacrylate, methyl-methacrylate), acrylic copolymer, silicone oil, dimethicone, polyester film fluoropolymer-coated.
Cured elastomer, resulting from the polymerisation of polydimethylsiloxane and tetrapropylorthosilicate in the presence of stannous octoate.
Polyethylene/ ethyl vinyl acetate (PET/ EVA), clear
HDPE bottle polypropylene measuring syringe
peripheral neuropathy, peripheral sensory neuropathy (see section 4.4),
Haemophilus type b polysaccharide (polyribosylribitol phosphate)
Pneumococcal polysaccharide serotype 4* Pneumococcal polysaccharide serotype 6B* Pneumococcal polysaccharide serotype 9V* Pneumococcal polysaccharide serotype 14* Pneumococcal oligosaccharide serotype 18C* Pneumococcal polysaccharide serotype 19F* Pneumococcal polysaccharide serotype 23F*
Inflammatory polyradiculoneuropathy Cases of inflammatory polyradiculoneuropathy have been observed in post-marketing surveillance in patients receiving Raptiva (see section 4.8).
Polyribosylribitol phosphate (PRP) from Haemophilus influenzae type b as PRP-OMPC
Haemophilus type b polysaccharide (polyribosylribitol phosphate)
Pneumococcal Polysaccharides Wyeth Pharmaceuticals, Division of Wyeth Holdings Corporation 401 North Middletown Road NY 10965, Pearl River, USA
Polysorbate 20, histidine, histidine hydrochloride monohydrate and sucrose.
au Sodium chloride Polysorbate 80
Polysorbate 80 and phosal 50 PG (phosphatidylcholine, propylene glycol, monodiglycerides, ethanol (1.5% to 2.5%), soya fatty acids, and ascorbyl palmitate).
Polysorbate 80 Phosal 50 PG (phosphatidylcholine, propylene glycol, mono-, di-glycerides, ethanol (1.5% to 2.5%), soya fatty acids and ascorbyl palmitate).
Polysorbate 80 (Polyoxyethylene sorbitan monooleate)
Sorbitan oleate (sorbitan monoleate) Polysorbate 85 (Polyoxyethylene sorbitan trioleate)
Polyvinyl alcohol Titanium dioxide E171 Talc E553b Lecithin soya E322 Xanthan gum E415
ointment 5 g x 1 tube 10 g x 1 tube 15 g x 1 tube
Marginally Weighted (OM) Mean (SE) Idursulfase Placebo
ITT-LOCF population At least 4 points improvement on ADAS-Cog with no worsening on ADCS- CGIC and ADCS-ADL
Porcilis AR-T DF is given as a dose of 2 ml by intramuscular (into a muscle) injection to female pigs of 18 weeks of age and older.
Porcilis AR-T DF suspension for injection for pigs
Porcilis PCV is a vaccine for use in pigs, which is available as an emulsion for injection.
Porcilis Pesti contains Classical Swine Fever Virus -E2 subunit antigen. isa
Porcilis Pesti is used to immunise healthy pigs from the age of 5 weeks onwards to prevent death and or
- Film coated tablet - 5 mg - 13 presentations
Pigs (after weaning) Oral bioavailability of doxycycline ranges between 50-60% values.
Wear protective gloves and spectacles during the ampoule thawing and opening operations.
Wear protective gloves and spectacles during the ampoule thawing and opening operations.
• Wear protective gloves and spectacles during the ampoule thawing and opening operations. • Remove from the liquid nitrogen container only those ampoules which are to be used immediately. • Thaw the contents of the ampoules rapidly by agitation in water at 25-30°C.
Wear waterproof gloves and soak up the liquid with an appropriate absorbent.
Wear waterproof gloves and soak up the liquid with an appropriate absorbent.
Operators should wear gloves when mixing the concentrate solution or handling the implant and avoid self injection.
Tel.: +48-22-572 35 00 Portugal Bayer Portugal S. A Tel: +351-21-416 42 00 România SC Bayer SRL Tel.: +40 21 528 59 00 Slovenija Bayer d. o. o.
Portugal BRISTOL-MYERS SQUIBB FARMACÊUTICA PORTUGUESA, S.A.
Portugal EF-Eisai Farmacêutica, Unipessoal Lda Tel: +351 21 421 7399
España GlaxoSmithKline, S.A.
España Roche Farma S.A.
España Roche Farma S.A.
Smith Kline & French Portuguesa, Produtos Farmacêuticos, Lda.
España Swedish Orphan International S. L Tel: + 34 913 91 35 80
Portugal GlaxoSmithKline - Produtos Farmacêuticos, Lda Tel: + 351 21 412 95 00 FI. PT@gsk. com
Portugal JANSSEN-CILAG FARMACEUTICA, LDA Tel: +351 21-4368835
România JOHNSON AND JOHNSON d. o. o Tel: +40 21 207 1800
Portugal Lilly Portugal - Produtos Farmacêuticos, Lda Tel: + 351 21 412 6600
Portugal Lilly Portugal - Produtos Farmacêuticos, Lda Tel: + 351-21-4126600
Portugal Lilly Portugal - Produtos Farmacêuticos, Lda Tel: + 351 -21 -4126600
România IVAX Pharmaceuticals s.r.o Tel: +420 553 641 111
Portugal Merck Sharp & Dohme, Lda Tel: +351 21 446 57 00 informacao_doente@merck.com
Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 informacao_doente@merck. com
Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 informacao_doente@merck. com România Merck Sharp & Dohme Romania S. R. L.
Portugal Novartis Farma - Produtos Farmacêuticos, S.A.
José GUIMARAES MORAIS Dr Henrique LUZ-RODRIGUES (6)
Rua Agualva dos Açores 16
P-2735-557 Agualva-Cacém Tel: + 351-21 433 93 00
Portugal sanofi-aventis - Produtos Farmacêuti cos, S.A.
Portugal sa–ofi-aventis - Produtos Farmacêuti cos, S.A.
France Sanofi Pasteur MSD, SA Tel: +351 21 470 4550
Ελλάδα, Κύπρος, Malta Ipsen EΠΕ Αγ.
Posaconazole/ Efavirenz --/ 400 mg once daily
Posaconazole SP must only be used as directed by your doctor.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Posaconazole SP is also used to treat patients with oropharyngeal candidiasis or ‘ thrush’, a fungal infection of the mouth and throat due to Candida.
Posaconazole SP is used if the disease is severe, or if the patient is immunocompromised (with a weakened immune system).
27 • Medicines used to decrease stomach acid such as cimetidine and ranitidine or omeprazole and similar medicines that are called proton pump inhibitors.
Posatex is an ear drop suspension, white to off white in colour.
Set up the following items on a clean surface.
Set up the following items on a clean surface.
positive< baseline positive> baseline
Uncommon side effects (these can affect from 1 to 10 users in 1,000 patients treated) • Throat inflammation. • Feeling agitated, feeling disorientated, feeling sleepy, having a poor quality of sleep, lack of motivation or increased yawning. • Tasting things differently than usual, disturbance in attention or spasms and involuntary movements of the muscles. • Weight loss or weight gain, burping, indigestion or gastroenteritis. • Inflammation of the liver that may cause abdominal pain, tiredness or yellow coloration of the skin. • Vertigo, tinnitus (perception of sound in the ear when there is no external sound, ear pain. • Larger pupils (the dark centre of the eye) or visual disturbance. • Flushing, increase in blood pressure, feeling cold in your fingers and/ or toes, feeling dizzy (particularly when standing up too quickly), fast or irregular heart beat, night sweats, cold sweats, shivering or fainting. • Changes in ejaculation, abnormal periods, including heavy or prolonged periods • Allergic reactions, increased tendency to bruise, blisters or sensitivity to sunlight. • Muscle twitching. • Need to pass urine during the night or difficulty or inability to pass urine. • Grinding of teeth, dehydration, feeling hot/ cold, thirst, throat tightness or nose bleeds • Increased level of cholesterol in the blood.
- nosebleeds, difficulty in breathing, cough, inflammation of the throat
Holding the cup at eye level, carefully and slowly pour the prescribed amount of solution from the bottle into the dosing cup until the solution reaches the top of the appropriate graduation.
Note for Guidance on photosafety testing
Posology In adults, adolescents and children older than 2 years:
Dosage in the female There are great inter- and intra-individual variations in the response of the ovaries to exogenous gonadotrophins.
Dosage in patients with renal insufficiency
Posology for CML in children Dosing for children should be on the basis of body surface area (mg/ m2).
Posology for GIST The recommended dose of Glivec is 400 mg/ day for patients with unresectable and/ or metastatic malignant GIST.
Posology for MDS/ MPD The recommended dose of Glivec is 400 mg/ day for patients with MDS/ MPD.
Maintenance dose The maintenance dose is 10 mg once daily.
Dose From day 1 to day 3, you should take one white CHAMPIX 0.5 mg film-coated tablet once a day.
Dosing in patients with renal impairment The elimination of pramipexole is dependent on renal function.
Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will determine how much Apidra you will need.
Dosage Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will determine how much Apidra you will need.
Dosage Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will determine how much Apidra you will need.
Dosing procedure using the drop dispenser of the bottle:
Dosage and duration of combined administration
Posology and method of administration It is recommended that treatment should be conducted under the care of physicians experienced in the treatment of obesity.
The capsules may be opened but the minitablets inside may not be chewed or crushed.
2 tablets, 3 times per day 3 tablets,3 times per day 4 tablets, 3 times per day
Initial or subsequent once weekly dose:
• Posology • Instructions for administration • Information on gel depot formation and possible injections site reactions • Information on the identified and potential risks.
Dosage The recommended dose is 0.5 ml - 3.0 ml per patient.
61 Dosage The dose recommendations made are in nominal dose.
Dosage The dose recommendations made are in nominal dose.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
DOSAGE FOR EACH SPECIES, METHOD AND ROUTE(S) OF ADMINISTRATION
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
DOSAGE, METHOD AND ROUTE(S) OF ADMINISTRATION
DOSAGE, ROUTE AND METHOD OF ADMINISTRATION
DOSAGE, ROUTE(S) AND METHOD OF ADMINISTRATION
Dosing for children and adolescents
One 200 mg tablet is taken with each levodopa/ dopa decarboxylase inhibitor dose.
Posology One 200 mg tablet is taken with each levodopa/ dopa decarboxylase inhibitor dose.
Recommended dosage in adults (including the elderly)
Dosage • You should normally inject Liprolog within 15 minutes of a meal.
Dosage • You should normally inject Liprolog Mix25 within 15 minutes of a meal.
Dosage • You should normally inject Liprolog Mix50 within 15 minutes of a meal.
Dosage • You should normally inject Liprolog Mix50 within 15 minutes of a meal.
Dosage • You should normally inject Liprolog within 15 minutes of a meal.
order to minimise the potential risk of thromboembolic events.
Merck Sharp & Dohme B. V., Postbox 581, Waarderweg 39, NL-2031 BN, Haarlem The Netherlands
Postbus 313 3740 Ah Baarn Baarnsche Dijk 1 3741 Ln Baarn The Netherlands
Postę pu 18APL - 02-676 Warszawa Tel.: + 48 22 606-10-50
Postępu 18A PL - 02-676 Warszawa Tel.: + 48 22 606-10-50
Postępu 18A PL-02-676 Warszawa Tel.: + 48 22 606-10-50
Postę pu 18A PL-02-676 Warszawa Tel.: + 48 22 606-10-50
Posts authorised for Posts authorised for 1996 1997
the field of information technology as programmer, systems analyst and project manager, working as a senior consultant from 1990 to 1992.
80-100 Repeat infusion every 8-24 hours until adequate wound healing, then (pre- and therapy for at least another 7 days to postoperative) maintain a factor IX activity of 30% to 60% (IU/ dl).
13 Potassium and potassium-sparing diuretics Based on experience with the use of other substances that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other substances that may increase serum potassium levels (e. g. heparin) may lead to increases in serum potassium.
Potassium and potassium-sparing diuretics Based on experience with the use of other substances that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing
Potassium and potassium-sparing diuretics Based on experience with the use of other substances that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other substances that may increase serum potassium levels (e. g. heparin) may lead to
Carcinogenicity Long-term (2-year) carcinogenicity studies of raltegravir in rodents are ongoing but have not been completed.
Mutagenicity No evidence of mutagenicity or genotoxicity was observed in in vitro microbial mutagenesis (Ames) tests, in vitro alkaline elution assays for DNA breakage and in vitro and in vivo chromosomal aberration studies.
Limited but relevant mutagenesis tests have been carried out.
From 1972 to 1989 Mr Pott held a number of teaching and research posts, including a research fellowship at the Institute of Peace Research and Security Policy, University of Hamburg.
From 1972 to 1989 Mr Pott held a number of teaching and research posts, including a research fellowship at the Institute of Peace Research and Security Policy, University of Hamburg.
Off-white to slightly yellow powder in a capsule with yellow cap and yellow body, with red imprint “ ENA 713 1,5 mg” on body.
Off-white to slightly yellow powder in a capsule with yellow cap and yellow body, with red imprint “ EXELON 1,5 mg ” on body.
Off-white to slightly yellow powder in a capsule with orange cap and orange body, with red imprint “ ENA 713 3 mg” on body.
Off-white to slightly yellow powder in a capsule with orange cap and orange body, with red imprint “ EXELON 3 mg ” on body.
Off-white to slightly yellow powder in a capsule with red cap and orange body, with red imprint “ ENA 713 6 mg” on body.
Off-white to slightly yellow powder in a capsule with red cap and orange body, with red imprint “ EXELON 6 mg ” on body.
Off-white to slightly yellow powder in a capsule with red cap and red body, with white imprint “ ENA 713 4,5 mg” on body.
White to yellow powder in a light yellow to orange-yellow opaque capsule, marked “ NVR SH”.
White to yellow powder in an orange to greyish-orange opaque capsule, marked “ NVR SI”.
White lyophilized powder and solvent for solution for injection.
Powder (carboxymethylcellulose): vial (glass/ alu)
White to off-white compact, lyophilised powder.
Almost white or yellowish, crystalline dry powder
Powder (eptotermin alfa): vial (glass/ alu)
Powder and solvent for solution for injection 1 vial (powder) and 1 pre-filled syringe (1.5 ml solvent).
Powder and solvent for solution for injection or infusion
Powder and solvent for solution for injection White to off-white powder.
Powder and solvent for solution for injection White powder.
Powder and solvent for solution for injection (powder in a vial (1.3 mg), solvent in a vial (1 ml)).
Powder and solvent for solution for injection (Powder for injection and solvent)
Powder and solvent for solution for infusion (isolated limb perfusion; ILP)
Powder and solvent for solution for injection
Powder and solvent for Intravenous use
Powder and solvent for Intravenous use solution for injection
Powder and solvent for solution for injection
Powder and solvent for solution for injection
Powder and solvent for solution for injection
Powder and solvent for solution for injection
Powder and suspension for suspension for injection t
Powder and suspension for suspension for injection Vial: powder Pre-filled syringe: suspension
Bag PP/ polyamide/ PE)
White to off-white friable powder.
White to off-white plug or powder.
White to off-white lyophilised solid.
Powder Mannitol Citric acid monohydrate Sodium chloride Hydrochloric acid, dilute (for pH adjustment) Sodium hydroxide 1N (for pH adjustment)
Powder for concentrate for solution for infusion White to off-white lyophilized cake or powder
White or cream coloured powder or friable solid.
Powder for injection 50 IU, 100 IU, 75 IU, 150 IU 16 Present ations
Powder for injection or infusion 50mg 1 Present ation
Powder for concentrate for solution for injection or infusion.
Powder for concentrate for solution for injection or infusion
Powder for concentrate for solution for infusion
Powder for solution for injection – intramuscular administration:
Powder for solution for injection or infusion.
Powder for solution for injection White to off-white powder.
1mg/ml,15mg/ml, 20mg/ml, 30mg/ml, 40mg/ml
Single Test Powder for oral solution Please read enclosed instructions for use.
Powder for solution for infusion 1 vial of 100 mg temozolomide
Powder for solution for infusion and intravesical instillation
Powder for solution for infusion
Powder for suspension for implantation, (1 g in a vial - Pack size of 1).
Powder: sucrose, histidine, histidine hydrochloride monohydrate and polysorbate 20.
Pouet de Camilo, 2 E-46394 Ribarroja del Turia (Valencia) Tel.: +34-96-2722800
Pouet de Camilo, 2E-46394 Ribarroja del Turia (Valencia) Tel: + 34 96 2722800
Chickens: broilers, pullets and breeders
A10B03 Combination treatment of diabetes mellitus Type II
1000 patient -ye ars versus diet alone 20.6 events/ 1000 patient-years (p=0.011), and versus the combined sulfonylurea and insulin monotherapy groups 18.9 events/ 1000 patient-years (p=0.021);
1000 patient-years versus diet alone 20.6 events/ 1000 patient-years (p=0.011), and versus the combined sulfonylurea and insulin monotherapy groups 18.9 events/ 1000 patient-years, (p=0.021);
13.5 events/1,000 patient -ye ars versus diet alone 20.6 events/1,000 patient-years (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/1,000 patient- years (p=0.021);
13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years (p=0.0 11), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/ 1,000 patient- years (p=0.021);
For oral use in calves after feeding:
For intravenous, single dose administration
To work properly in controlling asthma and treating COPD symptoms, Viani must be taken every day as directed by your doctor.
- To stimulate growth if growing is already finished (closed epiphyses).
In order to improve the handling of the increased workload, further measures were implemented.
To analyse the carbon dioxide in breath a broad band infrared radiation bunch emitted by an infrared radiation source is alternately sent through the measuring chamber and a reference chamber by means of a beam chopper.
To analyse the carbon dioxide in breath a broad band infrared radiation bunch emitted by an infrared radiation source is alternately sent through the measuring chamber and a reference chamber by means of a beam chopper.
To analyse the separated carbon dioxide sample gas its molecules must be ionised, formed into a beam, accelerated by an electric field, deflected in a magnetic field, and finally detected.
To analyse the separated carbon dioxide sample gas its molecules must be ionised, formed into a beam, accelerated by an electric field, deflected in a magnetic field, and finally detected.
To analyse the separated carbon dioxide sample gas its molecules must be ionised, formed into a beam, accelerated by an electric field, deflected in a magnetic field, and finally detected.
To maintain sterility, Raptiva must be used immediately after first opening and reconstitution.
The Applicant/ MAH subsequently proposed to follow the same proposal for other diarrhoea indications, taking into account data supporting oral 500 mg bid daily dose and considering bioavailability purposes, the corresponding IV dosage should be 400 mg bid.
For calculation of ml/ hour, multiply infusion rate in IU/ h/ kg by kg bw/ concentration of solution (IU/ ml).
Mixing is best done by gently tilting the cartridge or pen (with the cartridge in it) back and forth at least 10 times.
Mixing is best done by gently tilting the pen back and forth at least 10 times.
Therefore, keep injection syringes and injection needles as well.
Therefore, keep injection syringes and needles as well.
Therefore, keep injection syringes and needles as well.
Therefore, keep injection syringes and needles as well.
Therefore, keep injection syringes and needles as well.
The Coordination Committee will hold regular teleconferences.
The doctor does this by using a special imaging camera that reveals areas of radioactivity to see where the infections are located.
Before using for the first time patients should remove the mouthpiece cover by gently squeezing the sides of the cover, shake the inhaler well, and release puffs into the air until the counter reads 120 to make sure that it works.
This will be done by identifying areas where expertise needs to be reinforced and developed.
This is achieved by thoroughly mixing Aivlosin 8.5 mg/g Oral Powder into the daily ration for each individual pig.
One way to do that is to note the injection site on the enclosed medication record card.
Of those with no acne at baseline, similar percentages (14%) reported acne following treatment with Vaniqa or vehicle.
Percent technetium-99m non-mobile material = A
prevalent fracture at baseline Percentage of patients with new fracture Non-vertebral fractures Percentage of patients with non-vertebral fracture
Percentage of patients with new fracture New radiographic vertebral fracture in patients with ≥ 1
Percentage of patients with new fracture New radiographic vertebral fracture in patients without any
Proportion of patients (%) achieving HbA1c ≤ 7% (patients completing studies)
Percent technetium (99mTc) pertechnetate, technetium-99m labelled glucoheptonate and technetium-99m labelled edetate = B
Median mEASI Percentage Decrease (Primary Endpoint)§ ro
Sixty-nine percent of the patients underwent surgery for cancer. ici
For storage conditions of the reconstituted medicinal product, see section 6.3.
For Kaposi's sarcoma, around 70% of the patients had a complete or partial response to treatment, with similar results in the study of patients who had been treated before.
For select medicinal products (eg alprazolam) the inhibitory effects of ritonavir on CYP3A4 may decrease over time.
au inadequate response to previous therapy, and the main measure of effectiveness was the change in symptoms after 12 weeks of treatment.
These patients should not be rechallenged with nimesulide.
These patients should not be rechallenged with nimesulide.
In these patients, phospholipid encapsulated microspheres can bypass the lung and directly enter the arterial circulation.
For these reasons, it must be done in a clinic or a similar setting.
For reasons of drug safety, moxifloxacin is therefore contraindicated in patients with:
For these reasons ,< Zocord > should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant.
For the update, cohorts of vigabatrin patients from open-label extensions of 7 clinical studies were used.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
For each term, the frequency count was based on ADRs of all grades.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
For each component of the vaccine, the following immune responses have been documented one month after completion of the primary vaccination schedule.
Treatment cycles were every three weeks in each trial and G-CSF was used in 38-56% of the cycles.
For every following injection move the pen up and down between position 1 and 2 at least ten times until the liquid appears uniformly white and cloudy.
For every following injection move the pen up and down between position 1 and 2 at least ten times until the liquid appears uniformly white and cloudy.
For every following injection move the pen up and down between the two positions at least ten times until the liquid appears uniformly white and cloudy.
For every following injection move the pen up and down between the two positions at least ten times until the liquid appears uniformly white and cloudy.
34 Flea treatment and prevention
Study results were obtained with the 80 mg dose strength.
For storage conditions of the reconstituted medicinal product, see section 6.3.
For storage conditions of the reconstituted medicinal product see section 6.3.
For storage conditions of the reconstituted product see section 6.3.
For storage conditions of the diluted medicinal product, see section 6.3.
For storage conditions of the reconstituted product see section 6.3.
For storage conditions of the reconstituted product, see section 6.3.
For storage conditions of the reconstituted medicinal product, see section 6.3.
To maintain the immunity, a single injection of one dose should be carried out 2 – 4 weeks before each subsequent farrowing.
To check a dose you set • Note the figure on the cap next to the dosage indicator • Note the highest figure you can see on the push-button scale • Add the two together to show the dose you set • If you have set a wrong dose, simply turn the cap forwards or backwards until you set the right number of units.
To check a dose you set • Note the figure on the cap next to the dosage indicator • Note the highest figure you can see on the push-button scale • Add the two together to show the dose you set • If you have set a wrong dose, simply turn the cap forwards or backwards until you set the right number of units.
- If you have further questions, please ask your doctor.
Potential leakage should be measured by radioactively labelled albumin or erythrocytes injected into the perfusion circuit, with appropriate measures for continuous monitoring of radioactivity leakage into the systemic circulation (Hoekstra HJ, Naujocks T, Schraffordt Koops H, Beekhuis H, van Groningen a Stuling R, ter Veen H, et. al..
Requests for general information packs should be sent to
For doses corresponding to full turns, the scale should line up with the correct dose marking.
Treatment should be titrated for optimal effect according to individual needs of the patient.
Treatment should be titrated for optimal effect according to individual needs of the patient.
Transient rashes do not necessitate interruption of treatment.
Changes consisted in irregular thickening of the femoral growth plate, hypocellularity of the bone marrow next to the altered growth plate and alterations of the dentin composition.
For information on pre-treatment, see section 4.4 and for further instructions, see section 6.6.
For detailed instructions for administration, see section 6.6.
The whole length of the needle should be inserted perpendicularly into a skin fold held between the thumb and the forefinger; the skin fold should be held throughout the injection. lo For additional instructions for use and handling and disposal see section 6.6. no
For additional instructions for use and handling and disposal see section 6.6.
For instructions on reconstitution, see section 6.6
For heavy breeds, or in hot weather, the quantity of water may be increased up to 40 litres per 1 000 doses.
Due to safety considerations, Siklos is contraindicated in patients with severe hepatic impairment (see sections 4.3 and 4.4).
From a microbiological point of view, the product should be used immediately.
If convenient, it may also be given in the abdominal wall (tummy), the gluteal region (buttocks) or the deltoid region (shoulder).
A decision on whether to continue/ discontinue breast-feeding or to continue/ discontinue therapy with lansoprazole should be made taking into account the benefit of breast-feeding to the child and the benefit of lansoprazole therapy to the woman.
To minimize the risk of potential drug interactions, it is advisable to leave 30 minutes between the intake of betaine and amino acids mixtures and/ or medicinal products containing vigabatrin and GABA analogues (see section 4.5).
To carry out the test, the patient must collect six breath samples, three before taking the Pylobactell tablet and three after taking it.
See http: / /pharmacos. eudra. org/ F2/ register/ o050. htm for the Orphan designation for Wilzin.
In order to be able to take action immediately, patients should carry glucose with them at all times. na
take action immediately, patients should carry glucose with them at all times.
Eligible patients for this study were to have biopsy-proven HGD in Barrett's oesophagus (BO).
In order to prevent delays in future it would be better that class actions concerning more than one substance are avoided.
Changing the injection site with each injection may help to prevent such skin changes.
Changing the injection site with each injection may help to prevent such skin changes.
To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle.
To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas, or other surfaces with the dropper tip of the bottle.
To prevent contamination of the dropper tip and solution, care should be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle.
To prevent contamination of the dropper tip and suspension, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle.
To prevent painful injections and minimise leakage from the injection site Fertavid should be slowly administered intramuscularly or subcutaneously.
To prevent painful injections and minimise leakage from the injection site Puregon should be slowly administered intramuscularly or subcutaneously.
To make sure that the sponge does not cling to the moistened glove or swab, and loosens itself from the wound, the sponge can be held down at one end e. g. by using a pair of forceps.
To avoid skin burns, Neupro should be removed if the patient has to undergo magnetic resonance imaging (MRI) or cardioversion.
To avoid accidental ingestion administer the tablet to the dog immediately after removal from the blister packaging.
To avoid injection of air and ensure proper dosing: • Hold Actraphane 40 NovoLet with the needle pointing upwards • Tap the cartridge gently with your finger a few times.
To avoid injection of air and ensure proper dosing: • Hold Mixtard 40 NovoLet with the needle pointing upwards • Tap the cartridge gently with your finger a few times.
To avoid injection of air and ensure proper dosing: • Hold NovoRapid NovoLet with the needle pointing upwards • Tap the cartridge gently with your finger a few times.
For the 1 mg product, the spine of the blister card has one raised ridge with the individual blisters embossed
To facilitate joint learning a training room was set up with 17 workstations.
To facilitate accurate measurement, use the enclosed calibrated pipette or a graduated measure.
- When you close the Diskus, it clicks shut.
amended for Gadovist detailed in Annex I;
For HPV-18, the difference between the vaccine and control groups was not statistically significant for CIN2+ and 12 month persistent infection (TVC-1 cohort).
However, in a pre-specified analysis (TVC-2) that was identical to the
To inject Ultratard on its own • Just before injecting this insulin, roll the vial between your hands until the liquid is uniformly white and cloudy rod
FOR INTRAMUSCULAR GLUTEAL INJECTION ONLY.
Read the package leaflet before use.
Localisation of the involved muscles with electromyographic guidance or nerve stimulation techniques may be useful.
Concerning compatibility with insulin infusion pumps, reservoirs, catheters and needles, see section 6.6.
For storage after first opening, see section 6.3.
For the storage of unused broken tablets, see HOW TO ST0RE SIKLOS.
For storage of unused broken tablets see section 6.6
For storage of the medicinal product in the syringe, see section 6.3.
CRF following both intravenous and subcutaneous administration. a
CRF following both intravenous and subcutaneous administration. a
For skin disinfection use an appropriate disinfectant.
For desloratadine, mean steady state peak plasma concentrations (Cmax and AUC (0-12 h)) of approximately 1.7 ng/ ml and 16 ng• hr/ ml were observed, respectively.
In the detection of leftover thyroid cells, using Thyrogen to stimulate thyroglobulin production and uptake of radioactive iodine was comparable to using THST.
For recommended dose see paragraph below.
For relapsing-remitting MS, efficacy has been demonstrated for therapy for the first two years.
For relapsing-remitting MS, efficacy has been demonstrated for therapy for the first two years.
For relapsing-remitting multiple sclerosis, efficacy has been demonstrated for therapy for the first two years.
For cisplatin dose adjustments, see the corresponding summary of product characteristics.
For cisplatin dose adjustments, see the corresponding summary of product characteristics.
For a full list of excipients see 6.1
For a full list of excipients, see section 6.1
For a full list of excipients, see section 6.1
For a full list of excipients, see section 6.1.
For a full list of excipients, see section 6.1.
For excipients, see 6.1.
of excipients, see section 6.1.
For a full list of excipients, see section 6.1.
For a full list of excipients, see section 6.1
The optimum dose is 1 mg once daily for most patients.
For the majority of breeds, the use of ibafloxacin is contra-indicated in dogs less than 8 months of age and in giant breeds less than 18 months old.
For Niemann-Pick type C disease, the effectiveness of Zavesca was studied in one main study involving 31 patients, 12 of whom were less than 12 years old.
For Parkinson's disease, the starting dose is 0.088 mg three times per day.
For memantine, no clinical data on exposed pregnancies are available.
For the same reason you should avoid exposing the patch on the skin to direct heat such as electric blankets, hot-water bottles, sauna, solarium or hot baths.
Multiple events were therefore counted only once for the purposes of the analysis.
Multiple events were therefore, counted only once in any given 12 week period for the purposes of the analysis.
If you have to stop taking this medicine, see Section 3, ‘If you stop using Neupro‘.
For most patients, the right dose is between 8 mg and 16 mg per day (reached within 3 to 7 weeks).
“ For most patients the recommended dose is 25 mg intramuscular every two weeks.
For most patients, the dose ranges from 0.5- 1.0 mg/ kg per day.
In rheumatoid arthritis, MabThera was studied in 520 patients.
For the primary endpoint, triglycerides, the secondary endpoints, LDL cholesterol, apo B, HDL cholesterol, non-HDL cholesterol, and VLDL cholesterol, the trends tests were significant in the response across placebo, simvastatin 20, simvastatin 40, and simvastatin 80 mg.
For the 150 ml package, a measuring spoon or an oral measuring syringe is provided, marked for doses of 2.5 ml and 5 ml.
For long-term prophylaxis against bleeding in patients with severe haemophilia A, the usual doses are 20 to 40 IU of factor VIII per kg body weight at intervals of 2 to 3 days.
For long-term prophylaxis of haemorrhages in patients with severe haemophilia B, doses of 20 to 40 IU of factor IX per kilogram of body weight could be given at intervals of 3 to 4 days.
For pseudoephedrine, the mean Tmax occurred at 6-7 hours post dose and mean peak plasma concentrations (Cmax and AUC) of approximately 263 ng/ ml and 4,588 ng• hr/ ml, respectively, were observed.
For pseudoephedrine, mean steady state peak plasma concentrations (Cmax and AUC (0-12 h)) of 459 ng/ ml and 4,658 ng• hr/ ml were observed.
For quantity to be applied see 4.2 Method of administration.
For quantity to be applied see 4.2 Method of administration.
To reconstitute, add 5 ml of sterile sodium chloride 9 mg/ml (0.9%) solution for injection, without preservative, to the 200 mg vial or 25 ml sterile sodium chloride 9 mg/ml (0.9%) solution for injection, without preservative, to the 1000 mg vial.
- For reconstitution use only the sterilised water for injections and the reconstitution device
For lower back spine fusion, the damaged disc between the vertebrae is removed and replaced with two metal cages filled with InductOs.
For radioiodine imaging or ablation, radioiodine administration should be given 24 hours following the final Thyrogen injection.
For section 4.6, the CHMP discussed the wording, moving the mention of galactorrhea to section 4.8 and adopting the following harmonised wording:
For viral safety see section 4.4
Dexmedetomidine 40 mcg/ kg intramuscularly
The dose by injection is 3 mg once every three months.
For ankylosing spondylitis, Humira and placebo as an add-on to existing treatment were compared over 12 weeks in two studies involving 397 patients.
For combination with trastuzumab, adverse events (all grades) reported in ≥ 10% are displayed.
For continuation of the treatment please consult your doctor.
For renal safety in patients pre- and post-transplantation with lamivudine-resistant HBV, see section 4.8.
For poultry comment was required on the current use of the product, in particular on the dose used or prescribed under field conditions.
For zidovudine (200 mg every 8 hours) a 25% decrease in AUC was reported when combined with ritonavir (300 mg every 6 hours).
For zidovudine (200 mg every 8 hours) a 25% decrease in AUC was reported when combined with ritonavir (300 mg every 6 hours).
For capecitabine dose calculation according to body surface area, see capecitabine summary of product characteristics.
For in vivo diagnosis of gastroduodenal Helicobacter pylori (H. pylori) infection.
For serum thyroglobulin (Tg) testing, your doctor or nurse will take a serum sample 72 hours after the last injection of Thyrogen.
For the 150 ml package, a measuring spoon or an oral measuring syringe is provided, marked for doses of 2.5 ml and 5 ml.
In diffuse large B-cell lymphoma, the effectiveness of adding MabThera to CHOP chemotherapy was examined in a study involving 399 patients who were all over 60 years of age.
For instructions for use, see section 4.2 of the enclosed Summary of Product Characteristics.
For instructions for preparation see section 6.6.
For all 101 treated PUPs, regardless of inhibitor development, the median number of exposure days is 197 (range 1-1299).
For full contra-indications, see package insert.
For cats, the corresponding “ Advocate for cat ” product, which contains 100 mg/ ml imidacloprid and 10 mg/ ml moxidectin, must be used.
For cats, the corresponding “ Advocate for cat” product, which contains 100 mg/ ml imidacloprid and 10 mg/ ml moxidectin, must be used.
Dogs weighing under 2 kg, apply 2 drops to the ear once a day.
Dogs weighing 15 kg or more, apply 8 drops to the ear once a day.
25.3% risk reduction for doubling of the serum creatinine (p = 0.006); 28.6% risk reduction for end-stage renal failure (p = 0.002); 19.9% risk reduction for end-stage renal failure or death (p = 0.009); 21.0% risk reduction for doubling of serum creatinine or end-stage renal failure (p = 0.01).
For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.
For storage conditions of the reconstituted medicinal product, see section 6.3.
For storage conditions of the reconstituted medicinal product, see section 6.3.
For storage conditions of the reconstituted medicinal product, see section 6.3.
For storage conditions after opening, see section 6.3.
7 For storage conditions of the diluted medicinal product, see section 6.3.
For storage conditions of the diluted medicinal product see section 6.3
For storage conditions of the diluted medicinal product see section 6.3.
For storage conditions of the diluted medicinal product, see section 6.3.
For in-use storage conditions of the medicinal product, see section 6.3.
For storage conditions of the in-use medicinal product, see section 6.3.
For storage conditions of the in-use medicinal product, see section 6.3.
For storage conditions of the in-use medicinal product, see section 6.3.
For storage conditions of the radiolabeled product see section 6.3.
For storage conditions of the reconstituted medicinal product, and infusion solutions see section 6.3.
For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.
For storage conditions of the reconstituted or the diluted medicinal product, see section 6.3.
For storage conditions of the reconstituted medicinal product, see section 6.3.
For storage conditions of the reconstituted medicinal product see section 6.3.
For storage conditions of the reconstituted medicinal product, see section 6.3.
For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.
For storage conditions of the reconstituted medicinal product see section 6.3.
For storage conditions of the reconstituted medicinal product, see section 6.3.
For storage conditions of the reconstituted product see section 6.3.
For storage conditions of the reconstituted product, see section 6.3.
For the storage condition of the reconstituted product see section 6.3.
For storage conditions of the diluted medicinal product, see section 6.3.
For storage conditions of the reconstituted medicinal product, see section 6.3.
For in-use storage conditions, see section 6.3.
25 For storage conditions of the reconstituted diluted medicinal product see section 6.3.
For storage conditions of the reconstituted diluted medicinal product see section 6.3.
For myoclonic seizures, 58.3% of the patients who received Keppra had at least a halving of the number of seizure days per week, compared with 23.3% of the patients who received placebo.
For treatment cycles 1-3 with Ceplene and IL-2
documents are available either on the Internet at http://www.emea.eu.int or by writing to:
For both surgery types, treatment should not be started if there is bleeding from the site of operation.
For doses of 400 mg and above (see dosage recommendation below) a 400 mg tablet (not divisible) is available.
For dose-related adverse reactions the frequency category reflects the higher dose of rosiglitazone.
For children from six to 11 years of age, the dose is 2.5 mg once a day, taken either as 5 ml of the syrup or oral solution, or as one 2.5 mg orodispersible tablet.
For children from one to five years of age, the dose is 1.25 mg once a day, taken as 2.5 ml syrup or oral solution.
For children 6-9 years limited clinical data exists.
For children 6-9 years limited clinical data exists (see section 5.1).
Children under 10 years of age should take 100 mg per kilogram of body weight a day, divided into two equal doses.
For children from one to five years of age, the dose is 1.25 mg once a day, taken as 2.5 ml syrup or oral solution.
For children or adolescents who cannot swallow a capsule, an oral solution of ribavirin is available.
For children who have problems consuming a chewable tablet, an oral granule formulation is available. • Your child should take only one tablet of SINGULAIR once a day as prescribed by your doctor. • It should be taken even when your child has no symptoms or if he/ she has an acute asthma attack. • Always have your child take SINGULAIR as your doctor has told you.
For children, remove only the portion of liquid as directed by your child's doctor.
For common adverse events which required dose modification or discontinuation see section 4.8.
For excipients, see section 6.1.
For excipients, see Section 6.1 List of excipients.
For breast-feeding women, see section 4.6.
For multiple vial entry, an aspirating needle or multi-dose syringe is recommended to avoid excessive broaching of the stopper.
For multiple vial entry, an aspirating needle or multi-dose syringe is recommended to avoid excessive broaching of the stopper.
For information on reconstituting Synagis, see section 6.6.
For information on reconstituting Synagis, see section 6.6.
For general information about the dosage and how to use Ceplene and IL-2, please see Section 3, “ HOW TO USE CEPLENE”.
For information on product incompatibilities see section 6.2
For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.
For reconstitution instructions see section 6.6.
For storage instructions after reconstitution:, see section 6.3.
For preparation and administration instructions, see section 6.6.
For preparation and administration instructions, see section 6.6.
For instructions on preparation and handling, see section 6.6.
For instructions on preparation, see section 6.6.
For instructions for preparation see section 6.6.
For reconstitution instructions prior to administration, see section 6.6.
In the interest of patients, it is recommended that every time ReFacto AF is administered, the name and batch number of the product should be recorded.
For instructions on reconstitution of Nplate, see section 6.6.
For instructions on reconstitution and administration, please see section 6.6.
For reconstitution directions see section 6.6.
For instructions for use see section 6.6.
For instructions for use, see section 6.6.
For Instructions for Use, see section 6.6.
For instructions for reconstitution prior to administration, see section 6.6.
For instructions for use and handling, see section 6.6.
22 For instructions on preparation and handling RISPERDAL CONSTA, see section 6.6.
For instructions for preparation, see section 12.
For instructions on preparation, see section 6.6.
For instructions on handling RISPERDAL oral solution see section 6.6.
For instructions on reconstitution of the product before administration, see section 6.6.
For instructions on the use of the calendar pack, see “USER INSTRUCTIONS” at the end of the package leaflet.
In resistant isolates, resistance to other antibacterial agents of the carbapenem class was seen in some but not all isolates.
The MRA is still awaiting ratification at Member State level and did not start as foreseen in early 2001.
For operator warnings - read the package leaflet before use.
For operator warnings – read the package leaflet before use.
For instruction on use, see section 6.6.
For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.
Haematopoetic growth factor has been used in patients with resistant myelosuppression.
For sodium, see leaflet for further information.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.
For patients with pre-existing fractures, number needed to treat (NNT) is 21 patients.
For patients at risk or with ulcers that are difficult to heal, a longer course of treatment and/ or a higher dose should be considered.
Sebivo oral solution may be considered for patients who have difficulties swallowing tablets.
For patients who received their thienopyridine within 3 days prior to CABG, the frequencies of TIMI major or minor bleeding were 26.7% (12 of 45 patients) in the prasugrel group, compared with 5.0% (3 of 60 patients) in the clopidogrel group.
Patients with a gastrostomy or nasogastric tube:
For patients with type 2 diabetes, the recommended starting dose of NovoMix 30 is 6 U at breakfast and 6 U at dinner (evening meal).
For patients from the Arimidex Alone arm who switched to Herceptin, only AEs before the 1st Herceptin administration are displayed
Patients currently treated with an ESA can be switched to MIRCERA administered once a month as a single intravenous or subcutaneous injection.
For patients requiring 30 – 60 mg doses, please follow these instructions to ensure proper dosing.
For children weighing less than 47 kg a solution formulation is available.
Patients who have severe problems with their kidneys should take CHAMPIX as 1 mg once daily.
At the end of the 12 weeks, in patients who stopped smoking, doctors may choose to carry on treatment for another 12 weeks.
For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks treatment with CHAMPIX at 1 mg twice daily may be considered (see section 5.1).
For randomised patients, the mean time of prior antiretroviral exposure was 138 weeks for PIs, 281 weeks for NRTIs, and 85 weeks for NNRTIs.
Patients on higher dosages of the used oral antipsychotic should be considered for the higher RISPERDAL CONSTA dose of 37.5 mg.
For patients treated weekly with 25 mg temsirolimus OS was 13.8 months (95% CI:
In PVC/ PVDC/ aluminium blisters, store below 30°C.
For pigs of 40-50 kg, it was possible to derive a withdrawal period of 35 days based on injection site residues.
For fattening pigs over the age of 10 weeks, however, one intramuscular injection with one dose is administered. od
For fattening pigs over the age of 10 weeks, however, one intramuscular injection with one dose is administered.
In use pens For storage precautions, see section 6.3.
In-use pens For storage precautions, see section 6.3.
For storage precautions, see section 6.3.
For storage precautions, see section 6.3.
For storage precautions, see section 6.3.
For storage precautions, see section 6.3.
In use cartridges For storage precautions, see section 6.3.
In use pens For storage precautions, see section 6.3.
Opened vials For storage precautions, see section 6.3.
For storage conditions of the reconstituted medicinal product see section 6.3.
For storage conditions of the recosntituted medicinal product see section 6.3.
For the first and subsequent annual reassessments the Marketing Authorisation Holder should provide annually an updated risk assessment on the continuous use of the vaccine taking into account the continued need for the vaccine, its history of use over the previous twelve months and progress made in addressing the items that require resolution in order for the authorisation to revert to normal status.
Resource allocation for information technology
After successful operation within the EMEA, testing with a number of partners began in 2000.
Canary Wharf UK – London E14 4H
The EMEA receives safety reports from within the EU and outside
A subscription service is available for all EMEA public documents, distributing documents electronically or in paper form.
Sustained virologic response rates for treatment groups treated for one year with IntronA alone or in combination with ribavirin (from two studies) are shown in Table 3.
Urine levels of interferon were below the detection limit following each of the three routes of administration.
Urine levels of interferon were below the detection limit following each of the three routes of administration. lp
For waist circumference, the mean change was -4.5 cm for orlistat 60 mg (baseline 103.7 cm) and -3.6 cm for placebo (baseline 103.5 cm).
For the long term treatment Vimpat tablets and syrup are available.
For treatment of cattle over 250 kg body weight, divide the dose so that no more than 10 ml are injected at one site.
For treatment of cattle over 300 kg body weight, divide the dose so that no more than 7.5 ml are injected at one site.
For treatment of cattle over 300 kg body weight, divide the dose so that no more than 7.5 ml are injected at one site.
For the treatment of bacteraemia in patients with right-sided infective endocarditis, 8 (42%) of the 19 patients given Cubicin were treated successfully, compared with 7 (44%) of the 16 given standard treatment.
For the treatment of lymphomatous meningitis, the dose for adults is 50 mg (one vial) administered intrathecally (lumbar puncture or intraventricularly via an Ommaya reservoir).
For the treatment of post-menopausal osteoporosis and osteoporosis in men, the recommended dose is a single intravenous infusion of 5 mg Aclasta administered once a year.
In pre-pubertal children it usually varies from 0.7 to 1.0 IU/ kg.
For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.
For the treatment of respiratory tract As for Germany infections, urogenital, gastrointestinal and skin infections caused by pathogens sensitive to trimethoprim and sulfamethoxasole in pigs and poultry (broilers).
For treatment and prevention of Swine Dysentery The dosage is 4.25 mg tylvalosin per kg bodyweight per day for 10 consecutive days.
For use in individual pigs on farms where only a small number of pigs are to receive the medicine.
For the treatment of individual pigs or a small number of animals, the animal owner mixed the medicine into the pig feed.
The placebo-adjusted improvement in mean 6MWD at week 12 in patients in the 10 mg group in ARIES-1 was 51.4 m (95% CI:
For vardenafil as well as M1, protein binding is independent of total drug concentrations.
For the active immunisation of healthy cats 9 weeks or older against Feline Panleukopenia and Feline Leukaemia viruses and against respiratory diseases caused by Feline Rhinotracheitis virus, Feline Calicivirus and Feline Chlamydophila felis.
For active immunisation of pigs over the age of 2 weeks against Porcine Circovirus Type 2 (PCV2).
For insulin human, no clinical data on exposed pregnancies are available.
For SUI, the recommended dose of Ariclaim is 40 mg twice a day.
For both surgeries, if haemostasis is not secured, initiation of treatment should be delayed.
For both surgeries, if haemostasis is not secured, initiation of treatment should be delayed.
To the user: • Repetitive contact with the product may lead to skin allergies. • Avoid skin and eye contact with the product.
To retain protection against tetanus, horses need to be revaccinated.
To retain protection, horses need to be revaccinated.
To measure the dose: • shake the bottle lightly before opening • take the correct measuring spoon:
To minimise the dose of radiation absorbed by the bladder, the intake of fluids should be increased during the first few hours after injection to permit frequent voiding.
To minimise foam formation in solutions of ORENCIA the vial should be rotated with gentle swirling until the contents are completely dissolved.
- To minimise foam formation in solutions of ORENCIA, the vial should be rotated with gentle
To minimize the possibility of agglutination, it is important to limit the amount of blood entering the tubing.
To minimize the possibility of agglutination, it is important to limit the amount of blood entering the tubing.
To minimize the possibility of agglutination, it is important to limit the amount of blood entering the tubing.
To minimise accidental injury, recap the needle only if instructed to do so by your healthcare provider, and in the manner demonstrated to you by your healthcare provider.
To minimise potential nephrotoxicity, oral probenecid and intravenous saline prehydration must be administered with each VISTIDE infusion.
For a dose of 5 micrograms iloprost at mouthpiece it is recommended to complete two inhalation cycles with 2.5 micrograms pre-set dose program with a filling of one ampoule containing 2 ml Ventavis nebuliser solution, which shows two coloured rings (white – pink).
To achieve such accountability, any organisation needs to set clear and realistic performance targets and then measure whether those targets are met.
If use of a separate line is not possible, the line should be flushed out with saline
Cooling procedures such as ice packs should have been removed from the area at least 15 min before the Savene administration in order to allow sufficient blood flow.
To permit adequate absorption of alendronate:
For user convenience, the needle ‘ bevel up'position is orientated to the lever arm, as shown in Figure 3.
For user convenience, the needle ‘ bevel up'position is orientated to the lever arm, as shown in Figure 3.
- If you have any further questions, ask your doctor or pharmacist.
(See Storing Your BYETTA Pen in Section 1 of this user manual for more information.) • When it is time for your next routine dose, go to Section 3, Step 1, and repeat Steps 1 - 7.
For additional information contact your healthcare professional.
Further information can be obtained from the above address or from
Chapter 4 Technical coordination activities
For information on pre-treatment see section 4.4 and for further instructions see section 6.6.
For more information please refer to: http: / /www. emea. eu. int/ pdfs/ human/ referral/ SSRIs/ 29783705en. pdf http: / /www. emea. eu. int/ pdfs/ human/ referral/ SSRIs/ EMEA-H-A-31-651-SSRIs-en. pdf
For more information see: http: / /www. mhra. gov. uk/ home/ groups/ pl-p/ documents/ drugsafetymessage/ con2018037. pdf
For additional information, contact your healthcare professional.
For additional information, contact your healthcare professional.
To find out more about these medicines, please ask your doctor or read the Package Leaflet that comes with these medicines.
For information on the infusion of Aclasta, see section 6.6.
For preparation and administration instructions see section 6.6.
For further information on reconstitution and administration see section 6.6.
For information on mixing with other solutions: see sections 6.2 and 6.6.
Information on the prescription status of this product may be found on the labelling.
For information on reconstitution of Xolair, see section 6.6.
If you need more information about how this product may be used, you should consult your national veterinary authority.
For more information, see the Package Leaflet provided with the other medicine. • Norvir can also be used as an antiviral medicine.
(For further information see section 4.10 of the Summary of Product Characteristics).
To comply with the growing needs of the Agency, as well as to take on the specific tasks of the Technical Co-ordination Unit, two recruitment competitions were organised to identify new staff for positions in each of the four sectors.
For storage precautions, see section 6.3.
injections to the PegIntron powder vial;
injections to the ViraferonPeg powder vial;
injections to the IntronA powder vial;
To prevent these gastrointestinal symptoms, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals.
Changing the injection site with each injection may help to prevent such skin changes.
Changing the injection site with each injection may help to prevent such skin changes.
Changing the injection site with each injection may help to prevent such skin changes.
Insulin that you inject in such a site may not work very well.
• To prevent mortality and to reduce clinical signs and lesions of Infectious Bursal disease.
To prevent manic episodes, the same dose should be continued.
To prevent vomiting and to protect the liver, an infusion of dexamethasone (a corticosteroid) should be given before each Yondelis dose.
To prevent vomiting, tablets should be given more than 1 hour in advance.
For publication with complete documentation after commission decision:
Why has Clopidogrel Winthrop been approved?
Why do I keep my medication in the refrigerator?
• Why should I use a new needle for each injection?
2/ 3 Why has Duloxetine Boehringer Ingelheim been approved?
Page 2/ 3 ©EMEA 2008 Why has Equilis Prequenza Te been approved?
Why do I see BYETTA leaking from my needle after I have fin ished my injection?
Why do I see BYETTA leaking from my needle after I have finished my injection?
• Why is it difficult to push the Dose Knob when I try to inject?
• Why should I prime my Pen before each dose?
Why has Filgrastim ratiopharm been approved?
Why has Fluticasone Furoate GSK been approved?
Why has Helicobacter Test INFAI been approved?
Why has Irbesartan Hydrochlorothiazide BMS been approved?
Why has Irbesartan Hydrochlorothiazide Winthrop been approved?
Why has Irbesartan Winthrop been approved?
Why the particles of 6 µm or up to 8 µm, which are deposited in stage 1, are considered with regards to safety only. c.
Why has Mycophenolate mofetil Teva been approved?
• Why can I not dial the dose to use the small amount of insulin that remains in my cartridge?
Why has Nobilis Influenza H5N2 been approved?
Why has Nobilis Influenza H7N1 been approved?
Why has Olanzapine Neopharma been approved?
Why is normal saline solution given with VISTIDE?
Why has Suvaxyn Aujeszky 783 + O/ W been approved?
Why has Twinrix Paediatric been approved?
Why are there air bubbles in the cartridge? • A small air bubble is normal.
NeoSpect is radiolabelled by mixing it with a solution of radioactive technetium (99mTc).
keep the patch from sticking to your skin properly,
To reconstitute, use the solvent supplied.
In order to reduce the likelihood of mis-diagnosis and in order to better ensure the appropriate use of the medicinal product, the CHMP emphasised that the product information should reflect that the initial diagnosis and initial prescription should be undertaken by physicians with experience in the treatment of AD.
In order to reduce the risk of undesirable effects the maintenance dose is achieved by upward titration of 5 mg per week over the first 3 weeks as follows.
In order to reduce the risk of undesirable effects the maintenance dose is achieved by upward titration of 5 mg per week over the first 3 weeks as follows.
In order to reduce the risk of side effects this dose is achieved gradually by the following daily treatment scheme.
In order to reduce the risk of side effects this dose is achieved gradually by the following daily treatment scheme.
To re-suspend, vigorously roll the syringe between the palms until a uniform, cloudy suspension is achieved.
To remove the clear plastic cap push towards the syringe and then pull the cap off.
In order to embark on this ambitious set of tasks, it will be critical to during 1997 recruit highly qualified staff with senior level technical and project management skills and experience.
ETOMEP is part of the European Commission Joint Research Centre’s Institute for Health and Consumer Protection.
The Unit coordinated the Agency’s quality management initiative and a quality manager, Marijke Korteweg, was appointed to continue and maintain the 51 progress of the initiative.
For Mass Spectrometry For Infrared Spectroscopy
Continued provision of scientific advice on issues relating to the quality, safety and efficacy of medicines during different stages of their development;
Therapeutic regimen (week 2 onwards)
Continue your treatment for as long as your doctor advises.
Continue using the cream for as long as your doctor advises.
This dosage should be continued for three weeks.
The whole Agency will be transferred to the new system during the early part of 2002 in order to be able to take advantage of the improvement in accessibility of documents that the system offers.
⋅ to progress the re-evaluation of guidelines on injection site residues and to reach consensus within CVMP
Continue treatment as needed to maintain a therapeutic response.
The number of key PI-resistance mutations increases markedly the longer a failing PI-containing regimen is continued.
However, paclitaxel belongs to a class of substances which are potentially carcinogenic based on their mechanism of action.
For a full list of excipients, see
For all patients, the loading dose could be administered anytime between randomisation and 1 hour after the patient left the catheterisation lab.
- For all MAHs, in addition to routine pharmacovigilance activities, identified and potential risks
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
tho For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
For any information about this medicine, please contact the Manufacturer:
127 For any information about this medicinal product, please contact the local representative of the Marketing Authorisation.
18 For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
21 For any information about this medicine please contact the local representative of the Marketing Authorisation Holder.
26 For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
35 For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
46 For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
48 For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
72 For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
76 For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
For any information about this medicinal product, please contact the local representative of the
For any information about this medicinal product, please contact the local representative of the
For any information about this medicinal product, please contact the local representative of the dic
For any information about this medicinal product, please contact the local representative of the Marketing
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
For any information about this medicinal product, please contact the Marketing Authorisation Holder.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder given below:
For any information about this medicine product, please contact the local representative of the Marketing Authorisation Holder.
FURTHER INFORMATION For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
ed For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
For any information about this medicine, please contact the Marketing Authorisation Holder.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
For information on preparation of Lucentis, see section 6.6.
For general Kivexa information enquiries, contact ………
Information on the prescription status of this product may be found on the label/ outer package.
Information on the prescription status of this product may be found on the label/ outer package.
Information on the prescription status of this product may be found on the labelling.
Information on the prescription status of this product may be found on the label of the carton.
Information on the prescription status of this product may be found on the label/ outer package.
Information on the prescription status of this product may be found on the label/ outer package.
Information on the prescription status of this product may be found on the label of the carton.
Information on the prescription status of this product may be found on the outer package.
Information on the prescription status of this product may be found on the label/ outer package.
The European Commission granted a marketing authorisation valid throughout the European Union, for Meloxivet to Janssen Pharmaceutica N. V. on 14 November 2007 Information on the prescription status of this product may be found on the label of the carton.
Information on the prescription status of this product may be found on the labelling.
Information on the prescription status of this product may be found on the outer package.
Information on the prescription status of this product may be found on the labelling.
Information on the prescription status of this product may be found on the label/ outer package.
Information on the prescription status of this product may be found on the outer package.
Information on the prescription status of this product may be found on the label/ outer package.
Information on the prescription status of this product may be found on the label/ outer package.
Information on the prescription status of this product may be found on the label/ outer package.
Information on the prescription status of this product may be found on the label/ outer package.
Information on the prescription status of this product may be found on the label of the carton.
Information on the prescription status of this product may be found on the label/ outer package.
Information on the prescription status of this product may be found on the label/ outer package.
Information on the prescription status of this product may be found on the label/outer package.
Information on the prescription status of this product may be found on the outer package.
Information on the prescription status of this product may be found on the label of the bottle.
149 For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
155 For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
166 For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
177 For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.
Information on the prescription status of this product may be found on the labelling.
Information on the prescription status of this product may be found on the label/ outer package.
Information on the prescription status of this product may be found on the outer package.
Information on the prescription status of this product may be found on the label of the carton.
Information on the prescription status of this product may be found on the label of the carton box that contains the product.
Information on the prescription status of this product may be found on the label/ outer package.
Information on the prescription status of this product may be found on the label/ outer package.
Information on the prescription status of this product may be found on the label/ outer package.
For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.
- If you have any further questions, ask your doctor or pharmacist.
For all other diseases studied, Enbrel produced a greater improvement in symptoms than placebo.
In all other diseases studied, Remicade produced a greater improvement in symptoms than placebo.
In all indications, Erbitux is administered once a week.
For all packages except the 150 ml bottle, a measuring spoon is provided, marked for doses of 2.5 ml and 5 ml.
FOR ALL MEDICINAL PRODUCTS CONTAINING CELECOXIB, ETORICOXIB, LUMIRACOXIB, PARECOXIB, AND VALDECOXIB
- then every year for the rhinotracheitis and calicivirosis components, and every three years
See leaflet for further information
To treat some types of heart attack, a health professional may give the first dose into a vein (intravenously). • Do not inject Arixtra into muscle.
- the signs and symptoms of Parkinson’s disease either alone or in combination with the drug
- the signs and symptoms of Parkinson’s disease either alone or in combination with the drug
For treatment of anorexic calves, the product should be administered in half a litre of an electrolyte solution.
For treatment of anorexic calves, the product should be administered in half of a litre of an electrolyte solution.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
In order to treat a dog with separation anxiety, the animal should not only receive medicines but also behavioural modification therapy.
For optimum control of flea problems in a multi-pet household, all pets in the household should be treated with a suitable insecticide.
For accurate dosing, the oral dispenser supplied should be used exclusively.
A 10 litre gas cylinder filled at 155 bar absolute brings 1535 litres of gas under pressure of 1 bar at 15oC.
A 2 litre gas cylinder filled at 155 bar absolute brings 307 litres of gas under pressure of 1 bar at 15oC.
For a fractured tibia, InductOs is placed around the broken bone to aid healing.
For mask induction using sevoflurane, inspired concentrations of 5 to 7% sevoflurane with oxygen are employed to induce surgical anaesthesia in the healthy dog.
For complete information be sure to read the “How to take” section of the Package Leaflet for peginterferon alfa-2b or interferon alfa-2b.
For a full list of excipients, see section 6.1
For a full list of excipients, see section 6.1.
For a full list of excipients, see section 6.1
For a full list of excipients see section 6.1
For a full list of excipients, see section 6.1
For a full list of excipients, see section 6.1.
For a list of excipients see section 6.1
For a list of excipients, see section 6.1
The Committee for Medicinal Products for Human
See the Package Leaflet for the list of the medicines that may interact with Sutent.
To give your medicine the best chance of working, take it at the right time and do not miss a dose.
A minority of patients were tested using fluorescence in-situ hybridization (FISH).
For children who weigh less than 50 kg • The starting dose will normally be 0.25 mg once a day • The dose may be increased every other day in steps of 0.25 mg per day. • The usual maintenance dose is 0.25 mg to 0.75 mg once a day.
Results from up to 24 months (median:
20 For long-term prevention of bleeding in individuals with severe haemophilia B, doses of 20 IU to 40 IU of factor IX per kilogram body weight should be given at intervals of 3 to 4 days.
The pen cap must be put back on the pen after each injection in order to protect from light.
For a subset of the 56 patients, data are available from baseline to 24 months.
Above 100 kg body weight, 50 ml is usually sufficient to provide a diagnostically adequate contrast effect.
63 To use this table, look for the line that shows how much the patient weighs.
Please follow the 4 major steps below to use the pen.
For intravenous use, single use administration only.
For intravenous use, single use administration only.
For intravenous use, single use administration only.
⋅ to maintain need for additional safety guidelines in conjunction with VICH initiative and to co-ordinate further progress through SRWP
For your convenience, place a sticker on your calendar each week as a reminder to take your ADROVANCE.
For your convenience, place a sticker on your calendar each week as a reminder to take your FOSAVANCE.
For your personal safety the treatment with Privigen will take place under the supervision of your doctor or health care professional.
ache, fever, nausea, vomiting, intestinal blockage), dark or black stools, inflammation of the gullet (can cause difficulty in swallowing), inflammation of the pancreas (can lead to stomach pain)
shock, or serious skin conditions associated with red spots, blisters. rod
sign of serious bowel inflammation which may occur very rarely following treatment with antibiotics (very rare).
can write the date and time you applied the patch.
ge Please also read the “Instructions for Use” of the inhaler at the end of the package leaflet carefully before taking EXUBERA.
acid anhydrous, sodium citrate, magnesium stearate, acesulfame potassium and natural lemon and lime flavour.
croscarmellose sodium, magnesium stearate and the colouring agent titanium dioxide E171.
Tetanus, HepB and Poliomyelitis
1 000 000 1.81% 245 220 0.44%
André PAUWELS, Frans GOSSELINCKX Ib VALSBORG, Jytte LYNGVIG 5 Hermann Josef PABEL, Gerhard Josef KOTHMANN, (Vice-chairman)
*EPP=eligible patient population; **ITT=intent-to-treat population
*PPP=per-protocol population; **ITT=intent-to-treat population
Prac-tic 137.5 mg Spot-on solution for small dogs
Prac-tic 275 mg Spot-on solution for medium dogs
Prac-tic 56.25 mg Spot-on solution for very small dogs Prac-tic 137.5 mg Spot-on solution for small dogs Prac-tic 275 mg Spot-on solution for medium dogs Prac-tic 625 mg Spot-on solution for large dogs
Prac-tic 56.25 mg Spot-on solution for very small dogs Prac-tic 137.5 mg Spot-on solution for small dogs Prac-tic 275 mg Spot-on solution for medium dogs Prac-tic 625 mg Spot-on solution for large dogs
Prac-tic 56.25 mg Spot-on solution for very small dogs
Prac-tic 625 mg Spot-on solution for large dogs
Practice Guidelines in Oncology-v.2.2008 (HCCN, USA), the CCO (Cancer Care Ontario) Formulary, revised 2006/ 2007, and the Guidelines on penile cancer (March 2004) of the European Association of Urology.
Prac-tic should not be used in dogs less than 8 weeks old or less than 2 kg bodyweight since it has not sufficiently been studied in these animals.
Prac-tic Spot-on for dogs Pyriprole
Prac-tic Spot-on for dogs Pyriprole
Prac-tic Spot-on for dogs Pyriprole
Pradaxa is used to prevent the formation of blood clots in the veins after knee or hip replacement surgery.
Pradaxa should also not be used in patients taking quinidine (another medicine used to regulate the heart rhythm).
Prasugrelb Clopidogrel b +ASA
Prasugrel is a prodrug and is rapidly metabolised in vivo to an active metabolite and inactive metabolites.
- not enough w alking or other weight-bearing exercise
- not enough walking or other weight-bearing exercise
Make a stab incision, approximately 5 mm long, along the elevated near end of the implant.
Administer injection following instructions above.
Administer injection following package instruction.
fibrosis, cirrhosis, viral hepatitis, neonatal liver disease or congenital enzyme defects)
34 Caution required with concomitant use
precautions are required.
Special care should be taken with Pedea
Preparation and administration precautions:
For this reason, the plasma levels of patients being treated with digoxin should be monitored and a dose adjustment of digoxin made if necessary.
You will need special medical attention if allergy-like reactions occur.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products
For user safety warnings – read the package leaflet before use.
Special precautions in patients undergoing peripheral blood progenitor cell mobilisation
Special precautions in cancer patients
SPECIAL STORAGE CONDITIONS
SPECIAL STORAGE CONDITIONS
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
SPECIAL STORAGE CONDITIONS
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
10 SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
10 SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF NECESSARY
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 291 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 293 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 297 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 299 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 305 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 317 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
73 OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
80 OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
87 OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
96 OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
Any unused product or waste material should be disposed of in accordance with local requirements 15 11.
Hepatotoxicity occurred at plasma exposures similar to those obtained at therapeutic doses in humans, in common with other antifungal agents.
Intravenous use only Not for bolus injection Read enclosed leaflet before use
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCT OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIAL DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 18 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 20 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 261 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 264 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 267 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 270 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 295 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 301 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 303 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 309 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 315 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE Any unused product or waste material should be disposed of in accordance with local requirements.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 11.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
Handling instructions for Retacrit:
Handling instructions for Silapo:
Special precautions for use in animals Heavy reliance on a single class of antibiotics may result in the induction of resistance in a bacterial population.
Special precautions for use in animals Only healthy animals should be vaccinated.
2 during breast-feeding are preferable, especially while nursing a newborn or preterm infant”.
au 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCT OR WASTE MATERIALS, IF ANY
12 SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, if any
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY 16 Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCT OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCT OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCTS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH VETERINARY MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCT OR WASTE MATERIALS IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
Precautions for the handling and disposal of DepoCyte
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
This medicinal product contains 50 mg of sorbitol per ml as excipient.
This medicine contains 50 mg of sorbitol per ml as excipient.
was not stated therefore the adequacy of the infections cannot be documented.
Radiopharmaceutical precursor - Not intended for direct application to patients.
Radiopharmaceutical precursor - Not intended for direct use in patients
Radiopharmaceutical precursor - Not intended for direct use in patients.
collagen synthesis in bone cell culture;
Predstavniš tvo za Hrvaš ko in Slovenijo (Hrvaš ka), Tel: +385 1 6386 250
Common (5/100 – 1/10) Respiratory Tract Infection Herpes Simplex Sinusitis Viral Infection Gastroenteritis
Withdrawing the right volume of your medicine with the help of the syringe markings
Withdraw 1.0 ml of the Thyrogen solution from the product vial.
Withdraw prescribed amount of Prometax oral solution from bottle.
• pass the flat back of a knife over the top of the spoon • the powder left in the spoon is one spoonful • take the correct number of spoonfuls of powder from the bottle
If you take more (Invented name)® than you should
Premedication in cats before induction and maintenance of general anaesthesia with ketamine.
Premedication in dogs before induction and maintenance of general anaesthesia.
- First data-lock point is 14 days later.
First, break the top off the ampoule with the sodium chloride solution (a., b.).
First, remove the flip-off cap of the vial.
Official and local antimicrobial policies should be taken into account when the product is used.
Administer the dose into the mouth by placing the tip of the syringe against the inside of the cheek.
Take the prescribed amount of suspension by using the measuring spoon.
Taking Mycophenolate mofetil Teva with food and drink Taking food and drink has no influence on your treatment with Mycophenolate mofetil Teva.
Taking Mycophenolate mofetil Teva with food and drink Taking food and drink has no influence on your treatment with Mycophenolate mofetil Teva.
- you need additional insulin ("bolus doses") at smaller doses or less often than usual.
Take a suitable in-line filter and connect it to the application set.
Following treatment cycles: • On days 1-4: take 40 mg dexamethasone once per day • On days 5-28: do NOT take dexamethasone After completing each cycle, start a new one.
Eat lower-fat meals to help manage these effects.
Take paracetamol or ibuprofen half an hour before your Avonex injection and continue taking it for up to a day.
Take paracetamol or ibuprofen half an hour before your Avonex injection and continue taking it for up to a day.
Take the dose immediately after removal from the blister.
Take the injection needle with the grey mark and remove its wrapping.
Take the solution immediately after mixing.
Take your next capsule at the usual time the next day.
Preotact is used for the treatment of osteoporosis (a disease that makes bones fragile) in postmenopausal women who are at high risk of fractures.
Preotact is used to treat osteoporosis in women past menopause with high risk of fractures.
Food and drink have no influence on the effect of Preotact.
Preotact is a white powder and solvent in a cartridge, which are made up into a solution for injection using a special injection pen.
Prepandrix has been developed to provide protection against this strain, so that it can be used before or during a flu pandemic.
Prepandrix is a vaccine that is given by injection.
Prepandrix is a vaccine for use in adults from 18 to 60 years old.
Prepandrix should under no circumstances be administered intravascularly or intradermally.
Preparing the Enbrel dose for injection using the “ dose preparation guide” (underside of the dose tray)
9 Preparation of the Aldurazyme Infusion (Use Aseptic Technique) Determine the number of vials to be diluted based on the individual patient's weight.
Preparation of the 50 mg/ m2 infusion for paediatric patients > 3 months of age (using a 50-mg vial) 1.
Preparation of the 50 mg/ m2 infusion for paediatric patients > 3 months of age (using a 70-mg vial) 1.
Preparation of the 70 mg/ m2 infusion for paediatric patients > 3 months of age (using a 50-mg vial) 1.
Preparation of the 70 mg/ m2 infusion for paediatric patients > 3 months of age (using a 70-mg vial) 1.
Preparation of the Naglazyme Infusion (Use Aseptic Technique)
Preparing the MIRCERA pre-filled syringe and the needle for injection
13 PREPARATION OF THE SOLUTION FOR INFUSION IN ADULTS
27 PREPARATION OF THE SOLUTION FOR INFUSION IN ADULTS
PREPARATION OF THE SOLUTION FOR INFUSION IN ADULTS
199 Preparing Liprolog Basal • Cartridges containing Liprolog Basal should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
271 Preparing Liprolog Basal KwikPen • The KwikPen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
227 Preparing Liprolog Basal Pen • The Pen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
Preparing Liprolog Mix25 • Cartridges containing Liprolog Mix25 should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
250 Preparing Liprolog KwikPen • Liprolog is already dissolved in water, so you do not need to mix it.
Preparing Liprolog Mix25 KwikPen • The KwikPen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
Preparing Liprolog Mix25 Pen • The Pen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
Preparing Liprolog Mix50 • Cartridges containing Liprolog Mix50 should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
Preparing Liprolog Mix50 KwikPen • The KwikPen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
Preparing Liprolog Mix50 Pen • The Pen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
206 Preparing Liprolog Pen • Liprolog is already dissolved in water, so you do not need to mix it.
Preparation of Myocet ASEPTIC TECHNIQUE MUST BE STRICTLY OBSERVED THROUGHOUT HANDLING OF MYOCET SINCE NO PRESERVATIVE IS PRESENT.
• Sample preparation for Infrared Spectroscopy (NDIR)
• Sample preparation for Infrared Spectroscopy (NDIR)
To determine the 13C/12C-ratio of carbon dioxide in breath by mass spectrometric analysis the carbon dioxide must be separated from the breath and introduced into the mass spectrometer.
233 Preparing Humalog BASAL • Cartridges containing Humalog BASAL should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
307 Preparing Humalog BASAL KwikPen • The KwikPen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
263 Preparing Humalog BASAL Pen • The Pen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
Preparing Humalog Mix25 • Cartridges containing Humalog Mix25 should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
284 Preparing Humalog KwikPen • Humalog is already dissolved in water, so you do not need to mix it.
203 Preparing Humalog Mix25 • Vials containing Humalog Mix25 should be rotated in the palms of the hands before use to resuspend insulin until it appears uniformly cloudy or milky.
Preparing Humalog Mix25 KwikPen • The KwikPen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
Preparing Humalog Mix25 Pen • The Pen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
Preparing Humalog Mix50 • Cartridges containing Humalog Mix50 should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
218 Preparing Humalog Mix50 • Vials containing Humalog Mix50 should be rotated in the palms of the hands before use to resuspend insulin until it appears uniformly cloudy or milky.
Preparing Humalog Mix50 KwikPen • The KwikPen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
Preparing Humalog Mix50 Pen • The Pen should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.
 105 Preparation of IntronA for intravenous infusion:
 126 Preparation of IntronA for intravenous infusion:
Preparation of IntronA for intravenous infusion:
Preparing the GONAL-f pre-filled pen to first use:
Preparing the GONAL-f pre-filled pen to first use:
Preparation and administration of Keppra concentrate
Preparing the syringe for use Warning:
Preparation Collect necessary items before you begin:
1 injection syringe, 2 injection needles and 1 cleansing swab
injections, 1 injection syringe, 2 injection needles and 1 cleansing swab
Prepare new 100 ml bags in the same way as described to allow the infusion to be continued.
Prepare the solution as described in section 6.6.
Prepare the ready-to-use solution by mixing the powder with 202 ml of water or by slowly adding water up to the fill mark on the bottle.
Prepare the injection site as directed by your healthcare professional.
Follow the New Pen Setup only once.
Follow the New Pen Setup only once.
Preparing to lose weight o Choose your start date o Decide on your weight loss goal o Set your calorie and fat targets
Almost 4,000 patients had diabetes without CHD.
Nearly a quarter of the patients were over 80 years of age.
Around a quarter of the patients in this study also had a reduction in tumour size.
{Name and address }< {tel }> < {fax }> < {e-mail }>
Specific treatment is not available for {PRODUCT NAME} overdosage.
- with hypersensitivity to the active substance or to any of the excipients
- acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative
classic subfoveal choroidal neovascularisation (CNV) or
Presentation (a) Form (b) Dosage (c) No of presentations
Presentation a) Form b) Dosage c) No. of presentations
Present ation a) Form b) Dose c) Number of Presentations
Present ation a) Form b) Dose c) Number of Presentations
Overview of the Technical Coordination Unit Head Head Head Head
Meet key targets identified in the Committee for Veterinary
Date of first authorization/ renewal of the authorization
19 658 000 31.74% 428 000 0.69% 180 000 0.29% 220 000 0.36%
MARKETING AUTHORISATION NUMBER
[Item to be completed by the Marketing Authorisation Holder once the Marketing Authorisation has been granted.]
red blood cells that carries oxygen around the body.
predominantly depressive episodes (see section 5.1).
have a known hypersensitivity to the active substance or to collagen;
(hallucinations), mania (mental condition characterised by episodes of overactivity, elation or irritability), paranoia, suicidal thoughts
(hallucinations), mania (mental condition characterised by episodes of overactivity, elation or irritability), paranoia, suicidal thoughts
conditions are met: • She has severe acne (such as nodular or conglobate acne or acne at risk of permanent scarring) resistant to adequate courses of standard therapy with systemic antibacterials and topical therapy. • She understands the teratogenic risk. • She understands the need for rigorous follow-up, on a monthly basis. • She understands and accepts the need for effective contraception, without interruption, 1 month before starting treatment, throughout the duration of treatment and 1 month after the end of treatment.
conditions are met: • She has severe acne (such as nodular or conglobate acne or acne at risk of permanent scarring) resistant to adequate courses of standard therapy with systemic antibacterials and topical therapy. • She understands the teratogenic risk. • She understands the need for rigorous follow-up, on a monthly basis. • She understands and accepts the need for effective contraception, without interruption, 1 month before starting treatment, throughout the duration of treatment and 1 month after the end of treatment.
- has severe liver function impairment
- has chronic liver diseases known to represent preneoplastic conditions (e. g. advanced liver
Almost all patients who receive Aldurazyme develop antibodies (proteins that are produced in response to Aldurazyme).
during treatment with etoricoxib.
In the event of elevated ALT and/ or AST during treatment, follow-up should be organised and dose reduction should be considered.
These include sepsis (blood infection), meningitis (infection of the membranes that surround the brain and spine), pneumonia (infection of the lungs), otitis media (infection of the middle ear) and bacteraemia (bacteria detected in the blood).
In addition, tell your doctor if your child experienced any symptoms that suggest an allergic reaction after any dose in the vaccination series.
If you have any of the following symptoms and they bother you, or last for some time, tell your doctor or a pharmacist.
Seek medical help immediately if you develop symptoms of a severe allergic reaction (such as difficulty in breathing, wheezing or hives) while taking this treatment.
Tell the doctor requesting these tests that you have recently received Pandemrix.
Tell the doctor requesting these tests that you have recently received Prepandrix.
If you have kidney and/ or liver disease, please inform your doctor, because he may have to adjust your treatment accordingly.
Tell your doctor, even when any of the above-mentioned circumstances had happened to you in the past.
Tell your doctor or go to the local casualty and stop using Raptiva immediately if you: • Notice serious hypersensitivity or allergic reactions, such as anaphylaxis.
Tell you doctor if your child has any known allergies. lP
Tell you doctor if your child has any known allergies. rod
Tell your doctor if you are breast-feeding or intend to breast-feed.
Tell your doctor if you notice any changes in your body shape due to changes in fat distribution.
Tell your doctor if you take or wish to take:
Tell your doctor if you notice any of the following side effects:
Notify your pharmacy and request a replacement vial.
• Prevention of diarrhoea due to diagnosed Cryptosporidium parvum, in farms with history of cryptosporidiosis.
Prevention of nephrotoxicity Therapy must be accompanied by administration of oral probenecid and adequate intravenous saline prehydration (see 6.6 for information on obtaining probenecid) with each cidofovir dose.
Prevention of HZ cases with severe pain in the entire study population ZOSTAVAX reduced the incidence of zoster with severe and long-lasting pain (severity-by-duration score > 600) by 73% (95% CI:
Prevention of Skeletal Events in Patients with Breast Cancer and Bone Metastases
- Prevention of depressive episodes in patients with bipolar I disorder who experience
- Prevention of depressive episodes in patients with bipolar I disorder who experience
Prevention of Venous Thromboembolic Events (VTE) in medical patients who are at high risk for thromboembolic complications due to restricted mobility during acute illness In a randomised double-blind clinical trial, 839 patients were treated with fondaparinux 2.5 mg once daily or placebo for 6 to 14 days.
Prevention of Venous Thromboembolic Events (VTE) in medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/ or acute du
Prevention of Venous Thromboembolic Events (VTE) in medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/ or acute respiratory disorders, and/ or acute infectious or inflammatory disease.
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery (see section 5.1).
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing major orthopaedic lo surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery. no
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery.
Prevention of Venous Thromboembolism (VTE) in patients following elective hip replacement surgery:
Prevention of Venous Thromboembolism (VTE) in patients following elective knee replacement surgery:
Prevention of Venous Thromboembolism (VTE) in patients following elective knee replacement surgery:
Prevention of Venous Thromboembolism (VTE) in patients following elective hip replacement surgery:
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing abdominal surgery ici
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery In a double-blind clinical study, 2,927 patients were randomized to receive fondaparinux 2.5mg once daily or dalteparin 5,000 IU once daily, with one 2,500 IU preoperative injection and a first 2,500 IU post-operative injection, for 7+2 days.
who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery In a double-blind clinical study, 2927 patients were randomized to receive fondaparinux 2.5mg once na
- Prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell
Prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery.
Prevention of invasive infections due to Vancomycin resistant
Prevention of patent ductus arteriosus in premature neonates
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing hip fracture lo surgery treated for up to 24 days following an initial prophylaxis of 1 week In a randomised double-blind clinical trial, 737 patients were treated with fondaparinux 2.5 mg once daily for 7 +/ - 1 days following hip fracture surgery.
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing hip fracture surgery treated for up to 24 days following an initial prophylaxis of 1 week In a randomised double-blind clinical trial, 737 patients were treated with fondaparinux 2.5 mg once daily for 7 +/ - 1 days following hip fracture surgery.
e The fondaparinux clinical program was designed to demonstrate the efficacy of fondaparinux for the prevention of venous thromboembolic events (VTE), i. e. proximal and distal deep vein thrombosis
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing major orthopaedic surgery of the lower limbs treated up to 9 days The fondaparinux clinical program was designed to demonstrate the efficacy of fondaparinux for the prevention of venous thromboembolic events (VTE), i. e. proximal and distal deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery.
• Prevention: Prevention of surgical site infections following surgery of the colon or rectum.
Previcox has been studied in laboratory animals, as well as in dogs and horses that were treated in various veterinary practices/ clinics across Europe (“ clinical studies”).
atrophic endometrium was lower (19%) than expected for a continuous combination.
Co-administration with PREZISTA/ritonavir may cause a large increase in the concentration of this benzodiazepine.
Prezista should be used with caution by patients with mild or moderate problems with their liver.
One further injection must be given, at least 2 weeks before farrowing. • Sows:
Nervous System Disorders Headache (15.3%) Somnolence (10.9%) Dizziness (10.3%)
evaluate the efficacy of simvastatin in patients with combined hyperlipidaemia (elevated cholesterol and triglycerides).
Major non-vertebral fragility fracturesc (hip, radius, humerus, ribs and pelvis)
- Other ingredients of Optisulin are: zinc chloride, m-cresol, glycerol, sodium hydroxide, hydrochloric
Active substance Difloxacin (as the hydrochloride)
Porcine circovirus type 2 ORF2 subunit antigen: at least 4.5 log2 ELISA units*
Active components Inactivated Feline Panleukopenia Virus (CU4 strain)
ad hoc Meeting of GCP inspection services
One of the major tasks undertaken in 2001 was to complete the reorganisation of the Unit for the Evaluation of Medicinal Products for Human Use in two units, dealing with pre-and
Prior to Remicade treatment: • You should not be treated with Remicade if
Looking at the results of the first four studies taken together, 320 (26%) of the 1,213 patients receiving 1.0 mg/ kg Raptiva per week responded to treatment, compared with 25 (4%) of the 715 receiving placebo.
33 Causes of a hyperglycaemia • Having forgotten to take your insulin • Repeatedly taking less insulin than you need • An infection or a fever
37 Causes of a hyperglycaemia • Having forgotten to take your insulin • Repeatedly taking less insulin than you need • An infection or a fever
Taking Actos 45mg tablets with food and drink:
Taking other medicines with Emselex Some medicines may interact with Emselex.
Taking other medicines Some medicines may affect the action of Zeffix.
Taking other medicines Comtan may increase the effects of other medicinal products (e. g. those containing rimiterol, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine, alpha-methyldopa, and apomorphine).
Taking other medicines → Please tell your anaesthetist if you are taking or have recently taken other medicines, including medicines obtained without a prescription or herbal products.
Taking other medicines Please tell your doctor if you are taking any medicine for pain or inflammation (swelling), such as medicines called “ nonsteroidal anti-inflammatory drugs” (NSAIDs), including medicines purchased without a doctor's prescription (such as ibuprofen).
Taking other medicines INTELENCE might interact with other medicines.
Taking other medicines ISENTRESS might interact with other medicines.
48 Using other medicines If Ciprofloxacin Kabi and one of the following medicines are given at the same time, special care should be taken: • theophylline (used to treat asthma), clozapine (used to treat schizophrenia), tacrine (used to treat symptoms of Alzheimer´s disease), ropinirol (used to treat Parkinson disease) and tizanidine (used to treat muscle spasms).
Taking other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription and herbal remedies.
Including medicines obtained without a prescription (e. g. paracetamol) and including herbal medicines (e. g.
Taking other medicines Please tell your doctor, pharmacist or nurse if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
103 Using other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
In some cases, medicines can affect the way other medicines work.
- medicines containing the active substance amantadine (used to treat Parkinson's disease)
Taking other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, 116 including medicines obtained without a prescription.
Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Taking other medicines You should consult your doctor if you are taking:
49 Taking Glustin 15mg tablets with food and drink:
Taking Glustin 30 mg tablets with food and drink:
Taking Glustin 45 mg tablets with food and drink:
Investigations Common: weight increased, blood creatinine phosphokinase increased
weight increased, blood creatinine phosphokinase increased
Weight increase Creatine phosphokinase increased
Weight increase Creatinine
Weight increase Creatinine phosphokinase increase
Weight increased Weight decreased Blood creatinine increased, blood creatine phosphokinase increased, blood lactate dehydrogenase increased, blood alkaline phosphatase increased
Taking Siklos with food and drink
tablet just after food will lower the risk of an upset stomach.
Taking or using other medicines and cosmetics Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Privigen 100 mg/ml (10%) solution for infusion Human normal immunoglobulin (IVIg)
Privigen contains 100 mg/ml (10%) human protein of which at least 98% is IgG. ● The other ingredients are the amino acid L-proline and water for injections.
Privigen is isotonic, with an osmolality of 320 mOsmol/ kg.
► Privigen is usually administered by your doctor or health care professional. ► Privigen is intended solely for the infusion into a vein (intravenous infusion). ► Your doctor decides how much Privigen you will receive.
Privigen can also reduce the symptoms in certain inflammatory disorders.
Kjell STRANDBERG Director-General Medicinal Products Agency Husargatan 8, Box 26 S-75103 Uppsala Tel: +46.18.17.46.00 Fax: +46.18.54.8566
Increased likelihood of haematological reactions (see section 4.4).
Probenecid Probenecid inhibits the renal excretion of ciprofloxacin resulting in an increase in the plasma concentration of ciprofloxacin.
Probenecid Probenecid inhibits the renal excretion of ciprofloxacin resulting in an increase in the plasma concentration of ciprofloxacin.
- Problems with your oral cavity, inflammation of the tongue, gums, mouth ulcers
oral cavity, inflammation of the tongue or gums, mouth ulcers, toothache or tooth abscess
‘Working Party'which meets in Brussels.
Inspect visually prior to use.
Inject the liquid as soon as you have mixed it.
Complete the other stages of injection without delay.
Complete the other stages of injection without delay For every following injection move the delivery system with the cartridge inside up and down between a and b (see picture B) at least 10 times until the liquid appears uniformly white and cloudy.
Committee for Orphan Medicinal Products
Summary of Product Characteristics
- Procedures for correctly switching gas cylinders and purging system
PROCOMVAX will not prevent hepatitis caused by other viruses known to infect the liver.
Procoralan is used in patients with a normal sinus rhythm (heartbeat), who cannot take, or cannot tolerate, beta- blockers (another type of medicine to treat angina).
− production and quality control of veterinary medicinal products derived 34 by recombinant DNA technology; − duration of protection and vaccination schemes; and
Contrast medium for diagnostic Magnetic Resonance Imaging (MRI) for the detection of lesions of the liver suspected to be due to metastatic disease or hepatocellular carcinomas.
Contrast medium for magnetic resonance imaging
recombinant DNA technology in E. coli.
Characteristics sections 4.1, 4.2, 4.3, 4.4, 5.1 and 5.2 and Package Leaflet relevant sections as set out in Annex III for Actira and associated names (see Annex I).
Characteristics sections 4.1, 4.2, 4.3, 4.4, 5.1 and 5.2 and Package Leaflet relevant sections as set out in Annex III for Avalox and associated names (see Annex I).
Generally, dose titration is recommended at the start of treatment.
* produced by genetic engineering from strain of Escherichia coli.
Iodine Contrast Media In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of the iodine product.
Iodinated contrast agents Intravascular administration of iodinated contrast agents may lead to renal failure, resulting in metformin accumulation and a risk of lactic acidosis.
Profender contains 21.4 mg/ ml emodepside and 85.8 mg/ ml praziquantel.
Profender should not be allowed to enter surface water as emodepside has shown harmful effects on aquatic organisms.
Profender can be used during pregnancy and lactation.
Professor of Pharmacology and Toxicology, Free University of Berlin.
Activity Profile for NovoMix 70 in Healthy Caucasian Subjects.
Pharmacovigilance Plan or risk minimisation activities
One dose (2 ml) of reconstituted emulsion containing ≥ 105.2 CCID50 of live attenuated Aujeszky's Disease Virus strain NIA3-783 for each pig.
Final Dosing Regimen Overall Response Rate (%)
Gradually, the bones become thin and fragile, and more likely to break (fracture).
Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon
1.5 mg 1.5 mg 1.5 mg 3 mg 3 mg 3 mg 4.5 mg 4.5 mg 4.5 mg 6 mg 6 mg 6 mg
2 mg/ ml 1.5 mg 3 mg 4.5 mg 6 mg
to promote health care through the effective regulation of new pharmaceuticals and better information for users and health professionals (see Article 51(i))
201 Predictability of sustained virological response – Naïve patients Virological reponse by week 12, defined as a 2-log viral load decrease or undetectable levels of HCV- RNA has been shown to be predictive for sustained response (Table 8).
reported with moxifloxacin (see section 4.8).
micrograms HA** per 0.5 ml dose
- Propensity towards drug abuse, known alcoholism.
Propensity towards drug abuse, known alcoholism.
• Prophylaxis of infections in neutropenic patients
• Prophylaxis of infections in neutropenic patients
Prophylaxis of glucocorticoid-induced osteoporosis.
• Prophylaxis of invasive infections due to Neisseria meningitidis
Prophylaxis of invasive infections due to Neisseria meningitidis
3 Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A, the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A, the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
Proportion (%) of patients with proven/ probable Aspergillosis On-treatment periodb 1899d 316e
Proportion (%) of patients with proven/ probable IFIs On-treatment periodb 1899d 316e
Proportion (%) of patients with proven/ probable IFIs On-treatment periodb 1899d 316e
Proportion of patients with increased ALT activity in Clinical Studies
‘ Proportion'of patients being event free at week 76
Proportion of daily On time (%) Baseline
Proposal for a core-data for Menthae piperitae folium (Peppermint leaf) (*)
Proposal for a core-data for Menthae piperitae aetheroleum (Peppermint oil) (*)
Proposal for a core-data for Melissae folium (Melissa leaf) (*)
Proposal for a core-data for Plantaginis ovatae semen (Ispaghula seed) (*)
Comments and proposals for revision Proposals for revision of Note for guidance'Quality of herbal remedies'
To propose and justify with data a suitable shelf life for the product, including an in-use shelf life where relevant.
Commitment proposals Other financial transactions Creation and revision of procedures
Quality Working Party and the ad hoc Good Manufacturing Practice Inspectors'meetings
Commitment proposals Payment orders Other financial transactions Personnel related
However, based on the minimal extent of pimecrolimus absorption after topical application of < Invented Name >, (see Section 5.2 “Pharmacokinetic properties”), the potential risk for humans is considered limited.
Notice to Applicants – Guideline on the Summary of Product Characteristics (EC December 1999 – Revised Version)
Protaphane 100 IU/ ml suspension for injection in a vial.
Protaphane is administered subcutaneously in the thigh.
Protaphane is administered subcutaneously in the thigh.
Protaphane is an isophane insulin suspension (NPH).
Protaphane was effective for both type 1 and type 2 diabetes, and when using a standard injection or one of the pens.
105 Protaphane should not be disposed of via wastewater or household waste.
114 Protaphane should not be disposed of via wastewater or household waste.
Protaphane Protaphane should not be disposed of via wastewater or household waste.
Protaphane should not be disposed of via wastewater or household waste.
Inner Pen cap needle cap
- Renal protection in patients with Type-2 diabetes and proteinuria
Protect your OptiSet from dust and dirt.
Elan Pharma International
Human clottable protein containing mainly fibrinogen and fibronectin * Component 2
L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant DNA technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived from the insect Trichoplusia ni.
L1 protein in the form of non -infectious virus-like particles (VLPs) produced by recombinant DNA technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived from the insect Trichoplusia ni.
L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant DNA technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived from the insect Trichoplusia ni.
Porcine circovirus type 2 ORF2 protein Carbomer
Porcine circovirus type 2 ORF2 protein: minimum RP* 1.0, maximum RP* 3.75 * Relative Potency (ELISA test) by comparison with a reference vaccine.
Porcine circovirus type 2 ORF2 protein: minimum RP* 1.0 maximum RP* 3.75 * Relative Potency (ELISA test) by comparison with a reference vaccine
* Human Osteogenic protein produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology
Aspartate aminotransferase increased Alanine aminotransferase increased
PROTELOS is used to treat osteoporosis (a disease that makes bones fragile) in postmenopausal women to reduce the risk of vertebral (spine) and hip fractures.
Protopic may be used on most parts of the body, including the face and neck and in the creases of your elbows and knees.
Protopic ointment should not be applied to lesions that are considered to be potentially malignant or pre-malignant.
Protopic ointment may be used on any part of the body, including face, neck and flexure areas, except on mucous membranes.
Protopic alters the abnormal immune response and relieves the skin inflammation and the itch.
Protopy 0.03% Ointment Tacrolimus monohydrate Cutaneous use
not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids.
Protopy 0.1% Ointment Tacrolimus monohydrate Cutaneous use
Protopy should be initiated by physicians with experience in the diagnosis and treatment of atopic ct
A statement that Protopy should not be used in children under 2 years.
Protopy is not recommended for use in children below age of 2 years until further data are available. ed
Protopy may be used on most parts of the body, including the face and neck and in the creases of your a
Protopy may be used on most parts of the body, including the face and neck and in the creases of your elbows and knees. ed
Protopy ointment is administered topically and is unlikely to have an effect on the ability to drive or use machines.
Protopy ointment should not be applied to lesions that
Protopy ointment should not be applied to lesions that lo are considered to be potentially malignant or pre-malignant. no
- Protopy ointment is not approved for children younger than 2 years of age.
Protopy ointment may be used on any part of the body, including face, neck and flexure areas, except on mucous membranes. ro
Prozac is authorised in most EU Member States for the treatment of major depressive episodes, obsessive-compulsive disorder and bulimia nervosa in adults.
PRP) of Haemophilus influenzae type b conjugated to tetanus toxoid.
PRT Quinta da Fonte - Edifício Vasco da Gama, 19 - Porto Salvo Paço d 'Arcos Portugal
PRT Quinta da Fonte – Edifício Vasco da Gama, 19 - Porto Salvo Paço d 'Arcos
PRT Quinta da Fonte - Edifício Vasco da Gama, 19 - Porto Salvo Paço d 'Arcos Portugal
Pruban contains the active principle resocortol butyrate.
Pruban is applied to the skin for the treatment of small areas of sudden onset moist irritated skin (acute moist dermatitis in dogs.
Pruban should not be used in puppies under 6 months of age.
Pruban reduces the inflammation of the skin locally.
patients who are taking other medicinal products which may cause orthostatic hypotension.
intra-ocular pressure is well controlled and the patient is monitored carefully for changes in intra- ocular pressure.
the intra-ocular pressure is well controlled and the patient is monitored carefully for changes in intra-ocular pressure.
Rash (including rash, pruritic rash, maculopapular rash, pustular rash)
urinary tract infection pruritus, sweating, nail disorder, dry skin, alopecia, acne, maculopapular rash
Inflammatory polyradiculo- neuropathy* Interstitial pneumonitis*
Psoriasis, photosensitivity reaction, maculopapular rash, dermatitis, face or peripheral oedema, erythematous rash, eczema, acne, furunculosis, erythema, urticaria, abnormal hair texture, nail disorder
- potassium supplements, potassium-containing salt substitutes or potassium-sparing medicines.
- Psychosis (e. g. comparable with symptoms of schizophrenia).
The European Agency for the Evaluation of Medicinal Products 7 Westferry Circus, Canary Wharf, London E14 4HB, United Kingdom Tel:
• Rise in number of applications from designated orphan drugs – about 40% of total applications in 2003 – will impact on working practices.
Adhere to regulatory timelines for active review time by the CPMP Publication of summaries of opinion at the time of adoption by the CPMP Rapid publication of EPARs after the European Commission decision granting marketing authorisation
Published by the European Commission in December 2001 in volume 9 of the 2001 edition of the Rules governing medicinal products in the European Union
Publish EPARs within five days of notification of the European Commission decision granting marketing authorisation
Suomi/ Finland GlaxoSmithKline Oy Puh/ Tel: + 358 (0)10 30 30 30 Finland. tuoteinfo@gsk. com
Tel: +39 (06) 669081
Tel: +39 06 361911 doccen@merck. com
Tel: +39 06 50 39 61
GlaxoSmithKline Oy Puh/ Tel: + 358 10 30 30 30 Finland. tuoteinfo@gsk. com
Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 10 30 30 30 Finland.tuoteinfo@gsk.com
Then add about 60 ml of water to each dosing cup (60 mls is about 4 tablespoons)
Then, the usual dose is one 75-mg tablet of Clopidogrel BMS per day to be taken orally with or without food, and at the same time each day.
Then eat something that has a long -acting effect in raising your blood sugar (such as bread or pasta).
Then eat something that has a long-acting effect in raising your blood sugar (such as bread or pasta).
Then eat something that has a long-acting effect in raising your blood sugar (such as bread or pasta).
Then eat something that has a long-acting effect in raising your blood sugar (such as bread or pasta).
Then eat something that has a long-acting effect in raising your blood sugar (such as bread or pasta).
Then eat something that has a long-acting effect in raising your blood sugar (such as bread or pasta).
Then eat something that has a long-acting effect in raising your blood sugar (such as bread or pasta).
Since many medicinal products and immunoglobulins are secreted into human milk, and because of the potential for serious adverse reactions in nursing infants, lactation should be discontinued during treatment and up to 5 months after treatment.
As the cardiovascular risk of cyclooxygenase-2 (COX-2) specific inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used.
Since animal data suggest that the substance may be passed into breast milk, it is recommended that mothers taking efavirenz do not breast feed their infants.
Since the CAPRIE trial was not powered to evaluate efficacy of individual subgroups, it is not clear whether the differences in relative risk reduction across qualifying conditions are real, or a result of chance.
Since such therapy can lead to additive or even synergistic toxicity (e. g. hepato- or haematotoxicity), combination with another DMARD (e. g. methotrexate) is not advisable.
Since such therapy can lead to additive or even synergistic toxicity (e. g. hepato- or haematotoxicity), combination with another DMARD (e. g. methotrexate) is not advisable.
Since such therapy can lead to additive or even synergistic toxicity (e. g. hepato- or haematotoxicity), combination with another DMARD (e. g. methotrexate) is not advisable.
Since lamivudine and the virus pass into breast milk, it is recommended that mothers taking Epivir do not breast-feed their infants.
output from diffusera (W)
Fibre optic power outputs and treatment times required to deliver 130 J/ cm of diffuser length using the centring balloon
Fibre optic power outputs and treatment times required to deliver 130 J/ cm of diffuser length using the centring balloon Balloon Window
Now the patient breathes gently through the straw until the inner surface of the sample tube steams up.
Puregon 100 IU solvent for parenteral use
Puregon was studied in 172 anovulatory women, measuring how many cycles of treatment would be needed for these women to ovulate.
Puregon should be reconstituted with the solvent provided.
Puregon is a powder and solvent to be made up into a solution for injection.
Purevax RCCh contains small amounts of weakened or killed viruses and bacteria that cause the diseases listed above.
Purevax RCCh is a vaccine containing the following active substances: • attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains), • attenuated Chlamydophila felis (905 strain).
Purevax RC contains small amounts of weakened or killed viruses that cause the diseases listed above.
Purevax RC is a vaccine containing the following active substances: • attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains).
Purevax RCPCh is a vaccine containing the following active substances: • attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains), • attenuated Chlamydophila felis (905 strain), • attenuated feline panleucopenia virus (PLI IV). • Purevax RCPCh is a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection.
Purevax RCPCh FeLV is a vaccine containing the following active substances: • attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains), • attenuated Chlamydophila felis (905 strain), • attenuated feline panleucopenia virus (PLI IV), • feline leukaemia virus (FeLV) recombinant canarypox virus (vCP97).
Purevax RCP contains small amounts of weakened or killed viruses that cause the diseases listed above.
Purevax RCP is a vaccine containing the following active substances: • attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains), • attenuated feline panleucopenia virus (PLI IV).
Purevax RCP is used to vaccinate cats from the age of 8 weeks against the following diseases: • feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus), • feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus), • feline panleucopenia (a serious illness causing bloody diarrhoea caused by a parvovirus).
Purevax RCP FeLV is a vaccine containing the following active substances: • attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains), • attenuated feline panleucopenia virus (PLI IV), • feline leukaemia virus (FeLV) recombinant canarypox virus (vCP97).
- the pressure regulator should be purged by the nitrogen-nitric oxide mixture before each new use
• The pen must be primed before each injection to make sure the pen is ready to dose.
Performing the priming step is important to confirm that insulin comes out when you push the injection button, and to remove air that may collect in the insulin cartridge during normal use.
The Pen must be primed to a stream of insulin (not just a few drops) before each injection to make sure the Pen is ready to dose.
, Idiopathic or thrombotic thrombocytopenic purpura
Idiopathic or thrombotic thrombocytopenic purpura
thrombotic thrombocytopenic purpura, hypoprothrombinaemia
Pylobactell 100 mg soluble tablet 13 C-urea Oral use
Pylobactell is used to diagnose Helicobacter pylori (H. pylori) infection in the stomach and duodenum (the part of the gut just below the stomach).
pyrexia, chest pain, asthenia, peripheral oedema, malaise
pyrexia (fever), asthenia, fatigue oedema, pain, chills, malaise tongue oedema, face oedema
pyrexia, infusion site swelling oedema peripheral
43 What Yondelis looks like and contents of the pack
QI02 AB (Inactivated bacterial vaccines for bovidae).
QUADRAMET has been studied in 373 patients in three main studies.
QUADRAMET is a solution for injection containing the active substance samarium [153Sm] lexidronam pentasodium.
QUADRAMET is only used in bone metastases that can take up a type of chemical called bisphosphonates, as this means that the metastases will also take up QUADRAMET.
QUADRAMET, solution for injection Samarium [153Sm] lexidronam pentasodium For intravenous use
Quadrisol has been developed especially for horses and is not intended for use in humans.
Quality, Non-clinical, Clinical, Pharmacovigilance 2.
 When medicines are made from human blood or plasma, certain measures are put into place to prevent infections being passed on to patients.
When Irbesartan Krka is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended.
When substance P attaches to these receptors, it causes nausea and vomiting.
When substance P attaches to these receptors, it causes nausea and vomiting.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
When exposed to any of these viruses later in life, the cat will either not become infected or have a much less serious infection.
When Pegasys is used alone in hepatitis B or C patients, some of these effects are less likely to occur.
When to take Diacomit Your child should take this medicine two or three times a day at regular intervals as directed by your child's doctor.
• When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached
When a person is given the vaccine, the immune system (the body’s natural defences) will make antibodies against the most commonly occurring types of rotavirus.
When a patient starts to take Effentora, the doctor will need to work out the appropriate individual dose that will provide adequate pain relief for the patient with few side effects.
When you first start your insulin treatment, it may disturb your vision, but the reaction usually disappears.
The CHMP considered the use of “ Control of Asthma” as the primary efficacy variable a reliable parameter of the patient clinical status and, as such, clinically meaningful.
It is noted from the example Table of blending that vaccine batches are blended to contain at least 13.4 log10 EID50 per 1,000 kg.
- Infected wounds and cellulitis. plunger provides sufficient - Salmonellosis. paste to medicate 50 kg - Antibacterial medication in bodyweight.
1 SA. U: quantity sufficient to obtain an agglutinating antibody titre of 1 log10 in the guinea pig.
Forty-one percent had antibodies to pertussis.
Forty patients (HBeAg negative or HBeAg positive) with either decompensated liver disease or recurrent HBV following liver transplantation and YMDD variant were also enrolled into an open label arm of the study.
Forty-four percent of patients experienced symptoms that could be associated with neuropathy; most were mild to moderate and were reversible upon cessation of treatment with TRISENOX.
Of the 46 patients (1.6%) who developed anti-tocilizumab antibodies, 6 had an associated medically significant hypersensitivity reaction, of which 5 led to permanent discontinuation of treatment.
Forty-six percent of patients continued on stable doses of methotrexate (≤ 25 mg/ week).
Quartiere Varignano, 12 - 13 - 14 55049 Viareggio (Lu) Italy
Quartiere Varignano, 12 - 13 - 14 55049 Viareggio (Lu) Italy
A further 14 patients were studied whose cyanide poisoning was due to something other than smoke inhalation; most of these patients had taken cyanide during a suicide attempt.
Fourteen days after administration the mean cefovecin concentration in plasma was 18 µg/ ml.
Fourteen subjects (18%) had headache considered related to study drug.
of 2833 patients, of which four were double-blind placebo-controlled studies and one was an open- label study.
Survival and tumour progression have been examined in five large controlled studies involving a total of 2833 patients, of which four were double-blind placebo-controlled studies and one was an open- label study.
Four of these studies compared Epivir in combination with zidovudine (another antiviral medicine) to either Epivir or zidovudine alone, or to the combination of Epivir and zalcitabine (another antiviral medicine).
The data from the four studies lon (O14392, O14393, O14874 and O15301) showed that the incidence and types of adverse events were similar in both placebo-treated and Zenapax-treated patients.
At 4 hours post first dose, there was a significant difference in the mean percentage change from baseline plasma uric acid concentration (p < 0.0001) in the Fasturtec group (-86.0%) compared to that for the allopurinol group (-12.1%).
Four weeks after completing the TMZ + RT concomitant phase, TMZ is administered for up to 6 cycles of monotherapy treatment.
90% of patients on Tarceva developed rash within the first 44 days.
Ninety-four percent (94%) of the urinary excretion occurred in the first 72 hours.
- free of any powder, oil, moisturiser, or lotion that could
The active substance is pemetrexed.
What Cardoreg 4 mg prolonged release tablets and associated names contains:
What Clopidogrel BMS contains The active substance is clopidogrel.
6 FURTHER INFORMATION What Doxagamma 4 mg prolonged release tablets and associated names contains
What EMEND contains The active substance is aprepitant.
What Erbitux contains • The active substance is cetuximab.
What Extavia conta ins − The active substance is interferon beta-1b.
One ml of Insuman Basal contains 100 IU (International
What Karvea contains The active substance is irbesartan.
What Liprolog KwikPen 100 U/ml solution for injection contains 253
The active substance of < Invented Name > Cream is pimecrolimus.
What {PRODUCT NAME} 10 mg contains The active substance of {PRODUCT NAME} is atorvastatin.
What Orfadin contains The active substance is nitisinone.
What Pelzont contains • The active substances are nicotinic acid and laropiprant.
What QUADRAMET contains The active substance is samarium [153Sm] lexidronam pentasodium.
What Remicade contains • The active substance is infliximab.
What SPRYCEL contains The active substance is dasatinib.
What STELARA contains • The active substance is ustekinumab.
What Tredaptive contains • The active substances are nicotinic acid and laropiprant.
What Trevaclyn contains • The active substances are nicotinic acid and laropiprant.
What should you do if your child misses an injection of Synagis?
What should you do if you feel that your child has become ill while being treated with Synagis?
What should I do before I give myself a subcutaneous injection of Aranesp?
What should I do before I give myself a subcutaneous injection of Biograstim?
What should I do before I give myself a subcutaneous injection of Filgrastim ratiopharm?
What should you do before you give yourself a subcutaneous injection of Kineret?
What should I do before I give myself a subcutaneous injection of LITAK?
What should I do before I give myself a subcutaneous injection of Nespo?
Preparing for a Neulasta injection?
What should I do before I give myself a subcutaneous injection of Neulasta?
or th What should I do before I give myself a subcutaneous injection of Neupopeg?
What should I do before I give myself a subcutaneous injection of Ratiograstim?
What should I do before I give myself a subcutaneous injection of Tevagrastim?
What should I do before I give myself a subcutaneous injection of Zarzio?
What should I do if BYETTA does not come out of the needle tip after four tries during New Pen Setup? • Remove the needle by carefully putting the outer needle shield back over the needle.
What should I do if side effects occur in my dog during Masivet treatment?
What should I do if I drop my NutropinAq Pen?
• What should I do if my full dose cannot be dialed?
• What should I do if I cannot completely push in the Dose Knob when priming the Pen?
What if I cannot pull, turn, or push the dose knob?
• What should I do if I dial a wrong dose (too high or too low)?
• What should I do if I see insulin leaking from the Pen needle while dialing the dose or correcting the dose?
• What should I do if I see an air bubble in the cartridge?
What should I do if there is not enough solution left in the cartridge for my next dose?
• What should I do if my dose is dialed and the Dose Knob is accidentally pushed in without a needle attached?
- the safety database to support repeat intermittent use of Botox and the suitability of the safety
is below 50 percent of normal.
is below 50 percent of normal.
I also hope that the project will involve other key interests, including health care professionals and management, patient and consumer bodies and the industry bodies concerned.
It considered the risk-benefit balance of terfenadine 6 mg/ ml oral suspension formulations acceptable and that the Marketing Authorisations should be maintained provided that the SPC is amended as stated in Annex I.
It considered the risk-benefit balance of terfenadine 30 mg tablet acceptable and that the Marketing Authorisation should be maintained provided that the SPC is amended as stated in Annex I.
They decided on that Forcaltonin's benefits are greater than its risks for prevention of bone loss due to sudden immobilisation, such as in patients with recent bone fractures caused by osteoporosis (a disease that makes bones fragile), for treatment of Paget's disease, and treatment of hypercalcaemia of ol malignancy.
That the safety database of Tracleer in the indication to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease is limited and physicians are encouraged to enrol patients in the surveillance programme/registry to further increase knowledge about the product.
Each ml contains 100 mg of levetiracetam.
What benefit has Aldurazyme shown during the studies?
What benefit has Azopt shown during the studies?
What benefit has CEPROTIN shown during the studies?
What benefit has Clopidogrel BMS shown during the studies?
What benefit has Equilis Prequenza shown during the studies?
What benefit has Equilis Prequenza Te shown during the studies?
What benefit has Fablyn shown during the studies?
What benefit has Fasturtec shown during the studies?
What benefit has Naglazyme shown during the studies?
What benefit has Nobivac Bb shown during the studies?
What benefit has Raptiva shown during the studies?
What benefit has Sebivo shown during the studies?
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
What benefit has Tritanrix HepB shown during the studies?
What benefit has Yondelis shown during the studies?
What is the risk associated with Nobivac Bb?
What is the time to allow before milk can be taken from the animal for human consumption?
What is the time allowed before the animal can be slaughtered and the meat used for human consumption (withdrawal period)?
What is the time to allow before a horse can be slaughtered and the meat used for human consumption (withdrawal period)?
What is the time to allow before the animal can be slaughtered and the meat used for human consumption (withdrawal period)?
What is the time to allow before treated pigs can be slaughtered and the meat used for human consumption (withdrawal period)?
What is the time to allow before milk can be taken from the animal for human consumption?
What is the time to allow before milk can be taken from the animal for human consumption?
How much to take The amount of Eucreas that people have to take varies depending on their condition.
How much to take The amount of Icandra that people have to take varies depending on their condition.
How much to take The amount of Zomarist that people have to take varies depending on their condition.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
How much STELARA is given • Your doctor will decide how much STELARA you need and for how long • This may depend on your weight • The usual starting dose is 45 mg ustekinumab.
Why was Bleomycin reviewed?
Why was Diovan reviewed?
Why was Sabumalin reviewed?
Why was Sanohex reviewed?
Why was Tritace reviewed?
Why was Tritazide reviewed?
Why was Implanon reviewed?
How has Clopidogrel BMS been studied?
How has Clopidogrel Winthrop been studied?
How has Mycophenolate mofetil Teva been studied?
How has Equilis Prequenza been studied?
How has Equilis Prequenza Te been studied?
BEFORE YOU TAKE REMERON
Before your child takes Diacomit 3.
BEFORE YOU USE ABILIFY
What Actos is and what it is used for 2.
BEFORE YOU TAKE ADROVANCE
Before you take Aerius 3.
Before you take AMMONAPS 3.
BEFORE YOU TAKE AMMONAPS
BEFORE YOU ARE GIVEN ATRIANCE
Before you take Baraclude 3.
Before you take Cardoreg 4 mg prolonged release tablets and associated names 3.
2 BEFORE YOU TAKE CELSENTRI
Before you take CHAMPIX 3.
BEFORE YOU TAKE CHAMPIX
Before you take Clopidogrel BMS 3.
Before you take Clopidogrel Winthrop 3.
Before you take Combivir 3.
Before you take Copalia 3.
Before you take DULOXETINE BOEHRINGER INGELHEIM 3.
BEFORE YOU TAKE EFEXOR DEPOT
BEFORE YOU USE EFFENTORA
Before you take EMEND 3.
BEFORE YOU TAKE EMEND
Before you take Emselex 3.
BEFORE YOU TAKE EXELON
Before you take Exforge 3.
BEFORE YOU TAKE EXJADE
Before you take EXUBERA 3.
BEFORE YOU TAKE EXUBERA
Before you use FIRMAGON 3.
BEFORE YOU USE FIRMAGON
BEFORE YOU T AKE HELICOBACTER TEST INFAI FOR CHILDREN OF THE AGE 3-11
Before you take Iscover 3.
BEFORE YOU TAKE ISCOVER
Before you take Karvea 3.
BEFORE YOU TAKE KIVEXA
BEFORE YOU TAKE MICARDIS
BEFORE YOU TAKE MYCOPHENOLATE MOFETIL TEVA
BEFORE YOU TAKE [NEURONTIN AND ASSOCIATED NAMES]
BEFORE YOU TAKE NIFEDIPINE PHARMAMATCH
BEFORE YOU TAKE< INVENTED NAME >
BEFORE YOU USE OMNITROPE
Before you take ORACEA 3.
BEFORE YOU TAKE ORACEA
Before you take Orfadin 3.
Before you take Pradaxa 3.
BEFORE YOU TAKE PRAMIPEXOLE TEVA
BEFORE YOU TAKE RIBAVIRIN TEVA
Before you take Riprazo 3.
BEFORE YOU ARE GIVEN SAVENE
Before you take Sebivo 3.
Before you take Sprimeo 3.
BEFORE YOU TAKE Tadalafil Lilly
Before you take Tarceva 3.
Before you take Tekturna 3.
Before you take Telzir 3.
BEFORE YOU USE TEMODAL
BEFORE YOU USE VECTIBIX
Before you take Zyrtec 3.
BEFORE YOU ARE GIVEN ACLASTA
BEFORE YOU ARE GIVEN ALIMTA
BEFORE YOU ARE GIVEN CIPROFLOXACIN BAYER
BEFORE YOU ARE GIVEN CUBICIN
Before you receive Fendrix 3.
BEFORE YOU ARE GIVEN GADOVIST
BEFORE YOU ARE GIVEN GEMZAR
BEFORE YOU ARE GIVEN Optimark
What Privigen is and what it is used for 2.
BEFORE YOU ARE GIVEN VASOVIST
Before you are given Yondelis 3.
BEFORE YOU ARE TREATED WITH EVICEL
BEFORE YOU USE ABSEAMED
BEFORE YOU USE ACTRAPHANE
BEFORE YOU USE ACTRAPID
BEFORE YOU USE ALDURAZYME
BEFORE YOU USE ALTARGO
BEFORE YOU ARE GIVEN ANGIOX
BEFORE YOU USE ARIXTRA
BEFORE YOU USE AVASTIN
BEFORE YOU USE BINOCRIT
BEFORE YOU USE BONDRONAT
BEFORE YOU USE BONVIVA
BEFORE YOU USE CELLCEPT
Before you use CEPROTIN 3.
BEFORE YOU USE CEREZYME
Before you use Cetrotide 3.
BEFORE YOU USE CETROTIDE
BEFORE YOU USE CIPROFLOXACIN HIKMA
BEFORE YOU USE CYANOKIT
Before you use CYSTAGON 3.
BEFORE YOU USE CYSTAGON
Before you are given DepoCyte 3.
BEFORE YOU ARE GIVEN DEPOCYTE
BEFORE YOU USE DYNASTAT
WHAT YOU SHOULD KNOW BEFORE YOU ARE TREATED WITH ECALTA
Before you use EMADINE 3.
Before you use EMADINE 3.
BEFORE YOU USE EMADINE
BEFORE YOU USE EMADINE
BEFORE YOU USE EPOETIN ALFA HEXAL
BEFORE YOU USE ERBITUX
BEFORE YOU USE EVOLTRA
BEFORE YOU USE EXTAVIA
BEFORE YOU USE FABRAZYME
BEFORE YOU USE FASLODEX
Before you use Fasturtec 3.
BEFORE YOU USE FASTURTEC
BEFORE YOU USE FENTANYL-RATIOPHARM
BEFORE YOU USE FERTAVID
BEFORE YOU USE FLEBOGAMMADIF
BEFORE YOU USE FORCALTONIN
BEFORE YOU USE GARDASIL
BEFORE YOU USE HBVAXPRO 40 micrograms / ml
BEFORE YOU USE HERCEPTIN
BEFORE YOU USE HUMALOG BASAL
BEFORE YOU USE HUMALOG BASAL KWIKPEN
BEFORE YOU USE HUMALOG
BEFORE YOU USE HUMALOG KWIKPEN
BEFORE YOU USE HUMALOG MIX25
BEFORE YOU USE HUMALOG MIX25 KWIKPEN
BEFORE YOU USE HUMALOG MIX50
BEFORE YOU USE HUMALOG MIX50 KWIKPEN
BEFORE YOU USE INSULATARD
BEFORE YOU USE INTANZA
WHAT YOU SHOULD CONSIDER BEFORE YOU USE INTRINSA
BEFORE YOU USE KENTERA
BEFORE YOU USE KEPIVANCE
Before you use Kineret 3.
BEFORE YOU USE KINERET
Before you use Liprolog Mix25 KwikPen 3.
WHAT YOU SHOULD CONSIDER BEFORE YOU USE LIVENSA
BEFORE YOU USE LUCENTIS
BEFORE YOU USE LUVERIS
BEFORE YOU ARE GIVEN MABCAMPATH
BEFORE MACUGEN IS USED
BEFORE YOU USE MIRCERA
BEFORE YOU USE MIXTARD
BEFORE YOU USE MYCAMINE
BEFORE YOU USE MYOZYME
Before you take Naglazyme 3.
BEFORE YOU USE NAGLAZYME
BEFORE YOU USE NEULASTA
BEFORE YOU USE NEULASTA
BEFORE YOU ARE GIVEN NEUROBLOC
Before you use < Invented Name > cream 3.
BEFORE YOU USE < INVENTED NAME > CREAM
BEFORE YOU USE NOVOMIX 30
BEFORE YOU USE NOVOMIX 50
BEFORE YOU USE NOVOMIX 70
Before you use NovoRapid 3.
BEFORE YOU USE NOVORAPID
BEFORE YOU USE NOVOSEVEN
BEFORE YOU USE NutropinAq
BEFORE YOU USE OMNITROPE
BEFORE YOU USE OPATANOL
BEFORE YOU USE OPTAFLU
Before you use OPTISON 3.
Before you use Optisulin 3.
BEFORE YOU USE ORENCIA
BEFORE YOU USE ORGALUTRAN
BEFORE YOU USE OSIGRAFT
BEFORE YOU USE OVITRELLE
BEFORE YOU USE PANRETIN
BEFORE YOU USE PERGOVERIS
BEFORE YOU USE PREOTACT
BEFORE YOU USE PREVENAR
BEFORE YOU USE PROMETAX
BEFORE YOU USE PROTAPHANE
BEFORE YOU USE PROTOPIC
BEFORE YOU USE PROTOPY lp
BEFORE YOU USE PUREGON
BEFORE YOU USE PYLOBACTELL
BEFORE YOU USE QUIXIDAR na
BEFORE YOU USE RAPILYSIN
Before you use Raptiva 3.
BEFORE YOU USE RAPTIVA
BEFORE YOU USE REFLUDAN
BEFORE YOU USE RELISTOR
BEFORE YOU USE REMICADE
BEFORE YOU USE RETACRIT
BEFORE YOU USE SILGARD
BEFORE YOU USE SILGARD
BEFORE YOU USE SONOVUE
Before you use STELARA 3.
BEFORE YOU USE STELARA
BEFORE YOU USE TESLASCAN
BEFORE YOU USE Tevagrastim
BEFORE YOU USE THYROGEN
BEFORE YOU USE TRISENOX
BEFORE YOU USE VIRAFERONPEG
BEFORE YOU USE YTRACIS
Before you use Yttriga 3.
BEFORE YOU USE YTTRIGA
BEFORE YOU USE ZENAPAX
BEFORE YOU ARE GIVEN ZOMETA
Before Synagis is given to your child 3.
BEFORE YOU ARE GIVEN XIGRIS
BEFORE YOU ARE GIVEN SIMULECT
BEFORE YOU ARE GIVEN VISUDYNE
Before your child receives Menitorix 3.
BEFORE YOU ARE GIVEN XOLAIR
As lansoprazole is mainly broken down by certain enzymes in the liver, interactions with other medicines that are broken down by the same enzymes are possible.
Helicobacter pylori, you should carefully read the package leaflets of these antibiotics, too
What are the measures to minimise the risk associated with Exubera? od
What are the measures to minimise the risk associated with Macugen?
Sometimes, symptoms may improve and then get worse later.
Sometimes your doctor will need to reduce the dose or stop Zavesca treatment to stop the tremor.
Use of nucleoside analogs, alone or in combination with other nucleosides, has resulted in lactic acidosis.
In sugammadex treated subjects a few cases of awareness were reported.
A few cases of Ehlers-Danlos like syndrome on elbows have been reported in children treated with high doses of different cysteamine preparations (cysteamine chlorhydrate or cystamine or cysteamine bitartrate) mostly above the maximal dose 1.95 g/ m2/ day.
Few cases of coagulopathic disorders such as increased D-dimer and
Few cases of coagulopathic disorders such as increased D-dimer and consumptive coagulopathy have been reported.
There have been a few reported cases of pemetrexed extravasation, which were not assessed as serious by the investigator.
There have been few reported cases of pemetrexed extravasation, which were not assessed as serious by the investigator.
Examples of such circumstances are: ● you are receiving Privigen at a high infusion rate or ● you are receiving Privigen for the first time or after a long break in treatment (e.g. several months).
The key EudraVigilance project entered implementation phase following successful testing with national competent authorities and a number of marketing authorisation holders.
Few patients included in the phase III trials were co-infected with hepatitis B/ C.
There have been rare reports of prolonged seizures in patients on fluoxetine receiving ECT treatment, therefore caution is advisable.
Rare reports of severe allergic (anaphylactic) reactions after injection of a conventional preparation containing the Botulinum toxin type A complex have been received.
What benefit has Nobivac Piro shown during the studies?
What benefit has Cetrotide shown during the studies?
What benefit has Exubera shown during the studies?
POSSIBLE SIDE EFFECTS
What are the side effects of Nobilis IB 4-91?
What is happening for DepoCyte for the treatment of lymphomatous meningitis?
What is happening with Vimpat used for the treatment of epilepsy?
WHAT COMPETACT IS AND WHAT IT IS USED FOR
What Naglazyme is and what it is used for 2.
WHAT ACLASTA IS AND WHAT IT IS USED FOR
What Activelle is and what it is used for 2.
WHAT ACTIVELLE IS AND WHAT IT IS USED FOR
What Actraphane looks like and contents of the pack The suspension for injection comes as a cloudy, white, aqueous suspension.
WHAT ACTRAPHANE IS AND WHAT IT IS USED FOR
WHAT ACTRAPID IS AND WHAT IT IS USED FOR
What ADENURIC is and what it is used for 2.
WHAT ADENURIC IS AND WHAT IT IS USED FOR
What Advagraf is and what it is used for 2.
WHAT AGOPTON IS AND WHAT IT IS USED FOR
WHAT AGOPTON IS AND WHAT IT IS USED FOR
What Aldurazyme looks like and contents of the pack Aldurazyme is supplied as a concentrate for solution for infusion.
WHAT IS ALENDRONATE HEXAL AND WHAT IT IS USED FOR
What Altargo is and what it is used for 2.
WHAT ALTARGO IS AND WHAT IT IS USED FOR
WHAT AMBIRIX IS AND WHAT IT IS USED FOR
What AMMONAPS is and what it is used for 2.
WHAT AMMONAPS IS AND WHAT IT IS USED FOR
What Apidra is and what it is used for 2.
WHAT APIDRA IS AND WHAT IT IS USED FOR
WHAT APIDRA IS AND WHAT IT IS USED FOR
What Aranesp is and what is it used for 2.
WHAT ARANESP IS AND WHAT IS IT USED FOR
What Arixtra is and what it is used for 2.
What Atriance is and what it is used for 2.
WHAT ATRIANCE IS AND WHAT IT IS USED FOR
What Atripla is and what it is used for 2.
WHAT ATRIPLA IS AND WHAT IT IS USED FOR
What Avaglim is and what it is used for 2.
What Avamys is and what it is used for 2.
WHAT AVAMYS IS AND WHAT IT IS USED FOR
What Avandamet is and what it is used for 2.
WHAT AXURA IS AND WHAT IT IS USED FOR
WHAT AXURA IS AND WHAT IT IS USED FOR
WHAT AZARGA IS AND WHAT IT IS USED FOR
WHAT AZOPT IS AND WHAT IT IS USED FOR
WHAT ABSEAMED IS AND WHAT IT IS USED FOR
WHAT ACTRAPHANE IS AND WHAT IT IS USED FOR
What ADROVANCE is and what it is used for Before you take ADROVANCE How to take ADROVANCE Possible side effects How to store ADROVANCE Further information
What ADROVANCE is and what it is used for Before you take ADROVANCE How to take ADROVANCE Possible side effects How to store ADROVANCE Further information
WHAT ADROVANCE IS AND WHAT IT IS USED FOR
WHAT ADROVANCE IS AND WHAT IT IS USED FOR
WHAT AERINAZE IS AND WHAT IT IS USED FOR
What Aerius orodispersible tablet is and what it is used for 2.
What Aerius is and what it is used for 2.
WHAT IS ALDARA CREAM AND WHAT IT IS USED FOR
27 What AMMONAPS looks like and contents of the pack AMMONAPS tablets are off-white, oval and embossed with “ UCY 500”.
What AMMONAPS looks like and contents of the pack AMMONAPS granules are off-white.
What Angiox is and what it is used for 2.
What Aprovel is and what it is used for 2.
WHAT APROVEL IS AND WHAT IT IS USED FOR
What Avandia is and what it is used for 2.
WHAT AVANDIA IS AND WHAT IT IS USED FOR
WHAT AVASTIN IS AND WHAT IT IS USED FOR
WHAT BARACLUDE IS AND WHAT IT IS USED FOR
What BeneFIX looks like and contents of the pack
WHAT BENEFIX IS AND WHAT IT IS USED FOR
WHAT IS BENEFIX AND WHAT IS IT USED FOR
WHAT IS BENEFIX AND WHAT IT IS USED FOR
WHAT BICALUTAMIDE IS AND WHAT IT IS USED FOR
195 What Binocrit looks like and contents of the pack
What Binocrit is and what it is used for 2.
WHAT BINOCRIT IS AND WHAT IT IS USED FOR
WHAT EBIXA IS AND WHAT IT IS USED FOR
What Bondenza is and what it is used for 2.
WHAT BONDRONAT IS AND WHAT IT IS USED FOR
WHAT BONVIVA IS AND WHAT IT IS USED FOR
WHAT BRIDION IS AND WHAT IT IS USED FOR
What BYETTA is and what it is used for 2.
WHAT BYETTA IS AND WHAT IT IS USED FOR
WHAT CAELYX IS AND WHAT IT IS USED FOR
What Carbaglu is and what it is used for 2.
WHAT CARBAGLU IS AND WHAT IT IS USED FOR
What Cardoreg 4 mg prolonged release tablets and associated names is and what it is used for 2.
WHAT CELLCEPT IS AND WHAT IT IS USED FOR
WHAT CELSENTRI IS AND WHAT IT IS USED FOR
What CELVAPAN is and what it is used for 2.
WHAT CELVAPAN IS AND WHAT IT IS USED FOR
What Ceplene is and what it is used for 2.
What CEPROTIN is and what it is used for 2.
WHAT CEPROTIN IS AND WHAT IT IS USED FOR
WHAT CEREZYME IS AND WHAT IT IS USED FOR
WHAT CERVARIX IS AND WHAT IT IS USED FOR
What Cetrotide is and what it is used for 2.
WHAT CETROTIDE IS AND WHAT IT IS USED FOR
What CHAMPIX is and what it is used for 2.
WHAT CHAMPIX IS AND WHAT IT IS USED FOR
WHAT CIALIS IS AND WHAT IT IS USED FOR
WHAT CIPROFLOXACIN BAYER IS AND WHAT IT IS USED FOR
WHAT CIPROFLOXACIN BAYER IS AND WHAT IT IS USED FOR
WHAT CIPROFLOXACIN HIKMA IS AND WHAT IT IS USED FOR
WHAT CIPROFLOXACIN KABI IS AND WHAT IT IS USED FOR
What Circadin is and what it is used for 2.
WHAT CIRCADIN IS AND WHAT IT IS USED FOR
WHAT CLOPIDOGREL BMS IS AND WHAT IT IS USED FOR
What CoAprovel is and what it is used for 2.
WHAT COAPROVEL IS AND WHAT IT IS USED FOR
What Combivir is and what it is used for 2.
WHAT COMBIVIR IS AND WHAT IT IS USED FOR
WHAT COMTAN IS AND WHAT IT IS USED FOR
WHAT COMTESS IS AND WHAT IT IS USED FOR
WHAT COPALIA IS AND WHAT IT IS USED FOR
WHAT CORLENTOR IS AND WHAT IT IS USED FOR
WHAT COZAAR COMP IS AND WHAT IT IS USED FOR
WHAT Cozaar IS AND WHAT IT IS USED FOR
What CRIXIVAN is and what it is used for 2.
WHAT CRIXIVAN IS AND WHAT IT IS USED FOR
WHAT CUBICIN IS AND WHAT IT IS USED FOR
What Cyanokit is and what it is used for 2.
WHAT CYANOKIT IS AND WHAT IT IS USED FOR
What Cystadane is and what it is used for 2.
WHAT CYSTADANE IS AND WHAT IT IS USED FOR
What CYSTAGON looks like and contents of the pack Hard Capsules
What CYSTAGON is and what it is used for 2.
WHAT CYSTAGON IS AND WHAT IT IS USED FOR
WHAT DAFIRO IS AND WHAT IT IS USED FOR
WHAT DaTSCAN IS AND WHAT IT IS USED FOR
What DepoCyte is and what it is given for 2.
WHAT DEPOCYTE IS AND WHAT IT IS GIVEN FOR
What Diacomit is and what it is used for 2.
WHAT DIACOMIT IS AND WHAT IT IS USED FOR
WHAT DIOVAN IS AND WHAT IT IS USED FOR
WHAT DORIBAX IS AND WHAT IT IS USED FOR
WHAT DuoTrav IS AND WHAT IT IS USED FOR
What Dynastat is and what it is used for 2.
What Dynastat is and what it's used for 2.
WHAT DYNASTAT IS AND WHAT IT IS USED FOR
What ECALTA is and what it is used for 2.
WHAT ECALTA IS AND WHAT IT IS USED FOR
WHAT EFIENT IS AND WHAT IT IS USED FOR
WHAT ELAPRASE IS AND WHAT IT IS USED FOR
WHAT EMADINE IS AND WHAT IT IS USED FOR
WHAT EMADINE IS AND WHAT IT IS USED FOR
What Enbrel is and what it is used for 2.
WHAT EPOETIN ALFA HEXAL IS AND WHAT IT IS USED FOR
WHAT EUCREAS IS AND WHAT IT IS USED FOR
WHAT EVOLTRA IS AND WHAT IT IS USED FOR
What EVRA is and what it is used for 2.
What EVRA is and what is it used for
What Exelon looks like and contents of the pack Exelon 1.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a yellow cap and yellow body, with red imprint “ EXELON 1,5 mg ” on the body.
WHAT EXELON IS AND WHAT IT IS USED FOR
What Exforge is and what it is used for 2.
WHAT EXFORGE IS AND WHAT IT IS USED FOR
WHAT FABRAZYME IS AND WHAT IT IS USED FOR
WHAT FASLODEX IS AND WHAT IT IS USED FOR
What Fasturtec looks like and contents of the pack
WHAT FASTURTEC IS AND WHAT IT IS USED FOR
What Fasturtec is and what it is used for 2.
What Fendrix is and what it is used for 2.
WHAT FENDRIX IS AND WHAT IT IS USED FOR
WHAT FENTANYL-RATIOPHARM IS AND WHAT IT IS USED FOR
WHAT FERRIPROX IS AND WHAT IT IS USED FOR
What Fertavid is and what it is used for 2.
WHAT FERTAVID IS AND WHAT IT IS USED FOR
WHAT EFEXOR DEPOT IS AND WHAT IT IS USED FOR
WHAT EFEXOR IS AND WHAT IT IS USED FOR
What Effentora looks like and contents of the pack The buccal tablets are flat-faced, round bevelled-edge tablet, embossed one side with a “ C” and on the other side with “ 1” for Effentora 100 micrograms, with “ 2” for Effentora 200 micrograms, with “ 4” for Effentora 400 micrograms, with “ 6” for Effentora 600 micrograms, with “ 8” for Effentora 800 micrograms.
WHAT EFFICIB IS AND WHAT IT IS USED FOR
WHAT FILGRASTIM HEXAL IS AND WHAT IT IS USED FOR
WHAT FIRAZYR IS AND WHAT IT IS USED FOR
What FIRMAGON looks like and contents of the pack
What FIRMAGON is and what it is used for 2.
WHAT FIRMAGON IS AND WHAT IT IS USED FOR
WHAT FLEBOGAMMADIF IS AND WHAT IT IS USED FOR
What FORCALTONIN is and what it is used for 2.
WHAT FORCALTONIN IS AND WHAT IT IS USED FOR
WHAT FOSAVANCE IS AND WHAT IT IS USED FOR
What Foscan is and what it is used for 2.
What Fuzeon is and what it is used for 2.
WHAT FUZEON IS AND WHAT IT IS USED FOR
What GADOVIST is and what it is used for 2.
WHAT GADOVIST IS AND WHAT IT IS USED FOR
What GADOVIST looks like and contents of the pack
WHAT GALVUS IS AND WHAT IT IS USED FOR
What GANFORT is and what it is used for 2.
GANFORT is an eye drop that is used to control glaucoma.
WHAT GARDASIL IS AND WHAT IT IS USED FOR
WHAT GEMZAR IS AND WHAT IT IS USED FOR
What Gliolan is and what it is used for 2.
WHAT GLIOLAN IS AND WHAT IT IS USED FOR
What Glivec is and what it is used for 2.
WHAT GLIVEC IS AND WHAT IT IS USED FOR
WHAT GLUBRAVA IS AND WHAT IT IS USED FOR
WHAT GLUCOMED IS AND WHAT IT IS USED FOR
WHAT GONAL-f IS AND WHAT IT IS USED FOR
WHAT HELICOBACTER TEST INFAI FOR CHILDREN AGED 3 TO 11 YEARS IS AND WHAT IT IS USED FOR
WHAT HERCEPTIN IS AND WHAT IT IS USED FOR
What Hycamtin is and what it is used for 2.
What Hycamtin is and what it is used for
What Hycamtin is and what it is used for
What IDflu is and what it is used for 2.
WHAT IDflu IS AND WHAT IT IS USED FOR
What Imprida is and what it is used for 2.
WHAT IMPRIDA IS AND WHAT IT IS USED FOR
WHAT INDUCTOS IS AND WHAT IT IS USED FOR
What INOmax is and what it is used for 2.
WHAT INOmax IS AND WHAT IT IS USED FOR
WHAT INOVELON IS AND WHAT IT IS USED FOR
WHAT INSULATARD IS AND WHAT IT IS USED FOR
WHAT INSULATARD IS AND WHAT IT IS USED FOR
What INTANZA is and what it is used for 2.
WHAT INTANZA IS AND WHAT IT IS USED FOR
WHAT INTRONA IS AND WHAT IT IS USED FOR
What INVEGA is and what it is used for 2.
WHAT INVEGA IS AND WHAT IT IS USED FOR
What IONSYS is and what it is used for 2.
WHAT IONSYS IS AND WHAT IT IS USED FOR
What Irbesartan BMS is and what it is used for 2.
WHAT ISCOVER IS AND WHAT IT IS USED FOR
What Jalra is and what it is used for 2.
WHAT JALRA IS AND WHAT IT IS USED FOR
WHAT JANUMET IS AND WHAT IT IS USED FOR
What Januvia is and what it is used for 2.
WHAT JANUVIA IS AND WHAT IT IS USED FOR
WHAT KALETRA IS AND WHAT IT IS USED FOR
What Karvea is and what it is used for 2.
WHAT KARVEA IS AND WHAT IT IS USED FOR
WHAT KARVEZIDE IS AND WHAT IT IS USED FOR
WHAT KEPIVANCE IS AND WHAT IT IS USED FOR
WHAT KEPPRA IS AND WHAT IT IS USED FOR
What Ketek is and what it is used for 2.
WHAT KETEK IS AND WHAT IT IS USED FOR
What Kineret is and what it is used for 2.
WHAT KINERET IS AND WHAT IT IS USED FOR
WHAT KINERET IS AND WHAT IT IS USED FOR
WHAT KINZALKOMB IS AND WHAT IT IS USED FOR
WHAT KINZALKOMB IS AND WHAT IT IS USED FOR
WHAT KINZALMONO IS AND WHAT IT IS USED FOR
WHAT KIOVIG IS AND WHAT IT IS USED FOR
What Kivexa is and what it is used for 2.
What KOGENATE Bayer 2000 IU is and what it is used for 2.
WHAT KUVAN IS AND WHAT IT IS USED FOR
WHAT CIPROFLOXACIN IS AND WHAT IT IS USED FOR
WHAT LAMICTAL IS AND WHAT IT IS USED FOR
WHAT THELIN IS AND WHAT IT IS USED FOR
WHAT LEVEMIR IS AND WHAT IT IS USED FOR
WHAT LEVITRA IS AND WHAT IT IS USED FOR
WHAT LEVVIAX IS AND WHAT IT IS USED FOR ge lon Levviax belongs to one of a group of medicines called ketolides, a new class of antibiotics related to macrolides.
WHAT LISONORM IS AND WHAT IT IS USED FOR
What Livensa is and what it is used for 2.
WHAT LUCENTIS IS AND WHAT IT IS USED FOR
What Luminity is and what it is used for 2.
What Luveris is and what it is used for 2.
WHAT LUVERIS IS AND WHAT IT IS USED FOR
WHAT LYSODREN IS AND WHAT IT IS USED FOR
WHAT MABTHERA IS AND WHAT IT IS USED FOR
What EMADINE looks like and the contents of the pack EMADINE is a liquid (a solution) supplied in single-dose plastic containers which contain 0.35 ml.
What EMADINE is and what it is used for 2.
WHAT EMEND IS AND WHAT IT IS USED FOR
WHAT EMEND IS AND WHAT IT IS USED FOR
WHAT MICARDIS IS AND WHAT IT IS USED FOR
What MicardisPlus is and what it is used for 2.
WHAT MICARDISPLUS IS AND WHAT IT IS USED FOR
WHAT MIMPARA IS AND WHAT IT IS USED FOR
What MIRAPEXIN is and what it is used for 2.
WHAT MIRAPEXIN IS AND WHAT IT IS USED FOR
What MIRCERA is and what it is used for 2.
WHAT MIRCERA IS AND WHAT IT IS USED FOR
What Mixtard looks like and contents of the pack The suspension for injection comes as a cloudy, white, aqueous suspension in packs.
WHAT MIXTARD IS AND WHAT IT IS USED FOR
What Emselex is and what it is used for 2.
WHAT EMSELEX IS AND WHAT IT IS USED FOR
WHAT EMTRIVA IS AND WHAT IT IS USED FOR
WHAT EMTRIVA IS AND WHAT IT IS USED FOR
WHAT MYCAMINE IS AND WHAT IT IS USED FOR
WHAT MYOCET IS AND WHAT IS IT USED FOR
What Naglazyme looks like and contents of the pack Naglazyme is supplied as a concentrate for solution for infusion.
What Neoclarityn is and what it is used for 2.
WHAT NEORECORMON IS AND WHAT IT IS USED FOR
WHAT NESPO IS AND WHAT IS IT USED FOR ct
WHAT NESPO IS AND WHAT IS IT USED FOR ic
WHAT NEULASTA IS AND WHAT IT IS USED FOR
WHAT NEUPOPEG IS AND WHAT IT IS USED FOR lo
What Neupro is and what it is used for 2.
WHAT NEUPRO IS AND WHAT IT IS USED FOR
WHAT NEUROBLOC IS AND WHAT IT IS USED FOR
WHAT [NEURONTIN AND ASSOCIATED NAMES] IS AND WHAT IT IS USED FOR
WHAT NEXAVAR IS AND WHAT IT IS USED FOR
WHAT NIFEDIPINE PHARMAMATCH RETARD IS AND WHAT IT IS USED FOR
WHAT [INVENTED NAME] 400 MG FILM-COATED TABLETS ARE AND WHAT THEY ARE USED FOR
WHAT< INVENTED NAME > IS AND WHAT IT IS USED FOR
WHAT < INVENTED NAME > CREAM IS AND WHAT IT IS USED FOR
What {PRODUCT NAME} 10 mg is and what it is used for 2.
WHAT {PRODUCT NAME} 10 mg IS AND WHAT IT IS USED FOR
WHAT NONAFACT IS AND WHAT IT IS USED FOR
WHAT NOVOMIX 30 IS AND WHAT IT IS USED FOR
What NovoMix 50 is and what it is used for 2.
WHAT NOVOMIX 50 IS AND WHAT IT IS USED FOR
What NovoMix 70 is and what it is used for 2.
WHAT NOVOMIX 70 IS AND WHAT IT IS USED FOR
What NovoNorm is and what it is used for 2.
WHAT NOVONORM IS AND WHAT IT IS USED FOR
92 What NovoRapid looks like and contents of the pack
What NovoRapid is and what it is used for 2.
WHAT NOVORAPID IS AND WHAT IT IS USED FOR
What NovoSeven is and what it is used for 2.
WHAT NOVOSEVEN IS AND WHAT IT IS USED FOR
What Noxafil is and what it is used for 2.
WHAT NOXAFIL IS AND WHAT IT IS USED FOR
What Nplate is and what it is used for 2.
WHAT NPLATE IS AND WHAT IT IS USED FOR
WHAT NutropinAq IS AND WHAT IT IS USED FOR
WHAT ENVIAGE IS AND WHAT IT IS USED FOR
What Olanzapine Teva is and what it is used for 2.
WHAT ONSENAL IS AND WHAT IT IS USED FOR
What Oprymea is and what it is used for 2.
WHAT OPRYMEA IS AND WHAT IT IS USED FOR
WHAT OPTAFLU IS AND WHAT IT IS USED FOR
OPTISON is a dispersion for injection.
What OPTISON is and what it is used for 2.
WHAT OPTISON IS AND WHAT IT IS USED FOR
What Optisulin is and what it is used for 2.
WHAT OPTISULIN IS AND WHAT IT IS USED FOR
WHAT ORGALUTRAN IS AND WHAT IT IS USED FOR
WHAT OSIGRAFT IS AND WHAT IT IS USED FOR
What OSSEOR is and what it is used for 2.
WHAT OSSEOR IS AND WHAT IT IS USED FOR
WHAT OVITRELLE IS AND WHAT IT IS USED FOR
What Pandemrix is and what it is used for 2.
WHAT PANDEMRIX IS AND WHAT IT IS USED FOR
What Panretin is and what it is used for 2.
WHAT PARAREG IS AND WHAT IT IS USED FOR
What Paxene is and what it is used for 2.
WHAT PAXENE IS AND WHAT IT IS USED FOR
What Pedea is and what it is used for 2.
WHAT PEDEA IS AND WHAT IT IS USED FOR
What PegIntron is and what it is used for 2.
What Pelzont is and what it is used for 2.
WHAT PELZONT IS AND WHAT IT IS USED FOR
What Pergoveris is and what it is used for 2.
WHAT PERGOVERIS IS AND WHAT IT IS USED FOR
WHAT PHOTOBARR IS AND WHAT IT IS USED FOR
What Epivir is and what it is used for 2.
WHAT EPIVIR IS AND WHAT IT IS USED FOR
WHAT PLAVIX IS AND WHAT IT IS USED FOR
WHAT PRAMIPEXOLE TEVA IS AND WHAT IT IS USED FOR
WHAT PRANDIN IS AND WHAT IT IS USED FOR
WHAT PREOTACT IS AND WHAT IT IS USED FOR
What Prepandrix is and what it is used for 2.
WHAT PREPANDRIX IS AND WHAT IT IS USED FOR
WHAT PREVENAR IS AND WHAT IT IS USED FOR
WHAT PREZISTA IS AND WHAT IT IS USED FOR
WHAT PRIALT IS AND WHAT IT IS USED FOR
WHAT PRITORPLUS IS AND WHAT IT IS USED FOR
WHAT PRIVIGEN IS AND WHAT IT IS USED FOR
WHAT PROCORALAN IS AND WHAT IT IS USED FOR
What Prometax looks like and contents of the pack Prometax 1.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a yellow cap and yellow body, with red imprint “ ENA 713 1,5 mg” on the body.
What Prometax is and what it is used for 2.
WHAT PROMETAX IS AND WHAT IT IS USED FOR
WHAT PROTAPHANE IS AND WHAT IT IS USED FOR
WHAT PROTAPHANE IS AND WHAT IT IS USED FOR
WHAT PROTOPIC IS AND WHAT IT IS USED FOR
What Protopy looks like and contents of the pack Protopy is a white to slightly yellowish ointment.
WHAT PUREGON IS AND WHAT IT IS USED FOR
What QUADRAMET is and what it is used for 2.
WHAT QUADRAMET IS AND WHAT IT IS USED FOR
What Ranexa is and what it is used for 2.
WHAT RANEXA IS AND WHAT IT IS USED FOR
WHAT RAPAMUNE IS AND WHAT IT IS USED FOR
WHAT RAPAMUNE IS AND WHAT IT IS USED FOR
WHAT RAPILYSIN IS AND WHAT IT IS USED FOR
WHAT RAPINYL IS AND WHAT IT IS USED FOR
What Raptiva is and what it is used for 2.
WHAT RAPTIVA IS AND WHAT IT IS USED FOR
What Rasilez is and what it is used for 2.
WHAT RASILEZ IS AND WHAT IT IS USED FOR
What Rasilez HCT is and what it is used for 2.
WHAT RASILEZ HCT IS AND WHAT IT IS USED FOR
What Erbitux is and what it is used for 2.
WHAT ERBITUX IS AND WHAT IT IS USED FOR
WHAT REBETOL IS AND WHAT IT IS USED FOR
WHAT REBIF IS AND WHAT IT IS USED FOR
WHAT REBIF IS AND WHAT IT IS USED FOR
WHAT REFLUDAN IS AND WHAT IT IS USED FOR
What RELISTOR is and what it is used for 2.
WHAT RELISTOR IS AND WHAT IT IS USED FOR
WHAT REMERON IS AND WHAT IT IS USED FOR
What Remicade is and what it is used for 2.
WHAT REMICADE IS AND WHAT IT IS USED FOR
WHAT RENAGEL IS AND WHAT IT IS USED FOR
WHAT REPLAGAL IS AND WHAT IT IS USED FOR
WHAT RETACRIT IS AND WHAT IT IS USED FOR
WHAT REVASC IS AND WHAT IT IS USED FOR
WHAT REVATIO IS AND WHAT IT IS USED FOR
WHAT REVLIMID IS AND WHAT IT IS USED FOR
What REYATAZ is and what it is used for 2.
WHAT REYATAZ IS AND WHAT IT IS USED FOR
What Ribavirin Teva is and what it is used for 2.
WHAT RIBAVIRIN TEVA IS AND WHAT IT IS USED FOR
What RILUTEK is and what it is used for 2.
WHAT RILUTEK IS AND WHAT IT IS USED FOR
What Riprazo is and what it is used for 2.
WHAT RIPRAZO IS AND WHAT IT IS USED FOR
What RISPERDAL CONSTA looks like and contents of the pack
What RISPERDAL CONSTA is and what it is used for 2.
WHAT RISPERDAL CONSTA IS AND WHAT IT IS USED FOR
What RISPERDAL is and what it is used for 2.
WHAT RISPERDAL IS AND WHAT IT IS USED FOR
WHAT ROACTEMRA IS AND WHAT IT IS USED FOR
WHAT ROTARIX IS AND WHAT IT IS USED FOR
What Savene is and what it is used for 2.
WHAT SAVENE IS AND WHAT IT IS USED FOR
What Sebivo looks like and contents of the pack Sebivo film-coated tablets are white to slightly yellowish, oval, film-coated tablets with “ LDT” imprinted on one side.
What Sebivo is and what it is used for 2.
WHAT SEBIVO IS AND WHAT IT IS USED FOR
WHAT SERETIDE IS AND WHAT IT IS USED FOR
What SIFROL is and what it is used for 2.
WHAT SIFROL IS AND WHAT IT IS USED FOR
What Silapo is and what it is used for 2.
WHAT SILAPO IS AND WHAT IT IS USED FOR
WHAT SILGARD IS AND WHAT IT IS USED FOR
WHAT SIMULECT IS AND WHAT IT IS USED FOR
What Soliris is and what it is used for 2.
WHAT SOLIRIS IS AND WHAT IT IS USED FOR
WHAT SONATA IS AND WHAT IT IS USED FOR
WHAT SONOVUE IS AND WHAT IT IS USED FOR
What Sprimeo is and what it is used for 2.
WHAT SPRIMEO IS AND WHAT IT IS USED FOR
WHAT STALEVO IS AND WHAT IT IS USED FOR
What Starlix is and what it is used for 2.
What STELARA looks like and contents of the pack STELARA is a clear to slightly opalescent, colourless to light yellow solution for injection.
What STELARA is and what it is used for 2.
WHAT STELARA IS AND WHAT IT IS USED FOR
WHAT SUBOXONE IS AND WHAT IT IS USED FOR
What SUTENT is and what it is used for 2.
WHAT SUTENT IS AND WHAT IT IS USED FOR
- The other ingredients are histidine, glycine and mannitol.
What Synagis is and what it is used for 2.
WHAT SYNAGIS IS AND WHAT IT IS USED FOR
WHAT TACHOSIL IS AND WHAT IT IS USED FOR
WHAT Tadalafil Lilly IS AND WHAT IT IS USED FOR
WHAT IS TARCEVA AND WHAT IT IS USED FOR
What Targretin is and what it is used for 2.
WHAT TARGRETIN IS AND WHAT IT IS USED FOR
WHAT TASIGNA IS AND WHAT IT IS USED FOR
What Tekturna is and what it is used for 2.
WHAT TEKTURNA IS AND WHAT IT IS USED FOR
Telzir is used to treat HIV (human immunodeficiency virus) infection.
WHAT TELZIR IS AND WHAT IT IS USED FOR
What Temodal is and what it is used for 2.
WHAT TEMODAL IS AND WHAT IT IS USED FOR
WHAT TEMODAL IS AND WHAT IT IS USED FOR
WHAT TESLASCAN IS AND WHAT IT IS USED FOR
What Tevagrastim looks like and contents of the pack Tevagrastim is a solution for injection or infusion in a pre-filled syringe.
What Tevagrastim is and what it is used for 2.
WHAT Tevagrastim IS AND WHAT IT IS USED FOR
What Tevagrastim is Tevagrastim contains the active substance filgrastim.
WHAT THALIDOMIDE CELGENE IS AND WHAT IT IS USED FOR
WHAT THYMANAX IS AND WHAT IT IS USED FOR
What Thyrogen is and what it is used for 2.
WHAT THYROGEN IS AND WHAT IT IS USED FOR
WHAT TORISEL IS AND WHAT IT IS USED FOR
WHAT TRACLEER IS AND WHAT IT IS USED FOR
WHAT TRAZEC IS AND WHAT IT IS USED FOR
WHAT TREDAPTIVE IS AND WHAT IT IS USED FOR
What Trevaclyn is and what it is used for 2.
WHAT TREVACLYN IS AND WHAT IT IS USED FOR
What TRISENOX looks like and contents of the pack
What TRITACE is and what it is used for 2.
WHAT TRITACE IS AND WHAT IT IS USED FOR
What Tritanrix HepB is and what it is used for 2.
WHAT TRIZIVIR IS AND WHAT IT IS USED FOR
WHAT TRUDEXA IS AND WHAT IT IS USED FOR no
WHAT TRUVADA IS AND WHAT IT IS USED FOR
WHAT TWINRIX ADULT IS AND WHAT IT IS USED FOR
What Tyverb is and what it is used for 2.
WHAT TYVERB IS AND WHAT IT IS USED FOR
WHAT PREPANDEMIC INFLUENZA VACCINE (H5N1) (SPLIT VIRION, INACTIVATED, ADJUVANTED) GLAXOSMITHKLINE BIOLOGICALS 3.75 µg IS AND WHAT IT IS USED FOR
WHAT VALDOXAN IS AND WHAT IT IS USED FOR
What Vectibix is and what it is used for 2.
WHAT VECTIBIX IS AND WHAT IT IS USED FOR
WHAT VELMETIA IS AND WHAT IT IS USED FOR
WHAT VELOSULIN IS AND WHAT IT IS USED FOR
What Viani is and what it is used for 2.
What Vimpat looks like and contents of the pack Vimpat 15 mg/ml syrup is a clear solution, slightly yellow to yellow-brown in colour.
What Vimpat is and what it is used for 2.
WHAT VIMPAT IS AND WHAT IT IS USED FOR
WHAT VIMPAT IS AND WHAT IT IS USED FOR
WHAT VIMPAT IS AND WHAT IT IS USED FOR
What Viraferon is and what it is used for 2.
What ViraferonPeg is and what it is used for 2.
WHAT VIRAFERONPEG IS AND WHAT IT IS USED FOR
WHAT VIRAFERONPEG IS AND WHAT IT IS USED FOR
What Viread looks like and contents of the pack
What Viread is and what it is used for 2.
WHAT VIREAD IS AND WHAT IT IS USED FOR
What VISTIDE is and what it is used for 2.
What VISTIDE is and what it is used for
WHAT VISUDYNE IS AND WHAT IT IS USED FOR
WHAT VIVANZA IS AND WHAT IT IS USED FOR
WHAT VOLIBRIS IS AND WHAT IT IS USED FOR
What Wilzin is and what it is used for 2.
WHAT WILZIN IS AND WHAT IT IS USED FOR
WHAT XELODA IS AND WHAT IT IS USED FOR
What Xenical is and what it is used for 2.
WHAT XENICAL IS AND WHAT IT IS USED FOR
WHAT XEOMIN IS AND WHAT IT IS USED FOR
WHAT XIGRIS IS AND WHAT IT IS USED FOR
WHAT XILIARX IS AND WHAT IT IS USED FOR
WHAT EXJADE IS AND WHAT IT IS USED FOR
What EXJADE is EXJADE contains an active substance called deferasirox.
WHAT XOLAIR IS AND WHAT IT IS USED FOR
What EXUBERA is and what it is used for 2.
What YENTREVE is and what it is used for 2.
What Yondelis is and what it is used for 2.
WHAT YONDELIS IS AND WHAT IT IS USED FOR
What YTRACIS is and what it is used for 2.
WHAT YTRACIS IS AND WHAT IT IS USED FOR
What Yttriga is and what it is used for 2.
WHAT YTTRIGA IS AND WHAT IT IS USED FOR
WHAT ZARZIO IS AND WHAT IT IS USED FOR
WHAT ZAVESCA IS AND WHAT IT IS USED FOR
WHAT ZEFFIX IS AND WHAT IT IS USED FOR
WHAT ZENAPAX IS AND WHAT IT IS USED FOR
WHAT ZERENE IS AND WHAT IT IS USED FOR
WHAT ZIAGEN IS AND WHAT IT IS USED FOR
What Zomarist is and what it is used for 2.
WHAT ZOMARIST IS AND WHAT IT IS USED FOR
What Zometa is and what it is used for 2.
WHAT ZOMETA IS AND WHAT IT IS USED FOR
What Zonegran is and what it is used for 2.
Clear and colorless liquid with slightly sweet taste and a banana flavor
WHAT Zyrtec IS AND WHAT IT IS USED FOR
WHAT HEPSERA IS AND WHAT IT IS USED FOR
WHAT HUMALOG BASAL IS AND WHAT IT IS USED FOR
WHAT HUMALOG BASAL KWIKPEN IS AND WHAT IT IS USED FOR
WHAT HUMALOG IS AND WHAT IT IS USED FOR
WHAT HUMALOG KWIKPEN IS AND WHAT IT IS USED FOR
WHAT HUMALOG MIX25 IS AND WHAT IT IS USED FOR
WHAT HUMALOG MIX25 KWIKPEN IS AND WHAT IT IS USED FOR
WHAT HUMALOG MIX50 IS AND WHAT IT IS USED FOR
WHAT HUMALOG MIX50 KWIKPEN IS AND WHAT IT IS USED FOR
What Icandra is and what it is used for 2.
WHAT ICANDRA IS AND WHAT IT IS USED FOR
What Infanrix Penta is and what it is used for 2.
WHAT Infanrix Penta IS AND WHAT IT IS USED FOR
WHAT INTELENCE IS AND WHAT IT IS USED FOR
What Intrinsa is and what it is used for 2.
WHAT INTRINSA IS AND WHAT IT IS USED FOR
What INVANZ is and what it is used for 2.
WHAT INVANZ IS AND WHAT IT IS USED FOR
WHAT INVIRASE IS AND WHAT IT IS USED FOR
What ISENTRESS is and what it is used for 2.
WHAT ISENTRESS IS AND WHAT IT IS USED FOR
This is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).
WHAT LIVENSA IS AND WHAT IT IS USED FOR
WHAT OMNITROPE IS AND WHAT IT IS USED FOR
WHAT OPGENRA IS AND WHAT IT IS USED FOR
WHAT Optimark IS AND WHAT IT IS USED FOR
What Optisulin is and what it is used for 2.
What OPTRUMA is and what it is used for 2.
What ORACEA looks like and contents of the pack ORACEA is a modified-release hard capsule.
What ORACEA is and what it is used for 2.
WHAT ORACEA IS AND WHAT IT IS USED FOR
What ORENCIA is and what it is used for 2.
WHAT ORENCIA IS AND WHAT IT IS USED FOR
What Orfadin is and what it is used for 2.
WHAT ORFADIN IS AND WHAT IT IS USED FOR
What Osigraft is and what it is used for 2.
WHAT TANDEMACT IS AND WHAT IT IS USED FOR
Questions to the CVMP:
QUESTIONS AND ANSWERS ON RECOMMENDATION FOR THE REFUSAL OF THE MARKETING AUTHORISATION for MYCOGRAB
Questions and answers on the referral for Bleomycin, powder for solution for injection, 15 U/ Vial, from Pharmachemie BV
Questions and answers on the referral for Diovan film coated tablets and hard capsules containing valsartan 40, 80, 160 or 320 mg
Questions and answers on the referral for Uman Big Human Hepatitis B Immunoglobulins, 180 IU/ ml, solution for injection
Questions and answers on the withdrawal of the marketing application for Advexin
Questions put to the Marketing Authorisation Holder
Quality issues No significant issues relating to quality were identified and the pharmaceutical particulars of the SPC were harmonised, except the sections, which need to be introduced nationally by the Member States when implementing the harmonised SPC.
Efficacy issues The efficacy of the product is established, nevertheless the population to be treated was questioned.
This will be increased every 4 - 7 days as directed by your doctor until your symptoms are controlled (maintenance dose).
doctor to monitor your blood clotting times.
necessary by your doctor for other reasons.
Treatment initiati on forms for male patients should also include:
- it is acknowledged that no specific dose-finding study was conducted, the data available is
2 • That there is an interaction with ciclosporin A which may lead to higher blood concentration of Thelin and hence an increased risk of adverse reactions.
Treatment initiation forms for female patients with no childbearing potential should also include:
- quinidine (used to treat abnormal heart rhythms);
The expiry date refers to the last day of the month.
Quinine: hydrochlorothiazide reduces quinine excretion.
Quinta da Fonte – Edifício Gil Eanes P – 2770-192 Paço de Arcos Tel: + 351 214 460 200 România Nycomed Pharma România Strada Episcop Chesarie, nr.15, Corp C, city Center Bucureş ti, Cod 020656-RO Tel: + 40213350391
Quinta da Fonte - Edifício Vasco da Gama, 19 - Porto Salvo P. O.
- certain antibiotics (e.g. clarithromycin, erythromycin, quinupristin/dalfopristin, dapsone,
In patients assessed for antibodies at least 56 days after discontinuation of abatacept, 15 of 203 (7.4%) developed antibodies.
Fifteen tubes each containing 0.25 ml (15 mg selamectin).
of patients, lead to a severe allergic reaction.
are sometimes given to patients after a transplant operation), cholestyramine (used to treat patients 39 with high blood cholesterol), rifampicin (antibiotic), antacids, phosphate binders (used in patients with chronic renal kidney failure to reduce the absorption of phosphate) or any other medicines (including those you can buy without a prescription) that your doctor does not know about?
are sometimes given to patients after a transplant operation), cholestyramine (used to treat patients with high blood cholesterol), rifampicin (antibiotic), antacids, phosphate binders (used in patients with chronic renal kidney failure to reduce the absorption of phosphate) or any other medicines (including those you can buy without a prescription) that your doctor does not know about?
(which are sometimes given to patients after a transplant operation), cholestyramine (used to treat patients with high blood cholesterol), rifampicin (antibiotic), antacids, phosphate binders (used in patients with chronic renal failure to reduce the absorption of phosphate) or any other medicines (including those you can buy without a prescription) that your doctor does not know about?
(which are sometimes given to patients after a transplant operation), cholestyramine (used to treat patients with high blood cholesterol), rifampicin (antibiotic), phosphate binders (used in patients with chronic renal failure to reduce the absorption of phosphate) or any other medicines (including those you can buy without a prescription) that your doctor does not know about?
(which are sometimes given to patients after a transplant operation), cholestyramine (used to treat patients with high cholesterol), rifampicin (antibiotic), antacids, phosphate binders (used in patients with chronic renal failure to reduce the absorption of phosphate) or any other medicines (including those you can buy without a prescription) that your doctor does not know about?
Quixidar (1.5 and 2.5 mg strengths) is used to prevent venous thromboembolic events (VTEs, no
No significant effect on lamivudine and zidovudine concentrations was observed.
B02BD02 Treatment and prophylaxis of bleeding
L01XX Treatment of age - related macular degeneration
Rabigen SAG2 can only be used by authorised personnel within the framework of vaccination campaigns against rabies.
Connect the infusion line and prime it with Erbitux before starting the infusion.
Connect the infusion line and prime it with the diluted Erbitux before starting the infusion.
Analysis of plasma concentration data from patients in clinical trials indicated that the clearance of enfuvirtide was not different in Afro-Americans compared to Caucasians.
3 Spinal / Epidural anaesthesia In patients undergoing major orthopaedic surgery, epidural or spinal haematomas that may result in long-term or permanent paralysis cannot be excluded with the concurrent use of fondaparinux and spinal/ epidural anaesthesia or spinal puncture.
ra Spinal / Epidural anaesthesia In patients undergoing major orthopaedic surgery, epidural or spinal haematomas that may result in long-term or permanent paralysis cannot be excluded with the concurrent use of fondaparinux and
Spinal / Epidural anaesthesia In patients undergoing major orthopaedic surgery, epidural or spinal haematomas that may result in long-term or permanent paralysis cannot be excluded with the concurrent use of fondaparinux and spinal/ epidural anaesthesia or spinal puncture.
18 Spinal anaesthesia/ epidural anaesthesia/ lumbar puncture:
4 Spinal anaesthesia/ epidural anaesthesia/ lumbar puncture:
- Rickets and osteomalacia, in addition to vitamin D3 therapy
analyse leakage; see Important information about BEROMUN, below)
Radioactivity in bottom piece of ITLC-SG MAM strip (Rf 0-0.40) A = 100 x ---------------------------------------------------------------------------------- Total radioactivity in both pieces of ITLC-SG MAM strip
Radioactivity in top piece of ITLC-SG SSCS strip (Rf 0.75-1.0) B = 100 x ------------------------------------------------------------------------------ Total radioactivity in both pieces of ITLC-SG SSCS Strip
- radiotherapy to bone for treatment of fractures/ impending fractures
RAD Neurim Pharmaceuticals EEC Limited One Forbury Square The Forbury Reading Berkshire RG1 3EB United Kingdom e-mail: neurim@neurim. com
Raheen Industrial Estate Raheen, Limerick Ireland
- muscle stiffness (hypertonia), painful muscles (myalgia), muscular debility (myasthenia), back
- muscle stiffness (hypertonia), painful muscles (myalgia), muscular debility (myasthenia), back
- muscle stiffness (hypertonia),painful muscles (myalgia), muscular weakness (myasthenia),
of these substances during production.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including those that are obtained without a prescription.
124 fainting may also occur.
2.5 mg 5 mg 10 mg 2.5 mg/ 5mg / 10mg
• Domenica TARUSCIO (Italy)
either pegylated interferon alfa-2b (1.5 µg/ kg/ week) plus ribavirin (800 mg/ day) or Viraferon (3 MIU TIW) plus ribavirin (800 mg/ day) for 48 weeks with a follow-up period of 6 months.
either pegylated interferon alfa-2b (1.5 µg/ kg/ week) plus ribavirin (800 mg/ day) or Viraferon (3 MIU TIW) plus ribavirin (800 mg/ day) for 48 weeks with a follow-up period of 6 months.
Ranexa 1000 mg twice daily increased plasma concentrations of simvastatin lactone, simvastatin acid, and the HMG-CoA reductase inhibitor activity by 1.4- to 1.6-fold.
Invented name Ranexa Ranexa Ranexa Ranexa Ranexa Ranexa Ranexa Ranexa Ranexa Ranexa Ranexa Ranexa
Rapamune should be taken four hours after each ciclosporin dose.
Rapamune has not been adequately studied in patients at high immunological risk (see section 5.1).
Sometimes you will need to remind other medical staff that you are being treated with Avonex.
Remember that the first dose of Menitorix should not be given before your child is 2 months of age.
Revaccination: during each pregnancy, according to the same schedule.
Tracleer (bosentan) This card contains important information about Tracleer.
Revaccination: • One injection at each gestation, at least 2 to 4 weeks before farrowing.
Revaccination: a single injection of one dose should be carried out 2 – 4 weeks prior to each subsequent farrowing.
Benefit/ Risk Intradermal injection of Botox, 50 U per axilla in a placebo-controlled clinical trial setting reduced mean sweat production to physiological levels within one week of administration and benefit was maintained on average for 30.6 weeks.
with the use of broad spectrum antibiotics including moxifloxacin; therefore it is important to consider this diagnosis in patients who develop serious diarrhoea during or after the use of moxifloxacin.
* reported by the parents as adversely affecting the child's daily activities
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE OPINION FOLLOWING AN ARTICLE 6 (12) REFERRAL
Take it back to your pharmacist who will dispose of it in a way that won't harm the environment.
Take them back to your pharmacist who will dispose of them in a way that won 't harm the environment.
Post marketing reports of another medicinal product of this class:
Non-EU case reports received/expected by the EMEA Serious suspected unexpected adverse drug reactions
Periodic Safety Update Reports (PSUR's):
operating procedure for scientific advice and a new guidance document on scientific advice was published on the EMEA
Period safety update reports, follow-up measures and specific obligations 1995-2000
100 Periodic safety update reports, follow-up measures and specific obligations 1999-2001 75
EU and non-EU adverse drug reports
account European requirements
Interim safety reports every 6 months.
This will lessen the chance for ribavirin to be left in the woman’s body.
EU and non-EU adverse drug reports 1995-2000
responsible for providing advice to sponsors on quality, safety or efficacy-related aspects of medicinal products.
Raptiva 100 mg/ ml powder and solvent for solution for injection Efalizumab
Raptiva 100 mg/ ml powder and solvent for solution for injection
Raptiva 100 mg/ ml Powder for solution for injection Efalizumab Subcutaneous use
Raptiva acts on the immune system, which may potentially increase your risk of infectious diseases or may reactivate old infections.
Patients have recovered after discontinuation of Raptiva, therefore Raptiva should be stopped following the diagnosis of inflammatory polyradiculoneuropathy.
Raptiva should be used with caution in patients who have problems with their liver or kidneys.
Raptiva is a medicine containing efalizumab, made by means of biotechnology.
Raptiva is a systemic psoriasis medicine.
Raptiva can be used in combination with topical corticosteroids.
Raptiva is a powder and solvent that are made up into a solution for injection.
Uveitis, scleritis, episcleritis
tinnitus, ear discomfort (including pain and
Rare: amnesia, depressed level of consciousness, loss of consciousness, parosmia.
Common: raised blood levels of liver enzymes and bilirubin Rare: liver disorders such as severe hepatomegaly with steatosis,
Rare: bronchiolitis, candida nappy rash, candidiasis, cellulitis, infectious croup, viral gastroenteritis, hand-foot-mouth disease, influenza, pseudocroup, respiratory infection, skin infection, tonsillitis, varicella ‡, viral conjunctivitis.
Rare: acute renal failure, impaired renal function, vaginal moniliasis, haematuria, crystalluria, interstitial nephritis.
Rare: acute renal failure, renal failure, proximal renal tubulopathy (including Fanconi syndrome), increased creatinine Very rare: acute tubular necrosis Not known: nephritis (including acute interstitial nephritis), nephrogenic diabetes insipidus
ra (oliguria); pain following surgery.
Rarely, such side effects as seizures (fits), headache, confusion, changes in vision, or an abnormal tube-like connection between the windpipe and the passage to the stomach (gullet), may occur.
19 In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg- Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy.
In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg- Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy.
Rarely, the skin rash can be severe and serious (Stevens Johnson syndrome).
Rare: myopathy, rhabdomyolysis (see section 4.4), myalgia, muscle cramps
Rare*: motor neuropathy (with resultant minor distal weakness)
Rare: photosensibility, erythema multiforme and erythema nodusum.
Rare: peripheral coldness, orthostatic hypotension.
Rare Cardiac arrest, Fast heart beat Loss of consciousness, Convulsion Conjunctivitis, Swelling (edema) of the eyelid Breathing difficulties (bronchospasm, swelling of the throat), Breathing arrest, Blueness of the lips, Cough, Sneezing Swelling (edema) of the face, Excessive sweating, Itching, Redness of the skin Fainting, Flushing Feeling hot, Generally feeling unwell Severe allergy-like reaction (shock)
intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Rare: influenza-like illness, injection-site desquamation, injection-site discoloration, injection-site pruritus, injection-site rash non-specific, injection-site reaction, injection-site scar, hyperthermia, pain, pain/ tenderness/ soreness.
Rare: influenza-like illness, injection-site desquamation, injection-site discoloration, injection-site pruritus, injection-site rash non-specific, injection-site reaction, injection-site scar, hyperthermia, pain, pain/ tenderness/ soreness.
polyuria, dysuria, pollakiuria rash, acne, photosensitivity, hyperhidrosis, oily skin, pruritus, skin lesion
Fever Asthenia, chills
Acute respiratory distress syndrome, pulmonary oedema, respiratory distress, chest pain
Rash Exfoliative dermatitis, face oedema, photosensitivity reaction, maculo-papular rash, macular rash, papular rash, cheilitis, pruritus, alopecia, erythema
Rash (usually maculopapular or urticarial)
Skin Rash (usually maculopapular or urticarial)
ori disorder, nail disorder, skin discolouration, pruritus, dry skin, erythema, bruise, sweating increased Musculoskeletal and
rash, photosensitivity reaction, alopecia, hyperhidrosis
Rash, Urticaria, Hyperhydrosis (sweating)
Rasilez HCT may have been prescribed to you because your previous treatment did not lower your blood pressure enough.
Combination studies looked at Rasilez used with an angiotensin converting enzyme inhibitor (ramipril), an angiotensin receptor blocker (valsartan), a beta-blocker (atenolol), a calcium-channel blocker (amlodipine) and a 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Ratiograstim 30 MIU/ 0.5 ml solution for injection or infusion
Ratiograstim 30 MIU/ 0.5 ml solution for injection or infusion
Ratiograstim 30 MIU/ 0.5 ml solution for injection or infusion Ratiograstim 48 MIU/ 0.8 ml solution for injection or infusion
Ratiograstim can also be used in patients who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow.
Contribution to the activities initiated by European Commission Directorate-General for Research related to medicinal products for developing countries
Ratiopharm GmBH Graf-Arco-Strasse 3 89079 Ulm, Germany Tel:
given that the latter is not a recognised DSM indication.
Reactine, Virlix, Cetirizine UCB 10mg, Zyrtec, Actifed Allergie cetirizine 10mg, Zyrtecset Germany:
Zyrtec P tropfen, Zyrtec tropfen Greece:
• Allergic reaction causing swelling of the eyes, lips or tongue* • Yeast infection around the anus or genitals • Damage to red blood cells (haemolytic anaemia) • Inflammation of the tongue • Difficulty in swallowing • Inflammation of the intestine • Inflammation or ulceration of the gullet • Inflammation of the skin causing flakiness • Worsening of the immune system disease known as systemic lupus erythematosus (SLE)
Allergic reaction, fever, radiation injury, pain, taste perversion
Allergic reaction, fever, radiation injury, face oedema, pain, taste perversion
General disorders and administration site conditions na
Nail loss, Skin necrosis
Skin ulcer, Rash, Urticaria, Photosensitivity reaction, Palmar erythema, Swelling face, Purpura
Abnormal liver function tests GGTP increased Photosensitivity reaction Face oedema Rash
Gastrointestinal Disorders incl. related Investigations
Photosensitivit y reaction Face oedema Rash
Photosensitivity reaction Face oedema Rash
Related Investigations Reproductive System and Breast Disorders
Alopecia, rash Photosensitivity reaction, maculopapular rash, eczema, acne, skin disorder, nail disorder, skin discolouration, pruritus, dry skin, erythema, bruise, sweating increased
Depression, emotional lability, insomnia Suicidal ideation, aggressive reaction, confusion, behaviour disorder, agitation, somnambulism, anxiety, nervousness, sleep disorder, abnormal dreaming, apathy
ori disorder, nail disorder, skin discolouration, pruritus, dry skin, erythema, bruise, sweating increased Musculoskeletal and
Alopecia, rash Photosensitivity reaction, maculopapular rash, eczema, acne, skin
Alopecia, rash Photosensitivity reaction, maculopapular rash, eczema, acne, skin disorder, nail disorder, skin discolouration, pruritus, dry skin,
Alopecia, rash Photosensitivity reaction, maculopapular rash, eczema, acne, skin
Musculoskeletal and connective tissue disorders
Anaphylactic reaction, lupus-like syndrome, allergic respiratory symptom Unknown:
Cross-reactive Immune Response Against Related H5N1 Strains
adverse drug reaction, chest discomfort, chest pain, chills, discomfort, drug withdrawal syndrome, face oedema, feeling abnormal, gait disturbance, generalized oedema, influenza like illness, malaise, oedema peripheral, peripheral coldness, pitting oedema, pyrexia, sluggishness, thirst
Adverse Drug Reaction Palpitations Vomiting, Nausea, Diarrhoea Influenza-like illness, Asthenia, Pyrexia, Rigors, Pain, Fatigue,
Metabolism and Nutrition Disorders
Injection site reaction, injection site inflammation, injection site pain, injection site oedema, injection site phlebitis
Allergy: increased allergic symptoms
• Allergic reactions - this product contains polyoxyl castor oil.
Allergic reactions have been reported in the same proportion (1.6%) of patients treated with desirudin (N=2,367) or with unfractionated heparin (N=1,1 34) in clinical trials, regardless of causality.
- allergic reactions (hypersensitivity), symptoms of infection (for example enlarged lymph nodes
- severe and potentially severe allergic reactions,
- severe allergic reaction (anaphylactic reaction, anaphylactic shock, serum sickness) which can
- severe allergic reactions (anaphylactic reaction or anaphylactic shock, which can be fatal -
Hypersensitivity (e. g. pruritis, rash, urticaria, anaphylactoid reaction, vasculitis, serum sickness-like reaction, angioedema) (see ‘ Contraindications'and ‘ Warnings’), chills, serotonin syndrome, photosensitivity, very rarely Toxic Epidermal Necrolysis (Lyell syndrome).
severe anaphylactic/ anaphylactoid reactions, vasculitis, including cutaneous necrotizing vasculitis
Anaphylactic reactions Thromboembolic events
Not known* Thromboembolic events
Anaphylactoid reactions in haemodialysis patients Anaphylactic shock has been reported in patients dialysed with polyacrylonitrile (e. g.
Application site reactions such as rash, pain, prickling sensation, slight scaling of the skin, dryness, swelling and worsening of eczema symptoms.
Application site reactions including pain, ulcer, irritation, paraesthesia, anaesthesia, erythema, oedema, swelling and vesicles
Injection site reactions (e. g. erythema, induration/ swelling, pain/ tenderness); fever ≥ 38 °C, irritability, crying, drowsiness, restless sleep.
Injection site reactions (burning sensations, reddening of the skin, pain, swelling, feeling of warmth, itching.) Common:
Cardiovascular reactions Cardiovascular reactions during clinical trials with MabThera monotherapy were reported in 18.8% of patients with the most frequently reported events being hypotension and hypertension.
Allergic skin reactions (e.g. swelling, itch or redness).
- severe sometimes life-threatening reactions (Stevens-Johnson syndrome, toxic epidermal
Hypersensitivity and allergic reactions As with any recombinant product, Raptiva is potentially immunogenic.
Hypersensitivity and allergic disorders:
Adverse event(s) from post-marketing surveillance with the pandemic vaccine: not applicable.
Gastrointestinal adverse reactions The most commonly reported gastrointestinal adverse reactions associated with azacitidine treatment included constipation, diarrhoea, nausea and vomiting.
7 Adverse reactions, probably or possibly related to Mycophenolate, reported in patients treated with Mycophenolate in renal, cardiac and hepatic clinical trials when used in combination with ciclosporin and corticosteroids
20 Adverse reactions, probably or possibly related to mycophenolate, reported in patients treated with mycophenolate in renal, cardiac and hepatic clinical trials when used in combination with ciclosporin and corticosteroids
7 Adverse reactions, probably or possibly related to Mycophenolate, reported in patients treated with Mycophenolate in renal, cardiac and hepatic clinical trials when used in combination with ciclosporin and corticosteroids
Adverse ReactionsReported Commonly and Greater than Placebo
Mild or moderate infusion-related reactions*; mild to moderate mucositis which may lead to epistaxis.
Infusion reactions Adverse events associated with infusion (selected events occurring during or within 24 hours of infusion) were reported by 6.9% of patients in the tocilizumab 8 mg/ kg plus DMARD group and 5.1% of patients in the placebo plus DMARD group.
*Reactions occurring during or within 24 hours of infusion.
Perform every month a blood measurement of albumin.
− Achieve definitive fracture reduction, fixation, and hemostasis prior to InductOs implantation.
Reoccurrence of thrombocytopenia and bleeding after cessation of treatment
Rebetol must be used in combination with either peginterferon alfa-2b (1.5 micrograms/ kg/ week) or interferon alfa-2b (3 million international units [MIU] three times a week).
Rebetol must be used in combination with interferon alfa-2b solution for injection, administered at a dose of 3 million international units (MIU)/m2 three times a week.
Rebetol must not be used by a female who is breast-feeding a baby.
Rebetol must not be used by a woman who is breast-feeding a baby.
Rebetol can be very damaging to an unborn baby, thus both female and male patients must take special precautions in their sexual activity if there is any chance for pregnancy to occur:
32 Rebif has not yet been investigated in patients with primary progressive multiple sclerosis, and should not be used in such patients.
40 Rebif has not yet been investigated in patients with primary progressive multiple sclerosis, and should not be used in such patients.
Rebif has not yet been investigated in patients with primary progressive multiple sclerosis, and should not be used in such patients.
Mail in Mail out Number of pages translated Conference services
Revenue from export certificates, parallel distributions and other similar administrative charges
Relapse of Virological Response after the End of Treatment in Genotype 2 or 3 Patients with a Rapid Viral Response Study NV17317
Relapse of Virological Response after the End of Treatment in Genotype 2 or 3 Patients with a Rapid Viral Response Study NV17317
Recip AB Lagervägen 7 136 50 Haninge Sweden Tel. +46 8 6025200
Reckitt Benckiser Healthcare (UK) Ltd Dansom Lane Hull, East Yorkshire HU8 7DS United Kingdom
- is receiving a concomitant therapy including hepatotoxic and/ or genotoxic properties
Antigen (S protein), adsorbed Inactivated type 1 Poliovirus Inactivated type 2 Poliovirus Inactivated type 3 Poliovirus Conjugate of Haemophilus influenzae
Table 3a Dose modification guidelines for PegIntron monotherapy
Dosing recommendations – Adults and adolescents over 12 years:
Dosing recommendations – Adults and adolescents weighing at least 30 kg::
(functionally anephric, requiring intermittent haemodialysis)* Recommended dose of Emtriva 10 mg/ ml oral solution every 24 hours
Reconcile 8 mg fluoxetine (as 9.04 mg fluoxetine hydrochloride) Reconcile 16 mg fluoxetine (as 18.08 mg fluoxetine hydrochloride) Reconcile 32 mg fluoxetine (as 36.16 mg fluoxetine hydrochloride) Reconcile 64 mg fluoxetine (as 72.34 mg fluoxetine hydrochloride)
Reconcile is used, in combination with behavioural modification techniques, to assist in the treatment of dogs that have behavioural problems (separation anxiety) caused by separation from their owners, their normal home, or other dogs.
Reconcile should not be used on its own but only in dogs that are also undergoing behavioural therapy.
Reconstitute with sodium pertechnetate (99mTc) injection
Reconstitute by swirling gently.
Reconstitute 100-mg vials with 4.2 ml of sodium chloride 9 mg/ ml (0.9%) solution for injection, without preservative, resulting in a solution containing 25 mg/ ml pemetrexed.
Reconstituting PegIntron powder for injection Before reconstitution, PegIntron may appear either as a white, tablet-shaped solid that is whole or in pieces, or as a white powder.
Reconstituting ViraferonPeg powder for injection Before reconstitution, ViraferonPeg may appear either as a white, tablet-shaped solid that is whole or in pieces, or as a white powder.
Reconstitution of Viraferon, powder for solution for injection, for parenteral administration:
RECORDATI ESPAÑA, SL Moxifloxacin Carretera De Zeneta, 149 hydrochloride 30588 Beniel (Murcia) Spain
Cover the tanks and allow to equilibrate with the solvent vapours.
Italia Nello MARTINI (4) Romano MARABELLI (Vice-Chairman)
ra adverse reactions was 15.7% for patients receiving rimonabant.
40 Ulcerative colitis Ulcerative colitis is an inflammatory disease of the bowel.
Collect post-urea (red top) breath samples.
Single-dose Vial Use 12 Withdraw the 0.5 ml dose of vaccine from the single-dose vial using a sterile needle and syringe free of preservatives, antiseptics, and detergents.
Single-dose Vial Use Withdraw the 0.5 ml dose of vaccine from the single-dose vial using a sterile needle and syringe free of preservatives, antiseptics, and detergents.
10 February 1995 for a provisional period of three years (Council Regulation (EC) No 297/ 95, Official Journal No L.35/ 1, 15.2.95).
Fat redistribution and metabolic disorders
Fat redistribution & metabolic disorders
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.
Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.
Reduction of post-operative pain (over a period of 24 hours):
Reduction of inflammation and relief of pain associated with musculo-skeletal disorders and soft tissue lesions (traumatic injuries and surgical trauma).
- reduction in red blood cells which can make the skin pale and cause weakness or breathlessness,
Blood and lymphatic system disorders Uncommon: increase in eosinophilic cells (eosinophilia), reduction in white blood cells (leucopenia) which makes infections more likely Rare: reduction in red blood cells (anaemia), increase in white blood cells (leucocytosis), alteration of the prothrombin (coagulation factor) values, reduction in blood platelets (thrombocytopenia) with bruises and tendency to bleed, increase in blood platelets (thrombocytosis) Very rare: reduction in red blood cells due to extensive destruction of these cells (haemolytic anaemia), severe reduction in blood cells (pancytopenia), severe reduction in white blood cells characterised by sudden high fever, very sore throat and mouth ulcers (agranulocytosis)
Risk reduction of suffering from multiple events** (%)
Relative risk reduction of clinical
Relative risk reduction of clinical vertebral fracture
micrograms Absolute Neutrophil Count
micrograms Absolute Neutrophil Count
Ribavirin Ribavirin to 600 mg
review of Botulinum neurotoxin type A treatment as an adequate therapy if no adverse reactions have occurred during the initial treatment, an additional course of treatment can be performed under the following conditions:
ReFacto AF was first authorised as ReFacto in April 1999, for use in previously treated and untreated patients with haemophilia A, based on the results of three main studies.
ReFacto AF contains the active substance moroctocog alfa.
The rate of administration should be determined by the patient's comfort level.
ReFacto AF should not be mixed with other infusion solutions.
ReFacto AF is appropriate for use in adults and children of all ages, including newborns.
ReFacto AF can be used in patients of all ages, including newborns.
ReFacto AF is a powder and solvent that are mixed together to make up a solution for injection.
Close the tube tightly after each use.
- The tube should be closed tightly after each use.
Refludan 50 mg powder for solution for injection or infusion Lepirudin Intravenous use.
REFLUDAN - 50 mg - Powder for solution for injection or infusion - 1 vial REFLUDAN - 50 mg - Powder for solution for injection or infusion - 10 vials
Refludan greatly reduces the risk of blood clots forming, preventing subsequent damage.
Refludan, once reconstituted with an appropriate solvent, will be administered into a vein, by injection and then by infusion.
Look in the window of the pen and make sure there is a white, to off-white tablet that is whole, or in pieces, or powdered.
Look in the window of the pen and make sure there is a white, to off-white tablet that is whole, or in pieces, or powdered.
Anti-retroviral Pregnancy Registry To monitor maternal-foetal outcomes in patients inadvertently administered ISENTRESS while pregnant, an Anti-retroviral Pregnancy Registry has been established.
Priming the Pen (check Insulin Flow).
Priming Pen (check insulin flow).
- Council Regulation (EEC) No 2377/90 as amended (OJ L 224, 18.8.1990, p.1)
- Council Regulation (EC) No 2743/98 (OJ L 345, 19.12.1998, p.3)
⋅ Council Regulation (EEC) No 2309/93 of 22 July 1993 (Official Journal No L.214/1 of 24.8.93)
⋅ Council Regulation (EEC) No 2377/90 of 26 June 1990 as amended (Official Journal No L.224/1 of 18.8.90)
- Abnormal or painful menstruation, pain in the breasts, disorder of ovary or vagina, impotence,
How has Regranex been studied?
Regranex healed 47% of the ulcers that were less than 5 cm2, when the percentage healed using either a placebo gel, or no treatment, were 35 and 30%, respectively.
Regranex contains becaplermin, a recombinant human Platelet Derived Growth Factor-BB (rhPDGF- BB).
Human erythropoietin is an endogenous glycoprotein hormone that is the primary regulator of erythropoiesis through specific interaction with the erythropoietin receptor on the erythroid progenitor cells in the bone marrow.
Contrast enhancement in magnetic resonance angiography (CE-MRA).
Contrast enhancement in magnetic resonance angiography (CE-MRA).
Contrast enhancement in cranial and spinal magnetic resonance imaging (MRI).
José António ARANDA DA SILVA Presidente Conselho de Administraçao INFARMED Parque Saúde de Lisboa Av. do Brasil, 53 P-1700 Lisboa Tel:
Kidney: kidney pain such as lower back pain, frequent urination
fracture, scoliosis (deviation of the vertebral column), bone deformity and fragility, hair discoloration, severe allergic reaction, somnolence, fits, nervousness, hallucination, decrease in white blood cells, gastrointestinal ulcer manifested by bleeding in the digestive tract and effect on the kidney manifested by swelling of the extremities and weight gain.
In particular the working party addressed the need and extent of testing carcinogenic potential in relation to the ICH guideline (ICH topic S1A: need for carcinogenicity studies of pharmaceuticals, ICH topic S1B: testing for carcinogenicity of pharmaceuticals).
At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 µmol in human frontal cortex.
Connect the infusion line to the syringe and start the infusion after priming the line with Erbitux or sterile sodium chloride 9 mg/ ml (0.9%) solution.
Connect the infusion line to the syringe, set and control the rate as explained in section 4.2 and start the infusion after priming the line with Erbitux or sterile sodium chloride 9 mg/ ml (0.9%) solution.
Connect the female luer lock of the gas tube (with the 0.2 μ m bacteriostatic filter) to a pressure regulator capable of delivering 1.0 to 2.0 bars pressure.
RELISTOR should only be used in patients who are receiving palliative care.
RELISTOR is given on top of your usual laxatives.
RELISTOR may cause dizziness, and this may have an effect on driving and use of machines.
RELISTOR can be taken with or without food.
RELISTOR can be injected without regard to food.
No more than 1.5 times the required diffuser power output should be needed from the laser.
Viani 50/ 100 microgram strength is not appropriate in adults and children with severe asthma.
Note: only AEs with onset from start of treatment to 1 calendar day after end of treatment are included.
Note: only AEs with onset from start of treatment to 1 calendar day after end of treatment are included.
If you are to receive more than one vial of BeneFIX the contents of multiple vials may be drawn into the same syringe through a separate, unused filter spike.
After you have completed these steps, a small amount of liquid may remain in the vial.
(Notice that the rear portion of the injection needle will pierce through the rubber membrane that you disinfected previously).
(Notice that the rear portion of the injection needle will pierce through the rubber membrane that you disinfected previously).
Remedina Gounari 25 & Areos Kamatero Attiki 13451 Greece
97 Remeron has minor or moderate influence on the ability to drive and use machines.
Remeron has minor or moderate influence on the ability to drive and use machines.
Now put back the pre-filled pen cap on the pre-filled pen.
Put the cap back on and close the bottle straight after you have used it.
Put back the pre-filled pen cap on the pre-filled pen.
Recap the needle as directed by your health care provider to minimise accidental injury while preparing the site for injection.
Remicade was studied in a clinical study in 120 patients (age range:
Remicade must be given concomitantly with methotrexate.
Remicade, in combination with methotrexate, is indicated for: the reduction of signs and symptoms as well as the improvement in physical function in: • patients with active disease when the response to disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate, has been inadequate. • patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.
Remicade is used with methotrexate (a medicine that acts on the immune system), • Crohn's disease (a disease causing inflammation of the digestive tract), when the disease is severe or fistulising(with the formation of fistulae, abnormal passageways between the gut and other organs), • ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut), • ankylosing spondylitis (a disease causing inflammation and pain in the joints of the spine), • psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints), • psoriasis (a disease causing red, scaly patches on the skin).
Scoop an overfilled spoon of loose powder from the bottle using the measuring spoon provided (see picture below).
Fill the syringe by drawing the plunger out slowly and smoothly.
Fill the syringe by drawing the plunger out slowly and smoothly.
Shake gently the vial of GONAL-f with the solvent.
appetite, hyperactive, excess of triglycerides (a type of fat) in the blood
Rentschler Biotechnologie GmbH Erwin-Rentschler-Strasse 21 D-88471 Laupheim Germany
RENTSCHLER Biotechnologie GmbH Erwin-Rentschler-Strasse 21 D-88471 Laupheim Germany
The implementation will be helped by the quality management system that has already been put in place within the Agency
Fat distribution: redistribution, accumulation or loss of body fat may occur in patients receiving combination antiretroviral therapy.
• Having forgotten to take your insulin • Repeatedly taking less insulin than you need • An infection or a fever • Eating more than usual • Less exercise than usual.
By feel, determine where the IONSYS system is, and which side of IONSYS is rounded.
By feel, determine where the IONSYS system is, and which side of IONSYS is rounded.
Notice the numbered marks on it.
Repeat infusion every 8-24 hours until threat is resolved.
Repeat infusion every 8-24 hours until adequate wound healing, then therapy for at least another 7 days to maintain a factor VIII activity of 30% to 60% (IU/ dl).
until adequate wound healing, then
Repeat the reconstitution procedure for the second dose.
Repeat the rolling and moving procedures (see pictures A and B until the liquid does appears uniformly white and cloudy.
Repeat the rolling and moving procedures (see pictures A and B) until the liquid does appear uniformly white and cloudy.
Repeat steps 8 and 9 until it appears.
• Before first use and just before injecting this insulin, shake the vial up and down at least 10 times and roll the vial between your hands.
Recap pen to protect from light.
Replace cap on pen in order to protect from light.
Replace the cap on the pen in order to protect from light.
in the outer package and discard or whenever possible hand in to your pharmacist.
Enzyme replacement therapy provides patients with the enzyme they are lacking.
ACR Response in Placebo-Controlled Psoriatic Arthritis Studies (Percent of Patients)
101 Table 9 ACR Response in Placebo-Controlled Psoriatic Arthritis Studies (Percent of Patients)
20 Table 9 ACR Response in Placebo-Controlled Psoriatic Arthritis Studies (Percent of Patients)
47 Table 9 ACR Response in Placebo-Controlled Psoriatic Arthritis Studies (Percent of Patients)
74 Table 9 ACR Response in Placebo-Controlled Psoriatic Arthritis Studies (Percent of Patients)
ACR Response in Placebo-Controlled Psoriatic Arthritis Studies (Percent of Patients)
ACR response The percent of abatacept-treated patients achieving ACR 20, 50, and 70 responses in Study II (patients with inadequate response to methotrexate) and Study III (patients with inadequate response to TNF blocking agent) are shown in Table 3.
Complete Response (No Emesis and No Rescue Medication)
[chemotherapy +/ - radiotherapy] (%) (95% CI) ***p-value
Radiographic response Structural joint damage was assessed radiographically over a two-year period in Study II.
ACR Responses in Placebo-Controlled Trials
ACR Responses in Placebo-Controlled Trials (Percent of Patients)
ACR Responses in Placebo-Controlled Trials
ACR Responses in Study V (percent of patients)
ACR Responses in Study V (percent of patients)
Table 4 ACR Responses in RA Study V (percent of patients)
Percent of Patients Inadequate Response to Inadequate Response to Methotrexate (MTX) TNF Blocking Agent Study II Study III a
ACR responses in placebo-/ MTX-/ DMARDs-controlled studies (% patients)
RESPONSES OF PATIENTS WITH PSORIASIS IN STUDIES 2, 3 AND 4 ------------------Study 2--------------- ---------------Study 3------------- ---------------Study 4-------------
RESPONSES OF PATIENTS WITH PSORIASIS IN STUDIES 2, 3 AND 4 ------------------Study 2--------------- ---------------Study 3------------- ---------------Study 4-------------
RESPONSES OF PATIENTS WITH PSORIASIS IN STUDIES 2, 3 AND 4 ------------------Study 2--------------- ---------------Study 3------------- ---------------Study 4-------------
RESPONSES OF PATIENTS WITH PSORIATIC ARTHRITIS IN PLACEBO-CONTROLLED TRIAL Percent of Patients
RESPONSES OF PATIENTS WITH PSORIATIC ARTHRITIS IN PLACEBO-CONTROLLED TRIAL Percent of Patients
Serological, Virological and Biochemical Responses in Chronic Hepatitis B
Virological Response in HCV Patients
21 Genotype 2/3/4 (n=26) * Number (%) of patients
Virological response in previously untreated children and adolescents Rebetol 15 mg/kg/day + interferon alfa-2b 3 MIU/m2 3 times a week
Virological response: previously untreated children and adolescents Rebetol 15 mg/kg/day + interferon alfa-2b 3 MIU/m2 3 times a week
Table 13 Sustained Virological Response in HALT-C by Previous Treatment Regimen in Non-responder Population Previous Treatment
Sustained virological response based on genotype after IntronA in combination with ribavirin versus pegylated interferon alfa-2b in combination with ribavirin in HCV/HIV co-infected patients Study 11 Study 22 pegylated pegylated interferon interferon alfa-2b alfa-2b (100 IntronA (1.5 µg/kg/ IntronA or (3 MIU TIW) week) + (3 MIU TIW) + 150c µg/week) + ribavirin ribavirin ribavirin p + ribavirin (800- p (800 mg) (800 mg) valuea (800- 1,200 mg)d valueb
Table 9 Sustained virological response based on genotype after Ribavirin in combination with peginterferon alfa-2b in HCV/ HIV co-infected patients
Predictability of sustained response by viral response at week 12 and genotype *
Predictability of sustained response by viral response at week 12 and genotype*
Predictability of sustained virological response – Naïve patients Virological reponse by week 12, defined as a 2-log viral load decrease or undetectable levels of HCV- RNA has been shown to be predictive for sustained response (Table 8).
Sustained virological res ponse based on genotype after PegIntron in combination with Ribavirin in HCV/HIV Co-infected patients Study 11 Study 22 PegIntron Interferon PegIntron Interferon (100 or alfa-2b (1.5 µg/kg/ alfa-2b 150c µg/week) (3 MIU TIW) week) + (3 MIU TIW) + + ribavirin + ribavirin
Sustained virological response based on genotype after PegIntron in combination with Ribavirin in HCV/HIV Co-infected patients Study 11 Study 22 PegIntron Interferon PegIntron Interferon (100 or alfa-2b (1.5 µg/kg/ alfa-2b 150c µg/week) (3 MIU TIW) week) + (3 MIU TIW) + + ribavirin + ribavirin
Sustained virological response based on genotype after Viraferon in combination with
Sustained virological response based on genotype ribavirin versus pegylated interferon alfa-2b in HCV/ HIV co-infected patients
Sustained virological response based on genotype ribavirin versus pegylated interferon alfa-2b in HCV/ HIV co-infected patients
Sustained virological response based on genotype after ViraferonPeg in combination with Ribavirin in HCV/HIV Co-infected patients Study 11 Study 22 ViraferonPeg Interferon ViraferonPeg Interferon (100 or alfa-2b (1.5 µg/kg/ alfa-2b 150c µg/week) (3 MIU TIW) week) + (3 MIU TIW) + + ribavirin + ribavirin ribavirin ribavirin p (800- (800- p (800 mg) (800 mg) valuea 1,200 mg) d 1,200 mg) d valueb
Method of administration
Record on the outer carton the date ReFacto AF is removed from the refrigerator and set at room temperature (up to 25oC).
You should refer to the package leaflet for dexamethasone for further information on its use and effects.
you have a severe infection. • You should be screened for TB.
1 st injection: _______________________ Following injections: _______________________
Carefully set the syringe down on the work surface, taking care not to touch the needle.
Carefully set the syringe down on the work- surface, taking care not to touch the needle.
Carefully set the syringe down on the work-surface, taking care not to touch the needle.
Set the syringe down carefully on the work-surface taking care not to touch the needle.
Resume MabCampath at 10 mg when ANC ≥ 500/μ L and platelet count ≥ 50,000/μ L.
Resume MabCampath at 30 mg when ANC ≥ 500/μ L and platelet count ≥ 50,000/μ L.
Authorised Representative in the EEA for Comar Plastics:
Luxembourg Dr Jean-Louis ROBERT Ms Jacqueline GENOUX-HAMES
Reproduction: decreased sex drive, male sexual difficulty
Vaginal haemorrhage, breast tenderness, dysmenorrhea, ovarian cyst, menopausal symptoms
When a child is given the vaccine, the immune system (the system that fights diseases) recognises the weakened virus as ‘ foreign'and makes antibodies against it (an antibody is a special protein that can neutralise or destroy an antigen, such as an infectious agent or virus).
Czech Republic, Hungary, Poland, Slovakia, and United Kingdom.
Restricted to duly designated competent administrative authorities.
28 Endogenous red cell reserve = blood volume [ml] x (PCV - 33) ÷ 100
39 Endogenous red cell reserve = blood volume [ml] x (PCV - 33) ÷ 100
50 Endogenous red cell reserve = blood volume [ml] x (PCV - 33) ÷ 100
Endogenous red cell reserve = blood volume [ml] x (PCV - 33) ÷ 100
Endogenous red cell reserve = blood volume [ml] x (PCV - 33) ÷ 100
* including two new combinations 3.1 Workload and goals of the Unit
Cross-resistance Cross-resistance has been observed among HBV nucleoside analogues (see section 4.4).
Resistance: the potency of efavirenz in cell culture against viral variants with amino acid substitutions at positions 48, 108, 179, 181 or 236 in RT or variants with amino acid substitutions in the protease was similar to that observed against wild type viral strains.
HIV-1 isolates with reduced susceptibility to enfuvirtide have been selected in vitro which harbour substitutions in amino acids (aa) 36-38 of the gp41 ectodomain.
In vivo resistance (antiretroviral-naïve patients):
In vivo resistance (Therapy experienced patients):
Follow the injection procedure as instructed by your health care professional.
Follow recommended safety measures for removal and disposal of needles (e. g. a one handed capping technique) in order to reduce the risk of accidental needle injury and transmission of infectious diseases.
Follow recommended safety measures for removal and disposal of needles (e.g. a one handed capping technique) in order to reduce the risk of accidental needle injury and transmission of infectious diseases.
87 Follow your doctor's instructions carefully.
Always use CYSTAGON exactly as your doctor or your child's doctor has told you.
Always take Mycophenolate mofetil Teva exactly as your doctor has told you.
Always use Prometax transdermal patches exactly as your doctor has told you.
Always take Sebivo exactly as your doctor has told you.
Always take Diovan exactly as your doctor has told you in order to get the best results and reduce the risk of side effects.
Always take Cardoreg 4 mg prolonged release tablets and associated names exactly as your doctor has told you.
Always take Clopidogrel BMS exactly as your doctor has told you.
Always use Liprolog Mix25 KwikPen exactly as your doctor has told you.
• difficulty in breathing • abdominal pain •
- Rapid breathing, constipation, indigestion, heartburn, nausea, vomiting, abdominal pain,
breathing (bronchospasm)
hives) while on this medication, seek medical help immediately.
snoring), treatment should be interrupted and the cause should be examined by a doctor.
Manufacturer authorisation holder responsible for batch release LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup, Denmark.
please tell your doctor or pharmacist.
Stay in shaded areas or go out when it is cloudy.
9 5-year results from large, multinational fracture trial (PEARL)
Clinical results In antiretroviral naive patients Study 138 is an international randomised, open-label, multicenter, prospective trial of 883 antiretroviral treatment naïve patients comparing REYATAZ/ ritonavir (300 mg/ 100 mg once daily) to lopinavir/ ritonavir (400 mg/ 100 mg twice daily), each in combination with fixed dose tenofovir/ emtricitabine (300 mg/ 200 mg tablets once daily).
Clinical results In antiretroviral naive patients Study 138 is an international randomised, open-label, multicenter, prospective trial of 883 antiretroviral treatment naïve patients comparing REYATAZ/ ritonavir (300 mg/ 100 mg once daily) to lopinavir/ ritonavir (400 mg/ 100 mg twice daily), each in combination with fixed dose tenofovir/ emtricitabine (300 mg/ 200 mg tablets once daily).
Clinical results from studies with treatment naïve and experienced patients
Clinical results from studies with treatment naïve and experienced patients
Secondary Efficacy Results (Breast Disease)
Disease activity outcomes In all three studies, rituximab 2 x 1000 mg significantly increased the proportion of patients achieving at least a 20% improvement in ACR score compared with patients treated with methotrexate alone
Efficacy results for studies AVF0780g and AVF2192g
Results from 3 years fracture study MF 4411 (%, 95% CI) for patients with lumbar spine BMD T-score below – 2.5 at baseline
Results from 3 years fracture study MF 4411 (%, 95% CI)
MEDAL Program Hepatic Safety Results:
Results for endpoint survival using the Cox regression model
It may cause transient and reversible changes to vision, including blurring, altered/ enhanced visual perception
results; other tests may therefore be necessary to confirm the presence of Helicobacter pylori.
results; other tests may therefore be necessary to confirm the presence of Helicobacter pylori.
Final results of studies EN3267-005 and 3267-007, including detailed exposure of patients and full safety analysis.
Pooled results across the 3 treatment levels
Pooled results across the 3 treatment levels
Results for endpoint survival using the Cox regression model
Combined results of the 30 week placebo controlled studies (intent to treat patients)
This document is a summary of the European Public Assessment Report.
This document is a summary of the European Public Assessment Report (EPAR).
Summary of Product Characteristics set out in Annex III of the CHMP Opinion with emphasis to the following:
See front label (Lot, Exp., Pot.)
Summary of Product Characterisitics, Section 4.2).
Summary of Product Characteristics, section 4.2.).
Summary of Product Characteristics, section 4.2).
Summary of Product Characteristics, Section 4.2).
Summary of Product Characteristics, section 4.2).
Summary of Product Characteristics, section 4.2).
Summary of baseline patient and disease characteristics in the VISTA study
Summary of Product Characteristics, section 4.2).
Summary of pharmacokinetic data from study GS-US-177-0105
Summary of adverse reactions with porfimer sodium in patients with HGD and BO
Tabulated summary of adverse reactions
Summary of requirements to active substances in part II of the
Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A (factor VIII ≤ 2%) Interquartile PK Parameter
Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A (factor VIII ≤ 2%) PK Parameter AUC0-∞ (IU· h/ dl) t1/ 2 (h) Adjusted Recovery
Summary of key efficacy results from placebo-controlled studies
Summary of Results of Efficacy Analyses as of Dates Studies Were Unblinded — Pooled Studies MM-009 and MM-010
Summary of signs and symptoms associated with hypersensitivity to abacavir (Signs and symptoms reported in at least 10% of patients with a hypersensitivity reaction to abacavir are in bold text).
This document is a summary of the European Public Assessment Report (EPAR).
This document is a summary of the European Public Assessment Report (EPAR).
This document is a summary of the European Public Assessment Report (EPAR).
Retacrit must not be used if • The blister sealing is broken or the blister is damaged in any way. • The liquid is coloured or you can see particles floating in it. • Any liquid has leaked out of the pre-filled syringe or condensation is visible within the sealed blister. • It may have been accidentally frozen.
Retapamulin is a semi-synthetic derivative of the compound pleuromutilin, which is isolated through fermentation from Clitopilus passeckerianus (formerly Pleurotus passeckerianus).
Retapamulin selectively inhibits bacterial protein synthesis by interacting at a unique site on the 50S subunit of the bacterial ribosome that is distinct from the binding sites of other non- pleuromutilin antibacterial agents that interact with the ribosome.
Retapamulin should not be used to treat abscesses.
Retapamulin ointment contains butylated hydroxytoluene, which may cause local skin reaction (e. g. contact dermatitis), or irritation to the eyes and mucous membranes.
Retapamulin ointment must be kept away from the eyes and mucous membranes.
Urinary hesitation Dysuria Nocturia Urine odour abnormal
Hold your breath for about 10 seconds or for as long as is comfortable.
- Fluid build up with swollen ankles, legs and/ or hands
- Excess of fluid, usually in the legs (peripheral oedema)
- Excess of fluid, usually in the legs (peripheral oedema)
Urinary Retention Dysuria Urinary hesitation Nocturia Polyuria Urine flow decreased
Urinary retention (including feeling of residual urine; micturition disorder); Urinary hesitation
Urinary retention, urinary tract disorder, bladder pain
Ongoing Ongoing Ongoing Withdrawn by the company Ongoing Ongoing Ongoing Ongoing Ongoing
Gently remove the plastic cover from the needle without twisting it.
Remove the needle after each injection and discard it.
Picture 8 Take the needle out of the skin without releasing the plunger.
If you see any bubbles, pull the plunger slightly back; tap the syringe gently, with the needle pointing up, until the bubbles disappear.
Pull off needle and throw away as directed by your healthcare professional.
Withdraw the needle quickly and apply pressure over the injection site with a dry, sterile pad.
Change the needle for the fine-bore needle and remove any air bubbles:
Turn the cap upside-down and replace the cap vertically over the tip seal as shown in the diagram.
Remove the tip cap by twisting it off.
Remove the plastic top from the vial by pushing upwards to expose the rubber stopper.
Take off the pen cap (as shown by the arrow).
Remove the plastic cap from the vial, exposing the stopper with the inner rubber circle.
Then take the cap off and put it back on again, lining up the 0 next to the dosage indicator.
Take off the inner needle cap and discard it.
Take off the inner needle cap and discard it.
Take off the inner needle cap and discard it.
Take off the inner needle cap and discard it.
Remove the safety cap from the bottle by squeezing the tabs on the cap and twisting.
Breathe out through your mouth, using a straw, into the sample tube. iii.
The infusion bottle/bag should be gently inverted to disperse the diluted solution but NOT agitated in order to avoid foaming.
The infusion bottle/ bag should be gently inverted to disperse the diluted solution but NOT agitated in order to avoid foaming.
The infusion bottle/bag should be gently inverted to disperse the diluted solution but NOT agitated in order to avoid foaming.
Gently invert or massage the infusion bag to mix the diluted solution.
Gently invert or lightly massage the infusion bag to mix the diluted solution.
Turn the bottle the correct way up and remove the syringe from the adapter.
Turn the bottle right way up and with a twisting movement separate the dosing syringe from the bottle.
- The OPTISON vial must be inverted and gently rotated for approximately three minutes to
Turn the bottle the correct way up and remove the syringe from the adapter.
Turn the bottle the correct way up and remove the syringe from the adapter 7.
Turn the entire unit right side up and remove the dispenser slowly from the bottle.
- tightening of the gullet (oesophagus), difficulty in swallowing that may cause pain
The ORGAM was established upon request of the new CPMP • The ad hoc group on paediatrics, chaired by Dr Daniel in January 2001.
Information technology Infrastructure Meetings at the EMEA Document management and publishing
(Co-)Rapporteur Meetings Working Party Meetings Ad-Hoc Working Party Meetings
reflects a relatively high number of class-related labelling changes submitted in 2000.
Meetings and delegates at the EMEA 2000-2002
Meetings Evaluations Translation Studies and consultants Publications
Meetings Evaluations Translation Studies and consultants Publications EU programmes
Operational expenditure
New arrangements for requesting certificates of a medicinal product were introduced in 2000 and posted on the EMEA web site.
Revasc is used in adult patients to prevent blood clotting after hip or knee replacement surgery.
Revatio should not be administered to breast- feeding mothers.
Taking Revatio with food and drink Revatio can be taken with or without food.
Revatio can be used with epoprostenol (another medicine used in PAH).
of thrombotic CV events,
thrombotic CV events,
Improvements to EMEA facilities are expected to be of particular benefit to the operation of the MRFG, in particular the additional meeting and videoconferencing rooms on the third floor of the Agency’s offices.
provision of support to European and international harmonisation activities of the CVMP and its working parties
– Development of guidelines and position papers: • Harmonisation of requirements for low (efficacy) and high (safety) potency and batch consistency of vaccines • Gene therapy • Vectored vaccines (when the vector is part of the vaccine) • Revision of CVMP guidance with regard to compliance with the European Pharmacopoeia • Review of equine influenza guidelines
advice by carrying out scientific reviews of the requests for advice from companies, providing a guarantee of proper and adequate expertise – Strengthen the level of interaction with companies,
– Continue to support the CPMP through provision of scientific
• review its arrangements for managing its own affairs to make sure they work efficiently
Independent Review of Response Rate and Duration
REYATAZ with ritonavir has not been studied in patients with hepatic impairment.
REYATAZ should be used during pregnancy only if the potential benefit justifies the potential risk.
John's wort (Hypericum perforatum) (see section 4.5).
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
REYATAZ/ ritonavir should be administered 2 hours before or 1 hour after antacids or buffered medicinal products.
REYATAZ/ RTV with tenofovir/ emtricitabine (fixed dose 300 mg/ 200 mg tablets once daily). b Lopinavir/ RTV with tenofovir/ emtricitabine (fixed dose 300 mg/ 200 mg tablets once daily). c Intent-to-treat analysis, with missing values considered as failures. d Number of patients evaluable.
Amenorrhea, breast pain, dysmenorrhea, menorrhagia, menstrual disorder, vaginal disorder
Dizziness, headache, concentration impaired, mouth dry Tremor, paresthesia, hypoesthesia, migraine, flushing, somnolence, taste perversion
Rhodor 7046R antifoam - Tetracycline (Hcl) HD - EVA (Ethyl Vinyl Acetate) - White soft paraffin - Paraffin 50/ 52° C - Seah Saur - Natural fish aroma
3 Psoriatic arthritis and ankylosing spondylitis
Psoriatic arthritis and ankylosing spondylitis no
Psoriatic arthritis and ankylosing spondylitis t uc
Psoriatic arthritis and ankylosing spondylitis
Psoriatic arthritis and ankylosing spondylitis no
ra including thyroid disorders, systemic lupus erythematosus, rheumatoid arthritis (new or aggravated), idiopathic and thrombotic thrombocytopenic purpura, vasculitis, neuropathies including mononeuropathies (see also section 4.4).
Ribavirin Ribavirin Ribavirin Ribavirin Ribavirin
Ribavirin Teva must be used in combination with either peginterferon alfa-2b (1.5 micrograms/ kg/ week) or interferon alfa-2b (3 million international units [MIU] three times a week).
Ribavirin Teva in combination with peginterferon alfa-2b or interferon alfa-2b may also cause: loss of use, drooping or loss of power of facial muscles, loss of feeling sensation, loss of consciousness, loss of vision, difficulty breathing, changes in the way your heart beats, chest pain, pain down left arm, jaw pain, dark, cloudy or abnormally coloured urine.
Ribavirin Teva must not be taken by women who are breast-feeding.
Ribavirin Teva is used in adults, in combination with either peginterferon alfa-2b or interferon alfa-2b, to treat patients who have chronic hepatitis C.
Duration of treatment – Naïve patients Predictability of sustained virological response:
Ribavirin Capsules in combination with interferon alfa-2b:
Ribavirin Teva must never be used on its own but only together with an interferon (another type of medicine used in hepatitis).
Ribavirin monotherapy must not be used.
The situations where Ribavirin Teva can be used with adults are listed below:
Ribavirin Teva can harm both the embryo
Ribavirin Teva on its own has no effect on eliminating the hepatitis C virus from the body.
Capsules (see section 6, further information)
There is no reason to suspect cross-allergenicity with sulphonylurea drugs due to the difference in chemical structure.
There is no reason to suspect cross-allergenicity with sulphonylurea drugs due to the difference of the chemical structure.
There is no indication that food influences the absorption of memantine.
Dose reduction of rifabutin and dose increase of Crixivan has not been confirmed in clinical
Dose reduction of rifabutin and dose increase of Crixivan has not been confirmed in clinical
103 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Rigevidon is a combined oral contraceptive (COC) containing 150µg levonorgestrel (LNG) and 30µ g ethinylestradiol (EE2).
RILUTEK stops the release of glutamate and this may help in preventing the nerve cells being damaged.
It is available as white, capsule- shaped 50 mg tablets.
Immediately rinse the dosing cup with water.
Repeat the rinsing operation once or twice.
150 mg 150 mg 150 mg 150 mg 150 mg 150 mg 150 mg 150 mg 150 mg 150 mg 300 mg 300 mg 300 mg 300 mg 300 mg 300 mg 300 mg 300 mg 300 mg 300 mg
Riprazo also reduced blood pressure in patients with diabetes, patients who were overweight, and those who were over 65 years of age.
Riprazo induced an additive blood-pressure-lowering effect when added to hydrochlorothiazide and to ramipril.
Combination studies looked at Riprazo used with an angiotensin converting enzyme inhibitor (ramipril), an angiotensin receptor blocker (valsartan), a beta-blocker (atenolol), a calcium-channel blocker (amlodipine) and a 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Riquent is a solution for injection that contains 50 mg/ ml of the active substance abetimus.
au Once broached, use within 8 hours if stored at 2°C-8°C
Forcaltonin should be used immediately after the single-use ampoule is opened. rod
The therapeutic margin of Nespo is very wide.
The majority of events were asymptomatic distal DVT.
ise Four studies of ACOMPLIA as a help to stop smoking were also carried out in over 7,000 patients, comparing it with placebo, and measuring the effect of the medicine given for 10 weeks (one year in one of the studies) on smoking cessation, and on relapses in the following year.
RISPERDAL CONSTA belongs to a group of medicines called ‘ anti-psychotics’.
RISPERDAL CONSTA has minor or moderate influence on the ability to drive and use machines due to potential nervous system and visual effects (see section 4.8).
RISPERDAL CONSTA should be administered with caution in this group of patients (see section 4.2).
RISPERDAL CONSTA should be administered every two weeks by deep intramuscular gluteal injection using the enclosed safety needle.
RISPERDAL CONSTA should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.
RISPERDAL CONSTA should be used with caution in patients with pre- existing hyperprolactinaemia and in patients with possible prolactin-dependent tumours.
RISPERDAL CONSTA should be used with caution in patients with risk factors for stroke.
RISPERDAL CONSTA is given as an intramuscular injection into the buttocks every two weeks, administered by a health care professional.
RISPERDAL CONSTA is intended for patients who are currently treated with oral (e. g. tablets, capsules) antipsychotics.
RISPERDAL CONSTA is indicated for the maintenance treatment of schizophrenia in patients currently stabilised with oral antipsychotics.
RISPERDAL CONSTA The following side effects have been reported with the use of RISPERDAL CONSTA, a long acting injection.
RISPERDAL CONSTA should not be used in acute exacerbations of schizophrenia without ensuring sufficient antipsychotic coverage with oral risperidone or the previous antipsychotic during the three- week lag period following the first RISPERDAL CONSTA injection.
RISPERDAL CONSTA taken by itself or with furosemide, may have an increased risk of stroke or death in elderly people with dementia.
RISPERDAL CONSTA may cause low blood pressure.
RISPERDAL CONSTA may cause you to gain weight.
Instructions for Three Needle System RISPERDAL CONSTA come in a form of a powder that must be mixed with only the solution in the syringe supplied in the dose pack, and must be administered only with the Needle-Pro safety needle supplied in the dose pack.
RISPERDAL CONSTA should be used with caution in elderly.
RISPERDAL is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorders.
RISPERDAL should not be used more than 6 weeks in patients with persistent aggression in Alzheimer's dementia.
RISPERDAL Oral The following side effects have been reported with the use of RISPERDAL Oral.
RISPERDAL can have minor or moderate influence on the ability to drive and use machines due to potential nervous system and visual effects (see section 4.8).
RISPERDAL may cause low blood pressure.
RISPERDAL Quicklet orodispersible tablets Only remove a tablet from the blister when it is time to take your medicine. • Peel open a blister to expose the tablet • Do not push the tablet through the foil because it may break • Remove the tablet from the blister with dry hands • Place the tablet on your tongue straight away • The tablet will begin disintegrating within seconds • It can then be swallowed with or without water.
Risperdal ®/ Rispolin ®/ Risperdal® Quicklet® / Rispolin® Quicklet® RISPERDAL® / Risperidone J-C ® / RISPERDAL Instasolv ® / Risperidone J-C Instasolv ®
RISPERDAL oral solution The solution comes with a syringe (pipette).
ris Produced by recombinant DNA technology in Escherichia coli.
Live attenuated vaccines: risk of systemic, possible fatal disease.
Risk of fatal generalised vaccinial disease (see section 4.3).
Potential medicinal product interactions affecting Zonegran
Potential for gastrointestinal obstruction Because the INVEGA tablet is non-deformable and does not appreciably change shape in the gastrointestinal tract, INVEGA should not ordinarily be administered to patients with preexisting severe gastrointestinal narrowing (pathologic or iatrogenic) or in patients with dysphagia or significant difficulty in swallowing tablets.
Non-acceptable risk to higher plants There is evidence of a non-acceptable risk for plants when manure obtained from Baycox 2.5% treated poultry are applied to agricultural land.
Relative Risk (95% CI) of GvHD and TRM Following treatment with G-CSF after bone marrow transplantation
Risks of using combined hormonal contraceptives
Venous thromboembolism The combination of lenalidomide with dexamethasone is associated with an increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with multiple myeloma (see sections 4.5 and 4.8).
If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice. in ic
effect on your blood glucose control. ed
recommended by your doctor.
Ritonavir oral solution contains castor oil polyoxyl which may cause stomach upset and diarrhoea.
From 1965 to 1976, Mr Riva was an official of the Italian Institute for Foreign Trade, serving at headquarters in Rome and at the Berlin
Rivastigmine oral solution and rivastigmine capsules may be interchanged at equal doses.
Rivastigmine oral solution and rivastigmine capsules may be interchanged at equal doses.
RoActemra is usually given in combination with methotrexate.
Tel: +31 (0) 348 438050
Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom
Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom.
Josep Torrent Farnell
România Astellas Pharma Internaţional Detalii de contact pentru România Şoseaua Bucureşti-Ploieşti 42-44 Clădire 1, Parter 013696-Bucureşti - RO Tel: +40 (0)21 361 04 95
România AstraZeneca UK Limited Reprezentanţ a România
România Boehringer Ingelheim Pharma Ges mbH Reprezentanţ a din România Tel: +40 21 330 99 63
România Boehringer Ingelheim RCV GmbH & Co KG Viena - Sucursala Bucuresti Tel: +4 021 330 99 63
România Ewopharma AG România Intrarea Eliza Zamfirescu Leonida nr.13, ap.2, sector 1 Bucureş ti 011372-RO Tel.: +40 21 260 13 44 E-mail: uk_medinfo@allergan. com
România EXUBERA – Centrul de Rela)ii cu Clien)ii Tel.:
România FARMACEUTICA REMEDIA SA Str.
România Merck Sharp & Dohme Romania S. R. L.
France sanofi-aventis France Tél:
România GE Healthcare (South Central Europe) Handels GmbH Representative Office Str. Navodari No.42 Sc.2 et.2 014108 Bucharest Tel:
România GlaxoSmithKline (GSK) SRL Tel: +40 (0)21 3028 208 www.gsk.ro
România Lundbeck Export A/S, Reprezentanta din Romania Bd.
Dunajska cesta 119 SI-1000 Lubliana, Slovenia Tel: +386 1 560 3 800
România Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 D-60318 Frankfurt
România Nycomed România Strada Despot Vodă nr.32A, Sect.2 Bucureşti, Cod 020656-RO Tel: + 40212123848
Very common side effects (occurring in at least 1 in 10 patients) are:
Merck Sharp & Dohme ROMANIA S. R. L, Bucharest Business Park, Soseaua Bucuresti-Ploiesti nr.1A, Corp C1, etaj 3, sector 1, 013681, Bucharest Romania
Slovenská republika TopoTarget A/ S Fruebjergvej 3 DK – 2100 Kodaň Tel: + 45 39 17 83 92 Suomi/ Finland TopoTarget A/ S Fruebjergvej 3 DK– 2100 Kööpenhamina Puh/ Tel: + 45 39 17 83 92 Sverige TopoTarget A/ S Fruebjergvej 3 DK – 2100 Köpenhamn Tel: + 45 39 17 83 92 United Kingdom TopoTarget A/ S Fruebjergvej 3 DK – 2100 Copenhagen Tel: + 45 39 17 83 92
Break the seal of the white plastic cover on the syringe Luer connector to remove the cover with the attached rubber tip cap (see Figure 1).
Break the seal of the white plastic cover on the syringe Luer connector to remove the cover with the attached rubber tip cap (see Figure 1).
Ronda General Mitre, 151 08022 Barcelona Spain Tel: + 34 93 291 30 00
Ronda General Mitre, 151 08022 Barcelona / Špan lsko / Spanien / Hispaania / / España / Spánn / / Sp nija / Ispanija / Spanyolország / Spanja / Spanje / Spania / Hiszpania / Spania / Španija / Španielsko / Espanja / Spanien Te /Tel/Tlf/T /Sími/Puh: +34 93 291 30 00
AstraZeneca UK Ltd, 600 Capability Green Luton, Bedfordshire, LU1 3LU, UK
Roselinde HURLEY Jean-Pierre REYNIER
An increase in plasma volume accompanied by decrease in red cell parameters and increase in heart weight.
An increase in plasma volume accompanied by decrease in red cell parameters and increase in heart weight.
Some medicines may affect the way Tyverb works or Tyverb may affect how other medicines work.
RotaTeq contains viruses that carry the antigens for some of the most commonly occurring types of rotaviruses.
RotaTeq does not protect against diarrhoea and vomiting due to causes other than rotavirus.
This vaccine is contained in a single-dose tube and is a pale yellow clear liquid that may have a pink tint.
cells in your blood or a reduced number of blood platelets,
- The active substance is bortezomib.
Redness, swelling, discoloration, inflammation, pain, hypersensitivity, necrosis and non-specific reactions were significantly associated with 250 microgram (8 million IU) Betaferon treatment.
Skin rash with or without severe itching and wheal formation (urticaria) Renal and urinary problems:
- flushing, itching and inflamed skin, inflammation of mucus (moist) linings such as the mouth
• Redness, swelling, bruising or itching at the injection site.
- flushed or painful palms or soles (hand foot syndrome)
Laboratoire GlaxoSmithKline, 100 Route de Versailles, 78163 Marly-le-Roi Cedex, France
Rowan House 41 London Street Reading, Berkshire, Rg1 4ps
United Kingdom Tritace 1.25 mg tablets, Tritace 2.5 mg tablets, Tritace 5 mg tablets, Tritace 10 mg tablets, Tritace 1.25 mg capsules, Tritace 2.5 mg capsules, Tritace 5 mg capsules, Tritace 10 mg capsules Tritace Titration Pack capsules, Tritace Titration Pack tablets
PRf n (%) nCR n (%) CR + PRf n (%) p-valued
Marketing Authorisation Holder
Sagres, 5ºA P-2685-338 Prior Velho Portugal
María de Molina, 40 E-28006 Madrid Línea de Información:
Divisão de Saúde Animal Rua da Quinta do Pinheiro, 5 P-2794-003 Carnaxide Tel: +351 21 4172121
Rua da Quinta dos Grilos, 30 P-2790-476 Carnaxide Tel: + 351 21 425 3242 E-mail: uk_medinfo@allergan. com
Henrique de Barros, Edifício Sagres, 3ºA P-2685-338 Prior Velho Portugal
Valejas 2745-663 Barcarena Portugal
Rua Manuel Ribeiro De Pavia, 1 - 1º - Venda Nova 2700-547 Amadora
Section 4.5 of the SPC and Section 12 of the Package Leaflet:
Rue de l'Institut 89 B-1330 Rixensart, Belgium t uc
Rue des Trois Arbres, 16b B-1180 Bruxelles Belgium
Rue du Bosquet, 15 B-1348 Louvain-la-Neuve Belgium
(351-21) 798 71 16 Fax (351-21) 798 71 24 E-mail: miguel.andrade@infarmed.pt Internet: http://www.infarmed.pt Rui MARQUES LEITÃO Director Geral Direcçao Geral de Veterinária Lg Academia Nacional de Belas Artes 2 P - 1294 Lisboa Tel.
Rusham Park Technical Centre Whitehall Lane Egham Surrey TW20 9NW United Kingdom
Rusham Park Technical Centre Whitehall Lane Egham, Surrey TW20 9NW United Kingdom
Rusham Park Technical Centre, Whitehall Lane, Egham, Surrey TW20 9NW United Kingdom
Slovenská republika Sandoz d. d. – organizač ná zlož ka Ruž inovská 42 SK-82103 Bratislava Tel: + 421-2-48 200 600
- irregular, rapid beating or pulsation of the heart (palpitation),
S01EX Reduction of elevated intraocular pressure in chronic open-angle
w.1 w.2 w.3 w.4 w.55 w.6 w.7 IL-2 16 400 IU/ kg followed by 0.5 ml
METHOD AND ROUTE(S) OF ADMINISTRATION
S ≤1 mg/l and R > 4 mg/l inferred from the methicillin breakpoint
S ≤1 mg/l and R > 4 mg/l S ≤1 mg/l and R > 4 mg/l S ≤1 mg/l and R > 4 mg/l S ≤1 mg/l and R > 1 mg/l S ≤ 1 mg/l and R > 1 mg/l “inappropriate target” S ≤ 1 mg/l and R > 1 mg/l IE (insufficient evidence) S ≤1 mg/l and R > 1 mg/l
*see dose modification for provisions for the modification to dose and dosage schedule
België/ Belgique/ Belgien Luxembourg/ Luxemburg SA Alcon-Couvreur NV + 32 (0)3 890 27 11 (België/ Belgique/ Belgien)
België/ Belgique/ Belgien Luxembourg/ Luxemburg SA Alcon-Couvreur NV + 32 (0)3 890 27 11 (België/ Belgique/ Belgien)
Sabumalin is a metered dose aerosol inhaler containing a suspension formulation of salbutamol sulphate 100 µg/ spray, with HFA 134a as propellant.
Sabumalin is used to relieve symptoms, and its use should not delay the use of inhaled steroids.
The cause can be unknown, or it can be due to heart, lung or liver problems.
Sucrose, calcium chloride dihydrate, L-histidine, polysorbate 80, sodium chloride.
Sucrose, Glycine, L-histidine, sodium chloride and Polysorbate 80.
Since lithium promotes the release of neutrophils, it is likely to potentiate the effect of filgrastim.
Sachets are made with a composite paper/ aluminium/ polyethylene film.
Sächsisches Serumwerk Dresden (SSW) Zirkusstraße 40 D-01069 Dresden Germany
Sächsisches Serumwerk Dresden (SSW) Zirkusstraβ e 40 D-01069 Dresden Germany
Clearance is approximately 0.066 l/ hr in patients with rheumatoid arthritis, somewhat lower than the value of 0.11 l/ hr observed in healthy volunteers.
Its plasma clearance is about 12 ml/ min (CV 22%) and its renal clearance about 7 ml/ min (CV 28%).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
These were usually mild or moderate in severity and no
In chemotherapy, three main studies have been carried out.
In systemic sclerosis with digital ulcers, two studies have compared Tracleer with placebo in a total of 312 patients.
In systemic sclerosis with digital ulcers, Tracleer was more effective at reducing the development of new digital ulcers than placebo.
In triple therapy, one study looked at the effect of adding rosiglitazone to a sulphonylurea (glibenclamide) and metformin in 1,202 patients whose blood glucose was not being controlled sufficiently.
In chronic hepatitis B, two studies have been carried out comparing Pegasys with lamivudine (another antiviral medicine) in 820 ‘ HBeAg-positive'patients (infected with the common type of the hepatitis B virus) and in 552 ‘ HBeAg-negative 'patients (infected with a virus that has mutated [changed], leading to a form of chronic hepatitis B that is more difficult to treat).
For glimepiride, information from scientific publications was used.
Concept paper on the Development of a CPMP Points to consider on the need for reproduction toxicity studies in the development of human insulin analogues Adopted December 2000
Glomerulonephritis, blood creatinine increased
− bleeding into the area surrounding the heart (haemopericardium) − blood clot in the lung (pulmonary embolism)
METALYSE will not be prescribed and given by your doctor
bleeding under the skin (petechiae)
- bleeding, including bleeding in the lungs in patients with non-small cell lung cancer,
- bleeding (including bleeding in the brain, gut wall and respiratory tract; haemorrhage)
The medicine also reduced the risk of regaining weight.
For the treatment of Salmonellosis, it is necessary to administer a double dose at 60 mg/ kg/ day.
Female salmonid fish such as Atlantic salmon (Salmo salar), rainbow trout (Oncorhynchus mykiss), brown trout (Salmo trutta) and Arctic charr (Salvelinus alpinus).
SANDOZ CALCIUM, comprimés Ca 500mg effervescents
Unit 37, Woolmer Way Bordon Hampshire Gu35 9qe United Kingdom
Sandoz Limited Woolmer way Bordon, Hants, GU35 9QE United Kingdom
- Blood in the urine that stains the urine pink or red
Blood: decrease of blood circulating cells (red and white) and platelets.
Lietuva Pfizer Luxembourg SARL Filialas Lietuvoje Tel. +3705 2514000
Blood alkaline phosphatase increased Anorexia Blood uric acid increased
If you get side effects → Tell your doctor or pharmacist if any of the side effects gets severe or troublesome, or if you lP
or who are not about to receive any other treatment to restore blood flow to the heart.
Sanofi-aventis Belgium Culliganlaan 1C 1831 Diegem Belgium
SANOFI-AVENTIS CYPRUS LTD Triatec 14 Charalambou Mouskou street 2015 – Nicosia Cyprus
SANOFI-AVENTIS DENMARK Triatec A/ S Slotsmarken 13 DK-2970 Hoersholm
SANOFI-AVENTIS DENMARK Triatec A/ S Slotsmarken 13 DK-2970 Hoersholm Denmark
SANOFI-AVENTIS NORGE AS Strandveien 15 P. O. Box 133 NO-1325 Lysaker
Sanohex is a metered dose aerosol inhaler containing a suspension formulation of salbutamol sulphate 100 µg/ spray, with HFA 134a as propellant.
Sanohex is used to relieve symptoms, and its use should not delay the use of inhaled steroids.
Sanquin, Plesmanlaan 125, NL-1066 CX Amsterdam, the Netherlands
harmless and lessen as treatment continues.
Non-prescription (including OTC)
medicines, including medicines obtained without a prescription.
medicines, including medicines obtained without a prescription.
S. A., Poligono Industrial Santa Rosa s/ n, 28806 Alcalá de Henares, Madrid, Spain
Purified Saponin, Cholesterol, Phosphatidylcholine, traces of Formaldehyde
Purified Saponin, Cholesterol, Phosphatidylcholine, Thiomersal traces, Formaldehyde traces
Aseptic technique is required for its preparation.
Its main measure of effectiveness was the proportion of patients who had movement symptoms.
Saquinavir/ Efavirenz (1,200 soft capsule formulation q8h/ 600 q. d.)
From 1974 to 1985 he was an audit manager in Spain with Ernst and Young and from 1985 to 1995 he was
Its safety and effectiveness have been studied in women aged 18 to 45 years.
Ensure hands are dry to prevent the tablet from sticking to fingers.
Ensure that the nasal drop is inhaled before freeing the bird.
Ensure the food or treat containing the medication is completely consumed.
Ensure that the powder is completely dissolved before use.
Assure that sodium chloride 9 mg/ ml (0.9%) solution for injection is added to the vial along the vial wall in order to prevent foaming.
Ensure the solution is at room temperature.
Care should be taken to ensure that the content of the pipette or the applied dose does not come into contact with the eyes or mouth of the recipient and/ or other animals.
Care should be taken to ensure that the contents of the pipette or the applied dose does not come into contact with the eyes or mouth of the recipient and/ or other animals.
Care should be taken to ensure that the content of the pipette or the applied dose does not come into contact with the eyes or mouth of the recipient and/ or other animals.
Ensure that the lyophilisate is completely reconstituted before use.
Make sure the child eats the full amount of the mixture of food and capsule contents.
Ensure that the parent or guardian has read and is aware of the indications and cautions presented in the package leaflet prior to administration to their baby.
Ensuring that the syringe plunger rod is still fully depressed, invert the vial.
Allow the application site to dry before permitting contact with such materials.
Allow the application site to dry before permitting contact with such materials.
Ensure that the administration site is clean and dry.
Make sure the cap of the tube is tightly closed after each use.
Ensure that the injection is not mistakenly given paravenously.
It is chemically unrelated to other anti-epileptic agents.
Bacteroides fragilis and species in the B. fragilis Group* Clostridium species (excluding C. difficile)* Eubacterium species* Fusobacterium species* Peptostreptococcus species* Porphyromonas asaccharolytica* Prevotella species* Species for which acquired resistance may be a problem:
Unless compatibility is proven, the solution for infusion should always be administered separately.
Savene is also supplied with an infusion bag containing the Savene diluent.
Savene is a detoxifying agent for anti-cancer treatment.
Savene is used to treat extravasation caused by some specific anti-cancer medicines known as ‘ anthracyclines’.
Savene was not compared to 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
antidepressive medicine can be taken together with Comtan);
Seal lid of box before returning samples for analysis
- Design: randomized (1:1), double-blinded, placebo-controlled.
Moderately Emetogenic Chemotherapy Regimen
Moderately Emetogenic Chemotherapy Regimen
Schering AG Müllerstrasse 178 D - 133 42 Berlin, Germany Telephone: +49 30 468-1111
Schering AG Müllerstrasse 178 D - 13342 Berlin, Germany Telephone: +49 30 468-1111
Schering Plough SPA Via Ripamonti, 89 I-20141 Milano, Italy
- Sciatica (pain in lower back or hip and may radiate into the leg)
appropriate levels of operational support while introducing new
SCINTIMUN was to be used in adults to locate an infection or inflammatory lesion and also to detect whether any metastasis is present in bone marrow.
- Systemic sclerosis with ongoing digital ulcer disease:
Systemic sclerosis with ongoing digital ulcer disease:
Systemic sclerosis with ongoing digital ulcer disease
Nervous system disorders multiple sclerosis, myelitis, facial palsy, polyneuritis such as Guillain-Barré syndrome (with ascending paralysis), encephalitis, encephalopathy
Nervous system disorders Multiple sclerosis, myelitis, facial palsy, polyneuritis such as Guillain-Barré syndrome (with ascending paralysis), optic neuritis
In some cases people with relapsing-remitting MS find that their symptoms increase and they progress to another form of MS called secondary progressive MS.
Secondary progressive multiple sclerosis (SP-MS) Two controlled clinical trials with Extavia involving a total of 1,657 patients with secondary progressive multiple sclerosis (baseline EDSS 3 to 6.5, i. e. patients were able to walk) were performed.
Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Total Score - Change From Baseline to End Point- LOCF for Studies R076477-SCH-303, R076477-SCH-304, and R076477-SCH-305:
Scotoma, scleral discolouration, eye pain, mydriasis, photophobia, myopia, lacrimation increased
Mr Seamus HEALY Assistant Secretary Department of Agriculture, Food and Forestry Agriculture House Kildare Street IRL-Dublin 2 Tel: +353.1.678.9011 Fax: +353.1.662.0198/661.6263
Sebivo is used to treat adults with chronic hepatitis B.
Sebivo should be used during pregnancy only if the benefit to the mother outweighs the potential risk to the foetus.
42 Sebivo may also cause other side effects:
Sebivo may also cause other side effects:
Sebivo oral solution contains approximately 47 mg sodium per 600 mg dose (30 ml), which should be taken into consideration by patients on a controlled sodium diet.
amenorrhoea, galactorrhoea, erectile dysfunction, gynaecomastia, breast discharge, menstruation irregular
- dry skin, flaking and inflammation of the skin, change in skin colour,
(11.9%) Constipation (10.3%) Renals and Urinary Disorders
Renals and Urinary Disorders
Renals and Urinary Disorders
Renals and Urinary Disorders
(< 7 ml/ kg/ month of packed red blood cells).
• L01XC • Second-line treatment of chronic lymphocytic leukaemia
arthralgia, back pain, joint stiffness, muscle spasms, muscle twitching, muscular weakness, musculoskeletal chest pain, musculoskeletal stiffness, myalgia, neck pain, pain in extremity, posture abnormal, rhabdomyolysis, torticollis
Wound secretion Anaemia postoperative Post procedural haematoma Post procedural haemorrhage
- Wound secretion (liquid exuding from the surgical wound)
Conference services • Meeting days
Sector for safety of residues (MRLs) Head of Sector:
SPC Section 4.1 - Therapeutic Indications Following the European Commission's request, Section 4.1 of the Summary of Product Characteristics was harmonised to include the following therapeutic indications as worded and described below:
Section 4.4 Special warnings and precautions for use:
Section I (pharmacokinetic and clinical evaluation)
Pharmacodynamic section of the SPC for anti-bacterial medicinal products
Sector for Document Management and Publishing European Agency for the Evaluation of Medicinal Products 7 Westferry Circus, Canary Wharf London E14 4HB – UK
10 Cardiovascular Safety – Long-Term Studies Involving Subjects With Sporadic Adenomatous Polyps:
Cardiovascular Safety – Long-Term Studies Involving Subjects With Sporadic Adenomatous Polyps:
For the efficacy and clinical safety part, the scope of harmonisation for the table of contents for study reports and tabulated listing of studies was agreed during the ICH meeting in Tokyo, which was held in September 1998.
Pharmacovigilance Plan or risk minimisation activities
Pharmacovigilance Plan or risk minimization activities
Goals and objectives for veterinary medicines.................................... .28 Veterinary marketing authorisation procedures................................. ..30 Safety of veterinary medicines............................................................... 32 Information technology........................................................................ ..33
Fernando GARCIA ALONSO Joint CPMP/CVMP Quality Working Party Jean-Louis ROBERT Safety Working Party Beatriz SILVA LIMA Scientific Advice Review Group Markku TOIVONEN
Jean-Hugues TROUVIN Efficacy Working Party
international normalized ratio (INR) in subjects treated with warfarin.
(notably most antipsychotics, antihistamine H1 antagonists, opioids).
Sixteen cases were identified as possible or probable cases of acquired renal failure.
Selamectin Selamectin Selamectin Selamectin Selamectin
Selamectin Selamectin Selamectin Selamectin Selamectin
Based on this analysis there were no cases in the vaccine group and 20 cases in the control group (Efficacy 100%; 97.9% CI:
Based on this pharmacokinetic study, ambrisentan would not be expected to significantly affect exposure to oestrogen- or progestogen- based contraceptives.
Depending on the dosage you take, these tests may be performed every two weeks or every two months.
Two doses of Paxene may be given:
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
International Health Regulations require re-vaccination, using the same dose as for primary vaccination, at intervals of 10 years in order to retain a valid certificate.
(Invented name)® has been shown to be significantly more effective than placebo as measured by the Hamilton Depression Rating Scale (HAM-D).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
In individual cases, only some of these symptoms and/ or findings may be evident.
Depending on the size of the defect (gap of bone break), more than a single 1g unit of Osigraft may be required.
Depending on the size of the defect, more than a single 1 g vial of Osigraft may be required.
The CHMP concluded that the data submitted showed only limited effect of veralipride in the treatment of vasomotor symptoms associated with the menopause.
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
Based on the Kaplan-Meier estimates, the proportion of patients who maintained MCyR for 1 year was 92% (95% CI:
Based on the Kaplan-Meier estimates, the proportion of patients who had progression-free survival (PFS) for 1 year was 91% (95% CI:
If a new manic, mixed, or depressive episode occurs, olanzapine treatment should be continued (with dose optimisation as needed), with supplementary therapy to treat mood symptoms, as clinically indicated.
The active substance in Lysodren, mitotane, is thought to work by preventing cells in the adrenal gland from working properly, by damaging their mitochondria (the energy-producing components), reducing the production of some steroid hormones.
Age has no clinically meaningful effect on pharmacokinetics of nicotinic acid (prolonged-release formulation) based on a composite analysis of subjects ages 18-65 years.
Through population pharmacokinetic analysis, weight was found to affect efalizumab clearance.
Dependent on how comfortable you are, your doctor may then gradually increase the infusion rate.
Based on your life-style and the results of your blood sugar (glucose) tests, your doctor will
476 Based on your life -style and the results of your blood sugar (glucose) tests, your doctor will
Based on your life -style and the results of your blood sugar (glucose) tests, your doctor will
Based on your life-style and the results of your blood sugar (glucose) tests, your doctor will
The Temodal dose may be adjusted, delayed or stopped depending on your blood counts and how you tolerate your medicine during each treatment cycle.
Calcium salts: thiazide diuretics may increase serum calcium levels due to decreased excretion.
Calcium salts and plasma calcium increasing medicinal products:
Thiazide diuretics may increase serum calcium levels due to the decreased excretion.
Calcium salts Thiazide diuretics may increase serum calcium levels due to decreased excretion.
- Zinc salts (oral use), described for zinc salts at doses > 30 mg/ d: reduction of the
Week 56 Clinical remission Clinical response (CR-100)
weeks, then repeat the skin test.
- light-headedness or fainting due to low blood pressure
burning, itching, stinging, sensitivity to light, eye pain, sticky eyes, dry eyes, a feeling of something in the eye, small breaks in the surface of the eye with or without inflammation, difficulty in seeing clearly, redness and itching of the eyelids, darkening of the eyelids
or headache; rapid heart beat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling
- feeling lethargic (somnolence); trembling; dizziness; disturbed taste
- feeling of numbness or tingling in hands or feet.
- a sensation of tingling, pricking, burning or numbness of the skin
- feeling thirsty and producing darker or less urine than normal, decreased or loss of appetite,
- feeling dizzy upon standing, uncontrollable movements of face or body, seizures, fainting,
abnormal sensation in eye, cataract, conjunctival haemorrhage, conjunctival hyperaemia, conjunctival oedema, conjunctivitis, corneal dystrophy, corneal epithelium defect, corneal epithelium disorder, corneal oedema, dry eye, endophthalmitis, eye discharge, eye inflammation, eye irritation, eye pruritus, eye redness, eye swelling, eyelid oedema, lacrimation increased, macular degeneration, mydriasis, ocular discomfort, ocular hypertension, periorbital haematoma, photophobia, photopsia, retinal haemorrhage, vision blurred, visual acuity reduced, visual disturbance, vitreous detachment, and vitreous disorder
numbness or tingling of
Dizziness, Headache, Sciatica Ear and labyrinth disorders Common:
disorders: dizziness, orthostatic dizziness*
• increased blood • decreased blood pressure •
- increased sensitivity to light (photosensitivity), erythema multiforme and erythema nodusum
of sadness, dejection etc) while on treatment with Pegasys (see section 4).
- feeling unusually sad, anxious or worthless.
Separate one capsule: tear along the cutting lines to separate one “ pocket” from the strip.
RR-MS, SP-MS and single clinical event suggestive of MS:
RR-MS, SP-MS and single clinical event suggestive of MS:
Seven hundred sixty (760) patients were randomized:
- Hepatic enzyme increased, blood creatinine increased, blood lactate dehydrogenase increased, blood urea increased, blood alkaline phosphatase increased, weight decreased
Sepsis, gastrointestinal candidiasis, urinary tract infection, herpes simplex, herpes zoster
Sepsis, gastrointestinal candidiasis, urinary tract infection, herpes simplex, herpes zoster
Puerperal septicaemia and toxaemia (MMA syndrome) with antibiotic therapy.
Seven major metabolites, including hydroxyl, demethyl, and hydroxydemethyl, are identifiable in whole blood.
Seven patients in each arm had an objective response.
HPV-16 and/ or HPV-18 DNA positive) of which only 0.5% were DNA positive for both types.
For incompatibilities see section 6.2. a
Please see cytokine release syndrome above for severe reactions.
Potentially serious hypokalaemia may result from systemic beta-2-agonist therapy but following inhalation at therapeutic doses plasma levels of salmeterol are very low.
Seretide is indicated for the symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
- Seretide may affect the normal production of steroid hormones in the body, particularly if you
Syringe with an automatic needle protection system
Syringe with a manual needle protection system
Syringe with a manual needle protection system
Syringe with an automatic needle protection system
syringe onto the food or directly into the m outh.
Pre-filled syringe (PP)
PRE-FILLED SYRINGE WITH 2.5 ML WATER FOR INJECTIONS
PRE-FILLED SYRINGE WITH 5.0 ML WATER FOR INJECTIONS
The syringes are provided either with (1- & 4-pack) or without (1-pack) a blister-wrapping.
Pre-filled oral syringes made of polypropylene, with a polyethylene cap, a rubber rod tip, and a polypropylene plunger rod.
Serotype 4 Serotype 9V Serotype 14 Serotype 18C Serotype 19F Serotype 23F Serotype 6B
Joint Interpreting and Conference Service (JICS)
Conference services................................................................................. 53
Portugal Serviço local de Atendimento ao utilizador de EXUBERA Tel:
ratios for overall survival ranged between 1.25 and 2.47 in favour of controls.
Its symptoms include multiple types of seizure (fit), abnormal electrical activity in the brain, learning disability and behavioural problems.
Triple pack 1 1st dosage step (0.25 ml) for treatment days 1, 3, 5
Triple pack 4 4th dosage step (1.0 ml) for treatment days 19, 21, 23
Only 1 ml should be withdrawn equal to 0.9 mg of thyrotropin alfa.
Of the metabolites found in urine only about 1% have been formed through oxidation.
Only about 2% of lamotrigine-related material is excreted in faeces.
Only at high inadvertent doses, it can cause headache and gastrointestinal upset.
Only a few doses of ABILIFY solution for injection may be needed.
Each vial contains nominally 250 IU nonacog alfa (recombinant coagulation factor IX).
Only the provided infusion set should be used.
Under field conditions, only sub-group A is infective and immunisation against sub-group A provides full protection against A, B and C.
Under field conditions, only sub-group A is infective and immunisation against sub- group A provides full protection against A, B and C.
Under field conditions, only sub-group A is infective and immunisation against sub-group A provides full protection against A, B and C.
Only 13 of these 88 patients (15%) had at least one clinically significant change in their LVEF, defined as an LVEF value less than 45% or a decrease of at least 20 points from baseline.
Only some of these medicines are authorised for the treatment of obsessive-compulsive disorder (OCD) in children and adolescents and atomoxetine is authorised for the treatment of attention deficit/ hyperactivity disorder (ADHD) in children and adolescents.
Not all included patients were estimated to have a high risk for a first cardiovascular event.
Only healthy horses which are at risk of infection should be vaccinated.
Only patients with adequate renal and hepatic function have been investigated to date (see section 4.4).
Only body weight and the presence of anti-natalizumab antibodies were found to influence natalizumab disposition.
Only healthy horses should be vaccinated.
Only tetrafluoroethylene or polyethylene catheters must be used.
Only healthy dogs should be vaccinated.
Only those adverse reactions marked with * occurred significantly more frequently in the lenalidomide/dexamethasone arm compared to the placebo/dexamethasone arm.
Only those adverse events occurring in subjects at an equivalent or greater rate than placebo have been included below.
Only experts appearing on the EMEA list may be used by the CPMP and CVMP in the evaluation of medicinal products, public hearings, working groups and the activities of the
Only patients who have no problems with their kidneys can be treated with Exjade.
Self administration of Fertavid should only be performed by patients who are well-motivated, adequately trained and with access to expert advice.
Self administration of Puregon should only be performed by patients who are well-motivated, adequately trained and with access to expert advice.
Only a small percentage of the excreted dose was unchanged darifenacin (3%).
In cattle and pigs both subcutaneous and intramuscular administration are well tolerated; only a slight temporary swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies.
In cattle and pigs, subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies.
Subcutaneous and intramuscular administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies.
Subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies.
Only a limited number of patients were co-infected with HBV (n=13) or HCV (n=26) in study GS-01-934.
Only a small proportion of patients included in pivotal clinical trials had severe depression (baseline HAM-D > 25).
Soliris should be given by a healthcare professional, such as a doctor or nurse, under the supervision of a doctor who has experience in the management of patients with blood disorders.
SevoFlo is used both to induce and maintain anaesthesia in dogs.
SevoFlo contains no stabiliser and does not affect the calibration or operation of these vaporisers in any way.
SevoFlo should not be used in dogs with a known or suspected sensitivity to such anaesthetics.
SevoFlo is presented in a cardboard box containing a 250 ml polyethylene naphthalate (PEN) bottle with a Quik-Fil closure.
th Excipients known to have a recognised action: sorbitol (E420), sodium acetate.
Serious refractory Candida infections The study comprised 55 patients with serious refractory systemic Candida infections (including candidaemia, disseminated and other invasive candidiasis) where prior antifungal treatment, particularly with fluconazole, had been ineffective.
Gender: no relevant differences in pharmacokinetics have been observed.
AUC was 14% higher in women than in men, due to differences in renal function and weight.
controlled with anti-diabetes tablets.
Paseo Pintor Rosales, 40 Bajo Izda.
Marketing Authorisation Holder Shire Human Genetic Therapies AB, Svärdvägen 11D, 182 33 Danderyd, Sweden
Shire Human Genetic Therapies AB, Svärdvägen 11D, 182 33 Danderyd, Sweden
Shire Human Genetic Therapies AB, Svärdvägen 11 D, 182 33 Danderyd, Sweden Tel: +46 8 5449 6400 Fax: +46 8 5449 6429
Shire Human Genetic Therapies AB, Svärdvägen 11 D, 182 33 Danderyd, Sweden Tel: +46 8 5449 6400 Fax: +46 8 5449 6429
Shire Pharmaceutical Contracts Ltd Basingstoke, RG24 8EP, UK
Shire Pharmaceutical Contracts Ltd Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom
Shotton Lane, Cramlington Northumberland NE23 3 JU United Kingdom
If you develop symptoms following exposure, such as a skin rash, you should seek medical advice and show the doctor this warning.
If you develop symptoms following exposure such as a skin rash or persistent eye irritation, you should seek medical advice.
If you develop symptoms following exposure such as a skin rash or persistent eye irritation, you should seek medical advice.
SIAMED SIAMED is an application originally developed by the WHO, and enhanced in the course of a joint WHO-EMEA project.
SIA ” Merck Sharp & Dohme Latvija” Skanstes iela 13 LV-1013 Riga Latvia
If you do not see liquid after 4 times, see Commonly Asked Questions, number 3, in Section 4 of this user manual.
If after a dose reduction, haemoglobin continues to
If after a dose reduction, haemoglobin continues
If after several attempts insulin does not come out of the tip of the needle, change the needle and repeat the priming steps.
If after six attempts a stream of insulin does not come out of the tip of the needle, change the needle and repeat the priming steps up to two more times.
If the control of epilepsy is not clinically significantly improved after an adequate trial, vigabatrin treatment should not be continued.
A definitive relationship between hormonal contraceptive use and clinical hypertension has not been established.
If no needle is available in the pack, use a needle not exceeding 25 mm in length to allow the needle guard to cover the needle completely.
If no improvement is noted within 4 weeks, case management should be re-evaluated.
If no improvement is noted within 4 weeks, consult your veterinary surgeon who will need to re-evaluate the dog's treatment.
If no cause is identified, a bone marrow examination should be considered for diagnosis of PRCA.
If no underlying condition is found, the following management procedures should be followed:
If your doctor thinks that you no longer need ARICLAIM he will ask you to reduce your dose over 2 weeks.
If Bridion is administered via the same infusion line that is also used for other medicinal products, it is important that the infusion line is adequately flushed (e. g. with sodium chloride 9 mg/ ml (0.9% solution)) between administration of Bridion and medicinal products for which incompatibility with Bridion has been demonstrated or for which compatibility with Bridion has not been established.
If this happens, contact your doctor or nurse immediately.
If this happens, you should not drive or use any tools or machines (see section “ Driving and using machines”).
If this happens, you should not drive or use any tools or machines (see section ” Driving and using machines”).
If required by local regulations, the design of the system allows separate disposal of the red fentanyl- containing bottom housing and the white electronic/ battery containing top housing.
If this is not possible, the dosage of SUTENT may need to be increased (see sections 4.2 and 4.5).
If this is not possible the doses of SUTENT may need to be reduced to a minimum of 37.5 mg daily, based on careful monitoring of the tolerability.
If this is not possible, the dosage of SUTENT may need to be reduced to a minimum of 37.5 mg daily, based on careful monitoring of the tolerability (see section 4.2).
If this is not possible, the dosage of SUTENT may need to be reduced (see sections 4.2 and 4.5).
If this is not possible, it is acceptable to take the two medicines at the same time.
If it does, rinse the skin or your eyes immediately with water.
If the moving procedure alone is not enough to give a uniformly white and cloudy liquid, repeat the rolling and moving procedures (see B and C) until the liquid does appear uniformly white and cloudy
If the moving procedure alone is not enough to give a uniformly white and cloudy liquid, repeat the rolling and moving procedures described above until the liquid does appear uniformly white and cloudy.
If this is not done, liquid will come out of the needle when a new cartridge is placed into the pen.
If not, change the needle and repeat the procedure no more than six times.
If not, change the needle and repeat the procedure no more than six times.
If not, change the needle and repeat the procedure no more than 6 times.
If not, change the needle and repeat the procedure no more than 6 times.
If not, change the needle and repeat the procedure no more than 6 times.
If not, change the needle and repeat the procedure no more than 6 times.
If not, change the needle and repeat the procedure no more than six times.
If not, change the needle and repeat the procedure no more than six times.
If not, change the needle and repeat the procedure no more than 6 times.
If not, change the needle and repeat the procedure no more than 6 times.
If it isn't, turn the cap until the push-button is fully depressed • Hold your NovoRapid NovoLet horizontally.
If not, change the needle and repeat the procedure no more than 6 times.
If this is not possible, they should take the tablets less often.
If agglutination of red blood cells in the tubing/ syringe is observed, discard all this material (tubing, syringe and BeneFIX solution) and resume administration with a new package.
If CEPROTIN is used in patients with severe congenital protein C deficiency, antibodies inhibiting protein C may develop.
If parts of the syringe are not clean, repeat the cleaning instructions.
While this will reduce in 1998, updating ICH-derived and purely European CPMP guidelines will remain a considerable task.
26 If these side effects occur while you are under anaesthesic, they will be seen and treated by your anaesthetist.
If these events are moderate to severe, then dosing should continue at the same level prior to each dose escalation, with appropriate premedication, until each dose is well tolerated.
If these manifestations appear during the course of the treatment Oracea should be discontinued and the patient should be referred to an ophthalmologist.
If such medicinal products are to be administered with food, patients should be advised to, if possible, take them with a meal when BYETTA is not administered.
If these medicinal products are co-administered, careful monitoring of full blood counts and adverse events related to increased rifabutin levels (e. g. uveitis) is recommended.
If this occurs, seek medical attention immediately.
If these symptoms occur, the administration has to be discontinued immediately.
If these symptoms occur, the administration should be immediately discontinued.
If these symptoms occur you must inform your doctor or nurse immediately.
If the condition persists or worsens, seek medical attention.
If these events continue or become severe, tell your doctor. lP
If these events continue or become severe, tell your doctor. rod
If the condition persists or worsens, you may have to bring your child to the doctor.
If Clopidogrel BMS is supplied in PVC/PVDC/aluminium blisters, store below 30°C.
41 If Clopidogrel Winthrop is supplied in PVC/PVDC/aluminium blisters, store below 30°C.
If Iscover is supplied in PVC/PVDC/aluminium blisters, store below 30°C.
If Plavix is supplied in PVC/PVDC/aluminium blisters, store below 30°C.
If this dose is considered to be the effective dose, treatment of successive episodes of BTP may be continued with a single 200 micrograms tablet of Effentora. • If a single 200 micrograms tablet of Effentora (or two 100 micrograms tablets) is not considered to be efficacious the patient can be instructed to use two 200 micrograms tablets (or four 100 micrograms tablets) to treat the next episode of BTP.
If this dose is considered to be the effective dose, treatment of successive episodes of BTP may be continued with a single 400 micrograms tablet of Effentora. • For titration to 600 micrograms and 800 micrograms, tablets of 200 micrograms should be used.
If there are more than 7 patch-free days, the user may not be protected against pregnancy.
If the condition persists or worsens, seek medical attention.
If the condition persists or worsens, seek medical attention.
Multiple occurrences of the same adverse event in one individual counted only once.
25 Using other medicines If Ciprofloxacin Hikma and one of the following medicines are given at the same time, special care should be taken: • theophylline (used to treat asthma), clozapine (used to treat schizophrenia), tacrine (used to treat symptoms of Alzheimer´s disease), ropinirol (used to treat Parkinson disease) and tizanidine (used to treat muscle spasms).
35 If additional injections or “ booster” are necessary, the doctor will tell you.
42 If additional injections or “booster” are necessary, the doctor will tell you.
If additional injections or “ booster” are necessary, the doctor will tell you.
If not, your doctor will advise you on the possible need to have extra doses.
If additional injections are necessary, the doctor will tell you.
If additional injections are necessary, the doctor will tell you.
Your doctor will advise on the possible need for extra doses.
If other eye medicines are also being used, there should be a gap of at least five minutes between using each medicine.
the CHMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Remeron and associated names (see Annex I).
If new skin lesions appear during or after therapy or if existing lesions change appearance, tell your doctor.
If antibodies would be developed, these may make test results to measure TSH difficult to interpret.
If seizures occur ciprofloxacin should be discontinued (see section 4.8).
Psychiatric reactions may occur even after the
If muscle pain, weakness or cramps occur while a patient is receiving Pelzont with a statin, their CK levels should be measured.
If muscle pain, weakness or cramps occur while a patient is receiving Tredaptive with a statin, their CK levels should be measured.
If muscle pain, weakness or cramps occur while a patient is receiving Trevaclyn with a statin, their CK levels should be measured.
If twice daily dosing with NovoMix 30 results in recurrent daytime hypoglycaemic episodes, the morning dose can be split into morning and lunchtime doses (thrice daily dosing).
If any similar skin or bone abnormalities appear, it is recommended to decrease the dose of CYSTAGON.
If solids remain, the vial must be discarded.
If solid parts of the lyophilisate are seen or the suspension is not homogeneous, the product should be discarded.
If solid parts are seen or the dispersion is not homogeneous, the product will be discarded.
If patients with renal impairment receive IONSYS, they should be observed carefully for signs of fentanyl toxicity.
After 15 days of treatment with St John's Wort (300 mg three times daily), plasma exposure following a single 400 mg dose of voriconazole decreased by 40-60%.
- If allergic or anaphylactic-type reactions occur, stop the infusion immediately and contact a doctor
If allergic/ anaphylactic reactions occur, the administration of BeneFIX should be discontinued at once.
If any reaction takes place that is thought to be related to the administration of ReFacto AF, the rate of infusion is to be decreased or the infusion stopped, as dictated by the response of the patient (see section 4.4).
If symptoms of tuberculosis (persistent cough, weight loss, listlessness, fever), or any other infection appear during therapy notify your doctor immediately.
If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy, tell your doctor immediately.  Hepatitis B:
If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy, tell your doctor immediately.  Hepatitis B:
If symptoms of tuberculosis (persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy tell your doctor immediately.
If symptoms of tuberculosis (persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy tell your doctor immediately.
If symptoms of tuberculosis (persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy tell your doctor immediately.
If symptoms of tuberculosis (persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy tell your doctor immediately.
If symptoms suggestive of serious acute arsenic toxicity (e. g. convulsions, muscle weakness and confusion) appear, TRISENOX must be immediately discontinued and chelating therapy with penicilamine at a daily dose ≤ 1 gm per day may be considered.
If vomiting occurs after the dose is administered, a second dose should not be administered that day.
If these reactions occur, the Aldurazyme infusion should be stopped immediately and appropriate treatment will be started by your doctor.
If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment.
If these reactions occur they require the immediate attention of a physician and intensive medical care.
If these reactions occur, immediate discontinuation of Aldurazyme is recommended and appropriate medical treatment should be initiated.
If such effects occur, a washout (see below) to reduce plasma levels of A771726 should be considered.
- If, during the infusion, Visudyne goes outside the vein, and especially if the affected area is
If blood appears, do not inject Ceplene because the needle has entered a blood vessel.
If taken on an empty stomach, the active substance is absorbed more rapidly.
If it is cloudy or discoloured or has flakes or particles in it, you must not use it.
If it cannot be used immediately, the solution may be refrigerated for up to 24 hours.
If it isn't in perfect condition when you get the vial, return the vial to your supplier ► If it hasn't been stored correctly or been frozen (see 6 How to store Actraphane) ► If it's not uniformly white and cloudy when it's resuspended.
If it isn't in perfect condition when you get the vial, return the vial to your supplier ► If it hasn't been stored correctly or been frozen (see 6 How to store Actrapid) ► If it does not appear water clear and colourless.
If it isn't in perfect condition when you get the vial, return the vial to your supplier ► If it hasn't been stored correctly or been frozen (see 6 How to store Actrapid) ► If it does not appear water clear and colourless.
If it isn't in perfect condition when you get the vial, return the vial to your supplier ► If it hasn't been stored correctly or been frozen (see 6 How to store Insulatard) ► If it's not uniformly white and cloudy when it's resuspended.
If it isn't in perfect condition when you get the vial, return the vial to your supplier ► If it hasn't been stored correctly or been frozen (see 6 How to store Mixtard) ► If it's not uniformly white and cloudy when it's resuspended.
If it isn't in perfect condition when you get the vial, return the vial to your supplier ► If it hasn't been stored correctly or if it has been frozen (see 6 How to store NovoRapid) ► If the insulin does not appear clear and colourless.
If it isn't in perfect condition when you get the vial, return the vial to your supplier If it hasn't been stored correctly or been frozen (see 6 How to store Protaphane) If it's not uniformly white and cloudy when it's resuspended.
Arachnoiditis can be fatal if left untreated.
If it occurs, appropriate dose adjustment should be made as provided.
If either is slowed, referral to a paediatrician should be considered.
In patients with diabetes, antidepressants may alter glycaemic control.
If Fendrix is to be given at the same time as specific hepatitis B immunoglobulins, these should be given at different injection sites.
Tell your veterinary surgeon if you notice any of the following: • significant loss of appetite.
Talk to your doctor or healthcare professional about these or any other unusual conditions you may find.
Talk to your doctor or healthcare professional about these or any other unusual conditions you may find.
Tell your doctor if your child has any known allergies.
- Tell your doctor if you have had problems with your liver before, including hepatitis B or C.
Tell your doctor immediately:  if you experience hair loss, enlargement of the clitoris, an increase in the amount of hair on the chin or upper lip, voice deepening or hoarseness, although these side effects may be mild.
Tell them immediately if you notice any of these effects.
5 Signs and symptoms No cases of overdose were reported during clinical trials.
► If the InnoLet is dropped, damaged or crushed, there is a risk of leakage of insulin ► If it hasn't been stored correctly or if it has been frozen (see 6 How to store NovoRapid) ► If the insulin does not appear clear and colourless.
Siklos may hence decrease the ability of men to father children.
If a package is opened or damaged, do not use this medical device.
If no moisture absorber is present, or if the moisture absorber is not intact, do not use and return system to manufacturer.
If no moisture absorber is present, or if the moisture absorber is not intact, do not use and return system to the manufacturer.
If the cartridge contains a small amount or looks empty, obtain a new BYETTA pen.
► If the cartridge or the device containing the cartridge is dropped, damaged or crushed, there is a risk of leakage of insulin ► If it hasn't been stored correctly or if it has been frozen (see 6 How to store NovoRapid) ► If the insulin does not appear clear and colourless.
If the breakthrough pain has stopped, do not take Effentora until the next breakthrough pain episode.
In case the factor VIIa activity fails to reach the expected level or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed.
If cytopenia is unrelated to leukaemia, reduce dose of Glivec to 400 mg.
If intravenous administration is impossible, naloxone hydrochloride can also be given intramuscularly or subcutaneously.
In case of poor tolerability of the 5.0 microgram dose, the dose should be reduced to 2.5 micrograms.
If the initial loading dose was well tolerated, the subsequent doses can be administered as a 30-minute infusion.
If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles.
If the loaded dose is not sufficient to complete your injection, you have two possibilities: a.
If your doctor’s instructions are different from the amounts on the table, follow your doctor’s instructions.
If insufficient sleep duration occurs, the likelihood of impaired alertness may be increased (see section 4.5).
If frozen, presentations of gadoversetamide in glass containers may be warmed to room temperature and shaken vigorously.
If fluoxetine has been prescribed chronically and/ or at a high dose, a longer interval should be considered.
If a capsule is damaged, avoid contact with your skin, eyes or nose.
If the needle is not correctly lined up with the centre of the stopper, you will feel constant resistance as it goes through the stopper and no “ pop .” The needle may then enter at an angle and bend, break or prevent proper removal of the vial contents.
If the needle is not correctly lined up, you will feel constant resistance as it goes through the stopper and no "pop".
If the needle is not correctly lined up, you will feel constant resistance as it goes through the stopper and no “ pop”.
If the same error occurs again, OptiSet may be damaged, use a new OptiSet.
If the same error occurs again, OptiSet may be damaged, use a new OptiSet.
Press the injection button in completely to discard the dose and select again.
The following symptoms may be observed in neonates if the mother has used an SSRI/ SNRI late in pregnancy: irritability, tremor, hypotonia, persistent crying, and difficulty in sucking or in sleeping.
If use of a separate line is not possible, the line should be flushed out with saline solution between chemotherapeutic agent infusions and rasburicase.
2 solution between infusion of chemotherapeutic agents and rasburicase.
When amprenavir is administered as monotherapy, resistant viruses rapidly emerge (see section 5.1).
If the animal is fed at the time of dosing, the absorption may be slightly delayed.
If the abnormality is reversed, ribavirin may be restarted at 600 milligrams daily, and further increased to 800 milligrams daily at the discretion of the treating physician.
If not est ablished on effective contraception, the patient must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated.
If not established on effective contraception, the patient must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated.
- If the skin is hairy, then cut the hair with scissors.
Please tell the doctor if the person to be vaccinated is taking or has recently taken any other medicines, including medicines obtained without a prescription or has recently received any other vaccine.
Please tell the doctor if the person to be vaccinated is taking or has recently taken any other medicines, including medicines obtained without a prescription or has recently received any other vaccine.
Unless weight loss is maintained, treatment should not be continued.
Silapo 30000 IU/0.75ml solution for injection in pre-filled syringe
Silapo has a wide safety margin and side effects due to an overdose of using Silapo are unlikely.
Silapo must not be mixed with other medicinal products (see section 6.2).
Silapo must not be used if • The blister sealing is broken or the blister is damaged in any way. • The liquid is coloured or you can see particles floating in it. • Any liquid has leaked out of the pre-filled syringe or condensation is visible within the sealed blister. • It may have been accidentally frozen.
Silapo can also lead to skin rash and flu-like symptoms.
• If you develop a fever as Yondelis may cause side-effects affecting your blood and liver.
In the event of once daily dosing when the patient has a history of nocturnal symptoms the dose should be given at night and when the patient has a history of mainly day-time symptoms the dose should be given in the morning.
In the event of once daily dosing when the patient has a history of nocturnal symptoms the dose should be given at night and when the patient has a history of mainly day-time symptoms the dose should be given in the morning.
If the first infusion is well tolerated, the second infusion may be administered over 60 minutes.
If blood pressure is difficult to control by initiation of appropriate measures, the haemoglobin may be reduced by decreasing or withholding the dose of Nespo (see section 4.2).
If blood pressure is difficult to control by initiation of appropriate measures, the haemoglobin may be reduced by decreasing or withholding the dose of Aranesp (see section 4.2).
If blood pressure is difficult to control by initiation of appropriate measures, the haemoglobin may be reduced by decreasing or withholding the dose of Nespo (see section 4.2).
If the amount poured into the cup exceeds the required dose,
If the severe skin reaction occurred for the first time, treatment may be resumed without any change in dose level.
If refrigerated, allow the refrigerated solution to reach room temperature before administration.
If refrigerated, allow the refrigerated solution to reach room temperature before administration.
- If the solution is cloudy (and the cloudiness does not disappear
If the solution is cloudy or hazy, do not inject it.
- if the solution is cloudy or there are particles in it.
If the solution is any colour except colourless or slightly yellow, or if you can see particles floating in it, do not inject.
If the solution is not clear and colourless it should be discarded.
If the solution is not clear and colourless it should be thrown away.
If the solution is not clear and colourless it should be discarded.
If the solution appears cloudy, particles are observed or if there is evidence of damage to the syringe, or if the plastic clip is missing or not attached to the syringe, Macugen should not be used.
If the solution is discoloured or contains particles, discard it and start again with a new single pack of supplies.
If the solution is discoloured or contains particles, discard it and start again with a syringe and vial out of your package.
If the solution is spilled on the skin, rinse thoroughly with water.
If the combination appears necessary, close cardiac monitoring is needed (see section 4.4).
If concomitant treatment of venlafaxine with an SSRI, an SNRI or a serotonin receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
If the combination appears necessary, close cardiac monitoring is needed.
• If your child's asthma or breathing gets worse, tell your doctor immediately.
If it is necessary to monitor a patient's uric acid level, a strict sample-handling procedure must be followed to minimise ex vivo degradation of the analyte.
If tolerated well after at least 7 days of treatment, the dose could be increased up to 20 mg/ day according to standard titration scheme.
If ALT increase is progressive or persistent, the dose should be reduced initially to 135 micrograms.
If ALT increase is progressive or persistent, the dose should be reduced initially to135 micrograms.
ra i) Increased insulin antibody levels j) Recommendation for special populations; underlying lung diseases such as asthma and COPD, congestive heart failure, pregnancy, children and adolescent
If the ductus arteriosus does not close 48 hours after the last injection or if it reopens, a second course of three doses may be given.
If the cat has high levels of antibodies inherited from the mother, the first vaccination should be delayed until 12 weeks of age.
If the cat has high levels of antibodies inherited from the mother, the first vaccination should be delayed until 12 weeks of age.
When disinfecting the neck of the ampoule with an antiseptic, to avoid any interaction with the Pedea solution, the ampoule must be completely dry before it is opened.
If the tablet is regurgitated or vomited later than 10 minutes following administration, treatment should not be repeated.
If the control of the disease is not sufficient, patients may benefit from switching to another similar medicine.
If well tolerated, the rate of administration may gradually be increased to a maximum of 6 ml/kg BW/hr.
If the patch detaches prematurely, it may be reapplied.
If the fentanyl gel contacts the skin during application or removal, the area should be washed with copious amounts of water.
If lapatinib is administered in combination with paclitaxel (175 mg/ m2 every three weeks), severe neutropenia may coincide with diarrhoea.
If lenalidomide is taken during pregnancy, a teratogenic effect of lenalidomide in humans is expected.
If the liquid is below the fill line, return the entire pack to the pharmacy.
If it is cloudy or there are particles in it, you must ed
If it is cloudy or there are particles in it, you must not use it.
If it is cloudy or there are particles in it, you must not use it.
If the liquid cannot drain out quickly enough, the pressure inside the eye builds up.
If the medicine is to be given to a child, make sure the child is sitting, or is held, upright before giving the medicine.
If taken on an empty stomach, the active substance is absorbed more rapidly.
If medicine doesn't appear within a few seconds, you may need to push the reset button again.
If the medicine is not used right away, it should be shaken vigorously to re-suspend.
If the child has, or is at risk of developing, a serious blood infection called sepsis.
If the child has any of the above symptoms he/ she may be having an allergic reaction to Enbrel, so you should seek immediate medical attention.
- If the child has Turner syndrome, the child's doctor should carefully check for ear infections
Tell the doctor or pharmacist if the child is taking, or has recently taken any other medicines, even those not prescribed by the child's doctor.
- If children have had a kidney transplant, growth hormone treatment will be stopped.
If the number of white blood cells is too low (neutropenia), the risk of infection increases.
If the number of your blood platelets is fewer than 150,000/ mm3 after chemotherapy
If during the 7 days preceding the first skipped day of patch application, the patch was worn correctly, no additional contraceptive use is required.
If the patient has difficulty with swallowing, tablets can be crushed and administered in half a glass of water.
If the patient has eaten a heavy meal then it will be necessary to fast for 6 hours prior to the test.
If the patient requires additional or continuation of pain relief, a new system may be applied to a new skin site on the upper outer arm or chest.
If the patient requires additional or continuation of pain relief, a new system may be applied to a new skin site on the upper outer arm or chest.
If the patient attempts to initiate a dose after 80 doses or 24 hours from the first dose, the system will not respond (i. e. no red light, no beep).
If the patient is switched to permanent prophylaxis with oral anticoagulants, protein C replacement is to be discontinued only when stable anticoagulation is obtained (See 4.5).
- if the patient is a child less than 3 years old.
If the patient experiences a loss of greater than 5 letters in visual acuity (ETDRS or one Snellen line equivalent), Lucentis should be administered.
If the patient experiences a loss of greater than 5 letters in visual acuity (ETDRS or one Snellen line equivalent), Lucentis should be administered.
25 5 If spraying is required, connect the tubing to the pressure regulator.
If erythropoietin is given concomitantly with ciclosporin, blood levels of ciclosporin should be monitored and the dose of ciclosporin adjusted as the haematocrit rises.
(If the breath bag remains open for more than 30 seconds, the test result might be falsified.)
If contractions come back, treatment with Tractocile can be repeated up to three more times during the pregnancy.
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet,
Acute toxicity symptoms are unlikely to occur in patients with normal renal function.
If white blood cells fall to a low level there may not be enough left in the body to fight bacteria and you may have an increased risk of infection.
When the instructions are followed carefully, Fertavid will be administered properly and with minimal discomfort.
When the instructions are followed carefully, Puregon will be administered properly and with minimal discomfort.
If subsequent EVRA patch change days are delayed
If the lesions have not all disappeared, a further four weeks of treatment may be necessary.
If patients develop neurotoxicity, subsequent doses of DepoCyte should be reduced, and DepoCyte should be discontinued if toxicity persists.
If the hair is long, a small area should be clipped, if required.
If the hair is long, a small area may be clipped, if required.
DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION
If symptoms continue or come back, a second injection can be given after six hours.
You should consult your doctor if symptoms of this syndrome occur.
If the condition persists or worsens, seek medical attention.
If psychiatric symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with IntronA be discontinued, and the patient followed, with psychiatric intervention as appropriate.
If psychiatric symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with PegIntron be discontinued, and the patient followed, with psychiatric intervention as appropriate.
If psychiatric symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Rebetol and interferon alfa-2b be discontinued, and the patient followed, with psychiatric intervention as appropriate.
If psychiatric symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Rebetol and peginterferon alfa-2b or interferon alfa-2b be discontinued, and the patient followed, with psychiatric intervention as appropriate.
If psychiatric symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Ribavirin and peginterferon alfa-2b or interferon alfa-2b be discontinued, and the patient followed, with psychiatric intervention as appropriate.
179 symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Viraferon be discontinued, and the patient followed, with psychiatric intervention as appropriate.
198 symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Viraferon be discontinued, and the patient followed, with psychiatric intervention as appropriate.
217 symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Viraferon be discontinued, and the patient followed, with psychiatric intervention as appropriate.
24 symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Viraferon be discontinued, and the patient followed, with psychiatric intervention as appropriate.
44 symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Viraferon be discontinued, and the patient followed, with psychiatric intervention as appropriate.
4 symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Viraferon be discontinued, and the patient followed, with psychiatric intervention as appropriate.
64 symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Viraferon be discontinued, and the patient followed, with psychiatric intervention as appropriate.
If psychiatric symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Viraferon be discontinued, and the patient followed, with psychiatric intervention as appropriate.
If psychiatric symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with ViraferonPeg be discontinued, and the patient followed, with psychiatric intervention as appropriate.
If symptoms reappear, treatment with Protopy 0.1% twice a day should be restarted.
If symptoms recur, twice daily treatment with Protopy 0.1% should be restarted.
If well tolerated, the rate of administration may gradually be increased to a maximum of 6 ml/kg bodyweight/hour.
animal source insulin) may result in a change in dosage.
If you are concerned that your OptiSet may be damaged, use a new one.
If it is nearly time for the next dose, just take that one.
If the condition persists or worsens, seek medical attention.
If it is cloudy or there are particles in it, you must not use it.
or cloudy or there are particles in it, you must not use it.
If vomiting continues, administer anti-emetics.
If the administration set available does not have an in-line filter incorporated, a filter should be added at the end of the set (i. e., an end-filter) before the admixture reaches the vein of the patient.
If the expected factor VIII plasma activity levels are not attained, or if bleeding is not controlled with an appropriate dose, an assay should be performed to determine if a factor VIII inhibitor is present.
If the expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, an assay should be performed to determine if a factor VIII inhibitor is present.
If expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, an assay should be performed to determine if factor VIII inhibitors are present.
If expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, an assay should be performed to determine if factor VIII inhibitors are present.
In patients with solid tumours or lymphoproliferative malignancies, if the haemoglobin value exceeds 12 g/ dl (7.5 mmol/ l), the dosage adaptation described in section 4.2 should be closely respected, in M
In patients with solid tumours or lymphoproliferative malignancies, if the haemoglobin value exceeds 12 g/ dl (7.5 mmol/ l), the dosage adaptation described in section 4.2 should be closely respected, in order to minimise the potential risk of thromboembolic events.
If the repeat test confirms a baseline CK > 5xULN, treatment should not be started.
If test is not successful, the pen might be damaged.
If test is not successful, the pen might be damaged.
If the seal is broken before first use, contact your pharmacist.
If therapy starts after the first day of withdrawal bleeding, a non-hormonal contraceptive must be used concurrently for 7 days.
If treatment of a BTP episode requires more than one tablet, an increase in dose to the next higher available strength should be considered to treat the next BTP episode.
John's wort due to induction of drug metabolising enzymes and/ or transport proteins by St.
If treatment is successful lower the dose to half a tablet a day.
If treatment is successful, lower the dose to half a tablet a day.
If patients infected with virus genotype 1, not responding to prior treatment with PEG-IFN and ribavirin are considered for treatment, the recommended total duration of therapy is 72 weeks (see section 5.1).
If treatment is not started on the day of the operation, it should start with two capsules once a day.
If Kivexa has been discontinued in patients due to experiencing any one of these symptoms and a decision is made to restart a medicinal product containing abacavir, this must be done in a setting where medical assistance is readily available (see section 4.4).
If therapy with Kivexa has been discontinued for any reason and restarting therapy is under consideration, the reason for discontinuation must be established to assess whether the patient had any symptoms of a hypersensitivity reaction.
If Trizivir has been discontinued in patients due to experiencing any one of these symptoms and a decision is made to restart a medicinal product containing abacavir, this must be done in a setting where medical assistance is readily available (see Section 4.4).
If Ziagen has been discontinued in patients due to experiencing any one of these symptoms and a decision is made to restart a medicinal product containing abacavir, this must be done in a setting where medical assistance is readily available (see section 4.4.).
If Ziagen has been discontinued in patients due to experiencing any one of these symptoms and a decision is made to restart a medicinal product containing abacavir, this must be done in a setting where medical assistance is readily available (see section 4.4.).
If therapy with Ziagen has been discontinued for any reason and restarting therapy is under consideration, the reason for discontinuation must be established to assess whether the patient had any symptoms of a hypersensitivity reaction.
(If the sample tube remains open for more than 30 seconds, the test result might be falsified.)
If seal is broken before first use, contact pharmacist.
If seal is broken before first use, contact pharmacist.
If seal is broken before first use, contact pharmacist.
If seal is broken before first use, contact pharmacist.
If Levitra is taken with a high fat meal, the onset of activity may be delayed.
If visible particles or discoloration are observed, the vial should not be used.
Where there is active bleeding or bleeding tendency it is generally not advisable to administer Refludan.
If hypotension becomes symptomatic, a reduction of dose or discontinuation of< COVERSYL and associated names > may be necessary.
colloidal anhydrous; magnesium stearate; hypromellose; titanium dioxide (E171); talc; macrogol.
If the immunosuppression is temporary, vaccination should be delayed until the immune function has recovered.
When the infection at treatment sites is cleared, treatment with < Invented Name > can be started.
If injected otherwise OPTISON bubbles will be destroyed.
If discontinuing opiates when initiating ziconotide therapy, opiate withdrawal should be gradual.
Change the needle and try again. • If no insulin comes out after changing the needle, your OptiSet may be damaged.
Change the needle and try again. • If no insulin comes out after changing the needle, your OptiSet may be damaged.
If there is lasting irritation, a doctor should be consulted.
If it hasn't been stored correctly or been frozen (see 6 How to store Velosulin) If it does not appear water clear and colourless. no
If no drop appears, use a different pen, and return the faulty pen to your provider.
ra If no drop appears, use a different pen, and return the faulty pen to your provider.
If the same patch cannot be reapplied, a new patch should be applied to another location.
If there is no labelled carbon dioxide in the breath, this means there are no bacteria in the stomach or duodenum.
If no blood appears, inject the solution slowly by pushing the plunger gently forward.
If the oedematous swelling involves the tongue, glottis or larynx, or it is likely to cause airway obstruction; emergency treatment should be initiated promptly.
If the eye fills up faster than it empties, the pressure inside the eye builds up.
In the future, if the birds are exposed to the avian flu virus, the immune system will be able to make those antibodies quicker and this will help them fight the disease.
If you see any bubbles, pull the plunger slightly back; tap the syringe gently, with the needle pointing up, until the bubbles disappear.
Looking at the studies taken together, it was more effective than placebo.
When compared to only 8.2% of patients that can reach target BP somewhat faster compared to a stepwise approach, the risk benefit ratio is negative both for patients with severe and for patients with mild to moderate hypertension.
Taking into account the number of meetings as well as the growing number of issues for each session, a 30 percent increase in workload of the PhVWP is anticipated.
So when receiving any other treatment please tell the health professional that you are using DuoTrav.
If ALT flares during Viraferon therapy to greater than or equal to 2 times baseline, Viraferon therapy may be continued unless signs and symptoms of liver failure are observed.
If your doctor thinks there is a possibility that they were related, you will be instructed never to take Kivexa or any other abacavir containing medicine (Ziagen or Trizivir) again.
If your doctor thinks there is a possibility that they were related, you will be instructed never to take Trizivir
If your doctor thinks there is a possibility that they were related, you will be instructed never to take Ziagen or any other medicine containing abacavir (i. e.
It is not necessary to administer any undissolved white powder as this is inert material.
Any unused suspension should be discarded after this date.
If there is some mixture left inside the bowl, rinse the bowl with a small amount of water and have the patient drink this remaining mixture.
If there are less than 12 units left, use a new one.
However, should this occur, the ILP should be terminated immediately and the limb washed out using at least 2 litres of dextran 70 intravenous infusion or similar fluid (see also section 4.4).
If some photosensitivity reaction occurs with the limited skin test, the patient should continue exercising precautions for another 2 weeks before retesting.
If exposed to the viruses in the future, the immune system will be able to make antibodies more quickly.
A tourniquet should be applied to the proximal limb.
If it is dropped or crushed, there is a risk of damage and leakage of insulin.
If it is dropped or crushed, there is a risk of damage and leakage of insulin.
If it is dropped or crushed, there is a risk of damage and leakage of insulin.
If it is dropped, damaged or crushed, there is a risk of leakage of insulin.
If Luminity is administered directly to the patient without undergoing the mechanical activation procedure using the Vialmix (see section 6.6), the product will not produce its intended effect.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
72 If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of these side effects gets serious or if you notice any side effects not listed, please tell your doctor or pharmacist.
If any of these side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of them were weakened or fractured in any way, the effectiveness of the system would be threatened.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, contact your doctor.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects get serious or if you notice any side effects not listed in this leaflet, please
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please
- If any of the side effects gets serious, or if you notice any side effects not listed in this
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, tell your
- If any of the side effects gets serious, or if you notice any side effects not listed on this leaflet,
It may harm them, even if their symptoms are the same as yours • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
It may harm them, even if their symptoms are the same as yours If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, tell your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell you doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please
- If any of the side effects gets serious, or if you notice any side effect not listed in this leaflet, please
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
- If any of the side effects get serious or if you notice any side effects not listed in the
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please
- If any of the side effects gets serious, or if you notice any side effect not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
- If any of the side effects gets serious, or if you notice any side effects not listed in thois leaflet,
- If any of the side effects gets serious, or if you notice any site effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice side effects not listed in this leaflet, please
It may harm them, even if their symptoms are the same as yours. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your child's doctor or pharmacist.
If any of the side effects gets serious, or if you notice any sided effects not listed in this leaflet, please tell your doctor or pharmacist.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
or If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or radiologist.
It may harm them, even if their ng symptoms are the same as yours. lo
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please
It may harm them, even if ng their symptoms are the same as yours. lo
When reconstituted with 10 ml water for injections each ml contains 1,000 U tenecteplase
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or you notice any side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice side effects not listed in this leaflet,
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet,
118 If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
38/ 44 If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of the following happen, do not take more Efexor.
Do not take Tredaptive if any of the above apply to you.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
If concomitant use is indicated because of demonstrated hypokalemia they should be used with caution and with frequent monitoring of serum potassium (see 4.4 Special warnings and special precautions for use).
If the use of ranitidine is considered, it should be used in a staggered manner; i. e.
If the use of ranitidine is considered, it should be used in a staggered manner; i.e.
If the use of antacids is considered necessary during treatment with Tarceva, they should be taken at least 4 hours before or 2 hours after the daily dose of Tarceva.
If the use of antacids is considered necessary during treatment with Tarceva, they should be taken at least 4 hours before or 2 hours after the daily dose of Tarceva.
(If the use of a 0.2 micrometre syringe filter is not feasible, the sterile concentrate should be pre-filtered with a 5 micrometre filter, diluted and then administered through a 0.22 micrometre in-line filter.)
If patch use results in uncomfortable irritation, a new patch may be applied to a new location until the next Change Day.
If the user wishes to move the Change Day the current cycle should be completed, removing the third EVRA patch on the correct day.
If you have any suspension left in a bottle more than four weeks after it was first opened, you should not use this medicine.
If you have any unwanted Telzir tablets, don't dispose of them in your waste water or your household waste.
Avoid contact with skin or eyes If eye exposure occurs, flush eyes immediately with clean water.
If eye exposure occurs, flush eyes immediately with clean water.
If there is an increased level of labelled carbon dioxide in the breath sample after 30 minutes (a positive test), the patient may have H. pylori in the stomach or duodenum.
If there is a loss of nerve cells containing dopamine (as occurs typically in patients with Parkinson's disease) the binding of DaTSCAN is greatly reduced and this can be seen on the scan.
Simultaneously, the MAH updated module 3 was updated to CTD format in this referral procedure.
of Myopathy% the last statin (with or without (No. exposed) gemfibrozil) compared to non-concurrent cerivastatin
Simvastatin/ Emtricitabine Simvastatin/ Tenofovir disoproxil fumarate HORMONAL CONTRACEPTIVES
Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.
Sinapultide, dipalmitoylphos- phatidylcholine, palmitoyl-
If necessary, monitor blood lithium closely and adjust the lithium dosage while the combination is being taken and when the NSAID is withdrawn.
If necessary, monitor blood lithium closely and adjust the lithium dosage while the combination is being taken and when the NSAID is withdrawn.
If necessary, dissect away any fibrous tissue to free the implant.
This can be followed if needed by a further injection of 5 or 10 mg two hours later.
If necessary the dose of erlotinib should be reduced, particularly if toxicity is observed.
When appropriate the dosage can be gradually increased up to a maximum of 60 mg.
When appropriate the dosage can be gradually increases up to a maximum of 60 mg.
If necessary the dose can be decreased by any amount (including stopping the infusion) for the management of adverse reactions.
If indicated, prevention of further absorption can be considered.
If indicated, prevention of further absorption can be considered.
Do not use Lansoprazol-ratiopharm after the expiry date which is stated on the carton and the blister.
is or th If you experience difficulties choose a more firm injection site.
The inspection window will be green, confirming the injection is complete.
If necessary, remove the empty cartridge and discard it properly.
If required, a second administration can be given after 24 hours.
If appropriate, resumption of hepatitis B therapy may be warranted.
If necessary, your doctor may increase this dose to the maximum of two tablets once a day.
Singulair 4 mg oral granules was approved by 16 member states (not by AT, BE, CZ, DK, FR, HU, NL, PL, SK) in MRP in 2002.
SINGULAIR can treat your child's asthma only if he/ she continues taking it.
SINGULAIR may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.2).
If water is not preferred, CRIXIVAN can be taken with skimmed or low– fat milk, juice, coffee, or tea.
If water is not preferred, CRIXIVAN can be taken with skimmed or low– fat milk, juice, coffee, or tea.
A lternatively, the injection can be given at the end of the dialysis session via the fistula needle tubing, followed by 10 ml of sodium chloride 9 mg/ml (0.9%) solution for injection to rinse the tubing and ensure satisfactory injection of the medicinal product into the circulation.
Alternatively, the injection can be given at the end of the dialysis session via the fistula needle tubing, followed by 10 ml of sodium chloride 9 mg/ ml (0.9%) solution for injection to rinse the tubing and ensure satisfactory injection of the medicinal product into the circulation.
Alternatively, the injection can be given at the end of the dialysis session via the fistula needle tubing, followed by 10 ml of sodium chloride 9 mg/ml (0.9%) solution for injection to rinse the tubing and ensure satisfactory injection of the medicinal product into the circulation.
Otherwise, return used patches to a pharmacy, preferably in the original packaging.
► If the NovoLet is dropped, damaged or crushed, there is a risk of leakage of insulin ► If it hasn't been stored correctly or if it has been frozen (see 6 How to store NovoRapid) ► If the insulin does not appear clear and colourless.
Sint Lenaartseweg 48/ 4 B-2320 Hoogstraten Belgium
Sinusitis Abnormal clotting factor
Dyspnea*, pharyngitis*, coughing*
Sinusitis, bronchitis, dysphonia, epistaxis, rhinitis, respiratory disorder, nasal congestion, rhinorrhea, nonproductive cough 104
Sinusitis, bronchitis, dysphonia, epistaxis, rhinitis, respiratory disorder, nasal congestion, rhinorrhea, nonproductive cough 12
Sinusitis, bronchitis, dysphonia, epistaxis, rhinitis, respiratory disorder, nasal congestion, rhinorrhea, nonproductive cough 127
Sinusitis, bronchitis, dysphonia, epistaxis, rhinitis, respiratory disorder, nasal congestion, rhinorrhea, nonproductive cough 150
Sinusitis, bronchitis, dysphonia, epistaxis, rhinitis, respiratory disorder, nasal congestion, rhinorrhea, nonproductive cough 173
Sinusitis, bronchitis, dysphonia, epistaxis, rhinitis, respiratory disorder, nasal congestion, rhinorrhea, nonproductive cough 219
Sinusitis, bronchitis, dysphonia, epistaxis, rhinitis, respiratory disorder, nasal congestion, rhinorrhea, nonproductive cough 35
Sinusitis, bronchitis, dysphonia, epistaxis, rhinitis, respiratory disorder, nasal congestion, rhinorrhea, nonproductive cough
Sinusitis, upper respiratory tract infection, urinary tract infection
Sinusitis Anaphylactoid reaction, hypersensitivity
- Acute bacterial sinusitis (adequately diagnosed)
- Acute bacterial sinusitis (adequately diagnosed).
- Sinusitis (sinus inflammation, sinus infection, blocked or painful sinuses), blocked or runny nose, sore
If the decision is made to administer another cyanide antidote with Cyanokit, these medicinal products must not be administered concurrently in the same intravenous line (see section 6.2).
If more Bridion is given to you than recommended As your anaesthetist will be monitoring your condition carefully, it is unlikely that you will be given too much Bridion.
An allergic reaction may be recognised as a rash, itching, a swollen face, swollen lips or shortness of breath.
allergic reaction may be recognised as a rash, itching, a swollen face, swollen lips or shortness of breath.
If you are given glucagon you will need glucose or a sugary snack as soon as you are conscious.
If you are given glucagon you will need glucose or a sugary snack as soon as you are conscious.
If you are given glucagon you will need glucose or a sugary snack as soon as you are conscious.
Collect Pre-Urea samples (White Caps - 3 times)
If more than 12 hours have gone by, start again as normal the next day.
If more than 2 years have passed since the last vaccination, the primary vaccination (2 doses) should be repeated.
If more than 2 years have passed since the last vaccination, the primary vaccination (3 doses) should be repeated.
If more than 2 years have elapsed since the last vaccination the primary course should be repeated.
If more Rapilysin is used than recommended:
If more than one sponge is used the sponges should overlap.
► If you have more than one sore injection site (multiple lesions) you must stop using Betaferon until your skin has healed.
If a patient normally treated with XYNTHA is prescribed ReFacto AF, the treating physician may consider adjustment of dosing recommendations based on factor VIII recovery values.
syrup 30 ml with 1 spoon 50 ml with 1 spoon 60 ml with 1 spoon 100 ml with 1 spoon 120 ml with 1 spoon 150 ml with 1 spoon 150 ml with 1 oral syringe 225 ml with 1 spoon 300 ml with 1 spoon
syrup 30 ml with 1 spoon 50 ml with 1 spoon 60 ml with 1 spoon 100 ml with 1 spoon 120 ml with 1 spoon 150 ml with 1 spoon 225 ml with 1 spoon 300 ml with 1 spoon
Sitagliptin Absorption Following oral administration of a 100-mg dose to healthy subjects, sitagliptin was rapidly absorbed, with peak plasma concentrations (median Tmax) occurring 1 to 4 hours post-dose, mean plasma AUC of sitagliptin was 8.52 μ M• hr, Cmax was 950 nM.
monohydrate, equivalent to 100 mg sitagliptin.
monohydrate, equivalent to 25 mg sitagliptin.
monohydrate, equivalent to 50 mg sitagliptin.
If this happens, the symptoms are tiredness and shortness of breath.
If this occurs, please seek immediate medical assistance.
However, should this occur, you will receive appropriate treatment from your doctor.
- situations where an increase in plasma levels may occur (see section 5.2 Pharmacokinetic
When mixing Actrapid with Ultratard immediate injection is necessary to avoid blunting of the fast acting no
If botulism is clinically suspected, hospitalisation for the monitoring of respiratory function (incipient respiratory failure) may be required.
In case anti-erythropoietin antibody- mediated PRCA is diagnosed, therapy with NeoRecormon must be discontinued and patients should not be switched to another erythropoietic protein (see section 4.4).
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
- If any of the side effects gets serious, or if you notice any side effects not listed in this
It may harm them, even if their symptoms are the same as yours. − If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
If a patch does begin to come off, you may be able to make it stick again by pressing on it firmly.
13 potassium or other substances that may increase serum potassium levels (e. g. heparin) may lead to increases in serum potassium.
4 potassium or other substances that may increase serum potassium levels (e. g. heparin) may lead to increases in serum potassium.
If PRCA is diagnosed, therapy with Retacrit must be immediately discontinued and testing for erythropoietin antibodies should be considered.
If PRCA is diagnosed, therapy with Silapo must be immediately discontinued and testing for erythropoietin antibodies should be considered.
- If general anaesthesia is required, therapy with Stalevo may be continued for as long as the
- If general anaesthesia is required, therapy with Stalevo may be continued for as long as the patient
If another cause is identified (eg acute hepatitis A, B or C virus, gallbladder disease, other medicinal products), then rechallenge with APTIVUS may be considered when ASAT/ ALAT have returned to the patient 's baseline levels.
If you have been prescribed a half dose of Avonex, you may need to use the Avostartclip your doctor will provide.
If a dose is forgotten, the following dose must not be increased.
If anti-erythropoietin, antibody-mediated PRCA is suspected, therapy with Binocrit should be discontinued immediately.
If extravasation occurs, the infusion should be immediately terminated.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
It may harm them, even if their symptoms are the same as yours. − If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
If an adverse event occurs during the administration of Soliris, the infusion may be slowed or stopped at the discretion of the physician.
165 If any of the side effects get serious, if you have any unusual effects, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If pregnancy occurs during use of EVRA, EVRA should be stopped immediately.
If you experience an infection with symptoms such as fever and serious deterioration of your general condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or urinary problems you should see your doctor immediately.
- If any infection of your lungs or airways is found, you must be treated sufficiently before
If a dose is missed, treatment should be continued with the next dose as planned.
If a dose is missed, treatment should be continued with the next dose as planned.
If skin or eye symptoms persist, or the product is accidentally swallowed, seek medical attention and show the package insert to the physician.
If skin or eye symptoms persist, or the product is accidentally swallowed, seek medical attention and show the package insert to the physician.
If a full day has gone by, check with your doctor.
If neutropenia develops, dosing with Mycophenolate mofetil Teva should be interrupted or the dose reduced (see section 4.4).
It is expected that an overdose of mycophenolate mofetil could possibly result in oversuppression of the immune system and increase susceptibility to infections and bone marrow suppression (see section 4.4). If neutropenia develops, dosing with Mycophenolate mofetil Teva should be interrupted or the dose reduced (see section 4.4).
If a waiting period of up to approximately 2 years under reliable contraception is considered unpractical, prophylactic institution of a washout procedure may be advisable.
If solution is left in the vial, invert the vial, pull back the needle until the opening of the needle is just inside the stopper.
If an episode of unstable angina pectoris (major or not) occurs during the first month of perindopril treatment, a careful appraisal of the benefit/ risk should be performed before treatment continuation.
If a hypersensitivity reaction is suspected, discontinue Efficib, assess for other potential causes of the event, and institute alternative treatment for diabetes (see section 4.8).
If a hypersensitivity reaction is suspected, discontinue Janumet, assess for other potential causes of the event, and institute alternative treatment for diabetes (see section 4.8).
If a hypersensitivity reaction is suspected, discontinue Velmetia, assess for other potential causes of the event, and institute alternative treatment for diabetes (see section 4.8).
If a hypersensitivity reaction cannot be ruled out, Kivexa or any other medicinal product containing abacavir (Ziagen or Trizivir) must not be restarted.
If a hypersensitivity reaction cannot be ruled out, Trizivir or any other medicinal product containing abacavir (i. e.
If a hypersensitivity reaction cannot be ruled out, Ziagen or any other medicinal product containing abacavir (i. e.
In case re-treatment with Raptiva is needed you should follow the guidance of your doctor.
If caloric supplementation is indicated, a protein-free product is recommended.
If active tuberculosis is diagnosed, Remicade therapy must not be initiated (see section 4.3).
If concomitant use is indicated because of demonstrated hypokalaemia they should be used with caution and with frequent monitoring of serum potassium.
If an adverse event occurs during the administration of Soliris, the infusion may be slowed or stopped at the discretion of the physician.
If a diamond (♦) is not seen in the centre of the dose window, continue pushing
If a medicinal product that affects potassium levels is to be prescribed in combination with lisinopril, monitoring of potassium serum levels is advised.
If a new manic, mixed, or depressive episode occurs, olanzapine treatment should be continued (with dose optimisation as needed), with supplementary therapy to treat mood symptoms, as clinically indicated.
John's wort, check viral levels and if possible saquinavir levels.
If gastrointestinal bleeding is suspected, administer gastric protectants.
If PRES is diagnosed, adequate blood pressure and seizure control and immediate discontinuation of systemic tacrolimus is advised.
If treatment with an HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Alternatively, breast-feeding must be stopped, if treatment with Cardoreg 4 mg prolonged release tablets and associated names is unavoidable.
If treatment with an HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended (see section 4.5).
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended (see section 4.5).
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended (see section 4.5).
If treatment with an HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended (see section 4.5).
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin are recommended (see section 4.5).
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended (see section 4.5).
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended (see section 4.5).
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended (see section 4.5).
If a vaccine against hepatitis B has not been given at birth, Tritanrix HepB can be given as early as eight weeks of age.
If Viagra is taken with food, the onset of activity may be delayed compared with taking Viagra without food.
If Vivanza is taken with a high fat meal, the onset of activity may be delayed.
You must use your fast acting ‘ rescue'medicine (such as salbutamol) for this purpose which you should carry with you at all times.
- if your dog is suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired
If you r depression and/or suicidal thoughts are severe, you will not be prescribed Betaferon (see also ‘Do not use Betaferon’).
If your depression and/or suicidal thoughts are severe, you will not be prescribed Betaferon (see also ‘Do not use Betaferon’).
If you suffer from severe depression and/or suicidal thoughts, you will not be treated with Betaferon (see also ‘Do not use Betaferon’).
If your depression and/or suicidal thoughts are severe, you will not be prescribed Extavia (see also “Do not use Extavia”).
• if your child has experienced any health problems after previous administration of a vaccine. • if your child has previously had any allergic reaction to Quintanrix, or any ingredient contained
• if your child has a bleeding problem or bruises easily. • if your child takes medicines or has any treatment which may affect the immune system.
32 • if your child has previously had any allergic reaction to Tritanrix HepB, or any ingredient contained in this vaccine.
38 • if your child has previously had any allergic reaction to Tritanrix HepB, or any ingredient contained in this vaccine.
If your child takes more Diacomit than he or she should Contact your child's doctor if you know or think your child has taken more medicine than he or she should have.
52 If your child takes more SINGULAIR than he/ she should
If your child takes more SINGULAIR than he/ she should
If your child is to have a heart operation (cardiac bypass surgery), he or she may be given an extra dose of Synagis after the operation.
- if your child is allergic to any component of the vaccine.
- if your child has bleeding disorders such as haemophilia or thrombocytopenia, special
• If your child is on anti-asthma medicines, be aware that if he/ she develops a combination of symptoms such as flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/ or rash, you should consult your doctor.
• If your child is on anti-asthma medicines, be aware that if the he/ she develops a combination of symptoms such as flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/ or rash, you should consult your doctor.
• if your child uses one of the following products:
Please tell your doctor, nurse or pharmacist if your child is taking or has recently taken any other medicines including medicines obtained without prescription or has recently received any other vaccine.
Please tell your doctor, nurse or pharmacist if your child is taking or has recently taken any other medicines including medicines obtained without prescription or has recently received any other vaccine
Please tell your doctor/health care professional if your child is taking or has recently taken any other medicine, including medicines obtained without a prescription.
Please tell your doctor or pharmacist if your child is taking or has recently taken any other medicines, including medicines obtained without a prescription.
Please tell your doctor or pharmacist if your child is taking or has recently taken other medicines, including those obtained without a prescription.
If your child is taking SINGULAIR, be sure that he/ she does not take any other medicines that contain the same active ingredient, montelukast.
If your child is taking SINGULAIR, be sure that your child does not take any other products that contain the same active ingredient, montelukast.
- if your child has fever (vaccination should be delayed).
- if your child has fever or other illness, particularly a cough, cold or flu (vaccination should be
Please tell your doctor if your child is unwell, as the use of Synagis may need to be delayed. − if your child has any bleeding disorders as Synagis is usually injected into the thigh.
- if your child has any present or past medical problems or allergies, including allergic reactions
- if your child has an hypersensitivity to neomycin, streptomycin and polymyxin B, due to the use
- if your child has a thrombocytopenia or a bleeding disorder since bleeding may occur following
Please tell your child's doctor or pharmacist if your child is using or has recently used any other medicines, including medicines obtained without a prescription.
If your child has problems with certain ingredients of Diacomit (e. g. aspartame, glucose, sorbitol).
- If your family has a history of degenerative eye diseases (such as retinitis pigmentosa)
If you have decreased kidney function, VISTIDE may not be appropriate therapy for you.
- If you have an underactive thyroid gland before starting treatment with Sutent, or if your thyroid
If your blood sugar is too high (hyperglycaemia), you may not have injected enough insulin.
697 If your blood sugar is too high (hyperglycaemia), you may not have injected enough insulin.
If your blood sugar is too high (hyperglycaemia), you may have not injected enough insulin.
If your blood sugar is too high (hyperglycaemia), you may not have injected enough insulin.
If your blood sugar is too high (hyperglycaemia), you may not have injected enough insulin.
If your blood sugar is too high (hyperglycaemia), you may not have injected enough insulin.
If you r blood sugar is too high (hyperglycaemia), you may not have injected enough insulin.
If your blood sugar is too high (hyperglycaemia), you may not have injected enough insulin.
If your blood sugar is too high (hyperglycaemia), you may not have injected enough insulin.
If your liver disease gets worse, you may need to stop taking Telzir for a while, or permanently.
- If your disease is due to a blocked or narrow vein in the lungs rather than a blocked or narrow
If your doctor decides to stop your treatment with Vimpat, he/ she will instruct you about how you should decrease the dose step by step.
If your doctor decides to stop your treatment with Vimpat, he/she will instruct you about how you should decrease the dose step by step.
If your doctor thinks that you no longer need ARICLAIM he will ask you to reduce your dose over at least 2 weeks before stopping treatment altogether.
- If your doctor determines that you have inadequate skin coverage (at the fracture site) and
If your doctor cannot be reached for any reason, an alternate should be contacted immediately.
If your doctor has switched you from one type or brand of insulin to another, your dose may have to be adjusted by your doctor.
If you have a low platelet count, you may notice that you bruise more easily.
If your skin is infected, your doctor may ask you to use an appropriate medicine to treat the infection.
If your skin becomes infected during treatment with < Invented Name >, you should inform your doctor.
- if your blood pressure is continuing to rise despite treatment (malignant hypertension).
− Reduction in platelets (blood cells important for blood clotting) has been reported.
If your treatment is stopped it should be done gradually over a minimum of 1 week.
- If your urine is darker than usual – it is important to drink plenty of water to avoid dehydration.
- If you are allergic (hypersensitive) to pramipexole or any of the other ingredients of Oprymea
If you are giving this medicine to a child, the doctor will tell you how much to give for each dose.
If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet.
If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet.
If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet.
If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet.
- if you are breast-feeding (please read the section “ Pregnancy and breast-feeding” below);
Tell your doctor if you are breast-feeding before using < Invented Name > or any other medicines.
If you are breast-feeding you must inform your doctor.
If you are a nursing mother, you should stop breast-feeding if you are to be given RoActemra.
If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet.
If you are breast - feeding consult your doctor as you may require adjustments in your insulin doses and your diet.
If you are breast -feeding consult your doctor as you may require adjustments in your insulin doses and your diet.
If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet.
If you stop using it your original hair growth may return in 2 months.
If you stop taking ADROVANCE It is important that you continue taking ADROVANCE for as long as your doctor prescribes the medicine.
If you stop taking Cardoreg 4 mg prolonged release tablets and associated names Do not stop taking your medicine without consulting your doctor.
If you stop taking Emselex It has been shown that taking all doses at the appropriate times can greatly increase the effectiveness of your medicine.
If stopping treatment, as with other antiepileptic medicines, Keppra should be discontinued gradually to avoid an increase of seizures.
If you stop taking Mycophenolate mofetil Teva Do not stop taking Mycophenolate mofetil Teva because you feel better.
• If you stop taking Nplate a low blood platelet count (thrombocytopenia) is likely to reoccur.
If you stop taking ORACEA You should continue to take ORACEA until your doctor tells you to stop.
If you stop taking Sebivo Stopping treatment with Sebivo may result in a worsening of your hepatitis B infection.
If you stop using Vimpat If your doctor decides to stop your treatment with Vimpat, he/she will decrease the dose step by step.
If you stop using AZOPT without speaking to your doctor, the pressure in your eye will not be controlled which could lead to loss of sight.
If you take less Liprolog Mix25 than you need, a high blood sugar may occur.
If you stop using Nplate, your low blood platelet count (thrombocytopenia) is likely to reoccur.
If you stop using RISPERDAL CONSTA You will lose the effects of the medicine.
If you stop too early, your depression might come back.
If you accidentally swallow some < Invented Name > If you or someone else accidentally swallows < Invented Name >, tell your doctor immediately.
If you have stopped treatment due to hypersensitivity syndrome, it should be permanent and you should not re-start therapy with PROTELOS.
If you have stopped treatment due to hypersensitivity reactions it should be permanent and you should not re-start therapy with OSSEOR.
If you have stopped treatment due to hypersensitivity reactions it should be permanent and you should not re-start therapy with PROTELOS.
If you have discontinued Trizivir due to a hypersensitivity reaction, YOU MUST NEVER TAKE Trizivir, or any other medicine containing abacavir (i. e.
If you have discontinued Ziagen due to this reaction, YOU MUST NEVER TAKE Ziagen or any other abacavir containing medicine (i. e.
If you have discontinued Trizivir due to a hypersensitivity reaction, YOU MUST NEVER TAKE Trizivir or any other medicine containing abacavir (i. e.
NEVER TAKE Ziagen, or any other medicine containing abacavir (i. e.
TAKE Ziagen or any other medicine containing abacavir (i. e.
If you need to repeat the test, a new kit will be required and it should not be carried out until the following day.
If you need dose titrations of less than 1 mg it is recommended you do not use EXUBERA (see section 3 “How to take EXUBERA” for further advice and section 6 “Further information”).
If you need therapy for repressing antibodies (inhibitors) this should be taken care of in a haemophilia treating centre.
- If you have any further questions, ask your doctor or pharmacist.
- If you have further questions, please ask your doctor or your pharmacist.
- If you have any further questions, ask your doctor or your pharmacist.
- If you have any further questions, ask your doctor or your pharmacist.
- If you have further questions, please ask your doctor or your pharmacist.
If you have any further questions regarding this product, ask your doctor or pharmacist.
- If you have further questions, please ask the doctor giving you VASOVIST (the radiologist) or
- If you have any further questions, ask your doctor or pharmacist.
- If you have any further questions, ask your doctor or pharmacist
- If you have any further questions, ask your doctor or pharmacist.
- If you have any further questions, ask your doctor or your pharmacist.
If you have any further questions, ask your doctor or your pharmacist.
You may need to read it again. − If you have any further questions, ask your doctor or pharmacist. − This medicine has been prescribed for you.
- If you have any further questions, ask your doctor or health care professional.
- If you have further questions, ask your doctor or your pharmacist.
- If you have further questions, please ask your doctor or your pharmacist.
If you have further questions, ask your doctor or pharmacist.
You may need to read it again. − If you have any further questions, ask your doctor or pharmacist. − This medicine has been prescribed for you.
- If you have any further questions, ask your doctor or pharmacist.
If you have any further questions, ask your child's doctor or pharmacist.
However, you still need to use Zyrtec carefully to get the best results from it.
- If you any have further questions, ask your doctor or pharmacist.
- If you have any further questions, ask your doctor.
- If you have any further questions, ask your doctor/health care professional.
- If you have any further questions, ask your doctor, nurse or your pharmacist.
- If you have any further questions, ask your doctor or pharmacist.
- If you have any further questions, ask your doctor or pharmacist.
- If you have any further questions, ask your doctor or pharmacist
- If you have any further questions, ask your doctor or pharmacist.
- If you have any further questions, ask your doctor or pharmacist.
- If you have any further questions, ask your doctor or your hospital pharmacist.
- If you have any further questions, ask your doctor or your pharmacist.
- If you have any further questions, please ask your doctor or your pharmacist.
- If you have further questions, ask your doctor.
- If you have further questions, ask your doctor or pharmacist.
- If you have further questions, ask your doctor or your pharmacist.
- If you have further questions, please ask your doctor, midwife or pharmacist.
- If you have further questions, please ask your doctor or pharmacist.
- If you have further questions, please ask your doctor or your pharmacist.
- If you have further questions, please ask your doctor or your pharmacist.
- If you have any further questions, ask your doctor.
If you have any further questions, ask your doctor.
- If you have any further questions, ask your doctor or pharmacist.
- If you have any further questions, ask your doctor or pharmacist.
If you have any further questions, ask your doctor or pharmacist.
If you have further questions, please ask your doctor or pharmacist.
If you have further questions, please ask your doctor or your pharmacist.
You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you.
You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you.
However, you still need to use Zyrtec carefully to get the best results from it.
You may need to read it again. • If you have any further questions, ask your doctor. • If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.
You may need to read it again. • If you have any further questions, ask your doctor or pharmacist • This medicine has been prescribed for you.
You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you.
You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you.
You may need to read it again. • If you have any further questions, ask your doctor or your pharmacist. • This medicine has been prescribed for you.
You may need to read it again If you have any further questions, please ask your doctor or pharmacist
If you have any further questions on the use of this product, please consult your doctor, the radiologist or MRI-centre personnel.
► If you have any further questions on the use of this product, ask your doctor or pharmacist.
► If you have any further questions on the use of this product, ask your doctor or pharmacist.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
If you have any further questions on the use of this product, ask your child's doctor or pharmacist.
If you have any further questions on the use of this product, ask your doctor.
27 If you have any further questions on the use of this product, ask your doctor or pharmacist.
If you feel you are suffering from a side effect, tell a doctor immediately to get advice before taking the next dose. lon If you have any further questions on the use of this product, ask your doctor or pharmacist. no
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
If you have any further questions on the use of this product, ask you doctor or pharmacist.
If you have any further questions on the use of this product, ask your doctor or pharmacist
If you have any further questions on the use of this product, ask your doctor or pharmacist.
If you have any further questions on the use of this product, ask your doctor or pharmacist as well.
If you have any further questions on the use of this product, ask your doctor or your pharmacist.
If you have any further questions on the use of this product, ask your physician or pharmacist.
If you have any further questions on the use of this product, as your doctor or pharmacist.
If you have any more questions about the use of this product, ask your doctor or pharmacist.
If you have further questions on the use of this product ask your doctor or pharmacist.
If you have further questions on the use of this product ask your doctor or pharmacist.
If you have further questions on the use of this product, ask your doctor or pharmacist.
ed If you have any further questions on the use of this product, ask your doctor or pharmacist.
If you have any further questionson the use of this product ask a doctor or pharmacist.
If you have further questions on the use of this product, ask your doctor or pharmacist.
If you have any further questions on the use of RoActemra, then please ask your doctor or pharmacist.
If you have a fever, drink plenty of water to keep you hydrated.
If you have a fever or any of these symptoms, contact your doctor immediately and go straight to your hospital.
If you have a raised temperature you should seek medical attention immediately.
If you know that you are allergic (hypersensitive) to any of the ingredients or if you become so, you must not use Betaferon.
- if you had a previous reaction to contrast media
If you have any unwanted Lamictal tablets, don’t dispose of them in your waste water or your household rubbish.
AMMONAPS tablets can get stuck in the esophagus and
If you have difficulty swallowing it is recommended to use AMMONAPS granules instead.
If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice.
If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice. ct du
If you have difficulty swallowing, you can use the tip of a spoon to crush the tablet.
If you have particular difficulty swallowing, you can use the tip of a spoon to crush the tablet.
If you have difficulty in swallowing the capsules, tell your doctor.
If you have chest pains during or after intercourse:
If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.
► If you have trouble with your kidneys or liver, or with your adrenal, pituitary or thyroid glands ► If you are drinking alcohol: watch for signs of a hypo and never drink alcohol on an empty stomach ► If you are exercising more than usual or if you want to change your usual diet ► If you are ill: carry on taking your insulin ► If you are going abroad: travelling over time zones may affect your insulin needs and the timing of your injections.
► If you have trouble with your kidneys or liver, or with your adrenal, pituitary or thyroid glands ► If you are drinking alcohol: watch for signs of a hypo and never drink alcohol on an empty stomach ► If you are exercising more than usual or if you want to change your usual diet ► If you are ill: carry on taking your insulin ► If you are going abroad: travelling over time zones may affect your insulin needs and the timing of your injections.
► If you have trouble with your kidneys or liver, or with your adrenal, pituitary or thyroid glands ► If you are drinking alcohol: watch for signs of a hypo and never drink alcohol on an empty stomach ► If you are exercising more than usual or if you want to change your usual diet ► If you are ill: carry on taking your insulin ► If you are going abroad: travelling over time zones may affect your insulin needs and the timing of your injections.
► If you have trouble with your kidneys or liver, or with your adrenal, pituitary or thyroid glands ► If you are drinking alcohol: watch for signs of a hypo and never drink alcohol on an empty stomach ► If you are exercising more than usual or if you want to change your usual diet ► If you are ill: carry on taking your insulin ► If you are going abroad: travelling over time zones may affect your insulin needs and the timing of your injections.
► If you have trouble with your kidneys or liver, or with your adrenal, pituitary or thyroid glands ► If you are drinking alcohol: watch for signs of a hypo ► If you are exercising more than usual or if you want to change your usual diet ► If you are ill: carry on taking your insulin ► If you are going abroad: travelling over time zones may affect your insulin needs
► If you have trouble with your kidneys or liver, or with your adrenal, pituitary or thyroid glands ► If you are drinking alcohol: watch for signs of a hypo ► If you are exercising more than usual or if you want to change your usual diet ► If you are ill: carry on taking your insulin ► If you are going abroad: travelling over time zones may affect your insulin needs
► If you are drinking alcohol: watch for signs of a hypo ► If you are exercising more than usual or if you want to change your usual diet ► If you are ill: carry on taking your insulin na
Your need for insulin may change If you have an infection, fever or have had an operation you may need more insulin than usual
If you are having problems using your BYETTA pen, contact your healthcare professional.
If you have any questions or are not sure about something, ask the doctor or MRI-centre personnel.
If you have an upset stomach • The amount of hormones you get from EVRA should not be affected by being sick (vomiting) or diarrhoea • You do not need to use extra contraception if you have an upset stomach.
If you have difficulty swallowing, you can crush the tablet.
If you have problems with swallowing the capsules, they may be opened and the powder suspended into a small amount of water or formula diet just before intake.
If you have been inactive for a long period of time, any activity should be started gradually after the Xeomin injection.
- if you have been treated with a medicine of the type called anthracyclines (frequently used in
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel BMS (1 tablet of 300 mg or 4 tablets of 75 mg) once at the start of treatment.
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel BMS (1 tablet of 300 mg or 4 tablets of 75 mg) once at the start of treatment.
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel Winthrop (1 tablet of 300 mg or 4 tablets of 75 mg) once at the start of treatment.
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel Winthrop (1 tablet of 300 mg or 4 tablets of 75 mg) once at the start of treatment.
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Iscover (1 tablet of 300 mg or 4 tablets of 75 mg) once at the start of treatment.
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Iscover (1 tablet of 300 mg or 4 tablets of 75 mg) once at the start of treatment.
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Plavix (1 tablet of 300 mg or 4 tablets of 75 mg) once at the start of treatment.
- If you are also being treated for HIV, please see Using other medicines.
If you have had tuberculosis (TB) or have symptoms of tuberculosis (persistent cough, weight loss, listlessness, mild fever) tell your doctor.
- If you have or have had low blood pressure
If you use more Trudexa than you should:
If you use more Trudexa than you should: t
If you use more Trudexa than you should:
If you use more Humira than you should:
If you are uncertain please be sure to ask your child's doctor or pharmacist.
If you experience skin lesions or spots on your skin that start out as small red areas and progress to look like mini targets, possibly with symptoms such as itching, fever, overall ill feeling, achy joints, vision problems, burning, painful or itchy eyes and mouth sores, stop using Aldara cream and tell your doctor immediately.
Tell your doctor immediately if you experience any of these side effects.
At present, there is not very much information about MabThera treatment in children and adolescents; if you are under 18 years of age, you or your parent/career should ask your doctor if MabThera is right for you.
But if you missed to administer Cetrotide 0.25 mg at the right time it is no problem to administer this dose at a different time of the same day.
If you miss a dose, continue to inject from the day of the next scheduled dose.
If you have or are at risk of developing a serious blood infection called sepsis.
• if you have/ your child has experienced any health problems after previous administration of a vaccine. • if you have/ your child has a bleeding problem or bruise/ bruises easily.
• if you have/ your child has experienced any health problems after previous administration of a vaccine. • if you have/ your child has a bleeding problem or bruise/ bruises easily.
If you have taken or are planning to take CIALIS, avoid excessive drinking (blood alcohol level of 0.08% or greater), since this may increase the risk of dizziness when standing up.
If you have taken or are planning to take Tadalafil Lilly, avoid excessive drinking (blood alcohol level of 0.08% or greater), since this may increase the risk of dizziness when standing up.
If you take more Agopton than prescribed
75 If you take more Agopton than prescribed
If you take more Agopton than prescribed
47 If you take more Atripla than you should
If you take more Carbaglu than you should:
If too much CellCept IV solution is given:
If you take more CellCept than you should:
If you take more CIALIS than you should Tell your doctor.
If you take more Combivir than you should Accidentally taking too much Combivir is unlikely to cause any serious problems.
If you take more Competact tablets than you should:
If you take more Actos 15mg tablets than you should:
If you take more Actos 30mg tablets than you should:
If you take more Actos 45mg tablets than you should:
If you take more Glustin 15 mg tablets than you should:
If you take more Glustin 30 mg tablets than you should:
If you take more Glustin 45 mg tablets than you should:
If you take more Corlentor than you should:
If you take more Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names than you should:
If you take more Keppra than you should:
If you take more Ketek than you should If you accidentally take one tablet too many, nothing is likely to happen.
If you use more Kineret than you should
If you use more KOGENATE Bayer 1000 IU than you should:
If you use more KOGENATE Bayer 2000 IU than you should:
If you use more KOGENATE Bayer 250 IU than you should:
If you use more KOGENATE Bayer 500 IU than you should:
If you take more Liprolog Basal than you need If you take more Liprolog Basal than you need, a low blood sugar may occur.
If you take more Liprolog Mix25 than you need If you take more Liprolog Mix25 than you need, a low blood sugar may occur.
If you take more Liprolog Mix50 than you need If you take more Liprolog Mix50 than you need, a low blood sugar may occur.
207 If you take more Liprolog than you need If you take more Liprolog than you need, a low blood sugar may occur.
If you take more Liprolog than you need If you take more Liprolog than you need, a low blood sugar may occur.
If you take more Lysodren than you should
If you take more MIRAPEXIN than you should If you accidentally take too many tablets
If you take more MIRAPEXIN than you should If you accidentally take too many tablets,
If you take more OSSEOR than you should:
If you receive more Privigen than you should
If you take more Procoralan than you should:
If you take more PROTELOS than you should:
If you take more Sebivo than you should If you have taken too much Sebivo, or if someone else accidentally takes your tablets, go to your doctor or hospital for advice straight away.
If you take more Sebivo than you should If you have taken too much Sebivo, or if someone else accidentally takes your oral solution, go to your doctor or hospital for advice straight away.
If you take more Siklos than you should
If you take more Sonata than you should
If you take more Sprimeo than you should If you have accidentally taken too many Sprimeo tablets, consult a doctor immediately.
If you take more Tadalafil Lilly than you should Tell your doctor.
If you take more Tarceva than you should:
If you take more Thalidomide Celgene than you should:
If you take more Tracleer than you should If you take more tablets than you have been told to take, contact your doctor at once.
If you use more Ventavis than you should:
If you take more VIRACEPT than you should:
If you take more Viread than you should
If you take more Wilzin than you should:
If you take more Xagrid than you should:
If you take more Zerene than you should
If you take more Zonegran than you should
If you take more Zyrtec than you should
If you take more Humalog Mix25 than you need If you take more Humalog Mix25 than you need, a low blood sugar may occur.
If you take more INVANZ than you should
If you take more Orfadin than you should:
If you have used more than one injection of Avonex in a three-day period, contact your doctor or pharmacist straight away for advice.
If you have had certain other types of antibody treatment before starting Zevalin, you may be more likely to have an allergic reaction (hypersensitivity).
If you get it in your eyes, wash them immediately with gently flowing water for at least 15 minutes.
If you get more Flebogammadif than you should, your body may take on too much fluid.
If you are given more Foscan than you should You may not be given the laser treatment.
If you receive more GADOVIST than you should have received:
If you have been given more Nplate than you should, contact your doctor immediately.
In case you may have received only the radioactive substance yttrium, your doctor will treat you as described in the product information of yttrium-90.
If you eject too much Raptiva back into the vial, simply repeat the drawing up process and continue.
This may be inborn, of unknown cause or due to other
- If you have any further questions, ask your doctor or your pharmacist.
If you feel uncertain, ask your doctor or pharmacist.
- if you have inflammation of the colon (ulcerative colitis) or intestinal tract (Crohn's disease)
If you have extensive eczema, treatment with < Invented Name > may have to be stopped before any vaccinations.
- if you have a known deficiency for the enzyme dihydropyrimidine dehydrogenase (DPD), or
− If you have a deformity of your penis or Peyronie's Disease.
− If you have a deformity of your penis or Peyronie's Disease.
If you or the child in your care have Wegener's granulomatosis talk to your doctor.
If you have an infection in or around the eye.
Pradaxa should not be used in children.
- If you have acute bowel obstruction or a history of repeated constipation.
If you have moderate to severe active rheumatoid arthritis, you may first be given other disease-modifying medicines, such as methotrexate.
If you have moderate to severe active rheumatoid arthritis, you may first be given other disease-modifying medicines, such as methotrexate. lP
If you have a skin reaction and it doesn’t clear up in a few days, contact your health care professional.
Stop using Altargo, carefully wipe off the ointment, and contact your doctor or pharmacist immediately.
If you have diabetic retinopathy and your blood glucose levels improve very fast, the retinopathy may get worse.
If you are sexually active and your period stops altogether, do not assume that this is caused by AMMONAPS.
- have a very slow heart rate (bradycardia),
If you have used the Avostartclip, the syringe (and the Avostartclip) must be thrown away afterwards.
If you use more Aldara cream than you should:
If too much Avastin is given:
If you use more Betaferon than you should:
If you use more BYETTA than you should:
38 If you use more Cetrotide than you should
If you use more Cetrotide than you should
If you use more CYSTAGON than you should:
If you use more Naglazyme than you should No case of overdose of Naglazyme has been reported.
If you use more Enbrel than you should:
● If you use more Pegasys than you should:
If you use more Prialt than you should:
If you use more Raptiva than you should If you have injected more Raptiva than told by your doctor, please contact your doctor or pharmacist.
If you use more REGRANEX than you should:
37 If you take more Ovitrelle than you should:
If you take more Ovitrelle than you should:
Before receiving treatment with Remicade, you should tell your doctor if you have lived in or traveled to an area where infections called histoplasmosis, coccidioidomycosis, or blastomycosis are common.
stomach If you are exercising more than usual or if you want to change your usual diet lp
If you change to treatment with oral anticoagulants, treatment with CEPROTIN must continue until the blood level of the oral anticoagulation is adequate and stable.
If you drive or use tools or machines: watch out for signs of a hypo.
If you drive or use tools or machines: watch out for signs of a hypo.
If you notice such effects, please contact your doctor.
If you notice any other side effects, please inform your veterinary surgeon.
If you notice any other side effects, please inform your veterinary surgeon.
If you notice any other side effects, please inform your veterinary surgeon.
If you notice any other side effects, please inform your veterinary surgeon.
If you see any signs of a severe rash with blistering or fever, stop taking Atripla and tell your doctor at once.
If you see any signs of a severe rash with blistering or fever, stop
If nevertheless complaints occur, such as fever, rash, itching, small red spots on the skin, you should consult your doctor since the treatment may need to be discontinued. • allergic reactions after the first administration of this medicine.
If your cartridge or pen is damaged, ask your doctor or nurse for a replacement.
Tell your doctor if you experience any excessive thirst or increased frequency and quantity of urination.
If you notice any other side effect, please inform your veterinary surgeon.
- If you feel a change in your heart rate;
- If you notice any side effects not listed in this leaflet:
 if you notice any skin reactions at the site of application such as redness, oedema, or blistering.
If you become pregnant, stop taking the tablets and consult your doctor.
If you put too much cream on your skin, it is unlikely to harm you.
Your doctor may ask you to stop using < Invented Name > until the infection has been adequately controlled. < Invented Name > may be associated with an increased risk of a severe herpes simplex skin infection (eczema herpeticum).
- if you develop signs of a severe allergic reaction (such as difficulty in breathing, wheezing or
- If you develop symptoms associated w ith a cold or other respiratory infection, such as fever, cough,
- if you develop symptoms of a severe allergic reaction (such as difficulty in breathing, wheezing, or
- if you develop symptoms of a severe allergic reaction (such as difficulty in breathing, wheezing, or hives)
- If you develop symptoms of a severe allergic reaction (such as difficulty in breathing, wheezing, or
- If you develop symptoms of a severe allergic reaction (such as d ifficulty in breathing, wheezing, or
- If you develop symptoms of a severe allergic reaction (such as difficulty in breathing, wheezing, or
- If you develop cancer while undergoing treatment, please contact your doctor who will
If you develop severe allergic reaction or hives, notify your doctor or nurse immediately.
If you develop a reaction, they will slow down or stop the infusion and may give you treatment to counteract the side effects.
Tell your doctor immediately if you have a severe reaction to < Invented Name >.
If you have to stop taking this medicine, see Section 3, ‘If you stop using Neupro‘.
- if you are going to have a contrast x-ray (a specific type of x-ray involving an injectable dye).
If your next scheduled dose is more than 7 days away… You should take one tablet the next morning after the day you remember; then, continue taking one tablet once a month on the scheduled days you’ve marked on your calendar.
If you need to have any vaccinations, please inform your doctor beforehand.
If you are outdoors after applying < Invented Name >, wear loose fitting clothing, use appropriate sunscreen products and minimise the amount of time you spend in the sun.
25 If you require laboratory tests, it is important to remind your doctor that you take AMMONAPS, since sodium phenylbutyrate may influence certain laboratory test results.
If you require laboratory tests, it is important to remind your doctor that you take AMMONAPS, since sodium phenylbutyrate may influence certain laboratory test results.
- if you need to have magnetic resonance imaging (method to visualise internal organs and
If it is necessary to carry your medication with you, fill the dosing syringe to the appropriate mark and place a cap securely on it – the cap should snap into place.
- If you are donating stem cells for yourself after chemotherapy, the usual dose is
If you experience severe muscle pain, you should seek medical attention immediately.
If you go into hospital, let your doctor know that you are taking Axura.
If you go into hospital, let your doctor know that you are taking Axura.
If you go into hospital, let your doctor know that you are taking Ebixa.
If any of these side effects cause you a problem, speak to your doctor.
• if you are allergic to Aranesp (darbepoetin alfa), r-HuEPO or to any of the other ingredients in Aranesp.
- If you are allergic to other antibiotics such as penicillins, cephalosporins or carbapenems (which
• if you are allergic to other products that are produced by DNA technology using the micro- organism E. coli;
• if you are allergic to other products that are produced by DNA technology using the micro- organism E coli;
• If you are allergic to venlafaxine or any of the other ingredients of Efexor. • If you are also taking or have taken any time within the last 14 days any medicines known as irreversible monoamine oxidase inhibitors (MAOIs), used to treat depression or Parkinson's disease.
- If you are allergic to imiquimod (the active ingredient) or any of the ingredients of the cream.
- if you are allergic to dabigatran etexilate, dabigatran or any of the other ingredients of Pradaxa.
- if you are allergic to peginterferon-alfa-2a, to any interferon or any of the other ingredients of
- if you are allergic to medicines called sulphonamides.
• if you are allergic (hypersensitive) to Kineret (anakinra) or to any of the other ingredients in Kineret;
• if you are allergic (hypersensitive) to Kineret (anakinra) or to any of the other ingredients in Kineret;
- if you are allergic (hypersensitive) to glucosamine or to any of the other ingredients of
• if you are allergic (hypersensitive) to Botulinum neurotoxin type A or any of the other ingredients of Xeomin (see section 6 “ Further information”) • if you suffer from generalised disorders of muscle activity (e. g. myasthenia gravis, Lambert-Eaton syndrome) • if an infection is present at the injection site.
- If you are allergic (hypersensitive) to pioglitazone, glimepiride, other sulphonylureas or
• If you are allergic (hypersensitive) to somatropin or any of the other ingredients of NutropinAq. • For growth promotion if growing is already finished. • If an active tumour arises.
- if you are allergic (hypersensitive) to somatropin or any of the other ingredients of the
- If you are allergic (hypersensitive) to somatropin or to any of the other ingredients of
- If you are allergic (hypersensitive) to exenatide or any of the other ingredients of BYETTA, listed
- if you are allergic (hypersensitive) to Yttrium (90Y) chloride or any of the other ingredients of
- if you are allergic (hypersensitive) to moroctocog alfa or any of the other ingredients of ReFacto
- if you are allergic (hypersensitive) to nilotinib or any of the other ingredients of Tasigna listed
- if you are allergic (hypersensitive) to any medicinal product in the tetracycline family,
- you are allergic (hypersensitive) to Chinese hamster ovary (CHO) cell products or to other
- If you are allergic (hypersensitive) to peginterferon alfa-2b or any of the other ingredients of
- If you are allergic (hypersensitive) to peginterferon alfa-2b or any of the other ingredients of
- if you are allergic (hypersensitive) to sodium phenylbutyrate or any of the other ingredients of
- if you are allergic (hypersensitive) to porfimer sodium other porphyrins or to any other
- If you are allergic (hypersensitive) to tacrolimus or any of the other ingredients of Protopy or to
- If you are allergic (hypersensitive) to tacrolimus or any of the other ingredients of Protopy or to
- If you are allergic (hypersensitive) to temsirolimus, to polysorbate 80 or any of the other ingredients
- If you are allergic (hypersensitive) to ziconotide or any of the other ingredients of Prialt.
- if you are allergic (hypersensitive) to zonisamide or to any of the other ingredients of Zonegran
you had a heart attack or stroke in the month before your treatment you have unstable angina pectoris (new or increasing chest pain) you are at risk of blood clots in the veins (deep venous thrombosis) – for example, if you have had clots before.
If you have Crohn's disease you will first be given other medicines.
If you have ankylosing spondylitis, you will first be given other medicines.
- If you are a cancer patient be aware that MIRCERA, like other ESAs may act as a growth
• If you are a cancer patient you should be aware that Aranesp may act as a blood cell growth factor and in some circumstances may have a negative impact on your cancer.
If you are a cancer patient you should be aware that NeoRecormon may act as a blood cell growth factor and in some circumstances may have a negative impact on your cancer.
• If you are a cancer patient you should be aware that Nespo may act as a blood cell growth factor and in some circumstances may have a negative impact on your cancer.
- if you have liver disease or increased liver enzymes
If you are a patient with cancer these PBPCs will be removed from your blood and returned after your chemotherapy and/ or radiotherapy.
If you have depression, your doctor may still prescribe Avonex for you, but it's important to let your doctor know if you have had depression or any similar problems affecting your moods.
- if you have severe depression or think about committing suicide.
- if you have severe depression or think about committing suicide.
If you have ulcerative colitis you will first be given other medicines.
If affected take care when driving or using machines.
If you have diabetes, this may make your diabetes worse • Blood test showing a higher amount of uric acid or more fat than usual in your blood • Painful, red, and swollen joints
Tell your doctor who may need to adjust your anti-diabetic medicine.
• If you are diabetic, overweight or have high cholesterol, talk to your doctor.
• If you are diabetic, overweight or have high cholesterol, talk to your doctor.
If you are diabetic, overweight or have high cholesterol, talk to your doctor.
If you are diabetic, overweight or have high cholesterol, talk to your doctor.
- If you are di abetic, your doctor may ask you to have an eye examination.
- If you are diabetic, your doctor may ask you to have an eye examination.
- if you are also being treated for HIV, please see Using other medicines.
- if you are al so being treated for HIV, please see Using other medicines.
- if you are also being treated for HIV, please see Using other medicines.
- If you could get pregnant, you need to use contraception while you use Avonex.
If you could get pregnant, use contraception while you are on Betaferon.
- if the fetus is growing insufficiently and has an abnormal fetal heart rate
If you are pregnant, the benefits of using Prometax transdermal patches must be assessed against the possible effects on your unborn child.
- if you are pregnant do not start using Avonex
- if you are pregnant, do not start using Avonex
- if you are pregnant ORACEA should not be used from the 4th month of because it may harm
• If you are pregnant or breast-feeding (see section 2., Take special care, ‘ Pregnancy, ‘ Breast-feeding’).
If you are pregnant or nursing a baby, taking Aerius syrup is not recommended.
If you are pregnant or nursing a baby, taking Neoclarityn syrup is not recommended.
As noted in the “do not take” section, Ribavirin Teva can be very harmful to the unborn baby.
This medicine should be taken during pregnancy only after consultation with your doctor.
− Haemophilia, as there have been reports of increased bleeding in patients with haemophilia who are taking this type of medicine (protease inhibitors).
If you are admitted to the hospital or if you are prescribed a new medicine, please tell your doctor that you are taking Fareston.
- if you are hypersensitive (allergic) to tolcapone or to any of the other ingredients of Tasmar.
If you are worried, talk to your doctor or pharmacist.
If you are worried, talk to your doctor or pharmacist.
However, if you are concerned about your pain relief, you should talk to your doctor.
- If you are ill or have a major injury then your blood sugar level may increase
- If you are ill or have a major injury then your blood sugar level may increase (hyperglycaemia).
- If you are ill or have a major injury then your blood sugar level may increase (hyperglycaemia).
- If you are ill or have a major injury then your blood sugar level may increase (hyperglycaemia).
- If you are ill or have a major injury then your blood sugar level may increase (hyperglycaemia).
- If you are ill or have a major injury then your blood sugar level may increase (hyperglycaemia).
- if you are being treated now or have been treated in the last 4 weeks with brivudine, sorivudine
Tell a doctor or pharmacist if you are worried about this.
Tell a doctor or pharmacist if you are worried about any of these.
- if you experience angioedema (difficulties in breathing, or swallowing, or swelling of the face,
If you are able to become pregnant, your doctor will record with each prescription that the necessary measures, as outlined above, have been taken and will give you a record of this on your patient card or any other relevant documents.
If you are treated with Neupro and levodopa at the same time, some side effects may get more serious, such as seeing or hearing things that are not real (hallucinations), involuntary movements related to Parkinson’s disease (dyskinesia), and swelling of legs and feet.
- if you are being treated or have been treated for blood clots.
- if you are being treated with Zometa, which contains the same active substance as Aclasta.
If you are being treated for CML, the usual starting dose given is:
If you are being treated for CML, the usual starting dose is:
If you are being treated for MDS/ MPD, the starting dose is 400 mg, to be taken as one tablet of 400 mg once a day.
If you are a woman, this treatment increases your risk of developing ovarian hyperstimulation syndrome (OHSS) (see section 4).
If you are a woman, this treatment increases your risk of developing ovarian hyperstimulation syndrome (OHSS) (see Section 4).
If you are a woman, this treatment increases your risk of developing ovarian hyperstimulation syndrome (OHSS) (see Section 4).
If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and must use adequate contraception while using STELARA and for at least 15 weeks after the last STELARA treatment. • If you are breast-feeding or if you plan to breast-feed while using STELARA.
If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and must use adequate contraception while using STELARA and for at least 15 weeks after the last STELARA treatment. • If you are breast-feeding or if you plan to breast-feed while using STELARA.
If you are a kidney patient under haemodialysis and at risk of shunt thrombosis, blood clots (thromboses) may form in your shunt (vessel used for connection to the dialysis system).
If you are a cancer patient you should be aware that Abseamed may act as a blood cell growth factor and in some circumstances may have a negative impact on your cancer.
If you are a cancer patient you should be aware that Binocrit may act as a blood cell growth factor and in some circumstances may have a negative impact on your cancer.
If you are a cancer patient you should be aware that Epoetin alfa HEXAL may act as a blood cell growth factor and in some circumstances may have a negative impact on your cancer.
- if you expose your skin to strong sunlight or artificial sunlight, because more severe
- if you act as a donor for another person and are treated with anticoagulants (blood thinning
If you suspect an allergy to EXUBERA, speak to your doctor imm ediately. • If you smoke, or if you have smoked in the last six months you must not take EXUBERA as
If you inadvertently inject into the tissues around the vein, patients may experience local irritation, pain and inflammation at the injection site.
If you feel you are suffering from a side effect, tell a doctor immediately to get advice before taking the next dose.
Instructions for proper use Your doctor, nurse or pharmacist should instruct you in the proper use of your inhaler.
If you drop the NutropinAq Pen, check to see if the cartridge is damaged.
You may lie down immediately after taking OSSEOR if you wish.
You may lie down immediately after taking PROTELOS if you wish.
If unable to activate, discard immediately into an approved sharps collector.
If for some reason you do not drink the medicine straight away, make sure you stir it again before drinking.
- if none of these appear on the exposed area, then you can gradually return to your normal
If you cannot completely push in the injection button, refer to the “Questions and Answers” section, Question 7, at the end of this manual.
If you cannot dial a full dose, see the “Questions and Answers” section, Question 5, at the end of this manual.
If you are not able to take food or nutritional supplement, your doctor will tell you to take 200 mg (one 5 ml spoonful) four times a day.
If you cannot turn the dose knob, see Commonly Asked Questions, number 8, Section 4 of this user manual.
If you have not been using these medicines you must not use Effentora, because it may increase the risk that breathing could become dangerously slow and/ or shallow, or even stop. • You are allergic (hypersensitive) to fentanyl or any of the other ingredients of Effentora. • You suffer from severe breathing problems or severe obstructive lung conditions.
- If you are skeletally immature (still growing).
If you are failing to respond to therapy with Valtropin, your doctor will test for antibodies.
If you do not respond well enough to these medicines, you will be given Remicade to: • reduce the signs and symptoms of your disease. • improve your physical function
Please observe these instructions for use, otherwise you will not fully benefit from VIRACEPT.
You should check with your doctor or pharmacist if you are not sure. no
You should check with your doctor or pharmacist if you are not sure. ro
You should check with your doctor or pharmacist if you are not sure. lo Your weight Below 50 kg
You should check with your doctor or pharmacist if you are not sure.
If you do not see any benefit after using it f or 4 months contact your doctor.
If no liquid appears the first time, repeat a second time until a drop of liquid appears at the needle tip.
If you do not see a diamond in the centre of the dose window, the pen has not been primed correctly and you are not ready to set your dose.
If you notice any other side effects, please inform your veterinary surgeon.
If you notice a change in your breathing while taking EXUBERA inform your doctor.
If you notice this side effect, tell your doctor. • headache.
If you notice any other side effects, please inform your veterinary surgeon.
If you notice your skin thickening or pitting at the injection site, tell your doctor.
your lymph nodes become swollen during treatment with Protopic, consult your doctor.
your lymph nodes become swollen during treatment with Protopy, consult your doctor.
If your child forgets to take Diacomit It is important that your child takes this medicine regularly at the same time each day.
If you forget to give SINGULAIR to your child
If you forget to take ADROVANCE If you miss a dose, just take one tablet on the morning after you remember.
If you forget to take Alendronate HEXAL If you miss a dose, just take one tablet on the morning after you remember.
If you accidentally miss a daily dose, just take the next dose as normal.
If you forget to take Aprovel If you accidentally miss a daily dose, just take the next dose as normal.
60 If you forget to take Baraclude It is important that you do not miss any doses.
65 If you forget to take Baraclude It is important that you do not miss any doses.
If you forget to take Baraclude It is important that you do not miss any doses.
If you forget to take Cardoreg 4 mg prolonged release tablets and associated names Try to take your tablets daily as prescribed.
If you forget to take FOSAVANCE If you miss a dose, just take one tablet on the morning after you remember.
If you forget to take Glustin 30 mg tablets:
If you forget to take Glustin 45 mg tablets:
If you accidentally miss a daily dose, just take the next dose as normal.
If you forget to take Irbesartan BMS If you accidentally miss a daily dose, just take the next dose as normal.
If you forget to take Irbesartan Hydrochlorothiazide BMS If you accidentally miss a daily dose, just take the next dose as normal.
If you forget to take Irbesartan Hydrochlorothiazide Winthrop If you accidentally miss a daily dose, just take the next dose as normal.
If you accidentally miss a daily dose, just take the next dose as normal.
If you forget to take Irbesartan Winthrop If you accidentally miss a daily dose, just take the next dose as normal.
If you accidentally miss a daily dose, just take the next dose as normal.
If you forget to take Karvea If you accidentally miss a daily dose, just take the next dose as normal.
If you forget to take Mycophenolate mofetil Teva If you forget to take your medicine at any time, take it as soon as you remember, then continue to take it at the usual times.
If you forget to take Mycophenolate mofetil Teva If you forget to take your medicine at any time, take it as soon as you remember, then continue to take it at the usual times.
If you forget to take Naglazyme If you forget to take Naglazyme, please contact your doctor.
If you forget to take a dose, continue taking your medicine as normal.
If you miss a dose or you vomit
If you miss a dose, take only one FOSAVANCE tablet on the morning after you remember.
If you miss a dose, take only one ADROVANCE tablet on the morning after you remember.
If you forget to use Aldurazyme If you have missed an Aldurazyme infusion, please contact your doctor.
If you forget to use Liprolog Mix25 If you take less Liprolog Mix25 than you need, a high blood sugar may occur.
If you forget to use Liprolog Mix50 If you take less Liprolog Mix50 than you need, a high blood sugar may occur.
If you forget to use STELARA If you forget a dose, contact your doctor or pharmacist.
If you forget one dose of HBVAXPRO 5 micrograms/ 0.5 ml:
If you or the child have, or are at risk of developing a serious blood infection called sepsis.
If you or the child have, or are at risk of developing a serious blood infection called sepsis.
If the child develops symptoms of an infection such as fever, chills or cough, notify your doctor immediately.
If you or the child develop symptoms of an infection such as fever, chills or cough, notify your doctor immediately.
If you or the child develop symptoms of an infection such as fever, chills or cough, notify your doctor immediately.
If you or the child in your care have Wegener's granulomatosis talk to your doctor.
If you or the child in your care have Wegener's granulomatosis talk to your doctor.
If you or anyone else accidentally swallows Vaniqa, contact your doctor.
- if you, or someone in your family, has ever had problems with the electrical rhythm of the heart
Tell the doctor if you/your child has headache with vomiting.
They should be monitored for progression of their scoliosis.
Benzyl alcohol must not be given to premature babies or neonates.
Hypoacusis (hearing loss) Tell the doctor if you/your child develop hearing problems.
- If you or your doctor know that your bowels are obstructed or your bowels are in a state where
If you go on holiday to an area with more sunshine, remember to repeat the skin test, especially if some areas of skin have not been exposed to sunlight since your PhotoBarr treatment.
If you think you are having this sort of insulin allergy with Humalog, tell your doctor at once.
If you think you are having this sort of insulin allergy with Liprolog Basal, tell your doctor at once.
If you think you are having this sort of insulin allergy with Liprolog, tell your doctor at once.
If you think you are having this sort of insulin allergy with Liprolog Mix25, tell your doctor at once.
Tell your doctor immediately if you think you are experiencing any of these side effects.
If you are concerned that you may have been given too much ECALTA, tell your doctor or another healthcare professional immediately.
If you are concerned that your OptiSet may be damaged, discard it and use a new one.
If you are concerned that your SoloStar may be damaged, use a new one.
- if you think you may have an infection, even a mild one like a cold.
If you get any of these symptoms or get short of breath, stop taking Aprovel and contact your doctor immediately.
If you get any of these symptoms or get short of breath, stop taking CoAprovel and contact your doctor immediately.
If you get any of these symptoms or get short of breath, stop taking Irbesartan BMS and contact your doctor immediately.
If you get any of these symptoms or get short of breath, stop taking Irbesartan Winthrop and contact your doctor immediately.
If you get any of these symptoms or get short of breath, stop taking Karvea and contact your doctor immediately.
If you get any of these symptoms or get short of breath, stop taking Karvezide and contact your doctor immediately.
101 you are developing such a reaction or get short of breath stop taking Irbesartan Hydrochlorothiazide Winthrop and seek immediate medical attention.
108 you are developing such a reaction or get short of breath stop taking Irbesartan Hydrochlorothiazide Winthrop and seek immediate medical attention.
122 you are developing such a reaction or get short of breath stop taking Irbesartan Hydrochlorothiazide Winthrop and seek immediate medical attention.
If you think you are developing such a reaction or get short of breath stop taking irbesartan and seek immediate medical attention.
If you are concerned that you are given more ABILIFY solution for injection than you feel necessary, tell your doctor or nurse of your concern.
If you think you have been injected with too much Optimark, tell the doctor or nurse/ technologist immediately.
If you think you have been injected with too much Optimark, tell the doctor or nurse/ technologist immediately.
If you miss a dose of Tygacil If you are concerned that you may have missed a dose, talk to your doctor or nurse immediately.
If you could become pregnant you must use adequate contraception whilst you use TRAVATAN.
If you could get pregnant you must use adequate contraception whilst you use the medicine.
If you administer the injections yourself or have it done by your partner, follow the instructions below carefully.
if you are currently taking any other medicines or if you have recently taken any other medicines.
If you are taking certain medicines, your doctor may need to check the dose of Lamictal.
Avonex may affect other medicines or be affected by them.
• if you take other medicines, which inhibit the production of blood cells in bone marrow.
- if you are taking other medicines, including those you can obtain without a prescription.
If you are receiving cyclosporine, your physician may order additional blood tests during your treatment.
If you are taking levodopa, the dose of levodopa is recommended to be reduced when you start treatment with MIRAPEXIN.
If you are also being treated for Human Immunodeficiency Virus (HIV) infection (AIDS) with zidovudine or stavudine, it is not certain if ribavirin will change the way these medicines work.
If you are also being treated for Human Immunodeficiency Virus (HIV) infection (AIDS) with zidovudine or stavudine, it is not certain if ribavirin will change the way these medicines work.
If you take zidovudine or stavudine as a treatment for HIV or AIDS, it is possible that ribavirin will affect the way these medicines work.
Before taking this medicine, make sure your doctor knows: if you have hepatitis B or C if you have type A or B haemophilia if you have diabetes if you are taking oral contraceptives ("the Pill") to prevent pregnancy if you are taking omeprazole or other proton pump inhibitors (used to treat diseases related to the acid in the stomach) if you notice changes in body fat.
- if you take blood thinners (like warfarin or other coumarin-derivatives) because Tarceva may
- If you are taking blood thinners, your doctor may need to make changes to the dose of your
100 Please tell your doctor if you are taking MAO inhibitors (e. g. moclobemide against depression or selegiline against Parkinson's disease) or have taken them within the last 14 days.
79 Please tell your doctor if you are taking MAO inhibitors (e. g. moclobemide against depression or selegiline against Parkinson's disease) or have taken them within the last 14 days.
86 Please tell your doctor if you are taking MAO inhibitors (e. g. moclobemide against depression or selegiline against Parkinson's disease) or have taken them within the last 14 days.
93 Please tell your doctor if you are taking MAO inhibitors (e. g. moclobemide against depression or selegiline against Parkinson's disease) or have taken them within the last 14 days.
If you take two 2.25 g doses of sodium oxybate each night you will take 0.82g of sodium, or if you take two 4.5 g doses of sodium oxybate each night you will take in 1.6g sodium.
- if you are also receiving heart or blood pressure medicine.
If you receive Erbitux in combination with radiation therapy, treatment with Erbitux is usually started one week before radiation therapy.
• if you are taking FABLYN, you should walk around or exercise your legs and feet at regular intervals when traveling long distances.
If you are using< Etoricoxib >, you must not breast- feed.
- if you are taking or have recently taken anticoagulant medication (see “Taking other
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines since other medicines could interfere with the effect of thalidomide.
This includes prescription and non-prescription medicines, and herbal supplements.
- Please tell your doctor or pharmacist if you are taking or have recently taken any other
Please tell your doctor or pharmacist if you are taking or have recently taken other medicines, including medicines obtained without a prescription or herbal medicines.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription and herbal medicines.
23 Please tell your doctor or nurse if you are taking any other medicines or have recently taken any other medicines including medicines obtained without prescription.
could be at increased risk of developing anaemia (low number of red blood cells).
could be at increased risk of developing anaemia (low number of red blood cells).
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including any that you obtained without a prescription.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines including medicines obtained without a prescription.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without prescription.
Please tell your doctor or pharmacist if you are taking or have recently taken other medicines, including medicines obtained without prescription.
If you are taking ritonavir therapy for the treatment of HIV, you should not take Revatio.
● If you are preparing both of your daily doses at one time, be sure to use new syringes, water for injections and Fuzeon for each dose.
● If you are preparing both of your daily doses at one time, be sure to use new syringes, water for injections, and Fuzeon for each dose.
your doctor knows before you start taking Onsenal:
- If you develop any of the signs and symptoms associated with a decrease in blood platelets,
If you have internal warts: do not use Aldara cream in the urethra (the hole from which urine is passed), the vagina (birth canal), the cervix (internal female organ), or anywhere inside your anus (rectum).
Do not drive or use any tools or machines if you are experiencing any of these side effects.
If you experience any of these or other symptoms that are troublesome, ask your doctor for further advice.
→ Tell your doctor immediately if you get any symptoms of these conditions, as hospitalisation may be necessary.
If you are concerned about any side effect, or if you notice any side effects that are not listed in this leaflet, please tell your doctor or pharmacist.
If you are concerned about any side effects, or if you notice any side effects that are not listed in this leaflet, please tell your doctor or pharmacist.
72 If any of these affect you severely, tell your doctor.
If you have any of these conditions, please talk to your doctor as he/ she may want to adjust your dose or monitor you for a while.
ris • If you have poorly controlled, unstable, or severe asthma. • If you have severe (GOLD stage III or IV), Chronic Obstructive Pulmonary Disease (COPD).
- if you are hypersensitive (allergic) to salmon calcitonin or any of the other ingredients of
taking EXUBERA you should monitor your blood glucose frequently and you may need to adjust your EXUBERA dose.
1 st injection: _______________________ Following injections: _______________________ _______________________
- if you have a severe liver impairment.
Take special care with Zyrtec If you are a patient with renal insufficiency.
If you experience any break in the skin, which may be associated with swelling or fluid leaking out from the injection site:
If you have active rheumatoid arthritis you first will be given other medicines.
You will have to be examined regularly for
If you plan to start using a hormonal contraceptive:
If you were switched over to Baraclude because the treatment with lamivudine was not successful, you should take Baraclude on an empty stomach once daily.
If you receive Herceptin with paclitaxel, docetaxel or an aromatase inhibitor you should also read the package inserts for these products.
If you receive more VASOVIST than you should have received:
Your doctor may recommend that you consider vaccination against hepatitis A and B if you regularly/ repeatedly receive human plasma-derived Protein C products.
If you are receiving HAART, the addition of PegIntron and ribavirin may increase your risk of lactic acidosis, liver failure, and development of blood abnormalities (reduction in number of red blood cells which carry oxygen, certain white blood cells that fight infection, and blood clotting cells called platelets).
If you are receiving HAART, the addition of PegIntron and ribavirin may increase your risk of lactic acidosis, liver failure, and development of blood abnormalities (reduction in number of red blood cells which carry oxygen, certain white blood cells that fight infection, and blood clotting cells called platelets).
If you are receiving HAART, the addition of Rebetol and peginterferon alfa-2b may increase your risk of lactic acidosis, liver failure, and development of blood abnormalities (reduction in number of red blood cells which carry oxygen, certain white blood cells that fight infection, and blood clotting cells called platelets).
If you are receiving HAART, the addition of ViraferonPeg and ribavirin may increase your risk of lactic acidosis, liver failure, and development of blood abnormalities (reduction in number of red blood cells which carry oxygen, certain white blood cells that fight infection, and blood clotting cells called platelets).
If you are receiving HAART, the addition of ViraferonPeg and ribavirin may increase your risk of lactic acidosis, liver failure, and development of blood abnormalities (reduction in number of red blood cells which carry oxygen, certain white blood cells that fight infection, and blood clotting cells called platelets).
If you are receiving HAART, the addition of ViraferonPeg and ribavirin may increase your risk of lactic acidosis, liver failure, and development of blood abnormalities (reduction in number of red blood cells which carry oxygen, certain white blood cells that fight infection, and blood clotting cells called platelets).
If you are receiving HAART, the addition of PegIntron and ribavirin may increase your risk of lactic acidosis and of liver failure.
If you are receiving HAART, the addition of PegIntron and ribavirin may increase your risk of lactic acidosis and of liver failure.
If you are receiving HAART, the addition of ViraferonPeg and ribavirin may increase your risk of lactic acidosis and of liver failure.
If you are receiving HAART, the addition of ViraferonPeg and ribavirin may increase your risk of lactic acidosis and of liver failure.
If you are switched to permanent prophylaxis with oral anticoagulants, protein C replacement is to be discontinued only when stable anticoagulation is obtained (see “ Important information about some of the ingredients of CEPROTIN”).
If you look from the side through the gap in the stopper, you can control the movement of the needle and the liquid.
effects, please contact your doctor.
If you notice any other effects, even ones not listed in this leaflet tell your doctor or pharmacist.
232 If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
29 If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If you notice any side effects relating to the eyes, you should contact your doctor immediately for an eye examination.
If you notice any side effects, please inform your doctor or pharmacist.
If you notice any muscle problems: → Tell your doctor.
If you notice such reactions during the infusion of Privigen, please tell your doctor immediately.
If you notice such reactions during the infusion of Privigen, please tell your doctor immediately.
If you notice any of these side effects, tell your doctor.
If you notice any symptoms of lactic acidosis, please tell your doctor immediately.
Changing the site with each injection may help to prevent such skin changes.
If you notice your skin pitting or thickening at the injection site, tell your doctor or diabetes nurse because these reactions can become more severe, or they may change the absorption of your insulin if you inject in such a site.
If you notice your skin pitting or thickening at the injection site, tell your doctor or diabetes nurse because these reactions can become more severe, or they may change the absorption of your insulin if you inject in such a site.
If you notice your skin pitting or thickening at the injection site, tell your doctor or nurse because these reactions can become more severe, or they may change the absorption of your insulin if you inject in such a site.
If you notice your skin pitting or thickening at the injection site, tell your doctor or nurse because these reactions can become more severe, or they may change the absorption of your insulin if you inject in such a site.
If you notice your skin pitting or thickening at the injection site, tell your doctor or nurse because these reactions can become more severe, or they may change the absorption of your insulin if you inject in such a site.
If you notice your skin pitting or thickening at the injection site, tell your doctor or nurse because these reactions can become more severe, or they may change the absorption of your insulin if you inject in such a site.
If you notice your skin pitting or thickening at the injection site, tell your doctor or diabetes nurse because these reactions can become more severe, or they may change the absorption of your insulin if you inject in such a site.
If you notice your skin pitting or thickening at the injection site, tell your doctor or diabetes nurse because these reactions can become more severe, or they may change the absorption of your insulin if you inject in such a site.
If you notice your skin pitting or thickening at the injection site, tell your doctor or diabetes nurse because these reactions can become more severe, or they may change the absorption of your insulin if you inject in such a site.
If you notice your skin pitting or thickening at the injection site, tell your doctor or diabetes nurse because these reactions can become more severe, or they may change the absorption of your insulin if you inject in such a site.
If you notice your skin pitting or thickening at the injection site, tell your doctor or diabetes nurse because these reactions can become more severe, or they may change the absorption of your insulin if you inject in such a site.
If you notice your skin pitting or thickening at the injection site, tell your doctor or diabetes nurse because these reactions can become ng more severe, or they may change the absorption of your insulin if you inject in such a site. lo
If you notice your skin becoming fragile and easily blistered (especially areas that are frequently exposed to sunlight) and/ or you have stomach or limb pain you should tell your doctor who may recommend that you stop treatment.
If you notice your skin becoming fragile and easily blistered (especially areas that are frequently exposed to sunlight) and/ or you have stomach or limb pain you should tell your doctor who may recommend that you stop treatment.
If y ou get any of the following, (potentially less serious), side effects:
If you notice any of the following, the child may need urgent medical attention.
If you notice any of the following, you or the child may need urgent medical attention.
If you notice any of the following, you or the child may need urgent medical attention.
If you notice any of these, or any other effects of the injections not mentioned, tell a doctor or nurse, as some of these effects may be serious enough to require immediate medical attention.
If you notice any of these, or any other effects of the injections not mentioned, tell a doctor or nurse, as some of these effects may be serious enough to require immediate medical attention.
- if you notice a marked decrease in your urine output (sign of kidney problem).
- If you notice any side effects that you are worried about, whether they are listed in this leaflet or
If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice.
If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice.
If you have any problems, please ask your doctor or nurse for help and advice.
If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice.
If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice.
If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice. od
If you develop swallowing difficulties, speech or breathing disorders, please contact medical emergency services immediately or ask your relatives to do so.
- if you experience frequent abdominal pain, particularly after eating or taking EXJADE.
If you experience any side effects that are not in this leaflet, please tell your doctor or pharmacist.
If you get side effects → Tell your doctor or pharmacist if any of the side effects gets severe or troublesome, or if you notice any side effects not listed in this leaflet.
If you experience clinical symptoms suggesting an injury of the liver, such as loss of appetite, nausea, vomiting and/ or jaundice, you should inform your doctor.
If you should experience one of these side effects, you are advised to contact your doctor.
If you get any of these signs: test your blood sugar level; test your urine for ketones if you can; then seek medical advice straight away.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
388 If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, tell your doctor or pharmacist.
396 If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, tell your doctor or pharmacist.
412 If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, tell your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, tell your doctor or pharmacist.
If you are concerned about any side effects, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If you experience any side effects during or soon after the injection, tell you doctor.
73 If you get side effects → Tell your doctor or pharmacist if any of the side effects become severe or troublesome, or if you notice any side effects not listed in this leaflet,
If you get side effects → Tell your doctor or pharmacist if any of the side effects become severe or troublesome, or if you notice any side effects not listed in this leaflet,
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your child's doctor or pharmacist.
- if you experience weakness, feel light-headed or dizzy or have difficulty breathing, as these
you spend time outdoors after applying Protopic, use a sunscreen and wear loose fitting clothing that protects the skin from the sun.
you spend time outdoors after applying Protopy, use a sunscreen and wear loose fitting clothing that protects the skin from the sun.
If you have COPD, or are a heavy smoker, you should discuss with your doctor t
If you suffer from Parkinson's disease you should not stop treatment with MIRAPEXIN abruptly.
If you suffer from Parkinson's disease you should not stop treatment with Oprymea abruptly.
If you suffer from Parkinson's disease you should not stop treatment with SIFROL abruptly.
If you suffer from Parkinson's disease, you may experience the following side effects:
generalised erythroderma (inflammatory reddening and scaling of the entire skin).
- if you suffer from unstable angina (a severe form in which chest pain occurs very frequently and
The usual dose is one tablet of Tarceva 100 mg each day if you have metastatic pancreatic cancer.
- if you get left upper abdominal pain or pain at the tip of your shoulder.
• if you get left upper abdominal pain or pain at the tip of your shoulder;
• if you get left upper abdominal pain or pain at the tip of your shoulder;
• if you get left upper abdominal pain or pain at the tip of your shoulder.
• if you get left upper abdominal pain or pain at the tip of your shoulder. • if you have an allergy to latex.
If an interruption to insulin flow is suspected, follow the instructions in the product literature and if appropriate, notify your doctor or clinic.
If an interruption to insulin flow is suspected, follow the instructions in the product literature and if appropriate, notify your doctor or clinic. • When used with an insulin infusion pump, Humalog should not be mixed with any other insulin.
251 • When used with an insulin infusion pump, Liprolog should not be mixed with any other insulin.
If an interruption to insulin flow is suspected, follow the instructions in the product literature and if appropriate, notify your doctor or clinic. • When used with an insulin infusion pump, Liprolog should not be mixed with any other insulin.
If an interruption to insulin flow is suspected, follow the instructions in the product literature and if appropriate, notify your health care professional.
If you use moisturisers, they should be applied immediately after < Invented Name >.
If you are using the active shield, slide the shield onto the pen and push the 2 black lock knobs on the needle shield toward the tip.
If your asthma gets worse or is not well controlled (you will feel wheezy and need more of your fast acting ‘ rescue'medicine), do not increase the number of puffs of Seretide you take.
If you use Mycamine you should not breast-feed.
If you are using Neupro for Parkinson’s disease the following side effects may occur:
If you are using < Invented Name >, do not cover the treated skin with bandages, dressings or wraps.
If you take more BeneFIX than you should:
If you use more CEPROTIN than you should
If you use more Fasturtec than you should If it does occur, the doctor will closely monitor the effects on your red blood cells and treat any symptoms that follow.
If you use more FORCALTONIN than you should:
If you are an adult and choose to use another measuring device (e. g. cup or teaspoon) please be sure that the entire dose is taken as some VIRAMUNE can remain in the cup or spoon.
If you are using a hormonal contraceptive, and you notice any changes in your menstrual pattern, such as breakthrough bleeding or spotting between periods:
If using a transfer needle, make sure to penetrate the centre of the rubber stopper.
If you use a transfer needle, make sure to penetrate the centre of the rubber stopper.
If you use oral contraceptives or HRT you have an increased chance of developing a skin rash while taking APTIVUS.
If you vomit frequently before or during treatment, ask your doctor about the best time to take Temodal until the vomiting is under control.
If you vomit frequently before or during treatment, ask your doctor about the best time to take Temodal until the vomiting is under control.
If you want to start treatment with CHAMPIX, your treatment should be timed so that you have completed the course before becoming pregnant.
If you are self injecting, you should not use the outer area of the upper arms.
If you are self injecting, you should not use the outer area of the upper arms..
If you feel depressed, please contact your doctor immediately.
- If you feel noticeably more sad or hopeless than before the treatment with Extavia, or if
If you see any bubbles, pull the plunger slightly back.
If you see any bubbles, pull the plunger slightly back; tap the syringe gently, with the needle pointing up, until the bubbles disappear.
If you see any bubbles, pull the plunger slightly back; tap the syringe gently, with the needle pointing upwards, until the bubbles disappear.
If you have been prescribed Wilzin with another anti-copper agent, such as penicillamine, keep an interval of at least 1 hour between the two medicines.
Of these 6 (40%) had normalised LVM by the end of the study.
Six applications were voluntarily withdrawn by applicants; 4 concerned converted ‘ ex-concertation'applications and 2 new applications.
Six placebo controlled trials have been performed to investigate the short term efficacy of Thymanax in major depressive disorder: two flexible dose studies and four fixed dose studies.
Six placebo controlled trials have been performed to investigate the short term efficacy of Valdoxan in major depressive disorder: two flexible dose studies and four fixed dose studies.
Six hours after treatment, the concentration of tylvalosin in the gastrointestinal tract mucosa has a mean concentration of 133 ng/g and in the gastrointestinal contents of 1040 ng/g.
Six metabolites were detected at trace levels and are not expected to contribute to the plasma DPP-4 inhibitory activity of sitagliptin.
Six months after successful eradication treatment, the risk of re-infection is low and relapse is therefore unlikely.
Six months after successful eradication treatment, the risk of re-infection is low and relapse is therefore unlikely.
Six months after successful eradication treatment, the risk of re infection is low and relapse is therefore unlikely.
Six per cent of the patients had amputations and 10% had new thromboembolic complications.
Six Efficacy and three Safety Working Party plenary meetings are foreseen in 1998.
Six weeks after vaccination these local reactions are considerably decreased.
Six glass tubes, with caps and bar code labels.
If Yttriga is administered inadvertently Since Yttriga is administered by a doctor under strictly controlled conditions there is little risk of possible overdose.
If Zactran comes in direct contact with the eyes, they should be flushed immediately with clean water.
Sjöberg, provides a forum for pre-clinical safety issues.
ALS or peripheral neuropathy) or known neuromuscular junctional disorders (e. g. myasthenia gravis or Lambert-Eaton syndrome) should not be given NeuroBloc.
This document is a summary of the European Public Assessment Report (EPAR).
ut with one raised dot each.
Slovakofarma As Nitrianská 100 92027 Hlomovec Hungary
(Slovenia) Brnciceva 1 SLO - 1001 Ljubljiana Slovenia
Slovenija Boehringer Ingelheim Pharma Podruž nica Ljubljana Tel: +386 1 586 40 00
Slovenija Boehringer Ingelheim RCV GmbH & Co KG Podruž nica Ljubljana Tel: +386 1 586 40 00
Tel: + 40 21 4023000 Slovenija Boehringer Ingelheim Pharma Tel.: +386 1 586 40 00
Slovenija Dunajska 22 SI-1000 Ljubljana
Slovenija Higiea d. o. o Blatnica 10 SI-1236 Trzin Tel: + 386 1 589 7221/ 25
Slovenija sanofi-aventis d.o.o.
Tel: +353 (0) 1 403 56 00
Slovenija Valentis Pharmaceuticals d.o.0 Tel: + 386 1 2000603
Slovenija Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 D-60318 Frankfurt Nemč ija Tel: +49 (0)69 1503 - 1
Slovenija Pfizer Luxembourg SARL Pfizer, podruž nica za svetovanje s področ ja farmacevtske dejavnosti, Ljubljana
Slovenija Pfizer Luxembourg SARL, Pfizer, podruž nica za svetovanje s področ ja farmacevtske dejavnosti, Ljubljana Tel: + 386 1 52 11 400
Slovenija Pfizer Luxembourg SARL Pfizer, podruž nica za svetovanje s področ ja farmacevtske dejavnosti, Ljubljana Tel: + 386 (0) 152 11 400
Slovenija Pfizer Luxembourg SARL Pfizer, podruž nica za svetovanje s področ ja farmacevtske dejavnosti, Ljubljana Tel: +386 (0)1 52 11 400
Slovenská republika Actelion Pharmaceuticals Ltd Tel: +420 2 3413 8150
Astellas Pharma s. r. o., organizač ná zlož ka Záborského 29
29 SK-831 03 Bratislava 3 Tel: +421 2 4444 2157
Slovenská republika Boehringer Ingelheim Pharma organizač ná zlož ka Tel: +421 2 5810 1211
Slovenská republika Boehringer Ingelheim Pharma organizač ná zlož ka Tel: +421 2 5810 1211
Slovenská republika Boehringer Ingelheim RCV GmbH & Co KG organizač ná zlož ka Tel: +421 2 5810 1211
Slovenská republika GlaxoSmithKline Slovakia s. r. o.
Slovenská Republika Alcon Pharmaceuticals Ltd – oz + 421 2 5441 0378
Slovenská republika Pfizer Luxembourg SARL, organizačná zložka Tel: +421-2-3355 5500
Tel: +386 1 560 48 00
Slovenská republika IVAX Pharmaceuticals s.r.o Tel: +420 553 641 111
Slovenská republika Nycomed Langebjerg 1 DK-4000 Roskilde Dánsko Tel: +45 46 77 11 11 info@nycomed.com
Slovenská republika Pfizer Luxembourg SARL, organizač ná zlož ka Tel: +421-2-3355 5500
Slovenská republika Pfizer Luxembourg SARL, organiza č ná zlož ka Tel: +421-2-3355 5500
Slovenská republika Pfizer Luxembourg SARL, organizač ná zlož ka Tel: +421-2-3355 5500
Slovenská republika Pfizer Luxembourg SARL, organizačná zložka Tel: +421–2–3355 5500
Slovenská republika Pfizer Luxembourg SARL, organizač ná zlož ka Tel: + 421-2-3355 5500
Slovenská republika Pfizer Luxembourg SARL, organizač ná zlož ka Tel: +421-2-3355 5500
Slovenská republika Pfizer Luxembourg SARL, organizač ná zlož ka Tel. :+ 421 2 3355 5500
Slovenská republika Sandoz d. d. – organizač ná zlož ka Ruž inovská 42 SK-82103 Bratislava Tel: + 421-2-48 200 600
Slovenská republika Sandoz d. d. – organizač ná zlož ka Ruž inovská 42 SK-82103 Bratislava Tel: + 421-2-48 200 600
Slovenská republika Sandoz d. d. – organizač ná zlož ka Ruž inovská 42 SK-82103 Bratislava Tel: + 421-2-48 200 600
Slovenská republika sanofi-aventis Pharma Slovakia s.r.o.
Slovenská republika sanofi -aventis Pharma Slovakia s.r.o.
Slovenská republika sanofi-aventis Pharma Slovakia s. r. o.
Slovenská republika Strakova 5 SK-811 01 Bratislava Tel: + 421 (2) 5920 2712
Slovenská republika Strakova 5 SK -811 01 Br atislava Tel: + 421 (2) 5920 2712
Strakova 5 SK -811 01 Br atislava Tel: + 421 (2) 5920 2712
Slovenská Republika Wyeth Whitehall Export GmbH, organizač ná zlož ka Tel: +42 1 2 654 128 16 Fax: +42 1 2 654 128 17
Slovenská Republika Wyeth Whitehall Export GmbH, organizač ná zlož ka Tel: +42 1 2 654 128 16 Fax: +42 1 2 654 128 17
Slovenská Republika Wyeth Whitehall Export GmbH, organizač ná zlož ka Tel: +42 1 2 654 128 16 Fax: +42 1 2 654 128 17
Š martinska 140 1000 Ljubljana Slovenia
Number of events (per patient)
Snaygill Industrial Estate Keighley Road Skipton North Yorkshire BD23 2RW United Kingdom
Snaygill Industrial Estate Keighley Road Skipton North Yorkshire, BD23 2RW United Kingdom
Do not put Insulin Human Winthrop Basal next to the freezer compartment or a freezer pack.
Do not put Insuman Basal next to the freezer compartment or a freezer pack.
Do not inject into areas where the skin is tender, bruised, red, or hard.
Visit (weeks) N=Number of Subjects at Baseline, week 52, week 104, week +6, week +12. ed
Societa 'Di Servizio Per L'industria Farmaceutica Ed Affini Via Dei Castelli Romani, 22 00040 Pomezia (Rm) Italy
anhydrous, disodium phosphate anhydrous, hydrochloric acid concentrated, sodium hydroxide, water for injections.
This should be taken into consideration by patients on a controlled sodium diet.
- either 400 mg to be taken as one tablet of 400 mg once a day,
Sixty-two of the patients also received interferon-gamma (another anticancer medicine).
Sixty-two of 2,237 (2.8%) patients developed binding antibodies.
Fifty-nine percent received study medicinal product as second or greater than second-line therapy.
Sixty seven percent (67%) of the patients experienced at least one infusion-associated reaction.
Sixty seven percent (67%) of the patients experienced at least one infusion-associated reaction.
Solacyl 100%, powder for oral solution for calves and pigs
SOLACYL 100%, powder for oral solution for calves and pigs
SOLACYL 100%, powder for oral solution for calves and pigs
Balance on outturn account of previous year
NAME OF THE MEDICINAL PRODUCT Soliris 300 mg concentrate for solution for infusion Eculizumab
Soliris 300 mg, concentrate for solution for infusion Eculizumab
Soliris should be administered by a health care professional.
Soliris is composed of two 448 amino acid heavy chains and two 214 amino acid light chains and has a molecular weight of approximately 148kDa.
Soliris is produced in a murine myeloma (NS0 cell line) expression system and purified by affinity and ion exchange chromatography.
Soliris is a recombinant humanised monoclonal IgG2/4k antibody that binds to the human C5 complement protein and inhibits the activation of terminal complement.
Soliris is used for the treatment of patients with a certain type of disease affecting the blood system called Paroxysmal Nocturnal Haemoglobinuria (PNH).
Soliris may be administered to patients aged 65 years and over.
SoloStar has to be used as recommended in these Instructions for Use (see section 6.6).
SoloStar has to be used as recommended in these Instructions for Use (see section 6.6).
oral solution 30 ml with 1 spoon 50 ml with 1 spoon 60 ml with 1 spoon 100 ml with 1 spoon 120 ml with 1 spoon 150 ml with 1 spoon 150 ml with 1 oral syringe 225 ml with 1 spoon 300 ml with 1 spoon
Oral Drops, solution Multipack comprising 10 packs, each containing 1 bottle with 50 g oral drops, solution.
NAME OF THE MEDICINAL PRODUCT FORCALTONIN 100 IU solution for injection
- Film coated tablet - 1 mg, 2 mg, 4 mg, 8 mg - 12 presentations
Solution for injection 1 x 10 ml This is part of a multipack and not for sale of individual vials
Solution for injection 5 x (1 x 10 ml) This is a multipack and not for sale of individual vials
Solusion for injection or infusion 5 x (1 x 10 ml) lo
Spot-on solution A clear, yellow to amber solution
Reconstituted and diluted solutions From a microbiological point of view, the product should be used immediately.
Solvent for Enbrel 1ml bacteriostatic water for injections
SOMAVERT is used in patients who did not respond well to surgery or radiation therapy, or to treatment with somatostatin analogues (another type of medicine used in acromegaly).
SOMAVERT is a powder and solvent that are mixed together to make up a solution for injection.
Sum of tylvalosin and 3-O- acetyltylosin
Sum of tylvalosin and 3-O- acetyltylosin
If you get side effects → Tell your doctor or pharmacist if any of the side effects gets severe or troublesome, or if you ed
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Its activity culminates in the synthesis of local hormones and inflammatory mediators, termed eicosanoids, which include several prostaglandins.
Its use is not recommended in pregnancy or while breast feeding.
It works best against cells which are multiplying quickly – such as cancer cells.
The effect will last for up to 24 hours depending on dose.
Its effectiveness has not been shown in patients with secondary progressive MS (the type of MS that comes after relapsing MS), when the disease is not in a relapsing phase.
Its protective effectiveness has not been studied in males.
Hepatic disease may delay elimination.
Secondary prevention of cardiovascular events has been approved in all Member States, Iceland and Norway.
Accidental injection/ self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
It works by blocking the breakdown of ‘ incretin'hormones in the body.
The mechanisms by which interferon beta-1b exerts its actions in multiple sclerosis are not clearly understood.
The mechanisms by which interferon beta-1b exerts its actions in multiple sclerosis are not clearly understood.
Its hepatic metabolism is scarce, showing traces of some metabolites at kidney level.
SonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography, leading to more specific lesion characterisation.
SonoVue should be administered immediately by injection into a peripheral vein.
SonoVue should be administered immediately after drawing into the syringe by injection into a peripheral vein.
SonoVue is a contrast agent that reflects ultrasound waves differently from the tissues of the body and improves the picture from the scan.
SonoVue has not been studied in patients aged 18 years or younger and should not be used in this group.
SonoVue is not suitable for use in ventilated patients, and those with unstable neurological diseases.
It is reported to cross the placenta and penetrate the eye.
Its active substance is samarium [153Sm] lexidronam pentasodium.
High-risk individuals susceptible to varicella include:
d suggest possible deleterious effects on embryonal/ foetal development (see section 5.3).
Therefore< Zocord > is not recommended for paediatric use.
Its use in combination with hydrochlorothiazide was also examined in 1,736 patients.
It considered that the addition of pseudoephedrine to terfenadine can increase its arrhythmogenic potential, therefore the risk/ benefit balance of terfenadine-pseudoephedrine tablet formulations was considered to be unfavourable.
It must not be used in patients who may have an infection of the eye or the area around the eye, or who have severe inflammation within the eye.
Lactation It is not known whether 99mTc-depreotide is excreted in human milk, 99mTc-depreotide is therefore contraindicated during lactation.
Therefore, its use is not recommended in these patients.
Its clinical use, therefore, cannot be recommended in breast-feeding women.
Its use is therefore not recommended in women who are breast-feeding.
Liquid sorbitol, non-crystallising Liquid paraffin Semolinea (declared on labelling as carrier)
or similar classes of substance as part of herpes zoster (chickenpox or shingles) therapy.
Remove the dose pack of RISPERDAL CONSTA from the refrigerator and allow it to come to room temperature prior to reconstitution.
Sortis and associated names contain atorvastatin, a HMG-CoA-reductase inhibitor (known as statin), which inhibits the synthesis of cholesterol.
A/ Solomon Islands/ 3/ 2006 (H1N1) like strain (A/ Solomon Islands/ 3/ 2006, IVR-145) A/ Wisconsin/ 67/ 2005 (H3N2) like strain (A/ Wisconsin/ 67/ 2005, NYMC X161B) B/ Malaysia/ 2506/ 2004 like strain (B/ Malaysia/ 2506/ 2004)
• Biotechnology Working Party •
These can increase your risk of heart disease.
Compared with pharmacokinetic data from adults with CRF where the same sampling duration was used, the ct
Lift the plastic flip-top and remove the crimp from the vial.
- The Company submits to the CPMP a review with proposals for updating the warnings and
- Reporting to be fortnightly for the first 3 months of the pandemic.
- Reporting to be fortnightly for the first 3 months of the pandemic.
(MedDRA) Renal and Urinary Disorders
Under simultaneous U. V. exposure, sparfloxacin can exhibit mutagenic properties and carcinogenetic effects.
- and provided that the Applicant fulfils the conditions to the Marketing Authorisation as listed in
For this reason, the vaccinee should remain under medical supervision for at least 30 minutes.
Median OS with the 24-h q3wk regime was 13.9 months (CI:
to support efforts in international co-operation (see Articles 51(f))
9. support for certain European policies at the request of the Commission or European Parliament
Executive support Integrated quality management and audit Legal sector
Remember, however, that no vaccine can provide complete, life-long protection in all people vaccinated.
You should self assess for increased acne, increased hair growth on your face, loss of hair, deepening of your voice or enlargement of your clitoris, which all could be signs of adverse effects of testosterone, which is the active substance in Intrinsa.
You should self assess for increased acne, increased hair growth on your face, loss of hair, deepening of your voice or enlargement of your clitoris, which all could be signs of adverse effects of testosterone, which is the active substance in Livensa.
Compared with pharmacokinetic data from adults with CRF where the same sampling duration was used, the ct
Eyelid spasm (blepharospasm) Usually, the first onset of effect is observed within four days after injection.
This will usually pass on its own but if it does not, tell your doctor.
Musculo- skeletal pain Muscle tightness Muscle spasm
Muscle spasm Muscle tightness Musculo- skeletal pain Trismus
Muscle spasm Muscle tightness Musculo- skeletal pain Trismus Hypo- thyroidism
Muscle spasm Muscle tightness Musculo- skeletal pain Trismus
Muscle spasm Muscle tightness Musculo- skeletal pain Trismus Hypo- thyroidism
Pharmaceutical Form
Urine levels of interferon were below the detection limit following each of the three routes of administration.
Specialist in internal medicine and clinical pharmacology.
Specialist in internal medicine and clinical pharmacology.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICI NAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
Released for consultation
• Specifications for determining 13 C/ 12C-ratios
• Specifications for determining 13C/12C-ratios
inhibitors appear to have no clinically relevant effect on zonisamide pharmacokinetic exposure parameters.
are taking Posaconazole SP.
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
Sugar spheres (containing sucrose) and aspartame (E951)
Spoo L-254 6 Luxembourg Tel: +352.478.5590 Fax: +352.22.4458
Sprimeo also reduced blood pressure in patients with diabetes, patients who were overweight, and those who were over 65 years of age.
Sprimeo induced an additive blood-pressure-lowering effect when added to hydrochlorothiazide and to ramipril.
Combination studies looked at Sprimeo used with an angiotensin converting enzyme inhibitor (ramipril), an angiotensin receptor blocker (valsartan), a beta-blocker (atenolol), a calcium-channel blocker (amlodipine) and a 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
SPRYCEL 20 mg film-coated tablets SPRYCEL 50 mg film-coated tablets SPRYCEL 70 mg film-coated tablets SPRYCEL 100 mg film-coated tablets
SPRYCEL is also indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.
SPRYCEL is also a treatment for adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL), and lymphoid blast CML who are not benefiting from prior therapies.
SPRYCEL is indicated for the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate.
Sprycel is used when patients cannot tolerate, or when their disease is not responding to other treatments including imatinib (another anticancer medicine); • it is also used in acute lymphoblastic leukaemia (ALL), a type of leukaemia where lymphocytes (another type of white blood cell) multiply too quickly, or blast phase CML, when the patients are ‘ Philadelphia chromosome positive '(Ph+).
In clinical trials small but consistent treatment group differences in decline of pulmonary function (particularly Forced Expiratory Volume in one second (FEV1)) favouring comparator treated subjects have been observed.
S-P Veterinary Ltd Breakspear Road South Harefield Uxbridge UB9 6LS United Kingdom
S-P Veterinary Ltd Breakspear Road South Harefield Uxbridge UB9 6LS United Kingdom
is What should I do before I give myself a subcutaneous injection of Dynepo?
Renal and urinary disorders
Arthralgia, myalgia, musculoskeletal pain
Arthralgia, myalgia, musculoskeletal pain
disorder, nail disorder, skin discolouration, pruritus, dry skin, erythema, bruise, sweating increased Musculoskeletal and connective tissue disorders Very common:
fever§, influenza-like symptoms§, malaise, irritability
General disorders and
General disorders and administration
myalgia Metabolism and nutrition disorders
SIRS (2 events; both were considered to be serious), capillary leak syndrome (3 events; all of which were serious) and tumour lysis syndrome (7 events; 4 of which were serious).
ß-dihydroxy-4,5 alpha-epoxy- 6ß-[N-methyl-trans-3-(3-furyl)
comparison showed that the pharmacokinetics of darbepoetin alfa were similar for paediatric and adult patients with CRF.
Stabilise the skin by spreading it or pinching up a large area.
Stability of reconstituted suspension in the vial:
Stability of the reconstituted suspension in the infusion bag:
Taking all of the epidemiological data together the evidence indicated that the risk of cardiotoxicity for all non-sedating antihistamines was low but was higher than in non users.
There was no evidence of a difference in risk between the NSAHs evaluated.
Stalevo is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/ dopa decarboxylase (DDC) inhibitor treatment.
Stalevo is used in patients who are being treated with a combination of levodopa and an inhibitor of dopa decarboxylase (two standard treatments for Parkinson's disease) but are having ‘ fluctuations'towards the end of the period between two doses of their medication that cannot be treated with the standard combination alone.
Starlix 60 mg film-coated tablets Starlix 120 mg film-coated tablets Starlix 180 mg film-coated tablets Nateglinide
Patients with rare hereditary problems of galactose intolerance, of the Lapp lactase deficiency or of glucose-galactose malabsorption should not take this medicine.
Starlix is given within one to 30 minutes before breakfast, lunch and dinner and the dose is adjusted to give the best control.
Starlix is a medicine to lower blood sugar (glucose), which is taken by mouth (these medicines are also known as oral anti-diabetics).
Starlix is used together with metformin (another antidiabetes medicine) to lower blood glucose (sugar) in patients whose diabetes cannot be controlled by metformin alone.
Invented name Starlix Starlix Starlix Starlix Starlix Starlix Starlix Starlix Starlix Starlix Starlix Starlix Starlix Starlix Starlix Starlix Starlix Starlix Starlix Starlix Starlix
STARTVAC is an ivory-coloured homogeneous emulsion for injection.
Startvac is an emulsion for injection that is available in vials (3, 10 and 50 ml).
Statistical principles for veterinary clinical trials
Concept paper on the Development of a CPMP Note for Guidance on Clinical investigation of medicinal products in the treatment of diabetes mellitus Adopted July 2000
Staff Regulations of officials of the European Communities, and in particular Articles 5 and 6 of Annex VII thereto.
Staff Regulations of officials of the European Communities, and in particular Articles 11 to 13 of Annex VII thereto.
Staff Regulations of officials of the European Communities, and in particular Articles 20 and 71 thereof and Article 10 of Annex VII thereto.
Staff Regulations of officials of the European Communities, and in particular Articles 20 and 71 thereof and Article 7 of Annex VII thereto.
Staff Regulations of officials of the European Communities, and in particular Articles 20 and 71 thereof and Article 9 of Annex VII thereto.
Staff Regulations of officials of the European Communities, and in particular Articles 27 to 31 and 33 thereof and Annex III thereto.
Staff Regulations of officials of the European Communities, and in particular Articles 64 and 65 thereof and Article 17(3) of Annex VII thereto.
Staff Regulations of officials of the European Communities, and in particular Articles 70, 74 and 75 thereof.
Staff Regulations of officials of the European Communities, and in particular Article 73 thereof and Article 15 of Annex VIII thereto.
stearate, polyethylene glycol, titanium dioxide (E171) and talc.
STELARA belongs to a group of medicines called immunosuppressants (medicines that inhibit your immune system).
STELARA contains the active substance ustekinumab, a monoclonal antibody.
Stelara is given under the supervision of a doctor who has experience in diagnosing and treating psoriasis.
STELARA is available in a 1 vial pack.
STELARA does not contain preservatives; therefore any unused product
STELARA must not be given to patients with active tuberculosis (see section 4.3).
Vascular stents It has been shown in published studies that MRA in the presence of metallic stents causes artifacts.
Stephen FAIRCHILD (until 15 April 2001)
Sterke Terfenadine- Tabletten 120 Bij overgevoeligheidsre acties Samenwerkende Apothekers, tabletten
Steve DEAN Chief Executive Veterinary Medicines Directorate Woodham Lane New Haw, Addlestone Surrey KT15 3LS United Kingdom Tel.
St Mary's Pharmaceutical Unit Quadrant Centre Cardiff Business Park, Llanishan, Cardiff, Wales CF14 5RA United Kingdom
St Mary’s Pharmaceutical Unit Quadrant Centre Cardiff Business Park Llanishan Cardiff Wales CF14 5RA United Kingdom.
STOCRIN is indicated in antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected adults, adolescents and children 3 years of age and older.
STOCRIN is indicated in antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected adults, adolescents and children 3 years of age and older.
Stomatitis, diarrhoea, dyspepsia, dysphagia, mouth dry
Gastroenteritis Haematochezia Stomatitis Gastritis Flatulence Eructation Breath odour
Vomiting Stomatitis Dyspepsia Abdominal pain C / distension
Mr Strachan Heppell and Dr Romano Marabelli were unanimously re-elected Chairman and Vice-Chairman for their second term of office.
Strada Provinciale Asolana 90 43056 San Polo di Torrile Parma Italy
Strada Solaro, 75/ 77 18038 Villa Sayonara – Sanremo (Im) Italy
Strada Solaro, 75/ 77 18038 Villa Sayonara – Sanremo (Im) Italy
Strada Statale 156 KM 50 04010 Borgo San Michele Latina Italy
Strada Statale 156 Km 50 04010 Borgo San Michele (Lt) Italy
Strada Statale 17, Km 22 lp
Strada Statale 17, Km 22 ro
ed Strada Statale No 17, km22 67019 Scoppito (L'Aquila) Italy
Strada Statale No 17, km 22 I-67019 Scoppito (L'Aquila), Italy
Strada Statale No 17, km 22 I-67019 Scoppito (L'Aquila), Italy
Strategies to prevent and treat hand-foot syndrome:
Bracco International B. V., Strawinskylaan 3051, NL - 1077 ZX Amsterdam, The Netherlands
Strawinskylaan 3051 NL - 1077 ZX Amsterdam The Netherlands
Strawinskylaan 3051 NL - 1077 ZX Amsterdam The Netherlands
Live deletion mutant Streptococcus equi strain TW928 109.0 to 109.4 cfu
Live deletion mutant Streptococcus equi strain TW928 109.0 to 109.4 cfu1
L01XX22 Ttopical treatment of cutaneous lesions in AIDS related Kaposi's sarcoma
Strides Arcolab International Limited 201 Jersey Road Isleworth, Middx TW7 4QJ United Kingdom
STRONGHOLD is available in packs of three tubes (all tube sizes), six tubes (all tube sizes except 15 mg selamectin), or fifteen tubes (15 mg selamectin tube size only).
STRONGHOLD is available in packs of three tubes (for all tube sizes), six tubes (for all tube sizes except 15 mg selamectin), or fifteen tubes (for 15 mg selamectin tube size only).
Revision of EMEA fees Transparency Interested parties International partners Quality management
Start of shelf-life of the finished dosage form
For storage precautions, see section 6.3.
100 200 300 400 600 800
Suboxone 2 mg/ 0.5 mg sublingual tablets buprenorphine / naloxone
Suboxone 2 mg/ 0.5 mg sublingual tablets buprenorphine / naloxone
Suboxone 8 mg/ 2 mg sublingual tablets buprenorphine / naloxone
Suboxone containing 2 mg buprenorphine and 0.5 mg naloxone is referred to as the "2 mg" tablets.
Suboxone containing 8 mg buprenorphine and 2 mg naloxone is referred to as the "8 mg" tablets.
Suboxone should be used cautiously when co-administered with:
Suboxone is contraindicated in patients with severe hepatic dysfunction (see section 4.3).
Suboxone should not be taken together with:
- The active substance is recombinant salmon calcitonin.
The active substances or any of the other ingredients of IDflu listed in section 6 of this leaflet in the section "FURTHER INFORMATION",
The active substances, or any of the other ingredients of IDflu listed in section 6 of this leaflet in the section "FURTHER INFORMATION",
The active substances or any of the other ingredients of INTANZA listed in section 6 of this leaflet in the section "FURTHER INFORMATION",
The active substances, or any of the other ingredients of INTANZA listed in section 6 of this leaflet in the section "FURTHER INFORMATION",
Mitotane is a hepatic enzyme inducer and it should be used with caution in case of concomitant use of medicinal products influenced by hepatic enzyme
DRUG ABUSE Methadone Individual Patient Dosing
DRUG ABUSE Methadone Individual Patient Dosing
P-gp substrate An in vitro study shows that zonisamide is a weak inhibitor of P-gp (MDR1) with an IC50 of 267 µmol/ L and there is the theoretical potential for zonisamide to affect the pharmacokinetics of drugs which are P-gp substrates.
Overall Treatment Success in the Per Protocol Set, Invasive Candidiasis Study
Succursale belge/Belgisch bijhuis Tél/ Tel: +32 (0) 2 373 42 11 MSDBelgium_info@merck. com
Succursale belge/Belgisch bijhuis Tél/Tel: +32 (0) 2 373 42 11 MSDBelgium_info@merck .com
Succursale belge/Belgisch bijhuis Tél/Tel: +32 (0) 2 373 42 11 MSDBelgium_info@merck.com
Succursale belge/Belgisch bijhuis Tél/Tel: +32 (0) 800 386 93 MSDBelgium_info@merck. com
Succursale belge Tél: +32 (0) 2 373 42 11 MSDBelgium_info@merck. com
Succursale belge Tél/ Tel: +32 (0) 2 373 42 11 MSDBelgium_info@merck. com
Succursale belge Tél/Tel: +32 (0) 2 373 42 11 MSDBelgium_info@merck.com
Succursale belge Tél/ Tel: +32 (0) 2 373 42 11 MSDBelgium_info@merck .com
Succursale belge Tél/Tel: +32 (0) 2 373 42 11 MSDBelgium_info@merck .com
Succursale belge Tél/Tel: +32 (0) 2 373 42 11 MSDBelgium_info@merck.com
- sucralfate (used for healing ulcers)
Sucrose Sorbitol Dextran 40 Casein hydrolysate Collagen hydrolysate Salts
sweats, +skin disorder hypertonia, myalgia, arthralgia, back pain, neck pain, pain
Sweden GlaxoSmithKline AB Box 516 SE-169 29 Solna Sweden
Sweden GlaxoSmithKline AB Box 516, SE-169 29 Solna Sweden
SWEDEN Gunnar ALVÁN Generaldirektör Läkemedelsverket Husargatan 8 Box 26 S - 751 03 Uppsala Tel.
SWEDEN Gunnar ALVÁN Generaldirektör Läkemedelsverket Husargatan 8 Box 26 S - 751 03 Uppsala Tel.
Sverige Meda AB Box 906 S-170 09 Solna Tel: +46 8 630 1900
- increased sweating, itching and rashes
soles of the feet, or small reddish or purple spots underneath the skin;
If you have any further questions, ask your doctor, nurse or pharmacist.
Suicide/ suicidal thoughts or clinical worsening
ra • rash or itchy skin • oozing from operation wound site
Rare side effects These may affect up to 1 in 1000 people treated with Quixidar. ro
- Exudation of a small amount of liquid from the incision made for a surgical procedure
Following the administration of a double dose in chickens and ducks, no adverse reactions other than those described in section 4.6 have been observed.
After first reconstitution the suspension should be used immediately.
Following disease progression, treatment with EGFR-targeting agents was initiated in 50% of patients in the irinotecan-alone arm, which most likely impacted survival results.
Following the referral to the CHMP, the Committee noted the position of the RMS and the objecting CMS and decided to adopt a List of Questions addressed to the Blood Products Working Party (BPWP), in order to receive the view of the working party, on both specific issues related to this specific product and on issues related to immunoglobulins in general.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 09 E-mail: mail@emea. eu. int http: / /www. emea. eu. int
As a result of inhibiting serotonin uptake, fluoxetine enhances serotonergic neurotransmission and produces functional effects resulting from increased activation of serotonin receptors.
Following injection, pigs may have an increased body temperature of 1.4°C for up to two days, and in some pigs of up to 2.5°C, but this should not last more than 24 hours after the injection.
Following a decision by the European Commission in July arrangements have been made for the Commission's delegation in London to legalise certificates.
Following reconstitution, 1 ml sodium pertechnetate [99mTc] is added.
FOLLOWING THE EXCHANGE OF LETTERS BETWEEN THE EU (EC AND EMEA) AND HEALTH CANADA (HPFB)
Follow your doctor’s instruction carefully on which medicines can be combined.
Carefully follow all instructions given to you by your doctor.
Follow all the doctor’s instructions carefully.
Please follow your doctor’s instructions for taking your medicine.
FOLLOW THESE INSTRUCTIONS WHEN USING NEUPRO:
When taking a hard capsule out of the bottle, please observe the following instructions:
Always use Betaferon exactly as your doctor has instructed you.
Follow carefully any extra instructions that come with the nebuliser.
Always follow these instructions when using Silapo:
Always follow the instructions of your doctor about the duration of the treatment with Tasmar.
- if you are on a low-salt diet and you use potassium containing salt substitutes or supplements
- desensitisation treatment to reduce allergy to bee or wasp stings
activities of its satellite groups (Invented Names Review Group, Organisational Matters Group, Meeting of the chairmen of the CPMP and working parties).
- followed by treatment with only Temodal (monotherapy phase).
A second dose may be injected 3 – 4 weeks after the first injection.
Follow the directions given by your doctor closely and use the instructions below as a guide:
Follow recommended safety measures for removal and disposal of needles (e. g. a one handed capping technique) in order to reduce the risk of accidental needle injury and transmission of infectious diseases.
Follow recommended safety measures for removal and disposal of needles (e. g. a one handed capping technique) in order to reduce the risk of accidental needle injury and transmission of infectious diseases.
Follow recommended safety measures for removal and disposal of needles (e.g. contact your healthcare professional) in order to reduce the risk of accidental needle injury and transmission of infectious diseases.
Follow recommended safety measures for removal and disposal of needles (e.g. a one handed capping technique) in order to reduce the risk of accidental needle injury and transmission of infectious diseases.
Please carefully follow the instructions of the veterinarian.
⋅ to implement fully the recommendations made for the unit following progress made in establishing a Quality Standard Programme in 1997
Please carefully follow the instructions of the veterinarian.
Elderly Steady state pharmacokinetics are similar in patients age 65 and over and young subjects.
Elderly, hepatic and renal impairment
Age alone had no clinically relevant effect on pharmacokinetic parameters.
No change in dosage is required for elderly patients.
Successful response to voriconazole therapy was seen in 16 (6 complete, 10 partial responses) of 28 patients with S. apiospermum and in 2 (both partial response) of 7 patients with S. prolificans infection.
Elderly population EMADINE has not been studied in elderly patients older than 65 years, and therefore its use is not recommended in this population.
Elderly Population EMADINE has not been studied in elderly patients older than 65 years, and therefore its use is not recommended in this population.
There is no experience in patients > 65 years old.
Elderly subjects Age had no impact on the exposure to rivastigmine in Alzheimer's disease patients treated with Prometax transdermal patches.
Elderly subjects Age had no impact on the exposure to rivastigmine in Alzheimer's disease patients treated with Exelon transdermal patches.
The pharmacokinetics of enfuvirtide have not been formally studied in elderly patients over 65 years of age.
The experience with the use of Nexavar in elderly patients is limited.
A modest increase in AUC (28%) and C24h (32%) was observed in elderly male subjects compared with young male subjects.
Patients with hepatic impairment No studies have been performed in patients with hepatic impairment.
Patients with renal impairment No dose adjustment is necessary in patients with renal impairment.
Subjects with uncorrected congenital malformation of the gastrointestinal tract that would predispose for intussusception.
Subjects with hepatic impairment No study was conducted with Prometax transdermal patches in subjects with hepatic impairment.
Subjects with hepatic impairment No study was conducted with Exelon transdermal patches in subjects with hepatic impairment.
Subjects with renal impairment Cmax and AUC of rivastigmine were more than twice as high in subjects with moderate renal impairment
Subjects with renal impairment No study was conducted with Exelon transdermal patches in subjects with renal impairment.
Subjects primed with 3 doses of licensed Meningitec** or Menjugate** N= 96
Subjects primed with 3 doses of Meningitec + Pediacel N= 115
Subjects primed with 3 doses of Menitorix* N= 349
Human erythropoietin is an endogenous glycoprotein hormone that is the primary regulator of erythropoiesis through specific interaction with the erythropoietin receptor on the erythroid progenitor cells in the bone marrow.
Medicines should not be disposed of via wastewater or household waste.
ed Medicines that may cause your blood sugar to fall include diabetes tablets, angiotensin converting enzyme (ACE) inhibitors (used for the treatment of certain heart conditions, high blood pressure or
ed Patients must not smoke during therapy with EXUBERA and must have stopped smoking at least 6 months prior to starting EXUBERA therapy.
ho Patients must not smoke during therapy with EXUBERA and must have stopped smoking at least 6 months prior to starting EXUBERA therapy.
Sulphamethoxazole/ Trimethoprim 800 mg/ 160 mg BID (maraviroc 300 mg BID)
Tell your doctor if you are taking either of the following medicines, as treatment with VFEND at the same time should be avoided if possible, and a dose adjustment of voriconazole may be required:  Rifabutin (used for treating tuberculosis)  Phenytoin (used to treat epilepsy)
Suomi/Finland Abbott OY Pihatörmä 1B/Gårdsbrinken 1B FIN-02240 Espoo/Esbo Puh/Tel: + 358 (0) 9 7518 4120
Suomi/ Finland Abbott OY Pihatörmä 1B/ Gårdsbrinken 1B FIN-02240 Espoo/ Esbo Puh/ Tel: + 358 (0) 9 7518 4120
Suomi/ Finland Allergan Norden AB Johanneslundsvägen 3-5 S-194 81 Upplands Väsby Ruotsi/ Sverige Puh/ Tel: + 46 (0)8 594 100 00 E-mail: uk_medinfo@allergan. com
Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30
Suomi/ Finland GlaxoSmithKline Oy Puh/ Tel: + 358 (0)10 30 30 30
Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30
Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 Finland.tuoteinfo@gsk.com
Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 Finland.tuoteinfo@gsk.com
Suomi/ Finland GlaxoSmithKline Oy Puh/ Tel: + 358 (0)10 30 30 30 Finland. tuoteinfo@gsk. com
GlaxoSmithKline Oy Puh/Tel: + 358 10 30 30 30 Finland.tuoteinfo@gsk.com
Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 10 30 30 30 Finland.tuoteinfo@gsk.com
Suomi/ Finland GlaxoSmithKline Oy Puh/ Tel: + 358 10 30 30 30 Finland. tuoteinfo@gsk. com
GlaxoSmithKline Oy Puh/Tel: + 358 10 30 30 30 Finland.tuoteinfo@gsk.com
Italia Abbott Srl I-0401 1 Campoverde di Aprilia (Latina) Tel: + 39 06 928921
Italia Pfizer Italia S.r.l.
Suomi/Finland Mayne Pharma (Nordic) AB, Ruotsi/ Sverige Tel: + 46 8 672 85 00
Suomi/ Finland Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 D-60318 Frankfurt Saksa Puh/ Tel: +49 (0)69 1503 – 1
Suomi/Finland Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 D-60318 Frankfurt Saksa Puh/ Tel: +49 (0)69 1503 – 1
Suomi/Finland OY BRISTOL-MYERS SQUIBB (FINLAND) AB Puh/Tel: + 358 9 251 21 230
Oy Eli Lilly Finland Ab Puh/Tel: + 358-(0) 9 85 45 250
Puh/Tel: + 358-(0) 9 85 45 250
Suomi/Finland Oy Eli Lilly Finland Ab Puh/Tel: + 358-(0) 9 85 45 250
Suomi/Finland Oy Eli Lilly Finland Ab Puh/Tel: + 358 -(0) 9 85 45 250
Tel: + 421 220 663 111 Suomi/Finland Oy Eli Lilly Finland Ab Puh/Tel: + 358 (0) 9 8545 250 Sverige Eli Lilly Sweden AB Tel: + 46 (0) 8 7378800 United Kingdom Eli Lilly and Company Limited Tel: +44 (0) 1256 315999
Tel: +40 21 4023000 Slovenija Eli Lilly farmacevtska družba, d.o.o.
FIN-02201 Espoo/Esbo Puh/ Tel: + 358-(0)20-7570 300
PL 3/PB 3 FIN-02201 Espoo/Esbo
Suomi/Finland PL 3/PB 3 FIN-02201 Espoo/Esbo
Suomi/Finland PL 3/PB 3 FIN-02201 E spoo/Esbo Puh/ Tel: + 358-(0)20-7570 300
Puh/Tel: + 358-(0)20-7570 300
Suomi/Finland PL 86/PB 86 FIN-02151 Espoo/Esbo Puh/Tel: + 358-(0)20 7570 300
Suomi/Finland PL 86/PB 86 FIN -02151 Espoo/Esbo Puh/Tel: + 358-(0)20-7570 300
Suomi/Finland PL 86/PB 86 FIN-02151 Espoo/Esbo Puh/Tel: + 358-(0)20-7570 300
Suomi/Finland PL 86/PB 86 FIN-02151 Espoo/Esbo Puh/Tel: + 358-(0)20-7570 300
Suomi/Finland PL 86/PB 86 FIN -02151 Espoo/Esbo Puh/Tel: + 358-(0)20-7570 300
Suomi/Finland PL 86/PB 86 FIN-02301 Espoo/Esbo Puh/Tel: + 358-(0)20-7570 300
Sverige Roche AB Tel: +46 (0) 8 726 1200
Suomi/Finland sanofi -aventis Oy Puh/Tel: +358 (0) 201 200 300
Suomi/Finland TIBOTEC JANSSEN-CILAG OY Vaisalantie/Vaisalavägen 2 FI-02130 Espoo/Esbo Puh/Tel: +358 207 531 300
Suomi/ Finland Wyeth Puh/ Tel: + 358 20 7414 870 Fax: + 358 20 7414 879
Suomi/ Finland Wyeth Puh/ Tel: + 358 20 7414 870 Fax: + 358 20 7414 879
Suomi/ Finland Wyeth Puh/ Tel: + 358 20 7414 870 Fax: + 358 20 7414 879
Sverige Wyeth AB Tel: +46 8 470 3200 Fax: +46 8 730 0666
Suomi/ Finland Wyeth Puh/ Tel: + 358 20 7414 870 Fax: + 358 9 20 7414 879
Administration of salbutamol 30 minutes prior to EXUBERA in non-diabetic subjects with mild- moderate asthma resulted in an increase in insulin AUC and Cmax of between 25 and 51% compared to ed
Potassium supplements and potassium-sparing diuretics: based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e. g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).
Potassium supplements and potassium-sparing diuretics: based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e. g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).
Potassium supplements and potassium-sparing diuretics: based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e. g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).
Potassium supplements and potassium-sparing diuretics: based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e. g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).
Potassium supplements and potassium-sparing diuretics:
Suprelorin is not recommended for use in dogs that have not yet reached puberty, as it has not been investigated in these animals.
ge Commonly reported side effects (at least 1 in every 100 patients, but less than 1 in every 10 patients): thirst, dehydration, high blood pressure, migraines, swollen glands, flushing, menstrual problems, lon decreased sexual drive, vaginal problem, breast pain, pain in testicle, problems with thyroid gland, red gums, dry mouth, red or sore mouth or tongue, tooth ache or tooth disorder, herpes simplex (fever blisters), taste change, upset stomach, dyspepsia (heartburn), constipation, enlargement of liver (liver problems, sometimes severe), loose stools, bedwetting in children, inflammation of the sinuses, bronchitis, eye pain, no
Of the 60 isolates from patients treated with either atazanavir or atazanavir + ritonavir, 18 (30%) displayed the I50L phenotype previously described in naive patients.
Of the 60 isolates from patients treated with either atazanavir or atazanavir + ritonavir, 18 (30%) displayed the I50L phenotype previously described in naive patients.
Out of 972 infusions, 815 (84%) infusions were rated to have “ good” or “ excellent” responses.
Over the 10-year observation period, the cumulative rate of varicella was 7.5% after 1 dose and 2.2% after 2 doses.
Over the 10-year observation period, the cumulative rate of varicella was 7.5% after 1 dose and 2.2% after 2 doses.
In animals with hepatic and renal failure, the dosage regimen should be carefully evaluated.
9 Ear and labyrinth disorders Common: vertigo.
Ear and labyrinth disorders Common: vertigo.
deafness, Meniere's disease aggravated, vertigo
content Heart Ileum Kidneys Liver Lungs Ovaries Pancreas Skeletal muscle Skin Spleen Stomach Thymus Thyroids Urinary bladder Uterus Effective Dose
• septic inflammation of a vein with blood clotting (septic thrombophlebitis) or blocked blood vessels at an infected site
Based on these considerations, terfenadine 120 mg tablet formulations have an unacceptable risk/ benefit balance.
Based on these reports and taking the estimated worldwide use of loratadine into account, the CPMP concluded that the spontaneous reporting data did not raise concerns regarding the use of loratadine during pregnancy.
Based on these findings it is scientifically reasonable to conclude that the effect of low dose doxycycline on the normal residential flora including E coli, Enterococci, Staphylococci and Streptococci to be almost non-existent and concluded that the risk of inducing resistance development is negligible.
On the basis of these data the two formulations are considered to exhibit an equivalent therapeutic ratio and to be clinically interchangeable”.
Based on these studies a 36 months shelf life for Methoxasol-T is claimed.
Based on this case assignment, the analysis excluded 3 CIN2+ cases (2 in the vaccine group and 1 in the control group) which were not considered to be causally associated with HPV-16 or HPV-18 infections acquired during the trial.
Based on the first experience this procedure proved to be very successful.
CHD = coronary heart disease; MI = myocardial infarction.
Based on urinary recovery, the extent of absorption is at least 56% and is not significantly influenced by the presence of food in the gastrointestinal tract.
Based on urinary recovery, the extent of absorption is at least 56% and is not significantly influenced by the presence of food in the gastrointestinal tract.
Based on these overall findings, It was concluded that the WOSCOPS findings observed in Scottish men could be extrapolated to men of other European countries.
Based on urinary excretion of unchanged drug, the bioavailability has been estimated to be at least 70%.
4 Potassium and potassium-sparing diuretics Based on experience with the use of other substances that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other substances that may increase serum potassium levels (e. g. heparin) may lead to increases in serum potassium.
No clear trend toward an increase in systemic exposure to AsIII, AsV, MMAV or DMAV was observed with decreasing level of hepatic function as assessed by dose-normalized (per mg dose) AUC.
Based on historical comparisons, methadone did not appear to alter plasma amprenavir pharmacokinetic parameters.
Based on the plasma concentrations observed in patients, milk concentrations of 9-cis-retinoic acid probably pose a low risk for the infant.
Based on in vitro studies, palonosetron does not inhibit or induce cytochrome P450 isoenzyme at clinically relevant concentrations.
On the basis of the grounds for referral, the points considered by the CPMP were:
Section 4.5 of the draft Summary of Product Characteristics for terfenadine containing medicinal products should be amended as set out in Annex I.
Based on the pharmacokinetic properties of TMZ, it is unlikely that dose reductions are required in patients with severe hepatic impairment or any degree of renal impairment.
Based on the ph armacokinetic properties of TMZ, it is unlikely that dose reductions are required in patients with severe hepatic impairment or any degree of renalimpairment.
Based on the pharmacokinetic properties of TMZ, it is unlikely that dose reductions are required in patients with severe hepatic impairment or any degree of renalimpairment.
Based on the pharmacokinetic properties of TMZ, it is unlikely that dose reductions are required in patients with severe hepatic impairment or any degree of renalimpairment.
Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.
Based on a residue study in pigs a 3 days withdrawal period was recommended.
1997, the concept of ‘document life cycle'will be introduced and version control systems implemented.
The graduated measuring spoon with the markings 1/ 2 is equivalent to 2.6 mL containing 2.5-mL of final suspension and 1/ 1 is equivalent to 5.2 mL containing 5.0 mL of final suspension.
The graduated measuring spoon with the markings 1/ 2 is equivalent to 2.6 mL containing 2.5 mL of final suspension and 1/ 1 is equivalent to 5.2 mL containing 5.0 mL of final suspension.
please tell your doctor or pharmacist.
A dose indicator on the Diskus indicates the number of doses left.
Directly below it is where the neck of the ampoule has been treated to make it easier to break.
From the pooled patient cohort 335 vigabatrin patients above 14 years of age had usable visual field results.
Of the 704 patients evaluated in the MM-009 and MM-010 studies, 44.6% were aged 65 or over.
Of the patients in the azacitidine group who were RBC transfusion dependent at baseline, 45.0% of these patients became RBC transfusion independent during the treatment period, compared with 11.4% of the patients in the combined CCR groups (a statistically significant (p < 0.0001) difference of 33.6% (95% CI:
From a microbiological point of view, the product shall be used immediately after opening.
From a microbiological point of view, the product should be used immediately.
Of the 182 treated patients who were assessed for antibodies to murine IgG, 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike.
Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary (CHO) cell protein, 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes.
Of the 2,182 patients treated, 25% were ≥ 65 years of age, while 5% were ≥ 75 years of age.
Of the 2532 randomised intention-to-treat (ITT) patients, a total of 59 patients experienced at least one new vertebral fracture, placebo:
Of the 278 patients randomised, 277 patients received at least 1 dose of study drug.
Reporting rates of rhabdomyolysis with the 0.8mg dose were greatly in excess of those seen with both the 0.4mg and lower doses.
Of 463 patients, 63% were male.
Of the 56 ADRs, none were reported in neonates, 16 were reported in 13/ 32 infants, 7 were reported in 4/ 56 children, 8 were reported in 4/ 31 adolescents and 25 were reported in 14/ 94 adults.
Of the 573 patients randomised, 335 (58%) achieved clinical response by week 2.
Eight of the 67 Type A resistant subjects (11.9%) had developed neutralising antibodies to Botulinum Toxin Type B within completion of 4 treatment cycles of NeuroBloc and 15 out of 67 subjects (22.4%) had developed neutralising antibodies at the time of interim study analysis.
Of the 97 patients treated with INOmax, 2(2%) were withdrawn from study drug due to methaemoglobin levels > 4%.
34 In human hepatocytes in culture, levetiracetam had little or no effect on CYP1A2, SULT1E1 or UGT1A1.
In human hepatocytes in culture, levetiracetam had little or no effect on CYP1A2, SULT1E1 or UGT1A1.
(on the cover inside) Handling steps See package insert
• on the Internet at www. emea. eu. int • by email request to info@emea. eu. int • by fax to (44-20) 7418 8670 • by writing to:
- Using "Actin FS" or "Neothromtin" on automated coagulometers the target range for the
With a median follow-up of 2.9 years, the median progression free survival (PFS) increased from 13.5 months (control) to 37 months (Zevalin; p < 0.0001; HR 0.465).
Over a 12 month period the risk of COPD exacerbations was reduced from 1.42 per year to 0.99 per year compared with placebo and the risk of exacerbations requiring oral corticosteroids was significantly reduced from 0.81 to 0.47 per year compared with placebo.
Over the 6-month (acute and chronic) follow- up period, there was a 22% reduction (p =0.008) in the severity-by-duration score and a 52% (95% CI:
Becaplermin was not mutagenic in a battery of in vitro and in vivo tests.
increased monitoring of adverse events when administered concomitantly with Invirase/ritonavir.
Patient Monitoring Proteinuria appears to be an early and sensitive indicator of cidofovir-induced nephrotoxicity.
eyes may need to be monitored.
under supervision of experienced hospital personnel.
under supervision of experienced hospital personnel.
Investigations: elevated liver enzymes, weight increased
Watchful waiting Radiotherapy Radical prostatectomy
Under these circumstances, treatment should be immediately discontinued and the patient referred to a specialised unit for investigation.
Under these circumstances, treatment should be immediately discontinued and the patient referred to a specialist unit for investigation.
(95% CI) Final analysis
*Median Progression Free Survival [95% CI] (weeks)
Progression Free Survival in First Line Study (by Treatment Group)
Progression Free Survival in First Line Study (by Treatment Group)
**: only applicable to patients achieving a CR;
Hazard ratio (97.5% CI)a
Increased tendency to bruise, alopecia, dry skin
suspected sensitivity to calcitonin prior to their treatment with calcitonin.
day 90 of the procedure), some 25 break-out sessions were held at the EMEA.
Ear drops suspension White to off-white oily suspension
Oral suspension containing 10mg, 20mg or 50mg per ml.
The suspension is white to off-white in colour.
Oral suspension in pre-filled oral applicator 1 pre-filled oral applicator 1 dose (1.5 ml)
Oral suspension in pre-filled oral applicator.
solution for infusion
DTPa-HBV-IPV suspension: sodium chloride (NaCl), medium 199 containing principally amino acids, mineral salts, vitamins and water for injections
DTPa-HBV-IPV suspension: sodium chloride (NaCl), medium 199 containing principally amino acids, mineral salts, vitamins and water for injections
Film coated tablet 250 mg, 500 mg, 750 mg, 1000 mg 26 presentations
Suspension for injection 10 vials 10 x 1 dose 1 dose (1 ml)
Suspension for injection 10 syringes 10 needles 10 x 1 dose 1 dose (1 ml)
Suspension for injection 10 syringes 10 x 1 dose 1 dose (1 ml)
Suspension for injection 1 syringe 1 needle 1 dose (1 ml)
Suspension for injection 1 x 10 ml This is part of a multipack and not for sale of individual vials
Suspension for injection 1 x 10 ml This is part of a multipack and not for sale of individual vials
Suspension for injection 25 vials 25 x 1 dose 1 dose (1 ml)
Suspension for injection 25 syringes 25 needles 25 x 1 dose 1 dose (1 ml)
Suspension for injection 25 syringes 25 x 1 dose 1 dose (1 ml)
Suspension for injection 5 x 3ml pre-filled pens
Suspension for injection 5 x 3ml pre-filled pens
Suspension for injection 5 X 3ml pre-filled pens
Suspension for injection 5 x (1 x 10 ml) This is a multipack and not for sale of individual vials
Turbid white suspension.
DepoCyte 50 mg suspension for injection Cytarabine
Suspension for injection diphtheria > 30 IU Tetanus > 40 IU Pertactin 2.5µ 1 presentation
18. 2.1997 22.10.1997 208 days 34 days
1 vial of 10 ml 5 vials of 10 ml
1 vial of 5 ml 5 vials of 5 ml
Suspension for injection in pre-filled syringe Slightly opaque white suspension.
Suspension for injection Part of a multi-pack of 2 x (5 x 3ml) pre-filled pens.
Suspension for injection Part of a multi-pack of 2 x (5 x 3ml) pre-filled pens.
Suspension for injection Part of a multi-pack of 2 x (5 x 3ml) pre-filled pens.
Suspension for injection Infanrix Penta is a turbid white suspension.
Suspension for injection Pre-filled syringe with a Micro-Injection System (0.1 ml) - pack of 1 Pre-filled syringe with a Micro-Injection System (0.1 ml) - pack of 10 Pre-filled syringe with a Micro-Injection System (0.1 ml) - pack of 20
Suspension for injection Slightly opaque white suspension.
Suspension for injection
Suspension for injection
Honey flavoured, yellowish viscous oral suspension with a green tinge.
Oral suspension Honey flavoured, yellowish viscous oral suspension with a green tinge.
inhalacijska suspenzija pod tlakom
Suspension for emulsion for injection 50 vials: suspension
For the constituted suspension:
Reconstituted suspension: do not store above 30°C.
Dimethyl sulfoxide Dilution medium
- high likelihood of left heart thrombus, e. g. mitral stenosis with atrial fibrillation
SUSTIVA is indicated in antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected adults, adolescents and children 3 years of age and older.
181 SUSTIVA should never be used alone to treat HIV.
SUSTIVA should never be used alone to treat HIV.
SUTENT 12.5 mg hard capsules SUTENT 25 mg hard capsules SUTENT 50 mg hard capsules Sunitinib Malate
SUTENT inhibits the growth of these cells.
It arises from uncontrolled cell growth of the supporting tissues of these organs.
Sutent is used to treat patients with one of the following types of cancer: • gastrointestinal stromal tumour (GIST), a type of cancer of the stomach and bowel, where there is uncontrolled growth of cells in the supporting tissues of these organs.
SUTENT was not studied in subjects with severe (Child-Pugh class C) hepatic impairment.
SUTENT has not been studied in subjects with Child-Pugh Class C hepatic impairment (see section 5.2).
37 SUTENT should not be used in paediatric population until further data become available.
SUTENT should not be used in paediatric population until further data become available.
SUTENT may be taken with or without food.
SUTENT will only be prescribed to you by a doctor with experience in medicines to treat renal cell cancer or gastrointestinal stromal tumours.
Suvaxyn Aujeszky 783 + O/ W, powder and solvent for emulsion for injection
Suvaxyn Aujeszky 783 + O/ W, powder and solvent for emulsion for injection.
Suvaxyn Ery is indicated for the active immunisation of pigs (gilts and sows) to reduce clinical signs caused by Erysipelothrix rhusiopathiae infections, serotype 2 and serotype 1.
Suvaxyn Parvo/ E is indicated for the active immunisation of pigs (gilts and sows) to prevent reproductive disorders caused by porcine parvovirus and to reduce clinical signs caused by Erysipelothrix rhusiopathiae infections, serotype 2 and serotype 1.
Sverige Abbott Scandinavia AB Box 509/Gårdsvägen 8 SE-169 29 Solna/SE-169 70 Solna Tel: + 46 (0) 8 5465 67 00
Sverige Abbott Scandinavia AB Box 509/ Gårdsvägen 8 SE-169 29 Solna/ SE-169 70 Solna Tel: + 46 (0) 8 5465 67 00
Alcon Sverige AB + 46 (0)8 634 40 00 E-post: receptionen@alconlabs. com
Sverige Alcon Sverige AB + 46 (0)8 634 40 00 E-post: receptionen@alconlabs.com
Sverige Alcon Sverige AB + 46 (0)8 634 40 00 E-post: receptionen@alconlabs. com
Sverige Allergan Norden AB Johanneslundsvägen 3-5 S-194 81 Upplands Väsby Tel: +46 (0)8 594 100 00 E-mail: uk_medinfo@allergan. com
Sverige Astellas Pharma AB Haraldsgatan 5 S-41314 Göteborg Tel: +46 (0)317416160
Sverige Box 6185 S -102 33 Stockholm Tel: + 46-(0)8 522 21 500
Sverige Box 6185 S-102 33 Stockholm Tel: + 46-(0)8 522 21 500
Sverige Cephalon Pharma Aps Sluseholmen 2-4 DK - SV 2450 Köpenhamn DANMARK Tel: +45 3694 4868
Sverige Eli Lilly Sweden AB Tel: + 46-(0) 8 7378800
Sverige Eli Lilly Sweden AB Tel: + 46 -(0) 8 7378800
Tel: +421 220 663 111 Suomi/Finland Oy Eli Lilly Finland Ab Puh/Tel: +358-(0) 9 85 45 250 Sverige Eli Lilly Sweden AB Tel: + 46 (0) 8 7378800 United Kingdom Daiichi Sankyo UK Ltd Tel: +44 (0) 1753 893 600
Frank HALLINAN Chief Executive Officer Irish Medicines Board The Earlsfort Centre Earlsfort Terrace Dublin 2 Ireland Tel:
Suomi/Finland JANSSEN-CILAG OY Metsänneidonkuja/Skogsjungfrugränden 8 FI-02130 Espoo/Esbo Puh/Tel: +358 9 4155 5300 Sverige JANSSEN-CILAG AB Box 7073 SE-192 07 Sollentuna Tel: +46 8 626 50 00 United Kingdom JANSSEN-CILAG Ltd.
Sverige KRKA Sverige AB Tel: + 46 8 643 67 66 United Kingdom KRKA Pharma Dublin, Ltd.
Sverige les Laboratoires Servier/ Frankrike Tel: +33 (0)1 55 72 60 00
Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 (0) 8 626 1400 medicinskinfo@merck.com
Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 (0) 8 626 14 00 medicinskinfo@merck.com
Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 (0) 8 626 14 00 medicinskinfo@merck. com
Sverige Merck Sharp & Dohme (Sweden) AB, Tel: +46 (0) 8 626 1400 medicinskinfo@merck. com
Sverige Nycomed AB Box 27264 SE-102 53 Stockholm Tel: +46 8 731 28 00 infosweden@nycomed.com
Sverige Orion Pharma Animal Health Tln: +46 (0)8-623 64 40
Sverige Sandoz AB Berga Allé 1E S-254 52 Helsingborg Tel: + 46 42 152065
Sverige Sandoz AB Berga Allé 1E S-254 52 Helsingborg Tel: + 46 42 152065
Sverige Sandoz AB Berga Allé 1E S-254 52 Helsingborg Tel: + 46 42 152065
Sverige sanofi-aventis AB Tel: +46 (0)8 634 50 00
Sverige TIBOTEC, en division inom JANSSEN-CILAG AB Box 7073 S-192 07 Sollentuna Tel: +46 8 626 50 00
Sverige UCB Nordic A/S Tel: + 46 / (0) 40 29 49 00
Sverige Wyeth AB Tel: +46 8 470 3200 Fax: +46 8 730 0666
Sverige Abbott Scandinavia AB
Visit (weeks) N=Number of Subjects at Baseline, week 52, week 104, week +6, week +12. ed
Marketing Authorisation Holder SWEDISH ORPHAN INTERNATIONAL AB Drottninggatan 98 SE-111 60 Stockholm Sweden
Swedish Orphan International AB Drottninggatan 98 SE-111 60 Stockholm Sweden
Österreich SWEDISH ORPHAN INTERNATIONAL GmbH Tel: +49 6103 20 26 90
S. xylosus, S. schleiferi, S. epidermidis) is 9.5%.
au hormone and danazol.
Vasopressor sympathomimetics and other substances (e. g. isoproterenol, dobutamine, dopamine, epinephrine) that may reduce the antihypertensive effect of TRITACE:
Alkylating Agents Fludarabine Number of Prior Regimens (range) Initial Dosing Regimen
Withdrawal symptoms seen on discontinuation of SSRI treatment:
Use in patients with renal impairment: it was agreed that the individualisation of the dosage may be desirable, and this concept was introduced in the text for harmonization.
Symptoms There is no experience of overdose with Copalia.
Symptoms There is no experience of overdose with Dafiro.
Symptoms There is no experience of overdose with Exforge.
Symptoms There is no experience of overdose with Imprida.
- Current or past medical history of cardio-vascular or cerebro-vascular disease
Pulmonary artery hypertension Severe arterial hypertension Current or past medical history of cardio-vascular or cerebro-vascular disease Current or past medical history of psychiatric disorders including anorexia nervosa and depression
Synagis contains an active ingredient called palivizumab which is an antibody that works specifically against a virus called respiratory syncytial virus, RSV.
Synagis should be given to your child at a dose of 15 mg/ kg body weight once a month for as long as the risk of RSV infection remains.
Synagis is given once a month when there is a risk of RSV infection in the community: in the northern hemisphere, this is from November to April.
Synagis will be given by injection to your child into a muscle, usually in the outer part of the thigh.
What Synagis looks like and contents of the pack Synagis is a white to off-white uniform dry cake in a 10 ml vial.
What Synagis looks like and contents of the pack Synagis is a white to off-white uniform dry cake in a 4 ml vial.
Synagis is a powder and solvent, which are made into a solution for injection.
syncope, hypertension, thromboembolic events
Syncope Abnormal gait Dystonia Hyperesthesia Neuropathy Taste perversion
Depersonalisation Personality disorder Abnormal thinking Impotence Nervousness
- compartment syndrome*, characterised by pain, swelling and neurological symptoms, as well as
20 Acute Coronary Syndrome (ACS) Patients experiencing an ACS have not been studied in rosiglitazone controlled clinical trials.
37 Patients experiencing an ACS have not been studied in rosiglitazone controlled clinical trials.
4 Acute Coronary Syndrome (ACS) Patients experiencing an ACS have not been studied in rosiglitazone controlled clinical trials.
Acute Coronary Syndrome (ACS) Patients experiencing an ACS have not been studied in rosiglitazone controlled clinical trials.
Metabolism and nutrition
Hypersensitivity to the active substance or to any of the excipients Severe hepatic impairment Severe renal impairment Sleep apnoea syndrome Myasthenia gravis Severe respiratory insufficiency Children (under 18 years of age)
• Churg-Strauss syndrome and hypereosinophilic syndrome Patients with severe asthma may rarely present systemic hypereosinophilic syndrome or allergic eosinophilic granulomatous vasculitis (Churg-Strauss syndrome), both of which are usually treated with systemic corticosteroids.
Churg-Strauss syndrome and hypereosinophilic syndrome Patients with severe asthma may rarely present systemic hypereosinophilic syndrome or allergic eosinophilic granulomatous vasculitis (Churg-Strauss syndrome), both of which are usually treated with systemic corticosteroids.
• tumour lysis syndrome is a special disorder which may begin with pains in the side and blood in the urine • bleeding in the brain (intracranial haemorrhage).
Asthenia, fever, flu syndrome, malaise, accidental injury, chills, chest pain, abdominal pain, back pain, pain Injury, poisoning and procedural complications
immune reconstitution syndrome (0.2% vs 0.2%), drug hypersensitivity (0.7% vs 0.7%)
Stevens Johnson syndrome*, toxic epidermal necrolysis*, erythema multiforme*
Stevens– Johnson Syndrome. toxic epidermal necrolysis.
Stevens Johnson syndrome, toxic epidermal necrolysis, injection site necrosis, erythema multiforme
Stevens Johnson syndrome, toxic epidermal necrolysis, injection site necrosis, erythema multiforme
carpal tunnel syndrome, disturbance in attention, dizziness postural, dysgeusia, hypersomnia, hypoaesthesia, lethargy, neuropathy, neuropathy peripheral, paraesthesia, somnolence, tension headache, tremor
Neuroleptic malignant syndrome Neuroleptic Malignant Syndrome (NMS), characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness, and elevated serum creatine phosphokinase levels has been reported to occur with antipsychotics, including paliperidone.
Neuroleptic Malignant Syndrome (NMS) NMS is a potentially life-threatening condition associated with antipsychotic medicinal product.
Neuroleptic Malignant Syndrome (NMS) NMS is a potentially life-threatening condition associated with antipsychotic medicinal product.
Neuroleptic Malignant Syndrome (NMS) NMS is a potentially life-threatening condition associated with antipsychotic medicinal products.
Neuroleptic Malignant Syndrome (NMS), Serotonergic syndrome, Delirium, Extrapyramidal reactions (including dystonia and dyskinaesia), Tardive dyskinaesia, Suicidal ideation and behaviours**
Injection site reactions such as swelling, erythema, pain, pruritus Influenza-like illness, swelling arms, weight increase, fatigue
This should be taken into consideration if you are on a strictly controlled sodium diet.
Injury, poisoning and procedural complications
Dizziness Tremor Lethargy Paraesthesia
Serotonin syndrome: in rare cases, serotonin syndrome has been reported in patients using SSRIs concomitantly with serotonergic medicinal products.
52 Serotonin syndrome: in rare cases, serotonin syndrome has been reported in patients using SSRIs (e. g. paroxetine, fluoxetine) concomitantly with serotonergic medicinal products.
5 Serotonin syndrome: in rare cases, serotonin syndrome has been reported in patients using SSRIs (e. g. paroxetine, fluoxetine) concomitantly with serotonergic medicinal products.
Serotonin syndrome: in rare cases, serotonin syndrome has been reported in patients using SSRIs (e. g. paroxetine, fluoxetine) concomitantly with serotonergic medicinal products.
Serotonin syndrome Interaction with serotonergic active substances: serotonin syndrome may occur when selective serotonin reuptake inhibitors (SSRIs) are used concomitantly with other serotonergic active substances (see section 4.5).
Synperonic NCA 830 Dimethyl sulfoxide Gamma-hexalactone
Quality management system and performance indicators
The MAH must ensure that the system of pharmacovigilance, as described in the July 2007 version, is in place and functioning before and whilst the product is on the market.
Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market and for as long as the marketed product remains in use.
Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market and for as long as the marketed product remains in use.
Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market.
Gastrointestinal System The occurrence of severe and persistent diarrhoea during or after treatment (including several weeks after treatment) may indicate an antibiotic-associated colitis (life-threatening with possible fatal outcome), requiring immediate treatment (see section 4.8).
Gastrointestinal System The occurrence of severe and persistent diarrhoea during or after treatment (including several weeks after treatment) may indicate an antibiotic-associated colitis (life-threatening with possible fatal outcome), requiring immediate treatment (see section 4.8).
Gastrointestinal System The occurrence of severe and persistent diarrhoea during or after treatment (including several weeks after treatment) may indicate an antibiotic-associated colitis (life-threatening with possible fatal outcome), requiring immediate treatment (see section 4.8).
(other than short -term treatment with cortisone-type medicine).
(other than short-term treatment w ith cortisone-type me dicine).
system (other than short -term treatment with cortisone-type medicine).
Central and peripheral nervous system Common: vertigo, headache.
Psychiatric and central nervous system (CNS):
Table 1: dosage adjustment in renal impairment
Table 5 Creatinine clearance (mean and SD)
Table 1 Undesirable Effects in Clinical Studies t
ADRs reported in clinical trials or during postmarketing surveillance in patients with NHL and CLL disease treated with MabThera monotherapy/ maintenance or in combination with chemotherapy
Adverse reactions reported in patients who received vildagliptin 100 mg daily as add-on therapy to metformin compared to placebo plus metformin in double-blind studies (N=208)
Table 1 Bleeding events broken down to major and any bleeding in the pivotal hip and knee study
Table 1 Urinary AER at baseline and at the end of 24 months of treatment Treatment
Patient Demographics and Characteristics in C04-001 and C04-002
Treatment should be resumed according to the guidelines in Table 2.
Table 2 DOSAGE OF GABAPENTIN IN ADULTS BASED ON RENAL FUNCTION Creatinine Clearance (ml/ min) ≥ 80 50-79 30-49 15-29 < 15c a
Table 2 Proportion of Patients with Serum Uric Acid Levels < 6.0 mg/ dl (357µmol/ l) Last Three Monthly Visits
Summary of on treatment ALT (IU/ L) flare – Pooled NV-02B-007/ NV-02B-015
Table 3 Progression or regression of retinopathy at 24 months
Viral infection, pharyngitis Fungal infection, bacterial infection, pulmonary infection, otitis media, tooth abscess, herpes simplex, urinary tract infection, vaginitis, gastroenteritis
Adverse reactions reported in patients who received Jalra 100 mg daily as monotherapy in double-blind studies (N=1,855)
Response in adult CML studies
Key efficacy results of vildagliptin in placebo-controlled monotherapy trials and in add-on combination therapy trials (primary efficacy ITT population)
Virological response in previously untreated paediatric patients IntronA 3 MIU/m2 3 times a week + ribavirin 15 mg/kg/day
Virological response in previously untreated paediatric patients Viraferon 3 MIU/ m2 3 times a week + ribavirin 15 mg/ kg/ day
Table 9 Summary of PASI response, PGA response and percent of patients with all nails cleared at Weeks 10, 24 and 50.
Support to CPMP and Working Parties
Oily spotting Flatus with discharge Faecal urgency Fatty oily stool Oily evacuation Flatulence Soft stools
- If you have any further questions, ask your doctor.
TachoSil may stick to surgical instruments or gloves covered with blood.
- Renal impairment - Skin hypertrophy, rash, acne, alopecia
bronchospasm, pharyngolaryngeal pain, rhinnorhoea, tachypnoea, upper respiratory tract congestion
Tacrolimus is a macrolide immunosuppressant belonging to the pharmacological class of the calcineurin inhibitors.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
TAD Pharmazeutisches Werk GmbH Heinz-Lohmann-Strasse 5 D-27472 Cuxhaven
Tafarnaubach Industrial Estate Tredegar Gwent NP22 3AA United Kingdom
PACKAGE SIZE n tio 50 ml (25 doses) – 100 ml (50 doses) – 250 ml (125 doses) isa
LT-CAGE Lumbar Tapered Fusion Device size (lead diameter x length)
Tallinna Farmaatsiatehase As 33 Tondi Street Ee – 11316, Tallinn Estonia
MAH, MA number, date of first authorisation/renewal of authorisation, Date of revision of the text.
Tandemact is contraindicated in patients with:
This is the diabetes that usually develops in adulthood.
- Both in preclinical investigations and in humans, changes in cardiac electrophysiology have been
Both minor and major bleeds were significantly less frequent with bivalirudin than the heparin plus GPIIb/ IIIa inhibitor comparator group.
Tap the narrow part of the pipette to ensure the contents remain within the main body of it.
Tap the narrow part of the pipette to ensure the contents remain within the main body of the pipette.
Tap the narrow part of the pipette to ensure the contents remain within the widest part.
Tap the syringe gently to bring the bubbles to the top.
Tap the top of the ampoule of solvent gently to make sure that all the liquid is at the bottom of the ampoule.
Gently flick the top section of the ampoule so that any fluid in the neck of the ampoule drops into the bottom chamber.
Gently flick the top section of the ampoule so that any fluid in the neck of the ampoule drops into the bottom chamber.
the plunger slightly back; tap the syringe gently, with the needle pointing upwards, until the bubbles disappear.
Tarceva 100 mg One film-coated tablet contains 100 mg erlotinib (as erlotinib hydrochloride).
Tarceva 150 mg One film-coated tablet contains 150 mg erlotinib (as erlotinib hydrochloride).
Tarceva 25 mg One film-coated tablet contains 25 mg erlotinib (as erlotinib hydrochloride).
Tarceva must be taken at least 2 hours before or 10 hours after ranitidine dosing.
Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer.
Tarceva is given in combination with gemcitabine treatment.
Tarceva or placebo was taken orally once daily until disease progression or unacceptable toxicity.
Tarceva or placebo was taken orally once daily until disease progression or unacceptable toxicity.
Tasigna blocks this signal, and thus stops the production of these cells.
Tasigna is indicated for the treatment of adults with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy including imatinib.
Tasigna is used in the ‘ chronic'and ‘ accelerated 'phases of CML.
Tasigna is used to treat adults with chronic myelogenous leukaemia (CML), a type of cancer of the white blood cells where granulocytes (a type of white blood cell) start growing out of control.
Tasigna may be given with hydroxyurea or anagrelide if clinically indicated.
Tasmar has been further studied in a ‘ switch'study in 150 patients.
Tasmar is contraindicated in patients with:
Vianex S. A Tatoiou Street 18 Km Athens-Lamia National Road 14671 Nea Erythrea Athens Greece
Tatoiou Street Lamia NationalRoad 14671 Nea Erythrea Greece
22 ALT/AST levels > 3 and ≤ 5 × ULN
4 ALT/ AST levels > 3 and ≤ 5 × ULN
≥ 0.5 and < 1.5 x 10 /l
≥ 0.5 and < 1.5 x 10 / l
Response (%) *Unstratified logrank test
(N=485) Response rate of ≥ 60% in
Response rate of ≥ 60% improvement in mEASI (Primary Endpoint)§§
Response rates (for patients with measurable disease)
(N = 56) Response rate (%, CI) at 4 hours after start of treatment
Response rate (95% CI) Median Duration of response
Sustained response rates with PegIntron + ribavirin (by ribavirin dose, genotype and viral load)
Sustained response rates with ViraferonPeg + ribavirin (by ribavirin dose, genotype and viral load)
Seroprotection rate* Seroconversion rate** Seroconversion factor*** * SRH area > 25 mm²
Confirmed Peripheral Vascular Events
Rates of Confirmed Thrombotic CV Events (Pooled MEDAL Program)
• Baseline values of hepatic aminotransferases (aspartate aminotransferases (AST) and/ or alanine aminotransferases (ALT)) > 3xULN (see sections 4.2 and 4.4).
Rate per 28-week period% reduction, p-value for rate ratio Physician's overall assessment
% reduction, p-value for rate ratio Physician's overall assessment
Rate per 28-week period% reduction, p-value for rate ratio Emergency visits
Factor VIII level required (%) (IU/ dl)
required (%) (IU/ dl)
Type of surgical procedure
TAXOTERE 20 mg concentrate and solvent for solution for infusion
TAXOTERE 80 mg concentrate and solvent for solution for infusion
TAXOTERE 80 mg concentrate and solvent for solution for infusion
TAXOTERE 80 mg concentrate and solvent for solution for infusion
Tazko 2,5 mg, comprimés à liberation prolongée
Information technology........................................................................... 47
Fitting out, lease & other building related costs IT, data processing Other current administrative expenditure
150 mg 150 mg 150 mg 150 mg 150 mg 150 mg 150 mg 150 mg 150 mg 150 mg 300 mg 300 mg 300 mg 300 mg 300 mg 300 mg 300 mg 300 mg 300 mg 300 mg
Tekturna also reduced blood pressure in patients with diabetes, patients who were overweight, and those who were over 65 years of age.
Tekturna induced an additive blood-pressure-lowering effect when added to hydrochlorothiazide and to ramipril.
Combination studies looked at Tekturna used with an angiotensin converting enzyme inhibitor (ramipril), an angiotensin receptor blocker (valsartan), a beta-blocker (atenolol), a calcium-channel blocker (amlodipine) and a 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Tel: + 31-(0) 30 60 25 800 Norge Eli Lilly Norge A. S.
Tel: + 31 23 567 2567 Fax: +31 23 567 2599
Tel: + 386 1 580 2884 Danmark Novartis Healthcare A/ S, Tlf: +45-39 16 84 00 Deutschland Novartis Tiergesundheit GmbH Tel: +49-(0)89 7877 713 Eesti Novartis Animal Health d. o. o.
Tel: +351 21 4232010
Pfizer România S. R. L Tel: +40 (0)21 207 28 00 Slovenija Pfizer Luxembourg SARL Pfizer, podruž nica za svetovanje s področ ja farmacevtske dejavnosti, Ljubljana Tel: + 386 (0)1 52 11 400
Tel: +356 2540 2600 medinfo_mt@merck. com
Tel: + 386 (0)1 580 00 10 Slovenská republika Eli Lilly Slovakia, s.r.o.
Tel: +39 - 039 2471
Tel: + 39- 055 42571 Κύπρος Boehringer Ingelheim Ellas A. E.
Tel: + 39- 055 42571 Κύπρος Phadisco Ltd Τηλ: + 357 22 715000 Latvija Eli Lilly Holdings Limited, pārstāvniecība Latvijā Tel: + 371 67364000 Lietuva Eli Lilly Holdings Limited atstovybė Tel. + 370 (5) 2649600
Tel: + 39- 055 42571 Κύπρος Phadisco Ltd Τηλ: +357 22 715000 Latvija Eli Lilly Holdings Limited pā rstā vniecī ba Latvijā Tel: +371 7364000 Lietuva Eli Lilly Holdings Limited atstovybė Tel. +370 (5) 2649600
Tel: + 40 21 4023000 Slovenija Boehringer Ingelheim Pharma Tel.: +386 1 586 40 00 Slovenská republika Boehringer Ingelheim Pharma Tel.: +421 2 5341 8445 Suomi/ Finland Oy Eli Lilly Finland Ab Puh/ Tel: +358 9 8545 250 Sverige Boehringer Ingelheim AB Tel: +46 8 721 21 00 United Kingdom Boehringer Ingelheim Ltd.
Tel: + 40 21 4023000 Slovenija Boehringer Ingelheim Pharma Tel.: +386 1 586 40 00 Slovenská republika Boehringer Ingelheim Pharma Tel.: +421 2 5341 8445 Suomi/ Finland Oy Eli Lilly Finland Ab Puh/ Tel: +358 9 8545 250 Sverige Boehringer Ingelheim AB Tel: +46 8 721 21 00 United Kingdom Boehringer Ingelheim Ltd.
Tel: + 40 21 4023000 Slovenija Eli Lilly, Podruž nica Ljubljana Tel: +386 (0)1 580 00 10 Slovenská republika Eli Lilly Slovakia, s. r. o.
Tel: + 40 21 4023000 Slovenija Eli Lilly, Podruž nica Ljubljana Tel: +386 (0)1 580 00 10 Slovenská republika Eli Lilly Slovakia, s. r. o.
46 Eesti Österreich Eli Lilly Holdings Limited Eesti filiaal Tel: +372 6817280 Ελλάδα ΦΑΡΜΑΣΕΡΒ -ΛΙΛΛΥ Α .Ε .Β .Ε.
Eesti IVAX Pharmaceuticals s.r.o Tel: +420 553 641 111
Tel: +421 2 4914 0172 Suomi/ Finland Meda Oy Puh. / Tel: +358 20 720 9550 Sverige Meda AB Tel: +46-(0) 8 630 19 00 United Kingdom Daiichi Sankyo UK Ltd Tel: +44-(0) 1753 893 600
Tel: +44(0) 1256 894000 Fax: +44(0) 1256 894708
Torbet Laboratories Limited, 14D Wendover Road, Rackheath Industrial Estate, Norwich, NR13 6LH, United Kingdom Tel. +44 (0)1603 735200 Fax. +44 (0)1603 735217 E-mail. customerservices@typharm. com
Tel:+39 06 927151 Fax:+39 06 23325555
Tel: +39 06 927151 Fax: +39 06 23325555
Tel.: +46 8 643 67 66 Ísland KRKA Sverige AB Sími: +46 (0)8 643 67 66 (SE)
Sverige Wyeth AB Tel:+46 8 470 3200 Fax:+46 8 730 0666
Portugal Lilly Portugal Produtos Farmacêuticos, Lda Tel: + 351-21-4126600 România Eli Lilly România S. R. L.
Tel. +48 (0) 22 440 33 00 Portugal Lilly Portugal - Produtos Farmacêuticos, Lda Tel: + 351 21 412 66 00
Tel.: +48 22 699 0 699 Portugal Boehringer Ingelheim, Lda Tel: +351 21 313 53 00 România Eli Lilly România S. R. L.
Telbivudine 600 mg film-coated tablet Alternative** dose adjustment with increased dose intervals
Telephone: + (421) 2 5726 7974 Suomi/Finland Teva Sweden AB Telephone:
Patient's Name: _____________________ Doctor's Name: _____________________
information. • Please make sure you also have a list of all your
reactions (such as swollen face or tongue) in patients attempting to quit smoking with CHAMPIX.
Telmisartan Borhringer Ingelheim telmisartan Part B
as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
fever or any difficulty in breathing).
Tél/Tel: + 32 2 656 21 11
Tél/ Tel: + 44 (0) 600 1400 (Royaume-Uni/ Verenigd Koninkrijk)
Telzir in combination with low dose ritonavir is indicated for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infected adults, adolescents and children of 6 years and above in combination with other antiretroviral medicinal products.
Telzir in combination with low dose ritonavir is indicated for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infected adults, adolescents and children of 6 years and above in combination with other antiretroviral medicinal products.
Telzir with ritonavir should be used with caution and at reduced doses in adults with mild, moderate, or severe hepatic impairment (see section 4.2. Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse events.
Telzir with low doses of ritonavir is used in combination with other anti-retroviral medicines (‘ combination therapy ’) to treat adults, adolescents and children aged over 6 years infected with HIV-1.
Telzir with low doses of ritonavir is used in combination with other anti-retroviral medicines (‘ combination therapy’) to treat adults, adolescents and children aged over 6 years infected with HIV-1.
Telzir tablet can be taken with or without food.
Telzir is a type of medicine known as an anti-retroviral.
Telzir is used to treat HIV (human immunodeficiency virus) infection.
Telzir (fosamprenavir) is a pro-drug of amprenavir and must not be administered concomitantly with other medicinal products containing amprenavir.
Telzir should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Telzir oral suspension is the recommended option for the most accurate dosing in children based on body weight.
Temodal 2.5 mg/ml is administered in combination with focal radiotherapy (concomitant phase) followed by up to 6 cycles of temozolomide (TMZ) monotherapy (monotherapy phase).
Temodal in combination treatment with radiotherapy in newly-diagnosed glioblastoma
Temodal monotherapy in recurrent or progressive glioma The following side effects may occur, and may require medical attention.
Temodal monotherapy in recurrent or progressive glioma
Temodal is used first with radiotherapy and then on its own; • adults and children three years of age and over with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, when the tumour has returned or got worse after standard treatment.
Temodal is used on its own in these patients.
Temodal is used for the treatment of patients with specific forms of brain tumours:
Meat and offal (chicken and turkeys):
Withdrawal periods - Meat and offal (chickens and turkeys):
Fondaparinux does not cross-react with sera from patients with heparin-induced thrombocytopaenia.
Turnaround time for submissions to financial control 1999-2000
Photo- sensitivity reactions Increased tendency to bruise Dermatitis contact Urticaria Cold sweat
- tendonitis (pain caused by inflammation in the membrane surrounding the tendons usually in the
back of the ankle (Achilles tendon) (see Section 2:
Alcohol content This medicinal product contains 24 vol% ethanol (alcohol); this is equivalent to 6 g ethanol in the 100 mg maintenance dose (administered over a 1.5-hour period), and 12 g ethanol in the 200 mg loading dose (administered over a 3-hour period).
Hold the syringe at eye level and make sure the tip of the needle is in the fluid all of the time.
Hold the syringe with the needle pointing up to see if it has any air bubbles inside.
Hold the pre-filled pen with the grey cap (labelled ‘1’) pointing up.
Hold your pen with the needle pointing straight up.
Hold your pen with the needle pointing up.
The content of vitamin D (200 IU) in Calcichew-D3 mite (and associated names) tablets should be considered when prescribing other medicinal products containing vitamin D.
The content of vitamin D (400 IU) in Calcichew-D3 (and associated names) tablets should be considered when prescribing other medicinal products containing vitamin D.
Effentora must be kept out of the reach and sight of children. • Do not use Effentora after the expiry/ use before date shown on the blister package label and the carton. • Store in the original package in order to protect from moisture. • Medicines should not be disposed of via wastewater or household waste.
Hold the spoon in a vertical (upright) position and fill it gradually to the mark corresponding to the prescribed dose.
The top of the tip will fold back against the pipette.
Then hold the pipette in an upright position, and twist and pull off cap.
Then hold the pipette in an upright position, and twist and pull off the cap.
Withdraw 0.2 ml of the reconstituted vaccine into the syringe provided (see Figure 1) and connect the applicator to the needle (see Figure 2).
Withdraw 0.2 ml of the reconstituted vaccine into the syringe provided with the vaccine (see Figure 1) and connect the applicator to the needle (see Figure 2).
Hold the breath bag upright and stick the bar-code label marked “00-minute-value” on the breath bag.
Hold the pen with needle pointing up and remove the outer needle cap and inner needle cover.
tenofovir disoproxil fumarate (N=244)
suicide attempt, suicide ideation, mania, paranoia, hallucination, euphoric mood, affect lability, confusional state, aggression
- thyroid hormones (used to treat thyroid gland disorders),
Terfenadine and Pseudoephedrine hydrochloride see Annex A tablet (including coated tablet and film coated tablet)
Dexfenfluramine; Fenfluramine
Terfenadine see Annex A oral suspension (including syrup and suspension syrup)
Marketing Authorisation Holder
Keep unlocked against skin
TESLASCAN 0.01 mmol/ ml solution for infusion mangafodipir trisodium
TESLASCAN has the following physicochemical properties:
TESLASCAN should be visually inspected for particulate matter and for the integrity of the container prior to use.
TESLASCAN is used as a single intravenous infusion at a dose of 0.5 ml per kilogram body weight.
TESLASCAN is for intravenous use and will be infused before the MRI examination.
TESLASCAN is isotonic with blood and normal body fluids.
TESLASCAN is a paramagnetic contrast medium used in connection with Magnetic Resonance Imaging (MRI), to improve the diagnostic information.
TESLASCAN is a ‘ contrast medium 'that is used to obtain a clearer scan.
TESLASCAN is used in magnetic resonance imaging (MRI) to detect certain lesions in the liver and pancreas.
TESLASCAN is used in patients who are undergoing magnetic resonance imaging (MRI) to detect lesions (damaged tissue) in the liver that might be caused by liver cancer or cancer that has spread to the liver from other parts of the body.
TESLASCAN has no effect on male or female fertility in rats.
TESLASCAN must not be used if you are pregnant.
TESLASCAN may be infused into a vein, normally an arm vein, via a thin plastic tube.
Test: single fixed-dose combination tablet taken under fasted conditions.
In a clinical study examining the pharmacodynamic effects of the recommended dose of the peptide in human volunteers during an oral GTT (Glucose Tolerance Test), no effects were observed other than the normal physiologic response to oral glucose challenge.
Pylobactell [13Carbon] -UREA BREATH TEST (13C-UBT) for Helicobacter pylori
Liver function tests Total bilirubin: = 1.5 ULN AST: > ULN (can be normal or< ULN if total bilirubin is > ULN)
Tests on the presence of extraneous viruses in veterinary
Denmark Teva Denmark A/ S, Parallelvej 10, 2800 Kongens Lyngby Denmark
Tevagrastim 30 MIU/ 0.5 ml solution for injection or infusion
Tevagrastim 30 MIU/ 0.5 ml solution for injection or infusion
Tevagrastim 30 MIU/ 0.5 ml solution for injection or infusion Tevagrastim 48 MIU/ 0.8 ml solution for injection or infusion
Tevagrastim 48 MIU/ 0.8 ml solution for injection or infusion
Tevagrastim is indicated for the mobilisation of peripheral blood progenitor cells (PBPC).
Tevagrastim is useful in several different conditions which are:
Tevagrastim and peripheral blood stem cell mobilisation If you are donating stem cells for yourself, the usual dose is 0.5 million to 1 million international units (MIU) per kilogram bodyweight each day.
Tevagrastim can also be used in patients who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow.
Teva Pharma BV, Computerweg 10, 3542 DR Utrecht, The Netherlands
Teva Pharma Bv Industrieweg 23 Po Box 217 3640 Ae Mijdrecht The Netherlands
Teva Pharma Bv Industrieweg 23 Po Box 217, 3640 Ae Mijdrecht The Netherlands
Teva Pharmaceutical Works, Pallagi út 13, 4042 Debrecen, Hungary Teva Pharmaceutical Works, Táncsics Mihály út 82, H-2 100 Gödöllo, Hungary Teva Kutno S.A., Sienkiewicza 25 str, 99 300 Kutno, Poland Gry-Pharma GmbH, Kandelstr.
Teva Pharma GmbH Kandelstr 10 D-79199 Kirchzarten Germany
TEVA Pharma - Produtos Farmacêuticos Lda Lagoas Park, Edifício 1, Piso 3, 2740-264 Porto Salvo, Portugal
Box 217, 3640 AE Mijdrecht, The Netherlands,
TEVA Santé Sa, Rue Bellocier, 89107, Sens, France
TEXT TO APPEAR ON THE ALUMINIUM FOIL WHICH IS USED FOR SEALING TRANSPARENT PLASTIC TRAY CONTAINING THE CARTRIDGE
- Abnormal hair texture, sun allergy, eczema, increased sweating, red-purple swelling on the legs,
(Mediterranean anaemia), sickle-cell anaemia.
Thalidomide Celgene is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4).
--------------------------------------------------------------------------------------------------------------------------- -- The following information is intended for medical or healthcare professionals only:
--------------------------------------------------------------------------------------------------------------------------- ------- The following information is intended for medical or healthcare professionals only:
< -------------------------------------------------------------------------------------------------------------------------- The following information is intended for medical or healthcare professionals only:
The Grange, 100 The High Street London, N14 6BN Verenigd Koninkrijk/Royaume-Uni/Vereinigtes Königreich Tel: +44 (0) 20 8447 8899 Email: sales@ecoanimalhealth .com
The Medicines Company UK Limited 115L Milton Park Abingdon Oxfordshire OX14 4SA UNITED KINGDOM
The Medicines Company UK Ltd 115L Milton Park Abingdon Oxfordshire OX14 4SA UNITED KINGDOM
Theophylline 250 mg SD (Indinavir 800 mg TID) ANTICOAGULANT
Theoretically, the effect of Botulinum neurotoxin may be potentiated by aminoglycoside antibiotics or other medicinal products that interfere with neuromuscular transmission e. g. tubocurarine-type muscle relaxants.
Theoretically, overdose can cause significant inhibition of both MAO-A and MAO-B.
or unwanted side effects of these medicines might be increased.
unwanted side effects of these medicines may be increased.
13 increased in an approximately dose proportional fashion from 1 mg to 6 mg when a maximum of two blisters from either strength or their combination was administered.
ge Thiazides, glucocorticoids, thyroid hormones and beta-sympathomimetics, growth hormone and danazol.
thrombocytopaenia (1.3% vs 1.3%), anaemia (3.5% vs 3.6%)
thrombocytopenia, eosinophilia, pancytopenia and agranulocytosis, anemia, leucopenia.
Hypothyroidism§, hyperthyroidism§ Diabetes, aggravated diabetes
Severe (platelets less than 25 x 109/ l) in 25% of patients (8% of courses); moderate (platelets between 25.0 and 50.0 x 109/ l) in 25% of patients (15% of courses).
Asthenia Injection site reactions including injection site pain and injection site inflammation1
Blood and lymphatic system
Over 8,000 patients (hip fracture – 1,711, hip replacement – 5,829, major knee surgery – 1,367) were studied in controlled
Thyrogen should only be administered into the buttock muscle.
Thyrotropin alfa stimulates thyroid tissue to take up iodine and produce thyroglobulin (Tg) and thyroid hormones (triiodothyronine (T3) and thyroxine (T4)).
Thyrogen (thyrotropin alfa) is indicated for pre-therapeutic stimulation in low risk (see section 5.1) post-thyroidectomy patients maintained on hormone suppression therapy (THST) for the ablation of thyroid remnant tissue (in combination) with 100 mCi (3.7 GBq) radioactive iodine (131I).
Thyrogen (thyrotropin alfa) is indicated for use with serum thyroglobulin (Tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post-thyroidectomy patients maintained on hormone suppression therapy (THST).
Tietgens Boulevard 40 DK-5220 Odense SØ Denmark Tlf: + 45 63 95 10 00
Tietgens Boulevard 40 DK-5220 Odense SØ Denmark Tlf: + 45 63 95 10 00
Tietgens Boulevard 40 DK-5220 Odense SØ Denmark Tlf: + 45 63 95 10 00
Tietgens Boulevard 40 DK-5220 Odense SØ Tlf: + 45 63 95 10 00
Tietgens Boulevard 40 DK-5220 Odense SØ Tlf: + 45 63 95 10 00
Tietgens Boulevard 40 DK-5220 Odense SØ Tlf: + 45 63 95 10 00
Tim Buxton completed articles with Touche Ross & Co in London in 1987.
Tipranavir/ ritonavir 500/ 200 mg BID
“ Pull here” (with Alert card attached)
“ Pull here” (with Alert card attached)
Pull out syringe plunger until the correct amount is withdrawn.
Pull out syringe plunger until the correct amount is withdrawn.
Pull the plum safety cap (labelled ‘2’) straight off to expose the plum coloured activation button at the top.
Titration in patients not switching from other fentanyl containing products The initial dose of Effentora should be 100 micrograms, titrating upwards as necessary through the range of available tablets strengths (100, 200, 400, 600, 800 micrograms).
Medicinal gases – pharmaceutical documentation
Omnipharm Ltd The Spire Egypt Road Nottingham NG7 7GD UK
Oral use Oral use Oral use Oral use Oral use Oral use
Marketing Authorisation Holder
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE no
10 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
11 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
12 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
13 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
14 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
20 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
28 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
42 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
44 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
46 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
8 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
9 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
9 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
82 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE AND MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE
Manufacturer for batch release:
Manufacturer for the batch release:
MANUFACTURING AUTHORISATION HOLDERRESPONSIBLE FOR BATCH RELEASE
Manufacturing Authorisation Holder responsible for batch release:
Manufacturing Authorisation Holder responsible for batch release:
Manufacturing Authorisation Holder responsible for batch release:
Manufacturer for batch release MERIAL Laboratory of Lyon Porte des Alpes Rue de l'Aviation, F-69800 Saint-Priest France
MERIAL Laboratory of Lyon Porte des Alpes Rue de l'Aviation, F-69800 Saint-Priest France
Manufacturing authorisation holder responsible for batch release MERIAL Laboratoire Porte des Alpes Rue de l'Aviation F-69800 Saint Priest France
Manufacturing authorisation holder responsible for batch release MERIAL Laboratoire Porte des Alpes Rue de l'Aviation F-69800 SAINT PRIEST FRANCE
MERIAL Laboratoire Porte des Alpes Rue de l'aviation F-69800 Saint-Priest France
MERIAL Laboratoire Porte des Alpes Rue de l'Aviation F-69800 Saint Priest France
MERIAL, Laboratoire Porte des Alpes, Rue de l'Aviation, F-69800 Saint Priest, France
Manufacturing authorisation holder responsible for batch release Merial Laboratoire Porte des Alpes Rue de l'Aviation F-69800 Saint Priest France
Name and address of the manufacturer responsible for batch release
Manufacturing Authorisation holder responsible for batch release Roche Pharma AG, Emil Barell Str.
MANUFACTURNG AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
Marketing Authorisation
Marketing Authorisation Holder
Marketing Authorisation Holder
Pfizer Limited Sandwich Kent CT13 9NJ United Kingdom
Pfizer Limited Sandwich Kent CT13 9NJ United Kingdom
MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION HOLDER
NAME OF THE MARKETING AUTHORISATION HOLDER a
Marketing Authorisation Holder AstraZeneca UK Limited Alderley Park Macclesfield Cheshire SK10 4TG United Kingdom
Marketing Authorisation Holder Axcan Pharma International B.V., Engelenkampstraat 72, NL -6131JJ Sittard, The Netherlands
22 Marketing authorization Holder BioMarin Europe Limited, 164 Shaftesbury Avenue London, WC2H 8HL United Kingdom
65 Marketing Authorisation Holder Boehringer Ingelheim International GmbH Binger Str.
73 Marketing Authorisation Holder Boehringer Ingelheim International GmbH Binger Str.
81 Marketing Authorisation Holder Boehringer Ingelheim International GmbH Binger Str.
Marketing Authorisation Holder Boehringer Ingelheim International GmbH Binger Str.
102 Marketing Authorisation Holder BRISTOL-MYERS SQUIBB PHARMA EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH - United Kingdom
109 Marketing Authorisation Holder BRISTOL-MYERS SQUIBB PHARMA EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH - United Kingdom
116 Marketing Authorisation Holder BRISTOL-MYERS SQUIBB PHARMA EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH - United Kingdom
123 Marketing Authorisation Holder BRISTOL-MYERS SQUIBB PHARMA EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH - United Kingdom
95 Marketing Authorisation Holder BRISTOL-MYERS SQUIBB PHARMA EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH - United Kingdom
BRISTOL-MYERS SQUIBB PHARMA EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH United Kingdom
Marketing Authorisation Holder BRISTOL-MYERS SQUIBB PHARMA EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH - United Kingdom
Marketing Authorisation Holder Celgene Europe Ltd Riverside House Riverside Walk Windsor SL4 1NA United Kingdom
Marketing Authorisation Holder Celgene Europe Ltd., Riverside House, Riverside Walk, Windsor, SL4 1NA, United Kingdom.
MARKETING AUTHORISATION HOLDER
Marketing Authorisation Holder CT Arzneimittel GmbH Lengeder Straße 42a D-13407 Berlin Germany info@ct-arzneimittel. de
MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION HOLDER
101 Marketing Authorisation Holder and Manufacturer
141 Marketing Authorisation Holder and Manufacturer
142 Marketing Authorisation Holder and Manufacturer
189 Marketing Authorisation Holder and Manufacturer
19 Marketing Authorisation Holder and Manufacturer
21 Marketing Authorisation Holder and Manufacturer
25 Marketing Authorisation Holder and Manufacturer
25 Marketing Authorisation Holder and Manufacturer
28 Marketing authorisation holder and manufacturer
304 Marketing Authorisation Holder and Manufacturer
30 Marketing Authorisation Holder and Manufacturer:
317 Marketing Authorisation Holder and Manufacturer
53 Marketing Authorisation Holder and Manufacturer
59 Marketing Authorisation Holder and Manufacturer
62 Marketing Authorisation Holder and Manufacturer
73 Marketing Authorisation Holder and Manufacturer
79 Marketing Authorisation Holder and Manufacturer
79 Marketing Authorisation Holder and Manufacturer
84 Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder and Manufacturer Allergan Pharmaceuticals Ireland Castlebar Road Westport Co.
Marketing Authorisation Holder and Manufacturer Allergan Pharmaceuticals Ireland Castlebar Road Westport Co.
Marketing Authorisation Holder and Manufacturer Howmedica International S. de R.
Marketing Authorisation Holder
MARKETING AUTHORISATION HOLDER
Marketing Authorisation Holder and Manufacturer
Marketing authorisation holder and manufacturer
Marketing Authorisation Holder and Manufacturer:
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder and Manufacturer:
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder and Manufacturer:
Marketing Authorisation Holder and Manufacturer
Marketing authorisation holder and manufacturer
Marketing authorisation holder and manufacturer:
Marketing authorisation Holder and Manufacturer
Marketing Authorisation holder and manufacturer
Marketing Authorisation Holder and Manufacturer:
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder and Manufacturer:
Marketing Authorisation Holder and Manufacturer:
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder and Manufacturer:
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder and Manufacturer:
Marketing Authorisation Holder and Manufacturer:
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder and Manufacturer
Marketing Authorization Holder and Manufacturer:
Marketing Authorization Holder and Manufacturer 201 Marketing Authorisation Holder:
Marketing Authorisation Holder and Manufacturer Merck KGaA, 64271 Darmstadt, Germany
Not all pack sizes may be marketed.
Marketing Authorisation Holder Novartis Vaccines and Diagnostics S. r. l. - Via Fiorentina, 1 – Siena, Italy.
Marketing Authorisation Holder and Manufacturer
The marketing authorisation holder and manufacturer:
Marketing Authorisation Holder and Manufacturer Orphan Europe SARL Immeuble “Le Wilson” F - 92058 Paris-La Défense France
Orphan Europe SARL Immeuble “ Le Wilson” F-92058 Paris La Défense - France
Marketing Authorisation Holder and Manufacturer SBL Vaccin AB, 105 21 Stockholm, Sweden.
Marketing Authorisation Holder and Manufacturer SCHWARZ PHARMA Ltd.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder and Manufacturer:
Marketing Authorisation Holder Teva Pharma B. V.
The marketing authorisation holder of REYATAZ is:
< This medicinal product is authorised in the Member States of the EEA under the following names: >
181 Marketing Authorisation Holder and Manufacturer
26 Marketing Authorisation Holder and Manufacturer
97 Marketing Authorisation Holder and Manufacturer
BRISTOL-MYERS SQUIBB PHARMA EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH United Kingdom
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park, Sanderson Road Uxbridge UB8 1DH United Kingdom
Marketing Authorisation Holder and Manufacturer
64 Marketing Authorisation Holder
Marketing Authorisation Holder
Marketing Authorisation Holder Ferring Pharmaceuticals A/ S Kay Fiskers Plads 11 2300 København S Denmark
Marketing authorisation holder Fort Dodge Animal Health C. J. van Houtenlaan 36 1381 CP Weesp The Netherlands
Fort Dodge Animal Health Holland C. J. van Houtenlaan 36 1381 CP Weesp The Netherlands
Fort Dodge Animal Health Holland C. J. van Houtenlaan 36 NL- 1381 CP Weesp The Netherlands
Fort Dodge Animal Health Holland C. J. van Houtenlaan 36 NL-1381 CP Weesp The Netherlands
Marketing authorisation holder Fort Dodge Animal Health Holland C. J. van Houtenlaan 36 NL- 1381 CP Weesp The Netherlands
Marketing authorisation holder Fort Dodge Animal Health Holland C. J. van Houtenlaan 36 NL-1381 CP Weesp The Netherlands
Marketing authorisation holder Genzyme Europe B.V., Gooimeer 10, NL-1411DD Naarden, The Netherlands.
Marketing authorisation Holder LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup, Denmark.
Marketing Authorisation holder:
Marketing Authorisation Holder
Marketing authorisation holder and manufacturer:
Marketing Authorisation Holder Orion Corporation
Marketing Authorisation Holder medac Gesellschaft für klinische Spezialpräparate mbH Fehlandtstraße 3 D-20354 Hamburg, Germany Tel. + 49 4103 8006 0 Fax: + 49 4103 8006 100
Marketing authorisation holder MERIAL 29 Avenue Tony Garnier 69007 Lyon, France
Marketing authorisation holder MERIAL 29, avenue Tony Garnier F-69007 Lyon France
Marketing authorisation holder MERIAL 29 avenue Tony Garnier F-69007 LYON France
Marketing authorisation holder MERIAL 29 avenue Tony Garnier F-69007 LYON FRANCE
MERIAL 29, avenue Tony Garnier F-69007 Lyon France
Not all pack-sizes may be marketed.
Marketing authorisation holder Novartis Sanidad Animal S. L.
MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION HOLDER lp
These elevations were dose related and were reversible in all patients.
Based on difference in crude events rates occurring over a median follow-up of 3.9 years.
Marketing Authorisation Holder Pierre Fabre Médicament 45, place Abel Gance F-92654 Boulogne-Billancourt cedex France
Manufacturing authorisation holders responsible for batch release:
Marketing Authorisation Holder Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom.
Marketing Authorisation Holder
Marketing Authorisation Holder Shire Pharmaceutical Contracts Limited Hampshire International Business Park Chineham, Basingstoke Hampshire RG24 8EP United Kingdom
Marketing Authorisation Holder Swedish Orphan International AB Drottninggatan 98 SE-111 60 Stockholm Sweden
Marketing Authorisation Holder Teva Generics GmbH Kandelstr.
Marketing Authorisation Holder Teva Pharma B. V.
Marketing Authorisation Holder Teva Pharma GmbH Kandelstrasse 10 D-79199 Kirchzarten Germany
The marketing authorisation holder is:
The Marketing Authorisation Holder is:
MARKETING AUTHORISATION HOLDER
128 Marketing Authorisation Holder
Succursale belge Chaussée de Waterloo 1135
MARKETING AUTHORISATION HOLDER MERIAL 29 avenue Tony Garnier 69007 LYON FRANCE
Marketing Authorisation Holders/ Applicants
is For subcutaneous or intravenous use.
tho One ampoule of Forcaltonin 100 IU contains 100 International Units (IU) corresponding to approximately 15 micrograms recombinant salmon calcitonin (produced by recombinant DNA technology in Escherichia coli) in 1 ml of an acetate buffer.
No clinical data on exposed pregnancies are available.
au This document is a summary of the European Public Assessment Report (EPAR).
is during use of Protopy ointment (see section 5.3).
Tobagi 7 IT-20068 Peschiera Borromeo – Milano Italy Tel: +39 (02) 516 861 Fax: +39 (02) 516 866 87
This medicine has been prescribed for you.
Re-administration of EXUBERA requires a careful risk evaluation, and may only be done under close medical monitoring with appropriate clinical facilities.
ho e) Magnitude of titration steps and resulting precautions f) The change in pulmonary function and the need for pulmonary function monitoring g) Smoking in relation to induced alteration in pharmacokinetics
The route of injection is the same as with r-HuEPO but your doctor will tell you how much you should take, and when, and may adjust your dose if necessary.
Renal impairment - Fondaparinux should not be used in patients with creatinine clearance < 20 ml/ min
Blood clotting can be a problem when blood flow is disturbed in any way.
The maintenance dose will be then decided by your doctor to maintain the level of your haemoglobin within the target range.
Survival and tumour progression have been examined in five large controlled studies involving a total ro
Pharmacovigilance Plan or risk minimisation activities
Cardiovascular safety: limited data exist with the use of CELSENTRI in patients with severe cardiovascular disease, therefore special caution should be exercised when treating these patients with CELSENTRI.
The efficacy and safety of fondaparinux have not been formally studied in patients with HIT type II. no
Hepatic safety: the safety and efficacy of CELSENTRI have not been specifically studied in patients with significant underlying liver disorders.
Intramuscular irritation has not been evaluated in animals following repeated administration to the same injection site.
• Local tolerance, contact sensitising and antigenicity potential
Tolerance Some loss of efficacy to the hypnotic effects of short-acting benzodiazepines and benzodiazepine-like agents may develop after repeated use for a few weeks.
of 2833 patients, of which four were double-blind placebo-controlled studies and one was an open- label study.
Survival and tumour progression have been examined in five large controlled studies involving a total ro
The preferred injection site for using the Nespo pre-filled pen is the front of the thigh.
37 Medicines should not be disposed of via wastewater or household waste.
Tacrolimus is extensively metabolised in the liver and although blood concentrations are low
please tell your doctor or pharmacist.
please tell your doctor or pharmacist.
A number of cleavage (hydrolysis) sites on the human insulin molecule have been proposed; none of the metabolites formed following the cleavage are active.
Some other medicines may affect the way that Quixidar works or be affected by Quixidar.
Fondaparinux should be used with caution in elderly patients (see section 4.2).
Topgen Esv E. Demunterlaan 1/ 8 B-1090 Brussels Belgium
A number of substances affect glucose metabolism and may require dose adjustment of insulin.
TopoTarget A/ S Fruebjergvej 3 DK-2100 Copenhagen Denmark Tel: +45 39 17 83 92 Fax: +45 39 17 94 92
TopoTarget A/ S Fruebjergvej 3 DK – 2100 Copenhagen Denmark
Please speak to your doctor immediately if you take EXUBERA and resume smoking or have smoked in the last 6 months before starting to take EXUBERA.
is Protopy should not be used in patients with congenital or acquired immunodeficiencies or in patients
tho 1 vial contains 10 ml equivalent to 400 IU
France 92 rue Baudin F-92300 Levallois-Perret
After subcutaneous administration of a single 40 mg dose, absorption and distribution of adalimumab uc
135 ed ris tho • Look at the expiry date on the syringe.
145 ed ris tho • Look at the expiry date on the syringe.
with 1 injection syringe, 2 injection needles and 1 cleansing swab.
Torbet Laboratories Limited 14D Wendover Road Rackheath Industrial Estate Norwich NR13 6LH United Kingdom
tho This document is a summary of the European Public Assessment Report (EPAR).
Each new injection should be given at least 3 cm from the last injection site.
In adult patients receiving interferon in combination with ribavirin, the achieved sustained response rate is 47%.
Women of childbearing potential are strongly recommended to use adequate contraception to prevent pregnancy and continue its use for at least five months after the last Trudexa treatment.
It is not known if rimonabant is excreted in human milk.
During use: do not refrigerate.
ed destruction were also decreased after Trudexa administration.
TORISEL must be given under the supervision of a doctor who has experience in the use of anticancer medicines.
TORISEL is a concentrate for infusion supplied with a diluent.
TORISEL has not been studied in patients undergoing haemodialysis.
and roll the vial between your hands.
in long-term clearance of the virus providing resolution of the hepatic infection and clinical'cure 'from uc
3 The vaccine will not prevent infection caused by other pathogens known to infect the liver such as hepatitis A, hepatitis C and hepatitis E virus.
tho This document is a summary of the European Public Assessment Report (EPAR).
response or were intolerant to infliximab were randomised to receive either 160 mg Trudexa at week 0 and 80 mg at week 2 or placebo at weeks 0 and 2.
The vaccine should never be given into a vein.
The HIB component of the vaccine does not protect against diseases due to capsular serotypes other
please tell your doctor or pharmacist.
ris < 30ml/ min) or patients with both severe renal impairment and co-existing hepatic impairment, as an optimal dosage format (600 mg) is not available.
Norge Aventis Pharma AS Tlf: +47 67 10 71 00
It is not known whether adalimumab passes into breast milk.
Because of the potential for adverse reactions in nursing infants, nursing should be discontinued prior to initiation of Me
response or were intolerant to infliximab were randomised to receive either 160 mg Trudexa at week 0 and 80 mg at week 2 or placebo at weeks 0 and 2.
Reconstitution of Viraferon, powder for solution for injection, for parenteral administration:
Torrent Farnell worked in internal medicine and clinical pharmacology in Spain and was Assistant Professor of Pharmacology at UAB.
Torrent i Farnell worked in internal medicine and clinical pharmacology in Spain and was Assistant Professor of Pharmacology at UAB.
Twisted neck (spasmodic torticollis) Usually, the first onset of effect is observed within seven days after injection.
Twisted neck (spasmodic torticollis) The following side effects were reported with Xeomin:
If you have any further questions on the use of this product ask your doctor or your pharmacist.
Stevens Johnson syndrome, toxic epidermal necrolysis,
Stevens Johnson syndrome, toxic epidermal necrolysis, erythema multiforme
Common torticollis (worsening from baseline), taste perversion
Any unused product must be discarded after withdrawal of the dose. no
Any unused product must be discarded after withdrawal of the dose. no
equal to 2 times baseline, Viraferon therapy may be continued unless signs and symptoms of liver failure are observed.
Your doctor will tell you how many Levviax tablets to take, at what time and for how long.
Shire Human Genetic Therapies AB
12 g/ dl (7.5 mmol/ l), the dosage adaptation described in section 4.2 should be closely respected, in ic
In patients with solid tumours or lymphoproliferative malignancies, if the haemoglobin value exceeds 12 g/ dl (7.5 mmol/ l), the dosage adaptation described in section 4.2 should be closely respected, in M
FORCALTONIN 100 IU solution for injection Recombinant salmon calcitonin
Total Pts with at least one AE Total number of AEs
Total EDTMP (as EDTMP. H2O) Calcium-EDTMP sodium salt (as Ca) Total sodium (as Na) Water for injections
Cholesterol levels should be periodically monitored.
Cholesterol levels should be periodically monitored.
is Any unused product or waste material should be disposed of in accordance with local requirements.
region of the eyelids and the lips (Quincke's oedema) and shock-like allergic reactions with symptoms of tingling, reddening, itching, hot flush and accelerated pulse.
Always pierce the stopper at its centre, within the marked area.
is Pre-filled syringe containing 10,000 IU per 0.5 ml dose (20,000 IU/ ml) of the active substance epoetin
is Pre-filled syringe containing 6,000 IU per 0.3 ml dose (20,000 IU/ ml) of the active substance epoetin
is Pre-filled syringe containing 8,000 IU per 0.4 ml dose (20,000 IU/ ml) of the active substance epoetin
Turn the nozzle to the open position The nozzle has two positions – locked and open.
Dial the Pen down to zero and prime the Pen again (see “Priming the Pen” steps 2 A-D).
Twist the cap to remove the tip seal (do not snap it off) leaving a hole through which the vaccine can be expelled.
All these cephalosporin antibiotics, including ceftiofur, kill bacteria by disrupting the building of the bacterial cell walls.
All of these effects subsided following discontinuation of VIRAMUNE.
Both patients were hospitalised and received prophylactic oral probenecid and vigorous hydration for 3 to 7 days.
All anaesthetic agents used for induction or maintenance of anaesthesia should be administered to effect.
- all other medicines to treat diabetes,
- all other medicines to treat diabetes,
- all other medicines to treat diabetes,
- all other medicines to treat diabetes,
All blisters in a box are the same size.
All blisters in a box are the same size.
All occurrences were asymptomatic and values above 2.5 fold ULN were not more frequent in the Raptiva group than in the placebo group.
All dogs received behavioural therapy and were treated either with Reconcile or with clomipramine (another medicine that can be used to treat dogs with separation-related disorders).
All dogs in a household should be treated.
All of the tablets contain the same dose of entacapone (200 mg).
Any unused container or waste materials should be disposed of in accordance with the local requirements.
All treatment cycles were administered at intervals of 3 weeks.
a) all initial cycles (number) b) full course (number) c) extension *
Waste materials should be disposed of in accordance with local requirements.
All subdomains of the HAQ were improved in patients treated with Enbrel compared to controls at 3 and 6 months.
All treatment-emergent adverse reactions considered possibly or probably related to Atripla reported in study AI266073 (over 48 weeks)
All adverse reactions have been rapidly reversible.
Numerically all of the components of the clinical composite endpoint were in favour of the PCI only regimen: death:
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with the local requirements
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with the local requirements.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
All known metabolites lack pharmacological activity.
All patients older than 13 years should take either 5 level scoops of the blue 5 gram spoon twice daily or 3 level scoops of the blue 5 gram spoon three times daily.
- All patients with PWS should have effective weight control before and during treatment with
10 BENCHMRK 1 and 2 Pooled Parameter
All patients† Baseline Characteristic‡
All patients were required to be on a stable dose of 6-MP, AZA or MTX (35% were also receiving corticosteroids at baseline).
All patients should have a baseline eye examination.
All patients should have a baseline eye examination.
All patients should be assessed at least once every two years.
All patients should have a baseline eye examination.
All patients must start therapy with a single 100 microgram sublingual tablet.
All patients should continue their diet with regular distribution of carbohydrate intake during the day.
Overweight patients should continue their energy -restricted diet.
- All patients should continue their diet with a regular distribution of carbohydrate intake during
All patients should continue their diet with an adequate distribution of carbohydrate intake during the day.
All patients must receive 20 mg of dexamethasone intravenously 30 minutes prior to Yondelis; not only as anti-emetic prophylaxis, but also because it appears to provide hepatoprotective effects.
Anti-emetic prophylaxis with dexamethasone must be administered to all patients (see section 4.2).
All patients should be pre-medicated with anticonvulsant medicinal products to prevent seizures reported with the use of high dose busulfan.
All patients should be administered a meningococcal vaccine at least two weeks prior to the first dose of Soliris (see section 4.4).
All patients were non-nucleoside reverse transcriptase inhibitor naïve.
All patients who did not have progressive disease were to receive CRT as per protocol (PF/ CRT).
All patients who did not have progressive disease were to receive chemoradiotherapy (CRT) as per protocol (TPF/ CRT).
Not all included patients were estimated to have a high risk for a first cardiovascular event.
All patients were followed for up to 76 weeks following first administration of study treatment.
All patients experienced a profound myelosuppression.
All patients were offered 1000 mg calcium per day and at least 400 IU vitamin D per day.
All patients received folate 1 mg bid.
All patients who develop a rash while taking Zonegran must be closely supervised, with additional levels of caution applied to those patients receiving concomitant antiepileptic agents that may independently induce skin rashes.
All patients receiving DepoCyte should be treated concurrently with corticosteroids (e. g., dexamethasone) to mitigate the symptoms of arachnoiditis.
All patients should have a baseline eye examination.
All patients should have a baseline eye examination.
All patients should have a baseline eye examination.
All patients should have a baseline eye examination.
should have a baseline eye examination.
All patients who were found to carry oseltamivir-resistant virus did so transiently, cleared the virus normally and showed no clinical deterioration.
All 12 signal evaluation reports should be provided, including those that were subsequently not identified as being signals.
All signal evaluation reports should be provided, including those that were subsequently not identified as being signals.
All signal evaluation reports should be provided, including those that were subsequently not identified as being signals.
Any unused product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Any unused veterinary medical product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with the local requirements.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Any unused veterinary product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with the local requirements.
All received 75 mg of 13C-urea, except 204 children under the age of 11 who received 45 mg.
Transferring a patient to a new type or brand of insulin should be done under strict medical supervision.
Transferring a patient to another type or brand of insulin should be done under strict medical ic
Transferring a patient to another type or brand of insulin should be done under strict medical supervision as this may result in a change in dosage. al
As well as the established working parties on Safety of Residues (see 4.3), Pharmacovigilance, Immunological and Quality (joint CVMP/ CPMP), the Efficacy Working Party was reconvened in 1997 as a result of the Committee's decision to review existing guidelines where justified, and to consider new topics where further guidance is required.
Any dispute arising between the parties to this contract and as a result of obligations under this contract shall be subject to the jurisdiction of the Court of First Instance of the European Communities.
Skin and eye contact should be avoided due to the potential for photosensitivity reactions upon exposure to light; use of rubber gloves and eye protection is recommended.
Any thyroid abnormality detected at that time must be treated with conventional therapy.
Any increase in 13CO2 will be measured by isotopic analysis.
- other circumstances arise that may promote an increased susceptibility to hypo- or
• any other condition in which bleeding might be especially dangerous or might occur at a site where it would be difficult to control
• have other tumours associated with an increased risk of bleeding
All gas cylinders should be returned to the supplier for disposal.
When during or after the treatment with ciprofloxacin or another fluoroquinolone severe and persistent diarrhoea occurs, pseudomembranous colitis must be taken into account (life-threatening with possibly fatal outcome).
A rise in haemoglobin of greater than 2 g/ dl (1.25 mmol/ l) over a four week period should be avoided.
Any Non-Bleeding Adverse Event
However, an ADI for penicillins was not established.
However, no antibody formation to the tenecteplase molecule has been observed.
These effects should however decrease over time.
These effects should however decrease over time.
These changes are, however, not considered to be clinically relevant.
These changes are not considered to be clinically relevant, however.
These changes are, however, not considered to be clinically relevant.
This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.
However, since no studies have been performed in lame birds, Dicural must not be used in birds with existing leg weakness or osteoporosis (brittle bones).
However, since this increase is within the normal variability of the bioavailability of ibandronic acid, no dose adjustment is considered necessary when Bondenza is administered with H2- antagonists or other active substances which increase gastric pH.
Nonetheless as stated in the 1998 objectives compliance with the deadlines laid down in the Regulations remains the major objective.
However, you should contact your doctor, nurse or pharmacist if this does happen.
However, you should contact your doctor, nurse or pharmacist if this does happen.
However, you should contact your doctor, nurse or pharmacist if this does happen.
However, you should contact your doctor, nurse or pharmacist if this does happen.
However, in some Member States (Czech Republic, Hungary, Italy, The Netherlands, Portugal and the United Kingdom) administration can be repeated after five days in the face of severe challenge.
However, in an interaction study with healthy volunteers, entacapone did not change the plasma levels of S-warfarin, while the AUC for R-warfarin increased on average by 18% [CI90 11– 26%].
However, in one study triglycerides tended to increased more when Cholestagel was given as a single dose with breakfast.
At higher doses, moderate changes in aPTT can occur.
However, rare spontaneous reports of aPTT prolongation have been received.
However, rare spontaneous reports of HIT in patients treated with fondaparinux have been received.
However, data suggested a 22% higher levetiracetam clearance in children taking enzyme- inducing antiepileptic medicinal products.
However, data suggested a 22% higher levetiracetam clearance in children taking enzyme- inducing antiepileptic medicinal products.
However, data suggested a 22% higher levetiracetam clearance in children taking enzyme- inducing antiepileptic medicinal products.
However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.
However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.
However, daily doses of up to 180 mg of lansoprazole have been administered in trials without significant undesirable effects.
Sensory neuropathy occurs frequently with Abraxane, although development of severe symptoms is less common.
Higher exposure for lansoprazole was also seen in newborns and babies up to an age of approx.
From a microbiological point of view, the product should be used immediately.
In case of overdose there is, however, a risk of parenchymatous hepatic and renal damage and of pancreatitis.
However, this finding is not clinically relevant as systemic exposure for both elderly and young subjects remained very low from ocular dosing.
However, this finding is not clinically relevant as systemic exposure for both elderly and young subjects remained very low from ocular dosing.
However, because the side effects of VISTIDE include kidney damage, it will be necessary to stop taking all other medications that may also cause kidney damage.
However, the consumption of alcohol is not compatible with the recommended dietary measures as a general rule.
However, patients must be cautioned to minimise exposure of treated areas to sunlight or other ultraviolet (UV) light (such as tanning lamps) (see section 5.3).
Tarceva has not been studied for its possible effects on the ability to drive and use machines but it is very unlikely that your treatment will affect this ability.
However, little information in patients over 75 years is available as only 3 patients over 75 years of age where included in the pharmacokinetic analysis.
Additional precautions Patients should be instructed never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of treatment.
However, male patients should be reminded that they must not share their medication with anyone, particularly not females.
However, there appears to be little benefit obtainable from injecting more than 5.0 U per site.
However, intranasal calcitonin has been administered at up to 1600 I. U. as a single dose and up to 800 I. U. per day for three days without causing any serious adverse event.
Nevertheless, renal oxygen consumption, and hence renal function, are preserved at mean arterial pressures above 40 mmHg.
However, the combination of SSRI treatment and alcohol is not advisable.
However, caution should be exercised when treating patients with a susceptibility to vitamin K or fat-soluble vitamin deficiencies, such as patients with malabsorption.
However, on-treatment HBV DNA response was not maintained off-therapy since all the patients had a rebound in HBV DNA after adefovir dipivoxil and pegylated interferon alpha-2a discontinuation.
However, the AUC of the M-2 metabolite was approximately 3% of the AUC of parent drug.
However, the second study showed that symptoms returned in 21% of the patients taking Thymanax over 24 weeks (34 out of 165), compared with 41% of the patients taking placebo (72 out of 174).
However, the second study showed that symptoms returned in 21% of the patients taking Valdoxan over 24 weeks (34 out of 165), compared with 41% of the patients taking placebo (72 out of 174).
The salmon calcitonin contained in Forcaltonin is not made by a conventional, chemical method but by genetic engineering. on However, the structure of the active substance of FORCALTONIN is the same as that of chemically synthesised salmon calcitonin.
However, the invasive ventilator-free survival was not recorded in the untreated historical cohort and a comparison of this endpoint is not possible.
However, the increase in these adverse reactions is not associated with an increased incidence of infections or haemorrhagic events.
However, the overall benefit was a 34% (95% CI:
The first time point where residues fell below their respective MRLs was 38 days in all injection site samples.
The first time point where residues fell below their respective MRLs was 80 days in all injection site samples.
However, shampooing or soaking the animal 2 or more hours after treatment will not reduce the efficacy of the product.
However, mineral oil should not be applied for at least two hours before or after the application of Panretin gel.
However, the number of abortions increased.
However, the major hydrolysis metabolite (LAY 151) can be removed by haemodialysis.
However, mineral oil must not be applied for at least two hours before or after the application of Panretin.
However, CYP3A4 inhibitors often also affect P-gp.
However, opioid analgesics impair the mental and/ or physical ability required for the performance of potentially dangerous tasks (e. g., driving a car or operating machinery).
However, patients found to have a documented fungal infection could be treated longer.
However, in vitro granulocyte function tests did not show significant changes when the sulesomab was added.
However, both the extent and the rate of topical absorption of tacrolimus decrease as the skin heals.
or the extent and the rate of topical absorption of tacrolimus decrease as the skin heals.
However, both the extent and the rate of topical absorption of tacrolimus decrease as the skin heals.
However, the clinical experience available in this patient population has not shown the necessity for any dosage adjustment.
27 smoking on olanzapine clearance and half-life is small in comparison to the overall variability between individuals.
Therefore the CHMP members recommended follow-up measures to further investigate the known cases and to initiate further studies
However, osteoporosis makes you more likely to break bones if you fall or hurt yourself.
However, osteoporosis makes you more likely to break bones if you fall or hurt yourself.
However, as a precaution, patients should be monitored for withdrawal syndrome.
However, as a general precautionary measure in the management of paediatric patients with transfusional iron overload, body weight, height and sexual development should be monitored at regular intervals (every 12 months).
146 You should consult your doctor if you have a rash, since some rashes may be serious; however, most cases of rash disappear without any change to your treatment with SUSTIVA.
155 You should consult your doctor if you have a rash, since some rashes may be serious; however, most cases of rash disappear without any change to your treatment with SUSTIVA.
164 You should consult your doctor if you have a rash, since some rashes may be serious; however, most cases of rash disappear without any change to your treatment with SUSTIVA.
You should consult your doctor if you have a rash, since some rashes may be serious; however, most cases of rash disappear without any change to your treatment with SUSTIVA.
If, however, the vaccine is given a few days before exposure, substantial protection may be afforded.
However, if necessary for patient compliance, an evening dosing may be considered.
However, a study in Parkinson's patients confirmed that after treatment discontinuation there was no significant change in levodopa pharmacokinetics or in patient response to levodopa compared to pretreatment levels.
However, a large part of the secretarial activities for breakout sessions and working parties are shared with the other sectors of the Unit.
However, hepatic disease with predominantly biliary damage, such as primary biliary cirrhosis, may show a different effect.
However, full protection against hepatitis B did not develop until the second dose of Ambirix had been given.
Nevertheless high quality secretarial support and project management for the co-ordination and follow- up of scientific advice will be ensured.
However, an increased rate of fused sternebrae was observed.
However, you should check with your doctor whether drinking alcohol is advisable for you.
Any spillage or waste material should be disposed of by incineration.
Any clinical fracture (1) Clinical vertebral fracture (2) Non-vertebral fracture (1) *p-value < 0.05, **p-value < 0.01
Pre existing hypertension should be adequately controlled before starting Avastin treatment.
Any material dislodged from the non-union site can cause bone formation (ectopic ossification) in the surrounding tissues with potential complications.
By continuously breathing the patient must pull out the straw and immediately close the breath bag with its stopper.
Any child with the onset of a limp during growth hormone therapy should be evaluated.
It is imperative that any dose re-titration of any analgesic is monitored by a health professional.
Holding the bottom ring, remove the entire pipette from the bottle.
Any person, in particular pregnant women, who are not taking Siklos should avoid to come in direct contact with the parts when breaking a tablet.
Everyone who takes Foscan will become sensitive to light for about 15 days after injection.
Use any eye ointment or eye gel last.
Discard unused portion.
Serious acute hypersensitivity (anaphylactic) reactions require immediate emergency treatment.
Readministration of riluzole to patients in this situation cannot be recommended.
Additional messages regarding the transition plan for replacement of ReFacto with ReFacto AF in the Member State(s)
Additional messages regarding the transition plan for replacement of ReFacto with ReFacto AF in the Member State(s).
All doses (n=147) 400 mg (n=73) 600 mg (n=74)
All concentrations of the combination of TnBP and Triton X-100 also tested negative in assays performed to determine mammalian cell mutageneicity, chromosomal aberrations and micronuclei induction.
All divergent opinions have been resolved.
All doses (n=147) 400 mg (n=73) 600 mg (n=74)
All studies were performed with Equilis Prequenza Te (comment: double; mentioned in next paragraph).
All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A (baseline factor VIII ≤ 2%).
All incidences of strictures were considered associated with treatment of which 1% was considered serious.
Horizontal familiarization between the organizations will be further strengthened, building on the positive experience obtained.
All histology findings were benign.
All treatment options should be considered without delay, including discontinuation of risperidone.
Not all pack sizes may be marketed.
Not all pack sizes may be marketed.
Not all pack sizes may be marketed.
Not all pack sizes may be marketed.
Not all pack sizes may be marketed.
Not all pack sizes may be marketed.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
*AUC 12 (ng.hr/ml) for ribavirin; AUC 0-24 (IU.hr/ml) for IntronA
11 Not all pack sizes may be marketed in all countries.
All packs sizes may not be marketed in all countries.
Not all pack sizes may be marketed in all countries.
Marketing Authorisation Holder and Manufacturer
Not all pack sizes may be available in all countries.
No t all pack sizes may be marketed.
Not all pack-sizes may be marketed.
Not all pack sizes may be marketed. a
Pack sizes of 1, 2 or 12 Not all pack sizes may be marketed.
Pack sizes of 6 Not all pack sizes may be marketed.
show three coloured rings (pink – red- red).
- The centre-dial made of coloured non-transparent polystyrene
However, not all pack sizes may be marketed in all countries.
Not all pack sizes may be marketed.
All packages except the 150 ml package are supplied with a measuring spoon marked for doses of 2.5 ml and 5 ml.
every three to four weeks to obtain IgG trough levels of at least 4–6 g/l
Any unused material after opening should be discarded.
- Any unusual tingling or numbness of the hands or feet, loss of feeling or difficulties with
• Freshly washed, but dry and cool (wait a few minutes after taking a hot bath or shower). • Free of body powder, lotion, and oil. • Free of cuts, rashes or any other skin irritation.
The entire content of the bottle should be used immediately after broaching and during the same procedure.
26 All items for preparation, administration or cleaning, including gloves, as well as liquid waste should be disposed of in accordance with local requirements.
All of the supplies you will need are in the PegIntron pack.
All items for administration or cleaning, including gloves, should be placed in high-risk, waste disposal bags for high-temperature incineration.
Any unused product or waste material should be disposed of in accordance with local requirements.
- Any medicine containing magnesium or aluminium such as antacids for indigestion, or any
Unused drug must be discarded and not used subsequently.
Any psychoactive medicinal product may impair judgment, thinking, and motor skills.
- any medicine that changes your blood pressure;
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Motion in the non-union site may disrupt the fracture healing process.
Any oxidant present in the sodium pertechnetate (99mTc) solution for injection might adversely affect the quality of the preparation.
Any patient with the onset of a limp or complaint of hip or knee pain should be evaluated.
Only one two-year course of Forsteo should be given to a patient in their lifetime.
Patients limping during treatment with somatropin, should be examined clinically.
Any patient complaining of ocular symptoms, including loss of visual acuity or visual field must have a prompt and complete eye examination.
Any patient complaining of changes in visual acuity or visual fields, or reporting other ophthalmologic symptoms during treatment with IntronA, must have a prompt and complete eye examination.
Any patient complaining of changes in visual acuity or visual fields, or reporting other ophthalmologic symptoms during treatment with Viraferon, must have a prompt and complete eye examination.
Any patient complaining of decrease or loss of vision must have a prompt and complete eye examination.
Any patient complaining of decrease or loss of vision must have a prompt and complete eye examination.
Any patient complaining of decrease or loss of vision must have a prompt and complete eye examination.
Any patient treated with bexarotene who experiences visual difficulties should have an appropriate ophthalmologic examination.
Any contrast medium solution left over in the bottle, the connecting tubes and all disposable parts of the injector system must be discarded within 8 hours.
Any contrast medium solution left over in the bottle, the connecting tubes and all disposable parts of the injector system must be discarded within 8 hours.
Any unused product or waste material should be disposed of in accordance with local requirements.
Any unused product should be disposed of in accordance with local requirements.
Any unused product or waste material should be disposed of in accordance with local requirements.
Any unused product or waste material should be disposed of in accordance with local requirements.
Any unused product or waste material should be disposed of in accordance with local requirements.
is Any unused product or waste material should be disposed of in accordance with local requirements.
Any unused product or waste material should be disposed of in accordance with local requirements.
Any unused product of waste material should be disposed of in accordance with local requirements.
Any unused product or waste material must be disposed of in accordance with local requirements.
Any unused product or waste material; should be disposed of in accordance with local requirements.
Any unusedproduct or waste material should be disposed of in accordance with local requirements.
Any unused vaccine or waste material should be disposed of in accordance with local requirements.
Date to which the bottle must be withdrawn:
is Any unused product or waste material should be disposed of in accordance with local requirements.
Any unused product or waste material should be disposed of, preferably by heat inactivation or incineration, in accordance with local requirements.
Waste materials should be disposed of in accordance with local requirements.
25 Any unused product, any items that come into contact with the product, and waste material must be disposed of in accordance with local requirements.
Any unused product, any items that come into contact with the product, and waste material must be disposed of in accordance with local requirements.
Before administration the Nespo solution should be inspected for visible particles.
If patients are switched from another fentanyl containing product, a new dose titration with Rapinyl is required.
Excess VISTIDE and all other materials used in the admixture preparation and administration
Previous treatment with anthracyclines may increase the risk of QT prolongation.
Raptiva treatment should be initiated by a doctor who specialises in dermatology (the treatment of skin conditions).
Treatment with Reyataz should be started by a doctor who has experience in the treatment of HIV infection.
Treatment with Stocrin should be started by a doctor who has experience in the management of HIV infection.
Treatment with Sustiva should be started by a doctor who has experience in the management of HIV infection.
Any agent which may enhance the risk of haemorrhage should be discontinued prior to initiation of desirudin therapy.
Any unused vaccine or waste material should be disposed of in accordance with local requirements.
Any unused vaccine or waste material should be disposed of in accordance with local requirements.
Any unused vaccine or waste material should be disposed of in accordance with local requirements.
Any unused vaccine or waste material should be disposed of in accordance with local requirements .”
All vaccines can be administered to infants with minor illnesses such as diarrhoea or mild upper-respiratory infection.
congestion, nasal oedema, pharyngolaryngeal pain, pneumonia aspiration, productive cough, pulmonary congestion, rales, respiratory disorder, respiratory tract congestion, rhinorrhoea, sinus congestion, sleep apnoea syndrome, wheezing
Cough Dysphonia Nasal dryness Dyspnoea exertional Nasal congestion Pleural effusion
The coughing is often accompanied by a “ whooping” sound, hence the common name “ whooping cough”.
Gastrointestinal disorders Very Common:
- cough, nasal symptoms (irritation, runny nose), high temperature
ut ra Cough - A cough may occur within seconds to minutes after inhaling EXUBERA.
TOVIAZ treats the symptoms of an overactive bladder such as • not being able to control when you empty your bladder (called urgency incontinence) • suddenly needing to empty your bladder (called urgency) • having to empty your bladder more than usual (called increased urinary frequency)
The IRU must be changed after accidental exposure to extremely moist conditions, e.g. steamy bathroom.
Acute (single-dose) toxicity Signs of oral toxicity in rodents were characteristic of potent antipsychotic compounds: hypoactivity, coma, tremors, clonic convulsions, salivation, and depressed weight gain.
Acute (single-dose) toxicity Signs of oral toxicity in rodents were characteristic of potent antipsychotic compounds: hypoactivity, coma, tremors, clonic convulsions, salivation, and depressed weight gain.
Acute (single-dose) toxicity Signs of oral toxicity in rodents were characteristic of potent neuroleptic compounds: hypoactivity, coma, tremors, clonic convulsions, salivation, and depressed weight gain.
Acute toxicity, toxicity on repeated injection, local tolerance, mutagenicity, antigenicity, human blood compatibility.
Cardiac toxicity Doxorubicin and other anthracyclines can cause cardiotoxicity.
Reproductive toxicity Olanzapine had no teratogenic effects.
15 Olanzapine had no teratogenic effects.
51 Reproductive toxicity Olanzapine had no teratogenic effects.
Reproductive toxicity Olanzapine had no teratogenic effects.
HAEMATOLOGICAL TOXICITY (ANC OR PLATELETS) – MANAGEMENT OF PATIENTS WITH BREAST OR OVARIAN CANCER
Toxicity Toxicity (%) (%)
Toxicity Toxicity (%) (%)
Toxicity Toxicity (%) (%)
Stevens Johnson syndrome, toxic epidermal necrolysis, erythema multiforme
(15 micrograms in 1.0 ml) of recombinant salmon calcitonin.
ed This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6. na
Cerebrovascular haemorrhage, cerbrovascular ischaemia, seizure, impaired consciousness, encephalopathy, neuropathy, polyneuropathy
Tremor, paresthesia, hypoesthesia, migraine, flushing, somnolence, taste perversion
In a large study, 1,071 patients were enrolled after treatment in a prior non pegylated interferon alfa-2b or non pegylated interferon alfa-2b/ ribavirin study to evaluate the durability of sustained virologic response and assess the impact of continued viral negativity on clinical outcomes.
Elimination The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
Amenorrhea, breast pain, dysmenorrhea, menorrhagia, menstrual disorder, vaginal disorder
Conjunctivitis, eye pain, abnormal vision, lacrimal gland disorder
5 ed Characteristics in patients There is a relationship between the subcutaneous dose of calcitonin and peak plasma concentrations.
lon In patients of 18 years and older:
Study 2 (P02080) was a randomized, single centre study that enrolled 95 previously untreated adult patients with chronic hepatitis C rod
Study 2 (P02080) was a randomized, single centre study that enrolled 95 previously untreated adult patients with chronic hepatitis C who were co-infected with HIV.
Urine levels of interferon were below the detection limit following each of the three routes of administration. lp
For subcutaneous, intramuscular or intravenous use. dic
indicator on the barrel. lon no
You should brush your teeth thoroughly twice daily and have regular dental examinations.
Cerebrovascular haemorrhage, cerbrovascular ischaemia, seizure, impaired consciousness, encephalopathy, neuropathy, polyneuropathy
Micturition frequency Renal failure, renal insufficiency, nephrotic syndrome
10 million IU/ ml powder and solvent for solution for injection 1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab t
Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease (see section 5.1).
Tracleer can also be used in patients with systemic sclerosis in whom poor blood circulation caused by the disease has led to the development of ‘ digital ulcers'(sores on the fingers and toes).
((Inside 1)) If you are a female patient of child bearing age read this page carefully Pregnancy Tracleer may harm the development of the foetus.
Tracleer reduces the number of new finger ulcers that appear.
Tracleer is intended to reduce the number of new digital ulcers that are formed.
Tractocile is used to delay birth in pregnant women who are at least 18 years of age, and who are 24 to 33 weeks pregnant, when they show signs that they may give birth pre-term (prematurely).
Patients with rare hereditary problems of galactose intolerance, of the Lapp lactase deficiency or of glucose-galactose malabsorption should not take this medicine.
Adjunctive treatment of homocystinuria, involving deficiencies or defects in: • cystathionine beta-synthase (CBS), • 5,10-methylene-tetrahydrofolate reductase (MTHFR), • cobalamin cofactor metabolism (cbl).
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis- agalactia syndrome) with appropriate antibiotic therapy.
- Long-term treatment of children with growth failure due to an inadequate secretion of normal
- Long-term treatment of children with growth failure due to inadequate endogenous growth
- have had Opgenra, eptotermin alfa or any similar medicine before.
therapy complete prior to the institution of growth hormone therapy.
Concurrent or prior treatment with immunosuppressants
105 Treatment in women Immune system disorders
treatment (potentially including initial parenteral treatment with ciprofloxacin) Cystic fibrosis
Concomitant therapy Timolol may interact with other medicinal products (see section 4.5).
Concomitant HMG CoA reductase inhibitors The risk of muscle damage may be increased in the event of combination with an HMG-CoA reductase inhibitor.
• Treatment of invasive candidiasis in adult or paediatric patients. • Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/ or itraconazole.
Treatment of invasive candidiasis Prophylaxis of Candida infection
Treatment of invasive candidiasis Treatment of oesophageal candidiasis Prophylaxis of Candida infection
Treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis sensitive to tulathromycin.
Treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis sensitive to tulathromycin.
Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response.
Treatment of Parkinson’s disease Patients not taking levodopa (early stage of Parkinson’s disease) You will start by using one Neupro 2 mg/24 h patch daily.
Treatment of narcolepsy with cataplexy in adult patients.
- Treatment of anaemia associated with chronic renal failure in paediatric and adult patients on
er Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and ng paediatric patients. lo Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. no
er Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and ng paediatric patients. lo Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. no
• Treatment of UA/ NSTEMI and STEMI - fondaparinux should not be used in patients with creatinine clearance < 20 ml/ min (see section 4.3).
- Treatment of short stature in children with Turner syndrome, confirmed by chromosome
Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see section 5.1).
Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see section 5.1).
Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see section 5.1).
Treatment of Porcine Proliferative Enteropathy caused by Lawsonia intracellularis.
Treatment of Porcine Proliferative Enteropathy caused by Lawsonia intracellularis in herds where there is a diagnosis based on clinical history, post-mortem findings and clinical pathology results.
Treatment of Porcine Proliferative Enteropathy (ileitis) caused by Lawsonia intracellularis in herds where there is a diagnosis based on clinical history, post-mortem findings and clinical pathology results.
Treatment of Porcine Proliferative Enteropathy (ileitis) caused by Lawsonia intracellularis in herds where there is a diagnosis based on clinical history, post-mortem findings and clinical pathology results.
Treatment of Porcine Proliferative Enteropathy (ileitis).
- Treatment of tumour-induced hypercalcaemia with or without metastases.
- Treatment of tumour-induced hypercalcaemia (TIH).
Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.
Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/ or gouty arthritis).
Incurin is indicated for the treatment of hormone-dependent urinary incontinence due to sphincter mechanism incompetence in female dogs.
- Treatment of inflammation in your oesophagus (reflux oesophagitis)
- Treatment of inflammation in your oesophagus (reflux oesophagitis)
Treatment of inflammation in your oesophagus (reflux oesophagitis): one 30 mg oro -dispersible tablet every day for 4 weeks
Treatment of inflammation in your oesophagus (reflux oesophagitis): one 30 mg capsule every day for 4 weeks
Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus with proteinuria > 0.5 g/ day as part of an antihypertensive treatment
“ Treatment of osteoporosis in men at increased risk of fracture.
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1).
Treatment of osteoporosis in men at increased risk of fracture.
Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).
Treatment of established post-menopausal osteoporosis in order to reduce the risk of vertebral fractures.
Treatment of osteoporosis in postmenopausal women at high risk of fractures (see section 5.1).
Treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1).
Treatment of postmenopausal osteoporosis in patients who are not receiving vitamin D supplementation and are at risk of vitamin D insufficiency.
Treatment of postmenopausal osteoporosis in patients at risk of vitamin D insufficiency.
Treatment of established post-menopausal osteoporosis in order to reduce the risk of vertebral fractures.
Treatment of osteoporosis • in post-menopausal women • in men at increased risk of fracture, including those with a recent low-trauma hip fracture.
Treatment of stomach ulcer: one 30 mg capsule every day for 4 weeks
of anaemia mentioned above.
Maintenance treatment: one vial of DepoCyte (50 mg) administered every 28 days for 4 doses (weeks 17, 21, 25 and 29).
As maintenance therapy in patients who have achieved objective remission (more than 50% reduction in myeloma protein) following initial induction chemotherapy.
Maintenance treatment in severe active Crohn's disease The efficacy of repeated infusions with infliximab was studied in a 1-year clinical study (ACCENT I).
Maintenance dose The usual effective maintenance dosage is 20 mg administered in a single daily dose.
Treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
First-line treatment of chronic lymphocytic leukaemia
- Treatment of prepubertal children with growth failure associated with chronic renal
- “ treatment of major depressive episodes”, with no inclusion of references to associated anxiety,
- “ treatment of major depressive episodes”, with no inclusion of references to associated anxiety,
• Treatment of infections in neutropenic patients
For the treatment of urinary tract infections associated with Escherichia coli.
(used to treat dyslipidaemia) or sulfinpyrazone (used to treat chronic gout).
For administration, the required volume of the reconstituted concentrate is added to a recommended compatible infusion solution (detailed below) to obtain a final voriconazole solution containing 0.5-5 mg/ ml.
Treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei)
Treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei).
Treatment of known or suspected cyanide poisoning.
Treatment of adult patients with Philadelphia chromosome or bcr/ abl translocation positive chronic myelogenous leukaemia.
Treatment of adult patients with Philadelphia chromosome or bcr/abl translocation positive chronic myelogenous leukaemia.
4.1 Therapeutic indications lon As an adjunct to diet and exercise for the treatment of obese patients (BMI ≥ 30 kg/ m2), or overweight patients (BMI > 27 kg/ m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1). no
Treatment of clinical outbreaks of Swine Dysentery in herds where the disease has been diagnosed, and prevention of further clinical cases.
Treatment of clinical outbreaks of Swine Dysentery in herds, where the disease has been diagnosed, and prevention of further clinical cases.
Treatment of clinical outbreaks of swine dysentery, caused by Brachyspira hyodysenteriae in herds where the disease has been diagnosed and prevention of further clinical cases.
Treatment of clinical outbreaks of Swine Dysentery in herds, caused by Brachyspira hyodysenteriae, where the disease has been diagnosed, and prevention of further clinical cases.
Treatment of Infantile Spasms (West's syndrome) Vigabatrin has been found to be an effective treatment for infants with infantile spasms.
Treatment of acute Deep Vein Thrombosis (DVT) and treatment of acute Pulmonary Embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.
Follow-up treatment: one vial of DepoCyte (50 mg) administered every 14 days for 3 doses (weeks 5, 7 and 9) followed by an additional dose at week 13.
- Treatment of duodenal and gastric ulcer confirmed by endoscopy or radiography
Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycemic control.
Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
- Treatment of growth retardation in pre-pubertal children with chronic renal insufficiency.
Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease- modifying antirheumatic drug therapy has been inadequate.
Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease- modifying antirheumatic drug therapy has been inadequate.
Treatment of Restless Legs Syndrome You will start by using one Neupro 1 mg/24 h patch daily.
- “ treatment of panic disorders with or without agoraphobia”, given that the data derived from the
Treatment of panic disorder, with or without agoraphobia.
Combination therapy with ribavirin in chronic hepatitis C In the case of combination therapy with Pegasys and ribavirin, please follow the dosing regimen recommended by your doctor.
Adjunctive therapy WITH valproate (inhibitor of lamotrigine glucuronidation – see section 4.5):
Simultaneous treatment with cardiotoxic substances (eg anthracyclines).
< 800,000 IU/ ml (Amplicor) who were treated for 24 weeks with a 6-month follow-up period. i
follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load < 800,000 IU/ ml (Amplicor) who were treated for 24 weeks with a 6-month follow-up period.
months after treatment.
Treatment and prevention of swine dysentery
For the treatment and prevention of swine dysentery.
The treatment and prevention of swine dysentery.
Treatment and prevention of Swine Dysentery.
Treatment and prevention of swine enzootic pneumonia.
Treatment and prevention of swine enzootic pneumonia
Treatment and prevention of Swine Enzootic Pneumonia.
Treatment and prevention of bacterial and mycoplasmal infections in cattle and pigs.
Treatment and prevention of bacterial and mycoplasmal infections in cattle.
Cattle Treatment and prevention of bovine respiratory disease associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis sensitive to tulathromycin.
Cattle Treatment and prevention of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis sensitive to tulathromycin.
Pigs Treatment and prevention of swine respiratory disease associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae and Haemophilus parasuis sensitive to tulathromycin.
Pigs Treatment and prevention of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, and Haemophilus parasuis sensitive to tulathromycin.
For Treatment and Prevention of Vomiting (except Motion Sickness)
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Start-up treatment: one vial of DepoCyte (50 mg) administered every 14 days for 2 doses (weeks 1 and 3).
Usual warning symptoms may disappear in patients with longstanding diabetes.
Intrathecal treatment of lymphomatous meningitis.
Treatment Elimination of the active substance and the restoration of stable cardiovascular conditions have priority.
24 Treatment or prevention of infections after a bone marrow transplantation (allogeneic bone marrow transplantation).
While fever may be associated with the flu-like syndrome reported commonly during interferon therapy, other causes of persistent fever must be ruled out. t uc
While fever may be associated with the flu-like syndrome reported commonly during interferon therapy, other causes of persistent fever must be ruled out. no
While fever may be associated with the flu-like syndrome reported commonly during interferon therapy, other causes of persistent fever must be ruled out. t uc
should be discontinued indefinitely.
Tacrolimus ointment does not affect collagen synthesis
Treatment with Protopy may be repeated if symptoms reappear.
Prophylaxis of reflux oesophagitis:
The lipid lowering effects of< (TRADENAME) > on total cholesterol and LDL-cholesterol are enhanced when combined with a bile acid-binding resin (e.g. cholestyramine, colestipol). < (TRADENAME) > should be given either one hour before or at least four hours after the resin (see section 4.5).
The lipid lowering effects of < (TRADENAME) > on total cholesterol and LDL-cholesterol are enhanced when combined with a bile acid-binding resin (e.g. cholestyramine, colestipol). < (TRADENAME) > should be given either one hour before or at least four hours after the resin (see section 4.5).
- Extracorporeal treatments leading to contact of blood with negatively charged surfaces (see
- Extracorporeal treatments leading to contact of blood with negatively charged surfaces (see
Replacement therapy in primary
Replacement therapy in primary immunodeficiency
Replacement therapy in secondary immunodeficiency
Secondary immunodeficiency
Replacement therapy in myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; replacement therapy in children with AIDS and recurrent infections.
For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.
For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.
For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.
Panretin gel is indicated for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma (KS) when:
Treated Major Bleeding Any bleeding
ischaemia (RI) within 9 days of randomisation.
Alanine amino- transferase increased, Aspartate amino- transferase increased
Transfer the Erbitux into the prepared infusion bag.
Transfer the Erbitux into a sterile evacuated container or bag.
10 Transfer the recommended dose to an infusion bag.
Transfer the solution back into the cartridge using the transfer set.
This is why the vaccine suspension should only be prepared as and when required.
Transfer the contents of the reconstituted 1 g vial of INVANZ to the 50 ml vial of sodium chloride 9 mg/ ml (0.9%) solution.
Transfer the contents of the reconstituted 1 g vial of INVANZ to the 50 ml vial of sodium chloride 9 mg/ ml (0.9%) solution.
Transfer BeneFIX solution into the tubing by depressing the syringe plunger until the tubing is filled completely.
- Transfer all of the dissolved solution back into the cartridge using
If necessary, plasma expanders and/ or blood transfusion may be used.
- the transmission of assessment reports, summaries of product characteristics, labels and package
4.3 Documentation and archiving
Transparency, communication and provision of information to patients, healthcare professionals and users of medicines
Kidney transplantation There is no experience regarding the administration of< COVERSYL and associated names > in patients with a recent kidney transplantation.
Transfer the solvent from the syringe to the vial by pushing the plunger in all the way.
Post-graduate work in cardiology and epidemiology at Erasmus University, Rotterdam.
TRAVATAN 40 micrograms/ ml eye drops, solution travoprost
TRAVATAN 40 micrograms/ ml eye drops, solution. travoprost
TRAVATAN 40 micrograms/ ml eye drops, solution Travoprost
Since TRAVATAN contains benzalkonium chloride, close monitoring is required with frequent or prolonged use.
TRAVATAN contains polyoxyethylene hydrogenated castor oil 40 which may cause skin reactions.
TRAVATAN contains benzalkonium chloride, which is known to discolour soft contact lenses.
TRAVATAN contains benzalkonium chloride which may cause irritation and is known to discolour soft contact lenses.
• TRAVATAN may increase the length, thickness, colour and/ or number of your eyelashes and may cause unusual hair growth on your eyelids.
TRAVATAN may gradually change the eye colour by increasing the number of melanosomes (pigment granules) in melanocytes.
Note for guidance on dry powder inhalers
Patients with rare hereditary problems of galactose intolerance, of the Lapp lactase deficiency or of glucose-galactose malabsorption should not take this medicine.
- 17.12.1999 - 16.11.2000 - 197 days - 159 days
Treatment of advanced idiopathic Parkinson’s disease with severe motor fluctuations and not responding to oral treatment
Treatment of N-acetylglutamate synthetase (NAGS) deficiency
Treatment of emphysema secondary to congenital alpha-1- antitrypsin deficiency
Treatment of emphysema secondary to congenital alpha 1- antitrypsin deficieny
Treatment of Familial Adenomatous Polyposis (FAP)
Treatment of glycogen storage disease type II (Pompe’s disease)
Treatment of tyrosinaemia type 1
Treatment of high-grade dysplasia in Barrett’s Esophagus
Treatment of Mucopolysaccharidosis type II
Acetyl isovaleryl tylosin tartrate
Commission - Opinion received - Date of Designation
Treatment of pulmonary arterial hypertension and chronic
Treatment of Severe Combined Immunodeficiency (SCID)-Xl Disease
● Tredaptive (1000 mg/ 20 mg to 2000 mg/ 40 mg at week 5) ▲ Nicotinic acid (prolonged-release 1000 mg to 2000 mg at week 5) ○ Placebo *Includes patients with moderate, severe, or extreme flushing symptoms † Dose advancement at Week 5
Tredaptive Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure, indicating little relevance to human use.
Tredaptive should be used in patients in combination with HMG-CoA reductase inhibitors (statins), when the cholesterol lowering effect of HMG-CoA reductase inhibitor monotherapy is inadequate.
It does this by lowering the levels of total cholesterol, LDL cholesterol, fatty substances called triglycerides and apo B (a part of LDL) in the blood; • to raise levels of ‘ good'cholesterol (HDL cholesterol) and apo A-I (a part of HDL).
It can be used as monotherapy only in patients in whom HMG-CoA reductase inhibitors are considered inappropriate or not tolerated.
92 isolates previously characterised as efavirenz-resistant were also resistant to nevirapine and delavirdine.
Five of these NNRTI-resistant isolates were found to have K103N or a valine-to-
Thirteen isolates previously characterised as efavirenz-resistant were also resistant to nevirapine and delavirdine.
- Feeling shaky and fast or irregular heartbeat (palpitations).
- Feeling shaky and fast or irregular heartbeat (palpitations).
anaphylactic / anaphylactoid reaction (see section 4.4), hypersensitivity
Thirty-two percent of patients in the study had a viral strain with fewer than two NRTI substitutions.
Very common: asthenia, pain, oedema including peripheral and face
Very common: at least 1 in 10 patients or more Common: at least 1 in 100 and less than 1 in 10 patients Uncommon: at least 1 in 1000 and less than 1 in 100 patients
Very common Hot flushes, injection site pain and redness.
Skin flushes (facial or upper body).
Very common: headache Uncommon: dizziness
Very common: in at least 1 out of 10 patients treated Common: in at least 1 out of 100 and less than 1 out 10 patients treated Uncommon: in at least 1 out of 1000 and less than 1 out 100 patients treated Rare: in at least 1 out of 10,000 and less than 1 out 1000 patients treated
Very common: diarrhoea, nausea Common: vomiting, abdominal pain, elevated amylase including elevated pancreatic amylase, elevated serum lipase, dyspepsia
Frequency grouping Very common • Dyspnoea –usually mild and passes rapidly without treatment
Very common: blood methionine increased.
Very common • Elevation of liver transaminases (AST and ALT) and alkaline phosphatase
Very common • Allergic skin rash frequently associated with pruritus • Alopecia
Very common: conjunctival hyperaemia, ocular hyperaemia Common: punctate keratitis, anterior chamber cell, anterior chamber flare, eye pain, photophobia, eye discharge, ocular discomfort, eye irritation, abnormal sensation in eye, foreign body sensation in eyes, visual acuity reduced, vision blurred, dry eye, eye pruritus, lacrimation increased, erythaema of eyelid, eyelid oedema, eyelids pruritis, growth of eyelashes, iris hyperpigmentation, eyelash discolouration Uncommon: corneal erosion, iridocyclitis, iritis, uveitis, visual field defect, keratitis, anterior chamber inflammation, eye swelling, corneal staining, photopsia, blepharitis, conjunctival oedema, conjunctivitis allergic, conjunctival disorder, conjunctivitis, conjunctival follicles, hypoaesthesia eye, ectropion, keratoconjunctivitis sicca, madarosis, cataract, eye allergy, eyelid pain, eyelid disorder, eyelid margin crusting, scleral hyperaemia, asthenopia
Very common: fever Common: pain, chills, infused-vein complications
Very common Common Common Common Common Common
Very common Common Common Common Common
uncommon rare very rare
Very common: haemorrhageb General disorders and administration site conditions
Very common: • Infection of the throat or airways.
Psychiatric disorders Very common: irritability Uncommon: sleep disorder, crying
Very common: nausea Common: diarrhoea, stomatitis, vomiting, mouth ulceration, abdominal pain, glossitis, constipation, nausea and vomiting
Very common: superficial oedemac, fatigue, pyrexia Common: pain, asthenia, chest pain a
Very common: pancytopenia/ myelosuppression *, purpura Common: petechiae, haemorrhages *
Gastrointestinal disorders Very common: loss of appetite Common: diarrhoea, vomiting, abdominal pain, flatulence, regurgitation of food Uncommon: constipation
ed ♦ Very common (more than 1 per 10 doses of vaccine): • Pain, redness or swelling at the injection site • Fever (more than 37.5°C)
Like all medicines, Twinrix Paediatric can cause side effects, although not everybody gets them.
Side effects that may occur are the following:
♦ Very common (These may occur with 1 in 10 doses or more of the vaccine): • loss of appetite • irritability
Very common: low blood sugar Common: constipation
Very common: somnolence Common: amnesia, ataxia, convulsion, dizziness, headache, hyperkinesia, tremor, balance disorder, disturbance in attention, memory impairment.
For cetirizine very rare clinical data on exposed pregnancies are available.
Very rare*: bowel obstruction, bowel perforation, pseudomembranous colitis, ischemic colitis, mesenteric thrombosis, necrotising enterocolitis, oesophagitis, ascites, acute pancreatitis
Very rare: parosmia (impaired smell), anosmia (usually reversible after interruption), grand mal convulsion, abnormal (unstable) gait, intracranial hypertension, ataxia, hyperesthesia, hypertonia.
22/ 30 Common: musculoskeletal pain Uncommon: arthralgia
Disorders of the liver and gall-bladder Rare: yellowing of the skin or whites of the eyes (icterus), icterus due to a condition where the bile can not flow normally from the liver (cholestatic icterus) Very rare:
Very rare: parosmia (impaired smell), anosmia (usually reversible after interruption), grand mal convulsion, abnormal (unstable) gait, intracranial hypertension.
Very rare: vasculitis (petechiae, hemorrhagic bullae, papules, crust formation).
In many cases these changes have been within the normal range and values have returned to baseline levels during treatment.
Very commonly the treated skin may be slightly itchy.
Very Commonly the treated skin may be slightly itchy.
● Trevaclyn (1000 mg/ 20 mg to 2000 mg/ 40 mg at week 5) ▲ Nicotinic acid (prolonged-release 1000 mg to 2000 mg at week 5) ○ Placebo *Includes patients with moderate, severe, or extreme flushing symptoms † Dose advancement at Week 5
11 (-41.0%, -28.8%, -17.1% respectively), and TC (-29.6%, -24.9%, -9.1% respectively), as well as LDL-C: HDL-C (-57.1%, -39.8%, -31.2% respectively), non-HDL-C (-45.8%, -33.4%, -18.1% respectively), and TC: HDL-C (-43.0%, -28.0%, -24.9% respectively), and significantly increased HDL-C (27.5%, 6.0%, 23.4% respectively).
Trevaclyn Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure, indicating little relevance to human use.
Therefore, Trevaclyn should be used with caution in patients with or predisposed to gout.
Trevaclyn should be used in patients in combination with HMG-CoA reductase inhibitors (statins), when the cholesterol lowering effect of HMG-CoA reductase inhibitor monotherapy is inadequate.
It does this by lowering the levels of total cholesterol, LDL cholesterol, fatty substances called triglycerides and apo B (a part of LDL) in the blood; • to raise levels of ‘ good'cholesterol (HDL cholesterol) and apo A-I (a part of HDL).
Trevaclyn is used on its own only in patients who cannot take statins.
It can be used as monotherapy only in patients in whom HMG-CoA reductase inhibitors are considered inappropriate or not tolerated.
Triateckit, comprime sécable
hexamethyl-11-[[3,4,6- Porcine trideoxy-3- (dimethylamino)-ß-D- xylohexopyranosyl]oxy]- 1-oxa-6- azacyclopentadecan-15-on, expressed as tulathromycin equivalents
Trinity-Chiesi Pharmaceuticals Limited Cheadlw Royal Business Park Highfield, Cheadle SK8 3GY United Kingdom
Trinity Chiesi Pharmaceuticals Ltd Cheadle Royal Business Park Highfield, Cheadle Sk8 3gy United Kingdom
TRISENOX 1 mg/ ml, concentrate for solution for infusion Arsenic trioxide
TRISENOX 1 mg/ ml, concentrate for solution for infusion Arsenic trioxide Intravenous use
TRISENOX 1 mg/ ml, concentrate for solution for infusion
TRISENOX has been authorised under “ Exceptional Circumstances”.
Trisenox contains less than 1 mmol sodium (23 mg) per dose i.e. essentially ‘sodium-free’.
TRISENOX is indicated for induction of remission and consolidation in adult patients with relapsed/ refractory acute promyelocytic leukaemia (APL), characterised by the presence of the t(15; 17) translocation and/ or the presence of the Pro-Myelocytic Leukaemia/ Retinoic-Acid-Receptor- alpha (PML/ RAR-alpha) gene.
TRISENOX is used to treat adult patients with acute promyelocytic leukaemia (APL), a rare form of leukaemia (cancer of the white blood cells).
Magnesium trisilicate (sepiolite) (declared on labelling as carrier) Wheat feed flour Hydroxypropyl cellulose Non-fat soyabean powder
Magnesium trisilicate (sepiolite) (declared on labelling as carrier) Wheat feed flour Hydroxypropyl cellulose Non-fat soyabean powder Paraffin light liquid
Magnesium trisilicate (sepiolite) Wheat feed flour Hydroxypropyl cellulose Non-fat soyabean powder Paraffin light liquid
Tritace 1.25 mg tabletten/ comprimés/ Tabletten, Tritace 2.5 mg tabletten/ comprimés/ Tabletten, Tritace 5 mg tabletten/ comprimés/ Tabletten, Tritace 10 mg tabletten/ comprimés/ Tabletten, Tritace 10 mg capsules/ gellules/ Kapseln Ramace 1.25 mg tabletten/ comprimés/ Tabletten, Ramace 2.5 mg tabletten/ comprimés/ Tabletten, Ramace 5 mg tabletten/ comprimés/ Tabletten
Triatec 1.25 mg tabletter, Triatec 2.5 mg tabletter, Triatec 5 mg tabletter, Triatec 10 mg tabletter, Triatec Hope tabletter Triatec start tabletter Ramipril Winthrop 1.25 mg tabletter, Ramipril Winthrop 2.5 mg tabletter, Ramipril Winthrop 5 mg tabletter, Ramipril Winthrop 10 mg tabletter Pramace 1.25 mg tabletter, Pramace 2.5 mg tabletter, Pramace 5 mg tabletter, Pramace 10 mg tabletter, Pramace 10 mg kapslar
47 Tritace 2.5 mg tabletki, Tritace 5 mg tabletki, Tritace 10 mg tabletki
Tritace has been authorised in the EU since 1989, first in France and then in the following countries:
Tritace mite 1.25 mg tablet Tritace 2.5 mg tablet Tritace 5 mg tablet Tritace 10 mg tablet
Tritace can also be available in the EU and the EEA under other trade names:
Tritanrix HepB has been studied in six studies involving a total of 872 infants aged between seven and 20 weeks, all of whom received the vaccine.
When an infant is given the vaccine, the immune system recognises the parts of the bacteria and viruses contained in the vaccine as ‘ foreign'and makes antibodies against them.
Tritanrix HepB contains diphtheria (D), tetanus (T) toxoids, inactivated pertussis bacteria (Pw) and the purified major surface antigen of the hepatitis B virus (HBV), adsorbed on aluminium salts.
Tritanrix HepB should be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.
Tritanrix HepB is for deep intramuscular injection, preferably in the anterolateral thigh.
Tritanrix HepB is given by deep injection into a muscle, preferably the thigh.
Tritanrix HepB is contraindicated if the child has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis containing vaccine.
Tritanrix HepB is available in the following pack sizes:
Tritanrix HepB is indicated for active immunisation against diphtheria, tetanus, pertussis and hepatitis B (HBV) in infants from 6 weeks onwards (see section 4.2).
Tritanrix HepB is a white, slightly milky liquid presented in a glass vial for 2 doses (1 ml) or in a glass vial for 10 doses (5 ml).
Tritanrix HepB is a vaccine, which is available as a suspension for injection.
Tritanrix HepB is a vaccine used in children to prevent four diseases: diphtheria, tetanus (lockjaw), pertussis (whooping cough) and hepatitis B.
As Tritanrix HepB is not intended for use in adults, information on the safety of the vaccine when used during pregnancy or lactation is not available.
Tritanrix HepB can be mixed with the lyophilised Hib vaccine (Hiberix).
Tritanrix HepB – Suspension for injection Diphtheria (D), tetanus (T), pertussis (whole cell) (Pw) and hepatitis B (rDNA) (HBV) vaccine (adsorbed)
Tritanrix HepB – Suspension for injection Diphtheria (D), tetanus (T), pertussis (whole cell) (Pw) and hepatitis B (rDNA) (HBV) vaccine (adsorbed)
Tritanrix HepB suspension for injection Diphtheria (D), tetanus (T), pertussis (whole cell) (Pw) and hepatitis B (rDNA) (HBV) vaccine (adsorbed)
Tritanrix HepB suspension for injection, multidose Diphtheria (D), tetanus (T), pertussis (whole cell) (Pw) and hepatitis B (rDNA) (HBV) vaccine (adsorbed)
Tritanrix HepB – Suspension for injection DTPw-HBV vaccine I. M.
Tritace 2.5 Comb 2.5 mg/12.5 mg tabletki, Tritace 5 Comb 5 mg/25 mg tabletki
Tritazide 2.5 mg/12.5 mg tablete, Tritazide 5 mg/25 mg tablete
Tritace 2.5 Plus 2.5 mg/12.5 mg comprimate, Tritace 5 Plus 5 mg/25 mg comprimate
Tritazide 2.5 mg/12.5 mg tablety, Tritazide 5 mg/25 mg tablety
Tritazide 5 mg/25 mg tabletten/comprimés/Tabletten
Tritazide has been authorised in the EU since 1993, first in Germany and then in the following countries:
Tritazide contains Ramipril, a second-generation nonsulfhydryl angiotensin converting enzyme inhibitor (ACE-I), and Hydrochlorothiazide (HCTZ), a thiazide diuretic.
Tritazide can also be available in the EU and the EEA under other trade names:
Triple therapy with nucleosides/ nucleotides:
These symptoms usually resolve upon discontinuation of abacavir.
FIN-02240 Espoo/Esbo Puh/Tel: + 358 (0) 9 7518 4120
31 of the 91 patients in the Vc+M+P treatment group who received prophylactic anti-virals developed herpes zoster reactivation.
Three (3%) of the 91 patients in the Vc+M+P treatment group who received prophylactic antivirals developed herpes zoster reactivation.
A further 3 samples of your breath will then be taken 30 minutes later.
After lower limb perfusion, 3 to 6 litres should be used, and after upper limb perfusion, 1 to 2 litres.
Three further studies from the published scientific literature looked at the effects of adding MabThera to other types of chemotherapy in a total of 1,347 patients.
Three cases of pneumonia (1 serious) and 2 cases of herpes zoster (both non-serious) were reported.
Three dosage spoons of different measures are provided.
Three measuring spoons dispense 1 g, 150 mg and 100 mg of betaine anhydrous.
Three measuring spoons dispense 1 g, 150 mg and 100 mg of betaine anhydrous.
Three measuring spoons are provided which dispense either 100 mg, 150 mg or 1 g of betaine anhydrous.
Three dosing spoons are provided which dispense 0.95 g, 2.9 g or 8.6 g of sodium phenylbutyrate.
Three spoons (one small, one medium and one large) are included to measure your daily dose.
Effectiveness was measured by looking at the change in symptoms (severity, pain and disability) after four weeks, measured using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS).
of recommendations and proposals on initiatives to
Three of the six cardiovascular thromboembolic events in the placebo/ valdecoxib treatment group occurred during the placebo treatment period; these patients did not receive valdecoxib.
Three of the six identified metabolites are active (M-II, M-III, and M-IV).
Three doses, each of 0.5 ml, should be given with an interval of at least 1 month between doses.
Taking three separate 1 mg blisters delivers more insulin to your lungs than a single 3 mg blister does.
Three clinical trials were performed with Aldurazyme to assess its efficacy and safety.
There were three placebo-controlled clinical trials of IT ziconotide.
Three clinical studies were conducted in 1054 patients in an at-home setting to define the period of responsiveness to CIALIS.
Three clinical studies were conducted in 1054 patients in an at-home setting to define the period of responsiveness to CIALIS on demand.
Three clinical studies were conducted in 1054 patients in an at-home setting to define the period of responsiveness to tadalafil.
Three studies have compared the effectiveness of dosing Viracept twice and three times a day, in combination with stavudine and lamivudine in 635 patients.
Three large, international, open-label, non-controlled phase II studies were conducted in patients with Philadelphia chromosome positive (Ph+) CML in advanced, blast or accelerated phase disease, other Ph+ leukaemias or with CML in the chronic phase but failing prior interferon-alpha (IFN) therapy.
The third trimester of pregnancy and breast-feeding (see sections 4.6 and 5.3).
The third trimester of pregnancy and breast-feeding (see sections 4.6 and 5.3).
The third trimester of pregnancy and breast-feeding (see sections 4.6 and 5.3).
Three mechanisms are generally considered responsible for resistance to the macrolide class of compounds.
4'-hydroxy-lumiracoxib, 5-carboxy-lumiracoxib and 4'- hydroxy-5-carboxy-lumiracoxib.
Three metabolites have been identified in the plasma: the sulphone, 5-hydroxy lansoprazole and the sulphide.
15 hydroxy sulphone, 5-hydroxy sulphide and 5-hydroxy lansoprazole.
5-hydroxy sulphone, 5- hydroxy sulphide and 5-hydroxy lansoprazole.
Three metabolites have been identified in the plasma: the sulphone, 5-hydroxy lansoprazole and the sulphide.
Three inserts, each with two 43.7mm openings per insert must be used.
Three cirrhotic patients (out of 6) who received repeated oral administration of sodium phenylbutyrate (20 g/ day in three doses) showed sustained plasma levels of phenylacetate on the third day that were five times higher than those achieved after the first dose.
Three patients from the single institution study and 15 patients from the multicentre study had stem cell transplants after completing TRISENOX.
Three patients discontinued the studies prematurely due to adverse events considered as unrelated to study drug.
Three patients in clinical trials, and one patient in the special treatment program experienced symptoms after receiving Thyrogen doses higher than those recommended.
• Compliance with post authorisation obligations
Three referrals for five active substances were initiated in 1997, in accordance with Article 15a of the same Directive.
Renal failure, renal insufficiency, nephrotic syndrome
Micturition frequency Renal failure, renal insufficiency, nephrotic syndrome
Micturition disorder, Nocturia, Increased urinary frequency
Ejaculation disorder Ejaculation delayed Sexual dysfunction Gynaecologica l haemorrhage
- smell disorder (parosmia), loss of smell (anosmia, the smell usually returns after termination of
- disturbed control of own behaviour and actions (psychotic reactions which may progress to self-
121 -Increase in muscle tone, muscle weakness caused by an abnormal immune system response -Abnormal brain function, Parkinson-like symptoms, convulsion -Sleepiness during infusion
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Important information about some of the ingredients of VFEND:
Ear disorderc Tympanic membrane disorder Skin and subcutaneous tissue disorders Common:
Skin disorder (cracking, scab, crusting, excoriation, drainage, oozing), Rash (erythema, redness, scaling, irritation, dermatitis), Pruritus (itching, pruritus) Common:
- Problems with blood flow in the liver
disturbance in attention, dizziness, headache, somnolence
- Atrio-ventricular conduction defects
consciousness, fits and visual symptoms including visual loss (reversible posterior leukoencephalopathy)
Renal failure, renal insufficiency
Erectile dysfunction Ejaculation delayed, sexual dysfunction Amenorrhoea, breast discharge, breast pain, dysmenorrhoea, hypertrophy breast
Memory and psychomotor impairment Benzodiazepines and benzodiazepine-like agents may induce anterograde amnesia and psychomotor impairment.
Metabolism and nutrition disorders Very common: anorexia (which may be severe).
Disorders of the skin such as acne, cold sores, shingles, skin growth, hair loss, rash, itching.
Alopecia was observed in 90% of the patients treated with Abraxane.
28/ 30 Musculoskeletal disorders Common: musculoskeletal pain Uncommon: arthralgia
VFEND is mainly for use in seriously ill patients.
Abnormal ejaculation, amenorrhoea, breast enlargement, gynecomastia, impotence, menorrhagia
Abnormal ejaculation, breast enlargement, gynecomastia, impotence, menorrhagia
Abnormal ejaculation, breast enlargement, gynecomastia, impotence, menorrhagia
Abnormal ejaculation/ orgas m (males), Anorgasmia, Erectile dysfunction (impotence), Urination impaired (mostly hesitancy), Menstrual disorders associated with increased bleeding or increased irregular bleeding (e. g., menorrhagia, metrorrhagia), Pollakiuria
Abnormal ejaculation/ orgasm (males), Anorgasmia, Erectile dysfunction (impotence), Urination impaired (mostly hesitancy), Menstrual disorders associated with increased bleeding or increased irregular bleeding (e. g., menorrhagia, metrorrhagia), Pollakiuria
Abnormal ejaculation/ orgasm, impotence, menstrual cycle disorders
speech disorder, Neuroleptic Malignant Syndrome (NMS), grand mal convulsion
Urinary incontinence, dysuria Renal failure, oliguria Urinary retention
Urinary incontinence, dysuria Renal failure, oliguria Urinary retention
Problems with sense of smell Breathing difficulties Vomiting Hives (nettle-type rash) Skin rash Low blood pressure Allergy-like reaction
Ear and labyrinth disorders Not known: nerve deafness
Ear and labyrinth disorders Rare: ear pain.
Ear and labyrinth disorders Uncommon:
10 System Organ Class Ear and labyrinth disorders
Ear and labyrinth disorders
• Depressive disorders Depressive disorders or mood alterations with depressive symptoms have been reported in up to 10%, and suicidal ideation in up to 1%, of patients receiving rimonabant (see section 4.8).
or Depressive disorders or mood alterations with depressive symptoms have been reported in up to 10%, and suicidal ideation in up to 1%, of patients receiving rimonabant (see section 4.8).
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Gastrointestinal disorders: diarrhoea, dry mouth, dyspepsia, nausea, vomiting.
General Disorders and Administrative Site Conditions
confusional state, anxiety, insomnia
Metabolism and Nutrition disorders Psychiatric disorders
tumour lysis syndrome3, cytokine release syndrome3, serum sickness, anaphylaxis
Metabolism and nutrition disorders Vascular disorders
Impaired glucose tolerance, gout.
Metabolic acidosis, alkalosis, decreased appetite
General disorders and administration site conditions Very common:
Hypersensitivity Common:
Metabolism and Nutrition Disorders Common:
Metabolism and nutrition disorders: hyperglycaemia Nervous system disorders: headache, dizziness Cardiac disorders: tachycardia, Vascular disorders: hot flush, hypotension Gastrointestinal disorders: vomiting General disorders and administration site conditions: injection site reaction
Metabolism and nutrition disorders hypoglycaemia* *
Metformin and a a PPARγ Agent Sulfonylurea3 (pioglitazone)4
Anorexia, hyperglycaemia, hyperuricaemia, hypokalaemia, hyponatraemia
Hypercalcaemia and hypercalciuria.
Skin and subcutaneous disorders Rare:
Metabolism and nutrition disorders Very common: anorexia (which may be severe).
Peripheral neuropathy Cerebrovascular haemorrhage, cerbrovascular ischaemia, seizure, impaired consciousness, encephalopathy
21 Metabolism and nutrition disorders Very common:
Metabolism and nutrition disorders Vascular disorders
hypokalaemia, lipids increased, appetite disorders (including anorexia), hyperuricaemia
Serious cases of allergic vasculitis, often with purpura (bruises and red patches) of the extremities and extracutaneous involvement have been reported.
Sleeping problems including insomnia, blurred vision, vomiting, stomach pains, diarrhoea, anorexia, weakness, abnormal dreams, tiredness, feeling drunk, sleep paralysis, sleepiness, trembling, confusion/ disorientation, nightmares, sleep walking, bed wetting, sweating, depression, muscle cramps, swelling, fall, joint pain, cataplexy, balance disorder, disturbance in attention, disturbed sensitivity particularly to touch, abnormal touch sensation, sedation, anxiety, difficulty in falling asleep in the middle of the night, nervousness, urinary incontinence, shortness of breath, snoring
46 • Inflammation of the liver, yellowing of the skin and whites of the eyes
Immune system disorders6 allergic vasculitis hypersensitivity reactions7
Nervous system disorders: vertigo, paraesthesia, light-headedness, restlessness
PIOGLITAZONE IN COMBINATION THERAPY WITH SULPHONYLUREA
Leukocytopenia, thrombocytopenia
Gastrointestinal disorders: nausea, diarrhoea, dyspepsia, dry mouth.
Gastrointestinal disorders: nausea, vomiting.
shivering* Gastrointestinal disorders such as abdominal pain, diarrhoea or dyspepsia*
General disorders and administration site conditions Common:
18 General disorders and administration site conditions
21 General disorders and administration site conditions:
30 General disorders and administration site conditions
6 General disorders and administration site conditions
administration site
administration site conditions
General disorders and administration site conditions Immune system disorders Psychiatric disorders
General disorders and administration site conditions Immune system disorders Investigations Nervous system disorders Skin and subcutaneous tissue disorders
General disorders and administration site conditions
Application site burning, application site pruritus
Asthaenia, chills, face oedema, generalised oedema, pain, peripheral oedema.
General disorders and administration site condition: asthenia, peripheral oedema.
General disorders and administration site conditions: asthenia, peripheral oedema
4 Common Gastro-intestinal disorders: nausea, abdominal pain, pelvic pain Reproductive system and breast disorders: ovarian hyperstimulation syndrome, ovarian cyst, breast pain General disorders and administration site conditions: headache, somnolence, injection site reaction
General disorders and administration site conditions Weakness: uncommon Injection site pain (reaction): common Oedema (local or generalised): common (1% - 10% in children; 10% in adults)
General disorders and administration site conditions Common (1-10%):
and administration site conditions tiredness.
General disorders and administration site conditions Common: asthenia.
General disorders and administration site conditions Common: peripheral oedema
General disorders and administration site conditions:
General disorders and administration site conditions common:
General disorders common:
General disorders and administration site
General disorders and administration site conditions
General disorders and administration site conditions:
General disorders and administrative site conditions:
General disorders and administrative site conditions Very common Common
General disorders and Asthenia administration site conditions
General disorders and asthenia, peripheral oedema administration site conditions:
General disorders and administration site conditions oedema
General disorders and administration site conditions oedema
General disorders and administration site conditions Oedema
General disorders and administration site conditions Uncommon
General disorders and administration site conditions Uncommon
General disorders and administration site conditions Uncommon Investigations
Not known General disorders and administration site Uncommon Investigations
Not known General disorders and administration site Uncommon Not known Investigations
29 General disorders and administration site conditions Uncommon - Oedema Oedema may occur upon initiation of insulin therapy.
General disorders and administration site conditions Uncommon - Oedema Oedema may occur upon initiation of insulin therapy.
General disorders and administration site conditions Uncommon - Oedema Oedema may occur upon initiation of insulin therapy.
Renal insufficiency
Renal insufficiency
General disorders and administration site conditions Very common: pyrexia, asthenia, fatigue.
General disorders and administration site conditions: very common: fever (rectal ≥ 38°C), swelling, pain, rednesscommon: injection site reaction uncommon: fever (rectal > 39.5°C), malaise 12 • Post-marketing experience
women who used oestrogen + progestagen combined HRT (CEE + MPA), the
General disorders and administration site conditions
General Disorders Very Common and Administration Fatigue, Asthenia Site Conditions
17 General disorders and administration site conditions: asthenia, fatigue, malaise.
5 General disorders and administration site conditions: asthenia, fatigue, malaise.
General disorders and administration site conditions: asthenia, fatigue, malaise.
General disorders and administration site conditions Very common: erythema, * pain/ tenderness, * swelling* Common: haematoma, pruritus, warmth
General disorders and administration site conditions Very common: erythema, * pain/ tenderness, * swelling* Common: haematoma, pruritus, warmth
General disorders and administration site conditions
Common: asthenia, fatigue, feeling drunk, oedema peripheral
General disorders and administration site conditions Injury, poisoning and procedural complications
Blood and lymphatic system disorders Lymphadenopathy
2 Hepatic impairment No dosage adjustment is required in patients with hepatic impairment.
tinnitus, ear pain
Acute and chronic musculo-skeletal disorders.
Musculo-skeletal disorders: single subcutaneous injection.
Nervous disorders: somnolence, rapid involuntary movements of the eyes (nystagmus), personality disorder, vertigo.
Neurological disorders, such as encephalomyelitis, neuritis and Guillain Barré syndrome
Metabolism and Nutrition Disorders Psychiatric Disorders Nervous System Disorders
Eye disorders Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone.
Eye disorders Post-marketing reports of new-onset or worsening diabetic macular oedema with increased visual acuity have been reported with thiazolidinediones, including pioglitazone.
Nervous system disorders: dizziness Eye disorders: allergic conjunctivitis, cataract, eyelash darkening, increased iris pigmentation, blepharospasm, eyelid retraction, retinal haemorrhage, uveitis.
Eye disorders Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including rosiglitazone.
Eye disorders Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone.
Eye disorders Ear and labyrinth disorders
Eye disorders Ear and labyrinth disorders
Parathyroid disorder System disorders:
Psychiatric disorders Not known: irritability
Psychiatric disorders*:
Peyronie's disease.
Pancreatitis Rare:
Respiratory, Thoracic and Mediastinal Disorders
UNCOMMON Rhinorrhoea
Vascular Disorders incl. related Investigations
Vascular Flushing Disorders incl. related Investigations
- Blood disorders (e. g increased number of small blood particles called platelets, which may
Sexual dysfunction (delayed or absent ejaculation, anorgasmia), priapism, galactorrhoea.
Thromboembolic and other vascular disorders
- Pre-existing thyroid disease unless it can be controlled with conventional treatment;
79 Urinary disorders such as kidney problems or the urgent need to pass urine.
Urinary disorders such as kidney problems or the urgent need to pass urine.
Vascular disorders Not known: vasculitis
Vascular disorders Common: flushing Uncommon: hypertension
Vascular disorders Common: flushing Uncommon: hypertension
Vascular disorders: hypotension, cerebrovascular accident, claudication, Raynaud's phenomenon, cold hands and feet, palpitation.
Skin flushes (facial or upper body).
(TRS 673, 1992) † Or equivalent antigenic quantity determined by a suitable immunochemical method
INFORMATION FOR THE USER
Trudexa 40 mg solution for injection in pre-fill ed syringe with needleguard Adalimumab
Trudexa Pre-filled Pen 40 mg solution for injection in pre-filled pen Adalimumab
Trudexa 40 mg solution for injection in pre-filled pen
Trudexa has been studied both in rheumatoid arthritis and psoriatic arthritis patients taking Trudexa as rod
Trudexa has been studied both in rheumatoid arthritis and psoriatic arthritis patients taking Trudexa as uc
Trudexa has been studied both in rheumatoid arthritis and psoriatic arthritis patients taking Trudexa as uc
ge Trudexa was evaluated in over 3000 patients in all rheumatoid arthritis clinical trials.
Trudexa 40 mg every other week was assessed in 393 patients in two randomised, 24 week double− blind, placebo− controlled studies in patients with active ankylosing spondylitis (mean t
ge administration by a caregiver, with 1 alcohol pad.
Trudexa is also available as a vial or a pre-filled pen.
Trudexa is intended for treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Trudexa can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. rod
Trudexa has been shown to reduce the rate of progression of joint damage as measured by X-ray and rod
Trudexa can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents rod
Truvada is a treatment for Human Immunodeficiency Virus (HIV) infection in adults over 18 years of age.
Thiazides, glucocorticoids, thyroid hormones and beta-sympathomimetics, growth hormone and danazol.
Thiazides, glucocorticoids, thyroid hormones and beta-sympathomimetics, growth hormone and danazol. lon Beta-blocking agents may mask the symptoms of hypoglycaemia and delay recovery from hypoglycaemia.
Staphylococcal bacteraemia Tuberculosis Bronchopneumonia Herpes ophthalmicus Beta haemolytic streptococcal infection Candidiasis Genital candidiasis Urinary tract infection Cystitis Body tinea
Staphylococcal bacteraemia Tuberculosis Bronchopneumonia Herpes ophthalmicus Beta haemolytic streptococcal infection Candidiasis Genital candidiasis Urinary tract infection Cystitis Body tinea Nasopharyngitis Rhinitis
tube (laminate) tube (laminate) tube (laminate) tube (laminate) tube (laminate) tube (laminate)
Advanced malignant hepatic tumours (see section 4.4).
Malignancy Immunomodulatory drugs may increase the risk of malignancy.
Blood and lymphatic system disorders
Malignancies In the placebo-controlled period of the psoriasis clinical studies, the incidence of malignancies excluding non-melanoma skin cancer was 0.25 per 100 patient-years of follow-up for ustekinumab-treated patients (1 patient in 406 patient-years of follow-up) compared with 0.57 for placebo-treated patients (1 patient in 177 patient-years of follow-up).
Malignancies Immunosuppressants like ustekinumab have the potential to increase the risk of malignancy.
Gastrointestinal Stromal Tumour (GIST) SUTENT is indicated for the treatment of unresectable and/ or metastatic malignant gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance.
Twinrix Paediatric is for intramuscular injection, preferably in the deltoid region in adolescents and children or in the anterolateral thigh in infants.
Active substance Tylvalosin (as Tylvalosin tartrate)
Tylvalosin (as tylvalosin tartrate)
Tylvalosin (as Tylvalosin tartrate)
Tylvalosin Tylvalosin (as Tylvalosin tartrate)
type 1 (Mahoney strain) 4 type 2 (MEF-1 strain) 4 type 3 (Saukett strain) 4
type 1 (Mahoney strain)4 type 2 (MEF-1 strain) 4 type 3 (Saukett strain) 4
type 1 (Mahoney strain)4 type 2 (MEF-1 strain)4 type 3 (Saukett strain)4
Characteristically, the cough is non- productive, persistent and resolves after discontinuation of therapy.
Characteristically, the cough is non- productive, persistent and resolves after discontinuation of therapy.
TYSABRI is indicated as a single disease modifying therapy in relapsing remitting multiple sclerosis to prevent relapses and delay progression of disability.
TYSABRI must not be mixed with other medicinal products except those mentioned in section 6.6.
Tyverb is also available in multipacks containing 140 tablets that comprise 2 packs, each containing 70 tablets.
ut 1 mg doses should not be used instead of one 3 mg dose because this gives a higher insulin dose and may increase the risk of hypoglycaemia.
paediatric and adult patients in the area under the curve from time 0 to infinity (AUC[0-∞]) was observed; however, this difference was less than the 2-fold range in AUC(0- ∞) observed for the ro
or to prevent clotting of the arterio-venous shunt.
ratios for overall survival ranged between 1.25 and 2.47 in favour of controls.
UCB-Group, Schwarz Pharma AG, Alfred-Nobel-Str.
UCB-Group, Schwarz Pharma AG., Alfred-Nobel-Str.
UCB Nordic A/ S (DK) Arne Jacobsens Allé 15 DK-2300 Kobenhavn S
In case PRCA is diagnosed, therapy with Nespo must be discontinued and patients should not be switched to another recombinant erythropoietic protein (see section 4.4).
When EXUBERA was administered to healthy volunteers following 2-hours of passive exposure to cigarette smoke in a controlled experimental setting, insulin AUC and Cmax were reduced by uc
Shire Pharmaceutical Contracts Ltd Hampshire International Business Park
Shire Pharmaceutical Contracts Ltd Hampshire International Business Park Chineham, Basingstoke Hampshire, RG24 8EP
Shire Pharmaceutical Contracts Ltd Hampshire International Business Park Chineham, Basingstoke Hampshire, RG24 8EP United Kingdom
pediatricpatients.
INH and INH washout N=158, 155, 143, 139, 123.
100 IU (International Units) of the active substance insulin human.
*IU=international units, a measurement specifying the amount of IL-2
Photosensitivity reaction, maculopapular rash, eczema, acne, skin
Ulceration Vesicle and sore formation Scaling
Corneal ulcerations have been reported very rarely in patients receiving Tarceva as a complication of mucocutaneous inflammation.
Duodenal, gastric, Nausea, acute oesophageal, pancreatitis, intestinal, and gastrointestinal colonic ulceration; haemorrhage, dysphagia, colitis/ colitis aggravated intestinal perforation; oesophagitis, melaena; pancreatitis
· recent bleeding into the brain (intracranial bleeding)
· recent bleeding into the brain (intracranial bleeding)
Infected skin ulcer Urinary tract infection Vascular disorders
- Ulcers (bleeding) in the stomach, gullet or intestines; or rupture of the intestine (can cause stomach
Painful erythema, oedema or ulcers and cannot eat
Painful erythema, oedema or ulcers but can eat.
In the future, the immune system will be able to make antibodies more quickly when it is exposed to the hepatitis B virus.
Ultratard 100 IU/ ml
Ultratard 100 IU/ ml Suspension for injection in a vial
Ultratard 40 IU/ ml
Ultratard 40 IU/ ml Suspension for injection in a vial
Ultratard has been studied in both type 1 and type 2 diabetes, and it has been compared to other types of insulin (porcine, human).
Ultratard was effective for both
Ultratard contains insulin mixed with another substance, zinc, in particles from which the insulin is absorbed much more slowly during the day; and this gives Ultratard a longer duration of action.
This means that it will start to lower your blood sugar about 4 hours after you take it, and the effect will last for approximately 28 hours.
Ultratard is a cloudy, white, aqueous suspension. lon 4.
What is Ultratard? ge lon Ultratard is an insulin suspension for injection.
UMAN BIG 180 180 IU/ ml I. E. / ml Injektionslösung
Eur. requirements, as well as reproducibility of quality characteristics, hence consistency of the biological response.
Pfizer Limited Ramsgate R oad Sandwich Kent CT13 9NJ
Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom
comparison showed that the pharmacokinetics of darbepoetin alfa were similar for paediatric and adult patients with CRF.
One to 18% of the injected dose of radioactivity appeared in the urine at 4 hours after injection.
A lowering of LDL-cholesterol of 27% was found with doses of 10mg simvastatin or 20mg lovastatin or 20mg pravastatin or 40mg fluvastatin or 0.2mg cerivastatin.
Greater emphasis will be placed on the quality of information documents (especially the summary of product characteristics and patient leaflets) during discussions with applicants.
For the constituted oral suspension:
Dosing adjustment is necessary in patients with moderate or severe renal impairment (see section 4.2).
16 Dosage adjustment may be necessary when transferring patients from one insulin preparation to another (see section 4.4).
23 Dosage adjustment may be necessary when transferring patients from one insulin preparation to another (see section 4.4).
2 Dosage adjustment may be necessary when transferring patients from one insulin preparation to another (see section 4.4).
30 Dosage adjustment may be necessary when transferring patients from one insulin preparation to another (see section 4.4).
37 Dosage adjustment may be necessary when transferring patients from one insulin preparation to another (see section 4.4).
9 Dosage adjustment may be necessary when transferring patients from one insulin preparation to another (see section 4.4).
Dosage adjustment may be necessary when transferring patients from one insulin preparation to another (see section 4.4).
Dosage adjustment may be necessary when transferring patients from one insulin preparation to another (see section 4.4).
Individual adjustment of dosage should be considered.
Individual adjustment of dosage should be considered.
Individual adjustment of dosage should be considered.
No dosage adjustment is necessary in patients with renal impairment whose renal creatinine clearance is ≥ 30 ml/ min (see sections 4.3 and 4.4).
CsA levels require progressive dose adjustment using therapeutic drug monitoring.
U Nákladového nádraž í 10 130 00 Praha3 Czech Republic Attn:
QT prolongation QT prolongation has very rarely been reported postmarketing.
At 1 year post-transplant 14 of 216 patients (6.5%) who received Zenapax and 4 of rod
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found in certain cells in the body.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found on certain cells in the body.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found in certain cells in the body.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found on certain cells in the body.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found in certain cells.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found on the surface of cells in the body.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) in the body.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found in the body.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found on certain cells in the body.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found in the body.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found in the body.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found in the body.
Patients should receive an antihistamine around 30 minutes before each dose of TORISEL.
2 Adequate calcium and vitamin D intake are recommended in association with Aclasta administration.
Adequate calcium and vitamin D intake are recommended in association with Aclasta administration.
Adequate calcium and vitamin D intake are recommended in association with Aclasta administration.
43 Agenerase oral solution contains vitamin E (46 IU/ ml), therefore additional vitamin E supplementation is not recommended.
Agenerase capsules contain vitamin E (109 IU/ 150 mg capsule), therefore additional vitamin E supplementation is not recommended.
Agenerase capsules contain vitamin E (36 IU/ 50 mg capsule), therefore additional vitamin E supplementation is not recommended.
A joint workshop organ- ised by the JRC, the Seville-based Institute for Prospective Technological Studies and the STOA group of the 2 Medicinal products for human use
An important workshop was held on pre-submission activities with potential applicants.
A multi-position autosampler and bar code reader should be used to allow samples to be tracked throughout the analysis.
A multi-position auto-sampler and bar code reader should be used to allow samples to be tracked throughout the analysis.
Another efficacy parameter was also defined: the proportion of patients who lost less than 30 letters (equivalent to 6 lines) of visual acuity at months 12 and 24 relative to baseline.
Another trial of calves aged from 24 to 48 hours demonstrated that Halocur can prevent diarrhoea due to Cryptosporidium parvum compared with placebo.
Another adverse reaction observed was leg cramps (5.5% for OPTRUMA, 1.9% for placebo in the prevention population and 9.2% for OPTRUMA, 6.0% for placebo in the treatment population).
3'-amino-3'- deoxythymidine (AMT) has been identified as a metabolite of zidovudine following intravenous dosing.
3'-amino-3'- deoxythymidine (AMT) has been identified as a metabolite of zidovudine following intravenous dosing.
Another patient accidentally received an overdose of the medicinal product (3000 mg instead of 1580 mg).
Another patient developed severe muscle cramps after taking Glivec 1,600 mg daily for six days.
A switch to a suitable alternative treatment should be carried out in advance of a planned pregnancy.
If symptoms persist or the condition is aggravated medical advice should be sought.
A positive opinion was adopted by y a majority of 19 out of 27 votes on 21 September 2006.
A positive opinion was adopted by consensus on 16 November 2006.
Spontaneous abortion was reported in 10.9% of exposed pregnancies.
10 A survival benefit of Tarceva was also observed in patients who did not achieve an objective tumour response (by RECIST).
25 A survival benefit of Tarceva was also observed in patients who did not achieve an objective tumour response (by RECIST).
40 A survival benefit of Tarceva was also observed in patients who did not achieve an objective tumour response (by RECIST).
• 0.75mg/kg body weight as an injection, followed immediately by an infusion of 1.75mg/kg body weight, per hour.
A recessed on-demand dosing button and red light are located on the top housing of the IONSYS system.
Building on the excellent relationships established in the past, efforts will continue to further opportunities with the key interested parties e.g.
One case of sleep apnoea was experienced during this study.
A case of peripheral neuropathy has been reported in a male after receiving four sets of injections of a conventional preparation containing the Botulinum toxin type A complex (for neck and back spasm, and severe pain) over an 11 week period.
Some pigs may also suffer oedema (swelling caused by fluid) or erythema (redness) on the hindquarters, and palpebral (eyelid) oedema.
A percentage of such pigs may also suffer oedema or erythema (posterior in distribution), and palpebral oedema.
A number of these products have been measured in the serum and cellular fractions of blood collected from patients treated with interferon beta-1b.
A number of these products have been measured in the serum and cellular fractions of blood collected from patients treated with interferon beta-1b.
A number of medicinal products are known to interact with glucose metabolism.
A number of medicinal products are known to interact with the glucose metabolism.
Data show that lamivudine and zidovudine penetrate the central nervous system (CNS) and reach the cerebrospinal fluid (CSF).
An up-to-date certificate of suitability should be provided for Rousselot Acid hide gelatin (European origin) II. E.
A clicking sound can be heard, which will stop when the injection button has been pressed in completely.
A clicking sound can be heard, which will stop when the injection button has been pressed. in completely.
A titration pack composed of four triple packs is available for the titration period and the patient 's initial treatment with Betaferon.
An independent expert panel determined that 41% (26/ 63) of patients receiving at least one dose of caspofungin had a favourable response.
1 tablet contains 200 mg sorafenib (as tosylate).
One film-coated tablet contains 40 mg of valsartan One capsule contains 40 mg of valsartan One film-coated tablet contains 80 mg of valsartan One capsule contains 80 mg of valsartan One film-coated tablet contains 160 mg of valsartan One capsule contains 160 mg of valsartan One film-coated tablet contains 320 mg of valsartan
The containers are fitted into plastic actuators incorporating an atomising mouthpiece and fitted with dustcaps.
A preservative in AZOPT (benzalkonium chloride) can affect soft lenses.
A preservative in AZOPT (benzalkonium chloride) may cause eye irritation and is also known to discolour soft contact lenses.
A preservative in OPATANOL (benzalkonium chloride) can affect soft lenses.
A preservative in EMADINE (benzalkonium chloride) may cause eye irritation and is known to discolour soft contact lenses.
A preservative in GANFORT (benzalkonium chloride) may cause eye irritation and is also known to discolour soft contact lenses.
A preservative in LUMIGAN called benzalkonium chloride may cause eye irritation and can discolour soft contact lenses.
Repeated dermal contact with masitinib may impair female fertility and foetal development.
Repeated dermal contact with masitinib may impair female fertility and foetal development.
A non- hormonal contraceptive must then be used concurrently for 7 days.
Adequate monitoring of serum potassium in patients at risk is recommended.
Glycaemic control should be monitored closely.
When warfarin or other oral anticoagulants are co-administered with Telzir a reinforced monitoring of INR (International normalised ratio) is recommended (see section 4.5).
Oral anticoagulants: a reinforced monitoring of the International Normalised Ratio is recommended in case of administration of Telzir with ritonavir with warfarin or other oral anticoagulants, due to a possible decrease or increase of their antithrombotic effect.
Glycaemic control should be monitored closely.
A coordinator from the EMEA and from the COMP is appointed for each application for designation.
A key secondary endpoint was the incidence of proven/ probable IFIs at 100 days post-randomization.
A key secondary endpoint was the incidence of proven/ probable IFIs during the on-treatment period (first dose to last dose of study medicinal product + 7 days).
Severe vitamin D deficiency may cause muscle weakness which can lead to falls and a greater risk of fractures.
A waiting time of 24 hours should be taken into account (see section 4.4).
Emollients should not be applied to the same area within 2 hours of applying Protopy ointment.
A white deposit and clear supernatant is observed upon storage of the oral applicator containing the solvent.
One of the medicines in Aerinaze, pseudoephedrine sulphate, has the potential to be abused and large doses of pseudoephedrine sulphate can be toxic.
A dose of 25 IU r-hLH daily (in combination with 150 IU follitropin alfa) resulted in insufficient follicular development.
Early diagnosis and immediate treatment are important to reduce the risk of disability.
The area of disagreement concerns the justification of the higher dose in the treatment of skin and associated soft tissue infections.
An accurate measuring device with suitable graduations should be used to ensure administration of the appropriate volume of solution.
A loop diuretic (e. g., furosemide) may then be used to further increase calcium excretion and to prevent volume overload, but thiazide diuretics should be avoided.
A qualified and experienced doctor or physician in the treatment of cancer will inject DepoCyte in the spinal fluid or lumber sac.
CK measurement should also be considered before starting treatment in persons over 70 years of age especially in the presence of other predisposing factors in this population.
A proconvulsant activity of rimonabant was found in one of two safety pharmacology studies.
rimonabant was found in one of two safety pharmacology studies.
Abacavir shows synergy in vitro in combination with nevirapine and zidovudine.
Rosiglitazone dose adjustment within the recommended posology or changes in diabetic treatment should be considered (see section 4.5).
Dose titration with rosiglitazone (added to the optimal dose of metformin) may be considered before the patient is switched to AVANDAMET.
No dose adjustment is necessary provided renal functions are normal.
From post marketing experience it appears that serotonin syndrome occurs very rarely in patients treated with Remeron alone (see section 4.8).
Dose modifications of zidovudine in this situation have not been formally evaluated.
It is recommended that dose adjustment of the benzodiazepine be considered during coadministration.
Long-term administration may be required to maintain the ANC > 2.0 x 109/ l.
Concomitant administration should be considered before the patient is switched to AVAGLIM.
- one administration of 140 mg/ m² melphalan (BuMel)
have an active malignancy or are undergoing treatment for a malignancy.
Disease exacerbations or infusion related events may indicate the development of antibodies against natalizumab.
Increased damage to tissue was noted.
Excessive shaking may aggregate pegfilgrastim, rendering it biologically inactive.
Excessive shaking may aggregate pegfilgrastim, rendering it biologically inactive. od
Excessive shaking may aggregate pegfilgrastim, rendering it biologically inactive. od
- a pen needle for subcutaneous injection.
A safety needle (SafetyGlide) for connection to the barrel is also provided.
Cross-allergenicity with sulphonylureas, sulphonamides or related substances is possible.
Complete alopecia related/ possibly related to topotecan administration was observed in 9% of patients and partial alopecia related/ possibly related to topotecan administration in 11% of patients.
Total or pronounced alopecia was observed in 30% of patients and partial alopecia in 15% of patients.
Deterioration of renal function may lead to a decrease in insulin requirements.
One of these patients experienced a minor transient change in renal function, while the other patient had no change in renal function (see section 4.4).
Clinically relevant improvement in these studies was defined a priori as at least 4-point improvement on the ADAS-Cog, improvement on the CIBIC-Plus, or at least a 10% improvement on the PDS.
Clinically relevant improvement was defined a priori as at least 4-point improvement on the ADAS- Cog, no worsening on the ADCS-CGIC, and no worsening on the ADCS-ADL.
Clinical studies with BYETTA have indicated improved beta-cell function, using measures such as the homeostasis model assessment for beta-cell function (HOMA-B) and the proinsulin to insulin ratio.
Improvement in liver function was also seen after one year of therapy
Improvement in liver function was also seen after one year of therapy.
Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
5.1 Pharmacodynamic properties
A 20% improvement in scores was seen in 48 to 52% of the patients using Neupro and in 19 to 30% of those using placebo.
Fast improvement in blood glucose control may cause disturbed sensation (numbness, weakness or pain) in legs or arms.
Fast improvement in blood glucose control may be associated with the condition “ acute painful neuropathy”, which is usually reversible.
Treatment with Thelin led to net improvement in NYHA functional class in 25% of patients (placebo 8%, p < 0.05).
A significant improvement in pruritus was observed within the first week of treatment in 44% of children and adolescents and in 70% of infants.
If your blood glucose levels improve very fast it may cause a burning, tingling or electric pain.
If your blood glucose levels improve very fast it may cause a burning, tingling or electric pain.
If your blood glucose levels improve very fast it may cause a burning, tingling or electric pain.
If your blood glucose levels improve very fast, you may get nerve related pain – this is called acute painful neuropathy and is usually transient.
If your blood glucose levels improve very fast, you may get nerve related pain – this is called acute painful neuropathy and is usually transient.
One ampoule contains 100 IU recombinant follicle-stimulating hormone (FSH) corresponding to 10 microgram of protein (specific in vivo bioactivity equal to approximately 10 000 IU FSH / mg protein).
One ampoule contains 150 IU recombinant follicle-stimulating hormone (FSH) corresponding to 15 microgram of protein (specific in vivo bioactivity equal to approximately 10 000 IU FSH / mg protein).
One ampoule contains 50 IU recombinant follicle-stimulating hormone (FSH) corresponding to 5 microgram of protein (specific in vivo bioactivity equal to approximately 10 000 IU FSH / mg protein).
One vial contains 75 IU recombinant follicle-stimulating hormone (FSH) corresponding to 7,5 microgram of protein (specific in vivo bioactivity equal to approximately 10 000 IU FSH / mg protein).
Each ampoule with 1 ml contains 10 micrograms iloprost.
Each ampoule with 1 ml contains 10 micrograms iloprost (as iloprost trometamol).
Each ampoule with 1 ml contains 10 micrograms iloprost (as iloprost trometamol).
Each ampoule with 2 ml contains 20 micrograms iloprost.
Each ampoule with 2 ml contains 20 micrograms iloprost (as iloprost trometamol).
1 ml water for Injections.
In 40 patients with PNH, a 1-compartmental model was used to estimate pharmacokinetic parameters after multiple doses.
A further analysis was carried out comparing patients with and without the ‘ YMDD mutation'(a change in the hepatitis B virus 's DNA that is often found after treatment with lamivudine).
An analysis has been developed for staff and operational expenses.
Furthermore, a separate analysis (not predefined) was performed after adjustment for baseline AER and centre, and only patients who attended the final visit were included in this analysis.
Final analysis was carried out on a total of 93 enrolled botulinum naive patients (46 in the NeuroBloc group) following a single injection, into 2 of 4 predetermined muscles.
In a post-hoc analysis, those patients with a baseline MRI with at least one Gd-enhancing lesion and nine T2 lesions had a two-year risk of suffering a second event of 56% in the placebo group and 21% in the AVONEX treatment group.
An additional analysis was conducted to determine vaccine efficacy against lesions likely to be causally associated with HPV-16 and/ or HPV-18.
Anencephaly and unilateral anophthalmia with secondary enlargement of the tongue were observed in one foetus, micro-ophthalmia was observed in another foetus, and cleft palate was observed in a third foetus.
Adequate anaesthesia and a broad-spectrum topical microbicide should be administered prior to the injection.
An approach based on the link between resources and objectives (‘management by objectives and activity-based budgeting’) has been attempted by the EMEA.
Arthralgia was reported in 32% of all patients (5% severe) and myalgia in 47% (6% severe).
Administrative and procedural assistance will be provided to SMEs by the dedicated SME Office within the Agency, which will become fully functional in 2006.
Circulatory support may be required.
Digestive system - diarrhoea and stomach upsets, vomiting, indigestion, difficulty swallowing or a change in taste, or a dry mouth.
If you have any of the above side effects, you should tell your doctor immediately.
20 oedema if patients report disturbances in visual acuity and appropriate ophthalmologic referral should be considered.
It is unclear whether or not there is a direct association between rosiglitazone and macular oedema but prescribers should be alert to the possibility of macular oedema if patients report disturbances in visual acuity and appropriate ophthalmologic referral should be considered.
This includes the ICH and the new VICH initiatives, and also the closer association of Iceland and Norway to the work of the EMEA.
Impaired fertility has been reported in rats exposed to pharmacological doses of follitropin alfa (≥ 40 IU/ kg/ day) for extended periods, through reduced fecundity.
Care should be taken to maintain adequate hydration in patients who develop diarrhoea or vomiting.
A particular attention should be also turned to the fastening of the pressure regulator so as to avoid the risks of accidental failures.
Caution must be exercised in the management and treatment of such patients by limitation or careful monitoring of antihistamine and other sedative medicinal product use.
Caution should be exercised in patients with pre-disposing factors for rhabdomyolysis.
Care should be exercised in patients with impaired renal function, due to lower renal excretion and probable increase in exposure to radioactivity.
Treatment with Aclasta resulted in an increase in BMD of 5.4% at the total hip and 4.3% at the femoral neck over 24 months as compared to placebo.
An increase to a dose greater than the recommended starting dose is advised only after appropriate clinical reassessment and should generally occur at intervals of not less than 24 hours.
An increase to a dose greater than the recommended starting dose is advised only after appropriate clinical reassessment and should generally occur at intervals of not less than 24 hours.
Since the orodispersible tablet is fragile, it should be taken immediately on opening the blister.
An approximately 2-fold increase in steady-state AUC is estimated in patients with severe hepatic impairment.
When a single 100 mg dose of sildenafil was administered with erythromycin, a specific CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).
This was compared with an increase of 2.6 points from 22.5 in the patients taking placebo.
There was an increase in digoxin Cmax (approximately 33%).
No dose adjustment required for Invirase/ritonavir.
Increase in dosage of probenecid or sulfinpyrazone may be necessary.
39 rosiglitazone dose may need to be increased.
The rosiglitazone dose may need to be increased.
An increase in the dose of a particular blood-thinning medicine (heparin) during haemodialysis is often needed during the course of therapy with Retacrit to minimize the risk of blood clotting.
An increase in the dose of a particular blood-thinning medicine (heparin) during haemodialysis is often needed during the course of therapy with Silapo to minimize the risk of blood clotting.
An increase in heparin dose during haemodialysis is frequently required during the course of therapy with erythropoietin as a result of the increased packed cell volume.
Increase in dosage of probenecid or sulfinpyrazone may be necessary.
Kidney patients – raised blood pressure which may require treatment with medicinal products or adjustment of the dosage of medicinal products you already take for high blood pressure.
4 Increased susceptibility to infection and the possible development of lymphoma and other malignancies, particularly of the skin, may result from immunosuppression (see section 4.8).
Increased susceptibility to infection and the possible development of lymphoma and other malignancies, particularly of the skin, may result from immunosuppression (see section 4.8).
There was a benefit in overall survival (OS) for Caelyx-treated patients over topotecan-treated patients as indicated by a hazard ratio (HR) of 1.216 (95% CI; 1.000, 1.478), p=0.050.
Race Increased systemic exposure has been seen in Japanese and Chinese subjects (see section 4.4 Special warnings and special precautions for use and section 5.2 Pharmacokinetic properties).
Increased deaths were observed when panitumumab was administered in combination with bevacizumab and chemotherapy combinations (see section 4.4).
As an increased incidence of thrombotic vascular events (TVEs) has been observed in cancer patients receiving erythropoiesis-stimulating agents (see section 4.8), this risk should be carefully weighed against the benefit to be derived from treatment (with epoetin alfa) particularly in cancer patients with an increased risk of thrombotic vascular events, such as obesity and patients with a prior history of TVEs (e. g. deep vein thrombosis or pulmonary embolism).
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse event reports of bone fracture from randomised, controlled, double blind clinical trials in over 8100 pioglitazone and 7400 comparator treated patients, on treatment for up to 3.5 years.
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse event reports of bone fracture from randomised, controlled, double blind clinical trials in over 8100 pioglitazone and 7400 comparator treated patients, on treatment for up to 3.5 years.
An increased incidence of hydroureter and/ or hydronephrosis was observed in rats given 2000 mg/ kg/ day in a fertility and general reproduction study, 1500 mg/ kg/ day in a teratology study, and 500, 1000, and 2000 mg/ kg/ day in a perinatal and postnatal study.
Weight gain ≥ 7% of baseline body weight was very common and ≥ 15% of baseline
Weight gain ≥ 7% of baseline body weight was very common and ≥ 15% of baseline body weight was common.
Weight gain 7% of baseline body weight was very common and 15% of baseline body weight was common.
- increased fatty acids (triglycerides), bilirubin or sugar levels in the blood
Increase of alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase and prothrombin levels have been reported.
A greater than dose-proportional increase in nelfinavir plasma concentrations was observed after single doses; however, this was not observed after multiple dosing.
Dose increases of indinavir/ ritonavir when given in combinatin with efavirenz have not been studied.
A more than 3-fold increase was seen in another 5 patients.
In patients with haemophilia Type A and B, there have been reports of increased bleeding while taking protease inhibitors.
There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses in haemophiliac patients type A and B treated with protease inhibitors.
There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophiliac patients type A and B treated with protease inhibitors.
Changes in total fasting cholesterol levels from borderline at baseline (≥ 5.17- < 6.2 mmol/ l) to high (≥ 6.2 mmol/ l) were very common.
Changes in total fasting cholesterol levels from borderline at baseline (5.17- < 6.2 mmol/ l) to high (6.2 mmol/ l) were very common.
Changes in total fasting cholesterol levels from borderline at baseline (≥ 5.17 - < 6.2 mmol) to high (≥ 6.2 mmol) were very common.
Changes in total fasting cholesterol levels from borderline at baseline (≥ 5.17 - < 6.2 mmol) to high (≥ 6.2 mmol) were very common.
Changes in total fasting cholesterol levels from borderline at baseline (≥ 5.17 - < 6.2 mmol) to high (≥ 6.2 mmol) were very common.
Changes in total fasting cholesterol levels from borderline at baseline (≥ 5.17- < 6.2 mmol) to high (≥ 6.2 mmol) were very common.
Changes in fasting glucose from borderline at baseline (≥ 5.56 - < 7 mmol/ l) to high (≥ 7 mmol/ l) were very common.
Changes in fasting glucose from borderline at baseline (≥ 5.56 - < 7 mmol/ l) to high (≥ 7 mmol/ l) were very common.
Changes in fasting glucose from borderline at baseline (≥ 5.56 - < 7 mmol/ l) to high (≥ 7 mmol/ l) were very common.
Changes in fasting glucose from borderline at baseline (≥ 5.56- < 7 mmol/ l) to high (≥ 7 mmol/ l) were very common.
Changes in fasting glucose from borderline at baseline (5.56 - < 7 mmol/ l) to high (7 mmol/ l) were very common.
• increased triglycerides (fatty acids), bile or sugar in the blood
• increased triglycerides (fatty acids), bile or sugar in the blood
- increased cardiac output and improved cardiac index.
Increase in dosage of probenecid or sulfinpyrazone may be necessary.
An increased relative risk for thromboembolic events was observed in the overall population (RR 1.62, 95% CI:
An increased relative risk of thromboembolic events (RR 1.67, 95% CI:
An increased relative risk of thromboembolic events (RR 1.67, 95% CI:
A mean increase in haemoglobin concentration of 0.26 g/ dl and a mean platelet count increase of 8.29 × 109/ l were observed.
Dose increase or reduction is recommended based on patient response and tolerability.
Dosage of methadone may need to be increased.
A slow increase in the dose may also improve gastrointestinal tolerability.
A slow increase of the dose may also improve gastrointestinal tolerability.
A slow increase of dose may improve gastrointestinal tolerability.
Significant increases in hip BMD (total, femoral neck, trochanter) were observed at study endpoint; 1.0, 1.8 and 1.0%, respectively, for Preotact versus -1.1, -0. 7 and -0.6% for placebo (p < 0.001).
A similar increase in BMD was seen in the treatment population who received OPTRUMA for up to 7 years.
A statistically significant increase in foetal malformations (misaligned sternabrae) was seen in litters of the OP-1 immunized group.
A statistically significant increase in foetal malformations (misaligned sternabrae) was seen in litters of the OP-1 immunized group.
A short transient increase in plasma testosterone may be seen immediately after implantation.
Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger – rarely causing the loss of a finger.
Diacomit has been given ‘ Conditional Approval’.
Intelence has been given ‘ Conditional Approval’.
Vectibix has been given ‘ Conditional Approval’.
Manufacturing Authorisation issued on 21 March 2001 by the Ministry of Health, Welfare and Sport, the Public Health Supervisory Service, Inspectorate of Health Care, P. O.
This medicinal product is authorised in the Member States of the EEA under the following names:
This medicinal product has been authorised under a so-called “ conditional approval” scheme.
This medicinal product has been authorised under a so-called “conditional approval” scheme.
This medicine has been given “conditional approval”.
This medicine has been given “conditional approval”.
Reyataz was originally authorised under ‘ Exceptional Circumstances’, because for scientific reasons it had not been possible to obtain complete information on the medicine.
Yondelis has been authorised under “ Exceptional Circumstances”.
Further analysis showed Trevaclyn (2000 mg/ 40 mg) co-administered with simvastatin when compared with simvastatin alone significantly increased apo A-I (8.6%, 2.3% respectively) and significantly decreased Lp(a) (-19.8%, 0.0% respectively).
Another study was also carried out 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Another study also compared the effectiveness of adding TRAVATAN to treat patients who were also receiving timolol (427 patients, 6-month duration).
A survey of 66 patients treated with Zavesca was also carried out.
Another study in juvenile mice (treated on postnatal days 4 to 21) has demonstrated that inhibition of the serotonin transporter had long lasting effects on the behaviour of the mice.
Another two-year carcinogenicity study was conducted in mice at oral doses up to 1,000 mg/ kg.
Another two-year carcinogenicity study was conducted in mice at oral doses up to 1000 mg/kg.
Another published study evaluated the efficacy and safety of indinavir/ ritonavir 400/ 100 mg every 12 hours in 40 antiretroviral-naïve patients.
Another randomised study included 66 patients on tacrolimus versus 67 patients on ciclosporin.
An additional study in 27 patients was used to show that Prometax capsules and oral solution produced similar levels of the active substance in the blood.
Further hydroxylation occurs prior to elimination.
Another initiative in 2002 will be the development of co-auditing between the internal audit teams and the financial control team.
Alternatively, the injection can be given at the end of the dialysis session via the fistula needle tubing, followed by 10 ml of isotonic saline to rinse the tubing and ensure satisfactory injection of the product into the circulation.
Reduced activity and lack of appetite in 10-20% of the animals may occur on the day of vaccination and/ or a transient swelling (max diameter:
Reduction in haemoglobin and platelets were less frequently (< 5%) reported.
- A significant fall in your red blood cell counts (anaemia),
A scientific memory database will be further developed as part of EMEA quality assurance.
Fosamprenavir was not mutagenic or genotoxic in a standard battery of in vitro and in vivo assays.
A box of Avonex Bioset has four doses of Avonex.
- one pack containing 50 vials of 2.5 ml suspension (antigen) for 10 doses
- one pack containing 50 vials of 2.5 ml suspension (active substance) for 10 doses
Insuman Infusat is supplied in cartridges containing 3.15 ml solution (315 IU).Pack of 5 cartridges of 3.15 ml is available.
Pack of 5 cartridges of 3.15 ml is available.
Good management and hygiene practices should be introduced in order to reduce the risk of re- infection.
Good management and hygiene practices should be introduced to reduce the risk of re-infection.
40 A healthy lifestyle will also help you to get the most benefit from your treatment.
48 A healthy lifestyle will also help you to get the most benefit from your treatment.
Bradycardia and hypothermia may accompany unconsciousness, as well as muscular hypotonia, but tendon reflexes remain intact.
Severe bradycardia should be treated symptomatically in a specialised environment.
Haemorrhagic cardiomyopathy was only observed in male mice and was considered to be secondary to severe coagulopathy mediated via the vitamin K pathway.
Patients taking Ferriprox, or their carers, must be given a reminder card that reminds the patient how to take the medicine safely.
There is also an Alert Card included in the Kivexa pack, to remind you and medical staff about abacavir hypersensitivity.
There is also an Alert Card included in the Trizivir pack, to remind you and medical staff about Trizivir hypersensitivity.
There is also an Alert Card included in the Ziagen pack, to remind you and medical staff about Ziagen hypersensitivity.
– Description of post injection syndrome – Recommendation for a 3-hour on-site observation period post injection – Recommendation that prior to giving the injection, the HCP should determine that the patient will not travel alone to their destination – Recommendation for informing patients that for the remainder of the day of the injection, they should not drive or operate machinery, should be vigilant for signs and symptoms of a post injection syndrome event, and should be able to obtain assistance if needed – Description of the most common symptoms reported with olanzapine overdose that represent the clinical manifestation in post injection syndrome events – Recommendation for appropriate monitoring until the event resolves if an event should occur
Patients who take Humira must be given the special alert card that summarises the safety information about the medicine.
Electrocardiograms must be obtained twice weekly, and more frequently for clinically unstable patients, during induction and consolidation.
Surgical resection was allowed following chemotherapy, before or after radiotherapy.
Doppler ultrasound measurements were performed with Luminity in conjunction with the pharmacokinetic evaluation of
Impaired healing following transplant surgery has been reported, including fascial dehiscence, incisional hernia, and anastomotic disruption (e. g. wound, vascular, airway, ureteral, biliary).
Approximately linear pharmacokinetics is observed at steady state in the population pharmacokinetic studies.
Liver cirrhosis may also affect the renal excretion of lepirudin.
Pseudomembranous colitis has been rarely reported including cases in patients who have not been concomitantly treated with antibiotics.
- an abnormal tube-like connection or passage between the windpipe and the gullet, or between
- A direct healthcare professional communication (DHPC) must be sent to all healthcare professionals
Comparison with intravenous data indicated an average bioavailability of about 50% at the recommended dose level of 1.0 mg/ kg/ wk subcutaneous.
There was a 41% risk reduction in hip fractures, when comparing all women taking Aclasta (with or without other osteoporosis medicines) with those taking placebo.
An administrative charge is made to cover handling, mailing and maintenance costs.
A maximum blood concentration of 0.8 ng/ml was measured in only 2 patients in week 6 of treatment.
Under the auspices of the World Health Organisation, a conference with national authorities of the new independent states of the former Soviet Union was held at the EMEA in October 1997, with representatives of the drug regulatory authorities of Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, the Russian Federation, Turkmenistan, Ukraine and Uzbekistan.
Consultation will be undertaken in 1997 and 1998 with consumers'and patients'organisations to improve the text of the package leaflets and to audit results.
Adequate contraceptive precautions should be used when either partner is receiving Busilvex.
A non-hormonal contraceptive must be used concurrently for the first 7 days of the new cycle only.
Oral antipsychotic supplementation should therefore be given during the first 3 weeks of RISPERDAL CONSTA treatment (see section 4.2).
Sufficient antipsychotic coverage should be ensured during the three-week lag period following the first RISPERDAL CONSTA injection (see section 5.2).
21 Sufficient antipsychotic coverage with oral risperidone or the previous antipsychotic should be ensured during the three-week lag period following the first RISPERDAL CONSTA injection (see section 5.2).
have inadequate skin coverage and vascularity at the site of spinal fusion;
A measuring spoon is provided with each bottle for measuring 2.5 and 5 ml doses of the oral suspension.
One measuring spoon of 1.5 g oral powder contains 50 mg of atazanavir (as sulphate).
One measuring spoon of 1.5 g of oral powder contains 50 mg atazanavir.
A measuring spoon is provided, marked for doses of 2.5 ml and 5 ml.
A measuring spoon or an oral measuring syringe is provided, marked for doses of 2.5 ml and 5 ml.
One medium sized spoon of AMMONAPS granules contains 360 mg of sodium.
One of these studies was designed specifically to evaluate the potential antiandrogenic effect of loratadine in male rat offspring.
A Decision was issued by the European Commission on 23 September 2008.
A Decision was issued by the European Commission on 3 September 2008.
A Decision was issued by the European Commission on 4 August 2006.
Deconjugation of glucuronidates in the intestine and subsequent reabsorption (enterohepatic recycling) is likely to occur.
A Request for Supplementary Information was adopted on 16 November 2006.
is of about 2-5 hours.
Flaking skin, peeling skin, scabs and tail sores with correlating histopathological changes were noted at doses ≥ 20 mg/kg/day (approximately 3 times human AUC
Flaking skin, peeling skin, scabs and tail sores with correlating histopathological changes were noted at doses ≥ 20 mg/kg/day (approximately 3 times human AUC exposure at the 100 mg dose).
The colour indicator of most CO2 absorbents does not necessarily change as a result of desiccation.
Treatment with Viani should not be stopped abruptly in patients with asthma due to risk of exacerbation.
Viani should be administered with caution in patients with severe cardiovascular disorders, including heart rhythm abnormalities, diabetes mellitus, untreated hypokalaemia or thyrotoxicosis.
- Difficulty breathing while asleep, called sleep apnoea, should be examined by a specialist.
Further dilution by a healthcare provider may be done.
A 10% reduction in the initial body weight was observed in 35% and 17% of patients, respectively.
Decreased gastric acidity due to lansoprazole increases gastric counts of bacteria normally present in the gastrointestinal tract.
Decreased gastric acidity due to lansoprazole might be expected to increase gastric counts of bacteria normally present in the gastrointestinal tract.
Decreased gastric acidity due to lansoprazole might be expected to increase gastric counts of bacteria normally present in the gastrointestinal tract.
A decrease in creatinine clearance down to 20 ml/ min may be associated with up to a 2.3-fold increase in pegaptanib AUC.
Elderly, cachectic, or debilitated patients may have a reduced clearance of fentanyl and, therefore, the active substance may have a prolonged terminal half-life in these patients.
An effect of abacavir is observed on zidovudine (Cmax reduced with 20%) and on lamivudine (Cmax reduced with 35%).
A decrease in plasma levels of amiodarone, when given as a single dose, has been observed in a limited number of healthy volunteers who received orlistat concomitantly.
Foetal growth restriction was apparent in animal studies with pioglitazone.
Shortening the treatment duration in patients infected with genotype 2 or 3 with HVL (> 800,000 IU/ mL) at baseline who become HCV negative by week 4 should be considered with more caution as this may significantly negatively impact the sustained virological response (see Table 1).
Shortening the treatment duration in patients infected with genotype 2 or 3 with HVL (> 800,000 IU/ mL) at baseline who become HCV negative by week 4 should be considered with more caution as this may significantly negatively impact the sustained virological response (see Table 1).
A decrease in blood pressure was observed in cyanide-poisoned patients.
Administration of exenatide has been shown to reduce food intake, due to decreased appetite and increased satiety.
Decreased milk production in nursing mothers has been reported with pseudoephedrine, a component of Aerinaze.
Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.
Virological response was first observed to decrease when the fold shift exceeded 2.3-fold; whereas virological benefit was not observed when the fold shift exceeded 12-fold.
Virological response was first observed to decrease when the fold shift exceeded 2.3-fold; whereas virological benefit was not observed when the fold shift exceeded 12-fold.
The calcium-lowering effect of calcitonin is caused both by a decrease in the efflux of calcium from rod
Reduced tolerance of docetaxel may occur, even at lower doses.
A reduction in haemoglobin concentrations by > 4 g/ dl was observed in 30% of patients treated with Ribavirin and peginterferon alfa-2b and 37% of patients treated with Ribavirin + interferon alfa-2b.
When amprenavir is combined with ritonavir, the effect of efavirenz is
Weight loss of 2.3 kg (2.6%) was achieved with BYETTA in the 26 week study and a loss of 2.5 kg (2.7%) in a 52-week study whereas treatment with insulin was associated with weight gain.
Inconsistent reduction in response to pertussis antigens as well as to inactivated polio vaccine (IPV) were observed.
A rapid decrease in CRP levels was also observed in patients with Crohn's disease.
A significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated (see section 5.1).
Another 4% had a transient decrease below the lower limit of normal.
Diplopia may develop as a result of Botulinum neurotoxin type A diffusion into the inferior oblique.
Diuresis or alkalisation of urine may not be useful due to high protein binding of valdecoxib.
A calculated dose of 451 mg to 499 mg should be rounded up to 500 mg corresponding to 5 tablets.
One dose contains approximately 1.1 g sodium.
A dose of 1.0 ml is recommended for adults and adolescents 16 years of age and above.
A dose of 1.0 ml is recommended for subjects from 1 year up to and including 15 years of age.
A 15 mg dose was also included in Study R076477-SCH-305, but results are not presented since this is above the maximum recommended daily dose of 12 mg.
A 1 mg blister of EXUBERA gives you abo ut the same insulin dose as 3 IU of subcutaneously
A 1 mg blister of inhaled insulin is approximately equivalent to 3 IU of subcutaneously injected fast- acting human insulin.
Approximate Guidelines for Initial, Pre-Meal EXUBERA Dose (based on patient
Approximate Guidelines for Initial, Pre-Meal EXUBERA Dose (based on patient lo
A dose of 2 mg/ kg sugammadex is recommended, if spontaneous recovery has occurred up to at least the reappearance of T2 following rocuronium or vecuronium induced blockade.
One dose of 2 ml by intramuscular injection to pigs of 18 weeks of age and older.
A dose of 3.0 ml is usually sufficient, but some patients may need higher doses.
A 3 mg blister of EXUBERA gives you about the same insulin
A dose of 4 mg/ kg sugammadex is recommended if recovery has reached at least 1-2 post-tetanic counts (PTC) following rocuronium or vecuronium induced blockade.
A lower starting dose (75 mg) should be considered for patients undergoing haemodialysis.
A lower starting dose (75 mg) should be considered for patients undergoing haemodialysis (see section 4.4).
One dose of IntronA is given on each scheduled day.
A double dose should not be taken on the next morning.
In patients between 12 months and 17 years of age, the dose depends on body surface area (calculated using the child 's height and weight).
The recommended start dose is 5 mg for patients of Japanese and Chinese ancestry.
A starting dose of 5 mg or lower is recommended in such patients.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Single intramuscular(IM) injection of one dose (1 ml) to pigs, irrespective of body weight.
Single intramuscular injection of one dose (1 ml), irrespective of body weight.
Single doses of 4.5g should not be given unless the patient has been titrated previously to that dose level.
There have been reports of muscle pain, tenderness, or weakness during treatment with ISENTRESS.
It may take up to 6 months for Herceptin to be removed from the body.
A duration of therapy less than 48 weeks has not been adequately studied.
A duration of therapy less than 48 weeks has not been adquately studied.
A duration of therapy less that 48 weeks has not been adequately studied.
The median observation period was 10 weeks.
A French national inquiry recorded 78 cases between 1985 and 1994.
- known or suspected necrotising enterocolitis;
A security label for re-sealing the kit is also provided.
A sticker explaining this is supplied with every pack of Cyanokit.
A sticker will be added to allow the patient to write the day of first use.
One study was carried out in diabetic men and another in post-prostatectomy patients (men who have had their prostate gland removed).
One study involved 20 patients who had already been taking Crixivan without ritonavir, and three involved a total of 123 patients who had not taken treatment for HIV infection before.
6 pharmacokinetics of Aldurazyme in patients less than 5 years old, but some efficacy measurements were included as well.
A study of trehalose, a major formulation excipient did not reveal any toxicities.
A study of patients showed that timolol did not dialyse readily.
A clinical study of institutionalised patients suffering from vitamin D deficiency indicated that a daily intake of two tablets of calcium 500 mg/vitamin D 400 IU for six months normalised the value of the 25-hydroxylated metabolite of vitamin D3 and reduced secondary hyperparathyroidism and alkaline phosphatases.
An additional monotherapy study was performed in 18 patients at a total daily dose of 150 mg, and results indicate reduced efficacy compared to a total daily dose of 300 mg.
In a study of Caucasians, Japanese, and Chinese subjects, there were no differences in the pharmacokinetic parameters among the three populations.
A study in juvenile mice has indicated that inhibition of the serotonin transporter prevents the accrual of bone formation.
A randomized double-blind placebo controlled study was conducted in 83 patients with FAP.
A three-year study of 2,027 patients who had at least one baseline vertebral (compression) fracture.
A three-year study with 2027 patients who had had at least one baseline vertebral (compression) fracture.
A long-term oral carcinogenicity study in mice showed a low incidence of duodenal tumours, considered likely related to high local concentrations in the gastrointestinal tract at a dose of 600 mg/ kg/ day.
A long-term oral carcinogenicity study in mice showed a low incidence of duodenal tumours, considered likely related to high local concentrations in the gastrointestinal tract at a dose of 600 mg/ kg/ day.
A long-term oral carcinogenicity study in mice showed a low incidence of duodenal tumours, considered likely related to high local concentrations of tenofovir disoproxil fumarate in the gastrointestinal tract at a dose of 600 mg/ kg/ day.
A carcinogenicity study with homologous erythropoietin in mice did not reveal any signs of proliferative or tumourigenic potential.
A two-year carcinogenicity study was conducted in rats at oral doses up to 900 mg/ kg (approximately 200 times human exposure at the maximum recommended dose).
A pre- and postnatal development study was performed in rats.
A fertility study in the rat has shown that abacavir had no effect on male or female fertility.
Phase I study evaluating the effect of capecitabine on the pharmacokinetics of docetaxel and vice versa showed no effect by capecitabine on the pharmacokinetics of docetaxel (Cmax and AUC) and no effect by docetaxel on the pharmacokinetics of a relevant capecitabine metabolite 5'-DFUR.
Higher doses of 5-ALA HCl enhanced the fluorescence quality and the fluorescence extent of the tumour core compared to demarcation of the tumour core under standard white illumination in a monotone, non-falling fashion.
A mass-balance study was done using 3H-iloprost in healthy subjects.
Furthermore, a EudraNet security study was completed in 2002 involving an analysis of requirements and a Public Key Infrastructure pilot with the European Commission (Directorate-General for Enterprise and the IDA programme).
A dermal sensitisation (maximisation test) and an antigenicity study in guinea pigs showed no sensitising potential.
A single and repeated dose oral toxicity study in mice suggests no special hazard to humans.
An interaction study based on data from 12 patients, assessing the effect of ketoconazole, a potent CYP3A4 inhibitor, showed a bortezomib AUC mean increase of 35% (CI90% [1.032 to 1.772]).
An interaction study assessing the effect of melphalan-prednisone on bortezomib showed a 17% increase in mean bortezomib AUC based on data from 21 patients.
An in vivo interaction study with cimetidine (non-specific cytochrome P450 inhibitor) has demonstrated a lack of a significant interaction.
P-gp potent inhibitors A single dose drug interaction study in healthy subjects has shown that ciclosporin (200 and 600 mg) increases Cmax of aliskiren 75 mg approximately 2.5-fold and AUC approximately 5-fold.
A single dose drug interaction study in healthy subjects has shown that ciclosporin (200 and 600 mg) increases Cmax of aliskiren 75 mg approximately 2.5-fold and AUC approximately 5-fold.
A single dose drug interaction study in healthy subjects has shown that ciclosporin (200 and 600 mg) increases Cmax of aliskiren 75 mg approximately 2.5-fold and AUC approximately 5-fold.
A four-year study with 4432 patients who had a low bone mass but had not had any vertebral fracture at the start of the study.
The plasma amprenavir pharmacokinetics were evaluated in a 14 day repeat-dose study in HIV-1 infected adult subjects with mild, moderate, or severe hepatic impairment receiving fosamprenavir with ritonavir compared to matched control subjects with normal hepatic function.
An ex vivo study using a term human placenta model demonstrated that stavudine reaches the foetal circulation by simple diffusion.
An ex vivo study using a term human placenta model demonstrated that stavudine reaches the foetal circulation by simple diffusion.
Frequent monitoring for adverse events and toxicity related to NSAIDs is recommended.
Standard doses of voriconazole and standard doses of efavirenz must not be coadministered.
An in vivo interaction study with warfarin indicated that rosiglitazone does not interact with CYP2C9 substrates in vivo.
An in vitro study with human liver tissue has shown no potential for drug interaction through inhibition of cytochrome P-450 enzymes by temoporfin.
After adjusting for differences in creatinine clearance and body weight, elderly subjects had a 12.5% higher AUC than young subjects. The population pharmacokinetic analysis covering patients in the age range 16-75 years did not identify age as significantly influencing entecavir pharmacokinetics.
A pivotal monotherapy study of memantine in the treatment of mild to moderate Alzheimer's disease (MMSE total scores at baseline of 10 to 22) included 403 patients.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer's disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14) included a total of 252 outpatients.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer's disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14) included a total of 252 outpatients.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer's disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14) included a total of 252 outpatients.
A pivotal monotherapy study of memantine in the treatment of mild to moderate Alzheimer's disease (MMSE total scores at baseline of 10 to 22) included 403 patients.
A study of 14C-docetaxel has been conducted in three cancer patients.
In a randomized placebo-controlled study in 160 healthy volunteers, inhaled doses of iloprost solution were given either with a fixed dose of 2.5 micrograms iloprost 6 times daily (total daily dose of 15 micrograms), or beginning with 5.0 microgram and increasing up to 20 micrograms, or the highest tolerated dose for a total of 6 dose inhalations (total daily dose of 70 micrograms).
European Commission Stefano MICOSSI Joaquim HEINE
A formal toxicologic and toxicokinetic interaction study in rats revealed no evidence that Kineret alters the toxicologic or pharmacokinetic profile of methotrexate.
A further study was also carried out in 15 female (carrier) patients.
Following careful benefit/ risk assessment, a decision should be made to discontinue either breast-feeding or treatment with Parareg.
A careful risk/ benefit assessment should be made, taking into consideration the liver toxicity of bosentan (see sections 4.4 and 4.8).
Some 322 MRL summary reports for old and new veterinary substances were completed by the end of 1997. • Another important initiative was the creation of a dedicated service within the EMEA to deal with the dissemination of information and publications.
- provision of further evaluation is given as laid down in Annex II
12 There have been literature reports alluding to possible increased absorption of aluminium with citrate salts.
An exception can be made if the doctor has expressly prescribed Fentanyl-ratiopharm.
A label extension to the indication “ Contrast-enhanced Magnetic resonance angiography” (CE-MRA) followed in November 2003.
A label extension to the indication “ Contrast-enhanced Magnetic resonance angiography” (CE-MRA) followed in November 2003.
A small amount of BYETTA will always remain in the cartridge.
A small quantity of pravastatin passes into the human breast milk.
A small amount of unstabilised tetrameric haemoglobin (< 5%) may be excreted through the kidneys, resulting in transient haemoglobinuria for < 4 hours.
The casing has a window for viewing the bottle contents.
One further change was seen which was not statistically significant (p > 0.05), but which did show a significant dose trend.
Zidovudine showed clastogenic effects in oral repeated dose micronucleus tests in mice and rats.
An effect of this magnitude is not generally expected to be clinically relevant.
In juvenile and prenatal animals exposed to quinolones effects on immature cartilage have been observed.
A dose dependent effect on TxB2 formation has been observed after high doses of celecoxib.
A dose-dependent effect on TxB2 formation has been observed after high doses of celecoxib.
An adverse effect of long-term bexarotene treatment on cataract formation in humans has not been excluded.
A mean placebo-corrected treatment effect of -3.9 mmHg was observed in favour of sildenafil (95% CI: -5.7, -2.1) (p=0.00003).
A more pronounced effect at 400 mg BID therefore cannot be excluded.
A significant effect was noted on the occurrence of heart failure.
Significant teratogenic and/ or embryocidal potential have been demonstrated for
Significant teratogenic and/or embryocidal potential have been demonstrated for
A very rare effect is skin rash with blisters affecting the lips, eyes, mouth, sometimes with headache, fever and/ or diarrhoea.
The Agency's infrastructure was expanded during 1996 and a great effort made to improving the quality of documents and the putting in place of an audit trail to permit a better follow-up to opinions and translations transmitted by the EMEA to the Commission.
Biliary fibrosis has been observed in rats.
A thin layer of ointment should be applied to the affected area twice daily for five days.
Significant Fab binding was also observed in the male reproductive tract (epididymis, sperm, seminal vesicle) and the skin.
In consequence there is a temperature fluctuation, which in its turn causes a fluctuating pressure in the front chamber of the infrared detector.
Ionisation, beam formation and acceleration all occur in the source, magnetic deflection takes place in the flight tube and detection takes place in the collector.
Once activated, these receptors function as ligand dependent transcription factors that regulate the expression of specific genes.
After administration of this medicinal product, exposure of eyes and skin to strong light sources (e. g. operating illumination, direct sunlight or brightly focused indoor light) should be avoided for 24 hours.
Once the medicine is reconstituted (made up with the solvent), do not store above 25°C.
Once there, the radioactivity from Ytracis helps to destroy the tumour.
Once there, the radioactivity from Yttriga helps to destroy the tumour.
After you have completed these steps, a small amount of liquid may remain in the vial.
Once these systems have been fully established they will be continually monitored and improved.
Once the transfer is complete, remove the long end of the needle from the BeneFIX vial, and properly discard the needle with the empty solvent vial.
When completely mixed, the vaccine is a clear pale yellow to light pink liquid.
When completely mixed, the vaccine is a clear pale yellow to light pink liquid.
Once in the cell, pemetrexed is rapidly and efficiently converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase.
Once the nose has cleared, patients can use desloratadine alone.
Once an effective dose has been established during titration, patients should continue to take this dose as a single tablet of that given strength.
When mTOR is bound in this complex, its ability to phosphorylate, and thereby control the activity of protein translation factors (4E-BP1 and S6K, both downstream of mTOR in the P13 kinase/ AKT pathway) that control cell division, is blocked.
After screwing the push rod into the syringe piston, it is important to turn the push rod an additional ½ turn so that the grey piston rotates freely.
After patient tolerance is established, the infusion rate may be increased gradually with subsequent infusions.
Once the vial has been entered under aseptic conditions, its contents should be used promptly.
The product may not be returned to refrigerated storage after storage at room temperature.
When the receptors are blocked, histamine cannot have its effect, and this leads to a decrease in the symptoms of allergy.
After treatment has been completed, it should not be reused.
- After treatment is completed, any unused gel should be discarded.
Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to ensure that the lowest approved dose of Aranesp is used to maintain haemoglobin at a level that controls the symptoms of anaemia.
ritonavir 200 mg QD)
The product should be used immediately after its withdrawal from the vial.
Once the needle is removed from the skin, check to make sure the black injection button is all the way in.
Once the addition is complete, the vial should be allowed to stand for a minimum of 5 minutes to ensure proper wetting of the solid.
Once the addition is complete, the vial should be allowed to stand for a minimum of 5 minutes to ensure proper wetting of the solid.
Following a CHMP opinion, it usually takes around 2 months for the European Commission to grant a licence.
Following CHMP opinion, it usually takes around 2 months for the European Commission to give a licence.
Following CHMP opinion, it usually takes around 2 months to the European Commission to give a licence.
Once the vaccine has been mixed with the solvent supplied, it should be either used immediately or stored in the refrigerator and used within eight hours.
After you have had chickenpox, the virus that caused it stays in your body in nerve cells.
The number in the dose window will return to “0” as you inject.
The mixed vaccine is a whitish emulsion.
This means that vaccinated birds make antibodies against these two antigens.
This means that vaccinated birds make antibodies against these two antigens.
When your condition has been brought under control, you will receive regular doses of Binocrit between 25 and 50 IU/ kg twice a week in two equal injections.
The recommended weekly dose is between 75 and 300 IU per kilogram.
A broken bone after the age of 50 may be a sign of osteoporosis.
One hard capsule contains 200 mg nilotinib (as hydrochloride monohydrate).
One capsule contains 200 mg of saquinavir as saquinavir mesilate.
- The other ingredients are sorbitol (E 420), glycerol, propylene glycol, saccharine sodium,
A drop of insulin should appear at the needle tip.
A drop of insulin should appear at the needle tip.
A drop of liquid must appear at the tip of the needle; this indicates that your pre-filled pen is primed for injection.
An additional drop should be administered 30-120 minutes prior to surgery.
One graduation mark of syrup contains 0.27 mmol (or 6.3 mg) sodium.
166 Ectopic pregnancy (embryo implanted outside the womb) may occur especially in women with a history of prior tubal disease.
176 Ectopic pregnancy (embryo implanted outside the womb) may occur especially in women with a history of prior tubal disease.
Ectopic pregnancy (embryo implanted outside the womb) may occur especially in women with a history of prior tubal disease.
Ectopic pregnancy (embryo implanted outside the womb) may occur especially in women with a history of prior tubal disease.
Severe gastrointestinal haemorrhage occurred in 4% of patients and generally required treatment interruption and transfusions.
Severe gastrointestinal haemorrhage occurred in 4% of patients and generally required treatment interruptions and transfusions.
ho and 11.1% (2/ 18) respectively, and in patients receiving the recommended regimen of unfractionated heparin in the treatment of PE were 6.9% (36/ 523), 3.1% (11/ 352), 11.1% (18/ 162) and 10.7% (3/ 28), respectively.
Occlusion of the dialysis system is possible if heparinisation is not optimum.
Hepatotoxicity and myopathies, including rhabdomyolysis are the most clinically serious adverse reactions.
A hormone called erythropoietin stimulates the production of red blood cells from the bone marrow.
Depressed mood may appear during smoking cessation with or without treatment.
- adequate hydration prior to the initiation of the infusion of IVIg
Leukocytosis (WBC > 50 x 109/ l) was observed in 41% of donors and transient thrombocytopenia (platelets < 100 x 109/ l) following filgrastim and leukapheresis was observed in 35% of donors.
have a hypersensitivity to the active subst ance or to any of the excipients;
- Hypersensitivity to the active substance or to any of the excipients.
- hypersensitivity to the active substance or to any of the excipients
- hypersensitivity to the active substance or to any of the excipients
- Hypersensitivity to the active substances, or to any of the excipients, or other sulphonylureas or
Grade 3 and 4 hypertension (requiring oral anti-hypertensive medication) in patients receiving Avastin ranged from 3.0% to 17.9%.
Injection site hypertrophy occurred in 24 subjects (32%).
Hypoacusis was reported in 15 subjects (20%).
Correction of moderately severe hypoglycaemia can be accomplished by intramuscular or subcutaneous administration of glucagon, followed by oral carbohydrate when the patient recovers sufficiently.
103 A hypo means your blood sugar level is too low.
Hypophosphatemia and a decrease in carnitine concentrations were reported each in 3% of patients on extended treatment.
Symptomatic hypotension may occur following initiation of therapy with< COVERSYL and associated names >; this is more likely in patients who are being treated concurrently with diuretics.
THIS SPC IS THE ONE THAT WAS ANNEXED TO THE COMMISSION DECISION CONCERNING THIS REFERRAL; THE TEXT WAS VALID AT THAT TIME.
Treatment-emergent acquired hypothyroidism was noted in 8 GIST patients (4%) on SUTENT versus 1 (1%) on placebo.
This scan will show exactly the distribution of the radioactivity within the body.
Salmon calcitonin is devoid of embryotoxic, teratogenic and mutagenic potential.
Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
er and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
An acute ocular infection may be masked by the topical use of anti-inflammatory medicines.
Infection with H. pylori will significantly change the 13C/ 12C - carbon isotope ratio.
JC virus infection resulting in PML has been reported in post-marketing surveillance in a patient with psoriasis receiving Raptiva (see section 4.4).
Slight to moderate inflammation of the meninges in the spinal cord and brain and/ or astrocytic activation were observed in animals receiving intrathecal DepoCyte.
Occasionally inflammation of the eye (conjunctivitis), mouth ulcers or low blood pressure may occur.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Background information on reticulin in the bone marrow.
Inspired by the success of the ICH process, a similar initiative was launched in 1996 for veterinary medicines – VICH.
Generally speaking this means every 5 to 6 months.
An injection of CEPROTIN gives an immediate but temporary increase in levels of protein C.
A glucagon injection can treat quite severe hypoglycaemia.
The vaccine is shaken before use and an intramuscular (into a muscle) injection of one dose (2 ml) is given in the neck behind the ear.
Inadvertent intravascular injection could lead to thromboembolic event and DIC, and there is also a risk of anaphylactic reaction (see 4.4).
One injection is enough to vaccinate sheep, but cattle will need a second injection three to four weeks later.
- cardiac failure or history of cardiac failure (New York Heart Association (NYHA) stages I to
Liver impairment could therefore result in an increase of tipranavir exposure and a worsening of its safety profile.
- Severe hepatic impairment (Child Pugh C).
Acute renal failure was reported uncommonly with a frequency of 0.4%.
An acute overdose of 16 g has been reported to cause acute renal failure.
Acute renal failure, reversible upon discontinuation of treatment, has been reported in at-risk patients receiving aliskiren in post-marketing experience.
The Committee for Orphan Medicinal Products (COMP) is responsible for making recommendations to the European Commission for the designation of orphan medicinal products
An interaction was observed with benserazide, which may lead to increased levels of benserazide and its active metabolite.
A clinically significant interaction due to ertapenem displacing another medicinal product or another medicinal product displacing ertapenem is unlikely.
For those benzodiazepins which are not metabolized by CYP3A4 (temazepam, nitrazepam, lorazepam) an interaction with Ketek is unlikely.
those benzodiazepins which are not metabolized by CYP3A4 (temazepam, nitrazepam, lorazepam) an interaction with Levviax is unlikely. na
PK/PD relationship An additive or synergistic pharmacodynamic interaction of micafungin and amphotericin B was found in a mouse model of pulmonary aspergillosis (immunosuppression with hydrocortisone, intranasal infection with Aspergillus fumigatus).
There was significant treatment interaction by antihypertensive baseline therapy.
A disruption or early ending of treatment with somatropin may impair the success of growth hormone therapy.
A disruption or early ending of the treatment with somatropin may impair the success of the growth hormone therapy.
Intolerance to contact lenses may occur which may necessitate the patient to wear glasses during treatment.
The dose levels, duration of treatment and total cumulative dose in these patients generally far exceeded those recommended for the treatment of acne.
Cyanide poisoning may be caused by exposure to smoke from household and industrial fires, breathing or swallowing cyanide, or contact with cyanide on skin.
Reversible irritancy of rabbits' eyes was detected.
1 KIU equals 1000 IU (International Units).
1 KIU equals 1000 IU (International Units).
A major portion of bile acids is then absorbed from the intestinal tract and returned to the liver via the enterohepatic circulation.
There may be a slight increase in body temperature.
Slight pain at injection was commonly reported.
Slight pain at injection was very commonly reported.
Mild, transient clinical reactions (fever, lethargy) may occur in the first 24 hours after vaccination.
A Dear Healthcare professional letter should be sent to relevant Healthcare professionals on 3 April 2006.
Leukopenia and neutropenia have also been observed in a similar group of patients receiving 800 mg/ day or higher dose.
A vented infusion line should be used for the administration of Privigen.
A separate infusion line must be used for the infusion, and the line must be flushed with sterile sodium chloride 9 mg/ ml (0.9%) solution for injection at the end of infusion.
Each foil has a perforation down the middle to allow the blisters to be separated into a daily dose of 5 tablets.
have an autoimmune disease, including Crohn’s disease, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, Sjögren’s syndrome and dermatomyositis/polymyositis;
A mild febrile illness, such as mild upper respiratory infection, is not usually reason to defer administration of palivizumab.
Take special care with Clopidogrel Winthrop:
Improved co-operation with national authorities allowed closer monitoring of expenses.
A statement reflecting the cases of malignancies reported in the post-marketing
A red imprint is stamped on each capsule (“ NVR/ TKI”).
A follow-up lung function measurement is recommended after the first 6 months of therapy.
A level scoop of the product should be measured
A meta-analysis of patients with moderate to severe Alzheimer's disease (MMSE total scores < 20) from the six phase III, placebo-controlled, 6-month studies (including monotherapy studies and studies with patients on a stable dose of acetylcholinesterase inhibitors) showed that there was a statistically significant effect in favour of memantine treatment for the cognitive, global, and functional domains.
A meta-analysis of patients with moderate to severe Alzheimer's disease (MMSE total scores < 20) from the six phase III, placebo-controlled, 6-month studies (including monotherapy studies and studies with patients on a stable dose of acetylcholinesterase inhibitors) showed that there was a statistically significant effect in favour of memantine treatment for the cognitive, global, and functional domains.
A meta-analysis of patients with moderate to severe Alzheimer's disease (MMSE total scores < 20) from the six phase III, placebo-controlled, 6-month studies (including monotherapy studies and studies with patients on a stable dose of acetylcholinesterase inhibitors) showed that there was a statistically significant effect in favour of memantine treatment for the cognitive, global, and functional domains.
Elevations in methaemoglobinaemia reduce the oxygen delivery capacity of the circulation.
An additional contraceptive method is recommended in case of severe diarrhoea (see section 4.4).
A minority of patients with orthostatic hypotension experienced syncopal events.
6- monthly updates on the progress of all preclinical studies should be provided.
An updated Risk Management Plan, as per the CHMP Guideline on Risk Management Systems for medicinal products for human use, should be submitted at the same time as the PSURs, within 60 days of an important (Pharmacovigilance or Risk minimisation) milestone being reached or when the results of a study becoming available or at the request of the Competent authority.
• A warning has been introduced in Section 4.4:
A statement reflecting the cases of malignancies reported in the post-marketing
A warning to advise that any lymphadenopathy present prior to initiation of therapy should be investigated and kept under assessment.
There is no need to change the dose in patients with impaired renal function.
Pioglitazone dose adjustment within the recommended posology or changes in diabetic treatment should be considered (see section 4.5).
Negative ADAS-Cog changes indicate improvement.
One molecule of hirudin binds to one molecule of thrombin and thereby blocks the thrombogenic activity of thrombin.
Transient mydriasis, salivation, vomiting and transient rapid respiration were observed.
Myelosuppression (neutropenia and thrombocytopenia), which is known dose-limiting toxicity for most cytotoxic agents, including TMZ, was observed.
Myelosuppression (neutropenia and thrombocytopenia), which is known dose-limiting toxicity for most cytotoxic agents, including TMZ, was observed.
Persistent severe myelosuppression, may result in superinfection or haemorrhage.
Enhanced nephrotoxicity has been observed following the administration of amphotericin B and ibuprofen in conjunction with tacrolimus.
Increased ciclosporin levels have been associated with nephrotoxicity.
Neuropathy occurred in 18% of patients treated with Paxene.
Neutropenia was present for > 7 days in 41% and for 30-35 days in 8% of patients.
Severe neutropenia (< 500 cells/ mm3) occurred in 20% and 39% of patients during the first course of treatment and the entire treatment period respectively.
Severe neutropenia (< 500 cells/ mm3) occurred in 26% of patients treated with Paxene during the entire treatment period.
One subject in the paediatric group had a fatal neurological event of status epilepticus.
The symptoms described above can be signs of the below listed side effects, which have been observed with Trudexa:
The Pharmacist should be requested to distribute a PAC to each patient at the time Ranexa is dispensed.
A new injection needle must be attached before each use.
A new injection needle must be attached before each use.
A new needle must be attached before each use.
A new needle should be used for every injection.
A new, sterile needle must be used for every injection.
Repeat doses should be administered when the clinical effect of a previous injection diminishes but not more frequently than every three months.
A full blood cell count including differential and platelet count must be performed at baseline, weekly for the first two cycles and then once between cycles (see section 4.2).
Inadequate thinning of the blood by heparin (heparinisation) may lead to occlusion of the dialysis system.
Occlusion of the dialysis system is possible if heparinisation is not optimum.
Nasolacrimal occlusion or gently closing the eyelid after administration is recommended.
Nasolacrimal occlusion or gently closing the eyelid after administration is recommended.
Nasolacrimal occlusion or gently closing the eyelid after instillation is recommended.
- A new pharmacoepidemiological study(ies) should be undertaken to get a better understanding of
Pulse oximetry may be useful but is not essential for adequate monitoring.
Skin thickening, moles, skin tags, and abnormal hair texture have been seen with INCRELEX treatment.
Pancytopenia has been reported.
persons in the European Community, or where for economic reasons such medicines would not be developed without incentives.
Part of the dose is absorbed systemically where it is extensively metabolised in the liver.
Part of it is converted into desethylene-, sulpho-, oxo- and formylciprofloxacin.
A female patient developed a nerve lesion affecting the arm (brachial plexopathy) two days after injection of a conventional preparation containing the Botulinum toxin type A complex for the treatment of twisted neck, with recovery after five months.
A female patient developed brachial plexopathy two days after injection of a conventional preparation containing the Botulinum toxin type A complex for the treatment of cervical dystonia, with recovery after five months.
A four-hour period of haemodialysis removed approximately 35% of the adefovir dose.
Loss of fat from the legs, arms and face may also happen.
Greater than 100-fold loss of susceptibility was observed against HIV variants expressing K103N in addition to other amino acid substitutions in RT.
Greater than 100-fold loss of susceptibility was observed against HIV variants expressing K103N in addition to other amino acid substitutions in RT.
Baseline elevations of several liver function tests (especially elevated bilirubin) should preclude the use of riluzole (see section 4.8).
In a small study on 27 paediatric patients it was also shown that montelukast seems to protect paediatric patients against exercise-induced broncho- constriction.
There may be a small amount of solution left in the vial.
A small amount of baby oil may also be used to remove any excess residue.
A small quantity (one unit) of Opgenra is placed directly on each side of the spine at the site requiring fusion.
Phlebotomy may be performed if excessively high haemoglobin levels occur.
Phlebotomy may be performed if excessively high haemoglobin levels occur.
Raised IOP causes damage to the retina (the light sensitive membrane at the back of the eye) and to the optic nerve that sends signals from the eye to the brain.
Mania/ hypomania may occur in a small proportion of patients with mood disorders who have received antidepressants, including venlafaxine.
Detailed planning will ensure a correct installation followed by extensive training of staff in order to optimise the effects of the change for day-to-day work.
The design, development and maintenance of the EMEA website has required the provision of technical
Polyploidy (numerical chromosome aberrations) was observed in human peripheral blood lymphocytes in vitro, both in the presence and absence of metabolic activation.
A starting dose of 0.25 mg twice daily is recommended.
Disease flare criteria were defined as a worsening of ≥ 30% from baseline in ≥ 3 of 6 Pediatric ACR core criteria, ≥ 2 active joints, and improvement of > 30% in no more than 1 of the 6 criteria.
Disease flare criteria were defined as a worsening of ≥ 30% from baseline in ≥ 3 of 6 Pediatric ACR core criteria, ≥ 2 active joints, and improvement of > 30% in no more than 1 of the 6 criteria.
Caution should be exercised when co-administering other agents that are known to have a deleterious effect on renal function.
Patients must receive premedication with antiemetics and appropriate hydration for cisplatin administration.
A 20 mg capsule is also available.
However, limited data are available to support the efficacy of YENTREVE 20 mg twice daily.
Raised intra-ocular pressure causes damage to the retina (the light-sensitive surface at the back of the eye) and to the optic nerve that sends signals from the eye to the brain.
Clinically significant weight gain (7%) appears to occur more frequently in the adolescent population compared to adults with comparable exposures.
Pioglitazone was associated with significant weight gain.
If you stop taking VIRAMUNE Taking all doses at the appropriate times greatly increase the effectiveness of your medicinal product combination regimen and reduce the development of viral resistance.
Taking all doses at the appropriate times greatly increase the effectiveness of your medicinal product combination regimen and reduces the development of viral resistance.
EudraVigilance is a database of safety information relating to all products on the market in the EU that is updated electronically, and whose information is available for analysis to all EU regulators.
A procedure for the systematic management of versions of multiple-language documents will be introduced and interaction with the Translation Centre in Luxembourg will be improved to further reduce turnaround time and enhance quality of translations.
Progression of Kaposi's sarcoma has been observed in rituximab-exposed patients with pre-existing Kaposi's sarcoma.
Progression to proliferative retinopathy or photocoagulation (levels 4 or 5) was examined in those with no or non-proliferative retinopathy at baseline.
Patients must receive premedication with antiemetics and appropriate hydration for cisplatin administration.
Prophylactic G-CSF may be used to mitigate the risk of hematological toxicities.
Prophylactic G-CSF may be used to mitigate the risk of hematological toxicities.
A proposal for an update of the SmPC and Package Leaflet based on the available data will be provided in parallel.
This will lead to a passive protection against tetanus for at least 21 days after concurrent administration.
An assessment of renal function should be considered during routine follow-up of patients treated with a dose of 40 mg.
When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.
When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.
Care should be taken in treating patients with hypovolaemia and hypotension.
Entacapone in association with levodopa has been associated with somnolence and episodes of sudden sleep onset in patients with Parkinson's disease and caution should therefore be exercised when driving or operating machines (see also section 4.7).
Therefore, special care should be taken during the titration process in patients with moderate or severe hepatic or renal impairment.
Caution is needed in these patients.
*Pyrexia occurred in 6.3% of the patients treated with TachoSil and in 5.9% of the patients treated with comparator treatment.
An appropriate quantity of sterile sodium chloride solution for injection and contents of the Osigraft vial are transferred to a sterile bowl and mixed with a sterile spatula or curette.
A potentially dangerous amount of fentanyl remains in the system after use.
MCyR was achieved in 55% of imatinib-resistant patients and 82% of imatinib-intolerant patients.
after any dose of HEXAVAC.
- a severe allergic (hypersensitive) reaction (hives, wheezing or other breathing difficulty),
An allergic reaction may be recognised as a rash, itching, a swollen face, swollen lips or shortness of breath.
An allergic reaction may be recognised as a rash, itching or shortness of breath.
A severe allergic reaction (rash, itching, swelling of the face, lips, mouth or throat that may cause difficulty in swallowing or breathing).
An anaphylactic reaction may occur rarely after injection of Botulinum neurotoxin type A (see section 4.8).
- A skin reaction on the palms of the hands or soles of the feet (including tingling, numbness,
A hypersensitivity reaction (serious allergic reaction) has been reported in about 5 in every 100 patients who have been treated with abacavir.
A hypersensitivity reaction (serious allergic reaction) has been reported in about 5 in every 100 patients who have been treated with abacavir.
A hypersensitivity reaction (serious allergic reaction) has been reported in about 5 in every 100 patients who have been treated with Ziagen.
Incompatibility appears with all infusion solutions/drugs that are physically or chemically unstable at the pH of the solution (e.g. penicillin, heparin solutions), especially in combination with solutions adjusted to an alkaline pH (pH of the ciprofloxacin infusion solutions:
Incompatibility appears with all infusion solutions/drugs that are physically or chemically unstable at the pH of the solution (e.g. penicillins, heparin solutions), especially in combination with solutions adjusted to an alkaline pH (pH of the ciprofloxacin infusion solutions:
A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate.
Testing for proteinuria is recommended prior to start of Avastin therapy.
Testing for antibodies to somatropin should be carried out in any patient who fails to respond to therapy.
There were recurrences in 40% of children; the survival rate at 5 years was 49%.
- Redistribution, accumulation or loss of body fat may occur in patients receiving combination
− Redistribution, accumulation or loss of body fat may occur in patients receiving combination antiretroviral therapy.
Fat redistribution: redistribution, accumulation or loss of body fat may occur in patients receiving combination antiretroviral therapy.
Redistribution, accumulation or loss of body fat may occur in patients receiving combination antiretroviral therapy.
Redistribution, accumulation or loss of body fat may occur in patients receiving combination antiretroviral therapy.
Clinically meaningful reductions in serum CTX levels were observed at all time points measured.
Reduction in the dose of alfentanil and other short acting opiates similar in structure to alfentanil and metabolised by CYP3A4, (e. g. fentanyl and sufentanil) should be considered when coadministered with voriconazole (see section 4.4).
Patients, especially children, with risk factors for acute pancreatitis (e. g. recent chemotherapy, hematopoietic stem cell translplantation (HSCT)), should be monitored closely during Vfend treatment.
Reduction in the dose of alfentanil and other short acting opiates similar in structure to alfentanil and metabolised by CYP3A4 (e. g fentanyl and sufentanil) should be considered when co-administered with voriconazole (see section 4.5).
Reduction in the dose of alfentanil and other short acting opiates similar in structure to alfentanil and metabolised by CYP3A4 (e. g. fentanyl and sufentanil) should be considered when co-administered with voriconazole (see section 4.5).
Dose reduction of Ceplene is normally not required in hepatically impaired patients, but caution should be used in these patients.
This should include laboratory evaluation, particularly serum creatinine.
Dosage reduction and/ or discontinuation of the diuretic and/ or< COVERSYL and associated names > may be required.
A reduction in GL-3 was observed in kidney, heart, skin and plasma at all doses.
Insomnia that persists or worsens after a short course of zaleplon treatment may indicate a need to re-evaluate the patient.
A causal relationship to somatropin therapy is unlikely.
A causal relationship to somatropin therapy is unlikely.
A causal relationship to somatropin therapy is unlikely.
It is unclear whether or not there is a direct association between pioglitazone and macular oedema but prescribers should be alert to the possibility of macular oedema if patients report disturbances in visual acuity; an appropriate ophthalmological referral should be considered.
A dose-dependency has been observed as indicated by a decrease in clearance and an increase in half-life at increasing doses.
An association between development of antibodies to infliximab and reduced duration of response has also been observed.
RESUSPENSION OF RISPERDAL CONSTA WILL BE NECESSARY PRIOR TO ADMINISTRATION AS SETTLING WILL OCCUR OVER TIME ONCE PRODUCT IS RECONSTITUTED.
An even distribution between members was ensured by requiring applicants to propose three or four alternatives.
A major cytogenetic response is defined by < 34% Ph+ leukaemic cells in the bone marrow, whereas a minor response is  34%, but < 90% Ph+ cells in the marrow.
A dose response was seen; results with 10 mg were intermediate between placebo and 25 mg.
In addition voriconazole shows in vitro fungicidal activity against emerging fungal pathogens, including those such as Scedosporium or Fusarium which have limited susceptibility to existing antifungal agents.
Successful response was seen in 24 patients (15 complete, 9 partial responses).
A successful global response required clinical improvement and microbiological eradication.
A transient hypotensive response is not a contraindication to further doses, which can be given usually without difficulty once the blood pressure has increased after volume expansion.
For some patients with BH4 deficiency, the dose may need to be divided into two or three doses over the course of the day to get 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Cross-resistance across the fluoroquinolone class of antibiotics is common.
Cross resistance occurs with other macrolides.
Cheyne-Stokes respiration and apnoea have been observed.
Generally speaking this means every 5 to 6 months.
Mild to moderate redness of the ear was common (2.4% of treated dogs).
Mild to moderate redness of the ear was common (2.4% of treated dogs).
Redness or induration > 2cm in diameter was reported in 22.6% and 13.9% of children respectively.
Redness, swelling, and itching can occur at the site of insulin injection.
An erythema caused by radiation therapy may be aggravated by hydroxycarbamide.
An Article 12 referral initiated, in the interest of the Community, in 1996 for chlormezanone-containing medicinal products, related to serious skin reactions, was finalised.
One Article 11 referral for the resolution of divergent national decisions initiated in 1996 by the marketing authorisation holder for an interferon a- containing product resulted in a Commission Decision amending the existing national marketing authorisations.
Scoliosis is common in patients with PWS.
Scoliosis may progress in any child during rapid growth.
A second population pharmacokinetic analysis was conducted that incorporated erlotinib data from 204 pancreatic cancer patients who received erlotinib plus gemcitabine.
A second dose of vaccine should be given after an interval of at least 3 weeks.
A second dose of vaccine should be given after an interval of at least three weeks.
Among all ZYPADHERA treated patients, sedation was reported by 4.7% of patients.
Sedation, amnesia, impaired concentration and impaired muscular function may adversely affect the ability to drive or to use machines.
Extreme sensitivity to salmon calcitonin may cause difficulties in breathing (bronchospasm), swelling of the tongue or throat, or even an anaphylactic shock (a
Sepsis related to leukopaenia was rarely (< 1%) observed.
Through a series of multiple stepwise regression analyses of baseline and on-treatment genotypes from all clinical studies, 16 amino acids have been associated with reduced tipranavir susceptibility and/ or reduced 48-week viral load response:
Each syringe provides one daily dose for a 500 kg horse.
A 10 ml graduated dosing syringe and an adapter are also included in the pack.
A 10 ml oral dosing syringe is provided to measure the dose.
kg bodyweight and each syringe is subdivided into 12 markings.
One syringe is intended for 600 kg bodyweight and each syringe is subdivided into 12 markings.
An oral syringe with a push-in bottle-neck adapter is included in the carton.
Pre-filled syringe containing 10,000 IU per 0.5 ml dose (20,000 IU/ ml) of the active substance epoetin delta.
Pre-filled syringe containing 1,000 IU per 0.5 ml dose (2,000 IU/ ml) of the active substance epoetin delta.
One pre-filled syringe containing 1 ml solution for injection.
Pre-filled syringe containing 2,000 IU per 0.5 ml dose (4,000 IU/ ml) of the active substance epoetin delta.
1 pre-filled syringe contains 200 micrograms of methoxy polyethylene glycol-epoetin beta.
One pre-filled syringe contains 200 micrograms of methoxy polyethylene glycol-epoetin beta* at a concentration of 667 micgrograms/ ml.
Pre-filled syringe containing 3,000 IU per 0.3 ml dose (10,000 IU/ ml) of the active substance epoetin delta.
One pre-filled syringe contains 360 micrograms of methoxy polyethylene glycol-epoetin beta*at a concentration of 600 micrograms/ ml.
1 pre-filled syringe contains 400 micrograms of methoxy polyethylene glycol-epoetin beta.
One pre-filled syringe contains 400 micrograms of methoxy polyethylene glycol-epoetin beta* at a concentration of 667 micrograms/ ml.
One pre-filled syringe contains 40 micrograms of methoxy polyethylene glycol-epoetin beta* at a concentration of 133 micrograms/ ml.
Pre-filled syringe containing 5,000 IU per 0.5 ml dose (10,000 IU/ ml) of the active substance epoetin delta.
One pre-filled syringe contains 50 micrograms of methoxy polyethylene glycol-epoetin beta* at a concentration of 167 micrograms/ ml.
Pre-filled syringe containing 6,000 IU per 0.3 ml dose (20,000 IU/ ml) of the active substance epoetin delta.
One pre-filled syringe contains 600 micrograms of methoxy polyethylene glycol-epoetin beta* at a concentration of 1000 micrograms/ ml.
One pre-filled syringe contains 60 micrograms of methoxy polyethylene glycol-epoetin beta* at a concentration of 200 micrograms/ ml.
One pre-filled syringe contains peginterferon alfa-2a*.................................................................................... .180 micrograms Each syringe of 0.5 ml solution contains 180 micrograms peginterferon alfa-2a*.
- one pre-filled syringe of solvent, 4 ml sterile sodium chloride 9 mg/ml (0.9%) solution for
• Set up the following items on a clean surface
A single dose pre-filled syringe delivers 1.65 mg pegaptanib sodium, corresponding to 0.3 mg of the free acid form of the oligonucleotide, in a nominal volume of 90 microlitres.
2 ml syringe) and needle (e. g.
10 ml LUER syringe),
One single administration is usually sufficient.
Sodium pertechnetate (99mTc) solution for injection containing oxidants ought not to be used for the preparation of the labelled product.
The injection is then flushed through with a saline injection to make sure none is left in the needle or tube used for the injection.
A strain which is resistant to one type of fluoroquinolone will also be resistant to other members of the class of fluoroquinolones.
A strain which is resistant to a fluoroquinolone will also be resistant to other members of the class of fluoroquinolones.
A subpopulation from the GOAL study (Gaining Optimal Asthma ControL study) i. e. stratum 1, addendum, step 1 (patients without ICS at entry who fulfilled the criteria for moderate persistent asthma and who are randomised to Viani 50/ 100 or FP 100 mcg), can be considered as an adequate target population to assess the adequacy of Viani as IMT.
cerebral palsy patients, two years of age or older.
A clinical trial evaluating use of moroctocog alfa (AF-CC) in children less than 6 years of age is on going.
Although a limited number of children have been studied, there is a tendency for higher frequencies of adverse events in children aged 7-16 as compared to adults. A clinical trial evaluating use of moroctocog alfa (AF-CC) in children less than 6 years of age is on going.
In a follow-up trial with the 80 mg/ 25 mg combination, blood pressure was further decreased (resulting in an overall reduction of 11.5/ 9.9 mm Hg (SBP/ DBP).
Note for guidance on the declaration of storage conditions for medicinal products in the products particulars
- a shortness of breath, wheezing or breathing problems
There was also a stimulatory effect on leukocyte production, as peripheral blood counts for neutrophils, lymphocytes, monocytes, and eosinophils were mildly increased.
A trainee from Estonia began an internship with the EMEA at the end of 1998.
A pharmacokinetic overexposure of zidovudine can occur, therefore close safety monitoring is warranted in these patients.
Overexpression of HER2 is observed in 20 %-30% of primary breast cancers.
Increased ALAT/ ASAT monitoring should be considered in these patients.
Careful monitoring of patients ≥ 60 years of age is advisable.
Careful monitoring of patients with compromised corneas, such as patients with diabetes mellitus or corneal dystrophies, is recommended.
Patients receiving Epivir or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with associated HIV diseases.
or recommended in these patients.
ECG monitoring should be performed in high-risk patients as clinically indicated.
Therapeutic concentration monitoring recommended.
126 In patients treated with other medicinal products associated with liver toxicity, monitoring of liver enzymes is also recommended.
150 In patients treated with other medicinal products associated with liver toxicity, monitoring of liver enzymes is also recommended.
In patients treated with other medicinal products associated with liver toxicity, monitoring of liver enzymes is also recommended.
Therefore monitoring is required with frequent or prolonged use of GANFORT in dry eye patients or where the cornea is compromised.
Acute renal failure has been observed in severely ill patients undergoing treatment with VFEND.
Care should be taken if it is given to patients who already have heart problems, and all patients need to be monitored during treatment to check their heart.
Close monitoring of prothrombin time is recommended if warfarin and voriconazole are coadministered.
Patients in need of the combination should be closely monitored.
7 administration of amprenavir and Kaletra, but close monitoring is advised because the safety and efficacy of this combination is unknown.
Particularly close blood glucose monitoring is therefore recommended in the initial phase of co-administration.
Close medical supervision and monitoring should continue until the patient recovers.
You will need special medical observation in some cases:
Pay careful attention to all possible bleeding sites (e. g. injection sites).
A closer monitoring of the leucocyte cystine levels is recommended in these patients.
Close supervision of high-risk patients should accompany antipsychotic therapy.
Regular monitoring should be undertaken by the veterinarian.
A white to off-white suspension for injection.
Syncope occurred in a fasting adult who had taken doxazosin 16 mg.
ASEPTIC TECHNIQUE MUST BE STRICTLY OBSERVED THROUGHOUT HANDLING OF TRISENOX SINCE NO PRESERVATIVE IS PRESENT.
Aseptic technique must be strictly observed throughout handling of VELCADE, since it contains no preservative.
ASEPTIC TECHNIQUE MUST BE STRICTLY OBSERVED THROUGHOUT HANDLING OF VELCADE SINCE NO PRESERVATIVE IS PRESENT.
Aseptic technique (meaning clean and germ free) should be used during the reconstitution procedure.
Adequate body temperature and fluid intake should be maintained.
RESIST participants receiving APTIVUS/ ritonavir tended to have an increased risk of bleeding; at 24 weeks the relative risk was 1.98 (95% CI=1.03, 3.80).
A non-statistically significant favourable trend was observed in the other two components.
A similar trend is also seen for the discontinuation rates.
An attempt should be made to reduce the frequency of application or to use the lower strength Protopy 0.03% ointment if the clinical condition allows.
- a thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a
Transient thrombocytopenia (platelets < 100 x 109/ l) following filgrastim administration and leukapheresis was observed in 35% of subjects studied.
Transient thrombocytopenia (platelets < 100 x 109/ l) following filgrastim administration and leukapheresis was observed in 35% of subjects studied.
Tolerance developed to the CNS depression.
Tolerance developed to the CNS depression.
The cough tended to occur within seconds to minutes after insulin inhalation and was predominantly mild in severity.
The cough tended to occur within seconds to minutes after insulin inhalation and was predominantly od
A third vaccination with Equilis Prequenza Te should be repeated at least four weeks later.
A third vaccination with Equilis Te should be repeated at least four weeks later.
A polystyrene resin / polyurethane carry case (Shuttle) which holds 3 capsules is included in each pack.
This dose is expected to be used in only a limited number of the treatments (less than 1%).
Early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid, for example, should be considered in chronic renal failure patients at risk of shunt thrombosis.
The new design reflects the rapid growth of both the quantity and type of documents made available on the site.
Extra vigilance is warranted in patients with chronic hepatitis B or hepatitis C co-infection, as these patients have an increased risk of hepatotoxicity.
Extra vigilance is warranted in patients with chronic hepatitis B or hepatitis C co-infection, as these patients have an increased risk of hepatotoxicity.
A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.
A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.
A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.
Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
A cumulative review up to 30 September 2007 of all hepatic reactions (serious and non-serious) and an overall assessment of the benefit/ risk ratio of moxifloxacin treatment was performed.
Before initiation of treatment with TYSABRI, a recent (usually within 3 months) Magnetic Resonance Image should be available.
If severe ulceration of the nasal mucosa occurs (e. g. penetration below the mucosa or association with heavy bleeding), intranasal calcitonin is to be discontinued.
Nasal examinations is to be performed before treatment begins and in the case of nasal complaints, medication should not be started.
A test to determine your liver function will be performed before the start of Eucreas treatment, at three-month intervals for the first year and periodically thereafter.
A test to determine your liver function will be performed before the start of Icandra treatment, at three- month intervals for the first year and periodically thereafter.
A test to determine your liver function will be performed before the start of Zomarist treatment, at three-month intervals for the first year and periodically thereafter.
Gynaecological examination should be performed before treatment administration, closely looking at pre-existing endometrial abnormality.
Summary of the EMEA work programme 2006 EMEA/ 62913/ 2006
A benchmarking exercise will begin in 2001 to compare good regulatory practices and quality management systems of competent authorities both in the European Economic Area and central and eastern European countries.
• One vial containing RISPERDAL CONSTA extended release microspheres • Two Hypoint 20G 2” TW needles for reconstitution • One prefilled syringe containing the solvent for RISPERDAL CONSTA • One Needle-Pro needle for intramuscular injection (safety 20G 2” TW needle with needle protection device)
• One vial containing RISPERDAL CONSTA extended release microspheres • One Alaris SmartSite needle-free vial access device for reconstitution • One prefilled syringe containing the solvent for RISPERDAL CONSTA • One Needle-Pro needle for intramuscular injection (safety 20G 2” TW needle-with needle protection device)
1 vial contains 0.02 -5 ml sterile Yttrium (90Y) solution (as Yttrium [90Y] chloride).
One vial contains 10 microgram of protein (specific in vivo bioactivity equal to approximately 10 000 IU FSH / mg protein).
One vial contains 150 IU (equivalent to 11 micrograms) of follitropin alfa (r-hFSH) and 75 IU (equivalent to 3.0 micrograms) of lutropin alfa (r-hLH).
One vial contains 15 microgram of protein (specific in vivo bioactivity equal to approximately 10 000 IU FSH / mg protein).
One vial contains 1g powder with 3.5 mg of eptotermin alfa*.
One vial contains 1 mg tasonermin (Tumor Necrosis Factor alfa-1a; TNFα -1a) exhibiting an activity of 3.0-6.0 x 107 IU.
One vial contains 1 mg tasonermin (Tumor Necrosis Factor alfa-1a; TNFα -1a) exhibiting an activity of 3.0-6.0 x 107 IU.
1 vial contains 200 micrograms of methoxy polyethylene glycol-epoetin beta.
One vial contains 20 microgram of protein (specific in vivo bioactivity equal to approximately 10 000 IU FSH / mg protein).
One vial contains 22.5 microgram of protein (specific in vivo bioactivity equal to approximately 10 000 IU FSH / mg protein).
One vial contains 25 microgram of protein (specific in vivo bioactivity equal to approximately 10 000 IU FSH / mg protein).
1 vial contains 400 micrograms of methoxy polyethylene glycol-epoetin beta.
One vial contains 5 microgram of protein (specific in vivo bioactivity equal to approximately 10 000 IU FSH / mg protein).
One vial contains 7,5 microgram of protein (specific in vivo bioactivity equal to approximately 10 000 IU FSH / mg protein).
A vial contains 9.75 mg (1.3 ml) aripiprazole.
One vial contains 0.925 to 3.700 GBq (see section 6.5).
One vial contains either 50,000 IU or 100,000 IU
1 bottle of 465 ml contains 6975 mg lacosamide.
One vial 4 mg One ampoule of solvent 5 ml Component of a multipack comprising ten packs, each containing one vial and one ampoule
ed One vial of 5 ml contains 25 mg of daclizumab* (5 mg/ ml).
One vial with 5 ml concentrate for solution for infusion Component of a multipack comprising ten packs, each containing one vial
- a vial of PegIntron powder for injection;
- one vial of moroctocog alfa 250, 500, 1000, or 2000 IU powder
One vial with powder for solution for injection contains nonacog alfa 1000 IU and excipients..
One vial with powder for solution for injection contains nonacog alfa 2000 IU and excipients.
One vial with powder for solution for injection contains nonacog alfa 500 IU and excipients One vial of 5 ml water for injections One double-ended needle One filter spike One mini sterile infusion set
One vial of Raptiva should be reconstituted with the solvent before use.
One vial of solvent contains:1 ml water for injections.
One vial of Synagis powder and one ampoule of water for injections per pack.
- a vial of ViraferonPeg powder for injection;
- a vial of Viraferon powder for injection;
ed One vial of Viraferon solution for injection, single dose vial, contains 10 million IU of recombinant interferon alfa-2b produced in E. coli by recombinant DNA technology, in 1 ml of solution.
ed One vial of Viraferon solution for injection, single dose vial, contains 3 million IU of recombinant interferon alfa-2b produced in E. coli by recombinant DNA technology, in 0.5 ml of solution.
- a vial of IntronA powder for injection;
One vial of Opgenra contains 1 g of powder including 3,5 mg of eptotermin alfa and the excipient bovine collagen.
An empty sterile mixing vial is supplied separately.
An internal forum for progressing user issues, the EMEA IT User Group, was set up.
- genotype 1 with low viral load (LVL) (≤ 800,000 IU/ mL) at baseline or
- genotype 1 with low viral load (LVL) (≤ 800,000 IU/ mL) at baseline or
A glossary of specialised and technical EMEA terms was also produced by JICS interpreters in 2000 to assist understanding and communication at the Agency's meetings.
A measuring cup with graduation marks (corresponding to 50 mg lacosamide) is provided with the syrup.
In fluconazole-resistant non albicans species, a successful outcome was seen in 3/ 3 C. krusei (complete responses) and 6/ 8 C. glabrata (5 complete, 1 partial response) infections.
- Metallic taste (3%) is common
- Metallic taste (3%) is common.
One gram of Protopic 0.03% ointment contains 0.3 mg tacrolimus (as tacrolimus monohydrate).
One gram of Protopy 0.03% ointment contains 0.3 mg tacrolimus (as tacrolimus monohydrate).
One gram of Protopy 0.1% ointment contains 1.0 mg tacrolimus (as tacrolimus monohydrate).
One gram of Renagel contains approximately 180 mg (5.1mEq) chloride.
Many of the side effects can be relieved by adjusting the dose.
A large number of these diseases affect children and newborn babies. • The EMEA plays an important new role in stimulating the development of orphan medicinal products.
Many of these patients were also receiving chemotherapy and corticosteroids.
Many of these patients were also receiving chemotherapy and corticosteroids.
Many of these are likely to be candidates for Annex II of Council Regulation (EEC) No 2377/90, but there remains approximately 100 additional substances yet to be evaluated which will necessitate additional work by the CVMP and its Safety of Residues Working Party.
Many of the guidelines adopted by the CPMP derive from the Agency’s work as part of the trilateral EU-Japan-US International Conference on Harmonisation (ICH).
guages for all CPMP and CVMP opin- ions and other notification documents.
members had fallen by 25% on the previous year, indicating more confidence in rapporteur and co-rapporteur assessment work
au Unigene UK Limited 191 Sparrows Herne Bushey Heath Hertfordshire WD23 1AJ United Kingdom
Unigene UK Limited, 191 Sparrows Herne, Bushey Heath, Hertfordshire WD23 1AJ, UK
A clinically relevant, low responding inhibitor was detected in 1 out of 65 BeneFIX patients who had previously received plasma derived products.
There should be an interval of at least 1 month between doses.
There should be an interval of at least 1 month between doses: such as 2, 3, 4 months; 2, 4, 6 months; 3, 5 months.
International Conference for Harmonisation of Technical Requirements
Unipril 1,25 mg compresse Unipril 2,5 mg compresse Unipril 5 mg compresse Unipril 10 mg compresse
For use only as preservatives in multidose vaccines at a concentration not exceeding 0.02%(concentration in the product is 0.004%)
UniTech BioPharma AB Storjorden 2 SE-864 31 Matfors Sweden
Prac-tic for very small dogs Prac-tic for small dogs Prac-tic for medium dogs Prac-tic for large dogs
The number of pages sent to the Luxembourg Translation Centre has reached a level of about 11 000 pages divided over a number of 225 documents.
• management and follow-up of marketing authorisation applications under the centralised procedure
Reinhard KROKER Direktor BgVV Diedersdorfer Weg, 1 D-12277 Berlin Tel:
România Genzyme CEE GmbH- Reprezentanta pentru Romania Tel: +40 318052960
United Kingdom Shire Pharmaceuticals Ltd Hampshire International Business Park Chineham, Basingstoke Hampshire, RG24 8EP Tel:
Italia Wyeth Lederle S.p.A.
Latvija Bauskas 58a -401 Rīga, LV-1004 Tel: + 371-7 21 38 25
Sverige Novartis Sverige AB Tel: +46 8 732 32 00
United Kingdom Lundbeck Limited Lundbeck House Caldecotte Lake Business Park Caldecotte Milton Keynes MK7 8LG - UK Tel: +44 1908 64 9966
United Kingdom Lundbeck Limited Lundbeck House Caldecotte Lake Business Park Caldecotte Milton Keynes MK7 8LG - UK Tel: +44 1908 649966
Malta Vivian Corporation Ltd.
European Commission Unit for Pharmaceuticals: regulatory framework and market authorisations
European Commission Unit for Pharmaceuticals: regulatory framework and market authorisations http://pharmacos.eudra.org
100 IU (International Units) of the active substance insulin human.
Units) of the active substance insulin human.
Mild reddening of the ear has been seen in around 2% of dogs.
There may be a little bleeding at the injection site.
A software package for terminological databases was introduced at the Translation Centre and tested at the EMEA.
Software for the management of the Help Desk has been developed in-house and is regularly updated.
Up to three containers of powder may be dissolved in the content of one ampoule of solvent.)
The Kaplan-Meier estimate for continued sustained response over 5 years for all patients is 97% with a 95% Confidence Interval of [95%, 99%].
The accumulation of bosentan in hepatocytes leading to cytolysis with potentially severe damage of the liver, or an immunological mechanism, are not excluded.
A possible mechanism is saturation of transporters at the absorption site or at the hepatobiliary clearance route.
A doctor who has experience in the care of renal failure patients should start any treatment with Dynepo.
Vectibix will be administered in a healthcare facility under the supervision of a doctor experienced in the use of anti-cancer medicines.
It is usually dripped into your arm over a period of about 2 hours.
A doctor or a nurse will give you the medicine as an infusion into a vein (a drip) in hospital.
A medicine labelled with Yttriga should not be used in women who are or may be pregnant.
35 kg body weight A horizontal ribbon mixer should be used to incorporate the product into the feeding stuff.
There must be at least a 4-week waiting period between end of treatment with sorivudine or its chemically related analogues such as brivudine and start of Xeloda therapy.
One ml contains 5000 U of Botulinum Toxin Type B (10,000 U per vial)
One ml contains 5000 U Botulinum Toxin Type B (2500 U per vial)
One ml contains 5000 U Botulinum Toxin Type B (5000 U per vial)
One ml contains 5000 U Botulinum Toxin Type B.
- One ml solution contains 100 micrograms ziconotide (as acetate).
- One ml of solution contains 10 million IU of interferon alfa-2b
- One ml of solution contains 6 million IU of interferon alfa-2b
One ml of suspension contains 0.10 mg benzalkonium chloride.
One ml of TRISENOX contains 1 mg of Arsenic trioxide
40 IU (International Units) of the active substance insulin human.
100 IU (International Units) of the active substance insulin human.
40 IU (International Units) of the active substance insulin human.
One ml of Insulin Human Winthrop Comb 25 contains
40 IU (International Units) of the active substance insulin human.
One ml of Insulin Human Winthrop Comb 50 contains
One mlof Insulin Human Winthrop Comb 50 contains
100 IU (International Units) of the active substance insulin human.
Units) of the active substance insulin human.
One ml of Insuman Basal contains 40 IU (International Units)
Units) of the active substance insulin human.
Units) of the active substance insulin human.
Units) of the active substance insulin human.
Units) of the active substance insulin human.
Units) of the active substance insulin human.
Units) of the active substance insulin human.
Units) of the active substance insulin human.
The approximate amount of perflutren gas in each ml of OPTISON is 0.19 mg
The approximate amount of perflutren gas in each ml of OPTISON is 0.19 mg.
1 ml (one vial) contains 1000 micrograms of methoxy polyethylene glycol-epoetin beta*.
1 ml (one vial) contains 100 micrograms of methoxy polyethylene glycol-epoetin beta*.
1 ml (one vial) contains 200 micrograms of methoxy polyethylene glycol-epoetin beta*.
1 ml (one vial) contains 300 micrograms of methoxy polyethylene glycol-epoetin beta*.
1 ml (one vial) contains 400 micrograms of methoxy polyethylene glycol-epoetin beta*.
1 ml (one vial) contains 50 micrograms of methoxy polyethylene glycol-epoetin beta*.
1 ml (one vial) contains 600 micrograms of methoxy polyethylene glycol-epoetin beta*.
Cardiovascular monitoring is necessary to detect possible arrhythmias.
Cardiovascular monitoring is necessary to detect possible arrhythmias.
Herings (1993), Pratt (1994), Hanrahan (1995), Staffa (1995), Brandebourg (abstract 1996) and two unpublished studies:
Seven cohort studies, with a size of study population between 23,949 and 1,007,467 patients, were taken in account (five published studies:
White blood cell counts of 100 x 109/ l or greater have been observed in less than 1% of patients receiving Neupopeg.
Peripheral blood lymphocytes from AIDS patients receiving zidovudine treatment have also been observed to contain higher numbers of chromosome breakages.
An insufficient number of patients has been studied with creatinine clearance of below 45 ml/ min.
Elderly: insufficient numbers of elderly patients have been evaluated in clinical studies of the components of Atripla to determine whether they respond differently than younger patients.
A small number of animals may show transient local reactions in the form of a mild, local swelling at the injection site post vaccination (maximum 1 cm in diameter) that resolve spontaneously within 1 to 2 days.
A small number of animals may show temporary local reactions, in the form of a mild, local swelling at the injection site post vaccination (maximum 1 cm in diameter), that resolve by themselves within 1 to 2 days.
There are limited data showing that nifedipine is excreted into human breast milk at low levels.
A limited number of patients (50 patients) have received a second infusion for hypercalcaemia.
A limited number of patients with late-onset Pompe disease (see section 5.1) have been treated with Myozyme.
Peripheral blood lymphocytes from AIDS patients receiving zidovudine treatment have also been observed to contain higher numbers of chromosome breakages.
Significantly fewer neonates in the INOmax group required ECMO compared to the control group (31% vs 57%, p < 0.001).
Limited data has been presented that shows use of doses in excess of 50mg / kg/ din neonates in situation other than meningitis.
A new contraceptive cycle begins on the next day following patch-free week; the next EVRA patch should be applied even if there has been no bleeding or if bleeding has not yet stopped.
The development of a part-time working policy began following a staff questionnaire.
A transient diffuse swelling may occur at the vaccination site in 50% of the animals, which persists for about 14 days.
A diffuse hard or soft swelling (max. diameter 5 cm) may occur at the injection site, regressing within 2 days.
A diffuse hard or soft swelling (max. diameter 5 cm) may occur, regressing within 2 days.
Oedema may occur upon initiation of insulin therapy.
Computers record the activity and translate that into images.
One patient experienced involuntary muscle contractions.
One rheumatoid arthritis patient mistakenly self- administered 62 mg Enbrel subcutaneously twice weekly for 3 weeks without experiencing undesirable effects.
One rheumatoid arthritis patient mistakenly self-administered 62 mg Enbrel subcutaneously twice weekly for 3 weeks without experiencing undesirable effects.
There was an un-vaccinated patient diagnosed with idiopathic membranous glomerulonephropathy who experienced meningococcal meningitis.
Therefore, episodes of sleepwalking should be fully evaluated and appropriate interventions considered.
A small percentage of vitamin D3 undergoes glucuronidation prior to elimination.
After subcutaneous administration of difloxacin peak plasma levels of 1.4 -1.9 µg/ ml are achieved in 3.1 hours post dosing.
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
EudraSafe – the secure document exchange service – was also reorganised with improved users account management and increased security.
A higher percentage of patients who received Visudyne, compared with those who received placebo, experienced adverse events (89.3% versus 82.5%), associated adverse events (42.7% versus 18.4%) and events leading to discontinuation (6.2% versus 0.9%).
One percent of patients experienced severe non-cardiogenic pulmonary oedema.
New onset nephrosis (nephrotic syndrome) was also reported (see section 4.8).
2002 • First prototype to reflect and test implementation of data elements for transmission of reports is in place in accordance with draft VICH guidelines GL 24, GL 30 and GL 35
Priapism Priapism may occur with RISPERDAL CONSTA treatment due to its alpha-adrenergic blocking effects.
Priapism may occur with RISPERDAL treatment due to its alpha-adrenergic blocking effects.
All three doses shared a similar safety profile.
A programme of 10-12 internal audits of key functions will be conducted in 2000 and in 2001.
intravitreal procedure as it was performed in the pivotal clinical studies
An education program to the health care professionals (HCP) (doctors-nurses-pharmacists) shall address,
Pruritis and/ or local swellings and occasionally a slight pain reaction on injection have been observed.
A PSUR covering the period 22 October 2004 – 21 October 2006 will be submitted in December 2006.
Conference services structure of the Unit remained stable under Karel de Neef, Head of Unit, and his four Heads of Sector, Stephen Fairchild, Beatrice Fayl, Sylvie Bénéfice and Michael Zouridakis.
A general reversal of these trends was noted during the 6 months follow- up post treatment.
A general reversal of these trends was noted during the 6 months follow-up post treatment.
Re-priming (approximately 6 sprays until a fine mist is seen) is only necessary if the cap is left off for 5 days or the intranasal device has not been used for 30 days or more.
• a puncture-proof container for safe disposal of the used syringe.
● Dedicated waste container with a lid for the safe disposal of the waste materials.
have severe problems with their liver or their kidneys. lp
Acute rejection occurred in 14.6% of patients by 6 months post-transplantation, and in 24.3% by 12 months.
A representative JICS is based at the EMEA as part of the cooperation between EU institutions and agencies.
A cumulative overview of all events reported during the period, stratified according to type of reporter (patient or health care professional), seriousness, expectedness, and whether spontaneous or solicited.
A cumulative overview of all events reported during the period, stratified according to type of reporter (patient or health care professional), seriousness, expectedness, and whether spontaneous or solicited.
All events reported by patients that have been entered into the database by data-lock point A cumulative overview of all events reported during the period, stratified according to type of reporter (patient or health care professional), seriousness, expectedness, and whether spontaneous or solicited.
A summary of the key efficacy endpoints is presented below.
A summary of the key study results is shown in Table 2.
A summary of the key study results is shown in Table 2.
10 A summary of the key study results from the combined analysis is shown in Table 1.
An increased risk of deep venous thrombosis (DVT) and pulmonary embolus (PE) has been reported in patients treated with thalidomide (see section 4.8).
A mutagenic risk for the use of therapeutic doses seems unlikely since effects appeared only at high concentrations.
When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.
An increased relative risk of thromboembolic events (RR 1.67, 95% CI:
A theoretical risk of hypersensitivity to rHA at a low frequency cannot be ruled out.
- A desiccant bag is included in the outer container
20 000 birds with an average bodyweight of 500 g).
20 000 birds with an average bodyweight of 50 g).
20,000 birds with an average bodyweight of 50 g).
A modified Total Sharp Score (mTSS), which included distal interphalangeal joints (i. e., not identical to the TSS used for rheumatoid arthritis), was used.
A subscription service has been developed and put into operation to allow automatic distribution of EMEA documents as soon as they are released.
A subscription service is available for all EMEA public documents, distributing documents electronically or in paper form.
A document dissemination service will be brought into operation in early 1997.
exercise in fee report, ActiTrak
A single case of heart failure related to Paxene was seen in the AIDS-KS clinical study.
Of these patients, 5 exhibited a significant improvement in FEV1 following discontinuation of therapy and one subject did not decrease further from the end of study value.
OHSS may be more severe and more protracted if pregnancy occurs.
A subset had recurrence of symptoms when rechallenged with the same medicinal product or another bisphosphonate.
A subset of women (N=776) vaccinated in study 001 was followed in study 007 up to 6.4 years (approximately 77 months) after the first dose (mean follow-up of 5.9 years).
A subset of children in this study were followed until they reached 4 to 5 years of age.
462 patients completed at least 5 years of long-term follow-up and only 12 sustained responders' out of 492 relapsed during this study. no
ge measured 6 months after the end of treatment.
Ophthalmologic monitoring is recommended at regular intervals or if vision abnormalities occur.
As Beromun is always administered by experienced surgical teams in the hospital setting, accidental overdose is extremely unlikely.
Acute overdose is unlikely to require any therapy other than observation.
Acute overdose could lead initially to a glucose decrease (hypoglycaemia) and subsequently to a glucose increase (hyperglycaemia).
Long-term overdose could result in signs and symptoms of gigantism and/ or acromegaly consistent with the known effects of excess growth hormone.
Long-term overdose could result in signs and symptoms of acromegaly consistent with the known effects of excess human growth hormone.
An overdose with DepoCyte may be associated with severe arachnoiditis including encephalopathy.
Chronic overdose with resulting hypercalcaemia can cause vascular and organ calcification.
Overdosage of desirudin could lead to bleeding complications.
Overdose of epoetin alfa may produce effects that are extensions of the pharmacological effects of the hormone.
An overdose of cysteamine may cause progressive lethargy.
10 (hypokalaemia, hypochloraemia) and hypovolaemia resulting from excessive diuresis.
23 (hypokalaemia, hypochloraemia) and hypovolaemia resulting from excessive diuresis.
Overdose of sulphonylureas, including glimepiride, can result in severe life-threatening hypoglycaemia lasting 12 to 72 hours, which may recur after apparent recovery.
Overdose leads to hypercalciuria and hypercalcaemia.
In case of overdose the risk of bleeding may be increased.
Massive overdose may result in pronounced hypotension requiring active cardiovascular support.
A topical overdose is not likely to occur or to be associated with toxicity.
An overdose will not accelerate the onset or increase the degree of ovulation.
A topical overdose of TRAVATAN may be flushed from the eye(s) with lukewarm water.
It is likely that nelarabine overdose would result in severe neurotoxicity (possibly including paralysis, coma), myelosuppression and potentially death.
Overdose can lead to hypervitaminosis and hypercalcaemia.
Symptoms of overdose may include nausea, vomiting, dizziness and breathing difficulties.
Overdosage following topical administration is unlikely.
A neonatal abstinence syndrome has been reported among newborns of women who have received buprenorphine during pregnancy.
An ovarian hyperstimulation syndrome should be treated symptomatically, e. g. with rest, intravenous electrolytes/ colloids and heparin therapy.
Nephrotic syndrome has been reported following attempted immune tolerance induction on haemophilia B patients with factor IX inhibitors and a history of allergic reaction.
A system has been put in place to disseminate European Public Assessment Reports (EPARs)
Together with the CPMP Pharmacovigilance Working Party and CPMP, a crisis management system will shortly be developed.
A calibrated measuring cup and a 2 ml calibrated dropper are included in the carton.
France Jean-René BRUNETIÈRE Jacques BOISSEAU
A similar incidence of infusion reactions (12.4%) and treatment discontinuation (1.5%) was observed in the breast cancer program.
Thus it appears that 5 days is acceptable for pigs.
Labelling time longer than six minutes or shorter than four minutes will result in inadequate radioincorporation.
Skin patch testing was used as a research tool for the PREDICT-1 study but has no utility in the clinical
A minority of patients were tested using fluorescence in-situ hybridisation (FISH).
One third of these infections have to be considered as severe (e. g. septicaemia, pneumonia).
It is expected that a total of about 65 new members of staff will join the EMEA in 2002.
A total of 109 patients received dasatinib 70 mg twice daily (99 resistant and 10 intolerant to imatinib).
A total of 1190 patients were treated (892 pegaptanib, 298 sham (control)) with a median age of 77 years.
A total of 11 patients (18%) experienced a-GVHD.
A total of 1291 serious reports were received where palivizumab had been administered as indicated and the duration of therapy was within one season.
A total of 14 patients (50%) experienced a-GVHD.
A total of 174 patients received dasatinib 70 mg twice daily (161 resistant and 13 intolerant to imatinib).
A total of 17 guidelines were drafted and released for consultation and 21 guidelines adopted.
A total of 283/ 1351 (21%) of patients had advanced fibrosis or cirrhosis, 85/ 1351 (6%) had cirrhosis.
A total of 283/ 1351 (21%) of patients had advanced fibrosis or cirrhosis, 85/ 1351 (6%) had cirrhosis.
The starting doses were 0.1mg/ day (15%), 0.2mg/ day (56.7%) and 0.3 mg/ day (26.3%), with up- and down-titration between these doses.
A total of 387 patients received dasatinib 70 mg twice daily (288 resistant and 99 intolerant).
diseases of immunological origin and metabolic diseases, of which a number are related to enzyme deficiencies.
A total of 48 patients with lymphoid blast CML received dasatinib 70 mg twice daily (42 resistant and 6 intolerant to imatinib).
A total of 573 patients were randomised to receive either TMZ + RT (n=287) or RT alone (n=286).
A total of 573 patients were randomised to receive either TMZ + RT (n=287) or RT alone (n=286).
A total of 611 patients were randomised to either the dasatinib 140 mg once daily or 70 mg twice daily group.
A total of 670 patients, of whom 498 were imatinib-resistant, were randomised to the dasatinib 100 mg once daily, 140 mg once daily, 50 mg twice daily, or 70 mg twice daily group.
A total of 6.9% of subjects receiving Circadin reported an adverse reaction compared with 5.9% of subjects taking placebo.
Following long-term treatment fentanyl may cause withdrawal in the newborn.
Long term treatment should be under regular (at least monthly) veterinary control.
Prior hormonal therapy for the treatment of metastatic disease was allowed.
Standard antidiarrhoeal treatments (e. g. loperamide) may be used.
Anti-emetic therapy may be administered (see section 4.4).
Prophylactic or empiric use of anti-infectives (bacterial, fungal, viral) should be considered for the prevention and management of infections during the neutropenic period.
Prophylactic antipyretic medication is recommended:
Anti-tuberculosis therapy should also be considered prior to initiation of STELARA in patients with a history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.
Use of anti-tuberculosis therapy should also be considered before the initiation of Humira in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.
It is not recommended to take ribavirin with didanosine and/or stavudine, as this can lead to the build up of lactic acid and the inflammation of the pancreas.
Concurrent treatment with glucosamine may increase the absorption and serum concentration of tetracyclines, but the clinical relevance of this interaction is probably limited.
Most patients required treatment for their orthostatic hypotension.
Treatment for only 16 weeks may be considered in selected patients infected with genotype 2 or 3 with LVL (≤ 800,000 IU/ mL) at baseline who become HCV negative by week 4 of treatment and remains HCV negative by week 16.
Treatment for only 16 weeks may be considered in selected patients infected with genotype 2 or 3 with LVL (≤ 800,000 IU/ mL) at baseline who become HCV negative by week 4 of treatment and remains HCV negative by week 16.
Treatment for 24 weeks may be considered in patients infected with
Treatment for 24 weeks may be considered in patients infected with
Effect ive therapy in treatment experienced patients is associated with a Cmin of approximately 100 ng/ml and an AUC0-24 of about 20,000 ng·h/ml.
Effective therapy in treatment experienced patients is associated with a Cmin of approximately 100 ng/ml and an AUC0-24 of about 20,000 ng·h/ml.
Effective therapy in treatment naïve patients is associated with a Cmin of approximately 50 ng/ml and an AUC0-24 of about 20,000 ng·h/ml.
Excessive glucocorticoid therapy will inhibit the growth-promoting effect of human growth hormone.
After intravenous initiation of treatment, the treatment can be continued orally as well.
Medical treatment should be sought straight away if you or your carer notice a sudden change in your mental state or sudden weakness or numbness of your face, arms or legs, especially on one side, or slurred speech, even for a short period of time.
Medical treatment should be sought straight away if you or your care-giver notice a sudden change in your mental state or sudden weakness or numbness of your face, arms or legs, especially on one side, or slurred speech, even for a short period of time.
Immediate medical treatment may be needed.
Treatment with Emselex may possibly mask symptoms associated with gallbladder disease.
Mimpara treatment should not be initiated in patients with a serum calcium (corrected for albumin) below the lower limit of the normal range.
- Tendon inflammation and rupture may occur with quinolone therapy including moxifloxacin,
Remicade must be given under the supervision and monitoring of a specialised doctor who has experience in the diagnosis and treatment of the diseases Remicade can be used to treat.
Only in case of a flare of severe disease not controlled by < Invented Name >, treatment with medium potency topical corticosteroids was initiated.
Treatment with Vistide should be prescribed by a doctor who has experience in the management of human immunodeficiency virus (HIV) infection.
When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.
have prior history of exposure to any bone morphogenetic protein (BMP) product;
Following long-term treatment, fentanyl may cause withdrawal in the new-born infant.
Long-term treatment during pregnancy may cause withdrawal symptoms in the new-born infant.
Dexamethasone was administered prophylactically before chemotherapy in 67% of patients.
Prophylaxis with adequate hydration and administration of uricostatics starting 48 hours prior to start of therapy is recommended for CLL patients to reduce the risk of tumour lysis syndrome.
Concurrent administration of potentially nephrotoxic drugs should be avoided as there might be an increased risk
Mild to moderate granulomas (small nodules) or abscesses may occur in the muscle tissue at the injection site.
Unilateral treatment can result in permanent heterochromia.
A third minor metabolite (M-24) is not detectable in human plasma.
• a type of leukaemia, called T-cell acute lymphoblastic leukaemia.
- stomach ulcers or any other bleeding disease of the gut
A dosage cup containing graduations at 3.75 ml (300 mg dose), 5 ml (400 mg dose), 6.25 ml (500 mg dose) and 7.5 ml (600 mg dose) is provided.
A volume of the sodium chloride 9 mg/ ml (0.9%) solution for infusion is to be withdrawn and discarded from a 250 ml infusion bag equal to the total volume of Naglazyme to be added.
Compared with pharmacokinetic data from adults with CRF where the same sampling duration was used, the ct
In order to ensure effective erythropoiesis, iron status should be evaluated for all patients prior to and during treatment and supplementary iron therapy may be necessary.
If blood pressure is difficult to control by initiation of appropriate measures, the haemoglobin may be reduced by decreasing or withholding the dose of Nespo (see section 4.2).
Do not substitute three 1 mg blisters for one 3 mg blister.
au Sodium chloride Polysorbate 80
with recombinant human erythropoietin and controls.
Urea, Sodium chloride, Polysorbate 20, Sodium dihydrogen phosphate dihydrate, Disodium phosphate dodecahyrate, Calcium chloride dihydrate, Glycine, L-Leucine, L-Isoleucine, L-Threonine, L-Glutamic acid, L-Phenylalanine, Water for injections.
Urea, sodium chloride, polysorbate 20, sodium dihydrogen phosphate dihydrate, disodium phosphate dodecahydrate, calcium chloride dihydrate, glycine, L-Leucine, L-Isoleucine, L- Threonine, L-glutamic acid, L-Phenylalanine, and water for injections.
Urea, sodium chloride, polysorbate 20, sodium dihydrogen phosphate, disodium hydrogen phosphate, calcium chloride, glycine, L-Leucine, L-Isoleucine, L-Threonine, L-Glutamic acid, and L-Phenylalanine.
Urea, Sodium chloride, Polysorbate 20, Sodium dihydrogen phosphate, Disodium hydrogen phosphate, Calcium chloride, Glycine, L-Leucine, L-Isoleucine, L-Threonine, L-Glutamic acid, L-Phenylalanine.
Human erythropoietin is an endogenous glycoprotein hormone that is the primary regulator of erythropoiesis through specific interaction with the erythropoietin receptor on the erythroid progenitor cells in the bone marrow.
Box 581 2003 PC Haarlem, The Netherlands
stranguria); central nervous system signs (incoordination, disorientation).
the kidneys'functions.
- urticaria, swelling of the face, eczema, excessive sweating, night sweats, hair loss, acne, dry or
Skin and subcutaneous tissue disorders
Urticaria, skin hyperpigmentation, allopecia, soft nails, rash, erythema
By binding selectively to ATIII, fondaparinux potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII.
- 327 patients undergoing hip fracture surgery treated for 3 weeks following an initial prophylaxis
35 Fondaparinux is excreted in rat milk but it is not known whether fondaparinux is excreted in human milk.
Fondaparinux is excreted in rat milk but it is not known whether fondaparinux is excreted in human milk.
ratios for overall survival ranged between 1.25 and 2.47 in favour of controls.
ed lower strength, Protopy 0.03% ointment, can be used.
au Lymphoma is a recognised and listed adverse effect for systemically administered calcineurin inhibitor products.
demonstrate the efficacy of fondaparinux for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
ra The fondaparinux clinical program in treatment of Venous Thromboembolism was designed to demonstrate the efficacy of fondaparinux for the treatment of deep vein thrombosis (DVT) and
Tacrolimus ointment does not affect collagen synthesis in humans.
Mutagenicity In vitro and in vivo tests did not indicate a genotoxic potential of tacrolimus.
comparison showed that the pharmacokinetics of darbepoetin alfa were similar for paediatric and adult patients with CRF.
e the incidence of death/ re-MI at Day 30 was significantly reduced from 14.0% on placebo to 11.3% (hazard ratio 0.80, 95% CI, 0.69, 0.93, p = 0.003).
e For a full list of excipients, see section 6.1
surgery treated for up to 24 days following an initial prophylaxis of 1 week In a randomised double-blind clinical trial, 737 patients were treated with fondaparinux 2.5 mg once du
A number of medicinal products are known to interact with glucose metabolism.
A local and in most cases transient swelling at the injection site may occur up to 4 weeks after
is not be used within two hours of applying Protopy.
Use with GPIIb/ IIIa inhibitors
Use in adults (16 years of age and above) Protopy is available in two strengths, Protopy 0.03% and Protopy 0.1% ointment.
Use in adults, adolescents ≥ 16 years of age and elderly
Use in adults, adolescents ≥ 16 years of age and elderly
Use in children As intranasal calcitonin is indicated for post-menopausal women, its use in children is not appropriate.
Additionally, only limited information concerning the long-term safety of (Invented name)® on growth, puberty, mental, emotional and behavioural development in this age group is available.
Use in children Sebivo is not recommended for use in children under 16 years of age.
Use in children The use of Zometa in children has not been studied and therefore it is not recommended.
Use in children The use of Zometa in children has not been studied and therefore it is not recommended.
VISTIDE has not been studied in children.
Use in children (including newborns) and adolescents < 16 years of age
Use in children (including neonates) and adolescents < 16 years of age
Use in children four years of age or older and less than 30 kg Patients < 30 kg not receiving valproate:
2 Use in children and adolescents: the clinical safety and effectiveness of bexarotene in the paediatric population (below 18 years of age) have not been studied and this product should not be used in a paediatric population until further data become available.
Use in children - There is no relevant indication for use of Foscan in children or adolescents.
Paediatric patients The efficacy and safety of DuoTrav in patients below the age of 18 years have not been established and its use is not recommended in these patients until further data become available.
Use in children The use of Cubicin in children has not been studied and is therefore not recommended.
Use in hepatic and renal impairment AZOPT has not been studied in patients with hepatic impairment and is therefore not recommended in such patients.
Use in hepatic and renal impairment Olopatadine in the form of eye drops (OPATANOL) has not been studied in patients with renal or hepatic disease.
Use in hepatic and renal impairment NEVANAC has not been studied in patients with hepatic disease or renal impairment.
Use in patients with hepatic impairment No dose adjustment is needed for patients with mild to moderate hepatic impairment.
14 Use in patients with hepatic impairment
3 Use in patients with hepatic impairment
Use in patients with hepatic impairment Losartan/ HCTZ is contraindicated in patients with severe hepatic impairment (see section 4.3.).
Use in patients with hepatic impairment
No initial dosage adjustment is necessary in patients with renal impairment and in haemodialysis patients.
Use in patients using other:
Use in patients with hepatic impairment
Use in patients with renal impairment
Use in patients with hepatic impairment: it was agreed to recommend in the SPC the individualization of dosage to overcome clearance variability between patients with hepatic impairment.
Use in patients with hepatic impairment: it was agreed to recommend in the SPC the individualization of dosage to overcome clearance variability between patients with hepatic impairment.
9 Use in patients with renal impairment: it was agreed that the individualisation of the dosage may be desirable, and this concept was introduced in the text for harmonisation.
Use in the elderly No dose adjustment is necessary for elderly patients (see section 5.2).
Use in the elderly No dose adjustment is necessary for elderly patients (see section 5.2).
Use in adult men In general, the recommended dose is 10 mg taken prior to anticipated sexual activity and with or without food.
Use in adult men In general, the recommended dose of tadalafil is 10 mg taken prior to anticipated sexual activity and with or without food.
Use in patients with impaired hepatic function Lenalidomide has not formally been studied in patients with impaired hepatic function and there are no specific dose recommendations.
Renal insufficiency The effect of any stage of renal insufficiency on melatonin pharmacokinetics has not been studied.
Using other medicines Interactions with other medicines are not known.
18 Using other medicines Avoid the use of other products on your treated KS lesions such as insect repellents that you use on your skin.
Using other medicines and other vaccines
Using other medicines and other vaccines:
Using other medicines or vaccines Please tell your doctor if you are/ your child is taking or have/ has recently taken any other medicines, including medicines obtained without a prescription or have/ has recently received any other vaccine.
Using other medicines or vaccines Please tell your doctor if you are/ your child is taking or have/ has recently taken any other medicines, including medicines obtained without a prescription or have/ has recently received any other vaccine.
Using other medicines or vaccines Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription or have recently received any other vaccine.
Using other medicines or vaccines Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription or have recently received any other vaccine.
Using other medicines or vaccines Please tell your doctor if your child is taking or has recently taken any other medicines, including medicines obtained without a prescription or has recently received any other vaccine.
Using other medicines Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription or have recently received any other vaccine.
Using other medicines You need to inform your doctor about any medicine or treatment that you are taking, have been given or are planning to have.
Using other medicines or vaccines Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription or have recently received any other vaccine.
18 Taking other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription
27 Using other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
39 Using other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
44 Using other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines obtained without a prescription.
Taking other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicine, including medicines obtained without a prescription.
Taking other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines including medicines obtained without a prescription.
Using other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Using other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Using other medicines Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Using other medicines Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Using other vaccines Please tell your doctor if your child is taking or has recently taken any other medicines, including medicines obtained without a prescription or has recently received any other vaccine.
Using CEPROTIN with food and drink
Using CEPROTIN with food and drink
Use of CHAMPIX with other therapies for smoking cessation The safety and benefits of taking CHAMPIX in combination with other medicines for stopping smoking have not been studied.
Using NovoNorm with food and drink
Using RISPERDAL CONSTA with food and drink You should avoid drinking alcohol when using RISPERDAL CONSTA.
Use with systemic immunosuppressive medicinal products
Using Yondelis with food and drink
2 Use of Humalog in an insulin infusion pump:
83 Use of Humalog in an insulin infusion pump:
Use of losartan in children and adolescents
Use during pregnancy and lactation Do not use during pregnancy and lactation.
12 Hepatic impairment No dose adjustment is required in patients with mild hepatic impairment.
2 Hepatic impairment No dose adjustment is required in patients with mild hepatic impairment.
Use in hepatic and renal impairment:
No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease.
Use in severe hepatic impairment: no dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease.
Use in renal impairment No dose adjustment is required in patients with impaired renal function.
Renal insufficiency No dose adjustment is required in patients with renal insufficiency and creatinine clearance above 15 ml/ min (see section 5.2).
Sibutramine should not be used during pregnancy.
ra co nditions, except topical administration), danazol (used for the treatment of some female hormonal disorders), oral contraceptives (used for birth control), thyroid hormones (used for the treatment of malfunction of the thyroid gland), growth hormones (used in endocrine conditions), sympathomimetic
Use the dosing pipette as provided with the product.
Hold pipette in upright position, twist and pull off cap and use the opposite end of the cap to break the seal.
Hold pipette in upright position, twist and pull off cap and use the opposite end of the cap to break the seal.
Use Prometax oral solution within 1 month of opening the bottle.
Always use the graduated measuring spoon to obtain the exact dose for administering the suspension.
Use calibrated dropper, so as to distribute 50 µl-drops.
If you smoke, the amount of insulin your body absorbs will be increased and you will have a greater od
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
25 Only use INCRELEX that is clear and colourless.
Use only syringes with clear, particle-free solutions and from undamaged containers.
Use the injection method as instructed by your health care professional.
Use the measuring cup provided in the carton to measure the correct dose.
You should take Neupro 2 mg for 7 days (e.g. if you start on a Sunday, switch to the next dose on the following Sunday.).
Only use OPATANOL as an eye drop.
Always use the measuring spoon provided.
Use a new needle and syringe for each injection. • it is the right medicine • it has not passed its expiry date • the vial is not damaged and the seal is not broken • the solution is not discoloured, cloudy or contains any foreign particles • the solution is not frozen.
Hormonal contraception Taking Telzir and ritonavir while taking the contraceptive pill may harm your liver and may stop the contraceptive from working properly. → Use an alternative non-hormonal type of contraception such as a condom.
For each single injection please use a new, sterile injection needle.
Use a moistened glove or a moist pad to keep the sponge in place.
Use the mirror if it helps. • Don’t touch your eye or eyelid, surrounding areas or other surfaces with the dropper.
Use the mirror if it helps. • Don’t touch your eye or eyelid, surrounding areas or other surfaces with the container tip.
You need to start and continue a reduced calorie diet and a physical activity program to get best results.
In patients with current suicidal ideations and/ or with a history of suicidal ideation and depressive disorder rimonabant
sanofi-aventis S. p. A., Strada Statale 17, Km 22, 67019 Scoppito (AQ), Italy
UVA, PUVA, UVB) or systemic immunosuppressive medicines (e.g. azathioprine or cyclosporin).
Do not substitute three 1 mg blisters for one 3 mg blister.
BRISTOL-MYERS SQUIBB PHARMA EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH United Kingdom
V08 C A VASOVIST is a formulation of a stable gadolinium diethylenetriaminepentaacetic acid (GdDTPA) chelate substituted with a diphenylcyclohexylphosphate group (gadofosveset trisodium), for use in magnetic resonance imaging (MRI).
V10X Radiolabelling of carrier molecules, specifically developed
second year of life following a three dose primary course N= 2009%
Vaccinations Immunosuppressants may affect responses to vaccination.
Vaccinations Live vaccines should not be given concurrently with ORENCIA or within 3 months of its discontinuation.
After reconstitution administer 0.2 ml submucosally to the inside of the upper lip.
Submucosal vaccination of 0.2 ml of reconstituted product.
3, 4, 5 months schedule
Vaccine against feline viral rhinotracheitis and feline calicivirosis.
Vaccine against feline viral rhinotracheitis, feline calicivirosis and feline panleucopenia.
Vaccine against feline viral rhinotracheitis, feline calicivirosis, chlamydiosis, feline panleucopenia and feline leukaemia.
Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia.
Purified subunit vaccine for the active immunisation of pregnant bitches to induce the passive protection of puppies against herpesvirus-induced fatal neonatal disease.
Pharmaco-therapeutic group (ATC Code):
certain types of vaccines during Raptiva treatment.
Live vaccine against feline upper respiratory tract disease caused by Bordetella bronchiseptica.
Live recombinant vaccine against Infectious Bursal Disease and Marek's Disease.
Placebo (n =88) Bosentan (n=80) Placebo (n=91) Bosentan (n=86) Baseline (BL); mean (SD) Change from BL; mean (SD) Treatment effect
- 29.01.1999 - 16.11.2000 - 214 days - 393 days
- Oral solution - 1 mg/ml - 5 presentations
Angina unstable, aortic valve incompetence, coronary artery atherosclerosis, sinus bradycardia, ventricular hypertropy
Vandral 37,5 mg comprimidos Vandral 50 mg comprimidos Vandral 75 mg comprimidos
Vaniqa is a white cream that contains 11.5% of the active substance eflornithine.
Vaniqa is a cream which is white to off white in colour.
Women use Vaniqa to reduce the growth of excessive hair on their faces.
Relapse rate derived variables / MRI-derived variables Placebo Natalizumab 315 627
Mean change in visual acuity from baseline to month 24 in study FVF2598g (MARINA) and study FVF2587g (ANCHOR)
Mean change in visual acuity from baseline to month 24 in study FVF3192g (PIER)
Mean change in visual acuity (letters) (SD)a a p < 0.01
Mean change from baseline in visual acuity ± SE (letters)
HAQ change from baseline over timee
Oesophageal or gastric varices or patients with oesophageal ulcers > 1 cm in diameter.
- Oesophageal or gastric varices or patients with oesophageal ulcers > 1 cm in diameter.
Use of injection sites should be rotated so that the same site is not used more than approximately once a month.
Use of the injection sites should be rotated so that the same is not used more than approximately once a month.
VARIPHARM ARZNEIMITTEL GmbH Lindenplatz 1 85540, Haar, Germany
disease and Peripheral arterial disease.
Cutaneous vasculitis (during long term use), alopecia, rash
Vasculitis, possibly associated with transient renal involvement
White soft paraffin E321 See package leaflet for further information
White soft paraffin Liquid paraffin Propylene carbonate White beeswax Hard paraffin
is White soft paraffin
Direct vasodilatation of the pulmonary arterial bed occur with consecutive significant improvement of pulmonary artery pressure, pulmonary vascular resistance and cardiac output as well as mixed venous oxygen saturation.
Vasovist 0.25 mmol/ ml, solution for injection Gadofosveset trisodium
This medicinal product is for diagnostic use only. • Contrast enhancement in magnetic resonance angiography (CE-MRA) VASOVIST is indicated for contrast-enhanced magnetic resonance angiography for visualization of abdominal or limb vessels in patients with suspected or known vascular disease.
VASOVIST is used in patients who are undergoing magnetic resonance angiography (MRA), a diagnostic method where pictures of the flow of the blood in the body are taken using a special scan called magnetic resonance imaging (MRI).
the hospital/ MRI-centre personnel
Vaxxitek HVT+IBD is a recombinant vaccine intended for use against Infectious Bursal Disease (also known as Gumboro Disease) and Marek's Disease in chickens.
Vaxxitek HVT+IBD is used to prevent the deaths of chickens and to reduce clinical signs and effects of Infectious Bursal disease which is a disease which damages the immune system of chickens.
Add Dex*** 20 mg (oral) (Days 1,2,4,5,8,9, 11,12)
Vd is also weight dependent, increasing with increasing body weight.
Vectibix 20 mg/ ml sterile concentrate Panitumumab IV
Vectibix contains the active substance panitumumab, which belongs to a group of medicines called monoclonal antibodies.
Vectibix must be administered as an intravenous (IV) infusion via an infusion pump, using a low protein binding 0.2 or 0.22 micrometer in-line filter, through a peripheral line or indwelling catheter.
Vectibix is used on its own in patients whose tumour cells have a protein on their surface called the epidermal growth factor receptor (EGFR) and which contain a non-mutated ‘ KRAS’.
Vectibix will be stored in the healthcare facility where it is used.
VEGF110, VEGF121 and VEGF165), thereby preventing binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2.
Care should be taken to avoid spraying into the eyes of the animal.
You should make sure that you use the medication chamber with the red latch for the 2.5 micrograms dose or the medication chamber with the purple latch for the 5 micrograms dose.
(Be careful not to touch the rubber seal.)
Do not use vials which are damaged, or if the solution is not clear or if it contains any particles.
Each new injection should be given at least 3 cm from an old site.
While you are taking Sebivo, make sure you do not run out of Sebivo.
Especially tell the doctor if you/your child takes insulin or other anti-diabetes medicines.
Velosulin 100 IU/ ml solution for injection or infusion in a vial.
These subjects experienced an average decrease in FEV1 of 21% (range 16%-33%) from baseline and were treated with EXUBERA for an average of 23 months.
Venlafaxine 50 mg TID (Indinavir 800 mg SD) CALCIUM CHANNEL BLOCKERS
Venta-Neb, a portable ultrasonic battery-powered nebuliser, has also been shown to be suitable for the administration of Ventavis.
VentaNeb, a portable ultrasonic battery-powered nebuliser, has also been shown to be suitable for the administration of Ventavis.
Venus, 26 Can Parellada Industrial 08228 Terrassa Spain
Verapamil, Felodipine, Nifedipine and Nicardipine LIPID LOWERING MEDICINAL PRODUCTS HMG Co-A Reductase Inhibitors
Multiple-dose administration of verapamil and sirolimus oral solution significantly affected the rate and extent of absorption of both drugs.
Variations type I/II, extensions, transfers, follow-up inspections
Visually check the vial for clumps.
You should check with your doctor or
You should check with your doctor or pharmacist if you are not sure.
● Make sure none of the items in your kit have been opened.
Double check the syringe to make sure that you have withdrawn the correct amount.
ge the Trudexa solution through the windows on the sides of the pre-filled pen.
Check the appearance of the Humira solution through the windows on the sides of the pre-filled pen.
Check the liquid to make sure it is clear and colourless.
Look for the needle tip inside the vial.
Nevertheless, check that the patch has not fallen off afterwards. • You should avoid external heat (for example excessive sunlight, saunas, hot baths heating pads or hot-water bottles) on the area of the patch. • If the patch has irritated your skin, you should keep that area protected from direct sunlight, as it may cause changes in the colour of the skin.
Severe hyperglycaemia or ketoacidosis must always be treated by a doctor, normally in a hospital.
not less than 106.0 CCID50
Pour the MAM and SSCS into separate developing tanks to a depth of approximately 0.5 cm.
Swallow the medicine directly from the measuring spoon.
versions influence the information in the Summary of Product Characteristics (SPC).
Tapeworms (Cestodes) Dipylidium caninum (adult) Taenia taeniaeformis (adult) Echinococcus multilocularis (adult)
Vertigo, Paraesthesia, Taste disturbance
Dizziness, hypertonia, numbness, general weakness, drowsiness, flu syndrome, malaise, oral dryness, nausea, headache, stiffness, soreness, rhinitis, upper respiratory infection.
Dizziness, nausea, itching red eruption of the skin (rash), black nails (melanonychia), hair loss.
Nervous system disorders: vertigo, paraesthesia, light-headedness, restlessness
Vertigo, hearing impairment/ loss, tinnitus, earache
Vertigo, hearing impairment/loss, tinnitus, earache
- dizziness, drowsiness, tingling or numbness
Vertigo Deafness, hypoacusia, tinnitus, ear pain, ear pruritus
Appli cation site vesicles Application site warmth Lethargy Discomfort Inflammation
mask, goggles and gloves
Human and veterinary medicinal products Official batch release excluded EC-Canada
veterinary professionals and the general public about medicinal products which have been evaluated within the Agency;
Please tell your doctor or health care professional
Please see the accompanying BYETTA Package Leaflet.
See the Package Leaflet for the full instructions on calculating and adjusting the doses.
See leaflet for further information.
Please see also the instructions for use (on reverse).
if you have a weakened immune system (immuno-compromised) whatever the cause.
23 Please see also section 2 of this leaflet about the risk of allergic reactions.
John's wort (Hypericum perforatum) or any
John´s Wort (Hypericum perforatum) or any
John's wort (Hypericum perforatum) or any other herbal
Please tell your doctor or health care professional prior to treatment
Please tell your doctor or health care professional if you are pregnant or breast-feeding.
Please inform your doctor or pharmacist if you are taking:
Tell your doctor if the child has a history of recurrent infections, or suffers from diabetes or other conditions that increase the risk of infection.  Infections/ monitoring:
Tell your doctor if the child has hepatitis C.
Tell your doctor if you have a history of recurrent infections, or suffer from diabetes or other conditions that increase the risk of infection.  Infections/ monitoring:
Tell your doctor if you or the child have a history of recurrent infections, or suffer from diabetes or other conditions that increase the risk of infection.  Infections/ monitoring:
Tell your doctor if you or the child have hepatitis C.
Please discuss with your healthcare professional which method is best for you: a) The Vial Adapter Method (MIXJECT™), b) The Non-Vial Adapter Method.
your doctor as this may affect the dose of Advagraf that you receive.
Please read the instructions carefully and follow them step by step.
Please read the instructions carefully and follow them step by step.
Please read the instructions carefully and rod
Before using the syringe, please read the following information carefully.
Please read the following instructions carefully before using your Actraphane 10 NovoLet.
Please read the following instructions carefully before using your Actraphane 20 NovoLet.
Please read the following instructions carefully before using your Actraphane FlexPen.
Please read the following instructions carefully before using your Actraphane 30 InnoLet.
Please read the following instructions carefully before using your Actraphane 30 NovoLet.
Please read the following instructions carefully before using your Actraphane 40 NovoLet.
Please read the following instructions carefully before using your Actraphane 50 NovoLet.
Please read the following instructions carefully before using your Levemir FlexPen.
Please read the following instructions carefully before using your Levemir InnoLet.
Please read the following instructions carefully before using your Mixtard 10 NovoLet.
Please read the following instructions carefully before using your Mixtard 20 NovoLet.
Please read the following instructions carefully before using your Mixtard 30 FlexPen.
Please read the following instructions carefully before using your Mixtard 30 InnoLet.
Please read the following instructions carefully before using your Mixtard 30 NovoLet.
Please read the following instructions carefully before using your Mixtard 40 NovoLet.
Please read the following instructions carefully before using your Mixtard 50 NovoLet.
Please read the following instructions carefully before using your NovoMix 30 FlexPen.
Please read the following instructions carefully before using your NovoMix 50 FlexPen.
Please read the following instructions carefully before using your NovoMix 70 FlexPen.
Please read the following instructions carefully before using your NovoRapid FlexPen.
Please read the following instructions carefully before using your Protaphane FlexPen.
Please read the following instructions carefully before using your Protaphane InnoLet.
Please read the following instructions carefully before using your Protaphane NovoLet.
Read all of this leaflet carefully including the Instructions for Use of Apidra, pre-filled pen, OptiSet before using this medicine.
You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you.
You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you.
You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you.
You may need to read it again. − If you have any further questions, please ask your doctor or pharmacist − This medicine has been prescribed for you.
You may need to read it again • If you have further questions, please ask your doctor or pharmacist • This medicine has been prescribed for you.
You may need to read it again. • If you have further questions, please ask your doctor or your pharmacist. • This medicine has been prescribed for you.
Keppra 100 mg/ ml concentrate for solution for infusion Levetiracetam
You may need to read it again. − If you have any further questions, ask your doctor or pharmacist. − This medicine has been prescribed for you.
You may need to read it again. • If you have further questions, please ask your doctor or your pharmacist. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
You may need to read it again. − If you have any further questions, ask your doctor or pharmacist. − This medicine has been prescribed for you.
You may need to read it again. • If you have further questions, please ask your doctor or pharmacist. • This medicine has been prescribed for you.
You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you.
You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
You may need to read it again. • If you have any further questions, ask your doctor. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.
You may need to read it again – If you have any further questions, ask your doctor, diabetes nurse or pharmacist – This medicine has been prescribed for you personally.
You may need to read it again. – If you have any further questions, ask your doctor, diabetes nurse or your pharmacist. – This medicine has been prescribed for you.
You may need to read it again. – If you have any further questions, ask your doctor, nurse or your pharmacist. – This medicine has been prescribed for you.
Please read this leaflet carefully before you start using this medicine.
Read all of this leaflet carefully before you start using < Invented Name > cream
You may need to read it again. – If you have any further questions, ask your doctor, diabetes nurse or your pharmacist. – This medicine has been prescribed for you.
You may need to read it again. – If you have any further questions, ask your doctor, diabetes nurse or your pharmacist. – This medicine has been prescribed for you.
You may need to read it again. – If you have any further questions, ask your doctor, diabetes nurse or your pharmacist. – This medicine has been prescribed for you.
You may need to read it again. – If you have any further questions, ask your doctor, diabetes nurse or your pharmacist. – This medicine has been prescribed for you.
You may need to read it again. – If you have any further questions, ask your doctor, diabetes nurse or your pharmacist. – This medicine has been prescribed for you.
You may need to read it again. – If you have any further questions, ask your doctor, nurse or your pharmacist. – This medicine has been prescribed for you.
You may need to read it again. – If you have any further questions, ask your doctor, nurse or your pharmacist. – This medicine has been prescribed for you.
You may need to read it again. – If you have any further questions, ask your doctor, diabetes nurse or your pharmacist. – This medicine has been prescribed for you.
You may need to read it again. – If you have any further questions, ask your doctor, diabetes nurse or your pharmacist. – This medicine has been prescribed for you.
You may need to read it again. – If you have any further questions, ask your doctor, diabetes nurse or your pharmacist. – This medicine has been prescribed for you.
You may need to read it again. – If you have any further questions, ask your doctor, nurse or your pharmacist. – This medicine has been prescribed for you.
Read all of this leaflet carefully before this medicine is administered to your baby.
Read all of this leaflet carefully before you are administered this medicine.
Read all of this leaflet carefully before your child receives this vaccine.
Read all of this leaflet before your child is vaccinated.
Read all of this leaflet carefully before your child is vaccinated.
You may need to read it again. • If you have further questions, ask your anaesthetist. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your anaesthetist or other doctor.
Read all of this leaflet carefully, including the Instructions for Use of Insulin Human Winthrop Comb 15, pre-filled pen, SoloStar, before you start using this medicine.
Read all of this leaflet carefully, including the Instructions for Use of Insulin Human Winthrop Comb 25, pre-filled pen, OptiSet, before you start using this medicine.
Read all of this leaflet carefully, including the Instructions for Use of Insulin Human Winthrop Comb 25, pre-filled pen, SoloStar, before you start using this medicine.
Read all of this leaflet carefully, including the Instructions for Use of Insulin Human Winthrop Comb 50, pre-filled pen, OptiSet, before you start using th is medicine.
Read all of this leaflet carefully, including the Instructions for Use of Insulin Human Winthrop Comb 50, pre-filled pen, SoloStar, before you start using th is medicine.
Read all of this leaflet carefully, including the Instructions for Use of Insulin Winthrop Rapid, pre-filled pen, SoloStar, before you start using this medicine.
Read all of this leaflet carefully including the Instructions for use of Insuman Comb 25, pre-filled pen, OptiSet, before you start using this medicine.
Read all of this leaflet carefully including the Instructions for Use of Insuman Comb 25, pre-filled pen, SoloStar, before you start using this medicine.
Read all of this leaflet carefully including the Instructions for use of Insuman Comb 50, pre-filled pen, OptiSet, before you start using th is medicine.
Read all of this leaflet carefully including the Instructions for Use of Insuman Comb 50, pre-filled pen, SoloStar, before you start using th is medicine.
Read all of this leaflet carefully including the Instructions for use of Insuman Rapid, pre-filled pen, OptiSet, before you start using this medicine.
Read all of this leaflet carefully including the Instructions for Use of Insuman Rapid, pre-filled pen, SoloStar, before you start using this medicine.
Read and follow all of these instructions carefully.
Read complete directions thoroughly before starting the preparation procedure.
Please read the instructions carefully and follow them step by step.
Please read the section below on breast-feeding.
Please read the information under ‘ Pregnancy and Breast feeding’. • if you are breast feeding. • if you have liver disease.
Please read all the information below before you begin to apply Kentera.
Please see the “Instructions for Use” at the end of the package leaflet for advice on how to use your insulin inhaler, M
Please follow the instructions provided with the Avostartclip.
PLEASE NOTE THAT APPLICANTS ARE NOT INCLUDED IN THIS ANNEX FOR CONFIDENTIALITY REASONS
Please contact your doctor if the rash worsens over time.
Please return left over medicine to your pharmacist.
Please observe these instructions for use, otherwise you will not fully benefit from Cetrotide 0.25 mg.
Using other medicines or vaccines Please tell your doctor if your child is taking or has recently taken any other medicines, including medicines obtained without a prescription or has recently received any other vaccine.
Please tell your doctor if your child is taking or has recently taken any other medicines, including medicines obtained without a prescription or has recently received any other vaccine.
is Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Please read enclosed instructions for use.
Please follow these instructions to ensure proper dosing.
When taking Pradaxa capsules out of the bottle, please observe the following instructions
Please check section 5 – How to store Insulin Human Comb 15 - of the reverse (insulin) side of this leaflet for OptiSet storage instructions.
Please check section 5 – How to store Insulin Human Winthrop Comb 25 - of the reverse (insulin) side of this leaflet for OptiSet storage instructions.
Please check section 5 – How to store Insulin Human Winthrop Comb 50 - of the reverse (insulin) side of this leaflet for OptiSet storage instructions.
Please check section 5 – How to store Insuman Basal - of the reverse (insulin) side of this leaflet for OptiSet storage instructions.
Please check section 5 - How to store Insuman Comb 15 - of the reverse (insulin) side of this leaflet for OptiSet storage instructions.
Please check section 5 – How to store Insuman Comb 25 - of the reverse (insulin) side of this leaflet for OptiSet storage instructions.
Please check section 5 – How to storeInsuman Comb 50 - of the reverse (insulin) side of this leaflet for OptiSet storage instructions.
Please check section 5 – How to store Insuman Rapid - of the reverse (insulin) side of this leaflet for OptiSet storage instructions.
- Breathing difficulty, chest pain, fluid accumulation in the lungs
VFEND has not been studied in patients with severe chronic hepatic cirrhosis (Child-Pugh C).
Invented name Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend Vfend
Via Complutense, 140 ES-28805 Alcalá de Henares Madrid, Spain
Via Complutense, 140 ES-28805 Alcalá de Henares Madrid, Spain
I-00144 Rome Italy Tel: + 39 06 500881
Via Franco Gorgone Zona Industriale 95030 Catania Italy
Via Franco Gorgone Zona Industriale 95100 Catania Italy
Via Franco Gorgone Zona Industriale 95100 Catania, Italy
Via Franco Gorgone Zona Industriale IT-95030 Catania Italy
Via Gramsci 731/733 - 50019 Sesto Fiorentino, Florence Italy
Via Luigi Einaudi 11 00012 Guidonia Montecelio/ Rome Italy
Vianex S. A Tatoiou Street 18 Km Athens-Lamia National Road 14671 Nea Erythrea Athens Greece
Viani Diskus is also used for the regular treatment of the symptoms of severe Chronic Obstructive Pulmonary Disease (COPD).
Viani Diskus Viani Diskus Viani Diskus Viani Diskus Viani Diskus Viani Diskus Aliflus Diskus Viani Diskus Vesaspir Diskus Brisair Accuhaler Viani Diskus Viani Accuhaler
Potentially serious hypokalaemia may result from systemic beta-2-agonist therapy but following inhalation at therapeutic doses plasma levels of salmeterol are very low.
Viani is indicated for the symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
Viani Evohaler should not be used to treat acute asthma symptoms for which a fast and short acting bronchodilator is required.
- Viani may affect the normal production of steroid hormones in the body, particularly if you
Via Tranquillo Cremona 10 20092 Cinisello Balsamo (Mi) Italy
Via Umberto Boccioni, 1 21040 Origgio, Varese Italy
Victor Babes Nr.50 Baia Mare, Jud Maramures Romania
Dosing procedure using the measuring syringe:
Vigabatrin/ Efavirenz Gabapentin/ Efavirenz
Vigabatrin/ Emtricitabine Gabapentin/ Emtricitabine
Vigabatrin/ Tenofovir disoproxil fumarate Gabapentin/ Tenofovir disoproxil fumarate
epilepsy with or without secondary generalization in cases where all other appropriate drug combinations have proved inadequate or have not been tolerated, and in monotherapy in children with infantile spasms, and, therefore, concluded that the Marketing Authorisations for these medicinal products should be maintained if amended in accordance with the Summary of Product Characteristics as set out in Annex III and under the conditions set out in Annex IV,
Vildagliptin 50 mg twice daily + pioglitazone (N=136)
Vildagliptin Absorption Following oral administration in the fasting state, vildagliptin is rapidly absorbed with peak plasma concentrations observed at 1.7 hours.
Vildagliptin Vildagliptin acts primarily by inhibiting DPP-4, the enzyme responsible for the degradation of the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).
Vildagliptin Information regarding overdose with vildagliptin is limited.
Vimpat is used to treat a certa in form of epilepsy (see below) in patients aged 16 years and older.
Vimpat is used to treat a certa in form of epilepsy (see below) in patients aged 16 years and older.
Vimpat syrup is provided with a measuring cup with graduation marks and instructions for use in the package leaflet.
Twenty-one days after the second injection, 86% of the people receiving the vaccine with 7.5 micrograms haemagglutinin had levels of antibodies that would protect them against H5N1.
Twenty-four of these patients (75.0%) regained clinical response after crossing over.
Twenty-seven (27, 75%) had undergone a nephrectomy.
VIOFAR EPE Terma Evaggelistrias GR-136 71 Acharnai Athens Greece
VIRACEPT 50 mg/g oral powder may be mixed with water, milk, formula, soy formula, soy milk, dietary supplements, or pudding.
Viracept has been studied in combination with other antiviral medicines in two main studies involving 605 patients aged 13 years or more, who were infected with HIV.
Viracept, in combination with other antiviral medicines, was more effective than the comparator medicines in both main studies.
VIRACEPT is indicated in antiretroviral combination treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children of 3 years of age and older.
VIRACEPT is indicated in antiretroviral combination treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children of 3 years of age and older.
Viracept should not be used in patients who are taking any of the following medicines: • rifampicin (used to treat tuberculosis); • St John's wort (a herbal preparation used to treat depression); • omeprazole (used to reduce stomach acid levels); • medicines that are broken down in the same way as Viracept and are harmful at high levels in the blood.
VIRACEPT may be mixed with water, milk, formula, soy formula, soy milk, dietary supplements, or pudding.
Viracept brought about similar reductions in viral load whether it was taken twice or three times a day.
Viraferon, 30 million IU/pen, solution for injection: lp
Viraferon, 60 million IU/pen, solution for injection: lp
Viraferon was administered at a dose of 3 MIU 3 times a week as monotherapy or in combination with na
Viraferon was administered at a dose of 3 MIU 3 times a week as monotherapy or in combination with na
Viraferon is administered subcutaneously at a dose of 3 million IU three times a week (every other day) to adult patients, whether administered as monotherapy or in combination with ribavirin.
Viraferon is administered subcutaneously at a dose of 3 million IU three times a week (every other day) to adult patients, whether administered as monotherapy or in combination with ribavirin. lon Children 3 years of age or older and adolescents:
Viraferon is given three times per week (every other day) by subcutaneous injection (under the skin).
Viraferon is given in combination with ribavirin. t uc
Viraferon is used for the treatment of: • chronic (long-term) hepatitis B (a disease of the liver due to an infection by the hepatitis B virus) t
ViraferonPeg 100 micrograms, powder and solvent for solution for injection in pre-filled pen
ViraferonPeg 150 micrograms, powder and solvent for solution for injection in pre-filled pen
ViraferonPeg 50 micrograms, powder and solvent for solution for injection in pre-filled pen
ViraferonPeg 80 micrograms, powder and solvent for solution for injection in pre-filled pen
ViraferonPeg 80 micrograms powder and solvent for solution for injection pre-filled pen peginterferon alfa-2b
ViraferonPeg monotherapy As monotherapy the ViraferonPeg regimen is 0.5 or 1.0 microgram/k g/week.
ViraferonPeg monotherapy As monotherapy the ViraferonPeg regimen is 0.5 or 1.0 microgram/kg/week.
ViraferonPeg is indicated for the treatment of chronic hepatitis C only in patients 18 years of age or older.
Viraferon is presented as a solution for injection uc
VIRAMUNE is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents, and children of any age (see section 4.4.).
VIRAMUNE is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents, and children of any age (see section 4.4).
Virbagen Omega contains the active substance recombinant omega interferon of feline origin (from cats) at 5 MU/ vial or 10 MU/ vial.
Viread 245 mg film-coated tablets Tenofovir disoproxil
Viread contains the active substance tenofovir disoproxil.
Viread is a treatment for Human Immunodeficiency Virus (HIV) infection in adults over 18 years of age.
Viread has not been studied in patients over 65 years of age.
- Viread should also not be administered concurrently with adefovir dipivoxil.
Viread should also not be administered concurrently with adefovir dipivoxil.
Viread [outer packaging only]
(Pertussis toxoid1, Filamentous haemagglutinin1, Pertactin1) Hepatitis B surface antigen2 Poliovirus (inactivated) type 1, 2, 3 Haemophilus type b polysaccharide (polyribosylribitol phosphate) 2
Split Influenza virus*, inactivated, containing antigens equivalent to the following strains:
Inactivated Feline Leukaemia Virus (61E strain) Adjuvants
Inactivated Feline Leukemia Virus (61E strain) Adjuvants
Active components Inactivated Feline Panleukopenia Virus (CU4 strain)
Inactivated Feline Panleukopenia Virus (CU4 strain):
Inactivated recombinant avian influenza virus of H5N3 subtype (strain rg-A/ ck/ VN/ C58/ 04) > 1:40 HI units per dose
Inactivated recombinant avian influenza virus of H5N3 subtype (strain rg-A/ ck/ VN/ C58/ 04)
hands and feet, eyes, lips and/ or tongue).
Increase in transaminases Increased bilirubin
If you have any further questions on the use of this product, ask your doctor.
Vision blurred, eye pain, eye inflammation, xerophthalmia
Vision blurred Vasodilatation Pharyngitis, sinus pain
- Blurred vision, increased sensitivity to light, eye disorders
- Abnormal vision, conjunctivitis, eye pain, swollen glands on the eyelids
- Blurred vision, conjunctivitis, eye pain, swollen gland on the eyelids
Blurred vision, conjunctivitis, eye pain, abnormal vision, lacrimal gland disorder
Blurred vision, conjunctivitis, eye pain, abnormal vision, lacrimal gland disorder
Vision blurred, diplopia Visual disturbance, eye swelling, visual field defect, visual acuity reduced, eye pain, asthenopia, dry eye, lacrimation increased
Blurred vision, Sensations described as eye pain, Swelling of eyelids, Conjunctival hyperaemia
68 Screw the needle straight and tightly onto your FlexPen.
Screw the needle straight and tightly onto your FlexPen.
Screw the needle straight and tightly onto your FlexPen.
Screw needle on until secure.
VISTIDE should be administered by health care professionals adequately experienced in the care of AIDS patients.
The therapy should be prescribed by a physician experienced in the management of HIV infection.
VISTIDE is indicated in the treatment of CMV retinitis in patients with Acquired Immunodeficiency Syndrome (AIDS).
VISTIDE should be used only when other agents are considered unsuitable.
You should not be given VISTIDE if you are breast feeding.
Visudyne is used for the treatment of predominantly classic CNV in AMD patients, and of all types of CNV in pathological myopia patients.
Vitamin D is easily absorbed in the small intestine.
Vitamin D is easily absorbed in the small intestine.
Content (concentration)
Method of administration
Route of administration Oral use Oral use Oral use
Route of Administration Oral use Oral use Oral use
Route of administration Oral use Oral use Oral use Oral use
Route of Administration Oral use Oral use Oral use Oral use Oral use Oral use
Route of Administration Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Route of Administration Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Route of administration Endotracheopulmonary use Endotracheopulmonary use
intranasal/ ocular, spray or drinking water
Intravenous use after reconstitution and dilution.
Intravenous use For single use only Read the enclosed package leaflet before use
Intravenous use as short infusion Read the package leaflet before use From a microbiological point of view, the product should be used immediately
Intravenous use Read the package leaflet before use.
Intravenous use Read the package leaflet before use
Read the package leaflet before use.
Read the package leaflet before use.
Intravenous use Intravenous use Intravenous use Intravenous use Intravenous use
For oral use Read the package leaflet before use Use only as directed by your doctor
bottle (amber glass) bottle (HDPE) bottle (HDPE) bottle (HDPE) bottle (HDPE)
Oral use Read the package leaflet before use
Oral use Read the leaflet before use
Oral use Read the package leaflet before use
Oral use Read the package leaflet before use.
Oral use Read the package leaflet before use
Oral use Do not chew or crush Read the package leaflet before use
Oral use Do not suck or chew tablets Read the package leaflet before use
blister (alu) blister (alu) blister (alu) blister (alu) blister (alu) blister (alu) blister (alu) blister (alu) blister (alu) blister (alu) blister (alu) blister (alu) blister (alu) blister (alu)
Oral use Shake gently before use Read the package leaflet before use.
Oral use Use only as directed by your doctor Read the package leaflet before use
oral use oral use oral use
oral use oral use oral use intravenous use intravenous use
oral use oral use oral use intravenous use intravenous use intravenous use
oral use oral use oral use intravenous use intravenous use intravenous use intravenous use
oral use oral use oral use oral use oral use intravenous use intravenous use intravenous use
oral use use oral use use oral use use oral use use intravenous use intravenous use intravenous use
Oral use Oral use Oral use Oral use Oral use
oral use oral use intravenous use intravenous use
intravenous use intravenous use intravenous use oral use oral use oral use oral use oral use oral use oral use
Oral use Oral use Oral use Oral use Oral use Oral use
Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Route of administration Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Route of administration Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Route of administration Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Intramuscular use Intramuscular use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Route of Administration Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Route of administration Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Route of administration Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Route of administration Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Intramuscular and subcutaneous use The contents of the vial should be used immediately after piercing of the rubber stopper.
For subcutaneous or intravenous use Read the package leaflet before use
Transdermal use Read the package leaflet before use.
< This medicine has been authorised under “exceptional circumstances”.
See BOXED INFORMATION ON ABACAVIR HYPERSENSITIVITY REACTIONS in section 4.4 and section 4.8.
See BOXED INFORMATION ON HYPERSENSITIVITY REACTIONS in section 4.4 and section 4.8.
See BOXED INFORMATION ON HYPERSENSITIVITY REACTIONS in sections 4.4. and 4.8.
The list of the product names concerned is given in Annex I.
*see Package Leaflet for VIRACEPT oral powder for patients less than 18 kg body weight.
*see Additional Information below.
See section 2 and 6.1 for further information on excipients.
See text on HMG-CoA reductase inhibitors.
see attached list solution for infusion parenteral
*see dose modification for provisions for the modification to dose and dosage schedule
hearing things that are not really there (hallucinations), suicide attempts, personality change, feeling abnormal
For step-by-step instructions please see over the page • Do not inject Arixtra into muscle.
For step-by-step instructions please see over the page. • Do not inject Arixtra into muscle.
• Do not inject Quixidar into muscle.
tablets (see Section 6, “ Further information”).
See Table 1 for the recommended preparation and administration of Keppra concentrate to achieve a total daily dose of 500 mg, 1000 mg, 2000 mg, or 3000 mg in two divided doses.
See Table 1 for the recommended preparation and administration of Keppra concentrate to achieve a total daily dose of 500 mg, 1000 mg, 2000 mg, or 3000 mg in two divided doses.
2 should be considered in elderly patients (see ‘ Use in patients with renal impairment'above and section 5.2).
Age associated decreased renal clearance with an increase in AUC levels should be considered in elderly patients (see ‘ Use in patients with renal impairment'above and section
Age associated decreased renal clearance with an increase in AUC levels should be considered in elderly patients (see ‘ Use in patients with renal impairment'above and section 5.2).
• Contraindication in patients with severe hepatic impairment (with or without cirrhosis) and in patients with baseline values of hepatic aminotransferases (AST and/ or ALT) > 3X ULN. • Hepatic aminotransferases (ALT and/ or AST) should be evaluated prior to initiation of ambrisentan. • During therapy, monthly monitoring of ALT and AST is recommended. • Discontinuation of ambrisentan therapy if patients develop sustained, unexplained clinically significant ALT and/ or AST elevation or if ALT and/ or AST elevation is accompanied by signs or symptoms of hepatic injury (e. g. jaundice). • In subjects without clinical symptoms of hepatic injury or jaundice, reinitiation of ambrisentan may be considered following resolution of hepatic enzyme abnormalities.
The pharmacokinetics of ambrisentan in patients with severe hepatic impairment (with or without cirrhosis) has not been studied.
Volibris has not been studied in individuals with severe hepatic impairment (with or without cirrhosis).
Volume to be Administered 0.25 ml 0.5 ml 1.0 ml 2.0 ml 4.0 ml 6.0 ml
blood volume [ml] = 41 [ml/ kg] x body weight [kg] + 1200 [ml] blood volume [ml] = 44 [ml/ kg] x body weight [kg] + 1600 [ml]
Vomiting Abdominal pain Hypophenylalaninemia
Vascular disorders General disorders
Vomiting and constipation Not known:
Vomiting or diarrhoea has been observed in one out of 10 dogs.
Diarrhoea Constipation Vomiting Dyspepsia Flatulence
Rash Sweating increased Night sweats
Alanine amino- transferase increased, Aspartate amino- transferase increased
Voriconazole/ Emtricitabine Voriconazole/ Tenofovir disoproxil fumarate ANTICONVULSANTS
Co-administration of sirolimus (2 mg single dose) with multiple-dose administration of oral voriconazole (400 mg every 12 hours for 1 day, then 100 mg every 12 hours for 8 days) in healthy subjects has been reported to increase sirolimus Cmax and AUC by an average of 7-fold and 11-fold respectively.
When treatment with voriconazole is stopped, the initial dosage of efavirenz should be restored.
blood sugar; too much or too little could harm your health and the baby's dic
Driving and using machines ► If you drive or use tools or machines: watch out for signs of a hypo.
your diet ► If you drive or use tools or machines: watch out for signs of a hypo.
You r ability to concentrate or react may be reduced if:
Your ability to concentrate or react may be reduced if:
Your ability to concentrate or react may be reduced if:
Your patient data will be registered anonymously – nobody will know it is information about you.
Your patient data will be registered anonymously– nobody will know it is information about you.
Your injections are given under the skin or into a vein.
Your syringes The syringes supplied with this medicine have a coloured needle protection device that is attached to the needle.
You should have regular eye examinations during treatment with MIRAPEXIN.
You should have regular eye examinations during treatment with SIFROL.
Your doctor or nurse must teach you how to inject BYETTA before you use it for the first time.
- your child has diarrhoea or is vomiting.
- your child has any disease which reduces his/her resistance to infection.
- your child was born with a malformation of the gastrointestinal system that might predispose for
Your child must NOT take Diacomit • if your child is allergic (hypersensitive) to stiripentol or to any of the other ingredients of Diacomit. • if your child has ever experienced attacks of delirium.
120 Your blood sugar level may either rise or fall if you take:
137 Your blood sugar level may either rise or fall if you take:
38 Your blood sugar level may either rise or fall if you take:
557 Your blood sugar level may either rise or fall if you take:
585 Your blood sugar level may either rise or fall if you take:
701 Your blood sugar level may either rise or fall if you take:
85 Your blood sugar level may either rise or fall if you take:
88 Your blood sugar level may either rise or fall if you take:
You r blood sugar level may either rise or fall if you take:
Your blood sugar level may either rise or fall if you take:
Your regular weekly Pegasys injection is on Monday.
Your injection is to be given under the skin (subcutaneous), and so you may use the Aranesp pre-filled pen.
Your insulin will work more ed
Your insulin will work more quickly if you inject around it the waist.
Your insulin will work more quickly if you inject around the waist.
Your insulin will work more quickly if you inject it around the waist.
Your insulin will work more quickly if you inject it around the waist.
Your doctor has decided that the Aranesp pre-filled pen is the best way for you, a nurse, or a carer to inject Aranesp.
Your doctor may decide that it is best for you or a carer to inject Aranesp.
Your doctor has determined the exact dosage for administration of IntronA according to your individual needs.
Your doctor will usually build up your dose gradually.
Your doctor will decide to treat you with MIRCERA administered as a single injection once a month.
Your doctor will choose RISPERDAL CONSTA 25 mg or 37.5 mg.
Your doctor will start you on a low dose, and gradually increase the dose over a few weeks until you reach a dose that works for you (called the effective dose).
Your doctor will carefully consider whether to treat you with combinations of tenofovir and didanosine.
Your doctor will decide on the dose of RISPERDAL CONSTA that is right for you.
When Zometa is given Your doctor will determine when you will be given Zometa.
Your doctor will determine the best dose for you.
Your doctor will determine your dose.
Your doctor will determine how many cycles of treatment you will need.
Your doctor might avoid treating you with these medicines while you are receiving Tarceva.
Your doctor must record the conduct of these tests on your alert card.
Expiry date of the constituted suspension:
Your doctor should advise you about using contraception before taking Mycophenolate mofetil Teva, whilst taking Mycophenolate mofetil Teva, and for 6 weeks after you have stopped taking Mycophenolate mofetil Teva.
Your doctor must treat you with caution if you have a glucuronidation disorder like Gilbert’s syndrome.
Your doctor will take blood samples weekly for at least 8 weeks to check your platelets, white and red blood cell counts which may slightly decrease due to the therapy.
Your doctor will make regular checks to make sure that Sebivo is working.
Your doctor knows about this and will look for signs of it.
Your doctor will consider what is the best treatment for you during your pregnancy. lp
Your doctor will consider whether or not this treatment would be too risky for your baby.
Your doctor will rule out any other reasons which could explain these symptoms before you are treated. ► who suffer from relapsing-remitting multiple sclerosis, with at least two relapses within the last two years. ► who suffer from secondary progressive multiple sclerosis with active disease shown by relapses.
Your doctor should only give you Cholestagel if a diet low in fat and cholesterol did not work well enough on its own.
Your or your child's doctor will arrange for the blood tests to be done.
Your doctor or nurse will show you how to inject yourself.
Your doctor or nurse will show you how to inject yourself.
Your doctor or his/her assistant will instruct you how to self- inject IntronA.
Your doctor or his/her assistant will instruct you how to self- inject IntronA.
Your doctor or hi s/her assistant will instruct you how to self-inject Viraferon.
Your doctor or hi s/her assistant will instruct you how to self-inject Viraferon.
Your doctor or his/her assistant will instruct you how to self-inject Viraferon.
Your doctor or his/ her assistant will instruct you on how to give the injections.
Your doctor or his/her assistant will instruct you how to self- inject PegIntron.
Your doctor or his/her assistant will instruct you how to self- inject ViraferonPeg.
Your doctor or his/ her assistant will instruct you how to self-inject Valtropin.
Your doctor or his/her assistant will show you how to self-inject with the PegIntron pre-filled pen.
Your doctor or his/her assistant will show you how to self-inject with the PegIntron pre-filled pen.
Your doctor or his/her assistant will show you how to self-inject with the ViraferonPeg pre-filled pen.
Your doctor or his/her assistant will show you how to self-inject with the ViraferonPeg pre-filled pen.
Your doctor or nurse will make it up into a solution that will be given as an injection.
Your doctor or nurse will have already advised you where to inject (e. g. tummy, front of thigh).
Your doctor or pharmacist are responsible for storing Vidaza.
Your doctor who may recommend that you stop treatment.
Your doctor may decide to gradually lower your dose of CHAMPIX at the end of treatment.
Your doctor may lower your dose of Telzir and ritonavir depending on the amount of liver damage.
Your doctor can limit these by immediately applying gentle pressure at the injection site.
Your doctor may want to increase the time you take to complete your injection, or change your dose.
Your doctor may allow you to take other medicines, including those used for constipation.
Your doctor may have prescribed Cardoreg 4 mg prolonged release tablets and associated names because your blood pressure is high, which if left uncontrolled can increase the risk of heart disease or stroke.
The chance of experiencing these side effects decreases with subsequent doses of Aclasta.
Hormonal contraceptives (such as the Pill) can affect the way Lamictal works Your doctor may recommend that you use a particular type of hormonal contraceptive, or another method of contraception, such as condoms, a cap or a coil.
ge Driving and using machines Do not drive or use machinery if you become drowsy, tired, or confused from this medicine. lon Important information about some of the ingredients of Viraferon Your doctor may recommend that you consider vaccination against hepatitis A and B if you regularly/ repeatedly receive human plasma-derived albumin. no
ge Driving and using machines Do not drive or use machinery if you become drowsy, tired, or confused from this medicine. lon Important information about some of the ingredients of Viraferon Your doctor may recommend that you consider vaccination against hepatitis A and B if you regularly/repeatedly receive human plasma-derived albumin. no
Your doctor may suggest you take a multivitamin supplement.
Your doctor may need to change the dose of these other medications or take other precautions.
Your doctor may need to change the dose of these other medicines or take other precautions.
Your doctor may change your recommended infusion rate to make the infusion more comfortable.
Your doctor may provide you with an Avostartclip that attaches onto the syringe and reduces the dose of Avonex that will be injected.
Your doctor may recommend that you stop treatment at least 3 weeks prior to this time.
Your doctor will perform appropriate laboratory tests to make sure that you have adequate Factor VIII levels.
334 blood or clots in stool (or black, tarry stool); fever or chills beginning after a few weeks of treatment, pain in your lower back or side; difficulty or inability to pass urine, painful or inflamed muscles (sometimes severe); problems with your eyes or your eyesight or hearing; severe or painful reddening of your skin or mucous membrane, severe bleeding from your nose.
347 blood or clots in stool (or black, tarry stool); fever or chills beginning after a few weeks of treatment, pain in your lower back or side; difficulty or inability to pass urine, painful or inflamed muscles (sometimes severe); problems with your eyes or your eyesight or hearing; severe or painful reddening of your skin or mucous membrane, severe bleeding from your nose.
360 blood or clots in stool (or black, tarry stool); fever or chills beginning after a few weeks of treatment, pain in your lower back or side; difficulty or inability to pass urine, painful or inflamed muscles (sometimes severe); problems with your eyes or your eyesight or hearing; severe or painful reddening of your skin or mucous membrane, severe bleeding from your nose.
373 blood or clots in stool (or black, tarry stool); fever or chills beginning after a few weeks of treatment, pain in your lower back or side; difficulty or inability to pass urine, painful or inflamed muscles (sometimes severe); problems with your eyes or your eyesight or hearing; severe or painful reddening of your skin or mucous membrane, severe bleeding from your nose.
Your doctor will test your blood to ensure that your white blood cell (cells that fight infection) and red blood cell (cells that carry oxygen) counts, platelets (blood clotting cells) and other laboratory values are at acceptable levels.
Your doctor will watch out for any effects on your immune system and treat them if necessary.
Your doctor will take this into account when treating your diabetes.
Your doctor will take this into account when treating your diabetes.
Your doctor will ensure that you receive the right amount of Nplate.
Your doctor will review the medicines you are currently taking to make sure you are not taking something that can’t be taken with the Tyverb.
Your doctor will check whether any symptoms you had may be related to this hypersensitivity reaction.
Your doctor will check whether any symptoms you had may be related to this hypersensitivity reaction.
The doctor will check your child's height regularly, and make sure he or she is taking the lowest possible effective dose.
Your doctor will test your blood to ensure that your white blood cell (cells that fight infection) and red blood cell (cells that carry iron
Your doctor will test your blood to ensure that your white blood cell (cells that fight infection) and red blood cell (cells that carry iron
Your doctor will test your blood to ensure that your white blood cell (cells that fight infection) and red blood cell (cells that carry iron and oxygen) counts, platelets (blood clotting cells) and other laboratory values are at acceptable levels.
Your doctor will test your blood to ensure that your white blood cell (cells that fight infection) and red blood cell (cells that carry iron and oxygen) counts, platelets (blood clotting cells) and other laboratory values are at acceptable levels.
Your doctor will test your blood to ensure that your white blood cell (cells that fight infection) and red blood cell (cells that carry iron and oxygen) counts, platelets (blood clotting cells) and other laboratory values are at acceptable levels.
Your doctor will te st your blood to ensure that your white blood cell (cells that fight infection) and red blood cell (cells that carry iron and oxygen) counts, platelets (blood clotting cells) and other laboratory values are at acceptable levels.
Your doctor will test your blood to ensure that your white blood cell (cells that fight infection) and red blood cell (cells that carry iron and oxygen) counts, platelets (blood clotting cells) and other labo ratory values are at acceptable levels.
Your doctor will test your blood to ensure that your white blood cell (cells that fight infection) and red blood cell (cells that carry iron and oxygen) counts, platelets (blood clotting cells) and other laboratory values are at acceptable levels.
Your doctor will check your blood pressure, pulse rate and lung function.
Your doctor has prescribed ADROVANCE to treat your osteoporosis and because you are at risk of vitamin D insufficiency.
BEROMUN has been prescribed and will be administered by your doctor, together with the anti- tumour agent melphalan, for the treatment of soft tissue sarcoma of the arms and legs.
Your doctor has prescribed FOSAVANCE to treat your osteoporosis and because you are at risk of vitamin D insufficiency.
Your doctor has prescribed INVANZ because you have one (or more) of the following types of infection: • Infection in the abdomen • Infection affecting the lungs (pneumonia) • Gynaecological infections • Skin infections of the foot in diabetic patients.
Your doctor has prescribed REYATAZ for you because you are infected by the HIV that causes Acquired Immunodeficiency Syndrome (AIDS).
Your doctor will advise if you should stop or continue breast-feeding and stop or continue your treatment.
Your doctor will advise you for how long you can use Avonex or when to stop.
Your doctor will take regular blood samples.
Your doctor will tell you how long your treatment may last.
Your doctor will tell you exactly when to stop taking Aranesp.
Your doctor should decide whether you can take Efexor with other medicines.
Your doctor should decide whether you can take Efexor depot with other medicines.
Your doctor will tell you how much you should take each day.
Your doctor will give this card to you before you start taking Tracleer.
Your doctor will advise you what to do.
Your doctor will decide on the dose of RISPERDAL CONSTA that is right for you • Your doctor may prescribe oral RISPERDAL for the first three weeks following your first injection.
Your doctor will tell you how many Efient tablets to take.
Your doctor will tell you how much you should inject.
Your doctor will tell you if and when you should stop the treatment.
51 You will get a booklet from your doctor which will help you to track your response to EXJADE.
Your body may develop antibodies after you received Botulinum toxin type A preparations.
- free of cuts, rashes and/ or irritations.
• your skin becoming fragile and easily blistered (especially areas that are frequently exposed to sunlight) • and/ or you have stomach or limb pain.
Your pharmacist should advise you how to measure the medicine using the multi-dosing oral syringe provided in the pack.
Your weight Below 50 kg Between 50 kg and 100 kg Over 100 kg
Your first injection of Avonex may be given by your doctor.
Your first injection of Avonex may be given by your doctor.
Your health care professional will be responsible for the correct storage, use and disposal of Faslodex.
Your FORSTEO contains 28 days of medication.
Your immune system may become impaired (immunosuppression).
If you stop using BYETTA this can affect your blood sugar levels.
Your treatment will usually last for about 14 days.
You will start the treatment with a single dose of 60 mg.
ge ► If it hasn't been stored correctly or been frozen (see 6 How to store Ultratard) ► If it's not uniformly white and cloudy after rolling.
ge ► If it hasn't been stored correctly or been frozen (see 6 How to store Ultratard) ► If it's not uniformly white and cloudy after rolling.
- You have a history of bleeding disorders (tendency to develop bruises).
Your doctor or nurse should have discussed this with you previously.
• you had a heart attack or stroke in the month before your treatment • you have unstable angina pectoris (new or increasing chest pain) • you are at risk of blood clots in the veins (deep venous thrombosis) – for example, if you have had clots before
- You had a skin rash with blisters during pregnancy (called ‘ herpes gestationis’)
You may have a very rare serious allergic reaction to Ultratard or one of its ingredients (called a systemic allergic reaction).
You are more likely to stop smoking if you are motivated to stop.
• You have taken antibiotics or medication to treat Helicobacter pylori within the last 28 days.
• You have taken proton pump inhibitors (stops indigestion) in the last 14 days.
you had a heart attack or stroke in the month before your treatment you have unstable angina pectoris – new or increasing chest pain you are at risk of blood clots in the veins (deep venous thrombosis) – for example, if you have had clots before.
- you drink alcohol, particularly if you are not eating much,
be photosensitive once the injection has been given.
- you change the area of skin where you inject insulin (for example from the thigh to the upper
- you change the area of skin where you inject insulin (for example from the thigh to the upper arm),
- you change the area of skin where you inject insulin (for example from the thigh to the upper
- you change the area of skin where you inject insulin (for example from the thigh to the upper
- you change the area of skin where you inject insulin (for example from the thigh to the upper
- you change the area of skin where you inject insulin (for example from the thigh to the upper
You may get a headache, feel dizzy, sick or faint, and your heart may beat faster than normal.
You will probably experience one or more of the following mild to moderate reactions at the place where you inject your medicine: ● itchiness ● swelling ● redness ● pain or tenderness ● hardened skin or bumps.
You will probably experience one or more of the following mild to moderate reactions at the place where you inject your medicine: ● itchiness ● swelling ● redness ● pain or tenderness ● hardened skin or bumps.
You may experience diet-related treatment effects (see Chapter 4).
- notice that your muscles get very rigid or jerk violently, or if you get tremors, agitation,
- notice that your muscles get very rigid or jerk violently, or if you get tremors, agitation, confusion,
These measures will help to protect the environment.
You control your own treatment, under the guidance of medical staff.
You should stop breast-feeding before using PhotoBarr.
You should have had training in how to inject Avonex.
You should have a pre-filled syringe containing clear liquid (the solvent) and one vial containing GONAL-f (the white powder).
You need to choose a new site for each injection to allow the area time to recover and help prevent infection.
You should stick a new Neupro patch onto the skin once a day.
You should start treatment with Pradaxa within 1 – 4 hours after surgery finishes, taking a single capsule.
You should complete this card and take it to your doctor at your next visit so that your doctor or gynaecologist can assess whether you need additional or alternative reliable contraceptive methods.
You should complete this card and take it to your doctor at your next visit so that your doctor or gynaecologist can assess whether you need additional or alternative reliable contraceptive methods.
MicardisPlus may increase the blood pressure lowering effect of other medicines and you should consult with your doctor if you need to adjust the dose of your other medicine while taking MicardisPlus.
You should consult your doctor before taking SINGULAIR if you are breast-feeding or intend to breast-feed.
You should also be aware that vaccination may not
You should also tell your doctor, if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal.
You should also tell your doctor, if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal.
You should also have a 12-lead electrocardiogram performed before your first dose.
You should also take calcium and vitamin-D supplements, as recommended by your doctor.
You should also inform your doctor if you have ever received Refludan, hirudin or a hirudin analogue.
You should also tell your doctor if you are already taking Tasigna and you are prescribed a new medicine that you have not taken previously during Tasigna treatment.
In addition, it is important to realise that BEROMUN and melphalan treatment can result in the above general side-effects becoming more severe and serious.
In particular, tell your doctor or pharmacist if you are using: other antibiotics for treating infections like aminoglycosides oral contraceptive pills.
You should get a replacement when the counter shows the number 020.
You should avoid drinking alcohol when taking RISPERDAL.
You should avoid taking MIRAPEXIN together with antipsychotic medicines.
You should avoid taking Oprymea together with antipsychotic medicines.
You should avoid taking SIFROL together with antipsychotic medicines.
Care should be taken to avoid contact of the skin with the suspension.
You are advised to avoid becoming pregnant and must use adequate contraception while using Humira and for at least 5 months after the last Humira treatment.
You are advised to avoid becoming pregnant and must use adequate contraception while using Trudexa and for at least 5 months after the last Trudexa treatment.
You should tell your doctor immediately if it happens.
You should speak with your doctor about any suspicious skin changes.
You should know these factors so that you are able to react correctly to changes in your blood sugar level and to prevent it from becoming too high or too low.
You normally should be able to recognise when your blood sugar is falling too much so that you can take the right actions.
You normally should be able to recognise when your blood sugar is falling too much so that you can take the right actions.
You normally should be able to recognise when your blood sugar is falling too much so that you can take the right actions.
In particular, you should tell your doctor if you are taking or have recently taken medicines with active substances like:
You should continue to inject Raptiva as long as instructed to do so by your doctor.
You should continue to take APTIVUS for as long as instructed by your doctor.
You should stay on a diet designed to lower cholesterol or other non-pharmacological treatments (e. g. exercise, weight reduction) while you take this medicine.
If you stop taking Xyrem You should continue to take Xyrem for as long as instructed by your Doctor.
You should take AMMONAPS with a large volume of water.
You should take AMMONAPS in equally divided doses by mouth, through a gastrostomy (tube through the abdomen to the stomach) or through a nasogastric tube (tube through the nose to the stomach).
You will need to have treatment and to follow a diet throughout your life, unless you have a successful liver transplantation.
You must receive a course of probenecid tablets administered orally with each VISTIDE dose.
Taking MIRAPEXIN with food and drink You should be cautious while drinking alcohol during treatment with MIRAPEXIN.
You should take Iscover for as long as your doctor continues to prescribe it.
You should take one capsule ORACEA each day in the morning.
You must tell the doctor or nurse/ technologist immediately if you feel pain around the area where the needle is placed.
You should measure out a level scoop of powder by using the handle of the second scoop to scrape off the extra powder (see picture below).
You must report any of the following symptoms immediately to the doctor or nurse/ technologist, and get immediate treatment as they can be or can become very serious: side effects affecting the heart (fainting, extra heart beats, chest pain) or the respiratory system (shortness of breath, tightening of the airways, swollen or tight throat, itchy or runny nose, sneezing).
You must report any of the following symptoms immediately to the doctor or nurse/ technologist, and get immediate treatment as they can be or can become very serious: side effects affecting the heart (fainting, extra heart beats, chest pain) or the respiratory system (shortness of breath, tightening of the airways, swollen or tight throat, itchy or runny nose, sneezing).
You must follow the instructions given to you to avoid sunlight and bright indoor light.
Using the cup measure another 23 ml water and add this to the bottle. You should always add a total of 46 ml (2 x 23 ml) of water irrespective of the dose you are taking.
Always follow your doctor’s instructions about when and how to take EXUBERA.
You should always use this special cup to take your Norvir oral solution to make sure you take the right dose.
You should use 16400 IU* per kg bodyweight.
You need to use the pen correctly in order to get the most benefit from BYETTA.
Use a new injection needle for each injection and dispose of it after each use.
You should check with your doctor if you are not sure.
You should brush your teeth thoroughly twice daily and have regular
You should brush your teeth thoroughly twice daily and have regular dental examinations.
You should brush your teeth thoroughly twice daily and have regular dental examinations.
Therefore, you should take special care in your dental hygiene.
You need to prime it before your first dose.
- you should be observed closely for the development of a serious form of chest infection called
need to stop taking Janumet for a couple of days before and after the procedure
need to stop taking Velmetia for a couple of days before and after the procedure
Your doctor’s instructions should be carefully observed.
Your doctor or nurse should have discussed this with you previously.
A clicking sound can be heard, which will stop when the injection button has been pressed in completely.
A clicking sound can be heard, which will stop when the injection button has been pressed in completely.
− if you are hypersensitive to the active ingredient (tenecteplase) or any of the other ingredients of METALYSE;
• you are allergic (hypersensitive) to docetaxel or any of the other ingredients of Docetaxel Winthrop. • the number of white blood cells is too low. • you have a severe liver disease. • you are pregnant or breast feeding.
• you are allergic (hypersensitive) to docetaxel or any of the other ingredients of Docetaxel Winthrop. • the number of white blood cells is too low. • you have a severe liver disease. • you are pregnant or breast feeding.
• you are allergic (hypersensitive) to docetaxel or any of the other ingredients of TAXOTERE. • the number of white blood cells is too low. • you have a severe liver disease. • you are pregnant or breast feeding.
Only you know how much pain you are having, and only you should operate IONSYS to start a dose of medicine.
You may be more likely to think like this:
ra If your blood sugar is too high (hyperglycaemia) Your blood sugar level may be too high, if for example: – you have not taken enough insulin, or if it has become less effective, e.g. through incorrect stora ge,
au A hypo means your blood sugar level is too low.
23 You will have blood tests before you begin treatment with Vidaza and at the start of each period of treatment (called a ‘cycle’).
- you inject too much insulin,
- you inject too much insulin,
These will be given in hospital, around the time of your transplant operation.
If test is not successful, the pen might be damaged.
Press the injection button in completely to discard the dose and select again.
There is one simple precaution because of the radioactivity:
You should not apply other topical medicines on your ulcer while using REGRANEX.
Therefore you should not take Invirase/ritonavir with other medicines without your doctor’s consent.
Under no circumstances should you change the dose without first speaking to your doctor.
Under no circumstances should you attempt to inject yourself unless you have been trained to do so.
Under no circumstances should you attempt to inject yourself unless you have been trained to do so.
This is always done by a pharmacist or a nurse and not by yourself.
You should not inject your medicine into moles, scar tissue, bruises or your navel.
But you must use it only if it looks like water.
You should not breast-feed during treatment with Prometax transdermal patches.
You should not stop this medicine unless told to do so by your doctor as your symptoms may return.
You should not stop this medicine told to do so by your doctor as your symptoms may return.
You should not stop or alter the medication without your doctor’s advice.
Do not change doses of Effentora or your other pain medicines on your own.
You should not start treatment with Betaferon (see ‘ Pregnancy’).
You should not start treatment with Betaferon (see ‘Pregnancy’).
You should not discontinue the treatment without first contacting your doctor.
You should not leave it more than 24 hours before you drink it.
You should not use ADENURIC if you are breast feeding, or if you are planning to breastfeed.
You should not take ADROVANCE if you are or think you may be pregnant, or if you are breast-feeding.
If you have severe depression or thoughts about suicide, you must not use Avonex.
You should not take this medicine if you have a condition called glucose-galactose malabsorption and should take note of this amount of glucose if you need to watch your sugar intake for any reason.
You should not take CHAMPIX while you are pregnant.
You should NOT take CIALIS more than once a day.
You should not take Cozaar Comp in the first 12 weeks of pregnancy, and you must not take them at all after the 13th week as their use during pregnancy may possibly be harmful to the baby.
Pregnancy and breast-feeding 69 You should not take losartan in the first 12 weeks of pregnancy, and you must not take them at all after the 13th week as their use during pregnancy may possibly be harmful to the baby.
You must not take losartan if you are breast-feeding.
You must not take Tracleer if you are pregnant and you must also not become pregnant while taking Tracleer, because it cannot be excluded that Tracleer may harm the foetus.
You must not take Tracleer if you are pregnant and you must also not become pregnant while taking Tracleer, because it cannot be excluded that Tracleer may harm the foetus.
You must not use Efficib if you are breast-feeding or plan to breast-feed.
You should not take FOSAVANCE if you are or think you may be pregnant, or if you are breast-feeding.
You must not use Janumet if you are breast-feeding or plan to breast-feed.
You should not take the following medicines while using Neupro, because they may decrease its effect: anti-psychotics (used to treat certain mental conditions) or metoclopramide (used to treat nausea and vomiting).
You must not take MicardisPlus if you are breast-feeding.
You should not take NovoNorm if you are breast-feeding.
50 You must not take Onsenal if you are breast feeding.
You must not take Onsenal if you are breast feeding.
You should NOT take Tadalafil Lilly more than once a day.
You should not take TRITACE if you are breast-feeding.
You must not use Velmetia if you are breast-feeding or plan to breast-feed.
You should not be given Aclasta if you are breast-feeding.
If your levels of the red blood pigment (haemoglobin) are too high you should not receive Epoetin alfa HEXAL, since you have an increased risk of blood clotting after the surgery.
You should not receive more than one treatment course of 24 months over your lifetime.
You should not have more than 3 injections in a 24 hour period and no more than 8 injections of Firazyr in total per month.
You must not use Yondelis if you will receive yellow fever vaccine and it is not recommended that you use Yondelis if you will receive a vaccine containing live virus particles.
You must not be given Zometa if you are breast-feeding.
If you have previously taken Jalra but had to stop taking it because of side effects (liver disease), you should not take Jalra again.
You should not use Fertavid if you are breast-feeding.
GANFORT should not be used if you are breast-feeding.
Do not use Kepivance if you are breast- feeding.
r You should not use Levviax with medicines containing ergotamine or dihydroergotamine tablets or
You should not use < Invented Name > if you are pregnant.
You should not take Revatio if you are taking these medicines.
You should not take Xolair when you are breast feeding.
You should not use Galvus if you are breast-feeding or plan to breast-feed.
You should not use Jalra if you are breast-feeding or plan to breast-feed.
You should not use Xiliarx if you are breast-feeding or plan to breast-feed.
You should not use Januvia if you are breast-feeding or plan to breast-feed.
You should not use TESAVEL if you are breast- feeding or plan to breast-feed.
You will not receive another ESA and your doctor will treat you for this condition.
23 You should not experience any effects from ECALTA if your doctor stops ECALTA treatment.
If your blood sugar is too low (hypoglycaemia) Your blood sugar levels may fall too much, if for example: – you take too much insulin, – you miss meals or delay them,
Cannot completely push in the injection button when priming the pen or injecting a dose.
When the pen is empty, you cannot use it again.
When the pre-filled pen is empty you cannot use it again.
When the pre-filled pen is empty you cannot use it again.
When the pre-filled pen is empty you cannot use it again.
When the KwikPen is empty you cannot use it again.
When the pre-filled pen is empty you cannot use it again.
You are not exposing other people to radiation.
You or someone else might also administer ADVATE as an injection, but only after receiving adequate training.
You or your child should continue to take VIRAMUNE for as long as instructed by you or your child's doctor.
You (or your child, if he/ she is being treated) must not receive Atriance • if you (or your child, if he/ she is being treated) are allergic (hypersensitive) to nelarabine or any of the other ingredients of Atriance.
You/ your child (if he/ she is being treated) will have an infusion (a drip) once a day for 5 days.
You may apply the next patch at the usual time the next day.
Once you have been shown how, you can also inject the solution yourself.
You may require medical attention.
You may need to read it again.
d • If you hav e any further questions, ask your doctor or pharmacist.
d • If you have any further questions, ask your doctor or pharmacist.
You may need to read it again. • If you have any further questions, ask your doctor or pharmacist.
• If you have further questions, please ask your doctor or your pharmacist.
You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you.
You may need to read it again. • If you have any further questions, ask your doctor or your pharmacist. • This medicine has been prescribed for you.
You may require medical attention.
You may experience convulsions, muscle weakness and confusion.
You may need urgent medical attention or hospitalisation.
You can drink water during the fasting period.
Change the injection site if you notice the area is red or sore.
You may want to store the big outer needle cap in the compartment.
You may store the product when kept in its outer carton at ambient room temperature (up to 25°C) for a single period of up to 3 months.
You may start treatment with Activelle on any convenient day.
Your body may develop antibodies (inhibitors) against factor IX, which will inactivate Nonafact.
You may need to read it again • If you have further questions, please ask your veterinary surgeon or your pharmacist • This medicine has been prescribed for your dog only and you should not pass it on to others.
You can inject Avonex yourself without the help of your doctor, if they have trained you to do this.
You can inject Avonex yourself without the help of your doctor, if they have trained you to do this.
(You can also take this dose as two 1 mg/500 mg tablets, twice a day.)
(You can also take this dose as two 2 mg/500 mg tablets, twice a day.)
You can then build up the dose again, as you did the first time.
468 The injection button cannot be pressed in.
539 The injection button cannot be pressed in.
609 The injection button cannot be pressed in.
679 The injection button cannot be pressed in.
The injection button cannot be pressed in.
If you wish, you may take it with water or another beverage of choice.
You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.
You might ask them to tell you if they think your depression is getting worse, or if they are worried about changes in your behaviour.
You may eat normally on the day you are treated with Aclasta.
It may take up to 2 months before you see results.
You may get best results if you take Agopton first thing in the morning.
You can get a larger print version of this leaflet by calling the local representatives.
You can take Avandia with or without food.
You may take CIALIS with or without food.
You can take CoAprovel with or without food.
You may take Efient with or without food.
You may take Keppra with or without food.
You can take the suspension at mealtimes or in between meals.
356 You can take the sachets at mealtimes or in between meals.
364 You can take the sachets at mealtimes or in between meals.
You can take MicardisPlus tablets with or without food.
You can take MicardisPlus with or without food.
You can take Oprymea with or without food.
You can take SIFROL with or without food.
You may take your tablets with or after a meal or on an empty stomach.
You might get infections more easily while you are receiving Remicade treatment.
You may have a very rare serious allergic reaction to Actraphane or one of its ingredients (called a systemic allergic reaction).
You may have a very rare serious allergic reaction to Actrapid or one of its ingredients (called a systemic allergic reaction).
You may have a very rare serious allergic reaction to Insulatard or one of its ingredients (called a systemic allergic reaction).
You may have a very rare serious allergic reaction to Insulatard or one of its ingredients (called a systemic allergic reaction).
You may have a very rare serious allergic reaction to Levemir or one of its ingredients (called a generalised allergic reaction).
You may have a very rare serious allergic reaction to Mixtard or one of its ingredients (called a systemic allergic reaction).
► If you suddenly feel unwell, and you: start sweating; start being sick (vomiting); have difficulty uc
You may have a very rare serious allergic reaction to NovoMix 30 or one of its ingredients (called a systemic allergic reaction).
You may have a very rare serious allergic reaction to NovoMix 50 or one of its ingredients (called a systemic allergic reaction).
You may have a very rare serious allergic reaction to NovoMix 70 or one of its ingredients (called a systemic allergic reaction).
You may have a very rare serious allergic reaction to NovoRapid or one of its ingredients (called a systemic allergic reaction).
You may have a very rare serious allergic reaction to Protaphane or one of its ingredients (called a systemic allergic reaction).
You may have a very rare serious allergic reaction to Protaphane or one of its ingredients (called a systemic allergic reaction).
You may have a very rare serious allergic reaction to Velosulin or one of its ingredients (called a ro
You can put a new patch on after the procedure.
You can gradually return to normal indoor lighting.
You can use moisturisers (emollients) with < Invented Name >.
You may want to hold the pen using the grip.
You can use < Invented Name > on all skin areas, including the head, face and neck and in the folds of the skin.
You may need to set an alarm clock to make sure you wake up to take the second dose.
You can see how much insulin is left by holding the KwikPen with the needle pointing up.
MIRCERA can be self-injected by yourself either under the skin or if you are on haemodialysis, through the haemodialysis line according to your doctor’s advice.
- you are taking any other medicines (see below),
Boehringer Ingelheim International GmbH Binger Strasse 173 D-55216 Ingelheim am Rhein Germany
- you are taking or have stopped taking certain other medicines (see section 2, "Using other
- you get painful reddening of the skin and/ or blisters on the body or in the mouth,
You produce many different kinds of antibodies.
You will receive appropriate training for you to do this.
You will receive this dose every day for 42 days (up to 49 days) in combination with radiation therapy.
You will be given other medicines to help protect your new kidney during this time, such as ciclosporin and corticosteroids and after you leave hospital.
You will be given Paxene every two weeks, as long as the results of your blood tests show that it is safe to carry on with your treatment.
You will be given Paxene every three weeks, as long as the results of your blood tests show that it is safe to carry on with your treatment.
You should usually receive your infusion once every 3 weeks.
You will be given the first injection within 5 to 15 minutes before the operation.
You/ your child will receive a total of two injections.
You/ your child will receive a total of three injections over 6 months.
It will contain the radioactive technetium isotope in an amount called 740-1110 MBq.
You will receive a total of three injections over 6 months.
If this happens, a general medical evaluation including liver function should be considered
If this happens, a general medical evaluation including liver function should be considered
Rinsing the mouth out with water and spitting it out immediately after taking each puff may help.
To help prevent side effects occurring, your doctor will make sure you are on the lowest dose of Viani that will control your asthma.
You will be monitored for 30 minutes after your examination.
Your treatment will be supervised by a doctor who specialises in the treatment of Fabry Disease.
You should expect to be monitored more carefully for problems with low levels of vitamins A, D, E, K and folic acid.
The following two blood tests will be carried out before you first take Thelin and at intervals during treatment
These and other documents are available either on the Internet at http://www.eudra.org/emea.html or by writing to:
These and other documents are available either on the Internet at http://www.eudra.org/emea.html or by writing to:
You will find this section under ‘ Other medicines and Telzir’.
Advice on which areas to choose is given in the first part of this Annex.
You will also find this information in the Patient Alert Card you have been given by your doctor.
- you are taking or have stopped taking certain other medicines (see section 2, "Using other
- you are taking or have stopped taking certain other medicines (see section 2, "Using other
- you are taking or have stopped taking certain other medicines (see section 2, "Using other
You will see a yellow indicator move into the windows during the injection.
Not sure how much insulin remains in the cartridge
- feel depressed, have suicidal thoughts, or notice unusual changes in your behaviour
An example of a medication record is also included.
An example of a medication record is also included (see Annex Part III).
patients deemed at risk of infection
The Committee for Proprietary Medicinal Products, having regard to its Opinion of 8 June 1995 and the grounds for appeal submitted on 11 August 1995, is of the Opinion that marketing authorisations for all medicinal products referred to in the Annexe to this final opinion should be withdrawn.
Waarderweg 39 2031 BN Haarlem 2003 PC Haarlem The Netherlands
Waarderweg 39, NL 2031 BN, Haarlem, Postbox 581 The Netherlands
Waarderweg 39 PO Box 581 2003 PC Haarlem The Netherlands
Waarderweg 39 P. O. Box 581 2003 PC HAARLEM the Netherlands
Waarderweg 39 P. O. Box 581 2031 BN Haarlem The Netherlands
Waarderweg 39 P. O. BOX 581 2031 BN Haarlem The Netherlands
Merck Sharp & Dohme B. V., Waarderweg 39, Postbus 581, 2003 PC Haarlem The Netherlands
Waarderweg 39 Postbus 581 2003 PC Haarlem The Netherlands
Waarderweg 39, Postbus 581 2003 PC Haarlem The Netherlands
Waarderweg 39, Postbus 581 NL-2003 PC Haarlem The Netherlands
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
Warfarin Co-administration of multiple doses of 10 mg of len alidomide had no effect on the single dose pharmacokinetics of R- and S- warfarin.
Warfarin Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of R- and S- warfarin.
Warfarin - Lasofoxifene had no effect on the pharmacokinetics of R- and S- warfarin.
Warfarin The effects of Enviage on warfarin pharmacokinetics have not been evaluated.
Warfarin The effects of Riprazo on warfarin pharmacokinetics have not been evaluated.
Warfarin The effects of Sprimeo on warfarin pharmacokinetics have not been evaluated.
Warfarin The effects of Tekturna on warfarin pharmacokinetics have not been evaluated.
• warfarin or other oral anti-coagulants (to thin the blood) • probenecid (for gout) • methotrexate (for certain types of cancer, psoriasis, rheumatoid arthritis) • theophylline (for breathing problems) • tizanidine (for muscle spasticity in multiple sclerosis) • clozapine (an antipsychotic)
• warfarin or other oral anti-coagulants (to thin the blood) • probenecid (for gout) • methotrexate (for certain types of cancer, psoriasis, rheumatoid arthritis) • theophylline (for breathing problems) • tizanidine (for muscle spasticity in multiple sclerosis) • clozapine (an antipsychotic) • ropinirole (for Parkinson’s disease) • phenytoin (for epilepsy)
Mr Wathion first worked as pharmacist in a retail pharmacy.
Mr Wathion first worked as pharmacist in a retail pharmacy.
Mr Wathion first worked as pharmacist in a retail pharmacy.
Miles Gray Road Basildon, Essex SS14 3FR United Kingdom United Kingdom
A new website was launched in September 1998 with an improved structure that will in particular allow for better access to documents in different languages.
Weimer Pharma Gmbh Im Steingerüst 30 D- 76437 Rastatt Germany
Whalton Road Morpeth Northumberland NE61 3YA United Kingdom
Wicklow +353-1-205-0900 Ísland Lyngháls 13 IS-110 Reykjavík +354-540-8080 Italia Centro Direzionale Milano 2 Palazzo Borromini IT-20090 Segrate MI Milano +39-2-210181
Wicklow, Ireland Przedsiebiorstwo Farmaceutyczne ANPHARM S. A., ul.
Wieb Pharm Vertriebs Gmbh & Co. Kg Diestraat 15 D-25870 Norderfriedrichskoog Germany
Wilzin 25 mg is an aqua blue hard capsule imprinted "93-376”.
Wilzin 50 mg is a orange opaque hard capsule imprinted “ 93-377”.
Wilzin should be taken on an empty stomach, separated from mealtimes.
Wilzin should be taken on an empty stomach, at least 1 hour before or 2-3 hours after meals.
Wilzin must be taken on an empty stomach, at least 1 hour before or 2-3 hours after meals.
Wilzin is prescribed for the treatment of Wilson's disease, which is a rare inherited defect in copper excretion.
Wilzin is used to treat Wilson's disease.
Wilzin was not compared to either a dummy treatment, or to the medicines already used in Wilson's disease.
Wilzin should not be given to patients who are allergic to zinc.
Box 31, 5830 AA Boxmeer, The Netherlands.
WINTHROP ARZNEIMITTEL GMBH Urmitzer Str.
Sverige Wyeth AB Tel: + 46 8 470 3200 Fax: + 46 8 730 0666
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION
Carretera A-1 Km 23 Desvio Algete Km 1 28700 San Sebastian de los Reyes Madrid Spain
Wyeth Farma S. A Carretera A-1 Km 23 Desvio Algete Km 1 28700 San Sebastian de los Reyes Madrid Spain
Sebastian de los Reyes, Madrid Spain
Wyeth-Lederle Pharma GmbH Efectin 50 mg - Tabletten Storchengasse 1 1150 Vienna Austria
Wyeth Medica Ireland Wyeth BioPharma Campus at Grange Castle Grange Castle Business Park Clondalkin Dublin 22 Ireland
Wyeth Pharmaceuticals New Lane, Havant, Hampshire, PO9 2NG United Kingdom
Wyeth Pharmaceuticals New Lane Havant Hampshire PO9 2NG United Kingdom
Wyeth Pharmaceuticals New Lane Havant Hampshire PO9 2NG United Kingdom.
Wyeth Pharmaceuticals New Lane Havant Hampshire PO9 2NG United Kingdom
Wyeth Pharmaceuticals New Lane Havant Hampshire, PO9 2NG United Kingdom
Wyeth Pharmaceuticals New Lane Havant Hampshire, PO9 2NG United Kingdom
Wyeth Pharmaceuticals New Lane Havant Hants PO9 2NG United Kingdom
Xagrid is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.
Xagrid are white capsules containing the active substance anagrelide 0.5 mg.
(E415), sodium benzoate (E211), saccharin sodium (E954), titanium dioxide (E171) and flavour.
Xarelto is used to prevent the formation of clots in the veins (venous thromboembolism, VTE) in adults who are undergoing surgery to replace a hip or knee.
Xeloda has minor or moderate influence on the ability to drive and use machines.
Xeloda is used with docetaxel (another anticancer medicine) after treatment with anthracyclines (another type of anticancer medicine) has failed.
Xenical reduces the absorption of supplements of some fat soluble nutrients, particularly beta-carotene and vitamin E.
22 Xenical should be taken with a well-balanced, calorie controlled diet that is rich in fruit and vegetables and contains an average of 30% of the calories from fat.
Xenical is indicated in the treatment of obesity in conjunction with a low calorie intake diet.
Xenical has no influence on the ability to drive and use machines.
Xenical only works in the presence of dietary fat.
Xeomin has minor or moderate influence on the ability to drive and use machines.
Xeomin is reconstituted prior to use with sterile unpreserved sodium chloride 9 mg/ ml (0.9%) solution for injection.
Xeomin is used for the treatment of the following conditions in adults: • eyelid spasm (blepharospasm) • twisted neck (spasmodic torticollis)
Xeomin has not been studied in the paediatric population and is therefore not recommended in the paediatric age group until further data become available.
Xeomin may only be used by health care professionals experienced in the application of Botulinum toxin.
The two related adverse events were reported in the same patient who received 30/ 60 U of Xeomin (one injection site pain and one dysphagia).
X and Y are the days (to be determined) when pre-treatment measurements should be performed.
Xolair is a powder and solvent, which are made up into a solution for injection.
Xyrem can also cause respiratory depression (inhibition of breathing).
Xyrem is supplied with a measuring device and a cup.
Yarvitan also has a slight appetite decreasing effect due to its mode of action.
Yarvitan is indicated as an aid in the management of overweight and obesity in adult dogs.
Yarvitan is used in adult dogs that are overweight or obese, to help them lose weight.
YENTREVE increases the levels of serotonin and norepinephrine in the nervous system.
Yentreve should not be used with monoamine oxidase inhibitors (a group of antidepressants), fluvoxamine (another antidepressant), or ciprofloxacin or enoxacin (types of antibiotic).
YENTREVE should not be used in combination with nonselective, irreversible Monoamine Oxidase Inhibitors - MAOIs (see section 4.5).
Yondelis 0.25 mg powder for concentrate for solution for infusion Trabectedin IV use
Yondelis 0.25 mg powder for concentrate for solution for infusion Trabectedin
Yondelis 0.25 mg powder for concentrate for solution for infusion.
Yondelis 0.25 mg powder for concentrate for solution for infusion Yondelis 1 mg powder for concentrate for solution for infusion Trabectedin
Yondelis 1 mg powder for concentrate for solution for infusion Trabectedin IV use
Yondelis 1 mg powder for concentrate for solution for infusion Trabectedin
Yondelis 1 mg powder for concentrate for solution for infusion.
Yondelis was more effective when it was given once every three weeks than the alternative dosing schedule.
Yondelis must be administered under the supervision of a physician experienced in the use of chemotherapy.
Yondelis must be given under the supervision of a doctor who is experienced in the use of chemotherapy.
Yondelis must be reconstituted and further diluted prior to infusion.
Yondelis is indicated for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.
Yondelis is used to treat patients with advanced soft tissue sarcoma, a type of cancer that develops from the soft, supporting tissues of the body.
Yondelis is a powder for concentrate for solution for infusion.
Yondelis is an anti-cancer medicine that works by preventing the tumour cells from multiplying.
Yondelis is used for the treatment of patients with advanced soft tissue sarcoma, when previous medicines have been unsuccessful or the patients are unsuited to receive them.
Yondelis must not be mixed or diluted with other medicinal products except those mentioned in section 6.6.
Yondelis must not be used in children until further information is available.
Yondelis must not be used in patients with elevated bilirubin.
Yondelis must not be used if you have severe liver or kidney damage.
You will start your treatment with a low dose of Vimpat, usually 50 mg twice a day, and increase it week by week.
YTRACIS is only to be used by specialists with the appropriate experience.
Ytracis is a solution containing the active substance yttrium (90Y) chloride.
YTRACIS is a radioactive medicine used in combination with another medicine product which targets specific body cells.
Ytracis must not be given directly to any patient.
Yttriga is a radioactive liquid, which contains the active substance yttrium (90Y) chloride.
In the case of Yttriga, the product is used to label medicines that have been specially developed for use with the active substance yttrium (90Y) chloride.
Yttriga must not be given directly to any patient.
Yttriga is not be administered directly to the patient.
ZACTRAN 150 mg/ ml solution for injection for cattle Gamithromycin
ZACTRAN 150mg/ ml solution for injection for cattle Gamithromycin
ZAGAM Sparfloxacin 100 mg White film coated tablets Oral administration
ZAGAM Sparfloxacin 200mg White film coated tablets Oral administration
Zalasta is also used to treat moderate to severe manic episodes (extremely high mood) in adults.
Zalcitabine and/ or Zidovudine (unboosted saquinavir)
Zalcitabine and/or Zidovudine (unboosted saquinavir)
Zalcitabine and/or Zidovudine (saquinavir/ritonavir)
Zarzio 30 MU/ 0.5 ml solution for injection or infusion in pre-filled syringe
Zarzio 30 MU/ 0.5 ml solution for injection or infusion in pre-filled syringe
Each pre-filled syringe contains 48 MU filgrastim in 0.5 ml, corresponding to 96 MU/ ml
Zarzio 48 MU/ 0.5 ml solution for injection or infusion in pre-filled syringe
Zarzio 48 MU/ 0.5 ml solution for injection or infusion in pre-filled syringe
Zarzio can also be used in people who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow.
Zavesca has been studied in indications where certain events reported as adverse drug reactions, such as neurological symptoms/ signs and thrombocytopenia could also be due to the underlying conditions.
Zavesca has not been evaluated in patients with hepatic impairment.
4.4 Special warnings and precautions for use
Zenapax does not increase this risk when it is used together with other immunosuppressive drugs, including cyclosporine and corticosteroids.
Zerene can be taken immediately before going to bed or after the patient has gone to bed and is experiencing difficulty falling asleep.
Zevalin is radiolabelled by mixing it with a solution of radioactive yttrium (90Y) chloride.
Zevalin must not be used in patients who are pregnant or breast feeding.
Ziagen is contraindicated in patients with severe hepatic impairment.
Ziagen should not be administered to patients with end-stage renal disease (see section 5.2).
Ziagen is unlikely to significantly interact with other medicines you are being treated with.
Ziagen, or any other medicinal product containing abacavir (i. e.
Ziduri Intre Vii Nr.22 Sector 2, Bucurest Romania
Common side effects, that affect more than 1 per 100 but less than1 per 10, that have occurred in patients on ZIMULTI include:
ZIMULTI is indicated in the treatment of obese or overweight ol
< Zocord > is effective alone or in combination with bile acid sequestrants.
Zometa 4 mg Powder for solution for infusion Zoledronic acid For intravenous use only
Zometa 4 mg Powder and solvent for solution for infusion Zoledronic acid
How Zometa is given Zometa is given as an infusion into a vein which should last no less than 15 minutes and should be administered as a single intravenous solution in a separate infusion line.
How Zometa is given Zometa is given as an infusion into a vein which should last no less than 15 minutes and should be administered as a single intravenous solution in a separate infusion line.
Zometa is contraindicated in breast-feeding women (see section 4.3).
Zometa was also as effective as pamidronate: the proportion of patients with one event was 44% with Zometa and 46% with pamidronate.
Zometa should not be used in that patient population until further data becomes available.
Strength 25 mg 25 mg 50 mg 100 mg 25 mg 100 mg 100 mg 100 mg 50 mg 50 mg 100 mg 50 mg 25 mg
Zonegran contains zonisamide, which is an antiepileptic medicine.
• Zonegran is meant to be taken as a long-term medicine.
Zonegran is a benzisoxazole derivative, which contains a sulphonamide group.
Zonegran can be taken with or without food.
Zone Industrielle de l'Ouriettaz 1170 Aubonne Switzerland
Zone Industrielle de l'Ouriettaz 1170 Aubonne SWITZERLAND
ZOSTAVAX is indicated for prevention of herpes zoster (“ zoster” or shingles) and herpes zoster-related post-herpetic neuralgia (PHN).
From 1985 to 1989, Mr Zouridakis held various positions in the field of information technology as programmer, systems analyst and project manager, work ing as a senior consultant from 1990 to 1992.
From 1985 to 1989, Mr Zouridakis held various positions in the field of information technology as programmer, systems analyst and project manager, working as a senior consultant from 1990 to 1992.
From 1985 to 1989, Mr Zouridakis held various positions in the field of information technology as programmer, systems analyst and project manager, working as a senior consultant from 1990 to 1992.
Zubrin acts by blocking enzymes, cyclooxygenase-1 and cyclooxygenase-2.
Zvolenská 19 SK-821 09 Bratislava 2 Tel: +421 2 5341 4218
EU/ 1/ 96/ 022/ 026 - ZYPREXA - 10 mg - coated tablets - 35 tablets, per box.
EU/ 1/ 96/ 022/ 010 - ZYPREXA - 10 mg - coated tablets - 56 tablets, per box.
EU/ 1/ 96/ 022/ 032 - ZYPREXA - 10 mg - coated tablets - 70 tablets, per box.
It is also a mood stabiliser that prevents further occurrences of the disabling high and low (depressed) extremes of mood associated with this condition.
Zyprexa is also used to treat moderate to severe manic episodes (extremely high mood) in adults.
ZYRTEC 10 MG/ ML PERORALNE KAPLJICE, RAZTOPINA
Alerlisin, Virlix, Reactine 5mg/ 5ml solución oral, Zyrtec solución oral Sweden:
Alerlisin, Virlix, Reactine, Zyrtec comprimidos recubiertos con pelicula, Alerrid 10 mg comprimidos recubiertos con pelicula Sweden:
Zyrtec filmtabletta, Zyrtec start filmtabletta Ireland:
You should not take Zyrtec during breast feeding because cetirizine passes into breast milk.
You should not take Zyrtec during breast feeding because cetirizine passes into breast milk.
Ακροπόλεως 25, 2006 Λευκωσία
Ελλάδα ALAPIS ABEE GR– 19300, Ασπρόπυργος Αττικής, Τ .Θ.
Eesti Österreich GlaxoSmithKline Eesti OÜ Tel: +372 667 6900 estonia@gsk.com lP
Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 D-60318 Frankfurt Γερμανία Τηλ: +49 (0)69 1503 - 1
274 Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ.: + 30-210 9 8 97 300
274 Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ.: + 30-210 98 97 300
284 Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ.: + 30-210 98 97 300
284 Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ.: + 30-210 98 97 300
294 Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ.: + 30-210 98 97 300
294 Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ.: + 30-210 98 97 300
304 Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ.: + 30-210 98 97 300
304 Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ.: + 30-210 98 97 300
314 Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ.: + 30-210 98 97 300
324 Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ.: + 30-210 98 97 300
337 Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ.: + 30-210 98 97 300
350 Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ.: + 30-210 98 97 300
 416 Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ: + 30-210 98 97 300
 425 Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ: + 30-210 98 97 300
 434 Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ: + 30-210 98 97 300
 465 Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ: + 30-210 98 97 300
59 Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ.: + 30-210 98 97 300
Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ.: + 30-210 98 97 300
Ελλάδα Αγίου Δημητρίου 63
Ελλάδα Αγίου Δημητρίου 63
Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ.: + 30-210 98 97 300
ΕΛΛΑΣ 211 Parnithos Ave GR-13671 Acharnal Athens Greece
Ι talia Addenda Pharma S. r. l., Tel: +39-06-9139 3303 info@addenda. it
Κηφισίας 41-45, Κτήριο Β GR-151 23 Μαρούσι Αθήνα Tηλ: +3 0-210-61 65 100
Κηφισίας 41-45, Κτήριο Β GR-151 23 Μαρούσι Αθήνα Tηλ: +30-210-61 65 100
Κηφισίας 41-45, Κτίριο Β GR-151 23 Μαρούσι Αθήνα Tηλ: +30-210-61 65 100
53 Κύπρος Cycon Chemicals Ltd 5, Promitheos, 1065 Nicosia CYPRUS/ΚΥΠΡΟΣ.
Κύ ρς πο Sverige KRKA, d.d., Novo mesto Τ λ+ 30 (0)210 9581143 (EL)
RISPOLEPT® CONSTA® RISPERDAL® CONSTA® RISPERDALCONSTA® LP
